The O
proximal O
IFN B
- I
stimulated I
response I
element I
( I
ISRE I
) I
and O
NF O
- O
kappa O
B O
binding O
sites O
positively O
regulated O
CXCL10 O
transcription O
during O
HCV O
infection O
as O
well O
as O
following O
exposure O
to O
poly O
( O
I O
- O
C O
) O
( O
a O
Toll O
- O
like O
receptor O
3 O
[ O
TLR3 O
] O
stimulus O
) O
and O
5 O
' O
poly O
( O
U O
) O
HCV O
RNA O
( O
a O
retinoic O
acid O
- O
inducible O
gene O
I O
[ O
RIG O
- O
I O
] O
stimulus O
) O
from O
two O
viral O
genotypes O
. O

Conversely O
, O
binding O
sites O
for O
AP O
- O
1 O
and O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( I
C I
/ I
EBP I
- I
beta I
) I
negatively O
regulated O
CXCL10 O
induction O
in O
response O
to O
TLR3 O
and O
RIG O
- O
I O
stimuli O
, O
while O
only O
C O
/ O
EBP O
- O
beta O
negatively O
regulated O
CXCL10 O
during O
HCV O
infection O
. O

We O
also O
demonstrated O
that O
interferonregulatory B
factor I
3 I
( I
IRF3 I
) I
is O
transiently O
recruited O
to O
the O
proximal O
ISRE O
during O
HCV O
infection O
and O
localizes O
to O
the O
nucleus O
in O
HCV O
- O
infected O
primary O
human O
hepatocytes O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
envelope B
protein I
2 I
( I
E2 I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
serves O
important O
yet O
undefined O
roles O
in O
the O
viral O
life O
cycle O
. O

We O
previously O
showed O
that O
the O
viability O
of O
HVR1 O
- O
deleted O
JFH1 O
- O
based O
recombinants O
with O
Core O
- O
NS2 O
of O
H77 O
( O
H77 O
( O
Delta O
HVR1 O
) O
, O
genotype O
1a O
) O
and O
S52 O
( O
S52 O
( O
Delta O
HVR1 O
) O
, O
genotype O
3a O
) O
in O
Huh7 O
. O

5 O
cells O
was O
rescued O
by O
E2 O
substitutions O
N476D O
/ O
S733F O
and O
an O
E1 O
substitution O
, O
A369V O
, O
respectively O
; O
HVR1 O
- O
deleted O
J6 O
( O
J6 O
( O
Delta O
HVR1 O
) O
, O
genotype O
2a O
) O
was O
fully O
viable O
. O

5 O
cells O
showed O
that O
HVR1 O
deletion O
decreased O
entry O
by O
20 O
- O
to O
100 O
- O
fold O
for O
H77 O
, O
J6 O
, O
and O
S52 O
; O
N476D O
/ O
S733F O
restored O
entry O
for O
H77 O
( O
Delta O
HVR1 O
) O
, O
while O
A369V O
further O
impaired O
S52 O
( O
Delta O
HVR1 O
) O
entry O
. O

Compared O
to O
parental O
viruses O
, O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
dependency O
was O
decreased O
for O
H77 O
( O
Delta O
HVR1 O
/ O
N476D O
/ O
S733F O
) O
, O
H77 O
( O
N476D O
/ O
S733F O
) O
, O
S52 O
( O
Delta O
HVR1 O
/ O
A369V O
) O
, O
and O
S52A369V O
, O
but O
not O
for O
J6 O
( O
Delta O
HVR1 O
) O
. O

low B
- I
density I
lipoprotein I
receptor I
( I
LDLr I
) I
dependency O
was O
decreased O
for O
HVR1 O
- O
deleted O
viruses O
, O
but O
not O
for O
H77 O
( O
N476D O
/ O
S733F O
) O
and O
S52A369V O
. O

apolipoprotein B
E I
( I
ApoE I
) I
- O
specific O
HCV O
neutralization O
was O
similar O
for O
H77 O
, O
J6 O
, O
and O
S52 O
viruses O
with O
and O
without O
HVR1 O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
major O
causative O
agent O
of O
hand O
, O
food O
, O
and O
mouth O
disease O
, O
which O
frequently O
occurs O
in O
young O
children O
. O

Since O
there O
are O
11 O
subgenotypes O
( O
A O
, O
B1 O
to O
B5 O
, O
and O
C1 O
to O
C5 O
) O
within O
EV71 O
, O
an O
EV71 O
vaccine O
capable O
of O
protecting O
against O
all O
of O
these O
subgenotypes O
is O
desirable O
. O

We O
report O
here O
the O
vaccine O
potential O
and O
protective O
mechanism O
of O
two O
chimeric O
virus B
- I
like I
particles I
( I
VLPs I
) I
presenting O
conserved O
neutralizing O
epitopes O
of O
EV71 O
. O

We O
show O
that O
fusions O
of O
hepatitis B
B I
core I
antigen I
( I
HBc I
) I
with O
the O
SP55 O
or O
SP70 O
epitope O
of O
EV71 O
, O
designated O
HBcSP55 O
and O
HBcSP70 O
, O
respectively O
, O
can O
be O
rapidly O
generated O
and O
self O
- O
assembled O
into O
VLPs O
with O
the O
epitopes O
displayed O
on O
the O
surface O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
synthesizes O
its O
DNA O
genome O
through O
reverse O
transcription O
, O
which O
is O
catalyzed O
by O
viral O
Polymerase B
( I
Pol I
) I
. O

Southern O
blot O
analysis O
showed O
that O
three O
mutants O
( O
R703A O
, O
D777A O
, O
and O
R781A O
mutants O
) O
yielded O
significantly O
reduced O
amounts O
of O
viral O
DNAs O
. O

Last O
- O
generation O
nucleoside O
/ O
nucleotide O
analogues O
are O
potent O
against O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
have O
a O
high O
barrier O
to O
resistance O
. O

Our O
data O
revealed O
that O
( O
i O
) O
the O
putative O
4th O
catalytic O
residue O
displays O
unexpected O
variability O
that O
could O
be O
explained O
by O
the O
overlap O
of O
the O
HBx O
gene O
and O
has O
no O
apparent O
impact O
on O
HBV O
replicative O
capacity O
and O
that O
( O
ii O
) O
the O
C O
- O
helix O
- O
containing O
basic O
protrusion O
, O
which O
is O
required O
to O
guide O
the O
RNA O
/ O
DNA O
heteroduplex O
into O
the O
catalytic O
site O
, O
is O
highly O
conserved O
and O
bears O
unique O
structural O
properties O
that O
can O
be O
used O
to O
target O
HBV O
- O
specific O
RNase O
H O
inhibitors O
without O
cross O
- O
species O
activity O
. O

We O
previously O
reported O
that O
exosomal O
transfer O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
positive O
- O
strand O
RNA O
from O
human O
Huh O
- O
7 O
hepatoma O
cells O
to O
human O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
triggers O
pDC O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
production O
in O
a O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
- O
dependent O
, O
virus O
- O
independent O
manner O
. O

Here O
we O
show O
that O
human O
pDCs O
are O
also O
activated O
by O
a O
TLR7 O
- O
dependent O
, O
virus O
- O
independent O
, O
exosomal O
RNA O
transfer O
mechanism O
by O
human O
and O
mouse O
hepatoma O
and O
nonhepatoma O
cells O
that O
replicate O
the O
negative O
- O
strand O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Apolipoprotein B
B I
mRNA I
- I
editing I
catalytic I
polypeptide I
3 I
( I
APOBEC3 I
) I
proteins O
are O
interferon B
( I
IFN I
) I
- O
inducible O
antiviral O
factors O
that O
counteract O
various O
viruses O
such O
as O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
by O
inducing O
cytidine O
( O
C O
) O
- O
to O
- O
uracil O
( O
U O
) O
mutations O
in O
viral O
DNA O
and O
inhibiting O
reverse O
transcription O
. O

However O
, O
whether O
APOBEC3 B
proteins I
( I
A3s I
) I
can O
hypermutate O
Human B
papillomavirus I
( I
HPV I
) I
viral O
DNA O
and O
exhibit O
antiviral O
activity O
in O
human O
keratinocyte O
remains O
unknown O
. O

Treatment O
of O
W12 O
cells O
with O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
increased O
expression O
levels O
of O
A3s O
such O
as O
A3A O
, O
A3F O
, O
and O
A3G O
and O
induced O
C O
- O
to O
- O
U O
conversions O
in O
the O
E2 O
gene O
in O
a O
manner O
depending O
on O
inhibition O
of O
uracil O
DNA O
glycosylase O
. O

IFN O
- O
beta O
- O
induced O
hypermutation O
was O
blocked O
by O
transfection O
of O
small O
interfering O
RNAs O
against O
A3G O
( O
and O
modestly O
by O
those O
against O
A3A O
) O
. O

Here O
, O
we O
characterized O
the O
hierarchy O
of O
HLA O
class O
I O
- O
restricted O
hepatitis B
B I
virus I
( I
HBV I
) I
epitopes O
targeted O
by O
CD8 O
T O
cells O
in O
HBV O
- O
infected O
subjects O
. O

The O
frequency O
of O
CD8 O
T O
cells O
specific O
for O
a O
panel O
of O
18 O
HBV O
epitopes O
( O
restricted O
by O
HLA O
- O
A O
* O
0201 O
/ O
03 O
/ O
07 O
[ O
hereinafter O
HLA O
- O
A0201 O
/ O
03 O
/ O
07 O
] O
, O
- O
A1101 O
, O
- O
A2402 O
/ O
07 O
, O
- O
B5801 O
, O
- O
B4001 O
, O
- O
B1301 O
, O
and O
- O
Cw0801 O
) O
was O
quantified O
in O
a O
total O
of O
59 O
subjects O
who O
resolved O
HBV O
infection O
. O

We O
found O
that O
the O
HLA O
- O
Cw0801 O
- O
restricted O
epitope O
comprised O
of O
Env B
residues I
171 I
to I
180 I
( I
Env I
( I
171 I
- I
180 I
) I
) I
is O
immunoprevalent O
in O
the O
Southeast O
Asian O
subjects O
( O
10 O
/ O
17 O
HLA O
- O
Cw0801 O
- O
positive O
subjects O
) O
and O
immunodominant O
in O
the O
majority O
of O
HLA O
- O
Cw0801 O
- O
positive O
subjects O
able O
to O
control O
HBV O
infection O
. O

HLA O
- O
Cw0801 O
- O
restricted O
Env O
( O
171 O
- O
180 O
) O
- O
specific O
CD8 O
T O
cells O
recognized O
endogenously O
produced O
HBV B
surface I
antigen I
( I
HBsAg I
) I
and O
tolerated O
amino O
acid O
variations O
within O
the O
epitope O
detected O
in O
HBV O
genotypes O
B O
and O
C O
. O

In O
conclusion O
, O
we O
demonstrate O
that O
the O
HLA O
- O
Cw0801 O
- O
restricted O
Env O
( O
171 O
- O
180 O
) O
T O
cell O
response O
is O
an O
important O
component O
of O
the O
HBV O
- O
specific O
adaptive O
T O
cell O
immunity O
in O
Asians O
infected O
with O
HBV O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
cause O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
worldwide O
. O

The O
pre O
- O
S O
- O
2 O
mutant O
large O
HBV O
surface O
protein O
( O
Delta O
2 O
LHBS O
) O
, O
which O
contains O
an O
in O
- O
frame O
deletion O
of O
approximately O
17 O
amino O
acids O
in O
LHBS O
, O
is O
highly O
associated O
with O
risks O
and O
prognoses O
of O
HBV O
- O
induced O
HCC O
. O

It O
was O
previously O
reported O
that O
Delta O
2 O
LHBS O
interacts O
with O
the O
Jun B
activation I
domain I
- I
binding I
protein I
1 I
( I
JAB1 I
) I
, O
a O
zinc O
metalloprotease O
. O

This O
promotes O
the O
degradation O
of O
the O
cell O
cycle O
regulator O
p27 O
( O
Kip1 O
) O
and O
is O
believed O
to O
be O
the O
major O
mechanism O
for O
Delta O
2 O
LHBS O
- O
induced O
HCC O
. O

The O
binding O
of O
JAB1 O
to O
Delta O
2 O
LHBS O
requires O
the O
JAB1 O
/ O
CSN5 O
MPN O
metalloenzyme O
( O
JAMM O
) O
motif O
and O
residue O
H138 O
that O
binds O
to O
Zn2 O
+ O
ions O
in O
JAB1 O
. O

Residues O
H71 O
and O
H116 O
in O
Delta O
2 O
LHBS O
, O
which O
also O
contact O
Zn2 O
+ O
ions O
, O
are O
also O
indispensable O
for O
Delta O
2 O
LHBS O
- O
mediated O
p27 O
( O
Kip1 O
) O
degradation O
in O
human O
HuH7 O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
causes O
chronic O
hepatitis O
in O
hundreds O
of O
millions O
of O
people O
worldwide O
, O
which O
can O
eventually O
lead O
to O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Further O
analysis O
revealed O
that O
HBV O
mRNAs O
possess O
a O
microRNA O
15a O
/ O
16 O
( O
miR O
- O
15a O
/ O
16 O
) O
- O
complementary O
site O
( O
HBV O
nucleotides O
[ O
nt O
] O
1362 O
to O
1383 O
) O
that O
acts O
as O
a O
sponge O
to O
bind O
and O
sequester O
endogenous O
miR O
- O
15a O
/ O
16 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
remains O
a O
challenging O
public O
health O
problem O
worldwide O
. O

The O
mature O
nucleocapsid B
( I
NC I
) I
of O
hepatitis O
B O
virus O
containing O
the O
relaxed B
circular I
( I
RC I
) I
DNA O
genome O
can O
be O
secreted O
extracellularly O
as O
virions O
after O
envelopment O
with O
the O
viral O
surface O
proteins O
or O
, O
alternatively O
, O
can O
be O
disassembled O
to O
release O
RC O
DNA O
( O
i O
. O

, O
uncoating O
) O
into O
the O
host O
cell O
nucleus O
to O
form O
the O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
which O
sustains O
viral O
replication O
and O
persistence O
. O

Genetic O
polymorphisms O
of O
HLA O
- O
DP O
have O
been O
associated O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
persistence O
. O

rs3077 O
, O
rs3135021 O
, O
rs9277535 O
, O
and O
rs2281388 O
were O
genotyped O
in O
1 O
, O
342 O
healthy O
controls O
, O
327 O
HBV O
clearance O
subjects O
, O
and O
2 O
, O
736 O
HBV O
- O
positive O
subjects O
, O
including O
1 O
, O
108 O
hepatocellular B
carcinoma I
( I
HCC I
) I
patients O
, O
using O
quantitative O
PCR O
. O

rs3077 O
( O
from O
subjects O
with O
genotype O
CT O
combined O
with O
those O
from O
subjects O
with O
genotype O
TT O
[ O
CT O
+ O
TT O
] O
versus O
CC O
) O
, O
rs3135021 O
( O
GA O
+ O
AA O
versus O
GG O
) O
, O
rs9277535 O
( O
GA O
+ O
AA O
versus O
GG O
) O
, O
and O
rs2281388 O
( O
CC O
versus O
CT O
+ O
TT O
) O
significantly O
decreased O
HBV O
persistence O
. O

HLA O
- O
DP O
polymorphisms O
promoting O
HBV O
clearance O
were O
associated O
with O
a O
lower O
prevalence O
of O
mutations O
increasing O
HCC O
risk O
( O
C1653T O
, O
T1674C O
/ O
G O
, O
A1846T O
, O
G1896A O
and O
pre O
- O
S2 O
mutations O
and O
pre O
- O
S O
deletion O
in O
genotype O
C O
) O
and O
a O
higher O
prevalence O
of O
mutations O
decreasing O
HCC O
risk O
( O
G1652A O
, O
T1673C O
, O
T1674C O
, O
G1719T O
, O
G1730C O
, O
and O
G1799C O
in O
genotype O
B O
and O
A1727T O
in O
genotype O
C O
) O
. O

A O
nationwide O
hepatitis B
B I
virus I
( I
HBV I
) I
vaccination O
program O
was O
implemented O
in O
China O
starting O
in O
1992 O
. O

To O
study O
the O
change O
in O
HBV O
variant O
prevalence O
with O
massive O
immunization O
, O
large B
HBV I
surface I
protein I
( I
LHBs I
) I
genes O
from O
HBV B
surface I
antigen I
( I
HBsAg I
) I
- O
positive O
sera O
were O
amplified O
and O
sequenced O
. O

Moreover O
, O
compared O
to O
the O
1992 O
survey O
, O
the O
child O
group O
Surface B
( I
S I
) I
protein O
mutation O
frequency O
specifically O
increased O
( O
P O
= O
0 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
- O
mediated O
chronic O
liver O
disease O
is O
a O
global O
health O
problem O
, O
and O
inflammation O
is O
believed O
to O
be O
an O
important O
player O
in O
disease O
pathogenesis O
. O

The O
proinflammatory O
cytokines O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
and O
IL O
- O
18 O
have O
critical O
roles O
in O
establishment O
of O
inflammation O
. O

Our O
results O
demonstrated O
that O
monocyte O
- O
derived O
human O
macrophages O
( O
THP O
- O
1 O
) O
incubated O
with O
cell O
culture O
- O
grown O
HCV O
enhance O
the O
secretion O
of O
IL O
- O
1 O
beta O
/ O
IL O
- O
18 O
into O
culture O
supernatants O
. O

A O
similar O
cytokine O
release O
was O
also O
observed O
for O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
- O
derived O
primary O
human O
macrophages O
and O
Kupffer O
cells O
( O
liver O
- O
resident O
macrophages O
) O
upon O
incubation O
with O
HCV O
. O

Like O
all O
other O
positive O
- O
strand O
RNA O
viruses O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
induces O
rearrangements O
of O
intracellular O
membranes O
that O
are O
thought O
to O
serve O
as O
a O
scaffold O
for O
the O
assembly O
of O
the O
viral O
replicase O
machinery O
. O

The O
most O
prominent O
membranous O
structures O
present O
in O
HCV O
- O
infected O
cells O
are O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
. O

To O
gain O
further O
insights O
into O
the O
biochemcial O
properties O
of O
HCV O
- O
induced O
membrane O
alterations O
, O
we O
generated O
a O
functional O
replicon O
containing O
a O
Hemagglutinin B
( I
HA I
) I
affinity O
tag O
in O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
, O
the O
supposed O
scaffold O
protein O
of O
the O
viral O
replication O
complex O
. O

In O
addition O
to O
viral O
factors O
, O
co O
- O
opted O
cellular O
proteins O
, O
such O
as O
vesicle B
- I
associated I
membrane I
protein I
- I
associated I
protein I
A I
( I
VAP I
- I
A I
) I
and O
VAP O
- O
B O
, O
that O
are O
crucial O
for O
viral O
RNA O
replication O
, O
as O
well O
as O
cholesterol O
, O
a O
major O
structural O
lipid O
of O
detergent O
- O
resistant O
membranes O
, O
are O
highly O
enriched O
in O
DMVs O
. O

We O
compared O
the O
plasma O
viromes O
of O
HIV O
- O
infected O
subjects O
with O
low O
versus O
high O
CD4 O
( O
+ O
) O
T O
cell O
counts O
from O
the O
United O
States O
and O
Uganda O
by O
using O
deep O
sequencing O
and O
detected O
HIV O
, O
hepatitis O
C O
virus O
, O
hepatitis O
B O
virus O
, O
GB O
virus O
C O
, O
anellovirus O
, O
and O
human B
endogenous I
retrovirus I
( I
HERV I
) I
reads O
. O

The O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
receptor O
, O
which O
exists O
as O
membrane O
- O
bound O
and O
soluble O
forms O
, O
plays O
critical O
roles O
in O
the O
immune O
response O
. O

The O
soluble B
IL I
- I
6 I
receptor I
( I
sIL6R I
) I
has O
been O
identified O
as O
a O
potential O
therapeutic O
target O
for O
preventing O
coronary O
heart O
disease O
. O

Furthermore O
, O
sIL6R O
mediated O
antiviral O
action O
via O
the O
p28 O
pathway O
and O
induced O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
by O
promoting O
the O
nuclear O
translocation O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
NF O
- O
kappa O
B O
, O
which O
led O
to O
the O
activation O
of O
downstream O
IFN O
effectors O
, O
including O
2 O
' O
, O
5 B
' I
- I
oligoadenylate I
synthetase I
( I
OAS I
) I
, O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
, O
and O
myxovirus O
resistance O
protein O
( O
Mx O
) O
. O

GB O
virus O
B O
( O
GBV O
- O
B O
; O
family O
Flaviviridae O
, O
genus O
Hepacivirus O
) O
has O
been O
studied O
in O
New O
World O
primates O
as O
a O
model O
for O
human O
hepatitis O
C O
virus O
infection O
, O
but O
the O
distribution O
of O
GBV O
- O
B O
and O
its O
relatives O
in O
nature O
has O
remained O
obscure O
. O

Here O
, O
we O
report O
the O
discovery O
of O
a O
novel O
and O
highly O
divergent O
GBV O
- O
B O
- O
like O
virus O
in O
an O
Old O
World O
monkey O
, O
the O
black O
- O
and O
- O
white O
colobus O
( O
Colobus O
guereza O
) O
, O
in O
Uganda O
. O

The O
new O
virus O
, O
guereza B
hepacivirus I
( I
GHV I
) I
, O
clusters O
phylogenetically O
with O
GBV O
- O
B O
and O
recently O
described O
hepaciviruses O
infecting O
African O
bats O
and O
North O
American O
rodents O
, O
and O
it O
shows O
evidence O
of O
ancient O
recombination O
with O
these O
other O
hepaciviruses O
. O

The O
viruses O
contain O
an O
exceptionally O
long O
nonstructural B
5A I
( I
NS5A I
) I
gene O
, O
approximately O
half O
of O
which O
codes O
for O
a O
protein O
with O
no O
discernible O
homology O
to O
known O
proteins O
. O

Human B
papillomavirus I
( I
HPV I
) I
transcripts O
were O
detected O
using O
RNA O
- O
Seq O
analysis O
in O
head O
- O
and O
- O
neck O
squamous O
cell O
carcinoma O
, O
uterine O
endometrioid O
carcinoma O
, O
and O
squamous O
cell O
carcinoma O
of O
the O
lung O
. O

Hepatitis O
B O
virus O
and O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
were O
detected O
using O
RNA O
- O
Seq O
in O
hepatocellular O
carcinoma O
and O
gastric O
carcinoma O
tumors O
, O
respectively O
. O

Occult O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
( O
OBI O
) O
is O
defined O
as O
low O
plasma O
level O
of O
HBV O
DNA O
with O
undetectable O
HBV B
surface I
antigen I
( I
HBsAg I
) I
outside O
the O
preseroconversion O
window O
period O
. O

HBsAg O
was O
quantified O
in O
culture O
supernatants O
and O
cell O
extracts O
of O
HuH O
- O
7 O
cells O
transiently O
transfected O
with O
plasmids O
containing O
the O
S O
gene O
of O
eight O
HBsAg O
( O
+ O
) O
controls O
and O
18 O
OBI O
clones O
. O

The O
intracellular O
( O
IC O
) O
/ O
extracellular B
( I
EC I
) I
HBsAg O
production O
ratio O
was O
similar O
to O
1 O
. O

Here O
, O
we O
have O
developed O
a O
novel O
HCV O
vaccine O
candidate O
based O
on O
the O
highly O
attenuated O
poxvirus O
vector O
MVA O
( O
referred O
to O
as O
MVA O
- O
HCV O
) O
expressing O
the O
nearly O
full O
- O
length O
( O
7 O
. O

The O
vaccine O
- O
induced O
T O
cell O
response O
was O
mainly O
mediated O
by O
CD8 O
T O
cells O
; O
however O
, O
although O
lower O
in O
magnitude O
, O
the O
CD4 O
( O
+ O
) O
T O
cells O
were O
highly O
polyfunctional O
. O

In O
homologous O
protocol O
( O
MVA O
- O
HCV O
/ O
MVA O
- O
HCV O
) O
the O
main O
CD8 O
( O
+ O
) O
T O
cell O
target O
was O
p7 O
+ O
NS2 O
, O
whereas O
in O
heterologous O
combination O
( O
DNA O
- O
HCV O
/ O
MVA O
- O
HCV O
) O
the O
main O
target O
was O
NS3 O
. O

Antigenic O
responses O
were O
also O
detected O
against O
other O
HCV O
proteins O
( O
Core O
, O
E1 O
- O
E2 O
, O
and O
NS4 O
) O
, O
but O
the O
magnitude O
of O
the O
responses O
was O
dependent O
on O
the O
protocol O
used O
. O

The O
majority O
of O
the O
HCV O
- O
induced O
CD8 O
( O
+ O
) O
T O
cells O
were O
triple O
or O
quadruple O
cytokine O
producers O
. O

The O
MVA O
- O
HCV O
vaccine O
induced O
memory O
CD8 O
( O
+ O
) O
T O
cell O
responses O
with O
an O
effector O
memory O
phenotype O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS4B O
protein O
has O
many O
roles O
in O
HCV O
genome O
replication O
. O

Indeed O
, O
replacement O
of O
the O
NS4B O
C B
- I
terminal I
domain I
( I
CTD I
) I
in O
the O
HCV O
JFH1 O
( O
genotype O
2a O
[ O
G2a O
] O
) O
genome O
with O
sequences O
from O
Con1 O
( O
G1b O
) O
or O
H77 O
( O
G1a O
) O
had O
a O
negligible O
impact O
on O
JFH1 O
genome O
replication O
but O
attenuated O
virus O
production O
. O

Further O
, O
two O
adaptive O
mutations O
( O
NS4B O
N216S O
and O
NS5A O
C465S O
) O
were O
identified O
, O
and O
introduction O
of O
these O
mutations O
into O
the O
chimera O
rescued O
virus O
production O
to O
various O
levels O
, O
suggesting O
a O
genetic O
interaction O
between O
the O
NS4B O
and O
NS5A O
proteins O
. O

Interestingly O
, O
cells O
infected O
with O
chimeric O
viruses O
displayed O
a O
markedly O
decreased O
NS5A O
hyperphosphorylation O
state O
( O
NS5A O
p58 O
) O
relative O
to O
JFH1 O
, O
and O
the O
adaptive O
mutations O
differentially O
rescued O
NS5A O
p58 O
formation O
. O

However O
, O
immunofluorescence O
staining O
indicated O
that O
the O
decrease O
in O
NS5A O
p58 O
did O
not O
alter O
NS5A O
colocalization O
with O
the O
core O
around O
lipid B
droplets I
( I
LDs I
) I
, O
the O
site O
of O
JFH1 O
assembly O
, O
suggesting O
that O
NS5A O
fails O
to O
facilitate O
the O
transfer O
of O
HCV O
RNA O
to O
the O
capsid O
protein O
on O
LDs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
forms O
an O
unusual O
interaction O
with O
human O
microRNA B
- I
122 I
( I
miR I
- I
122 I
) I
that O
promotes O
viral O
RNA O
accumulation O
in O
cultured O
human O
liver O
cells O
and O
in O
the O
livers O
of O
infected O
chimpanzees O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
a O
hepatotropic O
virus O
and O
close O
relative O
of O
HCV O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
and O
its O
satellite O
virus O
, O
hepatitis B
D I
virus I
( I
HDV I
) I
, O
primarily O
infect O
humans O
, O
chimpanzees O
, O
or O
tree O
shrews O
( O
Tupaia O
belangeri O
) O
. O

sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
is O
a O
functional O
receptor O
for O
HBV O
and O
HDV O
, O
and O
amino O
acids O
157 O
to O
165 O
of O
NTCP O
are O
critical O
for O
viral O
entry O
and O
likely O
limit O
viral O
infection O
of O
macaques O
. O

However O
, O
the O
molecular O
determinants O
for O
viral O
entry O
restriction O
in O
mouse B
NTCP I
( I
mNTCP I
) I
remain O
unclear O
. O

In O
this O
study O
, O
mNTCP O
was O
found O
to O
be O
unable O
to O
support O
either O
HBV O
or O
HDV O
infection O
, O
although O
it O
can O
bind O
to O
pre O
- O
S1 O
of O
HBV O
L O
protein O
and O
is O
functional O
in O
transporting O
substrate O
taurocholate O
; O
comprehensive O
swapping O
and O
point O
mutations O
of O
human O
NTCP O
( O
hNTCP O
) O
and O
mNTCP O
revealed O
molecular O
determinants O
restricting O
mNTCP O
for O
viral O
entry O
of O
HBV O
and O
HDV O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
has O
extremely O
restricted O
host O
and O
hepatocyte O
tropism O
. O

By O
applying O
a O
novel O
insertion O
strategy O
that O
preserves O
the O
continuity O
of O
the O
polymerase O
open B
reading I
frame I
( I
ORF I
) I
, O
recombinant B
HBV I
( I
rHBV I
) I
carrying O
protein O
or O
small B
interfering I
RNA I
( I
siRNA I
) I
genes O
were O
obtained O
that O
replicated O
and O
were O
packaged O
efficiently O
in O
cultured O
hepatocytes O
. O

We O
demonstrated O
that O
rHBV O
expressing O
a O
fluorescent O
reporter O
( O
DsRed O
) O
is O
highly O
infective O
in O
primary O
tree O
shrew O
hepatocytes O
, O
and O
rHBV O
expressing O
HBV O
- O
targeting O
siRNA O
successfully O
inhibited O
antigen O
expression O
from O
coinfected O
wild O
- O
type O
HBV O
. O

Our O
recent O
studies O
demonstrated O
that O
apolipoprotein O
E O
mediates O
cell O
attachment O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
through O
interactions O
with O
the O
cell O
surface O
heparan B
sulfate I
( I
HS I
) I
. O

HS O
is O
known O
to O
covalently O
attach O
to O
core O
proteins O
to O
form O
heparan B
sulfate I
proteoglycans I
( I
HSPGs I
) I
on O
the O
cell O
surface O
. O

The O
HSPG O
core O
proteins O
include O
the O
membrane O
- O
spanning O
syndecans B
( I
SDCs I
) I
, O
the O
lycosylphosphatidylinositol O
- O
linked O
glypicans B
( I
GPCs I
) I
, O
the O
basement O
membrane O
proteoglycan O
perlecan O
( O
HSPG2 O
) O
, O
and O
agrin O
. O

The O
knockdown O
of O
SDC1 O
expression O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
induced O
gene O
silence O
resulted O
in O
a O
significant O
reduction O
of O
HCV O
attachment O
to O
Huh O
- O
7 O
. O

Primary B
Tupaia I
hepatocytes I
( I
PTHs I
) I
are O
susceptible O
to O
woolly B
monkey I
hepatitis I
B I
virus I
( I
WMHBV I
) I
infection O
, O
but O
the O
identity O
of O
the O
cellular O
receptor O
( O
s O
) O
mediating O
WMHBV O
infection O
of O
PTHs O
remains O
unclear O
. O

Recently O
, O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
was O
identified O
as O
a O
functional O
receptor O
for O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
of O
primary O
human O
and O
Tupaia O
hepatocytes O
. O

In O
this O
study O
, O
a O
synthetic O
pre O
- O
S1 O
peptide O
from O
WMHBV O
was O
found O
to O
bind O
specifically O
to O
cells O
expressing O
Tupaia O
NTCP O
( O
tsNTCP O
) O
and O
it O
efficiently O
blocked O
WMHBV O
entry O
into O
PTHs O
; O
silencing O
of O
tsNTCP O
in O
PTHs O
significantly O
inhibited O
WMHBV O
infection O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
persistence O
may O
be O
due O
to O
impaired O
HBV O
- O
specific O
immune O
responses O
being O
unable O
to O
eliminate O
efficiently O
or O
cure O
infected O
hepatocytes O
. O

Therefore O
, O
we O
established O
a O
chronic O
HBV O
infection O
model O
in O
a O
mouse O
strain O
with O
human B
leukocyte I
antigen I
A2 I
/ I
DR1 I
( I
HLA I
- I
A2 I
/ I
DR1 I
) I
transgenes O
and O
an O
H O
- O
2 O
class O
I O
/ O
class O
II O
knockout O
. O

The O
liver O
of O
these O
mice O
was O
transduced O
with O
adeno B
- I
associated I
virus I
serotype I
2 I
/ I
8 I
( I
AAV2 I
/ I
8 I
) I
carrying O
a O
replication O
- O
competent O
HBV O
DNA O
genome O
. O

Herpesviruses O
enter O
cells O
either O
by O
direct O
fusion O
at O
the O
plasma O
membrane O
or O
from O
within O
endosomes O
, O
depending O
on O
the O
cell O
type O
and O
receptor O
( O
s O
) O
. O

We O
investigated O
two O
closely O
related O
herpesviruses O
of O
horses O
, O
equine B
herpesvirus I
type I
1 I
( I
EHV I
- I
1 I
) I
and O
EHV O
- O
4 O
, O
for O
which O
the O
cellular O
and O
viral O
determinants O
routing O
virus O
entry O
are O
unknown O
. O

Exchange O
of O
glycoprotein B
H I
( I
gH I
) I
between O
EHV O
- O
1 O
and O
EHV O
- O
4 O
resulted O
in O
rerouting O
of O
EHV O
- O
1 O
to O
the O
endocytic O
pathway O
, O
as O
did O
blocking O
of O
alpha O
4 O
beta O
1 O
integrins O
on O
the O
cell O
surface O
. O

The O
replication O
and O
infectivity O
of O
the O
lipotropic O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
regulated O
by O
cellular O
lipid O
status O
. O

Among O
differentially O
expressed O
microRNAs B
( I
miRNAs I
) I
, O
we O
found O
that O
miR O
- O
27a O
was O
preferentially O
expressed O
in O
HCV O
- O
infected O
liver O
over O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
infected O
liver O
. O

08 O
g O
/ O
cm O
( O
3 O
) O
, O
and O
increased O
viral O
replication O
and O
infectivity O
. O

Furthermore O
, O
miR O
- O
27a O
enhanced O
in O
vitro O
interferon B
( I
IFN I
) I
signaling O
, O
and O
patients O
who O
expressed O
high O
levels O
of O
miR O
- O
27a O
in O
the O
liver O
showed O
a O
more O
favorable O
response O
to O
pegylated O
IFN O
and O
ribavirin O
combination O
therapy O
. O

enterovirus B
71 I
( I
EV71 I
) I
has O
emerged O
as O
a O
major O
cause O
of O
neurological O
disease O
following O
the O
near O
eradication O
of O
poliovirus O
. O

Accumulating O
evidence O
suggests O
that O
mammalian O
microRNAs B
( I
miRNAs I
) I
, O
a O
class O
of O
noncoding O
RNAs O
of O
18 O
to O
23 O
nucleotides B
( I
nt I
) I
with O
important O
regulatory O
roles O
in O
many O
cellular O
processes O
, O
participate O
in O
host O
antiviral O
defenses O
. O

As O
determined O
by O
virus O
titration O
, O
quantitative B
real I
- I
time I
PCR I
( I
qRT I
- I
PCR I
) I
, O
and O
Western O
blotting O
, O
overexpression O
of O
hsa O
- O
miR O
- O
296 O
- O
5p O
inhibited O
, O
while O
inhibition O
of O
endogenous O
hsa O
- O
miR O
- O
296 O
- O
5p O
facilitated O
, O
EV71 O
infection O
. O

Additionally O
, O
two O
potential O
hsa O
- O
miR O
- O
296 O
- O
5p O
targets O
( O
nt O
2115 O
to O
2135 O
and O
nt O
2896 O
to O
2920 O
) O
located O
in O
the O
EV71 O
genome O
( O
strain O
BrCr O
) O
were O
bioinformatically O
predicted O
and O
validated O
by O
luciferase O
reporter O
assays O
and O
Western O
blotting O
. O

Meanwhile O
, O
compensatory O
mutations O
in O
corresponding O
hsa O
- O
miR O
- O
296 O
- O
5p O
target O
sequences O
of O
the O
EV71 O
HeN O
strain O
( O
GenBank O
accession O
number O
JN256064 O
) O
restored O
the O
inhibitory O
effects O
of O
the O
miRNA O
. O

The O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
is O
essential O
for O
virus O
replication O
and O
has O
been O
implicated O
in O
the O
development O
of O
liver O
cancer O
. O

Here O
, O
we O
purified O
HBx O
- O
associated O
factors O
in O
nuclear O
extracts O
from O
HepG2 O
hepatoma O
cells O
and O
identified O
protein B
arginine I
methyltransferase I
1 I
( I
PRMT1 I
) I
as O
a O
novel O
HBx O
- O
interacting O
protein O
. O

We O
showed O
that O
PRMT1 O
overexpression O
reduced O
the O
transcription O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
and O
this O
inhibition O
was O
dependent O
on O
the O
methyltransferase O
function O
of O
PRMT1 O
. O

Theiler B
murine I
encephalomyelitis I
virus I
( I
TMEV I
) I
infection O
of O
a O
mouse O
' O
s O
central O
nervous O
system O
is O
biphasic O
: O
first O
the O
virus O
infects O
motor O
neurons O
( O
acute O
phase O
) O
, O
and O
this O
is O
followed O
by O
a O
chronic O
phase O
in O
which O
the O
virus O
infects O
glial O
cells O
( O
primarily O
microglia O
and O
macrophages O
[ O
M O
- O
phi O
] O
) O
of O
the O
spinal O
cord O
white O
matter O
, O
leading O
to O
inflammation O
and O
demyelination O
. O

5 O
x O
10 O
( O
- O
8 O
) O
to O
5 O
. O

6 O
x O
10 O
( O
- O
8 O
) O
day O
( O
- O
1 O
) O
; O
the O
percent O
reduction O
of O
the O
infection O
rate O
due O
to O
the O
presence O
of O
virus O
- O
specific O
antibodies O
, O
which O
reaches O
98 O
. O

tripartite B
motif I
( I
TRIM I
) I
protein O
superfamily O
members O
are O
emerging O
as O
important O
effectors O
of O
the O
innate O
immune O
response O
against O
viral O
infections O
. O

In O
particular O
, O
TRIM22 O
was O
reported O
to O
exert O
antiviral O
activity O
against O
RNA O
viruses O
, O
such O
as O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
encephalomyocarditis B
virus I
( I
ECMV I
) I
, O
and O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

We O
demonstrate O
here O
, O
for O
the O
first O
time O
, O
that O
TRIM22 O
is O
upregulated O
by O
influenza B
A I
virus I
( I
IAV I
) I
infection O
at O
both O
mRNA O
and O
protein O
levels O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O

Depletion O
of O
TRIM22 O
also O
reduced O
the O
anti O
- O
IAV O
activity O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
suggesting O
that O
TRIM22 O
is O
an O
important O
IFN O
- O
stimulated O
gene O
that O
is O
required O
for O
maximal O
suppression O
of O
IAV O
by O
type O
I O
IFN O
. O

Restriction O
of O
IAV O
replication O
was O
accounted O
for O
by O
the O
interaction O
between O
TRIM22 O
and O
the O
viral O
nucleoprotein B
( I
NP I
) I
, O
resulting O
in O
its O
polyubiquitination O
and O
degradation O
in O
a O
proteasome O
- O
dependent O
manner O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replication O
requires O
reverse O
transcription O
of O
an O
RNA O
pregenome O
( O
pgRNA O
) O
by O
a O
multifunctional O
polymerase O
( O
HP O
) O
. O

HP O
initiates O
viral O
DNA O
synthesis O
by O
using O
itself O
as O
a O
protein O
primer O
and O
an O
RNA O
signal O
on O
pgRNA O
, O
termed O
epsilon O
( O
H O
epsilon O
) O
, O
as O
the O
obligatory O
template O
. O

The O
transferase O
activity O
was O
highly O
distributive O
, O
leading O
to O
the O
synthesis O
of O
DNA O
homo O
- O
and O
hetero O
- O
oligomeric O
and O
- O
polymeric O
ladders O
ranging O
from O
1 O
nucleotide B
( I
nt I
) I
to O
> O
100 O
nt O
in O
length O
, O
with O
single O
- O
nt O
increments O
. O

As O
with O
H O
epsilon O
- O
templated O
DNA O
synthesis O
, O
the O
protein O
- O
primed O
transferase O
reaction O
was O
characterized O
by O
an O
initial O
stage O
that O
was O
resistant O
to O
the O
pyrophosphate O
analog O
phosphonoformic B
acid I
( I
PFA I
) I
followed O
by O
PFA O
- O
sensitive O
DNA O
synthesis O
, O
suggestive O
of O
an O
HP O
conformational O
change O
upon O
the O
synthesis O
of O
a O
nascent O
DNA O
oligomer O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
considered O
to O
have O
a O
causative O
role O
in O
B O
- O
cell O
lymphoproliferative O
diseases O
, O
including O
B O
- O
cell O
lymphomas O
, O
in O
chronic O
virus O
carriers O
. O

Previous O
data O
from O
in O
vitro O
HCV O
- O
infected O
B O
- O
cell O
lines O
and O
peripheral O
blood O
mononuclear O
cells O
from O
HCV O
- O
positive O
individuals O
suggested O
that O
HCV O
might O
have O
a O
direct O
mutagenic O
effect O
on O
B O
cells O
, O
inducing O
mutations O
in O
the O
tumor O
suppressor O
gene O
TP53 O
and O
the O
proto O
- O
oncogenes O
BCL6 O
and O
CTNNB1 O
( O
beta O
- O
catenin O
) O
. O

Recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
promising O
therapeutic O
vaccine O
platform O
. O

Using O
a O
transgenic O
mouse O
model O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
, O
we O
evaluated O
the O
therapeutic O
potential O
of O
a O
VSV O
vector O
expressing O
the O
HBV O
middle O
surface O
envelope O
glycoprotein O
( O
MS O
) O
. O

In O
vitro O
propagation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
thus O
far O
been O
studied O
under O
atmospheric O
oxygen O
levels O
despite O
the O
fact O
that O
the O
liver O
tissue O
microenvironment O
is O
hypoxic O
. O

Hypoxia O
signaling O
pathway O
- O
focused O
DNA O
microarray O
and O
real O
- O
time O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
analyses O
revealed O
an O
upregulation O
of O
genes O
related O
to O
hypoxic O
stress O
, O
glycolytic O
metabolism O
, O
cell O
growth O
, O
and O
proliferation O
when O
cells O
were O
kept O
under O
low O
( O
3 O
% O
[ O
vol O
/ O
vol O
] O
) O
oxygen O
tension O
, O
likely O
reflecting O
cell O
adaptation O
to O
anaerobic O
conditions O
. O

Interestingly O
, O
hypoxia O
- O
mediated O
enhancement O
of O
HCV O
replication O
correlated O
directly O
with O
the O
increase O
in O
anaerobic O
glycolysis O
and O
creatine B
kinase I
B I
( I
CKB I
) I
activity O
that O
leads O
to O
elevated O
ATP O
production O
. O

Surprisingly O
, O
activation O
of O
hypoxia B
- I
inducible I
factor I
alpha I
( I
HIF I
- I
alpha I
) I
was O
not O
involved O
in O
the O
elevation O
of O
HCV O
replication O
. O

Capsid O
( O
core O
) O
assembly O
is O
essential O
for O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
. O

Assembly B
effectors I
( I
AEfs I
) I
are O
small O
molecules O
proposed O
to O
disrupt O
this O
balance O
by O
inappropriately O
enhancing O
core O
assembly O
. O

These O
studies O
show O
that O
the O
heteroaryldihydropyrimidine B
( I
HAP I
) I
binding O
pocket O
is O
a O
promiscuous O
target O
for O
inducing O
assembly O
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
from O
hepatitis O
B O
and O
human O
papillomaviruses O
have O
been O
successfully O
used O
as O
preventative O
vaccines O
against O
these O
infectious O
agents O
. O

We O
previously O
reported O
that O
an O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
mutant O
devoid O
of O
the O
terminal O
repeats O
( O
Delta O
TR O
) O
that O
act O
as O
packaging O
signals O
in O
herpesviruses O
produces O
substantial O
amounts O
of O
VLPs O
and O
of O
light B
particles I
( I
LPs I
) I
. O

The O
Delta O
BFLF1 O
/ O
BFRF1A O
viruses O
elicited O
a O
potent O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
that O
was O
indistinguishable O
from O
the O
one O
obtained O
with O
wild O
- O
type O
controls O
. O

Our O
previous O
study O
showed O
that O
miR O
- O
122 O
levels O
are O
significantly O
decreased O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
infected O
patients O
, O
which O
may O
facilitate O
viral O
replication O
and O
persistence O
( O
S O
. O

We O
next O
identified O
pituitary B
tumor I
- I
transforming I
gene I
1 I
( I
PTTG1 I
) I
binding O
factor O
( O
PBF O
) O
as O
a O
target O
of O
miR O
- O
122 O
and O
demonstrated O
that O
HBV O
replication O
causes O
an O
obvious O
increase O
in O
PBF O
levels O
. O

Furthermore O
, O
we O
observed O
that O
the O
miR O
- O
122 O
levels O
were O
decreased O
and O
PBF O
was O
upregulated O
in O
chronic B
hepatitis I
B I
( I
CHB I
) I
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
surface O
proteins O
not O
only O
are O
incorporated O
into O
the O
virion O
envelope O
but O
in O
addition O
form O
subviral B
particles I
( I
SVP I
) I
consisting O
solely O
of O
surface O
proteins O
and O
lipids O
. O

To O
investigate O
the O
role O
of O
the O
four O
transmembrane O
domains O
( O
TM O
) O
of O
S O
in O
this O
process O
, O
we O
introduced O
mutations O
in O
these O
regions O
and O
characterized O
their O
effects O
on O
SVP O
formation O
in O
transfected O
Huh7 O
cells O
. O

Chromosome B
region I
maintenance I
1 I
( I
CRM1 I
) I
that O
mediates O
the O
transport O
of O
proteins O
bearing O
the O
classical O
leucine O
- O
rich O
nuclear B
export I
signal I
( I
NES I
) I
is O
the O
best O
- O
characterized O
nuclear O
export O
receptor O
. O

The O
nuclear O
export O
of O
the O
large O
form O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
- I
L I
) I
, O
a O
nucleocapsid O
protein O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
which O
contains O
a O
CRM1 O
- O
independent O
proline O
- O
rich O
NES O
, O
is O
mediated O
by O
the O
host O
NES B
- I
interacting I
protein I
( I
NESI I
) I
. O

In O
addition O
, O
binding O
of O
the O
cargo O
HDAg O
- O
L O
to O
the O
C O
terminus O
of O
NESI O
was O
detected O
for O
the O
wild O
- O
type O
protein O
but O
not O
for O
the O
nuclear O
export O
- O
defective O
HDAg O
- O
L O
carrying O
a O
P205A O
mutation O
[ O
HDAg O
- O
L O
( O
P205A O
) O
] O
. O

Coronavirus O
subgenomic B
mRNA I
( I
sgmRNA I
) I
synthesis O
occurs O
via O
a O
process O
of O
discontinuous O
transcription O
involving O
transcription B
regulatory I
sequences I
( I
TRSs I
) I
located O
in O
the O
5 O
' O
leader O
sequence O
( O
TRS O
- O
L O
) O
and O
upstream O
of O
each O
structural O
and O
group O
- O
specific O
gene O
( O
TRS O
- O
B O
) O
. O

Several O
gammacoronaviruses O
including O
infectious B
bronchitis I
virus I
( I
IBV I
) I
contain O
a O
putative O
open B
reading I
frame I
( I
ORF I
) I
, O
localized O
between O
the O
M O
gene O
and O
gene O
5 O
, O
which O
is O
controversial O
due O
to O
the O
perceived O
absence O
of O
a O
TRS O
. O

Using O
an O
IBV O
reverse O
genetics O
system O
, O
we O
demonstrated O
that O
the O
template O
- O
switching O
event O
during O
intergenic B
region I
( I
IR I
) I
sgmRNA O
synthesis O
occurs O
at O
the O
5 O
' O
end O
of O
the O
noncanonical O
TRS O
- O
B O
and O
recombines O
between O
nucleotides O
5 O
and O
6 O
of O
the O
8 O
- O
nucleotide O
consensus O
TRS O
- O
L O
. O

Exposure O
to O
multiple O
small O
doses O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
frequent O
occurrence O
in O
high O
- O
risk O
groups O
, O
including O
close O
relatives O
of O
infected O
individuals O
, O
primary O
care O
givers O
, O
and O
intravenous O
drug O
users O
. O

Virus O
- O
naive O
animals O
were O
intravenously O
injected O
with O
6 O
weekly O
doses O
of O
110 O
DNase O
digestion O
- O
protected O
virions O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
injected O
again O
with O
6 O
weekly O
110 O
- O
virion O
doses O
after O
7 O
. O

1 O
x O
10 O
( O
6 O
) O
virions O
of O
the O
same O
inoculum O
. O

The O
kinetics O
of O
the O
virus O
- O
specific O
and O
mitogen O
- O
induced O
( O
generalized O
) O
T O
cell O
responses O
and O
the O
inability O
to O
induce O
immunoprotection O
against O
challenge O
with O
a O
large O
, O
liver O
- O
pathogenic O
virus O
dose O
were O
closely O
comparable O
to O
those O
previously O
reported O
for O
occult O
infection O
initiated O
by O
a O
single O
liver O
- O
nonpathogenic O
dose O
of O
WHV O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
- O
based O
therapy O
can O
effectively O
treat O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
, O
which O
causes O
life O
- O
threatening O
complications O
. O

Responses O
to O
IFN O
- O
alpha O
therapy O
vary O
greatly O
in O
chronic B
hepatitis I
B I
( I
CHB I
) I
patients O
, O
but O
underlying O
mechanisms O
are O
almost O
unknown O
. O

In O
this O
study O
, O
we O
found O
that O
IFN O
- O
alpha O
treatment O
induced O
a O
marked O
decrease O
of O
microRNA B
- I
122 I
( I
miR I
- I
122 I
) I
expression O
in O
hepatocytes O
. O

One O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
, O
NT5C3 O
, O
which O
was O
identified O
as O
a O
miR O
- O
122 O
target O
, O
efficiently O
inhibited O
miR O
- O
122 O
by O
binding O
and O
sequestering O
miR O
- O
122 O
with O
its O
mRNA O
3 B
' I
- I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
, O
indicating O
that O
this O
ISG O
is O
involved O
in O
IFN O
- O
alpha O
- O
mediated O
miR O
- O
122 O
suppression O
. O

Notably O
, O
the O
inhibitory O
effect O
of O
IFN O
- O
alpha O
on O
miR O
- O
122 O
was O
completely O
abolished O
by O
blocking O
IFN O
- O
alpha O
- O
induced O
upregulation O
of O
NT5C3 O
mRNA O
expression O
by O
RNA B
interference I
( I
RNAi I
) I
. O

Members O
of O
the O
tripartite B
interaction I
motif I
( I
TRIM I
) I
family O
of O
E3 O
ligases O
are O
emerging O
as O
critical O
regulators O
of O
innate O
immunity O
. O

In O
addition O
, O
most O
TRIM O
proteins O
previously O
identified O
to O
inhibit O
murine B
leukemia I
virus I
( I
MLV I
) I
demonstrated O
an O
ability O
to O
induce O
NF O
- O
kappa O
B O
/ O
AP O
- O
1 O
. O

In O
contrast O
, O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
gene O
expression O
was O
increased O
by O
TRIM O
proteins O
that O
induce O
NF O
- O
kappa O
B O
. O

HIV O
- O
1 O
resistance O
to O
inflammatory O
TRIM O
proteins O
mapped O
to O
the O
NF O
- O
kappa O
B O
sites O
in O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( I
LTR I
) I
U3 O
and O
could O
be O
transferred O
to O
MLV O
. O

Hepatitis B
B I
spliced I
protein I
( I
HBSP I
) I
is O
involved O
in O
the O
pathogenicity O
and O
/ O
or O
persistence O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Chronic O
HBV O
infection O
is O
one O
of O
the O
most O
important O
risk O
factors O
for O
the O
development O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Conversely O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
HBSP O
expression O
inhibited O
migration O
and O
invasion O
. O

By O
glutathione B
S I
- I
transferase I
( I
GST I
) I
pulldown O
, O
coimmunoprecipitation O
, O
and O
a O
mammalian O
two O
- O
hybrid O
assay O
, O
HBSP O
was O
found O
to O
directly O
interact O
with O
cathepsin B
B I
( I
CTSB I
) I
. O

Furthermore O
, O
the O
HBSP O
- O
overexpressing O
hepatoma O
cells O
were O
shown O
to O
have O
increased O
expression O
and O
activity O
of O
matrix B
metalloproteinase I
- I
9 I
( I
MMP I
- I
9 I
) I
and O
urokinase B
- I
type I
plasminogen I
activator I
( I
uPA I
) I
, O
and O
overexpression O
of O
HBSP O
significantly O
enhanced O
tumor O
- O
induced O
vascularization O
of O
endothelial O
cells O
. O

Expression O
of O
HBSP O
in O
the O
hepatoma O
cells O
appeared O
to O
activate O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
and O
Akt O
signaling O
pathway O
, O
as O
evidenced O
by O
increases O
in O
phosphorylation O
of O
p38 O
, O
Jun B
N I
- I
terminal I
protein I
kinase I
( I
JNK I
) I
, O
extracellular B
signal I
- I
regulated I
kinase I
( I
ERK I
) I
, O
and O
Akt O
. O

Virus O
infection O
activates O
host O
cellular O
signaling O
pathways O
, O
including O
the O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
/ O
Akt O
pathway O
, O
which O
regulates O
diverse O
cellular O
activities O
related O
to O
cell O
growth O
, O
survival O
, O
and O
apoptosis O
. O

The O
present O
study O
demonstrated O
for O
the O
first O
time O
that O
Porcine B
circovirus I
type I
2 I
( I
PCV2 I
) I
, O
a O
major O
causative O
agent O
of O
postweaning O
multisystemic O
wasting O
syndrome O
, O
which O
is O
an O
emerging O
and O
important O
swine O
disease O
, O
can O
transiently O
induce O
the O
PI3K O
/ O
Akt O
pathway O
in O
cultured O
cells O
at O
an O
early O
step O
during O
PCV2 O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
associated O
with O
numerous O
liver O
diseases O
and O
causes O
serious O
global O
health O
problems O
, O
but O
the O
mechanisms O
underlying O
the O
pathogenesis O
of O
HCV O
infections O
remain O
largely O
unknown O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
signal B
transducer I
and I
activator I
of I
transcription I
3 I
( I
STAT3 I
) I
, O
matrix B
metalloproteinase I
- I
2 I
( I
MMP I
- I
2 I
) I
, O
and O
B B
- I
cell I
lymphoma I
2 I
( I
Bcl I
- I
2 I
) I
are O
significantly O
stimulated O
in O
HCV O
- O
infected O
patients O
. O

We O
further O
show O
that O
HCV O
activates O
STAT3 O
, O
MMP O
- O
2 O
, O
Bcl O
- O
2 O
, O
extracellular B
regulated I
protein I
kinase I
( I
ERK I
) I
, O
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
in O
infected O
Huh7 O
. O

Functional O
screening O
of O
HCV O
proteins O
revealed O
that O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
is O
responsible O
for O
the O
activation O
of O
MMP O
- O
2 O
and O
Bcl O
- O
2 O
by O
stimulating O
STAT3 O
through O
repression O
of O
the O
suppressor B
of I
cytokine I
signaling I
3 I
( I
SOCS3 I
) I
. O

Our O
results O
also O
demonstrate O
that O
multiple O
signaling O
cascades O
, O
including O
several O
members O
of O
the O
protein B
kinase I
C I
( I
PKC I
) I
family O
, O
JNK O
, O
ERK O
, O
and O
STAT3 O
, O
play O
critical O
roles O
in O
the O
activation O
of O
MMP O
- O
2 O
and O
Bcl O
- O
2 O
mediated O
by O
NS4B O
. O

Further O
studies O
revealed O
that O
the O
C B
- I
terminal I
domain I
( I
CTD I
) I
of O
NS4B O
is O
sufficient O
for O
the O
activation O
of O
STAT3 O
, O
JNK O
, O
ERK O
, O
MMP O
- O
2 O
, O
and O
Bcl O
- O
2 O
. O

We O
also O
show O
that O
amino O
acids O
227 O
to O
250 O
of O
NS4B O
are O
essential O
for O
regulation O
of O
STAT3 O
, O
JNK O
, O
ERK O
, O
MMP O
- O
2 O
, O
and O
Bcl O
- O
2 O
, O
and O
among O
them O
, O
three O
residues O
( O
237L O
, O
239S O
, O
and O
245L O
) O
are O
crucial O
for O
this O
regulation O
. O

Porcine B
circovirus I
type I
2 I
( I
PCV2 I
) I
uses O
autophagy O
machinery O
to O
enhance O
its O
replication O
in O
PK O
- O
15 O
cells O
. O

By O
the O
use O
of O
specific O
inhibitors O
, O
RNA O
interference O
, O
and O
coimmunoprecipitation O
, O
we O
show O
that O
PCV2 O
induces O
autophagy O
in O
PK O
- O
15 O
cells O
through O
a O
pathway O
involving O
the O
kinases O
AMP B
- I
activated I
protein I
kinase I
( I
AMPK I
) I
and O
extracellular B
signal I
- I
regulated I
kinase I
1 I
/ I
2 I
( I
ERK1 I
/ I
2 I
) I
, O
the O
tumor O
suppressor O
protein O
TSC2 O
, O
and O
the O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
. O

HIV O
CRF01_AE O
accounted O
for O
84 O
% O
of O
the O
recent O
infections O
among O
men B
who I
have I
sex I
with I
men I
( I
MSM I
) I
in O
Liaoning O
Province O
of O
northeastern O
China O
. O

CRF01_AE O
strains O
were O
grouped O
into O
two O
distinct O
clusters O
( O
designated O
clusters O
1 O
and O
2 O
) O
that O
were O
also O
detected O
in O
other O
regions O
in O
China O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
to O
induce O
autophagy O
and O
the O
unfolded B
protein I
response I
( I
UPR I
) I
, O
but O
the O
mechanistic O
link O
between O
the O
induction O
of O
these O
two O
cellular O
processes O
remains O
unclear O
. O

Furthermore O
, O
both O
genotype O
1b O
and O
2a O
subgenomic O
replicons O
expressing O
nonstructural O
( O
NS3 O
- O
5B O
) O
proteins O
and O
JFH O
- O
1 O
virus O
lacking O
the O
envelope O
glycoproteins O
potently O
induced O
autophagy O
in O
the O
absence O
of O
detectable O
UPR O
. O

This O
ability O
was O
also O
shared O
by O
a O
subgenomic O
replicon O
derived O
from O
the O
related O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
. O

We O
also O
show O
that O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
silencing O
of O
the O
key O
UPR O
inducer O
, O
Ire1 O
, O
has O
no O
effect O
on O
HCV O
genome O
replication O
or O
the O
induction O
of O
autophagy O
, O
further O
demonstrating O
that O
the O
UPR O
is O
not O
required O
for O
these O
processes O
. O

Human B
papillomaviruses I
( I
HPV I
) I
are O
composed O
of O
the O
major O
and O
minor O
capsid O
proteins O
, O
L1 O
and O
L2 O
, O
that O
encapsidate O
a O
chromatinized O
, O
circular O
double O
- O
stranded O
DNA O
genome O
. O

At O
the O
outset O
of O
infection O
, O
the O
interaction O
of O
HPV B
type I
16 I
( I
HPV16 I
) I
( O
pseudo O
) O
virions O
with O
heparan O
sulfate O
proteoglycans O
triggers O
a O
conformational O
change O
in O
L2 O
that O
is O
facilitated O
by O
the O
host O
cell O
chaperone O
cyclophilin B
B I
( I
CyPB I
) I
. O

Inhibition O
and O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
CyPs O
blocked O
dissociation O
of O
L1 O
from O
the O
L2 O
/ O
DNA O
complex O
. O

All O
approved O
directly O
antiviral O
agents O
are O
nucleos O
( O
t O
) O
ide O
analogs O
( O
NAs O
) O
that O
target O
the O
DNA O
polymerase O
activity O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
P O
protein O
; O
resistance O
and O
cross O
- O
resistance O
may O
limit O
their O
long O
- O
term O
applicability O
. O

Priming O
requires O
P O
protein O
binding O
to O
the O
epsilon O
stem O
- O
loop O
on O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
template O
. O

Exploiting O
in O
vitro O
priming O
systems O
available O
for O
duck B
HBV I
( I
DHBV I
) I
but O
not O
HBV O
, O
we O
demonstrate O
that O
naphthylureas O
of O
the O
carbonyl O
J O
acid O
family O
, O
in O
particular O
KM O
- O
1 O
, O
potently O
suppress O
protein O
priming O
by O
targeting O
P O
protein O
and O
interfering O
with O
the O
formation O
of O
P O
- O
DHBV O
epsilon O
initiation O
complexes O
. O

human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
and O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
have O
been O
incurable O
to O
date O
because O
effective O
antiviral O
therapies O
target O
only O
replicating O
viruses O
and O
do O
not O
eradicate O
latently O
integrated O
or O
nonreplicating O
episomal O
viral O
genomes O
. O

Imprecise O
nonhomologous B
- I
end I
- I
joining I
( I
NHEJ I
) I
DNA O
repair O
following O
repeated O
cleavage O
at O
the O
same O
critical O
site O
may O
permanently O
disrupt O
translation O
of O
essential O
viral O
proteins O
. O

We O
discuss O
the O
benefits O
and O
drawbacks O
of O
three O
types O
of O
DNA O
cleavage O
enzymes O
( O
zinc O
finger O
endonucleases O
, O
transcription O
activator O
- O
like O
[ O
TAL O
] O
effector O
nucleases O
[ O
TALENs O
] O
, O
and O
homing O
endonucleases O
[ O
also O
called O
meganucleases O
] O
) O
, O
the O
development O
of O
delivery O
vectors O
for O
these O
enzymes O
, O
and O
potential O
obstacles O
for O
successful O
treatment O
of O
chronic O
viral O
infections O
. O

The O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
/ O
Akt O
signaling O
pathway O
controls O
cell O
fate O
decisions O
in O
many O
cell O
types O
by O
modulating O
the O
activity O
of O
downstream O
effectors O
, O
including O
the O
FOX O
( O
) O
family O
of O
transcription O
factors O
. O

We O
have O
observed O
dynamic O
, O
in O
vivo O
alterations O
in O
the O
phosphorylation O
levels O
of O
three O
key O
proteins O
( O
Akt O
, O
FOXO1 O
/ O
FOXO3 O
[ O
FOXO1 O
/ O
3 O
] O
, O
and O
mammalian O
target O
of O
rapamycin O
[ O
mTOR O
] O
) O
involved O
in O
this O
signaling O
cascade O
and O
have O
identified O
the O
transcription O
factor O
FOXO3 O
as O
a O
negative O
regulator O
of O
the O
magnitude O
and O
effector O
function O
of O
CD8 O
T O
cells O
during O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
in O
mice O
. O

Induction O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
cytotoxic O
T O
cells O
by O
therapeutic O
immunization O
may O
be O
a O
strategy O
to O
treat O
chronic O
hepatitis O
B O
. O

In O
the O
HBV O
animal O
model O
, O
woodchucks O
, O
the O
application O
of O
DNA O
vaccine O
expressing O
woodchuck B
hepatitis I
virus I
( I
WHY I
) I
core O
antigen O
( O
WHcAg O
) O
in O
combination O
with O
antivirals O
led O
to O
the O
prolonged O
control O
of O
viral O
replication O
. O

We O
developed O
a O
new O
DNA O
plasmid O
( O
pCGWHc O
) O
and O
recombinant O
adenoviruses B
( I
AdVs I
) I
showing O
high O
expression O
levels O
of O
WHcAg O
. O

Mice O
vaccinated O
with O
the O
improved O
plasmid O
pCGWHc O
elicited O
a O
stronger O
WHcAg O
- O
specific O
CD8 O
( O
+ O
) O
1 O
- O
cell O
response O
than O
with O
the O
previously O
used O
vaccines O
. O

60 O
mu O
M O
and O
a O
selectivity O
index O
( O
ratio O
of O
cytotoxic O
versus O
antiviral O
concentration O
) O
of O
112 O
. O

The O
compound O
had O
no O
effect O
on O
Hemagglutinin B
( I
HA I
) I
- O
mediated O
membrane O
fusion O
in O
an O
HA O
- O
polykaryon O
assay O
and O
did O
not O
inhibit O
the O
low O
- O
pH O
- O
induced O
refolding O
of O
the O
HA O
in O
a O
tryptic O
digestion O
assay O
. O

However O
, O
a O
marked O
inhibitory O
effect O
on O
the O
transduction O
exerted O
by O
retroviral O
pseudoparticles O
carrying O
an O
HA O
or O
vesicular B
stomatitis I
virus I
glycoprotein I
( I
VSV I
- I
G I
) I
fusion O
protein O
was O
noted O
, O
suggesting O
that O
SA O
- O
19 O
targets O
a O
cellular O
factor O
with O
a O
role O
in O
influenza O
virus O
and O
VSV O
entry O
. O

The O
lack O
of O
a O
suitable O
in O
vitro O
hepatitis B
B I
virus I
( I
HBV I
) I
infectivity O
model O
has O
limited O
examination O
of O
the O
early O
stages O
of O
the O
virus O
- O
cell O
interaction O
. O

HBV O
infection O
efficiency O
was O
markedly O
increased O
after O
dimethyl B
sulfoxide I
( I
DMSO I
) I
- O
induced O
differentiation O
of O
the O
cells O
. O

The O
pre O
- O
S1 O
domain O
of O
the O
large O
HBsAg O
( O
LHBsAg O
) O
protein O
specifically O
interacted O
with O
clathrin B
heavy I
chain I
( I
CHC I
) I
and O
clathrin O
adaptor O
protein O
AP O
- O
2 O
. O

In O
silico O
screening O
of O
metazoan O
genome O
data O
identified O
multiple O
endogenous O
hepadnaviral O
elements O
in O
the O
budgerigar O
( O
Melopsittacus O
undulatus O
) O
genome O
, O
most O
notably O
two O
elements O
comprising O
about O
1 O
. O

Phylogenetic O
and O
molecular O
dating O
analyses O
show O
that O
endogenous B
budgerigar I
hepatitis I
B I
viruses I
( I
eBHBV I
) I
share O
an O
ancestor O
with O
extant O
avihepadnaviruses O
and O
infiltrated O
the O
budgerigar O
genome O
millions O
of O
years O
ago O
. O

In O
the O
present O
study O
, O
we O
have O
obtained O
substantial O
evidence O
demonstrating O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
uses O
the O
cellular O
protein O
apolipoprotein B
E I
( I
ApoE I
) I
for O
its O
attachment O
to O
cells O
. O

Similarly O
, O
small O
interfering O
RNA O
- O
mediated O
knockdown O
of O
the O
key O
HCV O
receptor O
/ O
coreceptor O
molecules O
CD81 O
, O
claudin O
- O
1 O
, O
low B
- I
density I
lipoprotein I
receptor I
( I
LDLr I
) I
, O
occludin O
, O
and O
SR O
- O
BI O
did O
not O
affect O
HCV O
attachment O
but O
efficiently O
suppressed O
HCV O
infection O
, O
suggesting O
their O
important O
roles O
in O
HCV O
infection O
at O
postattachment O
steps O
. O

Here O
, O
we O
describe O
the O
analysis O
of O
human O
antibodies O
induced O
during O
an O
HIV O
- O
1 O
vaccine O
trial O
( O
GSK O
PRO O
HIV O
- O
002 O
) O
that O
used O
the O
clade O
B O
envelope B
( I
env I
) I
gp120 O
of O
clone O
W6 O
. O

Using O
dual O
- O
color O
antigen O
- O
specific O
sorting O
, O
we O
isolated O
Env O
- O
specific O
human B
monoclonal I
antibodies I
( I
MAbs I
) I
and O
studied O
the O
clonal O
persistence O
of O
antibodies O
in O
the O
setting O
of O
HIV O
- O
1 O
Env O
vaccination O
. O

These O
recombinant O
antibodies O
recapitulated O
the O
anti O
- O
HIV O
- O
1 O
activity O
of O
participant O
serum O
including O
pseudovirus O
neutralization O
and O
antibody B
- I
dependent I
cell I
- I
mediated I
cytotoxicity I
( I
ADCC I
) I
. O

One O
antibody O
( O
3491 O
) O
demonstrated O
a O
change O
in O
specificity O
following O
somatic O
mutation O
with O
binding O
of O
the O
inferred O
unmutated O
ancestor O
to O
a O
linear O
C2 O
peptide O
while O
the O
mutated O
antibody O
reacted O
only O
with O
a O
conformational O
epitope O
in O
gp120 O
Env O
. O

Genetic O
and O
biological O
characterization O
of O
new O
hepaciviruses O
infecting O
animals O
contributes O
to O
our O
understanding O
of O
the O
ultimate O
origins O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
in O
humans O
and O
dramatically O
enhances O
our O
ability O
to O
study O
its O
pathogenesis O
using O
tractable O
animal O
models O
. O

Animal O
homologs O
of O
HCV O
include O
a O
recently O
discovered O
canine O
hepacivirus O
( O
CHV O
) O
and O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
both O
viruses O
with O
largely O
undetermined O
natural O
host O
ranges O
. O

Here O
we O
used O
a O
versatile O
serology O
- O
based O
approach O
to O
determine O
the O
natural O
host O
of O
the O
only O
known O
nonprimate B
hepacivirus I
( I
NPHV I
) I
, O
CHV O
, O
which O
is O
also O
the O
closest O
phylogenetic O
relative O
of O
HCV O
. O

Recombinant O
protein O
expressed O
from O
the O
helicase O
domain O
of O
CHV O
NS3 O
was O
used O
as O
antigen O
in O
the O
luciferase B
immunoprecipitation I
system I
( I
LIPS I
) I
assay O
to O
screen O
several O
nonprimate O
animal O
species O
. O

RNA O
secondary O
structure O
prediction O
of O
the O
383 O
- O
base O
5 O
' O
untranslated O
region O
of O
NPHV O
was O
refined O
and O
extended O
through O
mapping O
of O
polymorphic O
sites O
to O
unpaired O
regions O
or O
( O
semi O
) O
covariant O
pairings O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
significantly O
increases O
the O
prevalence O
of O
type B
2 I
diabetes I
mellitus I
( I
T2DM I
) I
. O

Insulin B
receptor I
substrate I
1 I
( I
IRS I
- I
1 I
) I
plays O
a O
key O
role O
in O
insulin O
signaling O
, O
thus O
enabling O
metabolic O
regulation O
in O
mammalian O
cells O
. O

In O
this O
study O
, O
we O
further O
examined O
the O
status O
of O
total O
IRS O
- O
1 O
and O
the O
downstream O
regulation O
of O
the O
Akt O
pathway O
in O
understanding O
mTOR O
/ O
S6K1 O
signaling O
using O
HCV O
genotype O
2a O
( O
clone O
JFH1 O
) O
- O
infected O
hepatocytes O
. O

The O
status O
of O
the O
tuberous B
sclerosis I
complex I
( I
TSC I
- I
1 I
/ I
TSC I
- I
2 I
) I
was O
significantly O
decreased O
after O
HCV O
infection O
of O
human O
hepatocytes O
, O
showing O
a O
modulation O
of O
the O
downstream O
Akt O
pathway O
. O

Variants O
near O
the O
HLA O
- O
DP O
gene O
show O
the O
strongest O
genome O
- O
wide O
association O
with O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
and O
HBV O
recovery O
/ O
persistence O
in O
Asians O
. O

To O
test O
the O
effect O
of O
the O
HLA O
- O
DP O
region O
on O
outcomes O
to O
HBV O
infection O
, O
we O
sequenced O
the O
polymorphic O
HLA O
- O
DPB1 O
and O
DPA1 O
coding O
exons O
and O
the O
corresponding O
3 B
' I
untranslated I
regions I
( I
3 I
' I
UTRs I
) I
in O
662 O
individuals O
of O
European O
- O
American O
and O
African O
- O
American O
ancestry O
. O

The O
genome B
- I
wide I
association I
study I
( I
GWAS I
) I
variant O
( O
rs9277535 O
; O
550A O
/ O
G O
) O
in O
the O
3 O
' O
UTR O
of O
the O
HLA O
- O
DPB1 O
gene O
that O
associated O
most O
significantly O
with O
chronic O
hepatitis O
B O
and O
outcomes O
to O
HBV O
infection O
in O
Asians O
had O
a O
marginal O
effect O
on O
HBV O
recovery O
in O
our O
European O
- O
and O
African O
- O
American O
samples O
( O
odds O
ratio O
[ O
OR O
] O
= O
0 O
. O

However O
, O
we O
identified O
a O
novel O
variant O
in O
the O
HLA O
- O
DPB1 O
3 O
' O
UTR O
region O
, O
496A O
/ O
G O
( O
rs9277534 O
) O
, O
which O
associated O
very O
significantly O
with O
HBV O
recovery O
in O
both O
European O
and O
African O
- O
American O
populations O
( O
OR O
= O
0 O
. O

The O
496A O
/ O
G O
variant O
distinguishes O
the O
most O
protective O
HLA O
- O
DPBI O
allele O
( O
DPB1 O
* O
04 O
: O
01 O
) O
from O
the O
most O
susceptible O
( O
DPB1 O
* O
01 O
: O
01 O
) O
, O
whereas O
550A O
/ O
G O
does O
not O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replicates O
its O
DNA O
genome O
through O
reverse O
transcription O
of O
a O
pregenomic B
RNA I
( I
pgRNA I
) I
by O
using O
a O
multifunctional O
polymerase O
( O
HP O
) O
. O

A O
critical O
function O
of O
HP O
is O
its O
specific O
recognition O
of O
a O
viral O
RNA O
signal O
termed O
epsilon O
( O
H O
epsilon O
) O
located O
on O
pgRNA O
, O
which O
is O
required O
for O
specific O
packaging O
of O
pgRNA O
into O
viral O
nucleocapsids O
and O
initiation O
of O
viral O
reverse O
transcription O
. O

HP O
initiates O
reverse O
transcription O
by O
using O
itself O
as O
a O
protein O
primer O
( O
protein O
priming O
) O
and O
H O
epsilon O
as O
the O
obligatory O
template O
. O

There O
is O
increasing O
evidence O
that O
the O
function O
of O
NK O
cells O
in O
patients O
with O
chronic B
hepatitis I
B I
( I
CHB I
) I
infection O
is O
impaired O
. O

Since O
myeloid B
dendritic I
cells I
( I
mDC I
) I
are O
potent O
inducers O
of O
NK O
cells O
, O
we O
investigated O
the O
functional O
interaction O
of O
mDC O
and O
NK O
cells O
in O
CHB O
and O
the O
influence O
of O
antiviral O
therapy O
. O

Blood O
BDCA1 O
( O
+ O
) O
mDC O
and O
NK O
cells O
were O
isolated O
from O
16 O
healthy O
controls O
or O
39 O
CHB O
patients O
at O
baseline O
and O
during O
6 O
months O
of O
antiviral O
therapy O
. O

) O
C O
) O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
mDC O
were O
cocultured O
with O
NK O
cells O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
highly O
cytopathic O
virus O
being O
developed O
as O
a O
vaccine O
vector O
due O
to O
its O
ability O
to O
induce O
strong O
protective O
T O
cell O
and O
antibody O
responses O
after O
a O
single O
dose O
. O

We O
previously O
generated O
a O
VSV O
vector O
expressing O
the O
hepatitis O
B O
virus O
middle O
envelope O
surface O
glycoprotein O
( O
MS O
) O
that O
induces O
strong O
MS O
- O
specific O
T O
cell O
and O
antibody O
responses O
in O
mice O
. O

To O
better O
understand O
the O
contributions O
of O
secreted O
and O
intracellular O
protein O
to O
the O
VSV O
- O
induced O
immune O
response O
, O
we O
produced O
a O
vector O
expressing O
a O
secretion O
- O
deficient O
MS O
mutant O
( O
MSC69A O
) O
and O
compared O
the O
immunogenicity O
of O
this O
vector O
to O
that O
of O
the O
wild O
- O
type O
VSV O
- O
MS O
vector O
in O
mice O
. O

A O
variety O
of O
amino O
acid O
substitutions O
, O
such O
as O
K122I O
and O
G145R O
, O
have O
been O
identified O
around O
or O
within O
the O
a O
determinant O
of O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
, O
impair O
HBsAg O
secretion O
and O
antibody O
binding O
, O
and O
may O
be O
responsible O
for O
immune O
escape O
in O
patients O
. O

Mice O
preimmunized O
with O
wild B
- I
type I
HBsAg I
( I
wtHBsAg I
) I
or O
variant B
HBsAg I
( I
vtHBsAg I
) I
were O
challenged O
by O
hydrodynamic B
injection I
( I
HI I
) I
with O
a O
replication O
- O
competent O
hepatitis B
B I
virus I
( I
HBV I
) I
clone O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
one O
of O
the O
main O
causes O
of O
chronic O
liver O
disease O
. O

HCV O
replication O
was O
determined O
by O
detection O
of O
the O
HCV O
RNA O
replicative O
( O
negative O
) O
strand O
and O
viral O
proteins O
, O
while O
specific O
antibodies O
, O
knocking O
down O
gene O
expression O
and O
making O
otherwise O
- O
resistant O
cells O
prone O
to O
HCV O
, O
were O
employed O
to O
identify O
a O
receptor O
molecule O
determining O
T O
lymphocyte O
permissiveness O
to O
HCV O
infection O
. O

Blocking O
of O
T O
cell O
CD5 O
with O
antibody O
or O
silencing O
with O
specific O
short B
hairpin I
RNA I
( I
shRNA I
) I
decreased O
cell O
susceptibility O
to O
HCV O
, O
while O
increasing O
CD5 O
expression O
by O
mitogen O
stimulation O
had O
the O
opposite O
effect O
. O

The O
recent O
outbreak O
of O
enterovirus B
71 I
( I
EV71 I
) I
infected O
millions O
of O
children O
and O
caused O
over O
1 O
, O
000 O
deaths O
. O

Interferons B
( I
IFNs I
) I
have O
been O
successfully O
applied O
to O
treat O
patients O
with O
hepatitis O
B O
and O
C O
viral O
infections O
for O
decades O
but O
have O
failed O
to O
treat O
EV71 O
infections O
. O

Here O
, O
we O
provide O
the O
evidence O
that O
EV71 O
antagonizes O
type O
I O
IFN O
signaling O
by O
reducing O
the O
level O
of O
interferon B
receptor I
1 I
( I
IFNAR1 I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
leads O
to O
progressive O
liver O
disease O
and O
hepatocellular O
carcinoma O
. O

Multiple O
nuclear O
receptors O
, O
including O
hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
, O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
plus O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
, O
RXR O
alpha O
plus O
farnesoid B
X I
receptor I
alpha I
( I
FXR I
alpha I
) I
, O
liver B
receptor I
homolog I
1 I
( I
LRH1 I
) I
, O
and O
estrogen B
- I
related I
receptors I
( I
ERRs I
) I
, O
have O
been O
shown O
to O
support O
efficient O
viral O
biosynthesis O
in O
nonhepatoma O
cells O
in O
the O
absence O
of O
additional O
liver O
- O
enriched O
transcription O
factors O
. O

Although O
HNF4 O
alpha O
has O
been O
shown O
to O
be O
critical O
for O
the O
developmental O
expression O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
biosynthesis O
in O
the O
liver O
, O
the O
relative O
importance O
of O
the O
various O
nuclear O
receptors O
capable O
of O
supporting O
viral O
transcription O
and O
replication O
in O
the O
adult O
in O
vivo O
has O
not O
been O
clearly O
established O
. O

To O
investigate O
the O
role O
of O
the O
nuclear O
receptor O
FXR O
and O
the O
corepressor O
small B
heterodimer I
partner I
( I
SHP I
) I
in O
viral O
biosynthesis O
in O
vivo O
, O
SHP O
- O
expressing O
and O
SHP O
- O
null O
HBV O
transgenic O
mice O
were O
fed O
a O
bile O
acid O
- O
supplemented O
diet O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
an O
important O
pathogen O
that O
chronically O
infects O
more O
men O
than O
women O
. O

To O
understand O
the O
molecular O
mechanism O
of O
this O
gender O
disparity O
, O
we O
analyzed O
HBV O
replication O
in O
transgenic O
mice O
that O
carried O
the O
HBV O
genome O
with O
or O
without O
the O
ability O
to O
express O
the O
HBV B
X I
protein I
( I
HBx I
) I
. O

We O
found O
that O
gender O
had O
no O
effect O
on O
HBV B
surface I
antigen I
( I
HBsAg I
) I
, O
DNA O
, O
and O
RNA O
levels O
in O
mice O
before O
puberty O
, O
but O
its O
effect O
on O
HBV O
after O
puberty O
was O
apparent O
, O
with O
HBV O
replicating O
approximately O
twice O
more O
efficiently O
in O
male O
mice O
than O
in O
female O
mice O
whether O
or O
not O
HBx O
was O
expressed O
. O

The O
introduction O
of O
HBV O
genomic O
DNA O
and O
androgen B
receptor I
( I
AR I
) I
short I
hairpin I
RNA I
( I
shRNA I
) I
into O
the O
liver O
of O
naive O
mice O
by O
hydrodynamic O
injection O
revealed O
that O
the O
effect O
of O
androgen O
on O
HBV O
was O
dependent O
on O
its O
receptor O
, O
which O
apparently O
could O
also O
stimulate O
HBV O
replication O
via O
an O
androgen O
- O
independent O
pathway O
. O

Further O
studies O
indicated O
that O
the O
two O
previously O
identified O
androgen B
response I
elements I
( I
ARFs I
) I
in O
the O
HBV O
genome O
could O
indeed O
mediate O
the O
effect O
of O
androgen O
on O
HBV O
RNA O
transcription O
and O
DNA O
replication O
in O
vivo O
. O

The O
robust O
cell O
culture O
systems O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
limited O
to O
those O
using O
cell O
culture O
- O
adapted O
clones O
( O
HCV O
in O
cell O
culture O
[ O
HCVcc O
] O
) O
and O
cells O
derived O
from O
the O
human O
hepatoma O
cell O
line O
Huh7 O
. O

Among O
the O
cell O
lines O
that O
we O
examined O
, O
Hep3B O
cells O
stably O
expressing O
miR122 O
( O
Hep3B O
/ O
miR122 O
) O
exhibited O
a O
significant O
enhancement O
of O
HCVcc O
propagation O
. O

Antiviral O
CD8 O
( O
+ O
) O
T O
cells O
are O
a O
key O
component O
of O
the O
adaptive O
immune O
system O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

For O
the O
development O
of O
immune O
therapies O
, O
it O
is O
essential O
to O
understand O
how O
CD8 O
( O
+ O
) O
T O
cells O
contribute O
to O
clearance O
of O
infection O
and O
why O
they O
fail O
so O
often O
. O

We O
previously O
identified O
two O
HLA O
- O
B O
* O
15 O
- O
restricted O
CD8 O
( O
+ O
) O
epitopes O
in O
NS5B O
( O
LLRHHNMVY2450 O
- O
2458 O
and O
SQRQKKVTF O
( O
2466 O
- O
2474 O
) O
) O
, O
based O
on O
sequence O
analysis O
of O
a O
large O
HCV O
genotype O
1b O
outbreak O
. O

Covariation O
analysis O
of O
sequences O
from O
the O
database O
confirmed O
a O
significant O
association O
between O
escape O
mutations O
inside O
one O
of O
the O
epitopes O
( O
H2454R O
and O
M2456L O
) O
and O
substitutions O
in O
the O
epitope O
flanking O
region O
( O
S2439T O
and O
K2440Q O
) O
. O

plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
respond O
to O
viral O
infection O
by O
production O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
proinflammatory O
cytokines O
, O
and O
cell O
differentiation O
. O

The O
elimination O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
more O
than O
50 O
% O
of O
chronically O
infected O
patients O
by O
treatment O
with O
IFN O
- O
alpha O
suggests O
that O
pDCs O
can O
play O
an O
important O
role O
in O
the O
control O
of O
HCV O
infection O
. O

To O
further O
investigate O
the O
molecular O
mechanism O
of O
HCV O
sensing O
, O
we O
studied O
whether O
exposure O
of O
pDCs O
to O
HCV O
- O
infected O
hepatoma O
cells O
activates O
, O
in O
parallel O
to O
interferon B
regulatory I
factor I
7 I
( I
IRF7 I
) I
- O
mediated O
production O
of O
IFN O
- O
alpha O
, O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
- O
dependent O
pDC O
responses O
, O
such O
as O
expression O
of O
the O
differentiation O
markers O
CD40 O
, O
CCR7 O
, O
CD86 O
, O
and O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
related O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
and O
secretion O
of O
the O
proinflammatory O
cytokines O
TNF O
- O
alpha O
and O
interleukin B
6 I
( I
IL I
- I
6 I
) I
. O

In O
contrast O
, O
CpG O
- O
A O
and O
CpG O
- O
B O
induced O
production O
of O
TNF O
- O
alpha O
and O
IL O
- O
6 O
in O
pDCs O
exposed O
to O
the O
HCV O
- O
infected O
hepatoma O
cells O
, O
showing O
that O
cell O
- O
associated O
virus O
did O
not O
actively O
inhibit O
Toll B
- I
like I
receptor I
( I
TLR I
) I
- O
mediated O
NF O
- O
kappa O
B O
phosphorylation O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
T O
- O
cell O
responses O
are O
important O
in O
the O
natural O
history O
of O
HBV O
infection O
. O

We O
aimed O
to O
identify O
novel O
HBV O
T O
- O
cell O
epitopes O
by O
examining O
the O
relationship O
between O
HBV O
sequence O
variation O
and O
the O
human B
leukocyte I
antigen I
( I
HLA I
) I
type O
in O
a O
large O
prospective O
clinic O
- O
based O
cohort O
of O
Asian O
patients O
with O
chronic O
HBV O
infection O
recruited O
in O
Australia O
and O
China O
( O
n O
= O
119 O
) O
. O

High O
- O
resolution O
4 O
- O
digit O
HLA O
class O
I O
and O
II O
typing O
and O
full O
- O
length O
HBV O
sequencing O
were O
undertaken O
for O
treatment O
- O
naive O
individuals O
( O
52 O
% O
with O
genotype O
B O
, O
48 O
% O
with O
genotype O
C O
, O
63 O
% O
HBV O
e O
antigen O
[ O
HBeAg O
] O
positive O
) O
. O

Statistically O
significant O
associations O
between O
HLA O
types O
and O
HBV O
sequence O
variation O
were O
identified O
( O
n O
= O
49 O
) O
at O
41 O
sites O
in O
the O
HBV O
genome O
. O

Among O
the O
regions O
that O
could O
be O
tested O
, O
HLA O
binding O
was O
predicted O
for O
14 O
/ O
18 O
( O
78 O
% O
) O
. O

Enhanced O
viral O
adaptation O
( O
defined O
as O
the O
presence O
of O
the O
relevant O
HLA O
and O
the O
escaped O
amino O
acid O
) O
was O
independently O
associated O
with O
HBeAg O
- O
negative O
disease O
( O
P O
= O
0 O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
are O
associated O
with O
the O
development O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

The O
HBV B
X I
protein I
( I
HBx I
) I
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
HBV O
- O
associated O
HCC O
. O

The O
studies O
described O
here O
show O
that O
HBx O
stimulates O
calcium O
entry O
into O
cells O
, O
resulting O
in O
an O
increased O
plateau O
level O
of O
inositol O
1 O
, O
4 O
, O
5 O
- O
triphosphate O
( O
IP3 O
) O
- O
linked O
calcium O
signals O
. O

This O
increased O
calcium O
plateau O
can O
be O
inhibited O
by O
blocking O
mitochondrial O
calcium O
uptake O
and O
store B
- I
operated I
calcium I
entry I
( I
SOCE I
) I
. O

Previous O
reports O
have O
shown O
that O
cholesterol O
depletion O
of O
the O
membrane O
envelope O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
impairs O
viral O
infection O
of O
target O
cells O
. O

A O
potential O
function O
of O
this O
lipid O
in O
later O
steps O
of O
the O
viral O
life O
cycle O
remained O
controversial O
, O
with O
secretion O
of O
virions O
and O
subviral B
particles I
( I
SVP I
) I
being O
either O
inhibited O
or O
not O
affected O
, O
depending O
on O
the O
experimental O
approach O
employed O
to O
decrease O
the O
intracellular O
cholesterol O
level O
. O

Growing O
HBV O
- O
producing O
cells O
with O
lipoprotein B
- I
depleted I
serum I
( I
LPDS I
) I
resulted O
in O
an O
important O
reduction O
of O
the O
amount O
of O
cholesterol O
within O
24 O
h O
of O
treatment O
( O
about O
40 O
% O
) O
. O

HBV O
secretion O
was O
significantly O
inhibited O
in O
cholesterol O
- O
depleted O
cells O
( O
by O
similar O
to O
80 O
% O
) O
, O
while O
SVP O
release O
remained O
unaffected O
. O

Recent O
studies O
indicate O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
may O
induce O
autophagy O
to O
enhance O
its O
replication O
in O
cell O
cultures O
. O

rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
causes O
lethal O
fulminant O
hepatitis O
closely O
resembling O
acute B
liver I
failure I
( I
ALF I
) I
in O
humans O
. O

In O
this O
study O
, O
we O
investigated O
whether O
cardiotrophin B
- I
1 I
( I
CT I
- I
1 I
) I
, O
a O
cytokine O
with O
hepatoprotective O
properties O
, O
could O
attenuate O
liver O
damage O
and O
prolong O
survival O
in O
virus O
- O
induced O
ALF O
. O

Twenty O
- O
four O
rabbits O
were O
infected O
with O
2 O
x O
10 O
( O
4 O
) O
hemagglutination O
units O
of O
RHDV O
. O

Twelve O
received O
five O
doses O
of O
CT O
- O
1 O
( O
100 O
mu O
g O
/ O
kg O
) O
starting O
at O
12 O
h B
postinfection I
( I
hpi I
) I
( O
the O
first O
three O
doses O
every O
6 O
h O
and O
then O
two O
additional O
doses O
at O
48 O
and O
72 O
hpi O
) O
, O
while O
the O
rest O
received O
saline O
. O

Another O
cohort O
( O
n O
= O
22 O
) O
was O
infected O
and O
treated O
similarly O
, O
but O
animals O
were O
sacrificed O
at O
30 O
and O
36 O
hpi O
to O
analyze O
liver O
histology O
, O
viral O
load O
, O
and O
the O
expression O
of O
factors O
implicated O
in O
liver O
damage O
and O
repair O
. O

The O
pregenomic B
RNA I
( I
pgRNA I
) I
of O
hepatitis B
B I
virus I
( I
HBV I
) I
serves O
as O
the O
messenger O
for O
both O
core O
and O
P O
proteins O
, O
with O
the O
downstream O
P O
gene O
translated O
by O
ribosomal O
leaky O
scanning O
. O

It O
has O
a O
36 O
- O
nucleotide B
( I
nt I
) I
insertion O
in O
the O
5 O
' O
end O
of O
the O
core O
gene O
, O
adding O
12 O
residues O
to O
the O
core O
protein O
. O

Here O
, O
we O
investigate O
the O
mechanisms O
of O
trafficking O
and O
export O
for O
the O
hepadnaviruses O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
in O
polarized O
hepatocyte O
- O
derived O
cell O
lines O
and O
primary O
duck O
hepatocytes O
. O

Coinfection O
with O
human B
immunodeficiency I
virus I
type I
- I
1 I
( I
HIV I
- I
1 I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
global O
problem O
that O
is O
more O
prevalent O
in O
injection O
drug O
users O
because O
they O
have O
a O
higher O
risk O
for O
acquiring O
both O
viruses O
. O

Morphine O
( O
the O
bioactive O
product O
of O
heroin O
) O
, O
HIV O
- O
1 O
Tat O
and O
the O
MN O
strain O
gp120 O
( O
gp120 O
( O
MN O
) O
) O
proteins O
, O
and O
X4 O
HIV O
- O
1 O
( O
LAI O
/ O
IIIB O
) O
and O
R5 O
HIV O
- O
1 O
( O
SF162 O
) O
isolates O
were O
used O
to O
study O
the O
mechanisms O
of O
disease O
progression O
in O
HCV O
( O
JFH1 O
) O
- O
infected O
Huh7 O
. O

HCV O
increased O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
release O
and O
augmented O
production O
of O
reactive B
oxygen I
species I
( I
ROS I
) I
, O
nitric B
oxide I
( I
NO I
) I
, O
and O
3 B
- I
nitrotyrosine I
( I
3 I
- I
NT I
) I
in O
Huh7 O
. O

covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
the O
nuclear O
form O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
is O
synthesized O
by O
repair O
of O
the O
relaxed B
circular I
( I
RC I
) I
DNA O
genome O
. O

Ablation O
of O
expression O
of O
the O
envelope O
proteins O
led O
to O
an O
increase O
( O
> O
6 O
- O
fold O
) O
in O
the O
level O
of O
cccDNA O
. O

Subsequent O
restoration O
of O
envelope O
protein O
expression O
led O
to O
a O
decrease O
( O
> O
50 O
% O
) O
in O
the O
level O
of O
cccDNA O
, O
which O
inversely O
correlated O
with O
the O
level O
of O
the O
envelope O
proteins O
. O

Although O
human B
coronavirus I
OC43 I
- I
OC43 I
( I
HCoV I
- I
OC43 I
) I
is O
the O
coronavirus O
most O
commonly O
associated O
with O
human O
infections O
, O
little O
is O
known O
about O
its O
molecular O
epidemiology O
and O
evolution O
. O

Twenty O
- O
nine O
HCoV O
- O
OC43 O
strains O
from O
nasopharyngeal O
aspirates O
, O
collected O
from O
2004 O
to O
2011 O
, O
were O
subjected O
to O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
spike O
, O
and O
nucleocapsid O
gene O
analysis O
. O

This O
suggested O
the O
presence O
of O
four O
HCoV O
- O
OC43 O
genotypes O
( O
A O
to O
D O
) O
, O
with O
genotype O
D O
most O
likely O
arising O
from O
recombination O
. O

The O
V3 O
epitope O
is O
a O
known O
target O
for O
HIV O
- O
1 O
neutralizing B
antibodies I
( I
NAbs I
) I
, O
and O
V3 O
- O
scaffold O
fusion O
proteins O
used O
as O
boosting O
immunogens O
after O
gp120 O
DNA O
priming O
were O
previously O
shown O
to O
induce O
NAbs O
in O
rabbits O
. O

Rabbits O
were O
primed O
with O
codon O
- O
optimized O
clade O
C O
gp120 O
DNA O
and O
boosted O
with O
one O
of O
five O
V3 O
- O
cholera O
toxin O
B O
fusion O
proteins O
( O
V3 O
- O
CTBs O
) O
or O
with O
double O
combinations O
of O
these O
. O

Double O
combinations O
of O
V3 O
- O
CTB O
immunogens O
generally O
induced O
more O
broad O
and O
potent O
NAbs O
than O
did O
boosts O
with O
single O
V3 O
- O
CTB O
immunogens O
, O
with O
the O
most O
potent O
and O
broad O
NAbs O
elicited O
with O
the O
V3 O
- O
CTB O
carrying O
the O
consensus O
V3 B
of I
clade I
C I
( I
V3C I
- I
CTB I
) I
, O
or O
with O
double O
combinations O
of O
V3 O
- O
CTB O
immunogens O
that O
included O
V3C O
- O
CTB O
. O

Neutralization O
of O
tier O
1 O
and O
2 O
pseudoviruses O
from O
clades O
AG O
, O
B O
, O
and O
C O
and O
of O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
- O
grown O
primary O
viruses O
from O
clades O
A O
, O
AG O
, O
and O
B O
was O
achieved O
, O
demonstrating O
that O
priming O
with O
gp120 O
DNA O
followed O
by O
boosts O
with O
V3 O
- O
scaffold O
immunogens O
effectively O
elicits O
cross O
- O
clade O
NAbs O
. O

In O
this O
study O
, O
we O
analyzed O
the O
mechanisms O
underlying O
the O
activation O
of O
natural B
killer I
( I
NK I
) I
cells O
and O
their O
potential O
role O
in O
adaptive O
immunity O
during O
DNA O
- O
based O
immunization O
against O
hepatitis O
B O
virus O
surface O
antigen O
in O
mice O
. O

We O
observed O
that O
the O
mature O
Mac O
- O
1 O
( O
+ O
) O
CD27 O
( O
- O
) O
NK O
cell O
subset O
increased O
in O
the O
liver O
of O
mice O
early O
after O
DNA O
injection O
, O
whereas O
the O
number O
of O
the O
less O
mature O
Mac O
- O
1 O
( O
+ O
) O
CD27 O
( O
+ O
) O
NK O
cells O
in O
the O
liver O
and O
spleen O
was O
significantly O
reduced O
. O

During O
cell O
entry O
, O
native O
poliovirus O
( O
160S O
) O
converts O
to O
a O
cell O
- O
entry O
intermediate O
( O
135S O
) O
particle O
, O
resulting O
in O
the O
externalization O
of O
capsid O
proteins O
VP4 O
and O
the O
amino O
terminus O
of O
VP1 O
( O
residues O
1 O
to O
53 O
) O
. O

Externalization O
of O
these O
entities O
is O
followed O
by O
release O
of O
the O
RNA O
genome O
( O
uncoating O
) O
, O
leaving O
an O
empty O
( O
80S O
) O
particle O
. O

The O
antigen O
- O
binding O
fragment O
( O
Fab O
) O
of O
a O
monospecific O
peptide O
1 O
( O
P1 O
) O
antibody O
, O
which O
was O
raised O
against O
a O
peptide O
corresponding O
to O
amino O
- O
terminal O
residues O
24 O
to O
40 O
of O
VP1 O
, O
was O
utilized O
to O
track O
the O
location O
of O
the O
amino O
terminus O
of O
VP1 O
in O
the O
135S O
and O
80S O
states O
of O
poliovirus O
particles O
via O
cryogenic B
electron I
microscopy I
( I
cryo I
- I
EM I
) I
and O
three O
- O
dimensional O
image O
reconstruction O
. O

A O
vigorous O
CD8 O
T O
cell O
response O
was O
observed O
early O
following O
the O
onset O
of O
clinical O
symptoms O
, O
determined O
by O
the O
presence O
of O
high O
numbers O
of O
Ki67 O
( O
+ O
) O
CD38 O
( O
+ O
) O
HLA O
- O
DR O
( O
+ O
) O
effector O
CD8 O
T O
cells O
. O

Virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
with O
high O
levels O
of O
functional O
avidity O
have O
been O
associated O
with O
viral O
clearance O
in O
hepatitis O
C O
virus O
infection O
and O
with O
enhanced O
antiviral O
protective O
immunity O
in O
animal O
models O
. O

T B
- I
cell I
receptor I
( I
TCR I
) I
analyses O
revealed O
narrower O
TCR O
repertoires O
in O
higher O
- O
avidity O
CTL O
populations O
, O
which O
were O
dominated O
by O
public O
TCR O
sequences O
in O
HIV O
controllers O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
often O
associated O
with O
type O
2 O
diabetes O
. O

5 O
cells O
either O
harboring O
HCV O
- O
1b O
RNA O
replicons O
or O
infected O
with O
HCV O
- O
2a O
, O
we O
showed O
that O
HCV O
transcriptionally O
upregulated O
the O
genes O
for O
phosphoenolpyruvate B
carboxykinase I
( I
PEPCK I
) I
and O
glucose B
6 I
- I
phosphatase I
( I
G6Pase I
) I
, O
the O
rate O
- O
limiting O
enzymes O
for O
hepatic O
gluconeogenesis O
. O

In O
this O
way O
, O
HCV O
enhanced O
the O
cellular O
production O
of O
glucose B
6 I
- I
phosphate I
( I
G6P I
) I
and O
glucose O
. O

PEPCK O
and O
G6Pase O
gene O
expressions O
are O
controlled O
by O
the O
transcription O
factor O
forkhead B
box I
O1 I
( I
FoxO1 I
) I
. O

By O
using O
specific O
inhibitors O
of O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
and O
reactive B
oxygen I
species I
( I
ROS I
) I
, O
we O
demonstrated O
that O
HCV O
infection O
induced O
JNK O
activation O
via O
increased O
mitochondrial O
ROS O
production O
, O
resulting O
in O
decreased O
FoxO1 O
phosphorylation O
, O
FoxO1 O
nuclear O
accumulation O
, O
and O
, O
eventually O
, O
increased O
glucose O
production O
. O

In O
all O
hepadnaviruses O
, O
protein O
- O
primed O
reverse O
transcription O
of O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
is O
initiated O
by O
binding O
of O
the O
viral O
polymerase O
, O
P O
protein O
, O
to O
the O
epsilon O
RNA O
element O
. O

Complex O
formation O
triggers O
pgRNA O
encapsidation O
and O
the O
epsilon O
- O
templated O
synthesis O
of O
a O
DNA O
oligonucleotide O
( O
priming O
) O
that O
serves O
to O
generate O
minus O
- O
strand O
DNA O
. O

In O
vitro O
systems O
for O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
yielded O
important O
insights O
into O
the O
priming O
mechanism O
, O
yet O
their O
relevance O
in O
infection O
is O
largely O
unexplored O
. O

Moreover O
, O
additional O
functions O
encoded O
in O
the O
DHBV O
epsilon O
( O
D O
epsilon O
) O
sequence O
could O
affect O
in O
vivo O
fitness O
. O

All O
three O
showed O
enhanced O
priming O
and O
replication O
competence O
in O
vitro O
, O
and O
in O
one O
, O
DHBV B
e I
antigen I
( I
DHBeAg I
) I
production O
was O
restored O
. O

Initiation O
of O
reverse O
transcription O
in O
hepadnaviruses O
is O
accomplished O
by O
a O
unique O
protein O
- O
priming O
mechanism O
whereby O
a O
specific O
Y O
residue O
in O
the O
terminal B
protein I
( I
TP I
) I
domain O
of O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
acts O
as O
a O
primer O
to O
initiate O
DNA O
synthesis O
, O
which O
is O
carried O
out O
by O
the O
RT O
domain O
of O
the O
same O
protein O
. O

When O
separate O
TP O
and O
RT O
domains O
from O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
RT O
protein O
were O
tested O
in O
a O
trans O
- O
complementation O
assay O
in O
vitro O
, O
the O
RT O
domain O
could O
also O
serve O
, O
unexpectedly O
, O
as O
a O
protein O
primer O
for O
DNA O
synthesis O
, O
as O
could O
a O
TP O
mutant O
lacking O
the O
authentic O
primer O
Y O
( O
Y96 O
) O
residue O
. O

The O
cryptic O
priming O
site O
( O
s O
) O
in O
TP O
was O
found O
to O
be O
S O
/ O
T O
, O
while O
those O
in O
the O
RT O
domain O
were O
Y O
and O
S O
/ O
T O
. O

Similarly O
, O
we O
compared O
our O
rate O
estimates O
for O
the O
RNA O
polymerase O
3D O
( O
pol O
) O
gene O
from O
five O
viruses O
to O
four O
published O
3D O
( O
pol O
) O
rates O
. O

The O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
reverse O
transcriptase O
( O
P O
) O
is O
translated O
from O
the O
downstream O
position O
on O
a O
bicistronic O
mRNA O
, O
called O
the O
pregenomic O
RNA O
, O
through O
a O
poorly O
characterized O
ribosomal O
shunt O
. O

The O
E2 O
glycoprotein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
mediates O
viral O
attachment O
and O
entry O
into O
target O
hepatocytes O
and O
elicits O
neutralizing O
antibodies O
in O
infected O
patients O
. O

To O
characterize O
the O
structural O
and O
functional O
basis O
of O
HCV O
neutralization O
, O
we O
generated O
a O
novel O
panel O
of O
78 O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
E2 O
proteins O
from O
genotype O
1a O
and O
2a O
HCV O
strains O
. O

36 O
, O
showed O
markedly O
reduced O
binding O
when O
amino O
acids O
within O
hypervariable B
region I
1 I
( I
HVR1 I
) I
and O
at O
sites O
similar O
to O
100 O
to O
200 O
residues O
away O
were O
changed O
, O
suggesting O
binding O
to O
a O
discontinuous O
epitope O
. O

The O
development O
of O
therapeutic O
vaccines O
for O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
has O
been O
hampered O
by O
host O
immune O
tolerance O
and O
the O
generally O
low O
magnitude O
and O
inconsistent O
immune O
responses O
to O
conventional O
vaccines O
and O
proposed O
new O
delivery O
methods O
. O

Electroporation B
( I
EP I
) I
for O
plasmid B
DNA I
( I
pDNA I
) I
vaccine O
delivery O
has O
demonstrated O
the O
enhanced O
immunogenicity O
of O
HBV O
antigens O
in O
various O
animal O
models O
. O

In O
the O
present O
study O
, O
the O
efficiency O
of O
the O
EP O
- O
based O
delivery O
of O
pDNA O
expressing O
various O
reporter O
genes O
first O
was O
evaluated O
in O
normal O
woodchucks O
, O
and O
then O
the O
immunogenicity O
of O
an O
analog O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
surface O
antigen O
( O
WHsAg O
) O
pDNA O
vaccine O
was O
studied O
in O
this O
model O
. O

Herpes B
Simplex I
Virus I
( I
HSV I
) I
infection O
is O
a O
classic O
example O
of O
latent O
viral O
infection O
in O
humans O
and O
experimental O
animal O
models O
. O

The O
HSV O
- O
1 O
latency B
- I
associated I
transcript I
( I
LAT I
) I
plays O
a O
major O
role O
in O
the O
HSV O
- O
1 O
latency O
reactivation O
cycle O
and O
thus O
in O
recurrent O
disease O
. O

Whether O
the O
presence O
of O
LAT O
leads O
to O
generation O
of O
dysfunctional O
T O
cell O
responses O
in O
the O
trigeminal B
ganglia I
( I
TG I
) I
of O
latently O
infected O
mice O
is O
not O
known O
. O

To O
address O
this O
issue O
, O
we O
used O
LAT O
- O
positive O
[ O
LAT O
( O
+ O
) O
] O
and O
LAT O
- O
deficient O
[ O
LAT O
( O
- O
) O
] O
viruses O
to O
evaluate O
the O
effect O
of O
LAT O
on O
CD8 O
T O
cell O
exhaustion O
in O
TG O
of O
latently O
infected O
mice O
. O

The O
amount O
of O
latency O
as O
determined O
by O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
of O
viral O
DNA O
in O
total O
TG O
extracts O
was O
3 O
- O
fold O
higher O
with O
LAT O
( O
+ O
) O
than O
with O
LAT O
( O
- O
) O
virus O
. O

These O
results O
suggested O
that O
LAT O
( O
+ O
) O
TG O
contain O
both O
more O
CD8 O
( O
+ O
) O
T O
cells O
and O
more O
CD8 O
( O
+ O
) O
T O
cells O
expressing O
the O
exhaustion O
markers O
PD O
- O
1 O
and O
Tim O
- O
3 O
. O

This O
was O
confirmed O
by O
flow O
cytometry O
analyses O
of O
expression O
of O
CD3 O
/ O
CD8 O
/ O
PD O
- O
1 O
/ O
Tim O
- O
3 O
, O
HSV O
- O
1 O
, O
CD8 O
( O
+ O
) O
T O
cell O
pentamer O
( O
specific O
for O
a O
peptide O
derived O
from O
residues O
498 O
to O
505 O
of O
glycoprotein O
B O
[ O
gB O
( O
498 O
- O
505 O
) O
] O
) O
, O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

Together O
, O
these O
results O
may O
suggest O
that O
both O
PD O
- O
1 O
and O
Tim O
- O
3 O
are O
mediators O
of O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
and O
latency O
in O
HSV O
- O
1 O
infection O
. O

The O
Coronavirus B
( I
CoV I
) I
discontinuous O
transcription O
mechanism O
is O
driven O
by O
long O
- O
distance O
RNA O
- O
RNA O
interactions O
between O
transcription B
- I
regulating I
sequences I
( I
TRSs I
) I
located O
at O
the O
5 O
' O
terminal O
leader O
( O
TRS O
- O
L O
) O
and O
also O
preceding O
each O
mRNA O
- O
coding O
sequence O
( O
TRS O
- O
B O
) O
. O

polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
was O
reproducibly O
identified O
in O
association O
with O
positive O
- O
sense O
RNAs O
of O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
TRS O
- O
L O
and O
TRS O
- O
B O
by O
affinity O
chromatography O
and O
mass O
spectrometry O
. O

Silencing O
the O
expression O
of O
PTB O
with O
small O
interfering O
RNA O
in O
two O
cell O
lines O
( O
Huh7 O
and O
HEK O
293T O
) O
led O
to O
a O
significant O
increase O
of O
up O
to O
4 O
- O
fold O
in O
mRNA O
levels O
and O
virus O
titer O
, O
indicating O
a O
negative O
effect O
of O
PTB O
on O
CoV O
RNA O
accumulation O
. O

During O
CoV O
infection O
, O
PTB O
relocalized O
from O
the O
nucleus O
to O
novel O
cytoplasmic O
structures O
different O
from O
replication O
- O
transcription O
sites O
in O
which O
stress O
granule O
markers O
T B
- I
cell I
intracellular I
antigen I
- I
1 I
( I
TIA I
- I
1 I
) I
and O
TIA B
- I
1 I
- I
related I
protein I
( I
TIAR I
) I
colocalized O
. O

Reduction O
of O
CD8 O
( O
+ O
) O
T O
cell O
epitopes O
is O
one O
of O
the O
common O
strategies O
used O
for O
this O
purpose O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
member O
of O
the O
Hepadnaviridae O
family O
, O
has O
four O
open O
reading O
frames O
, O
with O
about O
50 O
% O
overlap O
between O
the O
genes O
they O
encode O
. O

We O
computed O
the O
CD8 O
( O
+ O
) O
T O
cell O
epitope O
density O
within O
HBV O
proteins O
and O
the O
mutations O
within O
the O
epitopes O
. O

Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
is O
implicated O
in O
the O
pathogenesis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
associated O
liver O
diseases O
. O

5 O
cells O
to O
produce O
a O
quasispecies O
of O
hypervariable B
region I
1 I
( I
HVR1 I
) I
that O
mimicked O
that O
circulating O
in O
vivo O
. O

An O
enhancement O
of O
NS2 O
- O
3 O
processing O
has O
been O
described O
as O
a O
major O
difference O
between O
the O
noncytopathogenic O
( O
non O
- O
CP O
) O
and O
the O
cytopathogenic B
( I
cp I
) I
biotypes O
of O
pestiviruses O
. O

The O
effects O
of O
accelerated O
versus O
delayed O
NS2 O
- O
3 O
processing O
on O
the O
maturation O
of O
the O
other O
nonstructural B
proteins I
( I
nsp I
) I
have O
never O
been O
compared O
. O

In O
this O
study O
, O
we O
analyzed O
the O
proteolytic O
processing O
of O
NSP O
in O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
. O

Key O
to O
the O
investigation O
was O
a O
panel O
of O
newly O
developed O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
facilitated O
monitoring O
of O
all O
nonstructural O
proteins O
involved O
in O
virus O
replication O
( O
NS2 O
, O
NS3 O
, O
NS4A O
, O
NS5A O
, O
and O
NS5B O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
- O
related O
research O
has O
been O
hampered O
by O
the O
lack O
of O
appropriate O
small O
- O
animal O
models O
. O

It O
has O
been O
reported O
that O
tree O
shrews O
, O
or O
tupaias O
( O
Tupaia O
belangeri O
) O
, O
can O
be O
infected O
with O
serum O
- O
derived O
HCV O
. O

Human O
CD81 O
, O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
, O
claudin B
1 I
( I
CLDN1 I
) I
, O
and O
occludin B
( I
OCLN I
) I
are O
considered O
essential O
receptors O
or O
coreceptors O
for O
HCV O
cell O
entry O
. O

Both O
CD81 O
and O
SR O
- O
BI O
of O
tupaia O
were O
found O
to O
be O
able O
to O
bind O
with O
HCV O
envelope B
protein I
2 I
( I
E2 I
) I
. O

In O
comparison O
with O
human O
CD81 O
, O
tupaia O
CD81 O
exhibited O
stronger O
binding O
activity O
with O
E2 O
and O
increased O
HCV B
pseudoparticle I
( I
HCVpp I
) I
cell O
entry O
2 O
- O
fold O
. O

HCVpp O
of O
diverse O
genotypes O
were O
able O
to O
infect O
Primary B
Tupaia I
hepatocytes I
( I
PTHs I
) I
, O
and O
this O
infection O
could O
be O
blocked O
by O
either O
anti O
- O
CD81 O
or O
anti O
- O
SR O
- O
BI O
. O

PTHs O
could O
be O
infected O
by O
cell O
culture O
- O
produced O
HCV O
( O
HCVcc O
) O
and O
did O
produce O
infectious O
progeny O
virus O
in O
culture O
supernatant O
. O

Virus O
- O
specific O
CD8 O
T O
cells O
are O
activated O
when O
their O
T B
- I
cell I
receptors I
( I
TCRs I
) I
recognize O
the O
specific O
viral O
peptide O
/ O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
( O
pMHC O
) O
complexes O
present O
on O
the O
surface O
of O
infected O
cells O
. O

To O
evaluate O
these O
possibilities O
, O
we O
created O
a O
monoclonal O
antibody O
able O
to O
specifically O
recognize O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
epitope O
( O
Env O
at O
positions O
183 O
to O
91 O
[ O
Env183 O
- O
91 O
] O
) O
presented O
by O
the O
HLA O
- O
A201 O
molecule O
, O
and O
we O
tested O
its O
ability O
to O
recognize O
HBV O
- O
infected O
hepatocytes O
and O
to O
deliver O
a O
cargo O
to O
a O
specific O
target O
. O

Native O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
spontaneously O
assembles O
into O
22 O
- O
nm O
subviral O
particles O
. O

The O
membrane B
- I
proximal I
exposed I
region I
( I
MPER I
) I
of O
gp41 O
is O
an O
important O
target O
of O
broadly O
reactive O
neutralizing O
antibodies O
against O
HIV O
- O
1 O
, O
and O
HBsAg O
- O
MPER O
particles O
may O
provide O
a O
good O
platform O
for O
future O
vaccine O
development O
. O

The O
immunologic O
mechanisms O
underlying O
the O
faster O
progression O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
disease O
in O
the O
presence O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
coinfection O
are O
not O
clearly O
understood O
. O

Our O
search O
for O
amino O
acid O
sequence O
homology O
between O
the O
HCV O
and O
HIV O
proteomes O
revealed O
two O
similar O
HLA O
- O
A2 O
- O
restricted O
epitopes O
, O
HIV O
- O
Gag O
( O
SLYNTVATL O
[ O
HIV O
- O
SL9 O
] O
) O
and O
HCV O
- O
NS5b O
( O
ALY O
DVVSKL O
[ O
HCV O
- O
AL9 O
] O
) O
. O

We O
found O
that O
4 O
out O
of O
20 O
HLA O
- O
A2 O
- O
positive O
( O
HLA O
- O
A2 O
( O
+ O
) O
) O
HIV O
- O
infected O
individuals O
had O
CD8 O
( O
+ O
) O
T O
cells O
that O
recognized O
both O
the O
HIV O
- O
SL9 O
and O
HCV O
- O
AL9 O
epitopes O
. O

Detailed O
phylogenetic O
analyses O
were O
performed O
to O
characterize O
an O
HIV O
- O
1 O
outbreak O
among O
injection O
drug O
users O
( O
IDUs O
) O
in O
Stockholm O
, O
Sweden O
, O
in O
2006 O
. O

Instead O
, O
the O
outbreak O
in O
Stockholm O
( O
and O
Helsinki O
) O
was O
best O
explained O
by O
an O
introduction O
of O
HIV O
into O
a O
standing O
network O
of O
previously O
uninfected O
IDUs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
can O
initiate O
infection O
by O
cell O
- O
free O
particle O
and O
cell O
- O
cell O
contact O
- O
dependent O
transmission O
. O

However O
, O
scavenger B
receptor I
BI I
( I
SR I
- I
BI I
) I
has O
a O
more O
prominent O
role O
in O
cell O
- O
to O
- O
cell O
transmission O
of O
the O
virus O
, O
with O
SR O
- O
BI O
- O
specific O
antibodies O
and O
small O
- O
molecule O
inhibitors O
showing O
preferential O
inhibition O
of O
this O
infection O
route O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
encodes O
the O
regulatory O
HBx O
protein O
, O
which O
is O
required O
for O
virus O
replication O
, O
although O
its O
specific O
role O
( O
s O
) O
in O
the O
replication O
cycle O
remains O
under O
investigation O
. O

One O
of O
these O
HBx O
binding O
partners O
is O
beta O
interferon B
promoter I
stimulator I
1 I
( I
IPS I
- I
1 I
) I
, O
an O
adaptor O
protein O
that O
plays O
a O
critical O
role O
in O
mediating O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
signaling O
, O
which O
leads O
to O
the O
activation O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
. O

The O
effect O
of O
HBx O
on O
IPS O
- O
1 O
- O
mediated O
IFN O
- O
beta O
signaling O
was O
tested O
in O
transfected O
293T O
and O
HepG2 O
cells O
, O
and O
we O
show O
that O
HBx O
inhibits O
double B
- I
stranded I
DNA I
( I
dsDNA I
) I
- O
mediated O
IFN O
- O
beta O
activation O
in O
a O
dose O
- O
dependent O
manner O
when O
expressed O
either O
alone O
or O
within O
the O
context O
of O
HBV O
replication O
. O

However O
, O
HBx O
does O
not O
inhibit O
poly O
( O
I O
: O
C O
) O
- O
activated O
IFN O
- O
beta O
signaling O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
is O
an O
approved O
medication O
for O
chronic O
hepatitis O
B O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
a O
key O
mediator O
of O
host O
innate O
and O
adaptive O
antiviral O
immunity O
against O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
in O
vivo O
. O

In O
an O
effort O
to O
elucidate O
the O
antiviral O
mechanism O
of O
these O
cytokines O
, O
37 O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
which O
are O
highly O
inducible O
in O
hepatocytes O
, O
were O
tested O
for O
their O
ability O
to O
inhibit O
HBV O
replication O
upon O
overexpression O
in O
human O
hepatoma O
cells O
. O

One O
ISG O
candidate O
, O
indoleamine B
2 I
, I
3 I
- I
dioxygenase I
( I
IDO I
) I
, O
an O
IFN O
- O
gamma O
- O
induced O
enzyme O
catalyzing O
tryptophan O
degradation O
, O
efficiently O
reduced O
the O
level O
of O
intracellular O
HBV O
DNA O
without O
altering O
the O
steady O
- O
state O
level O
of O
viral O
RNA O
. O

These O
viruses O
replicate O
their O
genome O
through O
reverse O
transcription O
of O
an O
RNA O
intermediate O
termed O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

There O
are O
multiple O
cis O
- O
acting O
sequences O
that O
contribute O
to O
the O
synthesis O
of O
minus O
- O
strand O
DNA O
for O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
. O

To O
identify O
cis O
- O
acting O
sequences O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
and O
heron B
hepatitis I
B I
virus I
( I
HHBV I
) I
, O
we O
analyzed O
variants O
containing O
200 O
- O
nucleotide B
( I
nt I
) I
deletions O
. O

Most O
variants O
of O
DHBV O
synthesized O
minus O
- O
strand O
DNA O
to O
50 O
to O
100 O
% O
of O
the O
wild B
- I
type I
( I
WT I
) I
level O
, O
while O
two O
variants O
synthesized O
less O
than O
50 O
% O
. O

Mutations O
in O
the O
S O
region O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
gene O
are O
associated O
with O
immune O
escape O
, O
occult O
infection O
, O
and O
resistance O
to O
therapy O
. O

The O
G119E O
mutation O
impaired O
detection O
of O
secreted O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
, O
suggesting O
immune O
escape O
. O

In O
fact O
, O
the O
M133T O
mutation O
creates O
a O
novel O
N O
- O
linked O
glycosylation O
site O
( O
( O
NST133 O
) O
- O
N O
- O
131 O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
establishes O
chronic O
infection O
in O
a O
significant O
number O
of O
infected O
humans O
, O
although O
the O
mechanisms O
for O
chronicity O
remain O
largely O
unknown O
. O

We O
have O
previously O
shown O
that O
HCV O
infection O
in O
immortalized B
human I
hepatocytes I
( I
IHH I
) I
induces O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
( O
T O
. O

In O
this O
study O
, O
the O
regulation O
of O
the O
IFN O
signaling O
pathway O
following O
HCV O
genotype O
1a O
( O
clone O
H77 O
) O
or O
genotype O
2a O
( O
clone O
JFH1 O
) O
infection O
of O
IHH O
was O
examined O
. O

In O
HCV O
- O
infected O
IHH O
, O
IFN O
- O
alpha O
expression O
initially O
increased O
( O
up O
to O
24 O
h O
) O
and O
then O
decreased O
at O
later O
time O
points O
, O
and O
IFN O
- O
alpha O
- O
inducible O
protein O
27 O
was O
not O
induced O
. O

Interestingly O
, O
HCV O
infection O
blocked O
IRF O
- O
7 O
nuclear O
translocation O
upon O
poly O
( O
I O
- O
C O
) O
or O
IFN O
- O
alpha O
treatment O
of O
IHH O
. O

We O
analyzed O
the O
biochemical O
and O
ultrastructural O
properties O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
produced O
in O
cell O
culture O
. O

Negative O
- O
stain O
electron O
microscopy O
revealed O
that O
the O
particles O
were O
spherical O
( O
similar O
to O
40 O
- O
to O
75 O
- O
nm O
diameter O
) O
and O
pleomorphic O
and O
that O
some O
of O
them O
contain O
HCV O
E2 O
protein O
and O
apolipoprotein O
E O
on O
their O
surfaces O
. O

The O
similar O
to O
60 O
- O
nm O
particles O
were O
characterized O
by O
a O
membrane O
bilayer O
( O
presumably O
an O
envelope O
) O
that O
is O
spatially O
separated O
from O
an O
internal O
structure O
( O
presumably O
a O
capsid O
) O
, O
and O
they O
were O
enriched O
in O
fractions O
that O
displayed O
a O
high O
infectivity O
- O
to O
- O
HCV O
RNA O
ratio O
. O

The O
endoplasmic B
reticulum I
( I
ER I
) I
chaperone O
BiP O
( O
immunoglobulin O
binding O
protein O
) O
plays O
a O
major O
role O
in O
the O
control O
of O
the O
unfolded O
protein O
response O
. O

We O
have O
previously O
shown O
that O
BiP O
levels O
are O
dramatically O
increased O
during O
human B
cytomegalovirus I
( I
HCMV I
) I
infection O
, O
where O
BiP O
performs O
unique O
roles O
in O
viral O
assembly O
and O
egress O
. O

We O
show O
that O
BiP O
mRNA O
levels O
increase O
during O
infection O
due O
to O
activation O
of O
the O
BiP O
promoter O
by O
the O
major B
immediate I
- I
early I
( I
MIE I
) I
proteins O
. O

The O
BiP O
promoter O
, O
like O
other O
ER O
stress O
- O
activated O
promoters O
, O
contains O
endoplasmic B
reticulum I
stress I
elements I
( I
ERSEs I
) I
, O
which O
are O
activated O
by O
unfolded B
protein I
response I
( I
UPR I
) I
- O
induced O
transcription O
factors O
. O

The O
BiP O
mRNA O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
which O
increases O
the O
level O
of O
BiP O
mRNA O
translation O
. O

Utilization O
of O
the O
BiP O
IRES O
can O
be O
activated O
by O
the O
La O
autoantigen O
, O
also O
called O
Sjogren B
' I
s I
syndrome I
antigen I
B I
( I
SSB I
) I
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
is O
an O
approved O
medication O
for O
chronic O
hepatitis O
B O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
a O
key O
mediator O
of O
host O
antiviral O
immunity O
against O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
in O
vivo O
. O

Using O
an O
immortalized O
murine O
hepatocyte O
( O
AML12 O
) O
- O
derived O
cell O
line O
supporting O
tetracycline O
- O
inducible O
HBV O
replication O
, O
we O
show O
in O
this O
report O
that O
both O
IFN O
- O
alpha O
and O
IFN O
- O
gamma O
efficiently O
reduce O
the O
amount O
of O
intracellular O
HBV O
nucleocapsids O
. O

The O
9 B
- I
aminoacridine I
( I
9AA I
) I
derivative O
quinacrine B
( I
QC I
) I
has O
a O
long O
history O
of O
safe O
human O
use O
as O
an O
anti O
- O
protozoal O
and O
antirheumatic O
agent O
. O

Internal B
ribosome I
entry I
sites I
( I
IRESs I
) I
that O
are O
required O
for O
initiation O
of O
translation O
of O
some O
viral O
and O
cellular O
mRNAs O
typically O
have O
complex O
structures O
. O

Here O
, O
we O
show O
that O
QC O
suppresses O
translation O
directed O
by O
the O
encephalomyocarditis B
virus I
( I
EMCV I
) I
and O
poliovirus O
IRESs O
in O
a O
cell O
- O
free O
system O
and O
in O
virus O
- O
infected O
HeLa O
cells O
. O

Expression O
of O
viral O
capsid O
proteins O
, O
replication O
of O
viral O
RNAs O
, O
and O
production O
of O
virus O
were O
all O
strongly O
inhibited O
by O
QC O
( O
and O
9AA O
) O
. O

dendritic B
cells I
( I
DCs I
) I
are O
of O
pivotal O
importance O
for O
the O
initiation O
of O
immune O
responses O
to O
control O
and O
eliminate O
viral O
infections O
. O

The O
molecular O
mechanisms O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
antigen O
uptake O
and O
processing O
by O
blood O
DCs O
are O
poorly O
defined O
. O

Following O
HCV O
uptake O
, O
human O
plasmacytoid O
and O
myeloid O
DC O
subsets O
deliver O
HCV O
antigen O
into O
distinct O
endocytotic O
compartments O
, O
which O
are O
dedicated O
to O
presentation O
to O
CD4 O
( O
+ O
) O
or O
CD8 O
( O
+ O
) O
T O
cells O
. O

Myeloid B
differentiation I
primary I
response I
protein I
88 I
( I
MyD88 I
) I
, O
which O
can O
be O
induced O
by O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
has O
an O
antiviral O
activity O
against O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

In O
addition O
, O
MyD88 O
inhibited O
the O
nuclear O
export O
of O
pre O
- O
S O
/ O
S O
RNAs O
via O
the O
posttranscriptional B
regulatory I
element I
( I
PRE I
) I
. O

Finally O
, O
we O
found O
that O
MyD88 O
inhibited O
the O
expression O
of O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
, O
a O
key O
nuclear O
export O
factor O
for O
PRE O
- O
containing O
RNA O
. O

Cell O
culture O
- O
adaptive O
mutations O
within O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
glycoprotein O
have O
been O
widely O
reported O
. O

We O
identify O
here O
a O
single O
mutation O
( O
N415D O
) O
in O
E2 O
that O
arose O
during O
long O
- O
term O
passaging O
of O
HCV O
strain O
JFH1 O
- O
infected O
cells O
. O

This O
mutation O
was O
located O
within O
E2 O
residues O
412 O
to O
423 O
, O
a O
highly O
conserved O
region O
that O
is O
recognized O
by O
several O
broadly O
neutralizing O
antibodies O
, O
including O
the O
mouse O
monoclonal B
antibody I
( I
Mab I
) I
AP33 O
. O

Introduction O
of O
N415D O
into O
the O
wild B
- I
type I
( I
WT I
) I
JFH1 O
genome O
increased O
the O
affinity O
of O
E2 O
to O
the O
CD81 O
receptor O
and O
made O
the O
virus O
less O
sensitive O
to O
neutralization O
by O
an O
antiserum O
to O
another O
essential O
entry O
factor O
, O
SR O
- O
BI O
. O

Unlike O
JFH1WT O
, O
the O
JFH1 O
( O
N415D O
) O
was O
not O
neutralized O
by O
AP33 O
. O

MAb O
AP33 O
neutralized O
JFH1 O
( O
T416A O
) O
and O
JFH1 O
( O
I422L O
) O
more O
efficiently O
than O
the O
WT O
virus O
, O
while O
neutralization O
of O
JFH1 O
( O
N417S O
) O
and O
JFH1 O
( O
G418D O
) O
was O
abrogated O
. O

The O
properties O
of O
all O
of O
these O
viruses O
in O
terms O
of O
receptor O
reactivity O
and O
neutralization O
by O
human O
antibodies O
were O
similar O
to O
JFH1 O
( O
N415D O
) O
, O
highlighting O
the O
importance O
of O
the O
E2 O
412 O
- O
423 O
region O
in O
virus O
entry O
. O

The O
variability O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
which O
likely O
contributes O
to O
immune O
escape O
, O
is O
most O
pronounced O
in O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
viral O
envelope O
protein O
2 O
. O

However O
, O
viruses O
lacking O
HVR1 O
( O
Delta O
HVR1 O
) O
are O
less O
infectious O
, O
and O
separation O
by O
density O
gradients O
revealed O
that O
the O
population O
of O
Delta O
HVR1 O
virions O
comprises O
fewer O
particles O
with O
low O
density O
. O

Moreover O
, O
Delta O
HVR1 O
particles O
exhibited O
impaired O
fusion O
, O
a O
defect O
that O
was O
partially O
restored O
by O
an O
E1 O
mutation O
( O
I347L O
) O
, O
which O
also O
rescues O
infectivity O
and O
which O
was O
selected O
during O
long O
- O
term O
culture O
. O

Liver O
- O
related O
mortality O
is O
increased O
in O
the O
setting O
of O
HIV O
- O
hepatitis B
B I
virus I
( I
HBV I
) I
coinfection O
. O

We O
infected O
human O
hepatic O
cell O
lines O
expressing O
HBV O
( O
Hep3B O
and O
AD38 O
cells O
) O
or O
not O
expressing O
HBV O
( O
Huh7 O
, O
HepG2 O
, O
and O
AD43 O
cells O
) O
with O
laboratory O
strains O
of O
HIV O
( O
NL4 O
- O
3 O
and O
AD8 O
) O
, O
as O
well O
as O
a O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
pseudotyped O
HIV O
expressing O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
. O

High O
- O
level O
infection O
of O
AD38 O
cells O
( O
50 O
% O
) O
was O
achieved O
using O
VSV O
- O
pseudotyped O
HIV O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
often O
associated O
with O
insulin O
resistance O
and O
hepatic O
steatosis O
. O

Insulin O
regulates O
gene O
expression O
of O
key O
enzymes O
in O
glucose O
and O
lipid O
metabolism O
by O
modulating O
the O
activity O
of O
specific O
Forkhead O
box O
transcriptional O
regulators O
( O
FoxO1 O
and O
FoxA2 O
) O
via O
the O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
- O
Akt O
signaling O
pathway O
in O
the O
liver O
. O

Phosphorylation O
of O
FoxO1 O
at O
Ser O
( O
256 O
) O
, O
a O
downstream O
target O
for O
Akt O
, O
was O
inhibited O
in O
hepatocytes O
infected O
with O
HCV O
or O
expressing O
the O
core O
protein O
or O
full B
- I
length I
( I
FL I
) I
genome O
of O
HCV O
. O

Hepatocytes O
infected O
with O
HCV O
, O
expressing O
the O
core O
protein O
alone O
or O
polyprotein O
displayed O
an O
increased O
level O
of O
glucose B
- I
6 I
- I
phosphatase I
( I
G6P I
) I
mRNA O
. O

On O
the O
other O
hand O
, O
microsomal B
triglycerol I
transfer I
protein I
( I
MTP I
) I
activity O
and O
apolipoprotein B
B I
( I
ApoB I
) I
secretion O
were O
significantly O
reduced O
in O
hepatocytes O
expressing O
HCV O
proteins O
. O

A O
recent O
experiment O
involving O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
infection O
of O
macaques O
revealed O
that O
the O
infectivity O
of O
this O
virus O
decreased O
over O
the O
first O
few O
months O
of O
infection O
. O

The O
model O
is O
fit O
to O
viral O
load O
data O
from O
eight O
( O
donor O
) O
monkeys O
infected O
by O
intravaginal O
inoculation O
of O
SIVmac251 O
, O
three O
monkeys O
infected O
by O
intravenous O
inoculation O
of O
virus O
isolated O
from O
the O
donors O
during O
the O
ramp O
- O
up O
phase O
of O
acute O
infection O
, O
and O
three O
monkeys O
infected O
by O
intravenous O
inoculation O
of O
virus O
isolated O
at O
the O
viral O
set O
- O
point O
. O

44 O
x O
10 O
( O
- O
11 O
) O
) O
. O

28 O
day O
( O
- O
1 O
) O
( O
95 O
% O
CI O
= O
0 O
. O

42 O
day O
( O
- O
1 O
) O
) O
. O

Control O
of O
viral O
replication O
is O
a O
major O
therapeutic O
goal O
to O
reduce O
morbidity O
and O
mortality O
from O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
. O

To O
better O
understand O
the O
mechanisms O
of O
HBV O
methylation O
, O
cell O
lines O
were O
exposed O
to O
HBV O
using O
a O
model O
system O
that O
mimics O
natural O
infection O
and O
the O
expression O
of O
host O
DNA B
methyltransferase I
genes I
( I
DNMTs I
) I
was O
measured O
. O

clevudine B
( I
CLV I
) I
is O
a O
nucleoside O
analog O
with O
potent O
antiviral O
activity O
against O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
. O

The O
aim O
of O
this O
study O
was O
to O
characterize O
CLV O
- O
resistant O
HBV O
in O
patients O
with O
viral O
breakthrough B
( I
BT I
) I
during O
long O
- O
term O
CLV O
therapy O
. O

The O
gene O
encoding O
HBV O
reverse B
transcriptase I
( I
RT I
) I
was O
analyzed O
from O
chronic O
hepatitis O
B O
patients O
with O
viral O
BT O
during O
CLV O
therapy O
. O

A O
quadruple O
mutant O
( O
L129M O
, O
V173L O
, O
M204I O
, O
and O
H337N O
) O
was O
identified O
that O
conferred O
greater O
replicative O
ability O
and O
strong O
resistance O
to O
both O
CLV O
and O
lamivudine O
. O

The O
entry O
mechanism O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
has O
not O
been O
defined O
, O
and O
this O
impedes O
development O
of O
antiviral O
therapies O
aimed O
at O
an O
early O
step O
in O
the O
viral O
life O
cycle O
. O

For O
the O
related O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
duck B
carboxypeptidase I
D I
( I
DCPD I
) I
has O
been O
proposed O
as O
the O
species O
- O
specific O
docking O
receptor O
, O
while O
glycine O
decarboxylase O
( O
DGD O
) O
may O
serve O
as O
a O
tissue O
- O
specific O
cofactor O
or O
secondary O
receptor O
. O

Interferons B
( I
IFNs I
) I
are O
induced O
as O
an O
initial O
response O
to O
viral O
infection O
after O
recognition O
of O
pathogen B
- I
associated I
molecular I
patterns I
( I
PAMPs I
) I
by O
pattern B
recognition I
receptors I
( I
PRRs I
) I
. O

Here O
, O
we O
report O
that O
different O
PAMPs O
induce O
type O
I O
and O
III O
IFN O
expression O
at O
different O
ratios O
after O
mucosal O
administration O
in O
the O
vaginas O
of O
mice O
and O
that O
Toll B
- I
like I
receptor I
9 I
( I
TLR9 I
) I
stimulation O
evokes O
a O
particularly O
strong O
IFN O
- O
lambda O
response O
, O
which O
is O
essential O
for O
optimal O
antiviral O
protection O
. O

Depletion O
of O
CD11c O
( O
+ O
) O
cells O
in O
vivo O
revealed O
that O
dendritic B
cells I
( I
DCs I
) I
in O
the O
vaginal O
epithelium O
are O
a O
key O
source O
of O
type O
I O
and O
III O
IFNs O
during O
herpes O
simplex O
virus O
infection O
and O
after O
specific O
stimulation O
of O
TLR9 O
. O

Inhibition O
of O
the O
NF O
- O
kappa O
B O
and O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
pathways O
with O
the O
NEMO O
- O
binding O
domain O
peptide O
and O
small B
interfering I
RNA I
( I
siRNA I
) I
, O
respectively O
, O
revealed O
that O
transcription O
of O
the O
type O
III O
IFN O
genes O
was O
more O
dependent O
on O
the O
NF O
- O
kappa O
B O
pathway O
than O
that O
of O
the O
type O
I O
IFN O
genes O
, O
which O
relied O
more O
on O
the O
IRF O
system O
. O

One O
such O
multifunctional O
domain O
is O
the O
coronavirus O
papain B
- I
like I
protease I
( I
PLP I
) I
, O
which O
processes O
the O
viral O
replicase O
polyprotein O
, O
has O
deubiquitinating B
( I
DUB I
) I
activity O
, O
and O
antagonizes O
the O
induction O
of O
type B
I I
interferon I
( I
IFN I
) I
. O

Here O
we O
characterized O
the O
DUB O
and O
IFN O
antagonism O
activities O
of O
the O
PLP O
domains O
of O
human O
coronavirus O
NL63 O
and O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
to O
determine O
if O
DUB O
activity O
mediates O
interferon O
antagonism O
. O

We O
found O
that O
NL63 O
PLP2 O
deconjugated O
ubiquitin B
( I
Ub I
) I
and O
the O
Ub O
- O
line O
molecule O
ISG15 O
from O
cellular O
substrates O
and O
processed O
both O
lysine O
- O
48 O
- O
and O
lysine O
- O
63 O
- O
linked O
polyubiquitin O
chains O
. O

cyclophilin B
A I
( I
CypA I
) I
, O
predominantly O
located O
intracellularly O
, O
is O
a O
multifunctional O
protein O
. O

We O
previously O
reported O
decreased O
CypA O
levels O
in O
hepatocytes O
of O
transgenic O
mice O
expressing O
hepatitis B
B I
virus I
( I
HBV I
) I
surface O
antigen O
( O
HBsAg O
) O
. O

In O
this O
study O
, O
we O
found O
that O
expression O
of O
HBV B
small I
surface I
protein I
( I
SHBs I
) I
in O
human O
hepatoma O
cell O
lines O
specifically O
triggered O
CypA O
secretion O
, O
whereas O
SHBs O
added O
extracellularly O
to O
culture O
medium O
did O
not O
. O

Little O
is O
known O
about O
hepatitis B
B I
virus I
( I
HBV I
) I
diversity O
changes O
within O
a O
host O
during O
the O
immunotolerant O
phase O
of O
chronic O
HBV O
infection O
. O

In O
this O
study O
, O
serial O
serum O
samples O
were O
collected O
from O
a O
long O
- O
term O
( O
> O
17 O
years O
) O
follow O
- O
up O
cohort O
of O
seven O
patients O
, O
and O
multiple O
copies O
of O
the O
full O
- O
length O
viral O
genome O
from O
serially O
sampled O
sera O
were O
recovered O
and O
analyzed O
. O

Viral O
genetic O
diversity O
was O
positively O
correlated O
with O
host O
immunity O
, O
represented O
by O
levels O
of O
alanine B
aminotransferase I
( I
ALT I
) I
, O
but O
was O
negatively O
correlated O
with O
the O
viral O
copy O
number O
. O

During O
the O
immunotolerant O
phase O
, O
when O
the O
host O
immunity O
was O
feeble O
( O
ALT O
< O
20 O
U O
/ O
liter O
) O
, O
viral O
nucleotide O
diversity O
decreased O
while O
copy O
numbers O
increased O
. O

6 O
x O
10 O
( O
- O
5 O
) O
to O
5 O
. O

4 O
x O
10 O
( O
- O
5 O
) O
/ O
site O
/ O
year O
) O
. O

As O
the O
disease O
progressed O
toward O
the O
immunoclearance O
phase O
( O
ALT O
> O
20 O
U O
/ O
liter O
) O
, O
viral O
diversity O
increased O
but O
copy O
numbers O
decreased O
. O

6 O
x O
10 O
( O
- O
6 O
) O
to O
3 O
. O

2 O
x O
10 O
( O
- O
4 O
) O
/ O
site O
/ O
year O
. O

More O
than O
half O
( O
19 O
/ O
32 O
sites O
) O
of O
positively O
selected O
sites O
resided O
in O
immune O
epitopes O
, O
suggesting O
their O
possible O
role O
in O
host O
immunity O
. O

The O
envelope O
of O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
contains O
three O
membrane O
proteins O
( O
L O
, O
M O
, O
and O
S O
) O
. O

Previously O
, O
a O
charge O
balance O
hypothesis O
was O
proposed O
to O
explain O
hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
stability O
, O
assembly O
, O
RNA O
encapsidation O
, O
and O
DNA O
replication O
. O

This O
hypothesis O
emphasized O
the O
importance O
of O
a O
balanced O
electrostatic O
interaction O
between O
the O
positive O
charge O
from O
the O
arginine B
- I
rich I
domain I
( I
ARD I
) I
of O
the O
core O
protein O
( O
HBc O
) O
and O
the O
negative O
charge O
from O
the O
encapsidated O
nucleic O
acid O
. O

However O
, O
most O
interestingly O
, O
it O
can O
be O
at O
least O
partially O
rescued O
by O
reducing O
negatively O
charged O
residues O
in O
the O
assembly O
domain O
, O
such O
as O
by O
glutamic O
acid O
- O
to O
- O
alanine O
( O
E O
- O
to O
- O
A O
) O
substitutions O
at O
position O
46 O
or O
117 O
and O
to O
a O
much O
lesser O
extent O
at O
position O
113 O
. O

interferon B
( I
IFN I
) I
signaling O
is O
initiated O
by O
the O
recognition O
of O
viral O
components O
by O
host O
pattern O
recognition O
receptors O
. O

dengue B
virus I
( I
DEN I
) I
triggers O
IFN O
- O
beta O
induction O
through O
a O
molecular O
mechanism O
involving O
the O
cellular O
RIG O
- O
I O
/ O
MAVS O
signaling O
pathway O
. O

The O
apoptotic O
role O
of O
MAVS O
in O
viral O
infection O
and O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
stimulation O
was O
demonstrated O
in O
cells O
with O
reduced O
endogenous O
MAVS O
expression O
induced O
by O
RNA O
interference O
. O

Following O
treatment O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
monoinfection O
, O
HBV O
- O
specific O
T O
- O
cell O
responses O
increase O
significantly O
; O
however O
, O
little O
is O
known O
about O
the O
recovery O
of O
HBV O
- O
specific O
T O
- O
cell O
responses O
following O
HBV O
- O
active O
highly B
active I
antiretroviral I
therapy I
( I
HAART I
) I
in O
HIV O
- O
HBV O
coinfected O
patients O
. O

HIV O
- O
HBV O
coinfected O
patients O
who O
were O
treatment O
naive O
and O
initiating O
HBV O
- O
active O
HAART O
were O
recruited O
as O
part O
of O
a O
prospective O
cohort O
study O
in O
Thailand O
and O
followed O
for O
48 O
weeks O
( O
n O
= O
24 O
) O
. O

Production O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
both O
HBV O
- O
and O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
was O
quantified O
using O
intracellular O
cytokine O
staining O
on O
whole O
blood O
. O

Following O
HBV O
- O
active O
HAART O
, O
the O
median O
( O
interquartile O
range O
) O
log O
decline O
from O
week O
0 O
to O
week O
48 O
for O
HBV O
DNA O
was O
5 O
. O

The O
frequency O
of O
HIV O
Gag O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
significantly O
decreased O
( O
IFN O
- O
gamma O
, O
P O
< O
0 O
. O

13 O
) O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
over O
48 O
weeks O
of O
HBV O
- O
active O
HAART O
. O

Of O
the O
14 O
individuals O
who O
were O
HBV B
e I
antigen I
( I
HBeAg I
) I
positive O
, O
5 O
/ O
14 O
( O
36 O
% O
) O
lost O
HBeAg O
during O
the O
48 O
weeks O
of O
follow O
- O
up O
. O

HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
detected O
in O
4 O
/ O
5 O
( O
80 O
% O
) O
of O
patients O
prior O
to O
HBeAg O
loss O
. O

Results O
from O
this O
study O
show O
no O
sustained O
change O
in O
the O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
following O
HBV O
- O
active O
HAART O
. O

Worldwide O
, O
there O
are O
over O
350 O
million O
people O
who O
are O
chronically O
infected O
with O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
; O
chronic O
HBV O
infections O
are O
associated O
with O
the O
development O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

The O
results O
of O
various O
studies O
suggest O
that O
the O
HBV B
X I
protein I
( I
HBx I
) I
has O
a O
role O
in O
the O
development O
of O
HBV O
- O
associated O
HCC O
. O

We O
demonstrate O
that O
HBx O
, O
both O
by O
itself O
and O
in O
the O
context O
of O
HBV O
replication O
, O
affected O
the O
levels O
and O
activities O
of O
various O
cell O
cycle O
- O
regulatory O
proteins O
to O
induce O
normally O
quiescent O
hepatocytes O
to O
enter O
the O
G O
( O
1 O
) O
phase O
of O
the O
cell O
cycle O
but O
not O
to O
proceed O
to O
S O
phase O
. O

Cumulatively O
, O
our O
studies O
suggest O
that O
HBx O
induces O
normally O
quiescent O
hepatocytes O
to O
enter O
the O
G O
( O
1 O
) O
phase O
of O
the O
cell O
cycle O
and O
that O
this O
calcium O
- O
dependent O
HBx O
activity O
is O
required O
for O
HBV O
replication O
. O

Consistent O
with O
this O
hypothesis O
, O
here O
we O
show O
that O
the O
structure O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
dimer O
, O
which O
can O
spontaneously O
self O
- O
assemble O
, O
is O
incompatible O
with O
capsid O
assembly O
. O

Hepatitis O
B O
and O
C O
viruses O
( O
HBV O
and O
HCV O
, O
respectively O
) O
are O
different O
and O
distinct O
viruses O
, O
but O
there O
are O
striking O
similarities O
in O
their O
disease O
potential O
. O

Our O
recent O
studies O
have O
suggested O
that O
replication O
of O
either O
of O
these O
viruses O
upregulates O
a O
cellular O
protein O
called O
serine B
protease I
inhibitor I
Kazal I
( I
SPIK I
) I
. O

Recently O
, O
Claudin B
- I
1 I
( I
CLDN1 I
) I
was O
identified O
as O
a O
host O
protein O
essential O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

These O
criteria O
were O
met O
by O
the O
human O
hepatoblastoma O
cell O
line O
HuH6 O
, O
which O
( O
i O
) O
displays O
low O
endogenous O
CLDN1 O
levels O
, O
( O
ii O
) O
efficiently O
replicates O
HCV O
RNA O
, O
and O
( O
iii O
) O
produces O
HCV O
particles O
with O
properties O
similar O
to O
those O
of O
particles O
generated O
in O
Huh O
- O
7 O
. O

Interestingly O
, O
complementation O
of O
HCV O
entry O
by O
human O
, O
rat O
, O
or O
hamster O
CLDN1 O
was O
highly O
efficient O
, O
while O
mouse B
CLDN1 I
( I
mCLDN1 I
) I
supported O
HCV O
genotype O
2a O
infection O
with O
only O
moderate O
efficiency O
. O

These O
differences O
were O
observed O
irrespective O
of O
whether O
cells O
were O
infected O
with O
HCV B
pseudoparticles I
( I
HCVpp I
) I
or O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
. O

Moreover O
, O
it O
was O
linked O
to O
three O
mouse O
- O
specific O
residues O
in O
the O
second O
extracellular O
loop O
( O
L152 O
, O
I155 O
) O
and O
the O
fourth O
transmembrane O
helix O
( O
V180 O
) O
of O
the O
protein O
. O

Immune O
escape O
variants O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
represent O
an O
emerging O
clinical O
challenge O
, O
because O
they O
can O
be O
associated O
with O
vaccine O
escape O
, O
HBV O
reactivation O
, O
and O
failure O
of O
diagnostic O
tests O
. O

We O
therefore O
systematically O
analyzed O
the O
functional O
impact O
of O
the O
most O
prevalent O
immune O
escape O
variants O
, O
the O
sG145R O
and O
sP120T O
mutants O
, O
on O
the O
viral O
replication O
efficacy O
and O
antiviral O
drug O
susceptibility O
of O
common O
treatment O
- O
associated O
mutants O
with O
resistance O
to O
lamivudine B
( I
LAM I
) I
and O
/ O
or O
HBeAg O
negativity O
. O

Replication O
- O
competent O
HBV O
strains O
with O
sG145R O
or O
sP120T O
and O
LAM O
resistance O
( O
rtM2041 O
or O
rtL180M O
/ O
rtM204V O
) O
were O
generated O
on O
an O
HBeAg O
- O
positive O
and O
an O
HBeAg O
- O
negative O
background O
with O
precore B
( I
pc I
) I
and O
basal B
core I
promoter I
( I
BCP I
) I
mutants O
. O

However O
, O
the O
concomitant O
occurrence O
of O
HBeAg O
negativity O
( O
PC O
/ O
BCP O
) O
, O
sP120T O
, O
and O
LAM O
resistance O
resulted O
in O
the O
restoration O
of O
replication O
to O
levels O
of O
wild O
- O
type O
HBV O
. O

scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
is O
an O
essential O
receptor O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
a O
cell O
surface O
high B
- I
density I
- I
lipoprotein I
( I
HDL I
) I
receptor O
. O

The O
kinetics O
of O
inhibition O
of O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
infection O
with O
an O
anti O
- O
SR O
- O
BI O
monoclonal O
antibody O
imply O
that O
the O
recognition O
of O
SR O
- O
BI O
by O
HCV O
is O
an O
early O
event O
of O
the O
infection O
process O
. O

Swapping O
and O
single O
- O
substitution O
mutants O
between O
mouse O
and O
human O
SR O
- O
BI O
sequences O
showed O
reduced O
binding O
to O
the O
recombinant O
soluble O
E2 O
( O
sE2 O
) O
envelope O
glycoprotein O
, O
thus O
suggesting O
that O
the O
SR O
- O
BI O
interaction O
with O
the O
HCV O
envelope O
is O
likely O
to O
involve O
species O
- O
specific O
protein O
elements O
. O

Investigation O
of O
the O
entry O
pathways O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
member O
of O
the O
family O
Hepadnaviridae O
, O
has O
been O
hampered O
by O
the O
lack O
of O
versatile O
in O
vitro O
infectivity O
models O
. O

In O
this O
study O
, O
we O
investigate O
the O
role O
of O
an O
important O
plasma O
membrane O
component O
, O
caveolin B
- I
1 I
( I
Cav I
- I
1 I
) I
, O
in O
HBV O
infection O
. O

The O
endocytic O
properties O
of O
the O
newly O
established O
cell O
lines O
, O
designated O
HepaRG O
( O
Cav O
- O
1 O
) O
, O
HepaRG O
( O
Cav O
- O
1 O
Delta O
1 O
- O
81 O
) O
, O
HepaRG O
( O
Dyn O
- O
2 O
) O
, O
and O
HepaRG O
( O
Dyn O
- O
2K44A O
) O
, O
were O
validated O
using O
specific O
markers O
for O
different O
entry O
routes O
. O

Removal O
of O
genome O
- O
bound O
viral O
DNA O
polymerase O
ought O
to O
be O
an O
essential O
step O
in O
the O
formation O
of O
hepadnavirus O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
. O

We O
previously O
demonstrated O
that O
deproteinized O
( O
DP O
) O
relaxed B
circular I
DNA I
( I
rcDNA I
) I
of O
hepatitis B
B I
virus I
( I
HBV I
) I
existed O
in O
both O
the O
cytoplasm O
and O
nuclei O
of O
infected O
cells O
and O
the O
vast O
majority O
of O
cytoplasmic O
DP O
rcDNA O
was O
associated O
with O
DNase O
I O
- O
permeable O
nucleocapsids O
. O

human B
cytomegalovirus I
( I
HCMV I
) I
is O
a O
member O
of O
the O
betaherpesvirus O
family O
that O
, O
unlike O
other O
herpesviruses O
, O
triggers O
a O
strong O
innate O
immune O
response O
in O
infected O
cells O
that O
includes O
transcription O
of O
the O
beta O
interferon O
gene O
via O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
. O

Moreover O
, O
we O
identify O
Z B
- I
DNA I
binding I
protein I
1 I
( I
ZBP1 I
) I
as O
being O
essential O
for O
IRF3 O
activation O
and O
interferon O
beta O
expression O
triggered O
by O
HCMV O
, O
as O
well O
as O
being O
sufficient O
to O
enhance O
HCMV O
- O
stimulated O
beta O
interferon O
transcription O
and O
secretion O
. O

Our O
previous O
studies O
have O
found O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
are O
enriched O
in O
apolipoprotein B
E I
( I
ApoE I
) I
and O
that O
apoE O
is O
required O
for O
HCV O
infectivity O
and O
production O
. O

Studies O
by O
others O
, O
however O
, O
suggested O
that O
both O
microsomal B
transfer I
protein I
( I
MTP I
) I
and O
apoB O
are O
important O
for O
HCV O
production O
. O

The O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
apoE O
expression O
remarkably O
suppressed O
the O
formation O
of O
HCV O
particles O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
entry O
occurs O
via O
a O
pH O
- O
and O
clathrin O
- O
dependent O
endocytic O
pathway O
and O
requires O
a O
number O
of O
cellular O
factors O
, O
including O
CD81 O
, O
the O
tight O
- O
junction O
proteins O
claudin B
1 I
( I
CLDN1 I
) I
and O
occludin O
, O
and O
scavenger B
receptor I
class I
B I
member I
I I
( I
SR I
- I
BI I
) I
. O

Cellular O
contact O
increased O
HCV B
pseudoparticle I
( I
HCVpp I
) I
and O
HCV O
particle O
( O
HCVcc O
) O
infection O
and O
accelerated O
the O
internalization O
of O
cell O
- O
bound O
HCVcc O
, O
suggesting O
that O
the O
cell O
contact O
modulation O
of O
receptor O
levels O
may O
facilitate O
the O
assembly O
of O
receptor O
complexes O
required O
for O
virus O
internalization O
. O

The O
human O
hepatoma O
cell O
lines O
HepG2 O
and O
Huh7 O
have O
been O
used O
extensively O
to O
study O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
. O

The O
effects O
of O
the O
coactivator B
peroxisome I
proliferator I
- I
activated I
receptor I
gamma I
coactivator I
1 I
alpha I
( I
PGC1 I
alpha I
) I
and O
corepressor O
small B
heterodimer I
partner I
( I
SHP I
) I
on O
HBV O
transcription O
and O
replication O
mediated O
by O
nuclear O
receptors O
were O
examined O
in O
the O
context O
of O
individual O
nuclear O
receptors O
in O
nonhepatoma O
cells O
and O
in O
hepatoma O
cells O
in O
an O
attempt O
to O
determine O
the O
relative O
contribution O
of O
the O
various O
nuclear O
receptors O
to O
viral O
biosynthesis O
in O
the O
hepatoma O
cells O
. O

Consistent O
with O
this O
suggestion O
, O
it O
appears O
that O
retinoid O
X O
receptor O
alpha O
/ O
farnesoid O
X O
receptor O
alpha O
and O
liver O
receptor O
homolog O
1 O
or O
estrogen B
- I
related I
receptor I
beta I
( I
ERR I
beta I
) I
may O
contribute O
to O
the O
majority O
of O
the O
viral O
replication O
observed O
in O
HepG2 O
cells O
, O
whereas O
ERR O
alpha O
and O
ERR O
gamma O
are O
probably O
responsible O
for O
the O
majority O
of O
viral O
biosynthesis O
in O
Huh7 O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
associated O
with O
the O
development O
of O
hepatocellular O
carcinoma O
and O
probably O
also O
non O
- O
Hodgkin O
' O
s O
B O
- O
cell O
lymphoma O
. O

The O
early O
steps O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
life O
cycle O
are O
still O
poorly O
understood O
. O

In O
addition O
, O
at O
the O
N O
- O
terminal O
extremity O
of O
the O
S O
domain O
, O
a O
putative O
fusion O
peptide O
, O
partially O
overlapping O
the O
first B
transmembrane I
( I
TM1 I
) I
domain O
and O
preceded O
by O
a O
PEST O
sequence O
likely O
containing O
several O
proteolytic O
cleavage O
sites O
, O
was O
identified O
. O

By O
introducing O
the O
mutations O
either O
in O
the O
L O
and O
M O
proteins O
or O
in O
the O
S O
protein O
, O
we O
demonstrated O
the O
following O
: O
( O
i O
) O
that O
in O
the O
TM1 O
domain O
of O
the O
L O
protein O
, O
three O
hydrophobic O
clusters O
of O
four O
residues O
were O
necessary O
for O
infectivity O
; O
( O
ii O
) O
that O
the O
same O
clusters O
were O
critical O
for O
S O
protein O
expression O
; O
and O
, O
finally O
, O
( O
iii O
) O
that O
the O
PEST O
sequence O
was O
dispensable O
for O
both O
assembly O
and O
infection O
processes O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
contains O
three O
coterminal O
envelope O
proteins O
on O
the O
virion O
surface O
: O
large B
( I
L I
) I
, O
middle O
( O
M O
) O
, O
and O
small B
( I
S I
) I
. O

hepatitis B
B I
virus I
( I
HBV I
) I
of O
a O
novel O
genotype O
( O
J O
) O
was O
recovered O
from O
an O
88 O
- O
year O
- O
old O
Japanese O
patient O
with O
hepatocellular O
carcinoma O
who O
had O
a O
history O
of O
residing O
in O
Borneo O
during O
the O
World O
War O
II O
. O

It O
was O
divergent O
from O
eight O
human O
( O
A O
to O
H O
) O
and O
four O
ape O
( O
chimpanzee O
, O
gorilla O
, O
gibbon O
, O
and O
orangutan O
) O
HBV O
genotypes O
, O
as O
well O
as O
from O
a O
recently O
proposed O
ninth O
human O
genotype O
I O
, O
by O
9 O
. O

Based O
on O
a O
comparison O
of O
four O
open O
reading O
frames O
, O
HBV O
/ O
J O
was O
closer O
to O
gibbon O
/ O
orangutan O
genotypes O
than O
to O
human O
genotypes O
in O
the O
P O
and O
large O
S O
genes O
and O
closest O
to O
Australian O
aboriginal O
strains O
( O
HBV O
/ O
C4 O
) O
and O
orangutan O
- O
derived O
strains O
in O
the O
S O
gene O
, O
whereas O
it O
was O
closer O
to O
human O
than O
ape O
genotypes O
in O
the O
C O
gene O
. O

In O
this O
study O
we O
show O
that O
, O
for O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
the O
size O
of O
the O
inoculum O
contributes O
to O
the O
kinetics O
of O
viral O
spread O
and O
immunological O
priming O
, O
which O
then O
determine O
the O
outcome O
of O
infection O
. O

Unexpectedly O
, O
despite O
vastly O
different O
viral O
kinetics O
, O
both O
high O
- O
dose O
inocula O
( O
10 O
( O
10 O
) O
genome O
equivalents O
[ O
GE O
] O
per O
animal O
) O
and O
low O
- O
dose O
inocula O
( O
10 O
( O
0 O
) O
GE O
per O
animal O
) O
primed O
the O
CD4 O
T O
- O
cell O
response O
after O
logarithmic O
spread O
was O
detectable O
, O
allowing O
infection O
of O
100 O
% O
of O
hepatocytes O
and O
requiring O
prolonged O
immunopathology O
before O
clearance O
occurred O
. O

In O
contrast O
, O
intermediate O
( O
10 O
( O
7 O
) O
and O
10 O
( O
4 O
) O
GE O
) O
inocula O
primed O
the O
T O
- O
cell O
response O
before O
detectable O
logarithmic O
spread O
and O
were O
abruptly O
terminated O
with O
minimal O
immunopathology O
before O
0 O
. O

Surprisingly O
, O
a O
dosage O
of O
10 O
( O
1 O
) O
GE O
primed O
the O
T O
- O
cell O
response O
after O
all O
hepatocytes O
were O
infected O
and O
caused O
either O
prolonged O
or O
persistent O
infection O
with O
severe O
immunopathology O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
genome O
replicates O
within O
the O
ribonucleoprotein B
( I
RNP I
) I
complex O
in O
the O
modified O
membranous O
structures O
extended O
from O
endoplasmic O
reticulum O
. O

A O
proteomic O
analysis O
of O
HCV O
RNP O
complexes O
revealed O
the O
association O
of O
oxysterol B
binding I
protein I
( I
OSBP I
) I
as O
one O
of O
the O
components O
of O
these O
complexes O
. O

The O
pleckstrin B
homology I
( I
PH I
) I
domain O
located O
in O
the O
N O
- O
terminal O
region O
of O
OSBP O
targeted O
this O
protein O
to O
the O
Golgi O
apparatus O
. O

OSBP O
deletion O
mutation O
in O
the O
PH O
( O
Delta O
PH O
) O
domain O
failed O
to O
localize O
to O
the O
Golgi O
apparatus O
and O
inhibited O
the O
HCV O
particle O
release O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
particles O
bear O
a O
receptor O
- O
binding O
site O
located O
in O
the O
pre O
- O
S1 O
domain O
of O
the O
large O
HBV O
envelope O
protein O
. O

Using O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
as O
a O
surrogate O
of O
HBV O
, O
a O
second O
infectivity O
determinant O
was O
recently O
identified O
in O
the O
envelope O
proteins O
antigenic B
loop I
( I
AGL I
) I
, O
and O
its O
activity O
was O
shown O
to O
depend O
upon O
cysteine O
residues O
that O
are O
essential O
for O
the O
structure O
of O
the O
HBV O
immunodominant O
a O
determinant O
. O

During O
a O
hepadnavirus O
infection O
, O
viral O
DNA O
integrates O
at O
a O
low O
rate O
into O
random O
sites O
in O
the O
host O
DNA O
, O
producing O
unique O
virus O
- O
cell O
junctions O
detectable O
by O
inverse B
nested I
PCR I
( I
invPCR I
) I
. O

4 O
- O
year O
- O
old O
woodchucks O
( O
Marmota O
monax O
) O
chronically O
infected O
with O
woodchuck O
hepatitis O
virus O
contained O
at O
least O
100 O
, O
000 O
clones O
of O
> O
1 O
, O
000 O
hepatocytes O
( O
W O
. O

In O
order O
to O
further O
investigate O
this O
issue O
, O
we O
looked O
for O
similar O
clonal O
expansion O
of O
hepatocytes O
in O
the O
livers O
of O
chimpanzees O
chronically O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Fifty O
clones O
ranging O
in O
size O
from O
similar O
to O
35 O
to O
10 O
, O
000 O
hepatocytes O
were O
detected O
using O
invPCR O
in O
32 O
liver O
biopsy O
fragments O
( O
similar O
to O
1 O
mg O
) O
containing O
, O
in O
total O
, O
similar O
to O
3 O
x O
10 O
( O
7 O
) O
liver O
cells O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
characterized O
by O
substantial O
acute O
pulmonary O
inflammation O
with O
a O
high O
mortality O
rate O
. O

Despite O
the O
identification O
of O
SARS B
coronavirus I
( I
SARS I
- I
CoV I
) I
as O
the O
etiologic O
agent O
of O
SARS O
, O
a O
thorough O
understanding O
of O
the O
underlying O
disease O
pathogenesis O
has O
been O
hampered O
by O
the O
lack O
of O
a O
suitable O
animal O
model O
that O
recapitulates O
the O
human O
disease O
. O

) O
infection O
of O
A O
/ O
J O
mice O
with O
the O
CoV O
mouse B
hepatitis I
virus I
strain I
1 I
( I
MHV I
- I
1 I
) I
induces O
an O
acute O
respiratory O
disease O
with O
a O
high O
lethality O
rate O
that O
shares O
several O
pathological O
similarities O
with O
SARS O
- O
CoV O
infection O
in O
humans O
. O

In O
this O
study O
, O
we O
examined O
virus O
replication O
and O
the O
character O
of O
pulmonary O
inflammation O
induced O
by O
MHV O
- O
1 O
infection O
in O
susceptible O
( O
A O
/ O
J O
, O
C3H O
/ O
HeJ O
, O
and O
BALB O
/ O
c O
) O
and O
resistant O
( O
C57BL O
/ O
6 O
) O
strains O
of O
mice O
. O

B O
and O
BALB O
/ O
c O
mice O
exhibited O
MHV O
- O
1 O
- O
induced O
weight O
loss O
, O
whereas O
all O
other O
strains O
of O
H O
- O
2 O
( O
b O
) O
and O
H O
- O
2 O
( O
d O
) O
mice O
did O
not O
show O
any O
signs O
of O
disease O
following O
MHV O
- O
1 O
infection O
. O

H O
- O
2 O
( O
k O
) O
mice O
demonstrated O
moderate O
susceptibility O
, O
with O
C3H O
/ O
HeJ O
mice O
exhibiting O
the O
most O
severe O
disease O
. O

C3H O
/ O
HeJ O
mice O
harbor O
a O
natural O
mutation O
in O
the O
gene O
that O
encodes O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
that O
disrupts O
TLR4 O
signaling O
. O

Here O
, O
we O
show O
that O
the O
productive O
infection O
of O
HeLa O
cells O
with O
encephalomyocarditis O
virus O
( O
a O
cardiovirus O
) O
was O
not O
accompanied O
by O
full O
- O
fledged O
apoptosis O
( O
although O
the O
activation O
of O
caspases O
was O
detected O
late O
in O
infection O
) O
but O
rather O
elicited O
a O
strong O
antiapoptotic O
state O
, O
as O
evidenced O
by O
the O
resistance O
of O
infected O
cells O
to O
viral O
and O
nonviral O
apoptosis O
inducers O
. O

The O
development O
of O
the O
antiapoptotic O
state O
appeared O
to O
depend O
on O
a O
function O
( O
s O
) O
of O
the O
viral O
leader O
( O
L O
) O
protein O
, O
since O
its O
mutational O
inactivation O
resulted O
in O
the O
efflux O
of O
cytochrome O
c O
from O
mitochondria O
, O
the O
early O
activation O
of O
caspases O
, O
and O
the O
appearance O
of O
morphological O
and O
biochemical O
signs O
of O
apoptosis O
in O
a O
significant O
proportion O
of O
infected O
cells O
. O

Although O
the O
exact O
nature O
of O
the O
antiapoptotic O
function O
( O
s O
) O
of O
cardioviruses O
remains O
obscure O
, O
our O
results O
suggested O
that O
it O
includes O
previously O
undescribed O
mechanisms O
operating O
upstream O
and O
possibly O
downstream O
of O
the O
mitochondrial O
level O
, O
and O
that O
L O
is O
involved O
in O
the O
control O
of O
these O
mechanisms O
. O

These O
proteins O
appear O
to O
be O
independent O
acquisitions O
in O
the O
evolution O
of O
picornaviruses O
, O
implying O
multiple O
cases O
of O
functional O
( O
though O
not O
structural O
) O
convergence O
. O

Broadly O
neutralizing O
antibodies O
are O
commonly O
present O
in O
the O
sera O
of O
patients O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

To O
elucidate O
possible O
mechanisms O
of O
virus O
escape O
from O
these O
antibodies O
, O
retrovirus O
particles O
pseudotyped O
with O
HCV B
glycoproteins I
( I
HCVpp I
) I
isolated O
from O
sequential O
samples O
collected O
over O
a O
26 O
- O
year O
period O
from O
a O
chronically O
infected O
patient O
, O
H O
, O
were O
used O
to O
characterize O
the O
neutralization O
potential O
and O
binding O
affinity O
of O
a O
panel O
of O
anti O
- O
HCV O
E2 O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
. O

Moreover O
, O
AP33 O
, O
a O
neutralizing O
murine O
monoclonal B
antibody I
( I
Mab I
) I
to O
a O
linear O
epitope O
in O
E2 O
, O
was O
also O
tested O
against O
selected O
variants O
. O

dendritic B
cells I
( I
DCs I
) I
are O
reported O
to O
be O
functionally O
deficient O
during O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

To O
better O
understand O
the O
effect O
of O
HCV O
on O
DC O
function O
, O
we O
treated O
freshly O
purified O
human B
myeloid I
DCs I
( I
mDCs I
) I
and O
plasmacytoid B
DCs I
( I
pDCs I
) I
with O
HCV O
JFH1 O
. O

We O
found O
that O
HCV O
upregulated O
mDC O
maturation O
marker O
( O
CD83 O
, O
CD86 O
, O
and O
CD40 O
) O
expression O
and O
did O
not O
inhibit O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
ligand O
[ O
poly O
( O
I O
: O
C O
) O
] O
- O
induced O
mDC O
maturation O
, O
a O
finding O
consistent O
with O
the O
phenotype O
of O
DCs O
from O
HCV O
- O
infected O
subjects O
. O

At O
the O
same O
time O
, O
HCV O
JFH1 O
inhibited O
the O
ability O
of O
poly O
( O
I O
: O
C O
) O
- O
treated O
mDCs O
to O
activate O
naive O
CD4 O
T O
cells O
. O

In O
contrast O
, O
although O
there O
was O
no O
direct O
effect O
of O
virus O
on O
pDC O
maturation O
, O
HCV O
JFH1 O
inhibited O
TLR7 O
ligand O
( O
R848 O
) O
- O
induced O
pDC O
CD40 O
expression O
, O
and O
this O
was O
associated O
with O
impaired O
ability O
to O
activate O
naive O
CD4 O
T O
cells O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
is O
a O
multifunctional O
protein O
that O
regulates O
numerous O
cellular O
signal O
transduction O
pathways O
, O
including O
those O
that O
modulate O
apoptosis O
. O

Recent O
evidence O
has O
shown O
that O
, O
like O
other O
viruses O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
requires O
a O
ubiquitin O
ligase O
for O
release O
from O
the O
infected O
cell O
. O

The O
HBV O
core O
protein O
contains O
two O
lysine O
residues O
( O
K7 O
and O
K96 O
) O
, O
and O
K96 O
has O
been O
suggested O
to O
function O
as O
a O
potential O
ubiquitin O
acceptor O
site O
based O
on O
the O
fact O
that O
previous O
studies O
have O
shown O
that O
mutation O
of O
this O
amino O
acid O
to O
alanine O
blocks O
HBV O
release O
. O

Persistent O
infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
diseases O
. O

The O
aim O
of O
this O
study O
was O
to O
identify O
host O
cell O
factor O
( O
s O
) O
participating O
in O
the O
HCV O
replication B
complex I
( I
RC I
) I
and O
to O
clarify O
the O
regulatory O
mechanisms O
of O
viral O
genome O
replication O
dependent O
on O
the O
host O
- O
derived O
factor O
( O
s O
) O
identified O
. O

We O
found O
that O
one O
of O
these O
candidates O
, O
creatine B
kinase I
B I
( I
CKB I
) I
, O
a O
key O
ATP O
- O
generating O
enzyme O
that O
regulates O
ATP O
in O
subcellular O
compartments O
of O
nonmuscle O
cells O
, O
is O
important O
for O
efficient O
replication O
of O
the O
HCV O
genome O
and O
propagation O
of O
infectious O
virus O
. O

Cytoplasmic O
viral O
RNAs O
with O
5 B
' I
triphosphates I
( I
5 I
' I
ppp I
) I
are O
detected O
by O
the O
RNA O
helicase O
RIG O
- O
I O
, O
initiating O
downstream O
signaling O
and O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
expression O
that O
establish O
an O
antiviral O
state O
. O

We O
demonstrate O
here O
that O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
3 I
' I
untranslated I
region I
( I
UTR I
) I
RNA O
has O
greater O
activity O
as O
an O
immune O
stimulator O
than O
several O
flavivirus O
UTR O
RNAs O
. O

We O
confirmed O
that O
the O
HCV O
3 O
' O
- O
UTR O
poly O
( O
U O
/ O
UC O
) O
region O
is O
the O
determinant O
for O
robust O
activation O
of O
RIG O
- O
I O
- O
mediated O
innate O
immune O
signaling O
and O
that O
its O
antisense O
sequence O
, O
poly O
( O
AG O
/ O
A O
) O
, O
is O
an O
equivalent O
RIG O
- O
I O
activator O
. O

The O
poly O
( O
U O
/ O
UC O
) O
region O
of O
the O
fulminant O
HCV O
JFH O
- O
1 O
strain O
was O
a O
relatively O
weak O
activator O
, O
while O
the O
antisense O
JFH O
- O
1 O
strain O
poly O
( O
AG O
/ O
A O
) O
RNA O
was O
very O
potent O
. O

Poly O
( O
U O
/ O
UC O
) O
activity O
does O
not O
require O
primary O
nucleotide O
sequence O
adjacency O
to O
the O
5 O
' O
ppp O
, O
suggesting O
that O
RIG O
- O
I O
recognizes O
two O
independent O
RNA O
domains O
. O

Whereas O
poly O
( O
U O
) O
50 O
- O
nt O
or O
poly O
( O
A O
) O
50 O
- O
nt O
sequences O
were O
minimally O
active O
, O
inserting O
a O
single O
C O
or O
G O
nucleotide O
, O
respectively O
, O
into O
these O
RNAs O
increased O
IFN O
- O
beta O
expression O
. O

Poly O
( O
U O
/ O
UC O
) O
RNAs O
transcribed O
in O
vitro O
using O
modified O
uridine O
2 O
' O
fluoro O
or O
pseudouridine O
ribonucleotides O
lacked O
signaling O
activity O
while O
functioning O
as O
competitive O
inhibitors O
of O
RIG O
- O
I O
binding O
and O
IFN O
- O
beta O
expression O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
pathogen O
that O
increases O
the O
severity O
of O
liver O
disease O
caused O
by O
hepatitis O
B O
virus O
. O

These O
RNAs O
are O
associated O
with O
the O
sole O
virally O
encoded O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
in O
infected O
cells O
; O
however O
, O
the O
nature O
of O
the O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
is O
not O
well O
understood O
. O

In O
an O
electrophoretic O
mobility O
shift O
assay O
, O
this O
protein O
produced O
a O
discrete O
, O
micrococcal O
nuclease O
- O
resistant O
complex O
with O
an O
similar O
to O
400 O
- O
nucleotide B
( I
nt I
) I
segment O
of O
HDV O
unbranched O
rod O
RNA O
. O

The O
selection O
of O
escape O
mutations O
has O
a O
major O
impact O
on O
immune O
control O
of O
infections O
with O
viruses O
such O
as O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
. O

Viral O
evasion O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
leaves O
predictable O
combinations O
of O
escape O
mutations O
, O
termed O
HLA O
footprints O
. O

Here O
we O
investigated O
the O
extent O
to O
which O
HLA O
footprint O
sites O
in O
HIV B
type I
1 I
( I
HIV I
- I
1 I
) I
are O
associated O
with O
viral O
evolution O
among O
and O
within O
clades O
. O

First O
, O
we O
examined O
the O
extent O
to O
which O
amino O
acid O
differences O
between O
HIV O
- O
1 O
clades O
share O
identity O
with O
sites O
of O
HLA O
- O
mediated O
selection O
pressure O
and O
observed O
a O
strong O
association O
, O
in O
particular O
with O
respect O
to O
sites O
of O
HLA O
- O
B O
selection O
( O
P O
< O
10 O
( O
- O
6 O
) O
) O
. O

Intracellular O
detection O
of O
RNA O
virus O
infection O
is O
mediated O
by O
the O
RNA O
helicases O
RIG B
- I
I I
( I
retinoic I
acid I
inducible I
gene I
I I
) I
and O
MDA O
- O
5 O
, O
which O
recognize O
viral O
RNA O
and O
signal O
through O
the O
adaptor O
molecule O
MAVS B
( I
mitochondrial I
antiviral I
signaling I
) I
to O
stimulate O
the O
phosphorylation O
and O
activation O
of O
the O
transcription O
factors O
IRF3 B
( I
interferon I
regulatory I
factor I
3 I
) I
and O
IRF7 O
. O

Interestingly O
, O
unlike O
other O
signaling O
molecules O
identified O
in O
this O
pathway O
, O
MAVS O
contains O
a O
C O
- O
terminal O
transmembrane B
( I
TM I
) I
domain O
that O
is O
essential O
for O
both O
type O
I O
interferon O
induction O
and O
localization O
of O
MAVS O
to O
the O
mitochondrial O
outer O
membrane O
. O

The O
activation O
of O
RIG O
- O
I O
/ O
MDA O
- O
5 O
leads O
to O
the O
TM O
- O
dependent O
dimerization O
of O
the O
MAVS O
N O
- O
terminal O
caspase O
recruitment O
domain O
, O
thereby O
providing O
an O
interface O
for O
direct O
binding O
to O
and O
activation O
of O
the O
downstream O
effector O
TRAF3 O
( O
tumor O
necrosis O
factor O
receptor O
- O
associated O
factor O
3 O
) O
. O

hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
is O
a O
secreted O
version O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
that O
promotes O
immune O
tolerance O
and O
persistent O
infection O
. O

Four O
RXXR O
motifs O
are O
present O
at O
the O
carboxyl O
terminus O
of O
the O
HBeAg O
precursor O
, O
with O
the O
first O
two O
fused O
as O
( O
151 O
) O
RRGRSPR O
( O
157 O
) O
. O

Genotype O
A O
possesses O
two O
extra O
amino O
acids O
at O
the O
first O
motif O
( O
( O
151 O
) O
RRDRGRSPR O
( O
159 O
) O
) O
, O
which O
weakens O
the O
first O
motif O
and O
separates O
it O
from O
the O
second O
one O
. O

Site O
- O
directed O
mutagenesis O
and O
transfection O
experiments O
with O
human O
hepatoma O
cell O
lines O
indicated O
that O
HBeAg O
of O
genotype O
B O
is O
derived O
from O
cleavage O
at O
the O
first O
( O
( O
151 O
) O
RRGR O
( O
154 O
) O
) O
motif O
. O

The O
major O
HBeAg O
form O
of O
genotype O
A O
corresponds O
to O
cleavage O
at O
the O
second O
( O
( O
RSPR159 O
) O
- O
R O
- O
156 O
) O
motif O
, O
and O
the O
other O
two O
forms O
are O
cleavage O
products O
of O
the O
first O
( O
( O
RRDR154 O
) O
- O
R O
- O
151 O
) O
and O
third O
( O
( O
RRRR169 O
) O
- O
R O
- O
166 O
) O
motifs O
, O
respectively O
. O

Characterization O
of O
the O
immune O
responses O
induced O
in O
the O
initial O
stages O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
is O
of O
critical O
importance O
for O
an O
understanding O
of O
early O
viral O
pathogenesis O
and O
prophylactic O
vaccine O
design O
. O

Here O
, O
we O
used O
sequential O
plasma O
samples O
collected O
during O
the O
eclipse O
and O
exponential O
viral O
expansion O
phases O
from O
subjects O
acquiring O
HIV O
- O
1 O
( O
or O
, O
for O
comparison O
, O
hepatitis O
B O
virus O
[ O
HBV O
] O
or O
hepatitis O
C O
virus O
[ O
HCV O
] O
) O
to O
determine O
the O
nature O
and O
kinetics O
of O
the O
earliest O
systemic O
elevations O
in O
cytokine O
and O
chemokine O
levels O
in O
each O
infection O
. O

The O
increase O
in O
plasma O
viremia O
in O
acute O
HIV O
- O
1 O
infection O
was O
found O
to O
be O
associated O
with O
elevations O
in O
plasma O
levels O
of O
multiple O
cytokines O
and O
chemokines O
, O
including O
rapid O
and O
transient O
elevations O
in O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
interleukin B
- I
15 I
( I
IL I
- I
15 I
) I
levels O
; O
a O
large O
increase O
in O
inducible B
protein I
10 I
( I
IP I
- I
10 I
) I
levels O
; O
rapid O
and O
more O
- O
sustained O
increases O
in O
tumor O
necrosis O
factor O
alpha O
and O
monocyte O
chemotactic O
protein O
1 O
levels O
; O
more O
slowly O
initiated O
elevations O
in O
levels O
of O
additional O
proinflammatory O
factors O
including O
IL O
- O
6 O
, O
IL O
- O
8 O
, O
IL O
- O
18 O
, O
and O
IFN O
- O
gamma O
; O
and O
a O
late O
- O
peaking O
increase O
in O
levels O
of O
the O
immunoregulatory O
cytokine O
IL O
- O
10 O
. O

Notably O
, O
there O
was O
comparatively O
little O
perturbation O
in O
plasma O
cytokine O
levels O
during O
the O
same O
phase O
of O
HBV O
infection O
and O
a O
delayed O
response O
of O
more O
intermediate O
magnitude O
in O
acute O
HCV O
infection O
, O
indicating O
that O
the O
rapid O
activation O
of O
a O
striking O
systemic O
cytokine O
cascade O
is O
not O
a O
prerequisite O
for O
viral O
clearance O
( O
which O
occurs O
in O
a O
majority O
of O
HBV O
- O
infected O
individuals O
) O
. O

The O
intense O
early O
cytokine O
storm O
in O
acute O
HIV O
- O
1 O
infection O
may O
have O
immunopathological O
consequences O
, O
promoting O
immune O
activation O
, O
viral O
replication O
, O
and O
CD4 O
( O
+ O
) O
T O
- O
cell O
loss O
. O

Although O
the O
virological O
features O
of O
serologically O
silent O
hepadnaviral O
primary B
occult I
infection I
( I
POI I
) I
have O
been O
relatively O
well O
recognized O
in O
the O
woodchuck O
model O
of O
hepatitis O
B O
virus O
infection O
, O
the O
characteristics O
of O
accompanying O
immune O
responses O
remain O
unknown O
. O

In O
this O
study O
, O
the O
kinetics O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
- O
specific O
and O
generalized O
( O
mitogen O
- O
induced O
) O
T O
- O
cell O
proliferative O
responses O
and O
cytokine O
expression O
profiles O
in O
circulating O
lymphoid O
cells O
and O
the O
liver O
, O
along O
with O
WHV O
- O
specific O
antibody O
responses O
, O
were O
investigated O
during O
experimentally O
induced O
POI O
and O
subsequent O
challenge O
with O
a O
liver O
- O
pathogenic O
dose O
( O
> O
10 O
( O
3 O
) O
virions O
) O
or O
liver O
- O
nonpathogenic O
dose O
( O
50 O
virions O
) O
of O
the O
same O
virus O
. O

Furthermore O
, O
immediately O
after O
exposure O
to O
a O
liver O
- O
nonpathogenic O
dose O
of O
WHV O
, O
lymphocytes O
acquired O
a O
heightened O
capacity O
to O
proliferate O
in O
response O
to O
mitogenic O
stimuli O
and O
displayed O
augmented O
expression O
of O
alpha O
interferon O
, O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
, O
and O
IL O
- O
2 O
, O
but O
not O
tumor O
necrosis O
factor O
alpha O
. O

Lentiviral O
vectors O
( O
lentivectors O
) O
are O
effective O
for O
stimulation O
of O
cell O
- O
mediated O
and O
humoral O
immunity O
following O
subcutaneous O
and O
intramuscular O
immunization O
. O

First O
, O
systemic O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
the O
model O
antigen O
ovalbumin O
were O
detected O
following O
subcutaneous O
injection O
of O
nonintegrating O
lentivectors O
. O

Furthermore O
, O
an O
enhanced O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
, O
peaking O
at O
7 O
days O
, O
was O
stimulated O
by O
coexpression O
of O
p38 O
MAP O
kinase O
or O
an O
NF O
- O
kappa O
B O
activator O
from O
the O
same O
vector O
. O

Second O
, O
we O
demonstrated O
systemic O
CD8 O
( O
+ O
) O
T O
- O
cell O
and O
antibody O
responses O
to O
the O
secreted O
hepatitis B
B I
virus I
( I
HBV I
) I
surface O
antigen O
expressed O
from O
a O
nonintegrating O
lentivector O
injected O
intramuscularly O
. O

To O
define O
the O
ratio O
of O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
RNA O
molecules O
to O
infectious O
virions O
in O
plasma O
, O
a O
ramp O
- O
up O
- O
stage O
plasma O
pool O
was O
made O
from O
the O
earliest O
viral B
RNA I
( I
vRNA I
) I
- O
positive O
plasma O
samples O
( O
collected O
approximately O
7 O
days O
after O
inoculation O
) O
from O
seven O
macaques O
, O
and O
a O
set O
- O
point O
- O
stage O
plasma O
pool O
was O
made O
from O
plasma O
samples O
collected O
10 O
to O
16 O
weeks O
after O
peak O
viremia O
from O
seven O
macaques O
; O
vRNA O
levels O
in O
these O
plasma O
pools O
were O
determined O
, O
and O
serial O
10 O
- O
fold O
dilutions O
containing O
1 O
to O
1 O
, O
500 O
vRNA O
copies O
/ O
ml O
were O
made O
. O

Furthermore O
, O
there O
is O
a O
high O
ratio O
of O
infectious O
virions O
to O
total O
virions O
in O
ramp O
- O
up O
- O
stage O
plasma O
( O
between O
1 O
: O
1 O
and O
1 O
: O
10 O
) O
and O
a O
lower O
ratio O
in O
set O
- O
point O
- O
stage O
plasma O
( O
between O
1 O
: O
75 O
and O
1 O
: O
750 O
) O
. O

interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
induction O
accompanies O
viral O
clearance O
in O
chronic O
hepatitis O
B O
virus O
infection O
. O

Here O
, O
we O
tested O
the O
therapeutic O
potential O
of O
IL O
- O
12 O
gene O
therapy O
in O
woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
an O
infection O
that O
closely O
resembles O
chronic O
hepatitis O
B O
. O

All O
woodchucks O
with O
viral O
loads O
below O
10 O
( O
10 O
) O
viral B
genomes I
( I
vg I
) I
/ O
ml O
showed O
a O
marked O
and O
sustained O
reduction O
of O
viremia O
that O
was O
accompanied O
by O
a O
reduction O
in O
hepatic O
WHV O
DNA O
, O
a O
loss O
of O
e O
antigen O
and O
surface O
antigen O
, O
and O
improved O
liver O
histology O
. O

These O
studies O
showed O
that O
lymphocytes O
from O
healthy O
woodchucks O
or O
from O
animals O
with O
low O
viremia O
levels O
produced O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
upon O
IL O
- O
12 O
stimulation O
, O
while O
lymphocytes O
from O
woodchucks O
with O
high O
viremia O
failed O
to O
upregulate O
IFN O
- O
gamma O
in O
response O
to O
IL O
- O
12 O
. O

In O
conclusion O
, O
IL O
- O
12 O
- O
based O
gene O
therapy O
is O
an O
efficient O
approach O
to O
treat O
chronic O
hepadnavirus O
infection O
in O
woodchucks O
with O
viral O
loads O
below O
10 O
( O
10 O
) O
vg O
/ O
ml O
. O

Increasing O
evidence O
points O
to O
the O
importance O
of O
the O
interferon B
( I
IFN I
) I
response O
in O
determining O
the O
host O
range O
and O
virulence O
of O
African B
swine I
fever I
virus I
( I
ASFV I
) I
. O

Infection O
with O
attenuated O
strains O
of O
ASFV O
leads O
to O
the O
upregulation O
of O
genes O
controlled O
by O
IFN O
pathways O
, O
including O
myxovirus O
resistance O
( O
Mx O
) O
genes O
that O
are O
potent O
effectors O
of O
the O
antiviral O
state O
. O

Arsenic B
trioxide I
( I
ATO I
) I
, O
a O
therapeutic O
reagent O
used O
for O
the O
treatment O
of O
acute O
promyelocytic O
leukemia O
, O
has O
recently O
been O
reported O
to O
increase O
human O
immunodeficiency O
virus O
type O
1 O
infectivity O
. O

However O
, O
in O
this O
study O
, O
we O
have O
demonstrated O
that O
replication O
of O
genome O
- O
length O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
( O
O O
strain O
of O
genotype O
1b O
) O
was O
notably O
inhibited O
by O
ATO O
at O
submicromolar O
concentrations O
without O
cell O
toxicity O
. O

RNA O
replication O
of O
HCV O
- O
JFH1 O
( O
genotype O
2a O
) O
and O
the O
release O
of O
core O
protein O
into O
the O
culture O
supernatants O
were O
also O
inhibited O
by O
ATO O
after O
the O
HCV O
infection O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
is O
an O
established O
model O
for O
human O
hepatitis O
B O
virus O
. O

Serum O
WHV B
DNA I
and I
surface I
antigen I
( I
WHsAg I
) I
were O
detected O
as O
early O
as O
1 O
to O
3 O
weeks O
following O
experimental O
infection O
and O
peaked O
between O
1 O
and O
5 O
weeks O
postinfection O
. O

Decreasing O
viremia O
correlated O
with O
transient O
liver O
injury O
marked O
by O
an O
increase O
in O
serum B
sorbitol I
dehydrogenase I
( I
SDH I
) I
levels O
. O

Circulating B
immune I
complexes I
( I
CICs I
) I
of O
WHsAg O
and O
antibodies O
against O
WHsAg O
( O
anti O
- O
WHs O
) O
that O
correlated O
temporarily O
with O
the O
peaks O
in O
serum O
viremia O
and O
WHs O
antigenemia O
were O
detected O
. O

Nuclear O
receptors O
have O
a O
unique O
role O
in O
governing O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
. O

hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
and O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
plus O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
have O
been O
shown O
to O
support O
viral O
biosynthesis O
in O
nonhepatoma O
cells O
in O
the O
absence O
of O
additional O
liver O
- O
enriched O
transcription O
factors O
. O

Direct O
population O
sequencing O
and O
reverse O
hybridization O
( O
line O
probe O
assay O
[ O
LiPA O
] O
) O
- O
based O
methods O
are O
the O
most O
common O
methods O
for O
detecting O
hepatitis B
B I
virus I
( I
HBV I
) I
drug O
resistance O
mutations O
, O
although O
only O
mutations O
present O
in O
viral O
quasispecies O
with O
a O
prevalence O
of O
> O
= O
20 O
% O
can O
be O
detected O
by O
sequencing O
, O
and O
only O
known O
mutations O
are O
detected O
by O
LiPA O
. O

Massively O
parallel O
ultradeep O
pyrosequencing O
( O
UDPS O
; O
GS O
FLX O
platform O
) O
was O
used O
to O
analyze O
HBV O
quasispecies O
in O
reverse B
transcriptase I
( I
RT I
) I
and O
hepatitis B
B I
S I
antigen I
( I
HBsAg I
) I
from O
five O
drug O
- O
naive O
patients O
and O
eight O
drug O
- O
resistant O
patients O
. O

During O
virus O
clearance O
antiviral O
cytokines O
are O
thought O
to O
block O
virus O
replication O
and O
formation O
of O
new O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
the O
viral O
transcriptional O
template O
. O

We O
have O
addressed O
these O
questions O
by O
asking O
if O
treatment O
of O
woodchucks O
with O
the O
nucleoside O
analog O
inhibitor O
of O
viral O
DNA O
synthesis O
entecavir B
( I
ETV I
) I
reduced O
hepatocyte O
turnover O
during O
clearance O
of O
transient O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
infections O
. O

The O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
protein O
plays O
a O
central O
role O
in O
innate O
antiviral O
immunity O
. O

Recognition O
of O
virus O
infections O
by O
pattern B
recognition I
receptors I
( I
PRRs I
) I
, O
such O
as O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
, O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
, O
and O
melanoma B
differentiation I
associated I
gene I
5 I
( I
MDA5 I
) I
, O
activates O
signaling O
pathways O
, O
leading O
to O
the O
induction O
of O
inflammatory O
cytokines O
that O
limit O
viral O
replication O
. O

To O
determine O
the O
effects O
of O
PRR O
- O
mediated O
innate O
immune O
response O
on O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
, O
a O
1 O
. O

3mer O
HBV O
genome O
was O
cotransfected O
into O
HepG2 O
or O
Huh7 O
cells O
with O
plasmid O
expressing O
TLR O
adaptors O
, O
myeloid B
differentiation I
primary I
response I
gene I
88 I
( I
Myd88 I
) I
, O
and O
TIR B
- I
domain I
- I
containing I
adaptor I
- I
inducing I
beta I
interferon I
( I
TRIF I
) I
, O
or O
RIG O
- O
I O
/ O
MDA5 O
adaptor O
, O
interferon B
promoter I
stimulator I
1 I
( I
IPS I
- I
1 I
) I
. O

Furthermore O
, O
our O
results O
suggest O
that O
besides O
NF O
- O
kappa O
B O
, O
additional O
signaling O
pathway O
( O
s O
) O
are O
required O
for O
TRIF O
to O
induce O
a O
maximum O
antiviral O
response O
against O
HBV O
. O

Activation O
of O
CD4 O
( O
+ O
) O
T O
cells O
helps O
establish O
and O
sustain O
other O
immune O
responses O
. O

We O
have O
previously O
shown O
that O
responses O
against O
a O
broad O
set O
of O
nine O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitopes O
were O
present O
in O
the O
setting O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
Armstrong O
infection O
in O
the O
context O
of O
H O
- O
2 O
( O
d O
) O
. O

This O
is O
quite O
disparate O
to O
the O
H O
- O
2 O
( O
b O
) O
setting O
, O
where O
only O
two O
epitopes O
have O
been O
identified O
. O

We O
were O
interested O
in O
determining O
whether O
a O
broad O
set O
of O
responses O
was O
unique O
to O
H O
- O
2 O
( O
d O
) O
or O
whether O
additional O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitopes O
could O
be O
identified O
in O
the O
setting O
of O
the O
H O
- O
2 O
( O
b O
) O
background O
. O

To O
pursue O
this O
question O
, O
we O
infected O
C57BL O
/ O
6 O
mice O
with O
LCMV O
Armstrong O
and O
determined O
the O
repertoire O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
using O
overlapping O
15 O
- O
mer O
peptides O
corresponding O
to O
the O
LCMV O
Armstrong O
sequence O
. O

We O
confirmed O
positive O
responses O
by O
intracellular O
cytokine O
staining O
and O
major B
histocompatibility I
complex I
( I
MHC I
) I
- O
peptide O
binding O
assays O
. O

These O
epitopes O
originate O
from O
the O
nucleoprotein B
( I
NP I
) I
and O
glycoprotein B
( I
GP I
) I
. O

Out O
of O
the O
six O
newly O
identified O
CD4 O
( O
+ O
) O
epitopes O
, O
four O
of O
them O
also O
stimulate O
CD8 O
( O
+ O
) O
T O
cells O
in O
a O
statistically O
significant O
manner O
. O

Furthermore O
, O
we O
assessed O
these O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
during O
the O
memory O
phase O
of O
LCMV O
Armstrong O
infection O
and O
after O
infection O
with O
a O
chronic O
strain O
of O
LCMV O
and O
determined O
that O
a O
subset O
of O
the O
responses O
could O
be O
detected O
under O
these O
different O
conditions O
. O

This O
is O
the O
first O
example O
of O
a O
broad O
repertoire O
of O
shared O
epitopes O
between O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
context O
of O
viral O
infection O
. O

The O
inherent O
sequence O
diversity O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
represents O
a O
major O
hurdle O
for O
the O
adaptive O
immune O
system O
to O
control O
viral O
replication O
. O

We O
analyzed O
it O
with O
a O
patient O
cohort O
with O
chronic O
HCV O
genotype O
1b O
infection O
and O
in O
a O
single O
- O
source O
outbreak O
( O
genotype O
1b O
) O
. O

When O
tested O
in O
the O
subgenomic O
replicon O
( O
Con1 O
) O
, O
the O
observed O
mutations O
reduce O
viral O
replication O
compared O
with O
the O
prototype O
sequence O
. O

We O
took O
advantage O
of O
the O
segregation O
of O
different O
hepatitis B
B I
virus I
( I
HBV I
) I
genotypes O
in O
geographically O
and O
genetically O
distinct O
host O
populations O
to O
directly O
analyze O
the O
impact O
that O
host O
and O
virus O
variables O
exert O
on O
these O
virus O
- O
specific O
T O
- O
cell O
parameters O
. O

T O
- O
cell O
responses O
against O
the O
entire O
HBV O
proteome O
were O
analyzed O
in O
a O
total O
of O
109 O
HBV O
- O
infected O
subjects O
of O
distinct O
ethnicities O
( O
47 O
of O
Chinese O
origin O
and O
62 O
of O
Caucasian O
origin O
) O
. O

We O
show O
that O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
attaches O
predominantly O
to O
detergent O
- O
soluble O
domains O
on O
the O
plasma O
membrane O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
core O
promoter O
activity O
is O
positively O
and O
negatively O
regulated O
by O
nuclear O
receptors O
, O
a O
superfamily O
of O
ligand O
- O
activated O
transcription O
factors O
, O
via O
cis O
- O
acting O
sequences O
located O
in O
the O
viral O
genome O
. O

In O
this O
study O
, O
we O
investigated O
the O
role O
of O
farnesoid B
X I
receptor I
alpha I
( I
FXR I
alpha I
) I
in O
modulating O
transcription O
from O
the O
HBV O
core O
promoter O
. O

FXR O
alpha O
is O
a O
liver O
- O
enriched O
nuclear O
receptor O
activated O
by O
bile O
acids O
recognizing O
hormone O
response O
elements O
by O
forming O
heterodimers O
with O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrated O
that O
FXR O
alpha O
- O
RXR O
alpha O
heterodimers O
can O
bind O
two O
motifs O
on O
the O
HBV O
enhancer O
II O
and O
core O
promoter O
regions O
, O
presenting O
high O
homology O
to O
the O
consensus O
( O
AGGTCA O
) O
inverted O
repeat O
FXR O
alpha O
response O
elements O
. O

The O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
induces O
a O
minimal O
type B
I I
interferon I
( I
IFN I
) I
response O
in O
several O
cell O
types O
in O
vitro O
despite O
the O
fact O
that O
the O
type O
I O
IFN O
response O
is O
important O
in O
protecting O
the O
mouse O
from O
infection O
in O
vivo O
. O

When O
infected O
with O
MHV O
, O
mice O
deficient O
in O
IFN O
- O
associated O
receptor O
expression O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
became O
moribund O
by O
48 O
h O
postinfection O
. O

To O
determine O
the O
pathway O
by O
which O
MHV O
is O
recognized O
in O
macrophages O
, O
IFN O
- O
beta O
mRNA O
expression O
was O
quantified O
following O
MHV O
infection O
of O
a O
panel O
of O
primary O
bone O
marrow O
- O
derived O
macrophages O
generated O
from O
mice O
lacking O
different O
pattern B
recognition I
receptors I
( I
PRRs I
) I
. O

We O
demonstrate O
a O
role O
for O
protein B
kinase I
A I
( I
PKA I
) I
in O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
. O

The O
inhibition O
of O
PKA O
with O
H89 O
, O
cyclic B
AMP I
( I
cAMP I
) I
antagonists O
, O
or O
the O
protein O
kinase O
inhibitor O
peptide O
reduced O
HCV O
entry O
into O
Huh O
- O
7 O
. O

Since O
viral O
entry O
is O
dependent O
on O
the O
host O
cell O
expression O
of O
CD81 O
, O
scavenger O
receptor O
BI O
, O
and O
Claudin B
- I
1 I
( I
CLDN1 I
) I
, O
we O
studied O
the O
role O
of O
PKA O
in O
regulating O
viral O
receptor O
localization O
by O
confocal O
imaging O
and O
fluorescence B
resonance I
energy I
transfer I
( I
FRET I
) I
analysis O
. O

5 O
cells O
induced O
a O
reorganization O
of O
CLDN1 O
from O
the O
plasma O
membrane O
to O
an O
intracellular O
vesicular O
location O
( O
s O
) O
and O
disrupted O
FRET O
between O
CLDN1 O
and O
CD81 O
, O
demonstrating O
the O
importance O
of O
CLDN1 O
expression O
at O
the O
plasma O
membrane O
for O
viral O
receptor O
activity O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
pathogenic O
RNA O
virus O
with O
a O
plant O
viroid O
- O
like O
genome O
structure O
. O

HDV O
encodes O
two O
isoforms O
of O
delta O
antigen O
( O
HDAg O
) O
, O
the O
small O
and O
large O
forms O
of O
HDAg O
( O
SHDAg O
and O
LHDAg O
) O
, O
which O
are O
essential O
for O
HDV O
RNA O
replication O
and O
virion O
assembly O
, O
respectively O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
both O
isoforms O
of O
HDAg O
interact O
with O
transcription O
factor O
YY1 B
( I
Yin I
Yang I
1 I
) I
in O
vivo O
and O
in O
vitro O
. O

Results O
of O
sucrose O
gradient O
centrifugation O
analysis O
indicated O
the O
cosedimentation O
of O
the O
majority O
of O
SHDAg O
and O
a O
portion O
of O
the O
LHDAg O
with O
YY1 O
and O
its O
associated O
acetyltransferases O
CBP B
( I
CREB I
- I
binding I
protein I
) I
and O
p300 O
as O
a O
large O
nuclear O
complex O
in O
vivo O
. O

The O
death O
of O
CD4 O
( O
+ O
) O
CCR5 O
( O
+ O
) O
T O
cells O
is O
a O
hallmark O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
infection O
. O

We O
studied O
the O
plasma O
levels O
of O
cell O
death O
mediators O
and O
products O
- O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
related O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
, O
Fas O
ligand O
, O
TNF O
receptor O
type O
2 O
( O
TNFR O
- O
2 O
) O
, O
and O
plasma O
microparticles O
- O
during O
the O
earliest O
stages O
of O
infection O
following O
HIV B
type I
1 I
( I
HIV I
- I
1 I
) I
transmission O
in O
plasma O
samples O
from O
U O
. O

2 O
days O
before O
the O
peak O
of O
plasma O
viral B
load I
( I
VL I
) I
, O
while O
TNFR O
- O
2 O
, O
Fas O
ligand O
, O
and O
microparticle O
level O
elevations O
occurred O
concurrently O
with O
maximum O
VL O
. O

We O
found O
that O
T O
- O
cell O
apoptotic O
microparticles O
also O
potently O
suppressed O
in O
vitro O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgA O
antibody O
production O
by O
memory O
B O
cells O
. O

The O
window O
of O
opportunity O
for O
a O
HIV O
- O
1 O
vaccine O
is O
from O
the O
time O
of O
HIV O
- O
1 O
transmission O
until O
establishment O
of O
the O
latently O
infected O
CD4 O
( O
+ O
) O
T O
cells O
. O

In O
the O
sera O
of O
patients O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
in O
addition O
to O
infectious O
particles O
, O
there O
is O
an O
excess O
( O
typically O
1 O
, O
000 O
- O
to O
100 O
, O
000 O
- O
fold O
) O
of O
empty O
subviral B
particles I
( I
SVP I
) I
composed O
solely O
of O
HBV O
envelope O
proteins O
in O
the O
form O
of O
relatively O
smaller O
spheres O
and O
filaments O
of O
variable O
length O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
assembly O
also O
uses O
the O
envelope O
proteins O
of O
HBV O
to O
produce O
an O
infectious O
particle O
. O

duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
a O
model O
virus O
for O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
, O
which O
infects O
approximately O
360 O
million O
individuals O
worldwide O
. O

HBV O
DNA O
is O
present O
in O
the O
nucleus O
as O
a O
covalently O
closed O
circular O
( O
cccDNA O
) O
form O
, O
where O
it O
drives O
viral O
transcription O
and O
progeny O
virus O
production O
. O

To O
target O
cccDNA O
, O
six O
different O
zinc B
finger I
proteins I
( I
ZFP I
) I
were O
designed O
to O
bind O
DNA O
sequences O
in O
the O
DHBV O
enhancer O
region O
. O

interferon B
( I
IFN I
) I
has O
been O
part O
of O
the O
standard O
treatment O
of O
chronic O
hepatitis O
B O
infection O
for O
more O
than O
2 O
decades O
, O
yet O
the O
mechanism O
of O
action O
of O
this O
antiviral O
remains O
poorly O
understood O
. O

It O
was O
recently O
observed O
that O
members O
of O
the O
human O
APOBEC O
family O
of O
cytidine O
deaminases O
endowed O
with O
anti O
- O
hepatitis B
B I
virus I
( I
HBV I
) I
activity O
are O
upregulated O
by O
type O
I O
and O
II O
IFNs O
. O

Here O
, O
we O
show O
that O
murine B
APOBEC3 I
( I
muA3 I
) I
can O
also O
block O
HBV O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
often O
causes O
persistent O
infection O
despite O
the O
presence O
of O
neutralizing O
antibodies O
against O
the O
virus O
in O
the O
sera O
of O
hepatitis O
C O
patients O
. O

Previously O
, O
we O
have O
shown O
that O
E2 O
- O
CD81 O
interaction O
induces O
hypermutation O
of O
heavy O
- O
chain O
immunoglobulin O
( O
V O
- O
H O
) O
in O
B O
cells O
. O

To O
test O
this O
hypothesis O
, O
we O
infected O
human O
hybridoma O
clones O
producing O
either O
neutralizing O
or O
non O
- O
neutralizing O
anti O
- O
E2 O
or O
anti O
- O
E1 O
antibodies O
with O
a O
lymphotropic O
HCV O
( O
SB O
strain O
) O
. O

Over O
350 O
million O
people O
are O
chronically O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
and O
a O
significant O
number O
of O
chronically O
infected O
individuals O
develop O
primary O
liver O
cancer O
. O

HBV O
encodes O
seven O
viral O
proteins O
, O
including O
the O
nonstructural O
X O
( O
HBx O
) O
protein O
. O

This O
strain O
( O
HBV O
- O
VH24 O
) O
had O
a O
novel O
intergenotypic O
recombination O
between O
genotypes O
A O
, O
C O
, O
and O
G O
. O

Reverse O
transcription O
in O
hepadnaviruses O
is O
primed O
by O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
( O
protein O
priming O
) O
and O
requires O
the O
interaction O
between O
the O
RT O
and O
a O
specific O
viral O
RNA O
template O
termed O
epsilon O
. O

, O
the O
attachment O
of O
the O
first O
deoxynucleotide O
to O
RT O
( O
initiation O
) O
and O
the O
subsequent O
addition O
of O
2 O
or O
3 O
deoxynucleotides O
( O
polymerization O
) O
. O

In O
particular O
, O
a O
truncated O
duck O
hepatitis O
B O
virus O
RT O
( O
MiniRT2 O
) O
is O
competent O
in O
initiation O
but O
defective O
in O
polymerization O
when O
tested O
in O
the O
presence O
of O
Mg2 O
+ O
. O

Development O
of O
a O
successful O
hepatitis B
C I
virus I
( I
HCV I
) I
vaccine O
requires O
the O
definition O
of O
neutralization O
epitopes O
that O
are O
conserved O
among O
different O
HCV O
genotypes O
. O

Five O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
are O
described O
that O
cross O
- O
compete O
with O
other O
antibodies O
to O
a O
cluster O
of O
overlapping O
epitopes O
, O
previously O
designated O
domain O
B O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
enveloped O
positive O
- O
stranded O
RNA O
hepatotropic O
virus O
. O

Three O
host O
cell O
molecules O
have O
been O
reported O
to O
be O
important O
entry O
factors O
or O
receptors O
for O
HCV O
internalization O
: O
scavenger O
receptor O
BI O
, O
the O
tetraspanin O
CD81 O
, O
and O
the O
tight O
junction O
protein O
Claudin B
- I
1 I
( I
CLDN1 I
) I
. O

Imaging O
techniques O
that O
take O
advantage O
of O
fluorescence B
resonance I
energy I
transfer I
( I
FRET I
) I
to O
study O
protein O
- O
protein O
interactions O
have O
been O
developed O
. O

5 O
cells O
with O
recombinant O
HCV O
E1 O
- O
E2 O
glycoproteins O
and O
anti O
- O
CD81 O
monoclonal O
antibody O
modulated O
homotypic O
( O
CD81 O
- O
CD81 O
) O
and O
heterotypic O
( O
CD81 O
- O
CLDN1 O
) O
coreceptor O
protein O
association O
( O
s O
) O
at O
specific O
cellular O
locations O
, O
suggesting O
distinct O
roles O
in O
the O
viral O
entry O
process O
. O

A O
characteristic O
feature O
in O
the O
immune O
response O
to O
many O
persistent O
viral O
infections O
is O
the O
dysfunction O
or O
deletion O
of O
antigen O
- O
specific O
T O
cells O
( O
exhaustion O
) O
. O

Here O
, O
we O
have O
established O
that O
in O
the O
murine O
lymphocytic B
choriomeningitis I
virus I
( I
LCW I
) I
model O
, O
induction O
of O
the O
T O
- O
cell O
receptor O
signaling O
inhibitor O
molecule O
E3 O
ligase O
Cbl O
- O
b O
is O
critically O
involved O
in O
this O
decision O
. O

In O
particular O
, O
our O
data O
revealed O
that O
Cbl O
- O
b O
controls O
the O
program O
responsible O
for O
T O
- O
cell O
tolerance O
( O
exhaustion O
) O
induction O
during O
a O
chronic O
viral O
infection O
. O

Thus O
, O
Cbl O
- O
b O
( O
- O
/ O
- O
) O
mice O
infected O
with O
a O
low O
dose O
of O
LCW O
Docile O
mount O
a O
strong O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
that O
rapidly O
clears O
the O
infection O
, O
and O
the O
animals O
remain O
healthy O
; O
in O
contrast O
, O
down O
- O
regulation O
of O
the O
epitope O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
population O
in O
persistently O
infected O
Cbl O
- O
b O
( O
- O
/ O
- O
) O
mice O
, O
compared O
to O
that O
in O
chronically O
infected O
B6 O
mice O
, O
was O
significantly O
delayed O
, O
and O
this O
was O
associated O
with O
increased O
morbidity O
and O
eventual O
death O
in O
nearly O
20 O
% O
of O
the O
animals O
. O

Interestingly O
, O
infection O
of O
Cbl O
- O
b O
( O
- O
/ O
- O
) O
mice O
with O
a O
moderate O
virus O
dose O
resulted O
in O
rapid O
death O
with O
100 O
% O
mortality O
by O
7 O
to O
8 O
days O
after O
infection O
, O
caused O
by O
a O
dysregulated O
antiviral O
T O
- O
cell O
response O
, O
whereas O
the O
infected O
B6 O
mice O
survived O
and O
remained O
healthy O
. O

Class B
B I
scavenger I
receptors I
( I
SR I
- I
Bs I
) I
bind O
lipoproteins O
and O
play O
an O
important O
role O
in O
lipid O
metabolism O
. O

Most O
recently O
, O
SR O
- O
B O
type O
I O
( O
SR O
- O
BI O
) O
and O
its O
splicing O
variant O
SR O
- O
BII O
have O
been O
found O
to O
mediate O
bacterial O
adhesion O
and O
cytosolic O
bacterial O
invasion O
in O
mammalian O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
SR O
- O
BI O
is O
a O
key O
host O
factor O
required O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
uptake O
and O
cross O
- O
presentation O
by O
human B
dendritic I
cells I
( I
DCs I
) I
. O

Finally O
, O
we O
demonstrate O
that O
anti O
- O
SR O
- O
BI O
antibodies O
inhibit O
the O
uptake O
of O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
in O
DCs O
. O

The O
nuclear O
hormone O
receptors O
Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
and O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
plus O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
heterodimer O
support O
hepatitis B
B I
virus I
( I
HBV I
) I
pregenomic O
RNA O
synthesis O
and O
viral O
replication O
in O
nonhepatoma O
cells O
. O

small B
heterodimer I
partner I
( I
SHP I
) I
, O
an O
orphan O
nuclear O
hormone O
receptor O
lacking O
a O
DNA O
binding O
domain O
, O
inhibits O
nuclear O
hormone O
receptor O
- O
mediated O
viral O
transcription O
and O
replication O
. O

Intracellular O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
display O
a O
distinctly O
higher O
buoyant O
density O
than O
do O
secreted O
virus O
particles O
, O
suggesting O
that O
the O
characteristic O
low O
density O
of O
extracellular O
HCV O
particles O
is O
acquired O
during O
viral O
egress O
. O

The O
results O
demonstrate O
that O
HCV O
assembly O
and O
maturation O
occur O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
post O
- O
ER O
compartments O
, O
respectively O
, O
and O
that O
both O
depend O
on O
microsomal O
transfer O
protein O
and O
apolipoprotein O
B O
, O
in O
a O
manner O
that O
parallels O
the O
formation O
of O
very B
- I
low I
- I
density I
lipoproteins I
( I
VLDL I
) I
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
reverse I
transcriptase I
( I
RT I
) I
plays O
a O
multitude O
of O
fundamental O
roles O
in O
the O
viral O
life O
cycle O
and O
is O
the O
key O
target O
in O
the O
development O
of O
anti O
- O
HBV O
chemotherapy O
. O

We O
report O
here O
that O
the O
endogenous O
small O
molecule O
iron O
protoporphyrin O
IX O
( O
hemin O
) O
and O
several O
related O
porphyrin O
compounds O
potently O
blocked O
a O
critical O
RT O
interaction O
with O
the O
viral O
RNA O
packaging O
signal O
/ O
origin O
of O
replication O
, O
called O
epsilon O
. O

As O
RT O
- O
epsilon O
interaction O
is O
essential O
for O
the O
initiation O
of O
viral O
reverse O
transcription O
, O
which O
is O
primed O
by O
RT O
itself O
( O
protein O
priming O
) O
, O
the O
porphyrin O
compounds O
dramatically O
suppressed O
the O
protein O
- O
priming O
reaction O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
a O
significantly O
increased O
prevalence O
of O
type B
2 I
diabetes I
mellitus I
( I
T2DM I
) I
. O

Since O
we O
and O
others O
have O
previously O
observed O
that O
HCV O
core O
protein O
activates O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
and O
mitogen O
- O
activated O
protein O
kinase O
, O
we O
examined O
the O
contribution O
of O
these O
pathways O
to O
insulin O
resistance O
in O
hepatocytes O
. O

Our O
experimental O
findings O
suggest O
that O
HCV O
core O
protein O
alone O
or O
in O
the O
presence O
of O
other O
viral O
proteins O
increases O
Ser O
( O
312 O
) O
phosphorylation O
of O
the O
insulin B
receptor I
substrate I
- I
1 I
( I
IRS I
- I
1 I
) I
. O

Hepatocytes O
infected O
with O
cell O
culture O
- O
grown O
HCV O
genotype O
la O
or O
2a O
displayed O
a O
significant O
increase O
in O
the O
Ser O
( O
473 O
) O
phosphorylation O
status O
of O
the O
Ser O
/ O
Thr O
kinase O
protein O
kinase O
B O
( O
Akt O
/ O
PKB O
) O
, O
while O
Thr O
( O
308 O
) O
phosphorylation O
was O
not O
significantly O
altered O
. O

HCV O
core O
protein O
- O
mediated O
Ser O
( O
312 O
) O
phosphorylation O
of O
IRS O
- O
1 O
was O
inhibited O
by O
JNK O
( O
SP600125 O
) O
and O
phosphatidylinositol O
- O
3 O
kinase O
( O
LY294002 O
) O
inhibitors O
. O

Taken O
together O
, O
our O
results O
demonstrated O
that O
HCV O
core O
protein O
increases O
IRS O
- O
1 O
phosphorylation O
at O
Ser O
( O
312 O
) O
which O
may O
contribute O
in O
part O
to O
the O
mechanism O
of O
insulin O
resistance O
. O

dendritic B
cells I
( I
DCs I
) I
play O
a O
central O
role O
in O
instructing O
antiviral O
immune O
responses O
. O

We O
recently O
demonstrated O
that O
human O
DCs O
can O
be O
productively O
infected O
with O
echoviruses B
( I
EVs I
) I
, O
but O
not O
coxsackie B
B I
viruses I
( I
CVBs I
) I
, O
both O
of O
which O
are O
RNA O
viruses O
belonging O
to O
the O
Enterovirus O
genus O
of O
the O
Picornaviridae O
family O
. O

These O
effects O
depended O
on O
recognition O
of O
viral O
RNA O
and O
could O
be O
mimicked O
by O
exposure O
to O
the O
synthetic O
double O
- O
stranded O
RNA O
analogue O
poly O
( O
I O
: O
C O
) O
but O
not O
other O
Toll B
- I
like I
receptor I
( I
TLR I
) I
ligands O
. O

We O
previously O
described O
mouse B
hepatitis I
virus I
( I
MHV I
) I
variant O
V51 O
derived O
from O
a O
persistent O
infection O
of O
murine O
DBT O
cells O
with O
an O
expanded O
host O
range O
( O
R O
. O

Protein O
sequences O
from O
multiple O
hepatitis B
B I
virus I
( I
HBV I
) I
isolates O
were O
analyzed O
for O
the O
presence O
of O
amino O
acid O
motifs O
characteristic O
of O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
and O
helper B
T I
- I
lymphocyte I
( I
HTL I
) I
epitopes O
with O
the O
goal O
of O
identifying O
conserved O
epitopes O
suitable O
for O
use O
in O
a O
therapeutic O
vaccine O
. O

The O
immunogenicity O
of O
peptides O
that O
bound O
with O
moderate O
to O
high O
affinity O
subsequently O
was O
assessed O
using O
HLA O
transgenic O
mice O
( O
CTL O
) O
and O
HLA O
cross O
- O
reacting O
H O
- O
2 O
( O
bxd O
) O
( O
BALB O
/ O
c O
x O
C57BL O
/ O
6J O
) O
mice O
( O
HTL O
) O
. O

The O
primary O
reservoir O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
in O
vivo O
is O
believed O
to O
be O
hepatocytes O
within O
the O
liver O
. O

Three O
host O
cell O
molecules O
have O
been O
reported O
to O
be O
important O
entry O
factors O
for O
receptors O
for O
HCV O
: O
the O
tetraspanin O
CD81 O
, O
scavenger B
receptor I
BI I
( I
SR I
- I
BI I
) I
, O
and O
the O
tight B
- I
junction I
( I
TJ I
) I
protein O
claudin B
1 I
( I
CLDN1 I
) I
. O

The O
recent O
discovery O
of O
a O
TJ O
protein O
as O
a O
critical O
coreceptor O
highlighted O
the O
importance O
of O
studying O
the O
effect O
( O
s O
) O
of O
TJ O
formation O
and O
cell O
polarization O
on O
HCV O
entry O
. O

duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
shares O
many O
fundamental O
features O
with O
human O
HBV O
. O

However O
, O
the O
DHBV B
core I
protein I
( I
DHBc I
) I
, O
forming O
the O
nucleocapsid O
shell O
, O
is O
much O
larger O
than O
that O
of O
HBV O
( O
HBc O
) O
and O
, O
in O
contrast O
to O
HBc O
, O
there O
is O
little O
direct O
information O
on O
its O
structure O
. O

Its O
major O
features O
are O
a O
HBc O
- O
like O
two O
- O
domain O
structure O
with O
an O
assembly O
domain O
comprising O
the O
first O
about O
185 O
amino O
acids O
and O
a O
C O
- O
terminal O
nucleic O
acid O
binding O
domain O
( O
CTD O
) O
, O
connected O
by O
a O
morphogenic O
linker O
region O
that O
is O
longer O
than O
in O
HBc O
and O
extends O
into O
the O
CTD O
. O

Since O
the O
first O
discovery O
of O
Torque B
teno I
virus I
( I
TTV I
) I
in O
1997 O
, O
many O
researchers O
focused O
on O
its O
epidemiology O
and O
transcriptional O
regulation O
, O
but O
the O
function O
of O
TTV O
- O
encoded O
proteins O
remained O
unknown O
. O

The O
function O
of O
the O
TTV O
open B
reading I
frame I
( I
ORF I
) I
in O
the O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
pathway O
has O
not O
yet O
been O
established O
. O

Finally O
, O
we O
found O
that O
the O
TTV O
ORF2 O
protein O
inhibited O
the O
transcription O
of O
NF O
- O
kappa O
B O
- O
mediated O
downstream O
genes O
( O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
IL O
- O
8 O
, O
and O
COX O
- O
2 O
) O
through O
down O
- O
regulation O
of O
NF O
- O
kappa O
B O
. O

The O
nonstructural O
hepatitis B
B I
virus I
( I
HBV I
) I
protein O
HBx O
has O
an O
important O
role O
in O
HBV O
replication O
and O
in O
HBV O
- O
associated O
liver O
disease O
. O

covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
of O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
formed O
by O
conversion O
of O
capsid O
- O
associated O
relaxed B
circular I
DNA I
( I
rcDNA I
) I
via O
unknown O
mechanisms O
and O
exists O
in O
the O
nucleus O
of O
the O
infected O
hepatocyte O
as O
a O
minichromosome O
that O
serves O
as O
the O
transcription O
template O
for O
viral O
RNAs O
. O

Following O
induction O
of O
HBV O
replication O
, O
the O
cells O
accumulate O
higher O
levels O
of O
cccDNA O
as O
well O
as O
larger O
amounts O
of O
deproteinized B
rcDNA I
( I
DP I
- I
rcDNA I
) I
than O
cells O
that O
replicate O
wild O
- O
type O
HBV O
genomes O
. O

Detailed O
analyses O
reveal O
the O
following O
: O
( O
i O
) O
DP O
- O
rcDNA O
exists O
in O
both O
cytoplasm O
and O
nucleus O
; O
( O
ii O
) O
while O
nuclear O
DP O
- O
rcDNA O
is O
sensitive O
to O
DNase O
I O
digestion O
, O
a O
small O
fraction O
of O
cytoplasmic O
DP O
- O
rcDNA O
is O
DNase O
I O
resistant O
; O
( O
iii O
) O
both O
DNase O
I O
- O
sensitive O
and O
- O
resistant O
cytoplasmic O
DP O
- O
rcDNAs O
cosediment O
with O
capsids O
and O
can O
be O
immunoprecipitated O
with O
HBV O
core O
antibody O
; O
and O
( O
iv O
) O
a O
primer O
extension O
assay O
maps O
the O
5 O
' O
end O
of O
the O
minus O
strand O
of O
DP O
- O
rcDNA O
at O
the O
authentic O
end O
of O
virion O
rcDNA O
. O

Interferons B
( I
IFNs I
) I
play O
a O
major O
role O
in O
the O
control O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
whether O
as O
endogenous O
cytokines O
limiting O
the O
spread O
of O
the O
virus O
during O
the O
acute O
phase O
of O
the O
infection O
or O
as O
drugs O
for O
the O
treatment O
of O
its O
chronic O
phase O
. O

Here O
, O
we O
show O
that O
type O
I O
and O
II O
IFN O
treatment O
of O
human O
hepatocytes O
induces O
the O
production O
of O
APOBEC3G B
( I
A3G I
) I
and O
, O
to O
a O
lesser O
extent O
, O
that O
of O
APOBEC3F B
( I
A3F I
) I
and O
APOBEC3B O
( O
A3B O
) O
but O
not O
that O
of O
two O
other O
cytidine O
deaminases O
also O
endowed O
with O
anti O
- O
HBV O
activity O
, O
activation B
- I
induced I
cytidine I
deaminase I
( I
AID I
) I
, O
and O
APOBEC1 O
. O

Most O
importantly O
, O
we O
reveal O
that O
blocking O
A3B O
, O
A3F O
, O
and O
A3G O
by O
combining O
RNA O
interference O
and O
the O
virion B
infectivity I
factor I
( I
Vif I
) I
protein O
of O
human O
immunodeficiency O
virus O
does O
not O
abrogate O
the O
inhibitory O
effect O
of O
IFNs O
on O
HBV O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
acute O
and O
chronic O
infections O
remain O
a O
major O
worldwide O
health O
problem O
. O

Towards O
developing O
an O
anti O
- O
HBV O
vaccine O
with O
single O
- O
dose O
scheme O
potential O
, O
we O
engineered O
infectious O
measles B
virus I
( I
MV I
) I
genomic O
cDNAs O
with O
a O
vaccine O
strain O
background O
and O
expression O
vector O
properties O
. O

hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
expression O
cassettes O
were O
inserted O
into O
this O
cDNA O
and O
three O
MVs O
expressing O
HBsAg O
at O
different O
levels O
generated O
. O

The O
two O
vectors O
inducing O
the O
highest O
HBsAg O
antibody O
levels O
were O
inoculated O
into O
rhesus O
monkeys O
( O
Macaca O
mulatta O
) O
. O

After O
challenge O
with O
a O
pathogenic O
MV O
strain O
( O
Davis O
( O
87 O
) O
) O
, O
control O
naive O
monkeys O
showed O
a O
classic O
measles O
rash O
and O
high O
viral O
loads O
. O

Treatment O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
could O
combine O
potent O
antiviral O
drugs O
and O
therapeutic O
vaccines O
to O
overcome O
immunological O
tolerance O
and O
induce O
the O
recovery O
phenotype O
to O
protect O
against O
disease O
progression O
. O

Conventional O
vaccination O
of O
woodchucks O
chronically O
infected O
with O
the O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
elicited O
differential O
T O
- O
cell O
response O
profiles O
depending O
on O
whether O
or O
not O
carriers O
were O
treated O
with O
the O
potent O
antiviral O
drug O
clevudine B
( I
CLV I
) I
, O
which O
significantly O
reduces O
viral O
and O
antigen O
loads O
. O

This O
study O
demonstrates O
that O
the O
envelope O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
could O
be O
incorporated O
into O
the O
lipid O
membrane O
of O
lentivirus O
pseudotype O
particles O
. O

The O
assembly O
procedure O
was O
initiated O
by O
the O
transfection O
of O
293T O
cells O
with O
three O
plasmids O
: O
( O
i O
) O
a O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
packaging O
construct O
, O
( O
ii O
) O
a O
transfer O
plasmid O
expressing O
a O
reporter O
gene O
, O
and O
( O
iii O
) O
a O
plasmid O
expressing O
large B
( I
L I
) I
, O
middle O
( O
M O
) O
, O
and O
small B
( I
S I
) I
HBV O
envelope O
proteins O
. O

Also O
, O
virus O
particles O
that O
were O
able O
to O
infect O
cultured O
primary B
human I
hepatocytes I
( I
PHH I
) I
were O
released O
. O

In O
addition O
, O
the O
susceptibility O
of O
PHH O
and O
the O
resistance O
of O
other O
cell O
types O
to O
the O
pseudotype O
particles O
were O
similar O
to O
those O
observed O
for O
HBV O
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
which O
shares O
the O
same O
L O
, O
M O
, O
and O
S O
. O

Genotype O
G O
is O
also O
unusual O
for O
possessing O
two O
nonsense O
mutations O
in O
the O
precore O
region O
, O
which O
together O
with O
the O
core O
gene O
encode O
a O
secreted O
nonstructural O
protein O
called O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
. O

The O
hepatitis O
C O
virus O
glycoprotein O
E2 O
receptor O
- O
binding O
domain O
is O
encompassed O
by O
amino O
acids O
384 O
to O
661 O
( O
E2 O
( O
661 O
) O
) O
and O
contains O
two O
hypervariable O
sequences O
, O
HVR1 O
and O
HVR2 O
. O

A O
secreted O
E2 O
( O
661 O
) O
glycoprotein O
with O
simultaneous O
deletions O
of O
the O
three O
variable O
sequences O
retained O
its O
ability O
to O
bind O
CD81 O
and O
conformation O
- O
dependent O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
displayed O
enhanced O
binding O
to O
a O
neutralizing O
MAb O
directed O
to O
E2 O
immunogenic O
domain O
B O
. O

The O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
- O
protein B
kinase I
B I
( I
Akt I
) I
signaling O
pathway O
is O
one O
of O
the O
major O
oncogenic O
pathways O
and O
is O
activated O
in O
many O
types O
of O
human O
cancers O
, O
including O
hepatocellular O
carcinoma O
. O

It O
can O
also O
be O
activated O
by O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructurall I
5A I
( I
NS5A I
) I
protein O
. O

In O
the O
present O
study O
, O
we O
set O
out O
to O
determine O
the O
regulatory O
effects O
of O
this O
pathway O
on O
the O
replication O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Mother O
- O
infant O
transmission O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
accounts O
for O
up O
to O
30 O
% O
of O
worldwide O
chronic O
infections O
. O

Free O
HBV O
( O
and O
infectious O
duck O
hepatitis O
B O
virus O
) O
transcytosed O
across O
trophoblastic O
cells O
at O
a O
rate O
of O
5 O
% O
in O
30 O
min O
. O

Both O
viral O
and O
host O
factors O
are O
thought O
to O
influence O
the O
pathogenesis O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

We O
studied O
strain O
HC O
- O
TN O
( O
genotype O
1a O
) O
, O
which O
caused O
fulminant O
hepatic O
failure O
in O
a O
patient O
and O
, O
subsequently O
, O
severe O
hepatitis O
in O
a O
chimpanzee O
( O
CH1422 O
) O
, O
to O
analyze O
the O
relationship O
between O
disease O
severity O
, O
host O
immune O
response O
, O
viral O
evolution O
, O
and O
outcome O
. O

A O
second O
chimpanzee O
( O
CH1581 O
) O
was O
infected O
from O
CH1422 O
plasma O
, O
and O
a O
third O
chimpanzee O
( O
CH1579 O
) O
was O
infected O
from O
RNA O
transcripts O
of O
a O
consensus O
cDNA O
of O
HC O
- O
TN O
( O
pHC O
- O
TN O
) O
. O

5 O
cells O
, O
which O
were O
recently O
found O
to O
be O
susceptible O
to O
infection O
with O
another O
fulminant O
HCV O
strain O
( O
JFH1 O
) O
. O

APOBEC3G B
( I
A3G I
) I
is O
a O
single O
- O
stranded O
DNA O
cytidine O
deaminase O
that O
targets O
retroviral O
minus O
- O
strand O
DNA O
and O
has O
potent O
antiviral O
activity O
against O
diverse O
retroviruses O
. O

Here O
we O
demonstrate O
that O
A3G O
, O
A3F O
, O
and O
, O
to O
a O
lesser O
extent O
, O
the O
noncatalytic O
A3GC291S O
block O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
replication O
by O
interfering O
with O
proviral O
DNA O
formation O
. O

The O
human O
MxA O
gene O
belongs O
to O
the O
class O
of O
interferon B
( I
IFN I
) I
- I
stimulated I
genes I
( I
ISGs I
) I
involved O
in O
antiviral O
resistance O
against O
influenza O
viruses O
. O

MxA O
is O
transcriptionally O
upregulated O
by O
type O
I O
( O
alpha O
and O
beta O
) O
and O
type O
III O
( O
lambda O
) O
IFNs O
. O

poliovirus B
( I
PV I
) I
mRNA O
is O
surprisingly O
resistant O
to O
cleavage O
by O
RNase O
L O
due O
to O
an O
RNA O
structure O
in O
the O
3C B
( I
pro I
) I
open B
reading I
frame I
( I
ORF I
) I
. O

The O
RNA O
structure O
associated O
with O
the O
inhibition O
of O
RNase O
L O
is O
phylogenetically O
conserved O
in O
group O
C O
enteroviruses O
, O
including O
PV B
type I
1 I
( I
PV1 I
) I
, O
PV2 O
, O
PV3 O
, O
coxsackie B
A I
virus I
11 I
( I
CAV11 I
) I
, O
CAV13 O
, O
CAV17 O
, O
CAV20 O
, O
CAV21 O
, O
and O
CAV24 O
. O

The O
RNA O
structure O
is O
not O
present O
in O
other O
human O
enteroviruses O
( O
group O
A O
, O
B O
, O
or O
D O
enteroviruses O
) O
. O

Treatment O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
been O
met O
with O
less O
than O
satisfactory O
results O
due O
primarily O
to O
its O
resistance O
to O
and O
significant O
side O
effects O
from O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
. O

Cyclosporine B
( I
CsA I
) I
, O
an O
immunosuppressive O
and O
anti O
- O
inflammatory O
drug O
for O
organ O
transplant O
patients O
, O
has O
recently O
been O
shown O
to O
be O
highly O
effective O
in O
suppressing O
HCV O
replication O
through O
a O
mechanism O
that O
is O
distinct O
from O
the O
IFN O
pathway O
. O

Interestingly O
, O
a O
point O
mutation O
( O
I432V O
) O
isolated O
from O
the O
most O
resistant O
replicon O
was O
able O
to O
rescue O
a O
lethal O
mutation O
( O
P540A O
) O
in O
NS5B O
that O
disrupts O
its O
interaction O
with O
its O
cofactor O
, O
cyclophilin B
B I
( I
CyPB I
) I
, O
even O
though O
the O
I432V O
mutation O
is O
located O
outside O
of O
the O
reported O
CypB O
binding O
site O
( O
amino O
acids O
520 O
to O
591 O
) O
. O

The O
5 B
' I
untranslated I
regions I
( I
UTRs I
) I
of O
the O
RNA O
genomes O
of O
Flaviviridae O
of O
the O
Hepacivirus O
and O
Pestivirus O
genera O
contain O
Internal B
ribosomal I
entry I
sites I
( I
IRESs I
) I
that O
are O
unrelated O
to O
the O
two O
principal O
classes O
of O
IRESs O
of O
Picornaviridae O
. O

The O
mechanism O
of O
translation O
initiation O
on O
hepacivirus B
/ I
pestivirus I
( I
HP I
) I
IRESs O
, O
which O
involves O
factor O
- O
independent O
binding O
to O
ribosomal O
40S O
subunits O
, O
also O
differs O
fundamentally O
from O
initiation O
on O
these O
picornavirus O
IRESs O
. O

In O
this O
study O
, O
a O
putative O
clathrin O
box O
known O
to O
be O
conserved O
in O
clathrin O
adaptors O
was O
identified O
at O
the O
C O
terminus O
of O
the O
large B
hepatitis I
delta I
antigen I
( I
HDAg I
- I
L I
) I
. O

HDAg O
- O
L O
is O
a O
nucleocytoplasmic O
shuttle O
protein O
important O
for O
the O
assembly O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
. O

Serum B
amyloid I
A I
( I
SAA I
) I
is O
an O
acute O
- O
phase O
protein O
induced O
by O
a O
variety O
of O
inflammatory O
stimuli O
, O
including O
bacterial O
and O
viral O
infections O
. O

We O
report O
here O
that O
SAA O
inhibited O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
in O
cultured O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
contains O
a O
small O
, O
partially O
double O
- O
stranded O
, O
relaxed B
circular I
( I
RC I
) I
DNA O
genome O
. O

RC O
DNA O
needs O
to O
be O
converted O
to O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
which O
serves O
as O
the O
template O
for O
all O
viral O
RNA O
transcription O
. O

As O
a O
first O
step O
toward O
understanding O
how O
CCC O
DNA O
is O
formed O
, O
we O
analyzed O
the O
viral O
and O
host O
factors O
that O
may O
be O
involved O
in O
CCC O
DNA O
formation O
, O
using O
transient O
and O
stable O
DNA O
transfections O
of O
HBV O
and O
the O
related O
avian O
hepadnavirus O
, O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

In O
contrast O
to O
that O
of O
DHBV O
, O
HBV O
CCC O
DNA O
formation O
in O
cultured O
cells O
was O
accompanied O
by O
the O
accumulation O
of O
a O
RC O
DNA O
species O
from O
which O
the O
covalently O
attached O
viral O
reverse B
transcriptase I
( I
RT I
) I
protein O
was O
removed O
( O
protein O
- O
free O
or O
PF O
- O
RC O
DNA O
) O
. O

Furthermore O
, O
whereas O
envelope O
deficiency O
led O
to O
increased O
CCC O
DNA O
formation O
in O
DHBV O
, O
it O
resulted O
mainly O
in O
increased O
PF O
- O
RC O
, O
but O
not O
CCC O
, O
DNA O
in O
HBV O
, O
suggesting O
that O
the O
envelope O
protein O
( O
s O
) O
may O
negatively O
regulate O
a O
step O
in O
CCC O
DNA O
formation O
that O
precedes O
deproteination O
in O
both O
HBV O
and O
DHBV O
. O

Hepadnaviruses O
utilize O
two O
template O
switches O
( O
primer O
translocation O
and O
circularization O
) O
during O
synthesis O
of O
plus O
- O
strand O
DNA O
to O
generate O
a O
relaxed B
- I
circular I
( I
RC I
) I
DNA O
genome O
. O

In O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
three O
cis O
- O
acting O
sequences O
, O
3E O
, O
M O
, O
and O
5E O
, O
contribute O
to O
both O
template O
switches O
through O
base O
pairing O
, O
3E O
with O
the O
3 O
' O
portion O
of O
M O
and O
5E O
with O
the O
5 O
' O
portion O
of O
M O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
also O
contains O
multiple O
cis O
- O
acting O
sequences O
that O
contribute O
to O
the O
accumulation O
of O
RC O
DNA O
, O
but O
the O
mechanisms O
through O
which O
these O
sequences O
contribute O
were O
previously O
unknown O
. O

Three O
of O
the O
HBV O
cis O
- O
acting O
sequences O
( O
h3E O
, O
hM O
, O
and O
h5E O
) O
occupy O
positions O
equivalent O
to O
those O
of O
the O
DHBV O
3E O
, O
M O
, O
and O
5E O
. O

Hepatic O
fibrosis O
is O
the O
primary O
mediator O
of O
disease O
due O
to O
chronic O
infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

We O
tested O
this O
hypothesis O
by O
studying O
individuals O
enrolled O
in O
a O
prospective O
study O
of O
chronic O
HCV O
- O
related O
hepatic O
fibrosis O
with O
little O
or O
no O
fibrosis O
at O
first O
biopsy O
( O
stage O
0 O
or O
1 O
) O
and O
a O
second O
planned O
liver O
biopsy O
sample O
obtained O
4 O
years O
later O
. O

Serum O
was O
obtained O
from O
five O
individuals O
with O
fast O
progression O
( O
FP O
; O
defined O
as O
a O
> O
2 O
- O
stage O
change O
between O
visits O
) O
and O
10 O
carefully O
matched O
individuals O
with O
slow O
progression O
( O
SP O
; O
defined O
as O
a O
< O
2 O
- O
stage O
change O
between O
visits O
) O
. O

We O
sequenced O
multiple O
cloned O
hemigenomic O
cDNAs O
from O
each O
person O
spanning O
six O
genes O
( O
core O
through O
NS3 O
) O
. O

In O
addition O
, O
mixed O
infections O
were O
detected O
in O
three O
subjects O
, O
with O
coexistence O
in O
two O
subjects O
( O
one O
FP O
, O
one O
SP O
) O
of O
subtypes O
1a O
and O
1b O
throughout O
the O
4 O
- O
year O
biopsy O
interval O
. O

The O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
plays O
a O
crucial O
role O
( O
s O
) O
in O
the O
viral O
life O
cycle O
and O
contributes O
to O
the O
onset O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Mitochondrial O
translocation O
of O
Raf O
- O
1 O
is O
mediated O
by O
HBx O
- O
induced O
oxidative O
stress O
and O
was O
dependent O
upon O
the O
phosphorylation O
of O
Raf O
- O
1 O
at O
the O
serine O
( O
338 O
/ O
339 O
) O
and O
Y O
- O
340 O
/ O
341 O
residues O
by O
p21 O
- O
activated O
protein O
kinase O
1 O
and O
Src O
kinase O
, O
respectively O
. O

Liver O
disease O
may O
become O
ameliorated O
in O
some O
patients O
with O
chronic O
hepatitis B
D I
virus I
( I
HDV I
) I
infection O
. O

Among O
the O
HLA O
- O
A O
* O
0201 O
cytotoxic O
T O
ligand O
epitopes O
, O
three O
consistent O
epitopes O
across O
all O
three O
genotypes O
were O
identified O
: O
amino B
acids I
( I
aa I
) I
43 O
to O
51 O
, O
50 O
to O
58 O
, O
and O
114 O
to O
122 O
. O

Three O
patients O
( O
60 O
% O
) O
had O
sites O
evolving O
under O
positive O
selection O
in O
the O
epitope O
from O
aa O
43 O
to O
51 O
, O
and O
four O
patients O
( O
80 O
% O
) O
had O
sites O
evolving O
under O
positive O
selection O
in O
the O
epitope O
from O
aa O
114 O
to O
122 O
. O

The O
APOBEC3 O
family O
of O
mammalian O
cytidine O
deaminases O
, O
including O
APOBEC3G B
( I
A3G I
) I
, O
has O
been O
shown O
to O
function O
as O
innate O
antiviral O
factors O
against O
retroviruses O
and O
can O
also O
suppress O
the O
replication O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
frequently O
associated O
with O
extrahepatic O
manifestations O
, O
including O
nonmalignant O
and O
malignant O
B O
- O
cell O
lymphoproliferative O
disorders O
. O

It O
has O
been O
reported O
that O
specific O
changes O
or O
recurring O
motifs O
in O
the O
amino O
acid O
sequence O
of O
the O
HCV O
hypervariable B
region I
1 I
( I
HVR1 I
) I
may O
be O
associated O
with O
cryoglobulinemia O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replication O
produces O
three O
envelope O
proteins O
( O
L O
, O
M O
, O
and O
S O
) O
that O
have O
a O
common O
C O
terminus O
. O

Thus O
, O
as O
an O
approach O
to O
studying O
these O
roles O
, O
the O
pre O
- O
S1 O
and O
/ O
or O
pre O
- O
S2 O
sequences O
of O
HBV O
( O
serotype O
adw2 O
, O
genotype O
A O
) O
were O
expressed O
as O
N O
- O
terminal O
fusions O
to O
the O
Fc O
domain O
of O
a O
rabbit O
immunoglobulin O
G O
chain O
. O

Such O
proteins O
, O
known O
as O
immunoadhesins O
( O
IA O
) O
, O
were O
highly O
expressed O
following O
transfection O
of O
cultured O
cells O
and O
, O
when O
the O
pre O
- O
S1 O
region O
was O
present O
, O
> O
80 O
% O
were O
secreted O
. O

In O
addition O
, O
some O
of O
these O
secreted O
IA O
, O
at O
nanomolar O
concentrations O
, O
inhibited O
infection O
of O
primary O
human O
hepatocytes O
either O
by O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
a O
subviral O
agent O
that O
uses O
HBV O
envelope O
proteins O
, O
or O
HBV O
. O

Hepatitis B
B I
virus I
splice I
- I
generated I
protein I
( I
HBSP I
) I
, O
encoded O
by O
a O
spliced O
hepatitis O
B O
virus O
RNA O
, O
was O
recently O
identified O
in O
liver O
biopsy O
specimens O
from O
patients O
with O
chronic O
active O
hepatitis O
B O
. O

We O
used O
transgenic O
mice O
devoid O
of O
murine O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
molecules O
and O
positive O
for O
human O
MHC O
class O
I O
molecules O
to O
characterize O
immune O
responses O
specific O
for O
HBSP O
. O

The O
response O
was O
multispecific O
, O
as O
several O
epitopes O
were O
recognized O
by O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
human O
T O
cells O
. O

Understanding O
the O
consequences O
of O
mutation O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
on O
HBV O
replication O
is O
critical O
for O
treating O
chronic O
HBV O
infection O
. O

In O
this O
study O
, O
HBV O
replication O
in O
HepG2 O
cells O
initiated O
by O
transduction O
with O
precore B
( I
pc I
) I
, O
rtM204I O
, O
and O
wild B
- I
type I
( I
WT I
) I
HBV O
recombinant O
baculoviruses O
was O
compared O
. O

Efficient O
assembly O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
was O
achieved O
by O
cotransfection O
of O
Huh7 O
cells O
with O
two O
plasmids O
: O
one O
to O
provide O
expression O
of O
the O
large O
, O
middle O
, O
and O
small O
envelope O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
the O
natural O
helper O
of O
HDV O
, O
and O
another O
to O
initiate O
replication O
of O
the O
HDV O
RNA O
genome O
. O

Among O
the O
novel O
findings O
were O
that O
( O
i O
) O
immunostaining O
for O
delta O
antigen O
6 O
days O
after O
infection O
with O
300 O
genome B
equivalents I
( I
GE I
) I
per O
cell O
showed O
only O
1 O
% O
of O
cells O
as O
infected O
, O
but O
this O
was O
increased O
to O
16 O
% O
when O
5 O
% O
polyethylene O
glycol O
was O
present O
during O
infection O
; O
( O
ii O
) O
uninfected O
cells O
did O
not O
differ O
from O
infected O
cells O
in O
terms O
of O
albumin O
accumulation O
or O
the O
presence O
of O
E O
- O
cadherin O
at O
cell O
junctions O
; O
and O
( O
iii O
) O
sensitive O
quantitative O
real O
- O
time O
PCR O
assays O
detected O
HDV O
replication O
even O
when O
the O
multiplicity O
of O
infection O
was O
0 O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
unusual O
in O
that O
its O
surface O
proteins O
( O
small O
[ O
S O
] O
, O
medium O
, O
and O
large O
[ O
L O
] O
) O
are O
not O
only O
incorporated O
into O
the O
virion O
envelope O
but O
they O
also O
bud O
into O
empty O
subviral O
particles O
in O
great O
excess O
over O
virions O
. O

We O
show O
here O
that O
, O
in O
contrast O
to O
the O
presumed O
model O
, O
the O
HBV O
subviral O
particle O
formed O
by O
the O
S O
protein O
self O
- O
assembles O
into O
branched O
filaments O
in O
the O
lumen O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

These O
long O
filaments O
are O
then O
folded O
and O
bridged O
for O
packing O
into O
crystal O
- O
like O
structures O
, O
which O
are O
then O
transported O
by O
ER O
- O
derived O
vesicles O
to O
the O
ER B
- I
Golgi I
intermediate I
compartment I
( I
ERGIC I
) I
. O

Entecavir O
( O
ETV O
; O
Baraclude O
) O
is O
a O
novel O
deoxyguanosine O
analog O
with O
activity O
against O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

ETV O
differs O
from O
the O
other O
nucleoside O
/ O
tide O
reverse O
transcriptase O
inhibitors O
approved O
for O
HBV O
therapy O
, O
lamivudine B
( I
LVD I
) I
and O
adefovir B
( I
ADV I
) I
, O
in O
several O
ways O
: O
ETV O
is O
> O
100 O
- O
fold O
more O
potent O
against O
HBV O
in O
culture O
and O
, O
at O
concentrations O
below O
1 O
mu O
M O
, O
displays O
no O
significant O
activity O
against O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
. O

Three O
- O
dimensional O
homology O
models O
of O
the O
catalytic O
center O
of O
the O
HBV O
reverse B
transcriptase I
( I
RT I
) I
- O
DNA O
- O
Deoxynucleoside B
triphosphate I
( I
dNTP I
) I
complex O
, O
based O
on O
the O
HIV O
RT O
- O
DNA O
structure O
, O
were O
used O
with O
in O
vitro O
enzyme O
kinetic O
studies O
to O
examine O
the O
mechanism O
of O
action O
of O
ETV O
against O
HBV O
RT O
. O

Dysfunctional O
CD8 O
( O
+ O
) O
T O
cells O
present O
in O
chronic O
virus O
infections O
can O
express O
programmed B
death I
I I
( I
PD I
- I
1 I
) I
molecules O
, O
and O
the O
inhibition O
of O
the O
engagement O
of O
PD O
- O
1 O
with O
its O
ligand O
( O
PD O
- O
L1 O
) O
has O
been O
reported O
to O
enhance O
the O
antiviral O
function O
of O
these O
T O
cells O
. O

We O
took O
advantage O
of O
the O
wide O
fluctuations O
in O
levels O
of O
viremia O
which O
are O
typical O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
to O
comprehensively O
analyze O
the O
impact O
of O
prolonged O
exposure O
to O
different O
virus O
quantities O
on O
virus O
- O
specific O
T O
- O
cell O
dysfunction O
and O
on O
its O
reversibility O
through O
the O
blocking O
of O
the O
PD O
- O
1 O
/ O
PD O
- O
L1 O
pathway O
. O

These O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
expressed O
PD O
- O
1 O
, O
and O
their O
function O
was O
improved O
by O
the O
blocking O
of O
PD O
- O
1 O
/ O
PD O
- O
L1 O
engagement O
. O

A O
direct O
involvement O
of O
the O
PreS O
domain O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
large O
envelope O
protein O
, O
and O
in O
particular O
amino O
acid O
residues O
21 O
to O
47 O
, O
in O
virus O
attachment O
to O
hepatocytes O
has O
been O
suggested O
by O
many O
previous O
studies O
. O

These O
peptides O
could O
bind O
to O
amino O
acids O
21 O
to O
47 O
of O
PreS1 O
and O
shared O
a O
linear O
motif O
( O
W1T2X3W4W5 O
) O
sufficient O
for O
binding O
specifically O
to O
PreS O
and O
viral O
particles O
. O

Analysis O
of O
their O
biochemical O
and O
structural O
properties O
suggested O
that O
lipoprotein B
lipase I
( I
LPL I
) I
, O
a O
key O
enzyme O
in O
lipoprotein O
metabolism O
, O
might O
interact O
with O
PreS O
and O
HBV O
particles O
. O

The O
nucleocapsid B
( I
N I
) I
protein O
of O
infectious B
bronchitis I
virus I
( I
IBV I
) I
localizes O
to O
the O
cytoplasm O
and O
nucleolus O
and O
contains O
an O
eight O
- O
amino O
- O
acid O
nucleolar O
retention O
motif O
. O

In O
this O
study O
, O
a O
leucine O
- O
rich O
nuclear B
export I
signal I
( I
NES I
) I
( O
291 O
- O
LQLDGLHL O
- O
298 O
) O
present O
in O
the O
C O
- O
terminal O
region O
of O
the O
IBV O
N O
protein O
was O
analyzed O
by O
using O
alanine O
substitution O
and O
deletion O
mutagenesis O
to O
investigate O
the O
relative O
contributions O
that O
leucine O
residues O
make O
to O
nuclear O
export O
and O
where O
these O
residues O
are O
located O
on O
the O
structure O
of O
the O
IBV O
N O
protein O
. O

Previous O
studies O
have O
attempted O
to O
clarify O
the O
roles O
of O
the O
pre O
- O
S1 O
and O
pre O
- O
S2 O
domains O
of O
the O
large O
envelope O
protein O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
attachment O
and O
entry O
into O
susceptible O
cells O
. O

Such O
difficulties O
can O
be O
circumvented O
with O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
which O
needs O
the O
HBV O
large O
envelope O
protein O
only O
for O
infectivity O
. O

Similarly O
, O
a O
deletion O
of O
the O
12 O
amino O
acids O
of O
a O
putative O
translocation B
motif I
( I
TLM I
) I
in O
pre O
- O
S2 O
had O
no O
effect O
. O

2 O
- O
kb O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
encodes O
a O
single O
regulatory O
protein O
termed O
HBx O
. O

In O
the O
present O
study O
, O
we O
combined O
an O
HBV O
plasmid O
- O
based O
replication O
assay O
with O
the O
hydrodynamic O
tail O
vein O
injection O
model O
to O
investigate O
the O
function O
( O
s O
) O
of O
HBx O
in O
vivo O
. O

Virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
are O
thought O
to O
be O
required O
for O
the O
induction O
and O
maintenance O
of O
many O
effective O
CD8 O
( O
+ O
) O
T O
- O
cell O
and O
B O
- O
cell O
immune O
responses O
in O
experimental O
animals O
and O
humans O
. O

Although O
the O
presence O
of O
human O
immunodeficiency O
virus O
( O
HM O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
has O
been O
documented O
in O
patients O
at O
all O
stages O
of O
HIV O
infection O
, O
many O
fundamental O
questions O
regarding O
their O
frequency O
and O
function O
remain O
. O

A O
10 O
- O
color O
, O
12 O
- O
parameter O
How O
cytometric O
panel O
was O
utilized O
to O
examine O
the O
frequency O
, O
memory O
phenotype O
( O
CD27 O
, O
CCR7 O
, O
and O
CD45RA O
) O
, O
and O
cytokine O
production O
( O
interleukin O
- O
2 O
[ O
IL O
- O
2 O
] O
, O
gamma O
interferon O
, O
and O
tumor O
necrosis O
factor O
alpha O
) O
of O
CD O
+ O
T O
cells O
specific O
for O
HIV O
antigens O
as O
well O
as O
for O
adenovirus O
, O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
, O
influenza O
H1N1 O
virus O
, O
influenza O
H3N2 O
virus O
, O
cytomegalovirus O
, O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
, O
and O
tetanus O
toxoid O
in O
normal O
controls O
, O
long B
- I
term I
nonprogressors I
( I
LTNP I
) I
, O
and O
HIN O
- O
infected O
patients O
with O
progressive O
disease O
on O
or O
off O
therapy O
. O

The O
HIV O
- O
specifie O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
LTNP O
and O
patients O
on O
therapy O
were O
similar O
in O
frequency O
, O
phenotype O
, O
and O
cytokine O
production O
to O
responses O
directed O
against O
adenovirus O
, O
EBV O
, O
influenza O
virus O
, O
and O
VZV O
. O

HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
from O
patients O
off O
antiretroviral O
therapy O
demonstrated O
a O
shift O
towards O
a O
CCR7 O
( O
- O
) O
CD45RA O
( O
- O
) O
phenotype O
and O
a O
reduced O
percentage O
of O
IL O
- O
2 O
- O
producing O
cells O
. O

The O
alterations O
in O
cytokine O
production O
during O
HIV O
viremia O
were O
found O
to O
be O
intrinsic O
to O
the O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
and O
caused O
a O
requirement O
for O
IL O
- O
2 O
supplied O
exogenously O
for O
proliferation O
to O
occur O
. O

These O
observations O
suggest O
that O
many O
previously O
described O
changes O
in O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
function O
and O
phenotype O
are O
a O
consequence O
of O
high O
levels O
of O
antigen O
in O
viremic O
patients O
. O

In O
addition O
, O
defects O
in O
function O
and O
phenotype O
of O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
are O
not O
readily O
discernible O
in O
the O
context O
of O
antiretroviral O
therapy O
but O
rather O
are O
similar O
to O
responses O
to O
other O
viruses O
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
is O
a O
membrane O
- O
associated O
essential O
component O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
. O

Confocal O
laser O
scanning O
microscopy O
, O
as O
well O
as O
membrane O
flotation O
analyses O
, O
demonstrated O
that O
NS5As O
from O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
GBV O
- O
C O
, O
and O
bovine O
viral O
diarrhea O
virus O
, O
the O
prototype O
pestivirus O
, O
display O
membrane O
association O
characteristics O
very O
similar O
to O
those O
of O
HCV O
NS5A O
. O

The O
main O
pathway O
for O
the O
induction O
of O
type O
I O
interferons B
( I
IFN I
) I
by O
viruses O
is O
through O
the O
recognition O
of O
viral O
RNA O
by O
cytosolic O
receptors O
and O
the O
subsequent O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
which O
drives O
IFN O
- O
alpha O
/ O
beta O
transcription O
. O

In O
addition O
to O
their O
role O
in O
inducing O
an O
antiviral O
state O
, O
type O
I O
IFN O
also O
play O
a O
role O
in O
modulating O
adaptive O
immune O
responses O
, O
in O
part O
via O
their O
effects O
on O
dendritic B
cells I
( I
DCs I
) I
. O

Many O
viruses O
have O
evolved O
mechanisms O
to O
interfere O
with O
type O
I O
IFN O
induction O
, O
and O
one O
recently O
reported O
strategy O
for O
achieving O
this O
is O
by O
targeting O
IRF O
- O
3 O
for O
degradation O
, O
as O
shown O
for O
rotavirus O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
. O

Our O
results O
demonstrate O
that O
IRF O
- O
3 O
was O
rapidly O
degraded O
in O
rotavirus O
- O
infected O
mouse B
embryonic I
fibroblasts I
( I
MEFs I
) I
and O
type O
I O
IFN O
was O
not O
detected O
in O
these O
cultures O
. O

In O
contrast O
, O
rotavirus O
induced O
type O
I O
IFN O
production O
in O
myeloid B
DCs I
( I
mDCs I
) I
, O
resulting O
in O
their O
activation O
. O

Type O
I O
IFN O
induction O
in O
response O
to O
rotavirus O
was O
reduced O
in O
mDCs O
from O
IRF O
- O
3 O
( O
- O
/ O
- O
) O
mice O
, O
indicating O
that O
IRF O
- O
3 O
was O
important O
for O
mediating O
the O
response O
. O

Because O
hepatocytes O
are O
susceptible O
to O
noncytolytic O
mechanisms O
of O
viral O
clearance O
, O
CD8 O
T O
- O
cell O
antiviral O
efficiency O
against O
hepatotropic O
viruses O
has O
been O
linked O
to O
their O
capacity O
to O
produce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
one O
of O
the O
most O
common O
viral O
pathogens O
causing O
severe O
lower O
respiratory O
tract O
infections O
in O
infants O
and O
young O
children O
. O

Infected O
host O
cells O
detect O
and O
respond O
to O
RNA O
viruses O
using O
different O
mechanisms O
in O
a O
cell O
- O
type O
- O
specific O
manner O
, O
including O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
dependent O
and O
Toll B
- I
like I
receptor I
( I
TLR I
) I
- O
dependent O
pathways O
. O

Short B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
RIG O
- O
I O
knockdown O
significantly O
inhibited O
early O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
and O
interferon B
response I
factor I
3 I
( I
IRF3 I
) I
activation O
9 O
h O
postinfection O
( O
p O
. O

Consistent O
with O
this O
finding O
, O
RSV O
- O
induced O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
, O
interferon B
- I
inducible I
protein I
10 I
( I
IP I
- I
10 I
) I
, O
chemokine B
ligand I
5 I
( I
CCL I
- I
5 I
) I
, O
and O
IFN B
- I
stimulated I
gene I
15 I
( I
ISG15 I
) I
expression O
levels O
were O
decreased O
in O
RIG O
- O
I O
- O
silenced O
cells O
during O
the O
early O
phase O
of O
infection O
but O
not O
at O
later O
times O
( O
18 O
h O
p O
. O

We O
further O
found O
that O
TLR3 O
induction O
following O
RSV O
infection O
was O
regulated O
by O
RIG O
- O
I O
- O
dependent O
IFN O
- O
beta O
secreted O
from O
infected O
airway O
epithelial O
cells O
and O
was O
mediated O
by O
both O
IFN B
response I
- I
stimulated I
element I
( I
ISRE I
) I
and O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
sites O
in O
its O
proximal O
promoter O
. O

Although O
the O
Janus B
kinase I
- I
signal I
transducer I
and I
activator I
of I
transcription I
( I
JAK I
- I
STAT I
) I
signaling O
pathway O
is O
part O
of O
the O
antiviral O
response O
in O
arthropods O
such O
as O
Drosophila O
, O
here O
we O
show O
that O
white B
spot I
syndrome I
virus I
( I
WSSV I
) I
uses O
a O
shrimp O
STAT O
as O
a O
transcription O
factor O
to O
enhance O
viral O
gene O
expression O
in O
host O
cells O
. O

In O
the O
Sf9 O
insect O
cell O
line O
, O
a O
specific O
protein O
- O
DNA O
complex O
was O
detected O
by O
using O
electrophoresis B
mobility I
shift I
assays I
( I
EMSA I
) I
with O
the O
P O
- O
32 O
- O
labeled O
STAT O
binding O
motif O
of O
the O
WSSV O
ie1 O
promoter O
as O
the O
probe O
. O

When O
recombinant B
Penaeus I
monodon I
STAT I
( I
rPmSTAT I
) I
was O
overexpressed O
in O
Sf9 O
cells O
, O
EMSA O
with O
specific O
antibodies O
confirmed O
that O
the O
STAT O
was O
responsible O
for O
the O
formation O
of O
the O
specific O
protein O
- O
DNA O
complex O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
is O
thought O
to O
play O
a O
key O
role O
in O
HBV O
replication O
and O
the O
development O
of O
liver O
cancer O
. O

Here O
, O
we O
demonstrated O
that O
the O
treatment O
of O
HBx O
- O
expressing O
cells O
with O
a O
microtubule O
- O
disrupting O
drug O
( O
nocodazole O
) O
abrogated O
mitochondrial O
clustering O
, O
while O
the O
removal O
of O
nocodazole O
restored O
clustering O
within O
30 O
to O
60 O
min O
, O
indicating O
that O
mitochondrial O
transport O
is O
occurring O
in O
a O
microtubule O
- O
dependent O
manner O
. O

In O
addition O
, O
HBx O
induced O
the O
activation O
of O
the O
p38 O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
and O
inhibition O
of O
the O
p38 O
kinase O
activity O
by O
SB203580 O
- O
attenuated O
HBx O
- O
induced O
mitochondrial O
clustering O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
induces O
the O
alpha O
- O
chemokine O
interleukin O
- O
8 O
( O
CXCL O
- O
8 O
) O
, O
which O
is O
regulated O
at O
the O
levels O
of O
transcription O
and O
mRNA O
stability O
. O

In O
the O
current O
study O
, O
CXCL O
- O
8 O
regulation O
by O
double B
- I
stranded I
( I
ds I
) I
RNA O
pathways O
was O
analyzed O
in O
the O
context O
of O
HCV O
infection O
. O

A O
constitutively O
active O
mutant O
of O
the O
retinoic O
acid O
- O
inducible O
gene O
I O
( O
RIG O
- O
1 O
) O
, O
RIG O
- O
N O
, O
activated O
CXCL O
- O
8 O
transcription O
. O

Promoter O
mutagenesis O
experiments O
indicated O
that O
NF O
- O
kappa O
B O
and O
interferon B
( I
IFN I
) I
- O
stimulated O
response O
element O
( O
ISRE O
) O
binding O
sites O
were O
required O
for O
the O
RIG O
- O
N O
induction O
of O
CXCL O
- O
8 O
transcription O
. O

IFN B
- I
beta I
promoter I
stimulator I
1 I
( I
IPS I
- I
1 I
) I
expression O
also O
activated O
CXCL O
- O
8 O
transcription O
, O
and O
mutations O
of O
the O
ISRE O
and O
NF O
- O
kappa O
B O
binding O
sites O
reduced O
and O
abrogated O
CXCL O
- O
8 O
transcription O
, O
respectively O
. O

Expression O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
stimulated O
transcription O
from O
both O
full O
- O
length O
and O
ISRE O
- O
driven O
CXCL O
- O
8 O
promoters O
. O

In O
the O
past O
several O
years O
, O
a O
number O
of O
cellular O
proteins O
have O
been O
identified O
as O
candidate O
entry O
receptors O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
by O
using O
surrogate O
models O
of O
HCV O
infection O
. O

Among O
these O
, O
the O
tetraspanin O
CD81 O
and O
scavenger B
receptor I
B I
type I
I I
( I
SR I
- I
BI I
) I
, O
both O
of O
which O
localize O
to O
specialized O
plasma O
membrane O
domains O
enriched O
in O
cholesterol O
, O
have O
been O
suggested O
to O
be O
key O
players O
in O
HCV O
entry O
. O

Recovery O
from O
acute O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
requires O
a O
broad O
, O
vigorous O
T O
- O
cell O
response O
, O
which O
is O
enhanced O
in O
mice O
when O
chemokine B
receptor I
5 I
( I
CCR5 I
) I
is O
missing O
. O

To O
test O
the O
hypothesis O
that O
production O
of O
a O
nonfunctional O
CCR5 O
( O
CCR5 O
Delta O
32 O
[ O
a O
functionally O
null O
allele O
containing O
a O
32 O
- O
bp O
deletion O
] O
) O
increases O
the O
likelihood O
of O
recovery O
from O
hepatitis O
B O
in O
humans O
, O
we O
studied O
526 O
persons O
from O
three O
cohorts O
in O
which O
one O
person O
with O
HBV O
persistence O
was O
matched O
to O
two O
persons O
who O
recovered O
from O
an O
HBV O
infection O
. O

We O
determined O
genotypes O
for O
CCR5 O
Delta O
32 O
and O
for O
polymorphisms O
in O
the O
CCR5 O
promoter O
and O
in O
coding O
regions O
of O
the O
neighboring O
genes O
, O
chemokine B
receptor I
2 I
( I
CCR2 I
) I
and O
chemokine B
receptor I
- I
like I
2 I
( I
CCRL2 I
) I
. O

Inhibition O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
and O
viral O
clearance O
from O
an O
infected O
host O
requires O
both O
the O
innate O
and O
adaptive O
immune O
responses O
. O

Expression O
of O
interferon B
( I
IFN I
) I
- O
inducible O
proteasome O
catalytic O
and O
regulatory O
subunits O
correlates O
with O
the O
IFN O
- O
alpha O
/ O
beta O
- O
and O
IFN O
- O
gamma O
- O
mediated O
noncytopathic O
inhibition O
of O
HBV O
in O
transgenic O
mice O
and O
hepatocytes O
, O
as O
well O
as O
with O
clearance O
of O
the O
virus O
in O
acutely O
infected O
chimpanzees O
. O

The O
retinoic B
acid I
- I
inducible I
gene I
I I
product I
( I
RIG I
- I
I I
) I
has O
been O
identified O
as O
a O
cellular O
sensor O
of O
RNA O
virus O
infection O
resulting O
in O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
induction O
. O

In O
the O
case O
of O
influenza O
A O
virus O
, O
the O
viral O
nonstructural B
protein I
1 I
( I
NS1 I
) I
prevents O
the O
induction O
of O
the O
IFN O
- O
beta O
promoter O
by O
inhibiting O
the O
activation O
of O
transcription O
factors O
, O
including O
IRY O
- O
3 O
, O
involved O
in O
IFN O
- O
beta O
transcriptional O
activation O
. O

The O
inhibitory O
properties O
of O
NS1 O
appear O
to O
be O
due O
at O
least O
in O
part O
to O
its O
binding O
to O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
resulting O
in O
the O
sequestration O
of O
this O
viral O
mediator O
of O
RIG O
- O
I O
activation O
. O

This O
inhibition O
was O
apparent O
even O
when O
a O
mutant O
RIG O
- O
I O
that O
is O
constitutively O
activated O
( O
in O
the O
absence O
of O
dsRNA O
) O
was O
used O
to O
trigger O
IFN O
- O
beta O
production O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
does O
not O
induce O
interferon B
( I
IFN I
) I
production O
in O
fibroblasts O
or O
bone O
marrow O
- O
derived O
dendritic O
cells O
. O

However O
, O
MHV O
was O
unable O
to O
inhibit O
the O
activation O
of O
these O
factors O
and O
subsequent O
IFN O
- O
beta O
production O
induced O
by O
poly O
( O
I O
: O
C O
) O
. O

Further O
, O
MHV O
infection O
did O
not O
inhibit O
IFN O
- O
beta O
production O
mediated O
by O
known O
host O
pattern B
recognition I
receptors I
( I
PRRs I
) I
( O
RIG O
- O
I O
, O
Mda O
- O
5 O
, O
and O
TLR3 O
) O
. O

Recently O
a O
cell O
culture O
model O
supporting O
the O
complete O
life O
cycle O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
was O
developed O
. O

Analysis O
of O
cell O
surface O
expression O
of O
CD81 O
and O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
, O
two O
molecules O
previously O
implicated O
in O
HCV O
entry O
, O
revealed O
similar O
expression O
levels O
for O
SR O
- O
BI O
, O
while O
CD81 O
surface O
expression O
was O
much O
higher O
on O
Huh O
- O
7 O
. O

5 O
cells O
by O
RNA O
interference O
indicated O
that O
a O
certain O
amount O
of O
this O
molecule O
( O
similar O
to O
7 O
x O
10 O
( O
4 O
) O
molecules O
per O
cell O
) O
is O
required O
for O
productive O
infection O
with O
a O
low O
dose O
of O
HCV O
. O

Understanding O
the O
mechanisms O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
pathogenesis O
and O
persistence O
has O
been O
hampered O
by O
the O
lack O
of O
small O
, O
convenient O
animal O
models O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
phylogenetically O
the O
closest O
related O
virus O
to O
HCV O
. O

We O
show O
here O
in O
cultured O
tamarin O
hepatocytes O
that O
GBV O
- O
B O
NS3 O
/ O
4A O
protease O
, O
but O
not O
a O
related O
catalytically O
inactive O
mutant O
, O
effectively O
blocks O
innate O
intracellular O
antiviral O
responses O
signaled O
through O
the O
RNA O
helicase O
, O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
, O
an O
essential O
sensor O
molecule O
that O
initiates O
host O
defenses O
against O
many O
RNA O
viruses O
, O
including O
HCV O
. O

GBV O
- O
B O
NS3 O
/ O
4A O
protease O
specifically O
cleaves O
mitochondrial O
antiviral O
signaling O
protein O
( O
MAVS O
; O
also O
known O
as O
IPS O
- O
1 O
/ O
Cardif O
/ O
VISA O
) O
and O
dislodges O
it O
from O
mitochondria O
, O
thereby O
disrupting O
its O
function O
as O
a O
RIG O
- O
I O
adaptor O
and O
blocking O
downstream O
activation O
of O
both O
interferon O
regulatory O
factor O
3 O
and O
nuclear O
factor O
kappa O
B O
. O

Development O
of O
full O
- O
length O
hepatitis B
C I
virus I
( I
HCV I
) I
RNAs O
replicating O
efficiently O
and O
producing O
infectious O
cell O
- O
cultured O
virions O
, O
HCVcc O
, O
in O
hepatoma O
cells O
provides O
an O
opportunity O
to O
characterize O
immunogenic O
domains O
on O
viral O
envelope O
proteins O
involved O
in O
entry O
into O
target O
cells O
. O

A O
panel O
of O
immunoglobulin O
G1 O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
to O
three O
immunogenic O
conformational O
domains O
( O
designated O
A O
, O
B O
, O
and O
C O
) O
on O
HCV O
E2 O
glycoprotein O
showed O
that O
epitopes O
within O
two O
domains O
, O
B O
and O
C O
, O
mediated O
HCVcc O
neutralization O
, O
whereas O
HMAbs O
to O
domain O
A O
were O
all O
nonneutralizing O
. O

For O
the O
neutralizing O
antibodies O
to O
domain O
B O
( O
with O
some O
to O
conserved O
epitopes O
among O
different O
HCV O
genotypes O
) O
, O
the O
inhibitory O
antibody O
concentration O
reducing O
HCVcc O
infection O
by O
90 O
% O
, O
IC90 O
, O
ranged O
from O
0 O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
proteins O
have O
the O
ability O
to O
assemble O
three O
types O
of O
viral O
particles O
, O
( O
i O
) O
the O
empty O
subviral B
particles I
( I
SVIPs I
) I
, O
( O
ii O
) O
the O
mature O
HBV O
virions O
, O
and O
( O
iii O
) O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
particles O
, O
in O
cells O
that O
are O
coinfected O
with O
HBV O
and O
HDV O
. O

These O
domains O
, O
referred O
to O
here O
as O
cytosollic O
loops O
I O
and O
II O
( O
CYL O
- O
I O
and O
- O
II O
, O
respectively O
) O
, O
were O
subjected O
to O
mutagenesis O
. O

The O
mutations O
were O
introduced O
in O
the O
three O
HBV O
envelope O
proteins O
, O
designated O
small O
, O
middle O
, O
and O
large O
( O
S O
- O
HBsAg O
, O
M O
- O
HBsAg O
, O
and O
L O
- O
HBsAg O
, O
respectively O
) O
. O

One O
mutation O
( O
P29A O
) O
was O
permissive O
for O
synthesis O
of O
the O
S O
- O
and O
M O
- O
HBsAg O
but O
adversely O
affected O
the O
synthesis O
or O
stability O
of O
L O
- O
HBsAg O
, O
thereby O
preventing O
the O
assembly O
of O
HBV O
virions O
. O

double B
- I
stranded I
RNA I
( I
dsRNA I
) I
can O
be O
detected O
by O
the O
cytoplasmic O
RNA O
helicase O
proteins O
RIG O
- O
1 O
and O
MDA5 O
, O
two O
proteins O
that O
share O
sequence O
similarities O
within O
a O
caspase B
recruitment I
domain I
( I
CARD I
) I
and O
a O
DExD O
/ O
H O
box O
RNA O
helicase O
domain O
. O

These O
proteins O
are O
considered O
dsRNA O
sensors O
and O
are O
thought O
to O
transmit O
the O
signal O
to O
the O
mitochondrial O
adapter O
, O
IPS O
- O
1 O
( O
also O
known O
as O
MAVS O
, O
VISA O
, O
or O
CARDIF O
) O
via O
CARD O
interactions O
. O

IPS O
- O
1 O
coordinates O
the O
activity O
of O
protein O
kinases O
that O
activate O
transcription O
factors O
needed O
to O
induce O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
transcription O
. O

Experiments O
suggest O
that O
LGP2 O
can O
compete O
with O
the O
kinase O
IKKi O
( O
also O
known O
as O
IKK O
epsilon O
) O
for O
a O
common O
interaction O
site O
on O
IPS O
- O
1 O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
pX O
) O
is O
implicated O
in O
hepatocarcinogenesis O
by O
an O
unknown O
mechanism O
. O

pX O
variants O
encoded O
by O
HBV O
genomes O
found O
integrated O
in O
genomic O
DNA O
from O
liver O
tumors O
of O
patients O
with O
hepatocellular B
carcinoma I
( I
HCC I
) I
generally O
lack O
amino O
acids O
134 O
to O
154 O
. O

Conditional O
expression O
of O
pX O
( O
51 O
- O
140 O
) O
in O
AML12 O
clone O
4 O
cell O
line O
activates O
the O
mitogenic O
pathways O
, O
induces O
endogenous O
cyclin O
A O
expression O
, O
and O
sensitizes O
cells O
to O
apoptosis O
, O
similar O
to O
wild B
- I
type I
( I
WT I
) I
pX O
. O

By O
contrast O
, O
pX O
( O
1 O
- O
115 O
) O
is O
inactive O
, O
supporting O
the O
idea O
that O
amino O
acids O
116 O
to O
140 O
are O
required O
for O
mitogenic O
pathway O
activation O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
leading O
cause O
of O
liver O
disease O
and O
hepatocellular O
carcinoma O
; O
over O
400 O
million O
people O
are O
chronically O
infected O
with O
HBV O
. O

HAP1 O
[ O
methyl O
4 O
- O
( O
2 O
- O
chloro O
- O
4 O
- O
fluorophenyl O
) O
- O
6 O
- O
methyl O
- O
2 O
- O
( O
pyridin O
- O
2 O
- O
yl O
) O
- O
1 O
, O
4 O
- O
dihydropyrimidine O
- O
5 O
- O
carboxylate O
] O
, O
a O
heteroaryldihydropyrimidine O
, O
is O
a O
potent O
HBV O
capsid O
assembly O
activator O
and O
misdirector O
. O

The O
recent O
development O
of O
a O
cell O
culture O
infection O
model O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
permits O
the O
production O
of O
infectious O
particles O
in O
vitro O
. O

Ultracentrifugation O
analyses O
indicate O
that O
intracellular O
infectious O
viral O
particles O
are O
similar O
in O
size O
( O
similar O
to O
65 O
to O
70 O
nm O
) O
but O
different O
in O
buoyant O
density O
( O
similar O
to O
1 O
. O

A O
woodchuck O
- O
derived O
hepatitis B
delta I
virus I
( I
HDV I
) I
inoculum O
was O
created O
by O
transfection O
of O
a O
genotype O
I O
HDV O
cDNA O
clone O
directly O
into O
the O
liver O
of O
a O
woodchuck O
that O
was O
chronically O
infected O
with O
woodchuck O
hepatitis O
virus O
. O

A O
limited O
number O
of O
modifications O
occurred O
in O
the O
consensus O
sequence O
of O
the O
viral O
genome O
that O
altered O
the O
sequence O
of O
the O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
. O

Lacking O
an O
RNA O
- O
dependent O
RNA O
polymerase O
, O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
which O
contains O
a O
circular O
RNA O
of O
1 O
. O

Furthermore O
, O
promyelocytic O
leukemia O
protein O
, O
RNA B
polymerase I
II I
( I
Pol I
II I
) I
, O
and O
the O
Pol O
I O
- O
associated O
transcription O
factor O
SL1 O
could O
be O
precipitated O
together O
with O
hepatitis O
delta O
antigen O
, O
suggesting O
the O
association O
of O
HDV O
replication O
complex O
with O
the O
Pol O
I O
and O
Pol O
II O
transcription O
machineries O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
an O
enveloped O
DNA O
virus O
which O
is O
highly O
infectious O
in O
vivo O
. O

Most O
strains O
of O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
express O
a O
cleavable O
spike O
glycoprotein O
that O
mediates O
viral O
entry O
and O
pH O
- O
independent O
cell O
- O
cell O
fusion O
. O

The O
MHV B
type I
2 I
( I
MHV I
- I
2 I
) I
strain O
of O
murine O
coronavirus O
differs O
from O
other O
strains O
in O
that O
it O
expresses O
an O
uncleaved O
spike O
and O
cannot O
induce O
cell O
- O
cell O
fusion O
at O
neutral O
pH O
values O
. O

With O
a O
novel O
search O
program O
written O
in O
python O
, O
we O
also O
identified O
an O
uncharacterized O
protein O
, O
KIAA1271 O
( O
K1271 O
) O
, O
containing O
a O
single O
CARD O
- O
like O
domain O
at O
the O
N O
terminus O
and O
a O
Leu O
- O
Val O
- O
rich O
C O
terminus O
that O
is O
identical O
to O
that O
of O
MAVS O
/ O
IPS O
- O
1 O
/ O
VISA O
/ O
Cardif O
. O

Synthesis O
of O
minus O
- O
strand O
DNA O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
can O
be O
divided O
into O
three O
phases O
: O
initiation O
of O
DNA O
synthesis O
, O
the O
template O
switch O
, O
and O
elongation O
of O
minus O
- O
strand O
DNA O
. O

Although O
much O
is O
known O
about O
minus O
- O
strand O
DNA O
synthesis O
, O
the O
mechanism O
( O
s O
) O
by O
which O
this O
occurs O
has O
not O
been O
completely O
elucidated O
. O

A O
subset O
of O
this O
region O
( O
termed O
Phi O
) O
has O
been O
hypothesized O
to O
base O
pair O
with O
the O
5 O
' O
half O
of O
epsilon O
( O
H O
. O

Primer O
extension O
analysis O
, O
using O
two O
primers O
simultaneously O
, O
was O
performed O
to O
measure O
encapsidated O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
minus O
- O
strand O
DNA O
synthesized O
in O
cell O
culture O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
is O
a O
multifunctional O
regulator O
of O
cellular O
signal O
transduction O
and O
transcription O
pathways O
and O
has O
a O
critical O
role O
in O
HBV O
replication O
. O

To O
further O
characterize O
upstream O
signal O
transduction O
pathways O
that O
are O
required O
for O
HBx O
activity O
, O
including O
activation O
of O
Sire O
and O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
cascades O
, O
we O
determined O
whether O
focal B
adhesion I
kinase I
( I
FAK I
) I
, O
a O
known O
regulator O
of O
Sire O
family O
kinases O
and O
the O
other O
member O
of O
the O
Pyk2 O
/ O
FAK O
kinase O
family O
, O
is O
activated O
by O
HBx O
. O

The O
small O
hepatitis O
B O
virus O
surface O
antigen O
( O
S O
- O
HBsAg O
) O
is O
capable O
of O
driving O
the O
assembly O
and O
secretion O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
particles O
by O
interacting O
with O
the O
HDV O
ribonucleoprotein B
( I
RNP I
) I
. O

Previously O
, O
a O
specific O
domain O
of O
the O
S O
- O
HBsAg O
protein O
carboxyl O
terminus O
, O
including O
a O
tryptophan O
residue O
at O
position O
196 O
( O
W196 O
) O
, O
was O
proven O
essential O
for O
HDV O
maturation O
( O
S O
. O

Mutation O
of O
W196 O
to O
phenylalanine O
( O
W196F O
) O
was O
permissive O
for O
HBV O
subviral B
particle I
( I
SVP I
) I
secretion O
but O
deleterious O
to O
HDV O
virion O
assembly O
. O

Here O
, O
the O
W196F O
S O
- O
HBsAg O
deficiency O
was O
assigned O
to O
a O
loss O
of O
its O
ability O
for O
interaction O
with O
the O
large B
HDV I
antigen I
( I
L I
- I
HDAg I
) I
, O
a O
major O
component O
of O
the O
RNP O
. O

The O
product O
of O
the O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
US3 O
gene O
is O
a O
multifunctional O
serine O
- O
threonine O
protein O
kinase O
that O
can O
block O
apoptosis O
induced O
by O
proapoptotic O
cellular O
proteins O
, O
exogenous O
agents O
, O
or O
replication O
- O
defective O
viruses O
. O

Earlier O
studies O
showed O
that O
the O
U O
, O
3 O
kinase O
activates O
and O
functionally O
overlaps O
cellular O
protein B
kinase I
A I
( I
PKA I
) I
. O

In O
this O
study O
we O
examined O
the O
status O
of O
phosphatidylinositol O
3 O
- O
kinase O
[ O
PI O
( O
3 O
) O
K O
] O
and O
of O
its O
effector O
, O
protein B
kinase I
B I
/ I
Akt I
( I
PKB I
/ I
Akt I
) I
, O
a O
component O
of O
a O
major O
pathway O
of O
mammalian O
antiapoptotic O
signaling O
systems O
. O

( O
i O
) O
Infection O
of O
target O
cells O
with O
HSV O
- O
1 O
induces O
transient O
phosphorylation O
of O
serine O
473 O
of O
PKB O
/ O
Akt O
early O
in O
infection O
, O
with O
a O
mechanism O
that O
is O
dependent O
on O
PI O
( O
3 O
) O
K O
. O

Inhibition O
of O
PI O
( O
3 O
) O
K O
induced O
apoptosis O
in O
mock O
- O
infected O
or O
Delta O
U O
( O
S O
) O
3 O
mutant O
- O
virus O
- O
infected O
but O
not O
in O
wild O
- O
typevirus O
- O
infected O
cells O
and O
reduced O
the O
accumulation O
of O
specific O
viral O
gene O
products O
, O
including O
the O
U O
( O
S O
) O
3 O
protein O
kinase O
, O
but O
had O
a O
marginal O
effect O
on O
virus O
yields O
. O

( O
ii O
) O
At O
later O
times O
after O
infection O
, O
the O
total O
amounts O
of O
PKB O
/ O
Akt O
decreased O
and O
phosphorylated O
PKB O
/ O
Akt O
forms O
disappeared O
in O
a O
U O
( O
S O
) O
3 O
- O
dependent O
and O
protein O
phosphatase O
2A O
- O
independent O
manner O
. O

( O
iii O
) O
Activation O
of O
PKA O
by O
forskolin O
did O
not O
mediate O
significant O
dephosphorylation O
of O
PKB O
/ O
Akt O
. O

Our O
results O
are O
consistent O
with O
the O
model O
that O
PKB O
/ O
Akt O
is O
activated O
early O
in O
infection O
and O
acts O
to O
block O
apoptosis O
in O
infected O
cells O
prior O
to O
the O
accumulation O
of O
U O
( O
S O
) O
3 O
protein O
kinase O
and O
that O
it O
persists O
and O
continues O
to O
function O
as O
an O
antiapoptotic O
protein O
in O
the O
absence O
of O
U O
, O
3 O
but O
becomes O
redundant O
or O
even O
inimical O
once O
U O
( O
S O
) O
3 O
protein O
kinase O
accumulates O
in O
effective O
amounts O
. O

hepatitis B
B I
virus I
surface I
antigen I
( I
HBsAg I
) I
is O
a O
complex O
macromolecular O
particle O
composed O
of O
glycoproteins O
and O
lipids O
. O

We O
compared O
the O
in O
vitro O
proliferative O
responses O
of O
established O
T O
- O
cell O
lines O
and O
nonfractionated O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
HBsAg O
vaccinees O
and O
chronic O
HBV O
patients O
when O
stimulated O
with O
partially O
delipidated O
HBsAg O
, O
untreated O
HBsAg O
, O
or O
sham O
- O
treated O
HBsAg O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
play O
a O
central O
role O
in O
the O
outcome O
of O
several O
viral O
infections O
, O
including O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
. O

A O
key O
feature O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
is O
the O
development O
of O
memory O
. O

It O
has O
been O
suggested O
that O
T O
- O
cell O
memory O
may O
depend O
on O
the O
survival O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
contraction O
phase O
. O

Indeed O
, O
a O
population O
of O
effector O
cells O
that O
express O
high O
levels O
of O
the O
interieukin O
- O
7 O
receptor O
alpha O
chain O
( O
CD127 O
) O
as O
the O
precursors O
of O
memory O
CD8 O
( O
+ O
) O
T O
cells O
has O
recently O
been O
identified O
in O
mice O
. O

To O
address O
these O
important O
issues O
, O
we O
analyzed O
the O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
longitudinally O
in O
a O
cohort O
of O
six O
patients O
with O
acute O
HBV O
infection O
who O
spontaneously O
cleared O
the O
virus O
. O

These O
results O
suggest O
that O
the O
expression O
of O
CD127 O
is O
a O
marker O
for O
the O
development O
of O
functionally O
and O
phenotypically O
defined O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
memory O
T O
cells O
in O
cleared O
human O
viral O
infections O
. O

There O
is O
growing O
interest O
in O
the O
tendency O
of O
B O
cells O
to O
change O
their O
functional O
program O
in O
response O
to O
overwhelming O
antigen O
loading O
, O
perhaps O
by O
regulating O
specific O
parameters O
, O
such O
as O
efficiency O
of O
activation O
, O
proliferation O
rate O
, O
differentiation O
to O
antibody B
- I
secreting I
cells I
( I
ASC I
) I
, O
and O
rate O
of O
cell O
death O
in O
culture O
. O

We O
show O
that O
individuals O
persistently O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
carry O
high O
levels O
of O
circulating O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgG B
- I
secreting I
cells I
( I
IgG I
- I
ASC I
) I
. O

This O
apparent O
discrepancy O
may O
reflect O
the O
unconventional O
activation O
kinetics O
and O
functional O
responsiveness O
of O
the O
CD27 O
( O
+ O
) O
B O
- O
cell O
subset O
in O
vitro O
. O

Following O
stimulation O
with O
T O
- O
cell O
- O
derived O
signals O
in O
the O
absence O
of O
B B
- I
cell I
receptor I
( I
BCR I
) I
engagement O
, O
CD27 O
( O
+ O
) O
B O
cells O
do O
not O
expand O
but O
rapidly O
differentiate O
to O
secrete O
Ig O
and O
then O
undergo O
apoptosis O
. O

Although O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
per O
se O
is O
highly O
immunogenic O
, O
its O
use O
as O
a O
vector O
for O
the O
delivery O
of O
foreign O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitopes O
has O
met O
with O
little O
success O
because O
of O
constraints O
on O
HBsAg O
stability O
and O
secretion O
imposed O
by O
the O
insertion O
of O
foreign O
sequence O
into O
critical O
hydrophobic O
/ O
amphipathic O
regions O
. O

The O
DNAs O
we O
tested O
formed O
chimeric O
HBsAg O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Cytoplasmic O
hepatitis B
B I
virus I
( I
HBV I
) I
capsids O
are O
not O
enveloped O
and O
secreted O
unless O
the O
packaged O
RNA O
pregenome O
is O
reverse O
transcribed O
. O

Initiation O
of O
reverse O
transcription O
and O
nucleocapsid O
assembly O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
depends O
on O
the O
specific O
recognition O
of O
an O
RNA O
signal O
( O
the O
packaging O
signal O
, O
E O
) O
on O
the O
pregenomic O
RNA O
by O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
. O

With O
respect O
to O
the O
epsilon O
RNA O
sequence O
, O
its O
internal O
bulge O
and O
, O
in O
particular O
, O
the O
first O
nucleotide O
( O
C O
) O
of O
the O
bulge O
were O
specifically O
required O
for O
RT O
binding O
. O

A O
comparison O
of O
the O
requirements O
for O
in O
vitro O
RT O
- O
epsilon O
interaction O
with O
those O
for O
in O
vivo O
pregenomic B
RNA I
( I
pgRNA I
) I
packaging O
clearly O
indicated O
that O
RT O
- O
epsilon O
interaction O
was O
necessary O
but O
not O
sufficient O
for O
pgRNA O
packaging O
. O

It O
is O
generally O
accepted O
that O
the O
host O
' O
s O
immune O
response O
rather O
than O
the O
virus O
itself O
is O
causing O
the O
hepatocellular O
damage O
seen O
in O
acute O
and O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
. O

To O
examine O
whether O
HBV O
has O
direct O
cytopathic O
effects O
in O
severely O
immune O
compromised O
hosts O
, O
we O
have O
infected O
severe O
combined O
immune O
deficient O
mice O
( O
uPA O
- O
SCID O
) O
, O
harboring O
human O
liver O
cells O
, O
with O
HBV O
. O

In O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
the O
persistence O
of O
hepatitis B
B I
surface I
antigen I
( I
HBs I
Ag I
) I
is O
sometimes O
associated O
with O
antibodies B
( I
Ab I
) I
to O
HBs O
( O
anti O
- O
HBs O
) O
. O

We O
selected O
14 O
patients O
who O
presented O
both O
markers O
( O
group O
I O
) O
in O
several O
consecutive O
samples O
and O
12 O
patients O
positive O
for O
HBs O
Ag O
only O
( O
group O
II O
) O
. O

7 O
times O
more O
frequent O
for O
group O
I O
than O
for O
group O
II O
patients O
and O
occurred O
mostly O
in O
the O
a O
determinant O
of O
the O
major B
hydrophilic I
region I
( I
MHR I
) I
, O
with O
9 O
. O

Ten O
patients O
( O
71 O
% O
) O
from O
group O
I O
, O
but O
only O
three O
( O
25 O
% O
) O
from O
group O
III O
, O
presented O
at O
least O
two O
residue O
changes O
in O
the O
MHR O
. O

APOBEC3G B
( I
A3G I
) I
and O
related O
cytidine O
deaminases O
, O
such O
as O
APOBEC3F B
( I
A3F I
) I
, O
are O
potent O
inhibitors O
of O
retroviruses O
. O

Formation O
of O
infectious O
human B
immunodeficiency I
virus I
type I
1 I
( I
HTV I
- I
1 I
) I
requires O
suppression O
of O
multiple O
cytidine O
deaminases O
by O
Vif O
. O

Hepatitis O
B O
virus O
X O
( O
HBX O
) O
is O
essential O
for O
the O
productive O
infection O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
vivo O
and O
has O
a O
pleiotropic O
effect O
on O
host O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
important O
human O
pathogen O
associated O
with O
chronic O
liver O
disease O
. O

We O
report O
on O
the O
highly O
potent O
and O
selective O
antipestivirus O
activity O
of O
5 O
- O
[ O
( O
4 O
- O
bromophenyl O
) O
methyl O
] O
- O
2 O
- O
phenyl O
- O
5H O
- O
imidazo O
[ O
4 O
, O
5 O
- O
c O
] O
pyridine O
( O
BPIP O
) O
. O

The O
50 B
% I
effective I
concentration I
( I
EC50 I
) I
for O
inhibition O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
- O
induced O
cytopathic O
effect O
formation O
was O
0 O
. O

The O
selectivity O
index O
( O
ratio O
of O
50 O
% O
cytostatic O
concentration O
/ O
EC50 O
) O
of O
BPIP O
was O
similar O
to O
2 O
, O
0 O
. O

Drug O
- O
resistant O
mutants O
were O
at O
least O
300 O
- O
fold O
less O
susceptible O
to O
BPIP O
than O
wild O
- O
type O
virus O
; O
showed O
cross O
- O
resistance O
to O
N O
- O
propyl O
- O
N O
- O
[ O
2 O
- O
( O
2H O
- O
1 O
, O
2 O
, O
4 O
- O
triazino O
[ O
5 O
, O
6 O
- O
b O
] O
indol O
- O
3 O
- O
ylthio O
) O
ethyl O
] O
- O
1 O
- O
propanamine O
( O
VP32947 O
) O
, O
and O
carried O
the O
F224S O
mutation O
in O
the O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

BPIP O
did O
not O
inhibit O
the O
in O
vitro O
activity O
of O
recombinant O
BVDV O
RdRp O
, O
but O
did O
inhibit O
the O
activity O
of O
replication B
complexes I
( I
RCs I
) I
. O

The O
pregenomic O
RNA O
directs O
replication O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
by O
serving O
both O
as O
the O
messenger O
for O
core O
protein O
and O
polymerase O
and O
as O
the O
genome O
precursor O
following O
its O
packaging O
into O
the O
core O
particle O
. O

The O
precore O
RNA O
has O
a O
slightly O
extended O
5 O
' O
end O
to O
cover O
the O
entire O
precore O
region O
and O
, O
consequently O
, O
directs O
the O
translation O
of O
a O
precore O
/ O
core O
protein O
, O
which O
is O
secreted O
as O
e O
antigen O
( O
HBeAg O
) O
following O
removal O
of O
precore O
- O
derived O
signal O
peptide O
and O
the O
carboxyl O
terminus O
. O

Lamivudine O
was O
the O
first O
approved O
inhibitor O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
reverse I
transcriptase I
( I
RT I
) I
. O

, O
within O
the O
YMDD O
catalytic O
motif O
( O
rtM204V O
/ O
I O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
induces O
inflammatory O
signals O
, O
leading O
to O
hepatitis O
, O
hepatocellular O
carcinomas O
, O
and O
lymphomas O
. O

In O
this O
study O
, O
we O
analyzed O
expression O
and O
regulation O
of O
the O
entire O
panel O
of O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
in O
human O
B O
cells O
following O
HCV O
infection O
in O
vitro O
. O

Among O
all O
of O
the O
TLRs O
( O
TLRs O
1 O
to O
10 O
) O
examined O
, O
only O
TLR4 O
showed O
an O
altered O
expression O
( O
a O
three O
- O
to O
sevenfold O
up O
- O
regulation O
) O
after O
HCV O
infection O
. O

HCV O
infection O
significantly O
increased O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
secretion O
from O
B O
cells O
, O
particularly O
after O
lipopolysaccharide O
stimulation O
. O

The O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
system O
is O
the O
first O
line O
of O
defense O
against O
viral O
infection O
and O
a O
critical O
link O
between O
the O
innate O
and O
adaptive O
immune O
responses O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
( O
genus O
Pestivirus O
) O
was O
reported O
to O
trigger O
interferon O
production O
in O
infected O
cultured O
cells O
under O
certain O
circumstances O
or O
to O
suppress O
it O
under O
others O
. O

Our O
studies O
with O
various O
cultured O
fibroblasts O
and O
epithelial O
bovine O
cells O
indicated O
that O
cytopathic B
( I
cp I
) I
BVDV O
induces O
IFN O
- O
alpha O
/ O
beta O
very O
inefficiently O
. O

A O
catalytically O
active O
mutant O
with O
a O
change O
at O
a O
conserved O
N O
- O
pro O
region O
near O
the O
N O
terminus O
( O
L8P O
) O
in O
both O
BVDV O
biotypes O
did O
not O
antagonize O
IFN O
- O
alpha O
/ O
beta O
production O
, O
confirming O
its O
involvement O
in O
this O
process O
. O

SARS B
coronavirus I
( I
SARS I
- I
CoV I
) I
encodes O
several O
unique O
group O
- O
specific O
open B
reading I
frames I
( I
ORFs I
) I
relative O
to O
other O
known O
coronaviruses O
. O

SARS O
- O
CoV O
spike B
( I
S I
) I
glycoprotein O
does O
not O
encode O
a O
rough B
endoplasmic I
reticulum I
( I
rER I
) I
/ O
Golgi O
retention O
signal O
, O
and O
it O
has O
been O
suggested O
that O
ORF3a O
interacts O
with O
and O
targets O
S O
glycoprotein O
retention O
in O
the O
rER O
/ O
Golgi O
apparatus O
. O

The O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
envelope O
is O
comprised O
of O
two O
transmembrane B
( I
TM I
) I
proteins O
, O
the O
large B
( I
L I
) I
and O
the O
small B
( I
S I
) I
, O
that O
assemble O
into O
virions O
and O
subviral O
particles O
. O

Although O
neutrophil O
recruitment O
to O
the O
liver O
has O
been O
shown O
to O
be O
involved O
in O
the O
exacerbation O
of O
liver O
inflammation O
, O
the O
function O
of O
neutrophil B
elastase I
( I
NE I
) I
in O
liver O
injury O
remains O
unclear O
. O

Here O
, O
we O
found O
that O
administration O
of O
an O
NE B
inhibitor I
( I
NEI I
) I
reduced O
serum B
alanine I
aminotransferase I
( I
sALT I
) I
activity O
and O
inflammatory O
cell O
infiltration O
into O
the O
liver O
from O
8 O
to O
24 O
h O
after O
injection O
of O
antigen O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
into O
hepatitis O
B O
virus O
transgenic O
mice O
. O

In O
addition O
, O
the O
NEI O
treatment O
suppressed O
the O
mRNA O
expressions O
of O
CC B
chemokine I
ligand I
3 I
( I
CCL I
- I
3 I
) I
, O
CCL O
- O
4 O
, O
and O
macrophage B
inflammatory I
protein I
2 I
( I
MIP I
- I
2 I
) I
in O
neutrophils O
in O
the O
liver O
at O
8 O
h O
after O
the O
CTL O
injection O
. O

The O
N O
terminus O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E2 O
contains O
a O
hypervariable B
region I
( I
HVR1 I
) I
which O
has O
been O
proposed O
to O
play O
a O
role O
in O
viral O
entry O
. O

We O
also O
used O
retroviral O
pseudotyped O
particles O
( O
HCVpp O
) O
harboring O
genotype O
la O
envelope O
glycoproteins O
to O
study O
the O
role O
of O
HVR1 O
basic O
residues O
in O
entry O
. O

The O
involvement O
of O
The B
scavenger I
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
was O
indirectly O
analyzed O
by O
measuring O
the O
enhancement O
of O
infectivity O
of O
the O
mutants O
in O
the O
presence O
of O
the O
natural O
ligand O
of O
SR O
- O
BI O
, O
high B
- I
density I
lipoproteins I
( I
HDL I
) I
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
widely O
distributed O
in O
both O
human O
and O
ape O
populations O
throughout O
the O
world O
and O
is O
a O
major O
cause O
of O
human O
morbidity O
and O
mortality O
. O

To O
examine O
the O
role O
of O
recombination O
in O
the O
evolution O
of O
HBV O
, O
large O
- O
scale O
data O
retrieval O
and O
automated O
phyllogenetic O
analysis O
( O
TreeOrder O
scanning O
) O
were O
carried O
out O
on O
all O
available O
published O
complete O
genome O
sequences O
of O
HBV O
. O

We O
detected O
a O
total O
of O
24 O
phylogenetically O
independent O
potential O
recombinants O
( O
different O
genotype O
combinations O
or O
distinct O
breakpoints O
) O
, O
eight O
of O
which O
were O
previously O
undescribed O
. O

In O
this O
work O
, O
we O
have O
shown O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
hepatitis B
B I
virus I
( I
HBV I
) I
can O
coexist O
in O
the O
same O
hepatocyte O
using O
double O
fluorescent O
in O
situ O
hybridization O
in O
liver O
biopsy O
samples O
from O
patients O
with O
chronic O
HCV O
infection O
with O
occult O
HBV O
infection O
. O

Hepatitis B
C I
( I
HCV I
) I
E2 O
glycoprotein O
is O
involved O
in O
virus O
attachment O
and O
entry O
, O
and O
its O
structural O
organization O
is O
largely O
unknown O
. O

Characterization O
of O
a O
panel O
of O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
to O
HCV O
by O
competition O
studies O
has O
led O
to O
an O
immunogenic O
organization O
model O
of O
E2 O
with O
three O
domains O
designated O
A O
, O
B O
, O
and O
C O
and O
epitopes O
in O
each O
domain O
having O
similar O
structural O
and O
functional O
properties O
. O

All O
six O
domain O
A O
HMAbs O
do O
not O
neutralize O
HCV B
retroviral I
pseudotype I
particle I
( I
HCVpp I
) I
infection O
on O
Huh O
- O
7 O
cells O
, O
and O
all O
six O
HMAbs O
have O
similar O
binding O
affinity O
and O
maximum O
binding O
, O
B O
- O
max O
, O
a O
relative O
indicator O
of O
epitope O
density O
, O
as O
other O
neutralizing O
HMAbs O
, O
suggesting O
that O
neutralization O
is O
epitope O
specific O
and O
not O
by O
binding O
to O
any O
surface O
epitope O
. O

However O
, O
the O
B O
- O
max O
values O
for O
low O
- O
pH O
- O
treated O
HCVpp O
with O
antibodies O
to O
domain O
A O
increased O
46 O
% O
, O
for O
domain O
C O
( O
CBH O
- O
7 O
) O
they O
increased O
23 O
% O
, O
and O
for O
domain O
B O
( O
CBH O
- O
5 O
) O
there O
was O
a O
decrease O
of O
12 O
% O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
has O
been O
shown O
to O
inhibit O
replication O
of O
subgenomic O
and O
genomic O
hepatitis B
C I
virus I
( I
HCV I
) I
RNAs O
in O
vitro O
and O
to O
noncytolytically O
suppress O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
in O
vivo O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
( I
NS I
) I
5A O
is O
a O
phosphoprotein O
that O
associates O
with O
various O
cellular O
proteins O
and O
participates O
in O
the O
replication O
of O
the O
HCV O
genome O
. O

Human B
vesicle I
- I
associated I
membrane I
protein I
- I
associated I
protein I
( I
VAP I
) I
subtype O
A O
( O
VAP O
- O
A O
) O
is O
known O
to O
be O
a O
host O
factor O
essential O
for O
HCV O
replication O
by O
binding O
to O
both O
NS5A O
and O
NS5B O
. O

We O
identified O
two O
novel O
naturally O
occurring O
mutations O
( O
W74L O
and O
L77R O
) O
in O
the O
small O
S O
envelope O
protein O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

8 O
- O
fold O
reduction O
of O
the O
extracellular O
HBV B
surface I
antigen I
( I
HBsAg I
) I
of O
mutant O
L77R O
from O
transfected O
Huh7 O
cells O
appeared O
to O
be O
correlated O
with O
a O
1 O
. O

7 O
- O
fold O
reduction O
of O
intracellular O
HBsAg O
, O
as O
measured O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

The O
wild O
- O
type O
HBsAg O
was O
usually O
more O
diffuse O
and O
evenly O
distributed O
in O
the O
cytoplasm O
, O
often O
outside O
the O
perinuclear O
endoplasmic B
reticulum I
( I
ER I
) I
and O
Golgi O
apparatus O
, O
as O
observed O
by O
immunofluorescence O
assay O
. O

The O
hepatitis B
B I
virus I
core I
protein I
( I
HBcAg I
) I
is O
a O
uniquely O
immunogenic O
particulate O
antigen O
and O
as O
such O
has O
been O
used O
as O
a O
vaccine O
carrier O
platform O
. O

To O
determine O
whether O
the O
rodent O
hepadnavirus O
core O
proteins O
derived O
from O
the O
woodchuck O
( O
WHcAg O
) O
, O
ground O
squirrel O
( O
GScAg O
) O
, O
and O
arctic O
squirrel O
( O
AScAg O
) O
viruses O
possess O
immunogen O
characteristics O
similar O
to O
those O
of O
HBcAg O
, O
comparative O
antigenicity O
and O
immunogenicity O
studies O
were O
performed O
. O

The O
results O
indicate O
that O
( O
i O
) O
the O
rodent O
core O
proteins O
are O
equal O
in O
immunogenicity O
to O
or O
more O
immunogenic O
than O
HBcAg O
at O
the O
B O
- O
cell O
and O
T O
- O
cell O
levels O
; O
( O
ii O
) O
major B
histocompatibility I
complex I
( I
MHC I
) I
genes O
influence O
the O
immune O
response O
to O
the O
rodent O
core O
proteins O
( O
however O
, O
nonresponder O
haplotypes O
were O
not O
identified O
) O
; O
( O
iii O
) O
WHcAg O
can O
behave O
as O
a O
T O
- O
cell O
- O
independent O
antigen O
in O
athymic O
mice O
; O
( O
iv O
) O
the O
rodent O
core O
proteins O
are O
not O
significantly O
cross O
- O
reactive O
with O
the O
HBcAg O
at O
the O
antibody O
level O
( O
however O
, O
the O
nonparticulate O
eAgs O
do O
appear O
to O
be O
cross O
- O
reactive O
) O
; O
( O
v O
) O
the O
rodent O
core O
proteins O
are O
only O
partially O
cross O
- O
reactive O
with O
HBcAg O
at O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
level O
, O
depending O
on O
MHC O
haplotype O
; O
and O
( O
vi O
) O
the O
rodent O
core O
proteins O
are O
competent O
to O
function O
as O
vaccine O
carrier O
platforms O
for O
heterologous O
, O
B O
- O
cell O
epitopes O
. O

The O
particulate O
hepatitis O
core O
protein O
( O
HBcAg O
) O
represents O
an O
efficient O
carrier O
platform O
with O
many O
of O
the O
characteristics O
uniquely O
required O
for O
the O
delivery O
of O
weak O
immunogens O
to O
the O
immune O
system O
. O

To O
address O
the O
assembly O
problem O
, O
we O
have O
developed O
the O
core O
protein O
from O
the O
woodchuck B
hepadnavirus I
( I
WHcAg I
) I
as O
a O
new O
particulate O
carrier O
platform O
system O
. O

Retroviral O
polypurine B
tracts I
( I
PPTs I
) I
serve O
as O
primers O
for O
plus O
- O
strand O
DNA O
synthesis O
during O
reverse O
transcription O
. O

We O
replaced O
the O
endogenous O
PPT O
from O
RSVP O
( O
A O
) O
Z O
, O
a O
replication O
- O
competent O
shuttle O
vector O
based O
on O
Rous B
sarcoma I
virus I
( I
RSV I
) I
, O
with O
alternate O
retroviral O
PPTs O
and O
the O
duck O
hepatitis O
B O
virus O
PPT O
. O

2 O
- O
LTR O
circle O
junction O
analysis O
showed O
that O
the O
alternate O
PPTs O
caused O
significant O
decreases O
in O
the O
fraction O
of O
viral O
DNAs O
with O
complete O
( O
consensus O
) O
ends O
and O
significant O
increases O
in O
the O
insertion O
of O
part O
or O
all O
of O
the O
PPT O
at O
the O
2 O
- O
LTR O
circle O
junctions O
. O

Examination O
of O
the O
( O
mis O
) O
cleavages O
of O
the O
alternate O
PPTs O
revealed O
preferential O
cleavages O
after O
GA O
dinucleotide O
sequences O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
causes O
acute O
and O
chronic O
hepatitis O
and O
hepatocellular O
carcinoma O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
and O
lamivudine O
have O
been O
shown O
to O
have O
anti O
- O
HBV O
effects O
through O
different O
mechanisms O
. O

The O
genetic O
diversity O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
strains O
has O
evolved O
through O
mutations O
such O
as O
point O
mutations O
, O
deletions O
or O
insertions O
, O
and O
recombination O
. O

We O
identified O
and O
characterized O
a O
novel O
type O
of O
mutation O
which O
is O
a O
complex O
of O
external O
insertion O
, O
deletion O
, O
and O
internal O
duplication O
in O
sequences O
from O
one O
of O
six O
patients O
with O
chronic O
hepatitis B
B I
virus I
genotype I
E I
( I
HBV I
/ I
E I
) I
. O

We O
provisionally O
named O
this O
mutation O
a O
replacement O
mutation O
; O
the O
core O
promoter O
upstream O
regulatory O
sequence O
/ O
basic O
core O
promoter O
was O
replaced O
with O
a O
part O
of O
the O
SI O
promoter O
covering O
the O
hepatocyte B
nuclear I
factor I
1 I
( I
HNF1 I
) I
binding O
site O
, O
followed O
by O
a O
tandem O
repeat O
of O
the O
HNF1 O
site O
. O

A O
longitudinal O
analysis O
of O
the O
HBV O
population O
over O
6 O
years O
showed O
the O
clonal O
change O
from O
wild O
- O
type O
HBV O
/ O
E O
to O
replacement O
- O
mutant O
type O
, O
resulting O
in O
a O
lower O
hepatitis B
B I
( I
HB I
) I
e O
antigen O
titer O
, O
a O
high O
HBV O
DNA O
level O
in O
serum O
, O
and O
progression O
of O
liver O
fibrosis O
. O

Residual O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
can O
be O
detected O
in O
serum O
and O
liver O
after O
apparent O
recovery O
from O
transient O
infection O
. O

In O
the O
current O
study O
, O
ducks O
inoculated O
with O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
were O
monitored O
for O
residual O
DHBV O
DNA O
following O
recovery O
from O
transient O
infection O
until O
9 O
months O
postinoculation O
( O
p O
. O

It O
has O
been O
difficult O
to O
propagate O
and O
titrate O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
tissue O
culture O
. O

We O
examined O
whether O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
pseudotypes O
bearing O
HBV B
surface I
( I
HBs I
) I
proteins O
infectious O
for O
human O
cell O
lines O
could O
be O
prepared O
. O

293T O
cells O
expressing O
HBs O
proteins O
were O
infected O
with O
VSV O
Delta O
G O
* O
- O
G O
, O
a O
recombinant O
VSV O
expressing O
green B
fluorescent I
protein I
( I
GFP I
) I
, O
to O
make O
VSV O
pseudotypes O
. O

The O
infectivities O
of O
freshly O
harvested O
supernatants O
were O
determined O
by O
quantifying O
the O
number O
of O
cells O
expressing O
GFP O
after O
neutralization O
with O
anti O
- O
VSV O
serum O
and O
mouse B
monoclonal I
antibodies I
( I
MAbs I
) I
against O
HBs O
protein O
. O

Namely O
, O
the O
infectious B
units I
( I
IU I
) I
of O
the O
culture O
supernatant O
samples O
neutralized O
with O
anti O
- O
VSV O
in O
the O
absence O
and O
presence O
of O
anti O
- O
HBs O
S O
MAbs O
and O
titrated O
on O
HepG2 O
cells O
ranged O
from O
1 O
, O
000 O
to O
4 O
, O
000 O
IU O
/ O
ml O
and O
200 O
to O
400 O
IU O
/ O
ml O
, O
respectively O
, O
suggesting O
the O
presence O
of O
VSV O
Delta O
G O
* O
( O
HBV O
) O
pseudotypes O
. O

Here O
we O
show O
that O
immunization O
with O
low O
doses O
( O
10 O
( O
6 O
) O
infectious O
units O
/ O
dose O
) O
of O
a O
recombinant O
human O
adenovirus O
type O
5 O
encoding O
a O
fusion O
of O
the O
E7 O
oncoprotein O
of O
human O
papillomavirus O
type O
16 O
to O
the O
carboxyl O
terminus O
of O
the O
surface O
antigen O
of O
hepatitis B
B I
virus I
( I
HBsAg I
) I
induces O
remarkable O
E7 O
- O
specific O
humoral O
and O
cellular O
immune O
responses O
. O

These O
data O
demonstrate O
that O
the O
presence O
of O
E7 O
on O
HBsAg O
particles O
does O
not O
interfere O
with O
particle O
secretion O
, O
as O
it O
occurs O
with O
bigger O
proteins O
fused O
to O
the O
C O
terminus O
of O
HBsAg O
, O
and O
results O
in O
enhancement O
of O
CD8 O
( O
+ O
) O
- O
mediated O
T O
- O
cell O
responses O
to O
E7 O
. O

The O
secretion O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
large O
( O
LHBs O
) O
and O
middle O
( O
MHBs O
) O
envelope O
polypeptides O
from O
tissue O
cultures O
requires O
proper O
protein O
folding O
and O
is O
prevented O
by O
inhibitors O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
glucosidase O
. O

In O
contrast O
, O
the O
HBV B
small I
( I
SHBs I
) I
protein O
was O
not O
affected O
. O

Recently O
, O
a O
rat O
pancreatic O
cell O
line O
( O
AR42J O
- O
B13 O
) O
was O
shown O
to O
transdifferentiate O
to O
hepatocyte O
- O
like O
cells O
upon O
induction O
with O
dexamethasone B
( I
DEX I
) I
. O

The O
aim O
of O
this O
study O
is O
to O
determine O
whether O
transdifferentiated O
hepatocytes O
can O
indeed O
function O
like O
bona O
fide O
liver O
cells O
and O
support O
replication O
of O
hepatotropic O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

A O
full O
spectrum O
of O
HBV O
replicative O
intermediates O
, O
including O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
and O
Dane O
particles O
, O
were O
detected O
only O
after O
induction O
with O
Dex O
and O
oncostatin O
M O
. O

When O
HBV O
RNAs O
were O
examined O
by O
primer O
extension O
analysis O
, O
novel O
core O
- O
and O
precore O
- O
specific O
transcripts O
were O
induced O
by O
Dex O
which O
initiated O
at O
nucleotide B
( I
nt I
) I
1820 O
and O
nt O
1789 O
, O
respectively O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
antagonizes O
the O
innate O
immune O
response O
by O
inhibition O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
induced O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
expression O
. O

In O
this O
report O
, O
we O
show O
that O
this O
is O
due O
to O
an O
interaction O
of O
HAV O
with O
the O
intracellular O
dsRNA O
- O
induced O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
mediated O
signaling O
pathway O
upstream O
of O
the O
kinases O
responsible O
for O
interferon O
regulatory O
factor O
3 O
( O
IRF O
- O
beta O
) O
phosphorylation O
( O
TBK1 O
and O
IKK O
epsilon O
) O
. O

In O
addition O
, O
we O
found O
that O
HAV O
reduces O
TRIF O
( O
TIR O
domain O
- O
containing O
adaptor O
inducing O
IFN O
- O
( O
3 O
) O
- O
mediated O
IRF O
- O
3 O
activation O
, O
which O
is O
part O
of O
the O
Toll O
- O
like O
receptor O
3 O
signaling O
pathway O
. O

Treatment O
with O
alpha O
interferon O
is O
a O
standard O
therapy O
for O
patients O
with O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
. O

The O
reason O
alpha O
interferon O
therapy O
is O
inefficient O
at O
resolving O
chronic O
HBV O
infections O
is O
assumed O
to O
be O
because O
it O
fails O
to O
eliminate O
covalently B
closed I
circular I
( I
CCC I
) I
HBV O
DNA O
from O
the O
nuclei O
of O
infected O
hepatocytes O
. O

Alpha O
/ O
beta O
interferon O
induction O
by O
polyinosinic O
- O
polycytidylic O
acid O
[ O
poly O
( O
IC O
) O
] O
treatment O
efficiently O
eliminated O
encapsidated O
cytoplasmic O
HBV O
replication O
intermediates O
while O
only O
modestly O
reducing O
nuclear O
HBV O
CCC O
DNA O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
major O
cause O
of O
chronic O
liver O
disease O
, O
which O
can O
lead O
to O
the O
development O
of O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

Recently O
, O
the O
activation O
of O
cyclooxygenase B
- I
2 I
( I
COX I
- I
2 I
) I
has O
been O
implicated O
in O
the O
HCV O
- O
associated O
hepatocellular O
carcinoma O
. O

The O
HCV O
- O
induced O
Cox O
- O
2 O
was O
sensitive O
to O
antioxidant O
( O
pyrrolidine O
dithiocarbamate O
) O
, O
Ca2 O
+ O
chelator O
( O
BAPTA O
- O
AM O
) O
, O
and O
calpain O
inhibitor O
( O
N O
- O
acetyl O
- O
Leu O
- O
Leu O
- O
Met O
- O
H O
) O
. O

The O
levels O
of O
prostaglandin B
E I
- I
2 I
( I
PGE I
( I
2 I
) I
) I
, O
the O
product O
of O
Cox O
- O
2 O
activity O
, O
are O
increased O
in O
HCV O
- O
expressing O
cells O
. O

Furthermore O
, O
HCV O
- O
expressing O
cells O
treated O
with O
the O
inhibitors O
of O
Cox O
- O
2 O
( O
celecoxib O
and O
NS O
- O
398 O
) O
showed O
significant O
reduction O
in O
PGE O
( O
2 O
) O
levels O
. O

These O
phosphorylation O
events O
were O
sensitive O
to O
inhibitors O
of O
Cox O
- O
2 O
( O
celecoxib O
and O
NS O
- O
398 O
) O
and O
phosphatidylinositol O
3 O
- O
kinase O
( O
LY294002 O
) O
. O

Our O
results O
also O
suggest O
a O
potential O
role O
of O
Cox O
- O
2 O
and O
PGE O
( O
2 O
) O
in O
HCV O
RNA O
replication O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
and O
woolly B
monkey I
hepatitis I
B I
virus I
( I
WMHBV I
) I
are O
primate O
hepadnaviruses O
that O
display O
restricted O
tissue O
and O
host O
tropisms O
. O

hepatitis B
D I
virus I
( I
HDV I
) I
particles O
pseudotyped O
with O
HBV O
and O
WMHBV O
envelopes O
( O
HBV O
- O
HDV O
and O
WM O
- O
HDV O
) O
preferentially O
infect O
human O
and O
spider O
monkey O
hepatocytes O
, O
respectively O
, O
thereby O
confirming O
host O
range O
bias O
in O
vitro O
. O

The O
analysis O
of O
chimeric O
HBV O
and O
WMHBV O
large B
( I
L I
) I
envelope O
proteins O
suggests O
that O
the O
pre O
- O
S1 O
domain O
may O
comprise O
two O
regions O
that O
affect O
infectivity O
: O
one O
within O
the O
amino O
- O
terminal O
40 O
amino O
acids O
of O
pre O
- O
S1 O
and O
one O
downstream O
of O
this O
region O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
forms O
the O
capsid O
of O
viral O
particles O
and O
is O
essential O
for O
viral O
genome O
DNA O
replication O
and O
maturation O
. O

Thorp O
and O
Gallagher O
first O
reported O
that O
depletion O
of O
cholesterol O
inhibited O
virus O
entry O
and O
cell O
- O
cell O
fusion O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
suggesting O
the O
importance O
of O
lipid O
rafts O
in O
MHV O
replication O
( O
E O
. O

Inoculation O
of O
3 O
- O
day O
- O
old O
( O
3D O
) O
or O
3 O
- O
week O
- O
old O
( O
3W O
) O
ducklings O
with O
duck O
hepatitis O
B O
virus O
results O
in O
chronic O
or O
wing O
transient O
infection O
, O
respectively O
. O

The O
hepadnaviral O
polymerase B
( I
P I
) I
functions O
in O
a O
complex O
with O
viral O
nucleic O
acids O
and O
cellular O
chaperones O
. O

To O
begin O
to O
identify O
contacts O
between O
P O
and O
its O
partners O
, O
we O
assessed O
the O
exposure O
of O
the O
epitopes O
of O
six O
Monoclonal B
antibodies I
( I
MAbs I
) I
to O
the O
terminal O
protein O
domain O
of O
the O
duck O
hepatitis O
B O
virus O
P O
protein O
in O
a O
partially O
denaturing O
buffer O
( O
RIPA O
) O
and O
a O
physiological O
buffer O
( O
IPP150 O
) O
. O

Epitopes O
for O
MAbs O
that O
immunoprecipitated O
P O
poorly O
in O
IPP150 O
were O
between O
amino B
acids I
( I
aa I
) I
138 O
and O
202 O
. O

Mutation O
of O
a O
highly O
conserved O
motif O
within O
this O
region O
( O
T3 O
; O
aa O
176 O
to O
183 O
) O
improved O
the O
immunoprecipitation O
of O
P O
by O
these O
MAbs O
and O
simultaneously O
inhibited O
DNA O
priming O
by O
P O
. O

These O
results O
indicate O
that O
( O
i O
) O
the O
conserved O
T3 O
motif O
is O
a O
molecular O
contact O
point O
whose O
ligand O
can O
be O
competed O
by O
soluble O
T3 O
peptides O
, O
( O
ii O
) O
the O
occupancy O
of O
T3 O
obscures O
the O
epitopes O
for O
three O
MAbs O
, O
and O
( O
iii O
) O
proper O
occupancy O
of O
T3 O
by O
its O
ligand O
is O
essential O
for O
DNA O
priming O
. O

The O
infectious O
particles O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
are O
coated O
with O
the O
large O
, O
middle O
, O
and O
small O
envelope O
proteins O
encoded O
by O
HBV O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
the O
control O
of O
acute O
Friend B
virus I
( I
FV I
) I
infections O
, O
but O
are O
rendered O
impotent O
by O
CD4 O
( O
+ O
) O
regulatory O
T O
cells O
during O
the O
chronic O
phase O
of O
infection O
. O

The O
current O
study O
examines O
this O
CD8 O
( O
+ O
) O
T O
- O
cell O
dysfunction O
by O
analyzing O
the O
production O
and O
release O
of O
cytolytic O
molecules O
by O
CD8 O
( O
+ O
) O
T O
cells O
. O

CD8 O
( O
+ O
) O
T O
cells O
with O
an O
activated O
phenotype O
( O
CD43 O
( O
+ O
) O
) O
from O
acutely O
infected O
mice O
produced O
all O
three O
key O
components O
of O
lytic O
granules O
: O
perforin O
, O
granzyme O
A O
, O
and O
granzyme O
B O
. O

In O
contrast O
, O
activated O
CD8 O
( O
+ O
) O
T O
cells O
from O
chronically O
infected O
mice O
were O
deficient O
in O
cytolytic O
molecules O
and O
showed O
little O
evidence O
of O
recent O
degranulation O
and O
poor O
in O
vivo O
cytotoxicity O
. O

Evidence O
from O
tetramer O
- O
positive O
CD8 O
( O
+ O
) O
T O
cells O
with O
known O
virus O
specificity O
confirmed O
the O
findings O
from O
the O
activated O
subset O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

These O
results O
demonstrate O
a O
broad O
impairment O
of O
cytotoxic O
CD8 O
( O
+ O
) O
T O
- O
cell O
effector O
function O
during O
chronic O
retroviral O
infection O
and O
explain O
the O
inability O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
to O
eliminate O
persistent O
virus O
. O

coxsackievirus B
B3 I
( I
CVB3 I
) I
is O
one O
of O
the O
most O
common O
pathogens O
for O
viral O
myocarditis O
. O

Pyrrolidine B
dithiocarbamate I
( I
PDTC I
) I
is O
an O
antioxidant O
and O
is O
recently O
reported O
to O
inhibit O
ubiquitin O
- O
proteasome O
- O
mediated O
proteolysis O
. O

CVB3 O
infection O
resulted O
in O
massive O
generation O
of O
reactive B
oxygen I
species I
( I
ROS I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
one O
of O
the O
leading O
causes O
of O
chronic O
liver O
diseases O
and O
B O
- O
lymphocyte O
proliferative O
disorders O
, O
including O
mixed O
cryoglobulinemia O
and O
B O
- O
cell O
lymphoma O
. O

Here O
, O
we O
show O
that O
the O
engagement O
of O
B O
cells O
by O
purified O
E2 O
induced O
double O
- O
strand O
DNA O
breaks O
specifically O
in O
the O
variable O
region O
of O
immunoglobulin O
( O
V O
- O
H O
) O
gene O
focus O
, O
leading O
to O
hypermutation O
in O
the O
V O
- O
H O
genes O
of O
B O
cells O
. O

E2 O
- O
CD81 O
interaction O
on O
B O
cells O
triggered O
the O
enhanced O
expression O
of O
activation B
- I
induced I
cytidine I
deaminase I
( I
AID I
) I
and O
also O
stimulated O
the O
production O
of O
tumor O
necrosis O
factor O
alpha O
. O

Three O
previously O
undescribed O
DNA O
viruses O
were O
also O
detected O
, O
a O
parvovirus O
and O
two O
viruses O
related O
to O
TT B
virus I
( I
TTV I
) I
. O

The O
immunodominant O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
of O
a O
highly O
neurovirullent O
strain O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
JHM O
, O
is O
thought O
to O
be O
essential O
for O
protection O
against O
virus O
persistence O
within O
the O
central O
nervous O
system O
. O

To O
test O
whether O
abrogation O
of O
this O
H O
- O
2D O
( O
b O
) O
- O
restricted O
epitope O
, O
located O
within O
the O
spike O
glycoprotein O
at O
residues O
S510 O
to O
518 O
( O
S510 O
) O
, O
resulted O
in O
delayed O
virus O
clearance O
and O
/ O
or O
virus O
persistence O
we O
selected O
isogenic O
recombinants O
which O
express O
either O
the O
wild O
- O
type O
JHM O
spike O
protein O
( O
RJHM O
) O
or O
spike O
containing O
the O
N514S O
mutation O
( O
RJHMN O
( O
514 O
) O
S O
) O
, O
which O
abrogates O
the O
response O
to O
S510 O
. O

In O
contrast O
to O
observations O
in O
suckling O
mice O
in O
which O
viruses O
encoding O
inactivating O
mutations O
within O
the O
S510 O
epitope O
( O
epitope O
escape O
mutants O
) O
were O
associated O
with O
persistent O
virus O
and O
increased O
neurovirulence O
( O
Pewe O
et O
al O
. O

72 O
: O
5912 O
- O
5918 O
, O
1998 O
) O
, O
RJHM O
( O
N514S O
) O
was O
not O
more O
virulent O
than O
the O
parental O
, O
RJHM O
, O
in O
4 O
- O
week O
- O
old O
C57BL O
/ O
6 O
( O
H O
- O
2 O
( O
b O
) O
) O
mice O
after O
intracranial O
injection O
. O

Whereas O
recombinants O
expressing O
the O
wild O
- O
type O
JHM O
spike O
( O
SJHM O
/ O
RA59 O
) O
were O
highly O
neurovirulent O
, O
A59 O
recombinants O
containing O
the O
N514S O
mutation O
( O
SJHM O
( O
N514S O
) O
/ O
RA59 O
) O
were O
attenuated O
, O
replicated O
less O
efficiently O
, O
and O
exhibited O
reduced O
virus O
spread O
in O
the O
brain O
at O
5 O
days O
postinfection O
( O
peak O
of O
infectious O
virus O
titers O
in O
the O
central O
nervous O
system O
) O
compared O
to O
parental O
virus O
encoding O
wild O
- O
type O
spike O
. O

Virulence O
assays O
in O
BALB O
/ O
c O
mice O
( O
H O
- O
2 O
( O
d O
) O
) O
, O
which O
do O
not O
recognize O
the O
S510 O
epitope O
, O
revealed O
that O
attenuation O
of O
the O
epitope O
escape O
mutants O
was O
not O
due O
to O
the O
loss O
of O
a O
pathogenic O
immune O
response O
directed O
against O
the O
S510 O
epitope O
. O

Mannose B
binding I
lectin I
( I
MBL I
) I
is O
a O
central O
component O
of O
the O
innate O
immune O
response O
and O
thus O
may O
be O
important O
for O
determining O
hepatitis B
B I
virus I
( I
HBV I
) I
persistence O
. O

Since O
Single B
- I
nucleotide I
polymorphisms I
( I
SNPs I
) I
in O
the O
gene O
encoding O
MBL O
( O
mbl2 O
) O
alter O
the O
level O
of O
functional O
MBL O
, O
we O
hypothesized O
that O
mbl2 O
genotypes O
are O
a O
determinant O
of O
HBV O
persistence O
or O
recovery O
from O
viral O
infection O
. O

Two O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
entry O
pathways O
have O
been O
described O
: O
direct O
fusion O
between O
the O
virion O
envelope O
and O
the O
plasma O
membrane O
, O
as O
seen O
on O
Vero O
cells O
, O
and O
low O
- O
pH O
- O
dependent O
endocytosis O
, O
as O
seen O
on O
CHO O
nectin O
- O
1 O
and O
HeLa O
cells O
. O

Gene O
therapy O
approaches O
based O
on O
liver O
- O
restricted O
and O
regulated O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
expression O
, O
recently O
shown O
to O
be O
effective O
in O
different O
murine O
hepatitis O
models O
, O
appear O
promising O
alternatives O
to O
inhibit O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
in O
patients O
and O
minimize O
side O
effects O
. O

Tamarins O
( O
Saguinus O
species O
) O
infected O
by O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
are O
considered O
a O
valid O
surrogate O
model O
for O
hepatitis O
C O
to O
study O
the O
biology O
of O
HCV O
infection O
and O
the O
development O
of O
new O
antiviral O
drugs O
. O

To O
test O
the O
efficacy O
of O
local O
delivery O
and O
expression O
of O
IFN O
- O
alpha O
in O
this O
model O
, O
we O
have O
developed O
HD O
- O
TET O
- O
tIFN O
, O
a O
helper O
- O
dependent O
adenovirus O
vector O
expressing O
tamarin B
IFN I
- I
alpha I
( I
tIFN I
) I
under O
the O
control O
of O
the O
tetracycline O
- O
inducible O
transactivator O
rtTA2 O
( O
s O
) O
- O
S2 O
. O

It O
has O
already O
been O
shown O
that O
three O
stem O
- O
loop O
structures O
( O
SL O
- O
A O
, O
SL O
- O
B O
, O
and O
SL O
- O
C O
, O
from O
the O
5 O
' O
end O
) O
formed O
at O
the O
5 O
' O
end O
of O
the O
genome O
are O
critical O
elements O
for O
viral O
RNA O
replication O
. O

We O
found O
that O
an O
additional O
structural O
element O
, O
a O
pseudoknot O
structure O
, O
is O
formed O
through O
base O
- O
pairing O
interaction O
between O
the O
loop O
segment O
of O
SL O
- O
B O
( O
nucleotides O
[ O
nt O
] O
57 O
to O
60 O
) O
and O
a O
sequence O
downstream O
of O
SL O
- O
C O
( O
nt O
112 O
to O
115 O
) O
and O
showed O
that O
the O
formation O
of O
this O
pseudoknot O
is O
critical O
for O
viral O
RNA O
replication O
. O

Toll B
- I
like I
receptors I
( I
TLR I
) I
play O
a O
key O
role O
in O
innate O
immunity O
. O

To O
examine O
the O
ability O
of O
diverse O
TLRs O
to O
modulate O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
, O
HBV O
transgenic O
mice O
received O
a O
single O
intravenous O
injection O
of O
ligands O
specific O
for O
TLR2 O
, O
TLR3 O
, O
TLR4 O
, O
TLR5 O
, O
TLR7 O
, O
and O
TLR9 O
. O

In O
addition O
to O
hepatocytes O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
infects O
immune O
cells O
, O
including O
macrophages O
. O

lipopolysaccharide B
( I
LPS I
) I
activates O
I B
kappa I
beta I
kinase I
( I
IKK I
) I
signalsome O
and O
NF O
- O
kappa O
beta O
, O
which O
leads O
to O
the O
expression O
of O
cyclooxygenase B
- I
2 I
( I
COX I
- I
2 I
) I
, O
which O
catalyzes O
production O
of O
prostaglandins O
, O
potent O
effectors O
on O
inflammation O
and O
possibly O
hepatitis O
. O

The O
cytosolic O
matrix B
domain I
( I
MD I
) I
located O
between O
amino B
acids I
( I
aa I
) I
103 O
and O
124 O
of O
the O
large O
hepatitis O
B O
virus O
envelope O
protein O
L O
is O
essential O
for O
virion O
formation O
. O

We O
reduced O
the O
distance O
between O
MD O
and O
the O
transmembrane O
domain O
( O
TD O
; O
aa O
254 O
to O
272 O
) O
by O
deletions O
starting O
at O
aa O
132 O
. O

Envelope O
proteins O
of O
hepadnaviruses O
undergo O
a O
unique O
folding O
mechanism O
which O
results O
in O
the O
posttranslational O
translocation O
of O
50 O
% O
of O
the O
large O
envelope O
protein O
( O
L O
) O
chains O
across O
the O
endoplasmic O
reticulum O
. O

This O
mechanism O
is O
essential O
for O
the O
eventual O
positioning O
of O
the O
receptor O
- O
binding O
domain O
on O
the O
surface O
of O
the O
virus O
particle O
and O
in O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
dependent O
on O
the O
small B
( I
S I
) I
envelope O
protein O
as O
part O
of O
the O
assembly O
process O
. O

Antibody O
mapping O
and O
mutagenesis O
studies O
indicated O
S O
- O
t O
to O
be O
C O
terminally O
truncated O
, O
spanning O
the O
N O
- O
terminal O
transmembrane O
domain O
( O
TM1 O
) O
plus O
the O
adjacent O
cysteine O
loop O
. O

We O
have O
previously O
shown O
that O
the O
mutation O
of O
two O
conserved O
polar O
residues O
in O
TM1 O
of O
S O
( O
S O
- O
AA O
) O
eliminates O
L O
translocation O
and O
assembly O
. O

The O
role O
and O
functional O
domain O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
in O
regulating O
HBV O
transcription O
and O
replication O
were O
investigated O
with O
a O
transient O
transfection O
system O
in O
the O
human O
hepatoma O
cell O
line O
HepG2 O
using O
wild O
- O
type O
or O
HBx O
- O
minus O
HBV O
genome O
constructs O
and O
a O
series O
of O
deletion O
or O
mutation O
HBx O
expression O
plasmids O
. O

The O
C O
- O
terminal O
two O
- O
thirds O
( O
amino O
acids O
[ O
aa O
] O
51 O
to O
154 O
) O
, O
which O
contain O
the O
transactivation O
domain O
, O
is O
required O
for O
this O
function O
of O
HBx O
; O
the O
N O
- O
terminal O
one O
- O
third O
( O
aa O
1 O
to O
50 O
) O
is O
not O
required O
. O

It O
is O
necessary O
to O
evaluate O
the O
cytokine O
secretion O
status O
of O
CD8 O
( O
+ O
) O
T O
lymphocytes O
and O
elucidate O
the O
factors O
influencing O
cytokine O
secretion O
, O
because O
the O
secretion O
of O
cytokines O
is O
also O
an O
important O
feature O
of O
CD8 O
( O
+ O
) O
T O
lymphocytes O
, O
and O
the O
cytokines O
usually O
play O
critical O
roles O
in O
the O
outcome O
of O
diseases O
. O

We O
showed O
here O
that O
peptide O
AYRPPNAPI O
, O
derived O
from O
the O
core O
antigen O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
could O
bind O
to O
H O
- O
2 O
K O
- O
d O
and O
induce O
primed O
splenocytes O
from O
HBcAg O
expression O
plasmid O
- O
immunized O
mice O
to O
produce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
in O
H O
- O
2 O
K O
- O
d O
- O
and O
CD8 O
- O
dependent O
manners O
instead O
of O
in O
a O
CD4 O
- O
dependent O
manner O
. O

These O
results O
suggest O
that O
this O
peptide O
is O
a O
special O
kind O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
, O
for O
which O
specific O
CD8 O
( O
+ O
) O
T O
cells O
can O
produce O
IFN O
- O
gamma O
when O
antigenic O
stimulation O
is O
encountered O
but O
which O
have O
no O
cytotoxic O
effect O
on O
the O
corresponding O
target O
cells O
both O
in O
vitro O
and O
in O
HBV O
transgenic O
mice O
. O

This O
phenomenon O
indicates O
initially O
that O
the O
functional O
mechanisms O
of O
CD8 O
( O
+ O
) O
T O
cells O
can O
be O
determined O
by O
their O
epitope O
specificity O
, O
which O
may O
be O
associated O
with O
the O
development O
of O
epitope O
- O
based O
immunotherapeutic O
approaches O
for O
infectious O
diseases O
and O
tumors O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
hepatitis O
worldwide O
. O

Primary B
Tupaia I
hepatocytes I
( I
PTH I
) I
have O
been O
shown O
to O
be O
susceptible O
to O
HCV O
infection O
in O
vitro O
and O
in O
vivo O
. O

Human O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
represents O
an O
HCV O
receptor O
candidate O
mediating O
the O
cellular O
binding O
of O
E2 O
glycoprotein O
to O
HepG2 O
hepatoma O
cells O
. O

entecavir B
( I
ETV I
) I
, O
a O
potent O
inhibitor O
of O
the O
hepadnaviral O
polymerases O
, O
prevented O
the O
development O
of O
persistent O
infection O
when O
administered O
in O
the O
early O
stages O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
infection O
. O

In O
two O
further O
experiments O
14 O
- O
day O
- O
old O
ducks O
were O
inoculated O
with O
DHBV O
- O
positive O
serum O
containing O
10 O
( O
4 O
) O
, O
10 O
( O
6 O
) O
, O
10 O
( O
8 O
) O
, O
or O
5 O
X O
10 O
( O
8 O
) O
viral O
genomes O
( O
vge O
) O
and O
were O
treated O
orally O
with O
1 O
. O

A O
relationship O
between O
virus O
dose O
and O
infection O
outcome O
was O
seen O
: O
non O
- O
ETV O
- O
treated O
ducks O
inoculated O
with O
10 O
( O
4 O
) O
vge O
had O
transient O
infection O
, O
while O
ducks O
inoculated O
with O
higher O
doses O
developed O
persistent O
infection O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
encapsidated O
by O
the O
envelope O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

The O
major O
HBV O
lamivudine B
( I
LMV I
) I
- O
resistant O
mutations O
in O
the O
polymerase O
gene O
within O
the O
reverse B
transcriptase I
( I
RT I
) I
region O
at O
rtM204V O
or O
rtM204I O
are O
associated O
with O
changes O
in O
the O
overlapping O
envelope O
gene O
products O
, O
in O
particular O
, O
the O
gene O
encoding O
small O
envelope O
protein O
( O
s O
) O
at O
sI195M O
or O
sW196L O
/ O
S O
/ O
Stop O
. O

interferon B
( I
IFN I
) I
is O
one O
important O
effector O
of O
the O
innate O
immune O
response O
, O
induced O
by O
different O
viral O
or O
bacterial O
components O
through O
Toll B
- I
like I
receptor I
( I
TLR I
) I
- O
dependent O
and O
- O
independent O
mechanisms O
. O

As O
part O
of O
its O
pathogenic O
strategy O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
interferes O
with O
the O
innate O
immune O
response O
and O
induction O
of O
IFN O
- O
beta O
via O
the O
HCV O
NS3 O
/ O
4A O
protease O
activity O
which O
inhibits O
phosphorylation O
of O
IRF O
- O
3 O
, O
a O
key O
transcriptional O
regulator O
of O
the O
IFN O
response O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
is O
essential O
for O
virus O
infection O
and O
has O
been O
implicated O
in O
the O
development O
of O
liver O
cancer O
associated O
with O
chronic O
infection O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural O
NS5A O
protein O
has O
been O
shown O
to O
bind O
to O
and O
activate O
phosphoinositide B
3 I
- I
kinase I
( I
PI3K I
) I
, O
resulting O
in O
activation O
of O
the O
downstream O
effector O
serine O
/ O
threonine O
kinase O
Akt O
/ O
protein O
kinase O
B O
. O

We O
further O
show O
that O
this O
results O
in O
the O
inhibition O
of O
the O
Akt O
substrate O
Forkbead O
transcription O
factor O
and O
the O
stimulation O
of O
phosphorylation O
of O
a O
second O
key O
Akt O
substrate O
, O
glycogen O
synthase O
kinase O
- O
3 O
beta O
( O
GSK O
- O
3 O
beta O
) O
. O

Sequence O
comparisons O
revealed O
that O
all O
but O
the O
mandarin O
duck O
viruses O
were O
closely O
related O
to O
existing O
isolates O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
while O
mandarin O
duck O
virus O
clones O
were O
closely O
related O
to O
Ross O
goose O
hepatitis O
B O
virus O
. O

The O
Chiloe O
wigeon O
and O
puna O
teal O
hepatitis O
B O
viruses O
, O
the O
two O
new O
isolates O
most O
closely O
related O
to O
DHBV O
, O
also O
lacked O
an O
AUG O
start O
codon O
at O
the O
beginning O
of O
their O
X O
open B
reading I
frame I
( I
ORF I
) I
. O

chicken B
anemia I
virus I
( I
CAV I
) I
is O
a O
small O
circular O
single O
- O
stranded O
DNA O
virus O
with O
a O
single O
promoter O
- O
enhancer O
region O
containing O
four O
consensus O
cyclic O
AMP O
response O
element O
sequences O
( O
AGCTCA O
) O
, O
which O
are O
similar O
to O
the O
estrogen B
response I
element I
( I
ERE I
) I
consensus O
half O
- O
sites O
( O
A O
) O
GGTCA O
. O

Transient O
- O
transfection O
assays O
which O
use O
a O
short O
CAV O
promoter O
construct O
that O
ended O
at O
the O
transcription O
start O
site O
and O
drive O
expression O
of O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
showed O
high O
basal O
activity O
in O
DF O
- O
1 O
, O
LMH O
, O
LMH O
/ O
2A O
, O
and O
primary O
theca O
and O
granulosa O
cells O
. O

The O
function O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
precore O
or O
HBeAg O
is O
largely O
unknown O
because O
it O
is O
not O
required O
for O
viral O
assembly O
, O
infection O
, O
or O
replication O
. O

As O
a O
model O
of O
chronic O
HBeAg O
exposure O
and O
to O
examine O
the O
tolerogenic O
potential O
of O
the O
HBV O
precore O
and O
core O
( O
HBcAg O
) O
proteins O
, O
HBc O
/ O
HBeAg O
- O
transgenic B
( I
Tg I
) I
mice O
crossed O
with O
T B
cell I
receptor I
( I
TCR I
) I
- O
Tg O
mice O
expressing O
receptors O
for O
the O
HBc O
/ O
HBeAgs O
( O
i O
. O

This O
study O
revealed O
three O
phenotypes O
of O
HBe O
/ O
HBcAg O
- O
specific O
T O
- O
cell O
tolerance O
: O
( O
i O
) O
profound O
T O
- O
cell O
tolerance O
most O
likely O
mediated O
by O
clonal O
deletion O
, O
( O
ii O
) O
T O
- O
cell O
clonal O
ignorance O
, O
and O
( O
iii O
) O
nondeletional O
T O
- O
cell O
tolerance O
mediated O
by O
clonal O
anergy O
and O
dependent O
on O
the O
structure O
, O
location O
, O
and O
concentration O
of O
the O
tolerogen O
. O

Functional O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
T O
cells O
are O
significantly O
diminished O
in O
individuals O
chronically O
infected O
with O
HBV O
compared O
to O
individuals O
with O
self O
- O
limiting O
HBV O
infection O
or O
those O
on O
anti O
- O
HBV O
therapy O
. O

In O
individuals O
infected O
with O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
coinfection O
with O
HBV O
is O
associated O
with O
an O
increased O
risk O
of O
worsening O
liver O
function O
following O
antiviral O
therapy O
and O
of O
more O
rapid O
HBV O
disease O
progression O
. O

The O
magnitude O
and O
breadth O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
HBV O
in O
peripheral O
blood O
were O
examined O
by O
flow O
cytometry O
to O
detect O
gamma O
interferon O
production O
following O
stimulation O
with O
HBV O
peptide O
pools O
. O

Chronic O
HBV O
carriers O
( O
n O
= O
34 O
) O
were O
studied O
, O
including O
individuals O
never O
treated O
for O
HBV O
infection O
( O
n O
= O
7 O
) O
, O
HBV O
- O
infected O
individuals O
receiving O
anti O
- O
HBV O
therapy O
( O
n O
= O
13 O
) O
, O
and O
HIV O
- O
1 O
- O
HBV O
- O
coinfected O
individuals O
receiving O
anti O
- O
HBV O
therapy O
( O
n O
= O
14 O
) O
. O

CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
HBV O
- O
specific O
T O
- O
cell O
responses O
were O
more O
frequently O
detected O
and O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
were O
of O
greater O
magnitude O
and O
breadth O
in O
subjects O
on O
anti O
- O
HBV O
treatment O
than O
in O
untreated O
chronic O
HBV O
carriers O
. O

HBV O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
were O
significantly O
( O
fivefold O
) O
reduced O
compared O
with O
HIV O
- O
specific O
responses O
. O

Although O
, O
the O
frequency O
and O
breadth O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
were O
comparable O
in O
the O
monoinfected O
and O
HIV O
- O
1 O
- O
HBV O
- O
coinfected O
groups O
, O
HBV O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
were O
significantly O
reduced O
in O
HIV O
- O
1 O
- O
HBV O
- O
coinfected O
individuals O
. O

The O
treatment O
of O
human O
embryonic O
kidney O
293 O
cells O
harboring O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
subgenomic O
replicon O
with O
the O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
mimic O
poly O
( O
I O
- O
C O
) O
inhibits O
HCV O
RNA O
replication O
through O
an O
undefined O
mechanism O
. O

Interferon B
regulatory I
factor I
3 I
( I
IRF I
3 I
) I
has O
been O
widely O
postulated O
to O
mediate O
various O
antiviral O
responses O
, O
and O
its O
role O
in O
mediating O
the O
response O
to O
dsRNA O
in O
293 O
cells O
was O
examined O
. O

Our O
results O
suggest O
that O
the O
inhibition O
of O
HCV O
RNA O
replication O
by O
poly O
( O
I O
- O
C O
) O
in O
293 O
cells O
is O
independent O
of O
IRF O
- O
3 O
activation O
. O

CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
regulatory O
T O
cells O
have O
been O
shown O
to O
maintain O
peripheral O
tolerance O
against O
self O
and O
foreign O
antigens O
. O

In O
this O
study O
we O
analyzed O
the O
effect O
of O
circulating O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
on O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
of O
patients O
with O
chronic O
and O
resolved O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
. O

We O
demonstrated O
that O
circulating O
CD4 O
+ O
CD25 O
( O
+ O
) O
T O
cells O
modulate O
the O
function O
and O
expansion O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
cells O
ex O
vivo O
in O
all O
patients O
, O
regardless O
of O
whether O
they O
have O
chronic O
or O
resolved O
HBV O
infection O
. O

The O
possible O
role O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
in O
the O
pathogenesis O
of O
chronic O
HBV O
infection O
is O
not O
supported O
by O
these O
data O
. O

CD8 O
( O
+ O
) O
T O
cells O
are O
important O
for O
clearance O
of O
neurotropic O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
A59 O
, O
although O
their O
possible O
role O
in O
A59 O
- O
induced O
demyelination O
is O
not O
well O
understood O
. O

We O
developed O
an O
adoptive O
- O
transfer O
model O
to O
more O
clearly O
elucidate O
the O
role O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
during O
the O
acute O
and O
chronic O
phases O
of O
infection O
with O
A59 O
that O
is O
described O
as O
follows O
. O

C57BL O
/ O
6 O
mice O
were O
infected O
with O
a O
recombinant O
A59 O
virus O
expressing O
the O
gp33 O
epitope O
, O
an O
H O
- O
2D O
( O
b O
) O
- O
restricted O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
encoded O
in O
the O
glycoprotein O
of O
lymphocytic O
choriomeningitis O
virus O
, O
as O
a O
fusion O
with O
the O
enhanced O
green O
fluorescent O
protein O
( O
RA59 O
- O
gfp O
/ O
gp33 O
) O
. O

P14 O
splenocytes O
( O
transgenic O
for O
a O
T O
- O
cell O
receptor O
specific O
for O
the O
gp33 O
epitope O
) O
were O
transferred O
at O
different O
times O
pre O
- O
and O
postinfection O
( O
p O
. O

Thus O
, O
an O
early O
robust O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
was O
necessary O
to O
reduce O
virus O
replication O
and O
spread O
, O
specifically O
to O
the O
spinal O
cord O
, O
which O
protected O
against O
demyelination O
in O
the O
chronic O
phase O
of O
the O
disease O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
important O
human O
pathogen O
. O

Group O
1 O
chickens O
( O
n O
= O
28 O
) O
were O
each O
inoculated O
with O
5 O
x O
10 O
( O
4 O
. O

5 O
) O
50 O
% O
chicken O
infectious O
doses O
of O
avian O
HEV O
by O
the O
oronasal O
route O
, O
group O
2 O
chickens O
( O
n O
= O
29 O
) O
were O
each O
inoculated O
with O
the O
same O
dose O
by O
the O
intravenous O
( O
i O
. O

) O
route O
, O
and O
group O
3 O
chickens O
( O
n O
= O
28 O
) O
were O
not O
inoculated O
and O
were O
used O
as O
controls O
. O

Two O
chickens O
from O
each O
group O
were O
necropsied O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
10 O
, O
13 O
, O
16 O
, O
20 O
, O
24 O
, O
28 O
, O
35 O
, O
and O
42 O
days B
postinoculation I
( I
dpi I
) I
, O
and O
the O
remaining O
chickens O
were O
necropsied O
at O
56 O
dpi O
. O

Lambda O
interferon O
( O
IFN O
- O
lambda O
) O
induces O
an O
intracellular O
IFN O
- O
alpha O
/ O
beta O
- O
like O
antiviral O
response O
through O
a O
receptor O
complex O
distinct O
from O
the O
IFN O
- O
alpha O
/ O
beta O
receptor O
. O

We O
therefore O
determined O
the O
ability O
of O
IFN O
- O
lambda O
to O
inhibit O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

The O
tropism O
of O
Sindbis B
virus I
( I
SB I
) I
for O
cells O
of O
the O
dendritic B
cell I
( I
DC I
) I
lineage O
and O
the O
virulence O
of O
SB O
in O
vivo O
are O
largely O
determined O
by O
the O
efficacy O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
- O
mediated O
antiviral O
responses O
. O

In O
the O
present O
studies O
, O
we O
investigated O
the O
nature O
of O
antiviral O
effects O
and O
identity O
of O
antiviral O
effectors O
primed O
by O
IFN O
- O
alpha O
/ O
beta O
treatment O
of O
bone O
marrow O
- O
derived O
I O
) O
DCs O
( O
BMDCs O
) O
generated O
from O
mice O
deficient O
in O
PKR O
and O
RNase O
L O
( O
TD O
) O
. O

To O
identify O
components O
of O
these O
alternative O
antiviral O
pathway O
( O
s O
) O
, O
we O
have O
compared O
global O
gene O
regulation O
in O
BMDCs O
derived O
from O
normal O
129 O
Sv O
/ O
Ev O
, O
IFNAR1 O
( O
- O
/ O
- O
) O
, O
and O
TD O
mice O
following O
infection O
with O
SB O
or O
treatment O
with O
IFN O
- O
alpha O
/ O
beta O
. O

Candidate O
effectors O
of O
alternative O
antiviral O
pathways O
were O
those O
genes O
induced O
by O
virus O
infection O
or O
IFN O
- O
alpha O
/ O
beta O
treatment O
in O
129 O
Sv O
/ O
Ev O
and O
TD O
- O
derived O
BMDC O
but O
not O
in O
virus O
- O
infected O
or O
IFN O
- O
alpha O
/ O
beta O
- O
treated O
IFNARI O
( O
- O
/ O
- O
) O
cells O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
causes O
chronic O
hepatitis O
, O
which O
often O
results O
in O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

The O
HCV O
- O
induced O
STAT O
- O
3 O
activation O
was O
inhibited O
in O
the O
presence O
of O
antioxidant O
( O
pyrrolidine O
dithiocarbamate O
) O
and O
Ca2 O
+ O
chelators O
( O
BAPTA O
- O
AM O
and O
TMB O
- O
8 O
) O
. O

The O
lack O
of O
an O
appropriate O
in O
vitro O
infection O
system O
for O
the O
major O
human O
pathogen O
hepatitis B
B I
virus I
( I
HBV I
) I
has O
prevented O
a O
molecular O
understanding O
of O
the O
early O
infection O
events O
of O
HBV O
. O

We O
found O
that O
a O
peptide O
consisting O
of O
the O
authentically O
myristoylated O
N O
- O
terminal O
47 O
amino O
acids O
of O
the O
pre O
- O
S1 O
domain O
of O
the O
large O
viral O
envelope O
protein O
( O
L O
protein O
) O
specifically O
prevented O
HBV O
infection O
, O
with O
a O
50 B
% I
inhibitory I
concentration I
( I
IC50 I
) I
of O
8 O
nM O
. O

Virus O
persistence O
in O
chronic O
hepatitis O
B O
patients O
is O
due O
to O
the O
sustaining O
level O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
within O
the O
nuclei O
of O
infected O
hepatocytes O
. O

3 O
- O
fold O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
, O
with O
a O
BclI O
genetic O
marker O
embedded O
in O
the O
redundancy O
region O
, O
to O
examine O
the O
transcriptional O
activity O
of O
cccDNA O
and O
the O
effect O
of O
the O
HBx O
protein O
on O
transcriptional O
regulation O
. O

After O
harvesting O
total O
RNA O
from O
transfected O
cells O
or O
stable O
lines O
, O
we O
specifically O
identified O
and O
monitored O
the O
transcripts O
from O
cccDNA O
by O
using O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
combined O
with O
the O
restriction O
enzyme O
digestion O
method O
. O

In O
this O
approach O
, O
we O
have O
found O
that O
( O
i O
) O
RT O
- O
PCR O
combined O
with O
detection O
of O
the O
BclI O
marker O
is O
a O
highly O
specific O
method O
for O
distinguishing O
cccDNA O
- O
derived O
transcripts O
from O
the O
original O
integrated O
viral O
genome O
, O
( O
ii O
) O
the O
transcriptional O
ability O
of O
cccDNA O
was O
less O
efficient O
than O
that O
from O
the O
integrated O
viral O
genome O
, O
and O
( O
iii O
) O
the O
transcriptional O
activity O
of O
cccDNA O
was O
significantly O
regulated O
by O
the O
HBx O
protein O
, O
a O
potential O
transcription O
activator O
. O

Previously O
, O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
mutant O
164 O
, O
which O
has O
a O
truncation O
at O
the O
C O
terminus O
of O
the O
HBV B
core I
antigen I
( I
HBcAg I
) I
, O
was O
speculated O
to O
secrete O
immature O
genomes O
. O

5 O
- O
kb O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
the O
mutant O
preferentially O
encapsidated O
the O
2 O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
caused O
by O
a O
novel O
coronavirus O
termed O
SARS O
- O
CoV O
. O

We O
and O
others O
have O
previously O
shown O
that O
the O
replication O
of O
SARS O
- O
CoV O
can O
be O
suppressed O
by O
exogenously O
added O
interferon B
( I
IFN I
) I
, O
a O
cytokine O
which O
is O
normally O
synthesized O
by O
cells O
as O
a O
reaction O
to O
virus O
infection O
. O

Nevertheless O
, O
the O
transcription O
factor O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
which O
is O
essential O
for O
IFN O
- O
beta O
promoter O
activity O
, O
was O
transported O
from O
the O
cytoplasm O
to O
the O
nucleus O
early O
after O
infection O
with O
SARS O
- O
CoV O
. O

Other O
signs O
of O
IRF O
- O
3 O
activation O
such O
as O
hyperphosphorylation O
, O
homodimer O
formation O
, O
and O
recruitment O
of O
the O
coactivator O
CREB B
- I
binding I
protein I
( I
CBP I
) I
were O
found O
late O
after O
infection O
with O
the O
control O
virus O
but O
not O
with O
SARS O
- O
CoV O
. O

The O
generation O
of O
subgenomic O
mRNAs O
in O
coronavirus O
involves O
a O
discontinuous O
mechanism O
of O
transcription O
by O
which O
the O
common O
leader O
sequence O
, O
derived O
from O
the O
genome O
5 O
' O
terminus O
, O
is O
fused O
to O
the O
5 O
' O
end O
of O
the O
mRNA O
coding O
sequence O
( O
body O
) O
. O

transcription B
- I
regulating I
sequences I
( I
TRSs I
) I
precede O
each O
gene O
and O
include O
a O
conserved O
core B
sequence I
( I
CS I
) I
surrounded O
by O
relatively O
variable O
sequences O
( O
5 O
' O
TRS O
and O
3 O
' O
TRS O
) O
. O

Regulation O
of O
transcription O
in O
coronaviruses O
has O
been O
studied O
by O
reverse O
- O
genetics O
analysis O
of O
the O
sequences O
immediately O
flanking O
a O
unique O
CS O
in O
the O
Transmissible O
gastroenteritis O
virus O
genome O
( O
CS O
- O
S2 O
) O
, O
located O
inside O
the O
S O
gene O
, O
that O
does O
not O
lead O
to O
detectable O
amounts O
of O
the O
corresponding O
mRNA O
, O
in O
spite O
of O
its O
canonical O
sequence O
. O

The O
presence O
of O
a O
canonical O
CS O
was O
not O
sufficient O
to O
drive O
transcription O
, O
but O
subgenomic O
synthesis O
requires O
a O
minimum O
base O
pairing O
between O
the O
leader B
TRS I
( I
TRS I
- I
L I
) I
and O
the O
complement O
of O
the O
body O
TRS O
( O
cTRS O
- O
B O
) O
provided O
by O
the O
CS O
and O
its O
adjacent O
nucleotides O
. O

The O
large B
hepatitis I
delta I
antigen I
( I
HDAg I
- I
L I
) I
mediates O
hepatitis B
delta I
virus I
( I
HDV I
) I
assembly O
and O
inhibits O
HDV O
RNA O
replication O
. O

Here O
, O
HDAg O
- O
L O
proteins O
from O
different O
HDV O
genotypes O
and O
genotype O
chimeric O
proteins O
were O
analyzed O
for O
their O
ability O
to O
incorporate O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Using O
a O
novel O
assay O
to O
quantify O
the O
extent O
of O
HDAg O
- O
L O
farnesylation O
, O
we O
found O
that O
genotype O
3 O
HDAg O
- O
L O
was O
inefficiently O
farnesylated O
when O
expressed O
in O
the O
absence O
of O
the O
small B
hepatitis I
delta I
antigen I
( I
HDAg I
- I
S I
) I
. O

The O
initiation O
of O
reverse O
transcription O
and O
nucleocapsid O
assembly O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
depends O
on O
the O
specific O
recognition O
of O
an O
RNA O
signal O
( O
the O
packaging O
signal O
, O
epsilon O
) O
on O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
by O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
. O

RT O
- O
epsilon O
interaction O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
was O
recently O
shown O
to O
require O
the O
molecular O
chaperone O
complex O
, O
the O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
. O

China O
is O
facing O
a O
rapid O
upsurge O
in O
cases O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
due O
to O
large O
numbers O
of O
paid B
blood I
donors I
( I
PBD I
) I
, O
injection B
drug I
users I
( I
IDU I
) I
, O
and O
sexual O
partners O
of O
infected O
individuals O
. O

Wild O
- O
type O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
exhibits O
selective O
export O
of O
virions O
containing O
mature O
genomes O
. O

In O
contrast O
, O
changing O
an O
isoleucine O
to O
a O
leucine O
at O
amino O
acid O
97 O
( O
I97L O
) O
of O
the O
HBV B
core I
antigen I
( I
HBcAg I
) I
causes O
it O
to O
release O
immature O
genomes O
. O

The O
carboxy O
- O
terminal O
sequence O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
constitutes O
a O
nucleic O
acid O
binding O
domain O
that O
is O
rich O
in O
arginine O
residues O
and O
contains O
three O
serine O
phosphorylation O
sites O
. O

0 O
- O
kbp O
double O
- O
stranded O
DNA O
molecule O
derived O
from O
spliced O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

The O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
polymerase I
( I
P I
) I
is O
translated O
by O
de O
novo O
initiation O
from O
a O
downstream O
open B
reading I
frame I
( I
ORF I
) I
that O
partially O
overlaps O
the O
core B
( I
C I
) I
ORF O
on O
the O
bicistronic O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

Translation O
of O
the O
pgRNA O
was O
found O
to O
be O
cap O
dependent O
, O
because O
inserting O
a O
stem O
- O
loop O
( O
BamHI O
- O
SL O
) O
that O
blocked O
> O
90 O
% O
of O
scanning O
ribosomes O
at O
the O
5 O
' O
end O
of O
the O
pgRNA O
greatly O
inhibited O
C O
and O
P O
synthesis O
. O

The O
nonstructural B
5A I
( I
NS5A I
) I
protein O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
multifunctional O
phosphoprotein O
that O
is O
implicated O
in O
viral O
replication O
and O
HCV O
- O
mediated O
pathogenesis O
. O

We O
report O
here O
that O
the O
NS5A O
protein O
from O
the O
HCV O
genotype O
la O
is O
processed O
into O
shorter O
distinct O
forms O
when O
expressed O
in O
mammalian O
cells O
( O
Vero O
, O
HepG2 O
, O
HuH O
- O
7 O
, O
and O
WRL68 O
) O
infected O
with O
an O
NS5A O
- O
expressing O
HSV O
- O
1 O
- O
based O
amplicon O
vector O
or O
when O
transiently O
transfected O
with O
NS5A O
- O
expressing O
plasmids O
in O
the O
absence O
of O
exogenous O
apoptotic O
stimuli O
. O

Thus O
, O
our O
results O
are O
consistent O
with O
recent O
data O
that O
demonstrated O
that O
NS5A O
is O
capable O
of O
perturbing O
intracellular O
calcium O
homeostasis O
and O
suggest O
that O
NS5A O
is O
both O
an O
inducer O
and O
a O
substrate O
of O
the O
calcium O
- O
dependent O
calpain O
protease O
( O
s O
) O
. O

This O
may O
imply O
that O
cleavage O
of O
NS5A O
by O
calpain O
( O
s O
) O
could O
play O
a O
role O
in O
the O
modulation O
of O
NS5A O
function O
. O

A O
subpopulation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
in O
cells O
harboring O
full O
- O
length O
HCV O
replicons O
is O
biochemically O
associated O
with O
detergent B
- I
resistant I
membranes I
( I
DRMs I
) I
in O
a O
manner O
similar O
to O
that O
of O
markers O
of O
classical O
lipid O
rafts O
. O

To O
investigate O
the O
role O
of O
the O
hepatitis B
C I
virus I
internal I
ribosome I
entry I
site I
( I
HCV I
IRES I
) I
domain O
IV O
in O
translation O
initiation O
and O
regulation O
, O
two O
chimeric O
IRES O
elements O
were O
constructed O
to O
contain O
the O
reciprocal O
domain O
IV O
in O
the O
otherwise O
HCV O
and O
classical O
swine O
fever O
virus O
IRES O
elements O
. O

The O
presence O
of O
human O
erythrovirus O
DNA O
in O
2 O
, O
440 O
blood O
donations O
from O
the O
United O
Kingdom O
and O
sub O
- O
Saharan O
Africa O
( O
Ghana O
, O
Malawi O
, O
and O
South O
Africa O
) O
was O
screened O
. O

Sensitive O
qualitative O
and O
real O
- O
time O
quantitative O
PCR O
assays O
revealed O
a O
higher O
prevalence O
of O
persistent O
infection O
with O
the O
simultaneous O
presence O
of O
immunoglobulin B
G I
( I
IgG I
) I
and O
viral O
DNA O
( O
0 O
. O

This O
condition O
was O
characterized O
by O
a O
low O
viral O
load O
( O
median O
, O
558 O
IU O
/ O
ml O
; O
range O
, O
42 O
to O
135 O
, O
000 O
IU O
/ O
ml O
) O
, O
antibody O
- O
complexed O
virus O
, O
free O
specific O
IgG O
, O
and O
potentially O
infectious O
free O
virus O
. O

Human O
erythrovirus O
genotype O
1 O
( O
formerly O
parvovirus O
B19 O
) O
was O
prevalent O
in O
the O
United O
Kingdom O
, O
Malawi O
, O
and O
South O
Africa O
. O

In O
contrast O
, O
only O
human O
erythrovirus O
genotype O
3 O
( O
erythrovirus O
variant O
V9 O
) O
was O
prevalent O
in O
Ghana O
. O

In O
vitro O
studies O
have O
described O
the O
synthesis O
of O
an O
alternative O
reading O
frame O
form O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
that O
was O
named O
F O
protein O
or O
ARFP O
( O
alternative O
reading O
frame O
protein O
) O
and O
includes O
a O
domain O
coded O
by O
the O
+ O
1 O
open O
reading O
frame O
of O
the O
RNA O
core O
coding O
region O
. O

Patients O
harboring O
three O
different O
viral O
genotypes O
( O
1a O
, O
1b O
, O
and O
3 O
) O
carried O
T O
lymphocytes O
reactive O
to O
genotype O
1b O
- O
derived O
peptides O
. O

The O
X O
gene O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
one O
of O
the O
major O
factors O
in O
HBV O
- O
induced O
hepatocarcinogenesis O
and O
is O
essential O
for O
the O
establishment O
of O
productive O
HBV O
replication O
in O
vivo O
. O

To O
better O
understand O
the O
mechanisms O
of O
transcriptional O
initiation O
of O
the O
X O
gene O
, O
we O
set O
out O
to O
biochemically O
purify O
the O
binding O
protein O
( O
s O
) O
for O
the O
21 O
- O
bp O
DNA O
. O

We O
report O
here O
the O
identification O
of O
the O
X O
gene O
minimal O
promoter O
- O
binding O
activity O
as O
nuclear B
respiratory I
factor I
1 I
( I
NRF1 I
) I
, O
a O
previously O
known O
transcription O
factor O
that O
activates O
the O
majority O
of O
nucleus O
- O
encoded O
mitochondrial O
genes O
and O
various O
housekeeping O
genes O
. O

Cytotoxic B
T I
- I
lymphocyte I
antigen I
4 I
( I
CTLA I
- I
4 I
) I
is O
an O
inhibitory O
T O
- O
cell O
receptor O
expressed O
by O
activated O
and O
regulatory O
T O
cells O
. O

We O
hypothesized O
that O
Single B
- I
nucleotide I
polymorphisms I
( I
SNPs I
) I
in O
the O
gene O
encoding O
CTLA O
- O
4 O
may O
affect O
the O
vigor O
of O
the O
T O
- O
cell O
response O
to O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
thus O
influencing O
viral O
persistence O
. O

The O
wild O
- O
type O
haplotype O
, O
which O
contains O
an O
SNP O
leading O
to O
a O
decreased O
T O
- O
cell O
response O
( O
+ O
6230A O
) O
, O
was O
associated O
with O
viral O
persistence O
( O
OR O
= O
1 O
. O

Whereas O
enhanced O
peripheral O
T O
- O
cell O
apoptosis O
and O
its O
association O
with O
autoimmunity O
have O
recently O
been O
reported O
, O
the O
apoptotic O
status O
of O
peripheral O
B O
cells O
in O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
remains O
ambiguous O
. O

Spontaneous O
apoptosis O
, O
the O
extent O
of O
apoptosis O
rescue O
, O
and O
NF O
- O
kappaB O
expression O
in O
peripheral O
B O
cells O
were O
studied O
in O
patients O
with O
chronic O
HCV O
infections O
( O
group O
1 O
) O
, O
in O
sustained O
responders O
after O
antiviral O
treatment O
( O
group O
2 O
) O
, O
and O
in O
healthy O
controls O
( O
group O
3 O
) O
. O

6 O
% O
) O
and O
apoptosis O
rescue O
was O
altered O
( O
39 O
% O
) O
compared O
to O
group O
3 O
( O
18 O
% O
+ O
/ O
- O
5 O
% O
and O
50 O
% O
, O
respectively O
; O
P O
= O
0 O
. O

Enhanced O
B O
- O
cell O
apoptosis O
was O
associated O
with O
decreased O
NF O
- O
kappaB O
expression O
and O
was O
found O
only O
in O
CD5 O
- O
negative O
( O
CD5 O
( O
neg O
) O
) O
B O
cells O
, O
whereas O
CD5 O
( O
pos O
) O
cells O
were O
apoptosis O
resistant O
. O

The O
relative O
resistance O
of O
the O
CD5 O
( O
pos O
) O
B O
- O
cell O
subpopulation O
to O
apoptosis O
may O
play O
a O
role O
in O
HCV O
- O
related O
autoimmunity O
and O
lymphoproliferation O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
variant O
MHV O
/ O
BHK O
can O
infect O
hamster O
, O
rat O
, O
cat O
, O
dog O
, O
monkey O
, O
and O
human O
cell O
lines O
but O
not O
the O
swine B
testis I
( I
ST I
) I
porcine O
cell O
line O
( O
J O
. O

The O
spike B
( I
S I
) I
gene O
of O
MHV O
/ O
BHK O
had O
63 O
point O
mutations O
and O
a O
21 O
- O
by O
insert O
that O
encoded O
56 O
amino O
acid O
substitutions O
and O
a O
7 O
- O
amino O
- O
acid O
insert O
compared O
to O
the O
parental O
MHV O
strain O
A59 O
. O

In O
contrast O
, O
MHV O
/ O
BHK O
and O
a O
recombinant O
virus O
, O
k6c O
, O
with O
the O
21 O
amino O
acid O
substitutions O
and O
7 O
- O
amino O
- O
acid O
insert O
in O
S O
bound O
to O
hamster O
( O
BHK O
) O
and O
ST O
cells O
as O
well O
as O
murine O
cells O
. O

Mechanisms O
of O
virion O
attachment O
, O
interaction O
with O
its O
receptor O
, O
and O
cell O
entry O
are O
poorly O
understood O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
because O
of O
a O
lack O
of O
an O
efficient O
and O
reliable O
in O
vitro O
system O
for O
virus O
propagation O
. O

Infectious O
HCV O
retroviral O
pseudotype O
particles O
( O
HCVpp O
) O
were O
recently O
shown O
to O
express O
native O
E1E2 O
glycoproteins O
, O
as O
defined O
in O
part O
by O
HCV O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
to O
conformational O
epitopes O
on O
E2 O
, O
and O
some O
of O
these O
antibodies O
block O
HCVpp O
infection O
( O
A O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
the O
virus O
most O
closely O
related O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
infects O
tamarins O
and O
causes O
acute O
hepatitis O
. O

The O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
an O
infectious O
GBV O
- O
B O
clone O
( O
pGBB O
) O
has O
a O
proximal O
short O
sequence O
followed O
by O
a O
poly O
( O
U O
) O
tract O
and O
a O
3 O
' O
terminal O
sequence O
. O

Here O
, O
we O
tested O
the O
effect O
of O
deleting O
the O
short O
sequence O
and O
/ O
or O
the O
poly O
( O
U O
) O
tract O
from O
pGBB O
; O
infectivity O
of O
each O
mutant O
was O
tested O
by O
intrahepatic O
transfection O
of O
two O
tamarins O
with O
transcribed O
RNA O
. O

However O
, O
mutants O
lacking O
either O
the O
short O
sequence O
or O
the O
poly O
( O
U O
) O
tract O
were O
viable O
. O

Whereas O
we O
found O
that O
five O
tamarins O
transfected O
with O
the O
wild O
- O
type O
clone O
pGBB O
had O
acute O
resolving O
infection O
, O
one O
tamarin O
transfected O
with O
the O
poly O
( O
U O
) O
deletion O
mutant O
became O
persistently O
infected O
. O

The O
genomes O
recovered O
at O
weeks O
2 O
, O
7 O
, O
15 O
, O
20 O
, O
60 O
, O
and O
90 O
lacked O
the O
poly O
( O
U O
) O
stretch O
. O

Inactivated O
parapoxvirus O
ovis O
( O
Orf O
virus O
; O
PPVO O
) O
recently O
displayed O
strong O
immunostimulating O
and O
modulating O
capacities O
in O
several O
animal O
models O
for O
acute O
and O
chronic O
virus O
infections O
through O
the O
induction O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
as O
a O
key O
mediator O
of O
antiviral O
activity O
. O

The O
data O
presented O
in O
this O
work O
demonstrate O
that O
inactivated O
PPVO O
has O
strong O
effects O
on O
cytokine O
secretion O
by O
human O
immune O
cells O
, O
including O
the O
upregulation O
of O
inflammatory O
and O
Th1 O
- O
related O
cytokines O
( O
IFN O
- O
gamma O
, O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
a O
] O
, O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
IL O
- O
8 O
, O
IL O
- O
12 O
, O
and O
IL O
- O
18 O
) O
as O
well O
as O
anti O
- O
inflammatory O
and O
Th2 O
- O
related O
cytokines O
( O
IL O
- O
4 O
, O
IL O
- O
10 O
, O
and O
IL O
- O
1 O
receptor O
antagonist O
[ O
IL O
- O
1ra O
] O
) O
. O

The O
virus O
particles O
activate O
monocytes O
or O
other O
antigen B
- I
presenting I
cells I
( I
APC I
) I
, O
e O
. O

The O
activation O
of O
monocytes O
or O
APC O
is O
followed O
by O
the O
release O
of O
early O
proinflammatory O
cytokines O
( O
TNF O
- O
alpha O
, O
IL O
- O
6 O
, O
and O
IL O
- O
8 O
) O
as O
well O
as O
the O
Thl O
- O
related O
cytokines O
IL O
- O
12 O
and O
IL O
- O
18 O
. O

The O
proinflammatory O
response O
is O
accompanied O
by O
the O
induction O
of O
anti O
- O
inflammatory O
and O
Th2 O
- O
related O
cytokines O
( O
IL O
- O
4 O
, O
IL O
- O
10 O
, O
and O
IL O
- O
1ra O
) O
, O
which O
exert O
a O
limiting O
effect O
on O
the O
inflammatory O
response O
induced O
by O
PPVO O
. O

In O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
, O
one O
of O
the O
most O
common O
mutations O
to O
the O
virus O
occurs O
at O
amino O
acid O
97 O
of O
the O
core O
protein O
, O
where O
leucine O
replaces O
either O
phenylalanine O
or O
isoleucine O
, O
depending O
on O
strain O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
gamma O
are O
able O
to O
suppress O
hepadnavirus O
replication O
. O

We O
investigated O
the O
effects O
of O
woodchuck B
- I
specific I
IFN I
- I
alpha I
( I
wIFN I
- I
alpha I
) I
and O
IFN O
- O
gamma O
( O
wIFN O
- O
gamma O
) O
on O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
replication O
in O
vivo O
by O
helper B
- I
dependent I
adenoviral I
( I
HD I
- I
Ad I
) I
vector O
- O
mediated O
gene O
transfer O
. O

The O
expression O
of O
biologically O
active O
IFNs O
was O
demonstrated O
in O
vitro O
after O
transduction O
of O
woodchuck O
cells O
with O
HD B
- I
Ad I
vectors I
encoding I
wIFN I
- I
alpha I
( I
HD I
- I
AdwIFN I
- I
alpha I
) I
or O
wIFN O
- O
gamma O
( O
HD O
- O
AdwIFN O
- O
gamma O
) O
. O

The O
transduction O
efficacy O
of O
the O
HD O
- O
Ad O
vector O
in O
woodchuck O
liver O
in O
vivo O
was O
tested O
with O
a O
vector O
expressing O
green B
fluorescence I
protein I
( I
GFP I
) I
. O

The O
Pekin O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
was O
used O
to O
investigate O
superinfection O
exclusion O
in O
hepadnavirus O
infections O
. O

Superinfection O
exclusion O
was O
shown O
to O
occur O
both O
in O
vivo O
and O
in O
vitro O
with O
a O
genetically O
marked O
DHBV O
, O
DHBV O
- O
ClaI O
, O
which O
was O
unable O
to O
establish O
an O
infection O
in O
either O
DHBV O
- O
infected O
ducklings O
or O
DHBV O
- O
infected O
primary B
duck I
hepatocytes I
( I
PDHs I
) I
. O

The O
large O
surface O
antigen O
is O
known O
to O
cause O
down O
- O
regulation O
of O
a O
DHBV O
receptor O
, O
carboxypeptidase B
D I
( I
CPD I
) I
. O

The O
infection O
itinerary O
was O
found O
to O
initiate O
with O
the O
attachment O
of O
viral O
particles O
to O
a O
low O
number O
of O
binding O
sites O
on O
hepatocytes O
( O
about O
104 O
per O
cell O
) O
. O

During O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
, O
mutations O
in O
the O
precore B
( I
pc I
) I
or O
basal B
core I
promoter I
( I
BCP I
) I
region O
affecting O
HBV B
e I
antigen I
( I
HBeAg I
) I
expression O
occur O
commonly O
and O
represent O
the O
predominant O
virus O
species O
in O
patients O
with O
HBeAg O
- O
negative O
chronic O
hepatitis O
B O
. O

The O
PC O
mutation O
( O
G1896A O
+ O
C1858T O
) O
creates O
a O
translational O
stop O
codon O
resulting O
in O
absent O
HBeAg O
expression O
, O
whereas O
BCP O
mutations O
( O
A1762T O
/ O
G1764A O
) O
reduce O
HBeAg O
expression O
by O
transcriptional O
mechanisms O
. O

Treatment O
of O
chronic O
HBV O
infection O
with O
lamivudine B
( I
LMV I
) I
often O
selects O
drug O
- O
resistant O
strains O
with O
single O
( O
rtM204I O
) O
or O
double O
( O
rtL180M O
+ O
rtM204V O
) O
point O
mutations O
in O
the O
YMDD O
motif O
of O
HBV O
reverse O
transcriptase O
. O

We O
cloned O
replication O
- O
competent O
HBV O
vectors O
( O
genotype O
A O
, O
adw2 O
) O
combining O
mutations O
in O
the O
core O
( O
wild O
type O
[ O
wt O
] O
, O
PC O
, O
and O
BCP O
) O
and O
polymerase O
gene O
( O
wt O
, O
rtM204I O
, O
and O
rtL180M O
/ O
M204V O
) O
and O
analyzed O
virus O
replication O
and O
drug O
sensitivity O
in O
vitro O
. O

Resistance O
to O
LMV O
( O
rtM204I O
/ O
rtL180M O
+ O
rtM204V O
) O
was O
accompanied O
by O
a O
reduced O
replication O
efficacy O
as O
evidenced O
by O
reduced O
pregenomic O
RNA O
, O
encapsidated O
progeny O
DNA O
, O
polymerase O
activity O
, O
and O
virion O
release O
. O

Packaging O
of O
hepadnavirus O
pregenomic B
RNA I
( I
pgRNA I
) I
into O
capsids O
, O
or O
encapsidation O
, O
requires O
several O
viral O
components O
. O

The O
viral O
polymerase B
( I
P I
) I
and O
the O
capsid O
subunit O
( O
C O
) O
are O
necessary O
for O
pgRNA O
encapsidation O
. O

Previous O
studies O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
indicated O
that O
two O
cis O
- O
acting O
sequences O
on O
pgRNA O
are O
required O
for O
encapsidation O
: O
epsilon O
, O
which O
is O
near O
the O
5 O
' O
end O
of O
pgRNA O
, O
and O
region O
II O
, O
located O
near O
the O
middle O
of O
pgRNA O
. O

We O
analyzed O
chimeras O
of O
DHBV O
and O
a O
related O
virus O
, O
heron B
hepatitis I
B I
virus I
( I
HHBV I
) I
, O
to O
gain O
insight O
into O
the O
interactions O
between O
the O
various O
viral O
components O
during O
pgRNA O
encapsidation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
causes O
hepatitis O
, O
hepatocellular O
carcinoma O
, O
and O
B O
- O
cell O
lymphomas O
in O
a O
significant O
number O
of O
patients O
. O

Here O
we O
report O
that O
HCV O
infection O
activated O
the O
immunologic O
( O
type O
II O
) O
isoform O
of O
nitric B
oxide I
( I
NO I
) I
synthase O
( O
NOS O
) O
, O
i O
. O

, O
inducible B
NOS I
( I
iNOS I
) I
, O
thereby O
inducing O
NO O
, O
which O
in O
turn O
induced O
DNA O
breaks O
and O
enhanced O
the O
mutation O
frequencies O
of O
cellular O
genes O
. O

Expression O
of O
the O
core O
protein O
or O
nonstructural B
protein I
3 I
( I
NS3 I
) I
, O
but O
not O
the O
other O
viral O
proteins O
, O
in O
B O
cells O
or O
hepatocytes O
induced O
iNOS O
and O
DNA O
breaks O
, O
which O
could O
be O
blocked O
by O
NOS O
inhibitors O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
core O
promoter O
contains O
a O
binding O
site O
for O
nuclear O
receptors O
. O

A O
natural O
double O
mutation O
in O
this O
binding O
site O
, O
which O
changes O
nucleotide B
( I
nt I
) I
1765 O
from O
A O
to O
T O
and O
nt O
1767 O
from O
G O
to O
A O
, O
selectively O
abolishes O
the O
binding O
of O
several O
nuclear O
receptors O
without O
affecting O
that O
of O
HNF4 O
. O

Our O
results O
indicate O
that O
HNF4 O
could O
stimulate O
the O
expression O
of O
the O
precore O
RNA O
and O
the O
core O
RNA O
from O
the O
core O
promoter O
of O
both O
the O
wild B
- I
type I
( I
WT I
) I
HBV O
and O
the O
double O
mutant O
, O
although O
its O
effect O
on O
the O
former O
was O
more O
prominent O
. O

We O
have O
previously O
reported O
the O
production O
of O
hepatitis B
C I
virus I
- I
like I
particles I
( I
HCV I
- I
LP I
) I
using O
a O
recombinant O
baculovirus O
containing O
the O
cDNA O
of O
the O
HCV O
structural O
proteins O
( O
core O
, O
E1 O
, O
and O
E2 O
) O
. O

Three O
groups O
of O
four O
baboons O
were O
immunized O
with O
HCV O
- O
LP O
, O
HCV O
- O
LP O
and O
adjuvant O
AS01B O
( O
monophosphoryl O
lipid O
A O
and O
QS21 O
) O
, O
or O
HCV O
- O
LP O
and O
the O
combination O
of O
AS01B O
and O
CpG O
oligodeoxynucleotides O
10105 O
. O

After O
four O
immunizations O
over O
an O
8 O
- O
month O
period O
, O
all O
animals O
developed O
HCV O
- O
specific O
humoral O
and O
cellular O
immune O
responses O
including O
antibodies O
to O
HCV O
structural O
proteins O
and O
gamma O
interferon O
( O
+ O
) O
( O
IFN O
- O
gamma O
( O
+ O
) O
) O
CD4 O
( O
+ O
) O
and O
IFN O
- O
gamma O
( O
+ O
) O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

Synthesis O
of O
the O
relaxed B
- I
circular I
( I
RC I
) I
DNA O
genomes O
of O
hepadnaviruses O
by O
reverse O
transcriptase O
involves O
two O
template O
switches O
during O
plus O
- O
strand O
DNA O
synthesis O
. O

These O
template O
switches O
require O
repeat O
sequences O
( O
so O
- O
called O
donor O
and O
acceptor O
sites O
) O
between O
which O
a O
complementary O
strand O
of O
nucleic O
acid O
is O
transferred O
. O

To O
determine O
cis O
- O
acting O
elements O
apart O
from O
the O
donor O
and O
acceptor O
sites O
that O
are O
required O
for O
plus O
- O
strand O
RC O
DNA O
synthesis O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
series O
of O
mutants O
bearing O
a O
small O
deletion O
were O
made O
and O
analyzed O
for O
their O
impact O
on O
the O
viral O
genome O
synthesis O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
an O
acute O
respiratory O
infectious O
disease O
that O
spread O
worldwide O
in O
early O
2003 O
. O

The O
cause O
was O
determined O
as O
a O
novel O
Coronavirus B
( I
CoV I
) I
, O
SARS B
- I
associated I
CoV I
( I
SARS I
- I
CoV I
) I
, O
with O
a O
single O
- O
stranded O
, O
plus O
- O
sense O
RNA O
. O

To O
exploit O
the O
possibility O
of O
using O
RNA O
interference O
as O
a O
therapeutic O
approach O
to O
fight O
the O
disease O
, O
plasm O
id O
- O
mediated O
small B
interfering I
RNAs I
( I
siRNAs I
) I
were O
generated O
to O
target O
the O
SARS O
- O
CoV O
genome O
. O

The O
eight O
genotypes O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
have O
different O
geographical O
distributions O
, O
virological O
characteristics O
, O
and O
clinical O
manifestations O
. O

A O
unique O
subtype O
of O
HBV O
genotype O
A O
( O
HBV O
/ O
A O
) O
was O
reported O
in O
sub O
- O
Saharan O
Africa O
, O
raising O
the O
possibility O
that O
patients O
infected O
with O
this O
subtype O
( O
HBV O
/ O
Aa O
[ O
a O
for O
African O
and O
Asian O
] O
) O
may O
have O
different O
clinical O
outcomes O
than O
other O
HBV O
/ O
A O
isolates O
( O
HBV O
/ O
Ae O
[ O
e O
for O
European O
] O
) O
. O

Comparison O
between O
30 O
HBV O
/ O
Aa O
and O
30 O
HBV O
/ O
Ae O
isolates O
indicated O
that O
almost O
all O
HBV O
/ O
Ae O
isolates O
had O
G O
at O
nucleotide B
( I
nt I
) I
1809 O
and O
C O
at O
nt O
1812 O
, O
whereas O
HBV O
/ O
Aa O
isolates O
had O
T1809 O
/ O
T1812 O
. O

Taking O
advantage O
of O
these O
two O
single B
nucleotide I
polymorphisms I
( I
SNPs I
) I
, O
a O
novel O
subtype O
- O
specific O
PCR O
assay O
in O
the O
X O
/ O
precore O
/ O
core O
region O
was O
developed O
. O

This O
assay O
was O
combined O
with O
a O
restriction O
fragment O
length O
polymorphism O
assay O
using O
BgIII O
in O
a O
different O
region O
( O
nt O
1984 O
to O
1989 O
) O
, O
which O
has O
a O
SNP O
distinguishing O
HBV O
/ O
Aa O
from O
HBV O
/ O
Ae O
, O
resulting O
in O
100 O
% O
specificity O
for O
the O
combined O
assay O
. O

mouse B
adenovirus I
type I
1 I
( I
MAV I
- I
1 I
) I
infection O
of O
B O
- O
cell O
- O
deficient O
and O
Bruton B
' I
s I
tyrosine I
kinase I
( I
Btk I
) I
- O
deficient O
mice O
resulted O
in O
fatal O
disseminated O
disease O
resembling O
human O
adenovirus O
infections O
in O
immunocompromised O
patients O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
demonstration O
that O
mice O
with O
an O
X O
- O
linked O
immunodeficiency O
phenotype O
( O
Btk O
deficient O
) O
are O
susceptible O
to O
virus O
- O
induced O
disease O
. O

Treatment O
of O
MAV O
- O
1 O
- O
infected O
Btk O
( O
- O
/ O
- O
) O
mice O
4 O
to O
9 O
days O
postinfection O
with O
antiserum O
harvested O
6 O
to O
9 O
days O
postinfection O
from O
MAV O
- O
1 O
- O
infected O
Btk O
( O
+ O
/ O
+ O
) O
mice O
was O
therapeutic O
. O

The O
cytotoxic O
T O
- O
cell O
response O
in O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
has O
been O
described O
as O
weak O
and O
mono O
- O
or O
oligospecific O
in O
comparison O
to O
the O
more O
robust O
virus O
- O
specific O
T O
- O
cell O
response O
present O
in O
resolved O
infection O
. O

Here O
we O
analyzed O
( O
both O
directly O
ex O
vivo O
and O
after O
in O
vitro O
stimulation O
) O
the O
HBV O
- O
specific O
CD8 O
T O
- O
cell O
responses O
against O
structural O
and O
nonstructural O
HBV O
proteins O
longitudinally O
in O
patients O
with O
different O
patterns O
of O
chronic O
infections O
. O

We O
found O
that O
the O
profiles O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
during O
chronic O
infections O
are O
highly O
heterogeneous O
and O
influenced O
more O
by O
the O
level O
of O
HBV O
replication O
than O
by O
the O
activity O
of O
liver O
disease O
. O

An O
HBV O
DNA O
load O
of O
< O
10 O
( O
7 O
) O
copies O
/ O
ml O
appears O
to O
be O
the O
threshold O
below O
which O
circulating O
multispecific O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
consistently O
detected O
. O

Furthermore O
, O
CD8 O
( O
+ O
) O
T O
cells O
with O
different O
specificities O
are O
differentially O
regulated O
during O
chronic O
infections O
. O

HBV O
core O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
associated O
with O
viral O
control O
, O
while O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
envelope O
and O
polymerase O
epitopes O
can O
occasionally O
be O
found O
in O
the O
setting O
of O
high O
levels O
( O
> O
10 O
( O
7 O
) O
copies O
) O
of O
HBV O
replication O
. O

Conjugated O
and O
unconjugated O
oligomers O
were O
tested O
to O
determine O
sequence O
- O
specific O
antiviral O
efficacy O
against O
a O
member O
of O
the O
Coronaviridae O
, O
mouse B
hepatitis I
virus I
( I
MRV I
) I
. O

The O
first O
3 O
or O
4 O
nucleotides B
( I
nt I
) I
of O
minus O
- O
strand O
DNA O
are O
synthesized O
by O
the O
use O
of O
a O
bulge O
in O
a O
stem O
- O
loop O
structure O
near O
the O
5 O
' O
end O
of O
the O
pregenome O
as O
a O
template O
. O

Here O
we O
report O
a O
novel O
cis O
- O
acting O
element O
, O
termed O
the O
beta5 O
region O
( O
28 O
nt O
in O
length O
) O
, O
located O
20 O
nt O
upstream O
of O
DR1 O
* O
, O
that O
facilitates O
minus O
- O
strand O
DNA O
synthesis O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
suggested O
to O
localize O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
through O
a O
C O
- O
terminal O
hydrophobic O
region O
that O
acts O
as O
a O
membrane O
anchor O
for O
core O
protein O
and O
as O
a O
signal O
sequence O
for O
El O
protein O
. O

The O
signal O
sequence O
of O
core O
protein O
is O
further O
processed O
by O
signal B
peptide I
peptidase I
( I
SPP I
) I
. O

Precise O
mutation O
analyses O
indicated O
that O
replacement O
of O
Leu O
( O
139 O
) O
, O
Val O
( O
140 O
) O
, O
and O
Lett O
( O
144 O
) O
of O
core O
protein O
by O
Ala O
inhibited O
processing O
by O
SPP O
, O
but O
cleavage O
at O
the O
core O
- O
E1 O
junction O
by O
signal O
peptidase O
was O
maintained O
. O

139 O
140 O
144 O
These O
results O
indicate O
that O
Leu O
( O
139 O
) O
, O
Val O
( O
140 O
) O
, O
and O
Leu O
( O
144 O
) O
in O
core O
protein O
play O
crucial O
roles O
in O
the O
ER O
retention O
and O
SPP O
cleavage O
of O
HCV O
core O
protein O
. O

We O
hypothesized O
that O
GM O
and O
KM O
allotypes O
affect O
the O
outcome O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

The O
presence O
of O
GM O
1 O
, O
3 O
, O
17 O
23 O
5 O
, O
13 O
phenotype O
( O
in O
the O
absence O
of O
KM O
3 O
) O
was O
associated O
with O
persistence O
( O
OR O
, O
0 O
. O

77 O
) O
, O
while O
its O
absence O
( O
in O
the O
presence O
of O
KM O
1 O
, O
3 O
) O
was O
associated O
with O
the O
clearance O
of O
infection O
( O
OR O
, O
2 O
. O

These O
results O
show O
epistatic O
interactions O
of O
genes O
on O
chromosomes O
14 O
( O
GM O
) O
and O
2 O
( O
KM O
) O
in O
influencing O
the O
outcome O
of O
an O
HCV O
infection O
. O

Further O
investigations O
involving O
candidate O
genes O
( O
GM O
, O
KM O
, O
HLA O
, O
and O
Fcgamma O
receptors O
) O
and O
cellular O
and O
humoral O
immune O
responses O
to O
HCV O
epitopes O
are O
needed O
to O
understand O
the O
mechanisms O
underlying O
these O
associations O
. O

The O
X O
protein O
( O
HBX O
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
not O
essential O
for O
the O
HBV O
life O
cycle O
in O
vitro O
but O
is O
important O
for O
productive O
infection O
in O
vivo O
. O

With O
the O
woodchuck O
model O
, O
we O
demonstrated O
that O
the O
X O
- O
deficient O
mutants O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
are O
not O
completely O
replication O
defective O
, O
possibly O
behaving O
like O
attenuated O
viruses O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
and O
woolly B
monkey I
hepatitis I
B I
virus I
( I
WMHBV I
) I
have O
natural O
host O
ranges O
that O
are O
limited O
to O
closely O
related O
species O
. O

As O
previously O
shown O
by O
using O
the O
hepatitis B
D I
virus I
( I
HDV I
) I
system O
, O
recombinant O
HBV O
- O
HDV O
particles O
were O
infectious O
in O
chimpanzee O
as O
well O
as O
human O
hepatocytes O
. O

Previous O
studies O
have O
implicated O
the O
pre O
- O
S1 O
region O
of O
the O
large B
( I
L I
) I
envelope O
protein O
in O
receptor O
binding O
and O
host O
range O
; O
therefore O
, O
recombinant O
HDV O
particles O
were O
pseudotyped O
with O
the O
hepadnaviral O
envelopes O
containing O
chimeric O
L O
proteins O
with O
the O
first O
40 O
amino O
acids O
from O
the O
pre O
- O
S1 O
domain O
exchanged O
between O
HBV O
and O
WMHBV O
. O

Alteration O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
secretion O
efficiency O
may O
have O
pathological O
consequences O
. O

We O
recently O
identified O
HBV O
genomes O
displaying O
high O
( O
4B O
) O
, O
substantially O
reduced O
( O
3 O
. O

4 O
) O
, O
or O
negative O
( O
4C O
) O
virion O
secretion O
. O

The O
mutated O
residues O
are O
predicted O
to O
lie O
in O
the O
luminal O
side O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
or O
to O
be O
embedded O
in O
the O
ER O
membrane O
and O
thus O
are O
not O
involved O
in O
contact O
with O
core O
particles O
during O
envelopment O
. O

Of O
the O
two O
mutations O
inhibitory O
of O
virion O
secretion O
, O
G510A O
greatly O
reduced O
small O
envelope O
protein O
( O
hepatitis O
B O
surface O
antigen O
[ O
HBsAg O
] O
) O
levels O
both O
inside O
cells O
and O
in O
culture O
medium O
, O
whereas O
G660C O
specifically O
abolished O
HBsAg O
secretion O
. O

The O
hallmarks O
of O
the O
immune O
response O
to O
viral O
infections O
are O
the O
expansion O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
after O
they O
encounter O
antigen O
- O
presenting O
cells O
in O
the O
lymphoid O
tissues O
and O
their O
subsequent O
redistribution O
to O
nonlymphoid O
tissues O
to O
deal O
with O
the O
pathogen O
. O

This O
is O
demonstrated O
during O
overwhelming O
infection O
with O
the O
noncytolytic O
murine O
lymphocytic O
choriomeningitis O
virus O
, O
in O
which O
clonal O
exhaustion O
( O
anergy O
and O
/ O
or O
deletion O
) O
of O
CTLs O
prevents O
immune O
- O
mediated O
pathology O
but O
allows O
persistence O
of O
the O
virus O
. O

However O
, O
these O
cells O
were O
unable O
to O
control O
the O
infection O
and O
progressively O
lost O
their O
antiviral O
capacities O
( O
cytotoxicity O
and O
cytokine O
secretion O
) O
in O
a O
hierarchical O
manner O
before O
their O
eventual O
physical O
elimination O
. O

The O
effector O
function O
of O
CD8 O
T O
cells O
is O
mediated O
via O
cell O
- O
mediated O
cytotoxicity O
and O
production O
of O
cytokines O
like O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

Using O
mice O
deficient O
for O
TNF O
receptor O
( O
TNFR O
) O
I O
and O
/ O
or O
II O
, O
we O
show O
that O
TNF O
- O
TNFR O
interactions O
have O
a O
dual O
role O
in O
mediating O
viral O
clearance O
and O
downregulating O
CD8 O
and O
CD4 O
T O
- O
cell O
responses O
during O
a O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
. O

While O
wild O
- O
type O
( O
+ O
/ O
+ O
) O
and O
TNFR O
II O
- O
deficient O
( O
p75 O
( O
- O
/ O
- O
) O
) O
mice O
cleared O
LCMV O
from O
the O
liver O
and O
lung O
, O
mice O
deficient O
in O
TNFR O
I O
( O
p55 O
( O
- O
/ O
- O
) O
) O
or O
both O
TNFR O
I O
and O
TNFR O
II O
( O
double O
knockout O
[ O
DKO O
] O
) O
exhibited O
impaired O
viral O
clearance O
. O

The O
inability O
of O
p55 O
( O
- O
/ O
- O
) O
and O
DKO O
mice O
to O
clear O
LCMV O
was O
not O
a O
sequel O
to O
either O
suboptimal O
activation O
of O
virus O
- O
specific O
CD8 O
or O
CD4 O
T O
cells O
or O
impairment O
in O
trafficking O
of O
LCW O
- O
specific O
CD8 O
T O
cells O
to O
the O
liver O
and O
lung O
. O

In O
fact O
, O
the O
expansion O
of O
LCW O
- O
specific O
CD8 O
and O
CD4 O
T O
cells O
was O
significantly O
higher O
in O
DKO O
mice O
compared O
to O
that O
in O
+ O
/ O
+ O
, O
p55 O
( O
- O
/ O
- O
) O
, O
and O
p75 O
( O
- O
/ O
- O
) O
mice O
. O

In O
order O
to O
test O
which O
mechanism O
, O
if O
not O
both O
, O
is O
used O
by O
hepatitis O
B O
viruses O
in O
order O
to O
spread O
, O
we O
used O
primary O
duck O
hepatocytes O
and O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
as O
an O
infection O
model O
. O

The O
pregenomic B
RNA I
( I
pgRNA I
) I
of O
hepadnaviruses O
is O
packaged O
into O
capsids O
where O
it O
is O
reverse O
transcribed O
to O
yield O
mature O
DNA O
genomes O
. O

Additional O
experiments O
show O
that O
the O
3 O
' O
ends O
of O
capsid O
pgRNA O
isolated O
by O
micrococcal O
nuclease O
treatment O
are O
heterogeneously O
dispersed O
from O
nucleotide O
2577 O
to O
the O
poly O
( O
A O
) O
tail O
. O

Using O
the O
model O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
in O
mice O
, O
we O
provide O
evidence O
that O
slowly O
replicating O
strains O
induce O
weaker O
cytotoxic B
- I
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
than O
a O
more O
rapidly O
replicating O
strain O
. O

A O
mathematical O
model O
for O
virus O
- O
CTL O
population O
dynamics O
( O
analogous O
to O
predator O
[ O
CTL O
] O
- O
prey O
[ O
virus O
] O
interactions O
) O
is O
applied O
in O
the O
clinical O
data O
- O
driven O
analysis O
of O
acute O
hepatitis O
B O
virus O
infection O
. O

hepatitis B
D I
virus I
( I
HDV I
) I
is O
a O
satellite O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
for O
transmission O
and O
propagation O
and O
infects O
nearly O
20 O
million O
people O
worldwide O
. O

The O
nucleotide O
sequences O
of O
hepatitis O
D O
viruses O
( O
HDV O
) O
vary O
5 O
to O
14 O
% O
among O
isolates O
of O
the O
same O
genotype O
and O
23 O
to O
34 O
% O
among O
different O
genotypes O
. O

The O
only O
viral O
- O
genome O
- O
encoded O
antigen O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
has O
two O
forms O
that O
differ O
in O
size O
. O

The O
small O
HDAg O
( O
HDAg O
- O
S O
) O
trans O
- O
activates O
viral O
replication O
, O
while O
the O
large O
form O
( O
HDAg O
- O
L O
) O
is O
essential O
for O
viral O
assembly O
. O

Both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
are O
required O
for O
clearance O
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
during O
acute O
infection O
. O

We O
investigated O
the O
effects O
of O
an O
epitope O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
on O
acute O
infection O
of O
MHV O
, O
strain O
A59 O
, O
in O
the O
murine O
CNS O
. O

Mice O
with O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
gp33 O
- O
41 O
( O
an O
H O
- O
2D O
( O
b O
) O
- O
restricted O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
derived O
from O
lymphocytic O
choriomeningitis O
glycoprotein O
) O
were O
infected O
with O
a O
recombinant O
MHV O
- O
A59 O
, O
also O
expressing O
gp33 O
- O
41 O
, O
as O
a O
fusion O
protein O
with O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
. O

By O
5 O
days O
postinfection O
, O
these O
mice O
showed O
significantly O
( O
approximately O
20 O
- O
fold O
) O
lower O
titers O
of O
infectious O
virus O
in O
the O
brain O
compared O
to O
control O
mice O
. O

Furthermore O
mice O
with O
gp33 O
- O
41 O
- O
specific O
CD8 O
( O
+ O
) O
cells O
exhibited O
much O
reduced O
levels O
of O
viral O
antigen O
in O
the O
brain O
as O
measured O
by O
immunohistochemistry O
using O
an O
antibody O
directed O
against O
viral O
nucleocapsid O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
frequently O
causes O
transient O
infections O
in O
adults O
but O
chronic O
infections O
in O
infants O
. O

Infection O
of O
ducks O
with O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
displays O
a O
similar O
dependence O
of O
outcome O
on O
the O
age O
of O
the O
host O
at O
the O
time O
of O
infection O
. O

Sequence O
alignment O
software O
, O
thermodynamic O
RNA O
folding O
programs O
, O
and O
classical O
comparative O
phylogenetic O
analysis O
were O
used O
to O
build O
models O
of O
six O
RNA O
elements O
in O
the O
coding O
region O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
- O
dependent O
RNA O
polymerase O
, O
NS5B O
. O

2 O
, O
blocked O
RNA O
replication O
, O
implicating O
it O
as O
an O
essential O
cis B
- I
acting I
replication I
element I
( I
CRE I
) I
. O

2 O
is O
about O
50 O
bases O
in O
length O
and O
is O
part O
of O
a O
larger O
predicted O
cruciform O
structure O
( O
5BSL3 O
) O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
which O
is O
closely O
related O
to O
human O
hepatitis O
B O
virus O
and O
is O
considered O
to O
be O
principally O
hepatotropic O
, O
invades O
the O
host O
' O
s O
lymphatic O
system O
and O
persists O
in O
lymphoid O
cells O
independently O
of O
whether O
the O
infection O
is O
symptomatic O
and O
serologically O
evident O
or O
concealed O
. O

This O
primary O
occult O
infection O
is O
caused O
by O
wild O
- O
type O
virus O
invading O
the O
host O
at O
a O
quantity O
usually O
not O
greater O
than O
10 O
( O
3 O
) O
virions O
. O

Various O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
recognize O
cell O
surface O
proteins O
on O
bovine O
cells O
were O
previously O
shown O
to O
efficiently O
block O
infection O
with O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
( O
C O
. O

The O
cDNA O
of O
bovine O
CD46 O
( O
CD46 O
( O
bov O
) O
) O
was O
cloned O
and O
further O
characterized O
. O

A O
putative O
function O
of O
CD46 O
( O
bov O
) O
as O
a O
BVDV O
receptor O
was O
studied O
with O
respect O
to O
virus O
binding O
and O
susceptibility O
of O
nonpermissive O
cells O
. O

While O
the O
expression O
of O
CD46 O
( O
bov O
) O
correlated O
well O
with O
the O
binding O
of O
[ O
H O
- O
3 O
] O
uridine O
- O
labeled O
BVDV O
, O
the O
susceptibility O
of O
cells O
nonpermissive O
for O
BVDV O
was O
not O
observed O
. O

However O
, O
the O
expression O
of O
CD46 O
( O
bov O
) O
resulted O
in O
a O
significant O
increase O
in O
the O
susceptibility O
of O
porcine O
cells O
to O
BVDV O
. O

These O
results O
provide O
strong O
evidence O
that O
CD46 O
( O
bov O
) O
serves O
as O
a O
cellular O
receptor O
for O
BVDV O
. O

Two O
binding O
partners O
for O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
pre O
- O
S O
envelope O
protein O
have O
been O
identified O
. O

duck B
carboxypeptidase I
D I
( I
DCPD I
) I
interacts O
with O
the O
full O
- O
length O
pre O
- O
S O
protein O
and O
is O
the O
DHBV O
docking O
receptor O
, O
while O
duck B
glycine I
decarboxylase I
( I
DGD I
) I
has O
the O
potential O
to O
bind O
several O
deletion O
constructs O
of O
the O
pre O
- O
S O
protein O
in O
vitro O
. O

Interestingly O
, O
DGD O
but O
not O
DCPD O
expression O
was O
diminished O
following O
prolonged O
culture O
of O
primary B
duck I
hepatocytes I
( I
PDH I
) I
, O
which O
impaired O
productive O
DHBV O
infection O
. O

The O
induction O
of O
humoral O
response O
in O
ducks O
by O
DNA O
- O
based O
immunization O
against O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
protein O
( O
DHBc O
) O
was O
investigated O
. O

Peptide O
scanning O
analysis O
of O
anti O
- O
DHBc O
response O
induced O
during O
chronic O
DHBV O
infection O
allowed O
us O
to O
identify O
six O
major O
antigenic O
regions O
( O
AR1 O
to O
AR6 O
) O
. O

To O
gain O
more O
insight O
into O
the O
location O
of O
antigenic O
regions O
, O
we O
built O
a O
three B
- I
dimensional I
( I
3 I
- I
D I
) I
model O
of O
DHBc O
protein O
based O
on O
human O
and O
duck O
core O
sequence O
alignment O
data O
and O
the O
HBc O
3 O
- O
D O
crystal O
structure O
. O

The O
results O
suggest O
that O
two O
identified O
antigenic O
regions O
( O
AR2 O
, O
amino O
acids O
[ O
aa O
] O
T O
- O
64 O
- O
P O
- O
84 O
, O
and O
AR5 O
, O
aa O
( O
183 O
) O
A O
- O
R O
- O
210 O
) O
are O
located O
at O
positions O
on O
the O
protein O
surface O
equivalent O
to O
those O
of O
the O
two O
HBc O
major O
epitopes O
. O

Moreover O
, O
we O
identified O
another O
antigenic O
region O
( O
AR3 O
, O
aa O
I O
- O
99 O
- O
I O
- O
112 O
) O
that O
was O
recognized O
by O
all O
sera O
from O
chronically O
infected O
, O
DNA O
- O
or O
protein O
- O
immunized O
ducks O
within O
the O
large O
45 O
- O
aa O
insertion O
in O
DHBc O
protein O
, O
suggesting O
that O
this O
region O
, O
which O
lacks O
HBc O
, O
is O
externally O
exposed O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
a O
flavivirus O
closely O
related O
to O
HCV O
, O
has O
previously O
been O
shown O
to O
infect O
and O
replicate O
to O
high O
titers O
in O
tamarins O
( O
Saguinus O
sp O
. O

This O
study O
describes O
the O
use O
of O
GBV O
- O
B O
infection O
and O
replication O
in O
the O
common O
marmoset O
( O
Callithrix O
jacchus O
) O
for O
the O
successful O
development O
and O
validation O
of O
a O
surrogate O
animal O
model O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Infection O
of O
marmosets O
with O
GBV O
- O
B O
produced O
a O
viremia O
that O
peaked O
at O
10 O
( O
8 O
) O
to O
109 O
genome O
copies O
/ O
ml O
for O
a O
period O
of O
40 O
to O
60 O
days O
followed O
by O
viral O
clearance O
at O
60 O
to O
80 O
days O
postinfection O
. O

Treatment O
of O
GBV O
- O
B O
- O
infected O
hepatocyte O
cultures O
with O
a O
novel O
class O
of O
HCV O
protease O
inhibitor O
( O
pyrrolidine O
5 O
, O
5 O
trans O
- O
lactams O
) O
reduced O
viral O
levels O
by O
more O
than O
2 O
logs O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
major O
human O
pathogen O
in O
much O
of O
the O
developing O
world O
. O

Finer O
mapping O
of O
the O
interacting O
RNA O
revealed O
that O
a O
76 O
- O
nucleotide B
( I
nt I
) I
region O
at O
the O
5 O
' O
end O
of O
the O
HEV O
genome O
was O
responsible O
for O
binding O
the O
ORF2 O
protein O
. O

Synthesis O
of O
the O
relaxed B
- I
circular I
( I
RC I
) I
genome O
of O
hepadnaviruses O
is O
a O
multistep O
process O
that O
requires O
template O
switching O
during O
reverse O
transcription O
. O

However O
, O
knowledge O
about O
cis O
- O
acting O
requirements O
distinct O
from O
the O
donor O
and O
acceptor O
sites O
for O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
was O
lacking O
. O

Two O
template O
switches O
are O
necessary O
during O
plus O
- O
strand O
DNA O
synthesis O
of O
the O
relaxed B
circular I
( I
RC I
) I
form O
of O
the O
hepadnavirus O
genome O
. O

Using O
both O
genetic O
and O
biochemical O
approaches O
, O
we O
now O
have O
found O
that O
the O
small O
DNA O
hairpin O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
makes O
a O
positive O
contribution O
to O
circularization O
. O

Two O
template O
switches O
are O
necessary O
during O
plus O
- O
strand O
DNA O
synthesis O
of O
the O
relaxed B
circular I
( I
RC I
) I
form O
of O
the O
hepadnavirus O
genome O
. O

In O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
a O
small O
terminal O
redundancy O
( O
5 O
' O
r O
and O
3 O
' O
r O
) O
on O
the O
ends O
of O
the O
minus O
- O
strand O
DNA O
has O
been O
shown O
to O
be O
important O
, O
but O
not O
sufficient O
, O
for O
circularization O
. O

The O
marine O
gammaherpesvirus O
68 O
( O
MHV O
- O
68 O
or O
gammaHV O
- O
68 O
) O
model O
provides O
many O
advantages O
for O
studying O
virus O
- O
host O
interactions O
involved O
in O
gammaherpesvirus O
replication O
, O
including O
the O
role O
of O
cellular O
responses O
to O
infection O
. O

We O
examined O
the O
effects O
of O
cellular O
cyclooxygenase B
- I
2 I
( I
COX I
- I
2 I
) I
and O
its O
by O
- O
product O
prostaglandin O
E O
, O
( O
PGE O
( O
2 O
) O
) O
on O
MHV O
- O
68 O
gene O
expression O
and O
protein O
production O
following O
de O
novo O
infection O
of O
cultured O
cells O
. O

Two O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
, O
a O
COX O
- O
2 O
- O
specific O
inhibitor O
( O
NS O
- O
398 O
) O
and O
a O
COX O
- O
1 O
- O
COX O
- O
2 O
inhibitor O
( O
indomethacin O
) O
, O
substantially O
reduced O
MHV O
- O
68 O
protein O
production O
in O
infected O
cells O
. O

Inhibition O
of O
viral O
protein O
expression O
and O
virion O
production O
by O
NS O
- O
398 O
was O
reversed O
in O
the O
presence O
of O
exogenous O
PGE O
( O
2 O
) O
. O

These O
studies O
suggest O
that O
COX O
- O
2 O
activity O
and O
PGE O
( O
2 O
) O
production O
may O
play O
significant O
roles O
during O
MHV O
- O
68 O
de O
novo O
infection O
. O

Instead O
of O
displaying O
the O
wild O
- O
type O
selective O
export O
of O
virions O
containing O
mature O
genomes O
, O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
mutant O
I97L O
, O
changing O
from O
an O
isoleucine O
to O
a O
leucine O
at O
amino O
acid O
97 O
of O
HBV B
core I
antigen I
( I
HBcAg I
) I
, O
lost O
the O
high O
stringency O
of O
selectivity O
in O
genome O
maturity O
during O
virion O
export O
. O

from O
the O
wild O
- O
type O
and O
mutant O
I97L O
HBV O
, O
in O
either O
full O
- O
length O
( O
HBcAgl O
- O
183 O
) O
or O
truncated O
core O
protein O
contexts O
( O
HBcAgl O
- O
149 O
and O
HBcAgl O
- O
140 O
) O
. O

In O
general O
, O
HBV O
capsid O
particles O
( O
HBcAgl O
- O
183 O
, O
HBcAgl O
- O
149 O
, O
and O
HBcAgl O
- O
140 O
) O
are O
very O
robust O
but O
will O
dissociate O
at O
pH O
2 O
or O
14 O
, O
at O
temperatures O
higher O
than O
75degreesC O
, O
or O
in O
0 O
. O

1 O
% O
sodium B
dodecyl I
sulfate I
( I
SDS I
) I
. O

No O
difference O
in O
the O
ratio O
between O
T O
= O
3 O
( O
78 O
% O
) O
and O
T O
= O
4 O
particles O
( O
20 O
. O

Whether O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
DNA O
vaccine O
can O
induce O
anti O
- O
HDV O
antibodies O
has O
been O
debatable O
. O

The O
role O
of O
the O
isoprenylated O
motif O
of O
hepatitis B
delta I
antigens I
( I
HDAg I
) I
in O
the O
generation O
of O
immune O
responses O
following O
DNA O
- O
based O
immunization O
has O
never O
been O
studied O
. O

Plasmids O
p2577L O
, O
encoding O
large B
HDAg I
( I
L I
- I
HDAg I
) I
, O
p2577S O
, O
expressing O
small B
HDAg I
( I
S I
- I
HDAg I
) I
, O
and O
p25L O
- O
211S O
, O
encoding O
a O
mutant O
form O
of O
L O
- O
HDAg O
with O
a O
cysteine O
- O
to O
- O
serine O
mutation O
at O
codon O
211 O
, O
were O
constructed O
in O
this O
study O
. O

The O
anti O
- O
HDV O
antibody O
titers O
, O
T O
- O
cell O
proliferation O
responses O
, O
T O
- O
helper O
responses O
, O
and O
HDV O
- O
specific O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
CD8 O
( O
+ O
) O
T O
cells O
were O
analyzed O
. O

proliferation O
responses O
and O
generate O
Th1 O
responses O
and O
HDV O
- O
specific O
, O
IFN O
- O
gamma O
- O
producing O
CD8 O
( O
+ O
) O
T O
cells O
. O

UV O
cross O
- O
linking O
experiments O
indicated O
that O
the O
lysine O
residue O
in O
the O
conserved O
motif O
AXXGXGK O
( O
110 O
) O
V O
is O
directly O
involved O
in O
ATP O
binding O
, O
whereas O
mutant O
R O
( O
205 O
) O
Q O
in O
the O
arginine O
- O
rich O
motif O
ER O
( O
205 O
) O
XGRXXR O
bound O
ATP O
at O
a O
level O
comparable O
to O
that O
of O
the O
wild O
- O
type O
protein O
. O

The O
RNA O
binding O
activity O
was O
drastically O
altered O
in O
the O
R O
( O
205 O
) O
Q O
mutant O
and O
was O
also O
affected O
in O
the O
K110N O
mutant O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
causes O
chronic O
hepatitis O
in O
most O
infected O
individuals O
by O
evading O
host O
immune O
defenses O
. O

In O
this O
investigation O
, O
we O
show O
that O
HCV O
- O
infected O
cells O
may O
go O
undetected O
in O
the O
immune O
system O
by O
suppressing O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
antigen O
presentation O
to O
cytotoxic O
T O
lymphocytes O
. O

HCV O
replicons O
induce O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
( O
K O
. O

Therapy O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
with O
the O
polymerase O
inhibitor O
lamivudine O
frequently O
is O
associated O
with O
the O
emergence O
of O
viral O
resistance O
. O

Genotypic O
changes O
in O
the O
YMDD O
motif O
( O
reverse O
transcriptase O
[ O
rt O
] O
mutations O
rtM204V O
/ O
I O
) O
conferred O
resistance O
to O
lamivudine O
as O
well O
as O
reducing O
the O
in O
vitro O
replication O
efficiency O
of O
HBV O
. O

Here O
we O
report O
the O
functional O
characterization O
of O
a O
third O
polymerase O
mutation O
( O
rtVI73L O
) O
associated O
with O
resistance O
to O
lamivudine O
and O
famciclovir O
. O

C57BL O
/ O
6 O
( O
B6 O
) O
mice O
infected O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
JHM O
develop O
a O
clinically O
evident O
, O
demyelinating O
encephalomyelitis O
. O

Here O
we O
show O
that O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
escape O
was O
not O
detected O
in O
MHV O
- O
infected O
BALB O
/ O
b O
mice O
( O
H O
- O
2 O
( O
b O
) O
haplotype O
) O
, O
even O
though O
the O
same O
CD8 O
T O
- O
cell O
epitopes O
were O
recognized O
as O
in O
B6 O
mice O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
and O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
replicons O
have O
been O
reported O
to O
replicate O
only O
in O
Hub7 O
cells O
. O

n O
- O
( O
n O
- O
Nonyl O
) O
- O
deoxygalactonojirimycin O
( O
n O
, O
n O
- O
DGJ O
) O
, O
an O
alkylated O
imino O
sugar O
, O
reduces O
the O
amount O
of O
HBV O
DNA O
produced O
within O
the O
stably O
transfected O
HBV O
- O
producing O
HepG2 O
. O

Following O
an O
acute O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
clearance O
or O
persistence O
is O
determined O
in O
part O
by O
the O
vigor O
and O
breadth O
of O
the O
host O
immune O
response O
. O

Since O
the O
human B
leukocyte I
antigen I
system I
( I
HLA I
) I
is O
an O
integral O
component O
of O
the O
immune O
response O
, O
we O
hypothesized O
that O
the O
highly O
polymorphic O
HLA O
genes O
are O
key O
determinants O
of O
viral O
clearance O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
plays O
an O
important O
role O
in O
the O
formation O
of O
the O
viral O
nucleocapsid O
and O
a O
regulatory O
protein O
involved O
in O
hepatocarcinogenesis O
. O

In O
this O
study O
, O
we O
have O
identified O
proteasome O
activator O
PA28gamma O
( O
1 O
IS O
regulator O
gamma O
) O
as O
an O
HCV O
core O
binding O
protein O
by O
using O
yeast O
two O
- O
hybrid O
system O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
associated O
with O
immune O
- O
mediated O
abnormalities O
and O
B O
- O
cell O
lymphoproliferation O
. O

It O
has O
recently O
been O
shown O
that O
peripheral O
B O
- O
cell O
CD81 O
overexpression O
and O
CD5 O
( O
+ O
) O
subpopulation O
expansion O
correlate O
with O
HCV O
viral O
load O
and O
are O
associated O
with O
the O
development O
of O
HCV O
- O
related O
autoimmunity O
. O

In O
the O
present O
study O
, O
we O
assessed O
the O
effects O
of O
combination O
antiviral O
therapy O
( O
alfa O
interferon O
and O
ribavirin O
) O
on O
peripheral O
B O
- O
cell O
CD81 O
expression O
and O
CD5 O
expansion O
and O
the O
presence O
of O
autoimmune O
markers O
. O

A O
significant O
posttreatment O
decrease O
in O
peripheral O
B O
- O
cell O
CD81 O
expression O
and O
disappearance O
of O
CD5 O
( O
+ O
) O
B O
- O
cell O
expansion O
were O
observed O
in O
all O
nine O
patients O
in O
whom O
a O
complete O
and O
sustained O
virological O
response O
was O
achieved O
( O
P O
< O
0 O
. O

01 O
) O
( O
comparable O
to O
those O
for O
healthy O
controls O
) O
. O

In O
contrast O
, O
in O
nonresponders O
overexpression O
of O
CD81 O
and O
expansion O
of O
the O
CD5 O
( O
+ O
) O
B O
- O
cell O
subpopulation O
were O
not O
significantly O
changed O
and O
were O
comparable O
to O
those O
for O
untreated O
patients O
. O

In O
conclusion O
, O
antiviral O
therapy O
down O
- O
regulates O
peripheral O
B O
- O
cell O
CD81 O
expression O
and O
the O
CD5 O
( O
+ O
) O
population O
, O
either O
directly O
or O
by O
its O
effect O
on O
HCV O
RNA O
load O
. O

The O
overexpression O
of O
CD81 O
and O
the O
expansion O
of O
the O
population O
of O
CD5 O
( O
+ O
) O
peripheral O
B O
cells O
in O
HCV O
- O
infected O
patients O
may O
possibly O
play O
a O
role O
in O
the O
development O
of O
HCV O
- O
associated O
autoimmunity O
and O
lymphoproliferation O
. O

Heterogeneous B
nuclear I
ribonucleoprotein I
( I
hnRNP I
) I
At O
has O
previously O
been O
shown O
to O
bind O
mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
at O
the O
3 O
' O
end O
of O
both O
plus O
and O
minus O
strands O
and O
modulate O
MHV O
RNA O
synthesis O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
leading O
cause O
of O
chronic O
liver O
disease O
worldwide O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
only O
known O
positive O
- O
stranded O
RNA O
virus O
that O
causes O
persistent O
lifelong O
infections O
in O
humans O
. O

Accumulation O
of O
HCV O
RNA O
can O
be O
inhibited O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
in O
vivo O
and O
in O
culture O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
chronic O
infection O
is O
characterized O
by O
low O
or O
undetectable O
cellular O
immune O
responses O
against O
HCV O
antigens O
. O

We O
have O
previously O
reported O
that O
the O
expression O
of O
HCV O
core O
and O
El O
proteins O
( O
CE1 O
) O
in O
dendritic B
cells I
( I
DC I
) I
impairs O
their O
ability O
to O
prime O
T O
cells O
in O
vitro O
. O

We O
show O
here O
that O
immunization O
of O
mice O
with O
immature O
DC O
transduced O
with O
an O
adenovirus O
encoding O
HCV O
core O
and O
El O
antigens O
( O
AdCE1 O
) O
induced O
lower O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
than O
immunization O
with O
DC O
transduced O
with O
an O
adenovirus B
encoding I
NS3 I
( I
AdNS3 I
) I
. O

Blockade O
of O
DC O
maturation O
by O
CE1 O
was O
manifested O
by O
a O
lower O
expression O
of O
maturation O
surface O
markers O
and O
was O
associated O
with O
a O
reduced O
ability O
of O
AdCE1 O
- O
transduced O
DC O
to O
activate O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
in O
vivo O
. O

The O
susceptibility O
of O
the O
tree O
shrew O
Tupaia O
belangeri O
to O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
has O
been O
demonstrated O
both O
in O
vivo O
and O
in O
vitro O
. O

A O
monoclonal B
antibody I
( I
Mab I
) I
, O
MA18 O
/ O
7 O
, O
directed O
against O
the O
pre O
- O
S1 O
domain O
of O
the O
large O
HBs O
protein O
, O
which O
has O
been O
shown O
to O
neutralize O
infectivity O
of O
HBV O
for O
primary O
human O
hepatocytes O
, O
also O
blocked O
infection O
of O
primary O
Tupaia O
hepatocytes O
. O

Hepatitis O
B O
immunoglobulin O
is O
used O
for O
prophylaxis O
against O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
is O
thought O
to O
act O
by O
neutralization O
of O
virions O
and O
hepatitis B
B I
virus I
surface I
antigen I
( I
HBsAg I
) I
- O
containing O
particles O
in O
circulation O
. O

Using O
a O
panel O
of O
hepatocyte O
- O
derived O
cell O
lines O
, O
the O
present O
study O
investigated O
in O
vitro O
whether O
HBs O
- O
specific O
immunoglobulin B
G I
( I
IgG I
) I
is O
internalized O
in O
hepatocytes O
and O
whether O
it O
interacts O
with O
HBsAg O
in O
the O
cells O
. O

These O
effects O
were O
not O
observed O
with O
F O
( O
ab O
) O
, O
fragments O
or O
nonimmune O
IgG O
as O
controls O
. O

The O
specificity O
of O
intracellular O
HBsAg O
- O
anti O
- O
HBs O
interaction O
was O
further O
investigated O
in O
cells O
transfected O
with O
HBV O
genomes O
expressing O
wild O
- O
type O
HBsAg O
or O
immune O
escape O
HBsAg O
( O
with O
a O
G145R O
mutation O
) O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
plays O
an O
essential O
role O
in O
viral O
replication O
and O
in O
the O
development O
of O
hepatocellular O
carcinoma O
. O

The O
yield O
of O
G418 O
- O
resistant O
Huh7 O
cell O
clones O
bearing O
subgenomic O
dicistronic O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
significantly O
affected O
by O
the O
insertion O
of O
a O
portion O
of O
the O
viral O
core O
gene O
between O
the O
GBV O
- O
B O
5 O
' O
untranslated O
region O
and O
the O
exogenous O
neomycin O
phosphotransferase O
selector O
gene O
( O
A O
. O

The O
replication O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
can O
be O
regulated O
by O
a O
variety O
of O
factors O
, O
including O
hormones O
, O
growth O
factors O
, O
and O
cytokines O
. O

This O
suppression O
of O
HBV O
replication O
by O
activated O
Ras O
was O
apparently O
mediated O
by O
the O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase O
pathway O
, O
as O
it O
was O
accompanied O
by O
activation O
of O
ERK1 O
/ O
2 O
and O
abolished O
by O
the O
MEK1 O
/ O
2 O
inhibitor O
U0126 O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
HBx O
protein O
is O
a O
multifunctional O
protein O
that O
activates O
cellular O
signaling O
pathways O
and O
is O
thought O
to O
be O
essential O
for O
viral O
infection O
. O

, O
cyclosporine O
A O
, O
cyclosporine O
H O
, O
and O
SDZ O
NIM811 O
, O
which O
block O
cytosolic O
calcium O
signaling O
and O
specifically O
the O
mitochondrial O
permeability O
transition O
pore O
( O
SDZ O
NIM811 O
) O
, O
also O
impaired O
HBV O
replication O
. O

An O
animal O
model O
has O
been O
established O
for O
woolly B
monkey I
hepatitis I
B I
virus I
( I
WMHBV I
) I
by O
using O
spider O
monkeys O
, O
since O
woolly O
monkeys O
are O
endangered O
. O

The O
nonstructural O
proteins O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
been O
shown O
previously O
to O
localize O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
when O
expressed O
singly O
or O
in O
the O
context O
of O
other O
HCV O
proteins O
. O

This O
reduction O
is O
also O
seen O
in O
cells O
that O
contain O
genome O
length O
HCV O
replicons O
: O
the O
rate O
of O
appearance O
of O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
on O
the O
cell O
surface O
was O
reduced O
by O
three O
- O
to O
fivefold O
compared O
to O
that O
for O
a O
cured O
cell O
line O
. O

The O
UV B
- I
damaged I
DNA I
- I
binding I
activity I
protein I
( I
UV I
- I
DDB I
) I
consists O
of O
two O
subunits O
, O
DDB1 O
and O
DDB2 O
, O
and O
functions O
in O
DNA O
repair O
and O
cell O
cycle O
regulation O
. O

The O
DDB1 O
subunit O
is O
a O
target O
for O
the O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
. O

DDB1 O
also O
interacts O
with O
the O
V O
proteins O
encoded O
by O
several O
paramyxoviruses O
including O
simian B
virus I
5 I
( I
SV5 I
) I
, O
which O
prevent O
interferon O
signaling O
by O
targeting O
either O
STAT1 O
or O
STAT2 O
proteins O
for O
proteolysis O
. O

Here O
we O
show O
that O
the O
V B
protein I
of I
SV5 I
( I
SV5 I
- I
V I
) I
and O
HBx O
exhibit O
strikingly O
similar O
DDB1 O
binding O
properties O
. O

We O
have O
characterized O
a O
conformational O
epitope O
on O
capsids O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
by O
cryo O
- O
electron O
microscopy O
and O
three O
- O
dimensional O
image O
reconstruction O
of O
Fab O
- O
labeled O
capsids O
to O
similar O
to10 O
- O
Angstrom O
resolution O
, O
combined O
with O
molecular O
modeling O
. O

An O
increasing O
number O
of O
viruses O
have O
been O
shown O
to O
initiate O
protein O
synthesis O
by O
a O
cap O
- O
independent O
mechanism O
involving O
Internal B
ribosome I
entry I
sites I
( I
IRESs I
) I
. O

Biophysical O
confirmation O
of O
the O
models O
has O
been O
achieved O
only O
for O
the O
IRES O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
which O
adopts O
an O
open O
structure O
consisting O
of O
two O
major O
stems O
. O

All O
of O
the O
flavivirus O
IRESs O
we O
examined O
( O
those O
of O
GB O
virus O
- O
B O
, O
GB O
virus O
- O
C O
, O
and O
classical O
swine O
fever O
virus O
) O
fold O
to O
give O
a O
structure O
similar O
to O
that O
of O
the O
HCV O
IRES O
, O
as O
does O
an O
IRES O
recently O
found O
on O
mRNA O
encoded O
by O
human O
herpesvirus O
8 O
. O

The O
larger O
picornavirus O
IRESs O
( O
those O
of O
foot O
- O
and O
- O
mouth O
disease O
virus O
, O
rhinovirus O
, O
encephalomyocarditis O
virus O
, O
and O
hepatitis O
A O
virus O
) O
are O
morphologically O
similar O
, O
comprising O
a O
backbone O
with O
two O
protruding O
stems O
, O
and O
distinct O
from O
the O
flavivirus O
IRESs O
. O

The O
core O
promoter O
mutants O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
emerge O
as O
the O
dominant O
viral O
population O
at O
the O
late O
HBeAg O
and O
the O
anti O
- O
HBe O
stages O
of O
HBV O
infection O
, O
with O
the O
A1762T O
/ O
G1764A O
substitutions O
as O
the O
hotspot O
mutations O
. O

The O
double O
core O
promoter O
mutations O
were O
found O
by O
many O
investigators O
to O
moderately O
enhance O
viral O
genome O
replication O
and O
reduce O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
expression O
. O

All O
12 O
HBV O
genomes O
derived O
from O
highly O
viremic O
sera O
( O
5 O
x O
10 O
( O
9 O
) O
to O
5 O
. O

7 O
x O
10 O
( O
9 O
) O
copies O
of O
viral O
genome O
/ O
ml O
) O
harbored O
wild O
- O
type O
core O
promoter O
sequence O
, O
whereas O
37 O
of O
43 O
clones O
from O
low O
- O
viremia O
samples O
( O
0 O
. O

2 O
x O
10 O
( O
7 O
) O
to O
4 O
. O

6 O
x O
10 O
( O
7 O
) O
copies O
/ O
ml O
) O
were O
core O
promoter O
mutants O
. O

All O
had O
1762 O
/ O
1764 O
mutations O
and O
an O
additional O
substitution O
at O
position O
1753 O
( O
T O
to O
C O
) O
, O
at O
position O
1766 O
( O
C O
to O
T O
) O
, O
or O
both O
. O

An O
inverse O
correlation O
between O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
steady O
- O
state O
levels O
of O
apolipoprotein O
AI O
and O
CIII O
mRNAs O
was O
observed O
in O
two O
hepatoma O
cell O
lines O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
particles O
are O
coated O
with O
the O
large B
( I
L I
) I
, O
middle O
( O
M O
) O
, O
and O
small B
( I
S I
) I
hepatitis O
B O
virus O
envelope O
proteins O
. O

We O
observed O
that O
the O
removal O
of O
N O
- O
linked O
carbohydrates O
on O
the O
S O
, O
M O
, O
and O
L O
proteins O
was O
tolerated O
for O
the O
assembly O
of O
subviral O
hepatitis B
B I
virus I
( I
HBV I
) I
particles O
but O
was O
partially O
inhibitory O
for O
the O
formation O
of O
HDV O
virions O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
mucosa O
- O
restricted O
virus O
that O
is O
a O
leading O
cause O
of O
epidemic O
respiratory O
tract O
infections O
in O
children O
. O

Ribavirin O
( O
1 O
- O
beta O
- O
D O
- O
ribofuranosyl O
- O
1 O
, O
2 O
, O
4 O
- O
triazole O
- O
3 O
- O
carboxamide O
) O
is O
a O
nontoxic O
antiviral O
agent O
currently O
licensed O
for O
the O
treatment O
of O
severe O
RSV O
lower O
respiratory O
tract O
infections O
. O

5 O
% O
of O
the O
RSV O
- O
inducible O
genes O
( O
total O
number O
of O
genes O
, O
272 O
) O
, O
suggesting O
that O
the O
epithelial O
- O
cell O
genetic O
program O
initiated O
by O
viral O
infection O
is O
independent O
of O
high O
- O
level O
RSV O
replication O
. O

In O
one O
group O
, O
ribavirin O
inhibited O
the O
expression O
of O
the O
RSV O
- O
inducible O
CC O
chemokines O
MIP O
- O
1alpha O
and O
- O
1beta O
, O
which O
are O
important O
in O
RSV O
- O
induced O
pulmonary O
pathology O
, O
and O
interferon B
( I
IFN I
) I
, O
a O
cytokine O
important O
in O
the O
mucosal O
immune O
response O
. O

In O
a O
second O
group O
, O
ribavirin O
further O
up O
- O
regulated O
a O
set O
of O
RSV O
- O
and O
IFN B
- I
stimulated I
response I
genes I
( I
ISGs I
) I
encoding O
antiviral O
proteins O
( O
MxA O
and O
p56 O
) O
, O
complement O
products O
, O
acute O
- O
phase O
response O
factors O
, O
and O
the O
STAT O
and O
IRF O
transcription O
factors O
. O

Ribavirin O
- O
enhanced O
TAP O
- O
1 O
- O
LMP2 O
expression O
was O
a O
transcriptional O
event O
where O
site O
mutations O
of O
the O
IFN B
- I
stimulated I
response I
element I
( I
ISRE I
) I
blocked O
RSV O
and O
ribavirin O
- O
inducible O
promoter O
activity O
. O

tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
is O
associated O
with O
noncytopathic O
clearance O
of O
hepatitis O
B O
virus O
in O
animal O
models O
. O

Here O
we O
demonstrate O
that O
the O
nuclear B
factor I
kappaB I
( I
NF I
- I
kappaB I
) I
signaling O
pathway O
is O
a O
central O
mediator O
of O
inhibition O
of O
hepatitis O
B O
virus O
by O
TNF O
- O
alpha O
and O
we O
describe O
the O
molecular O
mechanism O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
induces O
microtubule O
aggregates O
in O
infected O
hepatocytes O
. O

The O
reverse B
transcriptase I
( I
RT I
) I
encoded O
by O
hepadnaviruses O
( O
hepatitis O
B O
viruses O
) O
is O
a O
multifunctional O
protein O
critical O
for O
several O
aspects O
of O
viral O
assembly O
and O
replication O
. O

Using O
the O
RT O
from O
duck O
hepatitis O
B O
virus O
as O
a O
model O
, O
we O
previously O
demonstrated O
that O
RT O
- O
epsilon O
interaction O
and O
protein O
priming O
require O
the O
assistance O
of O
a O
host O
cell O
chaperone O
complex O
, O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
and O
its O
cochaperones O
, O
which O
associates O
with O
the O
RT O
and O
facilitates O
the O
folding O
of O
the O
RT O
into O
an O
active O
conformation O
. O

Surprisingly O
, O
the O
presence O
of O
detergent O
plus O
some O
yet O
- O
to O
- O
be O
- O
identified O
cytoplasmic O
factor O
( O
s O
) O
led O
to O
a O
dramatic O
suppression O
of O
the O
RT O
activities O
. O

The O
immunological O
correlates O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
immunity O
are O
not O
well O
understood O
. O

The O
animal O
that O
most O
rapidly O
cleared O
circulating O
HCV O
as O
determined O
by O
nested O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
displayed O
the O
most O
vigorous O
and O
sustained O
response O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
and O
proliferating O
CD4 O
( O
+ O
) O
T O
cells O
in O
the O
blood O
. O

Vigorous O
CD4 O
( O
+ O
) O
T O
- O
cell O
proliferation O
during O
viremia O
was O
followed O
by O
an O
increased O
frequency O
and O
a O
phenotypic O
and O
functional O
change O
of O
the O
tetramer O
( O
+ O
) O
CD8 O
( O
+ O
) O
T O
- O
cell O
population O
. O

The O
second O
animal O
cleared O
HCV O
initially O
with O
strong O
peripheral O
and O
intrahepatic O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
but O
experienced O
low O
- O
level O
HCV O
recrudescence O
12 O
weeks O
later O
, O
when O
HCV O
- O
specific O
T O
cells O
became O
undetectable O
. O

The O
third O
animal O
maintained O
minute O
amounts O
of O
circulating O
HCV O
, O
detectable O
only O
by O
nested O
RT O
- O
PCR O
, O
in O
the O
face O
of O
a O
weak O
IFN O
- O
gamma O
( O
+ O
) O
T O
- O
cell O
response O
. O

To O
facilitate O
investigations O
of O
replication O
and O
host O
cell O
interactions O
in O
the O
hepadnavirus O
system O
, O
we O
have O
developed O
cell O
lines O
permitting O
the O
conditional O
replication O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

Investigations O
of O
the O
stability O
of O
viral O
DNA O
intermediates O
indicated O
that O
both O
encapsidated O
DNA O
and O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
were O
turned O
over O
independently O
of O
cell O
division O
. O

This O
study O
analyzes O
the O
effect O
of O
highly B
active I
antiretroviral I
therapy I
( I
HAART I
) I
, O
and O
thus O
immunologic O
status O
, O
on O
hepatitis B
C I
virus I
( I
HCV I
) I
load O
and O
quasispecies O
diversity O
in O
patients O
coinfected O
with O
the O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
and O
HCV O
. O

However O
, O
in O
comparison O
to O
groups O
A O
and O
B O
, O
group O
C O
had O
significantly O
higher O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
cell O
counts O
, O
a O
trend O
toward O
a O
higher O
HCV O
load O
, O
and O
significantly O
increased O
number O
of O
HCV O
clones O
, O
entropy O
, O
genetic O
distance O
, O
and O
ratio O
of O
nonsynonymous O
substitutions O
per O
nonsynonymous O
site O
to O
synonymous O
substitutions O
per O
synonymous O
site O
( O
K O
- O
a O
/ O
K O
- O
s O
) O
. O

In O
addition O
, O
CD4 O
( O
+ O
) O
- O
cell O
count O
was O
positively O
correlated O
with O
HCV O
load O
, O
genetic O
distance O
, O
and O
K O
- O
a O
. O

Interestingly O
, O
patients O
infected O
with O
HCV O
genotype O
2 O
or O
3 O
had O
a O
significantly O
higher O
CD4 O
( O
+ O
) O
- O
cell O
count O
, O
HCV O
load O
, O
genetic O
distance O
, O
and O
K O
- O
a O
/ O
K O
- O
s O
than O
those O
infected O
with O
genotype O
1 O
. O

Direct O
DNA O
sequencing O
of O
amplified O
CHBV O
DNA O
as O
well O
a O
sequencing O
of O
cloned O
viral O
genomes O
revealed O
that O
CHBV O
is O
most O
closely O
related O
to O
, O
although O
distinct O
from O
, O
Ross B
' I
goose I
hepatitis I
B I
virus I
( I
RGHBV I
) I
and O
slightly O
less O
closely O
related O
to O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

In O
this O
study O
, O
we O
established O
a O
B O
- O
cell O
line O
( O
SB O
) O
from O
an O
HCV O
- O
infected O
non O
- O
Hodgkin O
' O
s O
B O
- O
cell O
lymphoma O
. O

15 O
g O
/ O
ml O
in O
sucrose O
and O
could O
infect O
primary O
human O
hepatocytes O
, O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
, O
and O
an O
established O
B O
- O
cell O
line O
( O
Raji O
cells O
) O
in O
vitro O
. O

We O
have O
reinvestigated O
the O
subcellular O
distribution O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
protein O
in O
infected O
duck O
hepatocytes O
and O
in O
transfected O
cells O
. O

By O
using O
indirect O
immunofluorescence O
, O
the O
protein O
was O
found O
to O
be O
localized O
not O
only O
in O
the O
cytoplasm O
, O
as O
described O
previously O
, O
but O
also O
within O
the O
cell O
nucleus O
, O
being O
concentrated O
in O
distinct O
, O
brightly O
staining O
nuclear B
core I
bodies I
( I
NCBs I
) I
. O

Foamy B
viruses I
( I
FVs I
) I
are O
classified O
in O
the O
family O
Retroviridae O
, O
but O
recent O
data O
have O
shown O
that O
they O
are O
not O
conventional O
retroviruses O
. O

Notably O
, O
several O
characteristics O
of O
their O
particle O
replication O
strategies O
are O
more O
similar O
to O
those O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
than O
those O
of O
typical O
retroviruses O
. O

Compared O
to O
conventional O
retroviruses O
, O
which O
require O
only O
Gag O
proteins O
for O
budding O
and O
release O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
, O
both O
FV O
and O
HBV O
require O
Env O
proteins O
. O

In O
the O
case O
of O
HBV O
, O
Env O
( O
S O
protein O
) O
alone O
is O
sufficient O
to O
form O
subviral B
particles I
( I
SVPs I
) I
. O

The O
Env O
proteins O
of O
FV O
and O
murine B
leukemia I
virus I
( I
MuLV I
) I
were O
both O
released O
into O
cell O
culture O
supernatants O
and O
migrated O
into O
isopycnic O
gradients O
; O
however O
, O
unlike O
MuLV O
Env O
, O
FV O
Env O
displayed O
characteristics O
of O
SVPs O
. O

Recent O
studies O
have O
shown O
that O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
plays O
critical O
roles O
in O
not O
only O
viral O
clearance O
but O
also O
lymphoid O
tissue O
development O
and O
stem O
cell O
differentiation O
. O

In O
this O
study O
, O
we O
attempted O
to O
induce O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
by O
immunization O
of O
TNF O
- O
alpha O
knockout O
( O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
) O
mice O
with O
HBsAg O
- O
encoding O
plasmid O
DNA O
. O

An O
immunization O
with O
the O
HBV O
plasmid O
failed O
to O
induce O
CTL O
responses O
in O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
mice O
, O
although O
CTLs O
were O
readily O
induced O
in O
wild O
- O
type O
mice O
by O
the O
same O
protocol O
. O

Weak O
CTL O
responses O
were O
produced O
in O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
mice O
after O
two O
sessions O
of O
immunization O
with O
the O
HBV O
plasmid O
; O
however O
, O
TNF O
- O
alpha O
was O
required O
to O
maintain O
the O
responses O
of O
these O
CTL O
lines O
to O
in O
vitro O
stimulation O
and O
, O
even O
then O
, O
the O
responses O
were O
lost O
after O
3 O
weeks O
. O

Interestingly O
, O
a O
limiting O
dilution O
of O
a O
CTL O
line O
showed O
that O
HBV O
- O
specific O
CTL O
clones O
with O
high O
specific O
cytotoxicity O
were O
present O
in O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
mice O
, O
but O
these O
clones O
again O
failed O
to O
proliferate O
for O
more O
than O
3 O
weeks O
. O

Furthermore O
, O
since O
exogenously O
added O
TNF O
- O
alpha O
enhanced O
the O
proliferation O
of O
a O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
clone O
but O
suppressed O
that O
of O
a O
TNF O
- O
alpha O
( O
+ O
/ O
+ O
) O
clone O
in O
vitro O
, O
TNF O
- O
a O
. O

To O
study O
the O
effects O
of O
the O
nuclear B
receptors I
( I
NRs I
) I
HNF4alpha O
and O
COUP O
- O
TF1 O
on O
the O
life O
cycle O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
the O
human O
hepatoma O
cell O
line O
Huh7 O
was O
transiently O
cotransfected O
with O
plasmids O
containing O
the O
HBV O
genome O
and O
encoding O
these O
two O
NRs O
. O

Although O
the O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
to O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
thought O
to O
be O
crucial O
for O
the O
control O
of O
HBV O
infection O
, O
the O
relative O
contribution O
of O
each O
T O
- O
cell O
subset O
as O
an O
effector O
of O
viral O
clearance O
is O
not O
known O
. O

Our O
results O
demonstrate O
that O
CD8 O
( O
+ O
) O
cells O
are O
the O
main O
effector O
cells O
responsible O
for O
viral O
clearance O
and O
disease O
pathogenesis O
during O
acute O
HBV O
infection O
, O
and O
they O
suggest O
that O
viral O
clearance O
is O
mediated O
by O
both O
noncytolytic O
and O
cytolytic O
effector O
functions O
of O
the O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
. O

We O
studied O
immune O
responses O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
genes O
delivered O
as O
DNA O
encoding O
the O
entire O
HCV O
protein O
coding O
genome O
in O
two O
polycistronic O
plasmids O
encoding O
HCV O
capsid O
- O
E1 O
- O
E2 O
- O
NS2 O
- O
NS3 O
and O
HCV O
NS3 O
- O
NS4 O
- O
NS5 O
in O
HLA O
- O
A2 O
. O

Interestingly O
, O
at O
10 O
months O
postimmunization O
( O
8 O
months O
after O
canarypox O
virus O
boost O
) O
, O
the O
protection O
in O
HCV O
DNA O
prime O
/ O
boost O
- O
immunized O
mice O
against O
recombinant O
HCV O
- O
vaccinia O
virus O
challenge O
was O
higher O
than O
that O
observed O
in O
HCV O
DNA O
prime O
/ O
canarypox O
virus O
boost O
- O
immunized O
mice O
. O

The O
crystal O
structure O
of O
recombinant O
hepatitis B
B I
virus I
( I
HBV I
) I
capsids O
formed O
by O
240 O
core O
proteins O
has O
recently O
been O
published O
. O

For O
this O
purpose O
, O
we O
individually O
mutated O
52 O
amino B
acids I
( I
aa I
) I
within O
the O
N O
- O
terminal O
140 O
aa O
of O
the O
185 O
- O
aa O
long O
core O
protein O
displaying O
their O
side O
chains O
to O
the O
external O
surface O
of O
the O
capsid O
to O
alanine O
residues O
. O

Eleven O
mutations O
( O
S17 O
, O
F18 O
, O
L60 O
, O
L95 O
, O
K96 O
, O
F122 O
, O
I126 O
, O
R127 O
, O
N136 O
, O
A137 O
, O
and O
I139 O
) O
allowed O
nucleocapsid O
formation O
but O
blocked O
particle O
envelopment O
and O
virion O
formation O
to O
undetectable O
levels O
. O

poliovirus B
( I
PV I
) I
can O
establish O
persistent O
infections O
in O
human O
neuroblastoma O
IMR O
- O
32 O
cells O
. O

We O
previously O
showed O
that O
during O
persistent O
infection O
, O
specific O
mutations O
were O
selected O
in O
the O
first O
extracellular O
domain O
of O
the O
PV O
receptor O
( O
CD155 O
) O
of O
these O
cells O
( O
N O
. O

The O
mutated O
CD155 O
( O
Thr67 O
) O
and O
the O
nonmutated O
IMR O
- O
32 O
CD155 O
( O
CD155 O
( O
IMR O
) O
) O
were O
expressed O
independently O
in O
murine O
LM O
cells O
lacking O
the O
CD155 O
gene O
. O

Levels O
of O
DNA O
fragmentation O
, O
caspase O
activity O
, O
and O
cytochrome O
c O
release O
were O
lower O
in O
LM O
- O
CD155 O
( O
Thr67 O
) O
cells O
than O
in O
LM O
- O
CD155 O
( O
IMR O
) O
cells O
. O

The O
Spike B
glycoprotein I
( I
S I
) I
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
binds O
to O
viral O
murine O
CEACAM O
receptor O
glycoproteins O
and O
causes O
membrane O
fusion O
. O

On O
virions O
, O
the O
180 O
- O
kDa O
S O
glycoprotein O
of O
the O
MHV O
- O
A59 O
strain O
can O
be O
cleaved O
by O
trypsin O
to O
form O
the O
90 O
- O
kDa O
N O
- O
terminal O
receptor O
- O
binding O
subunit O
( O
S1 O
) O
and O
the O
90 O
- O
kDa O
membrane O
- O
anchored O
fusion O
subunit O
( O
S2 O
) O
. O

Various O
murine O
CEACAM O
proteins O
triggered O
conformational O
changes O
in O
S O
on O
recombinant O
MHV O
strains O
expressing O
S O
glycoproteins O
of O
MHV O
- O
A59 O
or O
MHV O
- O
4 O
( O
MHV O
- O
JHM O
) O
with O
the O
same O
specificities O
as O
seen O
for O
virus O
neutralization O
and O
virus O
- O
receptor O
activities O
. O

A O
novel O
120 O
- O
kDa O
subunit O
was O
formed O
following O
incubation O
of O
the O
receptor O
- O
triggered O
S O
( O
A59 O
) O
H716D O
virions O
with O
trypsin O
at O
4degreesC O
. O

Using O
isogenic O
recombinant O
murine O
coronaviruses O
expressing O
wild O
- O
type O
murine B
hepatitis I
virus I
strain I
4 I
( I
MRV I
- I
4 I
) I
or O
MHV O
- O
A59 O
spike O
glycoproteins O
or O
chimeric O
MHV O
- O
4 O
/ O
MRV O
- O
A59 O
spike O
glycoproteins O
, O
we O
have O
demonstrated O
the O
biological O
functionality O
of O
the O
N O
- O
terminus O
of O
the O
spike O
, O
encompassing O
the O
receptor B
binding I
domain I
( I
RBD I
) I
. O

Recombinant O
viruses O
with O
spikes O
containing O
the O
RBD O
of O
either O
MRV O
- O
A59 O
or O
MHV O
- O
4 O
readily O
associated O
with O
liposomes O
at O
37degreesC O
in O
the O
presence O
of O
soluble O
mCEACAM1 O
( O
a O
) O
, O
except O
for O
S4R O
, O
which O
expresses O
the O
entire O
wild O
- O
type O
MHV O
- O
4 O
spike O
and O
associated O
only O
inefficiently O
with O
liposomes O
following O
incubation O
with O
soluble O
mCEACAM1 O
( O
a O
) O
. O

In O
contrast O
, O
soluble O
mCEACAM1 O
( O
b O
) O
allowed O
viruses O
with O
the O
MHV O
- O
A59 O
RBD O
to O
associate O
with O
liposomes O
more O
efficiently O
than O
did O
viruses O
with O
the O
MHV O
- O
4 O
RBD O
. O

In O
the O
second O
assay O
, O
which O
requires O
virus O
entry O
and O
replication O
, O
all O
recombinant O
viruses O
replicated O
efficiently O
in O
BHK O
cells O
expressing O
mCEACAM1 O
( O
a O
) O
. O

In O
BHK O
cells O
expressing O
mCEACAM1 O
( O
b O
) O
, O
only O
viruses O
expressing O
chimeric O
spikes O
with O
the O
MHV O
- O
A59 O
RBD O
could O
replicate O
, O
while O
replication O
of O
viruses O
expressing O
chimeric O
spikes O
with O
the O
MHV O
- O
4 O
RBD O
was O
undetectable O
. O

Despite O
having O
the O
MHV O
- O
4 O
RBD O
, O
S4R O
replicated O
in O
BHK O
cells O
expressing O
mCEACAM1 O
( O
b O
) O
; O
this O
is O
most O
probably O
due O
to O
spread O
via O
CEACAM1 O
receptor O
- O
independent O
cell O
- O
to O
- O
cell O
fusion O
, O
an O
activity O
displayed O
only O
by O
S O
, O
R O
among O
the O
recombinant O
viruses O
studied O
here O
. O

In O
this O
study O
, O
hepadnavirus O
- O
specific O
in O
situ O
PCR O
combined O
with O
the O
enzymatic O
elimination O
of O
extracellular O
virus O
and O
flow O
cytometry O
permitted O
detection O
of O
viral O
genomes O
in O
lymphoid O
cells O
without O
nucleic O
acid O
isolation O
and O
allowed O
quantification O
of O
infected O
cells O
during O
the O
course O
of O
persistent O
infection O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

We O
have O
previously O
shown O
that O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
inhibit O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
noncytopathically O
in O
the O
livers O
of O
HBV O
transgenic O
mice O
and O
in O
hepatocyte O
cell O
lines O
derived O
from O
these O
mice O
. O

Mutations O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
occur O
frequently O
within O
the O
capsid O
( O
core O
) O
protein O
in O
natural O
infections O
. O

The O
most O
frequent O
mutation O
of O
the O
core O
protein O
in O
HBV O
from O
Southeast O
Asia O
occurs O
at O
amino O
acid O
97 O
, O
changing O
an O
isoleucine O
( O
1 O
) O
to O
a O
leucine B
( I
L I
) I
. O

Hepatitis O
B O
and O
hepatitis O
C O
viruses O
( O
HBV O
and O
HCV O
) O
are O
both O
noncytopathic O
and O
can O
cause O
acute O
and O
chronic O
infections O
of O
the O
liver O
. O

In O
this O
study O
, O
we O
show O
that O
circulating O
HBV O
- O
and O
HCV O
- O
specific O
tetramer O
- O
positive O
CD8 O
cells O
during O
the O
acute O
phase O
of O
hepatitis O
B O
and O
C O
belong O
almost O
entirely O
to O
an O
effector O
- O
memory O
subset O
( O
CCR7 O
( O
- O
) O
CD45RA O
( O
- O
) O
) O
. O

HBV O
- O
specific O
tetramer O
- O
positive O
CD8 O
cells O
express O
high O
perforin O
content O
ex O
vivo O
, O
expand O
vigorously O
, O
and O
display O
efficient O
cytotoxic O
activity O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
upon O
peptide O
stimulation O
. O

We O
functionally O
analyzed O
the O
role O
of O
metal O
ions O
in O
RNA O
- O
dependent O
RNA O
synthesis O
by O
three O
recombinant O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
from O
GB B
virus I
- I
B I
( I
GBV I
) I
, O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
and O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
with O
emphasis O
on O
the O
HCV O
RdRp O
. O

RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
that O
initiate O
RNA O
synthesis O
by O
a O
de O
novo O
, O
mechanism O
should O
specifically O
recognize O
the O
template O
initiation O
nucleotide O
, O
T1 O
, O
and O
the O
substrate O
initiation O
nucleotide O
, O
the O
NTPi O
. O

The O
RdRps O
from O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
and O
GB O
virus O
- O
B O
all O
can O
initiate O
RNA O
synthesis O
by O
a O
de O
novo O
mechanism O
. O

We O
used O
RNAs O
and O
GTP O
analogs O
, O
respectively O
, O
to O
examine O
the O
use O
of O
the O
T1 O
nucleotide O
and O
the O
initiation O
nucleotide O
( O
NTPi O
) O
during O
de O
novo O
initiation O
of O
RNA O
synthesis O
. O

Vigorous O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
helper O
- O
cell O
responses O
are O
associated O
with O
successful O
control O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
other O
human O
viral O
infections O
, O
but O
the O
breadth O
and O
specificity O
of O
responses O
associated O
with O
viral O
containment O
have O
not O
been O
defined O
. O

To O
address O
this O
we O
evaluated O
the O
HCV O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
helper O
- O
cell O
response O
in O
HCV O
antibody O
- O
positive O
persons O
who O
lack O
detectable O
plasma O
viremia O
, O
and O
compared O
this O
response O
to O
that O
in O
persons O
with O
chronic O
HCV O
infection O
. O

This O
comprehensive O
analysis O
of O
the O
breadth O
and O
specificity O
of O
HCV O
- O
specific O
T O
- O
helper O
- O
cell O
responses O
indicates O
that O
up O
to O
14 O
viral O
epitopes O
can O
be O
simultaneously O
targeted O
by O
circulating O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
helper O
cells O
in O
a O
controlled O
human O
viral O
infection O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
transgenic O
mice O
expressing O
rat O
hepatocyte B
nuclear I
factor I
3beta I
( I
HNF3beta I
) I
were O
generated O
by O
breeding O
HBV O
transgenic O
mice O
with O
transgenic O
mice O
that O
constitutively O
overexpress O
the O
rat O
HNF3beta O
polypeptide O
in O
the O
liver O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA I
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
belongs O
to O
a O
class O
of O
membrane O
proteins O
termed O
tail O
- O
anchored O
proteins O
. O

Moreover O
, O
the O
HCV O
RdRp O
was O
found O
to O
be O
retained O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
or O
an O
ER O
- O
derived O
modified O
compartment O
both O
following O
transient O
transfection O
and O
in O
the O
context O
of O
a O
subgenomic O
replicon O
. O

Interleukin B
- I
18 I
( I
IL I
- I
18 I
) I
produced O
by O
activated O
antigen O
- O
presenting O
cells O
stimulates O
natural B
killer I
( I
NK I
) I
cells O
, O
Natural B
killer I
T I
( I
NKT I
) I
cells O
, O
and O
T O
cells O
to O
secrete O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

In O
this O
study O
, O
injection O
of O
a O
single O
10 O
- O
mug O
dose O
of O
recombinant O
murine O
IL O
- O
18 O
rapidly O
, O
reversibly O
, O
and O
noncytopathically O
inhibited O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
in O
the O
livers O
of O
HBV O
transgenic O
mice O
. O

DNAs O
from O
four O
wild O
chimpanzees O
( O
Pan O
troglodytes O
schweinfurthi O
) O
from O
eastern O
Africa O
were O
screened O
for O
14 O
DNA O
viruses O
and O
retroviruses O
. O

An O
entire O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
was O
amplified O
and O
sequenced O
from O
samples O
taken O
from O
one O
animal O
. O

In O
vivo O
evidence O
suggests O
that O
T O
- O
cell O
- O
derived O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
can O
directly O
inhibit O
the O
replication O
of O
herpes B
simplex I
virus I
type I
I I
( I
HSV I
- I
1 I
) I
. O

We O
have O
found O
that O
IFN O
- O
gamma O
synergizes O
with O
the O
innate O
IFNs O
( O
IFN O
- O
alpha O
and O
- O
beta O
) O
to O
potently O
inhibit O
HSV O
- O
1 O
replication O
in O
vitro O
and O
in O
vivo O
. O

Humans O
chronically O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
at O
further O
risk O
of O
liver O
cancer O
upon O
exposure O
to O
dietary O
aflatoxin B
B1 I
( I
AFB1 I
) I
, O
a O
carcinogenic O
product O
of O
the O
mold O
Aspergillus O
flavus O
. O

For O
the O
present O
study O
, O
we O
utilized O
double O
- O
transgenic O
mice O
( O
ATX O
mice O
) O
that O
express O
the O
HBV B
X I
protein I
( I
HBx I
) I
and O
possess O
a O
bacteriophage O
lambda O
transgene O
to O
evaluate O
the O
in O
vivo O
effect O
of O
HBx O
expression O
on O
AFB1 O
- O
induced O
DNA O
mutations O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
major O
causative O
agent O
of O
blood O
- O
borne O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
. O

endoplasmic B
reticulum I
( I
ER I
) I
stress O
signaling O
is O
an O
adaptive O
cellular O
response O
to O
the O
loss O
of O
ER O
Ca O
( O
2 O
+ O
) O
homeostasis O
and O
/ O
or O
the O
accumulation O
of O
misfolded O
, O
unassembled O
, O
or O
aggregated O
proteins O
in O
the O
ER O
lumen O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
is O
a O
positive O
- O
stranded O
RNA O
virus O
of O
the O
Flaviviridae O
family O
. O

We O
are O
using O
a O
cytopathic B
strain I
of I
BVDV I
( I
cpBVDV I
) I
that O
causes O
cellular O
apoptosis O
as O
a O
model O
system O
to O
determine O
how O
virus O
- O
induced O
ER O
stress O
contributes O
to O
pathogenesis O
. O

We O
show O
that O
, O
in O
a O
natural O
infection O
of O
MDBK O
cells O
, O
cpBVDV O
activates O
the O
ER B
transmembrane I
kinase I
PERK I
( I
PKR I
- I
like I
ER I
kinase I
) I
and O
causes O
hyperphosphorylation O
of O
the O
translation O
initiation O
factor O
eIF2alpha O
, O
consistent O
with O
the O
induction O
of O
an O
ER O
stress O
response O
. O

Hepatitis O
B O
virus O
X O
protein O
( O
pX O
) O
is O
implicated O
in O
hepatocarcinogenesis O
by O
an O
unknown O
mechanism O
. O

Our O
model O
is O
composed O
of O
a O
differentiated O
hepatocyte O
( O
AML12 O
) O
3pX O
- O
1 O
cell O
line O
that O
undergoes O
pX O
- O
dependent O
transformation O
and O
a O
. O

dedifferentiated O
hepatocyte O
( O
AML12 O
) O
4pX O
- O
1 O
cell O
line O
that O
does O
not O
exhibit O
transformation O
by O
pX O
. O

Employing O
dominant O
negative O
mutants O
and O
inhibitors O
of O
mitogenic O
pathways O
, O
we O
demonstrate O
that O
maximum O
, O
pX O
- O
dependent O
Stat3 O
transactivation O
is O
inhibited O
by O
the O
p38 O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
- O
specific O
inhibitor O
SB O
203580 O
. O

Importantly O
, O
pX O
- O
dependent O
activation O
of O
p38 O
MAPK O
inactivates O
Cdc25C O
by O
phosphorylation O
of O
Ser216 O
, O
thus O
initiating O
activation O
of O
the O
G O
( O
2 O
) O
/ O
M O
checkpoint O
, O
resulting O
in O
4pX O
- O
1 O
cell O
growth O
retardation O
. O

Moderation O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
is O
a O
likely O
prerequisite O
in O
the O
establishment O
of O
chronic O
infections O
and O
is O
thought O
to O
be O
mediated O
by O
the O
intracellular O
accumulation O
of O
large B
hepatitis I
delta I
antigen I
( I
L I
- I
HDAg I
) I
. O

The O
nucleoprotein B
( I
NP I
) I
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
functions O
primarily O
to O
encapsidate O
the O
virus O
genome O
for O
the O
purpose O
of O
RNA O
transcription O
, O
replication O
, O
and O
packaging O
. O

Here O
, O
we O
localized O
a O
conserved O
B O
- O
cell O
inummodominant B
epitope I
( I
IDE I
) I
spanning O
residues O
447 O
to O
455 O
and O
successfully O
generated O
a O
recombinant O
NDV O
lacking O
the O
IDE O
by O
reverse O
genetics O
. O

In O
addition O
, O
a O
B O
- O
cell O
epitope O
of O
the O
S2 O
glycoprotein O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
was O
inserted O
in O
- O
frame O
to O
replace O
the O
NP O
- O
IDE O
. O

pregenomic B
RNA I
( I
pgRNA I
) I
plays O
two O
major O
roles O
in O
the O
hepadnavirus O
life O
cycle O
. O

For O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
a O
spliced O
RNA O
is O
derived O
from O
pgRNA O
by O
removal O
of O
a O
single O
intron O
. O

The O
mechanism O
for O
the O
simultaneous O
cytoplasmic O
accumulation O
of O
unspliced O
( O
pgRNA O
) O
and O
spliced O
RNA O
was O
not O
known O
. O

One O
region O
is O
near O
the O
5 O
' O
end O
of O
pgRNA O
( O
region O
A O
) O
, O
while O
the O
second O
is O
near O
the O
middle O
of O
pgRNA O
( O
region O
B O
) O
. O

CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
are O
now O
recognized O
as O
important O
mediators O
of O
immunity O
against O
intracellular O
pathogens O
, O
including O
human O
immunodeficiency O
virus O
and O
tumors O
. O

It O
was O
formed O
by O
the O
self O
- O
assembly O
of O
a O
cationic O
peptide O
containing O
18 O
lysines O
and O
a O
CTL O
- O
epitope O
peptide O
of O
HBsAg28 O
- O
39 O
, O
with O
a O
plasmid O
encoding O
mouse O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
through O
electrostatic O
interactions O
. O

Furthermore O
, O
it O
was O
proved O
that O
mimovirus O
could O
induce O
an O
HBsAg O
( O
28 O
- O
39 O
) O
- O
specific O
CTL O
response O
in O
vivo O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
causes O
both O
acute O
and O
chronic O
liver O
disease O
throughout O
the O
world O
. O

Previous O
work O
has O
shown O
that O
the O
assembly O
of O
HDV O
virus B
- I
like I
particles I
( I
VLPs I
) I
could O
be O
abolished O
by O
BZA O
- O
5B O
, O
a O
compound O
with O
farnesyltransferase O
inhibitory O
activity O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
a O
cytoplasmic O
RNA O
virus O
with O
the O
unique O
or O
unusual O
feature O
of O
having O
a O
nucleocapsid B
( I
N I
) I
protein O
that O
is O
specifically O
transported O
to O
the O
nucleolus O
of O
virus O
- O
infected O
cells O
. O

The O
nuclear O
hormone O
receptors O
Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
and O
the O
retinoid B
X I
alpha I
( I
RXRalpha I
) I
plus O
the O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPARalpha I
) I
heterodimer O
support O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
in O
nonhepatoma O
cells O
. O

Hepatocyte B
nuclear I
factor I
3 I
( I
HNF3 I
) I
inhibits O
nuclear O
hormone O
receptor O
- O
mediated O
viral O
replication O
. O

hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
, O
encoded O
by O
the O
precore O
RNA O
, O
mediates O
part O
of O
the O
inhibition O
of O
viral O
replication O
by O
HNF3beta O
. O

Persistent O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
characterized O
by O
a O
weak O
and O
narrowly O
focused O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
to O
HBV O
that O
is O
thought O
to O
reflect O
the O
induction O
of O
central O
and O
/ O
or O
peripheral O
tolerance O
to O
HBV O
proteins O
in O
neonatal O
and O
adult O
onset O
infections O
, O
respectively O
. O

The O
present O
study O
was O
performed O
to O
compare O
the O
relative O
immunogenicities O
and O
tolerogenicities O
of O
HBV O
structural O
( O
envelope O
[ O
ENV O
] O
) O
and O
nonstructural O
( O
polymerase O
[ O
POL O
] O
) O
proteins O
at O
the O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
level O
in O
transgenic O
mice O
that O
replicate O
HBV O
in O
the O
liver O
and O
secrete O
infectious O
virus O
into O
the O
blood O
, O
thus O
representing O
an O
excellent O
model O
of O
persistent O
HBV O
infection O
. O

Previous O
analysis O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
indicated O
the O
presence O
of O
at O
least O
two O
cis O
- O
acting O
sequences O
required O
for O
efficient O
encapsidation O
of O
its O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
epsilon O
and O
region O
II O
. O

We O
found O
that O
the O
sequence O
between O
nucleotides B
( I
nt I
) I
438 O
and O
720 O
contributed O
to O
efficient O
pgRNA O
encapsidation O
, O
while O
the O
sequence O
between O
nt O
538 O
and O
610 O
made O
the O
largest O
contribution O
to O
encapsidation O
. O

We O
also O
analyzed O
heron B
hepatitis I
B I
virus I
( I
HHBV I
) I
for O
the O
presence O
of O
region O
H O
and O
found O
features O
similar O
to O
DHBV O
: O
a O
broad O
region O
necessary O
for O
efficient O
encapsidation O
that O
contained O
a O
critical O
region O
II O
sequence O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
remarkably O
efficient O
in O
establishing O
persistent O
infection O
, O
possibly O
mediated O
by O
an O
impaired O
immune O
response O
to O
HCV O
infection O
. O

To O
further O
characterize O
the O
immunomodulatory O
role O
of O
HCV O
core O
in O
vivo O
, O
we O
generated O
transgenic B
( I
Tg I
) I
mice O
by O
directing O
the O
expression O
of O
core O
protein O
to O
T O
lymphocytes O
by O
using O
the O
CD2 O
promoter O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replicates O
from O
a O
ribonucleoprotein B
( I
RNP I
) I
complex O
that O
is O
associated O
with O
the O
endoplasmic B
reticulum I
( I
ER I
) I
membrane O
. O

In O
response O
to O
this O
stress O
, O
cells O
expressing O
HCV O
replicons O
induce O
the O
unfolded B
protein I
response I
( I
UPR I
) I
, O
an O
ER O
- O
to O
- O
nucleus O
intracellular O
signaling O
pathway O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replication O
can O
occur O
in O
nonhepatoma O
cells O
when O
pregenomic O
RNA O
synthesis O
from O
viral O
DNA O
is O
activated O
by O
the O
expression O
of O
the O
nuclear O
hormone O
receptors O
Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
and O
the O
retinoid B
X I
receptor I
alpha I
( I
RXRalpha I
) I
plus O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPARalpha I
) I
heterodimer O
. O

Nuclear O
hormone O
receptor O
- O
dependent O
HBV O
replication O
is O
inhibited O
by O
Hepatocyte B
nuclear I
factor I
3 I
( I
HNF3 I
) I
. O

In O
contrast O
, O
HNF3 O
and O
HNF4 O
support O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
replication O
in O
nonhepatoma O
cells O
, O
whereas O
the O
RXRalpha O
- O
PPARalpha O
heterodimer O
inhibits O
HNF4 O
- O
dependent O
DHBV O
replication O
. O

Tamarins O
( O
Saguinus O
species O
) O
infected O
by O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
have O
recently O
been O
proposed O
as O
an O
acceptable O
surrogate O
model O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Phosphorylation O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
has O
recently O
been O
shown O
to O
be O
a O
prerequisite O
for O
pregenomic O
RNA O
encapsidation O
into O
viral O
capsids O
, O
but O
the O
host O
cell O
kinases O
mediating O
this O
essential O
step O
of O
the O
HBV O
replication O
cycle O
have O
not O
been O
identified O
. O

The O
95 O
- O
kDa O
kinase O
was O
purified O
and O
characterized O
as O
SR B
protein I
- I
specific I
kinase I
I I
( I
SRPK1 I
) I
by O
mass O
spectrometry O
. O

Treatment O
of O
patients O
with O
Lamivudine B
( I
3TC I
) I
results O
in O
loss O
of O
detectable O
levels O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
from O
serum O
; O
however O
, O
the O
relapse O
rate O
, O
with O
regard O
to O
both O
reappearance O
of O
virus O
in O
the O
bloodstream O
and O
hepatic O
inflammation O
, O
is O
high O
when O
therapy O
is O
terminated O
. O

X O
protein O
, O
also O
referred O
to O
as O
HBx O
in O
human O
virus O
and O
WHx O
in O
woodchuck O
virus O
, O
has O
been O
reported O
to O
bind O
to O
a O
number O
of O
cellular O
proteins O
, O
including O
the O
DDB1 O
subunit O
of O
the O
damaged B
DNA I
- I
binding I
( I
DDB I
) I
complex O
. O

Virion O
release O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
from O
hepatocytes O
is O
a O
tightly O
regulated O
event O
. O

In O
this O
study O
, O
our O
kinetic O
analysis O
of O
virion O
secretion O
of O
the O
mutant O
F97L O
( O
phenylalanine O
to O
leucine O
) O
indicates O
that O
the O
secretion O
of O
its O
immature O
genome O
does O
not O
occur O
earlier O
than O
that O
of O
its O
mature O
genome O
. O

Here O
, O
we O
further O
demonstrated O
that O
a O
pre O
- O
S1 O
envelope O
mutation O
at O
position O
119 O
, O
changing O
an O
Alanine B
( I
A I
) I
to O
a O
Phenylalanine B
( I
F I
) I
, O
can O
offset O
the O
immature O
secretion O
phenotype O
of O
the O
mutant O
197L O
( O
isoleucine O
to O
leucine O
) O
and O
successfully O
restore O
the O
wildtype O
- O
like O
selective O
export O
of O
the O
mature O
genome O
of O
the O
double O
mutant O
pre O
- O
S1 O
- O
A119F O
/ O
core O
- O
I97L O
. O

The O
presence O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
- O
containing O
particles O
in O
the O
low O
- O
density O
fractions O
of O
plasma O
has O
been O
associated O
with O
high O
infectivity O
. O

For O
a O
better O
analysis O
of O
HCV O
RNA O
- O
containing O
particles O
, O
we O
quantified O
HCV O
RNA O
in O
the O
low O
- O
density O
fractions O
of O
plasma O
corresponding O
to O
the O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
, O
intermediate O
- O
density O
lipoprotein O
, O
and O
low B
- I
density I
lipoprotein I
( I
LDL I
) I
fractions O
from O
untreated O
chronically O
HCV O
- O
infected O
patients O
. O

Surprisingly O
, O
immunoglobulins O
G O
and O
M O
were O
also O
found O
in O
the O
low O
- O
density O
fractions O
and O
could O
be O
used O
to O
purify O
the O
HCV O
RNA O
- O
containing O
particles O
( O
lipo O
- O
viro O
- O
particles O
[ O
LVP O
] O
) O
. O

Woodchucks O
chronically O
infected O
with O
the O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
were O
treated O
with O
the O
antiviral O
drug O
1 O
- O
( O
2 O
- O
fluoro O
- O
5 O
- O
methyl O
- O
beta O
- O
L O
- O
arabinofuranosyl O
) O
- O
uracil O
( O
L O
- O
FMAU O
) O
or O
placebo O
for O
32 O
weeks O
. O

Following O
vaccinations O
, O
cell O
- O
mediated O
immunity O
to O
surface O
antigen O
was O
demonstrated O
in O
both O
groups O
, O
independent O
of O
serum O
viral O
and O
antigen O
load O
, O
but O
was O
significantly O
enhanced O
in O
woodchucks O
treated O
with O
L O
- O
FMAU O
and O
was O
broadened O
to O
include O
other O
viral O
antigens O
( O
core O
, O
e O
, O
and O
x O
antigens O
and O
selected O
core O
peptides O
) O
. O

We O
have O
previously O
shown O
that O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
inhibit O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
by O
eliminating O
pregenomic O
RNA O
containing O
viral O
capsids O
from O
the O
hepatocyte O
. O

We O
have O
also O
shown O
that O
HBV O
- O
specific O
cytotoxic O
T O
lymphocytes O
that O
induce O
IFN O
- O
gamma O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
the O
liver O
can O
inhibit O
HBV O
gene O
expression O
by O
destabilizing O
preformed O
viral O
mRNA O
. O

Accordingly O
, O
hepatocytes O
were O
derived O
from O
the O
livers O
of O
HBV O
- O
transgenic O
mice O
that O
also O
expressed O
the O
constitutively O
active O
cytoplasmic O
domain O
of O
the O
human O
hepatocyte O
growth O
factor O
receptor O
( O
c O
- O
Met O
) O
. O

Here O
, O
we O
show O
that O
the O
resultant O
well O
- O
differentiated O
, O
continuous O
hepatocyte O
cell O
lines O
( O
HBV O
- O
Met O
) O
replicate O
HBV O
and O
that O
viral O
replication O
in O
these O
cells O
is O
efficiently O
controlled O
by O
IFN O
- O
alpha O
/ O
beta O
or O
IFN O
- O
gamma O
, O
which O
eliminate O
pregenomic O
RNA O
- O
containing O
capsids O
from O
the O
cells O
as O
they O
do O
in O
the O
liver O
. O

Reverse O
transcription O
in O
hepadnaviruses O
is O
primed O
by O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
( O
protein O
priming O
) O
and O
requires O
the O
specific O
interaction O
between O
the O
RT O
and O
a O
viral O
RNA O
signal O
termed O
epsilon O
, O
which O
bears O
the O
specific O
template O
sequence O
for O
protein O
priming O
. O

, O
the O
covalent O
attachment O
of O
the O
first O
nucleotide O
to O
the O
protein O
( O
RT O
deoxynucleotidylation O
) O
, O
but O
defective O
in O
any O
subsequent O
DNA O
polymerization O
. O

, O
the O
initial O
attachment O
of O
the O
first O
nucleotide O
to O
the O
RT O
( O
RT O
deoxynucleotidylation O
or O
initiation O
of O
protein O
priming O
) O
and O
the O
subsequent O
DNA O
synthesis O
( O
polymerization O
) O
to O
complete O
protein O
priming O
, O
with O
the O
second O
step O
entailing O
additional O
RT O
sequences O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
promoter O
regulates O
the O
transcription O
of O
two O
related O
RNA O
products O
named O
precore O
RNA O
and O
core O
RNA O
. O

Previous O
studies O
indicate O
that O
a O
double O
- O
nucleotide O
mutation O
that O
occurs O
frequently O
during O
chronic O
HBV O
infection O
converts O
a O
nuclear O
receptor O
binding O
site O
in O
the O
core O
promoter O
to O
the O
binding O
site O
of O
the O
transcription O
factor O
hepatocyte B
nuclear I
factor I
- I
1 I
( I
HNF I
- I
1 I
) I
and O
specifically O
suppresses O
the O
transcription O
of O
the O
precore O
RNA O
. O

In O
the O
present O
study O
, O
the O
capacity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
to O
elicit O
intracellular O
membrane O
alterations O
was O
investigated O
by O
expressing O
, O
in O
tetracycline O
- O
regulated O
cell O
lines O
, O
a O
comprehensive O
panel O
of O
HCV O
proteins O
individually O
as O
well O
as O
in O
the O
context O
of O
the O
entire O
HCV O
polyprotein O
. O

As O
visualized O
by O
electron B
microscopy I
( I
EM I
) I
, O
expression O
of O
the O
combined O
structural O
proteins O
core O
- O
E1 O
- O
E2 O
- O
p7 O
, O
the O
NS3 O
- O
4A O
complex O
, O
and O
protein O
NS4B O
induced O
distinct O
membrane O
alterations O
. O

By O
immunogold B
EM I
( I
IEM I
) I
, O
the O
membrane O
- O
altering O
proteins O
were O
always O
found O
to O
localize O
to O
the O
respective O
altered O
membranes O
. O

The O
entire O
nucleotide O
sequences O
of O
70 O
hepatitis B
B I
virus I
( I
HBV I
) I
isolates O
of O
genotype O
B O
( O
HBV O
/ O
B O
) O
, O
including O
38 O
newly O
determined O
and O
32 O
retrieved O
from O
the O
international O
DNA O
database O
( O
DDBJ O
/ O
EMBL O
/ O
GenBank O
) O
, O
were O
compared O
phylogenetically O
. O

The O
remaining O
41 O
HBV O
/ O
B O
isolates O
having O
the O
recombination O
with O
genotype O
C O
were O
from O
carriers O
in O
China O
( O
12 O
strains O
) O
, O
Hong O
Kong O
( O
3 O
strains O
) O
, O
Indonesia O
( O
4 O
strains O
) O
, O
Japan O
( O
3 O
strains O
) O
, O
Taiwan O
( O
4 O
strains O
) O
, O
Thailand O
( O
3 O
strains O
) O
, O
and O
Vietnam O
( O
12 O
strains O
) O
. O

Due O
to O
the O
frequency O
of O
the O
distribution O
of O
HBV O
/ O
B O
without O
the O
recombination O
( O
29 O
of O
32 O
isolates O
, O
or O
91 O
% O
) O
and O
the O
fact O
that O
it O
was O
exclusive O
to O
Japan O
, O
it O
was O
provisionally O
classified O
into O
the O
Bj O
( O
j O
standing O
for O
Japan O
) O
subgroup O
, O
and O
HBV O
/ O
B O
with O
the O
recombination O
was O
classified O
into O
the O
Ba O
( O
a O
for O
Asia O
) O
subgroup O
. O

Several O
candidate O
vaccines O
and O
immunotherapies O
for O
these O
infections O
aim O
at O
the O
induction O
or O
enhancement O
of O
cellular O
immune O
responses O
against O
viral O
epitopes O
presented O
by O
common O
human O
major O
his O
to O
compatibility O
complex O
( O
MHC O
) O
alleles O
. O

To O
identify O
and O
characterize O
chimpanzee O
MHC O
class O
I O
molecules O
that O
are O
functionally O
related O
to O
human O
alleles O
, O
we O
sequenced O
18 O
different O
Pan B
troglodytes I
( I
Patr I
) I
alleles O
of O
14 O
chimpanzees O
, O
2 O
of O
them O
previously O
unknown O
and O
3 O
with O
only O
partially O
reported O
sequences O
. O

Using O
cytotoxic O
T O
cells O
isolated O
from O
the O
blood O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
infected O
chimpanzees O
, O
we O
then O
mapped O
the O
Patr O
restriction O
of O
these O
HCV O
peptides O
and O
demonstrated O
functional O
homology O
between O
the O
Patr O
- O
HLA O
orthologues O
in O
cytotoxicity O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
release O
assays O
. O

Eight O
hepatitis B
B I
virus I
( I
HBV I
) I
isolates O
of O
genotype O
G O
were O
recovered O
from O
patients O
and O
sequenced O
over O
the O
entire O
genome O
. O

Six O
of O
them O
had O
a O
genomic O
length O
of O
3 O
, O
248 O
by O
and O
two O
had O
genomic O
lengths O
of O
3 O
, O
239 O
by O
( O
USG15 O
) O
and O
3 O
, O
113 O
by O
( O
USG18 O
) O
due O
to O
deletions O
. O

The O
10 O
HBV O
/ O
G O
isolates O
, O
including O
the O
8 O
sequenced O
isolates O
as O
well O
as O
the O
original O
isolate O
( O
AF160501 O
) O
and O
another O
isolate O
( O
B1 O
- O
89 O
) O
, O
had O
a O
close O
sequence O
homology O
of O
99 O
. O

8 O
% O
among O
themselves O
( O
excluding O
USG18 O
with O
a O
long O
deletion O
) O
but O
of O
< O
88 O
. O

The O
10 O
HBV O
/ O
G O
isolates O
clustered O
on O
a O
branch O
separate O
from O
those O
bearing O
the O
other O
six O
genotypes O
( O
A O
through O
F O
[ O
A O
- O
F O
] O
) O
in O
the O
phylogenetic O
tree O
constructed O
from O
full O
- O
length O
sequences O
of O
78 O
HBV O
isolates O
as O
well O
as O
in O
those O
constructed O
from O
the O
core O
, O
polymerase O
, O
X O
, O
and O
envelope O
genes O
. O

Despite O
two O
stop O
codons O
in O
the O
precore O
region O
that O
prohibited O
the O
translation O
of O
the O
HBV O
a O
antigen O
( O
HBeAg O
) O
, O
all O
of O
the O
eight O
patients O
with O
HBV O
/ O
G O
infection O
possessed O
the O
HBeAg O
in O
serum O
. O

By O
restriction O
fragment O
length O
polymorphism O
of O
the O
surface O
gene O
, O
all O
of O
the O
eight O
patients O
were O
found O
to O
be O
coinfected O
with O
HBV O
of O
genotype O
A O
( O
HBV O
/ O
A O
) O
, O
which O
would O
be O
responsible O
for O
the O
expression O
of O
HBeAg O
in O
them O
. O

covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
is O
a O
crucial O
intermediate O
in O
the O
replication O
of O
hepadnaviruses O
. O

Hepadnaviral O
reverse O
transcription O
requires O
template O
switches O
for O
the O
genesis O
of O
relaxed B
circular I
( I
RC I
) I
DNA O
, O
the O
major O
genomic O
form O
in O
virions O
. O

Studies O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
indicate O
that O
in O
addition O
to O
the O
requirement O
for O
repeated O
sequences O
at O
the O
donor O
and O
acceptor O
sites O
, O
template O
switching O
requires O
at O
least O
three O
other O
cis O
- O
acting O
sequences O
, O
5E O
, O
M O
, O
and O
3E O
. O

In O
this O
study O
we O
analyzed O
a O
series O
of O
variant O
heron B
hepatitis I
B I
viruses I
( I
HHBV I
) I
in O
which O
the O
regions O
of O
the O
genome O
that O
would O
be O
expected O
to O
contain O
5E O
, O
M O
, O
and O
3E O
were O
replaced O
with O
DHBV O
sequence O
. O

In O
studies O
of O
acute O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
the O
early O
host O
immune O
response O
is O
one O
of O
the O
determinants O
of O
viral O
persistence O
. O

The O
class O
I O
human B
leukocyte I
antigens I
( I
HLA I
) I
, O
which O
present O
foreign O
antigen O
to O
cytolytic O
T O
cells O
, O
are O
integral O
components O
of O
this O
response O
. O

HLA O
- O
B O
* O
53 O
has O
similar O
, O
but O
not O
necessarily O
identical O
, O
binding O
specificity O
to O
some O
HLA O
- O
B O
* O
35 O
subtypes O
( O
B O
* O
35 O
- O
Px O
group O
) O
. O

The O
association O
of O
HLA O
- O
Cw O
* O
04 O
with O
HCV O
persistence O
was O
codominant O
( O
two O
copies O
of O
the O
gene O
were O
more O
strongly O
associated O
with O
persistence O
than O
one O
copy O
) O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
capsids O
play O
an O
important O
role O
in O
viral O
nucleic O
acid O
metabolism O
and O
other O
elements O
of O
the O
virus O
life O
cycle O
. O

Misdirection O
of O
capsid O
assembly O
( O
leading O
to O
formation O
of O
aberrant O
particles O
) O
may O
be O
a O
powerful O
approach O
to O
interfere O
with O
virus O
production O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replication O
is O
inhibited O
in O
a O
noncytopathic O
manner O
by O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
. O

In O
order O
to O
find O
small O
RNA O
molecules O
that O
are O
specific O
and O
high O
- O
affinity O
ligands O
of O
nonstructural O
513 O
( O
NS5B O
) O
polymerase O
, O
we O
screened O
by O
SELEX O
( O
systematic O
evolution O
of O
ligands O
by O
exponential O
amplification O
) O
a O
structurally O
constrained O
RNA O
library O
with O
an O
NS5BDeltaC55 O
enzyme O
carrying O
a O
C O
- O
terminal O
biotinylation O
sequence O
. O

The O
aptamers O
appeared O
to O
he O
highly O
specific O
for O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
polymerase O
since O
interaction O
with O
the O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
NS5B O
protein O
cannot O
be O
observed O
. O

Assembly O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
in O
infected O
human O
hepatocytes O
involves O
association O
of O
the O
1 O
, O
679 O
- O
nucleotide O
single O
- O
stranded O
genomic O
RNA O
( O
deltaRNA O
) O
with O
multiple O
copies O
of O
both O
small O
and O
large O
forms O
of O
the O
delta O
protein O
( O
deltaAg O
) O
to O
form O
a O
ribonucleoprotein O
particle O
which O
in O
turn O
interacts O
with O
envelope O
proteins O
of O
the O
natural O
helper O
virus O
, O
hepatitis O
B O
virus O
. O

The O
cellular O
promyelocytic B
leukemia I
protein I
( I
PML I
) I
associates O
with O
the O
proteins O
of O
several O
viruses O
and O
in O
some O
cases O
reduces O
viral O
propagation O
in O
cell O
culture O
. O

To O
examine O
the O
role O
of O
PML O
in O
vivo O
, O
we O
compared O
immune O
responses O
and O
virus O
loads O
of O
PML O
- O
deficient O
and O
control O
mice O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
a O
viroid O
- O
like O
circular O
RNA O
that O
replicates O
via O
a O
double O
rolling O
circle O
replication O
mechanism O
. O

The O
export O
of O
genomic O
HDV O
RNA O
was O
resistant O
to O
leptomycin O
B O
, O
indicating O
that O
a O
cell B
region I
maintenance I
1 I
( I
Crm I
1 I
) I
- O
independent O
pathway O
was O
involved O
. O

The O
large B
form I
of I
hepatitis I
delta I
antigen I
( I
L I
- I
HDAg I
) I
, O
which O
is O
responsible O
for O
virus O
packaging O
, O
was O
not O
required O
for O
RNA O
export O
, O
as O
a O
mutant O
HDV O
RNA O
genome O
unable O
to O
synthesize O
L O
- O
HDAg O
was O
still O
exported O
. O

Although O
much O
is O
known O
about O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
, O
first O
cloned O
in O
1989 O
, O
little O
is O
known O
about O
HCV O
structure O
and O
assembly O
due O
to O
the O
lack O
of O
an O
efficient O
in O
vitro O
culture O
system O
for O
HCV O
. O

We O
demonstrate O
that O
the O
S4 O
genome O
segment O
of O
baboon B
reovirus I
( I
BRV I
) I
contains O
two O
sequential O
partially O
overlapping O
open B
reading I
frames I
( I
ORFs I
) I
, O
both O
of O
which O
are O
functional O
in O
vitro O
and O
in O
virus O
- O
infected O
cells O
. O

The O
15 O
- O
kDa O
gene O
product O
( O
p15 O
) O
of O
the O
5 O
' O
- O
proximal O
ORF O
induces O
efficient O
cell O
- O
cell O
fusion O
when O
expressed O
by O
itself O
in O
transfected O
cells O
, O
suggesting O
that O
p15 O
is O
the O
only O
viral O
protein O
required O
for O
induction O
of O
syncytium O
formation O
by O
BRV O
. O

The O
p15 O
protein O
is O
a O
small O
, O
hydrophobic O
, O
basic O
, O
integral O
membrane O
protein O
, O
properties O
shared O
with O
the O
p10 O
fusion B
- I
associated I
small I
transmembrane I
( I
FAST I
) I
proteins O
encoded O
by O
avian O
reovirus O
and O
Nelson O
Bay O
reovirus O
. O

We O
previously O
reported O
a O
number O
of O
features O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
chimeric O
glycoproteins O
related O
to O
pseudotype O
virus O
entry O
into O
mammalian O
cells O
. O

Neutralization O
( O
50 O
% O
reduction O
of O
pseudotype O
virus O
plaque O
formation O
) O
was O
observed O
with O
two O
human O
immunoglobulin O
G1 O
Monoclonal B
antibodies I
( I
MAbs I
) I
at O
concentrations O
of O
between O
2 O
. O

A O
hyperimmune O
rabbit O
antiserum O
to O
an O
E2 O
hypervariable B
region I
1 I
( I
HVR1 I
) I
mimotope O
also O
exhibited O
an O
HCV O
E2 O
pseudotype O
virus O
neutralization O
titer O
of O
similar O
to1 O
/ O
50 O
. O

An O
El O
pseudotype O
virus O
used O
as O
a O
negative O
control O
was O
not O
neutralized O
to O
a O
significant O
level O
( O
< O
1 O
/ O
10 O
) O
by O
these O
MAbs O
or O
rabbit O
antiserum O
to O
E2 O
HVR1 O
. O

Significant O
increases O
in O
the O
neutralization O
titers O
of O
the O
human O
MAbs O
( O
similar O
to60 O
- O
to O
160 O
- O
fold O
higher O
) O
and O
rabbit O
antiserum O
to O
HVR1 O
mimotopes O
( O
similar O
to10 O
- O
fold O
higher O
) O
were O
observed O
upon O
addition O
of O
guinea O
pig O
complement O
. O

We O
also O
determined O
that O
9 O
of O
56 O
HCV O
- O
infected O
patient O
sera O
( O
16 O
% O
) O
had O
detectable O
pseudotype O
virus O
neutralization O
activity O
at O
serum O
dilutions O
of O
between O
1 O
/ O
20 O
and O
1 O
/ O
50 O
and O
that O
complement O
addition O
enhanced O
the O
neutralization O
activity O
of O
some O
of O
the O
HCV O
- O
infected O
human O
sera O
. O

The O
current O
studies O
demonstrate O
complex O
and O
seemingly O
contradictory O
effects O
by O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
on O
Friend B
virus I
( I
FV I
) I
infection O
. O

Here O
, O
we O
describe O
a O
new O
HLA O
- O
B O
* O
3501 O
- O
restricted O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
epitope O
in O
the O
Influenza B
A I
virus I
( I
H3N2 I
) I
nucleoprotein O
, O
which O
was O
found O
to O
exhibit O
a O
high O
degree O
of O
variation O
at O
nonanchor O
residues O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
X O
gene O
encodes O
a O
multifunctional O
protein O
that O
can O
regulate O
cellular O
signaling O
pathways O
, O
interact O
with O
cellular O
transcription O
factors O
, O
and O
induce O
hepatocellular O
oncogenesis O
. O

We O
previously O
showed O
that O
the O
intrahepatic O
induction O
of O
cytokines O
such O
as O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
gamma O
interferon O
( O
ITN O
- O
gamma O
) O
inhibits O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
noncytopathically O
in O
the O
livers O
of O
transgenic O
mice O
. O

The O
intracellular O
pathway O
( O
s O
) O
responsible O
for O
this O
effect O
is O
still O
poorly O
understood O
. O

To O
identify O
interferon B
( I
IFN I
) I
- O
inducible O
intracellular O
genes O
that O
could O
play O
a O
role O
in O
our O
system O
, O
we O
crossed O
HBV O
transgenic O
mice O
with O
mice O
deficient O
in O
IFN B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
, O
the O
double B
- I
stranded I
RNA I
- I
activated I
protein I
kinase I
( I
PKR I
) I
, O
or O
RNase O
L O
( O
RNase O
L O
) O
( O
IRF O
- O
1 O
( O
- O
/ O
- O
) O
, O
PKR O
( O
- O
/ O
- O
) O
, O
or O
RNase O
L O
( O
- O
/ O
- O
) O
mice O
, O
respectively O
) O
, O
three O
well O
- O
characterized O
IFN O
- O
inducible O
genes O
that O
mediate O
antiviral O
activity O
. O

We O
showed O
that O
unmanipulated O
IRF O
- O
1 O
( O
- O
/ O
- O
) O
or O
PKR O
( O
- O
/ O
- O
) O
transgenic O
mice O
replicate O
HBV O
in O
the O
liver O
at O
slightly O
higher O
levels O
than O
the O
respective O
controls O
, O
suggesting O
that O
both O
IRF O
- O
1 O
and O
PKR O
individually O
appear O
to O
mediate O
signals O
that O
modulate O
HBV O
replication O
under O
basal O
conditions O
. O

These O
same O
animals O
were O
responsive O
to O
the O
antiviral O
effects O
of O
the O
IFN O
- O
alpha O
/ O
beta O
inducer O
poly O
( O
I O
- O
C O
) O
or O
recombinant O
murine O
IFN O
- O
gamma O
, O
suggesting O
that O
under O
these O
conditions O
, O
either O
the O
IRF O
- O
1 O
or O
the O
PKR O
genes O
can O
mediate O
the O
antiviral O
activity O
of O
the O
IFNs O
or O
other O
IFN O
- O
inducible O
genes O
mediate O
the O
antiviral O
effects O
. O

Finally O
, O
RNase O
L O
( O
- O
/ O
- O
) O
transgenic O
mice O
were O
undistinguishable O
from O
controls O
under O
basal O
conditions O
and O
after O
poly O
( O
I O
- O
C O
) O
or O
IFN O
- O
gamma O
administration O
, O
suggesting O
that O
RNase O
L O
does O
not O
modulate O
HBV O
replication O
in O
this O
model O
. O

The O
signal B
transducer I
and I
activator I
of I
transcription I
3 I
( I
STAT I
- I
3 I
) I
, O
a O
member O
of O
the O
STAT O
family O
of O
proteins O
, O
binds O
to O
a O
large O
number O
of O
transcriptional O
control O
elements O
and O
regulates O
gene O
expression O
in O
response O
to O
cytokines O
. O

We O
report O
here O
one O
such O
novel O
interaction O
between O
STAT O
- O
3 O
and O
hepatocyte B
nuclear I
factor I
3 I
( I
HNF I
- I
3 I
) I
in O
the O
absence O
of O
DNA O
. O

We O
have O
identified O
a O
STAT O
- O
3 O
binding O
site O
within O
the O
core O
domain O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
enhancer O
1 O
. O

The O
HBV O
enhancer O
I O
DNA O
- O
STAT O
- O
3 O
protein O
interaction O
is O
shown O
to O
be O
stimulated O
by O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
and O
epidermal O
growth O
factor O
, O
which O
leads O
to O
an O
overall O
stimulation O
of O
HBV O
enhancer O
I O
function O
and O
viral O
gene O
expression O
. O

Repeated O
sequences O
serve O
as O
donor O
and O
acceptor O
templates O
for O
these O
template O
switches O
, O
with O
direct O
repeat O
I O
( O
DR1 O
) O
and O
DR2 O
for O
primer O
translocation O
and O
5 O
' O
r O
and O
3 O
' O
r O
for O
circularization O
. O

Analysis O
of O
plus O
- O
strand O
DNA O
synthesis O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
has O
indicated O
that O
there O
are O
at O
least O
three O
other O
cis O
- O
acting O
sequences O
that O
make O
contributions O
during O
the O
synthesis O
of O
relaxed O
circular O
DNA O
. O

To O
make O
relaxed O
circular O
DNA O
, O
primer O
translocation O
must O
occur O
, O
resulting O
in O
the O
transfer O
of O
the O
primer O
generated O
at O
DR1 O
to O
the O
acceptor O
site O
( O
DR2 O
) O
near O
the O
opposite O
end O
of O
the O
minus O
- O
strand O
DNA O
. O

Administration O
of O
either O
lamivudine O
( O
2 O
' O
- O
deoxy O
- O
3 O
' O
- O
thiacytidine O
) O
or O
L O
- O
FMAU O
( O
2 O
' O
- O
fluoro O
- O
5 O
- O
methyl O
- O
beta O
- O
L O
- O
arabinofuranosyluracil O
) O
to O
woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
induces O
a O
transient O
decline O
in O
virus O
titers O
. O

In O
vitro O
proliferation O
of O
peripheral O
blood O
mononuclear O
cells O
was O
used O
to O
measure O
virus B
- I
specific I
cell I
- I
mediated I
immunity I
( I
vCMI I
) I
following O
neonatal O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
infection O
. O

Resolving O
woodchucks O
had O
robust O
, O
acute O
- O
phase O
vCMI O
to O
WHV O
antigens O
( O
core O
, O
surface O
, O
and O
x O
) O
and O
to O
several O
nonoverlapping O
core O
peptides O
. O

By O
analogy O
, O
these O
results O
suggest O
that O
the O
onset O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
in O
humans O
may O
be O
associated O
with O
deficiencies O
in O
the O
primary O
T O
- O
cell O
response O
to O
acute O
HBV O
infection O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
E1 O
and O
E2 O
should O
be O
anchored O
in O
the O
viral O
membrane O
by O
their O
C O
- O
terminal O
domains O
. O

During O
synthesis O
, O
they O
are O
translocated O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
lumen O
where O
they O
remain O
. O

Several O
three B
- I
dimensional I
( I
3 I
- I
D I
) I
models O
were O
generated O
. O

We O
have O
used O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
to O
study O
the O
interference O
with O
infection O
by O
a O
myristoylated O
peptide O
representing O
an O
N O
- O
terminal O
pre O
- O
S O
subdomain O
of O
the O
large O
viral O
envelope O
protein O
. O

Although O
lacking O
the O
essential O
part O
of O
the O
carboxypeptidase O
D O
( O
formerly O
called O
gp180 O
) O
receptor O
binding O
site O
, O
the O
peptide O
binds O
hepatocytes O
and O
subsequently O
blocks O
DHBV O
infection O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
an O
important O
mediator O
with O
multiple O
functions O
in O
the O
host O
defense O
against O
viral O
infection O
. O

IFN O
- O
gamma O
, O
in O
concert O
with O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
leads O
to O
a O
remarkable O
reduction O
of O
intrahepatic O
replication O
intermediates O
and O
specific O
mRNAs O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
by O
a O
noncytolytic O
mechanism O
in O
the O
transgenic O
mouse O
model O
. O

In O
the O
present O
study O
, O
we O
expressed O
recombinant O
woodchuck B
IFN I
- I
gamma I
( I
wIFN I
- I
gamma I
) I
in O
Escherichia O
coli O
and O
mammalian O
cells O
. O

It O
upregulated O
the O
mRNA O
level O
of O
the O
woodchuck O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
heavy O
chain O
in O
permanent O
woodchuck O
WH12 O
/ O
6 O
cells O
and O
regulated O
differentially O
the O
gene O
expression O
. O

However O
, O
the O
level O
of O
the O
replication O
intermediates O
and O
specific O
RNAs O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
in O
persistently O
WHV O
- O
infected O
primary O
woodchuck O
hepatocytes O
did O
not O
change O
despite O
a O
treatment O
with O
1 O
, O
000 O
U O
of O
wIFN O
- O
gamma O
per O
ml O
or O
with O
a O
combination O
of O
wIFN O
- O
gamma O
and O
woodchuck O
TNF O
- O
alpha O
. O

Initiation O
of O
reverse O
transcription O
in O
hepadnaviruses O
( O
hepatitis O
B O
viruses O
) O
depends O
on O
the O
specific O
binding O
of O
an O
RNA O
signal O
( O
the O
packaging O
signal O
, O
epsilon O
) O
on O
the O
pregenomic O
RNA O
template O
by O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
and O
is O
primed O
by O
the O
RT O
itself O
( O
protein O
priming O
) O
. O

We O
have O
developed O
a O
system O
for O
producing O
murine B
leukemia I
virus I
( I
MLV I
) I
pseudotyped O
with O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
large I
( I
L I
) I
and O
small B
( I
S I
) I
surface O
antigens O
( O
HBsAg O
) O
for O
targeting O
primary O
human O
hepatocytes O
. O

Using O
the O
MLV O
( O
HBV O
) O
pseudotype O
virus O
containing O
a O
beta O
- O
galactosidase O
reporter O
gene O
, O
we O
demonstrated O
that O
this O
pseudotype O
virus O
exhibits O
strict O
tropism O
for O
primary O
human O
hepatocytes O
, O
similar O
to O
the O
natural O
target O
cell O
specificity O
of O
HBV O
. O

It O
does O
not O
infect O
any O
of O
the O
established O
tissue O
culture O
cell O
lines O
, O
including O
human O
hepatoma O
cell O
lines O
( O
HepG2 O
and O
Huh O
- O
7 O
) O
, O
or O
rat O
primary O
hepatocytes O
. O

The O
infectivity O
of O
MLV O
( O
HBV O
) O
for O
human O
hepatocytes O
was O
inhibited O
by O
anti O
- O
HBs O
antibody O
. O

Functional O
analysis O
of O
the O
roles O
of O
the O
nuclear B
receptor I
response I
elements I
( I
NRREs I
) I
in O
the O
transcription O
and O
replication O
of O
hepatitis O
B O
virus O
( O
HBN O
in O
the O
context O
of O
its O
whole O
genome O
has O
been O
hampered O
by O
the O
extensive O
overlapping O
of O
the O
NRREs O
with O
the O
regions O
encoding O
viral O
proteins O
. O

Inactivation O
of O
the O
NRRE B
in I
either I
the I
preC I
promoter I
( I
NRREpreC I
) I
or O
enhancer O
I O
( O
NRREenhI O
) O
led O
to O
moderate O
reductions O
in O
synthesis O
of O
viral O
RNAs O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
core O
antigen O
( O
HBeAg O
) O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
are O
believed O
to O
play O
an O
important O
role O
in O
the O
control O
of O
human O
HBV O
infection O
. O

In O
the O
present O
study O
, O
HBcAg O
- O
specific O
, O
HLA O
- O
DR13 O
* O
- O
restricted O
CD4 O
( O
+ O
) O
Th1 O
- O
type O
T O
- O
cell O
clones O
were O
generated O
which O
secreted O
both O
gamma O
interferon O
and O
tumor O
necrosis O
factor O
alpha O
after O
in O
vitro O
antigen O
stimulation O
. O

These O
HBcAg O
- O
specific O
CD4 O
( O
+ O
) O
Th1 O
- O
type O
T O
cells O
were O
able O
to O
lyse O
HBc O
peptide O
- O
loaded O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphoblastoid O
target O
cells O
in O
vitro O
. O

To O
examine O
whether O
these O
HLA O
- O
DR13 O
* O
- O
restricted O
human O
CD4 O
( O
+ O
) O
Th1 O
T O
cells O
also O
display O
the O
same O
cytotoxic O
effects O
in O
vivo O
, O
we O
transferred O
peripheral B
blood I
leukocytes I
( I
PBL I
) I
derived O
from O
HBV O
- O
infected O
donors O
or O
an O
HBV O
- O
naive O
donor O
sharing O
the O
DR13 O
* O
, O
together O
with O
the O
HBcAg O
- O
specific O
CD4 O
( O
+ O
) O
Th1 O
- O
type O
T O
cells O
and O
HBcAg O
, O
directly O
into O
the O
spleen O
of O
optimally O
conditioned O
Nod O
/ O
LtSz O
- O
Prkdc O
( O
scid O
) O
/ O
Prkdc O
( O
scid O
) O
( O
NOD O
/ O
SCID O
) O
mice O
. O

The O
production O
of O
both O
secondary O
anti O
- O
HBc O
- O
immunoglobulin O
G O
( O
anti O
- O
HBc O
- O
IgG O
) O
and O
primary O
HBcAg O
- O
binding O
IgM O
in O
hu O
- O
PBL O
- O
NOD O
/ O
SCID O
mice O
was O
drastically O
inhibited O
by O
HBcAg O
- O
specific O
CD4 O
( O
+ O
) O
Th1 O
- O
type O
T O
cells O
. O

No O
inhibition O
was O
observed O
when O
CD4 O
( O
+ O
) O
Th1 O
cells O
and O
donor O
PBL O
did O
not O
share O
an O
HLA O
- O
DR13 O
. O

These O
results O
suggest O
that O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
Th1 O
T O
cells O
may O
be O
able O
to O
lyse O
HBcAg O
- O
binding O
, O
or O
- O
specific O
, O
B O
cells O
that O
have O
taken O
up O
and O
presented O
HBcAg O
in O
a O
class O
II O
- O
restricted O
manner O
. O

Thus O
, O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
Th1 O
- O
type O
T O
cells O
can O
modulate O
the O
function O
and O
exert O
a O
regulatory O
role O
in O
deleting O
HBcAg O
- O
binding O
, O
or O
- O
specific O
, O
human O
B O
cells O
in O
vivo O
, O
which O
may O
be O
of O
importance O
in O
controlling O
the O
infection O
. O

Infection O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
mainly O
restricted O
to O
humans O
. O

To O
investigate O
this O
assumption O
, O
we O
took O
advantage O
of O
the O
recent O
discovery O
of O
a O
second O
virus O
belonging O
to O
the O
primate O
Orthohepadnavirus O
genus O
, O
the O
woolly B
monkey I
HBV I
( I
WMHBV I
) I
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
play O
a O
vital O
role O
in O
host O
defense O
against O
viral O
and O
intracellular O
bacterial O
infections O
. O

Here O
we O
report O
that O
epidermal B
powder I
immunization I
( I
EPI I
) I
, O
a O
technology O
that O
delivers O
antigens O
on O
1 O
. O

Many O
Langerhans B
cells I
( I
LCs I
) I
at O
the O
vaccination O
site O
contained O
antigen O
- O
coated O
particles O
, O
as O
revealed O
by O
two O
- O
color O
immunofluorescence O
microscopy O
, O
and O
these O
cells O
were O
found O
in O
the O
draining O
lymph O
nodes O
20 O
h O
later O
. O

EPI O
with O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
and O
a O
synthetic O
peptide O
of O
influenza O
virus O
nucleoprotein O
( O
NP O
peptide O
) O
elicited O
antigen O
- O
specific O
CTL O
responses O
as O
well O
as O
antibody O
responses O
. O

In O
an O
in O
vitro O
cell O
depletion O
experiment O
, O
we O
demonstrated O
that O
the O
CTL O
activity O
against O
HBsAg O
elicited O
by O
EPI O
was O
attributed O
to O
CD8 O
( O
+ O
) O
, O
not O
CD4 O
( O
+ O
) O
, O
T O
cells O
. O

We O
further O
demonstrated O
that O
EPI O
with O
inactivated O
A O
/ O
Aichi O
/ O
68 O
( O
H3N2 O
) O
or O
A O
/ O
Sydney O
/ O
97 O
( O
H3N2 O
) O
influenza O
virus O
elicited O
complete O
protection O
against O
a O
mouse O
- O
adapted O
A O
/ O
Aichi O
/ O
68 O
virus O
. O

To O
explore O
functional O
domains O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
polymerase O
, O
two O
naturally O
occurring O
HBV O
isolates O
( O
56 O
and O
2 O
- O
18 O
) O
with O
98 O
. O

The O
complete O
polymerase B
( I
P I
) I
gene O
and O
its O
gene O
segments O
coding O
for O
the O
terminal B
protein I
( I
TP I
) I
, O
spacer B
( I
SP I
) I
, O
reverse B
transcriptase I
( I
RT I
) I
, O
and O
RNase O
H O
in O
2 O
- O
18 O
were O
separately O
replaced O
with O
their O
counterparts O
from O
56 O
to O
construct O
full O
- O
length O
chimeric O
genomes O
. O

Within O
the O
RT O
region O
, O
amino O
acid O
differences O
between O
isolates O
2 O
- O
18 O
and O
56 O
were O
located O
at O
positions O
617 O
( O
methionine O
versus O
leucine O
) O
, O
652 O
( O
serine O
versus O
proline O
) O
, O
and O
682 O
( O
valine O
versus O
leucine O
) O
. O

We O
show O
that O
viral O
integrations O
in O
tumor O
cells O
lie O
near O
cellular O
sequences O
identified O
as O
nuclear O
matrix B
attachment I
regions I
( I
MARs I
) I
, O
while O
integrations O
in O
nonneoplastic O
cells O
show O
no O
significant O
correlation O
with O
these O
regions O
. O

Transcriptional O
activation O
of O
diverse O
cellular O
genes O
by O
the O
X O
protein O
( O
HBx O
) O
of O
hepatitis O
B O
virus O
( O
HBV O
has O
been O
suggested O
as O
one O
of O
the O
mechanisms O
for O
HBV O
- O
associated O
hepatocellular O
carcinoma O
. O

We O
demonstrate O
that O
following O
virosome O
- O
mediated O
, O
delivery O
of O
HBx O
DNA O
, O
a O
large O
population O
( O
> O
50 O
% O
) O
of O
hepatocytes O
express O
the O
HBx O
protein O
in O
a O
dose O
- O
dependent O
manner O
, O
which O
induces O
a O
significant O
increase O
in O
the O
activity O
of O
extracellular B
signal I
- I
regulated I
kinases I
( I
ERKs I
) I
in O
the O
livers O
of O
HBx O
- O
transfected O
mice O
. O

Inhibition O
of O
HBx O
- O
induced O
ERK O
activation O
following O
intravenous O
administration O
of O
PD98059 O
, O
a O
mitogen O
- O
activated O
protein O
kinase O
kinase O
kinase O
( O
MEK O
) O
inhibitor O
, O
confirmed O
the O
requirement O
for O
MEK O
in O
the O
activation O
of O
ERKs O
by O
HBx O
. O

Interestingly O
, O
sustained O
activation O
of O
c B
- I
jun I
N I
- I
terminal I
kinases I
( I
JNKs I
) I
for O
up O
to O
30 O
days O
was O
also O
noted O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
( O
HBx O
) O
is O
critical O
for O
the O
life O
cycle O
of O
the O
virus O
. O

Studies O
with O
regenerating O
mouse O
liver O
indicate O
that O
during O
late O
G O
( O
1 O
) O
phase O
the O
nuclear O
levels O
of O
both O
subunits O
of O
DDB O
are O
transiently O
increased O
, O
followed O
by O
a O
sharp O
decrease O
in O
S O
phase O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
DDB1 O
and O
DDB2 O
would O
participate O
in O
the O
nuclear O
functions O
of O
HBx O
effectively O
only O
during O
the O
late O
- O
G O
( O
1 O
) O
phase O
of O
the O
cell O
cycle O
. O

At O
least O
in O
the O
case O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
host O
specificity O
seems O
controlled O
partly O
at O
the O
receptor O
level O
. O

The O
middle O
portion O
in O
the O
pre O
- O
S O
region O
of O
the O
viral O
large O
envelope O
protein O
binds O
specifically O
to O
duck B
carboxypeptidase I
D I
( I
DCPD I
) I
but O
not O
to O
its O
human O
or O
chicken O
homologue O
. O

We O
prepared O
and O
tested O
a O
panel O
of O
chimeric O
constructs O
consisting O
of O
DCPD O
and O
human B
carboxpeptidase I
D I
( I
HCPD I
) I
. O

Our O
results O
indicate O
that O
a O
short O
region O
at O
the O
N O
terminus O
of O
domain O
C O
( O
residues O
920 O
to O
949 O
) O
is O
critical O
to O
DHBV O
binding O
and O
is O
a O
major O
determinant O
for O
the O
host O
specificity O
of O
DHBV O
infection O
. O

Natural B
killer I
T I
( I
NKT I
) I
cells O
, O
a O
unique O
subpopulation O
of O
T O
cells O
, O
coexpress O
markers O
also O
present O
on O
NK O
cells O
and O
recognize O
the O
major O
histocompatibility O
complex O
class O
I O
- O
like O
CD1d1 O
molecule O
. O

Mice O
were O
infected O
with O
the O
nonhepatotropic O
Armstrong O
strain O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
at O
various O
times O
postinfection O
, O
mononuclear O
cells O
from O
the O
liver O
, O
peritoneum O
, O
and O
spleen O
were O
isolated O
. O

This O
loss O
of O
NKT O
cells O
was O
independent O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
interleukin B
12 I
( I
IL I
- I
12 I
) I
production O
, O
but O
did O
occur O
in O
mice O
treated O
, O
, O
vith O
poly O
( O
I O
- O
C O
) O
, O
a O
classical O
inducer O
of O
IFN O
- O
alpha O
/ O
beta O
. O

It O
was O
not O
observed O
in O
LCMV O
- O
infected O
DNA O
fragmentation O
factor O
45 O
- O
deficient O
mice O
, O
and O
an O
increase O
in O
active O
caspase O
3 O
- O
specific O
staining O
was O
found O
in O
liver O
NKT O
cells O
from O
LCMV O
- O
infected O
and O
poly O
( O
I O
- O
C O
) O
- O
treated O
mice O
compared O
to O
uninfected O
wild O
- O
type O
mice O
. O

The O
hepatitis O
B O
virus O
posttranscriptional B
regulatory I
element I
( I
PRE I
) I
is O
an O
RNA O
element O
that O
increases O
the O
expression O
of O
unspliced O
mRNAs O
, O
apparently O
by O
facilitating O
their O
export O
from O
the O
nucleus O
. O

We O
have O
identified O
a O
cellular O
protein O
that O
binds O
to O
the O
PRE O
as O
the O
polypyrimidine B
tract I
binding I
protein I
( I
PTB I
) I
, O
which O
shuttles O
rapidly O
between O
the O
nucleus O
and O
the O
cytoplasm O
. O

A O
natural O
hepatitis B
B I
virus I
( I
HBV I
) I
variant O
associated O
with O
seroconversion O
from O
HBeAg O
to O
anti O
- O
HBe O
antibody O
contains O
two O
nucleotide O
substitutions O
( O
A1764T O
and O
G1766A O
) O
in O
the O
proximal O
nuclear O
hormone O
receptor O
binding O
site O
in O
the O
nucleocapsid O
promoter O
. O

These O
nucleotide O
substitutions O
prevent O
the O
binding O
of O
the O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
- O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
heterodimer O
without O
greatly O
altering O
the O
efficiency O
of O
binding O
of O
Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
to O
this O
recognition O
sequence O
. O

The O
glucose O
- O
derived O
iminosugar O
derivatives O
N O
- O
butyl O
- O
and O
N O
- O
nonyl O
- O
deoxynojirimycin O
( O
DNJ O
) O
have O
an O
antiviral O
effect O
against O
a O
broad O
spectrum O
of O
viruses O
including O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
. O

Here O
we O
present O
the O
antiviral O
features O
of O
newly O
designed O
DNJ O
derivatives O
and O
report O
for O
the O
first O
time O
the O
antiviral O
activity O
of O
long O
- O
alkyl O
- O
chain O
derivatives O
of O
deoxygalactonojirimycin B
( I
DGJ I
) I
, O
a O
class O
of O
iminosugars O
derived O
from O
galactose O
which O
does O
not O
inhibit O
endoplasmic B
reticulum I
( I
ER I
) I
alpha O
- O
glucosidases O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
and O
hepatitis O
S O
virus O
( O
HBV O
) O
are O
closely O
similar O
with O
respect O
to O
genomic O
organization O
, O
host O
antiviral O
responses O
, O
and O
pathobiology O
of O
the O
infection O
. O

T O
- O
cell O
immunity O
against O
viral O
nucleocapsid O
( O
HBcAg O
or O
WHcAg O
) O
has O
been O
shown O
to O
play O
a O
critical O
role O
in O
viral O
clearance O
and O
protection O
against O
infection O
. O

Here O
we O
show O
that O
vaccination O
of O
healthy O
woodchucks O
by O
gene O
gun O
bombardment O
with O
a O
plasmid B
coding I
for I
WHcAg I
( I
pCw I
) I
stimulates O
proliferation O
of O
WHcAg O
- O
specific O
T O
cells O
but O
that O
these O
cells O
do O
not O
produce O
significant O
levels O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
upon O
antigen O
stimulation O
. O

In O
order O
to O
induce O
a O
Th1 O
cytokine O
response O
, O
another O
group O
of O
woodchucks O
was O
immunized O
with O
pCw O
together O
with O
another O
plasmid O
coding O
for O
woodchuck O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
small O
delta O
antigen O
( O
S O
- O
HDAg O
) O
plays O
a O
critical O
role O
in O
virus O
replication O
. O

Site O
- O
directed O
mutagenesis O
showed O
that O
alanine O
replacement O
of O
serine O
177 O
, O
which O
is O
conserved O
among O
all O
the O
known O
HDV O
strains O
, O
resulted O
in O
reduced O
phosphorylation O
of O
S O
- O
HDAg O
, O
while O
the O
mutation O
of O
the O
other O
two O
conserved O
serine O
residues O
( O
2 O
and O
123 O
) O
had O
little O
effect O
. O

Spontaneous O
revertants O
were O
found O
to O
be O
present O
at O
frequencies O
of O
1 O
x O
10 O
( O
- O
5 O
) O
to O
6 O
x O
10 O
( O
- O
5 O
) O
per O
G133E O
genome O
inoculated O
. O

8 O
x O
10 O
( O
- O
5 O
) O
to O
4 O
. O

5 O
x O
10 O
( O
- O
5 O
) O
per O
nucleotide O
per O
generation O
. O

Because O
rat O
hepatocytes O
plated O
on O
collagen O
- O
coated O
dishes O
and O
maintained O
in O
dimethyl B
sulfoxide I
( I
DMSO I
) I
- O
supplemented O
chemically O
defined O
medium O
are O
an O
excellent O
model O
system O
for O
studying O
liver O
function O
in O
vitro O
, O
we O
investigated O
the O
ability O
of O
baculoviruses O
to O
infect O
and O
deliver O
exogenous O
genes O
to O
cells O
in O
this O
culture O
system O
. O

Clinical O
and O
experimental O
evidence O
indicates O
that O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
glycoprotein O
( O
HCV O
/ O
E2 O
) O
is O
the O
most O
promising O
candidate O
for O
the O
development O
of O
an O
effective O
anti O
- O
HCV O
vaccine O
. O

Three O
unrelated O
epitopes O
recognized O
by O
antibodies O
with O
no O
neutralization B
- I
of I
- I
binding I
( I
NOB I
) I
activity O
were O
identified O
; O
a O
fourth O
, O
major O
epitope O
was O
defined O
as O
a O
clustering O
of O
minor O
epitopes O
recognized O
by O
Fabs O
endowed O
with O
strong O
NOB O
activity O
. O

While O
epitope O
variants O
trigger O
only O
subsets O
of O
T O
- O
cell O
effector O
functions O
, O
the O
response O
of O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
to O
various O
concentrations O
of O
the O
wild O
- O
type O
antigen O
has O
not O
been O
systematically O
studied O
. O

We O
stimulated O
hepatitis O
B O
virus O
core O
- O
and O
hepatitis O
C O
virus O
NS3 O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
which O
had O
been O
isolated O
from O
patients O
with O
acute O
hepatitis O
during O
viral O
clearance O
with O
a O
wide O
range O
of O
specific O
antigen O
concentrations O
and O
determined O
the O
phenotypic O
changes O
and O
the O
induction O
of O
T O
- O
cell O
effector O
functions O
in O
relation O
to O
T O
- O
cell O
receptor O
internalization O
. O

A O
low O
antigen O
concentration O
induced O
the O
expression O
of O
T O
- O
cell O
activation O
markers O
and O
adhesion O
molecules O
in O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
in O
the O
absence O
of O
cytokine O
secretion O
and O
proliferation O
. O

These O
data O
indicate O
that O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
can O
respond O
to O
specific O
antigen O
in O
a O
graded O
manner O
depending O
on O
the O
antigen O
concentration O
, O
which O
may O
have O
implications O
for O
a O
coordinate O
regulation O
of O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
the O
closest O
relative O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
is O
an O
attractive O
surrogate O
model O
for O
HCV O
antiviral O
studies O
. O

Treatment O
with O
human O
interferon O
provided O
only O
a O
marginal O
antiviral O
effect O
, O
while O
poly O
( O
I O
- O
C O
) O
yielded O
> O
3 O
and O
4 O
log O
units O
of O
reduction O
of O
cell O
- O
associated O
and O
secreted O
viral O
RNA O
, O
respectively O
. O

Guanosine O
blocked O
the O
antiviral O
effect O
of O
ribavirin O
, O
suggesting O
that O
inhibition O
of O
IMP O
dehydrogenase O
( O
IMPDH O
) O
and O
reduction O
of O
intracellular O
GTP O
levels O
were O
essential O
for O
the O
antiviral O
effect O
. O

The O
carboxyl O
terminus O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
3 I
( I
NS3 I
) I
possesses O
ATP O
- O
dependent O
RNA O
helicase O
activity O
. O

The O
expression O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
genes O
is O
regulated O
by O
a O
number O
of O
transcription O
factors O
. O

Moreover O
, O
while O
the O
downstream O
Spl O
site O
( O
the O
Sp1 O
- O
1 O
site O
) O
in O
the O
core O
promoter O
did O
not O
affect O
the O
transcription O
of O
the O
S O
gene O
and O
the O
X O
gene O
, O
the O
upstream O
Spl O
site O
( O
the O
Sp1 O
- O
2 O
site O
) O
in O
the O
core O
promoter O
was O
found O
to O
negatively O
regulate O
the O
transcription O
of O
the O
S O
gene O
and O
the O
X O
gene O
, O
as O
removal O
of O
the O
latter O
led O
to O
enhancement O
of O
transcription O
of O
these O
two O
genes O
. O

The O
SP1 O
binding O
site O
in O
the O
ENII O
enhancer O
( O
the O
Sp1 O
- O
3 O
site O
) O
positively O
regulates O
the O
expression O
of O
all O
of O
the O
HBV O
genes O
, O
as O
its O
removal O
by O
mutation O
suppressed O
the O
expression O
of O
all O
of O
the O
HBV O
genes O
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
play O
a O
major O
role O
in O
the O
recovery O
from O
primary O
viral O
infections O
and O
the O
accompanying O
tissue O
injuries O
. O

However O
, O
it O
is O
unclear O
to O
what O
extent O
the O
two O
main O
cytolytic O
pathways O
, O
perforin O
- O
granzyme O
A O
and O
B O
exocytosis O
and O
Fas B
ligand I
( I
FasL I
) I
- O
Fas O
interaction O
, O
contribute O
to O
these O
processes O
. O

The O
capsid B
( I
CA I
) I
protein O
, O
the O
major O
structural O
component O
of O
retroviruses O
, O
forms O
a O
shell O
that O
encases O
the O
ribonucleoprotein O
complex O
in O
the O
virion O
core O
. O

The O
most O
conserved O
region O
of O
CA O
, O
similar O
to O
20 O
amino O
acids O
of O
the O
major B
homology I
region I
( I
MHR I
) I
, O
lies O
within O
the O
carboxy O
- O
terminal O
domain O
of O
the O
protein O
. O

All O
four O
map O
to O
the O
sequence O
encoding O
the O
CA B
- I
spacer I
peptide I
( I
SP I
) I
region O
of O
Gag O
. O

In O
contrast O
to O
all O
retroviruses O
but O
similar O
to O
the O
hepatitis O
B O
virus O
, O
foamy B
viruses I
( I
FV I
) I
require O
expression O
of O
the O
envelope O
protein O
for O
budding O
of O
intracellular O
capsids O
from O
the O
cell O
, O
suggesting O
a O
specific O
interaction O
between O
the O
Gag O
and O
Env O
proteins O
. O

Capsid O
assembly O
occurs O
in O
the O
cytoplasm O
of O
infected O
cells O
in O
a O
manner O
similar O
to O
that O
for O
the O
B O
- O
and O
D O
- O
type O
viruses O
; O
however O
, O
in O
contrast O
to O
these O
retroviruses O
, O
FV O
Gag O
lacks O
an O
N O
- O
terminal O
myristylation O
signal O
and O
capsids O
are O
not O
targeted O
to O
the O
plasma B
membrane I
( I
PM I
) I
. O

We O
have O
found O
that O
mutation O
of O
an O
absolutely O
conserved O
arginine B
( I
Arg I
) I
residue O
at O
position O
50 O
to O
alanine O
( O
R50A O
) O
of O
the O
simian O
foamy O
virus O
SFV O
cpz O
( O
hu O
) O
inhibits O
proper O
capsid O
assembly O
and O
abolishes O
viral O
budding O
even O
in O
the O
presence O
of O
the O
envelope B
( I
env I
) I
glycoproteins O
. O

Particle O
assembly O
and O
extracellular O
release O
of O
virus O
can O
be O
restored O
to O
this O
mutant O
with O
the O
addition O
of O
an O
N O
- O
terminal O
Src O
myristylation O
signal O
( O
Myr O
- O
R50A O
) O
, O
presumably O
by O
providing O
an O
alternate O
site O
for O
assembly O
to O
occur O
at O
the O
PM O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
RNA O
is O
downregulated O
by O
inflammatory O
cytokines O
induced O
in O
the O
liver O
by O
adoptively O
transferred O
HBV O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
and O
during O
murine B
cytomegalovirus I
( I
MCMV I
) I
infections O
of O
the O
livers O
of O
HBV O
transgenic O
mice O
. O

Endonucleolytic O
activity O
that O
cleaved O
HBV O
RNA O
at O
positions O
1269 O
to O
1270 O
and O
1271 O
to O
1272 O
, O
immediately O
5 O
' O
of O
the O
stem O
- O
loop O
bound O
by O
the O
La O
protein O
( O
positions O
1272 O
to O
1293 O
) O
, O
was O
detected O
. O

Previous O
studies O
showed O
that O
hepatitis B
B I
virus I
polymerase I
( I
HBV I
Pol I
) I
interacts O
with O
host O
factors O
such O
as O
the O
Hsp90 O
complex O
, O
which O
is O
a O
critical O
step O
in O
viral O
genome O
replication O
. O

In O
vitro O
experiments O
showed O
that O
Hsp60 O
strongly O
affected O
human O
HBV O
Pol O
activity O
in O
that O
( O
i O
) O
blocking O
of O
Hsp60 O
by O
the O
protein O
- O
specific O
antibody O
reduced O
human O
HBV O
Pol O
activity O
, O
( O
ii O
) O
the O
activity O
was O
increased O
by O
addition O
of O
Hsp60 O
in O
the O
presence O
of O
ATP O
, O
and O
( O
iii O
) O
ATP O
synergistically O
activated O
human O
HBV O
Pol O
with O
Hsp60 O
. O

Naturally O
occurring O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
long O
been O
thought O
to O
induce O
a O
weak O
immunity O
which O
is O
insufficient O
to O
protect O
an O
individual O
from O
subsequent O
infections O
and O
has O
cast O
doubt O
on O
the O
ability O
to O
develop O
effective O
vaccines O
. O

A O
series O
of O
intrahepatic B
genetic I
inoculations I
( I
IHGI I
) I
with O
type O
la O
HCV O
RNA O
were O
performed O
in O
a O
chimpanzee O
to O
determine O
whether O
a O
form O
of O
genetic O
immunization O
might O
stimulate O
protective O
immunity O
. O

We O
demonstrate O
that O
the O
chimpanzee O
not O
only O
developed O
protective O
immunity O
to O
the O
homologous O
type O
la O
RNA O
after O
rechallenge O
by O
IHGI O
but O
was O
also O
protected O
from O
chronic O
HCV O
infection O
after O
sequential O
rechallenge O
with O
100 O
50 O
% O
chimpanzee O
infectious O
doses O
of O
a O
heterologous O
type O
la O
( O
H77 O
) O
and O
Ib O
( O
HC O
- O
J4 O
) O
whole O
- O
virus O
inoculum O
. O

Hepatitis O
B O
viruses O
replicate O
through O
reverse O
transcription O
of O
an O
RNA O
intermediate O
, O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

Replication O
is O
initiated O
de O
novo O
and O
requires O
formation O
of O
a O
ribonucleoprotein O
complex O
comprising O
the O
viral O
reverse O
transcriptase O
( O
P O
protein O
) O
, O
an O
RNA O
stem O
- O
loop O
structure O
( O
epsilon O
) O
on O
the O
pgRNA O
, O
and O
cellular O
proteins O
, O
including O
the O
heat O
shock O
protein O
Hsp90 O
, O
the O
cochaperone O
p23 O
, O
and O
additional O
, O
as O
yet O
unknown O
, O
factors O
. O

Functional O
complexes O
catalyze O
the O
synthesis O
of O
a O
short O
DNA O
primer O
that O
is O
templated O
by O
e O
and O
covalently O
linked O
to O
the O
terminal B
protein I
( I
TP I
) I
domain O
of O
P O
protein O
. O

Currently O
, O
the O
only O
system O
for O
generating O
such O
complexes O
in O
the O
test O
tube O
is O
in O
vitro O
translation O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
P O
protein O
in O
rabbit B
reticulocyte I
lysate I
( I
RRL I
) I
, O
which O
also O
provides O
the O
necessary O
factors O
. O

Because O
previous O
attempts O
to O
generate O
full O
- O
length O
P O
protein O
in O
bacteria O
have O
failed O
we O
investigated O
whether O
separate O
expression O
of O
the O
TP O
and O
reverse B
transcriptase I
- I
RNase I
H I
( I
RT I
- I
RH I
) I
domains O
would O
allow O
higher O
yields O
and O
whether O
these O
domains O
could O
trans O
complement O
each O
other O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
highly O
pathogenic O
human O
RNA O
virus O
whose O
genome O
is O
structurally O
related O
to O
those O
of O
plant O
viroids O
. O

Although O
its O
spread O
from O
cell O
to O
cell O
requires O
helper O
functions O
supplied O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
intracellular O
HDV O
RNA O
replication O
can O
proceed O
in O
the O
absence O
of O
HBV O
proteins O
. O

As O
HDV O
encodes O
no O
RNA O
- O
dependent O
RNA O
polymerase O
, O
the O
identity O
of O
the O
( O
presumably O
cellular O
) O
enzyme O
responsible O
for O
this O
reaction O
remains O
unknown O
. O

Primary O
cultures O
of O
intrahepatic B
bile I
duct I
epithelial I
( I
IBDE I
) I
cells O
isolated O
from O
duckling O
livers O
were O
successfully O
grown O
for O
studies O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

Southern O
blot O
analysis O
of O
infected O
IBDE O
preparations O
using O
a O
digoxigenin O
- O
labeled O
positive O
- O
sense O
DHBV O
riboprobe O
revealed O
the O
presence O
of O
hepadnavirus O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
minus O
- O
sense O
single B
- I
stranded I
( I
ss I
) I
DNA O
, O
double O
- O
stranded O
linear O
DNA O
, O
and O
relaxed O
circular O
DNA O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
major O
cause O
of O
liver O
disease O
worldwide O
, O
is O
frequently O
resistant O
to O
the O
antiviral O
alpha O
interferon B
( I
IFN I
) I
. O

The O
HCV B
nonstructural I
5A I
( I
NS5A I
) I
protein O
has O
been O
implicated O
in O
HCV O
antiviral O
resistance O
in O
many O
studies O
. O

NS5A O
antagonizes O
the O
IFN O
antiviral O
response O
in O
vitro O
, O
and O
one O
mechanism O
is O
via O
inhibition O
of O
a O
key O
IFN O
- O
induced O
enzyme O
, O
the O
double B
- I
stranded I
- I
RNA I
- I
activated I
protein I
kinase I
( I
PKR I
) I
, O
In O
the O
present O
study O
we O
determined O
if O
NS5A O
uses O
other O
strategies O
to O
subvert O
the O
IFN O
system O
. O

Expression O
of O
full O
- O
length O
NS5A O
proteins O
from O
patients O
who O
exhibited O
a O
complete O
response O
( O
FL O
- O
NS5A O
- O
CR O
) O
or O
were O
nonresponsive O
( O
FL O
- O
NS5A O
- O
NR O
) O
to O
IFN O
therapy O
in O
HeLa O
cells O
had O
no O
effect O
on O
IFN O
induction O
of O
IFN B
- I
stimulated I
gene I
factor I
3 I
( I
ISGF I
- I
3 I
) I
. O

Expression O
of O
mutant O
NS5A O
proteins O
lacking O
110 O
( O
NS5A O
- O
Delta O
N110 O
) O
, O
222 O
( O
NS5A O
- O
Delta O
N222 O
) O
, O
and O
334 O
amino O
- O
terminal O
amino O
acids O
and O
mutants O
lacking O
117 O
and O
230 O
carboxy O
- O
terminal O
amino O
acids O
also O
had O
no O
effect O
on O
ISGF O
- O
3 O
induction O
by O
IFN O
, O
Expression O
of O
FL O
- O
NS5A O
- O
CR O
and O
FL O
- O
NS5A O
- O
NR O
did O
not O
affect O
IFN O
- O
induced O
STAT O
- O
1 O
tyrosine O
phosphorylation O
or O
upregulation O
of O
PKR O
and O
major O
histocompatibility O
complex O
class O
I O
antigens O
, O
However O
, O
NS5A O
expression O
in O
human O
cells O
induced O
interleukin B
8 I
( I
IL I
- I
8 I
) I
mRNA O
and O
protein O
, O
and O
this O
effect O
correlated O
with O
inhibition O
of O
the O
antiviral O
effects O
of O
IFN O
in O
an O
in O
vitro O
bioassay O
, O
NS5A O
induced O
transcription O
of O
a O
reporter O
gene O
driven O
by O
the O
IL O
- O
8 O
promoter O
, O
and O
the O
first O
133 O
bp O
of O
the O
IL O
- O
8 O
promoter O
made O
up O
the O
minimal O
domain O
required O
for O
NS5A O
transactivation O
, O
NSSA O
- O
Delta O
N110 O
and O
NS5A O
- O
Delta O
N222 O
stimulated O
the O
1L O
- O
8 O
promoter O
to O
higher O
levels O
than O
did O
the O
full O
- O
length O
NS5A O
protein O
, O
and O
this O
correlated O
with O
increased O
nuclear O
localization O
of O
the O
proteins O
, O
Additional O
mutagenesis O
of O
the O
IL O
- O
8 O
promoter O
suggested O
that O
NF O
- O
kappaB O
and O
AP O
- O
1 O
were O
important O
in O
NS5A O
- O
Delta O
N222 O
transactivation O
in O
the O
presence O
of O
tumor O
necrosis O
factor O
alpha O
and O
that O
NF O
- O
IL O
- O
6 O
was O
inhibitory O
to O
this O
process O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
, O
a O
positive O
strand O
RNA O
virus O
, O
is O
an O
important O
causative O
agent O
of O
waterborne O
hepatitis O
. O

Expression O
of O
cDNA O
( O
encoding O
amino O
acids O
1 O
to O
979 O
of O
HEV O
nonstructural O
open O
reading O
frame O
1 O
) O
in O
insect O
cells O
resulted O
in O
synthesis O
of O
a O
110 O
- O
kDa O
protein O
( O
P110 O
) O
, O
a O
fraction O
of O
which O
was O
proteolytically O
processed O
to O
an O
80 O
- O
kDa O
protein O
. O

Immunopurified O
P110 O
catalyzed O
transfer O
of O
a O
methyl O
group O
from O
S O
- O
adenosylmethionine O
( O
AdoMet O
) O
to O
GTP O
and O
GDP O
to O
yield O
m O
( O
7 O
) O
GTP O
or O
m O
( O
7 O
) O
GDP O
. O

P110 O
was O
also O
a O
guanylyltransferase O
, O
which O
formed O
a O
covalent O
complex O
, O
P110 O
- O
m O
( O
7 O
) O
GMP O
, O
in O
the O
presence O
of O
AdoMet O
and O
GTP O
, O
because O
radioactivity O
from O
both O
[ O
alpha O
- O
P O
- O
32 O
] O
GTP O
and O
[ O
H O
- O
3 O
- O
methyl O
] O
AdoMet O
was O
found O
in O
the O
covalent O
guanylate O
complex O
. O

Cap O
analogs O
such O
as O
m O
( O
7 O
) O
GTP O
, O
m O
( O
7 O
) O
GDP O
, O
et O
( O
2 O
) O
m O
( O
7 O
) O
GMP O
, O
and O
m O
( O
2 O
) O
et O
( O
7 O
) O
GMP O
inhibited O
the O
methyltransferase O
reaction O
. O

HEV O
P110 O
capping O
enzyme O
has O
similar O
properties O
to O
the O
methyltransferase O
and O
guanylyltransferase O
of O
alphavirus O
nsP1 O
, O
tobacco O
mosaic O
virus O
P126 O
, O
brome O
mosaic O
virus O
replicase O
protein O
la O
, O
and O
bamboo O
mosaic O
virus O
( O
a O
potexvirus O
) O
nonstructural O
protein O
, O
indicating O
there O
is O
a O
common O
evolutionary O
origin O
of O
these O
distantly O
related O
plant O
and O
animal O
virus O
families O
. O

When O
human B
immunodeficiency I
virus I
type I
I I
( I
HIV I
- I
1 I
) I
is O
selected O
for O
resistance O
to O
3TC O
, O
the O
methionine O
normally O
present O
at O
position O
184 O
is O
replaced O
by O
valine O
or O
isoleucine O
. O

Structural O
and O
biochemical O
analysis O
of O
STC O
- O
resistant O
HIV O
- O
1 O
reverse B
transcriptase I
( I
RT I
) I
led O
to O
a O
model O
in O
which O
a O
beta O
- O
branched O
amino O
acid O
at O
position O
184 O
would O
act O
as O
a O
steric O
gate O
. O

Normal O
deoxynucleoside B
triphosphates I
( I
dNTPs I
) I
could O
still O
be O
incorporated O
; O
the O
oxathiolane O
ring O
of O
3TCTP O
would O
clash O
with O
the O
beta O
branch O
of O
the O
amino O
acid O
at O
position O
184 O
. O

However O
, O
it O
has O
been O
reported O
( O
14 O
) O
that O
murine B
leukemia I
viruses I
( I
MLVs I
) I
with O
valine O
( O
the O
amino O
acid O
present O
in O
the O
wild O
type O
) O
, O
isoleucine O
, O
alanine O
, O
serine O
, O
or O
methionine O
at O
the O
X O
position O
of O
the O
YXDD O
motif O
are O
all O
resistant O
to O
3TC O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
( O
HBc O
) O
antigen O
( O
HBcAg O
) O
is O
a O
highly O
immunogenic O
subviral O
particle O
. O

By O
using O
a O
human O
peripheral O
blood O
leukocyte O
( O
hu O
PBL O
) O
- O
Nod O
/ O
LtSz O
- O
Prkdc O
( O
scid O
) O
/ O
Prkdc O
( O
scid O
) O
( O
NOD O
/ O
SCID O
) O
mouse O
model O
, O
we O
show O
here O
that O
HBcAg O
also O
activates O
human O
B O
cells O
in O
vivo O
in O
a O
T O
- O
cell O
- O
independent O
way O
. O

HBcAg O
was O
capable O
of O
inducing O
the O
secretion O
of O
HBcAg O
- O
binding O
human B
immunoglobulin I
M I
( I
IgM I
) I
in O
naive O
human O
B O
cells O
derived O
from O
adult O
human O
and O
neonatal O
( O
cord O
blood O
) O
donors O
when O
these O
hu O
- O
PBL O
were O
transferred O
directly O
into O
the O
spleens O
of O
optimally O
conditioned O
NOD O
/ O
SCID O
mice O
. O

The O
nucleocapsid O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
composed O
of O
180 O
to O
240 O
copies O
of O
the O
HBV B
core I
( I
HBc I
) I
protein O
. O

HBc B
antigen I
( I
HBcAg I
) I
capsids O
are O
extremely O
immunogenic O
and O
can O
activate O
naive O
B O
cells O
by O
cross O
- O
linking O
their O
surface O
receptors O
. O

The O
functionality O
of O
this O
activation O
was O
evidenced O
in O
that O
low O
concentrations O
of O
HBcAg O
, O
but O
not O
the O
nonparticulate O
homologue O
HBV O
envelope O
antigen O
( O
HBeAg O
) O
, O
could O
prime O
naive O
B O
cells O
to O
produce O
anit O
- O
HBc O
in O
vitro O
with O
splenocytes O
from O
HBcAg O
and O
HBeAg O
- O
specific O
T O
- O
cell O
receptor O
transgenic O
mice O
. O

The O
frequency O
of O
these O
HBcAg O
- O
binding O
B O
cells O
was O
estimated O
by O
both O
hybridoma O
techniques O
and O
Row O
cytometry O
( O
B7 O
- O
2 O
induction O
and O
direct O
HBcAg O
binding O
) O
to O
be O
approximately O
4 O
to O
8 O
% O
of O
the O
B O
cells O
in O
a O
naive O
spleen O
. O

Cloning O
and O
sequence O
analysis O
of O
the O
immunoglobulin O
heavy O
- O
and O
light O
- O
chain O
variable O
( O
VH O
and O
VL O
) O
domains O
of O
seven O
primary O
HBcAg O
- O
binding O
hybridomas O
revealed O
that O
six O
( O
86 O
% O
) O
were O
related O
to O
the O
murine O
and O
human O
VH1 O
germ O
line O
gene O
families O
and O
one O
was O
related O
to O
the O
murine O
VH3 O
family O
. O

By O
using O
synthetic O
peptides O
spanning O
three O
VH1 O
sequences O
, O
one O
VH3 O
sequence O
, O
and O
one O
VL O
kappaV O
sequence O
, O
a O
linear O
motif O
in O
the O
framework B
region I
1 I
( I
FR1 I
) I
complementarity I
- I
determining I
region I
1 I
( I
CDR1 I
) I
junction O
of O
the O
VH1 O
sequence O
was O
identified O
that O
bound O
HBcAg O
. O

Finally O
, O
two O
monoclonal O
antibodies O
containing O
linear O
HBcAg O
- O
binding O
motifs O
blocked O
HBcAg O
presentation O
by O
purified O
naive O
B O
cells O
to O
purified O
HBcAg O
- O
primed O
CD4 O
( O
+ O
) O
T O
cells O
. O

Here O
we O
explored O
the O
ability O
of O
CpG O
containing O
oligodeoxynucleotides O
combined O
with O
recombinant O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
to O
induce O
Th1 O
responses O
in O
mice O
that O
are O
transgenic O
for O
this O
antigen O
and O
that O
represent O
a O
model O
for O
asymptomatic O
hepatitis O
B O
virus O
chronic O
carriers O
. O

Finally O
, O
adoptive O
transfer O
experiments O
with O
CD8 O
( O
+ O
) O
T O
cells O
primed O
in O
C57BL O
/ O
6 O
mice O
with O
HBsAg O
and O
CpG O
oligodeoxynucleotide O
based O
immunization O
show O
that O
these O
cells O
were O
able O
to O
partially O
control O
transgene O
expression O
in O
the O
liver O
and O
to O
clear O
the O
HBsAg O
from O
the O
sera O
of O
recipient O
transgenic O
mice O
without O
an O
antibody O
requirement O
. O

However O
, O
DNA O
vaccination O
of O
large O
animals O
appears O
to O
be O
less O
effective O
and O
requires O
repeated O
injections O
of O
Large O
amounts O
of O
plasmid O
DNA O
, O
Enhancement O
of O
the O
efficiency O
of O
DNA O
vaccines O
may O
be O
achieved O
by O
coapplication O
of O
cytokine O
- O
expressing O
plasmids O
, O
Here O
we O
investigated O
, O
with O
woodchucks O
, O
whether O
coadministration O
of O
an O
expression O
plasmid O
for O
woodchuck O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
pWIFN O
- O
gamma O
, O
can O
improve O
DNA O
vaccination O
with O
woodchuck B
hepatitis I
virus I
core I
antigen I
( I
WHcAg I
) I
, O
Animals O
were O
immunized O
with O
pWHcIm O
( O
a O
plasmid O
expressing O
WHcAg O
) O
alone O
or O
with O
a O
combination O
of O
pWHcIm O
and O
pWIFN O
- O
gamma O
using O
a O
gene O
gun O
. O

Six O
weeks O
postimmunization O
, O
all O
animals O
were O
challenged O
with O
10 O
( O
5 O
) O
genome O
equivalents O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

The O
Asian O
tree O
shrew O
, O
Tupaia O
belangeri O
, O
has O
been O
proposed O
as O
a O
novel O
animal O
model O
for O
studying O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
. O

Primary O
tupaia O
hepatocytes O
are O
also O
susceptible O
to O
infection O
with O
the O
recently O
discovered O
woolly B
monkey I
hepatitis I
B I
virus I
( I
WMHBV I
) I
but O
not O
to O
woodchuck O
hepatitis O
virus O
infection O
. O

For O
the O
outcome O
of O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
the O
viral O
L O
envelope O
protein O
with O
its O
pre O
- O
S O
domain O
performs O
pivotal O
functions O
by O
mediating O
attachment O
of O
HBV O
to O
liver O
cells O
, O
envelopment O
of O
viral O
capsids O
, O
release O
of O
( O
sub O
) O
viral O
particles O
, O
regulation O
of O
supercoiled O
DNA O
amplification O
, O
and O
transcriptional O
transactivation O
, O
To O
assess O
its O
multiple O
functions O
and O
host O
- O
protein O
assistance O
involved O
, O
we O
initiated O
a O
two O
- O
hybrid O
screen O
using O
the O
L O
- O
specific O
pre O
- O
S1 O
domain O
as O
bait O
. O

HBx O
has O
also O
been O
shown O
to O
promote O
early O
cell O
cycle O
progression O
, O
possibly O
by O
functionally O
replacing O
the O
TATA O
- O
binding O
protein O
- O
associated O
factor O
250 O
( O
TAF O
( O
II O
) O
250 O
) O
, O
a O
transcriptional O
coactivator O
, O
and O
/ O
or O
by O
stimulating O
cytoplasmic O
signal O
transduction O
pathways O
. O

To O
understand O
the O
basis O
for O
early O
cell O
cycle O
progression O
mediated O
by O
HBx O
, O
we O
characterized O
the O
molecular O
mechanism O
by O
which O
HBx O
promotes O
deregulation O
of O
the O
G O
( O
0 O
) O
and O
G O
( O
1 O
) O
cell O
cycle O
checkpoints O
in O
growth O
- O
arrested O
cells O
. O

We O
demonstrate O
that O
TAF O
( O
II O
) O
250 O
is O
absolutely O
required O
for O
HBx O
activation O
of O
the O
cyclin O
A O
promoter O
and O
for O
promotion O
of O
early O
cell O
cycle O
transit O
from O
G O
( O
0 O
) O
through O
G O
( O
1 O
) O
. O

Thus O
, O
HBx O
does O
not O
functionally O
replace O
TAF O
( O
II O
) O
250 O
for O
transcriptional O
activity O
or O
for O
cell O
cycle O
progression O
, O
in O
contrast O
to O
a O
previous O
report O
. O

Instead O
, O
HBx O
is O
shown O
to O
activate O
the O
cyclin O
A O
promoter O
, O
induce O
cyclin O
A O
- O
cyclin O
- O
dependent O
kinase O
2 O
complexes O
, O
and O
promote O
cycling O
of O
growth O
- O
arrested O
cells O
into O
G O
( O
1 O
) O
through O
a O
pathway O
involving O
activation O
of O
Src O
tyrosine O
kinases O
. O

HBx O
stimulation O
of O
Src O
kinases O
and O
cyclin O
gene O
expression O
was O
found O
to O
force O
growth O
- O
arrested O
cells O
to O
transit O
through O
G O
( O
1 O
) O
but O
to O
stall O
at O
the O
junction O
with O
S O
phase O
, O
which O
may O
be O
important O
for O
viral O
replication O
. O

Success O
in O
treating O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
with O
nucleoside O
analog O
drugs O
like O
lamivudine O
is O
limited O
by O
the O
emergence O
of O
drug O
- O
resistant O
viral O
strains O
upon O
prolonged O
therapy O
. O

The O
predominant O
lamivudine O
resistance O
mutations O
in O
HBV O
- O
infected O
patients O
are O
Met552IIe O
and O
Met552Val O
( O
Met552IIe O
/ O
Val O
) O
, O
frequently O
in O
association O
with O
a O
second O
mutation O
, O
Leu528Met O
. O

Susceptibility O
to O
lamivudine O
triphosphate O
( O
3TCTP O
) O
, O
emtricitabine O
triphosphate O
( O
FTCTP O
) O
, O
adefovir O
diphosphate O
, O
penciclovir O
triphosphate O
, O
and O
lobucavir O
triphosphate O
was O
assessed O
by O
determination O
of O
inhibition O
constants O
( O
K O
- O
i O
) O
. O

The O
results O
from O
the O
in O
vitro O
studies O
were O
as O
follows O
: O
( O
i O
) O
dCTP O
substrate O
binding O
was O
largely O
unaffected O
by O
the O
mutations O
, O
with O
K O
- O
m O
changing O
moderately O
, O
only O
in O
a O
range O
of O
0 O
. O

6 O
- O
fold O
; O
( O
ii O
) O
K O
( O
i O
) O
s O
for O
3TCTP O
and O
FTCTP O
against O
Met552IIe O
/ O
Val O
mutant O
HBV O
polymerases O
were O
increased O
8 O
to O
30 O
- O
fold O
; O
and O
( O
iii O
) O
the O
Leu528Met O
mutation O
had O
a O
modest O
effect O
on O
direct O
binding O
of O
these O
beta O
- O
L O
- O
oxathiolane O
ring O
- O
containing O
nucleotide O
analogs O
. O

Specifically O
, O
steric O
conflict O
between O
the O
C O
gamma2 O
- O
methyl O
group O
of O
Ire O
or O
Vat O
at O
position O
552 O
in O
HBV O
polymerase O
and O
the O
sulfur O
atom O
in O
the O
oxathiolane O
ring O
( O
common O
to O
both O
P O
- O
L O
- O
nucleoside O
analogs O
lamivudine O
and O
emtricitabine O
) O
is O
proposed O
to O
account O
for O
the O
resistance O
observed O
upon O
Met552IIe O
/ O
Val O
mutation O
. O

The O
iminosugar O
N O
- O
butyldeoxynojirimycin O
( O
NB O
- O
DNJ O
) O
, O
an O
endoplasmic O
reticulum O
a O
- O
glucosidase O
inhibitor O
, O
has O
an O
antiviral O
effect O
against O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
. O

5 O
min O
) O
, O
the O
folding O
of O
E1 O
occurs O
slowly O
( O
30 O
min O
) O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
infection O
and O
spread O
in O
vivo O
are O
dependent O
upon O
coinfection O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
and O
dual O
HDV O
/ O
HBV O
infection O
is O
frequently O
more O
severe O
than O
HBV O
infection O
alone O
, O
raising O
the O
possibility O
that O
HDV O
infection O
may O
be O
deleterious O
to O
cells O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
mutants O
with O
core B
internal I
deletions I
( I
CID I
) I
occur O
naturally O
in O
chronically O
WHV O
- O
infected O
woodchucks O
, O
as O
do O
hepatitis O
B O
virus O
mutants O
in O
humans O
. O

Consistent O
with O
previous O
results O
, O
WHV O
CID O
mutants O
from O
both O
animals O
had O
deletions O
of O
variable O
lengths O
( O
90 O
to O
135 O
bp O
) O
within O
the O
middle O
of O
the O
WHV O
core O
gene O
. O

Although O
WHV O
CID O
mutants O
were O
predominant O
in O
fractions O
of O
cellular O
WHV O
replicative O
intermediates O
, O
mutant O
covalently B
closed I
circular I
DNAs I
( I
cccDNAs I
) I
appeared O
to O
be O
a O
small O
part O
of O
cccDNA O
- O
enriched O
fractions O
. O

They O
developed O
anti B
- I
WHV I
core I
antigen I
( I
WHcAg I
) I
antibody O
, O
lymphoproliferative O
response O
to O
WHcAg O
, O
and O
anti O
- O
WHV O
surface O
antigen O
. O

Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
one O
of O
the O
major O
etiological O
factors O
in O
the O
development O
of O
human O
hepatocellular O
carcinoma O
. O

Transgenic O
mice O
that O
express O
the O
HBV B
X I
protein I
( I
HBx I
) I
have O
previously O
been O
shown O
to O
be O
more O
sensitive O
to O
the O
effects O
of O
hepatocarcinogens O
. O

To O
investigate O
these O
possibilities O
in O
vivo O
, O
we O
treated O
double O
- O
transgenic O
mice O
that O
both O
express O
HBx O
( O
ATX O
mice O
) O
and O
possess O
a O
bacteriophage O
lambda O
transgene O
with O
the O
hepatocarcinogen O
diethylnitrosamine B
( I
DEN I
) I
. O

Treatment O
of O
mice O
with O
DEN O
resulted O
in O
a O
six O
- O
to O
eightfold O
increase O
in O
the O
mutation B
frequency I
( I
MF I
) I
, O
as O
measured O
by O
a O
functional O
analysis O
of O
the O
lambda O
transgene O
. O

re O
recent O
identification O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
epitopes O
restricted O
by O
multiple O
HLA O
alleles O
has O
greatly O
expanded O
the O
epitope O
repertoire O
available O
for O
T O
- O
cell O
- O
mediated O
therapeutic O
vaccine O
development O
. O

The O
small B
envelope I
protein I
of I
hepatitis I
B I
virus I
( I
HBsAg I
- I
S I
) I
can O
self O
- O
assemble O
into O
highly O
organized O
virus O
like O
particles O
( O
VLPs O
) O
and O
induce O
an O
effective O
immune O
response O
. O

In O
this O
study O
, O
a O
restriction O
enzyme O
site O
was O
engineered O
into O
the O
cDNA O
of O
HBsAg O
- O
S O
at O
a O
position O
corresponding O
to O
the O
exposed O
site O
within O
the O
hydrophilic O
a O
determinant O
region O
( O
amino O
acid O
[ O
aa O
] O
127 O
- O
128 O
) O
to O
create O
a O
novel O
HBsAg O
vaccine O
vector O
allowing O
surface O
orientation O
of O
the O
inserted O
sequence O
. O

We O
inserted O
sequences O
of O
various O
lengths O
from O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
protein O
containing O
immunodominant O
epitopes O
and O
demonstrated O
secretion O
of O
the O
recombinant O
HBsAg O
VLPs O
from O
transfected O
mammalian O
cells O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
major O
human O
pathogen O
in O
the O
developing O
world O
. O

The O
C O
- O
terminal O
half O
of O
pORF3 O
is O
rich O
in O
proline O
residues O
and O
contains O
a O
putative O
Src B
homology I
3 I
( I
SH3 I
) I
binding O
domain O
and O
a O
mitogen O
- O
activated O
protein O
kinase O
phosphorylation O
site O
. O

We O
had O
previously O
shown O
that O
overexpression O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
led O
to O
selective O
downregulation O
of O
MxA O
gene O
expression O
, O
suggesting O
a O
mechanism O
by O
which O
the O
virus O
escapes O
from O
the O
host O
defense O
system O
( O
O O
. O

Viral O
protein O
secretion O
was O
profoundly O
reduced O
in O
MxA O
- O
expressing O
clones O
by O
80 O
% O
for O
HBV B
surface I
antigen I
( I
HBsAg I
) I
and O
70 O
% O
for O
HBV B
e I
antigen I
( I
HBeAg I
) I
. O

Indeed O
, O
using O
the O
well O
- O
characterized O
posttranscriptional B
regulation I
element I
( I
PRE I
) I
reporter O
system O
, O
we O
were O
able O
to O
demonstrate O
a O
marked O
reduction O
( O
three O
- O
to O
eightfold O
) O
in O
the O
nucleocytoplasmic O
export O
of O
unspliced O
RNA O
in O
MxA O
- O
expressing O
clones O
. O

The O
role O
of O
hepatocyte O
nuclear O
factor O
lot O
( O
HNF1 O
alpha O
) O
in O
the O
regulation O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
in O
vivo O
was O
investigated O
using O
a O
HNF1 O
alpha O
- O
null O
HBV O
transgenic O
mouse O
model O
. O

The O
increase O
in O
encapsidated O
cytoplasmic O
replication O
intermediates O
in O
HNF1 O
- O
null O
HBV O
transgenic O
mice O
was O
associated O
with O
the O
appearance O
of O
nonencapsidated O
nuclear O
covalently B
closed I
circular I
( I
CCC I
) I
viral O
genomic O
DNA O
. O

Four O
hepatitis O
C O
virus O
genome O
regions O
( O
the O
core O
, O
E1 O
, O
HVR1 O
, O
and O
NS5b O
) O
were O
amplified O
and O
sequenced O
from O
yearly O
samples O
obtained O
from O
a O
chronically O
infected O
chimpanzee O
over O
a O
rt O
- O
year O
span O
. O

120 O
x O
10 O
( O
- O
3 O
) O
, O
while O
phylogenetic O
ancestral O
comparison O
using O
the O
12 O
yearly O
sequences O
showed O
a O
rate O
of O
0 O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
, O
the O
causative O
agent O
of O
B O
- O
type O
hepatitis O
in O
humans O
, O
is O
a O
hepatotropic O
DNA O
- O
containing O
virus O
that O
replicates O
via O
reverse O
transcription O
. O

Some O
evidence O
suggests O
that O
tree O
shrews O
( O
tupaias O
) O
may O
be O
susceptible O
to O
infection O
with O
human O
HBV O
, O
albeit O
with O
low O
efficiency O
. O

Broadly O
directed O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
have O
been O
identified O
from O
liver O
- O
infiltrating O
lymphocytes O
but O
have O
been O
more O
difficult O
to O
assess O
in O
peripheral O
blood O
of O
infected O
persons O
. O

To O
enhance O
the O
detection O
of O
CTL O
from O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
we O
cocultured O
PBMC O
with O
autologous O
Epstein O
- O
Barr O
virus O
- O
transformed O
B O
- O
lymphoblastoid O
cell O
lines O
that O
had O
been O
infected O
with O
recombinant O
vaccinia O
virus O
constructs O
so O
that O
they O
expressed O
the O
entire O
translated O
polyprotein O
of O
HCV O
- O
H O
, O
a O
type O
1a O
strain O
. O

Subgenomic O
selectable O
RNAs O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
recently O
been O
shown O
to O
self O
- O
replicate O
to O
high O
levels O
in O
the O
human O
hepatoma O
cell O
line O
Huh O
- O
7 O
( O
V O
. O

Half O
- O
lives O
( O
t O
( O
1 O
/ O
2 O
) O
s O
) O
of O
mature O
proteins O
ranged O
from O
10 O
to O
16 O
h O
, O
with O
the O
exception O
of O
the O
hyperphosphorylated O
form O
of O
NS5A O
, O
which O
was O
less O
stable O
( O
t O
( O
1 O
/ O
2 O
) O
, O
similar O
to7 O
h O
) O
. O

Double O
- O
stranded O
- O
RNA O
( O
dsRNA O
) O
- O
dependent O
protein O
kinase O
PKR O
is O
induced O
by O
interferon O
and O
activated O
upon O
autophosphorylation O
. O

Eight O
amino O
acids O
, O
including O
these O
autophosphorylation O
sites O
, O
are O
duplicated O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
protein O
E2 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
causes O
acute O
and O
often O
also O
chronic O
liver O
disease O
. O

Four O
differentially O
expressed O
genes O
were O
found O
: O
( O
i O
) O
the O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
inducible O
chemokine O
IP O
- O
10 O
gene O
; O
( O
ii O
) O
the O
IFN O
- O
alpha O
/ O
beta O
- O
inducible O
antiviral O
MxA O
gene O
; O
( O
iii O
) O
the O
gene O
encoding O
IFN O
- O
alpha O
/ O
beta O
- O
inducible O
p44 O
, O
shown O
to O
be O
associated O
with O
ultrastructural O
cytoplasmic O
entities O
within O
hepatocytes O
of O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
- O
infected O
chimpanzees O
; O
and O
( O
iv O
) O
the O
gene O
encoding O
IFN O
- O
alpha O
/ O
beta O
/ O
gamma O
- O
inducible O
IFI O
- O
56K O
, O
a O
protein O
recently O
shown O
to O
interact O
with O
the O
eukaryotic O
translation O
initiation O
factor O
eIF O
- O
3 O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
and O
human O
hepatitis O
B O
virus O
are O
closely O
related O
, O
highly O
hepatotropic O
mammalian O
DNA O
viruses O
that O
also O
replicate O
in O
the O
lymphatic O
system O
. O

Applying O
PCR O
- O
based O
assays O
discriminating O
between O
the O
total O
pool O
of O
WHV O
genomes O
and O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
combined O
with O
enzymatic O
elimination O
of O
extracellular O
viral O
sequences O
potentially O
associated O
with O
the O
cell O
surface O
, O
our O
study O
documents O
that O
virus O
replicating O
in O
woodchuck O
lymphoid O
cells O
is O
infectious O
to O
homologous O
hepatocytes O
and O
lymphoid O
cells O
in O
vitro O
. O

The O
data O
also O
revealed O
that O
WHV O
from O
lymphoid O
cells O
can O
initiate O
classical O
acute O
viral O
hepatitis O
in O
susceptible O
animals O
, O
albeit O
small O
quantities O
( O
similar O
to O
10 O
( O
3 O
) O
virions O
) O
caused O
immunovirologically O
undetectable O
( O
occult O
) O
WHV O
infection O
that O
engaged O
the O
lymphatic O
system O
but O
not O
the O
liver O
. O

In O
this O
study O
, O
we O
analyze O
the O
signals O
determining O
capsid O
compartmentalization O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
animal O
model O
, O
as O
this O
system O
also O
allows O
us O
to O
study O
hepadnavirus O
infection O
of O
cultured O
primary O
hepatocytes O
. O

Using O
fusions O
to O
the O
green O
fluorescent O
protein O
as O
a O
functional O
assay O
, O
we O
have O
identified O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
that O
mediates O
nuclear O
pore O
association O
of O
the O
DHBV O
nucleocapsid O
and O
nuclear O
import O
of O
DHBV B
core I
protein I
( I
DHBc I
) I
derived O
polypeptides O
. O

Previously O
we O
showed O
that O
CD4 O
( O
+ O
) O
T O
cells O
play O
an O
essential O
role O
in O
keeping O
persistent O
retrovirus O
in O
check O
, O
The O
present O
in O
vitro O
experiments O
with O
a O
Friend O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clone O
revealed O
that O
these O
cells O
produce O
gamma O
interferon O
( O
IPN O
- O
gamma O
) O
, O
which O
acts O
with O
two O
distinct O
mechanisms O
of O
antiviral O
activity O
. O

The O
second O
mechanism O
of O
IFN O
- O
gamma O
- O
mediated O
antiviral O
activity O
was O
an O
enhancement O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
cytolytic O
activity O
. O

Entry O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
initiated O
by O
specific O
interaction O
of O
its O
large O
envelope O
protein O
( O
L O
) O
with O
a O
cellular O
entry O
receptor O
, O
recently O
identified O
as O
carboxypeptidase O
D O
( O
CPD O
; O
historically O
gp180 O
) O
. O

In O
this O
report O
, O
we O
present O
evidence O
demonstrating O
that O
this O
receptor O
is O
down O
- O
regulated O
as O
a O
result O
of O
DHBV O
infection O
: O
( O
i O
) O
receptor O
levels O
determined O
by O
Western O
blot O
were O
much O
reduced O
in O
DHBV O
- O
infected O
duck O
livers O
and O
undetectable O
by O
immunostaining O
in O
infected O
cultured O
hepatocytes O
; O
( O
ii O
) O
results O
from O
metabolic O
labeling O
experiments O
indicate O
enhanced O
receptor O
protein O
turnover O
; O
( O
iii O
) O
the O
kinetics O
of O
receptor O
loss O
from O
newly O
infected O
cells O
correlated O
with O
the O
accumulation O
of O
newly O
synthesized O
viral O
protein O
; O
( O
iv O
) O
expression O
of O
DHBV O
L O
protein O
, O
transduced O
from O
a O
recombinant O
adenovirus O
, O
was O
sufficient O
to O
eliminate O
gp180 O
/ O
CPD O
from O
the O
Golgi O
compartment O
, O
its O
normal O
predominant O
location O
; O
( O
v O
) O
gp180 O
/ O
CPD O
remained O
absent O
from O
the O
Golgi O
compartment O
in O
infected O
hepatocytes O
, O
even O
after O
overexpression O
from O
a O
recombinant O
adenovirus O
, O
while O
residual O
amounts O
subsequently O
became O
detectable O
in O
a O
perinuclear O
compartment O
, O
containing O
DHBV O
L O
protein O
; O
( O
vi O
) O
expression O
of O
DHBV O
L O
protein O
in O
a O
HepG2 O
cell O
line O
, O
stably O
expressing O
gp180 O
/ O
CPD O
, O
leads O
to O
incomplete O
receptor O
maturation O
and O
induces O
its O
degradation O
. O

Duck O
hepatitis O
B O
viruses O
( O
DHBV O
) O
, O
unlike O
mammalian O
hepadnaviruses O
, O
are O
thought O
to O
lack O
X O
genes O
, O
which O
encode O
transcription O
- O
regulatory O
proteins O
believed O
to O
contribute O
to O
the O
development O
of O
hepatocellular O
carcinoma O
. O

Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
promotes O
a O
high O
level O
of O
liver O
disease O
and O
cancer O
in O
humans O
. O

HBx O
stimulates O
cytoplasmic O
signal O
transduction O
pathways O
, O
moderately O
stimulates O
a O
number O
of O
transcription O
factors O
, O
including O
several O
nuclear O
factors O
, O
and O
in O
certain O
settings O
sensitizes O
cells O
to O
apoptosis O
by O
proapoptotic O
stimuli O
, O
including O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
etopocide O
. O

Viral O
RNAs O
, O
including O
the O
pregenome O
, O
are O
transcribed O
from O
a O
covalently B
closed I
circular I
( I
CCC I
) I
viral O
DNA O
that O
is O
found O
in O
the O
nucleus O
. O

Thus O
, O
during O
antiviral O
therapy O
, O
the O
rates O
of O
loss O
of O
cccDNA O
, O
infected O
hepatocytes O
( O
1 O
or O
more O
molecules O
of O
cccDNA O
) O
, O
and O
replicating O
DNAs O
may O
be O
quite O
different O
. O

In O
the O
present O
study O
, O
we O
asked O
how O
these O
losses O
compared O
when O
woodchucks O
chronically O
infected O
with O
woodchuck O
hepatitis O
virus O
were O
treated O
with O
L O
- O
FMAU O
[ O
1 O
- O
( O
2 O
- O
fluoro O
- O
5 O
- O
methyl O
- O
beta O
- O
L O
- O
arabinofuranosyl O
) O
uracil O
] O
, O
an O
inhibitor O
of O
viral O
DNA O
synthesis O
. O

Most O
patients O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
become O
chronic O
carriers O
. O

Given O
that O
T O
- O
cell O
growth O
and O
differentiation O
require O
the O
cytokine O
interleukin B
2 I
( I
IL I
- I
2 I
) I
, O
we O
asked O
whether O
HCV O
might O
modulate O
synthesis O
of O
IL O
- O
2 O
. O

Activation O
was O
dependent O
on O
nuclear B
factor I
of I
activated I
T I
cells I
( I
NFAT I
) I
, O
occurred O
in O
cells O
deficient O
in O
the O
tyrosine O
kinase O
p56 O
( O
lck O
) O
, O
and O
could O
be O
blocked O
by O
addition O
of O
cyclosporin O
A O
and O
by O
depletion O
of O
calcium O
. O

The O
core O
of O
the O
VP O
- O
1 O
and O
VP O
- O
2 O
proteins O
forming O
the O
T O
= O
1 O
icosahedral O
capsid O
of O
the O
prototype O
strain O
of O
the O
parvovirus B
minute I
virus I
of I
mice I
( I
MVMp I
) I
share O
amino O
acids O
sequence O
and O
a O
common O
three O
- O
dimensional O
structure O
; O
however O
, O
the O
roles O
of O
these O
polypeptides O
in O
the O
virus O
infection O
cycle O
differ O
. O

Chromatographic O
analysis O
of O
purified O
wild B
- I
type I
( I
WT I
) I
and O
mutant O
peptide O
B O
digested O
with O
a O
panel O
of O
specific O
proteases O
allowed O
us O
to O
identify O
the O
VP O
- O
2 O
residues O
Ser O
- O
2 O
, O
Ser O
- O
6 O
, O
and O
Ser O
- O
10 O
as O
the O
main O
phosphate O
acceptors O
for O
MVMp O
capsid O
during O
the O
natural O
viral O
infection O
. O

Reverse O
transcription O
in O
hepatitis O
B O
viruses O
is O
initiated O
through O
a O
unique O
protein O
priming O
mechanism O
whereby O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
first O
assembles O
into O
a O
ribonucleoprotein B
( I
RNP I
) I
complex O
with O
its O
RNA O
template O
and O
then O
initiates O
DNA O
synthesis O
de O
novo O
using O
the O
RT O
itself O
as O
a O
protein O
primer O
. O

RNP O
formation O
and O
protein O
priming O
require O
the O
assistance O
of O
host O
cell O
factors O
, O
including O
the O
molecular O
chaperone O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
. O

Our O
results O
show O
that O
( O
i O
) O
Hsp90 O
recognizes O
two O
independent O
domains O
of O
the O
RT O
, O
both O
of O
which O
are O
necessary O
for O
RNP O
formation O
and O
protein O
priming O
; O
( O
ii O
) O
Hsp90 O
function O
is O
required O
not O
only O
to O
establish O
, O
but O
also O
to O
maintain O
, O
the O
RT O
in O
a O
state O
competent O
for O
RNA O
binding O
; O
and O
( O
iii O
) O
Hsp90 O
is O
not O
required O
during O
RT O
synthesis O
and O
can O
activate O
the O
RT O
posttranslationally O
. O

Using O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
and O
a O
flotation O
assay O
, O
we O
found O
about O
half O
of O
the O
intracellular O
capsids O
to O
be O
membrane O
associated O
due O
to O
an O
intrinsic O
membrane O
- O
binding O
affinity O
. O

Previous O
mutagenesis O
studies O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
suggest O
that O
continued O
interactions O
with O
core O
are O
required O
for O
several O
steps O
in O
genomic O
replication O
. O

To O
examine O
core O
- O
polymerase O
( O
Pot O
) O
interactions O
, O
insect O
cells O
were O
coinfected O
with O
baculovirus O
constructs O
that O
independently O
expressed O
core O
and O
Pot O
. O

The O
results O
demonstrated O
several O
features O
with O
implications O
that O
core O
plays O
an O
interactive O
role O
with O
HBV O
Pot O
: O
( O
i O
) O
core O
coprecipitated O
with O
constructs O
expressing O
full O
- O
length O
Pol O
as O
well O
as O
the O
terminal B
protein I
( I
TP I
) I
, O
reverse B
transcriptase I
( I
RT I
) I
and O
RNase O
H O
domains O
of O
Pot O
, O
independently O
; O
( O
ii O
) O
coprecipitation O
of O
core O
was O
not O
dependent O
on O
the O
presence O
of O
an O
epsilon O
stem O
- O
loop O
sequence O
; O
and O
( O
iii O
) O
core O
- O
Pol O
complexes O
migrated O
as O
intact O
capsid O
particles O
, O
as O
detected O
by O
sucrose O
gradient O
analysis O
. O

We O
describe O
an O
improved O
genetic O
immunization O
strategy O
for O
eliciting O
a O
full O
spectrum O
of O
anti O
- O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
2 O
( O
E2 O
) O
glycoprotein O
responses O
in O
mammals O
through O
electrical B
gene I
transfer I
( I
EGT I
) I
of O
plasmid O
DNA O
into O
muscle O
fibers O
. O

Intramuscular O
injection O
of O
a O
plasmid O
encoding O
a O
cross O
- O
reactive O
hypervariable B
region I
1 I
( I
HVR1 I
) I
peptide O
mimic O
fused O
at O
the O
N O
terminus O
of O
the O
E2 O
ectodomain O
, O
followed O
by O
electrical O
stimulation O
treatment O
in O
the O
form O
of O
high O
- O
frequency O
, O
low O
- O
voltage O
electric O
pulses O
, O
induced O
more O
than O
10 O
- O
fold O
- O
higher O
expression O
levels O
in O
the O
transfected O
mouse O
tissue O
. O

The O
EGT O
- O
mediated O
enhancement O
of O
Immoral O
and O
cellular O
immunity O
is O
antigen O
independent O
, O
since O
comparable O
increases O
in O
antibody O
response O
against O
ciliary O
neurotrophic O
factor O
or O
in O
specific O
anti O
- O
human O
immunodeficiency O
virus O
type O
1 O
gag O
CD8 O
( O
+ O
) O
T O
cells O
were O
obtained O
in O
rats O
and O
mice O
. O

Using O
woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
we O
investigated O
the O
consequences O
of O
combining O
lamivudine O
treatment O
with O
immunotherapy O
mediated O
by O
an O
adenovirus O
superinfection O
. O

Eight O
infected O
woodchucks O
were O
treated O
with O
lamivudine O
and O
four O
were O
infected O
with O
similar O
to O
10 O
( O
13 O
) O
particles O
of O
an O
adenovirus O
type O
5 O
vector O
expressing O
beta O
- O
galactosidase O
. O

At O
the O
same O
time O
, O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
and O
viral O
mRNA O
levels O
both O
declined O
about O
two O
- O
to O
threefold O
in O
those O
woodchucks O
, O
while O
mRNA O
levels O
for O
gamma O
interferon O
and O
tumor O
necrosis O
factor O
alpha O
as O
well O
as O
for O
the O
T O
- O
cell O
markers O
CD4 O
and O
CD8 O
were O
elevated O
about O
twofold O
. O

GB O
virus O
- O
B O
( O
GBV O
- O
B O
) O
causes O
an O
acute O
hepatitis O
in O
tamarins O
characterized O
by O
increased O
alanine O
transaminase O
levels O
that O
quickly O
return O
to O
normal O
as O
the O
virus O
is O
cleared O
. O

Phylogenetically O
, O
GBV O
- O
B O
is O
the O
closest O
relative O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
and O
thus O
GBV O
- O
B O
infection O
of O
tamarins O
represents O
a O
powerful O
surrogate O
model O
system O
for O
the O
study O
of O
HCV O
. O

In O
this O
study O
, O
the O
course O
of O
infection O
of O
GBV O
- O
B O
in O
tamarins O
was O
followed O
using O
a O
real O
- O
time O
5 O
' O
exonuclease O
( O
TaqMan O
) O
reverse O
transcription O
- O
PCR O
assay O
to O
determine O
the O
level O
of O
GBV O
- O
B O
in O
the O
serum O
. O

Peak O
viremia O
levels O
exceeded O
10 O
( O
9 O
) O
genome O
equivalents O
/ O
ml O
, O
followed O
by O
viral O
clearance O
within O
14 O
to O
16 O
weeks O
. O

In O
vitro O
infection O
of O
normal O
hepatocytes O
resulted O
in O
rapid O
amplification O
of O
cell O
- O
associated O
viral O
RNA O
and O
secretion O
of O
up O
to O
10 O
( O
7 O
) O
genome O
equivalents O
/ O
ml O
of O
culture O
supernatant O
. O

The O
intrinsic O
variability O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
proteins O
El O
and O
E2 O
complicates O
the O
identification O
of O
protective O
antibodies O
. O

These O
proteins O
were O
then O
used O
to O
characterize O
10 O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
produced O
from O
peripheral O
B O
cells O
isolated O
from O
an O
individual O
infected O
with O
HCV O
genotype O
Ib O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
internal I
ribosome I
entry I
site I
( I
IRES I
) I
is O
a O
highly O
structured O
RNA O
element O
that O
directs O
cap O
- O
independent O
translation O
of O
the O
viral O
polyprotein O
. O

Mutagenesis O
studies O
of O
this O
region O
showed O
that O
the O
GGG O
triplet O
( O
nucleotides O
266 O
through O
268 O
) O
of O
the O
hexanucleotide O
apical O
loop O
of O
stem O
loop O
Ind O
is O
essential O
for O
IRES O
activity O
both O
in O
vitro O
and O
in O
vivo O
. O

Sequence O
comparison O
showed O
that O
apical O
loop O
nucleotides O
( O
UUGGGU O
) O
were O
absolutely O
conserved O
across O
HCV O
genotypes O
and O
the O
GGG O
triplet O
was O
strongly O
conserved O
among O
related O
Flavivirus O
and O
Pestivirus O
nontranslated O
regions O
. O

Chimeric O
IRES O
elements O
with O
IIId O
derived O
from O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
in O
the O
context O
of O
the O
HCV O
IRES O
possess O
translational O
activity O
. O

The O
carboxy O
- O
terminal O
region O
of O
the O
rabbit O
hemorrhagic O
disease O
virus O
p37 O
polyprotein O
cleavage O
product O
has O
been O
expressed O
in O
Escherichia O
coli O
as O
a O
glutathione B
S I
- I
transferase I
( I
GST I
) I
fusion O
protein O
. O

Site O
directed O
mutagenesis O
studies O
of O
the O
conserved O
residues O
G O
( O
522 O
) O
and O
T O
- O
529 O
in O
motif O
A O
, O
D O
- O
566 O
and O
E O
- O
567 O
in O
motif O
B O
, O
and O
K O
- O
600 O
in O
motif O
C O
were O
also O
performed O
. O

Human O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
natural O
subviral O
agent O
that O
uses O
hepatitis O
B O
virus O
as O
a O
helper O
. O

Three O
strategies O
were O
used O
to O
reduce O
such O
killing O
: O
( O
i O
) O
the O
delta O
protein O
was O
expressed O
from O
a O
separate O
expression O
vector O
, O
the O
amount O
of O
which O
was O
then O
reduced O
as O
much O
as O
33 O
- O
fold O
; O
( O
ii O
) O
the O
protein O
was O
expressed O
transiently O
, O
using O
a O
promoter O
under O
tetracycline O
control O
; O
and O
( O
iii O
) O
the O
transfected O
cells O
were O
treated O
with O
Z O
- O
VAD O
- O
fmk O
, O
a O
broad O
- O
spectrum O
caspase O
inhibitor O
, O
which O
reduced O
cell O
killing O
. O

Accurate O
translocation O
of O
the O
polymerase O
- O
linked O
oligomer O
to O
the O
acceptor O
site O
( O
DR1 O
* O
) O
in O
reverse O
transcription O
is O
crucial O
for O
maintaining O
the O
correct O
size O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
, O
Various O
sizes O
of O
foreign O
sequences O
were O
inserted O
at O
different O
sites O
of O
the O
HBV O
genome O
, O
and O
their O
effects O
on O
accurate O
translocation O
of O
polymerase O
- O
linked O
oligomer O
to O
DR1 O
* O
were O
tested O
. O

Three O
types O
of O
replicate O
DNA O
products O
were O
observed O
in O
these O
insertion O
mutants O
: O
RC O
( O
relaxed O
circle O
) O
and O
type O
I O
and O
type O
II O
DL O
( O
duplex O
linear O
) O
DNA O
. O

Our O
results O
indicated O
that O
the O
minus O
strand O
of O
RC O
and O
type O
I O
DL O
form O
was O
elongated O
from O
DR1 O
* O
, O
while O
the O
minus O
strand O
of O
the O
type O
II O
DL O
form O
was O
elongated O
from O
multiple O
internal O
acceptor O
sites O
( O
WS O
) O
, O
such O
as O
IAS2 O
, O
These O
IASs O
were O
also O
found O
to O
be O
used O
by O
wild O
- O
type O
HBV O
but O
with O
a O
very O
low O
frequency O
. O

equine B
arteritis I
virus I
( I
EAV I
) I
, O
the O
prototype O
arterivirus O
, O
is O
an O
enveloped O
plus O
- O
strand O
RNA O
virus O
with O
a O
genome O
of O
approximately O
13 O
kb O
. O

Previously O
, O
we O
reported O
the O
construction O
of O
pEDI O
, O
a O
full O
- O
length O
cDNA O
copy O
of O
EAV O
DI O
- O
b O
, O
a O
natural O
Defective B
interfering I
( I
DI I
) I
RNA O
of O
5 O
. O

As O
a O
result O
, O
EDI B
RNA I
contains I
a I
truncated I
replicase I
open I
reading I
frame I
( I
EDI I
- I
ORF I
) I
and O
encodes O
a O
truncated O
replicase O
polyprotein O
. O

The O
functional O
significance O
of O
naturally O
occurring O
variants O
of O
human O
hepatitis O
B O
virus O
( O
HEV O
) O
remains O
largely O
unkown O
. O

Previously O
, O
we O
reported O
an O
immature O
secretion O
phenotype O
caused O
by O
a O
highly O
frequent O
mutation O
at O
amino O
acid O
97 O
of O
the O
HBV O
core O
( O
capsid O
) O
protein O
( O
HBcAg O
) O
, O
This O
phenotype O
is O
characterized O
by O
a O
nonselective O
and O
excessive O
secretion O
of O
virions O
containing O
an O
immature O
genome O
of O
single O
- O
stranded O
viral O
DNA O
, O
To O
extend O
our O
study O
of O
virion O
secretion O
to O
other O
naturally O
occurring O
variants O
, O
we O
have O
characterized O
mutations O
at O
HBcAg O
codons O
5 O
, O
38 O
, O
and O
60 O
via O
site O
- O
directed O
mutagenesis O
. O

in O
the O
replication O
cycle O
of O
hepadnavirus O
DNA O
, O
the O
double O
- O
stranded O
linear O
form O
of O
viral O
DNA O
is O
generated O
as O
a O
minor O
replicative O
intermediate O
, O
which O
is O
efficiently O
converted O
to O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
by O
intramolecular O
recombination O
( O
W O
. O

We O
previously O
found O
a O
binding O
site O
of O
transcription O
factor O
Yin B
and I
Yang I
1 I
( I
YY1 I
) I
in O
one O
terminal O
region O
of O
the O
double O
- O
stranded O
linear O
replicative O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
( O
M O
. O

In O
this O
study O
, O
we O
established O
an O
HBV O
- O
producing O
system O
in O
which O
the O
cccDNA O
appeared O
to O
be O
generated O
from O
the O
transfected O
linear O
DNA O
or O
the O
linear O
replicative O
DNA O
by O
nonhomologous B
end I
joining I
( I
NHEJ I
) I
or O
by O
both O
NHEJ O
and O
homologous O
recombination O
between O
terminally O
repeated O
sequences O
, O
respectively O
. O

The O
nonstructural B
protein I
3 I
( I
NS3 I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
protease O
, O
nucleoside O
triphosphatase O
, O
and O
helicase O
activities O
. O

UV O
cross O
- O
linking O
experiments O
indicate O
that O
the O
lysine O
residue O
in O
the O
AX O
( O
4 O
) O
GKS O
motif O
is O
directly O
involved O
in O
ATP O
binding O
, O
whereas O
the O
NS3 O
( O
GR1490DT O
) O
mutant O
in O
which O
the O
arginine O
- O
rich O
motif O
( O
1486 O
- O
QRRGRTGR O
- O
1493 O
) O
was O
changed O
to O
QRRDTTGR O
bound O
ATP O
as O
well O
as O
the O
wild O
type O
. O

The O
binding O
activity O
of O
HCV O
NS3 O
helicase O
to O
the O
viral O
RNA O
was O
drastically O
reduced O
with O
the O
mutation O
at O
Arg1488 O
( O
R1488A O
) O
and O
was O
also O
affected O
by O
the O
K1236E O
substitution O
in O
the O
AX O
( O
4 O
) O
GKS O
motif O
and O
the O
R1490A O
and O
GR1490DT O
mutations O
in O
the O
arginine O
- O
rich O
motif O
. O

Following O
antigen O
recognition O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
induce O
a O
necroinflammatory O
liver O
disease O
in O
HBV O
- O
transgenic O
mice O
. O

Antibody O
to O
the O
capsid O
( O
PORF2 O
) O
protein O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
sufficient O
to O
confer O
immunity O
, O
but O
knowledge O
of O
B O
- O
cell O
epitopes O
in O
the O
intact O
capsid O
is O
limited O
. O

A O
panel O
of O
murine B
monoclonal I
antibodies I
( I
MAbs I
) I
was O
generated O
following O
immunization O
with O
recombinant O
ORF2 O
. O

1 O
protein O
, O
representing O
the O
C O
- O
terminal O
267 O
amino B
acids I
( I
aa I
) I
of O
the O
660 O
- O
aa O
capsid O
protein O
. O

1 O
protein O
expressed O
in O
Escherichia O
coli O
and O
the O
virus B
- I
like I
particles I
( I
VLPs I
) I
expressed O
using O
the O
baculovirus O
system O
were O
examined O
by O
competitive O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISAs I
) I
using O
five O
of O
these O
MAbs O
and O
HEV O
patient O
sera O
. O

The O
nonencapsidated O
reverse O
transcriptase O
is O
bound O
to O
a O
large O
cellular O
cytoplasmic O
structure O
( O
s O
) O
in O
a O
detergent O
- O
sensitive O
complex O
. O

The O
effects O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
on O
several O
signal O
transduction O
pathways O
in O
human O
nonneoplastic O
hepatocyte O
PH5CH8 O
cells O
were O
investigated O
using O
expression O
vectors O
encoding O
HCV O
proteins O
derived O
from O
HCV O
- O
infected O
human O
nonneoplastic O
cultured O
T O
- O
lymphocyte O
and O
hepatocyte O
cells O
( O
MT O
- O
2C O
and O
PH5CH7 O
) O
, O
which O
could O
support O
HCV O
replication O
. O

During O
the O
course O
of O
the O
study O
, O
we O
found O
that O
HCV O
core O
protein O
specifically O
activated O
the O
40 O
/ O
46 O
- O
kDa O
2 B
' I
- I
5 I
' I
- I
oligoadenylate I
synthetase I
( I
2 I
' I
- I
5 I
' I
- I
OAS I
) I
gene O
promoter O
in O
a O
dose O
dependent O
manner O
in O
different O
human O
hepatocyte O
cell O
lines O
( O
PH5CH8 O
, O
HepG2 O
, O
and O
PLC O
/ O
PRF O
/ O
5 O
) O
. O

Chronicity O
after O
infection O
with O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
can O
occur O
for O
a O
variety O
of O
reasons O
. O

To O
examine O
the O
characteristics O
of O
T O
cells O
capable O
of O
coexisting O
with O
the O
secreted O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
, O
T B
- I
cell I
receptor I
( I
TCR I
) I
transgenic I
( I
Tg I
) I
mice O
were O
produced O
. O

A O
TCR O
- O
Tg O
lineage O
( O
11 O
/ O
4 O
- O
12 O
) O
was O
produced O
that O
possessed O
a O
high O
frequency O
( O
similar O
to O
67 O
% O
) O
of O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
a O
Tg O
TCR O
specific O
for O
the O
HBeAg O
. O

As O
predicted O
, O
when O
11 O
/ O
4 O
- O
12 O
TCR O
- O
Tg O
mice O
were O
bred O
with O
HBeAg O
- O
Tg O
mice O
no O
deletion O
of O
the O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
occurred O
in O
the O
thymus O
or O
the O
spleen O
. O

Functional O
analysis O
of O
the O
TCR O
- O
Tg O
T O
cells O
revealed O
that O
the O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
escaped O
deletion O
in O
the O
thymus O
and O
periphery O
by O
virtue O
of O
low O
avidity O
. O

Therefore O
, O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
that O
can O
survive O
deletion O
or O
anergy O
in O
the O
presence O
of O
circulating O
HBeAg O
nonetheless O
are O
capable O
of O
being O
activated O
and O
of O
mediating O
liver O
injury O
in O
vive O
. O

The O
11 O
/ O
4 O
- O
12 O
TCR O
- O
TO O
lineage O
may O
serve O
as O
a O
monoclonal O
model O
for O
the O
HBe O
/ O
HBcAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
repertoire O
present O
in O
chronically O
infected O
HBV O
patients O
. O

Unique O
to O
pestiviruses O
, O
the O
N O
- O
terminal O
protein O
encoded O
by O
the O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
genome O
is O
a O
cysteine O
protease O
( O
Npro O
) O
responsible O
for O
a O
self O
- O
cleavage O
that O
releases O
the O
N O
terminus O
of O
the O
core O
protein O
( O
C O
) O
. O

To O
develop O
an O
antiviral O
assay O
that O
allows O
the O
assessment O
of O
anti O
- O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
protease O
inhibitors O
, O
a O
chimeric O
BVDV O
in O
which O
the O
coding O
region O
of O
Npro O
was O
replaced O
by O
that O
of O
an O
NS4A O
cofactor O
- O
tethered O
HCV O
NS3 O
protease O
domain O
was O
generated O
. O

Genomic O
RNA O
transcripts O
derived O
from O
both O
chimeric O
clones O
, O
P O
- O
H O
/ O
B O
( O
wild O
- O
type O
HCV O
NS3 O
protease O
) O
and O
P O
- O
H O
/ O
B O
( O
S139A O
) O
( O
mutant O
HCV O
NS3 O
protease O
) O
were O
then O
transfected O
into O
bovine O
cells O
( O
MDBK O
) O
. O

Only O
the O
RNA O
transcripts O
from O
the O
P O
- O
H O
/ O
B O
clone O
yielded O
viable O
viruses O
, O
whereas O
the O
mutant O
clone O
, O
P O
- O
H O
/ O
B O
( O
S139A O
) O
, O
failed O
to O
produce O
any O
signs O
of O
infection O
, O
suggesting O
that O
the O
unprocessed O
fusion O
protein O
rendered O
the O
BVDV O
core O
protein O
defective O
in O
capsid O
assembly O
. O

Like O
the O
wild O
- O
type O
BVDV O
( O
NADL O
) O
, O
the O
chimeric O
virus O
was O
cytopathic O
and O
formed O
plaques O
on O
the O
cell O
monolayer O
. O

Finally O
, O
to O
assess O
the O
genetic O
stability O
of O
the O
chimeric O
virus O
, O
an O
Npro O
- O
null O
BVDV O
( O
BVDV O
- O
Npro O
in O
which O
the O
entire O
Npro O
coding O
region O
was O
deleted O
) O
was O
produced O
. O

Orphan O
nuclear O
receptor O
fetoprotein O
transcription O
factor O
( O
FTF O
) O
was O
previously O
identified O
as O
a O
specific O
regulator O
of O
the O
a O
, O
alpha O
( O
1 O
) O
- O
fetoprotein O
gene O
during O
early O
liver O
development O
and O
in O
response O
to O
hormonal O
signals O
( O
L O
. O

16 O
: O
3853 O
- O
3865 O
, O
1996 O
) O
, O
Here O
we O
report O
a O
functional O
analysis O
of O
FTF O
interactions O
with O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
nucleocapsid O
promoter O
. O

To O
examine O
the O
cell O
fusion O
activity O
: O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
proteins O
( O
E1 O
and O
E2 O
) O
, O
we O
have O
established O
a O
sensitive O
cell O
fusion O
assay O
based O
on O
the O
activation O
of O
a O
reporter O
gene O
as O
described O
previously O
( O
O O
. O

These O
results O
suggest O
( O
i O
) O
that O
bath O
acv O
E1 O
and O
E2 O
proteins O
are O
responsible O
for O
fusion O
with O
the O
endosomal O
membrane O
after O
endocytosis O
and O
( O
ii O
) O
that O
certain O
protein O
molecules O
other O
than O
human O
CD81 O
and O
some O
glycosaminoglycans O
on O
the O
cell O
surface O
are O
also O
involved O
in O
the O
cell O
fusion O
induced O
by O
HCV O
. O

We O
have O
examined O
the O
structure O
and O
Fusion O
potential O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
envelope O
proteins O
bg O
treating O
subviral O
particles O
with O
deforming O
agents O
known O
to O
release O
envelope O
proteins O
of O
viruses O
from O
a O
metastable O
to O
a O
fusion O
- O
active O
state O
. O

Exposure O
of O
DHBV O
particles O
to O
low O
pH O
triggered O
a O
major O
structural O
change O
in O
the O
large O
envelope O
protein O
( O
L O
) O
, O
resulting O
in O
exposure O
of O
trypsin O
sites O
within O
its O
S O
domain O
but O
without O
affecting O
the O
same O
region O
in O
the O
small B
surface I
protein I
( I
S I
) I
subunits O
, O
This O
conformational O
change O
was O
associated O
with O
increased O
hydrophobicity O
of O
the O
particle O
surface O
, O
most O
likely O
arising O
from O
surface O
exposure O
of O
the O
hydrophobic O
first O
transmembrane O
domain O
( O
TM1 O
) O
. O

It O
has O
been O
suggested O
that O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
plays O
a O
role O
in O
the O
incapacitation O
of O
interferon O
by O
inactivation O
of O
RNA O
- O
dependent O
protein O
kinase O
PKR O
. O

Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
one O
of O
the O
major O
etiological O
factors O
in O
the O
development O
of O
human O
hepatocellular O
carcinoma O
. O

Transgenic O
mice O
that O
express O
the O
HBV B
X I
protein I
( I
HBx I
) I
have O
previously O
been O
shown O
to O
be O
more O
sensitive O
to O
the O
effects O
of O
hepatocarcinogens O
, O
although O
the O
mechanism O
for O
this O
cofactor O
role O
remains O
unknown O
. O

In O
the O
present O
study O
, O
primary O
hepatocytes O
isolated O
from O
transgenic O
mice O
that O
possess O
the O
HBV O
X O
gene O
under O
the O
control O
of O
the O
human O
alpha O
- O
1 O
- O
antitrypsin O
regulatory O
region O
( O
ATX O
mice O
) O
were O
found O
to O
be O
deficient O
in O
their O
ability O
to O
conduct O
unscheduled O
DNA O
synthesis O
in O
response O
to O
UV O
- O
induced O
DNA O
damage O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
, O
a O
single O
- O
stranded O
RNA O
virus O
, O
bears O
a O
single O
coding O
region O
whose O
product O
, O
the O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
is O
expressed O
in O
two O
isoforms O
, O
small O
( O
S O
- O
HDAg O
) O
and O
large O
( O
L O
- O
HDAg O
) O
. O

We O
found O
that O
L O
- O
HDAg O
was O
aggregated O
in O
specific O
nuclear O
domains O
and O
that O
over O
half O
of O
these O
domains O
were O
localized O
beside O
nuclear B
domain I
10 I
( I
ND10 I
) I
, O
At O
later O
times O
, O
ND10 O
- O
associated O
proteins O
like O
PML O
were O
found O
in O
larger O
HDAg O
complexes O
that O
had O
developed O
into O
apparently O
hollow O
spheres O
. O

The O
fact O
that O
viral O
components O
specifically O
linked O
to O
repression O
of O
replication O
can O
associate O
with O
one O
of O
the O
ND10 O
- O
associated O
proteins O
( O
PML O
) O
raises O
the O
possibility O
that O
this O
host O
protein O
may O
play O
a O
role O
in O
the O
regulation O
of O
HDV O
RNA O
synthesis O
. O

We O
characterized O
hepatitis B
B I
virus I
( I
HBV I
) I
isolates O
from O
sera O
of O
21 O
hepatitis O
B O
virus O
surface O
antigen O
- O
positive O
apes O
, O
members O
of O
the O
families O
Pongidae O
and O
Hylobatidae O
( O
19 O
gibbon O
spp O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
replicates O
by O
reverse O
transcription O
of O
an O
RNA O
intermediate O
, O
the O
pregenomic O
RNA O
. O

Therefore O
, O
bacterial O
endotoxin O
, O
which O
induces O
the O
secretion O
of O
proinflammatory O
mediators O
in O
the O
liver O
, O
was O
studied O
for O
its O
effect O
on O
hepadnavirus O
infection O
in O
vitro O
using O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
. O

As O
a O
primary O
endotoxin O
target O
, O
hepatic O
nonparenchymal B
cells I
( I
NPC I
) I
contaminating O
primary O
hepa O
tocyte O
cultures O
, O
and O
among O
these O
probably O
macrophages O
( O
Kupffer O
cells O
) O
, O
were O
identified O
to O
secrete O
polypeptide O
mediators O
into O
the O
cell O
culture O
medium O
. O

Finally O
, O
in O
hepatocytes O
infected O
with O
a O
replication O
- O
deficient O
recombinant O
DHBV O
- O
green B
fluorescent I
protein I
( I
GFP I
) I
virus O
, O
the O
endotoxin O
- O
induced O
mediators O
markedly O
reduced O
GFP O
expression O
from O
chimeric O
DHBV O
- O
GFP O
transcripts O
, O
indicating O
that O
the O
major O
effect O
is O
at O
a O
level O
of O
translation O
of O
viral O
RNAs O
, O
Taken O
together O
, O
the O
data O
obtained O
demonstrate O
that O
antiviral O
mediators O
, O
and O
among O
these O
the O
cytokines O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
gamma O
, O
are O
released O
from O
hepatic O
NPC O
, O
most O
probably O
liver O
macrophages O
, O
upon O
endotoxin O
stimulation O
; O
furthermore O
, O
these O
mediators O
act O
at O
a O
posttranscriptional O
step O
of O
hepadnavirus O
replication O
. O

Accumulated O
findings O
have O
indicated O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
integrates O
into O
the O
cellular O
DNA O
of O
HBV O
- O
infected O
chronic O
hepatitis O
tissues O
. O

The O
integrated B
sequence I
( I
IS I
) I
of O
HBV O
DNA O
at O
the O
virus O
- O
cell O
junction O
is O
conserved O
in O
a O
25 O
- O
bp O
region O
which O
is O
adjacent O
to O
direct O
repeat O
1 O
. O

A O
cellular O
protein O
which O
we O
purified O
from O
the O
nuclear O
extract O
of O
HepG2 O
cells O
binds O
to O
the O
IS O
and O
was O
designated O
IS O
binding O
protein O
3 O
( O
ISBP3 O
) O
. O

The O
amino O
acid O
sequence O
of O
ISBP3 O
was O
determined O
and O
found O
to O
be O
identical O
to O
that O
of O
transcription O
initiation O
factor O
Yin B
and I
Yang I
1 I
( I
YY1 I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
of O
genotype O
1 O
is O
the O
most O
resistant O
to O
interferon B
( I
IFN I
) I
therapy O
. O

IFN O
- O
treated O
, O
induced O
UHCV O
cells O
were O
found O
to O
better O
support O
the O
growth O
of O
encephalomyocarditis B
virus I
( I
EMCV I
) I
than O
IFN O
- O
treated O
, O
uninduced O
cells O
. O

The O
nonstructural B
5A I
( I
NS5A I
) I
protein O
of O
HCV O
has O
been O
reported O
to O
inhibit O
PKR O
, O
an O
HFN O
- O
induced O
kinase O
involved O
in O
the O
antiviral O
action O
of O
IFN O
, O
at O
the O
level O
of O
control O
of O
protein O
synthesis O
through O
the O
phosphorylation O
of O
the O
initiation O
factor O
eIF2 O
alpha O
( O
M O
, O
Gale O
, O
Jr O
. O

The O
effect O
of O
expression O
of O
HCV O
proteins O
on O
PKR O
activity O
was O
assayed O
in O
a O
reporter O
assay O
and O
by O
direct O
analysis O
of O
the O
in O
vivo O
phosphorylation O
of O
eIF2 O
alpha O
after O
treatment O
of O
cells O
with O
poly O
( O
I O
) O
- O
poly O
( O
C O
) O
. O

In O
conclusion O
, O
expression O
of O
HCV O
proteins O
in O
their O
biological O
context O
interferes O
with O
the O
development O
of O
the O
antiviral O
action O
of O
IFN O
, O
Although O
the O
possibility O
that O
some O
inhibition O
of O
PKR O
( O
by O
either O
NS5A O
or O
another O
viral O
protein O
) O
occurs O
at O
a O
very O
localized O
level O
cannot O
be O
excluded O
, O
the O
resistance O
to O
IFN O
, O
resulting O
from O
the O
expression O
of O
the O
HCV O
proteins O
, O
cannot O
be O
explained O
solely O
by O
inhibition O
of O
the O
negative O
control O
of O
translation O
by O
PKR O
. O

Recently O
, O
different O
classes O
of O
type O
C O
porcine B
endogenous I
retoviruses I
( I
PERV I
) I
which O
are O
infectious O
for O
human O
cells O
in O
vitro O
have O
been O
partially O
described O
. O

Several O
proviral O
PERV O
sequences O
were O
cloned O
and O
characterized O
, O
One O
molecular O
PERV O
class O
B O
clone O
, O
PERV O
- O
B O
( O
43 O
) O
, O
generated O
infectious O
particles O
after O
transfection O
into O
human O
293 O
cells O
. O

A O
second O
clone O
, O
PERV O
- O
B O
( O
33 O
) O
, O
which O
was O
highly O
homologous O
to O
PERV O
- O
B O
( O
43 O
) O
, O
showed O
a O
G O
- O
to O
- O
ii O
mutation O
in O
the O
first O
start O
codon O
( O
Met O
to O
Ile O
) O
of O
the O
env O
gene O
, O
preventing O
this O
provirus O
from O
replicating O
. O

However O
, O
a O
genetic O
recombinant O
, O
PERV O
- O
B O
( O
33 O
) O
/ O
ATG O
, O
carrying O
a O
restored O
env O
start O
codon O
, O
became O
infectious O
and O
could O
be O
serially O
passaged O
on O
293 O
cells O
similar O
to O
virus O
clone O
PERV O
- O
B O
( O
43 O
) O
, O
PERV O
protein O
expression O
was O
detected O
24 O
to O
48 O
h O
posttransfection O
( O
p O
. O

1 O
kb O
, O
PERV O
- O
B O
( O
33 O
and O
PERV O
- O
B O
( O
43 O
) O
differ O
in O
the O
number O
of O
copies O
of O
a O
39 O
- O
bp O
segment O
in O
the O
U3 O
region O
of O
the O
long O
terminal O
repeat O
. O

We O
have O
previously O
shown O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
is O
abolished O
in O
the O
liver O
of O
HBV O
transgenic O
mice O
by O
stimuli O
that O
induce O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
the O
liver O
. O

The O
present O
study O
was O
done O
to O
identify O
the O
step O
( O
s O
) O
in O
HBV O
replication O
that O
is O
affected O
by O
this O
cytokine O
in O
transgenic O
mice O
treated O
with O
the O
IFN O
- O
alpha O
/ O
beta O
inducer O
polyinosinic O
- O
polycytidylic O
acid O
[ O
poly O
( O
1 O
- O
C O
) O
] O
, O
Here O
we O
show O
that O
the O
pool O
of O
cytoplasmic O
HBV O
pregenomic B
RNA I
( I
pgRNA I
) I
- O
containing O
capsids O
is O
reduced O
10 O
- O
Fold O
within O
9 O
h O
after O
poly O
( O
1 O
- O
C O
) O
administration O
, O
while O
there O
is O
no O
change O
in O
the O
abundance O
of O
HBV O
mRNA O
or O
in O
the O
translational O
status O
of O
cytoplasmic O
HBV O
transcripts O
. O

Infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
was O
detected O
by O
serological O
testing O
for O
HBV O
surface O
antigen O
and O
by O
PCR O
assay O
for O
HBV O
DNA O
in O
serum O
samples O
from O
two O
common O
chimpanzees O
( O
Pan O
troglodytes O
subsp O
. O

These O
findings O
add O
to O
the O
recent O
evidence O
for O
infection O
in O
the O
wild O
of O
other O
Old O
and O
New O
World O
primates O
( O
gibbon O
, O
orangutan O
, O
and O
woolly O
monkey O
) O
with O
species O
- O
specific O
variants O
of O
HBV O
, O
There O
is O
no O
evidence O
for O
close O
phylogenetic O
clustering O
of O
variants O
found O
so O
far O
in O
primates O
with O
any O
of O
the O
established O
HBV O
genotypes O
from O
humans O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
closely O
related O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
causes O
acute O
hepatitis O
in O
tamarins O
( O
Saguinus O
species O
) O
, O
making O
it O
an O
attractive O
surrogate O
virus O
for O
in O
vivo O
testing O
of O
anti O
- O
HCV O
inhibitors O
in O
a O
small O
monkey O
model O
. O

It O
has O
been O
reported O
that O
the O
nonstructural B
protein I
3 I
( I
NS3 I
) I
serine O
protease O
of O
GBV O
- O
B O
shares O
similar O
substrate O
specificity O
with O
its O
counterpart O
in O
HCV O
. O

Authentic O
proteolytic O
processing O
of O
the O
HCV O
polyprotein O
junctions O
( O
NS4A O
/ O
4B O
, O
NS4B O
/ O
5A O
, O
and O
NS5A O
/ O
5B O
) O
can O
be O
accomplished O
by O
the O
GBV O
- O
B O
NS3 O
protease O
in O
an O
HCV O
NS4A O
cofactor O
- O
independent O
fashion O
. O

The O
minimum O
cofactor O
region O
that O
supported O
GBV O
- O
B O
protease O
activity O
was O
mapped O
to O
a O
central O
region O
of O
GBV O
- O
B O
NS4A O
( O
between O
amino O
acids O
Phe22 O
and O
Val36 O
) O
which O
overlapped O
with O
the O
cofactor O
region O
of O
HCV O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
similar O
to O
human O
hepatitis O
B O
virus O
, O
causes O
acute O
liver O
inflammation O
that O
can O
progress O
to O
chronic O
hepatitis O
and O
hepatocellular O
carcinoma O
, O
WHV O
also O
invades O
cells O
of O
the O
host O
lymphatic O
system O
, O
where O
it O
persists O
for O
life O
. O

We O
report O
here O
that O
acute O
and O
chronic O
hepadnavirus O
hepatitis O
is O
characterized O
by O
a O
profound O
difference O
in O
the O
expression O
of O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecules O
on O
the O
surface O
of O
infected O
hepatocytes O
and O
, O
notably O
, O
lymphoid O
cells O
. O

This O
inhibition O
in O
chronic O
hepatitis O
occurs O
despite O
augmented O
( O
as O
in O
acute O
infection O
) O
expression O
of O
hepatic O
genes O
for O
class O
I O
MHC O
heavy O
chain O
, O
beta O
( O
2 O
) O
- O
microglobulin O
, O
and O
transporters O
associated O
with O
antigen O
processing O
( O
TAP1 O
and O
TAP2 O
) O
, O
Further O
, O
the O
class O
I O
antigen O
inhibition O
is O
not O
related O
to O
the O
histological O
severity O
of O
hepatocellular O
injury O
, O
the O
extent O
of O
lymphocytic O
infiltrations O
, O
the O
level O
of O
intrahepatic O
gamma O
interferon O
induction O
, O
or O
the O
hepatic O
WHV O
load O
. O

To O
clarify O
the O
role O
of O
core O
protein O
phosphorylation O
in O
pregenomic O
- O
RNA O
encapsidation O
of O
human O
and O
duck O
hepatitis O
B O
viruses O
( O
HBV O
and O
DHBV O
, O
respectively O
) O
, O
we O
have O
examined O
the O
phosphorylation O
states O
of O
different O
forms O
of O
intracellular O
HBV O
core O
protein O
and O
the O
phenotypic O
effects O
of O
mutations O
in O
the O
phosphorylation O
sites O
of O
HBV O
and O
DHBV O
core O
proteins O
. O

The O
current O
therapy O
for O
hepatitis O
B O
and O
C O
is O
based O
on O
systemic O
administration O
of O
recombinant B
human I
alpha I
interferon I
( I
r I
- I
hIFN I
- I
alpha I
) I
. O

In O
an O
effort O
to O
maximize O
IFN O
- O
alpha O
antiviral O
efficacy O
, O
we O
have O
explored O
the O
therapeutic O
potential O
of O
murine B
IFN I
- I
alpha I
2 I
( I
mIFN I
- I
alpha I
2 I
) I
selectively O
expressed O
in O
the O
liver O
. O

To O
this O
end O
, O
we O
have O
developed O
a O
helper O
- O
dependent O
adenovirus O
vector O
( O
HD O
) O
containing O
the O
mIFN O
- O
alpha O
2 O
gene O
under O
the O
control O
of O
the O
liver O
- O
specific O
transthyretin O
promoter O
( O
HD O
- O
IFN O
) O
, O
Comparison O
with O
a O
first O
- O
generation O
adenovirus O
carrying O
the O
same O
mIFN O
- O
alpha O
2 O
expression O
cassette O
indicates O
that O
at O
certain O
HD O
- O
IFN O
doses O
, O
induction O
of O
antiviral O
genes O
tan O
be O
achieved O
in O
the O
absence O
of O
detectable O
circulating O
mIFN O
- O
alpha O
2 O
. O

The O
outcome O
and O
protective O
efficacy O
of O
maternal O
antibodies O
elicited O
by O
DNA O
immunization O
to O
the O
large B
( I
L I
) I
hepadnavirus O
envelope O
protein O
were O
studied O
using O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
, O
Following O
genetic O
immunization O
of O
breeding O
ducks O
with O
a O
DRBV O
L O
protein O
gene O
- O
bearing O
plasmid O
, O
specific O
and O
highly O
neutralizing O
antibodies O
were O
transferred O
from O
the O
sera O
of O
immunized O
ducks O
, O
via O
the O
egg O
yolk O
, O
to O
the O
progeny O
of O
vaccinees O
. O

Interestingly O
, O
large O
amounts O
( O
60 O
to O
100 O
mg O
/ O
egg O
) O
of O
high O
- O
titer O
and O
L O
protein O
- O
specific O
yolk O
immunoglobulins O
( O
immunoglobulin O
Y O
) O
accumulated O
in O
the O
egg O
yolk O
. O

The O
putative O
envelope O
2 O
( O
E2 O
) O
gene O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
highly O
variable O
region O
referred O
to O
as O
hypervariable B
region I
1 I
( I
HVR1 I
) I
. O

To O
test O
this O
hypothesis O
, O
we O
examined O
the O
E2 O
sequence O
of O
a O
human O
inoculum O
that O
was O
passaged O
through O
eight O
chimpanzees O
, O
which O
appear O
to O
have O
a O
replicative O
rate O
( O
opportunity O
for O
chance O
mutation O
) O
similar O
to O
that O
of O
humans O
. O

Acute O
- O
phase O
plasma O
samples O
from O
a O
human O
( O
the O
inoculum O
) O
and O
six O
of O
eight O
serially O
infected O
chimpanzees O
were O
studied O
. O

For O
each O
, O
33 O
cloned O
cDNAs O
were O
examined O
by O
a O
combined O
hetero O
- O
duplex O
- O
single O
- O
stranded O
conformational O
polymorphism O
assay O
to O
assess O
quasispecies O
complexity O
and O
optimize O
selection O
of O
clones O
with O
unique O
gel O
shift O
patterns O
( O
clonotypes O
) O
for O
sequencing O
. O

Similarly O
, O
the O
rates O
of O
protein O
sequence O
altering O
( O
nonsynonymous O
) O
substitution O
were O
lower O
in O
the O
chimpanzees O
than O
in O
the O
humans O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
can O
lead O
: O
to O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

The O
strongest O
effects O
were O
detectable O
in O
strains O
with O
mutations O
in O
the O
hepatocyte B
nuclear I
factor I
3 I
and I
4 I
( I
HNF3 I
and I
HNF4 I
) I
binding O
sites O
of O
the O
enhancer O
I O
core O
domain O
. O

We O
have O
investigated O
the O
mechanism O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
entry O
into O
susceptible O
primary B
duck I
hepatocytes I
( I
PDHs I
) I
, O
using O
mutants O
of O
carboxypeptidase O
D O
( O
gp180 O
) O
, O
a O
transmembrane O
protein O
shown O
to O
act O
as O
the O
primary O
cellular O
receptor O
for O
avian O
hepatitis O
B O
virus O
uptake O
, O
The O
variant O
proteins O
were O
abundantly O
produced O
from O
recombinant O
adenoviruses O
and O
tested O
for O
the O
potential O
to O
functionally O
outcompete O
the O
endogenous O
wild O
- O
type O
receptor O
, O
Overexpression O
of O
wild O
- O
type O
gp180 O
significantly O
enhanced O
the O
efficiency O
of O
DHBV O
infection O
in O
PDHs O
but O
did O
not O
affect O
ongoing O
DHBV O
replication O
, O
an O
observation O
further O
supporting O
gp180 O
receptor O
function O
. O

We O
have O
previously O
shown O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
is O
inhibited O
noncytopathically O
in O
the O
livers O
of O
transgenic O
mice O
following O
injection O
of O
HBV O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
or O
infection O
with O
unrelated O
hepatotropic O
viruses O
, O
including O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
adenovirus O
, O
These O
effects O
are O
mediated O
by O
gamma O
interferon O
( O
IFN O
gamma O
) O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
alpha I
) I
, O
and O
IFN O
alpha O
/ O
beta O
. O

In O
the O
present O
study O
, O
we O
crossed O
HBV O
transgenic O
mice O
with O
mice O
genetically O
deficient O
for O
IFN O
gamma O
( O
IFN O
gamma O
KO O
) O
, O
the O
TNF O
alpha O
receptor O
( O
TNF O
alpha O
RKO O
) O
, O
or O
the O
IFN O
alpha O
/ O
beta O
receptor O
( O
IFN O
alpha O
/ O
beta O
RKO O
) O
in O
order O
to O
determine O
the O
relative O
contribution O
of O
each O
cytokine O
to O
the O
antiviral O
effects O
observed O
in O
each O
of O
these O
systems O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
important O
etiological O
agent O
of O
epidemic O
and O
sporadic O
hepatitis O
, O
which O
is O
endemic O
to O
the O
Indian O
subcontinent O
and O
prevalent O
in O
most O
of O
the O
developing O
parts O
of O
the O
world O
. O

The O
presence O
of O
negative O
- O
sense O
RNA O
, O
indicative O
of O
viral O
replication O
, O
was O
demonstrated O
in O
the O
transfected O
cells O
by O
strand O
- O
specific O
reverse O
transcription O
PCR O
and O
slot O
blot O
hybridization O
, O
The O
viral O
proteins O
pORF2 O
and O
pORF3 O
and O
processed O
components O
of O
the O
pORF1 O
polyprotein O
( O
putative O
methyltransferase O
, O
helicase O
, O
and O
RNA O
- O
dependent O
RNA O
polymerase O
) O
were O
identified O
in O
the O
transfected O
cells O
by O
metabolic O
pulse O
- O
labeling O
with O
[ O
S O
- O
35 O
] O
methionine O
- O
cysteine O
, O
followed O
by O
immunoprecipitation O
with O
respective O
antibodies O
. O

Viral O
replication O
was O
detected O
in O
the O
transfected O
cells O
up O
to O
33 O
days O
posttransfection O
( O
six O
passages O
) O
. O

The O
culture O
supernatant O
from O
the O
transfected O
cells O
was O
able O
to O
produce O
HEV O
infection O
in O
a O
rhesus O
monkey O
( O
Macaca O
mulatta O
) O
following O
intravenous O
injection O
, O
indicating O
the O
generation O
of O
viable O
HEV O
particles O
following O
transfection O
of O
cells O
with O
in O
vitro O
- O
synthesized O
genomic O
RNA O
. O

A O
unique O
feature O
of O
the O
large O
hepadnavirus O
envelope O
protein O
( O
L O
) O
is O
its O
mixed O
transmembrane O
topology O
, O
resulting O
from O
partial O
posttranslational O
translocation O
of O
the O
pre O
- O
S O
domain O
. O

Using O
protease O
protection O
analysis O
, O
we O
demonstrate O
for O
duck O
hepatitis O
B O
virus O
an O
essential O
role O
for O
the O
small O
envelope O
protein O
( O
S O
) O
in O
this O
process O
, O
providing O
the O
first O
experimental O
evidence O
for O
an O
S O
translocation O
channel O
. O

Understanding O
the O
mechanism O
( O
s O
) O
of O
action O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
encoded O
protein O
HBx O
is O
fundamental O
to O
elucidating O
the O
underlying O
mechanisms O
of O
chronic O
liver O
disease O
and O
hepatocellular O
carcinoma O
caused O
by O
HBV O
infection O
. O

This O
cellular O
gene O
was O
identified O
as O
a O
third O
member O
of O
the O
family O
of O
human O
genes O
that O
encode O
the O
voltage O
- O
dependent O
anion O
channel O
( O
HVDAC3 O
) O
, O
In O
the O
present O
study O
, O
physical O
interaction O
between O
HBx O
and O
HVDAC3 O
was O
established O
by O
standard O
in O
vitro O
and O
in O
vivo O
methods O
, O
Confocal O
laser O
microscopy O
of O
transfected O
cells O
with O
respective O
expression O
vectors O
colocalized O
HVDAC3 O
and O
HBx O
to O
mitochondria O
. O

A O
serological O
analysis O
of O
30 O
captive O
gibbons O
revealed O
that O
47 O
% O
were O
positive O
for O
at O
least O
one O
marker O
of O
ongoing O
or O
previous O
infection O
with O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Viruses O
resembling O
human B
TT I
virus I
( I
TTV I
) I
were O
searched O
for O
in O
sera O
from O
nonhuman O
primates O
by O
PCR O
with O
primers O
deduced O
from O
well O
- O
conserved O
areas O
in O
the O
untranslated O
region O
. O

TTV O
DNA O
was O
detected O
in O
102 O
( O
98 O
% O
) O
of O
104 O
chimpanzees O
, O
9 O
( O
90 O
% O
) O
of O
10 O
Japanese O
macaques O
, O
4 O
( O
100 O
% O
) O
of O
4 O
red O
- O
bellied O
tamarins O
, O
5 O
( O
83 O
% O
) O
of O
6 O
cotton O
- O
tap O
tamarins O
, O
and O
5 O
( O
100 O
% O
) O
of O
5 O
douroucoulis O
tested O
. O

Sequences O
closely O
similar O
to O
human O
TTV O
ere O
determined O
by O
PCR O
with O
primers O
deduced O
from O
a O
coding O
region O
( O
N22 O
region O
) O
and O
were O
detected O
in O
49 O
( O
47 O
% O
) O
of O
the O
104 O
chimpanzees O
; O
they O
were O
not O
found O
in O
any O
animals O
of O
the O
other O
species O
. O

Sequence O
analysis O
of O
the O
N22 O
region O
( O
222 O
to O
225 O
nucleotides O
) O
of O
chimpanzee O
TTV O
DNAs O
disclosed O
four O
genetic O
groups O
that O
differed O
by O
36 O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
enhancer B
II I
( I
EnII I
) I
is O
a O
hepatotropic O
cis O
element O
which O
is O
responsible O
for O
the O
hepatocyte O
- O
specific O
gene O
expression O
of O
HBV O
. O

In O
this O
study O
, O
the O
region O
from O
HBV O
nucleotides B
( I
nt I
) I
1640 O
to O
1663 O
in O
EnII O
was O
demonstrated O
to O
be O
essential O
for O
enhancer O
activity O
and O
to O
be O
another O
target O
sequence O
of O
putative O
transcription O
factors O
. O

Because O
hepadnaviruses O
replicate O
in O
an O
integrase O
- O
independent O
manner O
, O
we O
were O
interested O
in O
investigating O
the O
characteristics O
of O
human B
foamy I
virus I
( I
HFV I
) I
integration O
. O

Our O
analyses O
have O
revealed O
that O
in O
single O
- O
cell O
clones O
derived O
from O
HFV O
- O
infected O
erythroleukemia O
- O
derived O
cells O
( O
H92 O
) O
, O
there O
were O
up O
to O
20 O
proviral O
copies O
per O
host O
cell O
genome O
as O
determined O
by O
Southern O
blot O
and O
fluorescent O
in O
situ O
hybridization O
analysis O
. O

Four O
of O
these O
seven O
mutants O
( O
two O
insertions O
[ O
GA O
downstream O
of O
All O
and O
EHCSP O
downstream O
of O
P50 O
] O
and O
two O
deletions O
[ O
S44 O
and O
A80 O
] O
) O
allowed O
virion O
morphogenesis O
and O
secretion O
. O

The O
hepatitis O
B O
virus O
X O
protein O
( O
pX O
) O
interacts O
directly O
with O
the O
bZip O
transactivator O
CREB O
and O
the O
bZip O
repressors O
ICERII O
gamma O
and O
ATF3 O
, O
increasing O
their O
DNA O
- O
binding O
affinity O
in O
vitro O
and O
their O
transcriptional O
efficacy O
in O
vivo O
. O

Transient O
transfections O
of O
the O
pX O
deletion O
mutants O
in O
AML12 O
hepatocytes O
demonstrate O
that O
pX O
( O
49 O
- O
115 O
) O
is O
as O
effective O
as O
the O
full O
- O
length O
pX O
in O
enhancing O
the O
ATF3 O
- O
and O
ICERII O
gamma O
- O
mediated O
transrepression O
. O

However O
, O
this O
pX O
region O
is O
inactive O
in O
increasing O
the O
transactivation O
efficacy O
of O
CREB O
; O
additional O
amino O
acid O
residues O
present O
in O
pX O
( O
49 O
- O
115 O
) O
are O
required O
to O
mediate O
the O
increased O
transactivation O
efficacy O
of O
CREB O
in O
vivo O
. O

It O
has O
been O
suggested O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
binds O
to O
a O
receptor O
on O
the O
plasma O
membrane O
of O
human O
hepatocytes O
via O
the O
pre O
- O
Si O
domain O
of O
the O
large O
envelope O
protein O
as O
an O
initial O
step O
in O
HBV O
infection O
, O
However O
, O
the O
nature O
of O
the O
receptor O
remains O
controversial O
, O
In O
an O
attempt O
to O
identify O
a O
cell O
surface O
receptor O
for O
HBV O
, O
purified O
recombinant O
fusion O
protein O
of O
the O
pre O
- O
SI O
domain O
of O
HBV O
with O
glutathione B
S I
- I
transferase I
( I
GST I
) I
, O
expressed O
in O
Escherichia O
roll O
, O
was O
used O
as O
a O
ligand O
, O
The O
surface O
of O
human O
hepatocytes O
or O
HepG2 O
cells O
was O
biotinylated O
, O
and O
the O
cell O
lysate O
( O
precleared O
lysate O
) O
which O
did O
not O
bind O
to O
GST O
and O
glutathione O
- O
Sepharose O
beads O
was O
used O
as O
a O
source O
of O
receptor O
molecules O
. O

The O
precleared O
lysate O
of O
the O
biotinylated O
cells O
was O
incubated O
with O
the O
GST O
- O
pre O
- O
S1 O
fusion O
protein O
, O
and O
the O
bound O
proteins O
were O
visualized O
by O
Western O
blotting O
and O
enhanced O
chemiluminescence O
, O
An O
approximately O
80 O
- O
kDa O
protein O
( O
p80 O
) O
was O
shown O
to O
bind O
specifically O
to O
the O
pre O
- O
SI O
domain O
of O
the O
fusion O
protein O
, O
The O
receptor O
binding O
assay O
using O
serially O
or O
internally O
deleted O
segments O
of O
pre O
- O
S1 O
showed O
that O
amino O
acid O
residues O
12 O
to O
20 O
and O
82 O
to O
90 O
are O
essential O
for O
the O
binding O
of O
pre O
- O
SI O
to O
p80 O
, O
p80 O
also O
bound O
specifically O
to O
the O
pre O
- O
SI O
of O
native O
HBV O
particles O
, O
Analysis O
of O
the O
tissue O
and O
species O
specificity O
of O
p80 O
expression O
in O
several O
available O
human O
primary O
cultures O
and O
cell O
lines O
of O
different O
tissue O
origin O
showed O
that O
p80 O
expression O
is O
not O
restricted O
to O
human O
hepatocytes O
, O
Taken O
together O
the O
results O
suggest O
that O
p80 O
may O
be O
a O
component O
of O
the O
viral O
entry O
machinery O
. O

We O
report O
that O
endoplasmic O
reticulum O
or O
- O
glucosidase O
inhibitors O
have O
antiviral O
effects O
on O
dengue B
( I
DEN I
) I
virus O
. O

We O
found O
that O
glucosidase O
inhibition O
strongly O
affects O
productive O
folding O
pathways O
of O
the O
envelope O
glycoproteins O
prM O
( O
the O
intracellular O
glycosylated O
precursor O
of O
M O
[ O
membrane O
protein O
] O
) O
and O
E B
( I
envelope I
protein I
) I
: O
the O
proper O
folding O
of O
prM O
bearing O
unprocessed O
N O
- O
linked O
oligosaccharide O
is O
inefficient O
, O
and O
this O
causes O
delayed O
formation O
of O
prME O
heterodimer O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
populations O
persist O
in O
vivo O
as O
a O
mixture O
of O
heterogeneous O
viruses O
called O
quasispecies O
. O

We O
have O
studied O
26 O
virus O
strains O
to O
determine O
the O
influence O
of O
hypervariable B
region I
1 I
( I
HVR I
- I
1 I
) I
of O
the O
HCV O
genome O
on O
the O
effectiveness O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
therapy O
. O

The O
degree O
of O
virus O
variation O
was O
assessed O
by O
analyzing O
20 O
clones O
per O
sample O
and O
by O
calculating O
nucleotide O
sequence O
entropy O
( O
complexity O
) O
and O
genetic O
distances O
( O
diversity O
) O
, O
Types O
of O
mutational O
changes O
were O
also O
determined O
by O
calculating O
nonsynonymous O
substitutions O
per O
nonsynonymous O
site O
( O
K O
- O
a O
) O
and O
synonymous O
substitutions O
per O
synonymous O
site O
( O
K O
- O
s O
) O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
a O
recently O
discovered O
hepatotropic O
flavivirus O
that O
is O
distantly O
related O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

We O
analyzed O
the O
translational O
activity O
of O
dicistronic O
RNA O
transcripts O
containing O
wild O
- O
type O
or O
mutated O
5 B
' I
nontranslated I
GBV I
- I
B I
RNA I
( I
5 I
' I
NTR I
) I
segments O
, O
placed O
between O
the O
coding O
sequences O
of O
two O
reporter O
proteins O
, O
in O
vitro O
in O
rabbit O
reticulocyte O
lysate O
and O
in O
vivo O
in O
transfected O
BT7 O
- O
H O
cells O
. O

Honda O
, O
et O
al O
, O
RNA O
2 O
: O
955 O
- O
968 O
, O
1996 O
) O
, O
We O
identified O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
bounded O
at O
its O
5 O
' O
end O
by O
structural O
domain O
II O
, O
a O
location O
analogous O
to O
the O
5 O
' O
limit O
of O
the O
IRES O
in O
both O
the O
HCV O
and O
pestivirus O
5 O
' O
NTRs O
, O
Mutational O
analysis O
confirmed O
the O
structure O
proposed O
for O
domain O
II O
of O
GBV O
- O
B O
RNA O
, O
and O
demonstrated O
that O
optimal O
IRES O
- O
mediated O
translation O
is O
dependent O
on O
each O
of O
the O
putative O
RNA O
hairpins O
in O
this O
domain O
, O
including O
two O
stem O
- O
loops O
not O
present O
in O
the O
HCV O
or O
pestivirus O
structures O
, O
IRES O
activity O
was O
also O
absolutely O
dependent O
on O
( O
i O
) O
phylogenetically O
conserved O
, O
adenosine O
- O
containing O
bulge O
loops O
in O
domain O
III O
and O
( O
ii O
) O
the O
primary O
nucleotide O
sequence O
of O
stem O
- O
loop O
IIIe O
, O
IRES O
- O
directed O
translation O
was O
inhibited O
by O
a O
series O
of O
point O
mutations O
predicted O
to O
stabilize O
stem O
- O
loop O
IV O
, O
which O
contains O
the O
initiator O
AUG O
codon O
in O
its O
loop O
segment O
. O

The O
frequency O
of O
integration O
was O
estimated O
to O
be O
at O
least O
one O
viral O
genome O
per O
10 O
( O
3 O
) O
to O
10 O
( O
4 O
) O
cells O
by O
6 O
days O
postinfection O
. O

To O
clarify O
the O
binding O
properties O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
and O
its O
viral O
RNA O
for O
the O
encapsidation O
, O
morphogenesis O
, O
and O
replication O
of O
HCV O
, O
the O
specific O
interaction O
of O
HCV O
core O
protein O
with O
its O
genomic O
RNA O
synthesized O
in O
vitro O
was O
examined O
in O
an O
in O
vivo O
system O
. O

The O
positive O
- O
sense O
RNA O
from O
the O
5 O
' O
end O
to O
nucleotide B
( I
nt I
) I
2327 O
, O
which O
covers O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
and O
a O
part O
of O
the O
coding O
region O
of O
HCV O
structural O
proteins O
, O
interacted O
with O
HCV O
core O
protein O
, O
while O
no O
interaction O
was O
observed O
in O
the O
same O
region O
of O
negative O
- O
sense O
RNA O
and O
in O
other O
regions O
of O
viral O
and O
antiviral O
sense O
RNAs O
. O

The O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
exists O
around O
the O
5 O
' O
UTR O
of O
HCV O
; O
therefore O
, O
the O
interaction O
of O
the O
core O
protein O
with O
this O
region O
of O
HCV O
RNA O
suggests O
that O
there O
is O
some O
effect O
on O
its O
cap O
- O
independent O
translation O
. O

Cells O
expressing O
HCV O
core O
protein O
were O
transfected O
with O
reporter O
RNAs O
consisting O
of O
nt O
I O
to O
709 O
of O
HCV O
RNA O
( O
the O
5 O
' O
UTR O
of O
HCV O
and O
about O
two O
- O
thirds O
of O
the O
core O
protein O
coding O
regions O
) O
followed O
by O
a O
firefly O
luciferase O
gene O
( O
HCV07Luc O
RNA O
) O
. O

The O
most O
Frequent O
mutation O
of O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
core O
antigen O
occurs O
at O
amino O
acid O
97 O
. O

Recently O
, O
a O
Phenylalanine B
( I
F I
) I
- O
to O
- O
leucine B
( I
L I
) I
mutation O
at O
this O
position O
( O
mutant O
F97L O
) O
in O
HBV O
surface O
antigen O
subtype O
ayw O
has O
been O
shown O
to O
result O
in O
an O
immature O
secretion O
phenotype O
, O
which O
is O
characterized O
by O
the O
nonselective O
export O
of O
an O
excessive O
amount O
of O
virions O
containing O
minus O
- O
strand O
, O
single O
- O
stranded O
HBV O
DNA O
. O

We O
report O
here O
that O
the O
immature O
secretion O
phenotype O
indeed O
can O
be O
found O
in O
an O
HBV O
strain O
( O
subtype O
adr O
) O
prevalent O
in O
Asia O
, O
changing O
from O
an O
Isoleucine B
( I
I I
) I
to O
a O
leucine O
( O
mutant O
197L O
) O
. O

Recombinant O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
produced O
in O
insect O
cells O
has O
been O
shown O
to O
possess O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
. O

Prompted O
by O
a O
recent O
report O
that O
removal O
of O
the O
C O
- O
terminal O
hydrophobic O
domain O
significantly O
improved O
the O
solubility O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
NS5B O
, O
we O
constructed O
a O
similar O
deletion O
of O
24 O
amino O
acids O
at O
the O
C O
terminus O
of O
BVDV O
NS5B O
, O
The O
resulting O
fusion O
protein O
, O
NS5B O
Delta O
CT24 O
- O
His O
, O
was O
purified O
to O
homogeneity O
and O
demonstrated O
to O
direct O
RNA O
replication O
via O
both O
primer O
- O
dependent O
( O
elongative O
) O
and O
primer O
- O
independent O
( O
de O
novo O
) O
mechanisms O
, O
Furthermore O
, O
BVDV O
RdRp O
was O
found O
to O
utilize O
a O
circular O
single O
- O
stranded O
DNA O
as O
a O
template O
for O
RNA O
synthesis O
, O
suggesting O
that O
synthesis O
does O
not O
require O
ends O
in O
the O
template O
. O

Finally O
, O
deletions O
of O
up O
to O
90 O
amino O
acids O
from O
the O
N O
terminus O
did O
not O
significantly O
affect O
RdRp O
activities O
, O
whereas O
deletions O
of O
more O
than O
24 O
amino O
acids O
at O
the O
C O
terminus O
resulted O
in O
either O
insoluble O
products O
or O
soluble O
proteins O
( O
Delta O
CT179 O
and O
Delta O
CT218 O
) O
that O
lacked O
RdRp O
activities O
. O

The O
role O
of O
the O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
in O
regulating O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
in O
vivo O
was O
investigated O
in O
an O
HBV O
transgenic O
mouse O
model O
. O

Here O
we O
have O
examined O
whether O
the O
activity O
of O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
core O
gene O
in O
vivo O
depends O
on O
X O
coexpression O
. O

To O
this O
end O
we O
compared O
core O
gene O
expression O
between O
four O
lineages O
of O
transgenic O
mice O
carrying O
the O
HBV O
core O
gene O
in O
cis O
arrangement O
with O
the O
X O
gene O
( O
cex O
lineage O
) O
and O
six O
lineages O
containing O
a O
modified O
construct O
in O
which O
the O
start O
codon O
of O
the O
X O
gene O
had O
been O
deleted O
( O
ce O
lineage O
) O
. O

To O
test O
whether O
core O
gene O
expression O
could O
be O
restored O
by O
providing O
an O
intact O
; O
X O
gene O
in O
trans O
, O
we O
crossbred O
mice O
of O
two O
lines O
which O
expressed O
no O
core O
mRNA O
or O
core O
protein O
with O
transgenic O
mice O
expressing O
the O
X O
- O
gene O
product O
under O
the O
transcriptional O
regulation O
of O
the O
liver O
- O
specific O
major O
- O
urinary O
- O
protein O
promoter O
/ O
enhancer O
( O
MUP O
- O
X O
mice O
) O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
a O
virus O
of O
the O
family O
Flaviviridae O
that O
infects O
small O
primates O
( O
Saguinus O
sp O
. O

[ O
tamarins O
] O
) O
and O
shows O
similarities O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
genome O
organization O
, O
protein O
function O
, O
tissue O
tropism O
, O
and O
pathogenicity O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
leading O
cause O
of O
liver O
disease O
worldwide O
. O

Alpha O
interferon O
( O
IFN O
- O
cw O
) O
therapy O
of O
chronic O
hepatitis O
C O
leads O
to O
a O
sustained O
response O
in O
10 O
to O
20 O
% O
of O
patients O
only O
. O

Previous O
studies O
have O
described O
a O
170 O
to O
180 O
kDa O
molecule O
( O
p170 O
or O
gp180 O
) O
that O
binds O
in O
vitro O
to O
the O
pre O
- O
S O
domain O
of O
the O
large O
envelope O
protein O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
; O
cDNA O
cloning O
revealed O
the O
binding O
protein O
to O
be O
duck B
carboxypeptidase I
D I
( I
DCPD I
) I
, O
In O
the O
present O
study O
, O
the O
DCPD O
cDNA O
was O
transfected O
into O
several O
nonpermissive O
human O
- O
, O
monkey O
- O
, O
and O
avian O
species O
- O
derived O
cell O
lines O
. O

The O
DHBV O
binding O
to O
DCPD O
- O
reconstituted O
cells O
was O
blocked O
by O
a O
monoclonal O
antibody O
that O
neutralizes O
DHBV O
infection O
of O
primary B
duck I
hepatocytes I
( I
PDH I
) I
and O
also O
by O
a O
pre O
- O
S O
peptide O
previously O
shown O
to O
inhibit O
DHBV O
infection O
of O
PDH O
. O

Mice O
infected O
with O
Mouse B
hepatitis I
virus I
strain I
JHM I
( I
MHV I
- I
JHM I
) I
develop O
a O
chronic O
demyelinating O
encephalomyelitis O
that O
is O
in O
large O
part O
immune O
mediated O
. O

Mice O
deficient O
in O
recombinase O
- O
activating O
gene O
function O
( O
RAG1 O
( O
- O
/ O
- O
) O
) O
, O
defective O
in O
B O
- O
and O
T O
- O
cell O
maturation O
, O
become O
persistently O
infected O
with O
MHV O
but O
do O
not O
develop O
demyelination O
. O

Adoptive O
transfer O
of O
splenocytes O
from O
mice O
immunized O
to O
MHV O
into O
RAG1 O
( O
- O
/ O
- O
) O
mice O
infected O
with O
an O
attenuated O
strain O
of O
the O
virus O
results O
in O
the O
rapid O
and O
progressive O
development O
of O
demyelination O
. O

Apoptotic O
cells O
were O
identified O
in O
both O
the O
gray O
and O
white O
matter O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
from O
RAG1 O
( O
- O
/ O
- O
) O
mice O
before O
and O
after O
adoptive O
transfer O
, O
with O
a O
moderate O
increase O
in O
number O
, O
but O
not O
distribution O
, O
of O
apoptotic O
cells O
following O
the O
development O
of O
demyelination O
. O

These O
results O
, O
showing O
that O
macrophage O
recruitment O
and O
myelin O
destruction O
occur O
rapidly O
after O
immune O
reconstitution O
of O
RAG O
( O
- O
/ O
- O
) O
mice O
, O
suggest O
that O
this O
will O
be O
a O
useful O
system O
for O
investigating O
MHV O
- O
induced O
demyelination O
. O

The O
large O
form O
of O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
protein O
( O
L O
) O
can O
be O
isoprenylated O
near O
its O
C O
terminus O
, O
and O
this O
modification O
is O
considered O
essential O
for O
particle O
assembly O
. O

The O
slower O
species O
could O
be O
labelled O
by O
the O
incorporation O
of O
[ O
C O
- O
14 O
] O
mevalonolactone O
and O
is O
interpreted O
to O
be O
isoprenylated O
L O
( O
L O
- O
i O
) O
. O

( O
i O
) O
Relative O
to O
L O
, O
L O
- O
i O
was O
preferentially O
assembled O
into O
virus O
- O
like O
particles O
. O

( O
ii O
) O
L O
- O
i O
could O
coassemble O
the O
unmodified O
L O
and O
the O
small O
delta O
protein O
, O
S O
. O

( O
iii O
) O
In O
contrast O
, O
a O
form O
of O
L O
with O
a O
deletion O
in O
the O
dimerization O
domain O
was O
both O
isoprenylated O
and O
assembled O
, O
but O
it O
could O
not O
support O
the O
coassembly O
of O
S O
. O

( O
i O
) O
The O
unique O
C O
- O
terminal O
19 O
amino O
acids O
present O
on O
L O
relative O
to O
S O
caused O
a O
significant O
increase O
in O
the O
hydrophobicity O
. O

( O
ii O
) O
This O
increase O
was O
independent O
of O
isoprenylation O
. O

( O
iii O
) O
In O
contrast O
, O
other O
, O
artificial O
modifications O
at O
either O
the O
N O
or O
C O
terminus O
of O
S O
did O
not O
increase O
the O
hydrophobicity O
. O

( O
iv O
) O
The O
increased O
hydrophobicity O
was O
not O
sufficient O
for O
particle O
assembly O
; O
nevertheless O
, O
we O
speculate O
that O
it O
might O
facilitate O
virion O
assembly O
. O

The O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
is O
essential O
for O
the O
establishment O
of O
HBV O
infection O
in O
vivo O
and O
exerts O
a O
pleiotropic O
effect O
on O
diverse O
cellular O
functions O
. O

We O
demonstrated O
that O
infection O
of O
17CI O
- O
1 O
cells O
with O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
induced O
caspase O
- O
dependent O
apoptosis O
. O

6 O
% O
) O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
was O
suspected O
in O
195 O
formerly O
captive O
orangutans O
due O
to O
a O
large O
number O
of O
serum O
samples O
which O
cross O
- O
reacted O
with O
human O
HBV O
antigens O
, O
It O
was O
assumed O
that O
such O
viral O
infections O
were O
contracted O
from O
humans O
during O
captivity O
. O

A O
truncated O
soluble O
form O
of O
the O
hepatitis O
C O
virus O
E2 O
glycoprotein O
, O
E2 O
( O
661 O
) O
, O
binds O
specifically O
to O
the O
surface O
of O
cells O
expressing O
human O
CD81 O
( O
hCD81 O
) O
but O
not O
other O
members O
of O
the O
tetraspanin O
family O
( O
CD9 O
, O
CD63 O
, O
and O
CD151 O
) O
. O

No O
differences O
were O
noted O
between O
the O
level O
of O
E2 O
( O
661 O
) O
binding O
to O
hCDS1 O
expressed O
on O
the O
surface O
of O
rat O
RBL O
or O
KM3 O
cells O
compared O
to O
Daudi O
and O
Molt O
- O
4 O
cells O
, O
suggesting O
that O
additional O
human O
- O
cell O
- O
specific O
factors O
are O
not O
required O
for O
the O
primary O
interaction O
of O
E2 O
with O
the O
cell O
surface O
. O

E2 O
did O
not O
interact O
with O
African B
green I
monkey I
( I
AGM I
) I
CD81 O
on O
the O
surface O
of O
COS O
cells O
, O
which O
differs O
from O
the O
hCD81 O
sequence O
at O
four O
residues O
within O
the O
second O
extracellular O
region O
( O
EC2 O
) O
( O
amino O
acids O
[ O
aa O
] O
: O
163 O
, O
186 O
, O
188 O
, O
and O
196 O
) O
, O
suggesting O
that O
one O
or O
more O
of O
these O
residues O
defines O
the O
site O
of O
interaction O
with O
E2 O
. O

Finally O
, O
we O
demonstrate O
that O
ligation O
of O
CD81 O
by O
E2 O
( O
661 O
) O
induced O
aggregation O
of O
lymphoid O
cells O
and O
inhibited O
B O
- O
cell O
proliferation O
, O
demonstrating O
that O
E2 O
interaction O
with O
CD81 O
can O
modulate O
cell O
function O
. O

human B
foamy I
virus I
( I
HFV I
) I
is O
the O
prototype O
member O
of O
the O
spumaviruses O
. O

While O
similar O
in O
genomic O
organization O
to O
other O
complex O
retroviruses O
, O
foamy O
viruses O
share O
several O
features O
with O
their O
more O
distant O
relatives O
, O
the O
hepadnaviruses O
such O
as O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
prevalent O
worldwide O
and O
has O
become O
a O
major O
cause O
of O
liver O
dysfunction O
and O
hepatocellular O
carcinoma O
. O

The O
high O
prevalence O
of O
HCV O
reflects O
the O
persistent O
nature O
of O
infection O
and O
the O
large O
frequency O
of O
cases O
that O
resist O
the O
current O
interferon B
( I
IFN I
) I
- O
based O
anti O
- O
HCV O
therapeutic O
regimens O
. O

HCV O
resistance O
to O
IFN O
has O
been O
attributed O
, O
in O
part O
, O
to O
the O
function O
of O
the O
viral O
nonstructural B
5A I
( I
NS5A I
) I
protein O
. O

Here O
we O
examined O
the O
relationship O
between O
HCV O
persistence O
and O
resistance O
to O
IFN O
therapy O
, O
When O
expressed O
in O
mammalian O
cells O
, O
NS5A O
from O
IFN O
- O
resistant O
HCV O
conferred O
IFN O
resistance O
to O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
which O
normally O
is O
sensitive O
to O
the O
antiviral O
actions O
of O
IFN O
. O

NS5A O
blocked O
viral O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
induced O
PKR O
activation O
and O
phosphorylation O
of O
eIF O
- O
2 O
alpha O
in O
IFN O
- O
treated O
cells O
, O
resulting O
in O
high O
levels O
of O
VSV O
mRNA O
translation O
. O

A O
combinatorial O
screening O
method O
has O
been O
used O
to O
identify O
hairpin O
ribozymes O
that O
inhibit O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
in O
transfected O
human O
hepatocellular O
carcinoma O
( O
HCG O
) O
cells O
. O

A O
hairpin O
ribozyme O
library O
( O
5 O
x O
10 O
( O
5 O
) O
variants O
) O
containing O
a O
randomized O
substrate O
- O
binding O
domain O
was O
used O
to O
identify O
accessible O
target O
sites O
within O
3 O
. O

Evidence O
is O
presented O
that O
the O
previously O
cloned O
type O
I O
duck B
interferon I
( I
DuIFN I
) I
cDNA O
encodes O
a O
homologue O
of O
mammalian O
interferon O
- O
alpha O
( O
IFN O
- O
alpha O
) O
. O

Recombinant O
DuIFN O
- O
alpha O
was O
used O
to O
study O
the O
inhibition O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
replication O
in O
primary O
hepatocytes O
in O
order O
to O
determine O
the O
IFN O
- O
sensitive O
steps O
of O
the O
virus O
replication O
cycle O
. O

A O
very O
frequent O
missense O
mutation O
at O
codon O
97 O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
core O
antigen O
( O
HBcAg O
) O
has O
been O
found O
in O
chronic O
carriers O
worldwide O
. O

Functional O
characterization O
of O
this O
mutant O
revealed O
one O
intracellular O
and O
two O
extracellular O
phenotypes O
in O
contrast O
to O
wild O
- O
type O
HBV O
: O
( O
i O
) O
a O
6 O
- O
to O
12 O
- O
fold O
decrease O
in O
the O
level O
of O
the O
full O
- O
length O
relaxed O
circular O
DNA O
, O
a O
4 O
- O
to O
5 O
- O
fold O
decrease O
ire O
the O
plus O
- O
strand O
DNA O
, O
and O
an O
approximately O
1 O
. O

8 O
- O
fold O
decrease O
in O
the O
minus O
- O
strand O
and O
overall O
DNA O
levels O
in O
the O
intracellular O
viral O
core O
particles O
; O
( O
ii O
) O
a O
5 O
. O

7 O
- O
fold O
increase O
in O
the O
immature O
secretion O
of O
Bane O
particles O
, O
containing O
minus O
- O
strand O
, O
single O
- O
stranded O
virion O
DNA O
; O
and O
( O
iii O
) O
a O
significant O
reduction O
of O
nonenveloped O
core O
particles O
in O
the O
medium O
. O

We O
recently O
identified O
three O
nuclear O
proteins O
( O
p45 O
, O
p39 O
, O
and O
p26 O
) O
that O
bind O
to O
a O
91 O
- O
nucleotide B
( I
nt I
) I
RNA O
element O
between O
nt O
1243 O
and O
1333 O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
RNA O
, O
and O
we O
showed O
that O
these O
proteins O
and O
HBV O
RNA O
are O
regulated O
coordinately O
by O
gamma O
interferon O
and O
tumor O
necrosis O
factor O
alpha O
. O

Furthermore O
, O
in O
competition O
experiments O
we O
found O
that O
all O
three O
La O
proteins O
bind O
, O
in O
a O
phosphorylation O
- O
dependent O
manner O
, O
to O
the O
same O
predicted O
stem O
- O
loop O
structure O
located O
between O
nt O
1275 O
and O
1291 O
of O
HBV O
, O
with O
K O
( O
d O
) O
s O
of O
approximately O
1 O
. O

The O
effects O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
on O
anti O
- O
Fas O
( O
CD95 O
/ O
APO O
- O
1 O
) O
antibody O
- O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
apoptosis O
in O
different O
human O
cell O
lines O
were O
investigated O
by O
magnetic O
concentration O
of O
cells O
which O
transiently O
produced O
the O
exogenous O
protein O
. O

We O
also O
found O
that O
the O
core O
functioned O
in O
the O
activation O
of O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
in O
all O
cells O
examined O
. O

B10 O
- O
H2 O
( O
b O
) O
/ O
LiMcdJ O
[ O
Balb O
. O

B O
] O
, O
CB6F O
( O
1 O
) O
/ O
J O
[ O
( O
Balbic O
x O
B6 O
) O
F O
- O
1 O
] O
, O
B6C3F O
( O
1 O
) O
/ O
J O
[ O
( O
B6 O
x O
C3H O
) O
F O
- O
1 O
] O
, O
and O
BALB O
/ O
cj O
SCID O
) O
received O
5 O
x O
10 O
( O
9 O
) O
PFU O
of O
the O
first O
- O
generation O
adenovirus O
, O
which O
expresses O
human O
alpha O
( O
1 O
) O
- O
antitrypsin O
( O
Ad O
/ O
RSVhAAT O
) O
, O
While O
all O
strains O
studied O
showed O
similar O
patterns O
of O
anti O
- O
adenovirus O
antibody O
formation O
, O
only O
Balbic O
and O
C3H O
mice O
developed O
significant O
levels O
of O
anti O
- O
hAAT O
antibodies O
by O
8 O
weeks O
posttransduction O
, O
In O
addition O
, O
while O
all O
strains O
had O
quantitatively O
comparable O
amounts O
of O
adenovirus O
genomes O
and O
hAAT O
mRNA O
transcripts O
in O
the O
liver O
9 O
days O
posttransduction O
, O
only O
Balbic O
mice O
had O
undetectable O
adenovirus O
vector O
genomes O
and O
hAAT O
mRNA O
in O
the O
liver O
40 O
days O
posttransduction O
. O

B O
and O
B6 O
mice O
, O
vector O
genome O
, O
hAAT O
mRNA O
transcripts O
, O
and O
hAAT O
protein O
levels O
persisted O
for O
at O
least O
40 O
days O
posttransduction O
, O
This O
persistence O
correlated O
with O
poor O
anti O
- O
hAAT O
antibody O
formation O
and O
minimal O
hepatocyte O
toxicity O
, O
The O
expression O
of O
hAAT O
in O
( O
Balbic O
x O
B6 O
) O
F O
- O
1 O
pups O
was O
found O
to O
be O
intermediate O
between O
the O
duration O
observed O
in O
the O
parental O
strains O
, O
while O
in O
( O
C3H O
x O
B6 O
) O
F O
- O
1 O
pups O
hAAT O
expression O
was O
similar O
to O
that O
seen O
in O
the O
B6 O
parents O
, O
which O
together O
support O
polygenic O
control O
of O
the O
immune O
responses O
in O
these O
mice O
, O
In O
summary O
, O
these O
findings O
suggest O
that O
there O
are O
three O
different O
profiles O
and O
at O
least O
two O
defined O
immune O
system O
- O
mediated O
mechanisms O
resulting O
in O
the O
loss O
of O
hAAT O
expression O
in O
mice O
and O
that O
different O
strains O
differ O
in O
the O
capacity O
to O
utilize O
these O
mechanisms O
. O

It O
has O
been O
shown O
previously O
that O
measles B
virus I
( I
MV I
) I
can O
be O
successfully O
used O
to O
express O
foreign O
proteins O
( O
M O
. O

80 O
: O
101 O
- O
106 O
, O
1998 O
) O
, O
To O
develop O
an O
inexpensive O
MV O
- O
based O
vaccine O
, O
we O
generated O
recombinant O
MVs O
that O
produce O
structural O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
A O
recombinant O
virus O
that O
expressed O
the O
HBV B
small I
surface I
antigen I
( I
HBsAg I
) I
was O
analyzed O
in O
terms O
of O
its O
replication O
characteristics O
, O
its O
genetic O
stability O
in O
cell O
culture O
, O
and O
its O
immunogenic O
potential O
in O
genetically O
modified O
mice O
. O

A O
precore O
- O
deficient O
mutant O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
produced O
by O
site O
directed O
mutagenesis O
was O
tested O
for O
its O
ability O
to O
compete O
with O
wild O
- O
type O
virus O
in O
a O
mixed O
infection O
of O
3 O
- O
day O
- O
old O
ducklings O
, O
The O
mutation O
was O
shown O
to O
produce O
a O
cis O
- O
acting O
defect O
, O
resulting O
in O
a O
replication O
rate O
that O
was O
about O
one O
- O
half O
that O
of O
wild O
- O
type O
virus O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
the O
etiological O
agent O
for O
viral O
hepatitis O
type O
E O
, O
which O
is O
a O
major O
problem O
in O
the O
developing O
world O
. O

HEV O
is O
a O
positive O
- O
strand O
RNA O
virus O
with O
three O
potential O
open B
reading I
frames I
( I
ORFs I
) I
, O
one O
of O
which O
( O
ORF2 O
) O
is O
postulated O
to O
encode O
the O
major O
viral O
capsid O
protein O
( O
pORF2 O
) O
. O

70 O
: O
207 O
- O
216 O
, O
1996 O
) O
pORF2 O
to O
be O
a O
similar O
to O
88 O
- O
kDa O
glycoprotein O
, O
carrying O
N O
- O
linked O
glycans O
and O
a O
potential O
endoplasmic B
reticulum I
( I
ER I
) I
- O
directing O
signal O
at O
its O
N O
terminus O
. O

Hepadnavirus O
polymerases O
are O
multifunctional O
enzymes O
that O
play O
critical O
roles O
during O
the O
viral O
life O
cycle O
but O
have O
been O
difficult O
to O
study O
due O
to O
a O
lack O
of O
a O
Hell O
- O
defined O
panel O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

We O
have O
used O
recombinant O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
polymerase I
( I
Pol I
) I
expressed O
in O
and O
purified O
from O
baculovirus O
- O
infected O
insect O
cells O
to O
generate O
a O
panel O
of O
six O
: O
MAbs O
directed O
against O
HBV O
Pol O
protein O
. O

Using O
these O
MAbs O
as O
probes O
together O
with O
various O
deletion O
mutants O
of O
Pol O
expressed O
in O
insect O
cells O
, O
we O
mapped O
the O
B O
- O
cell O
epitopes O
of O
Pol O
recognized O
by O
these O
MAbs O
to O
amino B
acids I
( I
aa I
) I
8 O
to O
20 O
and O
20 O
to O
30 O
in O
the O
terminal B
protein I
( I
TP I
) I
region O
of O
Pol O
, O
to O
aa O
225 O
to O
250 O
in O
the O
spacer O
region O
, O
and O
to O
sa O
800 O
to O
832 O
in O
the O
RNase O
it O
domain O
. O

We O
have O
previously O
shown O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
surface O
antigens O
( O
HBsAgs O
) O
are O
highly O
immunogenic O
after O
genetic O
immunization O
. O

Compared O
to O
the O
secreted O
middle B
HBV I
surface I
proteins I
( I
MHBs I
) I
or O
small B
HBV I
surface I
proteins I
( I
SHBs I
) I
, O
the O
nonsecreted O
large B
HBV I
surface I
protein I
( I
LHBs I
) I
, O
however O
, O
induced O
significantly O
weaker O
humoral O
and O
cellular O
immune O
responses O
that O
could O
not O
be O
augmented O
by O
genetic O
coimmunizations O
with O
cytokine O
expression O
plasmids O
, O
In O
order O
to O
understand O
the O
mechanisms O
underlying O
this O
phenomenon O
, O
we O
examined O
the O
effect O
of O
coimmunizations O
with O
an O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
DNA O
expression O
plasmid O
on O
the O
immunogenicity O
at O
the O
B O
- O
and O
T O
- O
cell O
level O
of O
nonsecreted O
wild O
- O
type O
LHBs O
, O
a O
secreted O
mutant O
LHBs O
, O
wild O
- O
type O
SHBs O
, O
and O
a O
nonsecreted O
mutant O
SHBs O
. O

To O
date O
, O
no O
detailed O
analysis O
of O
the O
neutralization O
properties O
of O
duck O
hepatitis O
a O
virus O
( O
DHBV O
) O
has O
been O
reported O
, O
and O
it O
is O
not O
clear O
whether O
any O
of O
the O
known O
neutralization O
epitopes O
correspond O
to O
the O
viral O
receptor O
binding O
site O
or O
to O
sequences O
involved O
in O
the O
cell O
entry O
pathway O
. O

We O
demonstrate O
here O
that O
antibodies O
directed O
against O
two O
overlapping O
peptides O
( O
amino O
acids O
83 O
to O
97 O
and O
93 O
to O
107 O
) O
, O
covering O
the O
sequences O
of O
most O
DHBV O
pre O
- O
S O
neutralizing O
epitopes O
, O
both O
inhibit O
virus O
binding O
to O
primary O
duck O
hepatocytes O
and O
neutralize O
virus O
infectivity O
. O

An O
extensive O
mutagenesis O
of O
the O
motif O
( O
WTP90 O
) O
- O
W O
- O
88 O
, O
which O
is O
the O
shortest O
sequence O
of O
the O
epitope O
recognized O
by O
the O
virus O
- O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
900 O
was O
performed O
in O
order O
to O
define O
the O
amino O
acids O
involved O
in O
these O
interactions O
. O

Interestingly O
, O
mutants O
with O
two O
and O
three O
consecutive O
residue O
replacements O
( O
SIP O
and O
SIH O
) O
within O
this O
epitope O
retained O
replication O
competence O
but O
were O
no O
longer O
infectious O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
each O
amino O
acid O
of O
the O
DHBV O
pre O
- O
S O
sequence O
( O
WTP90 O
) O
- O
W O
- O
88 O
is O
critical O
for O
recognition O
by O
the O
neutralizing O
MAb O
900 O
and O
that O
replacement O
of O
the O
first O
two O
or O
all O
three O
residues O
strongly O
reduces O
virus O
interaction O
with O
hepatocytes O
and O
abrogates O
infectivity O
. O

These O
data O
imply O
that O
the O
motif O
( O
WTP90 O
) O
- O
W O
- O
88 O
contains O
key O
residues O
which O
are O
critical O
for O
interaction O
with O
both O
the O
neutralizing O
MAb O
and O
the O
host O
cell O
. O

The O
nucleocapsid O
core O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
to O
trans O
- O
act O
on O
several O
viral O
or O
cellular O
promoters O
. O

We O
hypothesized O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
persistence O
is O
related O
to O
the O
sequence O
variability O
of O
putative O
envelope O
genes O
. O

This O
hypothesis O
was O
tested O
by O
characterizing O
quasispecies O
in O
specimens O
collected O
every O
six O
months O
from O
a O
cohort O
of O
acutely O
HCV O
- O
infected O
subjects O
( O
mean O
duration O
of O
specimen O
collection O
, O
72 O
months O
after O
seroconversion O
) O
. O

We O
evaluated O
5 O
individuals O
who O
spontaneously O
cleared O
viremia O
and O
10 O
individuals O
with O
persistent O
viremia O
by O
cloning O
33 O
1 O
- O
kb O
amplicons O
that O
spanned O
E1 O
and O
the O
5 O
' O
half O
of O
E2 O
, O
including O
hypervariable B
region I
1 I
( I
HVR1 I
) I
, O
To O
assess O
the O
quasispecies O
complexity O
and O
to O
detect O
variants O
For O
sequencing O
, O
the O
first O
PCR O
- O
positive O
sample O
was O
examined O
by O
using O
a O
previously O
described O
method O
that O
combines O
heteroduplex O
analysis O
and O
analysis O
of O
single O
- O
stranded O
conformational O
polymorphisms O
. O

The O
ratio O
of O
nonsynonymous O
to O
synonymous O
substitutions O
( O
d O
( O
N O
) O
/ O
d O
( O
S O
) O
) O
within O
each O
sample O
was O
evaluated O
as O
an O
indicator O
of O
relative O
selective O
pressure O
. O

Amino O
acid O
sequences O
were O
analyzed O
for O
signature O
patterns O
, O
glycosylation O
signals O
, O
and O
charger O
Quasispecies O
complexity O
was O
higher O
and O
E1 O
d O
( O
N O
) O
/ O
d O
( O
S O
) O
ratios O
( O
selective O
pressure O
) O
were O
lower O
in O
those O
with O
persistent O
viremia O
; O
the O
association O
with O
persistence O
was O
strengthened O
by O
the O
presence O
of O
a O
combination O
of O
both O
characteristics O
, O
In O
contrast O
, O
a O
trend O
toward O
higher O
HVR1 O
d O
( O
N O
) O
/ O
d O
( O
S O
) O
, O
ratios O
was O
detected O
among O
those O
with O
persistent O
viremia O
. O

Interferon O
gamma O
( O
IFN O
- O
gamma O
) O
, O
which O
has O
been O
cloned O
in O
several O
mammalian O
species O
and O
recently O
in O
birds O
, O
plays O
a O
critical O
role O
in O
modulating O
immune O
system O
function O
, O
IFN O
- O
gamma O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
have O
been O
shown O
to O
be O
crucial O
in O
the O
pathogenesis O
of O
viral O
hepatitis O
and O
in O
the O
transient O
disappearance O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
from O
the O
liver O
after O
adoptive O
transfer O
of O
HBV O
- O
specific O
cytotoxic O
T O
lymphocytes O
into O
HBV O
- O
transgenic O
mice O
, O
Similar O
studies O
in O
the O
natural O
animal O
hosts O
of O
related O
hepadnaviruses O
have O
been O
limited O
because O
the O
corresponding O
probes O
and O
recombinant O
cytokines O
were O
not O
available O
, O
For O
this O
reason O
, O
we O
initiated O
studies O
to O
clone O
and O
characterize O
cytokines O
from O
the O
duck O
, O
the O
natural O
host O
of O
the O
duck O
hepatitis O
B O
virus O
( O
DHBV O
, O
We O
describe O
here O
the O
cDNA O
cloning O
and O
initial O
characterization O
of O
the O
IFN O
- O
gamma O
homologue O
of O
ducks O
( O
DuIFN O
- O
gamma O
) O
, O
The O
DuIFN O
- O
gamma O
cDNA O
codes O
for O
a O
predicted O
mature O
protein O
of O
145 O
amino O
acids O
with O
a O
molecular O
mass O
of O
16 O
. O

Time O
course O
analysis O
revealed O
that O
IFN O
- O
gamma O
treatment O
does O
not O
affect O
initial O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
conversion O
but O
inhibits O
the O
synthesis O
of O
progeny O
cccDNA O
by O
amplification O
. O

Box O
alpha O
is O
an O
essential O
element O
of O
both O
the O
upstream O
regulatory O
sequence O
of O
the O
core O
promoter O
and O
the O
second O
enhancer O
, O
which O
positively O
regulate O
the O
transcription O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
genes O
. O

Two O
chimpanzees O
( O
Ch1535 O
and O
Ch1536 O
) O
became O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
following O
intrahepatic O
inoculation O
with O
RNA O
transcribed O
from O
a O
full O
- O
length O
cDNA O
clone O
of O
the O
virus O
. O

They O
showed O
similar O
responses O
to O
infection O
, O
with O
transient O
liver O
enzyme O
elevations O
and O
liver O
inflammatory O
responses O
, O
which O
peaked O
at O
weeks O
17 O
( O
Ch1535 O
) O
and O
12 O
( O
Ch1536 O
) O
postinoculation O
( O
p O
. O

Antibody O
responses O
to O
structural O
and O
nonstructural O
proteins O
were O
first O
detected O
at O
weeks O
13 O
( O
Ch1535 O
) O
and O
10 O
( O
Ch1536 O
) O
p O
. O

Despite O
direct O
evidence O
of O
humoral O
immune O
responses O
to O
multiple O
viral O
antigens O
, O
including O
hypervariable B
region I
1 I
( I
HVR1 I
) I
, O
both O
animals O
remained O
chronically O
infected O
. O

( O
Ch1535 O
) O
and O
week O
22 O
p O
. O

( O
Ch1536 O
) O
, O
respectively O
, O
and O
could O
represent O
immune O
escape O
mutations O
. O

57 O
x O
10 O
( O
- O
3 O
) O
and O
1 O
. O

48 O
x O
10 O
( O
- O
3 O
) O
nucleotide O
substitutions O
/ O
site O
/ O
year O
for O
Ch1535 O
and O
Ch1536 O
, O
respectively O
. O

The O
carboxyl O
- O
terminal O
domain O
of O
the O
small B
( I
S I
) I
envelope O
protein O
of O
hepatitis O
B O
virus O
was O
subjected O
to O
mutagenesis O
to O
identify O
sequences O
important O
for O
the O
envelopment O
of O
the O
nucleocapsid O
during O
morphogenesis O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
virions O
. O

One O
exception O
was O
a O
mutant O
carrying O
a O
deletion O
of O
residues O
214 O
to O
218 O
, O
which O
exhibited O
a O
twofold O
increase O
in O
HDV O
assembly O
( O
or O
stability O
) O
, O
whereas O
deletions O
of O
residues O
179 O
to O
183 O
, O
194 O
to O
198 O
, O
and O
199 O
to O
203 O
were O
the O
most O
inhibitory O
. O

A O
number O
of O
human B
immunodeficiency I
type I
1 I
( I
HIV I
- I
1 I
) I
- O
based O
vectors O
have O
recently O
been O
shown O
to O
transduce O
nondividing O
cells O
in O
vivo O
as O
well O
as O
in O
vitro O
. O

Our O
data O
show O
that O
the O
best O
vector O
yield O
is O
achieved O
in O
the O
presence O
of O
the O
Rev B
/ I
Rev I
- I
responsive I
element I
( I
RRE I
) I
system O
. O

We O
previously O
described O
a O
complementation O
assay O
for O
analysis O
of O
the O
roles O
of O
the O
TP O
and O
RT O
domains O
of O
HBV O
reverse O
transcriptase O
( O
pol O
) O
in O
the O
priming O
reaction O
. O

During O
the O
life O
cycle O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
the O
large O
envelope O
protein O
( O
L O
) O
plays O
a O
pivotal O
role O
. O

We O
generated O
a O
large O
number O
of O
mutations O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
gene O
inserted O
into O
a O
bacterial O
expression O
vector O
, O
The O
new O
mutagenesis O
procedure O
generated O
deletions O
and O
insertions O
( O
as O
sequence O
repeats O
) O
of O
various O
lengths O
at O
random O
positions O
between O
M1 O
and O
E145 O
but O
not O
substitutions O
, O
The O
R O
- O
rich O
30 O
- O
amino O
- O
acid O
C O
- O
terminal O
domain O
was O
not O
analyzed O
. O

Crowther O
, O
Nature O
386 O
: O
88 O
- O
91 O
, O
1997 O
) O
; O
V27 O
to O
P50 O
( O
second O
loop O
) O
; O
L60 O
to O
V86 O
( O
upper O
half O
of O
the O
alpha O
helix O
forming O
the O
N O
- O
terminal O
part O
of O
the O
spike O
and O
the O
tip O
of O
the O
spike O
) O
; O
and O
V124 O
to O
L140 O
( O
C O
- O
terminal O
part O
of O
the O
C O
- O
terminal O
helix O
and O
downstream O
loop O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
initiates O
translation O
of O
its O
polyprotein O
under O
the O
control O
of O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
that O
comprises O
most O
of O
the O
341 O
- O
nucleotide B
( I
nt I
) I
5 I
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
. O

A O
comparative O
analysis O
of O
related O
flaviviral O
sequences O
suggested O
that O
an O
RNA O
segment O
for O
which O
secondary O
structure O
was O
previously O
ill O
defined O
( O
domain O
II O
, O
nt O
44 O
to O
118 O
) O
forms O
a O
conserved O
stem O
- O
loop O
that O
is O
located O
at O
the O
5 O
' O
border O
of O
the O
HCV O
IRES O
and O
thus O
may O
function O
in O
viral O
translation O
. O

A O
PCR O
- O
based O
technique O
was O
used O
to O
detect O
hepatitis B
B I
virus I
( I
HBV I
) I
integration O
in O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
. O

Integrated O
HBV O
DNA O
sequences O
, O
with O
virus O
- O
cell O
junctions O
located O
in O
the O
cohesive O
region O
between O
direct B
repeat I
1 I
( I
DR1 I
) I
and O
DR2 O
, O
were O
found O
in O
2 O
of O
10 O
studied O
patients O
. O

A O
double O
mutation O
which O
converts O
nucleotide O
1765 O
from O
A O
to O
T O
and O
nucleotide O
1767 O
from O
G O
to O
A O
is O
frequently O
found O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
isolated O
from O
HBV O
patients O
with O
chronic O
hepatitis O
symptoms O
. O

Analysis O
of O
host O
- O
viral O
DNA O
junctions O
of O
DHBV O
identified O
the O
terminally O
duplicated O
r O
region O
of O
the O
viral O
genome O
as O
a O
hotspot O
for O
integration O
, O
Since O
the O
r O
region O
is O
present O
on O
the O
5 O
' O
and O
3 O
' O
ends O
of O
double B
- I
stranded I
linear I
( I
dsL I
) I
hepadnavirus O
DNAs O
, O
these O
molecules O
have O
been O
implicated O
as O
integration O
precursors O
. O

We O
have O
produced O
a O
LMH O
chicken O
hepatoma O
cell O
line O
( O
LMH O
66 O
- O
1 O
DSL O
) O
which O
replicates O
exclusively O
DSL O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
DNA O
. O

The O
genomes O
of O
the O
spumaviruses O
, O
of O
which O
human B
foamy I
virus I
( I
HFV I
) I
is O
the O
prototype O
, O
are O
very O
similar O
to O
those O
of O
other O
complex O
retroviruses O
, O
However O
, O
in O
some O
aspects O
of O
the O
viral O
replicative O
cycle O
, O
HFV O
more O
closely O
resembles O
pararetroviruses O
such O
as O
hepatitis O
B O
virus O
, O
Previous O
work O
indicated O
that O
HFV O
extracellular O
particles O
contain O
apparently O
full O
- O
length O
double O
- O
stranded O
DNA O
, O
as O
well O
as O
RNA O
. O

Experiments O
with O
the O
reverse O
transcriptase O
inhibitor O
3 O
' O
- O
azido O
- O
3 O
' O
- O
deoxythymidine O
( O
AZT O
) O
suggest O
that O
reverse O
transcription O
is O
largely O
complete O
before O
extracellular O
virus O
infects O
new O
cells O
. O

Our O
previous O
study O
indicated O
that O
the O
core O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
associate O
with O
Tumor B
necrosis I
factor I
receptor I
( I
TNFR I
) I
- O
related O
lymphotoxin B
- I
beta I
receptor I
( I
LT I
- I
beta I
R I
) I
and O
Chat O
this O
protein O
- O
protein O
interaction O
plays O
a O
modulatory O
effect O
on O
the O
cytolytic O
activity O
of O
recombinant O
form O
LT O
- O
beta O
R O
ligand O
( O
LT O
- O
alpha O
1 O
beta O
2 O
) O
but O
not O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
certain O
cell O
types O
. O

Since O
both O
TNF O
- O
alpha O
/ O
TNFR O
and O
LT O
- O
alpha O
1 O
beta O
2 O
/ O
LT O
- O
beta O
R O
are O
also O
engaged O
in O
transcriptional O
activator O
NF O
- O
kappa O
B O
activation O
or O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
activation O
, O
the O
biological O
effects O
of O
the O
HCV O
core O
protein O
on O
these O
regards O
were O
elucidated O
in O
this O
study O
. O

Evidence O
from O
clinical O
and O
experimental O
studies O
of O
human O
and O
chimpanzees O
suggests O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E2 O
is O
a O
key O
antigen O
for O
developing O
a O
vaccine O
against O
HCV O
infection O
. O

To O
identify O
B O
- O
cell O
epitopes O
in O
HCV O
E2 O
, O
six O
murine B
monoclonal I
antibodies I
( I
MAbs I
) I
, O
CET O
- O
1 O
to O
- O
6 O
, O
specific O
for O
HCV O
E2 O
protein O
were O
generated O
by O
using O
recombinant O
proteins O
containing O
E2t O
( O
a O
C O
- O
terminally O
truncated O
domain O
of O
HCV O
E2 O
[ O
amino O
acids O
386 O
to O
693 O
] O
fused O
to O
human O
growth O
hormone O
and O
glycoprotein O
D O
) O
. O

In O
woodchucks O
, O
we O
tested O
the O
protective O
efficacy O
of O
immune O
response O
to O
woodchuck O
hepatitis O
core O
antigen O
( O
WHcAg O
) O
and O
surface O
antigen O
( O
WHsAg O
) O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
elicited O
by O
DNA O
- O
based O
vaccination O
. O

With O
an O
increase O
in O
the O
dose O
to O
1 O
mg O
of O
pWHcIm O
per O
injection O
, O
transient O
anti O
- O
WHcAg O
response O
and O
WHcAg O
- O
specific O
proliferation O
of O
peripheral O
mononuclear O
blood O
cells O
( O
PMBCs O
) O
appeared O
in O
woodchucks O
after O
repeated O
immunizations O
. O

Four O
woodchucks O
vaccinated O
with O
pWHcIm O
were O
challenged O
with O
10 O
( O
4 O
) O
or O
10 O
( O
5 O
) O
of O
the O
WHV O
50 O
% O
infective O
dose O
. O

They O
remained O
negative O
for O
markers O
of O
WHV O
replication O
( O
WHV O
DNA O
and O
WHsAg O
) O
in O
peripheral O
blood O
and O
developed O
anti O
- O
WHs O
in O
week O
5 O
after O
challenge O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
gene O
expression O
is O
downregulated O
in O
the O
liver O
of O
HBV O
transgenic O
mice O
by O
a O
posttranscriptional O
mechanism O
that O
is O
triggered O
by O
the O
local O
production O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
during O
intrahepatic O
inflammation O
( O
hepatitis O
) O
. O

In O
this O
study O
, O
we O
identified O
three O
HBV O
RNA O
- O
binding O
liver O
nuclear O
proteins O
( O
p45 O
, O
p39 O
, O
and O
p26 O
) O
the O
relative O
abundance O
of O
which O
correlates O
with O
the O
abundance O
of O
HBV O
RNA O
in O
response O
to O
the O
induction O
of O
IFN O
- O
gamma O
and O
TNF O
- O
alpha O
. O

We O
have O
shown O
by O
transient O
expression O
in O
plant O
protoplasts O
that O
the O
viral O
coat B
protein I
( I
CP I
) I
, O
which O
is O
processed O
from O
the O
product O
of O
open O
reading O
frame O
IV O
, O
contains O
an O
N O
- O
terminal O
nuclear B
localization I
signal I
( I
NLS I
) I
. O

The O
putative O
core O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
regulates O
cellular O
growth O
and O
a O
number O
of O
cellular O
promoters O
. O

To O
further O
understand O
its O
effect O
, O
we O
investigated O
the O
role O
of O
the O
core O
protein O
in O
the O
endogenous O
regulation O
of O
two O
distinct O
transcription O
factors O
, O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
and O
activating B
protein I
- I
1 I
( I
AP I
- I
1 I
) I
, O
and O
the O
related O
mitogen B
- I
activated I
protein I
kinase I
kinase I
( I
MAPKK I
) I
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
. O

Stable O
cell O
transfectants O
expressing O
the O
HCV O
core O
protein O
suppressed O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
induced O
NF O
- O
kappa O
B O
activation O
. O

We O
identified O
cia O
- O
acting O
elements O
in O
the O
intronless O
herpes O
simplex O
virus O
type O
I O
thymidine B
kinase I
( I
TK I
) I
gene O
that O
facilitate O
intron O
independent O
gene O
expression O
. O

TK O
sequences O
functionally O
replaced O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
posttranscriptional I
regulatory I
element I
( I
PRE I
) I
by O
inducing O
the O
expression O
of O
the O
intronless O
HBV O
surface O
message O
. O

Woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
are O
a O
valuable O
model O
for O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
in O
studies O
of O
pathogenesis O
, O
immunity O
, O
and O
antiviral O
therapy O
. O

The O
structure O
of O
the O
WHV O
surface O
proteins O
( O
WHs O
proteins O
) O
has O
not O
yet O
been O
adequately O
elucidated O
. O

The O
bands O
that O
would O
be O
expected O
for O
glycosylated O
and O
nonglycosylated O
small B
( I
S I
) I
WHs O
protein O
are O
found O
by O
sodium O
dodecyl O
sulfate O
gel O
electrophoresis O
of O
purified O
WHs O
protein O
, O
but O
the O
bands O
corresponding O
to O
the O
middle O
( O
M O
) O
and O
large B
( I
L I
) I
WHs O
proteins O
of O
HBV O
are O
not O
seen O
at O
the O
expected O
sizes O
, O
even O
though O
the O
sequences O
of O
the O
WHV O
and O
HBV O
surface O
protein O
genes O
are O
60 O
% O
homologous O
. O

A O
protein O
of O
49 O
kDa O
was O
blocked O
at O
the O
N O
terminus O
, O
which O
using O
immunoblotting O
with O
an O
antiserum O
against O
WHV O
pre O
- O
SI O
( O
positions O
126 O
to O
146 O
) O
was O
identified O
, O
together O
with O
a O
part O
of O
the O
45 O
- O
kDa O
protein O
, O
as O
glycosylated O
and O
nonglycosylated O
LWHs O
protein O
of O
the O
expected O
size O
. O

Phosphorylation O
of O
cytosolic O
pre O
- O
S O
domains O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
large O
envelope O
protein O
( O
L O
) O
was O
identified O
as O
a O
regulatory O
modification O
involved O
in O
intracellular O
signaling O
. O

By O
using O
biochemical O
and O
mass O
spectrometric O
analyses O
of O
phosphopeptides O
obtained O
from O
metabolically O
radiolabeled O
L O
protein O
, O
a O
single O
phosphorylation O
site O
was O
identified O
at O
serine O
118 O
as O
part O
of O
a O
PX O
( O
S O
/ O
T O
) O
P O
motif O
, O
which O
is O
strongly O
preferred O
by O
ERR O
- O
type O
mitogen O
- O
activated O
protein O
kinases O
( O
MAP O
kinases O
) O
. O

Functional O
analysis O
with O
transfected O
cells O
showed O
that O
DHBV O
L O
possesses O
the O
ability O
to O
activate O
gene O
expression O
in O
trans O
and O
, O
by O
using O
mutations O
eliminating O
( O
S O
- O
- O
> O
A O
) O
or O
mimicking O
( O
S O
- O
- O
> O
D O
) O
serine O
phosphorylation O
, O
that O
this O
function O
correlates O
with O
L O
phosphorylation O
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
DNA O
Polymerase B
( I
Pol I
) I
mRNA O
, O
which O
contains O
a O
noncanonical O
polyadenylation O
signal O
, O
UAUAAA O
, O
is O
cleaved O
and O
polyadenylated O
inefficiently O
( O
S O
, O
C O
, O
S O
. O

Key O
and O
J O
, O
S O
, O
Pagano O
, O
Virology O
234 O
: O
147 O
- O
159 O
, O
1997 O
) O
, O
We O
postulated O
that O
the O
EBV O
early O
proteins O
SM O
and O
frl O
, O
which O
appear O
to O
act O
posttranscriptionally O
and O
are O
homologs O
of O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
ICP27 O
, O
might O
compensate O
for O
the O
inefficient O
processing O
of O
pol O
pre O
- O
mRNA O
, O
Here O
we O
show O
that O
the O
SM O
and O
M O
proteins O
interact O
with O
each O
other O
in O
vitro O
. O

In O
addition O
, O
glutathione O
S O
- O
transferase O
- O
SM O
/ O
M O
fusion O
proteins O
precipitate O
the O
heterogeneous B
ribonucleoprotein I
( I
hnRNP I
) I
C1 O
splicing O
protein O
. O

69 O
: O
4029 O
- O
4036 O
, O
1995 O
) O
we O
showed O
that O
virus O
particles O
containing O
linear O
DNA O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
could O
initiate O
an O
infection O
of O
primary O
duck O
hepatocytes O
. O

No O
specific O
therapy O
exists O
for O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
which O
can O
cause O
severe O
liver O
disease O
. O

In O
order O
to O
identify O
potential O
sites O
of O
hepadnavirus O
X O
protein O
action O
, O
we O
have O
investigated O
the O
subcellular O
distribution O
and O
the O
stability O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
X O
protein O
( O
WHx O
) O
in O
primary O
hepatocytes O
isolated O
from O
woodchucks O
with O
persistent O
WHV O
infection O
. O

In O
vivo O
cell O
labeling O
and O
cell O
fractionation O
studies O
showed O
that O
the O
majority O
of O
WHx O
is O
a O
soluble O
cytoplasmic O
protein O
while O
a O
minor O
part O
of O
newly O
synthesized O
WHx O
is O
associated O
with O
a O
nuclear O
framework O
fraction O
( O
20 O
% O
) O
and O
with O
cytoskeletal O
components O
( O
5 O
to O
10 O
% O
) O
. O

Pulse O
- O
chase O
experiments O
revealed O
that O
cytoplasmic O
WHx O
has O
a O
short O
half O
- O
life O
and O
decays O
with O
bimodal O
kinetics O
( O
approximately O
20 O
min O
and O
3 O
h O
) O
. O

Functionally O
relevant O
hepadnavirus O
- O
cell O
surface O
interactions O
were O
investigated O
with O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
animal O
model O
by O
using O
an O
in O
vitro O
infection O
competition O
assay O
. O

Pre O
- O
S O
polypeptides O
from O
heron B
hepatitis I
B I
virus I
( I
HHBV I
) I
competed O
DHBV O
infection O
equally O
well O
despite O
a O
50 O
% O
difference O
in O
amino O
acid O
sequence O
and O
a O
much O
- O
reduced O
infectivity O
of O
HHBV O
for O
duck O
hepatocytes O
. O

These O
observations O
are O
taken O
to O
indicate O
( O
i O
) O
that O
the O
functionality O
of O
the O
DHBV O
pre O
- O
S O
subdomain O
, O
which O
interacts O
with O
the O
cellular O
receptor O
, O
is O
determined O
predominantly O
by O
a O
defined O
three O
- O
dimensional O
structure O
rather O
than O
by O
primary O
sequence O
elements O
; O
( O
ii O
) O
that O
cellular O
uptake O
of O
hepadnaviruses O
is O
a O
multistep O
process O
involving O
more O
than O
a O
single O
cellular O
receptor O
component O
; O
and O
( O
iii O
) O
that O
gp180 O
, O
a O
cellular O
receptor O
candidate O
unable O
to O
discriminate O
between O
DHBV O
and O
HHBV O
, O
is O
a O
common O
component O
of O
the O
cellular O
receptor O
complex O
for O
avian O
hepadnaviruses O
. O

Carboxypeptidase O
D O
( O
gp180 O
) O
, O
one O
of O
many O
candidate O
receptors O
proposed O
for O
hepatitis B
B I
viruses I
( I
HBVs I
) I
, O
was O
examined O
and O
found O
to O
be O
the O
actual O
cellular O
receptor O
for O
avian O
HBVs O
. O

This O
conclusion O
was O
based O
on O
the O
following O
observations O
: O
( O
i O
) O
gp180 O
was O
the O
only O
host O
protein O
that O
bound O
with O
high O
affinity O
to O
the O
pre O
- O
S O
ectodomain O
of O
the O
large O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
envelope O
protein O
, O
which O
is O
known O
to O
be O
essential O
for O
virus O
infection O
; O
( O
ii O
) O
a O
pre O
- O
S O
subdomain O
which O
determines O
physical O
binding O
to O
gp180 O
was O
found O
to O
coincide O
with O
a O
domain O
functionally O
defined O
in O
infection O
competition O
experiments O
as O
a O
receptor O
binding O
domain O
; O
( O
iii O
) O
soluble O
gp180 O
, O
lacking O
the O
membrane O
anchor O
, O
efficiently O
inhibited O
DHBV O
infection O
; O
( O
iv O
) O
efficient O
interspecies O
gp180 O
- O
pre O
- O
S O
interaction O
was O
limited O
to O
the O
natural O
hosts O
of O
avian O
hepadnaviruses O
; O
and O
( O
v O
) O
expression O
of O
gp180 O
in O
a O
heterologous O
hepatoma O
cell O
line O
mediated O
cellular O
attachment O
and O
subsequent O
internalization O
of O
fluorescently O
labeled O
viral O
particles O
into O
vesicular O
structures O
. O

The O
induction O
of O
an O
efficient O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
critical O
for O
control O
of O
the O
chronicity O
of O
HCV O
infection O
. O

The O
ability O
of O
HCV O
structural O
protein O
endogenously O
expressed O
in O
an O
antigen B
- I
presenting I
cell I
( I
APC I
) I
to O
be O
presented O
by O
class O
II O
major O
histocompatibility O
complex O
molecules O
to O
CD4 O
( O
+ O
) O
T O
cells O
was O
investigated O
by O
in O
vitro O
culture O
analyses O
using O
HCV O
core O
- O
specific O
T O
- O
cell O
lines O
and O
autologous O
Epstein O
- O
Barr O
virus O
- O
transformed O
B B
- I
lymphoblastoid I
cell I
lines I
( I
B I
- I
LCLs I
) I
expressing O
structural O
HCV O
antigens O
. O

By O
stimulation O
with O
autologous O
B O
- O
LCLs O
expressing O
viral O
antigens O
, O
strong O
T O
- O
cell O
proliferative O
responses O
were O
induced O
in O
two O
of O
three O
patients O
, O
while O
no O
substantial O
stimulatory O
effects O
were O
produced O
by O
B O
- O
LCLs O
expressing O
a O
control O
protein O
( O
chloramphenicol O
acetyltransferase O
) O
or O
by O
B O
- O
LCLs O
alone O
. O

Titrating O
numbers O
of O
APCs O
, O
we O
showed O
that O
as O
few O
as O
10 O
( O
4 O
) O
transfected O
B O
- O
LCL O
APCs O
were O
sufficient O
to O
stimulate O
T O
cells O
. O

This O
presentation O
pathway O
was O
found O
to O
be O
leupeptin O
sensitive O
, O
and O
it O
can O
be O
blocked O
by O
antibody O
to O
HLA O
class O
II O
( O
DR O
) O
. O

In O
this O
study O
, O
we O
have O
constructed O
various O
DNA O
vaccine O
vectors O
that O
carried O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
genes O
without O
and O
with O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene O
in O
several O
different O
ways O
. O

mouse B
hepatitis I
virus I
receptor I
( I
MHVR I
) I
is O
a O
murine O
biliary O
glycoprotein O
( O
Bgp1 O
( O
a O
) O
) O
. O

Purified O
, O
soluble O
MHVR O
expressed O
from O
a O
recombinant O
vaccinia O
virus O
neutralized O
the O
infectivity O
of O
the O
A59 O
strain O
of O
mouse O
hepatitis O
virus O
( O
MHV O
A59 O
) O
in O
a O
concentration O
dependent O
manner O
. O

These O
include O
MHVR O
isoforms O
containing O
four O
or O
two O
extracellular O
domains O
and O
the O
corresponding O
Bgp1 O
( O
b O
) O
glycoproteins O
from O
MHV O
- O
resistant O
SJL O
/ O
J O
mice O
, O
as O
well O
as O
Bgp2 O
and O
truncation O
mutants O
of O
MHVR O
and O
Bgp1 O
( O
b O
) O
comprised O
of O
the O
first O
two O
immunoglobulin O
- O
like O
domains O
. O

The O
soluble O
four O
- O
domain O
MHVR O
glycoprotein O
( O
sMHVR O
[ O
1 O
- O
4 O
] O
) O
had O
fourfold O
more O
MHV O
- O
A59 O
neutralizing O
activity O
than O
the O
corresponding O
soluble O
Bgp1 O
( O
b O
) O
( O
sBgp1 O
( O
b O
) O
) O
glycoprotein O
and O
at O
least O
1 O
, O
000 O
- O
fold O
more O
neutralizing O
activity O
than O
sBgp2 O
. O

Although O
virus O
binds O
to O
the O
N O
- O
terminal O
domain O
( O
domain O
1 O
) O
, O
soluble O
truncation O
mutants O
of O
MHVR O
and O
Bgp1 O
( O
b O
) O
containing O
only O
domains O
1 O
and O
2 O
bound O
virus O
poorly O
and O
had O
10 O
- O
and O
300 O
- O
fold O
less O
MHV O
- O
A59 O
neutralizing O
activity O
than O
the O
corresponding O
four O
- O
domain O
glycoproteins O
. O

In O
contrast O
, O
the O
soluble O
MHVR O
glycoprotein O
containing O
domains O
1 O
and O
4 O
( O
sMHVR O
[ O
1 O
, O
4 O
] O
) O
had O
as O
much O
neutralizing O
activity O
as O
the O
four O
- O
domain O
glycoprotein O
, O
sMHVR O
[ O
1 O
- O
4 O
] O
. O

The O
sBgp1 O
( O
b O
) O
[ O
1 O
- O
4 O
] O
glycoprotein O
had O
500 O
- O
fold O
less O
neutralizing O
activity O
for O
MHV O
- O
JHM O
than O
for O
MHV O
- O
A59 O
. O

Human O
immunodeficiency O
virus O
type O
1 O
Rev O
export O
depends O
upon O
the O
presence O
of O
the O
nuclear B
export I
signal I
( I
NES I
) I
, O
a O
leucine O
- O
rich O
stretch O
of O
hydrophobic O
amino O
acids O
. O

The O
function O
of O
the O
atypical O
NES O
- O
containing O
Rev O
- O
like O
proteins O
of O
equine B
infectious I
anemia I
virus I
( I
EIAV I
) I
and O
feline O
immunodeficiency O
virus O
( O
FN O
) O
is O
inhibited O
by O
leptomycin O
B O
, O
a O
drug O
that O
specifically O
blocks O
NES O
- O
CRM1 O
interactions O
. O

In O
contrast O
to O
the O
inhibition O
of O
EIAV O
Rev O
and O
FIV O
Rev O
, O
the O
cytoplasmic O
accumulation O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
posttranscriptional I
regulatory I
element I
( I
PRE I
) I
- O
containing O
and O
Mason B
- I
Pfizer I
monkey I
virus I
( I
MPMV I
) I
constitutive I
transport I
element I
( I
CTE I
) I
- O
containing O
RNAs O
is O
not O
inhibited O
by O
leptomycin O
B O
treatment O
. O

Synthesis O
and O
association O
of O
the O
middle O
( O
M O
) O
and O
small B
( I
S I
) I
surface O
proteins O
could O
be O
shown O
in O
vitro O
. O

For O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
DR2 O
is O
located O
within O
50 O
nucleotides O
of O
the O
5 O
' O
end O
of O
the O
minus O
- O
strand O
DNA O
template O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
enhancer B
II I
( I
EnII I
) I
is O
located O
; O
upstream O
of O
the O
major O
pregenomic O
RNA O
promoter O
and O
is O
thought O
to O
play O
an O
important O
role O
in O
the O
insertional O
activation O
of O
the O
N O
- O
myc2 O
gene O
during O
WHV O
hepatocarcinogenesis O
. O

In O
HepG2 O
cells O
transiently O
transfected O
with O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
whose O
expression O
is O
dependent O
upon O
EnII O
, O
mutations O
in O
either O
the O
HNF O
- O
1 O
or O
the O
HNP O
- O
4 O
site O
strongly O
reduced O
CAT O
activity O
, O
while O
ablation O
of O
the O
Oct O
- O
1 O
site O
decreased O
CAT O
expression O
only O
twofold O
, O
Mutations O
in O
more O
than O
one O
site O
completely O
abolished O
reporter O
expression O
. O

We O
conclude O
that O
( O
i O
) O
EnII O
is O
primarily O
devoted O
to O
the O
regulation O
of O
pregenomic O
RNA O
in O
WHV O
, O
( O
ii O
) O
HNF O
- O
1 O
is O
essential O
for O
EnII O
function O
in O
vivo O
, O
and O
( O
iii O
) O
HNF O
- O
4 O
plays O
a O
demonstrable O
but O
adjunctive O
role O
in O
EnII O
function O
. O

Functional O
analysis O
of O
naturally O
occurring O
hepatitis B
B I
virus I
( I
HBV I
) I
mutations O
is O
crucial O
in O
understanding O
their O
impact O
on O
disease O
. O

We O
have O
recently O
identified O
two O
mutations O
in O
the O
REV O
core O
promoter O
of O
an O
HBV O
strain O
associated O
with O
fulminant O
hepatitis O
leading O
to O
highly O
( O
15 O
- O
fold O
) O
enhanced O
replication O
as O
a O
result O
of O
increased O
viral O
encapsidation O
of O
pregenomic O
RNA O
into O
the O
core O
particles O
( O
T O
. O

In O
this O
study O
, O
we O
define O
the O
molecular O
mechanism O
whereby O
the O
two O
core O
promoter O
mutations O
( O
C O
to O
T O
at O
nucleotide O
[ O
nt O
] O
1768 O
and O
T O
to O
A O
at O
nt O
1770 O
) O
result O
in O
enhanced O
viral O
encapsidation O
and O
replication O
. O

, O
The O
effect O
of O
these O
mutations O
leading O
to O
increased O
encapsidation O
is O
mediated O
through O
enhanced O
core O
protein O
synthesis O
( O
W O
- O
fold O
) O
by O
the O
mutant O
virus O
. O

Among O
the O
three O
viral O
proteins O
present O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
, O
both O
the O
small O
and O
large O
polypeptides O
, O
but O
not O
the O
middle O
polypeptide O
, O
are O
necessary O
for O
the O
production O
of O
complete O
viral O
particles O
. O

In O
contrast O
, O
the O
polypeptide O
lacking O
the O
first O
5 O
amino O
acids O
of O
pre O
- O
S2 O
( O
amino O
acids O
109 O
to O
113 O
) O
was O
unable O
to O
support O
viral O
secretion O
, O
This O
result O
shows O
that O
the O
domain O
of O
the O
large O
surface O
protein O
, O
required O
for O
this O
process O
, O
must O
be O
extended O
to O
the O
N O
- O
terminal O
extremity O
of O
pre O
- O
S2 O
, O
We O
then O
demonstrated O
that O
all O
the O
mutants O
competent O
for O
virion O
release O
were O
able O
to O
infect O
normal O
human O
hepatocytes O
in O
primary O
culture O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
frequently O
leads O
to O
chronic O
hepatitis O
and O
cirrhosis O
of O
the O
liver O
and O
has O
been O
linked O
to O
development O
of O
hepatocellular O
carcinoma O
. O

We O
previously O
identified O
a O
small O
yeast O
RNA O
( O
IRNA O
) O
capable O
of O
specifically O
inhibiting O
poliovirus B
( I
PV I
) I
internal I
ribosome I
entry I
site I
( I
IRES I
) I
- O
mediated O
translation O
. O

A O
number O
of O
human O
hepatoma O
( O
Huh O
- O
7 O
) O
cell O
lines O
expressing O
IRNA O
were O
prepared O
and O
characterized O
. O

In O
contrast O
, O
replication O
of O
a O
PV O
- O
encephalomyocarditis B
virus I
( I
EMCV I
) I
chimera O
containing O
the O
EMCV O
IRES O
element O
was O
not O
affected O
significantly O
in O
the O
IRNA O
- O
producing O
cell O
line O
. O

First O
, O
an O
unusual O
DNA O
polymerase O
activity O
employing O
exogenous O
RNAs O
( O
the O
trans O
reaction O
) O
that O
was O
originally O
discovered O
with O
recombinant O
duck O
hepatitis O
B O
virus O
polymerase O
expressed O
in O
Saccharomyces O
cerevisiae O
yeasts O
was O
shown O
to O
be O
an O
authentic O
property O
of O
the O
viral O
polymerase O
. O

The O
maturation O
and O
subcellular O
localization O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
were O
investigated O
with O
both O
a O
vaccinia O
virus O
expression O
system O
and O
CHO O
cell O
lines O
stably O
transformed O
with O
HCV O
cDNA O
. O

Two O
HCV O
core O
proteins O
, O
with O
molecular O
sizes O
of O
21 O
kDa O
( O
p21 O
) O
and O
23 O
kDa O
( O
p23 O
) O
, O
were O
identified O
. O

Direct O
activation O
of O
the O
N O
- O
myc2 O
oncogene O
by O
insertion O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
DNA O
is O
a O
major O
oncogenic O
step O
in O
woodchuck O
hepatocarcinogenesis O
. O

We O
previously O
reported O
that O
WHV B
enhancer I
II I
( I
We2 I
) I
, O
which O
controls O
expression O
of O
the O
core O
/ O
pregenome O
RNA O
, O
can O
also O
activate O
the O
N O
- O
myc2 O
promoter O
in O
hepatoma O
cell O
lines O
. O

This O
viral O
insert O
was O
made O
of O
11 O
concatemerized O
WHV O
fragments O
, O
5 O
of O
which O
overlapped O
with O
We2 O
sequences O
and O
1 O
with O
WHV O
sequence O
homologous O
to O
that O
of O
hepatitis O
B O
virus O
enhancer O
I O
( O
We1 O
) O
, O
In O
transient O
transfection O
assays O
in O
hepatoma O
- O
derived O
cells O
, O
the O
We2 O
activator O
was O
found O
to O
be O
fully O
effective O
only O
when O
inserted O
in O
close O
proximity O
to O
the O
N O
- O
myc2 O
promoter O
whereas O
the O
We1 O
element O
by O
itself O
was O
apparently O
devoid O
of O
activity O
. O

The O
hepatitis O
B O
virus O
posttranscriptional O
regulatory O
element O
( O
HBVPRE O
) O
is O
a O
cis O
- O
acting O
RNA O
element O
that O
partially O
overlaps O
with O
enhancer O
I O
and O
is O
required O
for O
the O
cytoplasmic O
accumulation O
of O
HBV O
surface O
RNAs O
. O

We O
find O
that O
the O
closely O
related O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
which O
has O
been O
shown O
to O
lack O
a O
functional O
enhancer O
I O
, O
also O
contains O
a O
posttranscriptional O
regulatory O
element O
( O
WPRE O
) O
. O

human B
foamy I
virus I
( I
HFV I
) I
is O
the O
prototype O
of O
the O
Spumavirus O
genus O
of O
retroviruses O
. O

These O
viruses O
have O
a O
genomic O
organization O
close O
to O
that O
of O
other O
complex O
retroviruses O
but O
have O
similarities O
to O
hepadnaviruses O
such O
as O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
. O

In O
contrast O
, O
assembly O
of O
extracellular O
HBV O
particles O
containing O
DNA O
requires O
core O
structural O
protein O
and O
polymerase O
( O
P O
protein O
) O
for O
assembly O
of O
nucleocapsids O
and O
requires O
surface O
glycoproteins O
for O
release O
from O
the O
cell O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
known O
to O
be O
a O
multifunctional O
protein O
, O
besides O
being O
a O
component O
of O
viral O
nucleocapsids O
, O
Previously O
, O
we O
have O
shown O
that O
the O
core O
protein O
binds O
to O
the O
cytoplasmic O
domain O
of O
lymphotoxin O
beta O
receptor O
, O
which O
is O
a O
member O
of O
Tumor B
necrosis I
factor I
receptor I
( I
TNFR I
) I
family O
. O

We O
have O
further O
shown O
that O
stable O
expression O
of O
the O
core O
protein O
in O
a O
mouse O
cell O
line O
( O
BC10ME O
) O
or O
human O
cell O
Hines O
( O
HepG2 O
and O
HeLa O
cells O
) O
sensitized O
them O
to O
TNF O
- O
induced O
apoptosis O
, O
as O
determined O
by O
the O
TNF O
cytotoxicity O
or O
annexin O
V O
apoptosis O
assay O
. O

Core O
protein O
is O
the O
major O
component O
of O
the O
core O
particle O
( O
nucleocapsid O
) O
of O
human O
hepatitis O
B O
virus O
. O

This O
kinase O
is O
referred O
to O
as O
core B
- I
associated I
kinase I
( I
CAK I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
chronic O
hepatitis O
in O
the O
world O
. O

In O
insect O
cells O
, O
expressed O
HCV O
structural O
proteins O
assembled O
into O
enveloped O
viruslike O
particles O
( O
40 O
to O
60 O
nm O
in O
diameter O
) O
in O
large O
cytoplasmic O
cisternae O
, O
presumably O
derived O
from O
the O
endoplasmic O
reticulum O
. O

The O
clinical O
course O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
in O
a O
chimpanzee O
cohort O
was O
examined O
to O
better O
characterize O
the O
outcome O
of O
this O
valuable O
animal O
model O
. O

Results O
of O
a O
cross O
- O
sectional O
study O
revealed O
that O
a O
low O
percentage O
( O
39 O
% O
) O
of O
HCV O
- O
inoculated O
chimpanzees O
were O
viremic O
based O
on O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
analysis O
. O

This O
study O
also O
revealed O
that O
a O
low O
percentage O
( O
33 O
% O
) O
of O
HCV O
- O
inoculated O
chimpanzees O
were O
persistently O
viremic O
. O

The O
effect O
of O
glucagon O
on O
the O
establishment O
of O
hepadnavirus O
infection O
was O
studied O
in O
vitro O
with O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
, O
The O
presence O
of O
the O
peptide O
hormone O
throughout O
infection O
or O
starting O
up O
to O
8 O
h O
after O
virus O
uptake O
resulted O
in O
a O
dose O
- O
dependent O
reduction O
in O
the O
levels O
of O
intra O
- O
and O
extracellular O
viral O
gene O
products O
and O
of O
secreted O
virions O
, O
Treatment O
with O
forskolin O
or O
dibutyryl O
- O
cyclic O
AMP O
, O
two O
drugs O
that O
also O
stimulate O
the O
cyclic B
AMP I
( I
cAMP I
) I
signal O
transduction O
pathway O
, O
resulted O
in O
comparable O
inhibition O
, O
suggesting O
that O
the O
inhibitor O
effect O
is O
related O
to O
changes O
in O
the O
activity O
of O
protein O
kinase O
A O
, O
In O
persistently O
infected O
hepatocytes O
, O
only O
a O
slight O
, O
but O
continuous O
, O
decrease O
in O
viral O
replication O
was O
observed O
upon O
prolonged O
drug O
treatment O
, O
Time O
course O
analysis O
, O
including O
detection O
of O
DHBV O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
templates O
, O
revealed O
that O
glucagon O
acts O
late O
during O
the O
establishment O
of O
infection O
, O
at O
a O
time O
when O
the O
, O
virus O
is O
already O
internalized O
, O
but O
before O
detectable O
ccc O
DNA O
accumulation O
in O
the O
nucleus O
, O
These O
data O
suggest O
that O
nuclear O
import O
( O
and O
reimport O
) O
of O
DHBV O
DNA O
genomes O
from O
cytosolic O
capsids O
is O
subject O
to O
cAMP O
- O
mediated O
regulation O
by O
cellular O
factors O
responding O
to O
changes O
in O
the O
state O
of O
the O
host O
cell O
. O

We O
have O
previously O
demonstrated O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
and O
gene O
expression O
are O
abolished O
in O
the O
livers O
of O
HBV O
transgenic O
mice O
by O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
and O
during O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
, O
stimuli O
that O
trigger O
the O
production O
of O
alpha O
/ O
beta O
interferon O
, O
gamma O
interferon O
, O
and O
tumor O
necrosis O
factor O
alpha O
in O
the O
liver O
, O
We O
now O
report O
that O
hepatic O
HBV O
replication O
and O
gene O
expression O
are O
inhibited O
by O
the O
local O
induction O
of O
these O
cytokines O
during O
adenovirus O
- O
and O
murine B
cytomegalovirus I
us I
( I
MCMV I
) I
- O
induced O
hepatitis O
, O
Further O
, O
we O
show O
that O
MCMV O
also O
blocks O
HBV O
replication O
and O
gene O
expression O
in O
the O
proximal O
convoluted O
tubules O
of O
the O
kidney O
by O
causing O
interstitial O
nephritis O
and O
inducing O
the O
same O
cytokines O
in O
the O
renal O
parenchyma O
. O

The O
double O
- O
stranded O
DNA O
genome O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
and O
related O
hepadnaviruses O
is O
reverse O
transcribed O
from O
a O
pregenomic O
RNA O
by O
a O
viral O
Polymerase B
( I
Pol I
) I
harboring O
both O
priming O
and O
RNA O
- O
and O
DNA O
- O
dependent O
elongation O
activities O
, O
Although O
hepadnavirus O
replication O
occurs O
inside O
viral O
nucleocapsids O
, O
or O
cores O
, O
biochemical O
systems O
for O
analyzing O
this O
reaction O
are O
currently O
limited O
to O
unencapsidated O
Pols O
expressed O
in O
heterologous O
systems O
, O
Here O
, O
we O
describe O
cis O
and O
trans O
classes O
of O
replicative O
HBV O
cores O
, O
produced O
in O
the O
recombinant O
baculovirus O
system O
via O
coexpression O
of O
HBV O
core O
and O
Pol O
proteins O
from O
either O
a O
single O
RNA O
( O
i O
. O

e O
, O
, O
in O
cis O
) O
or O
two O
distinct O
RNAs O
( O
in O
trans O
) O
, O
Upon O
isolation O
from O
insect O
cells O
, O
cis O
and O
trans O
cores O
contained O
Pol O
- O
linked O
HBV O
minus O
- O
strand O
DNA O
with O
5 O
' O
ends O
mapping O
to O
the O
authentic O
elongation O
origin O
DR1 O
and O
also O
plus O
- O
strand O
DNA O
species O
, O
Only O
trans O
cores O
, O
however O
, O
were O
highly O
active O
for O
the O
de O
novo O
priming O
and O
reverse O
transcription O
of O
authentic O
HBV O
minus O
strands O
in O
in O
vitro O
endogenous O
polymerase O
assays O
, O
This O
reaction O
strictly O
required O
HBV O
Pol O
but O
not O
the O
epsilon O
stem O
- O
loop O
element O
, O
although O
the O
presence O
of O
one O
epsilon O
, O
or O
better O
, O
two O
epsilon O
s O
, O
enhanced O
minus O
- O
strand O
synthesis O
up O
to O
10 O
- O
fold O
, O
Compared O
to O
unencapsidated O
Pol O
enzymes O
, O
encapsidated O
Pol O
appeared O
to O
be O
( O
i O
) O
highly O
processive O
, O
able O
to O
extend O
minus O
- O
strand O
DNAs O
of O
400 O
nucleotides O
from O
DR1 O
in O
vitro O
, O
and O
( O
ii O
) O
more O
active O
for O
HBV O
plus O
- O
strand O
synthesis O
. O

A O
40 O
- O
amino O
- O
acid O
sequence O
located O
in O
the O
nonstructural B
5A I
( I
NS5A I
) I
protein O
of O
hepatitis B
C I
virus I
genotype I
Ib I
( I
HCV I
- I
lb I
) I
was O
recently O
suggested O
to O
be O
the O
interferon B
sensitivity I
- I
determining I
region I
( I
ISDR I
) I
, O
because O
HCV O
- O
lb O
strains O
with O
an O
ISDR O
amino O
acid O
sequence O
identical O
to O
that O
of O
the O
prototype O
strain O
HCV O
- O
J O
were O
found O
to O
be O
resistant O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
whereas O
strains O
vc O
; O
with O
amino O
acid O
substitutions O
were O
Pound O
to O
be O
sensitive O
( O
N O
. O

We O
used O
single B
- I
strand I
conformation I
polymorphism I
( I
SSCP I
) I
analysis O
, O
combined O
with O
cloning O
and O
sequencing O
strategies O
, O
to O
characterize O
NS5A O
quasispecies O
in O
HCV O
- O
1b O
- O
infected O
patients O
and O
determine O
the O
relationships O
between O
pre O
- O
and O
posttreatment O
NS5A O
quasispecies O
mutations O
and O
the O
IFN O
- O
alpha O
sensitivity O
of O
HCV O
- O
1b O
. O

Sustained O
HCV O
RNA O
clearance O
was O
associated O
with O
low O
viral O
load O
and O
low O
nucleotide O
sequence O
entropy O
, O
suggesting O
( O
i O
) O
that O
the O
replication O
kinetics O
when O
treatment O
is O
started O
plays O
a O
critical O
role O
in O
HCV O
- O
1b O
sensitivity O
to O
IFN O
- O
a O
: O
and O
( O
ii O
) O
that O
HCV O
- O
1b O
resistance O
to O
IFN O
- O
alpha O
could O
be O
conferred O
by O
numerous O
and O
/ O
or O
related O
mutations O
that O
could O
be O
patient O
specific O
and O
located O
at O
different O
positions O
throughout O
the O
viral O
genome O
and O
could O
allow O
escape O
variants O
to O
be O
selected O
by O
IFN O
- O
ol O
- O
stimulated O
immune O
responses O
. O

In O
this O
work O
we O
have O
studied O
the O
intracellular O
Localization O
properties O
of O
the O
Gag O
and O
Env O
proteins O
of O
Moloney B
murine I
leukemia I
virus I
( I
MLV I
) I
and O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
in O
dorsal B
root I
ganglion I
( I
DRG I
) I
neurons O
of O
rat O
. O

Persistent O
infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
associated O
with O
the O
development O
of O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
, O
To O
examine O
the O
oncogenic O
potential O
of O
the O
HCV O
core O
gene O
product O
, O
primary O
rat O
embryo O
fibroblasts O
( O
REFs O
) O
were O
transfected O
with O
the O
core O
gene O
in O
the O
presence O
or O
absence O
of O
the O
R O
- O
ms O
oncogene O
, O
In O
contrast O
to O
a O
previous O
report O
( O
R O
. O

70 O
: O
4438 O
- O
4443 O
, O
1996 O
) O
, O
HCV O
core O
proteins O
from O
two O
different O
genotypes O
( O
type O
la O
and O
type O
Ib O
) O
were O
not O
found O
to O
transform O
REFs O
to O
tumorigenic O
phenotype O
in O
cooperation O
with O
the O
W O
- O
ras O
oncogene O
, O
although O
the O
core O
protein O
was O
successfully O
expressed O
20 O
days O
after O
transfection O
, O
In O
addition O
, O
REFs O
transfected O
with O
E1A O
- O
but O
not O
core O
- O
expressing O
plasmid O
showed O
the O
phenotype O
of O
immortalized O
cells O
when O
selected O
with O
G518 O
. O

Expression O
of O
the O
protein O
product O
( O
HBx O
) O
appears O
necessary O
for O
establishment O
of O
natural O
infection O
. O

The O
primary O
cellular O
receptor O
for O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
murine O
coronavirus O
, O
is O
MHVR O
( O
also O
referred O
to O
as O
Bgp1 O
( O
a O
) O
or O
C O
- O
CAM O
) O
, O
a O
transmembrane O
glycoprotein O
with O
four O
immunoglobulin O
- O
like O
domains O
in O
the O
murine O
biliary B
glycoprotein I
( I
Bgp I
) I
subfamily O
of O
the O
carcinoembryonic B
antigen I
( I
CEA I
) I
family O
. O

Other O
murine O
glycoproteins O
in O
the O
Bgp O
subfamily O
, O
including O
Bgp1 O
( O
b O
) O
and O
Bgp2 O
, O
also O
can O
serve O
as O
MHV O
receptors O
when O
transfected O
into O
MHV O
- O
resistant O
cells O
. O

Previous O
studies O
have O
shown O
that O
the O
108 O
- O
amino O
- O
acid O
N O
- O
terminal O
domain O
of O
MHVR O
is O
essential O
for O
virus O
receptor O
activity O
and O
is O
the O
binding O
site O
for O
monoclonal B
antibody I
( I
Mab I
) I
CCl O
, O
an O
antireceptor O
MAb O
that O
blocks O
MHV O
infection O
in O
vivo O
and O
in O
vitro O
. O

To O
further O
elucidate O
the O
regions O
of O
MHVR O
required O
for O
virus O
receptor O
activity O
and O
MAb O
CCl O
binding O
, O
we O
constructed O
chimeras O
between O
MHVR O
and O
other O
members O
of O
the O
CEA O
family O
and O
tested O
them O
for O
MHV B
strain I
A59 I
( I
MHV I
- I
A59 I
) I
receptor O
activity O
and O
MAb O
CCl O
binding O
activity O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
encodes O
two O
isoforms O
of O
its O
principal O
gene O
product O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
These O
two O
forms O
play O
distinctive O
and O
complementary O
roles O
in O
viral O
replication O
, O
Here O
we O
report O
that O
the O
large O
( O
LHDAg O
) O
, O
but O
not O
the O
small O
( O
SHDAg O
) O
, O
isoform O
of O
HDAg O
has O
the O
capacity O
to O
activate O
the O
expression O
of O
cotransfected O
genes O
driven O
by O
a O
variety O
of O
promoters O
, O
including O
the O
pre O
- O
S O
, O
S O
, O
and O
C O
promoters O
of O
hepatitis O
B O
virus O
. O

Naturally O
occurring O
variants O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
containing O
the O
core B
internal I
deletion I
( I
CID I
) I
mutation O
have O
been O
found O
frequently O
in O
HBV O
carriers O
worldwide O
, O
Despite O
numerous O
sequence O
analysis O
reports O
of O
CID O
variants O
in O
patients O
, O
in O
the O
past O
decade O
, O
CID O
variants O
hale O
not O
been O
characterized O
functionally O
, O
and O
thus O
their O
biological O
significance O
to O
HBV O
infection O
remains O
unclear O
. O

We O
have O
characterized O
a O
major O
regulatory O
element O
of O
ground B
squirrel I
hepatitis I
virus I
( I
GSHV I
) I
located O
within O
a O
90 O
- O
nucleotide O
fragment O
of O
the O
core O
promoter O
upstream O
sequences O
and O
have O
compared O
its O
organization O
to O
that O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
enhancer O
II O
( O
We2 O
) O
. O

The O
GSHV O
element O
( O
Ge2 O
) O
stimulates O
transcription O
from O
the O
viral O
core O
promoter O
and O
heterologous O
promoters O
in O
an O
orientation O
- O
independent O
manner O
hut O
displays O
a O
lower O
level O
of O
activity O
than O
We2 O
in O
transient O
transfection O
assays O
in O
human O
hepatoma O
cells O
, O
The O
general O
organization O
of O
Ge2 O
into O
binding O
sites O
for O
the O
liver O
- O
enriched O
HNF O
- O
1 O
and O
HNF O
- O
4 O
proteins O
and O
for O
ubiquitous O
factors O
of O
the O
NF1 O
and O
Oct O
families O
was O
found O
to O
be O
mostly O
conserved O
with O
respect O
to O
the O
homologous O
We2 O
region O
, O
Accordingly O
, O
transactivation O
by O
HNF O
- O
1 O
and O
HNF O
- O
4 O
plays O
an O
essential O
role O
in O
the O
liver O
specific O
transcriptional O
activity O
of O
both O
the O
GSHV O
and O
WHV O
core O
promoters O
, O
Distinctive O
features O
of O
the O
GSHV O
enhancer O
consist O
of O
its O
ability O
to O
bind O
C O
/ O
EBP O
family O
factors O
in O
a O
central O
motif O
that O
overlaps O
with O
one O
of O
the O
two O
HNF O
- O
4 O
sites O
and O
its O
differential O
binding O
affinities O
for O
HNF O
- O
4 O
. O

The O
efficacy O
of O
DNA O
vaccines O
encoding O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
pre O
- O
S O
/ O
S O
and O
S O
proteins O
were O
tested O
in O
Pekin O
ducks O
. O

The O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
is O
a O
broadly O
acting O
transactivator O
implicated O
in O
the O
development O
of O
liver O
cancer O
. O

The O
normal O
function O
of O
XAP O
- O
1 O
/ O
UVDDB O
is O
thought O
to O
involve O
binding O
to O
damaged O
DNA O
, O
the O
first O
step O
in O
nucleotide B
excision I
repair I
( I
NER I
) I
; O
therefore O
, O
we O
hypothesized O
that O
this O
interaction O
may O
affect O
the O
cell O
' O
s O
capacity O
to O
correct O
lesions O
in O
the O
genome O
. O

When O
tested O
in O
two O
independent O
assays O
that O
measure O
NER O
( O
unscheduled O
DNA O
synthesis O
and O
host O
cell O
reactivation O
) O
, O
the O
expression O
of O
HBx O
significantly O
inhibited O
the O
ability O
of O
cells O
to O
repair O
damaged O
DNA O
. O

Defective B
interfering I
( I
DI I
) I
particles O
have O
been O
found O
in O
many O
RNA O
and O
DNA O
viruses O
of O
bacteria O
, O
plants O
, O
and O
animals O
since O
their O
first O
discovery O
in O
influenza O
virus O
. O

Using O
a O
new O
approach O
, O
here O
we O
provide O
the O
first O
experimental O
evidence O
for O
the O
existence O
of O
DI O
- O
like O
viruses O
in O
human O
chronic O
carriers O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Functional O
characterization O
of O
naturally O
occurring O
core B
internal I
deletion I
( I
CID I
) I
variants O
of O
HBV O
revealed O
all O
of O
the O
features O
of O
DI O
particles O
. O

Unlike O
those O
of O
the O
S O
and O
the O
L O
envelope O
proteins O
, O
the O
functional O
role O
of O
the O
related O
M O
protein O
in O
the O
life O
cycle O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
less O
understood O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
major O
human O
pathogen O
in O
the O
developing O
world O
. O

We O
expressed O
pORF3 O
in O
transiently O
transfected O
COS O
- O
1 O
and O
Huh O
- O
7 O
cells O
and O
showed O
that O
it O
is O
a O
phosphoprotein O
which O
is O
modified O
at O
a O
serine O
residue O
( O
s O
) O
. O

This O
residue O
is O
present O
within O
a O
conserved O
primary O
sequence O
that O
showed O
consensus O
sites O
for O
phosphorylation O
by O
p34 O
( O
cdc2 O
) O
kinase O
( O
cdc2K O
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
. O

On O
subcellular O
fractionation O
, O
pORF3 O
was O
found O
to O
partition O
with O
the O
cytoskeletal O
fraction O
, O
and O
this O
association O
with O
the O
cytoskeleton O
was O
lost O
on O
deletion O
of O
hydrophobic O
domain O
I O
( O
amino O
acid O
residues O
1 O
to O
32 O
) O
. O

Normal O
human O
keratinocytes O
and O
dermal O
fibroblasts O
were O
transduced O
with O
recombinant O
retroviruses O
expressing O
a O
reporter O
gene O
( O
lacZ O
) O
. O

Treatment O
of O
transduced O
cells O
with O
a O
proinflammatory O
cytokine O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
significantly O
reduced O
lacZ O
expression O
to O
less O
than O
25 O
% O
of O
that O
of O
nontreated O
cells O
. O

The O
inhibition O
was O
concentration O
dependent O
( O
peak O
at O
5 O
ng O
/ O
ml O
) O
and O
time O
dependent O
( O
maximal O
at O
16 O
h O
for O
transcript O
and O
24 O
h O
for O
protein O
) O
; O
expression O
remained O
repressed O
in O
the O
continued O
presence O
of O
IFN O
- O
gamma O
but O
returned O
to O
normal O
levels O
24 O
h O
after O
IFN O
- O
gamma O
withdrawal O
. O

Similar O
results O
were O
obtained O
by O
treatment O
of O
transduced O
cells O
with O
IFN O
- O
alpha O
but O
not O
with O
other O
proinflammatory O
cytokines O
, O
including O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
- O
2 O
( O
IL O
- O
1 O
) O
, O
IL O
- O
4 O
, O
and O
granulocyte O
colony O
- O
stimulating O
factor O
. O

Interestingly O
, O
IFN O
- O
gamma O
also O
suppressed O
transgene O
expression O
driven O
by O
a O
cellular O
promoter O
( O
involucrin O
) O
inserted O
in O
an O
internal O
position O
in O
the O
retroviral O
vector O
. O

Experiments O
with O
neutralizing O
antibodies O
demonstrated O
that O
although O
virus O
- O
induced O
Tumor B
necrosis I
factor I
( I
TNF I
) I
can O
have O
antiviral O
effects O
, O
it O
also O
mediated O
significant O
liver O
pathology O
. O

The O
necrotic O
foci O
and O
liver O
enzyme O
indications O
of O
pathology O
occurred O
independently O
of O
NK O
and O
T O
cells O
, O
because O
mice O
rendered O
NK O
- O
cell O
deficient O
by O
treatment O
with O
antibodies O
, O
T O
- O
and O
B O
- O
cell O
- O
deficient O
Rag O
( O
- O
/ O
- O
) O
mice O
, O
and O
NK O
- O
and O
T O
- O
cell O
- O
deficient O
E26 O
mice O
all O
manifested O
both O
parameters O
of O
disease O
. O

Envelopment O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
nucleocapsid O
depends O
on O
the O
large O
envelope O
protein O
L O
, O
which O
is O
expressed O
as O
a O
transmembrane O
polypeptide O
at O
the O
endoplasmic O
reticulum O
membrane O
, O
Previous O
studies O
demonstrated O
that O
the O
cytosolic O
exposure O
of O
the O
N O
- O
terminal O
pre O
- O
S O
domain O
( O
174 O
amino O
acids O
) O
of O
L O
was O
required O
for O
virion O
formation O
. O

Synthesis O
of O
the O
pre O
- O
C O
and O
pregenomic O
RNAs O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
is O
directed O
by O
two O
overlapping O
yet O
separate O
promoters O
( O
X O
, O
Yu O
and O
J O
, O
E O
, O
Mertz O
, O
J O
, O
Virol O
, O
70 O
: O
8719 O
- O
8726 O
, O
1996 O
) O
. O

Previously O
, O
we O
reported O
the O
identification O
of O
a O
binding O
site O
for O
the O
nuclear O
receptor O
Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
spanning O
the O
TATA O
box O
- O
like O
sequence O
of O
the O
pre O
- O
C O
promoter O
, O
This O
HNF4 O
- O
binding O
site O
consists O
of O
an O
imperfect O
direct O
repeat O
of O
the O
consensus O
half O
- O
site O
sequence O
5 O
' O
- O
AGGTCA O
- O
3 O
' O
separated O
by O
one O
nucleotide O
; O
i O
. O

, O
it O
is O
a O
DR1 O
hormone B
response I
element I
( I
HRE I
) I
, O
We O
show O
here O
that O
other O
receptors O
, O
including O
chicken B
ovalbumin I
upstream I
promoter I
transcription I
factor I
1 I
( I
COUP I
- I
TF1 I
) I
, O
human B
testicular I
receptor I
2 I
( I
TR2 I
) I
, O
and O
peroxisome B
proliferator I
- I
activated I
receptors I
( I
PPARs I
) I
as O
heterodimers O
with O
retinoid B
X I
receptors I
( I
RXRs I
) I
, O
can O
also O
specifically O
bind O
this O
DR1 O
HRE O
. O

The O
template O
for O
synthesis O
of O
hepadnaviral O
RNAs O
is O
a O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
located O
in O
the O
nucleus O
of O
the O
infected O
hepatocyte O
. O

The O
viral O
reverse O
transcriptase O
inhibitors O
Lamivudine B
( I
3TC I
) I
[ O
( O
- O
) O
- O
beta O
- O
L O
- O
2 O
' O
, O
3 O
' O
- O
dideoxy O
- O
3 O
' O
- O
thiacytidine O
) O
, O
FTC O
( O
5 O
- O
fluoro O
- O
2 O
' O
, O
3 O
' O
- O
dideoxy O
- O
3 O
' O
- O
thiacytidine O
) O
and O
ddC O
( O
2 O
' O
, O
3 O
' O
- O
dideoxycytidine O
) O
were O
added O
to O
the O
cultures O
beginning O
at O
4 O
days O
postinfection O
. O

Previous O
studies O
suggest O
that O
the O
core O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
a O
pleiotropic O
function O
in O
the O
replication O
cycle O
of O
the O
virus O
. O

One O
such O
cellular O
gene O
was O
isolated O
and O
characterized O
as O
the O
gene O
encoding O
the O
lymphotoxin B
- I
beta I
receptor I
( I
LT I
- I
beta I
R I
) I
. O

Similar O
to O
other O
members O
of O
the O
Tumor B
necrosis I
factor I
( I
TNF I
) I
receptor O
superfamily O
, O
LT O
- O
beta O
R O
is O
involved O
in O
the O
cytotoxic O
effect O
of O
the O
signaling O
pathway O
and O
thus O
we O
have O
elucidated O
the O
biological O
consequence O
of O
interaction O
between O
the O
HCV O
core O
protein O
and O
LT O
- O
beta O
R O
. O

Given O
the O
known O
roles O
of O
LT O
- O
beta O
R O
/ O
LT O
- O
alpha O
( O
1 O
) O
beta O
( O
2 O
) O
receptor O
- O
ligand O
interactions O
in O
the O
normal O
development O
of O
peripheral O
lymphoid O
organs O
and O
in O
triggering O
cytolytic O
activity O
and O
NF O
- O
kappa O
B O
activation O
in O
certain O
cell O
types O
, O
our O
finding O
implies O
that O
the O
HCV O
core O
protein O
may O
aggravate O
these O
biological O
functions O
of O
LT O
- O
beta O
R O
, O
resulting O
in O
pathogenesis O
in O
HCV O
- O
infected O
cells O
. O

The O
biosynthesis O
and O
topology O
of O
the O
large B
envelope I
protein I
( I
L I
protein I
) I
of O
hepadnaviruses O
was O
investigated O
using O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
model O
, O
which O
also O
allows O
the O
study O
of O
hepadnavirus O
morphogenesis O
in O
experimentally O
infected O
hepatocytes O
. O

During O
L O
biosynthesis O
and O
DHBV O
morphogenesis O
, O
pre O
- O
S O
, O
together O
with O
the O
neighboring O
transmembrane O
domain O
( O
TM O
- O
I O
) O
, O
initially O
remained O
cytoplasmically O
disposed O
and O
was O
translocated O
only O
posttranslationally O
. O

In O
murine O
17 O
Cl O
1 O
cells O
persistently O
infected O
with O
murine O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
expression O
of O
the O
virus O
receptor O
glycoprotein O
MHVR O
was O
markedly O
reduced O
( O
S O
. O

Unlike O
the O
parental O
MHV O
- O
A59 O
, O
this O
variant O
virus O
also O
infected O
the O
BHK B
- I
21 I
( I
BHK I
) I
line O
of O
hamster O
cells O
. O

Virus O
plaque O
purified O
on O
BHK O
cells O
( O
MHV O
/ O
BHK O
) O
grew O
more O
slowly O
in O
murine O
cells O
than O
did O
MHV O
- O
A59 O
and O
the O
rate O
of O
viral O
RNA O
synthesis O
was O
lower O
and O
the O
development O
of O
the O
viral O
nucleocapsid B
( I
N I
) I
protein O
was O
slower O
than O
those O
of O
MHV O
- O
A59 O
. O

MHV O
/ O
BHK O
was O
100 O
- O
fold O
more O
resistant O
to O
neutralization O
with O
the O
purified O
soluble B
recombinant I
MHV I
receptor I
glycoprotein I
( I
sMHVR I
) I
than O
was O
MHV O
- O
A59 O
. O

To O
determine O
whether O
a O
hemagglutinin B
esterase I
( I
HF I
) I
glycoprotein O
that O
could O
bind O
the O
virions O
to O
9 O
- O
O O
- O
acetylated O
neuraminic O
acid O
moieties O
on O
the O
cell O
surface O
was O
expressed O
by O
MHV O
/ O
BHK O
an O
in O
situ O
esterase O
assay O
was O
used O
. O

MHV O
/ O
BHK O
was O
able O
to O
infect O
cell O
lines O
from O
many O
mammalian O
species O
, O
including O
murine O
( O
17 O
Cl O
1 O
) O
, O
hamster O
( O
BHK O
) O
, O
feline O
( O
Fcwf O
) O
, O
bovine O
( O
MDBK O
) O
, O
rat O
( O
RIE O
) O
, O
monkey O
( O
Vero O
) O
, O
and O
human O
( O
L132 O
and O
HeLa O
) O
cell O
lines O
. O

MHV O
/ O
BHK O
could O
not O
infect O
dog O
kidney O
( O
MDCK O
I O
) O
or O
swine B
testis I
( I
ST I
) I
cell O
lines O
. O

We O
previously O
identified O
two O
sequences O
, O
UBS O
and O
DBS O
( O
upstream O
and O
downstream O
binding O
sites O
) O
, O
present O
in O
multiple O
copies O
in O
and O
adjacent O
to O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
terminal O
redundancy O
, O
that O
were O
specifically O
recognized O
by O
a O
65 O
- O
kDa O
host O
factor O
, O
p65 O
. O

The O
possible O
roles O
of O
these O
two O
sequences O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
were O
investigated O
in O
the O
context O
of O
the O
intact O
viral O
genome O
. O

The O
DBS O
sequence O
, O
which O
is O
located O
downstream O
of O
the O
pgRNA O
polyadenylation O
site O
, O
overlaps O
the O
core B
( I
C I
) I
protein O
coding O
region O
. O

Nuclear O
export O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
RNA O
is O
mediated O
by O
a O
specific O
RNA O
element O
but O
, O
in O
contrast O
to O
lentivirus O
genomic O
RNA O
, O
does O
not O
depend O
on O
viral O
proteins O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
pathogenic O
agent O
that O
causes O
fecally O
- O
orally O
transmitted O
acute O
hepatitis O
. O

The O
genome O
, O
a O
single O
- O
stranded O
positive O
- O
sense O
RNA O
encodes O
three O
forward O
open B
reading I
frames I
( I
ORFs I
) I
, O
in O
which O
an O
approximately O
2 O
- O
kb O
structural O
protein O
is O
located O
in O
the O
3 O
' O
end O
, O
To O
produce O
HEV O
- O
like O
particles O
the O
structural O
protein O
, O
with O
its O
N O
terminus O
truncated O
( O
amino O
acid O
residues O
112 O
to O
660 O
of O
ORF2 O
) O
, O
was O
expressed O
in O
insect O
Tn5 O
cells O
by O
a O
recombinant O
baculovirus O
, O
In O
addition O
to O
the O
primary O
translation O
product O
with O
a O
molecular O
mass O
of O
58 O
kDa O
, O
a O
large O
amount O
of O
a O
further O
- O
processed O
molecule O
with O
a O
molecular O
mass O
of O
50 O
kDa O
was O
generated O
and O
efficiently O
released O
into O
the O
culture O
medium O
, O
Electron O
microscopic O
observation O
of O
the O
culture O
medium O
revealed O
that O
the O
50 O
- O
kDa O
protein O
self O
- O
assembled O
to O
form O
empty O
virus B
- I
like I
particles I
( I
VLPs I
) I
, O
The O
buoyant O
density O
of O
the O
VLPs O
in O
CsCl O
was O
1 O
. O

285 O
g O
/ O
cm O
( O
3 O
) O
and O
their O
diameter O
was O
23 O
. O

7 O
nm O
, O
a O
little O
smaller O
than O
the O
27 O
nm O
of O
native O
HEV O
particles O
secreted O
into O
the O
bile O
or O
stools O
of O
experimentally O
infected O
monkeys O
, O
The O
yield O
of O
the O
VLPs O
was O
1 O
mg O
per O
10 O
( O
7 O
) O
cells O
as O
a O
purified O
form O
, O
The O
particles O
possess O
antigenicity O
similar O
to O
that O
of O
authentic O
HEV O
particles O
and O
, O
consequently O
, O
they O
appear O
to O
be O
a O
good O
antigen O
for O
the O
sensitive O
detection O
of O
HEV O
- O
specific O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgM O
antibodies O
, O
Furthermore O
, O
the O
VLP O
may O
be O
the O
most O
promising O
candidate O
get O
for O
an O
HEV O
vaccine O
, O
owing O
to O
its O
potent O
immunogenicity O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
codes O
for O
three O
forms O
of O
surface O
protein O
, O
The O
minor O
, O
large O
form O
is O
translated O
from O
transcripts O
specified O
by O
the O
preS1 O
promoter O
, O
while O
the O
middle O
and O
small O
forms O
are O
translated O
from O
transcripts O
specified O
by O
the O
downstream O
S O
promoter O
, O
When O
the O
large O
surface O
protein O
is O
overexpressed O
, O
the O
secretion O
of O
both O
subviral O
and O
virion O
particles O
is O
blocked O
within O
the O
secretory O
pathway O
, O
We O
show O
here O
that O
overexpression O
of O
the O
large O
surface O
protein O
leads O
to O
up O
to O
a O
10 O
- O
fold O
activation O
of O
the O
S O
promoter O
but O
not O
of O
an O
unrelated O
promoter O
, O
Neither O
the O
middle O
nor O
the O
small O
surface O
protein O
, O
nor O
a O
secretable O
form O
of O
the O
large O
surface O
protein O
, O
activates O
the O
S O
promoter O
, O
but O
agents O
that O
induce O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
have O
an O
effect O
similar O
to O
that O
of O
the O
large O
surface O
protein O
, O
The O
large O
surface O
protein O
also O
activates O
the O
S O
promoter O
in O
the O
contest O
of O
the O
entire O
viral O
genome O
, O
Therefore O
, O
it O
appears O
that O
HBV O
has O
evolved O
a O
feedback O
mechanism O
, O
such O
that O
ER O
stress O
induced O
by O
accumulation O
of O
the O
large O
surface O
protein O
increases O
the O
synthesis O
of O
the O
middle O
and O
small O
surface O
proteins O
, O
which O
in O
combination O
with O
the O
large O
surface O
protein O
can O
form O
mixed O
, O
secretable O
particles O
, O
In O
addition O
, O
like O
other O
agents O
that O
induce O
ER O
stress O
, O
the O
large O
surface O
protein O
can O
activate O
the O
cellular O
grp78 O
and O
grp94 O
promoters O
, O
raising O
the O
possibility O
that O
it O
may O
alter O
the O
physiology O
of O
the O
host O
cell O
. O

Given O
the O
extent O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
as O
a O
worldwide O
health O
problem O
and O
the O
lack O
of O
effective O
treatment O
, O
the O
development O
of O
anti O
- O
HCV O
drugs O
is O
an O
important O
and O
pressing O
objective O
. O

To O
gain O
further O
insight O
into O
the O
biochemical O
and O
biophysical O
properties O
of O
the O
NS3 O
enzyme O
binding O
pocket O
( O
s O
) O
and O
to O
generate O
biological O
tools O
for O
developing O
antiviral O
strategies O
, O
we O
decided O
to O
engineer O
macromolecular O
ligands O
of O
the O
NS3 O
protease O
domain O
. O

Phage O
- O
displayed O
repertoires O
of O
minibodies O
( O
' O
' O
minimized O
' O
' O
antibody O
- O
like O
proteins O
) O
and O
human O
pancreatic O
secretory O
trypsin O
inhibitor O
were O
sampled O
by O
using O
the O
recombinant O
NS3 O
protease O
domain O
as O
a O
ligate O
molecule O
. O

We O
report O
the O
presence O
of O
two O
elements O
, O
pet O
and O
net O
, O
that O
are O
required O
for O
proper O
transcription O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

6 O
- O
kb O
region O
of O
the O
hepatitis B
G I
virus I
( I
HGV I
) I
genome O
at O
nucleotide O
positions O
5829 O
to O
8421 O
were O
designed O
and O
used O
to O
analyze O
serum O
specimens O
obtained O
from O
patients O
with O
community O
- O
acquired O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
who O
were O
HGV O
RNA O
positive O
. O

Plasmids O
expressing O
different O
domains O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
E2 O
glycoprotein O
from O
a O
genotype O
la O
isolate O
were O
constructed O
to O
compare O
the O
immunogenic O
potential O
of O
E2 O
in O
nucleic O
acid O
- O
based O
immunizations O
. O

SE2E O
, O
encoded O
the O
adjacent O
60 O
- O
amino O
- O
acid O
( O
aa O
) O
sequences O
of O
E2 O
( O
inserts O
A O
to O
E O
) O
expressed O
as O
a O
fusion O
with O
the O
hepatitis O
B O
virus O
surface O
antigen O
. O

) O
via O
a O
gene O
gun O
( O
biolistic O
introduction O
) O
, O
and O
induced O
humoral O
immune O
responses O
were O
evaluated O
. O

Three O
restricted O
immunogenic O
domains O
, O
E2A O
( O
aa O
384 O
to O
443 O
) O
, O
E2C O
( O
aa O
504 O
to O
555 O
) O
, O
and O
E2E O
( O
aa O
609 O
to O
674 O
) O
, O
that O
yielded O
antibody O
titers O
ranging O
from O
1 O
: O
59 O
to O
> O
1 O
: O
43 O
, O
700 O
could O
be O
identified O
. O

We O
carried O
out O
a O
comparative O
analysis O
of O
several O
proposed O
host O
protein O
partners O
of O
the O
human O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
using O
both O
the O
GAL O
- O
4 O
- O
and O
the O
LexA O
- O
based O
yeast O
two O
- O
hybrid O
system O
. O

We O
showed O
that O
the O
interaction O
of O
HBx O
with O
the O
UV B
- I
damaged I
DNA I
- I
binding I
protein I
( I
UVDDB I
) I
is O
positive O
in O
both O
yeast O
systems O
, O
detectable O
in O
cotransfected O
human O
cells O
, O
conserved O
by O
rodent O
hepadnavirus O
X O
proteins O
( O
known O
to O
transactivate O
in O
human O
cells O
) O
, O
and O
tightly O
correlated O
with O
the O
transactivation O
proficiency O
of O
X O
- O
insertion O
mutants O
. O

hepatitis B
B I
viruses I
( I
HBVs I
) I
replicate O
by O
reverse O
transcription O
of O
an O
RNA O
intermediate O
, O
Packaging O
of O
this O
RNA O
pregenome O
into O
nucleocapsids O
and O
replication O
initiation O
depend O
crucially O
on O
the O
interaction O
of O
the O
reverse O
transcriptase O
, O
P O
protein O
, O
with O
the O
cis O
- O
acting O
, O
5 O
' O
end O
- O
proximal O
encapsidation O
signal O
epsilon O
, O
The O
overall O
secondary O
structure O
is O
similar O
in O
all O
of O
the O
hepadnaviral O
epsilon O
signals O
, O
with O
a O
lower O
and O
an O
upper O
stem O
, O
separated O
by O
a O
bulge O
, O
and O
an O
apical O
loop O
, O
However O
, O
while O
epsilon O
is O
almost O
perfectly O
conserved O
in O
all O
mammalian O
viruses O
, O
the O
epsilon O
signals O
of O
duck B
HBV I
( I
DHBV I
) I
and O
heron O
HBV O
( O
D O
epsilon O
and O
H O
epsilon O
, O
respectively O
) O
differ O
substantially O
in O
their O
upper O
stem O
regions O
, O
both O
in O
primary O
sequence O
and O
in O
secondary O
structure O
; O
nonetheless O
, O
H O
epsilon O
interacts O
productively O
with O
DHBV O
P O
protein O
, O
as O
shown O
by O
its O
ability O
to O
stimulate O
priming O
, O
i O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
a O
recently O
discovered O
virus O
responsible O
for O
hepatitis O
in O
tamarins O
( O
Saguinus O
species O
) O
, O
GBV O
- O
B O
belongs O
to O
the O
Flaviviridae O
family O
and O
is O
closely O
related O
to O
the O
human O
pathogen O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

nonstructural B
protein I
3 I
( I
NS3 I
) I
of O
HCV O
has O
been O
shown O
to O
encompass O
a O
serine O
protease O
domain O
required O
for O
viral O
maturation O
. O

These O
template O
switches O
, O
as O
for O
the O
template O
snitches O
or O
strand O
transfers O
of O
other O
reverse O
- O
transcribing O
genetic O
elements O
, O
require O
repeated O
sequences O
( O
the O
donor O
and O
acceptor O
sites O
) O
between O
which O
a O
complementary O
strand O
of O
nucleic O
acid O
is O
transferred O
. O

To O
determine O
whether O
sequences O
other O
than O
the O
donor O
and O
acceptor O
sites O
are O
involved O
in O
the O
template O
switches O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
a O
series O
of O
molecular O
clones O
which O
express O
viral O
genomes O
hearing O
deletion O
mutations O
were O
analyzed O
. O

duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
a O
DNA O
virus O
that O
replicates O
via O
reverse O
transcription O
of O
a O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
Synthesis O
of O
the O
first O
strand O
of O
DNA O
( O
minus O
- O
strand O
DNA O
) O
for O
DHBV O
can O
be O
divided O
into O
two O
steps O
: O
( O
i O
) O
synthesis O
of O
the O
first O
four O
nucleotides O
of O
minus O
- O
strand O
DNA O
, O
which O
is O
primed O
by O
the O
viral O
polymerase B
( I
P I
) I
protein O
and O
copied O
from O
the O
sequence O
5 O
' O
- O
UUAC O
- O
3 O
' O
within O
the O
phylogenetically O
conserved O
bulge O
in O
the O
encapsidation O
signal O
( O
epsilon O
) O
near O
the O
5 O
' O
end O
of O
pgRNA O
; O
and O
( O
ii O
) O
a O
template O
snitch O
of O
the O
four O
- O
nucleotide O
minus O
- O
strand O
DNA O
from O
epsilon O
to O
an O
acceptor O
site O
near O
the O
3 O
' O
end O
of O
pgRNA O
and O
synthesis O
of O
a O
complete O
minus O
- O
strand O
DNA O
, O
To O
understand O
why O
only O
four O
nucleotides O
of O
minus O
- O
strand O
DNA O
were O
synthesized O
before O
the O
template O
switch O
, O
we O
introduced O
small O
insertions O
immediately O
5 O
' O
to O
the O
UUAC O
sequence O
in O
epsilon O
and O
determined O
whether O
these O
epsilon O
variants O
were O
competent O
for O
protein O
priming O
and O
whether O
minus O
strands O
longer O
than O
four O
nucleotides O
were O
synthesized O
, O
Then O
we O
determined O
, O
in O
cell O
culture O
, O
whether O
the O
longer O
minus O
- O
strand O
DNAs O
were O
competent O
to O
undergo O
a O
template O
switch O
, O
Also O
, O
we O
analyzed O
the O
structure O
of O
the O
epsilon O
variants O
, O
in O
solution O
, O
We O
found O
that O
the O
epsilon O
variants O
were O
functional O
for O
protein O
priming O
and O
RNA O
encapsidation O
and O
that O
the O
insertions O
were O
copied O
into O
minus O
- O
strand O
DNA O
, O
However O
, O
two O
mutant O
viruses O
that O
contained O
two O
different O
three O
- O
nucleotide O
insertions O
failed O
to O
synthesize O
minus O
- O
strand O
DNA O
efficiently O
from O
the O
acceptor O
site O
, O
even O
though O
seven O
nucleotides O
of O
the O
donor O
and O
acceptor O
sites O
were O
identical O
, O
These O
results O
suggest O
that O
the O
length O
and O
/ O
or O
sequence O
of O
the O
minus O
- O
strand O
DNA O
copied O
from O
epsilon O
can O
be O
important O
for O
an O
efficient O
template O
switch O
, O
The O
RNA O
structural O
analysis O
of O
the O
epsilon O
variants O
indicated O
alteration O
in O
the O
position O
and O
size O
of O
the O
bulge O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
has O
been O
reported O
to O
exist O
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
but O
it O
is O
not O
clear O
whether O
it O
replicates O
there O
. O

61 O
: O
3491 O
- O
3498 O
, O
1987 O
) O
, O
very O
little O
is O
known O
about O
the O
effects O
of O
agents O
which O
damage O
chromosomal O
DNA O
on O
the O
frequency O
of O
hepadnaviral O
DNA O
integrations O
, O
Using O
a O
recently O
developed O
subcloning O
approach O
to O
detect O
stable O
new O
integrations O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
( O
S O
. O

Virol O
, O
70 O
: O
2000 O
- O
2007 O
, O
1996 O
) O
, O
we O
tested O
the O
effects O
of O
increased O
chromosomal O
DNA O
damage O
induced O
by O
H2O2 O
, O
or O
of O
the O
disturbance O
in O
DNA O
repair O
due O
to O
the O
inhibition O
of O
Poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( I
PARP I
) I
, O
on O
the O
frequency O
of O
DHBV O
DNA O
integrations O
, O
Subclones O
of O
LMH O
- O
D21 O
- O
6 O
cells O
, O
which O
replicate O
DHBV O
, O
were O
grown O
in O
the O
presence O
of O
various O
H2O2 O
concentrations O
and O
exhibited O
up O
to O
a O
threefold O
increase O
in O
viral O
DNA O
integration O
frequency O
in O
a O
dose O
- O
dependent O
manner O
, O
Moreover O
, O
inhibition O
of O
PARP O
, O
which O
plays O
a O
role O
in O
cellular O
responses O
to O
DNA O
breakage O
, O
by O
3 O
- O
aminobenzamide O
( O
3 O
- O
AB O
) O
resulted O
in O
a O
sevenfold O
increase O
in O
the O
total O
number O
of O
new O
DHBV O
DNA O
integrations O
into O
host O
chromosomal O
DNA O
, O
Removal O
of O
either O
H2O2 O
or O
3 O
- O
AB O
from O
the O
culture O
medium O
in O
a O
subsequent O
cycle O
of O
subcloning O
was O
accompanied O
by O
a O
reversion O
back O
towards O
the O
original O
lower O
frequency O
of O
stable O
DHBV O
DNA O
integrations O
for O
LMH O
- O
D21 O
- O
6 O
cells O
, O
These O
data O
support O
the O
hypothesis O
that O
DNA O
damage O
sites O
can O
serve O
as O
sites O
for O
hepadnaviral O
DNA O
integration O
, O
and O
that O
increasing O
the O
number O
of O
DNA O
damage O
sites O
dramatically O
increases O
viral O
integration O
frequency O
. O

Hepatitis O
B O
virus O
small O
surface O
protein O
is O
synthesized O
as O
a O
transmembrane O
protein O
of O
the O
rough B
endoplasmic I
reticulum I
( I
rER I
) I
and O
then O
buds O
into O
the O
lumen O
in O
the O
form O
of O
subviral O
particles O
that O
are O
secreted O
, O
The O
closely O
related O
large O
surface O
protein O
is O
also O
targeted O
to O
the O
RER O
but O
is O
retained O
in O
a O
pre O
- O
Golgi O
compartment O
and O
cannot O
be O
secreted O
, O
It O
has O
been O
assumed O
that O
the O
large O
surface O
protein O
remains O
as O
a O
transmembrane O
RER O
protein O
and O
hence O
cannot O
form O
particles O
, O
possibly O
because O
of O
binding O
to O
a O
host O
factor O
on O
the O
cytosolic O
face O
of O
the O
RER O
membranes O
. O

We O
have O
reexamined O
this O
question O
and O
found O
the O
following O
results O
, O
( O
i O
) O
The O
retained O
large O
surface O
protein O
is O
associated O
not O
with O
RER O
but O
, O
rather O
, O
with O
a O
more O
distal O
compartment O
. O

( O
ii O
) O
Electron O
microscopy O
reveals O
intravesicular O
20 O
- O
nm O
particles O
, O
similar O
to O
those O
formed O
by O
the O
small O
surface O
protein O
, O
( O
iii O
) O
The O
large O
surface O
protein O
colocalizes O
with O
and O
binds O
to O
calnexin O
, O
an O
ER O
chaperone O
protein O
, O
Therefore O
, O
our O
results O
indicate O
that O
the O
large O
surface O
protein O
is O
capable O
of O
budding O
and O
forming O
particles O
, O
and O
hence O
its O
intracellular O
retention O
cannot O
be O
attributed O
to O
a O
cytosolic O
factor O
, O
We O
interpret O
the O
data O
as O
evidence O
that O
the O
large O
surface O
protein O
is O
retained O
by O
virtue O
of O
interacting O
with O
calnexin O
, O
a O
component O
of O
what O
is O
considered O
the O
quality O
control O
mechanism O
of O
the O
ER O
. O

The O
content O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
replicative O
forms O
and O
HBV O
core O
protein O
in O
the O
liver O
of O
HBV O
transgenic O
mice O
is O
transiently O
reduced O
during O
massive O
liver O
regeneration O
following O
partial O
hepatectomy O
while O
the O
steady O
- O
state O
content O
of O
viral O
RNA O
is O
unchanged O
. O

As O
an O
approach O
to O
identifying O
hepatocyte O
receptors O
for O
the O
avian O
hepadnavirus O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
hybridomas O
were O
prepared O
from O
mice O
immunized O
with O
permissive O
duck O
hepatocytes O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
were O
screened O
for O
the O
ability O
to O
inhibit O
binding O
of O
DHBV O
particles O
to O
primary O
duck O
hepatocytes O
and O
to O
block O
infection O
. O

Both O
MAbs O
immunoprecipitated O
a O
55 O
- O
kDa O
protein O
( O
p55 O
) O
expressed O
in O
duck O
liver O
and O
several O
other O
duck O
tissues O
. O

We O
examined O
the O
full O
- O
length O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
( O
surface O
antigen O
or O
HBV O
small O
surface O
antigen O
[ O
HBsAg O
] O
) O
sequences O
of O
12 O
different O
liver O
samples O
from O
10 O
different O
hepatoma O
- O
containing O
chronic O
carriers O
. O

Surprisingly O
, O
novel O
and O
frequent O
mutations O
occurred O
predominantly O
at O
amino O
acids O
40 O
and O
47 O
of O
HBsAg O
, O
in O
addition O
to O
within O
a O
known O
protective O
B O
- O
cell O
epitope O
( O
so O
- O
called O
group O
a O
determinant O
of O
HBsAg O
121 O
- O
148 O
) O
. O

cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
activity O
appears O
to O
play O
an O
important O
role O
in O
resolving O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
and O
the O
ability O
to O
induce O
such O
responses O
remains O
an O
important O
goal O
for O
developing O
effective O
immunotherapeutics O
. O

A O
panel O
of O
recombinant O
retrovirus O
vectors O
expressing O
different O
forms O
of O
the O
HBV B
core I
antigen I
( I
HBcAg I
) I
or O
e O
antigen O
( O
eAg O
) O
were O
found O
to O
induce O
antigen O
- O
specific O
major O
histocompatibility O
complex O
- O
restricted O
CTL O
responses O
in O
both O
mice O
and O
macaques O
. O

In O
addition O
, O
a O
novel O
retrovirus O
vector O
expressing O
an O
HBcAg B
- I
neomycin I
phosphotransferase I
II I
( I
HBc I
- I
Neo I
) I
fusion O
protein O
[ O
LHBc O
- O
NEO O
( O
6A3 O
) O
] O
, O
which O
allows O
the O
measurement O
of O
the O
anti O
- O
Neo O
antibody O
response O
as O
a O
means O
of O
directly O
tracking O
biological O
activity O
of O
the O
vector O
, O
was O
generated O
. O

Doses O
greater O
than O
10 O
( O
7 O
) O
CFU O
were O
necessary O
to O
induce O
CTL O
responses O
in O
H O
- O
2 O
( O
k O
) O
mice O
. O

Intramuscular O
injections O
with O
10 O
( O
8 O
) O
CFU O
of O
the O
LHBc O
- O
NEO O
( O
6A3 O
) O
retrovirus O
vector O
into O
rhesus O
monkeys O
induced O
HBc O
/ O
eAg O
- O
specific O
antibody O
production O
and O
CD8 O
( O
+ O
) O
CTLs O
. O

We O
recently O
expressed O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
reverse O
transcriptase O
( O
pol O
) O
in O
insect O
cells O
by O
using O
the O
recombinant O
baculovirus O
system O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
the O
tyrosine O
residue O
at O
amino O
acid O
number O
63 O
within O
the O
TP B
( I
terminal I
protein I
) I
domain O
of O
the O
polymerase O
is O
the O
site O
of O
covalent O
linkage O
of O
the O
first O
nucleotide O
of O
minus O
- O
strand O
DNA O
. O

Analysis O
of O
pol O
polypeptides O
with O
mutations O
in O
the O
TP O
and O
RT B
( I
reverse I
transcriptase I
) I
domains O
indicated O
that O
both O
domains O
were O
not O
capable O
of O
complementing O
each O
other O
in O
the O
nucleotide O
priming O
reaction O
, O
suggesting O
that O
transcomplementation O
between O
full O
- O
length O
polypeptides O
was O
not O
possible O
. O

interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
is O
a O
heterodimeric O
cytokine O
produced O
by O
antigen O
- O
presenting O
cells O
that O
has O
the O
ability O
to O
induce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
secretion O
by O
T O
and O
natural O
killer O
cells O
and O
to O
generate O
normal O
Th1 O
responses O
, O
These O
properties O
suggest O
that O
IL O
- O
12 O
may O
play O
an O
important O
role O
in O
the O
immune O
response O
to O
many O
viruses O
, O
including O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

Secretion O
of O
the O
hepatitis O
B O
virus O
( O
HBV B
e I
antigen I
( I
HBeAg I
) I
has O
been O
conserved O
throughout O
the O
evolution O
of O
hepadnaviruses O
. O

We O
therefore O
examined O
the O
possibility O
that O
the O
tno O
structural O
forms O
of O
the O
viral O
nucleoprotein O
, O
the O
particulate O
HBV O
core O
( O
HBcAg O
) O
and O
the O
nonparticulate O
HBeAg O
, O
may O
preferentially O
elicit O
different O
T B
helper I
( I
Th I
) I
cell O
subsets O
. O

For O
this O
purpose O
, O
mice O
were O
immunized O
with O
recombinant O
HBcAg O
and O
HBeAg O
in O
the O
presence O
and O
absence O
of O
adjuvants O
, O
and O
the O
immunoglobulin B
G I
( I
IgG I
) I
isotype O
profiles O
of O
anti O
- O
HBc O
and O
anti O
- O
HBe O
antibodies O
were O
determined O
. O

HBcAg O
- O
primed O
Th O
cells O
efficiently O
produced O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
and O
gamma O
interferon O
IFN O
- O
gamma O
) O
and O
low O
levels O
of O
IL O
- O
4 O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
may O
play O
a O
role O
in O
clearance O
of O
OBLV60 O
from O
infected O
immunocompetent O
BALB O
/ O
c O
mice O
through O
a O
nonlytic O
mechanism O
. O

Among O
the O
variety O
of O
immunomodulatory O
activities O
of O
IFN O
- O
gamma O
is O
the O
induction O
of O
expression O
of O
inducible B
nitric I
oxide I
synthase I
( I
iNOS I
) I
, O
an O
enzyme O
responsible O
for O
the O
production O
of O
nitric B
oxide I
( I
NO I
) I
, O
Studies O
were O
undertaken O
to O
investigate O
the O
role O
of O
IFN O
- O
gamma O
and O
NO O
in O
host O
defense O
and O
clearance O
of O
OBLV60 O
from O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
Exposure O
of O
OBLV60 O
- O
infected O
OBL21a O
cells O
, O
a O
mouse O
neuronal O
cell O
line O
, O
to O
the O
NO O
- O
generating O
compound O
S O
- O
nitroso O
- O
L O
- O
acetyl O
penicillamine O
resulted O
in O
a O
significant O
decrease O
in O
viral O
replication O
, O
indicating O
that O
NO O
interfered O
with O
viral O
replication O
, O
Furthermore O
, O
infection O
of O
IFN B
- I
gamma I
knockout I
( I
GKO I
) I
mice O
and O
athymic O
nude O
mice O
with O
OBLV60 O
resulted O
in O
low O
- O
level O
expression O
of O
iNOS O
mRNA O
and O
protein O
in O
the O
brains O
compared O
to O
that O
of O
OBLV60 O
- O
infected O
BALB O
/ O
c O
mice O
. O

However O
, O
very O
little O
is O
known O
about O
the O
role O
of O
specific O
T O
cells O
during O
hepatitis B
delta I
virus I
( I
HDV I
) I
infection O
in O
humans O
. O

In O
this O
study O
, O
the O
T O
- O
cell O
response O
to O
HDV O
in O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
carriers O
with O
HDV O
superinfection O
was O
investigated O
at O
different O
levels O
. O

Analysis O
of O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
proliferation O
in O
response O
to O
a O
recombinant O
form O
of O
large O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
revealed O
that O
8 O
of O
30 O
patients O
studied O
( O
27 O
% O
) O
specifically O
responded O
to O
HDAg O
. O

A O
panel O
of O
HDAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
from O
three O
HDV O
- O
infected O
individuals O
and O
fine O
- O
specificity O
analysis O
revealed O
that O
the O
clones O
tested O
individually O
recognized O
four O
epitopes O
corresponding O
to O
amino B
acids I
( I
aa I
) I
26 O
to O
41 O
, O
50 O
to O
65 O
, O
66 O
to O
81 O
, O
or O
106 O
to O
121 O
of O
HDAg O
sequence O
. O

The O
study O
of O
human B
leukocyte I
antigen I
( I
HLA I
) I
restriction O
revealed O
that O
peptides O
50 O
to O
65 O
and O
106 O
to O
121 O
were O
presented O
to O
specific O
T O
cells O
in O
association O
with O
multiple O
class O
II O
molecules O
. O

Cytokine O
secretion O
analysis O
showed O
that O
all O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
assayed O
were O
able O
to O
produce O
high O
levels O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
belonging O
either O
to O
T B
helper I
- I
1 I
( I
Th1 I
) I
or O
Th0 O
subsets O
and O
that O
some O
of O
them O
were O
cytotoxic O
in O
a O
specific O
assay O
. O

The O
HDAg O
epitopes O
identified O
here O
and O
particularly O
those O
recognized O
by O
CD4 O
( O
+ O
) O
T O
cells O
in O
association O
with O
multiple O
major O
histocompatibility O
complex O
class O
II O
molecules O
may O
be O
potentially O
exploited O
for O
the O
preparation O
of O
a O
vaccine O
for O
prophylaxis O
and O
therapy O
of O
HDV O
infection O
. O

The O
X O
- O
ray O
crystallographic O
structure O
of O
a O
catalytically O
active O
mutant O
of O
the O
hepatitis B
A I
virus I
( I
HAV I
) I
3C O
proteinase O
( O
C24S O
) O
has O
been O
determined O
. O

211 O
( O
R O
( O
free O
) O
= O
0 O
. O

Two O
temperature O
sensitive O
( O
ts O
) O
mutants O
of O
mouse O
hepatitis O
virus O
strain O
A59 O
, O
ts43 O
and O
ts379 O
, O
have O
been O
described O
previously O
to O
be O
ts O
in O
infectivity O
but O
unaffected O
in O
RNA O
synthesis O
( O
M O
. O

We O
present O
a O
detailed O
analysis O
of O
the O
protein O
synthesis O
of O
the O
mutant O
viruses O
at O
the O
permissive O
( O
31 O
degrees O
C O
) O
and O
nonpermissive O
( O
39 O
. O

The O
mature O
Golgi O
form O
of O
S O
was O
not O
present O
at O
the O
nonpermissive O
temperature O
for O
the O
ts O
viruses O
, O
in O
contrast O
to O
wild B
- I
type I
( I
WT I
) I
virus O
. O

The O
role O
of O
members O
of O
the O
nuclear O
receptor O
superfamily O
of O
transcription O
factors O
in O
regulating O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
was O
investigated O
. O

Hepatocyte B
nuclear I
factor I
4 I
( I
HNF4 I
) I
, O
the O
Retinoid B
X I
receptor I
( I
RXR I
) I
, O
and O
the O
peroxisome B
proliferator I
- I
activated I
receptor I
( I
PPAR I
) I
were O
examined O
for O
their O
capacity O
to O
modulate O
the O
level O
of O
transcriptional O
activity O
from O
the O
four O
HBV O
promoters O
by O
transient O
- O
transfection O
analysis O
in O
the O
dedifferentiated O
hepatoma O
cell O
line O
, O
HepG2 O
. O

We O
have O
investigated O
the O
membrane O
topology O
of O
the O
large O
envelope O
protein O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
by O
protease O
protection O
and O
Western O
blot O
analysis O
, O
using O
monoclonal O
antibodies O
specific O
for O
the O
pre O
- O
S O
and O
S O
regions O
of O
the O
DHBV O
envelope O
to O
characterize O
protease O
- O
resistant O
polypeptides O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
a O
multifunctional O
protein O
. O

Interestingly O
, O
more O
than O
half O
of O
these O
clones O
encode O
the O
cytoplasmic O
domain O
of O
lymphotoxin O
- O
beta O
receptor O
( O
LT O
beta O
R O
) O
, O
which O
is O
a O
member O
of O
the O
tumor O
necrosis O
factor O
receptor O
family O
. O

In O
order O
to O
identify O
these O
viral O
proteins O
, O
we O
purified O
woodchuck B
hepadnavirus I
( I
WHV I
) I
core O
particles O
from O
infected O
woodchuck O
liver O
, O
isolated O
WHV O
DNA O
, O
and O
extracted O
the O
covalent O
complex O
of O
viral O
polymerase O
from O
the O
particles O
using O
urea O
, O
Intact O
core O
particles O
, O
the O
polymerase O
- O
DNA O
complex O
, O
or O
protein O
- O
free O
WHV O
DNA O
from O
core O
particles O
was O
added O
to O
digitonin O
- O
permeabilized O
HuH O
- O
7 O
cells O
, O
in O
which O
the O
cytosol O
mas O
substituted O
by O
rabbit B
reticulocyte I
lysate I
( I
RRL I
) I
and O
an O
ATP O
- O
generating O
system O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
protease O
cleaves O
the O
viral O
polyprotein O
at O
specific O
sites O
to O
release O
the O
putative O
components O
of O
the O
HCV O
replication O
machinery O
. O

Translation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
is O
initiated O
by O
internal O
entry O
of O
ribosomes O
into O
the O
5 B
' I
noncoding I
region I
( I
NCR I
) I
, O
This O
process O
depends O
on O
genomic O
elements O
within O
the O
5 O
' O
NCR O
called O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
and O
may O
involve O
host O
factors O
, O
The O
alpha O
- O
branch O
structure O
( O
nucleotides O
47 O
to O
67 O
) O
of O
the O
HCV O
IRES O
is O
considered O
a O
cis O
- O
acting O
element O
critical O
for O
translation O
initiation O
because O
it O
is O
indispensable O
for O
translation O
in O
vitro O
( O
S O
. O

NSP5 O
( O
NS26 O
) O
, O
the O
product O
of O
rotavirus O
gene O
11 O
, O
is O
a O
phosphoprotein O
whose O
role O
in O
the O
virus O
replication O
cycle O
is O
unknown O
. O

By O
immunoprecipitation O
and O
immunoblotting O
experiments O
, O
we O
showed O
that O
( O
i O
) O
NSP5 O
appears O
in O
many O
different O
phosphorylated O
forms O
in O
rotavirus O
- O
infected O
cells O
; O
( O
ii O
) O
immunoprecipitated O
NSP5 O
from O
rotavirus O
- O
infected O
cells O
can O
be O
phosphorylated O
in O
vitro O
by O
incubation O
with O
ATP O
; O
( O
iii O
) O
NSP5 O
, O
produced O
either O
by O
transient O
transfection O
of O
rotavirus O
gene O
11 O
or O
by O
infection O
by O
gene O
11 O
recombinant O
vaccinia O
virus O
or O
baculovirus O
, O
can O
be O
phosphorylated O
in O
vivo O
and O
in O
vitro O
; O
( O
iv O
) O
NSP5 O
expressed O
in O
Escherichia O
coli O
is O
phosphorylated O
in O
vitro O
, O
and O
thus O
NSP5 O
is O
a O
potential O
protein O
kinase O
; O
and O
( O
v O
) O
NSP5 O
forms O
dimers O
and O
interacts O
with O
NSP2 O
. O

Specific O
activation O
of O
T O
cells O
appears O
to O
be O
a O
prerequisite O
for O
viral O
clearance O
during O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
. O

Characterization O
of O
the O
T O
- O
cell O
response O
to O
the O
core O
protein O
( O
WHcAg O
) O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
in O
woodchucks O
contributes O
to O
the O
understanding O
of O
these O
mechanisms O
, O
Therefore O
, O
we O
investigated O
the O
response O
of O
woodchuck O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
to O
WHcAg O
and O
WHcAg O
- O
derived O
peptides O
, O
using O
our O
5 O
- O
bromo O
- O
2 O
' O
- O
deoxyuridine O
assay O
. O

Using O
a O
cross O
- O
reacting O
anti O
- O
human O
T O
- O
cell O
( O
CD3 O
) O
antiserum O
, O
we O
identified O
nonadherent O
cells O
as O
woodchuck O
T O
cells O
. O

T O
- O
cell O
epitope O
mapping O
with O
overlapping O
peptides O
, O
covering O
the O
entire O
WHcAg O
, O
revealed O
T O
- O
cell O
responses O
of O
acutely O
WHV O
- O
infected O
woodchucks O
to O
peptide O
( O
1 O
- O
20 O
) O
, O
peptide O
( O
100 O
- O
119 O
) O
, O
and O
peptide O
( O
112 O
- O
131 O
) O
. O

Detailed O
epitope O
analysis O
in O
the O
WHcAg O
region O
from O
amino O
acids O
97 O
to O
140 O
showed O
that O
T O
cells O
especially O
recognized O
peptide O
( O
97 O
- O
110 O
) O
. O

Establishment O
of O
polyclonal O
T O
- O
cell O
lines O
with O
WHcAg O
or O
peptide O
( O
97 O
- O
110 O
) O
, O
revealed O
reciprocal O
stimulation O
by O
peptide O
( O
97 O
- O
110 O
) O
or O
WHcAg O
, O
respectively O
. O

We O
vaccinated O
woodchucks O
with O
peptide O
( O
97 O
- O
110 O
) O
or O
WHcAg O
to O
prove O
the O
importance O
of O
this O
immunodominant O
T O
- O
cell O
epitope O
. O

All O
woodchucks O
immunized O
with O
peptide O
( O
97 O
- O
110 O
) O
or O
WHcAg O
were O
protected O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
presence O
of O
identical O
copies O
of O
the O
redundancy O
on O
the O
minus O
- O
strand O
DNA O
template O
was O
necessary O
and O
/ O
or O
sufficient O
for O
the O
template O
switch O
and O
at O
what O
position O
( O
s O
) O
within O
the O
redundancy O
the O
switch O
occurs O
for O
duck O
hepatitis O
B O
virus O
. O

In O
this O
study O
, O
we O
show O
that O
the O
efficacy O
of O
a O
DNA O
vaccine O
can O
be O
greatly O
improved O
by O
simultaneous O
expression O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
. O

Plasmid O
vectors O
encoding O
the O
major O
( O
S O
) O
or O
middle O
( O
pre O
- O
S2 O
plus O
S O
) O
envelope O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
were O
constructed O
and O
compared O
for O
their O
potential O
to O
induce O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
- O
specific O
immune O
responses O
with O
a O
vector O
encoding O
the O
middle O
envelope O
and O
IL O
- O
2 O
fusion O
protein O
or O
with O
a O
bicistronic O
vector O
separately O
encoding O
the O
middle O
envelope O
protein O
and O
IL O
- O
2 O
. O

When O
restimulated O
with O
antigen O
in O
vitro O
, O
splenocytes O
from O
mice O
that O
received O
plasmids O
coexpressing O
IL O
- O
2 O
and O
the O
envelope O
protein O
produced O
much O
stronger O
T B
helper I
1 I
( I
Th1 I
) I
- O
like O
responses O
than O
did O
those O
from O
mice O
that O
had O
been O
given O
injections O
of O
plasmids O
encoding O
the O
envelope O
protein O
alone O
. O

This O
molecule O
will O
be O
further O
modified O
at O
the O
C O
- O
terminal O
region O
to O
generate O
p17 O
, O
and O
the O
truncated O
protein O
is O
secreted O
from O
the O
cell O
as O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
, O
The O
function O
of O
the O
precore O
gene O
in O
the O
biology O
of O
hepadnaviruses O
is O
unknown O
. O

We O
found O
that O
ablation O
of O
the O
precore O
gene O
resulted O
in O
the O
generation O
of O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
species O
, O
vith O
a O
high O
- O
replication O
- O
level O
phenotype O
. O

These O
experiments O
suggest O
that O
expression O
of O
the O
precore O
gene O
may O
be O
important O
in O
the O
regulation O
of O
HBV O
replication O
and O
describe O
a O
possible O
molecular O
mechanism O
( O
s O
) O
for O
this O
effect O
. O

We O
used O
two O
- O
dimensional O
electrophoresis O
( O
nonequilibrium O
pH O
gradient O
electrophoresis O
followed O
by O
sodium O
dodecyl O
sulfate O
- O
10 O
% O
polyacrylamide O
gel O
electrophoresis O
) O
coupled O
with O
P O
- O
32 O
labeling O
and O
immunoblotting O
detection O
with O
I O
- O
125 O
- O
protein O
A O
to O
detect O
and O
quantitate O
phosphorylation O
of O
the O
large O
and O
small O
forms O
of O
the O
delta O
antigen O
( O
delta O
Ag O
- O
L O
and O
delta O
Ag O
- O
S O
, O
respectively O
) O
. O

( O
i O
) O
No O
detectable O
phosphorylation O
of O
delta O
Ag O
- O
S O
occurred O
, O
( O
ii O
) O
In O
virions O
from O
the O
serum O
of O
an O
infected O
animal O
and O
in O
the O
particles O
secreted O
from O
cotransfected O
cells O
, O
none O
of O
the O
delta O
Ag O
- O
L O
was O
phosphorylated O
. O

( O
iii O
) O
Only O
in O
the O
infected O
liver O
and O
in O
transfected O
cells O
was O
any O
phosphorylation O
detected O
; O
it O
corresponded O
to O
a O
monophosphorylated O
form O
of O
delta O
Ag O
- O
L O
. O

Given O
these O
results O
, O
we O
carried O
out O
serine O
- O
to O
- O
alanine O
mutagenesis O
of O
the O
delta O
Ag O
- O
L O
to O
determine O
whether O
the O
monophosphorylation O
was O
predominantly O
at O
a O
specific O
site O
on O
the O
unique O
19 O
- O
amino O
- O
acid O
( O
aa O
) O
extension O
, O
We O
mutated O
each O
of O
the O
two O
serines O
, O
aa O
207 O
and O
210 O
, O
on O
this O
extension O
and O
also O
the O
serine O
at O
aa O
177 O
. O

In O
contrast O
, O
mutagenesis O
to O
alanine O
of O
the O
cysteine O
at O
aa O
211 O
, O
which O
normally O
acts O
as O
the O
acceptor O
for O
farnesylation O
, O
completely O
inhibited O
phosphorylation O
, O
Our O
interpretation O
is O
that O
the O
site O
( O
s O
) O
of O
phosphorylation O
is O
probably O
not O
in O
the O
19 O
- O
aa O
extension O
unique O
to O
delta O
Ag O
- O
L O
and O
that O
phosphorylation O
of O
delta O
Ag O
- O
L O
may O
depend O
upon O
prior O
farnesylation O
. O

Posttranslational O
processing O
and O
subcellular O
localization O
of O
the O
HCV O
core O
protein O
are O
critical O
steps O
involved O
in O
the O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

The O
Gag O
protein O
of O
human B
foamy I
virus I
( I
HFV I
) I
lacks O
Cys O
- O
His O
boxes O
present O
in O
the O
nucleocapsid B
( I
NC I
) I
domains O
of O
other O
retroviruses O
; O
instead O
it O
contains O
three O
glycine O
- O
arginine O
- O
rich O
motifs O
( O
GR O
boxes O
) O
, O
We O
have O
expressed O
the O
carboxyl O
end O
of O
HFV O
Gag O
containing O
the O
GR O
boxes O
( O
the O
NC O
domain O
equivalent O
) O
and O
analyzed O
its O
nucleic O
acid O
binding O
properties O
. O

heron B
hepatitis I
B I
virus I
( I
HHBV I
) I
is O
an O
avian O
hepadnavirus O
that O
is O
closely O
related O
to O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

This O
clone O
, O
named O
HDE1 O
, O
expresses O
a O
chimeric O
pregenomic O
RNA O
, O
a O
chimeric O
polymerase B
( I
P I
) I
protein O
, O
and O
a O
core B
( I
C I
) I
protein O
with O
a O
one O
- O
amino O
- O
acid O
substitution O
at O
its O
carboxy O
terminus O
. O

These O
data O
indicate O
the O
presence O
of O
one O
or O
more O
formerly O
unrecognized O
cis O
- O
acting O
sequences O
for O
DNA O
synthesis O
within O
the O
chimeric O
region O
( O
nucleotides O
403 O
to O
1364 O
) O
, O
These O
cis O
- O
acting O
sequences O
in O
the O
middle O
of O
the O
genome O
might O
interact O
directly O
or O
indirectly O
with O
known O
cis O
elements O
that O
are O
located O
near O
the O
ends O
of O
the O
genome O
. O

The O
viral B
ribonucleoprotein I
particles I
( I
vRNPs I
) I
delivered O
into O
the O
cytosol O
then O
dissociate O
from O
the O
matrix O
protein O
, O
M1 O
, O
and O
from O
each O
other O
, O
after O
which O
they O
are O
individually O
imported O
into O
the O
nucleus O
via O
the O
nuclear O
pores O
, O
For O
some O
time O
, O
it O
has O
been O
believed O
that O
the O
low O
pH O
in O
endosomes O
may O
, O
in O
some O
way O
, O
trigger O
the O
capsid O
disassembly O
events O
necessary O
for O
nuclear O
transport O
, O
This O
report O
provides O
direct O
evidence O
that O
the O
association O
of O
M1 O
with O
vRNPs O
is O
sensitive O
to O
mildly O
acidic O
pH O
within O
the O
infected O
cell O
. O

Transcriptional O
activation O
of O
myc O
family O
proto O
- O
oncogenes O
through O
the O
insertion O
of O
viral O
sequences O
is O
the O
predominant O
mechanism O
by O
which O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
induces O
liver O
tumors O
in O
chronically O
infected O
animals O
. O

Here O
we O
identify O
a O
major O
, O
liver O
- O
specific O
regulatory O
element O
in O
the O
WHV O
genome O
( O
We2 O
) O
which O
efficiently O
activates O
the O
N O
- O
myc2 O
promoter O
in O
cultured O
hepatoma O
cells O
. O

Transcription O
from O
these O
mutants O
was O
examined O
both O
in O
cell O
- O
free O
transcription O
systems O
derived O
from O
hepatoma O
( O
HepG2 O
) O
and O
nonliver O
( O
HeLa O
) O
cell O
lines O
and O
by O
transient O
transfection O
of O
hepatoma O
cell O
lines O
( O
Huh7 O
and O
HepG2 O
) O
, O
The O
data O
from O
these O
experiments O
indicated O
that O
synthesis O
of O
the O
pre O
- O
C O
and O
pregenomic O
RNAs O
is O
directed O
by O
two O
distinct O
promoters O
and O
that O
the O
basal O
elements O
of O
these O
two O
promoters O
partially O
overlap O
, O
yet O
are O
genetically O
separable O
, O
with O
each O
consisting O
of O
its O
own O
transcriptional O
initiator O
and O
a O
TATA O
box O
- O
like O
sequence O
situated O
approximately O
25 O
to O
30 O
bp O
upstream O
of O
its O
sites O
of O
initiation O
, O
A O
15 O
- O
bp O
insertion O
was O
found O
to O
be O
sufficient O
to O
physically O
separate O
these O
two O
promoters O
, O
Furthermore O
, O
these O
two O
promoters O
can O
be O
differentially O
regulated O
, O
with O
the O
transcriptional O
activator O
Spl O
specifically O
activating O
transcription O
from O
the O
pregenomic O
promoter O
and O
the O
hepatocyte O
nuclear O
factor O
3 O
specifically O
repressing O
transcription O
from O
the O
pre O
- O
C O
promoter O
, O
Thus O
, O
we O
conclude O
that O
the O
promoters O
used O
in O
synthesis O
of O
the O
pre O
- O
C O
and O
pregenomic O
mRNAs O
are O
genetically O
distinct O
and O
separately O
regulated O
. O

The O
gene O
coding O
for O
the O
S O
protein O
, O
the O
smaller O
of O
the O
two O
envelope O
antigens O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
is O
transcribed O
from O
a O
TATA O
- O
less O
promoter O
. O

Located O
at O
position O
- O
25 O
relative O
to O
the O
transcriptional O
start O
site O
was O
a O
sequence O
conforming O
to O
the O
consensus O
binding O
site O
for O
Hepatocyte B
nuclear I
factor I
3 I
( I
HNF3 I
) I
. O

The O
results O
of O
electrophoretic B
mobility I
shift I
analysis I
( I
EMSA I
) I
demonstrated O
that O
a O
double O
- O
stranded O
oligonucleotide O
containing O
this O
sequence O
formed O
a O
specific O
complex O
, O
vith O
DNA O
- O
binding O
proteins O
from O
LMH O
and O
HepG2 O
cells O
but O
not O
, O
vith O
nuclear O
extracts O
obtained O
from O
HepG2 O
. O

A O
strong O
and O
transient O
hepatitis B
B I
virus I
core I
( I
HBc I
) I
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
has O
been O
shown O
to O
be O
associated O
with O
viral O
elimination O
in O
acute O
self O
- O
limited O
hepatitis O
B O
but O
to O
be O
absent O
in O
chronic O
hepatitis O
B O
, O
So O
far O
. O

little O
is O
known O
about O
immunological O
mechanisms O
involved O
in O
the O
regulation O
of O
the O
HBc O
- O
specific O
CD4 O
( O
+ O
) O
T O
cell O
response O
, O
We O
studied O
28 O
patients O
with O
acute O
hepatitis O
B O
, O
and O
frequently O
a O
sudden O
decrease O
in O
the O
HBc O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
was O
found O
between O
4 O
and O
8 O
weeks O
after O
disease O
onset O
, O
Thirty O
- O
two O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
specific O
for O
amino O
acids O
50 O
to O
69 O
, O
81 O
to O
105 O
, O
117 O
to O
131 O
, O
or O
141 O
to O
165 O
of O
HBc O
were O
isolated O
from O
a O
patient O
shortly O
before O
the O
peripheral O
blood O
mononuclear O
cell O
response O
to O
most O
HBc O
- O
derived O
peptides O
abruptly O
disappeared O
, O
TH1 O
clones O
, O
but O
not O
TH0 O
clones O
, O
could O
be O
anergized O
in O
vitro O
by O
stimulation O
with O
specific O
peptides O
even O
in O
the O
presence O
of O
costimulatory O
cells O
, O
Moreover O
, O
when O
anergic O
cells O
were O
mixed O
with O
responsive O
cells O
, O
the O
proliferation O
of O
HBc O
- O
specific O
TH1 O
or O
TH0 O
clones O
was O
inhibited O
antigen O
specifically O
by O
anergic O
cells O
, O
The O
unusual O
susceptibility O
of O
HBc O
- O
specific O
TH1 O
clones O
to O
anergy O
induction O
in O
vitro O
as O
well O
as O
their O
potential O
to O
inhibit O
other O
HBc O
- O
specific O
TH1 O
and O
TH0 O
clones O
suggests O
that O
anergy O
induction O
may O
be O
involved O
in O
the O
downregulation O
of O
the O
virus O
- O
specific O
immune O
response O
during O
acute O
hepatitis O
B O
in O
vivo O
. O

The O
terminal O
regions O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
pregenomic I
RNA I
( I
pgRNA I
) I
harbors O
sites O
governing O
many O
essential O
functions O
in O
the O
viral O
life O
cycle O
, O
including O
polyadenylation O
, O
translation O
, O
RNA O
encapsidation O
, O
and O
DNA O
synthesis O
. O

By O
UV O
cross O
- O
linking O
labeled O
RNA O
to O
HepG2 O
cell O
extracts O
, O
we O
have O
identified O
a O
65 B
- I
kDa I
factor I
( I
p65 I
) I
of O
nuclear O
origin O
which O
can O
specifically O
bind O
to O
this O
region O
. O

One O
binding O
site O
( O
termed O
UBS O
) O
overlaps O
a O
portion O
of O
the O
highly O
conserved O
stem O
- O
loop O
structure O
( O
epsilon O
) O
, O
while O
the O
other O
site O
( O
termed O
DBS O
) O
maps O
35 O
nucleotides O
downstream O
of O
the O
hexanucleotide O
polyadenylation O
sequence O
. O

In O
this O
study O
, O
we O
examined O
the O
ability O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
precore O
, O
envelope O
, O
and O
X O
gene O
products O
to O
modulate O
HBV O
replication O
in O
the O
livers O
of O
transgenic O
mice O
that O
replicate O
the O
virus O
, O
Hepatic O
HBV O
replication O
was O
not O
affected O
by O
overexpression O
of O
the O
envelope O
or O
X O
gene O
products O
when O
these O
animals O
were O
crossed O
with O
transgenic O
mice O
that O
express O
the O
corresponding O
viral O
genes O
in O
the O
hepatocyte O
. O

However O
, O
the O
mechanism O
of O
the O
protein O
- O
protein O
interaction O
is O
still O
poorly O
understood O
, O
A O
small O
region O
in O
the O
capsid O
protein O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
contains O
four O
hydrophobic O
residues O
, O
including O
leucine O
101 O
, O
leucine O
108 O
, O
valine O
115 O
, O
and O
phenylalanine O
122 O
, O
that O
are O
conserved O
and O
spaced O
every O
seventh O
residue O
in O
the O
primary O
sequence O
to O
form O
a O
hydrophobic B
heptad I
repeat I
( I
hhr I
) I
. O

In O
addition O
, O
we O
examined O
the O
in O
vivo O
infectivity O
of O
a O
WHV O
genome O
bearing O
a O
naturally O
occurring O
single O
amino O
acid O
change O
( O
histidine O
104 O
- O
- O
> O
proline O
) O
in O
the O
hhr O
region O
. O

The O
phenotype O
of O
each O
altered O
genome O
was O
determined O
in O
both O
eukaryotic O
and O
prokaryotic O
systems O
by O
a O
capsid O
protein O
assay O
and O
electron O
microscopic O
examination O
, O
We O
show O
that O
replacement O
of O
any O
one O
of O
the O
four O
hydrophobic O
residues O
with O
alanine O
did O
not O
prevent O
capsid O
assembly O
, O
However O
, O
assembled O
capsid O
particles O
were O
not O
detected O
if O
combinations O
bf O
any O
two O
of O
the O
four O
residues O
were O
substituted O
with O
alanines O
or O
if O
the O
spacing O
of O
these O
four O
hydrophobic O
residues O
was O
changed O
, O
An O
individual O
introduction O
of O
a O
proline O
( O
which O
dramatically O
changes O
the O
secondary O
structure O
of O
proteins O
) O
into O
different O
positions O
of O
this O
small O
region O
also O
abolished O
capsid O
assembly O
in O
vitro O
or O
viral O
replication O
in O
vivo O
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
are O
thought O
to O
control O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
since O
they O
are O
readily O
detectable O
in O
patients O
who O
clear O
the O
virus O
whereas O
they O
are O
hard O
to O
detect O
during O
chronic O
HBV O
infection O
. O

In O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
however O
, O
the O
virus O
persists O
in O
the O
face O
of O
a O
CTL O
response O
. O

Indeed O
, O
most O
infected O
patients O
respond O
to O
one O
or O
more O
HCV O
- O
1 O
( O
genotype O
1a O
) O
- O
derived O
CTL O
epitopes O
in O
the O
core O
, O
NS3 O
, O
and O
NS4 O
proteins O
, O
and O
the O
CTL O
response O
is O
equally O
strong O
in O
patients O
infected O
by O
infected O
by O
different O
HCV O
genotypes O
, O
suggesting O
broad O
cross O
- O
reactivity O
. O

We O
recently O
found O
that O
a O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
- O
infected O
cell O
line O
, O
MT O
- O
2 O
, O
could O
support O
the O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
( O
N O
. O

Integrated O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
is O
found O
in O
the O
great O
majority O
of O
human O
hepatocellular O
carcinomas O
, O
suggesting O
that O
these O
viral O
integrations O
may O
be O
implicated O
in O
liver O
ontogenesis O
. O

Besides O
the O
insertional O
mutagenesis O
characterized O
in O
a O
few O
selected O
cases O
and O
the O
contribution O
of O
viral O
transactivators O
to O
cell O
transformation O
to O
malignancy O
, O
HBV O
has O
been O
shown O
to O
generate O
gross O
chromosomal O
rearrangements O
potentially O
involved O
in O
carcinogenesis O
, O
Here O
, O
we O
report O
a O
t O
( O
3 O
; O
8 O
) O
chromosomal O
translocation O
present O
in O
a O
hepatocellular O
carcinoma O
developed O
in O
noncirrhotic O
liver O
tissue O
, O
One O
side O
of O
the O
translocation O
, O
in O
8p23 O
, O
is O
shown O
to O
he O
in O
the O
vicinity O
of O
the O
carboxypeptidase O
N O
gene O
, O
a O
locus O
that O
is O
heavily O
transcribed O
in O
liver O
tissue O
and O
frequently O
deleted O
in O
hepatocellular O
carcinomas O
and O
other O
epithelial O
tumors O
. O

A O
key O
early O
step O
in O
replication O
is O
binding O
of O
the O
polymerase O
to O
an O
RNA O
stem O
- O
loop O
( O
epsilon O
) O
of O
the O
pregenome O
; O
epsilon O
is O
both O
the O
RNA O
encapsidation O
signal O
and O
the O
origin O
of O
reverse O
transcription O
. O

These O
two O
sets O
of O
data O
( O
i O
) O
support O
a O
model O
in O
which O
binding O
of O
epsilon O
to O
the O
polymerase O
induces O
a O
structural O
alteration O
of O
the O
polymerase O
prior O
to O
the O
development O
of O
enzymatic O
activity O
and O
( O
ii O
) O
suggest O
that O
this O
alteration O
may O
be O
required O
for O
the O
polymerase O
to O
mature O
to O
an O
active O
form O
. O

A O
total O
of O
17 O
antibodies O
, O
raised O
in O
several O
nonhuman O
species O
and O
specific O
for O
different O
regions O
on O
the O
delta B
antigen I
( I
delta I
Ag I
) I
, O
were O
used O
to O
map O
, O
via O
immunoprecipitation O
, O
those O
domains O
exposed O
on O
the O
surface O
of O
the O
viral O
ribonucleoprotein B
( I
RNP I
) I
. O

When O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
was O
released O
by O
treatment O
of O
viral O
RNP O
with O
vanadyl O
ribonucleoside O
complexes O
, O
no O
change O
in O
the O
pattern O
of O
delta O
Ag O
epitope O
presentation O
was O
detected O
, O
consistent O
with O
the O
interpretation O
that O
a O
multimeric O
protein O
structure O
persists O
in O
the O
absence O
of O
RNA O
. O

The O
basal B
core I
promoter I
( I
BCP I
) I
of O
hepatitis B
B I
virus I
( I
HBV I
) I
controls O
the O
transcription O
of O
both O
the O
precore O
RNA O
and O
the O
core O
RNA O
, O
The O
precore O
RNA O
codes O
for O
the O
secreted O
e O
antigen O
, O
while O
the O
core O
RNA O
codes O
for O
the O
major O
core O
protein O
and O
the O
DNA O
polymerase O
and O
also O
is O
the O
pregenomic O
RNA O
. O

Our O
results O
indicate O
that O
the O
mutated O
BCP O
can O
no O
longer O
bind O
a O
liver O
- O
enriched O
transcription O
factor O
( O
s O
) O
and O
that O
the O
transcription O
of O
only O
precore O
RNA O
and O
, O
consequently O
, O
the O
expression O
of O
e O
antigen O
were O
reduced O
. O

Infection O
by O
human O
and O
animal O
hepadnaviruses O
displays O
remarkable O
host O
and O
tissue O
tropism O
, O
The O
infection O
cycle O
probably O
initiates O
with O
binding O
of O
the O
pre O
- O
S O
domain O
of O
viral O
envelope O
protein O
to O
surface O
receptors O
present O
on O
the O
hepatocyte O
, O
Three O
types O
of O
neutralizing O
monoclonal O
antibodies O
against O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
have O
their O
binding O
sites O
clustered O
within O
residues O
83 O
to O
107 O
of O
the O
pre O
- O
S O
protein O
, O
suggesting O
that O
this O
region O
may O
constitute O
a O
major O
receptor O
binding O
site O
, O
A O
170 O
- O
or O
180 O
- O
kDa O
duck O
protein O
( O
p170 O
or O
gp180 O
) O
which O
binds O
DHBV O
particles O
through O
this O
part O
of O
the O
pre O
- O
S O
sequence O
has O
been O
identified O
recently O
, O
Although O
the O
p170 O
binding O
protein O
is O
host O
( O
duck O
) O
specific O
, O
its O
distribution O
is O
not O
restricted O
to O
DHBV O
- O
infectible O
tissues O
, O
Using O
the O
pre O
- O
S O
protein O
fused O
to O
glutathione O
S O
- O
transferase O
and O
immobilized O
on O
Sepharose O
beads O
, O
we O
have O
now O
identified O
an O
additional O
binding O
protein O
with O
a O
size O
of O
120 O
kDa O
( O
p120 O
) O
, O
p120 O
expression O
is O
restricted O
to O
the O
liver O
, O
kidney O
, O
and O
pancreas O
, O
the O
three O
major O
organs O
of O
DHBV O
replication O
, O
While O
optimal O
p170 O
binding O
requires O
an O
intact O
pre O
- O
S O
protein O
, O
binding O
to O
p120 O
occurs O
much O
more O
efficiently O
with O
a O
few O
N O
- O
or O
C O
- O
terminally O
truncated O
forms O
, O
The O
p120 O
binding O
site O
was O
mapped O
to O
residues O
98 O
to O
102 O
of O
the O
pre O
- O
S O
region O
, O
which O
overlaps O
with O
a O
cluster O
of O
known O
virus O
- O
neutralizing O
epitopes O
, O
Site O
- O
directed O
mutagenesis O
revealed O
residues O
100 O
to O
102 O
( O
Phe O
- O
Arg O
- O
Arg O
) O
as O
the O
critical O
p120 O
contact O
site O
; O
nonconservative O
substitution O
in O
any O
of O
the O
three O
positions O
abolished O
p120 O
binding O
, O
Double O
mutations O
at O
positions O
100 O
to O
102 O
markedly O
reduced O
DHBV O
infectivity O
in O
cell O
culture O
, O
Short O
pre O
- O
S O
peptides O
covering O
the O
clustered O
neutralizing O
epitopes O
( O
also O
p170 O
and O
p120 O
binding O
sites O
) O
reduced O
DHBV O
infectivity O
in O
primary O
duck O
hepatocyte O
cultures O
, O
Thus O
, O
p120 O
represents O
a O
candidate O
component O
of O
the O
DHBV O
receptor O
complex O
. O

In O
this O
study O
, O
we O
made O
four O
mutants O
in O
which O
single O
amino O
acids O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
RNase O
H O
region O
were O
altered O
, O
In O
two O
of O
them O
, O
amino O
acids O
at O
locations O
comprising O
the O
putative O
catalytic O
site O
were O
changed O
, O
while O
the O
remaining O
mutants O
had O
alterations O
at O
amino O
acids O
conserved O
among O
hepadnaviruses O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
two O
virus O
- O
specific O
delta O
antigens O
( O
HDAgs O
) O
, O
large O
and O
small O
forms O
, O
which O
are O
identical O
in O
sequence O
except O
that O
the O
large O
one O
contains O
19 O
extra O
amino O
acids O
at O
the O
C O
terminus O
. O

In O
this O
study O
, O
we O
have O
characterized O
the O
phosphorylative O
property O
of O
HDAg O
in O
a O
Human B
Hepatoma I
Cell I
line I
( I
Huh I
- I
7 I
) I
and O
examined O
the O
role O
of O
phosphorylation O
in O
HDAg O
function O
. O

As O
demonstrated O
by O
in O
vivo O
labeling O
and O
kinase O
inhibitor O
experiments O
, O
the O
phosphorylation O
levels O
of O
both O
HDAgs O
were O
diminished O
by O
the O
inhibitor O
of O
casein B
kinase I
II I
( I
CKII I
) I
. O

Nevertheless O
, O
phosphorylation O
of O
only O
the O
small O
form O
could O
be O
markedly O
reduced O
by O
the O
protein B
kinase I
C I
( I
PKC I
) I
inhibitor O
, O
suggesting O
different O
phosphorylation O
properties O
between O
the O
two O
HDAgs O
. O

Core O
gene O
mutations O
with O
phenotypes O
consistent O
with O
this O
concept O
have O
previously O
been O
identified O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

In O
the O
cytoplasm O
, O
HBx O
was O
shown O
to O
stimulate O
the O
Ras O
- O
Raf O
- O
mitogen B
- I
activated I
protein I
kinase I
( I
MAP I
kinase I
) I
cascade O
, O
which O
is O
essential O
for O
activation O
of O
transcription O
factor O
AP O
- O
l O
. O

HBx O
protein O
stimulates O
the O
extracellular B
signal I
- I
regulated I
kinases I
( I
ERKs I
) I
and O
the O
c B
- I
jun I
N I
- I
terminal I
kinases I
( I
JNKs I
) I
. O

New O
c O
- O
Jun O
synthesis O
was O
blocked O
by O
coexpression O
with O
a O
dominant O
- O
negative O
MAP O
kinase O
kinase O
( O
MEK O
kinase O
, O
MEKK O
- O
1 O
) O
, O
confirming O
that O
HBx O
stimulates O
the O
prolonged O
synthesis O
of O
c O
- O
Jun O
by O
activating O
JNK O
signalling O
pathways O
. O

Transcription O
and O
replication O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
are O
performed O
by O
the O
cellular O
enzyme O
RNA B
polymerase I
II I
( I
Pol I
II I
) I
, O
As O
DNA O
is O
the O
normal O
template O
for O
Pol O
II O
, O
the O
enzyme O
must O
undergo O
template O
switching O
, O
The O
mechanism O
for O
this O
is O
unknown O
, O
but O
since O
HDV O
RNA O
can O
form O
a O
rod O
- O
like O
molecule O
by O
extensive O
intramolecular O
base O
pairing O
, O
it O
has O
been O
suggested O
that O
a O
double O
- O
stranded O
region O
( O
s O
) O
of O
HDV O
RNA O
serves O
as O
a O
recognition O
site O
for O
Pol O
II O
, O
A O
bidirectional O
promoter O
has O
been O
identified O
previously O
on O
HDV O
cDNA O
( O
T O
, O
B O
, O
Macnaughton O
, O
M O
, O
R O
, O
Beard O
, O
M O
, O
Chao O
, O
E O
, O
J O
, O
Gowans O
, O
and O
M O
, O
M O
, O
C O
, O
Lai O
, O
Virology O
196 O
: O
629 O
- O
636 O
, O
1993 O
) O
. O

Specific O
inhibition O
of O
core O
protein O
synthesis O
was O
observed O
in O
a O
chicken O
hepatoma O
cell O
line O
( O
LMH O
) O
cotransfected O
with O
core O
and O
polymerase O
plasmid O
DNA O
. O

Genetic O
and O
biochemical O
studies O
have O
provided O
convincing O
evidence O
that O
the O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
conserved O
among O
viral O
isolates O
worldwide O
and O
that O
translation O
of O
HCV O
is O
directed O
by O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
located O
within O
the O
5 O
' O
NCR O
. O

Oligonucleotides O
were O
evaluated O
for O
activity O
after O
treatment O
of O
a O
human O
hepatocyte O
cell O
line O
expressing O
the O
HCV O
5 O
' O
NCR O
, O
core O
protein O
coding O
sequences O
, O
and O
the O
majority O
of O
the O
envelope B
gene I
( I
El I
) I
. O

The O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
X O
gene O
( O
WHx O
) O
is O
required O
for O
infectivity O
of O
WHV O
in O
woodchucks O
, O
and O
the O
gene O
encodes O
a O
broadly O
acting O
transcription O
factor O
, O
Several O
lines O
of O
evidence O
from O
cell O
culture O
and O
transgenic O
mice O
suggest O
that O
X O
proteins O
can O
promote O
hepatocarcinogenesis O
. O

To O
determine O
whether O
WHx O
- O
encoded O
proteins O
are O
present O
during O
persistent O
infection O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
in O
woodchucks O
, O
we O
surveyed O
livers O
and O
HCCs O
from O
a O
panel O
of O
WHV O
carrier O
woodchucks O
for O
the O
presence O
of O
WHx O
by O
utilizing O
an O
immunoprecipitation O
- O
Western O
blot O
( O
immunoblot O
) O
procedure O
. O

Comparative O
immunoprecipitation O
experiments O
revealed O
that O
there O
were O
4 O
x O
10 O
( O
4 O
) O
to O
8 O
x O
10 O
( O
4 O
) O
molecules O
of O
WHx O
per O
primary O
woodchuck O
hepatocyte O
. O

Although O
the O
biological O
importance O
of O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
in O
the O
life O
cycle O
of O
hepatitis O
B O
virus O
has O
been O
well O
established O
, O
the O
cellular O
and O
molecular O
basis O
of O
its O
function O
remains O
largely O
undefined O
. O

Using O
the O
Saccharomyces O
cerevisiae O
two O
- O
hybrid O
system O
, O
we O
have O
identified O
and O
characterized O
a O
novel O
subunit O
of O
the O
proteasome O
complex O
( O
XAPC7 O
) O
that O
interacts O
specifically O
with O
HBX O
. O

We O
present O
evidence O
for O
a O
novel O
member O
of O
the O
hepadnavirus O
family O
that O
is O
endemic O
in O
wild O
arctic O
ground O
squirrels O
( O
Spermophylus O
parryi O
kennicotti O
) O
in O
Alaska O
. O

This O
virus O
, O
designated O
arctic B
squirrel I
hepatitis I
virus I
( I
ASHV I
) I
, O
was O
initially O
detected O
in O
the O
livers O
of O
animals O
bearing O
large O
hepatic O
nodules O
by O
nucleic O
acid O
hybridization O
with O
hepadnavirus O
probes O
and O
in O
plasma O
by O
cross O
- O
reactivity O
with O
antibodies O
to O
hepadnavirus O
surface O
and O
core O
antigens O
. O

The O
complete O
nucleotide O
sequence O
of O
the O
3 O
, O
302 O
- O
bp O
- O
long O
ASHV O
genome O
was O
determined O
and O
compared O
with O
those O
of O
ground B
squirrel I
hepatitis I
virus I
( I
GSHV I
) I
and O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
; O
all O
sequences O
were O
organized O
into O
four O
open O
reading O
frames O
, O
designated O
pre O
- O
C O
/ O
C O
, O
Dre O
- O
S O
/ O
S O
, O
pol O
, O
and O
X O
. O

Despite O
roughly O
equivalent O
variability O
among O
the O
three O
rodent O
hepadnaviruses O
( O
around O
16 O
% O
base O
and O
19 O
% O
amino O
acid O
exchanges O
) O
, O
ASHV O
appeared O
to O
be O
more O
closely O
related O
to O
GSHV O
than O
to O
WHV O
in O
phylogenetic O
analysis O
. O

Assembly O
of O
the O
enveloped O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
initiated O
by O
packaging O
of O
the O
RNA O
pregenome O
and O
the O
viral O
reverse O
transcriptase O
- O
DNA O
polymerase O
into O
a O
nucleocapsid O
, O
The O
pregenome O
is O
then O
reverse O
transcribed O
into O
single O
- O
stranded O
minus O
- O
polarity O
DNA O
, O
which O
is O
subsequently O
replicated O
to O
double O
- O
stranded O
DNA O
. O

The O
RNAs O
of O
the O
hepatitis O
11 O
virus O
( O
HBV O
) O
contain O
a O
cis O
- O
acting O
regulatory O
element O
which O
facilitates O
the O
cytoplasmic O
localization O
of O
unspliced O
transcripts O
( O
J O
. O

Such O
localization O
is O
presumed O
to O
be O
mediated O
by O
cellular O
factors O
which O
interact O
with O
the O
element O
, O
The O
HBV B
posttranscriptional I
regulatory I
element I
( I
HBVPRE I
) I
can O
efficiently O
activate O
an O
RNA O
export O
reporter O
system O
in O
an O
orientation O
- O
dependent O
and O
position O
- O
independent O
manner O
, O
Deletion O
analysis O
reveals O
that O
the O
HBVPRE O
consists O
of O
two O
subelements O
which O
function O
synergistically O
. O

A O
synergistic O
effect O
was O
also O
observed O
when O
the O
5 O
' O
( O
PRE O
alpha O
) O
or O
3 O
' O
( O
PRE O
beta O
) O
subelements O
were O
duplicated O
. O

We O
found O
that O
livers O
from O
woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
contained O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
molecules O
with O
deletions O
and O
insertions O
indicative O
of O
their O
formation O
from O
linear O
viral O
DNA O
by O
nonhomologous O
recombination O
, O
as O
Ive O
previously O
described O
for O
the O
duck O
hepatitis O
B O
virus O
( O
W O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
efficiently O
induces O
hepatocellular O
carcinoma O
in O
chronically O
infected O
hosts O
. O

WHV O
enhancer B
II I
( I
En I
II I
) I
is O
the O
major O
cis O
- O
acting O
element O
involved O
in O
this O
activation O
. O

WHV O
En O
II O
activity O
is O
strongly O
liver O
specific O
and O
maps O
to O
an O
88 O
- O
nucleotide O
DNA O
segment O
( O
nucleotides O
1772 O
to O
1859 O
) O
located O
5 O
' O
to O
the O
pregenomic O
RNA O
start O
site O
. O

An O
RGD O
- O
containing O
epitope O
from O
the O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
VP1 O
protein O
was O
inserted O
into O
the O
el O
loop O
of O
the O
hepatitis B
B I
virus I
core I
( I
HBc I
) I
protein O
. O

The O
chimeric O
particles O
also O
bound O
to O
purified O
integrins O
, O
and O
inhibition O
by O
chain O
- O
specific O
anti O
- O
integrin O
monoclonal O
antibodies O
implicated O
alpha O
( O
5 O
) O
beta O
( O
1 O
) O
as O
a O
candidate O
cell O
receptor O
for O
both O
the O
chimeric O
particle O
and O
FMDV O
. O

Some O
serotypes O
of O
FMDV O
bound O
to O
beta O
( O
1 O
) O
integrins O
in O
solid O
- O
phase O
assays O
, O
and O
the O
chimeric O
particles O
competed O
with O
FMDV O
for O
binding O
to O
susceptible O
eukaryotic O
cells O
. O

During O
chronic O
hepadnavirus O
infection O
, O
virus O
persistence O
depends O
on O
the O
regulation O
of O
the O
pool O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
which O
is O
the O
template O
for O
transcription O
of O
viral O
RNA O
species O
. O

The O
development O
of O
in O
vitro O
infection O
of O
duck O
hepatocyte O
primary O
cultures O
by O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
provides O
a O
unique O
opportunity O
to O
study O
the O
regulation O
of O
cccDNA O
synthesis O
. O

The O
addition O
of O
a O
cell O
cycle O
blocker O
, O
n O
- O
butyrate O
, O
completely O
inhibited O
[ O
H O
- O
3 O
] O
thymidine O
incorporation O
and O
blocked O
duckling O
hepatocytes O
in O
the O
G O
( O
1 O
) O
phase O
of O
the O
cell O
cycle O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
is O
a O
small O
DNA O
virus O
that O
replicates O
inside O
the O
viral O
nucleocapsid O
by O
reverse O
transcription O
of O
an O
RNA O
intermediate O
. O

The O
human O
T O
- O
and O
B O
- O
cell O
lines O
HPBMa10 O
- O
2 O
and O
Daudi O
produced O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
for O
more O
than O
1 O
year O
after O
infection O
. O

The O
human O
hepatoblastoma O
cell O
line O
HepG2 O
produces O
and O
secretes O
hepatitis B
B I
virus I
( I
HBV I
) I
after O
transfection O
of O
cloned O
HBV O
DNA O
. O

Recently O
, O
we O
observed O
pre O
- O
S O
- O
independent O
, O
nonspecific O
binding O
between O
hepatitis B
B I
surface I
( I
HBs I
) I
particles O
and O
HepG2 O
cells O
after O
treatment O
of O
HBs O
antigen O
particles O
with O
VS O
protease O
, O
which O
cleaves O
next O
to O
a O
putative O
fusion O
sequence O
. O

However O
, O
apoptosis O
in O
N O
- O
myc2 O
- O
expressing O
alpha O
ML O
cells O
is O
strongly O
inhibited O
by O
insulin B
- I
like I
growth I
factor I
II I
( I
IGF I
II I
) I
. O

We O
previously O
characterized O
episomally O
derived O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
integrations O
in O
LMH O
- O
D2 O
cells O
that O
replicate O
wild O
- O
type O
DHBV O
. O

By O
transfecting O
hepatoma O
cells O
with O
wild O
- O
type O
or O
mutant O
viral O
genomic O
DNA O
, O
we O
have O
shown O
that O
one O
such O
mutant O
gives O
rise O
to O
extremely O
small O
amounts O
of O
S O
transcripts O
, O
as O
expected O
, O
and O
therefore O
expresses O
very O
little O
of O
the O
middle O
and O
small O
surface O
( O
viral O
envelope O
) O
proteins O
that O
are O
translated O
from O
these O
transcripts O
, O
In O
addition O
, O
this O
mutant O
gives O
rise O
to O
greater O
- O
than O
- O
wild O
- O
type O
levels O
of O
the O
preS1 O
transcripts O
, O
which O
are O
translated O
into O
the O
large O
surface O
protein O
, O
Because O
the O
large O
surface O
protein O
, O
unlike O
the O
other O
forms O
of O
surface O
protein O
, O
is O
incompetent O
for O
secretion O
, O
cells O
transfected O
with O
the O
mutant O
viral O
DNA O
contain O
large O
amounts O
of O
20 O
- O
nm O
particles O
within O
dilated O
perinuclear O
vesicles O
, O
Therefore O
, O
this O
and O
similar O
S O
promoter O
mutants O
may O
be O
one O
contributing O
factor O
in O
the O
pathogenesis O
of O
ground O
- O
glass O
cells O
, O
which O
are O
hepatocytes O
containing O
nonsecretable O
viral O
surface O
proteins O
within O
dilated O
vesicles O
and O
are O
commonly O
found O
during O
chronic O
hepatitis O
B O
, O
Interestingly O
, O
DNA O
- O
containing O
virion O
particles O
are O
secreted O
into O
the O
medium O
by O
cells O
transfected O
with O
the O
mutant O
DNA O
, O
in O
amounts O
that O
are O
slightly O
larger O
than O
those O
secreted O
from O
wild O
- O
type O
- O
transfected O
cells O
, O
apparently O
because O
the O
amount O
of O
large O
surface O
protein O
is O
insufficient O
to O
block O
virion O
secretion O
, O
This O
finding O
mag O
explain O
how O
such O
mutants O
can O
become O
the O
predominant O
circulating O
species O
in O
the O
serum O
, O
especially O
if O
there O
are O
selection O
pressures O
against O
the O
mild O
- O
type O
virus O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
major O
human O
pathogen O
in O
much O
of O
the O
developing O
world O
. O

kb O
polyadenylated O
genome O
consisting O
of O
three O
open B
reading I
frames I
( I
ORFs I
) I
, O
In O
the O
absence O
of O
an O
in O
vitro O
culture O
system O
, O
the O
replication O
and O
expression O
strategy O
of O
HEV O
and O
the O
nature O
of O
its O
encoded O
polypeptides O
are O
not O
well O
understood O
, O
We O
have O
expressed O
the O
two O
ORFs O
constituting O
the O
structural O
portion O
of O
the O
HEV O
genome O
in O
COS O
- O
1 O
cells O
by O
using O
simian O
virus O
40 O
- O
based O
expression O
vectors O
and O
in O
vitro O
by O
using O
a O
coupled O
transcription O
- O
translation O
system O
. O

We O
show O
here O
that O
the O
major O
capsid O
protein O
, O
encoded O
by O
ORF2 O
, O
is O
an O
88 O
- O
kDa O
glycoprotein O
which O
is O
expressed O
intracellularly O
as O
well O
as O
on O
the O
cell O
surface O
and O
has O
the O
potential O
to O
form O
noncovalent O
homodimers O
, O
It O
is O
synthesized O
as O
a O
precursor O
( O
ppORF2 O
) O
which O
is O
processed O
through O
signal O
sequence O
cleavage O
into O
the O
mature O
protein O
( O
pORF2 O
) O
, O
which O
is O
then O
glycosylated O
( O
gpORF2 O
) O
, O
The O
minor O
protein O
, O
pORF3 O
, O
encoded O
by O
ORF3 O
is O
a O
13 O
. O

To O
define O
cytotoxic B
T I
- I
cell I
( I
CTL I
) I
epitopes O
, O
the O
common O
approach O
involving O
the O
use O
of O
a O
series O
of O
overlapping O
synthetic O
peptides O
covering O
the O
whole O
protein O
sequence O
is O
impractical O
for O
large O
proteins O
. O

To O
identify O
human O
CTL O
epitopes O
in O
the O
NS3 O
region O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
we O
modified O
an O
approach O
using O
recombinant O
protein O
and O
the O
ability O
of O
short O
peptides O
to O
bind O
to O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecules O
. O

The O
most O
active O
fraction O
was O
sequenced O
, O
identifying O
a O
15 O
- O
residue O
peptide O
( O
NS3 O
- O
1J O
; O
TITTGAPVTYSTYGK O
) O
. O

CTL O
lines O
specific O
for O
NS3 O
- O
1J O
were O
established O
from O
two O
HCV O
- O
infected O
patients O
( O
both O
HLA O
- O
A2 O
and O
- O
B7 O
positive O
) O
by O
stimulation O
with O
the O
synthetic O
peptide O
in O
vitro O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
is O
a O
small O
DNA O
virus O
that O
replicates O
inside O
the O
viral O
nucleocapsid O
by O
reverse O
transcription O
of O
an O
RNA O
intermediate O
, O
the O
pregenome O
. O

We O
have O
recently O
shown O
that O
HBV O
minus O
- O
strand O
DNA O
synthesis O
involves O
transfer O
of O
a O
short O
DNA O
primer O
copied O
from O
5 O
' O
- O
epsilon O
to O
3 O
' O
- O
DR1 O
( O
DR1 O
* O
) O
. O

Since O
the O
I O
kappa O
B O
- O
alpha O
inhibitory O
subunit O
proteolytic O
degradation O
, O
which O
follows O
its O
phosphorylation O
/ O
modification O
, O
is O
a O
key O
event O
in O
NF O
- O
kappa O
B O
activation O
by O
different O
stimuli O
( O
such O
as O
growth O
factors O
, O
phorbol O
esters O
, O
tumor O
necrosis O
factor O
, O
UV O
irradiation O
, O
and O
oxygen O
radicals O
) O
, O
we O
investigated O
pX O
effects O
on O
I O
kappa O
B O
- O
alpha O
, O
as O
well O
as O
the O
possible O
involvement O
of O
known O
signalling O
pathways O
in O
pX O
- O
induced O
NF O
- O
kappa O
B O
- O
dependent O
transcription O
. O

The O
NS2 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
released O
from O
its O
polyprotein O
precursor O
by O
two O
proteolytic O
cleavages O
. O

To O
characterize O
the O
biogenesis O
of O
NS2 O
encoded O
by O
the O
BK O
strain O
of O
HCV O
, O
we O
have O
defined O
the O
minimal O
region O
of O
the O
polyprotein O
required O
for O
efficient O
cleavage O
at O
the O
NS2 O
- O
3 O
site O
and O
analyzed O
the O
interaction O
of O
the O
mature O
polypeptide O
with O
the O
membrane O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

RNA O
editing O
plays O
a O
central O
role O
in O
the O
life O
cycle O
of O
hepatitis B
D I
virus I
( I
HDV I
) I
, O
a O
subviral O
human O
pathogen O
, O
Previous O
studies O
( O
J O
. O

In O
order O
to O
study O
the O
integration O
process O
, O
we O
have O
utilized O
LMH O
- O
D2 O
cells O
, O
which O
replicate O
wild O
- O
type O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
to O
develop O
the O
first O
protocol O
to O
detect O
and O
characterize O
integrations O
of O
DHBV O
originating O
from O
episomal O
viral O
DNAs O
. O

Complete O
characterization O
of O
one O
integration O
revealed O
a O
single O
- O
genome O
- O
length O
integrant O
with O
the O
structure O
of O
double B
- I
stranded I
linear I
( I
dsL I
) I
DHBV O
DNAs O
which O
are O
produced O
by O
in O
situ O
priming O
during O
viral O
replication O
. O

CD8 O
( O
+ O
) O
T O
cells O
with O
cytotoxic O
activity O
against O
the O
surface O
glycoprotein O
( O
S O
) O
of O
mouse O
hepatitis O
virus O
, O
strain O
JHM O
, O
have O
been O
identified O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
both O
acutely O
and O
chronically O
infected O
C57BL O
/ O
6 O
mice O
. O

In O
this O
report O
, O
two O
specific O
epitopes O
recognized O
by O
these O
CNS O
- O
derived O
cells O
were O
identified O
, O
using O
a O
panel O
of O
peptides O
chosen O
because O
they O
conformed O
to O
the O
allele O
- O
specific O
binding O
motif O
for O
MHC O
class O
I O
H O
- O
2K O
( O
b O
) O
and O
H O
- O
2D O
( O
b O
) O
. O

The O
active O
peptides O
encompassed O
residues O
510 O
to O
518 O
( O
CSLWNGPHL O
, O
H O
- O
2D O
( O
b O
) O
) O
and O
598 O
to O
605 O
( O
RCQIFANI O
, O
H O
- O
2K O
( O
b O
) O
) O
. O

Since O
C57BL O
/ O
6 O
mice O
become O
persistently O
infected O
more O
commonly O
than O
many O
other O
strains O
of O
mice O
, O
these O
data O
are O
consistent O
with O
a O
role O
for O
CD8 O
( O
+ O
) O
T O
- O
cell O
escape O
mutants O
in O
the O
pathogenesis O
of O
the O
demyelinating O
disease O
. O

This O
is O
the O
first O
report O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
Localization O
within O
the O
S O
protein O
, O
the O
protein O
most O
strongly O
implicated O
thus O
far O
in O
pathogenesis O
in O
the O
host O
. O

The O
large O
hepatitis B
B I
virus I
( I
HBV I
) I
surface O
protein O
( O
L O
) O
forms O
two O
isomers O
which O
display O
their O
N O
- O
terminal O
pre O
- O
S O
domain O
at O
the O
internal O
and O
external O
side O
of O
the O
viral O
envelope O
, O
respectively O
, O
The O
external O
pre O
- O
S O
domain O
has O
been O
implicated O
in O
binding O
to O
a O
virus O
receptor O
, O
To O
investigate O
functions O
of O
the O
internal O
pre O
- O
S O
domain O
, O
a O
secretion O
signal O
sequence O
was O
fused O
to O
the O
N O
terminus O
of O
L O
( O
sigL O
) O
, O
causing O
exclusive O
expression O
of O
external O
pre O
- O
S O
domains O
. O

A O
fusion O
construct O
with O
a O
nonfunctional O
signal O
( O
s25L O
) O
, O
which O
corresponds O
in O
its O
primary O
sequence O
to O
sigL O
cleaved O
by O
signal O
peptidase O
, O
was O
used O
as O
a O
control O
. O

( O
i O
) O
SigL O
lost O
the O
inhibitory O
effect O
of O
L O
or O
s25L O
on O
secretion O
of O
subviral O
hepatitis O
B O
surface O
antigen O
particles O
, O
suggesting O
that O
the O
retention O
signal O
mapped O
to O
the O
N O
terminus O
of O
L O
is O
recognized O
in O
the O
cytosol O
and O
not O
in O
the O
lumen O
of O
the O
endoplasmic O
reticulum O
. O

( O
ii O
) O
SigL O
was O
secreted O
into O
the O
culture O
medium O
even O
in O
the O
absence O
of O
the O
major O
HBV O
surface O
protein O
( O
S O
) O
, O
while O
release O
of O
an O
L O
mutant O
lacking O
the O
retention O
signal O
was O
still O
dependent O
on O
S O
coexpression O
. O

( O
iii O
) O
s25L O
but O
not O
sigL O
could O
complement O
an O
L O
negative O
HBV O
genome O
defective O
for O
virion O
secretion O
in O
cotransfections O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
proteins O
, O
termed O
core O
proteins O
, O
with O
two O
to O
four O
- O
amino O
- O
acid O
insertions O
were O
assessed O
for O
capsid O
formation O
, O
RNA O
encapsidation O
, O
and O
the O
ability O
to O
support O
reverse O
transcription O
of O
the O
pregenome O
by O
the O
polymerase O
molecule O
, O
Velocity O
sedimentation O
analysis O
of O
insect O
cell O
- O
expressed O
recombinant O
core O
proteins O
revealed O
that O
only O
two O
of O
the O
nine O
insertion O
mutant O
proteins O
formed O
capsids O
with O
the O
tight O
banding O
patterns O
of O
wild O
type O
capsids O
, O
The O
remaining O
mutant O
core O
proteins O
were O
spread O
over O
the O
gradients O
, O
suggesting O
aggregate O
formation O
, O
or O
at O
the O
top O
of O
the O
gradients O
, O
suggesting O
lack O
of O
stable O
capsid O
formation O
, O
The O
mutant O
capsid O
proteins O
were O
coexpressed O
in O
Huh7 O
cells O
with O
an O
HBV O
genome O
lacking O
a O
functional O
core O
gene O
to O
test O
for O
trans O
complementation O
of O
HBV O
replication O
, O
Three O
of O
the O
mutant O
core O
proteins O
formed O
capsids O
containing O
HBV O
RNA O
, O
but O
only O
two O
of O
these O
contained O
reverse O
- O
transcribed O
HBV O
DNA O
, O
While O
the O
core O
protein O
has O
shown O
resiliency O
in O
capsid O
formation O
following O
insertion O
of O
foreign O
residues O
into O
the O
major O
B O
- O
cell O
epitope O
, O
several O
of O
the O
small O
insertions O
severely O
reduced O
the O
efficiency O
of O
capsid O
formation O
and O
inhibited O
capsid O
function O
. O

We O
have O
fused O
the O
pre O
- O
S O
domain O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
large O
envelope O
protein O
to O
glutathione O
S O
- O
transferase O
and O
demonstrated O
a O
170 O
- O
kDa O
binding O
protein O
( O
p170 O
) O
in O
[ O
S O
- O
35 O
] O
methionine O
- O
labeled O
duck O
hepatocyte O
lysates O
, O
This O
glycoprotein O
was O
found O
abundantly O
in O
all O
extrahepatic O
tissues O
infectible O
with O
DHBV O
and O
in O
some O
noninfectible O
tissues O
, O
though O
it O
is O
not O
secreted O
into O
the O
blood O
, O
The O
interaction O
of O
pre O
- O
S O
fusion O
protein O
with O
p170 O
was O
competitively O
inhibited O
by O
wild O
- O
type O
DHBV O
in O
a O
dose O
- O
dependent O
manner O
, O
In O
addition O
, O
infection O
of O
hepatocytes O
with O
DHBV O
blocked O
the O
binding O
of O
pre O
- O
S O
fusion O
protein O
to O
p170 O
, O
which O
suggests O
a O
biological O
role O
for O
p170 O
during O
natural O
infection O
, O
The O
p170 O
binding O
site O
was O
mapped O
to O
a O
conserved O
sequence O
of O
16 O
amino O
acid O
residues O
( O
positions O
87 O
to O
102 O
) O
by O
using O
24 O
pre O
- O
S O
deletion O
mutants O
; O
this O
binding O
domain O
coincides O
with O
a O
major O
virus O
- O
neutralizing O
antibody O
epitope O
, O
Furthermore O
, O
site O
- O
directed O
mutagenesis O
revealed O
that O
an O
arginine O
residue O
at O
position O
97 O
is O
critical O
for O
p170 O
binding O
, O
p170 O
was O
purified O
by O
a O
combination O
of O
ion O
- O
exchange O
and O
affinity O
chromatographies O
, O
and O
four O
peptide O
sequences O
were O
obtained O
, O
Two O
peptides O
showed O
significant O
similarities O
to O
human O
and O
animal O
carboxypeptidases O
H O
, O
M O
, O
and O
N O
. O

The O
efficiency O
of O
different O
vaccination O
techniques O
to O
prime O
in O
vivo O
major O
histocompatibility O
complex O
class O
I O
- O
restricted O
murine O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
precursors O
to O
hepatitis B
B I
virus I
small I
surface I
antigen I
( I
HBsAg I
) I
was O
investigated O
. O

Mice O
were O
immunized O
either O
by O
injection O
of O
a O
low O
dose O
of O
recombinant O
HBsAg O
protein O
preparations O
( O
native O
HBsAg O
particles O
or O
denatured O
HBsAg O
monomers O
) O
without O
adjuvants O
, O
by O
infection O
with O
recombinant O
vaccinia O
virus O
carrying O
an O
HBsAg O
- O
encoding O
gene O
, O
or O
by O
intramuscular O
transfer O
of O
plasmid O
DNA O
encoding O
HBsAg O
under O
appropriate O
promoter O
control O
, O
In O
H O
- O
2 O
( O
d O
) O
mice O
, O
an O
L O
( O
d O
) O
- O
restricted O
, O
S O
- O
28 O
- O
39 O
- O
specific O
CTL O
response O
was O
efficiently O
primed O
by O
all O
alternative O
vaccination O
techniques O
tested O
, O
but O
the O
most O
potent O
priming O
of O
class O
I O
- O
restricted O
CTL O
to O
HBsAg O
in O
vivo O
was O
observed O
with O
DNA O
immunization O
, O
Priming O
of O
anti O
- O
HBsAg O
CTL O
in O
H O
- O
2 O
( O
b O
) O
mice O
was O
not O
detectable O
after O
infection O
with O
a O
recombinant O
vaccinia O
virus O
or O
after O
injection O
with O
exogenous O
recombinant O
HBsAg O
preparations O
, O
After O
DNA O
immunization O
, O
however O
, O
both O
K O
- O
b O
- O
and O
D O
- O
b O
- O
restricted O
CTL O
reactivity O
to O
HBsAg O
emerged O
in O
H O
- O
2 O
( O
b O
) O
mice O
, O
Hence O
, O
nucleic O
acid O
immunization O
revealed O
class O
I O
- O
restricted O
CTL O
responsiveness O
to O
HBsAg O
in O
a O
mouse O
strain O
previously O
considered O
to O
be O
a O
nonresponder O
at O
the O
CTL O
level O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
transgenic O
mice O
whose O
hepatocytes O
replicate O
the O
virus O
at O
levels O
comparable O
to O
that O
in O
the O
infected O
livers O
of O
patients O
, O
vith O
chronic O
hepatitis O
have O
been O
produced O
, O
without O
any O
evidence O
of O
cytopathology O
. O

murine B
hepatitis I
virus I
strain I
3 I
( I
MHV I
- I
3 I
) I
produces O
a O
strain O
- O
dependent O
pattern O
of O
disease O
which O
has O
been O
used O
as O
a O
model O
for O
fulminant O
viral O
hepatitis O
. O

Peritoneal O
macrophages O
were O
isolated O
from O
resistant O
A O
/ O
J O
and O
susceptible O
BALB O
/ O
cJ O
mice O
and O
, O
following O
stimulation O
with O
MHV O
- O
3 O
or O
lipopolysaccharide B
( I
LPS I
) I
, O
analyzed O
for O
transcription O
of O
mRNA O
and O
production O
of O
interleukin B
- I
1 I
( I
IL I
- I
1 I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
, O
mouse O
fibrinogen O
- O
like O
protein O
( O
musfiblp O
) O
, O
tissue B
factor I
( I
TF I
) I
, O
leukotriene O
B O
- O
4 O
, O
and O
prostaglandin B
E I
( I
2 I
) I
( I
PGE I
( I
2 I
) I
) I
. O

Levels O
of O
production O
of O
PGE O
( O
2 O
) O
by O
MHV O
- O
3 O
- O
stimulated O
macrophages O
from O
resistant O
and O
susceptible O
mice O
were O
equivalent O
; O
however O
, O
the O
time O
course O
for O
induction O
of O
PGE O
( O
2 O
) O
differed O
, O
but O
the O
total O
quantity O
of O
PGE O
, O
produced O
was O
insufficient O
to O
inhibit O
induction O
of O
musfiblp O
, O
a O
procoagulant O
known O
to O
correlate O
with O
development O
of O
fulminant O
hepatic O
necrosis O
in O
susceptible O
mice O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
encodes O
two O
proteins O
, O
the O
small B
delta I
antigen I
( I
SHDAg I
) I
and O
large B
delta I
antigen I
( I
LHDAg I
) I
. O

While O
SHDAg O
is O
required O
for O
HDV O
replication O
, O
LHDAg O
inhibits O
replication O
and O
, O
together O
with O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
, O
is O
required O
for O
the O
assembly O
of O
HDV O
. O

The O
last O
19 O
C O
- O
terminal O
amino O
acids O
of O
LHDAg O
are O
essential O
for O
HDV O
assembly O
, O
Most O
of O
LHDAg O
( O
amino O
acids O
19 O
to O
146 O
and O
163 O
to O
195 O
) O
had O
been O
shown O
to O
be O
dispensable O
for O
packaging O
with O
HBsAg O
. O

The O
two O
agents O
, O
GB O
viruses O
A O
and O
B O
( O
GBV O
- O
A O
and O
GBV O
- O
B O
, O
respectively O
) O
, O
have O
genomes O
of O
9 O
, O
493 O
and O
9 O
, O
143 O
nucleotides O
, O
respectively O
, O
and O
single O
large O
open O
reading O
frames O
that O
encode O
potential O
polyprotein O
precursors O
of O
2 O
, O
972 O
and O
2 O
, O
864 O
amino O
acids O
, O
respectively O
, O
The O
genomes O
of O
these O
agents O
are O
organized O
much O
like O
those O
of O
other O
pestiviruses O
and O
flaviviruses O
, O
with O
genes O
predicted O
to O
encode O
structural O
and O
nonstructural O
proteins O
located O
at O
the O
5 O
' O
and O
3 O
' O
ends O
, O
respectively O
. O

Amino O
acid O
sequence O
alignments O
and O
subsequent O
phylogenetic O
analysis O
of O
the O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
of O
GBV O
- O
A O
and O
GBV O
- O
B O
show O
that O
they O
possess O
conserved O
sequence O
motifs O
associated O
with O
supergroup O
II O
RNA O
polymerases O
of O
positive O
- O
strand O
RNA O
viruses O
, O
On O
the O
basis O
of O
similar O
analyses O
, O
the O
GBV O
- O
A O
- O
and O
GBV O
- O
B O
- O
encoded O
helicases O
show O
significant O
identity O
with O
the O
supergroup O
II O
helicases O
of O
positive O
- O
strand O
RNA O
viruses O
, O
Within O
the O
Supergroup O
II O
RNA O
polymerases O
and O
helicases O
, O
GBV O
- O
A O
and O
GBV O
- O
B O
are O
most O
closely O
related O
to O
the O
hepatitis O
C O
virus O
group O
, O
Across O
their O
entire O
open O
reading O
frames O
, O
the O
GB O
agents O
exhibit O
27 O
% O
amino O
sequence O
identity O
to O
each O
other O
, O
approximately O
28 O
% O
identity O
to O
hepatitis O
C O
virus O
type O
1 O
, O
and O
approximately O
20 O
% O
identity O
to O
either O
bovine O
viral O
diarrhea O
virus O
oi O
yellow O
fever O
virus O
, O
The O
degree O
of O
sequence O
divergence O
between O
GBV O
- O
A O
and O
GBV O
- O
B O
and O
other O
Flaviviridae O
members O
demonstrates O
that O
the O
GB O
agents O
are O
representatives O
of O
two O
new O
genera O
within O
the O
Flaviviridae O
family O
. O

However O
, O
the O
nature O
of O
the O
product O
( O
s O
) O
of O
the O
polymerase O
gene O
predicted O
to O
mediate O
these O
functions O
is O
unclear O
. O

Biochemical O
studies O
of O
the O
polymerase O
protein O
( O
s O
) O
have O
been O
limited O
by O
its O
apparent O
low O
abundance O
in O
virus O
particles O
and O
, O
until O
recently O
, O
the O
inability O
to O
express O
active O
polymerase O
protein O
( O
s O
) O
heterologously O
. O

We O
have O
used O
activity O
gel O
assays O
to O
detect O
DNA O
- O
and O
RNA O
- O
dependent O
DNA O
polymerase O
activities O
associated O
, O
vith O
highly O
purified O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
particles O
( O
S O
. O

Its O
apparent O
size O
is O
smaller O
than O
any O
of O
the O
DNA O
polymerase O
activities O
that O
we O
detected O
previously O
and O
significantly O
smaller O
than O
the O
full O
- O
length O
protein O
predicted O
from O
the O
polymerase O
open O
reading O
frame O
( O
p85 O
for O
DHBV O
) O
. O

Vectors O
expressing O
the O
first O
58 O
amino O
acids O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
nucleocapsid O
alone O
or O
as O
a O
fusion O
protein O
with O
the O
middle O
( O
pre O
- O
S2 O
and O
S O
) O
or O
major O
( O
S O
) O
surface O
antigens O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
were O
constructed O
. O

Anti O
- O
HCV O
serum O
titers O
formed O
plateaus O
of O
approximately O
1 O
: O
3 O
, O
000 O
; O
these O
remained O
stable O
until O
the O
end O
of O
the O
study O
( O
18 O
weeks O
postinfection O
) O
. O

Anti O
- O
HBV O
immune O
responses O
were O
found O
to O
be O
lower O
in O
the O
chimera O
- O
injected O
animals O
( O
< O
200 O
mIU O
/ O
ml O
) O
than O
in O
those O
immunized O
with O
the O
native O
HBV O
vector O
( O
> O
2 O
, O
000 O
mIU O
/ O
ml O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
causative O
agent O
of O
parenterally O
transmitted O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
. O

Intramuscular O
inoculation O
of O
recombinant O
plasmid O
DNA O
into O
BALB O
/ O
c O
mice O
( O
H O
- O
2 O
( O
d O
) O
) O
generated O
HCV O
core O
- O
specific O
antibody O
responses O
, O
lymphoproliferative O
responses O
, O
and O
cytotoxic O
T O
- O
lymphocyte O
activity O
. O

Surprisingly O
, O
despite O
the O
presence O
of O
heterologous O
promoters O
linked O
5 O
' O
of O
the O
X O
gene O
, O
the O
transgene O
expression O
is O
mostly O
due O
to O
core B
promoter I
( I
CP I
) I
activity O
present O
in O
the O
X O
coding O
sequence O
. O

To O
test O
the O
hypothesis O
that O
susceptibility O
of O
hepatocytes O
to O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
infection O
requires O
cell O
surface O
receptors O
that O
bind O
the O
virus O
in O
a O
specific O
manner O
, O
we O
developed O
an O
assay O
for O
the O
binding O
of O
DHBV O
particles O
to O
monolayers O
of O
intact O
cells O
, O
using O
radiolabeled O
immunoglobulin O
G O
specific O
for O
DHBV O
envelope O
protein O
. O

Both O
noninfectious O
DHBV O
surface O
antigen O
particles O
and O
infectious O
virions O
bound O
to O
a O
susceptible O
fraction O
( O
approximately O
60 O
% O
) O
of O
Pekin O
duck O
hepatocytes O
, O
In O
contrast O
, O
binding O
did O
not O
occur O
to O
cells O
that O
were O
not O
susceptible O
to O
DHBV O
infection O
, O
including O
Pekin O
duck O
fibroblasts O
and O
chicken O
hepatocytes O
, O
and O
binding O
to O
Muscovy O
duck O
hepatocytes O
, O
which O
are O
only O
weakly O
susceptible O
( O
approximately O
1 O
% O
of O
cells O
) O
to O
DHBV O
infection O
, O
was O
virtually O
undetectable O
, O
Within O
a O
monolayer O
, O
individual O
Pekin O
duck O
hepatocytes O
appeared O
to O
differ O
markedly O
in O
the O
capacity O
to O
bind O
DHBV O
, O
which O
may O
explain O
difficulties O
that O
have O
been O
encountered O
in O
infecting O
100 O
% O
of O
cells O
in O
culture O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
hepatotropic O
and O
frequently O
causes O
fulminant O
hepatitis O
in O
both O
human O
and O
nonhuman O
primate O
hosts O
. O

All O
of O
the O
recombinants O
showed O
a O
temperature O
- O
sensitive O
phenotype O
, O
regardless O
of O
the O
genetic O
background O
( O
attenuated O
or O
wild O
type O
) O
from O
which O
they O
were O
derived O
. O

To O
establish O
a O
readily O
manipulable O
small O
- O
animal O
system O
for O
the O
study O
of O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
in O
vivo O
, O
plasmid O
DNAs O
containing O
head O
- O
to O
- O
tail O
cDNA O
dimers O
of O
HDV O
were O
inoculated O
intramuscularly O
into O
mice O
. O

The O
intramuscular O
accumulation O
of O
HDV O
RNA O
was O
determined O
to O
be O
the O
direct O
result O
of O
viral O
RNA O
replication O
by O
three O
lines O
of O
evidence O
: O
( O
i O
) O
injected O
tissues O
also O
accumulated O
antigenomic O
- O
sense O
HDV O
RNA O
, O
( O
ii O
) O
plasmid O
DNA O
that O
synthesized O
primary O
transcripts O
of O
antigenomic O
sense O
also O
led O
to O
the O
accumulation O
of O
genomic O
- O
sense O
HDV O
RNA O
, O
and O
( O
iii O
) O
injection O
of O
a O
cDNA O
dimer O
defective O
in O
antigenomic O
RNA O
cleavage O
failed O
to O
produce O
detectable O
HDV O
RNA O
in O
muscle O
. O

The O
products O
of O
this O
recombination O
are O
( O
i O
) O
monomeric O
covalently B
closed I
circular I
DNAs I
( I
cccDNAs I
) I
with O
deletions O
and O
insertions O
around O
the O
site O
of O
joining O
and O
( O
ii O
) O
oligomeric O
forms O
in O
which O
monomers O
are O
joined O
near O
the O
ends O
in O
random O
orientation O
. O

Processing O
of O
the O
nonstructural O
viral O
polyprotein O
requires O
the O
viral O
serine O
- O
type O
proteinase O
present O
in O
nonstructural B
protein I
3 I
( I
NS3 I
) I
. O

Hepadnaviruses O
replicate O
by O
reverse O
transcription O
of O
an O
RNA O
pregenome O
, O
Reverse O
transcription O
initiates O
within O
the O
stem B
- I
loop I
( I
SL I
) I
of O
the O
epsilon O
RNA O
packaging O
signal O
and O
is O
discontinuous O
: O
the O
nascent O
minus O
- O
polarity O
DNA O
is O
transferred O
to O
direct B
repeat I
1 I
( I
DR1 I
) I
at O
the O
3 O
' O
end O
of O
the O
pregenomic O
RNA O
prior O
to O
extensive O
elongation O
. O

We O
have O
expressed O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
polymerase I
( I
Pol I
) I
in O
insect O
cells O
, O
using O
the O
recombinant O
baculovirus O
system O
. O

Analysis O
of O
immunoaffinity O
- O
purified O
pol O
indicated O
that O
( O
i O
) O
a O
portion O
of O
pol O
had O
initiated O
minus O
- O
strand O
DNA O
synthesis O
within O
infected O
insect O
cells O
; O
( O
ii O
) O
the O
pol O
mRNA O
appeared O
to O
be O
the O
template O
for O
reverse O
- O
transcription O
; O
( O
iii O
) O
the O
products O
were O
small O
( O
100 O
to O
500 O
nucleotides O
) O
; O
( O
iv O
) O
only O
minus O
- O
strand O
DNA O
was O
synthesized O
; O
( O
v O
) O
the O
products O
were O
covalently O
bound O
to O
protein O
; O
and O
( O
vi O
) O
the O
5 O
' O
end O
of O
the O
minus O
- O
strand O
DNA O
mapped O
to O
DR1 O
by O
primer O
extension O
. O

The O
influence O
of O
Hepatocyte B
nuclear I
factor I
3 I
( I
HNF3 I
) I
on O
the O
level O
of O
transcriptional O
activity O
from O
the O
four O
hepatitis O
B O
virus O
promoters O
was O
investigated O
by O
transient O
- O
transfection O
analysis O
in O
the O
dedifferentiated O
hepatoma O
cell O
line O
, O
HepG2 O
. O

Replication O
of O
hepadnaviruses O
requires O
a O
persistent O
population O
of O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
molecules O
in O
the O
nucleus O
of O
the O
infected O
cell O
. O

These O
studies O
were O
undertaken O
on O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
CCC O
DNA O
present O
in O
the O
liver O
cell O
nuclei O
of O
DHBV O
- O
infected O
ducks O
, O
The O
organization O
and O
protein O
associations O
of O
the O
DHBV O
CCC O
DNA O
in O
situ O
were O
inferred O
from O
sedimentation O
, O
micrococcal O
nuclease O
digestion O
, O
and O
DNA O
superhelicity O
analyses O
. O

Overcoming O
hepatitis O
B O
virus O
infection O
essentially O
depends O
on O
the O
appropriate O
immune O
response O
of O
the O
infected O
host O
, O
Among O
the O
hepatitis O
B O
virus O
antigens O
, O
the O
core O
( O
HBcAg O
) O
and O
e O
( O
HBeAg O
) O
proteins O
appear O
highly O
immunogenic O
and O
induce O
important O
lymphocyte O
effector O
functions O
. O

In O
order O
to O
investigate O
the O
importance O
of O
HBcAg O
/ O
HBeAg O
- O
specific O
T O
lymphocytes O
in O
patients O
with O
acute O
and O
chronic O
hepatitis O
B O
and O
to O
identify O
immunodominant O
epitopes O
within O
the O
HBcAg O
/ O
HBeAg O
, O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
hepatitis O
B O
virus O
- O
encoded O
HBcAg O
and O
HBcAg O
/ O
HBeAg O
- O
derived O
peptides O
were O
studied O
in O
49 O
patients O
with O
acute O
and O
39 O
patients O
with O
chronic O
hepatitis O
B O
, O
The O
results O
show O
a O
frequent O
antigen O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
activation O
during O
acute O
hepatitis O
B O
infection O
, O
a O
rare O
HBcAg O
/ O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
among O
HBeAg O
+ O
chronic O
carriers O
, O
and O
no O
response O
in O
patients O
with O
anti O
- O
HBe O
+ O
chronic O
hepatitis O
. O

An O
increasing O
CD4 O
( O
+ O
) O
T O
cell O
response O
to O
HBcAg O
/ O
HBeAg O
coincides O
with O
loss O
of O
HBeAg O
and O
hepatitis B
B I
virus I
surface I
antigen I
( I
HBsAg I
) I
. O

Functional O
analysis O
of O
peptide O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
revealed O
a O
heterogeneous O
population O
with O
respect O
to O
lymphokine O
production O
. O

Epitope O
mapping O
within O
the O
HBcAg O
/ O
HBeAg O
peptide O
defined O
amino B
acids I
( I
aa I
) I
1 O
to O
25 O
and O
aa O
61 O
to O
85 O
, O
irrespective O
of O
the O
HLA O
haplotype O
, O
as O
the O
predominant O
CD4 O
( O
+ O
) O
T O
- O
cell O
recognition O
sites O
. O

Other O
important O
sequences O
could O
be O
identified O
in O
the O
amino O
- O
terminal O
part O
of O
the O
protein O
, O
aa O
21 O
to O
45 O
, O
aa O
41 O
to O
65 O
, O
and O
aa O
81 O
to O
105 O
, O
The O
immunodominant O
epitopes O
are O
expressed O
in O
both O
proteins O
, O
HBcAg O
and O
HBeAg O
, O
Our O
findings O
lead O
to O
the O
conclusion O
that O
activation O
of O
CD4 O
( O
+ O
) O
T O
lymphocytes O
by O
HBcAg O
/ O
HBeAg O
is O
a O
prerequisite O
for O
viral O
elimination O
, O
and O
further O
studies O
have O
to O
focus O
on O
the O
question O
of O
how O
to O
enhance O
or O
induce O
this O
type O
of O
T O
- O
cell O
response O
in O
chronic O
carriers O
. O

We O
have O
previously O
defined O
a O
basal O
core O
promoter O
, O
which O
contains O
four O
TA O
- O
rich O
sequences O
( O
TA1 O
through O
TA4 O
) O
but O
no O
canonical O
TATA O
element O
, O
that O
can O
direct O
transcription O
of O
both O
messages O
. O

Clinical O
evidence O
suggests O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
etiologically O
involved O
in O
hepatic O
cancer O
and O
liver O
cirrhosis O
. O

Regulatory O
T B
- I
helper I
( I
Th I
) I
cells O
have O
been O
categorized O
into O
two O
functional O
subsets O
, O
Th O
- O
1 O
and O
Th O
- O
2 O
cells O
, O
which O
produce O
distinct O
lymphokines O
. O

Recent O
serological O
studies O
suggest O
that O
the O
Th O
- O
1 O
- O
Th O
- O
2 O
balance O
may O
be O
relevant O
in O
acute O
and O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
potential O
of O
the O
nucleocapsid O
antigens B
( I
Ags I
) I
( O
hepatitis O
B O
core O
and O
e O
Ags O
[ O
HBc O
/ O
eAg O
] O
) O
of O
HBV O
to O
preferentially O
elicit O
either O
a O
Th O
- O
1 O
or O
a O
Th O
- O
2 O
dominant O
response O
. O

S O
( O
peptide O
120 O
- O
131 O
) O
and O
B10 O
( O
peptide O
129 O
- O
140 O
) O
mice O
were O
used O
as O
immunogens O
. O

The O
functions O
of O
delta O
antigens O
( O
HDAgs O
) O
in O
the O
morphogenesis O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
have O
been O
studied O
previously O
. O

The O
C O
terminus O
of O
large O
HDAg O
has O
been O
shown O
to O
complex O
with O
the O
small O
surface O
antigen O
( O
HBsAg O
) O
of O
helper O
hepatitis O
B O
virus O
, O
whereas O
the O
assembly O
of O
small O
HDAg O
requires O
interaction O
with O
the O
N O
terminus O
of O
large O
HDAg O
( O
M O
. O

Large O
HDAg O
is O
capable O
of O
complexing O
with O
monomeric O
HDV O
genomic O
RNA O
to O
form O
ribonucleoprotein B
particles I
( I
RNPs I
) I
and O
is O
capable O
of O
forming O
enveloped O
HDV O
- O
like O
particles O
in O
the O
presence O
of O
small O
HBsAg O
without O
undergoing O
HDV O
replication O
. O

The O
polyprotein O
encoded O
by O
a O
single O
open O
reading O
frame O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
processed O
by O
host O
- O
and O
virus O
- O
encoded O
proteases O
. O

The O
viral O
protease O
NS3 O
is O
responsible O
for O
the O
cleavage O
of O
at O
least O
four O
sites O
( O
NS3 O
/ O
4A O
, O
NS4A O
/ O
4B O
, O
NS4B O
/ O
5A O
, O
and O
NS5A O
/ O
5B O
junctions O
) O
in O
the O
nonstructural O
protein O
region O
. O

Deletion O
of O
the O
C O
- O
terminal O
two O
- O
thirds O
from O
NS3 O
in O
an O
NS3 O
- O
NS4A O
- O
4B O
polypeptide O
( O
NS3 O
Delta O
C O
- O
4A O
- O
4B O
) O
hampered O
cleavage O
of O
the O
NS3 O
/ O
4A O
junction O
but O
not O
that O
of O
the O
NS4A O
/ O
4B O
junction O
. O

The O
HCV O
protease O
NS3 O
- O
4A O
is O
inhibited O
by O
chymotrypsin O
- O
specific O
inhibitors O
N O
- O
tosyl O
- O
L O
- O
phenylalanine O
chloromethyl O
ketone O
( O
TPCK O
) O
, O
chymostatin O
, O
and O
Pefabloc O
SC O
but O
not O
by O
trypsin O
- O
like O
protease O
inhibitors O
antipain O
, O
leupeptin O
, O
and O
N O
- O
alpha O
- O
p O
- O
tosyl O
- O
L O
- O
lysine O
chloromethyl O
ketone O
( O
TLCK O
) O
or O
by O
the O
protease O
inhibitors O
E O
- O
64 O
, O
bestatin O
, O
pepstatin O
, O
and O
phosphoramidon O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
genomic O
RNA O
is O
translated O
into O
a O
large O
polyprotein O
that O
is O
processed O
into O
structural O
and O
nonstructural O
proteins O
. O

Anti B
- I
idiotypic I
antibodies I
( I
anti I
- I
Ids I
) I
have O
been O
successfully O
used O
to O
characterize O
and O
isolate O
receptors O
of O
several O
cell O
ligands O
. O

To O
prepare O
an O
immunological O
probe O
for O
identification O
of O
cellular O
components O
interacting O
with O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
polyclonal O
antisera O
against O
a O
panel O
of O
five O
HBV O
- O
specific O
Monoclonal B
antibodies I
( I
MAbs I
) I
were O
produced O
in O
syngeneic O
BALB O
/ O
c O
mice O
. O

MAbs O
to O
HBV O
used O
for O
immunization O
( O
Ab1 O
) O
recognized O
biologically O
important O
and O
potentially O
neutralizing O
epitopes O
, O
located O
in O
the O
pre O
- O
S1 O
, O
pre O
- O
S2 O
, O
or O
S O
region O
- O
encoded O
domains O
of O
HBV O
proteins O
. O

All O
the O
anti O
- O
Ids O
( O
Ab2 O
) O
were O
specific O
to O
idiotopes O
of O
the O
homologous O
Ab1 O
and O
inhibited O
their O
interaction O
with O
the O
corresponding O
viral O
epitopes O
, O
suggesting O
that O
they O
recognized O
unique O
determinants O
on O
the O
paratope O
of O
each O
immunizing O
Ab1 O
. O

Immunohistochemical O
studies O
demonstrated O
the O
attachment O
of O
viral O
and O
recombinant O
( O
S O
, O
M O
) O
hepatitis O
B O
surface O
antigen O
particles O
with O
the O
pre O
- O
S2 O
region O
- O
encoded O
epitopes O
to O
the O
fibronectin O
of O
human O
liver O
sinusoids O
. O

In O
contrast O
, O
recombinant O
( O
S O
, O
L O
* O
) O
hepatitis O
B O
surface O
antigen O
particles O
, O
in O
which O
the O
epitope O
recognized O
by O
F124 O
MAb O
was O
not O
expressed O
, O
did O
not O
show O
any O
binding O
capacity O
. O

Hepatitis O
B O
virus O
core O
protein O
( O
antigen O
) O
is O
an O
important O
serologic O
marker O
of O
hepatitis O
B O
virus O
infection O
. O

The O
mechanism O
of O
action O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
X O
protein O
in O
transcriptional O
transactivation O
and O
in O
tumorigenesis O
remains O
obscure O
, O
We O
have O
used O
the O
yeast O
two O
- O
hybrid O
system O
to O
identify O
a O
cellular O
protein O
that O
can O
interact O
with O
HBV O
X O
protein O
. O

This O
protein O
, O
designated O
X B
- I
associated I
protein I
1 I
( I
XAP I
- I
1 I
) I
, O
is O
a O
human O
homolog O
of O
the O
UV B
- I
damaged I
DNA I
- I
binding I
protein I
( I
UV I
- I
DDB I
) I
recovered O
from O
a O
monkey O
cell O
cDNA O
library O
. O

We O
previously O
demonstrated O
that O
the O
core O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
suppress O
gene O
expression O
and O
replication O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
a O
Human B
Hepatoma I
Cell I
line I
( I
Huh I
- I
7 I
) I
. O

Our O
results O
indicated O
that O
both O
the O
full O
- O
length O
HCV O
core O
protein O
( O
22 O
kDa O
) O
and O
its O
processed O
or O
degraded O
forms O
( O
14 O
to O
18 O
kDa O
) O
were O
phosphorylated O
in O
insect O
cells O
. O

As O
demonstrated O
by O
using O
the O
glutathione O
S O
- O
transferase O
fusion O
protein O
expression O
system O
and O
in O
vitro O
transcription O
and O
translation O
system O
, O
the O
phosphorylation O
of O
HCV O
core O
protein O
was O
carried O
out O
by O
protein B
kinase I
A I
( I
PKA I
) I
and O
protein B
kinase I
C I
( I
PKC I
) I
in O
vitro O
, O
In O
both O
kinase O
reactions O
, O
it O
was O
determined O
that O
the O
phosphorylated O
amino O
acid O
was O
a O
serine O
residue O
. O

Mutation O
of O
the O
former O
two O
serine O
residues O
to O
alanine O
or O
aspartate O
residues O
led O
to O
a O
drastic O
loss O
of O
the O
inhibitory O
effects O
of O
HCV O
core O
protein O
on O
HBV O
gene O
expression O
( O
both O
transcription O
and O
antigen O
production O
) O
and O
pregenomic O
RNA O
encapsidation O
, O
as O
well O
as O
the O
release O
of O
HBV O
virus O
particles O
. O

This O
property O
is O
in O
accordance O
with O
the O
observation O
that O
Ser O
- O
99 O
and O
Ser O
- O
116 O
are O
the O
predominant O
phosphorylation O
sites O
in O
the O
HCV O
core O
construct O
, O
All O
serine O
mutants O
( O
including O
those O
with O
mutations O
in O
PKA O
, O
PKC O
, O
and O
both O
kinase O
recognition O
sites O
) O
of O
HCV O
core O
protein O
retained O
the O
ability O
to O
translocate O
into O
the O
nucleus O
. O

The O
virus O
family O
Hepadnaviridae O
comprises O
two O
genera O
: O
orthohepadnaviruses O
isolated O
from O
humans O
( O
hepatitis O
B O
virus O
[ O
HBV O
] O
) O
and O
rodents O
( O
e O
. O

They O
carry O
in O
their O
envelopes O
two O
( O
DHBV O
) O
or O
three O
( O
HBV O
and O
WHV O
) O
coterminal O
proteins O
referred O
to O
as O
small B
( I
S I
) I
, O
middle O
( O
M O
) O
, O
or O
large B
( I
L I
) I
surface O
protein O
. O

T7 O
RNA O
polymerase O
transcripts O
of O
a O
putative O
full O
- O
length O
cDNA O
clone O
of O
hepatitis B
C I
virus I
type I
1 I
( I
HCV I
- I
1 I
) I
were O
used O
to O
transfect O
a O
differentiated O
human O
hepatoma O
cell O
line O
, O
Huh7 O
. O

The O
hepatitis O
B O
virus O
enhancer O
1 O
contains O
a O
retinoic B
acid I
responsive I
element I
( I
RARE I
) I
. O

We O
have O
previously O
demonstrated O
that O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
transactivates O
enhancer O
1 O
by O
binding O
to O
the O
RARE O
. O

The O
present O
study O
has O
revealed O
that O
a O
heterodimeric O
complex O
composed O
of O
RXR O
alpha O
and O
peroxisome B
proliferator I
- I
activated I
receptor I
( I
PPAR I
) I
interacts O
with O
the O
hepatitis O
B O
virus O
RARE O
. O

The O
agent O
( O
s O
) O
responsible O
for O
sporadic O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
in O
humans O
was O
serially O
transmitted O
in O
rhesus O
monkeys O
by O
intravenous O
inoculation O
of O
the O
stool O
extract O
from O
a O
patient O
. O

A O
novel O
agent O
called O
HFV O
( O
hepatitis O
French O
[ O
origin O
] O
virus O
) O
was O
present O
as O
27 O
- O
to O
37 O
- O
nm O
particles O
in O
the O
infectious O
stool O
extract O
. O

The O
Spike B
glycoprotein I
( I
S I
) I
of O
coronavirus O
, O
the O
major O
target O
for O
virus O
- O
neutralizing O
antibodies O
, O
is O
assumed O
to O
mediate O
the O
attachment O
of O
virions O
to O
the O
host O
cell O
. O

A O
26 O
- O
kilodalton O
fragment O
proteolytically O
cleaved O
from O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
S O
protein O
was O
previously O
shown O
to O
bear O
two O
adjacent O
antigenic O
sites O
, O
A O
and O
B O
, O
both O
defined O
by O
high O
- O
titer O
neutralizing O
antibodies O
. O

Coexpression O
of O
one O
of O
these O
truncated O
protein O
S O
derivatives O
with O
aminopeptidase B
N I
( I
APN I
) I
, O
a O
cell O
surface O
molecule O
acting O
as O
a O
receptor O
for O
TGEV O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
clones O
were O
propagated O
from O
57 O
carriers O
with O
antibody O
to O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
and O
sequenced O
within O
nucleotides B
( I
nt I
) I
1685 O
to O
1926 O
including O
the O
core O
promoter O
( O
nt O
1732 O
to O
1849 O
) O
and O
the O
pre O
- O
C O
region O
( O
nt O
1814 O
to O
1900 O
) O
. O

All O
of O
these O
mutations O
involved O
the O
TTAAA O
sequence O
( O
nt O
1758 O
to O
1762 O
) O
at O
28 O
hp O
upstream O
of O
the O
initiation O
site O
for O
shorter O
pre O
- O
C O
mRNAs O
( O
nt O
1790 O
+ O
/ O
- O
1 O
) O
. O

The O
ATAAATT O
sequence O
( O
nt O
1789 O
to O
1795 O
) O
at O
23 O
bp O
upstream O
of O
the O
initiation O
site O
for O
the O
pregenome O
RNA O
( O
nt O
1818 O
) O
, O
however O
, O
remained O
intact O
in O
all O
335 O
HBV O
DNA O
clones O
. O

The O
hepatitis B
C I
virus I
H I
strain I
( I
HCV I
H I
) I
polyprotein O
is O
cleaved O
to O
produce O
at O
least O
10 O
distinct O
products O
, O
in O
the O
order O
of O
NH2 O
- O
C O
- O
E1 O
- O
E2 O
- O
p7 O
- O
NS2 O
- O
NS3 O
- O
NS4A O
- O
NS4B O
- O
NS5A O
- O
NS5B O
- O
COOH O
. O

An O
HCV O
- O
encoded O
serine O
proteinase O
activity O
in O
NS3 O
is O
required O
for O
cleavage O
at O
four O
sites O
in O
the O
nonstructural O
region O
( O
3 O
/ O
4A O
, O
4A O
/ O
4B O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
) O
. O

In O
this O
report O
, O
the O
HCV O
- O
H O
serine O
proteinase O
domain O
( O
the O
N O
- O
terminal O
181 O
residues O
of O
NS3 O
) O
was O
tested O
for O
its O
ability O
to O
mediate O
trans O
- O
processing O
at O
these O
four O
sites O
. O

To O
begin O
to O
examine O
the O
conservation O
( O
or O
divergence O
) O
of O
serine O
proteinase O
- O
substrate O
interactions O
during O
HCV O
evolution O
, O
we O
demonstrated O
that O
similar O
trans O
- O
processing O
occurred O
when O
the O
proteinase O
domains O
and O
substrates O
were O
derived O
from O
two O
different O
HCV O
subtypes O
. O

Initially O
, O
four O
bases O
( O
5 O
' O
- O
GTAA O
- O
3 O
' O
) O
are O
added O
to O
a O
tyrosine O
residue O
of O
the O
viral O
polymerase O
by O
reverse O
transcription O
of O
a O
bulge O
sequence O
in O
epsilon O
, O
a O
stem O
- O
loop O
structure O
which O
functions O
as O
the O
packaging O
signal O
for O
pregenomic O
RNA O
. O

By O
using O
cell O
- O
free O
expression O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
reverse O
transcriptase O
( O
G O
. O

Seeger O
, O
Cell O
71 O
: O
663 O
- O
670 O
, O
1992 O
) O
, O
the O
5 O
' O
- O
triphosphate O
of O
the O
thymidine O
analog O
fialuridine B
( I
FIAU I
) I
was O
shown O
to O
inhibit O
the O
incorporation O
of O
radiolabeled O
TMP O
into O
primer O
DNA O
in O
a O
dose O
- O
dependent O
manner O
. O

Inhibition O
by O
the O
5 O
' O
- O
triphosphate O
of O
FIAU O
( O
FIAU O
- O
TP O
) O
was O
nearly O
complete O
at O
a O
concentration O
of O
10 O
mu O
M O
. O

duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
DNA O
synthesis O
in O
congenitally O
infected O
ducks O
is O
inhibited O
by O
2 B
' I
- I
deoxycarbocyclic I
guanosine I
( I
2 I
' I
- I
CDG I
) I
. O

To O
assess O
the O
possible O
role O
of O
hepatocyte O
turnover O
in O
these O
changes O
, O
5 B
- I
bromo I
- I
2 I
' I
- I
deoxyuridine I
( I
BUdR I
) I
was O
administered O
8 O
h O
before O
liver O
biopsy O
to O
label O
host O
DNA O
in O
hepatocytes O
passing O
through O
S O
phase O
, O
and O
stained O
nuclei O
were O
detected O
in O
tissue O
sections O
by O
using O
an O
antibody O
reactive O
to O
BUdR O
. O

To O
test O
this O
possibility O
further O
, O
antiviral O
therapy O
was O
carried O
out O
with O
another O
strong O
inhibitor O
of O
DHBV O
DNA O
synthesis O
, O
5 O
- O
fluoro O
- O
2 O
' O
, O
3 O
' O
- O
dideoxy O
- O
3 O
' O
- O
thiacytidine O
( O
524W O
) O
, O
which O
did O
not O
accelerate O
hepatocyte O
turnover O
in O
ducks O
. O

50 O
% O
( O
and O
perhaps O
more O
) O
were O
still O
infected O
after O
3 O
months O
of O
therapy O
. O

We O
now O
report O
that O
epsilon O
is O
sufficient O
for O
activation O
of O
the O
reverse O
transcriptase O
to O
prime O
DNA O
synthesis O
through O
the O
formation O
of O
a O
stable O
RNA O
- O
protein O
( O
RNP O
) O
complex O
. O

A O
synthetic O
gene O
encoding O
an O
artificial O
polypeptide O
composed O
of O
antigenic O
epitopes O
of O
the O
hepatitis B
E I
virus I
( I
HEV I
) I
proteins O
was O
constructed O
from O
short O
oligodeoxyribonucleotides O
by O
using O
PCR O
. O

The O
polypeptide O
comprises O
a O
mosaic O
of O
three O
antigenically O
active O
dominant O
regions O
from O
the O
protein O
encoded O
by O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
, O
one O
antigenically O
active O
region O
from O
the O
protein O
encoded O
by O
ORF3 O
of O
the O
Burmese O
HEV O
strain O
, O
and O
one O
antigenically O
active O
region O
from O
the O
protein O
encoded O
by O
ORF3 O
of O
the O
Mexican O
HEV O
strain O
. O

Translation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
is O
initiated O
by O
cap O
- O
independent O
internal O
ribosome O
binding O
to O
the O
5 B
' I
noncoding I
region I
( I
NCR I
) I
. O

Since O
the O
pyrimidine O
- O
rich O
tract O
is O
considered O
a O
characteristic O
feature O
of O
picornavirus O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
elements O
, O
our O
mutational O
analysis O
focused O
on O
two O
putative O
pyrimidine O
tracts O
( O
Py O
- O
I O
and O
Py O
- O
II O
) O
within O
the O
HCV O
5 O
' O
NCR O
, O
Translational O
efficiency O
of O
these O
mutant O
RNAs O
was O
examined O
by O
in O
vitro O
translation O
and O
after O
RNA O
transfection O
into O
liver O
- O
derived O
cells O
. O

Mutational O
analysis O
of O
Py O
- O
I O
( O
nucleotides O
120 O
to O
130 O
) O
, O
supported O
by O
compensatory O
mutants O
, O
demonstrates O
that O
the O
primary O
sequence O
of O
this O
motif O
is O
not O
important O
but O
that O
a O
helical O
structural O
element O
associated O
with O
this O
region O
is O
critical O
for O
HCV O
IRES O
function O
. O

Mutations O
in O
Py O
- O
II O
( O
nucleotides O
191 O
to O
199 O
) O
show O
that O
this O
motif O
is O
dispensable O
for O
IRES O
function O
as O
well O
. O

The O
two O
major O
envelope O
proteins O
( O
large O
[ O
L O
] O
and O
small O
[ O
S O
] O
) O
of O
duck O
hepatitis O
B O
virus O
are O
encoded O
by O
the O
pre O
- O
S O
/ O
S O
open O
reading O
frame O
. O

We O
propose O
that O
at O
lest O
one O
possible O
phosphorylation O
site O
is O
located O
at O
a O
novel O
( O
S O
/ O
T O
) O
PPL O
motif O
which O
is O
conserved O
near O
the O
carboxyl O
end O
of O
the O
pre O
- O
S1 O
domain O
in O
all O
hepadnavirus O
sequences O
. O

Two O
to O
three O
additional O
( O
S O
/ O
Ta O
) O
P O
motifs O
are O
also O
present O
in O
the O
carboxyl O
half O
of O
the O
pre O
- O
S1 O
( O
but O
not O
pre O
- O
S2 O
or O
S O
) O
domain O
of O
all O
hepadnaviruses O
. O

Using O
as O
substrates O
a O
series O
of O
chimeric O
proteins O
containing O
various O
fragments O
of O
the O
hepatitis O
C O
virus O
precursor O
polyprotein O
between O
Escherichia O
coli O
maltose O
binding O
protein O
and O
dihydrofolate O
reductase O
, O
we O
analyzed O
the O
substrate O
requirements O
of O
hepatitis O
C O
viral O
serine O
proteinase O
( O
Cpro O
- O
2 O
) O
for O
intermolecular O
polypeptide O
cleavage O
in O
E O
. O

The O
cleavage O
sites O
were O
estimated O
by O
determining O
the O
amino O
( O
N O
) O
- O
terminal O
aminoacid O
sequences O
of O
dihydrofolate O
reductase O
- O
fused O
processed O
products O
purified O
partially O
by O
affinity O
chromatography O
from O
the O
lysates O
, O
indicating O
that O
cleavage O
occurred O
at O
sites O
identical O
to O
those O
observed O
in O
eukaryotic O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
encodes O
two O
putative O
virion O
glycoproteins O
( O
E1 O
and O
E2 O
) O
which O
are O
released O
from O
the O
polyprotein O
by O
signal O
peptidase O
cleavage O
. O

In O
this O
report O
, O
we O
have O
characterized O
the O
complexes O
formed O
between O
E1 O
and O
E2 O
( O
called O
E1E2 O
) O
for O
two O
different O
HCV O
strains O
( O
H O
and O
BK O
) O
and O
studied O
their O
intracellular O
localization O
. O

Vaccinia O
virus O
and O
Sindbis O
virus O
vectors O
were O
used O
to O
express O
the O
HCV O
structural O
proteins O
in O
three O
different O
cell O
lines O
( O
HepG2 O
, O
BHK O
- O
21 O
, O
and O
PK O
- O
15 O
) O
. O

At O
this O
boundary O
in O
the O
precursor O
polyprotein O
, O
the O
most O
carboxy O
- O
terminal O
of O
the O
structural O
proteins O
, O
gp70 O
( O
E2 O
) O
, O
is O
proximal O
to O
the O
amino O
terminal O
of O
the O
nonstructural O
protein O
p21 O
( O
NS2 O
) O
. O

The O
presence O
of O
a O
novel O
microsomal O
membrane O
- O
dependent O
cleavage O
site O
was O
observed O
at O
the O
region O
upstream O
of O
the O
amino O
- O
terminal O
end O
of O
p21 O
( O
NS2 O
) O
in O
the O
precursor O
polyprotein O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
composed O
of O
four O
specific O
components O
. O

The O
second O
and O
third O
components O
are O
nucleocapsid O
proteins O
, O
referred O
to O
as O
small O
and O
targe O
hepatitis B
delta I
antigens I
( I
HDAgs I
) I
. O

The O
potential O
of O
the O
simian B
immunodeficiency I
virus I
( I
SIV I
) I
variable I
2 I
( I
V2 I
) I
domain O
as O
an O
effective O
region O
to O
boost O
SIV O
- O
neutralizing O
antibodies O
and O
to O
protect O
against O
live O
SIV O
challenge O
was O
tested O
in O
rhesus O
macaques O
. O

In O
this O
study O
, O
two O
rhesus O
macaques O
were O
primed O
with O
vaccinia O
virus O
recombinants O
expressing O
the O
surface O
glycoprotein O
gp140 O
of O
SIVmac O
and O
were O
given O
booster O
injections O
with O
the O
SIVmac O
V2 O
domain O
presented O
by O
a O
highly O
immunogenic O
carrier O
, O
the O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
agent O
of O
humans O
which O
is O
dependent O
upon O
hepatitis O
B O
virus O
as O
a O
helper O
for O
transmission O
. O

HDV O
can O
be O
experimentally O
transmitted O
to O
woodchucks O
by O
using O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
as O
the O
helper O
. O

At O
5 O
to O
10 O
days O
after O
infection O
with O
HDV O
, O
liver O
biopsies O
of O
these O
two O
groups O
of O
animals O
indicated O
that O
around O
1 O
% O
of O
the O
hepatocytes O
were O
infected O
( O
HDV O
antigen O
positive O
) O
. O

To O
localize O
the O
epitopes O
recognized O
by O
Monoclonal B
antibodies I
( I
MAbs I
) I
specific O
for O
the O
S1 O
subunit O
of O
the O
murine O
coronavirus O
JHMV O
spike O
protein O
, O
we O
have O
expressed O
S1 O
proteins O
with O
different O
deletions O
from O
the O
C O
terminus O
of O
S1 O
. O

S1utt O
is O
composed O
of O
the O
entire O
769 O
- O
amino O
- O
acid O
( O
aa O
) O
S1 O
protein O
; O
S1NM O
, O
S1N O
, O
S1N O
( O
330 O
) O
, O
and O
S1N O
( O
220 O
) O
are O
deletion O
mutants O
with O
594 O
, O
453 O
, O
330 O
, O
and O
220 O
aa O
from O
the O
N O
terminus O
of O
the O
81 O
protein O
. O

All O
MAbs O
classified O
in O
groups O
A O
and O
B O
, O
those O
reactive O
to O
most O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strains O
and O
those O
specific O
for O
isolate O
JHMV O
, O
respectively O
, O
recognized O
S1N O
( O
330 O
) O
and O
the O
larger O
S1 O
deletion O
mutants O
but O
failed O
to O
react O
with O
S1N O
( O
220 O
) O
. O

It O
was O
demonstrated O
that O
the O
S1N O
( O
330 O
) O
protein O
as O
well O
as O
other O
S1 O
deletion O
mutants O
larger O
than O
S1N O
( O
330 O
) O
bound O
to O
the O
receptor O
. O

Core O
particles O
of O
hepatitis O
B O
virus O
are O
assembled O
from O
dimers O
of O
a O
single O
185 O
- O
residue O
( O
subtype O
adw O
) O
viral O
capsid O
or O
core O
protein O
( O
P21 O
. O

Hepatitis O
B O
viruses O
encode O
a O
polymerase B
( I
P I
) I
protein O
with O
key O
roles O
in O
both O
reverse O
transcription O
and O
genomic O
RNA O
encapsidation O
. O

We O
now O
show O
that O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
polymerase O
binds O
specifically O
and O
with O
high O
affinity O
to O
this O
RNA O
stem O
- O
loop O
structure O
. O

Virus O
replication O
depends O
on O
the O
pool O
of O
viral O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
molecules O
, O
which O
serve O
as O
transcriptional O
templates O
in O
the O
nuclei O
of O
infected O
cells O
. O

the B
hypervariable I
region I
1 I
( I
HVR1 I
) I
of O
the O
putative O
second O
envelope O
glycoprotein O
( O
gp70 O
) O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
sequence O
- O
specific O
immunological O
B O
- O
cell O
epitope O
that O
induces O
the O
production O
of O
antibodies O
restricted O
to O
the O
specific O
viral O
isolate O
, O
and O
anti O
- O
HVR1 O
antibodies O
are O
involved O
in O
the O
genetic O
drift O
of O
HVR1 O
driven O
by O
immunoselection O
( O
N O
. O

We O
further O
investigated O
the O
sequence O
variability O
of O
the O
HCV O
genomic O
region O
that O
entirely O
encodes O
the O
envelope O
proteins O
( O
gp35 O
and O
gp70 O
) O
; O
these O
sequences O
were O
derived O
from O
virus O
isolated O
during O
the O
acute O
and O
chronic O
phases O
of O
hepatitis O
in O
one O
patient O
, O
and O
we O
found O
that O
HVR1 O
was O
a O
major O
site O
for O
genetic O
mutations O
in O
HCV O
after O
the O
onset O
of O
hepatitis O
. O

We O
carried O
out O
epitope O
mapping O
experiments O
using O
the O
HVR1 O
sequence O
derived O
from O
the O
acute O
phase O
of O
hepatitis O
and O
identified O
two O
overlapping O
epitopes O
which O
are O
each O
composed O
of O
11 O
amino O
acids O
( O
positions O
394 O
to O
404 O
and O
397 O
to O
407 O
) O
. O

The O
nonstructural O
protein O
NS3 O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
two O
enzymatic O
domains O
which O
are O
thought O
to O
be O
essential O
for O
the O
virus O
life O
cycle O
: O
an O
N O
- O
terminal O
serine O
- O
type O
proteinase O
, O
responsible O
for O
the O
processing O
of O
nonstructuraI O
polypeptides O
, O
and O
a O
C O
- O
terminal O
nucleoside O
triphosphatase O
/ O
helicase O
, O
presumably O
involved O
in O
the O
unwinding O
of O
the O
viral O
genome O
. O

We O
have O
generated O
a O
human B
monoclonal I
antibody I
( I
hMAb I
) I
, O
designated O
CM3 O
. O

B6 O
recognized O
a O
92 O
- O
amino O
- O
acid O
sequence O
( O
clone O
8 O
, O
amino O
acids O
1363 O
to O
1454 O
) O
selected O
from O
an O
NS3 O
DNase O
fragment O
library O
but O
failed O
to O
bind O
to O
12 O
- O
mer O
peptides O
synthesized O
from O
the O
same O
region O
, O
suggesting O
recognition O
of O
a O
conformational O
B O
- O
cell O
epitope O
. O

B6 O
to O
the O
NS3 O
protein O
was O
efficiently O
inhibited O
by O
39 O
of O
44 O
( O
89 O
% O
) O
sera O
from O
HCV O
- O
infected O
patients O
, O
suggesting O
that O
the O
hMAb O
recognized O
an O
immunodominant O
epitope O
within O
the O
NS3 O
region O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
H O
strain O
polyprotein O
is O
cleaved O
to O
produce O
at O
least O
nine O
distinct O
products O
: O
NH2 O
- O
C O
- O
E1 O
- O
E2 O
- O
NS2 O
- O
NS3 O
- O
NS4A O
- O
NS4B O
- O
NS5A O
- O
NS5B O
- O
COOH O
. O

Hepadnaviruses O
encode O
a O
single O
core B
( I
C I
) I
protein O
which O
assembles O
into O
a O
nucleocapsid O
containing O
the O
polymerase B
( I
P I
) I
protein O
and O
pregenomic O
RNA O
during O
viral O
replication O
in O
hepatocytes O
. O

Using O
a O
two O
- O
hybrid O
assay O
in O
HepG2 O
cells O
, O
we O
observed O
cross O
- O
oligomerization O
among O
the O
core O
proteins O
from O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
woodchuck O
hepatitis O
virus O
, O
and O
ground O
squirrel O
hepatitis O
virus O
. O

These O
functions O
include O
a O
priming O
activity O
which O
initiates O
minus O
- O
strand O
DNA O
synthesis O
, O
a O
polymerase O
activity O
which O
synthesizes O
DNA O
by O
using O
either O
RNA O
or O
DNA O
templates O
( O
reverse O
transcriptase O
) O
, O
a O
nuclease O
activity O
which O
degrades O
the O
RNA O
strand O
of O
RNA O
- O
DNA O
hybrids O
( O
RNase O
H O
) O
, O
and O
involvement O
in O
packaging O
the O
RNA O
pregenome O
into O
nucleocaspsids O
. O

In O
a O
previous O
study O
, O
we O
found O
that O
a O
single O
point O
mutation O
at O
position O
711 O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
P O
gene O
product O
RNase O
H O
domain O
prevented O
viral O
RNA O
packaging O
. O

As O
reported O
here O
, O
we O
have O
been O
able O
to O
use O
such O
a O
commercially O
available O
formulation O
( O
Lipofectamine O
) O
and O
introduce O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
into O
lines O
of O
cultured O
cells O
and O
demonstrate O
replication O
of O
the O
HDV O
genome O
both O
by O
immunofluorescence O
and O
by O
Northern O
( O
RNA O
) O
analysis O
. O

( O
i O
) O
The O
ribonucleoprotein O
structure O
of O
HDV O
was O
isolated O
from O
disrupted O
virions O
and O
demonstrated O
as O
being O
sufficient O
to O
transfect O
Huh7 O
cells O
. O

( O
ii O
) O
From O
a O
study O
of O
cells O
transfected O
with O
HDV O
particles O
, O
it O
was O
found O
that O
, O
even O
after O
as O
long O
as O
7 O
weeks O
and O
the O
associated O
replication O
of O
the O
transfected O
cells O
, O
the O
HDV O
RNA O
genome O
was O
still O
replicating O
. O

We O
cloned O
the O
integrated O
ground B
squirrel I
hepatitis I
B I
virus I
( I
GSHV I
) I
sequences O
from O
two O
hepatomas O
showing O
a O
single O
viral O
insertion O
. O

We O
recently O
have O
shown O
that O
binding O
of O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
to O
cells O
in O
culture O
requires O
an O
arginine B
- I
glycine I
- I
aspartic I
acid I
( I
RGD I
) I
sequence O
in O
the O
G O
- O
H O
loop O
of O
the O
capsid O
protein O
VP1 O
( O
P O
. O

In O
this O
report O
, O
we O
show O
that O
FMDV O
type O
A O
( O
12 O
) O
viruses O
found O
in O
infected O
bovine B
tongue I
tissue I
( I
BTT I
) I
differ O
from O
their O
tissue O
culture O
- O
grown O
derivatives O
at O
amino O
acid O
residues O
near O
the O
RGD O
. O

Viruses O
genetically O
engineered O
to O
contain O
VP1 O
sequences O
found O
in O
animal O
tissue O
( O
BTT O
viruses O
) O
were O
antigenically O
different O
from O
their O
tissue O
culture O
derivatives O
and O
hound O
to O
BHK O
cells O
more O
poorly O
than O
did O
the O
tissue O
culture O
- O
adapted O
viruses O
. O

It O
is O
now O
demonstrated O
that O
wild B
- I
type I
p53 I
( I
wt I
- I
p53 I
) I
inhibits O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
long I
terminal I
repeat I
( I
LTR I
) I
- O
directed O
chloramphenicol O
acetyltransferase O
activity O
in O
a O
cotransfection O
assay O
system O
. O

The O
upstream O
elements O
of O
the O
HIV O
- O
1 O
LTR O
, O
including O
the O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
KB I
) I
binding O
sites O
, O
decrease O
the O
p53 O
- O
induced O
inhibitory O
effects O
on O
viral O
transcription O
. O

In O
the O
ACH O
- O
2 O
cell O
line O
, O
which O
is O
now O
demonstrated O
to O
contain O
an O
endogenous O
mutant O
form O
of O
p53 O
( O
amino O
acid O
248 O
, O
Arg O
to O
Gln O
) O
, O
additional O
mutant O
p53 O
proteins O
did O
not O
alter O
HIV O
- O
1 O
replication O
. O

( O
i O
) O
The O
presence O
of O
phosphoserines O
at O
residues O
245 O
and O
259 O
stimulates O
DNA O
synthesis O
within O
viral O
nucleocapsids O
, O
( O
ii O
) O
The O
absence O
of O
phosphoserine O
at O
residue O
257 O
and O
at O
residues O
257 O
and O
259 O
stimulates O
covalently O
closed O
circular O
DNA O
synthesis O
and O
virus O
production O
, O
respectively O
. O

( O
iii O
) O
The O
presence O
of O
phosphoserine O
at O
position O
259 O
is O
required O
for O
initiation O
of O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
accounts O
for O
most O
cases O
of O
acute O
and O
chronic O
non O
- O
A O
and O
non O
- O
B O
hepatitis O
with O
serious O
consequences O
that O
may O
lead O
to O
hepatocellular O
carcinoma O
. O

The O
putative O
envelope B
glycoproteins I
( I
E1 I
and I
E2 I
) I
of O
HCV O
probably O
play O
a O
role O
in O
the O
pathophysiology O
of O
the O
virus O
. O

In O
order O
to O
map O
the O
immunodominant O
domains O
of O
the O
El O
glycoprotein O
, O
two O
epitopes O
from O
amino O
acid O
residues O
210 O
to O
223 O
( O
P1 O
) O
and O
315 O
to O
327 O
( O
P2 O
) O
were O
predicted O
from O
the O
HCV O
sequence O
. O

Immunization O
of O
mice O
with O
the O
synthetic O
peptides O
conjugated O
to O
bovine O
serum O
albumin O
induced O
an O
antibody O
response O
, O
and O
the O
antisera O
immunoprecipitated O
the O
E1 O
glycoprotein O
( O
similar O
to O
33 O
kDa O
) O
of O
HCV O
expressed O
by O
recombinant O
vaccinia O
virus O
. O

We O
found O
that O
tinker O
- O
encoded O
amino O
acid O
substitutions O
in O
at O
least O
one O
region O
of O
the O
pre O
S O
envelope O
protein O
p36 O
produced O
defects O
in O
both O
the O
production O
of O
enveloped O
virus O
and O
the O
regulation O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
synthesis O
. O

Previous O
work O
suggested O
that O
reverse O
transcription O
of O
minus O
- O
strand O
DNA O
initiates O
within O
the O
sequence O
element O
DR1 O
( O
direct O
repent O
1 O
) O
and O
that O
disruption O
of O
DR1 O
activates O
a O
cryptic O
initiation O
site O
in O
a O
downstream O
copy O
of O
epsilon O
. O

The O
biosynthesis O
and O
biochemical O
properties O
of O
the O
putative O
nucleocapsid O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
were O
investigated O
. O

Processing O
of O
the O
translation O
products O
was O
dependent O
on O
microsomal O
membranes O
and O
signal O
recognition O
particle O
, O
suggesting O
that O
release O
of O
the O
21 O
- O
kDa O
core O
protein O
from O
the O
polyprotein O
precursor O
is O
mediated O
solely O
by O
the O
signal O
peptidase O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
is O
achieved O
by O
the O
removal O
of O
a O
putative O
signal O
sequence O
of O
approximately O
18 O
residues O
located O
at O
its O
C O
terminus O
. O

The O
proteolytic O
cleavages O
at O
the O
NS3 O
- O
NS4A O
, O
NS4A O
- O
NS4B O
, O
NS4B O
- O
NS5A O
, O
and O
NS5A O
- O
NS5B O
junctions O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
polyprotein O
are O
effected O
by O
the O
virus O
- O
encoded O
serine O
protease O
contained O
within O
NS3 O
. O

The O
hepatitis B
delta I
virus I
( I
HDV I
) I
envelope O
contains O
the O
large B
( I
L I
) I
, O
middle O
( O
hi O
) O
, O
and O
small B
( I
S I
) I
surface O
proteins O
encoded O
by O
coinfecting O
hepatitis O
B O
virus O
. O

The O
capsid O
protein O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
phosphorylated O
at O
multiple O
sites O
during O
viral O
infection O
. O

The O
present O
study O
confirms O
this O
indication O
by O
identifying O
the O
nucleotide O
- O
linked O
amino O
acid O
in O
the O
P O
protein O
sequence O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

In O
a O
first O
set O
of O
experiments O
, O
mutational O
analysis O
of O
three O
phylogenetically O
conserved O
tyrosine O
residues O
in O
the O
DNA O
terminal O
( O
TP O
) O
domain O
indicated O
that O
of O
these O
, O
only O
tyrosine O
96 O
was O
essential O
for O
both O
viral O
DNA O
synthesis O
in O
transfected O
cells O
and O
priming O
of O
DNA O
synthesis O
in O
a O
cell O
- O
free O
system O
. O

Mobility O
in O
high O
- O
performance O
liquid O
chromatography O
, O
as O
well O
as O
the O
release O
in O
stepwise O
amino O
acid O
sequencing O
of O
phospholabel O
and O
of O
[ O
S O
- O
35 O
] O
methionine O
, O
identified O
the O
priming O
amino O
acid O
unequivocally O
as O
the O
tyrosine O
in O
the O
sequence O
( O
91 O
) O
KLSGLYQMR O
( O
99 O
) O
which O
is O
located O
in O
the O
center O
of O
the O
TP O
domain O
. O

Weak O
sequence O
similarity O
to O
picornavirus O
genome O
- O
linked O
polypeptides O
( O
VPgs O
) O
and O
similar O
gene O
organization O
suggest O
a O
common O
origin O
for O
the O
mechanisms O
that O
use O
protein O
priming O
to O
initiate O
synthesis O
of O
viral O
DNA O
genomes O
or O
RNA O
genomes O
from O
an O
RNA O
template O
. O

Several O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitopes O
have O
been O
defined O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
. O

CTL O
from O
H O
- O
2 O
( O
d O
) O
mice O
responded O
to O
a O
single O
16 O
- O
residue O
synthetic O
peptide O
( O
HCV O
129 O
- O
144 O
) O
. O

This O
conserved O
epitope O
was O
presented O
by O
a O
murine O
class O
I O
major O
histocompatibility O
molecule O
( O
H O
- O
2D O
( O
d O
) O
) O
to O
conventional O
CD4 O
( O
- O
) O
CD8 O
( O
+ O
) O
CTL O
mapped O
by O
using O
transfectants O
expressing O
D O
- O
d O
, O
L O
( O
d O
) O
, O
or O
K O
- O
d O
, O
but O
was O
not O
seen O
by O
CTL O
restricted O
by O
H O
- O
2 O
( O
b O
) O
. O

CTL O
from O
two O
HLA O
- O
A2 O
- O
positive O
patients O
with O
acute O
and O
chronic O
hepatitides O
C O
recognized O
a O
9 O
- O
residue O
fragment O
( O
DLMGYIPLV O
) O
of O
the O
peptide O
presented O
by O
BLA O
- O
A2 O
and O
containing O
an O
HLA O
- O
A2 O
- O
binding O
motif O
, O
extending O
only O
1 O
residue O
beyond O
the O
murine O
epitope O
. O

The O
two O
regions O
defined O
by O
these O
deletions O
are O
located O
36 O
to O
126 O
( O
region O
I O
) O
and O
1046 O
to O
1214 O
( O
region O
II O
) O
nucleotides O
downstream O
of O
the O
5 O
' O
end O
of O
the O
pregenome O
and O
contain O
sequences O
which O
are O
required O
in O
cis O
for O
encapsidation O
of O
the O
duck O
hepatitis O
B O
virus O
pregenome O
. O

We O
have O
identified O
a O
180 O
- O
kDa O
cellular O
glycoprotein O
( O
gp180 O
) O
that O
binds O
with O
high O
affinity O
to O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
particles O
. O

Hepatitis O
B O
viruses O
( O
hepadnaviruses O
) O
can O
cause O
chronic O
, O
productive O
infections O
of O
hepatocytes O
. O

We O
have O
previously O
demonstrated O
that O
a O
plasma O
membrane O
- O
enriched O
fraction O
isolated O
from O
human O
liver O
is O
capable O
of O
binding O
recombinant B
hepatitis I
B I
surface I
antigen I
( I
rHBsAg I
) I
( O
P O
. O

The O
binding O
protein O
was O
identified O
as O
apolipoprotein B
H I
( I
apo I
H I
) I
, O
also O
known O
as O
beta O
2 O
- O
glycoprotein O
I O
, O
on O
the O
basis O
of O
copurification O
of O
the O
rHBsAg O
- O
binding O
activity O
with O
the O
apo O
H O
protein O
and O
the O
ability O
of O
cDNA O
- O
expressed O
apo O
H O
to O
bind O
rHBsAg O
. O

To O
test O
the O
hypothesis O
that O
in O
vivo O
resistance O
to O
hepadnavirus O
infection O
was O
due O
to O
resistance O
of O
host O
hepatocytes O
, O
we O
isolated O
hepatocytes O
from O
Muscovy O
ducklings O
and O
chickens O
, O
birds O
that O
have O
been O
shown O
to O
be O
resistant O
to O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
infection O
, O
and O
attempted O
to O
infect O
them O
in O
vitro O
with O
virus O
from O
congenitally O
infected O
Pekin O
ducks O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
was O
extracted O
from O
sera O
of O
six O
carriers O
with O
hepatitis O
B O
e O
antigen O
as O
well O
as O
antibody O
to O
hepatitis O
B O
surface O
antigen O
and O
sequenced O
within O
the O
pre O
- O
S O
regions O
and O
the O
S O
gene O
. O

We O
have O
recently O
reported O
that O
administration O
of O
recombinant O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
to O
hepatitis B
B I
virus I
( I
HBV I
) I
transgenic O
mice O
reduces O
the O
hepatic O
steady O
- O
state O
content O
of O
HBV O
- O
specific O
mRNA O
by O
up O
to O
80 O
% O
in O
the O
absence O
of O
liver O
cell O
injury O
. O

Hepatic O
HBV O
mRNA O
content O
was O
reduced O
by O
up O
to O
90 O
% O
following O
administration O
of O
a O
single O
noncytopathic O
dose O
( O
100 O
, O
000 O
U O
) O
of O
interleukin B
2 I
( I
IL I
- I
2 I
) I
. O

Comparable O
effects O
were O
produced O
by O
administration O
of O
alpha O
and O
beta O
interferons O
( O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
) O
, O
but O
only O
after O
multiple O
injections O
of O
at O
least O
500 O
, O
000 O
U O
per O
mouse O
. O

Importantly O
, O
the O
regulatory O
effect O
of O
IL O
- O
2 O
was O
completely O
blocked O
by O
the O
prior O
administration O
of O
antibodies O
to O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
which O
did O
not O
block O
the O
effect O
ofIFN O
- O
alpha O
or O
IFN O
- O
beta O
. O

Immune O
responses O
to O
components O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
assumed O
to O
play O
an O
essential O
role O
not O
only O
in O
the O
elimination O
of O
the O
virus O
but O
also O
in O
the O
pathogenesis O
of O
HBV O
- O
induced O
hepatitis O
. O

Protective O
humoral O
immunity O
to O
HBV O
is O
mediated O
by O
immune O
responses O
to O
HBV B
surface I
antigen I
( I
HBsAg I
) I
. O

We O
studied O
in O
BALB O
/ O
c O
mice O
the O
humoral O
( O
antibody O
) O
response O
and O
the O
class O
I O
- O
restricted O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
to O
different O
preparations O
of O
HBsAg O
particles O
: O
recombinant O
, O
small O
protein O
particles O
; O
plasma O
- O
derived O
, O
mixed O
particles O
formed O
by O
large O
, O
medium O
, O
and O
small O
surface O
proteins O
; O
and O
different O
preparations O
of O
recombinant O
, O
mixed O
particles O
formed O
by O
large O
and O
small O
surface O
proteins O
. O

1 O
to O
10 O
mu O
g O
per O
mouse O
, O
all O
HBsAg O
preparations O
tested O
efficiently O
primed O
specific O
CD8 O
( O
+ O
) O
CTL O
of O
defined O
restriction O
and O
epitope O
specificity O
. O

We O
developed O
an O
in O
vitro O
assay O
for O
antibodies O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
that O
bind O
to O
virions O
and O
prevent O
initiation O
of O
the O
replication O
cycle O
in O
susceptible O
cells O
in O
vitro O
. O

However O
, O
plasma O
collected O
a O
gear O
later O
( O
1991 O
, O
14 O
years O
after O
onset O
of O
hepatitis O
) O
contained O
neutralizing O
antibody O
to O
the O
1990 O
, O
but O
not O
the O
1977 O
, O
strain O
of O
HCV O
These O
results O
suggest O
that O
HCV O
does O
induce O
antivirion O
antibody O
, O
as O
measured O
by O
blocking O
of O
initiation O
of O
the O
replication O
cycle O
of O
virus O
in O
cells O
and O
by O
the O
formation O
of O
immunoprecipitable O
antigen O
- O
antibody O
complexes O
but O
that O
these O
antibodies O
are O
isolate O
specific O
and O
change O
over O
time O
. O

In O
a O
previous O
study O
, O
we O
have O
identified O
endonexin B
II I
( I
E I
- I
II I
) I
on O
human O
liver O
plasma O
membranes O
as O
a O
specific O
, O
Ca2 O
+ O
- O
dependent O
, O
small O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
- O
binding O
protein O
. O

In O
this O
article O
, O
we O
describe O
the O
spontaneous O
development O
of O
anti O
- O
HBs O
antibodies O
in O
rabbits O
immunized O
with O
native O
or O
recombinant O
human O
liver O
E O
- O
II O
and O
in O
chickens O
immunized O
with O
the O
F O
( O
ab O
' O
) O
( O
2 O
) O
fragment O
of O
rabbit O
anti O
- O
human O
liver O
E O
- O
II O
immunoglobulin O
G O
. O

The O
existence O
of O
an O
anti O
- O
idiotypic O
antibody O
is O
further O
demonstrated O
by O
competitive O
binding O
of O
human O
liver O
E O
- O
II O
and O
this O
antibody O
( O
Ab2 O
) O
to O
small O
HBsAg O
, O
suggesting O
that O
Ab2 O
mimics O
a O
specific O
E O
- O
II O
epitope O
that O
interacts O
with O
small O
HBsAg O
In O
addition O
, O
it O
was O
demonstrated O
that O
anti O
- O
HBs O
antibodies O
developed O
in O
rabbits O
after O
immunization O
with O
intact O
human O
liver O
E O
- O
II O
or O
in O
chickens O
after O
immunization O
with O
F O
( O
ab O
' O
) O
( O
2 O
) O
fragments O
of O
rabbit O
anti O
- O
human O
liver O
E O
- O
II O
immunoglobulin O
G O
recognize O
the O
same O
epitopes O
on O
small O
HBsAg O
. O

We O
have O
found O
that O
transcription O
of O
the O
pregenome O
of O
an O
avian O
hepadnavirus O
, O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
is O
dependent O
on O
the O
presence O
of O
a O
small O
element O
in O
the O
5 O
' O
transcribed O
region O
of O
the O
pregenome O
- O
encoding O
sequence O
. O

This O
element O
, O
which O
we O
have O
named O
pet O
( O
positive O
effector O
of O
transcription O
) O
, O
exerts O
its O
effect O
in O
cis O
in O
a O
position O
and O
orientation O
- O
dependent O
manner O
, O
suggesting O
that O
it O
may O
function O
as O
part O
of O
the O
nascent O
pregenome O
transcript O
. O

The O
hepatitis O
B O
virion O
is O
a O
spherical O
double O
- O
shelled O
particle O
carrying O
three O
surface O
proteins O
( O
large O
[ O
L O
] O
, O
middle O
[ O
M O
] O
, O
and O
small O
[ O
S O
] O
) O
in O
its O
envelope O
. O

This O
organization O
defines O
three O
protein O
domains O
( O
pre O
- O
S1 O
, O
pre O
- O
S2 O
, O
and O
S O
) O
. O

( O
i O
) O
N O
- O
terminal O
deletion O
mutants O
lacking O
up O
to O
102 O
of O
the O
119 O
amino O
acids O
of O
the O
pre O
- O
Si O
domain O
still O
allowed O
virion O
maturation O
, O
showing O
that O
the O
N O
- O
terminal O
5 O
/ O
6 O
of O
the O
pre O
- O
S1 O
sequence O
is O
dispensable O
for O
this O
process O
. O

( O
ii O
) O
Mutants O
lacking O
110 O
or O
more O
N O
- O
terminal O
amino O
acids O
were O
unable O
to O
substitute O
for O
the O
L O
protein O
in O
virion O
assembly O
, O
although O
they O
were O
stably O
expressed O
and O
secreted O
as O
components O
of O
subviral O
20 O
- O
nm O
hepatitis O
B O
surface O
antigen O
particles O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
mutants O
unable O
to O
synthesize O
HBV O
e O
antigen O
have O
been O
described O
in O
association O
with O
fulminant O
hepatitis O
. O

This O
strain O
contained O
, O
in O
addition O
to O
two O
G O
- O
to O
- O
A O
mutations O
in O
the O
precore O
region O
( O
nucleotides O
1898 O
and O
1901 O
) O
, O
numerous O
other O
mutations O
in O
conserved O
nucleotide O
positions O
resulting O
in O
significant O
amino O
acid O
substitutions O
in O
HBV O
gene O
products O
. O

All O
viral O
constructs O
produced O
and O
secreted O
similar O
levels O
of O
envelope O
proteins O
( O
HBV O
surface O
antigen O
) O
. O

While O
cells O
transfected O
with O
mutant O
and O
wild O
- O
type O
HBV O
DNAs O
synthesized O
similar O
levels O
of O
viral O
RNAs O
, O
the O
fulminant O
strain O
directed O
the O
synthesis O
of O
a O
much O
higher O
level O
of O
core O
- O
associated O
replicative O
intermediates O
( O
as O
well O
as O
virion O
particles O
) O
than O
the O
wild O
type O
and O
mutants O
with O
either O
or O
both O
of O
the O
precore O
mutations O
. O

Located O
at O
nucleotides B
( I
nt I
) I
1646 O
to O
1741 O
, O
it O
can O
stimulate O
the O
surface O
and O
X O
promoters O
from O
a O
downstream O
position O
. O

In O
this O
study O
, O
we O
report O
the O
identification O
and O
characterization O
of O
a O
negative B
regulatory I
element I
( I
NRE I
) I
upstream O
of O
enhancer O
II O
( O
nt O
1613 O
to O
1636 O
) O
which O
can O
repress O
both O
the O
enhancer O
and O
upstream O
stimulatory O
function O
of O
the O
enhancer O
LT O
sequence O
in O
differentiated O
liver O
cells O
. O

Gel O
shift O
analysis O
reveals O
that O
this O
negative O
regulatory O
region O
can O
be O
recognized O
by O
a O
specific O
protein O
factor O
( O
s O
) O
present O
at O
the O
0 O
. O

We O
have O
independently O
constructed O
two O
variants O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
with O
mutations O
in O
the O
X O
coding O
region O
. O

The O
assembly O
of O
large O
delta O
antigen O
( O
HDAg O
) O
is O
mediated O
by O
copackaging O
with O
the O
small O
surface O
antigen O
of O
hepatitis B
B I
virus I
( I
HBsAg I
) I
, O
and O
the O
assembly O
of O
small O
HDAg O
requires O
interactions O
with O
large O
HDAg O
. O

Simultaneous O
infection O
with O
hepatitis B
delta I
virus I
( I
HDV I
) I
and O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
humans O
is O
often O
associated O
with O
severe O
viral O
liver O
disease O
including O
fulminant O
hepatitis O
. O

To O
examine O
these O
alternate O
possibilities O
, O
we O
Produced O
transgenic O
mice O
that O
express O
the O
small O
and O
large O
delta O
antigens O
( O
HDAg O
) O
in O
hepatocyte O
nuclei O
at O
levels O
equal O
to O
those O
observed O
during O
natural O
HDV O
infection O
. O

The O
carbocyclic O
analog O
of O
2 B
' I
- I
deoxyguanosine I
( I
2 I
' I
- I
CDG I
) I
is O
a O
strong O
inhibitor O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
synthesis O
in O
HepG2 O
cells O
( O
P O
. O

We O
now O
report O
that O
2 O
' O
- O
CDG O
inhibited O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
DNA O
synthesis O
in O
primary O
cultures O
of O
duck O
hepatocytes O
and O
in O
experimentally O
infected O
ducks O
. O

Like O
foscarnet O
( O
phosphonoformic O
acid O
[ O
PFA O
] O
) O
and O
2 O
' O
- O
, O
3 O
' O
- O
dideoxycytidine O
( O
ddC O
) O
, O
2 O
' O
- O
CDG O
blocked O
viral O
DNA O
replication O
in O
primary O
hepatocyte O
cultures O
when O
present O
during O
an O
infection O
but O
failed O
to O
inhibit O
the O
DNA O
repair O
reaction O
that O
occurs O
during O
the O
initiation O
of O
infection O
to O
convert O
virion O
relaxed O
circular O
DNA O
to O
covalently O
closed O
circular O
DNA O
, O
the O
template O
for O
viral O
mRNA O
transcription O
. O

The O
roles O
of O
different O
regions O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
protein O
on O
viral O
capsid O
assembly O
and O
related O
functions O
were O
examined O
. O

The O
N O
- O
terminal O
region O
( O
amino O
acids O
3 O
to O
66 O
) O
of O
DHBV O
core O
protein O
was O
important O
for O
its O
tertiary O
structure O
and O
function O
in O
E O
. O

In O
addition O
, O
the O
mutant O
with O
a O
C O
- O
terminal O
region O
deletion O
( O
amino O
acids O
181 O
to O
228 O
) O
lost O
most O
of O
the O
nucleic O
acid O
- O
binding O
activity O
of O
the O
DHBV O
core O
protein O
. O

In O
order O
to O
study O
cell O
tropism O
and O
attenuation O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
, O
the O
genome O
of O
HAV O
wild O
- O
type O
GBM O
and O
two O
cell O
culture O
- O
adapted O
variants O
, O
GBM O
/ O
FRhK O
and O
GBM O
/ O
HFS O
, O
were O
cloned O
and O
sequenced O
after O
amplification O
by O
reverse O
transcriptase O
- O
PCR O
, O
During O
virus O
cultivation O
, O
the O
HAV O
variant O
GBM O
/ O
FRhK O
had O
a O
strict O
host O
range O
for O
FRhK O
- O
4 O
cells O
, O
in O
contrast O
to O
GBM O
/ O
HFS O
, O
which O
can O
be O
grown O
in O
HFS O
and O
FRhK O
- O
4 O
cells O
. O

Our O
result O
concerning O
the O
2B O
/ O
2C O
region O
confirms O
a O
mutation O
at O
position O
3889 O
( O
C O
- O
- O
> O
T O
, O
alanine O
to O
valine O
) O
, O
which O
had O
been O
shown O
to O
be O
of O
importance O
for O
cell O
culture O
adaptation O
( O
S O
. O

We O
have O
recently O
demonstrated O
that O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
downregulate O
the O
hepatic O
steady O
- O
state O
content O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
mRNA O
in O
vivo O
in O
HBV O
- O
transgenic O
mice O
and O
that O
the O
IL O
- O
2 O
effect O
is O
mediated O
by O
TNF O
- O
alpha O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
posttransfusion O
and O
community O
- O
acquired O
hepatitis O
, O
and O
a O
majority O
of O
individuals O
infected O
with O
this O
virus O
will O
subsequently O
develop O
chronic O
hepatitis O
. O

Cellular O
immune O
responses O
, O
especially O
those O
mediated O
by O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
are O
important O
in O
the O
control O
of O
many O
viral O
diseases O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
consists O
of O
two O
protein O
species O
of O
195 O
and O
214 O
amino O
acids O
, O
respectively O
, O
which O
are O
identical O
in O
sequence O
except O
that O
the O
large O
HDAg O
has O
additional O
19 O
amino O
acids O
at O
its O
C O
terminus O
and O
is O
prenylated O
. O

Previous O
studies O
have O
shown O
that O
the O
large O
HDAg O
and O
the O
surface O
antigen O
of O
hepatitis B
B I
virus I
( I
HBsAg I
) I
together O
can O
form O
empty O
hepatitis B
delta I
virus I
( I
HDV I
) I
particles O
. O

Biochemical O
studies O
of O
the O
polymerase O
protein O
( O
s O
) O
have O
been O
limited O
by O
the O
inability O
to O
purify O
useful O
quantities O
of O
functional O
enzyme O
from O
virus O
particles O
and O
, O
until O
recently O
, O
to O
express O
enzymatically O
active O
polymerase O
proteins O
in O
heterologous O
systems O
. O

Since O
conventional O
methods O
have O
not O
allowed O
purification O
of O
useful O
quantities O
of O
enzymatically O
active O
polymerase O
protein O
( O
s O
) O
, O
we O
have O
devised O
a O
protocol O
for O
purifying O
large O
quantities O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
particles O
to O
near O
homogeneity O
. O

Hepatitis O
B O
and O
C O
viruses O
( O
HBV O
and O
HCV O
, O
respectively O
) O
are O
associated O
with O
acute O
and O
chronic O
liver O
diseases O
and O
hepatocellular O
carcinoma O
. O

To O
elucidate O
the O
molecular O
status O
of O
superinfection O
with O
these O
two O
hepatitis O
viruses O
, O
we O
cotransfected O
the O
full O
- O
length O
or O
truncated O
version O
of O
HCV O
structural O
genes O
( O
core O
and O
envelope O
1 O
) O
together O
with O
the O
cloned O
HBV O
DNA O
into O
a O
Human B
Hepatoma I
Cell I
line I
( I
Huh I
- I
7 I
) I
. O

1 O
kb O
) O
, O
as O
well O
as O
HBV O
antigens O
( O
hepatitis O
B O
surface O
antigen O
and O
hepatitis O
B O
e O
and O
core O
antigens O
) O
, O
was O
reduced O
about O
two O
- O
to O
fourfold O
by O
the O
presence O
of O
the O
HCV O
structural O
genes O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
HCV O
core O
protein O
has O
revealed O
that O
it O
is O
a O
basic O
protein O
which O
contains O
a O
putative O
DNA O
- O
binding O
motif O
( O
SPRG O
) O
, O
as O
well O
as O
triplicate O
nuclear O
localization O
signals O
and O
several O
putative O
protein O
kinase O
A O
and O
C O
recognition O
sites O
. O

Either O
parts O
or O
multiple O
copies O
of O
the O
core O
gene O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
were O
fused O
to O
the O
3 O
' O
terminus O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
gene O
with O
34 O
codons O
removed O
. O

As O
many O
as O
four O
copies O
of O
HCV O
core O
protein O
( O
720 O
amino O
acids O
) O
were O
fused O
to O
the O
carboxy O
terminus O
of O
truncated O
HBV O
core O
protein O
( O
149 O
amino O
acids O
) O
without O
preventing O
the O
assembly O
of O
HBV O
core O
particles O
. O

We O
have O
analyzed O
the O
structures O
, O
relative O
organization O
, O
and O
activities O
of O
binding O
sites O
for O
nuclear O
factors O
in O
the O
duck B
hepatitis I
B I
virus I
( I
duck I
HBV I
) I
enhancer O
. O

The O
emergence O
of O
HBe O
- O
minus O
hepatitis B
B I
virus I
( I
HBV I
) I
mutants O
, O
usually O
through O
a O
UAG O
nonsense O
mutation O
at O
codon O
28 O
of O
the O
precore O
region O
, O
helps O
the O
virus O
to O
survive O
the O
anti O
- O
HBe O
immune O
response O
of O
the O
host O
. O

It O
converts O
a O
wobble O
U O
- O
G O
pair O
in O
the O
packaging O
signal O
between O
nucleotide O
3 O
of O
codon O
15 O
( O
CCU O
) O
and O
nucleotide O
2 O
of O
codon O
28 O
( O
UGG O
) O
into O
a O
U O
- O
A O
pair O
. O

Both O
mutants O
contained O
an O
additional O
nucleotide O
substitution O
( O
s O
) O
which O
was O
found O
by O
transfection O
experiments O
to O
be O
required O
for O
efficient O
packaging O
of O
pregenomic O
RNA O
. O

The O
double O
- O
stranded O
DNA O
genome O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
reverse O
transcribed O
from O
the O
viral O
pregenome O
RNA O
template O
by O
a O
virally O
encoded O
reverse O
transcriptase O
enzyme O
( O
RT O
) O
that O
possesses O
both O
priming O
and O
elongation O
activities O
. O

We O
demonstrate O
the O
production O
of O
an O
immunoprecipitable O
96 O
- O
kDa O
HBV O
RT O
protein O
and O
show O
, O
using O
a O
simple O
in O
vitro O
RT O
assay O
, O
that O
oocyte O
lysates O
containing O
this O
protein O
possess O
an O
activity O
that O
( O
i O
) O
catalyzes O
an O
RNA O
- O
dependent O
deoxynucleotide O
triphosphate O
polymerization O
reaction O
by O
using O
an O
as O
- O
vet O
- O
unidentified O
RNA O
template O
and O
( O
ii O
) O
is O
sensitive O
to O
the O
RT O
inhibitors O
actinomycin O
D O
and O
phosphonoformate O
. O

Gene O
products O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
possible O
major O
causative O
agent O
of O
posttransfusion O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
, O
are O
considered O
to O
be O
produced O
from O
a O
precursor O
polyprotein O
via O
proteolytic O
processing O
mediated O
by O
either O
host O
cell O
or O
viral O
proteinases O
. O

Two O
distinct O
proteinase O
activities O
which O
function O
in O
the O
production O
of O
a O
70 O
- O
kDa O
protein O
( O
p70 O
) O
from O
the O
precursor O
polyprotein O
were O
detected O
. O

One O
of O
these O
proteinase O
activities O
, O
which O
cleaved O
the O
carboxyl O
( O
C O
) O
- O
terminal O
side O
of O
p70 O
, O
required O
the O
presence O
of O
the O
serine O
proteinase O
motif O
, O
which O
is O
located O
in O
the O
amino O
( O
N O
) O
- O
terminal O
region O
of O
p70 O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
P O
gene O
which O
encodes O
the O
reverse O
transcriptase O
and O
other O
proteins O
required O
for O
replication O
is O
expressed O
on O
the O
bicistronic O
mRNA O
pregenome O
which O
also O
encodes O
the O
capsid O
protein O
in O
its O
first O
cistron O
. O

The O
capacities O
to O
induce O
the O
synthesis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
unit O
- O
length O
DNA O
were O
compared O
for O
two O
HBV O
DNAs O
with O
an O
overall O
sequence O
diversity O
of O
about O
10 O
% O
. O

They O
had O
been O
cloned O
from O
serum O
( O
DNA2 O
) O
and O
from O
a O
hepatocellular O
carcinoma O
( O
DNA4 O
) O
, O
respectively O
. O

We O
recently O
found O
that O
alterations O
of O
amino O
acids O
in O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
putative O
envelope O
glycoprotein O
( O
gp70 O
) O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
occurred O
sequentially O
in O
the O
chronic O
phase O
of O
hepatitis O
at O
intervals O
of O
several O
months O
. O

To O
explore O
this O
possibility O
, O
we O
examined O
the O
humoral O
immune O
response O
to O
HVR1 O
with O
our O
assay O
system O
, O
in O
which O
immunoprecipitation O
was O
carried O
out O
with O
sera O
from O
patients O
by O
using O
an O
HVR1 O
( O
27 O
- O
amino O
- O
acid O
) O
dihydrofolate O
reductase O
fusion O
protein O
synthesized O
by O
in O
vitro O
transcription O
and O
translation O
. O

This O
observation O
suggests O
that O
anti O
- O
HVR1 O
antibodies O
are O
involved O
in O
the O
genetic O
drift O
of O
HVR1 O
( O
minor O
antigenic O
variation O
) O
by O
immunoselection O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
enhancer O
I O
contains O
cis O
- O
acting O
elements O
that O
are O
both O
sufficient O
and O
essential O
for O
liver O
- O
specific O
enhancer O
function O
. O

Among O
these O
proteins O
, O
we O
demonstrate O
that O
HNF O
- O
4 O
, O
RXR B
( I
Retinoid I
X I
receptor I
) I
, O
and O
COUP O
- O
TF O
bind O
to O
the O
GB O
element O
in O
vitro O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
a O
positive O
- O
sense O
RNA O
genome O
which O
encodes O
a O
large O
polyprotein O
of O
3 O
, O
010 O
amino O
acids O
. O

Here O
we O
show O
that O
the O
amino O
- O
terminal O
region O
of O
the O
HCV O
polyprotein O
is O
processed O
in O
vitro O
by O
cellular O
proteases O
releasing O
three O
structural O
proteins O
: O
p21 O
( O
core O
) O
, O
gp37 O
( O
El O
) O
, O
and O
gp61 O
( O
E2 O
) O
. O

2 O
- O
kb O
genome O
is O
exemplified O
by O
the O
pre O
- O
C O
/ O
C O
gene O
from O
which O
two O
proteins O
with O
largely O
overlapping O
primary O
sequences O
but O
distinctly O
different O
properties O
are O
synthesized O
: O
the O
self O
- O
assembling O
core O
protein O
p21c O
( O
hepatitis O
B O
core O
antigen O
[ O
HbcAg O
] O
) O
and O
the O
secretory O
, O
nonparticulate O
protein O
p17e O
( O
hepatitis O
B O
e O
antigen O
[ O
HbeAg O
] O
) O
. O

Mature O
p17e O
carries O
a O
10 O
- O
amino O
- O
acid O
N O
- O
terminal O
extension O
with O
a O
Cys O
residue O
( O
Cys O
- O
7 O
) O
. O

A O
hepatitis B
B I
virus I
( I
HBV I
) I
binding O
factor O
( O
HBV O
- O
BF O
) O
was O
identified O
in O
normal O
human O
serum O
interacting O
with O
the O
pre O
- O
SI O
and O
pre O
- O
S2 O
epitopes O
of O
the O
viral O
envelope O
located O
within O
the O
protein O
domains O
involved O
in O
recognition O
of O
hepatocyte O
receptor O
( O
s O
) O
. O

Sedimentation O
, O
electrophoresis O
, O
and O
autoradiography O
revealed O
the O
presence O
of O
virions O
, O
provirions O
, O
procapsids O
, O
and O
14S O
( O
pentameric O
) O
subunits O
. O

The O
results O
of O
this O
study O
suggest O
that O
cleavage O
of O
the O
hepatitis O
A O
virus O
polyprotein O
to O
produce O
pentamers O
is O
protracted O
( O
though O
not O
rate O
limiting O
) O
early O
in O
infection O
, O
while O
the O
assembly O
of O
pentamers O
into O
higher O
structures O
is O
a O
rapid O
process O
once O
sufficient O
viral O
RNA O
is O
produced O
for O
encapsidation O
. O

Selective O
encapsidation O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
genomic O
RNA O
within O
cytoplasmic O
core O
particles O
requires O
recognition O
of O
the O
cis O
- O
encapsidation O
signal O
, O
( O
termed O
epsilon O
) O
located O
at O
the O
5 O
' O
end O
of O
genomic O
RNA O
. O

By O
transfecting O
plasmids O
expressing O
chimeric O
RNAs O
bearing O
HBV O
sequences O
fused O
to O
lacZ O
, O
we O
have O
mapped O
the O
minimal O
region O
of O
epsilon O
to O
the O
5 O
' O
94 O
nucleotides B
( I
nt I
) I
of O
genomic O
RNA O
. O

Enzymatic O
probing O
of O
the O
RNA O
secondary O
structure O
in O
this O
region O
( O
by O
using O
either O
in O
vitro O
transcripts O
or O
RNA O
extracted O
from O
HBV O
core O
particles O
) O
reveals O
a O
stem O
- O
loop O
structure O
containing O
a O
lower O
stem O
, O
a O
6 O
- O
nt O
bulge O
, O
an O
upper O
stem O
with O
a O
single O
unpaired O
U O
residue O
, O
and O
a O
6 O
- O
nt O
loop O
. O

These O
studies O
reveal O
that O
( O
i O
) O
in O
the O
lower O
stem O
, O
base O
pairing O
but O
not O
specific O
primary O
sequence O
is O
required O
for O
function O
; O
( O
ii O
) O
there O
is O
no O
requirement O
for O
base O
pairing O
in O
the O
lower O
portion O
of O
the O
upper O
stem O
, O
but O
base O
pairing O
elsewhere O
in O
this O
stem O
contributes O
to O
packaging O
efficiency O
; O
( O
iii O
) O
the O
presence O
of O
the O
6 O
- O
nt O
bulge O
, O
but O
not O
its O
primary O
sequence O
, O
is O
important O
for O
function O
; O
and O
( O
iv O
) O
specific O
nucleotide O
sequences O
in O
the O
loop O
and O
in O
regions O
of O
the O
upper O
stem O
are O
critical O
for O
RNA O
encapsidation O
. O

Human O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
satellite O
agent O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

By O
using O
UV O
cross O
- O
linking O
, O
equilibrium O
density O
centrifugation O
, O
and O
immunoprecipitation O
, O
we O
obtained O
evidence O
consistent O
with O
the O
interpretation O
that O
delta O
antigen O
and O
genomic O
RNA O
form O
a O
stable O
ribonucleoprotein B
( I
RNP I
) I
complex O
within O
the O
virion O
. O

We O
also O
isolated O
HDV O
- O
specific O
RNP O
structures O
from O
the O
nuclei O
of O
cells O
undergoing O
HDV O
genome O
replication O
; O
both O
the O
genome O
and O
antigenome O
( O
a O
complement O
of O
the O
genome O
) O
of O
HDV O
were O
found O
to O
be O
in O
such O
complexes O
. O

Human O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
obtained O
from O
the O
serum O
of O
an O
experimentally O
infected O
woodchuck O
, O
was O
injected O
into O
either O
the O
peritoneal O
cavity O
or O
the O
tail O
vein O
of O
both O
adult O
CB17 O
mice O
and O
mice O
with O
a O
severe O
combined O
immunodeficiency O
( O
CB17 O
- O
scid O
mice O
) O
. O

Three O
lines O
of O
evidence O
indicated O
that O
the O
virus O
was O
able O
to O
reach O
the O
liver O
and O
infect O
hepatocytes O
: O
( O
i O
) O
the O
amount O
of O
HDV O
genomic O
RNA O
detected O
in O
the O
liver O
by O
Northern O
( O
RNA O
) O
analysis O
increased O
during O
the O
first O
5 O
to O
10 O
days O
postinoculation O
, O
reaching O
a O
peak O
that O
was O
about O
threefold O
the O
amount O
in O
the O
original O
inoculum O
; O
( O
ii O
) O
also O
detected O
in O
the O
liver O
was O
the O
viral O
antigenomic O
RNA O
, O
which O
is O
complementary O
to O
the O
genomic O
RNA O
found O
in O
virions O
, O
and O
is O
diagnostic O
for O
vims O
replication O
; O
and O
( O
iii O
) O
by O
immunoperoxidase O
staining O
of O
liver O
sections O
, O
the O
delta O
antigen O
was O
detected O
in O
the O
nuclei O
of O
scattered O
cells O
identifiable O
as O
hepatocytes O
. O

The O
hematopoietic O
cell O
lines O
HL O
- O
60 O
and O
THP O
- O
1 O
were O
challenged O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
vitro O
to O
study O
interactions O
between O
the O
virus O
and O
host O
cell O
. O

Exposure O
to O
HBV O
suppressed O
the O
ability O
of O
HL O
- O
60 O
cells O
to O
differentiate O
into O
granulocytes O
after O
treatment O
with O
retinoic B
acid I
( I
RA I
) I
or O
dimethyl B
sulfoxide I
( I
DMSO I
) I
, O
and O
RA O
- O
induced O
activation O
of O
the O
monocytic O
cell O
line O
THP O
- O
1 O
was O
also O
suppressed O
. O

Terminal O
differentiation O
of O
both O
cell O
lines O
by O
Phorbol B
12 I
- I
myristate I
13 I
- I
acetate I
( I
PMA I
) I
was O
not O
affected O
by O
HBV O
. O

At O
5 O
days O
postinfection O
, O
extracellular O
viral O
DNA O
was O
detected O
in O
immature O
but O
not O
in O
differentiated O
cultures O
and O
higher O
levels O
of O
core O
antigen O
( O
HBcAg O
) O
and O
surface O
antigen O
( O
HBsAg O
) O
were O
seen O
in O
undifferentiated O
cells O
than O
in O
RA O
- O
or O
PMA O
- O
treated O
cells O
. O

A O
hepatitis B
B I
core I
antigen I
( I
HBcAg I
) I
gene O
bearing O
the O
39 O
- O
amino O
- O
acid O
- O
long O
domain O
A O
of O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
within O
the O
HBcAg O
immunodominant O
loop O
has O
been O
constructed O
and O
expressed O
in O
Escherichia O
coli O
. O

The O
functions O
of O
delta O
antigens O
( O
HDAgs O
) O
in O
the O
replication O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
have O
been O
identified O
previously O
. O

A O
sequence O
- O
specific O
cellular O
factor O
was O
found O
to O
bind O
to O
the O
promoter O
region O
upstream O
of O
the O
first O
ATG O
( O
nucleotide O
[ O
nt O
] O
1248 O
) O
of O
the O
X O
open O
reading O
frame O
. O

S1 O
nuclease O
analysis O
of O
X O
gene O
transcripts O
demonstrated O
the O
binding O
site O
to O
be O
adjacent O
to O
two O
major O
start O
sites O
( O
nt O
1117 O
and O
1125 O
) O
of O
X O
mRNA O
. O

Hepatitis O
delta O
virus O
expresses O
two O
forms O
of O
a O
single O
protein O
, O
the O
small O
( O
deltaAg O
- O
S O
) O
and O
large O
( O
deltaAg O
- O
L O
) O
antigens O
, O
which O
are O
identical O
except O
for O
an O
additional O
19 O
residues O
present O
at O
the O
C O
terminus O
of O
deltaAg O
- O
L O
. O

While O
deltaAg O
- O
S O
is O
required O
to O
promote O
genome O
replication O
, O
deltaAg O
- O
L O
potently O
inhibits O
this O
process O
and O
also O
facilitates O
packaging O
of O
the O
viral O
genome O
by O
envelope O
proteins O
of O
the O
helper O
virus O
( O
hepatitis O
B O
virus O
) O
. O

( O
i O
) O
Although O
the O
removal O
of O
the O
nuclear O
localization O
signal O
from O
either O
antigen O
resulted O
in O
significant O
cytoplasmic O
accumulation O
, O
both O
proteins O
still O
had O
access O
to O
the O
nucleus O
. O

( O
ii O
) O
The O
RNA O
- O
binding O
domain O
, O
although O
necessary O
for O
deltaAg O
- O
S O
function O
, O
could O
be O
deleted O
from O
deltaAg O
- O
L O
without O
compromising O
its O
ability O
to O
either O
inhibit O
replication O
or O
promote O
packaging O
. O

( O
iii O
) O
In O
contrast O
, O
the O
coiled O
- O
coil O
dimerization O
domain O
was O
required O
for O
both O
the O
activation O
of O
replication O
by O
deltaAg O
- O
S O
and O
the O
inhibition O
of O
replication O
by O
deltaAg O
- O
L O
. O

( O
iv O
) O
The O
packaging O
property O
of O
deltaAg O
- O
L O
required O
a O
C O
- O
terminal O
Pro O
/ O
Gly O
- O
rich O
region O
which O
is O
hypothesized O
to O
interact O
with O
the O
hepatitis O
B O
virus O
envelope O
proteins O
during O
the O
assembly O
process O
. O

Processing O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
H O
strain O
polyprotein O
yields O
at O
least O
nine O
distinct O
cleavage O
products O
: O
NH2 O
- O
C O
- O
E1 O
- O
E2 O
- O
NS2 O
- O
NS3 O
- O
NS4A O
- O
NS4B O
- O
NS5A O
- O
NS5B O
- O
COOH O
. O

All O
four O
cleavages O
which O
occur O
C O
terminal O
to O
the O
proteinase O
domain O
( O
3 O
/ O
4A O
, O
4A O
/ O
4B O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
) O
were O
abolished O
by O
substitution O
of O
alanine O
for O
either O
of O
two O
predicted O
residues O
( O
His O
- O
1083 O
and O
Ser O
- O
1165 O
) O
in O
the O
proteinase O
catalytic O
triad O
. O

These O
features O
include O
an O
acidic O
residue O
( O
Asp O
or O
Glu O
) O
at O
the O
P6 O
position O
, O
a O
Cys O
or O
Thr O
residue O
at O
the O
P1 O
position O
, O
and O
a O
Ser O
or O
Ala O
residue O
at O
the O
P1 O
' O
position O
. O

Consequently O
, O
we O
have O
chosen O
as O
a O
model O
one O
such O
virus O
, O
the O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
and O
have O
previously O
reported O
the O
design O
of O
specific O
anti O
- O
LCMV O
ribozymes O
( O
Z O
. O

The O
buoyant O
density O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
with O
high O
in O
vivo O
infectivity O
( O
strain O
H O
) O
or O
low O
in O
vivo O
infectivity O
( O
strain O
F O
) O
, O
was O
determined O
by O
sucrose O
gradient O
equilibrium O
centrifugation O
. O

In O
immunoprecipitation O
experiments O
with O
anti O
- O
human O
immunoglobulin O
, O
HCV O
( O
as O
measured O
by O
HCV O
RNA O
) O
was O
precipitated O
from O
the O
samples O
with O
low O
infectivity O
and O
high O
density O
but O
not O
from O
those O
with O
high O
infectivity O
and O
low O
density O
. O

Using O
panels O
of O
truncated O
and O
overlapping O
peptides O
, O
we O
now O
show O
that O
the O
optimal O
amino O
acid O
sequence O
recognized O
by O
cytotoxic O
T O
cells O
is O
a O
10 O
- O
mer O
( O
residues O
18 O
to O
27 O
) O
containing O
the O
predicted O
peptide O
- O
binding O
motif O
for O
HLA O
- O
A2 O
and O
that O
this O
peptide O
can O
stimulate O
cytotoxic O
T O
cells O
able O
to O
recognize O
endogenously O
synthesized O
hepatitis O
B O
core O
antigen O
. O

The O
X O
gene O
overlaps O
the O
polymerase O
and O
precore O
genes O
as O
well O
as O
two O
newly O
identified O
open B
reading I
frames I
( I
ORFs I
) I
termed O
ORF5 O
and O
ORF6 O
. O

In O
this O
investigation O
, O
we O
examined O
whether O
ORF5 O
, O
ORF6 O
, O
and O
the O
X O
gene O
were O
important O
for O
the O
replication O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
in O
susceptible O
woodchucks O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
major O
cause O
of O
transfusion O
- O
acquired O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
. O

In O
this O
study O
, O
a O
cDNA O
clone O
encompassing O
the O
long O
open O
reading O
frame O
of O
the O
HCV O
H O
strain O
( O
3 O
, O
011 O
amino O
acid O
residues O
) O
has O
been O
assembled O
and O
sequenced O
. O

Putative O
structural O
proteins O
, O
located O
in O
the O
N O
- O
terminal O
one O
- O
fourth O
of O
the O
polyprotein O
, O
include O
the O
capsid O
protein O
C O
( O
21 O
kDa O
) O
followed O
by O
two O
possible O
virion O
envelope O
proteins O
, O
El O
( O
31 O
kDa O
) O
and O
E2 O
( O
70 O
kDa O
) O
, O
which O
are O
heavily O
modified O
by O
N O
- O
linked O
glycosylation O
. O

The O
remainder O
of O
the O
polyprotein O
probably O
encodes O
nonstructural O
proteins O
including O
NS2 O
( O
23 O
kDa O
) O
, O
NS3 O
( O
70 O
kDa O
) O
, O
NS4A O
( O
8 O
kDa O
) O
, O
NS4B O
( O
27 O
kDa O
) O
, O
NS5A O
( O
58 O
kDa O
) O
, O
and O
NS5B O
( O
68 O
kDa O
) O
. O

An O
82 O
- O
to O
88 O
- O
kDa O
glycoprotein O
which O
reacted O
with O
both O
E2 O
and O
NS2 O
- O
specific O
HCV O
antisera O
was O
also O
identified O
( O
called O
E2 O
- O
NS2 O
) O
. O

Gel O
retardation O
analysis O
with O
Huh7 O
nuclear O
extracts O
demonstrated O
that O
each O
of O
the O
three O
recognition O
elements O
bound O
the O
same O
or O
similar O
transcription O
factor O
( O
s O
) O
as O
that O
recognized O
by O
the O
Spl O
consensus O
sequence O
recognition O
element O
. O

A O
monoclonal O
antibody O
( O
1 O
- O
18 O
) O
was O
raised O
against O
an O
enneapeptide O
representing O
amino O
acids O
125 O
to O
133 O
of O
the O
product O
of O
the O
S O
gene O
of O
hepatitis O
B O
virus O
DNA O
[ O
S O
( O
125 O
- O
133 O
) O
segment O
] O
with O
a O
sequence O
of O
Thr O
- O
Ile O
- O
126 O
- O
Pro O
- O
Ala O
- O
Gln O
- O
Gly O
- O
Thr O
- O
Ser O
- O
Met O
. O

Another O
monoclonal O
antibody O
( O
T O
- O
7 O
) O
was O
raised O
against O
an O
S O
( O
125 O
- O
133 O
) O
segment O
in O
which O
Ile O
- O
126 O
was O
replaced O
by O
Thr O
- O
126 O
. O

In O
a O
panel O
of O
16 O
samples O
of O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
with O
known O
S O
gene O
sequences O
, O
1 O
- O
18 O
reacted O
with O
5 O
with O
Ile O
- O
126 O
. O

They O
were O
expressed O
in O
a O
mutually O
exclusive O
fashion O
in O
216 O
( O
83 O
% O
) O
of O
260 O
HBsAg O
samples O
from O
asymptomatic O
carriers O
. O

They O
were O
not O
detected O
in O
36 O
( O
14 O
% O
) O
samples O
; O
the O
failure O
to O
detect O
an O
i O
or O
t O
determinant O
was O
particularly O
common O
in O
HBsAg O
samples O
of O
subtype O
ayw O
( O
26 O
[ O
79 O
% O
] O
of O
33 O
) O
. O

In O
eight O
( O
3 O
% O
) O
of O
the O
samples O
, O
both O
i O
and O
t O
determinants O
were O
detected O
; O
the O
presence O
of O
i O
and O
t O
on O
the O
selfsame O
HBsAg O
particles O
was O
verified O
by O
sandwiching O
the O
particles O
between O
1 O
- O
18 O
and O
T O
- O
7 O
. O

A O
point O
mutation O
from O
thymine O
to O
cytosine O
at O
nucleotide O
377 O
in O
the O
S O
gene O
, O
contributing O
different O
second O
letters O
to O
codon O
126 O
( O
ATT O
for O
Ile O
and O
ACT O
for O
Thr O
) O
, O
would O
have O
been O
responsible O
for O
the O
assembly O
of O
HBsAg O
particles O
with O
both O
i O
and O
t O
determinants O
by O
means O
of O
phenotypic O
mixing O
. O

We O
have O
previously O
reported O
the O
identification O
and O
characterization O
of O
the O
second O
enhancer O
( O
enhancer O
II O
) O
of O
hepatitis O
B O
virus O
. O

Assembly O
of O
hepatitis O
B O
virus O
capsid O
- O
like O
( O
core O
) O
particles O
occurs O
efficiently O
in O
a O
variety O
of O
heterologous O
systems O
via O
aggregation O
of O
approximately O
180 O
molecules O
of O
a O
single O
21 O
. O

The O
data O
revealed O
that O
( O
i O
) O
p21 O
. O

5 O
dimers O
and O
capsids O
are O
antigenically O
distinct O
, O
( O
ii O
) O
capsid O
assembly O
is O
a O
highly O
cooperative O
and O
concentration O
- O
dependent O
process O
, O
and O
( O
iii O
) O
p21 O
. O

The O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
coated O
with O
large B
( I
L I
) I
, O
middle O
( O
M O
) O
, O
and O
small B
( I
S I
) I
envelope O
proteins O
encoded O
by O
coinfecting O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

To O
study O
the O
role O
of O
the O
HBV O
envelope O
proteins O
in O
the O
assembly O
and O
infectivity O
of O
HDV O
, O
we O
produced O
three O
types O
of O
recombinant O
particles O
in O
Huh7 O
cells O
by O
transfection O
with O
HBV O
DNA O
and O
HDV O
cDNA O
: O
( O
i O
) O
particles O
with O
an O
envelope O
containing O
the O
S O
HBV O
envelope O
protein O
only O
, O
( O
ii O
) O
particles O
with O
an O
envelope O
containing O
S O
and O
M O
proteins O
, O
and O
( O
iii O
) O
particles O
with O
an O
envelope O
containing O
S O
, O
M O
, O
and O
L O
proteins O
. O

Although O
the O
resulting O
S O
- O
, O
SM O
- O
, O
and O
SML O
- O
HDV O
particles O
contained O
both O
hepatitis O
delta O
antigen O
and O
HDV O
RNA O
, O
only O
particles O
coated O
with O
all O
three O
envelope O
proteins O
( O
SML O
) O
showed O
evidence O
of O
infectivity O
in O
an O
in O
vitro O
culture O
system O
susceptible O
to O
HDV O
infection O
. O

Liver O
specificity O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
has O
been O
attributed O
to O
the O
action O
of O
its O
second O
enhancer O
( O
EII O
) O
. O

The O
DNA O
- O
binding O
proteins O
which O
recognize O
the O
regulatory O
sequence O
elements O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
major O
surface O
antigen O
promoter O
were O
examined O
by O
ge O
[ O
retardation O
analysis O
, O
using O
nuclear O
extracts O
from O
the O
human O
hepatoma O
cell O
line O
Huh7 O
. O

Using O
this O
assay O
, O
we O
identified O
four O
regions O
( O
B O
, O
D O
, O
E O
, O
and O
F O
) O
of O
the O
promoter O
that O
interact O
with O
the O
same O
or O
similar O
transcription O
factor O
( O
s O
) O
. O

In O
addition O
, O
the O
recognition O
sequence O
for O
the O
Spl O
transcription O
factor O
bound O
the O
same O
or O
similar O
transcription O
factor O
( O
s O
) O
present O
in O
Huh7 O
cell O
nuclear O
extracts O
, O
and O
this O
binding O
was O
inhibited O
by O
the O
four O
major O
surface O
antigen O
promoter O
elements O
, O
B O
, O
D O
, O
E O
, O
and O
F O
. O

Purified O
Spl O
transcription O
factor O
was O
shown O
to O
bind O
to O
three O
( O
B O
, O
D O
, O
and O
F O
) O
of O
the O
major O
surface O
antigen O
promoter O
regulatory O
sequence O
elements O
by O
DNase O
I O
footprinting O
. O

Like O
most O
coronaviruses O
, O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
exhibits O
strong O
species O
specificity O
, O
causing O
natural O
infection O
only O
in O
mice O
. O

MHV O
- O
A59 O
virions O
use O
as O
a O
receptor O
a O
110 O
- O
to O
120 O
- O
kDa O
glycoprotein O
( O
MHVR O
) O
in O
the O
carcinoembryonic B
antigen I
( I
CEA I
) I
family O
of O
glycoproteins O
( O
G O
. O

The O
role O
of O
virus O
- O
receptor O
interactions O
in O
determining O
the O
species O
specificity O
of O
MHV O
- O
A59 O
was O
examined O
by O
comparing O
the O
binding O
of O
virus O
and O
antireceptor O
antibodies O
to O
cell O
lines O
and O
intestinal O
brush B
border I
membranes I
( I
BBM I
) I
from O
many O
species O
. O

Polyclonal O
antireceptor O
antiserum O
( O
anti O
- O
MHVR O
) O
raised O
by O
immunization O
of O
SJL O
/ O
J O
mice O
with O
BALB O
/ O
c O
BBM O
recognized O
MHVR O
specifically O
in O
immunoblots O
of O
BALB O
/ O
c O
BBM O
but O
not O
in O
BBM O
from O
adult O
SJL O
/ O
J O
mice O
that O
are O
resistant O
to O
infection O
with O
MHV O
- O
A59 O
, O
indicating O
a O
major O
difference O
in O
epitopes O
between O
MHVR O
and O
its O
SJL O
/ O
J O
homolog O
which O
does O
not O
bind O
MHV O
( O
7 O
) O
. O

Two O
regions O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
have O
been O
shown O
to O
display O
properties O
of O
a O
transcriptional O
enhancer O
. O

The O
hepatitis O
B O
virus O
genome O
contains O
a O
unique O
polyadenylation O
( O
TATAAA O
) O
signal O
which O
is O
differentially O
utilized O
in O
the O
formation O
of O
the O
various O
hepatitis O
B O
vims O
transcripts O
. O

A O
head O
- O
to O
- O
tail O
multiple O
- O
copy O
insertion O
of O
a O
viral O
fragment O
comprising O
the O
viral O
enhancer O
, O
the O
X O
promoter O
, O
the O
X O
open O
reading O
frame O
, O
and O
the O
viral O
poly O
( O
A O
) O
signal O
in O
transgenic O
mice O
allowed O
us O
to O
monitor O
tissue O
- O
specific O
differences O
in O
the O
expression O
of O
transcripts O
initiating O
from O
the O
X O
promoter O
. O

While O
secretion O
of O
wild O
- O
type O
S O
protein O
was O
specifically O
blocked O
by O
the O
formation O
of O
intracellularly O
retained O
mixed O
envelope O
aggregates O
, O
secretion O
of O
an O
unrelated O
protein O
( O
interleukin O
9 O
) O
was O
completely O
unaffected O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
is O
the O
only O
known O
protein O
of O
hepatitis O
delta O
virus O
and O
was O
previously O
shown O
to O
localize O
in O
the O
nucleoplasm O
of O
infected O
liver O
cells O
. O

However O
, O
a O
fusion O
protein O
( O
N65Z O
) O
containing O
beta O
- O
galactosidase O
and O
the O
N O
- O
terminal O
65 O
amino O
acids O
of O
HDAg O
, O
containing O
NLS1 O
, O
was O
localized O
exclusively O
in O
the O
cytoplasm O
and O
perinuclear O
region O
. O

In O
addition O
, O
two O
putative O
casein O
kinase O
II O
sites O
( O
SRSE O
- O
5 O
and O
SREE O
- O
126 O
) O
that O
may O
be O
important O
in O
controlling O
the O
rate O
of O
nuclear O
transport O
were O
found O
in O
HDAg O
. O

5 O
) O
binds O
nucleic O
acid O
through O
a O
carboxy O
- O
terminal O
protamine O
region O
that O
contains O
nucleic O
acid O
- O
binding O
motifs O
organized O
into O
four O
repeats O
( O
I O
to O
IV O
) O
. O

coli O
capsids O
on O
agarose O
gels O
and O
disclosing O
their O
RNA O
content O
with O
ethidium O
bromide O
, O
required O
only O
the O
proximal O
repeat O
I O
( O
RRRDRGRS O
) O
. O

In O
contrast O
, O
probing O
immobilized O
core O
proteins O
with O
P O
- O
32 O
- O
nucleic O
acid O
revealed O
an O
activity O
which O
( O
i O
) O
required O
more O
of O
the O
protamine O
region O
( O
repeats O
I O
and O
II O
) O
, O
( O
ii O
) O
appeared O
to O
bind O
DNA O
better O
than O
RNA O
, O
and O
( O
iii O
) O
was O
apparently O
modulated O
by O
phosphorylation O
in O
p21 O
. O

To O
determine O
the O
P3 O
region O
protein O
- O
processing O
sites O
cleaved O
by O
the O
hepatitis O
A O
virus O
3C O
protease O
, O
a O
nested O
set O
of O
constructs O
containing O
a O
portion O
of O
3A O
( O
3A O
* O
[ O
the O
asterisk O
denotes O
an O
incomplete O
protein O
] O
) O
, O
3B O
, O
and O
3C O
and O
various O
amounts O
of O
3D O
, O
fused O
in O
frame O
to O
Escherichia O
coli O
TrpE O
- O
coding O
sequences O
under O
control O
of O
the O
tryptophan O
promoter O
, O
was O
made O
. O

Additional O
plasmids O
that O
encoded O
a O
portion O
of O
2C O
( O
2C O
* O
) O
and O
the O
P3 O
proteins O
, O
including O
complete O
or O
incomplete O
3D O
sequences O
, O
were O
constructed O
. O

In O
persistent O
hepadnavirus O
infections O
, O
a O
distinctive O
feature O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
is O
the O
coupling O
of O
frequent O
viral O
integrations O
into O
myc O
family O
genes O
with O
the O
rapid O
onset O
of O
primary O
liver O
tumors O
. O

Recently O
, O
it O
was O
reported O
that O
3 O
' O
truncation O
of O
an O
integrated O
surface O
gene O
( O
pre O
- O
S2 O
/ O
S O
) O
cloned O
from O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
associated O
hepatoma O
gave O
rise O
to O
the O
generation O
of O
a O
C O
- O
terminally O
truncated O
middle O
surface O
protein O
( O
MHBs O
( O
t O
) O
) O
, O
which O
surprisingly O
exerted O
a O
transcriptional O
transactivator O
function O
. O

To O
define O
the O
molecular O
requirements O
for O
the O
generation O
of O
transactivating O
MHBs O
( O
t O
) O
proteins O
, O
a O
3 O
' O
deletion O
analysis O
of O
the O
HBV O
pre O
- O
S2 O
/ O
S O
gene O
was O
performed O
. O

The O
results O
of O
this O
study O
define O
a O
range O
within O
the O
S O
open O
reading O
frame O
( O
between O
HBV O
nucleotides O
221 O
and O
573 O
) O
, O
termed O
the O
trans O
- O
activity O
- O
on O
region O
, O
in O
which O
3 O
' O
deletions O
give O
rise O
to O
the O
generation O
of O
transactivating O
MHBs O
( O
t O
) O
proteins O
. O

Within O
this O
region O
, O
not O
only O
3 O
' O
deletions O
but O
also O
the O
introduction O
of O
a O
stop O
codon O
activated O
the O
transactivator O
function O
, O
indicating O
that O
point O
mutations O
of O
integrated O
HBV O
DNA O
also O
may O
give O
rise O
to O
the O
synthesis O
of O
transactivating O
MHBs O
( O
t O
) O
proteins O
in O
vivo O
. O

The O
molecular O
basis O
of O
the O
biophysical O
and O
antigenic O
differences O
between O
the O
cellular O
core O
protein O
( O
HBc O
protein O
) O
and O
the O
secreted O
core O
protein O
( O
HBe O
protein O
) O
of O
human O
hepatitis O
B O
virus O
was O
examined O
. O

In O
the O
spherical O
capsid O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
intermolecular O
disulfide O
bonds O
cross O
- O
link O
the O
approximately O
180 O
p21 O
. O

5 O
Cys O
residues O
( O
positions O
48 O
, O
61 O
, O
107 O
, O
and O
185 O
) O
play O
in O
capsid O
assembly O
and O
/ O
or O
stabilization O
. O

5 O
Cys O
residues O
were O
either O
replaced O
by O
Ala O
or O
removed O
( O
Cys O
- O
185 O
) O
by O
carboxyl O
- O
terminal O
truncation O
, O
creating O
Cys O
- O
minus O
mutants O
which O
were O
expressed O
in O
Xenopus O
oocytes O
via O
microinjected O
synthetic O
mRNAs O
. O

5 O
structures O
, O
as O
evidenced O
by O
the O
marked O
reduction O
in O
stability O
of O
Cys O
- O
minus O
dimers O
and O
capsids O
( O
i O
) O
in O
nonreducing O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
and O
( O
ii O
) O
upon O
protease O
digestion O
. O

The O
most O
common O
mutation O
observed O
is O
a O
substitution O
of O
G O
to O
A O
in O
the O
distal O
precore O
gene O
that O
converts O
a O
codon O
specifying O
Trp O
( O
TGG O
) O
to O
a O
termination O
codon O
( O
TAG O
) O
. O

Using O
oligonucleotide O
- O
directed O
mutagenesis O
, O
we O
have O
produced O
the O
same O
point O
mutation O
in O
the O
precore O
gene O
of O
an O
infectious O
clone O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

Recently O
, O
we O
showed O
that O
a O
murine O
member O
of O
the O
carcinoembryonic O
antigen O
family O
of O
glycoproteins O
serves O
as O
a O
cellular O
receptor O
( O
MHVR O
) O
for O
the O
coronavirus O
Mouse B
hepatitis I
virus I
A59 I
( I
MHV I
- I
A59 I
) I
( O
G O
. O

Expression O
from O
the O
vaccinia O
virus O
recombinant O
( O
Vac O
- O
MHVR O
) O
in O
BHK O
- O
21 O
cells O
resulted O
in O
high O
levels O
of O
MHVR O
glycoprotein O
on O
the O
cell O
surface O
and O
made O
these O
cells O
susceptible O
to O
MHV O
- O
A59 O
infection O
. O

These O
three O
nonglycosylated O
MHVR O
proteins O
were O
recognized O
by O
polyclonal O
antibody O
against O
affinity O
- O
purified O
receptor O
but O
did O
not O
bind O
antireceptor O
monoclonal B
antibody I
( I
Mab I
) I
CC1 O
or O
MHV O
- O
A59 O
virions O
. O

These O
results O
suggest O
that O
either O
a O
carbohydrate O
moiety O
is O
an O
element O
of O
the O
MHVR O
- O
binding O
site O
( O
s O
) O
for O
virus O
and O
MAb O
CC1 O
or O
a O
posttranslational O
membrane O
- O
associated O
process O
is O
required O
for O
functional O
conformation O
of O
the O
receptor O
glycoprotein O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
either O
acute O
or O
chronic O
, O
has O
been O
one O
of O
the O
leading O
health O
problems O
in O
the O
world O
. O

We O
identify O
a O
short O
sequence O
( O
from O
nucleotides O
[ O
nt O
] O
1744 O
to O
1851 O
, O
referred O
to O
as O
the O
basic O
core O
promoter O
[ O
BCP O
] O
) O
that O
is O
sufficient O
to O
direct O
correct O
initiation O
of O
both O
precore O
and O
pregenomic O
messages O
. O

Sequences O
upstream O
of O
the O
BCP O
( O
from O
nt O
1636 O
to O
1744 O
, O
referred O
to O
as O
the O
core O
upstream O
regulatory O
sequence O
[ O
CURS O
] O
) O
, O
have O
a O
strong O
stimulating O
effect O
on O
the O
BCP O
. O

Among O
these O
elements O
, O
box O
- O
alpha O
( O
from O
nt O
1646 O
to O
1668 O
) O
and O
box O
- O
gamma O
- O
delta O
( O
from O
nt O
1671 O
to O
1703 O
) O
are O
two O
regulatory O
elements O
which O
individually O
stimulate O
promoter O
activity O
more O
than O
100 O
- O
fold O
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
have O
been O
found O
to O
mediate O
protection O
in O
vivo O
against O
certain O
virus O
infections O
. O

CTL O
also O
may O
play O
an O
important O
role O
in O
control O
of O
infection O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
but O
no O
CTL O
epitopes O
have O
yet O
been O
defined O
in O
any O
HCV O
protein O
. O

Mice O
were O
immunized O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
the O
HCV O
nonstructural O
region O
corresponding O
to O
the O
flavivirus O
NS5 O
gene O
( O
RNA O
polymerase O
) O
, O
and O
the O
primed O
spleen O
cells O
were O
restimulated O
in O
vitro O
with O
peptides O
. O

CTL O
from O
H O
- O
2d O
mice O
responded O
to O
a O
single O
16 O
- O
residue O
synthetic O
peptide O
( O
HCV O
2422 O
to O
2437 O
) O
. O

This O
relatively O
conserved O
epitope O
was O
presented O
by O
H O
- O
2d O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecules O
to O
conventional O
CD4 O
- O
CD8 O
+ O
CTL O
but O
was O
not O
recognized O
by O
CTL O
restricted O
by O
H O
- O
2b O
. O

Moreover O
, O
exon O
shuffle O
experiments O
using O
several O
transfectants O
expressing O
recombinant O
D O
( O
d O
) O
/ O
L O
( O
d O
) O
and O
K O
( O
d O
) O
demonstrated O
that O
this O
peptide O
is O
seen O
in O
association O
with O
alpha O
- O
1 O
and O
alpha O
- O
2 O
domains O
of O
the O
D O
( O
d O
) O
class O
I O
MHC O
molecule O
. O

Therefore O
, O
these O
conservative O
mutations O
affected O
peptide O
interaction O
neither O
with O
the O
D O
( O
d O
) O
class O
I O
MHC O
molecule O
nor O
with O
the O
T O
- O
cell O
receptor O
. O

Assembly O
of O
replication O
- O
competent O
hepatitis B
B I
virus I
( I
HBV I
) I
nucleocapsids O
requires O
the O
interaction O
of O
the O
core O
protein O
, O
the O
P O
protein O
, O
and O
the O
RNA O
pregenome O
. O

Moreover O
, O
almost O
all O
positive O
- O
strand O
DNA O
originated O
from O
in O
situ O
priming O
, O
whereas O
in O
wild O
- O
type O
particles O
, O
this O
type O
of O
priming O
not O
supporting O
the O
formation O
of O
relaxed B
circular I
DNA I
( I
RC I
- I
DNA I
) I
accounted O
for O
about O
one O
half O
of O
the O
positive O
strands O
. O

Expression O
of O
mRNAs O
capable O
of O
encoding O
only O
one O
of O
each O
X O
protein O
all O
individually O
transactivate O
class O
III O
( O
RNA O
polymerase O
III O
) O
- O
transcribed O
promoters O
. O

However O
, O
class O
II O
( O
RNA O
polymerase O
II O
) O
- O
transcribed O
promoters O
displayed O
various O
requirements O
for O
the O
different O
X O
proteins O
. O

Since O
hepatitis B
B I
virus I
( I
HBV I
) I
characteristically O
induces O
a O
vigorous O
lymphomononuclear O
inflammatory O
response O
in O
the O
liver O
during O
acute O
and O
chronic O
hepatitis O
, O
it O
is O
possible O
that O
hepatocellular O
HBV O
gene O
expression O
may O
also O
be O
modulated O
by O
one O
or O
more O
of O
the O
cytokines O
produced O
by O
these O
cells O
. O

Using O
bacterial O
lipopolysaccharide B
( I
LPS I
) I
as O
a O
surrogate O
inducer O
of O
inflammatory O
cytokines O
in O
vivo O
, O
we O
have O
tested O
this O
hypothesis O
in O
a O
transgenic O
mouse O
model O
system O
. O

The O
intracellular O
mechanism O
( O
s O
) O
responsible O
for O
this O
effect O
and O
its O
pathophysiologic O
relevance O
remain O
to O
be O
elucidated O
. O

Dogs O
were O
vaccinated O
intradermally O
with O
vaccinia O
virus O
recombinants O
expressing O
the O
rabies O
virus O
glycoprotein O
( O
G O
protein O
) O
or O
nucleoprotein O
( O
N O
protein O
) O
or O
a O
combination O
of O
both O
proteins O
. O

Five O
( O
71 O
% O
) O
of O
seven O
dogs O
vaccinated O
with O
the O
N O
protein O
sickened O
, O
with O
incubation O
periods O
3 O
to O
7 O
days O
shorter O
than O
that O
of O
the O
control O
dogs O
; O
however O
, O
three O
( O
60 O
% O
) O
of O
the O
five O
rabid O
dogs O
recovered O
without O
supportive O
treatment O
. O

Thus O
, O
five O
( O
71 O
% O
) O
of O
seven O
vaccinated O
with O
the O
rabies O
N O
protein O
were O
protected O
against O
a O
street O
rabies O
challenge O
. O

To O
analyze O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
cytotoxic B
T I
- I
cell I
( I
CTL I
) I
response O
during O
acute O
and O
chronic O
viral O
hepatitis O
, O
target O
cells O
that O
express O
HBV O
- O
encoded O
antigens O
in O
the O
context O
of O
the O
appropriate O
HLA O
restriction O
element O
must O
be O
available O
for O
each O
subject O
studied O
. O

Transfectants O
that O
stably O
express O
the O
HBV O
nucleocapsid O
( O
core O
) O
antigen O
were O
found O
to O
serve O
as O
excellent O
targets O
for O
the O
detection O
of O
HLA O
class O
I O
- O
restricted O
CTL O
that O
recognize O
endogenously O
synthesized O
HBV O
core O
antigen O
in O
this O
patient O
; O
they O
were O
also O
successfully O
used O
to O
stimulate O
the O
specific O
expansion O
of O
these O
CTL O
in O
vitro O
. O

The O
pH O
dependency O
for O
initiation O
of O
infection O
by O
the O
hepadnavirus O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
was O
investigated O
in O
primary O
duck O
hepatocytes O
. O

The O
large O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
has O
been O
found O
to O
be O
essential O
for O
the O
assembly O
of O
the O
hepatitis O
delta O
virion O
. O

Furthermore O
, O
in O
a O
cotransfection O
experiment O
, O
the O
large O
HDAg O
itself O
, O
without O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
genome O
and O
small O
HDAg O
, O
could O
be O
packaged O
into O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
particles O
. O

We O
describe O
rapid O
and O
simple O
methods O
for O
fractionating O
these O
species O
on O
a O
small O
scale O
either O
with O
step O
gradients O
of O
10 O
to O
60 O
% O
( O
wt O
/ O
vol O
) O
sucrose O
or O
by O
centrifugation O
to O
pellet O
the O
particles O
, O
and O
we O
characterize O
the O
oocyte O
core O
particles O
. O

Sequencing O
of O
multiple O
recombinant O
clones O
generated O
from O
polymerase O
chain O
reaction O
- O
amplified O
products O
demonstrated O
that O
the O
degree O
of O
heterogeneity O
of O
two O
well O
- O
conserved O
regions O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
within O
individual O
plasma O
samples O
from O
a O
single O
patient O
was O
consistent O
with O
a O
quasispecies O
structure O
of O
HCV O
genomic O
RNA O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
satellite O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

We O
report O
that O
the O
HDV O
genomic O
RNA O
and O
the O
delta O
antigen O
can O
be O
packaged O
by O
coat O
proteins O
of O
either O
HBV O
or O
the O
related O
hepadnavirus O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

Our O
study O
provides O
evidence O
that O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
proteins O
can O
also O
be O
efficiently O
processed O
and O
presented O
by O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
to O
other O
T O
cells O
in O
a O
human O
leukocyte O
antigen O
class O
II O
- O
restricted O
fashion O
. O

hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
produced O
by O
recombinant O
DNA O
technology O
is O
now O
widely O
and O
safely O
used O
worldwide O
for O
hepatitis O
B O
vaccination O
. O

We O
used O
the O
HBsAg O
particle O
as O
a O
carrier O
molecule O
for O
presentation O
of O
selected O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
determinants O
to O
the O
immune O
system O
. O

First O
, O
to O
better O
characterize O
chronic O
infection O
, O
Pekin O
ducks O
, O
congenitally O
infected O
with O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
were O
used O
to O
asses O
age O
- O
dependent O
variations O
in O
viremia O
, O
percentage O
of O
DHBV O
- O
infected O
hepatocytes O
, O
and O
average O
levels O
of O
DNA O
replication O
intermediates O
in O
the O
cytoplasm O
and O
of O
covalently O
closed O
circular O
DNA O
in O
the O
nuclei O
of O
infected O
hepatocytes O
. O

The O
putative O
envelope O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
was O
expressed O
in O
insect O
cells O
by O
using O
a O
baculovirus O
expression O
vector O
and O
in O
monkey O
COS O
cells O
under O
the O
control O
of O
exogenous O
promoters O
. O

The O
expressed O
envelope O
proteins O
, O
identified O
by O
immunoblot O
analysis O
using O
sera O
from O
patients O
with O
chronic O
HCV O
infection O
, O
were O
a O
series O
of O
glycoproteins O
of O
35 O
to O
24 O
kDa O
( O
gp35 O
- O
24 O
) O
in O
insect O
cells O
and O
a O
single O
species O
of O
glycoprotein O
of O
35 O
kDa O
( O
gp35 O
) O
in O
monkey O
cells O
. O

The O
results O
showed O
that O
( O
i O
) O
the O
antibody O
is O
detected O
in O
2 O
to O
17 O
% O
of O
various O
patients O
with O
hepatitis O
C O
, O
( O
ii O
) O
three O
patients O
were O
apparently O
cured O
after O
acquiring O
the O
antienvelope O
antibody O
, O
and O
( O
iii O
) O
in O
sera O
of O
patients O
with O
more O
than O
a O
20 O
- O
year O
history O
of O
infection O
, O
the O
antibody O
sometimes O
coexisted O
with O
HCV O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
is O
the O
only O
protein O
encoded O
by O
hepatitis B
delta I
virus I
( I
HDV I
) I
. O

By O
expressing O
fusion O
proteins O
consisting O
of O
the O
different O
portions O
of O
HDAg O
and O
alpha O
- O
globin O
, O
we O
have O
identified O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
within O
the O
N O
- O
terminal O
one O
- O
third O
of O
HDAg O
. O

A O
diverse O
group O
of O
extra O
- O
and O
intracellular O
agents O
, O
including O
growth O
factors O
and O
the O
human O
immunodeficiency O
virus O
tat O
protein O
, O
have O
been O
shown O
to O
require O
a O
functional O
protein B
kinase I
C I
( I
PKC I
) I
system O
to O
achieve O
activation O
of O
NF O
- O
kappa O
- O
B O
. O

In O
this O
study O
, O
we O
show O
that O
CD4 O
+ O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
- O
specific O
T O
- O
cell O
clones O
produced O
by O
stimulation O
with O
a O
particulate O
antigen O
preparation O
are O
able O
to O
recognize O
and O
kill O
not O
only O
autologous O
antigen O
- O
presenting O
cells O
incubated O
with O
exogenous O
HBV O
envelope O
antigens O
but O
also O
autologous O
HLA O
class O
II O
- O
positive O
cells O
expressing O
endogenously O
synthesized O
HBV O
envelope O
antigens O
following O
infection O
with O
recombinant O
vaccinia O
viruses O
or O
transfection O
with O
recombinant O
Epstein O
- O
Barr O
virus O
expression O
vectors O
. O

The O
hepatitis B
B I
x I
( I
HBx I
) I
gene O
is O
the O
smallest O
open O
reading O
frame O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
. O

While O
the O
HBx O
protein O
( O
pX O
) O
has O
been O
shown O
to O
trans O
- O
activate O
the O
transcription O
of O
a O
wide O
range O
of O
viral O
and O
cellular O
genes O
and O
to O
induce O
liver O
cancer O
in O
transgenic O
mice O
, O
the O
significance O
of O
pX O
for O
the O
life O
cycle O
of O
HBV O
itself O
has O
not O
been O
elucidated O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
particles O
were O
produced O
in O
Huh7 O
human O
hepatoma O
cells O
by O
transfection O
with O
cloned O
hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
and O
HDV O
cDNA O
. O

These O
data O
demonstrate O
that O
HDV O
particles O
produced O
in O
vitro O
are O
infectious O
and O
indicate O
( O
i O
) O
that O
infectious O
particles O
are O
coated O
with O
HBV O
envelope O
proteins O
that O
contain O
the O
pre O
- O
S1 O
and O
pre O
- O
S2 O
regions O
, O
( O
ii O
) O
that O
epitopes O
of O
the O
pre O
- O
S1 O
and O
pre O
- O
S2 O
domains O
of O
HBV O
envelope O
proteins O
are O
exposed O
at O
the O
surface O
of O
HDV O
particles O
, O
and O
( O
iii O
) O
that O
antibodies O
directed O
against O
those O
epitopes O
have O
neutralizing O
activity O
against O
HDV O
. O

A O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
genome O
cloned O
from O
a O
domestic O
duck O
from O
the O
People O
' O
s O
Republic O
of O
China O
has O
been O
sequenced O
and O
exhibits O
no O
variation O
in O
sequences O
known O
to O
be O
important O
in O
viral O
replication O
or O
generation O
of O
gene O
products O
. O

Using O
genetic O
approaches O
, O
it O
was O
determined O
that O
a O
change O
of O
cysteine O
to O
tyrosine O
in O
position O
711 O
in O
the O
polymerase B
( I
P I
) I
gene O
C O
terminus O
led O
to O
this O
RNA O
- O
packaging O
defect O
. O

We O
have O
analyzed O
the O
translocation O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
precore I
( I
PC I
) I
proteins O
by O
using O
Xenopus O
oocytes O
injected O
with O
a O
synthetic O
PC O
mRNA O
. O

5 O
- O
kDa O
HBV O
capsid O
or O
core B
( I
C I
) I
protein O
( O
p21 O
. O

Protease O
protection O
and O
membrane O
cosedimentation O
experiments O
reveal O
that O
all O
PC O
proteins O
behave O
as O
expected O
for O
proteins O
that O
are O
translocated O
into O
the O
lumen O
of O
the O
endoplasmic O
reticulum O
except O
for O
the O
single O
largest O
PC O
protein O
( O
p25 O
) O
, O
which O
is O
not O
translocated O
. O

Recently O
, O
the O
simian B
virus I
40 I
( I
SV40 I
) I
17 O
- O
kDa O
small O
- O
t O
antigen O
was O
shown O
to O
stimulate O
transcription O
of O
polymerase O
II O
and O
III O
genes O
in O
transient O
transfection O
assays O
. O

For O
the O
second O
approach O
, O
a O
recombinant O
adenovirus O
was O
constructed O
in O
which O
small O
- O
t O
was O
expressed O
from O
a O
replication O
origin O
- O
negative O
SV40 O
early O
promoter O
in O
the O
EIA O
region O
of O
an O
adenovirus B
vector I
( I
Ad I
- I
SV I
- I
t I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
has O
an O
envelope O
composed O
of O
large O
- O
, O
middle O
- O
, O
and O
small O
- O
form O
hepatitis B
B I
surface I
antigens I
( I
HBsAgs I
) I
provided O
by O
the O
helper O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

In O
order O
to O
examine O
the O
roles O
of O
individual O
HBsAgs O
in O
HDV O
assembly O
, O
we O
constructed O
plasmids O
containing O
each O
specific O
HBsAg O
gene O
and O
then O
cotransfected O
each O
plasmid O
with O
HDV O
cDNA O
into O
a O
permissive O
Human B
Hepatoma I
Cell I
line I
( I
Huh I
- I
7 I
) I
to O
examine O
the O
effects O
on O
HDV O
production O
. O

The O
discovery O
that O
hepatitis O
B O
' O
virus O
( O
HBV O
) O
integrates O
into O
host O
chromosomes O
raises O
the O
question O
of O
whether O
such O
viral O
DNA O
integration O
correlates O
directly O
with O
the O
activation O
of O
specific O
oncogenes O
or O
the O
inactivation O
of O
anti O
- O
oncogenes O
. O

Here O
we O
examined O
whether O
this O
sequence O
is O
important O
only O
for O
translocation O
of O
the O
HBe O
precursor O
( O
the O
precore O
protein O
) O
or O
whether O
it O
also O
contributes O
to O
the O
structural O
and O
biophysical O
properties O
of O
the O
mature O
HBe O
protein O
. O

When O
the O
authentic O
signal O
sequence O
of O
the O
precore O
protein O
( O
the O
pre O
- O
C O
sequence O
) O
was O
replaced O
by O
the O
unrelated O
signal O
sequence O
of O
an O
influenza O
virus O
hemagglutinin O
, O
not O
only O
the O
full O
- O
length O
but O
also O
the O
C O
- O
terminally O
truncated O
protein O
was O
expressed O
and O
secreted O
with O
high O
efficiency O
. O

Western O
blot O
( O
immunoblot O
) O
analyses O
with O
nonreducing O
gels O
and O
conformation O
- O
specific O
monoclonal O
antibodies O
revealed O
that O
the O
HBe O
protein O
secreted O
under O
control O
of O
the O
pre O
- O
C O
signal O
sequence O
was O
a O
monomer O
with O
HBe O
antigenicity O
, O
whereas O
the O
HBe O
- O
like O
protein O
secreted O
under O
control O
of O
the O
hemagglutinin O
signal O
sequence O
was O
a O
disulfide O
- O
bridge O
- O
linked O
dimer O
with O
both O
HBe O
and O
HBc O
antigenicity O
. O

The O
regulatory O
elements O
involved O
in O
transcription O
of O
the O
C O
gene O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
were O
investigated O
. O

Several O
DHBV O
DNA O
fragments O
were O
assayed O
for O
C O
gene O
promoter O
, O
enhancer O
, O
and O
silencer O
activity O
by O
using O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
and O
transfection O
of O
established O
liver O
and O
nonliver O
cell O
lines O
. O

The O
cloned O
transcription O
factor O
hepatocyte B
nuclear I
factor I
1 I
( I
HNF1 I
) I
transactivates O
transcription O
from O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
large O
surface O
antigen O
promoter O
but O
does O
not O
influence O
the O
transcriptional O
activities O
of O
the O
other O
three O
HBV O
promoters O
. O

1 O
has O
been O
mapped O
to O
a O
region O
that O
is O
rich O
in O
glutamine O
and O
proline O
residues O
( O
9 O
of O
18 O
) O
and O
is O
different O
from O
the O
previously O
identified O
regions O
of O
this O
factor O
responsible O
for O
in O
vitro O
transcriptional O
activation O
of O
a O
promoter O
containing O
human O
albumin O
promoter O
HNF1 O
binding O
sites O
. O

Large O
epidemic O
outbreaks O
of O
enterically O
transmitted O
non O
- O
A O
, O
non O
- O
B O
viral O
hepatitis O
( O
ET O
- O
NANBH O
) O
have O
been O
documented O
in O
developing O
countries O
. O

A O
molecular O
clone O
derived O
from O
the O
causative O
agent O
, O
the O
hepatitis B
E I
virus I
( I
HEV I
) I
, O
has O
recently O
been O
described O
( O
G O
. O

When O
compared O
with O
the O
available O
full O
- O
length O
sequence O
of O
the O
Burma O
strain O
of O
HEV O
, O
it O
was O
discovered O
that O
the O
cDNA O
clones O
were O
encoded O
in O
different O
open B
reading I
frames I
( I
ORFs I
) I
. O

The O
capsid O
protein O
of O
hepatitis O
B O
virus O
( O
p21c O
) O
is O
made O
of O
183 O
amino O
acids O
coded O
for O
by O
the O
C O
gene O
. O

By O
using O
p21c O
isolated O
from O
Dane O
particles O
( O
hepatitis O
B O
virus O
) O
as O
an O
immunogen O
, O
a O
monoclonal O
antibody O
( O
no O
. O

2212 O
antibody O
bound O
to O
p21c O
from O
core O
particles O
derived O
from O
Dane O
particles O
or O
hepatocellular O
carcinoma O
tissues O
( O
PLC O
/ O
342 O
) O
propagated O
in O
nude O
mice O
but O
did O
not O
bind O
to O
p21c O
from O
core O
particles O
expressed O
in O
Escherichia O
coli O
or O
yeast O
cells O
, O
indicating O
different O
states O
of O
phosphorylation O
in O
them O
. O

Since O
the O
serum O
from O
an O
asymptomatic O
carrier O
, O
with O
a O
high O
titer O
for O
antibody O
to O
hepatitis O
B O
core O
antigen O
, O
specifically O
bound O
to O
phosphorylated O
undecapeptide O
( O
amino O
acids O
165 O
to O
175 O
) O
, O
the O
epitope O
would O
stimulate O
humoral O
antibody O
responses O
in O
the O
human O
host O
. O

The O
location O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
nucleocapsid O
( O
core O
particle O
) O
assembly O
in O
infected O
cells O
remains O
controversial O
. O

We O
show O
that O
anucleate O
oocytes O
support O
efficient O
core O
particle O
formation O
, O
indicating O
that O
( O
i O
) O
the O
nucleus O
is O
not O
essential O
for O
assembly O
and O
( O
ii O
) O
the O
cytoplasm O
can O
assemble O
most O
core O
particles O
found O
in O
oocytes O
. O

On O
the O
basis O
of O
our O
data O
, O
we O
propose O
that O
in O
oocytes O
, O
most O
core O
particle O
assembly O
( O
up O
to O
95 O
% O
) O
occurs O
in O
the O
cytoplasm O
, O
but O
that O
at O
least O
approximately O
5 O
% O
of O
the O
cellular O
core O
particles O
are O
assembled O
in O
the O
nucleus O
and O
remain O
there O
. O

We O
constructed O
A B
- I
type I
inclusion I
body I
( I
ATI I
) I
hybrid O
promoters O
, O
that O
is O
, O
late O
ATI O
promoters O
followed O
by O
tandemly O
repeated O
early O
regions O
of O
the O
promoter O
for O
the O
7 O
. O

The O
identity O
of O
the O
trans O
- O
acting O
factor O
encoded O
by O
the O
1 O
, O
828 O
- O
bp O
BamHI O
DNA O
fragment O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
that O
suppresses O
the O
transcription O
of O
the O
human O
beta O
interferon O
gene O
was O
investigated O
. O

Each O
complete O
and O
partial O
open B
reading I
frame I
( I
ORF I
) I
present O
within O
the O
1 O
, O
828 O
- O
bp O
BamHI O
HBV O
DNA O
fragment O
was O
cloned O
into O
a O
simian O
virus O
40 O
expression O
vector O
, O
and O
the O
resulting O
gene O
products O
were O
assayed O
for O
their O
ability O
to O
inhibit O
the O
activity O
of O
the O
regulatory O
DNA O
region O
that O
governs O
the O
expression O
of O
the O
beta O
interferon O
gene O
. O

Seven O
regions O
( O
A O
to O
G O
) O
of O
the O
major O
surface O
antigen O
promoter O
located O
within O
200 O
nucleotides O
of O
the O
RNA O
initiation O
site O
have O
been O
identified O
which O
influence O
the O
level O
of O
transcription O
from O
this O
promoter O
. O

The O
three O
distal O
regions O
( O
A O
to O
C O
) O
, O
located O
between O
- O
188 O
and O
- O
68 O
, O
appear O
to O
possess O
a O
level O
of O
redundancy O
in O
their O
ability O
to O
influence O
the O
transcriptional O
activity O
from O
the O
major O
surface O
antigen O
promoter O
. O

The O
three O
proximal O
regions O
( O
E O
to O
G O
) O
are O
located O
within O
45 O
nucleotides O
of O
the O
major O
transcription O
initiation O
site O
. O

The O
first O
proteolytic O
event O
removes O
the O
signal O
peptide O
and O
results O
in O
the O
translocation O
of O
the O
precursor O
protein O
, O
P22 O
, O
into O
the O
lumen O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

For O
identification O
and O
characterization O
of O
3 O
' O
ends O
of O
X O
gene O
open B
reading I
frame I
( I
ORF I
) I
- O
related O
transcripts O
, O
RNA O
was O
reverse O
transcribed O
into O
cDNA O
and O
subjected O
to O
polymerase O
chain O
reaction O
. O

Cloned O
amplification O
products O
from O
tumor O
tissue O
of O
one O
patient O
represented O
an O
approximately O
even O
distribution O
of O
transcripts O
terminating O
at O
the O
established O
poly O
( O
A O
) O
signal O
( O
standard O
transcripts O
) O
and O
of O
truncated O
transcripts O
terminating O
at O
a O
CATAAA O
poly O
( O
A O
) O
signal O
within O
the O
3 O
' O
end O
region O
of O
X O
gene O
ORF O
( O
truncated O
transcripts O
) O
. O

Amplified O
cDNA O
from O
tumor O
tissue O
of O
the O
second O
patient O
could O
be O
attributed O
mainly O
to O
the O
standard O
type O
of O
transcripts O
, O
whereas O
cDNA O
from O
the O
nontumor O
tissue O
of O
the O
same O
patient O
could O
be O
assigned O
to O
four O
groups O
of O
transcripts O
: O
( O
i O
) O
standard O
transcripts O
, O
( O
ii O
) O
transcripts O
with O
internal O
deletions O
affecting O
the O
3 O
' O
end O
of O
the O
X O
gene O
, O
( O
iii O
) O
truncated O
transcripts O
, O
and O
( O
iv O
) O
hybrid O
transcripts O
displaying O
5 O
' O
sequences O
from O
the O
X O
gene O
ORF O
fused O
to O
cellular O
sequences O
. O

An O
in O
vitro O
culture O
system O
was O
developed O
for O
assaying O
the O
infectivity O
of O
the O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
. O

When O
repeated O
experiments O
were O
carried O
out O
on O
cells O
derived O
from O
an O
animal O
free O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
HDV O
infection O
occurred O
in O
a O
consistent O
fashion O
but O
there O
was O
no O
indication O
of O
infection O
with O
the O
HBV O
that O
was O
present O
in O
the O
inoculum O
. O

The O
biosynthesis O
of O
the O
secretory O
core O
gene O
product O
of O
the O
duck O
hepatitis O
B O
virus O
( O
DHBe O
protein O
) O
was O
examined O
. O

Recombinant O
vaccinia O
viruses O
were O
constructed O
encoding O
either O
the O
full O
- O
length O
or O
C O
- O
terminally O
truncated O
forms O
of O
the O
DHBe O
precursor O
protein O
( O
precore O
protein O
) O
and O
used O
to O
express O
these O
proteins O
in O
the O
human O
hepatoma O
cell O
line O
HepG2 O
. O

In O
addition O
, O
there O
are O
two O
other O
related O
proteins O
( O
large O
S O
and O
middle O
S O
) O
, O
but O
their O
role O
in O
envelope O
formation O
has O
not O
yet O
been O
elucidated O
. O

We O
have O
shown O
, O
by O
analyzing O
serial O
serum O
samples O
from O
a O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
carrier O
, O
the O
emergence O
of O
HBV O
DNA O
molecules O
with O
nucleotide O
rearrangements O
in O
the O
pre O
- O
S O
/ O
S O
and O
pre O
- O
C O
/ O
C O
genes O
. O

Serum O
samples O
were O
obtained O
at O
four O
different O
times O
( O
1983 O
, O
1985 O
, O
1988 O
, O
and O
1989 O
) O
from O
an O
HBsAg O
- O
and O
HBeAg O
- O
positive O
carrier O
with O
chronic O
hepatitis O
. O

We O
characterized O
11 O
DNA O
polymerase O
mutants O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
which O
contain O
single O
missense O
or O
nonsense O
mutations O
in O
the O
various O
domains O
within O
this O
gene O
. O

The O
regulatory O
immediate B
- I
early I
( I
IE I
) I
protein O
pp89 O
of O
murine O
cytomegalovirus O
induces O
CD8 O
+ O
T O
lymphocytes O
that O
protect O
against O
lethal O
murine O
cytomegalovirus O
infection O
. O

The O
IE1 O
epitope O
is O
the O
only O
epitope O
of O
pp89 O
that O
is O
recognized O
by O
BALB O
/ O
c O
cytolytic B
T I
lymphocytes I
( I
CTL I
) I
. O

In O
infected O
cells O
expressing O
the O
chimeric O
proteins O
, O
only O
IE1 O
epitope O
sequences O
that O
were O
recognized O
as O
synthetic O
peptides O
at O
concentrations O
lower O
than O
10 O
( O
- O
6 O
) O
M O
were O
presented O
to O
CTL O
. O

Cells O
infected O
with O
hepatitis O
B O
virus O
produce O
both O
virions O
and O
20 O
- O
nm O
subviral O
( O
surface O
antigen O
or O
HBsAg O
) O
particles O
; O
the O
latter O
are O
composed O
of O
viral O
envelope O
proteins O
and O
host O
- O
derived O
lipid O
. O

Although O
hepatitis O
B O
virus O
encodes O
three O
envelope O
proteins O
( O
L O
, O
M O
, O
and O
S O
) O
, O
all O
of O
the O
information O
required O
to O
produce O
an O
HBsAg O
particle O
resides O
within O
the O
S O
protein O
. O

Lesions O
in O
the O
N O
terminal O
signal O
sequence O
( O
signal O
I O
) O
can O
still O
insert O
into O
the O
endoplasmic O
reticulum O
bilayer O
but O
do O
not O
participate O
in O
any O
of O
the O
subsequent O
steps O
in O
assembly O
. O

Deletion O
of O
the O
major O
internal O
signal O
( O
signal O
II O
) O
completely O
destabilizes O
the O
chain O
. O

The O
correct O
transmembrane O
disposition O
of O
the O
N O
terminus O
of O
the O
molecule O
is O
important O
for O
particle O
formation O
: O
addition O
of O
a O
heterologous O
( O
globin O
) O
domain O
to O
this O
region O
impairs O
secretion O
, O
but O
the O
defect O
can O
be O
corrected O
by O
provision O
of O
an O
N O
- O
terminal O
signal O
sequence O
that O
restores O
the O
proper O
topology O
of O
this O
region O
. O

The O
genome O
of O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
contains O
an O
enhancer O
element O
. O

This O
sequence O
, O
of O
192 O
bp O
, O
is O
located O
in O
the O
3 O
' O
- O
terminal O
coding O
region O
of O
the O
DNA O
polymerase O
gene O
( O
nucleotides O
2159 O
to O
2351 O
) O
, O
upstream O
from O
the O
pregenomic O
RNA O
start O
site O
. O

We O
present O
evidence O
to O
demonstrate O
that O
the O
HBc O
antigen O
formed O
oligomers O
through O
disulfide O
linkages O
in O
the O
extracellular O
hepatitis B
B I
virus I
core I
( I
HBc I
) I
particles O
. O

A O
structural O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
was O
expressed O
in O
monkey O
COS O
cells O
under O
the O
control O
of O
an O
exogenous O
promoter O
, O
and O
a O
protein O
of O
22 O
kDa O
was O
identified O
by O
immunoblot O
analysis O
. O

This O
protein O
( O
p22 O
) O
, O
which O
was O
produced O
by O
processing O
in O
COS O
cells O
, O
reacted O
specifically O
to O
sera O
of O
chronic O
hepatitis O
C O
patients O
, O
and O
its O
coding O
region O
was O
mapped O
at O
the O
most O
amino O
- O
terminal O
part O
of O
the O
HCV O
polyprotein O
. O

These O
results O
suggested O
that O
the O
p22 O
protein O
is O
the O
nucleocapsid O
( O
core O
) O
protein O
of O
HCV O
. O

To O
define O
the O
cis O
- O
acting O
sequences O
required O
for O
pregenome O
encapsidation O
in O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
, O
we O
assayed O
the O
packaging O
efficiency O
of O
a O
series O
of O
pregenomic O
RNA O
deletion O
mutants O
and O
hybrid O
DHBV O
/ O
lacZ O
fusion O
transcripts O
. O

To O
define O
the O
3 O
' O
boundary O
of O
the O
encapsidation O
signal O
, O
fusion O
transcripts O
bearing O
foreign O
( O
lacZ O
) O
sequences O
fused O
to O
DHBV O
at O
different O
sites O
3 O
' O
to O
the O
pregenomic O
RNA O
start O
site O
were O
examined O
. O

However O
, O
at O
least O
one O
mutant O
( O
pH1093 O
+ O
2 O
) O
, O
which O
was O
ca O
. O

The O
hepatitis O
B O
virus O
X O
protein O
( O
pX O
) O
trans O
activates O
transcription O
of O
a O
wide O
variety O
of O
viral O
and O
cellular O
genes O
, O
apparently O
by O
interacting O
with O
multiple O
cellular O
transcription O
factors O
. O

It O
has O
been O
shown O
previously O
that O
the O
simian O
virus O
40 O
early O
- O
region O
gene O
products O
( O
large O
- O
T O
and O
small O
- O
t O
antigens O
) O
prevent O
trans O
activation O
by O
pX O
. O

We O
have O
mapped O
a O
set O
of O
preferred O
topoisomerase B
I I
( I
Topo I
I I
) I
cleavage O
sites O
in O
the O
region O
of O
DR1 O
on O
plus O
- O
strand O
DNA O
and O
in O
the O
cohesive O
overlap O
near O
DR2 O
and O
have O
tested O
whether O
Topo O
I O
is O
capable O
of O
mediating O
illegitimate O
recombination O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
DNA O
with O
cellular O
DNA O
by O
developing O
an O
in O
vitro O
assay O
for O
Topo O
I O
- O
mediated O
linking O
. O

Mutations O
introduced O
into O
the O
capsid O
gene O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
were O
tested O
for O
their O
effects O
on O
viral O
DNA O
synthesis O
and O
assembly O
of O
enveloped O
viruses O
. O

Chronic O
infection O
with O
hepatitis O
B O
viruses O
( O
hepadnaviruses O
) O
is O
a O
major O
cause O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
, O
but O
the O
incubation O
time O
varies O
from O
1 O
to O
2 O
years O
to O
several O
decades O
in O
different O
host O
species O
infected O
with O
indigenous O
viruses O
. O

To O
discern O
the O
influence O
of O
viral O
and O
host O
factors O
on O
the O
kinetics O
of O
induction O
of O
HCC O
, O
we O
exploited O
the O
recent O
observation O
that O
ground B
squirrel I
hepatitis I
virus I
( I
GSHV I
) I
is O
infectious O
in O
woodchucks O
( O
C O
. O

61 O
: O
3241 O
- O
3247 O
, O
1987 O
) O
to O
compare O
the O
pathogenic O
potential O
of O
GSHV O
and O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
in O
chronically O
infected O
woodchucks O
. O

The O
transcriptional O
map O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
has O
been O
expanded O
recently O
by O
the O
discovery O
of O
a O
singly O
spliced O
transcript O
in O
hepatoma O
cell O
lines O
transfected O
with O
cloned O
viral O
DNA O
and O
a O
doubly O
spliced O
one O
in O
naturally O
infected O
human O
liver O
tissues O
. O

A O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
was O
cloned O
from O
human O
liver O
. O

The O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
defective O
virus O
with O
a O
coat O
composing O
of O
the O
surface O
antigen O
of O
its O
helper O
virus O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
causative O
agent O
of O
posttransfusion O
non O
- O
A O
, O
non O
- O
B O
hepatitis O
, O
which O
often O
develops O
into O
malignant O
chronic O
diseases O
, O
including O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

We O
have O
cloned O
from O
human O
carriers O
overlapping O
cDNAs O
( O
9 O
, O
416 O
bp O
) O
covering O
the O
entire O
coding O
region O
of O
the O
HCV O
genome O
. O

The O
initial O
product O
of O
reverse O
transcription O
, O
minus O
- O
strand O
DNA O
, O
contains O
two O
copies O
of O
a O
short O
direct O
repeat O
( O
DR O
) O
sequence O
, O
termed O
DR1 O
and O
DR2 O
. O

These O
results O
indicate O
that O
( O
i O
) O
plus O
- O
strand O
primer O
cleavage O
and O
translocation O
are O
distinct O
steps O
that O
can O
be O
dissociated O
by O
mutation O
, O
( O
ii O
) O
lesions O
in O
sequences O
not O
included O
in O
the O
primer O
can O
severely O
inhibit O
primer O
translocation O
, O
and O
( O
iii O
) O
elongation O
of O
such O
untranslocated O
primers O
is O
responsible O
for O
the O
variable O
quantities O
of O
linear O
DNA O
that O
are O
found O
in O
all O
hepadnaviral O
stocks O
. O

Mutants O
defective O
in O
the O
pre O
- O
S O
/ O
S O
protein O
accumulated O
high O
levels O
of O
covalently B
closed I
circular I
viral I
DNA I
( I
cccDNA I
) I
compared O
with O
the O
wild O
type O
or O
with O
a O
mutant O
defective O
in O
only O
the O
S O
protein O
. O

Expression O
of O
the O
hepatitis B
B I
virus I
core I
antigen I
( I
HBcAg I
) I
in O
mouse O
NIH O
3T3 O
fibroblasts O
has O
been O
shown O
previously O
( O
A O
. O

By O
immunofluorescence O
and O
cell O
fractionation O
analysis O
, O
it O
was O
demonstrated O
that O
regions O
of O
the O
HBcAg O
polypeptide O
including O
the O
most O
carboxyl O
- O
terminal O
( O
cluster O
1 O
) O
and O
amino O
- O
terminal O
( O
cluster O
4 O
) O
clusters O
of O
arginine O
residues O
represent O
distinct O
and O
independent O
nuclear O
localization O
sequences O
for O
this O
polypeptide O
. O

By O
the O
end O
of O
the O
2016 O
Zika B
virus I
( I
ZIKV I
) I
outbreak O
, O
it O
is O
estimated O
that O
there O
were O
up O
to O
100 O
million O
infections O
in O
the O
Americas O
. O

The O
recent O
reemergence O
of O
yellow B
fever I
virus I
( I
YFV I
) I
in O
Brazil O
has O
raised O
serious O
concerns O
due O
to O
the O
rapid O
dissemination O
of O
the O
virus O
in O
the O
southeastern O
region O
. O

To O
better O
understand O
YFV O
genetic O
diversity O
and O
dynamics O
during O
the O
recent O
outbreak O
in O
southeastern O
Brazil O
, O
we O
generated O
18 O
complete O
and O
nearly O
complete O
genomes O
from O
the O
peak O
of O
the O
epidemic O
curve O
from O
nonhuman B
primates I
( I
NHPs I
) I
and O
human O
infected O
cases O
across O
the O
Espirito O
Santo O
and O
Rio O
de O
Janeiro O
states O
. O

The O
Zika B
virus I
( I
ZIKV I
) I
life O
cycle O
involves O
multiple O
steps O
and O
requires O
interactions O
with O
host O
factors O
. O

Among O
the O
hits O
, O
URMC O
- O
099 O
, O
a O
mixed B
- I
lineage I
kinase I
3 I
( I
MLK3 I
) I
inhibitor O
, O
significantly O
facilitated O
ZIKV O
replication O
in O
both O
SNB O
- O
19 O
cells O
and O
the O
neonatal O
mouse O
brain O
. O

Mechanistically O
, O
MLK3 O
negatively O
regulated O
ZIKV O
replication O
through O
induction O
of O
the O
inflammatory O
cytokines O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
IL O
- O
8 O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
and O
monocyte B
chemoattractant I
protein I
1 I
( I
MCP I
- I
1 I
) I
but O
did O
not O
modulate O
host O
interferon O
- O
related O
pathways O
. O

Importantly O
, O
ZIKV O
activated O
the O
MLK3 O
/ O
MKK7 O
/ O
Jun B
N I
- I
terminal I
protein I
kinase I
( I
JNK I
) I
pathway O
in O
both O
SNB O
- O
19 O
cells O
and O
neonatal O
mouse O
brain O
. O

IMPORTANCE O
Zika O
fever O
, O
an O
infectious O
disease O
caused O
by O
the O
Zika B
virus I
( I
ZIKV I
) I
, O
normally O
results O
in O
mild O
symptoms O
. O

The O
recent O
yellow B
fever I
virus I
( I
YFV I
) I
epidemic O
in O
Brazil O
in O
2017 O
and O
Zika B
virus I
( I
ZIKV I
) I
epidemic O
in O
2015 O
serve O
to O
remind O
us O
of O
the O
importance O
of O
flaviviruses O
as O
emerging O
human O
pathogens O
. O

A O
common O
trait O
of O
all O
flaviviruses O
studied O
thus O
far O
is O
their O
ability O
to O
antagonize O
interferon B
( I
IFN I
) I
signaling O
so O
as O
to O
enhance O
viral O
replication O
and O
dissemination O
. O

Previously O
, O
we O
reported O
that O
YFV O
NS5 O
requires O
the O
presence O
of O
type O
I O
IFN O
( O
IFN O
- O
alpha O
/ O
beta O
) O
for O
its O
engagement O
with O
human O
signal O
transducer O
and O
activator O
of O
transcription O
2 O
( O
hSTAT2 O
) O
. O

In O
this O
manuscript O
, O
we O
report O
that O
like O
the O
NS5 O
proteins O
of O
ZIKV O
and O
Dengue B
Virus I
( I
DENV I
) I
, O
YFV O
NS5 O
protein O
is O
able O
to O
bind O
hSTAT2 O
but O
not O
murine B
STAT2 I
( I
mSTAT2 I
) I
. O

IMPORTANCE O
Flaviviruses O
such O
as O
yellow B
fever I
virus I
( I
YFV I
) I
, O
Zika B
virus I
( I
ZIKV I
) I
, O
and O
Dengue B
Virus I
( I
DENV I
) I
are O
important O
human O
pathogens O
. O

A O
common O
flavivirus O
trait O
is O
the O
antagonism O
of O
interferon B
( I
IFN I
) I
signaling O
to O
enhance O
viral O
replication O
and O
spread O
. O

We O
report O
that O
like O
ZIKV O
NS5 O
and O
DENV O
NS5 O
, O
YFV O
NS5 O
binds O
human B
STAT2 I
( I
hSTAT2 I
) I
but O
not O
mouse B
STAT2 I
( I
mSTAT2 I
) I
, O
a O
type O
I O
IFN O
( O
IFN O
- O
alpha O
/ O
beta O
) O
pathway O
component O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
a O
mosquito O
- O
borne O
virus O
of O
the O
family O
Flaviviridae O
. O

nonstructural B
protein I
1 I
( I
NS1 I
) I
is O
a O
multifunctional O
protein O
actively O
secreted O
in O
vertebrate O
and O
mosquito O
cells O
during O
infection O
. O

The O
caveolin B
chaperone I
complex I
( I
CCC I
) I
is O
a O
cytoplasmic O
complex O
formed O
by O
caveolin O
- O
1 O
and O
the O
chaperones O
FKBP52 O
, O
Cy40 O
, O
and O
CyA O
and O
is O
responsible O
for O
the O
cholesterol O
traffic O
inside O
the O
cell O
. O

Insect B
- I
specific I
viruses I
( I
ISVs I
) I
of O
the O
yellow O
fever O
mosquito O
Aedes O
aegypti O
have O
been O
demonstrated O
to O
modulate O
transmission O
of O
arboviruses O
such O
as O
Dengue B
Virus I
( I
DENV I
) I
and O
West O
Nile O
virus O
by O
the O
mosquito O
. O

In O
this O
study O
, O
we O
characterized O
Aedes B
anphevirus I
( I
AeAV I
) I
, O
a O
negative O
- O
sense O
RNA O
virus O
from O
the O
order O
Mononegavirales O
. O

To O
understand O
the O
incidence O
and O
genetic O
diversity O
of O
AeAV O
, O
we O
assembled O
17 O
coding O
- O
complete O
and O
two O
partial O
genomes O
of O
AeAV O
from O
available O
transcriptome O
sequencing O
( O
RNA O
- O
Seq O
) O
data O
. O

aegypti O
cells O
coinfected O
with O
AeAV O
and O
Wolbachia O
produces O
an O
abundant O
RNA B
interference I
( I
RNAi I
) I
response O
consistent O
with O
persistent O
virus O
replication O
. O

IMPORTANCE O
The O
mosquito O
Aedes O
aegypti O
transmits O
a O
number O
of O
arthropod O
- O
borne O
viruses O
( O
arboviruses O
) O
, O
such O
as O
dengue O
virus O
and O
Zika O
virus O
. O

The O
mosquito O
- O
transmitted O
Dengue B
Virus I
( I
DENV I
) I
infects O
millions O
of O
people O
in O
tropical O
and O
subtropical O
regions O
. O

9 O
mu O
M O
against O
DENV3 O
wild B
- I
type I
( I
WT I
) I
protease O
. O

The O
Flavivirus O
genus O
contains O
several O
arthropod O
- O
borne O
viruses O
that O
pose O
global O
health O
threats O
, O
including O
Dengue B
viruses I
( I
DENV I
) I
, O
yellow B
fever I
virus I
( I
YFV I
) I
, O
and O
Zika B
virus I
( I
ZIKV I
) I
. O

In O
these O
screens O
, O
we O
identified O
ribosomal O
proteins O
RPLP1 B
and I
RPLP2 I
( I
RPLP1 I
/ I
2 I
) I
to O
be O
among O
the O
most O
crucial O
putative O
host O
factors O
required O
for O
DENV O
and O
YFV O
infection O
. O

We O
identified O
two O
specific O
ribosomal O
proteins O
that O
are O
strictly O
required O
for O
flavivirus O
infection O
of O
human O
cells O
and O
mosquitoes O
: O
RPLP1 B
and I
RPLP2 I
( I
RPLP1 I
/ I
2 I
) I
. O

Dengue B
Virus I
( I
DENV I
) I
infects O
millions O
of O
people O
worldwide O
and O
is O
a O
major O
public O
health O
problem O
. O

DENV O
nonstructural B
protein I
1 I
( I
NS1 I
) I
is O
a O
conserved O
glycoprotein O
that O
associates O
with O
membranes O
and O
is O
also O
secreted O
into O
the O
plasma O
in O
DENV O
- O
infected O
patients O
. O

We O
first O
identified O
the O
terminal O
complement O
regulator O
vitronectin B
( I
VN I
) I
as O
a O
novel O
DENV2 O
NS1 O
binding O
partner O
by O
using O
a O
yeast O
two O
- O
hybrid O
system O
. O

This O
interaction O
was O
further O
assessed O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
and O
surface B
plasmon I
resonance I
( I
SPR I
) I
assay O
. O

We O
also O
demonstrated O
that O
the O
DENV2 O
NS1 O
protein O
, O
either O
by O
itself O
or O
by O
interacting O
with O
VN O
, O
hinders O
the O
formation O
of O
the O
membrane B
attack I
complex I
( I
MAC I
) I
and O
C9 O
polymerization O
. O

Finally O
, O
we O
showed O
that O
DENV2 O
, O
West B
Nile I
virus I
( I
WNV I
) I
, O
and O
Zika B
virus I
( I
ZIKV I
) I
NS1 O
proteins O
produced O
in O
mammalian O
cells O
inhibited O
C9 O
polymerization O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
a O
highly O
lethal O
pneumonia O
that O
emerged O
in O
2012 O
. O

Human B
dipeptidyl I
peptidase I
4 I
knock I
- I
in I
( I
hDPP4 I
- I
KI I
) I
mice O
and O
a O
mouse O
- O
adapted O
MERS O
- O
CoV O
strain O
( O
MERSMA O
- O
6 O
- O
1 O
- O
2 O
) O
were O
recently O
described O
. O

In O
this O
work O
, O
a O
mouse O
- O
adapted O
MERS O
- O
CoV O
infectious O
cDNA O
was O
engineered O
by O
introducing O
nonsynonymous O
mutations O
contained O
in O
the O
MERSMA O
- O
6 O
- O
1 O
- O
2 O
genome O
into O
a O
MERS O
- O
CoV O
infectious O
cDNA O
, O
leading O
to O
a O
recombinant B
mouse I
- I
adapted I
virus I
( I
rMERS I
- I
MA I
) I
that O
was O
virulent O
in O
hDDP4 O
- O
KI O
mice O
. O

To O
study O
the O
role O
of O
protein O
5 O
, O
two O
additional O
viruses O
were O
engineered O
expressing O
a O
full O
- O
length O
gene O
5 O
( O
rMERS O
- O
MA O
- O
5FL O
) O
or O
containing O
a O
complete O
gene O
5 O
deletion O
( O
rMERS O
- O
MA O
- O
Delta O
5 O
) O
. O

Unexpectedly O
, O
all O
mice O
died O
after O
infection O
with O
rMERS O
- O
MA O
- O
Delta O
5 O
, O
in O
contrast O
to O
those O
infected O
with O
the O
parental O
virus O
, O
which O
contains O
a O
17 O
- O
nucleotide B
( I
nt I
) I
deletion O
and O
a O
stop O
codon O
in O
protein O
5 O
at O
position O
108 O
. O

IMPORTANCE O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
a O
zoonotic O
virus O
causing O
human O
infections O
with O
high O
mortality O
rate O
( O
similar O
to O
35 O
% O
) O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
2 I
( I
SARS I
- I
CoV I
- I
2 I
) I
and O
other O
SARS O
- O
related O
CoVs O
encode O
3 O
tandem O
macrodomains O
within O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

The O
first O
macrodomain O
, O
Mac1 O
, O
is O
conserved O
throughout O
CoVs O
and O
binds O
to O
and O
hydrolyzes O
mono B
- I
ADP I
- I
ribose I
( I
MAR I
) I
from O
target O
proteins O
. O

SARS O
- O
CoV O
- O
2 O
, O
SARS O
- O
CoV O
, O
and O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
Mac1 O
domains O
exhibit O
similar O
structural O
folds O
, O
and O
all O
3 O
proteins O
bound O
to O
ADP O
- O
ribose O
with O
affinities O
in O
the O
low O
micromolar O
range O
. O

Importantly O
, O
using O
ADP O
- O
ribose O
- O
detecting O
binding O
reagents O
in O
both O
a O
gel O
- O
based O
assay O
and O
novel O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISAs I
) I
, O
we O
demonstrated O
de O
- O
MARylating O
activity O
for O
all O
3 O
CoV O
Mac1 O
proteins O
, O
with O
the O
SARS O
- O
CoV O
- O
2 O
Mac1 O
protein O
leading O
to O
a O
more O
rapid O
loss O
of O
substrate O
than O
the O
others O
. O

All O
coronaviruses O
encode O
a O
highly O
conserved O
macrodomain O
( O
Mac1 O
) O
that O
binds O
to O
and O
removes O
ADP O
- O
ribose O
adducts O
from O
proteins O
in O
a O
dynamic O
posttranslational O
process O
that O
is O
increasingly O
being O
recognized O
as O
an O
important O
factor O
that O
regulates O
viral O
infection O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
severe O
respiratory O
illness O
and O
has O
a O
high O
mortality O
of O
- O
34 O
% O
. O

To O
develop O
a O
vaccine O
against O
multiple O
strains O
of O
MERS O
- O
CoV O
, O
we O
targeted O
Spike B
glycoprotein I
( I
S I
) I
using O
prime O
- O
boost O
vaccination O
with O
DNA O
and O
insect O
cell O
- O
expressed O
recombinant O
proteins O
for O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
, O
S1 O
, O
S2 O
, O
S O
Delta O
TM O
, O
or O
S O
Delta O
ER O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
2 I
( I
SARS I
- I
CoV I
- I
2 I
) I
emerged O
in O
China O
at O
the O
end O
of O
2019 O
and O
has O
rapidly O
caused O
a O
pandemic O
, O
with O
over O
20 O
million O
recorded O
COVID O
- O
19 O
cases O
in O
August O
2020 O
( O
https O
: O
/ O
/ O
covid19 O
. O

Here O
, O
we O
present O
data O
on O
the O
antiviral O
activity O
of O
20 O
FDA O
- O
approved O
drugs O
against O
SARS O
- O
CoV O
- O
2 O
that O
also O
inhibit O
SARS O
- O
CoV O
and O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Autonomously O
replicating O
subgenomic O
Bungowannah B
virus I
( I
BuPV I
) I
RNAs O
( O
BuPV O
replicons O
) O
with O
deletions O
of O
the O
genome O
regions O
encoding O
the O
structural O
proteins O
C O
, O
E O
- O
RNS O
, O
E1 O
, O
and O
E2 O
were O
constructed O
on O
the O
basis O
of O
an O
infectious O
cDNA O
clone O
of O
BuPV O
. O

nanoluciferase B
( I
NLuc I
) I
insertion O
was O
used O
to O
compare O
the O
replication O
efficiencies O
of O
all O
constructs O
after O
electroporation O
of O
in O
vitro O
- O
transcribed O
RNA O
from O
the O
different O
clones O
. O

Deletion O
of O
C O
, O
E1 O
, O
E2 O
, O
or O
the O
complete O
structural O
protein O
genome O
region O
( O
C O
- O
ERNS O
- O
E1 O
- O
E2 O
) O
prevented O
the O
production O
of O
infectious O
progeny O
virus O
, O
whereas O
deletion O
of O
E O
- O
RNS O
still O
allowed O
the O
generation O
of O
infectious O
particles O
. O

The O
E O
- O
RNS O
- O
defective O
BuPV O
particles O
showed O
clearly O
limited O
growth O
in O
cell O
culture O
but O
were O
capable O
of O
several O
rounds O
of O
infection O
, O
expression O
of O
foreign O
genes O
, O
and O
highly O
efficient O
trans O
- O
complementation O
to O
rescue O
virus B
replicon I
particles I
( I
VRPs I
) I
. O

For O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
, O
the O
spike B
( I
S I
) I
protein O
is O
the O
main O
determinant O
of O
viral O
entry O
. O

Proteolytic O
cleavage O
of O
the O
S O
protein O
exposes O
its O
fusion B
peptide I
( I
FP I
) I
, O
which O
initiates O
the O
process O
of O
membrane O
fusion O
. O

Previous O
studies O
on O
the O
related O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
FP O
have O
shown O
that O
calcium O
ions O
( O
Ca2 O
+ O
) O
play O
an O
important O
role O
in O
fusogenic O
activity O
via O
a O
Ca2 O
+ O
binding O
pocket O
with O
conserved O
Glutamic B
acid I
( I
E I
) I
and O
Aspartic B
acid I
( I
D I
) I
residues O
. O

SARS O
- O
CoV O
and O
MERS O
- O
CoV O
FPs O
share O
a O
high O
sequence O
homology O
, O
and O
here O
, O
we O
investigated O
whether O
Ca2 O
+ O
is O
required O
for O
MERS O
- O
CoV O
fusion O
by O
screening O
a O
mutant O
array O
in O
which O
E O
and O
D O
residues O
in O
the O
MERS O
- O
CoV O
FP O
were O
substituted O
with O
neutrally O
charged O
alanines O
( O
A O
) O
. O

Upon O
verifying O
mutant O
cell O
surface O
expression O
and O
proteolytic O
cleavage O
, O
we O
tested O
their O
ability O
to O
mediate O
pseudoparticle O
( O
PP O
) O
infection O
of O
host O
cells O
in O
modulating O
Ca2 O
+ O
environments O
. O

Our O
results O
demonstrate O
that O
intracellular O
Ca2 O
+ O
enhances O
MERS O
- O
CoV O
wild B
- I
type I
( I
WT I
) I
PP O
infection O
by O
approximately O
2 O
- O
fold O
and O
that O
E891 O
is O
a O
crucial O
residue O
for O
Ca2 O
+ O
interaction O
. O

Subsequent O
electron B
spin I
resonance I
( I
ESR I
) I
experiments O
revealed O
that O
this O
enhancement O
could O
be O
attributed O
to O
Ca2 O
+ O
increasing O
MERS O
- O
CoV O
FP O
fusion O
- O
relevant O
membrane O
ordering O
. O

IMPORTANCE O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
a O
major O
emerging O
infectious O
disease O
with O
zoonotic O
potential O
and O
has O
reservoirs O
in O
dromedary O
camels O
and O
bats O
. O

Traditionally O
, O
the O
emergence O
of O
Coronaviruses B
( I
CoVs I
) I
has O
been O
attributed O
to O
a O
gain O
in O
receptor O
binding O
in O
a O
new O
host O
. O

Our O
previous O
work O
with O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
like O
viruses O
argued O
that O
bats O
already O
harbor O
CoVs O
with O
the O
ability O
to O
infect O
humans O
without O
adaptation O
. O

In O
this O
work O
, O
we O
describe O
overcoming O
host O
restriction O
of O
two O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
- O
like O
bat O
CoVs O
using O
exogenous O
protease O
treatment O
. O

antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
viral O
entry O
has O
been O
a O
major O
concern O
for O
epidemiology O
, O
vaccine O
development O
, O
and O
antibody O
- O
based O
drug O
therapy O
. O

In O
this O
study O
, O
we O
investigated O
how O
a O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
, O
which O
targets O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
of O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
coronavirus O
spike O
, O
mediates O
viral O
entry O
using O
pseudovirus O
entry O
and O
biochemical O
assays O
. O

IMPORTANCE O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
viral O
entry O
has O
been O
observed O
for O
many O
viruses O
. O

Continued O
reports O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infecting O
humans O
have O
occurred O
since O
the O
identification O
of O
this O
virus O
in O
2012 O
. O

Here O
, O
at O
the O
molecular O
level O
, O
we O
found O
that O
all O
purified O
bat B
CD26s I
( I
bCD26s I
) I
from O
a O
diverse O
range O
of O
species O
interact O
with O
the O
receptor B
binding I
domain I
( I
RBD I
) I
of O
MERS O
- O
CoV O
, O
with O
equilibrium O
dissociation O
constant O
values O
ranging O
from O
several O
to O
hundreds O
at O
the O
micromolar O
level O
. O

IMPORTANCE O
In O
this O
study O
, O
we O
found O
that O
bat B
CD26s I
( I
bCD26s I
) I
from O
different O
species O
exhibit O
large O
diversities O
, O
especially O
in O
the O
region O
responsible O
for O
binding O
to O
the O
receptor B
binding I
domain I
( I
RBD I
) I
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Coronavirus B
( I
CoV I
) I
nucleocapsid B
( I
N I
) I
proteins O
are O
key O
for O
incorporating O
genomic O
RNA O
into O
progeny O
viral O
particles O
. O

In O
infected O
cells O
, O
N O
proteins O
are O
present O
at O
the O
replication B
- I
transcription I
complexes I
( I
RTCs I
) I
, O
the O
sites O
of O
CoV O
RNA O
synthesis O
. O

It O
has O
been O
shown O
that O
N O
proteins O
are O
important O
for O
viral O
replication O
and O
that O
the O
one O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
commonly O
used O
model O
CoV O
, O
interacts O
with O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
, O
a O
component O
of O
the O
RTCs O
. O

Outbreaks O
of O
severe O
diarrhea O
in O
neonatal O
piglets O
in O
Guangdong O
, O
China O
, O
in O
2017 O
resulted O
in O
the O
isolation O
and O
discovery O
of O
a O
novel O
swine B
enteric I
alphacoronavirus I
( I
SeACoV I
) I
derived O
from O
the O
species O
Rhinolophus O
bat O
coronavirus O
HKU2 O
( O
Y O
. O

SeACoV O
was O
later O
referred O
to O
as O
swine B
acute I
diarrhea I
syndrome I
CoV I
( I
SADS I
- I
CoV I
) I
by O
another O
group O
( O
P O
. O

We O
identified O
that O
splenic O
dendritic B
cells I
( I
DCs I
) I
are O
the O
major O
targets O
of O
virus O
infection O
by O
immunofluorescence O
and O
flow O
cytometry O
approaches O
. O

IMPORTANCE O
Infections O
with O
bat O
- O
origin O
Coronaviruses B
( I
CoVs I
) I
( O
severe O
acute O
respiratory O
syndrome O
CoV O
[ O
SARS O
- O
CoV O
] O
and O
Middle O
East O
respiratory O
syndrome O
CoV O
[ O
MERS O
- O
CoV O
] O
) O
have O
caused O
severe O
illness O
in O
humans O
after O
host O
jump O
events O
. O

Recently O
, O
a O
novel O
bat O
- O
HKU2 O
- O
like O
CoV O
named O
swine B
acute I
diarrhea I
syndrome I
CoV I
( I
SADS I
- I
CoV I
) I
has O
emerged O
in O
southern O
China O
, O
causing O
lethal O
diarrhea O
in O
newborn O
piglets O
. O

It O
is O
important O
to O
assess O
the O
species O
barriers O
of O
SADS O
- O
CoV O
infection O
since O
the O
animal O
hosts O
( O
other O
than O
pigs O
and O
bats O
) O
and O
zoonotic O
potential O
are O
still O
unknown O
. O

Here O
, O
we O
sequenced O
multiple O
complete O
genomes O
of O
dromedary B
camel I
coronavirus I
HKU23 I
( I
DcCoV I
- I
HKU23 I
) I
from O
Nigeria O
, O
Morocco O
, O
and O
Ethiopia O
and O
identified O
several O
genomic O
positions O
indicative O
of O
cross O
- O
species O
virus O
recombination O
events O
among O
other O
betacoronaviruses O
of O
the O
subgenus O
Embecovirus O
( O
Glade O
A O
beta O
- O
CoVs O
) O
. O

Recombinant O
fragments O
of O
a O
rabbit O
coronavirus O
( O
RbCoV O
- O
HKU14 O
) O
were O
identified O
at O
the O
hemagglutinin O
esterase O
gene O
position O
. O

Our O
results O
highlighted O
active O
recombination O
of O
coronaviruses O
circulating O
in O
dromedaries O
and O
are O
also O
relevant O
to O
the O
emergence O
and O
evolution O
of O
other O
betacoronaviruses O
, O
including O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Our O
work O
demonstrates O
that O
when O
the O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
ORF4a O
accessory O
gene O
is O
expressed O
in O
yeast O
it O
causes O
a O
slow O
- O
growth O
phenotype O
. O

IMPORTANCE O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
initially O
emerged O
in O
2012 O
and O
has O
since O
been O
responsible O
for O
over O
2 O
, O
300 O
infections O
, O
with O
a O
case O
fatality O
ratio O
of O
approximately O
35 O
% O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
uses O
the O
S1 O
( O
B O
) O
domain O
of O
its O
spike O
protein O
to O
bind O
to O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
, O
its O
functional O
receptor O
, O
and O
its O
S1 O
( O
A O
) O
domain O
to O
bind O
to O
sialic O
acids O
. O

However O
, O
MERS O
- O
CoV O
S1 O
( O
A O
) O
does O
not O
indiscriminately O
bind O
to O
all O
alpha O
2 O
, O
3 O
- O
sialic O
acids O
, O
and O
the O
species O
- O
specific O
binding O
and O
tissue O
distribution O
of O
these O
sialic O
acids O
in O
different O
MERS O
- O
CoV O
- O
susceptible O
species O
have O
not O
been O
investigated O
. O

We O
established O
a O
novel O
method O
to O
detect O
these O
sialic O
acids O
on O
tissue O
sections O
of O
various O
organs O
of O
different O
susceptible O
species O
by O
using O
nanoparticles O
displaying O
multivalent O
MERS O
- O
CoV O
S1 O
( O
A O
) O
. O

In O
contrast O
, O
S1 O
( O
A O
) O
nanoparticles O
did O
not O
bind O
to O
the O
intestinal O
epithelium O
of O
serotine O
bats O
and O
frugivorous O
bat O
species O
, O
nor O
did O
they O
bind O
to O
the O
nasal O
epithelium O
of O
pigs O
and O
rabbits O
. O

IMPORTANCE O
MERS O
- O
CoV O
uses O
the O
S1 O
( O
B O
) O
domain O
of O
its O
spike O
protein O
to O
attach O
to O
its O
host O
receptor O
, O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
. O

On O
the O
other O
hand O
, O
the O
S1 O
( O
A O
) O
domain O
, O
the O
N O
- O
terminal O
domain O
of O
this O
spike O
protein O
, O
preferentially O
binds O
to O
several O
glycotopes O
of O
alpha O
2 O
, O
3 O
- O
sialic O
acids O
, O
the O
attachment O
factor O
of O
MERS O
- O
CoV O
. O

Here O
we O
show O
, O
using O
a O
novel O
method O
, O
that O
the O
S1 O
( O
A O
) O
domain O
specifically O
binds O
to O
the O
nasal O
epithelium O
of O
dromedary O
camels O
, O
alveolar O
epithelium O
of O
humans O
, O
and O
intestinal O
epithelium O
of O
common O
pipistrelle O
bats O
. O

This O
finding O
supports O
the O
importance O
of O
the O
S1 O
( O
A O
) O
domain O
in O
MERS O
- O
CoV O
infection O
and O
tropism O
, O
suggests O
its O
role O
in O
transmission O
, O
and O
highlights O
its O
potential O
use O
as O
a O
component O
of O
novel O
vaccine O
candidates O
. O

Transmembrane O
serine O
protease O
TMPRSS2 O
activates O
the O
spike O
protein O
of O
highly O
pathogenic O
human O
coronaviruses O
such O
as O
severe B
acute I
respiratory I
syndrome I
- I
related I
coronavirus I
( I
SARS I
- I
CoV I
) I
and O
Middle B
East I
respiratory I
syndrome I
- I
related I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Th1 O
- O
prone O
C57BL O
/ O
6 O
mice O
and O
TMPRSS2 O
- O
knockout B
( I
KO I
) I
mice O
were O
used O
for O
SARS O
- O
CoV O
infection O
, O
and O
transgenic O
mice O
expressing O
the O
human O
MERS O
- O
CoV O
receptor O
DPP4 O
( O
hDPP4 O
- O
Tg O
mice O
) O
and O
TMPRSS2 O
- O
KO O
hDPP4 O
- O
Tg O
mice O
were O
used O
for O
MERS O
- O
CoV O
infection O
. O

However O
, O
TMPRSS2 O
- O
KO O
mice O
showed O
weakened O
inflammatory O
chemokine O
and O
/ O
or O
cytokine O
responses O
to O
intranasal O
stimulation O
with O
poly O
( O
I O
center O
dot O
C O
) O
, O
a O
Toll O
- O
like O
receptor O
3 O
agonist O
. O

Transmembrane B
protease I
serine I
type I
2 I
( I
TMPRSS2 I
) I
, O
a O
protease O
belonging O
to O
the O
type O
II O
transmembrane O
serine O
protease O
family O
, O
cleaves O
the O
coronavirus O
spike O
protein O
, O
making O
it O
a O
potential O
therapeutic O
target O
for O
coronavirus O
infections O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infection O
can O
manifest O
as O
a O
mild O
illness O
, O
acute O
respiratory O
distress O
, O
organ O
failure O
, O
or O
death O
. O

Here O
, O
we O
developed O
transgenic B
( I
Tg I
) I
mice O
on O
a O
C57BL O
/ O
6 O
background O
; O
these O
mice O
expressed O
human B
CD26 I
/ I
dipeptidyl I
peptidase I
4 I
( I
hDPP4 I
) I
, O
a O
functional O
receptor O
for O
MERS O
- O
CoV O
, O
under O
the O
control O
of O
an O
endogenous O
hDPP4 O
promoter O
. O

IMPORTANCE O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infections O
are O
endemic O
in O
the O
Middle O
East O
and O
a O
threat O
to O
public O
health O
worldwide O
. O

Rodents O
are O
not O
susceptible O
to O
the O
virus O
because O
they O
do O
not O
express O
functional O
receptors O
; O
therefore O
, O
we O
generated O
a O
new O
animal O
model O
of O
MERS O
- O
CoV O
infection O
based O
on O
transgenic O
mice O
expressing O
human B
DPP4 I
( I
hDPP4 I
) I
. O

The O
pattern O
of O
hDPP4 O
expression O
in O
this O
model O
was O
similar O
to O
that O
in O
human O
tissues O
( O
except O
lymphoid O
tissue O
) O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
poses O
a O
threat O
to O
public O
health O
. O

The O
MERS O
- O
CoV O
spike B
( I
S I
) I
protein O
binds O
to O
the O
cellular O
protein O
DPP4 O
via O
its O
receptor B
binding I
domain I
( I
RBD I
) I
and O
mediates O
viral O
entry O
into O
target O
cells O
. O

Nonstructural B
protein I
15 I
( I
Nsp15 I
) I
encoded O
by O
Coronavirus B
( I
CoV I
) I
is O
a O
nidoviral B
uridylate I
- I
specific I
endoribonuclease I
( I
NendoU I
) I
that O
plays O
an O
essential O
role O
in O
the O
life O
cycle O
of O
the O
virus O
. O

Structural O
information O
on O
this O
crucial O
protein O
from O
the O
Middle B
East I
respiratory I
syndrome I
CoV I
( I
MERS I
- I
CoV I
) I
, O
which O
is O
lethally O
pathogenic O
and O
has O
caused O
severe O
respiratory O
diseases O
worldwide O
, O
is O
lacking O
. O

IMPORTANCE O
The O
lethally O
pathogenic O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
and O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS O
- O
Coy O
) O
pose O
serious O
threats O
to O
humans O
. O

Stress B
granule I
( I
SG I
) I
formation O
is O
generally O
triggered O
as O
a O
result O
of O
stress O
- O
induced O
translation O
arrest O
. O

The O
impact O
of O
SG O
formation O
on O
virus O
replication O
varies O
among O
different O
viruses O
, O
and O
the O
significance O
of O
SGs O
in O
Coronavirus B
( I
CoV I
) I
replication O
is O
largely O
unknown O
. O

The O
present O
study O
examined O
the O
biological O
role O
of O
SGs O
in O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
- O
CoV O
replication O
. O

The O
MERS O
- O
CoV O
4a O
accessory O
protein O
is O
known O
to O
inhibit O
SG O
formation O
in O
cells O
in O
which O
it O
was O
expressed O
by O
binding O
to O
double O
- O
stranded O
RNAs O
and O
inhibiting O
protein B
kinase I
R I
( I
PKR I
) I
- O
mediated O
phosphorylation O
of O
the O
alpha O
subunit O
of O
eukaryotic B
initiation I
factor I
2 I
( I
eIF2 I
alpha I
) I
. O

Replication O
of O
MERS O
- O
CoV O
lacking O
the O
genes O
for O
4a O
and O
4b O
( O
MERS O
- O
CoV O
- O
Delta O
p4 O
) O
, O
but O
not O
MERS O
- O
CoV O
, O
induced O
SG O
accumulation O
in O
MERS O
- O
CoV O
- O
susceptible O
HeLa O
/ O
CD26 O
cells O
, O
while O
replication O
of O
both O
viruses O
failed O
to O
induce O
SGs O
in O
Vero O
cells O
, O
demonstrating O
cell O
type O
- O
specific O
differences O
in O
MERS O
- O
CoV O
- O
Delta O
p4 O
- O
induced O
SG O
formation O
. O

IMPORTANCE O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
respiratory O
failure O
with O
a O
high O
case O
fatality O
rate O
in O
patients O
, O
yet O
effective O
antivirals O
and O
vaccines O
are O
currently O
not O
available O
. O

Stress B
granule I
( I
SG I
) I
formation O
is O
one O
of O
the O
cellular O
stress O
responses O
to O
virus O
infection O
and O
is O
generally O
triggered O
as O
a O
result O
of O
stress O
- O
induced O
translation O
arrest O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
utilizes O
host O
cellular O
proteases O
to O
enter O
cells O
. O

A O
previous O
report O
shows O
that O
furin O
, O
which O
is O
distributed O
mainly O
in O
the O
Golgi O
apparatus O
and O
cycled O
to O
the O
cell O
surface O
and O
endosomes O
, O
proteolytically O
activates O
the O
MERS O
- O
CoV O
spike B
( I
S I
) I
protein O
following O
receptor O
binding O
to O
mediate O
fusion O
between O
the O
viral O
and O
cellular O
membranes O
. O

The O
newly O
emerged O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
continues O
to O
infect O
humans O
and O
camels O
, O
calling O
for O
efficient O
, O
cost O
- O
effective O
, O
and O
broad O
- O
spectrum O
strategies O
to O
control O
its O
spread O
. O

nanobodies B
( I
Nbs I
) I
are O
single O
- O
domain O
antibodies O
derived O
from O
camelids O
and O
sharks O
and O
are O
potentially O
cost O
- O
effective O
antivirals O
with O
small O
size O
and O
great O
expression O
yield O
. O

In O
this O
study O
, O
we O
developed O
a O
novel O
neutralizing O
Nb O
( O
NbMS10 O
) O
and O
its O
human O
- O
Fc O
- O
fused O
version O
( O
NbMS10 O
- O
Fc O
) O
, O
both O
of O
which O
target O
the O
MERS O
- O
CoV O
spike O
protein O
receptor B
- I
binding I
domain I
( I
RBD I
) I
. O

Because O
of O
their O
small O
size O
, O
nanobodies B
( I
Nbs I
) I
have O
advantages O
as O
antiviral O
therapeutics O
( O
e O
. O

Here O
, O
we O
have O
developed O
novel O
Nbs O
that O
specifically O
target O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
of O
MERS O
- O
CoV O
spike O
protein O
. O

The O
emergence O
of O
Middle O
East O
respiratory O
syndrome O
showed O
once O
again O
that O
Coronaviruses B
( I
CoVs I
) I
in O
animals O
are O
potential O
source O
for O
epidemics O
in O
humans O
. O

Four O
novel O
deltacoronaviruses O
were O
detected O
from O
eight O
birds O
of O
four O
species O
by O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
: O
FalCoV O
UAE O
- O
HKU27 O
from O
a O
falcon O
, O
HouCoV O
UAE O
- O
HKU28 O
from O
a O
houbara O
bustard O
, O
PiCoV O
UAE O
- O
HKU29 O
from O
a O
pigeon O
, O
and O
QuaCoV O
UAE O
- O
HKU30 O
from O
five O
quails O
. O

Western O
blotting O
detected O
specific O
anti O
- O
FalCoV O
UAE O
- O
HKU27 O
antibodies O
in O
33 O
( O
75 O
% O
) O
of O
44 O
falcon O
serum O
samples O
, O
supporting O
genuine O
infection O
in O
falcons O
after O
virus O
acquisition O
. O

QuaCoV O
UAE O
- O
HKU30 O
belongs O
to O
the O
same O
CoV O
species O
as O
porcine B
coronavirus I
HKU15 I
( I
PorCoV I
HKU15 I
) I
and O
sparrow B
coronavirus I
HKU17 I
( I
SpCoV I
HKU17 I
) I
, O
discovered O
previously O
from O
swine O
and O
tree O
sparrows O
, O
respectively O
, O
supporting O
avian O
- O
to O
- O
swine O
transmission O
. O

FalCoV O
UAE O
- O
HKU27 O
, O
HouCoV O
UAE O
- O
HKU28 O
, O
and O
PiCoV O
UAE O
- O
HKU29 O
originated O
from O
recombination O
between O
white B
- I
eye I
coronavirus I
HKU16 I
( I
WECoV I
HKU16 I
) I
and O
magpie B
robin I
coronavirus I
HKU18 I
( I
MRCoV I
HKU18 I
) I
, O
QuaCoV O
UAE O
- O
HKU30 O
from O
recombination O
between O
PorCoV O
HKU15 O
/ O
SpCoV O
HKU17 O
and O
munia B
coronavirus I
HKU13 I
( I
MunCoV I
HKU13 I
) I
, O
and O
PorCoV O
HKU15 O
from O
recombination O
between O
SpCoV O
HKU17 O
and O
bulbul B
coronavirus I
HKU11 I
( I
BuCoV I
HKU11 I
) I
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
has O
represented O
a O
human O
health O
threat O
since O
2012 O
. O

Although O
several O
MERS O
- O
related O
CoVs O
that O
belong O
to O
the O
same O
species O
as O
MERS O
- O
CoV O
have O
been O
identified O
from O
bats O
, O
they O
do O
not O
use O
the O
MERS O
- O
CoV O
receptor O
, O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
a O
highly O
lethal O
pulmonary O
infection O
with O
similar O
to O
35 O
% O
mortality O
. O

Using O
a O
probe O
- O
based O
single O
B O
cell O
cloning O
strategy O
, O
we O
have O
identified O
and O
characterized O
multiple O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
specifically O
binding O
to O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
or O
S1 O
( O
non O
- O
RBD O
) O
regions O
from O
a O
convalescent O
MERS O
- O
CoV O
- O
infected O
patient O
and O
from O
immunized O
rhesus O
macaques O
. O

Using O
structurally O
defined O
probes O
for O
the O
MERS O
- O
CoV O
Spike B
glycoprotein I
( I
S I
) I
, O
the O
target O
for O
neutralizing O
antibodies O
, O
single O
B O
cells O
were O
sorted O
from O
a O
convalescent O
human O
and O
immunized O
nonhuman B
primates I
( I
NHPs I
) I
. O

MAbs O
produced O
from O
paired O
immunoglobulin O
gene O
sequences O
were O
mapped O
to O
multiple O
epitopes O
within O
and O
outside O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
and O
protected O
against O
lethal O
MERS O
infection O
in O
a O
murine O
model O
following O
passive O
immunization O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
an O
emerging O
human O
pathogen O
that O
is O
the O
causative O
agent O
for O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
. O

As O
part O
of O
its O
viral O
genome O
, O
MERS O
- O
CoV O
encodes O
a O
papain B
- I
like I
protease I
( I
PLpro I
) I
that O
has O
been O
observed O
to O
act O
as O
a O
deubiquitinase O
and O
deISGylase O
to O
antagonize O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
immune O
pathways O
. O

As O
a O
result O
, O
the O
interface O
of O
MERS O
- O
CoV O
and O
human B
interferon I
- I
stimulated I
gene I
product I
15 I
( I
hISG15 I
) I
was O
probed O
with O
isothermal O
calorimetry O
, O
which O
suggests O
that O
the O
C O
- O
terminal O
domain O
of O
hISG15 O
is O
principally O
responsible O
for O
interactions O
. O

IMPORTANCE O
Coronaviruses O
, O
such O
as O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
, O
encode O
a O
papain B
- I
like I
protease I
( I
PLpro I
) I
that O
possesses O
the O
ability O
to O
antagonize O
interferon O
immune O
pathways O
through O
the O
removal O
of O
ubiquitin O
and O
interferon B
- I
stimulated I
gene I
product I
15 I
( I
ISG15 I
) I
from O
target O
proteins O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
utilizes O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
as O
an O
entry O
receptor O
. O

However O
, O
in O
vivo O
studies O
are O
limited O
because O
MERS O
- O
CoV O
cannot O
infect O
wildtype O
mice O
due O
to O
incompatibilities O
between O
the O
virus O
spike O
and O
the O
mouse O
host O
cell O
receptor O
, O
mouse B
DPP4 I
( I
mDPP4 I
) I
. O

Although O
shrews O
are O
one O
of O
the O
largest O
groups O
of O
mammals O
, O
little O
is O
known O
about O
their O
role O
in O
the O
evolution O
and O
transmission O
of O
viral O
pathogens O
, O
including O
Coronaviruses B
( I
CoVs I
) I
. O

We O
captured O
266 O
Asian O
house O
shrews O
( O
Suncus O
murinus O
) O
in O
Jiangxi O
and O
Zhejiang O
Provinces O
, O
China O
, O
during O
2013 O
to O
2015 O
. O

Notably O
, O
these O
viruses O
were O
most O
closely O
related O
to O
alphacoronaviruses O
but O
sufficiently O
divergent O
that O
they O
should O
be O
considered O
a O
novel O
member O
of O
the O
genus O
Alphacoronavirus O
, O
which O
we O
denote O
Wencheng B
shrew I
virus I
( I
WESV I
) I
. O

Here O
, O
we O
describe O
a O
novel O
alphacoronavirus O
( O
Wencheng O
shrew O
virus O
[ O
WESV O
] O
) O
that O
was O
sampled O
from O
Asian O
house O
shrews O
in O
China O
. O

Bats O
are O
natural O
reservoirs O
for O
many O
pathogenic O
viruses O
, O
and O
increasing O
evidence O
supports O
the O
notion O
that O
bats O
can O
also O
harbor O
group O
A O
rotaviruses B
( I
RVAs I
) I
, O
important O
causative O
agents O
of O
diarrhea O
in O
children O
and O
young O
animals O
. O

Specific O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
screening O
found O
four O
RVA O
strains O
. O

7 O
% O
( O
48 O
/ O
448 O
) O
of O
bat O
sera O
by O
an O
indirect B
immunofluorescence I
assay I
( I
IIFA I
) I
. O

IMPORTANCE O
Bat O
viruses O
, O
such O
as O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
, O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
, O
Ebola O
, O
Hendra O
, O
and O
Nipah O
viruses O
, O
are O
important O
pathogens O
causing O
outbreaks O
of O
severe O
emerging O
infectious O
diseases O
. O

However O
, O
little O
is O
known O
about O
bat O
viruses O
capable O
of O
causing O
gastroenteritis O
in O
humans O
, O
even O
though O
8 O
group O
A O
viruses O
( O
RVAs O
) O
have O
been O
identified O
from O
bats O
so O
far O
. O

The O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
nonstructural I
protein I
16 I
( I
nsp16 I
) I
is O
an O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( I
SAM I
) I
- O
dependent O
2 B
' I
- I
O I
- I
methyltransferase I
( I
2 I
' I
- I
O I
- I
MTase I
) I
that O
is O
thought O
to O
methylate O
the O
ribose O
2 O
' O
- O
OH O
of O
the O
first O
transcribed O
nucleotide O
( O
N O
- O
1 O
) O
of O
viral O
RNA O
cap O
structures O
. O

The O
SAM O
binding O
promotes O
the O
assembly O
of O
the O
enzymatically O
active O
nsp10 O
/ O
nsp16 O
complex O
that O
converted O
( O
7m O
) O
GpppG O
( O
cap O
- O
0 O
) O
into O
( O
7m O
) O
GpppG O
( O
2 O
' O
Om O
) O
( O
cap O
- O
1 O
) O
RNA O
by O
2 O
' O
- O
OH O
methylation O
of O
N1 O
in O
a O
SAM O
- O
dependent O
manner O
. O

Alanine O
mutagenesis O
and O
RNA O
binding O
assays O
allowed O
the O
identification O
of O
the O
nsp16 O
residues O
involved O
in O
RNA O
recognition O
forming O
the O
RNA O
binding O
groove O
( O
K46 O
, O
K170 O
, O
E203 O
, O
D133 O
, O
R38 O
, O
Y47 O
, O
and O
Y181 O
) O
and O
the O
cap O
- O
0 O
binding O
site O
( O
Y30 O
, O
Y132 O
, O
and O
H174 O
) O
. O

We O
previously O
showed O
that O
2 B
' I
, I
5 I
' I
- I
phosphodiesterases I
( I
2 I
' I
, I
5 I
' I
- I
PDEs I
) I
encoded O
by O
the O
prototypical O
Betacoronavirus O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
and O
by O
Middle O
East O
respiratory O
syndrome O
- O
associated O
coronavirus O
antagonize O
the O
oligoadenylate O
- O
RNase O
L O
( O
OAS O
- O
RNase O
L O
) O
pathway O
. O

We O
used O
a O
chimeric O
MHV O
system O
( O
MHVMut O
) O
in O
which O
exogenous O
PDEs O
were O
expressed O
from O
an O
MHV O
backbone O
lacking O
the O
gene O
for O
a O
functional O
NS2 O
protein O
, O
the O
endogenous O
RNase O
L O
antagonist O
. O

With O
this O
system O
, O
we O
found O
that O
2 O
' O
, O
5 O
' O
- O
PDEs O
encoded O
by O
the O
human O
coronavirus O
HCoV O
- O
OC43 O
( O
OC43 O
; O
an O
agent O
of O
the O
common O
cold O
) O
, O
human B
enteric I
coronavirus I
( I
HECoV I
) I
, O
equine B
coronavirus I
( I
ECoV I
) I
, O
and O
equine B
torovirus I
Berne I
( I
BEV I
) I
are O
enzymatically O
active O
, O
rescue O
replication O
of O
MHVMut O
in O
bone O
marrow O
- O
derived O
macrophages O
, O
and O
inhibit O
RNase O
L O
- O
mediated O
rRNA O
degradation O
in O
these O
cells O
. O

Additionally O
, O
PDEs O
encoded O
by O
OC43 O
and O
BEV O
rescue O
MHVMut O
replication O
and O
restore O
pathogenesis O
in O
wild B
- I
type I
( I
WT I
) I
B6 O
mice O
. O

IMPORTANCE O
Viruses O
in O
the O
family O
Coronaviridae O
include O
important O
human O
and O
animal O
pathogens O
, O
including O
the O
recently O
emerged O
viruses O
severe B
acute I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
SARS I
- I
CoV I
) I
and O
Middle B
East I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

We O
showed O
previously O
that O
two O
viruses O
within O
the O
genus O
Betacoronavirus O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
and O
MERS O
- O
CoV O
, O
encode O
2 B
' I
, I
5 I
' I
- I
phosphodiesterases I
( I
2 I
' I
, I
5 I
' I
- I
PDEs I
) I
that O
antagonize O
the O
OAS O
- O
RNase O
L O
pathway O
, O
and O
we O
report O
here O
that O
these O
proteins O
are O
furthermore O
conserved O
among O
additional O
coronavirus O
superfamily O
members O
, O
including O
lineage O
A O
betacoronaviruses O
and O
toroviruses O
, O
suggesting O
that O
they O
may O
play O
critical O
roles O
in O
pathogenesis O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
an O
important O
emerging O
pathogen O
that O
was O
first O
described O
in O
2012 O
. O

While O
the O
cell O
surface O
receptor O
for O
MERS O
- O
CoV O
has O
been O
identified O
as O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
, O
the O
mouse O
DPP4 O
homologue O
does O
not O
allow O
virus O
entry O
into O
cells O
. O

Depletion O
of O
CD4 O
( O
+ O
) O
T O
cells O
, O
CD8 O
( O
+ O
) O
T O
cells O
, O
or O
macrophages O
has O
no O
effect O
on O
MERS O
- O
CoV O
replication O
in O
the O
lungs O
of O
infected O
mice O
. O

However O
, O
we O
found O
that O
depletion O
of O
CD8 O
( O
+ O
) O
T O
cells O
protects O
and O
depletion O
of O
macrophages O
exacerbates O
MERS O
- O
CoV O
- O
induced O
pathology O
and O
clinical O
symptoms O
of O
disease O
. O

IMPORTANCE O
The O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
a O
highly O
pathogenic O
respiratory O
virus O
that O
emerged O
from O
zoonotic O
sources O
in O
2012 O
. O

human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
, O
a O
causative O
agent O
of O
the O
common O
cold O
, O
enters O
host O
cells O
via O
two O
distinct O
pathways O
: O
one O
is O
mediated O
by O
cell O
surface O
proteases O
, O
particularly O
transmembrane B
protease I
serine I
2 I
( I
TMPRSS2 I
) I
, O
and O
the O
other O
by O
endosomal O
cathepsin O
L O
. O

Here O
, O
we O
examined O
the O
mechanism O
of O
cell O
entry O
used O
by O
a O
pseudotyped O
virus O
bearing O
the O
HCoV O
- O
229E O
spike B
( I
S I
) I
protein O
in O
the O
presence O
or O
absence O
of O
protease O
inhibitors O
. O

Two O
amino O
acid O
substitutions O
( O
R642M O
and O
N714K O
) O
in O
the O
S O
protein O
of O
HCoV O
- O
229E O
clinical O
isolates O
altered O
their O
sensitivity O
to O
a O
cathepsin O
L O
inhibitor O
, O
suggesting O
that O
these O
amino O
acids O
were O
responsible O
for O
cathepsin O
L O
use O
. O

After O
20 O
passages O
in O
HeLa O
cells O
, O
the O
ability O
of O
the O
isolate O
to O
use O
cathepsin O
increased O
so O
that O
it O
was O
equal O
to O
that O
of O
the O
laboratory O
strain O
; O
this O
increase O
was O
caused O
by O
an O
amino O
acid O
substitution O
( O
I577S O
) O
in O
the O
S O
protein O
. O

human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
utilizes O
endosomal O
cathepsin O
L O
to O
activate O
the O
spike O
protein O
after O
receptor O
binding O
. O

Therefore O
, O
therapeutic O
agents O
for O
coronavirus O
- O
mediated O
diseases O
, O
such O
as O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
and O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
, O
should O
target O
cell O
surface O
TMPRSS2 O
rather O
than O
endosomal O
cathepsin O
. O

20 O
( O
enfuvirtide O
) O
and O
other O
peptides O
derived O
from O
the O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
gp41 O
C B
- I
terminal I
heptad I
repeat I
( I
CHR I
) I
region O
inhibit O
HIV O
fusion O
by O
binding O
to O
the O
hydrophobic O
grooves O
on O
the O
N B
- I
terminal I
heptad I
repeat I
( I
NHR I
) I
trimer O
and O
blocking O
six B
- I
helix I
- I
bundle I
( I
6 I
- I
HB I
) I
formation O
. O

After O
the O
addition O
of O
IDL O
( O
Ile O
- O
Asp O
- O
Leu O
) O
to O
the O
C O
terminus O
of O
CHR O
peptide O
WQ O
or O
MT O
- O
WQ O
, O
the O
conjugated O
peptides O
, O
WQ O
- O
IDL O
and O
MT O
- O
WQIDL O
, O
showed O
much O
more O
potent O
activities O
than O
WQ O
and O
T20 O
, O
respectively O
, O
in O
inhibiting O
HIV O
- O
1 O
IIIB O
infection O
. O

IMPORTANCE O
The O
hydrophobic O
groove O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
gp41 O
NHR O
trimer O
has O
been O
known O
as O
the O
classic O
drug O
target O
to O
develop O
fusion O
inhibitors O
derived O
from O
the O
gp41 O
CHR O
. O

We O
identified O
a O
shallow O
pocket O
adjacent O
to O
the O
groove O
in O
the O
NHR O
trimer O
and O
added O
a O
short O
artificial O
peptide O
consisting O
of O
three O
amino O
acids O
( O
IDL O
) O
to O
the O
C O
terminus O
of O
a O
fusion O
inhibitor O
to O
fit O
this O
new O
target O
. O

The O
inhibition O
activity O
of O
this O
new O
conjugated O
peptide O
was O
significantly O
enhanced O
, O
by O
77 O
- O
fold O
, O
making O
it O
much O
more O
potent O
than O
T20 O
( O
enfuvirtide O
) O
and O
suggesting O
that O
the O
IDL O
tail O
can O
be O
adopted O
for O
optimizing O
existing O
HIV O
- O
1 O
CHR O
peptide O
fusion O
inhibitors O
. O

This O
new O
approach O
of O
identifying O
a O
potential O
binding O
pocket O
outside O
the O
traditional O
target O
and O
creating O
an O
artificial O
tail O
anchor O
can O
be O
widely O
applied O
to O
design O
novel O
fusion O
inhibitors O
against O
other O
class O
I O
enveloped O
viruses O
, O
such O
as O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
binds O
to O
cellular O
receptor O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
via O
the O
spike B
( I
S I
) I
protein O
receptor B
- I
binding I
domain I
( I
RBD I
) I
. O

Here O
, O
we O
constructed O
four O
recombinant B
RBD I
( I
rRBD I
) I
proteins O
with O
single O
or O
multiple O
mutations O
detected O
in O
representative O
human O
MERS O
- O
CoV O
strains O
from O
the O
2012 O
, O
2013 O
, O
2014 O
, O
and O
2015 O
outbreaks O
, O
respectively O
, O
and O
one O
rRBD O
protein O
with O
multiple O
changes O
derived O
from O
camel O
MERS O
- O
CoV O
strains O
. O

Like O
the O
RBD O
of O
prototype O
EMC2012 O
( O
EMC O
- O
RBD O
) O
, O
all O
five O
RBDs O
maintained O
good O
antigenicity O
and O
functionality O
, O
the O
ability O
to O
bind O
RBD O
- O
specific O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
the O
DPP4 O
receptor O
, O
and O
high O
immunogenicity O
, O
able O
to O
elicit O
S O
- O
specific O
antibodies O
. O

We O
then O
constructed O
two O
RBDs O
mutated O
in O
multiple O
key O
residues O
in O
the O
receptor B
- I
binding I
motif I
( I
RBM I
) I
of O
RBD O
and O
demonstrated O
their O
strong O
cross O
- O
reactivity O
with O
anti O
- O
EMC O
- O
RBD O
antibodies O
. O

Mutations O
in O
its O
spike B
( I
S I
) I
protein O
receptor B
- I
binding I
domain I
( I
RBD I
) I
, O
a O
key O
vaccine O
target O
, O
have O
been O
identified O
, O
raising O
concerns O
over O
the O
efficacy O
of O
RBD O
- O
based O
MERS O
vaccines O
against O
circulating O
human O
and O
camel O
MERS O
- O
CoV O
strains O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
emerged O
in O
2012 O
and O
is O
a O
highly O
pathogenic O
respiratory O
virus O
. O

To O
address O
this O
need O
, O
we O
developed O
an O
inactivated O
rabies B
virus I
( I
RABV I
) I
that O
contains O
the O
MERS O
- O
CoV O
spike B
( I
S I
) I
protein O
expressed O
on O
its O
surface O
. O

Therefore O
, O
we O
developed O
a O
RABV O
- O
MERS O
vector O
that O
contained O
the O
MERS O
- O
CoV O
S1 O
domain O
of O
the O
MERS O
- O
CoV O
S O
protein O
fused O
to O
the O
RABV O
G O
protein O
C O
terminus O
( O
BNSP333 O
- O
S1 O
) O
. O

Next O
, O
we O
challenged O
both O
vaccinated O
mice O
and O
control O
mice O
with O
MERS O
- O
CoV O
after O
adenovirus O
transduction O
of O
the O
Human B
dipeptidyl I
peptidase I
4 I
( I
hDPP4 I
) I
receptor O
and O
then O
analyzed O
the O
ability O
of O
mice O
to O
control O
MERS O
- O
CoV O
infection O
. O

Endoribonuclease B
( I
NendoU I
) I
is O
unique O
and O
conserved O
as O
a O
major O
genetic O
marker O
in O
nidoviruses O
that O
infect O
vertebrate O
hosts O
. O

Arterivirus O
nonstructural B
protein I
11 I
( I
nsp11 I
) I
was O
shown O
to O
have O
NendoU O
activity O
and O
play O
essential O
roles O
in O
the O
viral O
life O
cycle O
. O

Here O
, O
we O
report O
three O
crystal O
structures O
of O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
and O
equine B
arteritis I
virus I
( I
EAV I
) I
nsp11 O
mutants O
. O

The O
structures O
of O
arterivirus O
nsp11 O
contain O
two O
conserved O
compact O
domains O
: O
the O
N B
- I
terminal I
domain I
( I
NTD I
) I
and O
C B
- I
terminal I
domain I
( I
CTD I
) I
. O

The O
structures O
of O
PRRSV O
and O
EAV O
endoribonucleases O
are O
similar O
and O
conserved O
in O
the O
arterivirus O
, O
but O
they O
are O
greatly O
different O
from O
that O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
and O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
Coronaviruses B
( I
CoV I
) I
, O
representing O
important O
human O
pathogens O
in O
the O
Nidovirales O
order O
. O

IMPORTANCE O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
and O
equine O
arteritis O
virus O
are O
two O
major O
members O
of O
the O
arterivirus O
family O
. O

PRRSV O
costs O
the O
swine O
industry O
around O
$ O
644 O
million O
annually O
in O
the O
United O
States O
and O
almost O
( O
sic O
) O
1 O
. O

To O
find O
a O
way O
to O
combat O
these O
viruses O
, O
we O
focused O
on O
the O
essential O
viral O
nonstructural B
protein I
11 I
( I
nsp11 I
) I
. O

Previous O
reports O
have O
demonstrated O
that O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERSCoV I
) I
predominantly O
utilizes O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
for O
cell O
entry O
. O

In O
the O
current O
study O
, O
using O
the O
virus B
overlay I
protein I
binding I
assay I
( I
VOPBA I
) I
, O
we O
identified O
carcinoembryonic B
antigen I
- I
related I
cell I
adhesion I
molecule I
5 I
( I
CEACAM5 I
) I
as O
a O
novel O
cell O
surface O
binding O
target O
of O
MERS O
- O
CoV O
. O

Disrupting O
the O
interaction O
between O
CEACAM5 O
and O
MERS O
- O
CoV O
spike O
with O
anti O
- O
CEACAM5 O
antibody O
, O
recombinant O
CEACAM5 O
protein O
, O
or O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
CEACAM5 O
significantly O
inhibited O
the O
entry O
of O
MERS O
- O
CoV O
. O

Recombinant O
expression O
of O
CEACAM5 O
did O
not O
render O
nonpermissive O
baby B
hamster I
kidney I
( I
BHK21 I
) I
cells O
susceptible O
to O
MERS O
- O
CoV O
infection O
. O

IMPORTANCE O
Infection O
with O
the O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
associated O
with O
the O
highest O
mortality O
rate O
among O
all O
known O
human O
- O
pathogenic O
coronaviruses O
. O

The O
identification O
of O
carcinoembryonic B
antigen I
- I
related I
cell I
adhesion I
molecule I
5 I
( I
CEACAM5 I
) I
as O
a O
novel O
cell O
surface O
binding O
target O
of O
MERS O
- O
CoV O
advanced O
our O
knowledge O
on O
the O
cell O
binding O
biology O
of O
MERS O
- O
CoV O
. O

In O
this O
regard O
, O
CEACAM5 O
could O
serve O
as O
a O
novel O
target O
, O
in O
addition O
to O
dipeptidyl B
peptidase I
- I
4 I
( I
DPP4 I
) I
, O
in O
the O
development O
of O
antiviral O
strategies O
for O
MERS O
- O
CoV O
. O

The O
novel O
emerging O
coronavirus O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
binds O
to O
its O
receptor O
, O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
, O
via O
14 O
interacting O
amino O
acids O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
not O
efficiently O
transmitted O
between O
humans O
, O
but O
it O
is O
highly O
prevalent O
in O
dromedary O
camels O
. O

Here O
we O
report O
that O
the O
MERS O
- O
CoV O
receptor O
- O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
- O
is O
expressed O
in O
the O
upper O
respiratory O
tract O
epithelium O
of O
camels O
but O
not O
in O
that O
of O
humans O
. O

Middle B
East I
respiratory I
syndrome I
- I
related I
coronavirus I
( I
MERS I
- I
CoV I
) I
spreads O
to O
humans O
via O
zoonotic O
transmission O
from O
camels O
. O

MERS O
- O
CoV O
belongs O
to O
lineage O
C O
of O
betacoronaviruses B
( I
betaCoVs I
) I
, O
which O
also O
includes O
viruses O
isolated O
from O
bats O
and O
hedgehogs O
. O

A O
large O
portion O
of O
the O
betaCoV O
genome O
consists O
of O
two O
open O
reading O
frames O
( O
ORF1a O
and O
ORF1b O
) O
that O
are O
translated O
into O
polyproteins O
. O

These O
are O
cleaved O
by O
viral O
proteases O
to O
generate O
16 O
nonstructural O
proteins O
( O
nsp1 O
to O
nsp16 O
) O
which O
compose O
the O
viral O
replication O
- O
transcription O
complex O
. O

Adaptive O
evolution O
at O
nsp3 O
is O
ongoing O
in O
MERS O
- O
CoV O
strains O
, O
and O
two O
selected O
sites O
( O
G720 O
and O
R911 O
) O
were O
detected O
in O
the O
protease O
domain O
. O

Characterized O
animal O
models O
are O
needed O
for O
studying O
the O
pathogenesis O
of O
and O
evaluating O
medical O
countermeasures O
for O
persisting O
Middle B
East I
respiratory I
syndrome I
- I
coronavirus I
( I
MERS I
- I
CoV I
) I
infections O
. O

Here O
, O
we O
further O
characterized O
a O
lethal O
transgenic O
mouse O
model O
of O
MERS O
- O
CoV O
infection O
and O
disease O
that O
globally O
expresses O
human B
CD26 I
( I
hCD26 I
) I
/ O
DPP4 O
. O

The O
50 B
% I
infectious I
dose I
( I
ID50 I
) I
and O
lethal B
dose I
( I
LD50 I
) I
of O
virus O
were O
estimated O
to O
be O
< O
1 O
and O
10 O
TCID50 O
of O
MERS O
- O
CoV O
, O
respectively O
. O

In O
contrast O
to O
the O
overwhelming O
infection O
seen O
in O
the O
mice O
challenged O
with O
10 O
( O
5 O
) O
LD50 O
of O
MERS O
- O
CoV O
, O
we O
were O
able O
to O
recover O
infectious O
virus O
from O
these O
mice O
only O
infrequently O
, O
although O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
tests O
indicated O
early O
and O
persistent O
lung O
infection O
and O
delayed O
occurrence O
of O
brain O
infection O
. O

We O
previously O
showed O
that O
close O
relatives O
of O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
exist O
in O
African O
bats O
. O

Here O
, O
we O
tested O
2 O
, O
087 O
fecal O
specimens O
from O
11 O
bat O
species O
sampled O
in O
Ghana O
for O
HCoV O
- O
229E O
- O
related O
viruses O
by O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
. O

Bat O
viruses O
were O
5 O
- O
and O
6 O
- O
fold O
more O
diversified O
than O
HCoV O
- O
229E O
in O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
and O
spike O
genes O
. O

Analyses O
of O
four O
full O
genomes O
from O
229E O
- O
related O
bat O
CoVs O
revealed O
an O
eighth O
open O
reading O
frame O
( O
ORF8 O
) O
located O
at O
the O
genomic O
3 O
' O
end O
. O

IMPORTANCE O
The O
ancestral O
origins O
of O
major O
human B
coronaviruses I
( I
HCoVs I
) I
likely O
involve O
bat O
hosts O
. O

The O
evolutionary O
history O
of O
HCoV O
- O
229E O
likely O
shares O
important O
characteristics O
with O
that O
of O
the O
recently O
emerged O
highly O
pathogenic O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
coronavirus O
. O

In O
2012 O
, O
the O
first O
cases O
of O
infection O
with O
the O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
were O
identified O
. O

Replication O
- O
competent O
recombinant O
measles B
virus I
( I
MV I
) I
expressing O
foreign O
antigens O
constitutes O
a O
promising O
tool O
to O
induce O
protective O
immunity O
against O
corresponding O
pathogens O
. O

Therefore O
, O
we O
generated O
MVs O
expressing O
the O
spike O
glycoprotein O
of O
MERS O
- O
CoV O
in O
its O
full O
- O
length O
( O
MERS O
- O
S O
) O
or O
a O
truncated O
, O
soluble B
variant I
of I
MERS I
- I
S I
( I
MERS I
- I
solS I
) I
. O

The O
genes O
encoding O
MERS O
- O
S O
and O
MERS O
- O
solS O
were O
cloned O
into O
the O
vaccine O
strain O
MVvac2 O
genome O
, O
and O
the O
respective O
viruses O
were O
rescued O
( O
MVvac2 O
- O
CoV O
- O
S O
and O
MVvac2 O
- O
CoV O
- O
solS O
) O
. O

The O
replication O
of O
MVvac2 O
- O
CoV O
- O
S O
in O
Vero O
cells O
turned O
out O
to O
be O
comparable O
to O
that O
of O
the O
control O
virus O
MVvac2 O
- O
GFP O
( O
encoding O
green O
fluorescent O
protein O
) O
, O
while O
titers O
of O
MVvac2 O
- O
CoV O
- O
solS O
were O
impaired O
approximately O
3 O
- O
fold O
. O

In O
vivo O
, O
immunization O
of O
type O
I O
interferon O
receptor O
- O
deficient O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
- O
CD46Ge O
mice O
with O
2 O
x O
10 O
( O
5 O
) O
50 O
% O
tissue O
culture O
infective O
doses O
of O
MVvac2 O
- O
CoV O
- O
S O
( O
H O
) O
or O
MVvac2 O
- O
CoV O
- O
solS O
( O
H O
) O
in O
a O
prime O
- O
boost O
regimen O
induced O
robust O
levels O
of O
both O
MV O
- O
and O
MERS O
- O
CoV O
- O
neutralizing O
antibodies O
. O

Coronaviruses B
( I
CoVs I
) I
assemble O
by O
budding O
into O
the O
lumen O
of O
the O
early O
Golgi O
complex O
prior O
to O
exocytosis O
. O

The O
small O
CoV O
envelope B
( I
E I
) I
protein O
plays O
roles O
in O
assembly O
, O
virion O
release O
, O
and O
pathogenesis O
. O

CoV O
E O
has O
a O
single O
hydrophobic B
domain I
( I
HD I
) I
, O
is O
targeted O
to O
Golgi O
complex O
membranes O
, O
and O
has O
cation O
channel O
activity O
in O
vitro O
. O

Structural O
data O
for O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
CoV O
E O
protein O
suggest O
that O
it O
assembles O
into O
a O
homopentamer O
. O

The O
E O
protein O
from O
the O
avian B
infectious I
bronchitis I
virus I
( I
IBV I
) I
has O
dramatic O
effects O
on O
the O
secretory O
system O
which O
require O
residues O
in O
the O
HD O
. O

A O
high O
- O
order O
oligomer O
of O
IBV O
E O
is O
required O
for O
the O
production O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
, O
implicating O
this O
form O
of O
the O
protein O
in O
virion O
assembly O
. O

IMPORTANCE O
CoVs O
are O
important O
human O
pathogens O
with O
significant O
zoonotic O
potential O
, O
as O
demonstrated O
by O
the O
emergence O
of O
SARS O
- O
CoV O
and O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
- O
CoV O
. O

Coronavirus O
spike B
( I
S I
) I
glycoproteins O
mediate O
receptor O
binding O
, O
membrane O
fusion O
, O
and O
virus O
entry O
and O
determine O
host O
range O
. O

Murine O
betacoronavirus B
( I
beta I
- I
CoV I
) I
in O
group O
A O
uses O
the O
N B
- I
terminal I
domain I
( I
NTD I
) I
of O
S O
protein O
to O
bind O
to O
its O
receptor O
, O
whereas O
the O
beta O
- O
CoVs O
severe O
acute O
respiratory O
syndrome O
CoV O
in O
group O
B O
and O
Middle O
East O
respiratory O
syndrome O
CoV O
in O
group O
C O
and O
several O
alpha O
- O
CoVs O
use O
the O
downstream O
C O
domain O
in O
their O
S O
proteins O
to O
recognize O
their O
receptor O
proteins O
. O

To O
identify O
the O
receptor O
- O
binding O
domain O
in O
the O
spike O
of O
human O
beta O
- O
CoV O
HKU1 O
in O
group O
A O
, O
we O
generated O
and O
mapped O
a O
panel O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
to O
the O
ectodomain O
of O
HKU1 O
spike O
protein O
. O

Two O
of O
the O
MAbs O
blocked O
HKU1 O
virus O
infection O
of O
primary O
human B
tracheal I
- I
bronchial I
epithelial I
( I
HTBE I
) I
cells O
. O

These O
data O
suggest O
that O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
of O
HKU1 O
spike O
protein O
is O
located O
in O
the O
C O
domain O
, O
where O
the O
spike O
proteins O
of O
alpha O
- O
CoVs O
and O
beta O
- O
CoVs O
in O
groups O
B O
and O
C O
bind O
to O
their O
specific O
receptor O
proteins O
. O

To O
understand O
how O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
transmitted O
from O
bats O
to O
humans O
, O
we O
compared O
the O
virus O
surface O
spikes O
of O
MERS O
- O
CoV O
and O
a O
related O
bat O
coronavirus O
, O
HKU4 O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
severe O
respiratory O
disease O
in O
humans O
. O

We O
tested O
a O
recombinant O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
vaccine O
expressing O
full O
- O
length O
MERS O
- O
CoV O
spike B
( I
S I
) I
glycoprotein O
by O
immunizing O
BALB O
/ O
c O
mice O
with O
either O
intramuscular O
or O
subcutaneous O
regimens O
. O

In O
all O
cases O
, O
MVA O
- O
MERS O
- O
S O
induced O
MERS O
- O
CoV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
and O
virus O
- O
neutralizing O
antibodies O
. O

Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
is O
a O
highly O
lethal O
pulmonary O
infection O
. O

The O
ability O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
to O
infect O
small O
animal O
species O
may O
be O
restricted O
given O
the O
fact O
that O
mice O
, O
ferrets O
, O
and O
hamsters O
were O
shown O
to O
resist O
MERS O
- O
CoV O
infection O
. O

Ubiquitin B
- I
like I
domains I
( I
Ubls I
) I
now O
are O
recognized O
as O
common O
elements O
adjacent O
to O
viral O
and O
cellular O
proteases O
; O
however O
, O
their O
function O
is O
unclear O
. O

Structural O
studies O
of O
the O
papain B
- I
like I
protease I
( I
PLP I
) I
domains O
of O
Coronaviruses B
( I
CoVs I
) I
revealed O
an O
adjacent O
Ubl O
domain O
in O
severe O
acute O
respiratory O
syndrome O
CoV O
, O
Middle O
East O
respiratory O
syndrome O
CoV O
, O
and O
the O
murine O
CoV O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

Using O
reverse O
genetics O
, O
we O
engineered O
Ubl O
mutant O
viruses O
and O
found O
that O
AM2 O
( O
V787S O
) O
and O
AM3 O
( O
V785S O
) O
viruses O
replicate O
efficiently O
at O
37 O
degrees O
C O
but O
generate O
smaller O
plaques O
than O
wild B
- I
type I
( I
WT I
) I
virus O
, O
and O
AM2 O
is O
defective O
for O
replication O
at O
higher O
temperatures O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
isolates O
JHM O
. O

These O
two O
JHM O
variants O
encode O
homologous O
proteins O
with O
few O
polymorphisms O
, O
and O
little O
is O
known O
about O
which O
viral O
proteins O
( O
s O
) O
is O
responsible O
for O
the O
liver O
tropism O
of O
JHM O
. O

The O
spread O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
and O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
into O
human O
populations O
demonstrates O
the O
zoonotic O
potential O
of O
emerging O
coronaviruses O
, O
and O
there O
are O
currently O
no O
vaccines O
or O
effective O
antivirals O
for O
human O
coronaviruses O
. O

The O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
emerged O
in O
2012 O
as O
the O
causative O
agent O
of O
a O
severe O
respiratory O
disease O
with O
a O
fatality O
rate O
of O
approximately O
30 O
% O
. O

The O
high O
virulence O
and O
mortality O
rate O
prompted O
us O
to O
analyze O
aspects O
of O
MERS O
- O
CoV O
pathogenesis O
, O
especially O
its O
interaction O
with O
innate O
immune O
cells O
such O
as O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
. O

Particularly O
, O
we O
analyzed O
secretion O
of O
type O
I O
and O
type O
III O
Interferons B
( I
IFNs I
) I
by O
APCs O
, O
i O
. O

, O
B O
cells O
, O
macrophages O
, O
monocyte B
- I
derived I
/ I
myeloid I
dendritic I
cells I
( I
MDDCs I
/ I
mDCs I
) I
, O
and O
by O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
of O
human O
and O
murine O
origin O
after O
inoculation O
with O
MERS O
- O
CoV O
. O

Production O
of O
large O
amounts O
of O
type O
I O
and O
III O
IFNs O
was O
induced O
exclusively O
in O
human O
pDCs O
, O
which O
were O
significantly O
higher O
than O
IFN O
induction O
by O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
CoV O
. O

However O
, O
receptor O
binding O
, O
endosomal O
uptake O
, O
and O
probably O
signaling O
via O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
were O
critical O
for O
sensing O
of O
MERS O
- O
CoV O
by O
pDCs O
. O

Taken O
together O
, O
our O
results O
point O
toward O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
- O
dependent O
endosomal O
uptake O
and O
subsequent O
infection O
of O
human O
pDCs O
by O
MERS O
- O
CoV O
. O

In O
addition O
to O
transporting O
ions O
, O
the O
multisubunit O
Na O
+ O
, O
K O
+ O
- O
ATPase O
also O
functions O
by O
relaying O
cardiotonic B
steroid I
( I
CTS I
) I
- O
binding O
- O
induced O
signals O
into O
cells O
. O

In O
this O
study O
, O
we O
analyzed O
the O
role O
of O
Na O
+ O
, O
K O
+ O
- O
ATPase O
and O
, O
in O
particular O
, O
of O
its O
ATP1A1 O
alpha O
subunit O
during O
Coronavirus B
( I
CoV I
) I
infection O
. O

As O
controls O
, O
the O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
influenza B
A I
virus I
( I
IAV I
) I
were O
included O
. O

Using O
gene O
silencing O
, O
the O
ATP1A1 O
protein O
was O
shown O
to O
be O
critical O
for O
infection O
of O
cells O
with O
murine B
hepatitis I
virus I
( I
MHV I
) I
, O
feline B
infectious I
peritonitis I
virus I
( I
FIPV I
) I
, O
and O
VSV O
but O
not O
with O
IAV O
. O

Consistently O
, O
nanomolar O
concentrations O
of O
the O
cardiotonic O
steroids O
ouabain O
and O
bufalin O
, O
which O
are O
known O
not O
to O
affect O
the O
transport O
function O
of O
Na O
+ O
, O
K O
+ O
- O
ATPase O
, O
inhibited O
infection O
of O
cells O
with O
MHV O
, O
FIPV O
, O
Middle B
East I
respiratory I
syndrome I
( I
MERS I
) I
- O
CoV O
, O
and O
VSV O
, O
but O
not O
IAV O
, O
when O
the O
compounds O
were O
present O
during O
virus O
inoculation O
. O

IMPORTANCE O
Coronaviruses B
( I
CoVs I
) I
are O
important O
pathogens O
of O
animals O
and O
humans O
, O
as O
demonstrated O
by O
the O
recent O
emergence O
of O
new O
human O
CoVs O
of O
zoonotic O
origin O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
utilizes O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
as O
an O
entry O
receptor O
. O

mouse B
DPP4 I
( I
mDPP4 I
) I
does O
not O
support O
MERS O
- O
CoV O
entry O
; O
however O
, O
changes O
at O
positions O
288 O
and O
330 O
can O
confer O
permissivity O
. O

Although O
the O
severe B
acute I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
SARS I
- I
CoV I
) I
epidemic O
was O
controlled O
by O
nonvaccine O
measures O
, O
coronaviruses O
remain O
a O
major O
threat O
to O
human O
health O
. O

Protection O
against O
eosinophilic O
immunopathology O
by O
vaccines O
containing O
delta O
inulin O
adjuvants O
correlated O
better O
with O
enhanced O
T O
- O
cell O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
recall O
responses O
rather O
than O
reduced O
interleukin B
- I
4 I
( I
IL I
- I
4 I
) I
responses O
, O
suggesting O
that O
immunopathology O
predominantly O
reflects O
an O
inadequate O
vaccine O
- O
induced O
Th1 O
response O
. O

IMPORTANCE O
Coronaviruses O
such O
as O
SARS O
- O
CoV O
and O
Middle B
East I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
MERS I
- I
CoV I
) I
cause O
high O
case O
fatality O
rates O
and O
remain O
major O
human O
public O
health O
threats O
, O
creating O
a O
need O
for O
effective O
vaccines O
. O

We O
discovered O
a O
novel O
Betacoronavirus O
lineage O
A O
coronavirus O
, O
China B
Rattus I
coronavirus I
( I
ChRCoV I
) I
HKU24 O
, O
from O
Norway O
rats O
in O
China O
. O

Its O
unique O
putative O
cleavage O
sites O
between O
nonstructural O
proteins O
1 O
and O
2 O
and O
in O
the O
spike B
( I
S I
) I
protein O
and O
low O
sequence O
identities O
to O
other O
lineage O
A O
betacoronaviruses O
( O
beta O
CoVs O
) O
in O
conserved O
replicase O
domains O
support O
ChRCoV O
HKU24 O
as O
a O
separate O
species O
. O

ChRCoV O
HKU24 O
possessed O
genome O
features O
that O
resemble O
those O
of O
both O
Betacoronavirus O
1 O
and O
murine O
coronavirus O
, O
being O
closer O
to O
Betacoronavirus O
1 O
in O
most O
predicted O
proteins O
but O
closer O
to O
murine O
coronavirus O
by O
G O
+ O
C O
content O
, O
the O
presence O
of O
a O
single O
nonstructural O
protein O
( O
NS4 O
) O
, O
and O
an O
absent O
transcription O
regulatory O
sequence O
for O
the O
envelope B
( I
E I
) I
protein O
. O

Its O
N B
- I
terminal I
domain I
( I
NTD I
) I
demonstrated O
higher O
sequence O
identity O
to O
the O
bovine B
coronavirus I
( I
BCoV I
) I
NTD O
than O
to O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
NTD O
, O
with O
3 O
of O
4 O
critical O
sugar O
- O
binding O
residues O
in O
BCoV O
and O
2 O
of O
14 O
contact O
residues O
at O
the O
MHV O
NTD O
/ O
murine O
CEACAM1a O
interface O
being O
conserved O
. O

IMPORTANCE O
While O
bats O
and O
birds O
are O
hosts O
for O
ancestors O
of O
most O
Coronaviruses B
( I
CoVs I
) I
, O
lineage O
A O
beta O
CoVs O
have O
never O
been O
found O
in O
these O
animals O
and O
the O
origin O
of O
Betacoronavirus O
lineage O
A O
remains O
obscure O
. O

We O
discovered O
a O
novel O
lineage O
A O
beta O
CoV O
, O
China O
Rattus O
coronavirus O
HKU24 O
( O
ChRCoV O
HKU24 O
) O
, O
from O
Norway O
rats O
in O
China O
with O
a O
high O
seroprevalence O
. O

Our O
data O
suggest O
that O
ChRCoV O
HKU24 O
represents O
the O
murine O
origin O
of O
Betacoronavirus O
1 O
, O
with O
interspecies O
transmission O
from O
rodents O
to O
other O
mammals O
having O
occurred O
centuries O
ago O
, O
before O
the O
emergence O
of O
human B
coronavirus I
( I
HCoV I
) I
OC43 O
in O
the O
late O
1800s O
. O

The O
receptor B
binding I
domain I
( I
RBD I
) I
of O
the O
spike B
( I
S I
) I
glycoprotein O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
is O
a O
major O
target O
of O
protective O
immunity O
in O
vivo O
. O

Although O
a O
large O
number O
of O
neutralizing B
antibodies I
( I
NAbs I
) I
have O
been O
developed O
, O
it O
remains O
unclear O
if O
a O
single O
RBD O
- O
targeting O
nAb O
or O
two O
in O
combination O
can O
prevent O
neutralization O
escape O
and O
, O
if O
not O
, O
attenuate O
viral O
virulence O
in O
vivo O
. O

In O
this O
study O
, O
we O
used O
a O
large O
panel O
of O
human O
nAbs O
against O
an O
epitope O
that O
overlaps O
the O
interface O
between O
the O
RBD O
and O
its O
receptor O
, O
angiotensin B
- I
converting I
enzyme I
2 I
( I
ACE2 I
) I
, O
to O
assess O
their O
cross O
- O
neutralization O
activities O
against O
a O
panel O
of O
human O
and O
zoonotic O
SARS O
- O
CoVs O
and O
neutralization O
escape O
mutants O
. O

Interestingly O
, O
in O
mice O
the O
neutralization O
escape O
mutant O
viruses O
showed O
either O
attenuation O
( O
Urbani O
background O
) O
or O
increased O
virulence O
( O
GD03 O
background O
) O
consistent O
with O
the O
different O
binding O
affinities O
between O
their O
RBDs O
and O
the O
mouse O
ACE2 O
. O

IMPORTANCE O
The O
emergence O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
in O
2002 O
and O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
in O
2012 O
has O
resulted O
in O
severe O
human O
respiratory O
disease O
with O
high O
death O
rates O
. O

Broadly O
neutralizing B
antibodies I
( I
NAbs I
) I
that O
prevent O
infection O
of O
related O
viruses O
represent O
an O
important O
immunostrategy O
for O
combating O
coronavirus O
infections O
; O
however O
, O
for O
this O
strategy O
to O
succeed O
, O
it O
is O
essential O
to O
uncover O
nAb O
- O
mediated O
escape O
pathways O
and O
to O
pioneer O
strategies O
that O
prevent O
escape O
. O

Here O
, O
we O
used O
SARS O
- O
CoV O
as O
a O
research O
model O
and O
examined O
the O
escape O
pathways O
of O
broad O
nAbs O
that O
target O
the O
receptor B
binding I
domain I
( I
RBD I
) I
of O
the O
virus O
. O

Our O
results O
suggest O
that O
targeting O
conserved O
regions O
with O
less O
plasticity O
and O
more O
structural O
constraint O
rather O
than O
the O
SARS O
- O
CoV O
RBD O
- O
like O
region O
( O
s O
) O
should O
have O
broader O
utility O
for O
antibody O
- O
based O
immunotherapy O
. O

The O
papain B
- I
like I
protease I
( I
PLpro I
) I
domain O
from O
the O
deadly O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
was O
overexpressed O
and O
purified O
. O

MERS O
- O
CoV O
PLpro O
constructs O
with O
and O
without O
the O
putative O
ubiquitin B
- I
like I
( I
UBL I
) I
domain O
at O
the O
N O
terminus O
were O
found O
to O
possess O
protease O
, O
deubiquitinating O
, O
deISGylating O
, O
and O
interferon O
antagonism O
activities O
in O
transfected O
HEK293T O
cells O
. O

The O
quaternary O
structure O
and O
substrate O
preferences O
of O
MERS O
- O
CoV O
PLpro O
were O
determined O
and O
compared O
to O
those O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
PLpro O
, O
revealing O
prominent O
differences O
between O
these O
closely O
related O
enzymes O
. O

Steady O
- O
state O
kinetic O
analyses O
of O
purified O
MERS O
- O
CoV O
and O
SARS O
- O
CoV O
PLpros O
uncovered O
significant O
differences O
in O
their O
rates O
of O
hydrolysis O
of O
5 O
- O
aminomethyl B
coumarin I
( I
AMC I
) I
from O
C O
- O
terminally O
labeled O
peptide O
, O
ubiquitin O
, O
and O
ISG15 O
substrates O
, O
as O
well O
as O
in O
their O
rates O
of O
isopeptide O
bond O
cleavage O
of O
K48 O
- O
and O
K63 O
- O
linked O
polyubiquitin O
chains O
. O

IMPORTANCE O
Unlocking O
the O
secrets O
of O
how O
coronavirus B
( I
CoV I
) I
papain I
- I
like I
proteases I
( I
PLpros I
) I
perform O
their O
multifunctional O
roles O
during O
viral O
replication O
entails O
a O
complete O
mechanistic O
understanding O
of O
their O
substrate O
recognition O
and O
enzymatic O
activities O
. O

Here O
, O
we O
exploit O
a O
biosafety B
level I
2 I
( I
BSL I
- I
2 I
) I
chimeric O
Sindbis O
virus O
system O
to O
evaluate O
protease O
activities O
and O
the O
efficacy O
of O
inhibitors O
directed O
against O
the O
papain B
- I
like I
protease I
( I
PLpro I
) I
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
a O
biosafety B
level I
3 I
( I
BSL I
- I
3 I
) I
pathogen O
. O

We O
engineered O
Sindbis O
virus O
to O
coexpress O
PLpro O
and O
a O
substrate O
, O
murine O
interferon B
- I
stimulated I
gene I
15 I
( I
ISG15 I
) I
, O
and O
found O
that O
PLpro O
mediates O
removal O
of O
ISG15 O
( O
deISGylation O
) O
from O
cellular O
proteins O
. O

Infection O
of O
alpha O
/ O
beta O
interferon O
receptor O
knockout O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
mice O
with O
these O
chimeric O
viruses O
revealed O
that O
PLpro O
deISGylation O
activity O
removed O
ISG15 O
- O
mediated O
protection O
during O
viral O
infection O
. O

We O
extended O
the O
chimeric O
- O
virus O
platform O
to O
evaluate O
the O
papain O
- O
like O
protease O
/ O
deISGylating O
activity O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
to O
provide O
a O
small O
- O
animal O
model O
to O
evaluate O
PLpro O
inhibitors O
of O
this O
recently O
emerged O
pathogen O
. O

The O
type B
II I
transmembrane I
serine I
protease I
( I
TTSP I
) I
TMPRSS2 O
cleaves O
and O
activates O
the O
influenza O
virus O
and O
coronavirus O
surface O
proteins O
. O

The O
emerging O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
lethal O
respiratory O
infections O
mainly O
on O
the O
Arabian O
Peninsula O
. O

We O
determined O
the O
full O
genome O
sequence O
of O
a O
CoV O
directly O
from O
fecal O
material O
obtained O
from O
a O
South O
African O
Neoromicia B
capensis I
bat I
( I
NeoCoV I
) I
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
emerged O
in O
2012 O
. O

Recently O
, O
the O
MERS O
- O
CoV O
receptor O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
was O
identified O
and O
the O
specific O
interaction O
of O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
of O
MERS O
- O
CoV O
spike O
protein O
and O
DPP4 O
was O
determined O
by O
crystallography O
. O

Modeling O
the O
binding O
energies O
of O
MERS O
- O
CoV O
spike O
protein O
RBD O
to O
DPP4 O
of O
human O
( O
susceptible O
) O
or O
hamster O
( O
nonsusceptible O
) O
identified O
five O
amino O
acid O
residues O
involved O
in O
the O
DPP4 O
- O
RBD O
interaction O
. O

Prophylactic O
and O
therapeutic O
strategies O
are O
urgently O
needed O
to O
combat O
infections O
caused O
by O
the O
newly O
emerged O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
. O

Here O
, O
we O
have O
developed O
a O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
, O
designated O
Mersmab1 O
, O
which O
potently O
blocks O
MERS O
- O
CoV O
entry O
into O
human O
cells O
. O

Biochemical O
assays O
reveal O
that O
Mersmab1 O
specifically O
binds O
to O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
of O
the O
MERS O
- O
CoV O
spike O
protein O
and O
thereby O
competitively O
blocks O
the O
binding O
of O
the O
RBD O
to O
its O
cellular O
receptor O
, O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
. O

The O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
recently O
spread O
from O
an O
animal O
reservoir O
to O
infect O
humans O
, O
causing O
sporadic O
severe O
and O
frequently O
fatal O
respiratory O
disease O
. O

Cell O
entry O
begins O
with O
virus O
spike B
( I
S I
) I
protein O
binding O
to O
DPP4 O
receptors O
. O

However O
, O
even O
the O
low O
- O
affinity O
receptors O
could O
hypersensitize O
cells O
to O
infection O
when O
an O
S O
- O
cleaving O
protease O
( O
s O
) O
was O
present O
, O
indicating O
that O
affinity O
thresholds O
for O
virus O
entry O
must O
be O
considered O
in O
the O
context O
of O
host O
- O
cell O
proteolytic O
environments O
. O

Human B
dipeptidyl I
peptidase I
4 I
( I
hDPP4 I
) I
was O
recently O
identified O
as O
the O
receptor O
for O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infection O
, O
suggesting O
that O
other O
mammalian O
DPP4 O
orthologs O
may O
also O
support O
infection O
. O

However O
, O
employing O
mouse O
DPP4 O
as O
a O
scaffold O
, O
we O
identified O
two O
critical O
amino O
acids O
( O
A288L O
and O
T330R O
) O
that O
regulate O
species O
specificity O
in O
the O
mouse O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
an O
emerging O
pathogen O
that O
causes O
severe O
disease O
in O
human O
. O

MERS O
- O
CoV O
4a O
protein O
contains O
a O
double O
- O
stranded O
RNA O
- O
binding O
domain O
capable O
of O
interacting O
with O
poly O
( O
I O
center O
dot O
C O
) O
. O

Expression O
of O
MERS O
- O
CoV O
4a O
protein O
suppressed O
the O
interferon O
production O
induced O
by O
poly O
( O
I O
center O
dot O
C O
) O
or O
Sendai O
virus O
. O

The O
identification O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
in O
2012 O
reaffirmed O
the O
importance O
of O
understanding O
how O
coronaviruses O
emerge O
, O
infect O
, O
and O
cause O
disease O
. O

By O
comparing O
what O
is O
known O
about O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
to O
what O
has O
recently O
been O
found O
for O
MERS O
- O
CoV O
, O
researchers O
are O
discovering O
similarities O
and O
differences O
that O
may O
be O
important O
for O
pathogenesis O
. O

The O
outbreak O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infections O
and O
diseases O
represents O
a O
potential O
threat O
for O
worldwide O
spread O
and O
requires O
development O
of O
effective O
therapeutic O
strategies O
. O

In O
this O
study O
, O
we O
revealed O
a O
novel O
positive O
function O
of O
an O
exchange O
protein O
directly O
activated O
by O
cyclic O
AMP O
1 O
( O
cAMP O
- O
1 O
; O
Epac O
- O
1 O
) O
on O
MERS O
- O
CoV O
replication O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
replicates O
in O
cells O
of O
different O
species O
using O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
as O
a O
functional O
receptor O
. O

Adenosine B
deaminase I
( I
ADA I
) I
, O
a O
DPP4 O
binding O
protein O
, O
competed O
for O
virus O
binding O
, O
acting O
as O
a O
natural O
antagonist O
for O
MERS O
- O
CoV O
infection O
. O

Bats O
are O
known O
to O
host O
viruses O
closely O
related O
to O
important O
human B
coronaviruses I
( I
HCoVs I
) I
, O
such O
as O
HCoV O
- O
229E O
, O
severe O
- O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS O
- O
CoV O
) O
, O
and O
Middle B
East I
respiratory I
syndrome I
CoV I
( I
MERS I
- I
CoV I
) I
. O

As O
RNA O
viruses O
may O
coevolve O
with O
their O
hosts O
, O
we O
sought O
to O
investigate O
the O
closest O
sister O
taxon O
to O
bats O
, O
the O
Eulipotyphla O
, O
and O
screened O
European O
hedgehogs O
( O
Erinaceus O
europaeus O
) O
from O
Germany O
for O
CoV O
by O
nested O
reverse O
transcriptase O
PCR O
. O

9 O
% O
of O
hedgehog O
fecal O
specimens O
were O
positive O
for O
the O
novel O
CoV O
( O
EriCoV O
) O
at O
7 O
. O

9 O
log O
( O
10 O
) O
mean O
RNA O
copies O
per O
ml O
. O

The O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
utilizes O
host O
proteases O
for O
virus O
entry O
into O
lung O
cells O
. O

In O
the O
current O
study O
, O
Vero O
cells O
constitutively O
expressing O
type O
II O
transmembrane O
serine O
protease O
( O
Vero O
- O
TMPRSS2 O
cells O
) O
showed O
larger O
syncytia O
at O
18 O
h O
after O
infection O
with O
MERS O
- O
CoV O
than O
after O
infection O
with O
other O
coronaviruses O
. O

In O
contrast O
, O
a O
single O
camostat O
treatment O
suppressed O
MERS O
- O
CoV O
entry O
into O
human O
bronchial O
submucosal O
gland O
- O
derived O
Calu O
- O
3 O
cells O
by O
10 O
- O
fold O
and O
virus O
growth O
by O
270 O
- O
fold O
, O
although O
treatment O
with O
both O
camostat O
and O
( O
23 O
, O
25 O
) O
- O
trans O
- O
epoxysuccinyl O
- O
L O
- O
leucylamindo O
- O
3 O
- O
methylbutane O
ethyl O
ester O
, O
a O
cathepsin O
inhibitor O
, O
or O
treatment O
with O
leupeptin O
, O
an O
inhibitor O
of O
cysteine O
, O
serine O
, O
and O
threonine O
peptidases O
, O
was O
no O
more O
efficacious O
than O
treatment O
with O
camostat O
alone O
. O

Human O
Coronaviruses B
( I
CoVs I
) I
such O
as O
severe B
acute I
respiratory I
syndrome I
CoV I
( I
SARS I
- I
CoV I
) I
and O
Middle B
East I
respiratory I
syndrome I
CoV I
( I
MERS I
- I
CoV I
) I
cause O
epidemics O
of O
severe O
human O
respiratory O
disease O
. O

A O
conserved O
step O
of O
CoV O
replication O
is O
the O
translation O
and O
processing O
of O
replicase O
polyproteins O
containing O
16 O
nonstructural O
protein O
domains O
( O
nsp O
' O
s O
1 O
to O
16 O
) O
. O

The O
CoV O
nsp5 O
protease O
( O
3CLpro O
; O
Mpro O
) O
processes O
nsp O
' O
s O
at O
11 O
cleavage O
sites O
and O
is O
essential O
for O
virus O
replication O
. O

To O
test O
for O
conservation O
of O
nsp5 O
structure O
- O
function O
determinants O
, O
we O
engineered O
chimeric O
betacoronavirus O
murine B
hepatitis I
virus I
( I
MHV I
) I
genomes O
encoding O
nsp5 O
proteases O
of O
human O
and O
bat O
alphacoronaviruses O
and O
betacoronaviruses O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
recently O
emerged O
as O
a O
severe O
worldwide O
public O
health O
concern O
. O

It O
is O
known O
that O
the O
surface O
spike B
( I
S I
) I
proteins O
of O
coronaviruses O
mediate O
receptor O
recognition O
and O
membrane O
fusion O
, O
thereby O
playing O
an O
indispensable O
role O
in O
initiating O
infection O
. O

In O
this O
process O
, O
heptad O
repeats O
1 O
and O
2 O
( O
HR1 O
and O
HR2 O
) O
of O
the O
S O
protein O
assemble O
into O
a O
complex O
called O
the O
fusion O
core O
, O
which O
represents O
a O
key O
membrane O
fusion O
architecture O
. O

We O
identified O
the O
domains O
of O
CD26 O
involved O
in O
the O
binding O
of O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
using O
distinct O
clones O
of O
anti O
- O
CD26 O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
has O
recently O
emerged O
as O
a O
causative O
agent O
of O
severe O
respiratory O
disease O
in O
humans O
. O

Here O
, O
we O
constructed O
recombinant O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
expressing O
full O
- O
length O
MERS O
- O
CoV O
spike B
( I
S I
) I
protein O
( O
MVA O
- O
MERS O
- O
S O
) O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
causes O
severe O
acute O
respiratory O
infection O
with O
as O
yet O
unclear O
epidemiology O
. O

Accessory O
protein O
4a O
was O
found O
to O
block O
interferon O
induction O
at O
the O
level O
of O
Melanoma B
Differentiation I
- I
Associated I
protein I
5 I
( I
MDA5 I
) I
activation O
presumably O
by O
direct O
interaction O
with O
double O
- O
stranded O
RNA O
. O

The O
newly O
emerged O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
has O
infected O
at O
least O
77 O
people O
, O
with O
a O
fatality O
rate O
of O
more O
than O
50 O
% O
. O

Here O
we O
have O
identified O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
from O
the O
MERS O
- O
CoV O
spike O
protein O
and O
determined O
its O
crystal O
structure O
. O

A O
novel O
human B
Middle I
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
caused O
outbreaks O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
like O
illness O
with O
a O
high O
mortality O
rate O
, O
raising O
concerns O
of O
its O
pandemic O
potential O
. O

dipeptidyl B
peptidase I
- I
4 I
( I
DPP4 I
) I
was O
recently O
identified O
as O
its O
receptor O
. O

Here O
we O
showed O
that O
residues O
377 O
to O
662 O
in O
the O
S O
protein O
of O
MERS O
- O
CoV O
specifically O
bound O
to O
DPP4 O
- O
expressing O
cells O
and O
soluble O
DPP4 O
protein O
and O
induced O
significant O
neutralizing O
antibody O
responses O
, O
suggesting O
that O
this O
region O
contains O
the O
receptor B
- I
binding I
domain I
( I
RBD I
) I
, O
which O
has O
a O
potential O
to O
be O
developed O
as O
a O
MERS O
- O
CoV O
vaccine O
. O

The O
newly O
emerged O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
infects O
human O
bronchial O
epithelial O
Calu O
- O
3 O
cells O
. O

Unlike O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
CoV O
, O
which O
exclusively O
infects O
and O
releases O
through O
the O
apical O
route O
, O
this O
virus O
can O
do O
so O
through O
either O
side O
of O
polarized O
Calu O
- O
3 O
cells O
. O

The O
spike B
( I
S I
) I
protein O
of O
the O
recently O
emerged O
human B
Middle I
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
mediates O
infection O
by O
binding O
to O
the O
cellular O
receptor O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
. O

Here O
we O
mapped O
the O
receptor O
binding O
domain O
in O
the O
S O
protein O
to O
a O
231 O
- O
amino O
- O
acid O
fragment O
( O
residues O
358 O
to O
588 O
) O
by O
evaluating O
the O
interaction O
of O
spike O
truncation O
variants O
with O
receptor O
- O
expressing O
cells O
and O
soluble O
DPP4 O
. O

While O
the O
novel O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
closely O
related O
to O
Tylonycteris O
bat O
CoV O
HKU4 O
( O
Ty O
- O
BatCoV O
HKU4 O
) O
and O
Pipistrellus O
bat O
CoV O
HKU5 O
( O
Pi O
- O
BatCoV O
HKU5 O
) O
in O
bats O
from O
Hong O
Kong O
, O
and O
other O
potential O
lineage O
C O
betacoronaviruses O
in O
bats O
from O
Africa O
, O
Europe O
, O
and O
America O
, O
its O
animal O
origin O
remains O
obscure O
. O

Ty O
- O
BatCoV O
HKU4 O
and O
Pi O
- O
BatCoV O
HKU5 O
were O
detected O
in O
29 O
% O
and O
25 O
% O
of O
alimentary O
samples O
from O
lesser O
bamboo O
bat O
( O
Tylonycteris O
pachypus O
) O
and O
Japanese O
pipistrelle O
( O
Pipistrellus O
abramus O
) O
, O
respectively O
. O

Sequencing O
of O
their O
RNA O
polymerase O
( O
RdRp O
) O
, O
spike B
( I
S I
) I
, O
and O
nucleocapsid B
( I
N I
) I
genes O
revealed O
that O
MERS O
- O
CoV O
is O
more O
closely O
related O
to O
Pi O
- O
BatCoV O
HKU5 O
in O
RdRp O
( O
92 O
. O

Coxsackievirus B
A1 I
( I
CVA1 I
) I
belongs O
to O
human O
enterovirus O
species O
C O
within O
the O
family O
Picornaviridae O
, O
order O
Picornavirales O
. O

Enteroviruses B
( I
EVs I
) I
, O
members O
of O
the O
family O
Picornaviridae O
, O
are O
a O
genetically O
and O
antigenically O
diverse O
range O
of O
viruses O
causing O
acute O
infections O
in O
humans O
and O
several O
Old B
World I
monkey I
( I
OWM I
) I
species O
. O

Genetic O
characterization O
of O
the O
VP1 O
, O
VP4 O
, O
and O
partial O
VP2 O
genes O
, O
the O
5 O
' O
untranslated O
region O
, O
and O
partial O
3Dpol O
sequences O
enabled O
chimpanzee O
- O
derived O
EVs O
to O
be O
identified O
as O
( O
i O
) O
the O
species O
A O
type O
, O
EV76 O
, O
( O
ii O
) O
a O
new O
species O
D O
type O
assigned O
as O
EV111 O
, O
along O
with O
a O
human O
isolate O
from O
the O
Democratic O
Republic O
of O
Congo O
previously O
described O
by O
the O
International O
Committee O
on O
the O
Taxonomy O
of O
Viruses O
, O
and O
( O
iii O
) O
a O
new O
species O
B O
type O
( O
assigned O
as O
EV110 O
) O
most O
closely O
related O
to O
, O
although O
a O
distinct O
type O
from O
, O
the O
SA5 O
isolate O
recovered O
from O
a O
vervet O
monkey O
. O

feline B
calicivirus I
( I
FCV I
) I
, O
a O
member O
of O
the O
Vesivirus O
genus O
, O
provides O
a O
tractable O
model O
, O
since O
it O
may O
be O
propagated O
in O
cell O
culture O
. O

Feline B
junctional I
adhesion I
molecule I
1 I
( I
fJAM I
- I
1 I
) I
was O
recently O
identified O
as O
a O
functional O
receptor O
for O
FCV O
. O

enterovirus B
70 I
( I
EV70 I
) I
, O
the O
causative O
agent O
of O
acute O
hemorrhagic O
conjunctivitis O
, O
exhibits O
a O
restricted O
tropism O
for O
conjunctival O
and O
corneal O
cells O
in O
vivo O
but O
infects O
a O
wide O
spectrum O
of O
mammalian O
cells O
in O
culture O
. O

The O
complement O
regulatory B
protein I
decay I
- I
accelerating I
factor I
( I
DAF I
/ I
CD55 I
) I
is O
an O
attachment O
receptor O
for O
enterovirus B
70 I
( I
EV70 I
) I
, O
a O
member O
of O
the O
Picornaviridae O
, O
commonly O
associated O
with O
an O
eye O
infection O
in O
humans O
known O
as O
acute O
hemorrhagic O
conjunctivitis O
. O

Nucleotide O
sequences O
of O
the O
genome O
RNA O
encoding O
capsid O
protein O
VP1 O
( O
918 O
nucleotides O
) O
of O
18 O
enterovirus B
70 I
( I
EV70 I
) I
isolates O
collected O
from O
various O
parts O
of O
the O
world O
in O
1971 O
to O
1981 O
were O
determined O
, O
and O
nucleotide O
substitutions O
among O
them O
were O
studied O
. O

53 O
X O
10 O
( O
- O
3 O
) O
substitution O
per O
nucleotide O
per O
gear O
, O
while O
the O
nonsynonymous O
rate O
was O
extremely O
low O
at O
0 O
. O

32 O
X O
10 O
( O
- O
3 O
) O
substitution O
per O
nucleotide O
per O
year O
. O

00 O
X O
10 O
( O
- O
3 O
) O
substitution O
per O
nucleotide O
per O
gear O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
directed O
against O
the O
prototype O
enterovirus O
70 O
( O
EV O
- O
70 O
) O
strain O
J670 O
/ O
71 O
were O
generated O
and O
characterized O
in O
order O
to O
produce O
anti O
- O
idiotypic O
MAbs O
( O
MAb2s O
) O
for O
use O
as O
surrogate O
immunogens O
. O

An O
EV O
- O
70 O
- O
neutralizing O
antibody O
, O
MAb O
/ O
ev O
- O
12 O
( O
MAb1 O
) O
, O
was O
selected O
for O
the O
production O
of O
MAb2s O
. O

Immunization O
with O
each O
of O
the O
MAb2s O
was O
carried O
out O
for O
the O
production O
of O
anti O
- O
anti O
- O
idiotypic O
antibodies O
( O
Ab3 O
) O
. O

Coxsackievirus B
A5 I
( I
CV I
- I
A5 I
) I
has O
recently O
emerged O
as O
a O
main O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
pathogen O
. O

Following O
a O
large O
- O
scale O
vaccination O
campaign O
against O
enterovirus B
71 I
( I
EV I
- I
71 I
) I
in O
China O
, O
the O
number O
of O
HFMD O
- O
associated O
cases O
with O
EV O
- O
71 O
was O
reduced O
, O
especially O
severe O
and O
fatal O
cases O
. O

Within O
14 O
days O
postchallenge O
, O
groups O
of O
mice O
immunized O
with O
three O
formulations O
, O
empty B
particles I
( I
EPs I
) I
, O
full B
particles I
( I
FPs I
) I
, O
and O
a O
mixture O
of O
the O
EP O
and O
FP O
vaccine O
candidates O
, O
all O
survived O
, O
while O
100 O
% O
of O
the O
mock O
- O
immunized O
mice O
died O
. O

Neutralizing B
antibodies I
( I
NtAbs I
) I
were O
detected O
in O
the O
sera O
of O
immunized O
mice O
, O
and O
the O
NtAb O
levels O
were O
correlated O
with O
the O
survival O
rate O
of O
the O
challenged O
mice O
. O

Another O
interesting O
finding O
was O
the O
identification O
of O
CV O
- O
A5 O
dense B
particles I
( I
DPs I
) I
, O
facilitating O
morphogenesis O
study O
. O

Three O
particle O
forms O
, O
empty B
particles I
( I
EPs I
) I
, O
full B
particles I
( I
FPs I
) I
, O
and O
dense B
particles I
( I
DPs I
) I
, O
were O
obtained O
and O
characterized O
after O
purification O
. O

Human B
enteroviruses I
( I
EVs I
) I
, O
including O
coxsackieviruses O
, O
the O
numbered O
enteroviruses O
, O
and O
echoviruses O
, O
cause O
a O
wide O
range O
of O
diseases O
, O
such O
as O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
encephalitis O
, O
myocarditis O
, O
acute B
flaccid I
myelitis I
( I
AFM I
) I
, O
pneumonia O
, O
and O
bronchiolitis O
. O

Here O
, O
we O
demonstrate O
that O
FNC O
( O
2 O
' O
- O
deoxy O
- O
2 O
' O
- O
beta O
- O
fluoro O
- O
4 O
' O
- O
azidocytidine O
) O
, O
a O
small O
nucleoside O
analog O
inhibitor O
that O
has O
been O
demonstrated O
to O
be O
a O
potent O
inhibitor O
of O
HIV O
and O
entered O
into O
a O
clinical O
phase O
II O
trial O
in O
China O
, O
potently O
inhibits O
the O
viral O
replication O
of O
a O
multitude O
of O
EVs O
, O
including O
enterovirus B
71 I
( I
EV71 I
) I
, O
coxsackievirus B
A16 I
( I
CA16 I
) I
, O
CA6 O
, O
EVD68 O
, O
and O
coxsackievirus B
B3 I
( I
CVB3 I
) I
, O
at O
the O
nanomolar O
level O
. O

The O
antiviral O
mechanism O
of O
FNC O
involves O
mainly O
positive O
- O
and O
negative O
- O
strand O
RNA O
synthesis O
inhibition O
by O
targeting O
and O
competitively O
inhibiting O
the O
activity O
of O
EV71 O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
( O
3D O
( O
pol O
) O
) O
, O
as O
demonstrated O
through O
quantitative O
real O
- O
time O
reverse B
transcriptionPCR I
( I
RT I
- I
qPCR I
) I
, O
in O
vitro O
3D O
( O
pol O
) O
activity O
, O
and O
isothermal B
titration I
calorimetry I
( I
ITC I
) I
experiments O
. O

IMPORTANCE O
Human B
enterovirus I
( I
EV I
) I
pathogens O
cause O
various O
contagious O
diseases O
such O
as O
hand O
, O
foot O
, O
and O
mouth O
disease O
, O
encephalitis O
, O
myocarditis O
, O
acute O
flaccid O
myelitis O
, O
pneumonia O
, O
and O
bronchiolitis O
, O
which O
have O
become O
serious O
health O
threats O
. O

Further O
investigation O
revealed O
that O
FNC O
inhibits O
positive O
- O
and O
negative O
- O
strand O
RNA O
synthesis O
of O
EVs O
by O
interacting O
and O
interfering O
with O
the O
activity O
of O
EV71 O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
( O
3D O
( O
pol O
) O
) O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
causative O
agent O
of O
hand O
- O
foot O
- O
mouth O
disease O
, O
and O
it O
sometimes O
causes O
severe O
neurological O
disease O
. O

To O
overcome O
these O
problems O
, O
we O
used O
a O
mouse O
model O
expressing O
human B
scavenger I
receptor I
B2 I
( I
hSCARB2 I
) I
that O
showed O
lifelong O
susceptibility O
to O
EV71 O
. O

Here O
, O
we O
describe O
a O
novel O
EV71 O
vaccine O
efficacy O
test O
based O
on O
these O
hSCARB2 O
transgenic B
( I
Tg I
) I
mice O
and O
these O
virulent O
viruses O
. O

Virus O
- O
encoded O
proteases O
play O
diverse O
roles O
in O
the O
efficient O
replication O
of O
enterovirus B
71 I
( I
EV71 I
) I
, O
which O
is O
the O
causative O
agent O
of O
human O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
. O

Here O
, O
we O
designed O
activity B
- I
based I
probes I
( I
ABPs I
) I
based O
on O
an O
inhibitor O
of O
the O
main O
EV71 O
protease O
( O
3Cpro O
) O
, O
which O
is O
responsible O
for O
the O
hydrolysis O
of O
the O
EV71 O
polyprotein O
, O
and O
successfully O
identified O
host O
candidates O
that O
bind O
to O
the O
ABPs O
. O

Among O
the O
candidates O
, O
the O
host O
cysteine O
protease O
autophagy B
- I
related I
protein I
4 I
homolog I
B I
( I
ATG4B I
) I
, O
a O
key O
component O
of O
the O
autophagy O
machinery O
, O
was O
demonstrated O
to O
hydrolytically O
process O
the O
substrate O
of O
EV71 O
3Cpro O
and O
had O
activity O
comparable O
to O
that O
of O
the O
viral O
protease O
. O

IMPORTANCE O
enterovirus B
71 I
( I
EV71 I
) I
, O
one O
of O
the O
major O
pathogens O
of O
human O
HFMD O
, O
has O
caused O
outbreaks O
worldwide O
. O

hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
a O
highly O
contagious O
disease O
in O
children O
, O
is O
caused O
by O
human O
enteroviruses O
, O
including O
enterovirus B
71 I
( I
EV71 I
) I
, O
coxsackievirus B
A16 I
( I
CVA16 I
) I
, O
and O
coxsackievirus B
A6 I
( I
CVA6 I
) I
. O

Among O
them O
, O
brilliant O
black O
BN O
( O
E151 O
) O
was O
able O
to O
inhibit O
all O
EV71 O
, O
CVA16 O
, O
and O
CVA6 O
strains O
tested O
. O

IMPORTANCE O
Human B
enterovirus I
71 I
( I
EV71 I
) I
is O
one O
of O
the O
causative O
agents O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
in O
children O
and O
is O
responsible O
for O
thousands O
of O
deaths O
in O
the O
past O
20 O
years O
. O

Here O
, O
we O
discovered O
that O
one O
of O
these O
dyes O
, O
brilliant O
black O
BN O
( O
E151 O
) O
, O
was O
particularly O
effective O
in O
inhibiting O
the O
infectivity O
of O
EV71 O
in O
both O
cell O
culture O
and O
mouse O
model O
studies O
. O

enterovirus B
71 I
( I
EV71 I
) I
infection O
is O
generally O
associated O
with O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
and O
may O
cause O
severe O
neurological O
disorders O
and O
even O
death O
. O

We O
developed O
a O
transgenic B
( I
Tg I
) I
mouse O
that O
expresses O
an O
EV71 O
receptor O
, O
that O
is O
, O
human B
scavenger I
receptor I
class I
B I
member I
2 I
( I
hSCARB2 I
) I
, O
in O
a O
pattern O
highly O
similar O
to O
that O
of O
endogenous O
murine B
SCARB2 I
( I
mSCARB2 I
) I
protein O
. O

A O
FLAG O
- O
tagged O
SCARB2 O
cDNA O
fragment O
composed O
of O
exons O
3 O
to O
12 O
was O
inserted O
into O
a O
murine O
Scarb2 O
gene O
- O
containing O
bacterial B
artificial I
chromosome I
( I
BAC I
) I
clone O
, O
and O
the O
resulting O
transgene O
was O
used O
for O
establishment O
of O
chimeric O
receptor O
- O
expressing O
Tg O
mice O
. O

Enterovirus O
71 O
( O
EV O
- O
A71 O
) O
is O
a O
human O
pathogen O
that O
causes O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
and O
fatal O
neurological O
diseases O
, O
and O
no O
effective O
treatment O
is O
available O
. O

Furthermore O
, O
we O
show O
that O
Hsp27 O
plays O
a O
crucial O
role O
in O
regulating O
viral O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
activities O
by O
two O
different O
mechanisms O
. O

Hsp27 O
markedly O
promoted O
2A B
( I
pro I
) I
- O
mediated O
eukaryotic O
initiation O
factor O
4G O
cleavage O
, O
an O
important O
process O
for O
selecting O
and O
initiating O
IRES O
- O
mediated O
translation O
. O

hnRNP O
A1 O
is O
a O
key O
IRES B
trans I
- I
acting I
factor I
( I
ITAF I
) I
for O
enhancing O
IRES O
- O
mediated O
translation O
. O

Most O
importantly O
, O
the O
Hsp27 O
inhibitor O
1 O
, O
3 O
, O
5 O
- O
trihydroxy O
- O
13 O
, O
13 O
- O
dimethyl O
- O
2H O
- O
pyran O
[ O
7 O
, O
6 O
- O
b O
] O
xanthone O
( O
TDP O
) O
, O
a O
compound O
isolated O
from O
a O
traditional O
Chinese O
herb O
, O
significantly O
protected O
against O
cytopathic O
effects O
and O
inhibited O
EV O
- O
A71 O
infection O
. O

Human B
enteroviruses I
of I
species I
A I
( I
EV I
- I
A I
) I
are O
the O
leading O
cause O
of O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
. O

IMPORTANCE O
Human B
enteroviruses I
of I
species I
A I
( I
EV I
- I
A I
) I
, O
including O
EV O
- O
A71 O
, O
are O
the O
leading O
cause O
of O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
and O
may O
also O
cause O
severe O
neurological O
manifestations O
. O

Coxsackievirus B
A6 I
( I
CV I
- I
A6 I
) I
is O
an O
emerging O
pathogen O
associated O
with O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
. O

IMPORTANCE O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
is O
a O
major O
and O
persistent O
threat O
to O
infants O
and O
children O
. O

Besides O
the O
most O
common O
pathogens O
, O
such O
as O
enterovirus B
A71 I
( I
EV I
- I
A71 I
) I
and O
coxsackievirus B
A16 I
( I
CV I
- I
A16 I
) I
, O
other O
enteroviruses O
are O
increasingly O
contributing O
to O
HFMD O
. O

Fibronectin B
( I
FN I
) I
is O
a O
high O
- O
molecular O
- O
weight O
extracellular O
matrix O
protein O
that O
contains O
the O
RGDS O
motif O
, O
which O
is O
required O
to O
bind O
to O
integrins O
. O

Here O
, O
we O
identified O
that O
synthetic O
RGDS O
peptides O
significantly O
inhibit O
Human B
enterovirus I
71 I
( I
EV71 I
) I
infection O
in O
cell O
cultures O
. O

Unfortunately O
, O
no O
effective O
antiviral O
drugs O
are O
available O
for O
Human B
enterovirus I
71 I
( I
EV71 I
) I
, O
one O
of O
the O
viruses O
that O
cause O
hand O
, O
foot O
, O
and O
mouth O
disease O
. O

In O
this O
study O
, O
we O
found O
that O
the O
host O
factor O
Fibronectin B
( I
FN I
) I
facilitated O
EV71 O
replication O
by O
interacting O
with O
EV71 O
particles O
and O
further O
mediated O
their O
entry O
. O

coxsackievirus B
A16 I
( I
CV I
- I
A16 I
) I
and O
enterovirus B
A71 I
( I
EV I
- I
A71 I
) I
are O
closely O
related O
enteroviruses O
that O
cause O
the O
same O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
but O
neurological O
complications O
occur O
only O
very O
rarely O
in O
CV O
- O
A16 O
compared O
to O
EV O
- O
A71 O
infections O
. O

To O
elucidate O
host O
responses O
that O
may O
be O
able O
to O
explain O
these O
differences O
, O
we O
performed O
transcriptomic O
analysis O
and O
real B
- I
time I
quantitative I
PCR I
( I
RT I
- I
qPCR I
) I
in O
CV O
- O
A16 O
- O
infected O
neuroblastoma O
cells O
( O
SK O
- O
N O
- O
SH O
) O
, O
and O
the O
results O
showed O
that O
the O
radical O
S O
- O
adenosylmethionine O
domain O
containing O
2 O
( O
RSAD2 O
) O
was O
the O
highest O
up O
- O
regulated O
gene O
in O
the O
antimicrobial O
pathway O
. O

Absent B
in I
melanoma I
2 I
( I
AIM2 I
) I
, O
which O
is O
associated O
with O
pyroptotic O
cell O
death O
, O
was O
upregulated O
in O
EV O
- O
A71 O
- O
infected O
neurons O
but O
not O
in O
CV O
- O
A16 O
infection O
, O
suggesting O
that O
the O
AIM2 O
inflammasome O
played O
a O
significant O
role O
in O
suppressing O
EV O
- O
A71 O
replication O
. O

Chimeric O
viruses O
derived O
from O
CV O
- O
A16 O
and O
EV O
- O
A71 O
but O
containing O
swapped O
5 B
' I
nontranslated I
regions I
( I
5 I
' I
NTRs I
) I
showed O
that O
RSAD2 O
expression O
/ O
viral O
replication O
and O
AIM2 O
expression O
/ O
viral O
replication O
patterns O
may O
be O
linked O
to O
the O
5 O
' O
NTRs O
of O
parental O
viruses O
. O

IMPORTANCE O
Although O
coxsackievirus B
A16 I
( I
CV I
- I
A16 I
) I
and O
enterovirus B
A17 I
( I
EV I
- I
A71 I
) I
both O
cause O
hand O
, O
foot O
, O
and O
mouth O
disease O
, O
EV O
- O
A71 O
has O
emerged O
as O
a O
leading O
cause O
of O
nonpolio O
, O
enteroviral O
fatal O
encephalomyelitis O
among O
young O
children O
. O

coxsackievirus B
A6 I
( I
CVA6 I
) I
has O
recently O
emerged O
as O
one O
of O
the O
predominant O
causative O
agents O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
. O

Our O
previous O
work O
shows O
that O
recombinant O
virus B
- I
like I
particles I
( I
VLPs I
) I
of O
CVA6 O
represent O
a O
promising O
CVA6 O
vaccine O
candidate O
. O

Here O
, O
we O
report O
the O
first O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structure O
of O
the O
CVA6 O
VLP O
at O
3 O
. O

The O
CVA6 O
VLP O
exhibits O
the O
characteristic O
features O
of O
enteroviruses O
but O
presents O
an O
open O
channel O
at O
the O
2 O
- O
fold O
axis O
and O
an O
empty O
, O
collapsed O
VP1 O
pocket O
, O
which O
is O
broadly O
similar O
to O
the O
structures O
of O
the O
enterovirus B
71 I
( I
EV71 I
) I
VLP O
and O
coxsackievirus B
A16 I
( I
CVA16 I
) I
135S O
expanded O
particle O
, O
indicating O
that O
the O
CVA6 O
VLP O
is O
in O
an O
expanded O
conformation O
. O

By O
immunological O
assays O
, O
we O
identified O
two O
CVA6 O
- O
specific O
linear O
B O
- O
cell O
epitopes O
( O
designated O
P42 O
and O
P59 O
) O
located O
at O
the O
GH O
loop O
and O
the O
C O
- O
terminal O
region O
of O
VP1 O
, O
respectively O
, O
in O
agreement O
with O
the O
structure O
- O
based O
prediction O
of O
antigenic O
sites O
. O

IMPORTANCE O
coxsackievirus B
A6 I
( I
CVA6 I
) I
is O
becoming O
one O
of O
the O
major O
pathogens O
causing O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
leading O
to O
significant O
morbidity O
and O
mortality O
in O
children O
and O
adults O
. O

Our O
previous O
work O
shows O
that O
recombinant O
virus B
- I
like I
particles I
( I
VLPs I
) I
of O
CVA6 O
are O
a O
promising O
CVA6 O
vaccine O
candidate O
. O

The O
overall O
architecture O
of O
the O
CVA6 O
VLP O
is O
similar O
to O
those O
of O
the O
expanded O
structures O
of O
enterovirus B
71 I
( I
EV71 I
) I
and O
coxsackievirus B
A16 I
( I
CVA16 I
) I
, O
but O
careful O
structural O
comparisons O
reveal O
significant O
differences O
in O
the O
surface O
- O
exposed O
loops O
and O
C O
termini O
of O
each O
capsid O
protein O
of O
these O
particles O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
the O
major O
causative O
agent O
of O
severe O
hand O
, O
foot O
, O
and O
mouth O
disease O
, O
which O
affects O
millions O
of O
young O
children O
in O
the O
Asia O
- O
Pacific O
region O
annually O
. O

In O
this O
study O
, O
we O
engineered O
a O
novel O
EV71 O
virus B
- I
like I
particle I
( I
VLP I
) I
that O
lacks O
VP4 O
( O
therefore O
designated O
VLP O
. O

The O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structure O
of O
VLP O
. O

IMPORTANCE O
enterovirus B
71 I
( I
EV71 I
) I
infection O
may O
lead O
to O
severe O
hand O
, O
foot O
, O
and O
mouth O
disease O
, O
with O
significant O
morbidity O
and O
mortality O
. O

enterovirus B
71 I
( I
EV71 I
) I
can O
cause O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
in O
young O
children O
. O

Here O
, O
we O
report O
that O
EV71 O
induces O
degradation O
of O
gasdermin B
D I
( I
GSDMD I
) I
, O
an O
essential O
component O
of O
pyroptosis O
. O

This O
cleavage O
produces O
a O
shorter O
N O
- O
terminal O
fragment O
spanning O
amino O
acids O
1 O
to O
193 O
( O
GSDMD O
( O
1 O
- O
193 O
) O
) O
. O

Importantly O
, O
a O
T239D O
or O
F240D O
substitution O
abrogates O
the O
activity O
of O
GSDMD O
consisting O
of O
amino O
acids O
1 O
to O
275 O
( O
GSDMD O
( O
1 O
- O
275 O
) O
) O
. O

IMPORTANCE O
Recently O
, O
it O
has O
been O
reported O
that O
GSDMD O
plays O
a O
critical O
role O
in O
regulating O
lipopolysaccharide O
and O
NLRP3 O
- O
mediated O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
secretion O
. O

Notably O
, O
GSDMD O
( O
1 O
- O
275 O
) O
( O
p30 O
) O
inhibits O
EV71 O
replication O
whereas O
GSDMD O
( O
1 O
- O
193 O
) O
does O
not O
. O

Coxsackievirus O
A16 O
( O
CV O
- O
A16 O
; O
Picornaviridae O
) O
is O
an O
enterovirus B
( I
EV I
) I
type O
associated O
with O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
in O
children O
. O

To O
investigate O
the O
spatial O
spread O
of O
CV O
- O
A16 O
, O
we O
used O
viral O
sequence O
data O
sampled O
during O
a O
prospective O
sentinel O
surveillance O
of O
HFMD O
in O
France O
( O
2010 O
to O
2014 O
) O
and O
phylogenetic O
reconstruction O
. O

The O
time O
origins O
of O
clades O
B O
and O
D O
were O
assessed O
in O
1978 O
( O
1973 O
to O
1981 O
) O
and O
2004 O
( O
2001 O
to O
2007 O
) O
, O
respectively O
. O

CV O
- O
A16 O
transmission O
is O
driven O
by O
movements O
of O
infected O
individuals O
at O
different O
geographic O
levels O
: O
within O
a O
country O
( O
local O
dynamics O
) O
, O
between O
neighboring O
countries O
( O
regional O
dynamics O
) O
, O
and O
between O
distant O
countries O
( O
transcontinental O
dynamics O
) O
. O

coxsackievirus B
A16 I
( I
CV I
- I
A16 I
) I
, O
CV O
- O
A6 O
, O
and O
enterovirus B
D68 I
( I
EV I
- I
D68 I
) I
belong O
to O
the O
Picomaviridae O
family O
and O
are O
major O
causes O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
and O
pediatric O
respiratory O
disease O
worldwide O
. O

In O
this O
study O
, O
we O
discovered O
that O
the O
3C B
( I
pro I
) I
proteins O
from O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV O
- O
D68 O
bind O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
and O
inhibit O
its O
interaction O
with O
MAVS O
. O

Consequently O
, O
MDA5 O
- O
triggered O
type B
I I
interferon I
( I
IFN I
) I
signaling O
in O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
- I
like I
receptor I
( I
RLR I
) I
pathway O
was O
blocked O
by O
the O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV B
- I
D68 I
3C I
( I
pro I
) I
proteins O
. O

Furthermore O
, O
the O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV B
- I
D68 I
3C I
( I
pro I
) I
proteins O
all O
cleave O
transforming O
growth O
factor O
beta O
- O
activated O
kinase O
1 O
( O
TAK1 O
) O
, O
resulting O
in O
the O
inhibition O
of O
NF O
- O
kappa O
B O
activation O
, O
a O
host O
response O
also O
critical O
for O
Toll B
- I
like I
receptor I
( I
TLR I
) I
- O
mediated O
signaling O
. O

Blocking O
the O
ability O
of O
3C B
( I
pro I
) I
proteins O
from O
diverse O
enteroviruses O
and O
cox O
- O
sackieviruses O
to O
interfere O
with O
type O
I O
IFN O
induction O
should O
restore O
IFN O
antiviral O
function O
, O
offering O
a O
potential O
novel O
antiviral O
strategy O
. O

Here O
we O
demonstrate O
that O
the O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV B
- I
D68 I
3C I
( I
pro I
) I
proteins O
block O
MDA5 O
- O
triggered O
type O
I O
IFN O
induction O
. O

The O
3C B
( I
pro I
) I
proteins O
of O
these O
viruses O
bind O
MDA5 O
and O
inhibit O
its O
interaction O
with O
MAVS O
. O

In O
addition O
, O
the O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV B
- I
D68 I
3C I
( I
pro I
) I
proteins O
cleave O
TAK1 O
to O
inhibit O
the O
NF O
- O
kappa O
B O
response O
. O

These O
findings O
indicate O
the O
potential O
merit O
of O
targeting O
the O
CV O
- O
A16 O
, O
CV O
- O
A6 O
, O
and O
EV B
- I
D68 I
3C I
( I
pro I
) I
proteins O
as O
an O
antiviral O
strategy O
. O

hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
is O
a O
reemerging O
illness O
caused O
by O
a O
variety O
of O
enteroviruses O
. O

The O
main O
causative O
agents O
are O
enterovirus B
71 I
( I
EV71 I
) I
, O
coxsackievirus B
A16 I
( I
CVA16 I
) I
, O
and O
, O
most O
recently O
, O
coxsackievirus B
A6 I
( I
CVA6 I
) I
. O

Viral O
persistence O
for O
weeks O
postinfection O
( O
wpi O
) O
has O
also O
been O
documented O
by O
the O
demonstration O
of O
virus O
in O
children O
' O
s O
stools O
. O

Infection O
of O
BALB O
/ O
c O
mice O
with O
a O
bioluminescent O
mouse B
- I
adapted I
EV71 I
construct I
( I
mEV71 I
- I
NLuc I
) I
resulted O
in O
a O
lack O
of O
clinical O
signs O
of O
disease O
but O
in O
relatively O
high O
viral O
replication O
, O
as O
visualized O
by O
luminescence O
, O
for O
2 O
wpi O
. O

In O
contrast O
, O
mEV71NLuc O
infection O
of O
AG129 O
mice O
( O
alpha O
/ O
beta O
and O
gamma O
interferon O
receptor O
deficient O
) O
showed O
rapid O
spread O
and O
long O
- O
term O
persistence O
of O
the O
virus O
in O
the O
brain O
. O

IMPORTANCE O
We O
report O
here O
that O
a O
stable O
full O
- O
length O
enterovirus B
71 I
( I
EV71 I
) I
reporter O
construct O
was O
used O
to O
visualize O
real O
- O
time O
viral O
spread O
in O
AG129 O
and O
BALB O
/ O
c O
mice O
. O

The O
nanoluciferase B
( I
NLuc I
) I
gene O
, O
one O
of O
the O
smallest O
luciferase O
genes O
currently O
available O
, O
was O
shown O
to O
be O
stable O
in O
the O
EV71 O
genome O
for O
eight O
passages O
on O
rhabdomyosarcoma O
cells O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
an O
emerging O
pathogen O
causing O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
and O
fatal O
neurological O
diseases O
in O
infants O
and O
young O
children O
due O
to O
their O
underdeveloped O
immunocompetence O
. O

Ubiquitination O
and O
SUMOylation O
are O
extensively O
studied O
posttranslational B
modifications I
( I
PTMs I
) I
that O
play O
critical O
roles O
in O
diverse O
biological O
processes O
. O

enterovirus B
71 I
( I
EV71 I
) I
, O
an O
RNA O
virus O
belonging O
to O
the O
family O
Picornaviridae O
, O
is O
a O
common O
cause O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
. O

Here O
, O
we O
demonstrate O
that O
the O
3D O
protein O
, O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
of O
EV71 O
, O
is O
modified O
by O
small B
ubiquitin I
- I
like I
modifier I
1 I
( I
SUMO I
- I
1 I
) I
both O
during O
infection O
and O
in O
vitro O
. O

IMPORTANCE O
Infection O
with O
enterovirus B
71 I
( I
EV71 I
) I
often O
causes O
neurological O
diseases O
in O
children O
, O
and O
EV71 O
is O
responsible O
for O
the O
majority O
of O
fatalities O
. O

hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
has O
spread O
throughout O
the O
Asia O
- O
Pacific O
region O
, O
affecting O
millions O
of O
young O
children O
, O
who O
develop O
symptoms O
ranging O
from O
painful O
blisters O
around O
their O
mouths O
and O
hands O
to O
neurological O
complications O
. O

Many O
members O
of O
the O
genus O
Enterovirus O
( O
family O
Picornaviridae O
) O
cause O
HFMD O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
one O
of O
the O
primary O
causative O
agents O
and O
has O
been O
linked O
to O
severe O
disease O
. O

Previously O
, O
we O
generated O
a O
mouse B
- I
adapted I
EV71 I
( I
mEV71 I
) I
capable O
of O
infecting O
12 O
- O
week O
- O
old O
interferon O
receptor O
- O
deficient O
AG129 O
mice O
and O
used O
the O
model O
to O
evaluate O
the O
efficacy O
of O
candidate O
HFMD O
vaccines O
. O

Using O
reverse O
genetics O
, O
a O
VP1 O
mutation O
( O
K244E O
) O
was O
shown O
to O
be O
necessary O
for O
mEV71 O
virulence O
in O
adult O
mice O
. O

Another O
VP1 O
mutation O
( O
H37R O
) O
was O
required O
for O
mEV71 O
recovery O
on O
rhabdomyosarcoma B
( I
RD I
) I
cells O
. O

Viral O
loads O
determined O
by O
Real B
- I
time I
reverse I
transcription I
( I
RT I
) I
- O
PCR O
confirmed O
the O
presence O
of O
mEV71 O
in O
the O
sera O
and O
multiple O
organs O
of O
mice O
. O

We O
determined O
that O
a O
VP1 O
mutation O
( O
K244E O
) O
was O
needed O
for O
EV71 O
virulence O
in O
adult O
AG129 O
mice O
. O

Our O
previous O
study O
demonstrated O
that O
the O
nonstructural O
protein O
2C O
of O
enterovirus B
71 I
( I
EV71 I
) I
, O
which O
is O
the O
major O
pathogen O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
, O
inhibits O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
activation O
of O
NF O
- O
kappa O
B O
by O
suppressing O
I B
kappa I
B I
kinase I
beta I
( I
IKK I
beta I
) I
phosphorylation O
. O

We O
demonstrate O
that O
EV71 O
2C O
interacts O
with O
all O
isoforms O
of O
the O
protein B
phosphatase I
1 I
( I
PP1 I
) I
catalytic O
subunit O
( O
the O
PP1 O
alpha O
, O
PP1 O
beta O
, O
and O
PP1 O
gamma O
isoforms O
) O
through O
PP1 O
- O
docking O
motifs O
. O

Notably O
, O
we O
reveal O
that O
other O
human O
enteroviruses O
, O
including O
poliovirus B
( I
PV I
) I
, O
coxsackie B
A I
virus I
16 I
( I
CVA16 I
) I
, O
and O
coxsackie B
B I
virus I
3 I
( I
CVB3 I
) I
, O
use O
2C O
proteins O
to O
recruit O
PP1 O
, O
leading O
to O
the O
inhibition O
of O
IKK O
beta O
phosphorylation O
. O

Enteroviruses O
include O
a O
number O
of O
important O
human O
pathogens O
, O
including O
poliovirus B
( I
PV I
) I
, O
EV71 O
, O
and O
coxsackieviruses B
( I
CVs I
) I
. O

enterovirus B
71 I
( I
EV71 I
) I
, O
a O
positive O
- O
stranded O
RNA O
virus O
, O
is O
the O
major O
cause O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
in O
children O
, O
which O
can O
cause O
severe O
central O
nervous O
system O
disease O
and O
death O
. O

The O
capsids O
of O
EV71 O
consist O
of O
60 O
copies O
of O
each O
of O
four O
viral O
structural O
proteins O
( O
VP1 O
to O
VP4 O
) O
, O
with O
VP1 O
, O
VP2 O
, O
and O
VP3 O
exposed O
on O
the O
surface O
and O
VP4 O
arranged O
internally O
. O

Antibodies O
play O
a O
critical O
role O
in O
immunity O
against O
enterovirus B
71 I
( I
EV71 I
) I
. O

Here O
we O
report O
the O
working O
mechanism O
for O
a O
group O
of O
three O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
potently O
neutralize O
EV71 O
. O

We O
found O
that O
these O
three O
MAbs O
( O
termed O
D5 O
, O
H7 O
, O
and O
C4 O
, O
respectively O
) O
recognize O
the O
same O
conserved O
neutralizing O
epitope O
within O
the O
VP1 O
GH O
loop O
of O
EV71 O
. O

IMPORTANCE O
enterovirus B
71 I
( I
EV71 I
) I
is O
a O
major O
causative O
agent O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
which O
has O
caused O
significant O
morbidities O
and O
mortalities O
in O
young O
children O
. O

Here O
, O
we O
unraveled O
an O
unusual O
mechanism O
of O
EV71 O
neutralization O
by O
a O
group O
of O
three O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

coxsackievirus B
A16 I
( I
CVA16 I
) I
is O
one O
of O
the O
major O
etiological O
agents O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
in O
children O
. O

Unlike O
previous O
observations O
with O
enterovirus B
71 I
( I
EV71 I
) I
infection O
, O
here O
we O
show O
that O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
or O
invariant O
NK O
T O
cell O
deficiency O
does O
not O
affect O
disease O
development O
or O
the O
survival O
of O
CVA16 O
- O
infected O
mice O
. O

Similarly O
, O
a O
deficiency O
of O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
and O
TRIF O
, O
but O
not O
other O
pattern O
recognition O
receptors O
, O
led O
to O
the O
decreased O
survival O
of O
CVA16 O
- O
infected O
mice O
. O

IMPORTANCE O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
is O
a O
major O
threat O
to O
public O
health O
in O
the O
Asia O
- O
Pacific O
region O
. O

enterovirus B
71 I
( I
EV71 I
) I
and O
coxsackievirus B
A16 I
( I
CVA16 I
) I
are O
the O
primary O
causes O
of O
the O
epidemics O
of O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
that O
affect O
more O
than O
a O
million O
children O
in O
China O
each O
year O
and O
lead O
to O
hundreds O
of O
deaths O
. O

The O
recombinant O
particles O
, O
produced O
in O
insect O
cells O
( O
a O
system O
suitable O
for O
making O
vaccine O
antigen O
) O
, O
are O
stabilized O
by O
recruiting O
from O
the O
insect O
cells O
a O
small O
molecule O
that O
is O
different O
from O
that O
used O
by O
the O
virus O
in O
a O
normal O
infection O
. O

enterovirus B
A71 I
( I
EV I
- I
A71 I
) I
is O
a O
major O
cause O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
and O
is O
particularly O
prevalent O
in O
parts O
of O
Southeast O
Asia O
, O
affecting O
thousands O
of O
children O
and O
infants O
each O
year O
. O

We O
generated O
the O
full O
genome O
sequences O
of O
200 O
EV O
- O
A71 O
strains O
sampled O
from O
various O
locations O
in O
Viet O
Nam O
between O
2011 O
and O
2013 O
and O
used O
these O
sequence O
data O
to O
determine O
the O
evolutionary O
history O
and O
phylodynamics O
of O
EV O
- O
A71 O
in O
Viet O
Nam O
, O
providing O
estimates O
of O
the O
effective O
reproduction O
number O
( O
R O
- O
e O
) O
of O
the O
infection O
through O
time O
. O

The O
N O
- O
terminal O
region O
of O
the O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
3D O
polymerase O
contains O
the O
sequence O
MRKTKLAPT O
( O
residues O
16 O
to O
24 O
) O
that O
acts O
as O
a O
nuclear O
localization O
signal O
. O

Here O
, O
we O
report O
the O
biochemical O
and O
structural O
characterization O
of O
different O
mutant O
polymerases O
harboring O
substitutions O
at O
residues O
18 O
and O
20 O
, O
in O
particular O
, O
K18E O
, O
K18A O
, O
K20E O
, O
K20A O
, O
and O
the O
double O
mutant O
K18A O
K20A O
( O
KAKA O
) O
. O

All O
mutant O
enzymes O
exhibit O
low O
RNA O
binding O
activity O
, O
low O
processivity O
, O
and O
alterations O
in O
nucleotide O
recognition O
, O
including O
increased O
incorporation O
of O
ribavirin B
monophosphate I
( I
RMP I
) I
relative O
to O
the O
incorporation O
of O
cognate O
nucleotides O
compared O
with O
the O
wild O
- O
type O
enzyme O
. O

The O
structural O
analysis O
shows O
an O
unprecedented O
flexibility O
of O
the O
3D O
mutant O
polymerases O
, O
including O
both O
global O
rearrangements O
of O
the O
closed O
- O
hand O
architecture O
and O
local O
conformational O
changes O
at O
loop O
beta O
9 O
- O
alpha O
11 O
( O
within O
the O
polymerase O
motif O
B O
) O
and O
at O
the O
template O
- O
binding O
channel O
. O

Thus O
, O
the O
Nterminal O
region O
of O
FMDV O
3D O
that O
acts O
as O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
and O
in O
template O
binding O
is O
also O
involved O
in O
nucleotide O
recognition O
and O
can O
affect O
the O
incorporation O
of O
nucleotide O
analogues O
. O

IMPORTANCE O
The O
study O
documents O
multifunctionality O
of O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
located O
at O
the O
N O
- O
terminal O
region O
of O
the O
foot O
- O
andmouth O
disease O
viral O
polymerase O
( O
3D O
) O
. O

Human B
enterovirus I
71 I
( I
EV71 I
) I
and O
coxsackievirus B
A16 I
( I
CVA16 I
) I
are O
the O
two O
major O
causative O
agents O
for O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
. O

Previously O
, O
we O
demonstrated O
that O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
for O
EV71 O
produced O
from O
Saccharomyces O
cerevisiae O
is O
a O
potential O
vaccine O
candidate O
against O
EV71 O
infection O
, O
and O
an O
EV71 O
/ O
CVA16 O
chimeric O
VLP O
can O
elicit O
protective O
immune O
responses O
against O
both O
virus O
infections O
. O

IMPORTANCE O
Our O
previous O
studies O
demonstrated O
that O
the O
enterovirus B
71 I
( I
EV71 I
) I
virus I
- I
like I
particle I
( I
VLP I
) I
produced O
from O
yeast O
is O
a O
vaccine O
candidate O
against O
EV71 O
infection O
and O
that O
a O
chimeric O
EV71 O
/ O
coxsackievirus B
A16 I
( I
CVA16 I
) I
VLP O
with O
the O
replacement O
of O
4 O
amino O
acids O
in O
the O
VP1 O
GH O
loop O
can O
confer O
protection O
against O
both O
EV71 O
and O
CVA16 O
infections O
. O

Together O
, O
this O
study O
provided O
insights O
into O
the O
structural O
basis O
of O
enterovirus O
neutralization O
and O
evidence O
that O
the O
yeast O
- O
produced O
VLPs O
can O
be O
developed O
into O
novel O
vaccines O
against O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
and O
other O
enterovirus O
- O
associated O
diseases O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
responsible O
for O
seasonal O
outbreaks O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
in O
the O
Asia O
- O
Pacific O
region O
. O

Like O
poliovirus O
infection O
, O
severe O
infection O
with O
enterovirus B
71 I
( I
EV71 I
) I
can O
cause O
neuropathology O
. O

Unlike O
poliovirus O
, O
EV71 O
is O
often O
associated O
with O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
. O

While O
the O
NOD O
/ O
SCID O
mice O
developed O
limb O
paralysis O
and O
death O
at O
near O
- O
100 O
% O
efficiency O
, O
the O
gamma O
interferon O
receptor O
knockout O
( O
ifngr O
KO O
) O
and O
stat O
- O
1 O
knockout O
mice O
exhibited O
paralysis O
and O
death O
rates O
near O
78 O
% O
and O
30 O
% O
, O
respectively O
. O

The O
pathology O
of O
the O
NOD O
/ O
SCID O
model O
includes O
( O
i O
) O
inflammation O
and O
expression O
of O
viral O
VP1 O
antigen O
in O
muscle O
, O
( O
ii O
) O
increased O
neutrophil O
levels O
and O
decreased O
eosinophil O
and O
lymphocyte O
levels O
, O
and O
( O
iii O
) O
hair O
loss O
and O
skin O
rash O
. O

The O
characteristic O
pathology O
of O
the O
stat O
- O
1 O
knockout O
model O
includes O
( O
i O
) O
a O
strong O
tropism O
of O
EV71 O
for O
the O
central O
nervous O
system O
, O
( O
ii O
) O
detection O
of O
VP1 O
protein O
in O
the O
Purkinje O
layer O
of O
cerebellar O
cortex O
, O
pons O
, O
brain O
stem O
, O
and O
spinal O
cord O
, O
( O
iii O
) O
amplification O
of O
microglial O
cells O
, O
and O
( O
iv O
) O
dystrophy O
of O
intestinal O
villi O
. O

IMPORTANCE O
In O
the O
past O
decade O
, O
enterovirus B
71 I
( I
EV71 I
) I
has O
emerged O
as O
a O
major O
threat O
to O
public O
health O
in O
the O
Asia O
- O
Pacific O
region O
. O

Disease O
manifestations O
include O
subclinical O
infection O
, O
common O
- O
cold O
- O
like O
syndromes O
, O
hand B
- I
foot I
- I
and I
- I
mouth I
disease I
( I
HFMD I
) I
, O
uncomplicated O
brain O
stem O
encephalitis O
, O
severe O
dysregulation O
of O
the O
autonomic O
nerve O
system O
, O
fatal O
pulmonary O
edema O
, O
and O
cardiopulmonary O
collapse O
. O

enterovirus B
71 I
( I
EV71 I
) I
, O
a O
positive O
- O
stranded O
RNA O
virus O
, O
is O
the O
major O
cause O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
with O
severe O
neurological O
symptoms O
. O

Antiviral O
type O
I O
interferon O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
responses O
initiated O
from O
innate O
receptor O
signaling O
are O
inhibited O
by O
EV71 O
- O
encoded O
proteases O
. O

In O
this O
report O
, O
we O
found O
that O
EV71 O
alone O
cannot O
activate O
Toll B
- I
like I
receptor I
9 I
( I
TLR9 I
) I
signaling O
, O
but O
supernatant O
from O
EV71 O
- O
infected O
cells O
is O
capable O
of O
activating O
TLR9 O
. O

We O
hypothesized O
that O
TLR9 O
- O
activating O
signaling O
from O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
may O
contribute O
to O
host O
defense O
mechanisms O
. O

To O
test O
our O
hypothesis O
, O
Flt3 B
ligand I
- I
cultured I
DCs I
( I
Flt3L I
- I
DCs I
) I
from O
both O
wild B
- I
type I
( I
WT I
) I
and O
TLR9 B
knockout I
( I
TLR9KO I
) I
mice O
were O
infected O
with O
EV71 O
. O

In O
contrast O
, O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
monocyte B
chemotactic I
protein I
1 I
( I
MCP I
- I
1 I
) I
, O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
IFN O
- O
gamma O
, O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
and O
IL O
- O
10 O
levels O
were O
increased O
in O
Flt3L O
- O
DCs O
from O
WT O
mice O
infected O
with O
EV71 O
compared O
with O
TLR9KO O
mice O
. O

IMPORTANCE O
The O
host O
innate O
immune O
system O
is O
equipped O
with O
pattern B
recognition I
receptors I
( I
PRRs I
) I
, O
which O
are O
useful O
for O
defending O
the O
host O
against O
invading O
pathogens O
. O

During O
enterovirus B
71 I
( I
EV71 I
) I
infection O
, O
the O
innate O
immune O
system O
is O
activated O
by O
pathogen B
- I
associated I
molecular I
patterns I
( I
PAMPs I
) I
, O
which O
include O
viral O
RNA O
or O
DNA O
, O
and O
these O
PAMPs O
are O
recognized O
by O
PRRs O
. O

toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
and O
TLR7 O
/ O
8 O
recognize O
viral O
nucleic O
acids O
, O
and O
TLR9 O
senses O
unmethylated O
CpG O
DNA O
or O
pathogen O
- O
derived O
DNA O
. O

These O
PRRs O
stimulate O
the O
production O
of O
type B
I I
interferons I
( I
IFNs I
) I
to O
counteract O
viral O
infection O
, O
and O
they O
are O
the O
major O
source O
of O
antiviral O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
production O
in O
pDCs O
, O
which O
can O
produce O
200 O
- O
to O
1 O
, O
000 O
- O
fold O
more O
IFN O
- O
alpha O
than O
any O
other O
immune O
cell O
type O
. O

In O
addition O
to O
PAMPs O
, O
danger B
- I
associated I
molecular I
patterns I
( I
DAMPs I
) I
are O
known O
to O
be O
potent O
activators O
of O
innate O
immune O
signaling O
, O
including O
TLR9 O
. O

enterovirus B
71 I
( I
EV71 I
) I
causes O
hand O
, O
foot O
, O
and O
mouth O
disease O
in O
young O
children O
and O
infants O
. O

Emerging O
evidence O
suggests O
that O
EV71 O
modulates O
type B
I I
interferon I
( I
IFN I
) I
and O
cytokine O
responses O
. O

However O
, O
little O
is O
known O
about O
its O
connection O
to O
enterovirus B
71 I
( I
EV71 I
) I
. O

enterovirus B
71 I
( I
EV71 I
) I
and O
coxsackievirus B
A16 I
( I
CA16 I
) I
are O
the O
two O
most O
common O
etiological O
agents O
responsible O
for O
the O
epidemics O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
a O
childhood O
illness O
with O
occasional O
severe O
neurological O
complications O
. O

Here O
, O
we O
generated O
a O
secreted O
version O
of O
EV71 O
and O
CA16 O
virus B
- I
like I
particles I
( I
VLPs I
) I
using O
a O
baculovirus O
- O
insect O
cell O
expression O
system O
and O
reconstructed O
the O
three B
- I
dimensional I
( I
3D I
) I
structures O
of O
both O
VLPs O
by O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
single O
- O
particle O
analysis O
at O
5 O
. O

Human B
enterovirus I
71 I
( I
EV71 I
) I
is O
the O
major O
causative O
agent O
of O
severe O
hand B
- I
foot I
- I
and I
- I
mouth I
diseases I
( I
HFMD I
) I
in O
young O
children O
, O
and O
structural O
characterization O
of O
EV71 O
during O
its O
life O
cycle O
can O
aid O
in O
the O
development O
of O
therapeutics O
against O
HFMD O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
picornavirus O
that O
causes O
outbreaks O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
primarily O
in O
the O
Asia O
- O
Pacific O
area O
. O

enterovirus B
71 I
( I
EV71 I
) I
causes O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
severe O
neurological O
disorders O
in O
children O
. O

human B
scavenger I
receptor I
class I
B I
member I
2 I
( I
hSCARB2 I
) I
and O
P B
- I
selectin I
glycoprotein I
ligand I
- I
1 I
( I
PSGL I
- I
1 I
) I
are O
identified O
as O
receptors O
for O
EV71 O
. O

The O
endocytosis O
required O
for O
EV71 O
entry O
were O
investigated O
in O
Jurkat O
T O
and O
mouse O
L929 O
cells O
constitutively O
expressing O
human O
PSGL O
- O
1 O
( O
PSGL O
- O
1 O
- O
L929 O
) O
or O
human B
rhabdomyosarcoma I
( I
RD I
) I
cells O
displaying O
high O
SCARB2 O
but O
no O
PSGL O
- O
1 O
by O
treatment O
of O
specific O
inhibitors O
or O
siRNA O
. O

Picornavirus O
RNA O
replication O
is O
initiated O
by O
VPg O
uridylylation O
, O
during O
which O
the O
hydroxyl O
group O
of O
the O
third O
tyrosine O
residue O
of O
the O
virally O
encoded O
protein O
VPg O
is O
covalently O
linked O
to O
two O
UMP O
molecules O
by O
RNA O
- O
dependent O
RNA O
polymerase O
( O
RdRp O
; O
also O
known O
as O
3D O
( O
pol O
) O
) O
. O

We O
previously O
identified O
site O
311 O
, O
located O
at O
the O
base O
of O
the O
palm O
domain O
of O
the O
enterovirus B
71 I
( I
EV71 I
) I
RdRp O
, O
to O
be O
the O
site O
for O
EV71 O
VPg O
binding O
and O
uridylylation O
. O

Here O
we O
report O
the O
crystal O
structure O
of O
EV71 O
3D O
( O
pol O
) O
complexed O
with O
VPg O
. O

VPg O
was O
anchored O
at O
the O
bottom O
of O
the O
palm O
domain O
of O
the O
3D O
( O
pol O
) O
molecule O
and O
exhibited O
an O
extended O
V O
- O
shape O
conformation O
. O

The O
corresponding O
interface O
on O
3D O
( O
pol O
) O
was O
mainly O
formed O
by O
residues O
within O
site O
311 O
and O
other O
residues O
in O
the O
palm O
and O
finger O
domains O
. O

Mutations O
of O
the O
amino O
acids O
of O
3D O
( O
pol O
) O
involved O
in O
the O
VPg O
interaction O
( O
( O
3D O
) O
L319A O
, O
( O
3D O
) O
D320A O
, O
and O
( O
3D O
) O
Y335A O
) O
significantly O
disrupted O
VPg O
binding O
to O
3D O
( O
pol O
) O
, O
resulting O
in O
defective O
VPg O
uridylylation O
. O

In O
contrast O
, O
these O
mutations O
did O
not O
affect O
the O
RNA O
elongation O
activity O
of O
3D O
( O
pol O
) O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
the O
causative O
agent O
of O
hand O
- O
foot O
- O
and O
- O
mouth O
disease O
and O
can O
trigger O
neurological O
disorders O
. O

To O
evaluate O
vaccine O
efficacy O
in O
protecting O
against O
coxsackievirus B
A16 I
( I
CA16 I
) I
, O
which O
causes O
human O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
we O
established O
the O
first O
neonatal O
mouse O
model O
. O

To O
establish O
a O
mouse O
model O
, O
a O
BJCA08 O
/ O
CA16 O
strain O
( O
at O
260 O
50 O
% O
lethal O
doses O
[ O
LD50 O
] O
) O
was O
isolated O
from O
a O
patient O
and O
used O
to O
intracerebrally O
( O
i O
. O

Pathological O
examination O
and O
Immunohistochemistry B
( I
IHC I
) I
staining O
indicated O
that O
BJCA08 O
had O
a O
strong O
tropism O
to O
muscle O
and O
caused O
severe O
necrosis O
in O
skeletal O
and O
cardiac O
muscles O
. O

The O
coxsackievirus B
B4 I
( I
CVB4 I
) I
belongs O
to O
human O
enterovirus O
B O
species O
within O
the O
family O
Picornaviridae O
. O

The O
complete O
genome O
consists O
of O
7 O
, O
293 O
nucleotides O
, O
excluding O
the O
3 O
' O
poly O
( O
A O
) O
tail O
, O
and O
has O
an O
open O
reading O
frame O
that O
maps O
between O
nucleotide O
positions O
742 O
and O
7293 O
and O
encodes O
a O
2 O
, O
183 O
- O
amino O
- O
acid O
polyprotein O
. O

Phylogenetic O
analysis O
based O
on O
different O
genome O
regions O
reveals O
that O
CVB4 O
/ O
GX O
/ O
10 O
is O
closest O
to O
a O
CVB4 O
strain O
, O
EPIHFMD O
- O
CLOSE O
CONTACT O
- O
16 O
, O
in O
the O
5 O
' O
half O
( O
VP4 O
similar O
to O
2B O
) O
of O
the O
genome O
, O
although O
it O
is O
closer O
to O
a O
Chinese O
CVB5 O
strain O
, O
CVB5 O
/ O
Henan O
/ O
2010 O
, O
in O
the O
3 O
' O
half O
( O
2C O
similar O
to O
3D O
) O
of O
the O
genome O
. O

Coxsackievirus B
B5 I
( I
CVB5 I
) I
belongs O
to O
the O
human O
enterovirus O
B O
species O
within O
the O
family O
Picornaviridae O
. O

The O
complete O
genome O
consists O
of O
7 O
, O
399 O
nucleotides O
, O
excluding O
the O
3 O
' O
poly O
( O
A O
) O
tail O
, O
and O
has O
an O
open O
reading O
frame O
that O
maps O
between O
nucleotide O
positions O
744 O
and O
7301 O
and O
encodes O
a O
2 O
, O
185 O
- O
amino O
- O
acid O
polyprotein O
. O

Human B
enterovirus I
species I
A I
( I
HEY I
- I
A I
) I
consists O
of O
at O
least O
16 O
members O
of O
different O
serotypes O
that O
are O
known O
to O
be O
the O
causative O
agents O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
herpangina O
, O
and O
other O
diseases O
, O
such O
as O
respiratory O
disease O
and O
polio O
- O
like O
flaccid O
paralysis O
. O

enterovirus B
71 I
( I
EV71 I
) I
and O
coxsacicievirus B
A16 I
( I
CVA16 I
) I
are O
the O
major O
causative O
agents O
of O
HFMD O
. O

We O
have O
previously O
shown O
that O
human B
scavenger I
receptor I
class I
B I
, I
member I
2 I
( I
SCARB2 I
) I
is O
a O
cellular O
receptor O
for O
EV71 O
and O
CVA16 O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
responsible O
for O
frequent O
large O
- O
scale O
outbreaks O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
worldwide O
and O
represent O
a O
major O
etiological O
agent O
of O
severe O
, O
sometimes O
fatal O
neurological O
disease O
. O

EV71 O
variants O
have O
been O
classified O
into O
three O
genogroups O
( O
GgA O
, O
GgB O
, O
and O
GgC O
) O
, O
and O
the O
latter O
two O
are O
further O
subdivided O
into O
subgenogroups O
B1 O
to O
B5 O
and O
C1 O
to O
C5 O
. O

To O
investigate O
the O
dual O
roles O
of O
recombination O
and O
evolution O
in O
the O
epidemiology O
and O
transmission O
of O
EV71 O
worldwide O
, O
we O
performed O
a O
large O
- O
scale O
genetic O
analysis O
of O
isolates O
( O
n O
= O
308 O
) O
collected O
from O
19 O
countries O
worldwide O
over O
a O
40 O
- O
year O
period O
. O

The O
likelihood O
of O
recombination O
increased O
with O
VP1 O
sequence O
divergence O
; O
mean O
half O
- O
lives O
for O
EV71 O
recombinant B
forms I
( I
RFs I
) I
of O
6 O
and O
9 O
years O
for O
GgB O
and O
GgC O
overlapped O
with O
those O
observed O
for O
the O
EV O
- O
B O
serotypes O
, O
echovirus B
9 I
( I
E9 I
) I
, O
E30 O
, O
and O
E11 O
, O
respectively O
( O
1 O
. O

Human B
enterovirus I
71 I
( I
HEV71 I
) I
is O
the O
causative O
agent O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
associated O
acute O
neurological O
disease O
. O

Studies O
of O
related O
enteroviruses O
have O
indicated O
that O
the O
untranslated B
regions I
( I
UTRs I
) I
, O
which O
control O
virus O
- O
directed O
translation O
and O
replication O
, O
also O
exert O
significant O
influence O
on O
neurovirulence O
. O

Replacement O
of O
the O
entire O
HEV71 O
5 O
' O
UTR O
with O
that O
of O
human B
rhinovirus I
2 I
( I
HRV2 I
) I
resulted O
in O
a O
small O
reduction O
in O
growth O
efficiency O
in O
cells O
of O
both O
nonneuronal O
( O
rhabdomyosarcoma O
) O
and B
neuronal I
( I
SH I
- I
SY5Y I
) I
origin O
due O
to O
reduced O
translational O
efficiency O
. O

This O
observation O
is O
similar O
to O
that O
made O
with O
stem B
- I
loop I
domain I
Z I
( I
SLD I
Z I
) I
- O
deleted O
coxsackievirus O
B3 O
- O
HRV2 O
5 O
' O
- O
UTR O
chimeras O
reported O
previously O
and O
provides O
the O
first O
evidence O
of O
a O
potentially O
functional O
SLD O
Z O
in O
the O
3 O
' O
UTR O
in O
human O
enterovirus O
A O
species O
viruses O
. O

Enterovirus B
type I
71 I
( I
EV71 I
) I
causes O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
which O
is O
mostly O
self O
- O
limited O
but O
may O
be O
complicated O
with O
a O
severe O
to O
fatal O
neurological O
syndrome O
in O
some O
children O
. O

In O
this O
study O
, O
we O
showed O
that O
human B
annexin I
II I
( I
Anx2 I
) I
protein O
could O
bind O
to O
the O
EV71 O
virion O
via O
the O
capsid O
protein O
VP1 O
. O

Stable O
transfection O
of O
plasmids O
expressing O
Anx2 O
protein O
into O
HepG2 O
cells O
( O
HepG2 O
- O
Anx2 O
cells O
) O
could O
enhance O
EV71 O
infectivity O
, O
with O
an O
increased O
virus O
yield O
, O
especially O
at O
a O
low O
infective O
dose O
, O
and O
the O
enhanced O
infectivity O
could O
be O
reversed O
by O
pretreating O
HepG2 O
- O
Anx2 O
cells O
with O
an O
anti O
- O
Anx2 O
antibody O
. O

EV71 O
is O
the O
primary O
pathogenic O
cause O
of O
hand B
- I
foot I
- I
mouth I
disease I
( I
HFMD I
) I
, O
but O
an O
effective O
antiviral O
drug O
currently O
is O
unavailable O
. O

Rupintrivir O
, O
an O
inhibitor O
against O
human B
rhinovirus I
( I
HRV I
) I
, O
has O
potent O
antiviral O
activities O
against O
EV71 O
. O

We O
determined O
the O
high O
- O
resolution O
crystal O
structures O
of O
the O
EV71 B
3C I
( I
pro I
) I
/ O
rupintrivir O
complex O
, O
showing O
that O
although O
rupintrivir O
interacts O
with O
EV71 B
3C I
( I
pro I
) I
similarly O
to O
HRV B
3C I
( I
pro I
) I
, O
the O
C O
terminus O
of O
the O
inhibitor O
cannot O
accommodate O
the O
leaving O
- O
group O
pockets O
of O
EV71 O
3C B
( I
pro I
) I
. O

Our O
structures O
reveal O
that O
EV71 B
3C I
( I
pro I
) I
possesses O
a O
surface O
- O
recessive O
S2 O
' O
pocket O
that O
is O
not O
present O
in O
HRV B
3C I
( I
pro I
) I
that O
contributes O
to O
the O
additional O
substrate O
binding O
affinity O
. O

We O
discovered O
the O
role O
of O
a O
previously O
uncharacterized O
residue O
, O
Arg39 O
of O
EV71 B
3C I
( I
pro I
) I
, O
that O
can O
neutralize O
the O
negative O
charge O
of O
Glu71 O
, O
which O
may O
subsequently O
assist O
deprotonation O
of O
His40 O
during O
proteolysis O
. O

enterovirus B
71 I
( I
EV71 I
) I
and O
coxsackievirus B
A16 I
( I
CVA16 I
) I
are O
the O
major O
causative O
agents O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
which O
is O
prevalent O
in O
Asia O
. O

More O
importantly O
, O
the O
complex O
structures O
of O
EV71 O
and O
CVA16 O
3Cs O
with O
rupintrivir O
, O
a O
specific O
human B
rhinovirus I
( I
HRV I
) I
3C O
protease O
inhibitor O
, O
were O
solved O
. O

enterovirus B
71 I
( I
EV71 I
) I
causes O
hand O
- O
foot O
- O
and O
- O
mouth O
disease O
and O
neurological O
complications O
in O
young O
children O
. O

In O
infected O
cells O
, O
EV71 O
suppresses O
type O
I O
interferon O
responses O
mediated O
by O
retinoid B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
. O

In O
the O
present O
study O
, O
we O
report O
that O
EV71 O
inhibits O
the O
induction O
of O
innate O
immunity O
by O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
via O
a O
distinct O
mechanism O
. O

In O
HeLa O
cells O
stimulated O
with O
poly O
( O
I O
center O
dot O
C O
) O
, O
EV71 O
inactivates O
interferon O
regulatory O
factor O
3 O
and O
drastically O
suppresses O
interferon O
- O
stimulated O
gene O
expression O
. O

Notably O
, O
EV71 O
specifically O
down O
- O
regulates O
a O
TRIF O
, O
TIR O
domain O
- O
containing O
adaptor O
inducing O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
. O

TRIF O
cleavage O
mediated O
by O
EV71 O
may O
be O
a O
mechanism O
to O
impair O
type O
I O
IFN O
production O
in O
response O
to O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
activation O
. O

We O
previously O
identified O
human B
scavenger I
receptor I
class I
B I
, I
member I
2 I
( I
SCARB2 I
) I
, O
as O
a O
cellular O
receptor O
for O
enterovirus B
71 I
( I
EV71 I
) I
. O

Expression O
of O
human B
SCARB2 I
( I
hSCARB2 I
) I
permitted O
mouse O
L929 O
cells O
to O
efficiently O
bind O
to O
virions O
and O
to O
produce O
both O
viral O
proteins O
and O
progeny O
viruses O
upon O
EV71 O
infection O
. O

Mouse B
Scarb2 I
( I
mScarb2 I
) I
exhibited O
85 O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
human O
pathogen O
that O
induces O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
fatal O
neurological O
diseases O
. O

In O
a O
murine O
model O
, O
EV71 O
does O
not O
facilitate O
the O
production O
of O
type B
I I
interferon I
( I
IFN I
) I
that O
plays O
a O
critical O
role O
in O
the O
first O
- O
line O
defense O
against O
viral O
infection O
. O

Here O
, O
we O
report O
that O
EV71 O
suppresses O
the O
induction O
of O
antiviral O
immunity O
by O
targeting O
the O
cytosolic O
receptor B
retinoid I
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
. O

In O
infected O
cells O
, O
EV71 O
inhibits O
the O
expression O
of O
IFN O
- O
beta O
, O
IFN B
- I
stimulated I
gene I
54 I
( I
ISG54 I
) I
, O
ISG56 O
, O
and O
tumor O
necrosis O
factor O
alpha O
. O

Human B
enterovirus I
71 I
( I
EV I
- I
71 I
) I
is O
one O
of O
the O
major O
etiologic O
causes O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
among O
young O
children O
worldwide O
, O
with O
fatal O
instances O
of O
neurological O
complications O
becoming O
increasingly O
common O
. O

Global O
VP1 O
capsid O
sequences O
( O
n O
= O
628 O
) O
sampled O
over O
4 O
decades O
were O
collected O
and O
subjected O
to O
comprehensive O
evolutionary O
analysis O
using O
a O
suite O
of O
phylogenetic O
and O
population O
genetic O
methods O
. O

We O
estimated O
that O
the O
common O
ancestor O
of O
human O
EV O
- O
71 O
likely O
emerged O
around O
1941 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1929 O
to O
1952 O
) O
, O
subsequently O
diverging O
into O
three O
genogroups O
: O
B O
, O
C O
, O
and O
the O
now O
extinct O
genogroup O
A O
. O

Genealogical O
analysis O
revealed O
that O
diverse O
lineages O
of O
genogroup O
B O
and O
C O
( O
subgenogroups O
B1 O
to O
B5 O
and O
C1 O
to O
C5 O
) O
have O
each O
circulated O
cryptically O
in O
the O
human O
population O
for O
up O
to O
5 O
years O
before O
causing O
large O
HFMD O
outbreaks O
, O
indicating O
the O
quiescent O
persistence O
of O
EV O
- O
71 O
in O
human O
populations O
. O

enterovirus B
71 I
( I
EV71 I
) I
causes O
childhood O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
neurological O
complications O
, O
and O
no O
vaccines O
or O
therapeutic O
drugs O
are O
currently O
available O
. O

Formaldehyde O
- O
inactivated O
whole O
- O
virus O
vaccines O
derived O
from O
EV71 O
clinical O
isolates O
and O
a O
mouse B
- I
adapted I
virus I
( I
MAV I
) I
were O
tested O
in O
a O
mouse O
model O
of O
EV71 O
encephalomyelitis O
. O

The O
successful O
use O
of O
a O
dendrimeric O
peptide O
to O
protect O
pigs O
against O
challenge O
with O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
, O
which O
causes O
the O
most O
devastating O
animal O
disease O
worldwide O
, O
is O
described O
. O

Interestingly O
, O
a O
potent O
anti O
- O
FMDV O
immunoglobulin O
A O
response O
( O
local O
and O
systemic O
) O
was O
observed O
, O
despite O
the O
parenteral O
administration O
of O
the O
peptide O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
causative O
agent O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
is O
also O
associated O
with O
serious O
neurological O
disorders O
. O

An O
attenuated O
EV71 O
strain O
[ O
EV71 O
( O
S1 O
- O
3 O
' O
) O
] O
has O
been O
established O
in O
the O
cynomolgus O
monkey O
infection O
model O
; O
this O
strain O
contains O
the O
attenuation O
determinants O
derived O
from O
the O
type O
I O
poliovirus O
vaccine O
strain O
, O
Sabin O
1 O
[ O
PV1 O
( O
Sabin O
) O
] O
, O
in O
the O
5 B
' I
nontranslated I
region I
( I
NTR I
) I
, O
3D O
polymerase O
, O
and O
3 O
' O
NTR O
. O

In O
this O
study O
, O
we O
analyzed O
the O
effect O
of O
the O
attenuation O
determinants O
of O
PV1 O
( O
Sabin O
) O
on O
EV71 O
infection O
in O
a O
NOD O
/ O
SCID O
mouse O
infection O
model O
. O

We O
isolated O
a O
mouse O
- O
adapted O
EV71 O
strain O
[ O
EV71 O
( O
NOD O
/ O
SCID O
) O
] O
that O
causes O
paralysis O
of O
the O
hind O
limbs O
in O
3 O
- O
to O
4 O
- O
week O
- O
old O
NOD O
/ O
SCID O
mice O
by O
adaptation O
of O
the O
virulent O
EV71 O
( O
Nagoya O
) O
strain O
in O
the O
brains O
of O
NOD O
/ O
SCID O
mice O
. O

A O
single O
mutation O
at O
nucleotide O
2876 O
that O
caused O
an O
amino O
acid O
change O
in O
capsid O
protein O
VP1 O
( O
change O
of O
the O
glycine O
at O
position O
145 O
to O
glutamic O
acid O
) O
was O
essential O
for O
the O
mouse O
- O
adapted O
phenotype O
in O
NOD O
/ O
SCID O
mice O
. O

Next O
, O
we O
introduced O
attenuation O
determinants O
derived O
from O
PVI O
( O
Sabin O
) O
along O
with O
the O
mouse O
adaptation O
mutation O
into O
the O
EV71 O
( O
Nagoya O
) O
genome O
. O

These O
results O
suggest O
that O
a O
cooperative O
effect O
of O
the O
attenuation O
determinants O
of O
PVI O
( O
Sabin O
) O
is O
essential O
for O
attenuated O
neurovirulence O
of O
EV71 O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
causative O
agent O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
is O
also O
sometimes O
associated O
with O
serious O
neurological O
disorders O
. O

In O
this O
study O
, O
we O
characterized O
the O
antigenicity O
and O
tissue O
specificity O
of O
an O
attenuated O
strain O
of O
EV71 O
[ O
EV71 O
( O
S1 O
- O
3 O
' O
) O
] O
, O
which O
belongs O
to O
genotype O
A O
, O
in O
a O
monkey O
infection O
model O
. O

Three O
cynomolgus O
monkeys O
were O
inoculated O
with O
EV71 O
( O
S1 O
- O
3 O
' O
) O
, O
followed O
by O
lethal O
challenge O
with O
the O
parental O
virulent O
strain O
EV71 O
( O
BrCr O
- O
TR O
) O
via O
an O
intravenous O
route O
on O
day O
45 O
postinoculation O
of O
EV71 O
( O
S1 O
- O
3 O
' O
) O
. O

Monkeys O
inoculated O
with O
EV71 O
( O
S1 O
- O
3 O
' O
) O
showed O
a O
mild O
neurological O
symptom O
( O
tremor O
) O
but O
survived O
lethal O
challenge O
by O
virulent O
EV71 O
( O
BrCr O
- O
TR O
) O
without O
exacerbation O
of O
the O
symptom O
. O

For O
the O
strains O
examined O
, O
the O
sera O
showed O
the O
highest O
neutralization O
activity O
against O
the O
homotype O
( O
genotype O
A O
) O
and O
the O
lowest O
neutralization O
activity O
against O
genotype O
C2 O
. O

To O
examine O
the O
tissue O
specificity O
of O
EV71 O
( O
S1 O
- O
3 O
' O
) O
, O
two O
monkeys O
were O
intravenously O
inoculated O
with O
EV71 O
( O
S1 O
- O
3 O
' O
followed O
by O
examination O
of O
virus O
distribution O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
extraneural O
tissues O
. O

In O
the O
CNS O
, O
EV71 O
( O
S1 O
- O
3 O
' O
) O
was O
isolated O
only O
from O
the O
spinal O
cord O
. O

These O
results O
indicate O
that O
EV71 O
( O
S1 O
- O
3 O
' O
) O
acts O
as O
an O
effective O
antigen O
, O
although O
this O
attenuated O
strain O
was O
still O
neurotropic O
when O
inoculated O
via O
the O
intravenous O
route O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
frequent O
cause O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
epidemics O
associated O
with O
severe O
neurological O
sequelae O
in O
a O
small O
proportion O
of O
cases O
. O

In O
this O
study O
, O
we O
show O
that O
four O
genetic O
lineages O
of O
EV71 O
have O
been O
prevalent O
in O
the O
Asia O
- O
Pacific O
region O
since O
1997 O
, O
including O
two O
previously O
undescribed O
genogroups O
( O
B3 O
and O
B4 O
) O
. O

enterovirus B
71 I
( I
EV71 I
) I
( O
genus O
Enterovirus O
, O
family O
Picornaviridae O
) O
, O
a O
common O
cause O
of O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
, O
may O
also O
cause O
severe O
neurological O
diseases O
, O
such O
as O
encephalitis O
and O
poliomyelitis O
- O
like O
paralysis O
, O
To O
examine O
the O
genetic O
diversity O
and O
rate O
of O
evolution O
of O
EV71 O
, O
we O
have O
determined O
and O
analyzed O
complete O
VPI O
sequences O
( O
891 O
nucleotides O
) O
for O
113 O
EV71 O
strains O
isolated O
in O
the O
United O
States O
and O
five O
other O
countries O
from O
1970 O
to O
1998 O
, O
Nucleotide O
sequence O
comparisons O
demonstrated O
three O
distinct O
EV71 O
genotypes O
, O
designated O
A O
, O
B O
, O
and O
C O
, O
The O
genetic O
variation O
within O
genotypes O
( O
12 O
% O
or O
fewer O
nucleotide O
differences O
) O
was O
less O
than O
the O
variation O
between O
genotypes O
( O
16 O
. O

35 O
x O
10 O
( O
- O
2 O
) O
substitutions O
per O
nucleotide O
and O
is O
similar O
to O
the O
rate O
observed O
for O
poliovirus O
, O
The O
results O
indicate O
that O
EV71 O
is O
a O
genetically O
diverse O
, O
rapidly O
evolving O
virus O
, O
Its O
worldwide O
circulation O
and O
potential O
to O
cause O
severe O
disease O
underscore O
the O
need O
for O
additional O
surveillance O
and O
improved O
methods O
to O
identify O
EV71 O
in O
human O
disease O
. O

Sandfly B
fever I
Sicilian I
virus I
( I
SFSV I
) I
is O
one O
of O
the O
most O
widespread O
and O
frequently O
identified O
members O
of O
the O
genus O
Phlebovirus O
( O
order O
Bunyavirales O
, O
family O
Phenuiviridae O
) O
infecting O
humans O
. O

Being O
transmitted O
by O
Phlebotomus O
sandflies O
, O
SFSV O
causes O
a O
self O
- O
limiting O
, O
acute O
, O
often O
incapacitating O
febrile O
disease O
( O
sandfly O
fever O
, O
Pappataci O
fever O
, O
or O
dog O
disease O
) O
that O
has O
been O
known O
since O
at O
least O
the O
beginning O
of O
the O
20th O
century O
. O

We O
show O
that O
, O
similarly O
to O
other O
pathogenic O
phleboviruses O
, O
SFSV O
suppresses O
the O
induction O
of O
the O
antiviral O
type B
I I
interferon I
( I
IFN I
) I
system O
in O
an O
NSs O
- O
dependent O
manner O
. O

SFSV O
NSs O
interfered O
with O
the O
TBK1 O
- O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
branch O
of O
the O
RIG O
- O
I O
signaling O
pathway O
but O
not O
with O
NF O
- O
kappa O
B O
activation O
. O

In O
further O
studies O
, O
we O
identified O
the O
DNA O
- O
binding O
domain O
of O
IRF3 O
( O
amino O
acids O
1 O
to O
113 O
) O
as O
sufficient O
for O
NSs O
binding O
and O
found O
that O
SFSV O
NSs O
prevented O
the O
association O
of O
activated O
IRF3 O
with O
the O
IFN O
- O
13 O
promoter O
. O

We O
show O
how O
the O
nonstructural O
NSs O
protein O
of O
SFSV O
counteracts O
the O
upregulation O
of O
the O
antiviral O
interferon B
( I
IFN I
) I
system O
. O

SFSV O
NSs O
specifically O
inhibits O
promoter O
binding O
by O
IFN O
transcription O
factor O
3 O
( O
IRF3 O
) O
, O
a O
molecular O
strategy O
which O
is O
unique O
among O
phleboviruses O
and O
, O
to O
our O
knowledge O
, O
among O
human O
pathogenic O
RNA O
viruses O
in O
general O
. O

( O
Diptera O
; O
Psychodidae O
) O
in O
the O
province O
of O
Adana O
, O
in O
the O
Mediterranean O
region O
of O
Turkey O
. O

Toscana B
virus I
( I
TOSV I
) I
, O
which O
is O
transmitted O
by O
Phlebotomus O
spp O
. O

Like O
other O
members O
of O
the O
genus O
Phlebovirus O
of O
the O
family O
Bunyaviridae O
, O
TOSV O
encodes O
a O
nonstructural O
protein O
( O
NSs O
) O
in O
its O
small O
RNA O
segment O
. O

Although O
the O
NSs O
of O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
has O
been O
identified O
as O
an O
important O
virulence O
factor O
, O
which O
suppresses O
host O
general O
transcription O
, O
inhibits O
transcription O
from O
the O
beta O
interferon O
promoter O
, O
and O
promotes O
the O
proteasomal O
degradation O
of O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
, O
little O
is O
known O
about O
the O
functions O
of O
NSs O
proteins O
encoded O
by O
less O
- O
pathogenic O
members O
of O
this O
genus O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
pediatric O
respiratory O
disease O
. O

Using O
an O
in O
vitro O
model O
of O
the O
differenti O
- O
ated O
airway O
epithelium O
, O
we O
found O
that O
the O
addition O
of O
physiological O
concentrations O
of O
neutrophils O
to O
RSV O
- O
infected O
nasal O
cultures O
was O
associated O
with O
greater O
epithelial O
damage O
with O
lower O
ciliary O
activity O
, O
cilium O
loss O
, O
less O
tight O
junction O
expression O
( O
ZO O
- O
1 O
) O
, O
and O
more O
detachment O
of O
epithelial O
cells O
than O
is O
seen O
with O
RSV O
infection O
alone O
. O

Epithelial O
damage O
in O
response O
to O
RSV O
infection O
was O
associated O
with O
neutrophil O
activation O
( O
within O
1 O
h O
) O
and O
neutrophil O
degranulation O
, O
with O
significantly O
greater O
cellular O
expression O
of O
CD11b O
and O
myeloperoxidase O
and O
higher O
levels O
of O
neutrophil O
elastase O
and O
myeloperoxidase O
activity O
in O
apical O
surface O
media O
than O
in O
media O
with O
mock O
- O
infected O
airway B
epithelial I
cells I
( I
AECs I
) I
. O

We O
also O
recovered O
more O
apoptotic O
neutrophils O
from O
RSV O
- O
infected O
cul O
- O
tures O
( O
40 O
% O
) O
than O
from O
mock O
- O
infected O
cultures O
( O
< O
5 O
% O
) O
after O
4 O
h O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
an O
enveloped O
RNA O
virus O
which O
is O
responsible O
for O
approximately O
80 O
% O
of O
lower O
respiratory O
tract O
infections O
in O
children O
. O

Current O
lines O
of O
evidence O
have O
supported O
the O
functional O
involvement O
of O
long B
noncoding I
RNA I
( I
lncRNA I
) I
in O
many O
viral O
infectious O
diseases O
. O

quantitative B
PCR I
( I
qPCR I
) I
detection O
indicated O
that O
the O
expression O
of O
lncRNA O
negative B
regulator I
of I
antiviral I
response I
( I
NRAV I
) I
in O
RSV O
- O
positive O
patients O
was O
significantly O
lower O
than O
that O
in O
uninfected O
patients O
, O
but O
lncRNA O
psoriasis O
- O
associated O
non O
- O
protein O
coding O
RNA O
induced O
by O
stress O
( O
PRINS O
) O
, O
nuclear B
paraspeckle I
assembly I
transcript I
1 I
( I
NEAT1 I
) I
, O
and O
Nettoie B
Salmonella I
pas I
Theiler I
' I
s I
( I
NeST I
) I
showed O
no O
difference O
in O
vivo O
and O
in O
vitro O
. O

RNA O
fluorescent B
in I
situ I
hybridization I
( I
FISH I
) I
confirmed O
that O
NRAV O
was O
mainly O
located O
in O
the O
cytoplasm O
. O

In O
this O
study O
, O
we O
found O
that O
the O
expression O
of O
long B
noncoding I
RNA I
( I
lncRNA I
) I
negative I
regulator I
of I
antiviral I
response I
( I
NRAV I
) I
was O
reduced O
in O
RSV O
- O
infected O
patients O
, O
and O
overexpression O
of O
NRAV O
facilitated O
RSV O
production O
in O
vitro O
, O
suggesting O
that O
the O
reduction O
of O
NRAV O
in O
RSV O
infection O
was O
part O
of O
the O
host O
antiviral O
response O
. O

In O
this O
study O
, O
we O
examined O
the O
antiviral O
activity O
of O
natural O
compounds O
against O
the O
following O
influenza O
virus O
strains O
: O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
, O
A O
/ O
Udorn O
/ O
72 O
( O
H3N2 O
) O
, O
and O
B O
/ O
Lee O
/ O
40 O
. O

Papaverine O
( O
a O
nonnarcotic O
alkaloid O
that O
has O
been O
used O
for O
the O
treatment O
of O
heart O
disease O
, O
impotency O
, O
and O
psychosis O
) O
was O
found O
to O
be O
an O
effective O
inhibitor O
of O
multiple O
strains O
of O
influenza O
virus O
. O

An O
alteration O
in O
influenza O
virus O
morphology O
and O
viral B
ribonucleoprotein I
( I
vRNP I
) I
localization O
was O
observed O
as O
an O
effect O
of O
papaverine O
treatment O
. O

Papaverine O
is O
a O
well O
- O
known O
phosphodiesterase O
inhibitor O
and O
also O
modifies O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
pathway O
by O
downregulating O
the O
phosphorylation O
of O
MEK O
and O
extracellular B
signal I
- I
regulated I
kinase I
( I
ERK I
) I
. O

Interestingly O
, O
papaverine O
also O
inhibited O
paramyxoviruses O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
human B
parainfluenza I
virus I
3 I
( I
HPIV3 I
) I
, O
and O
respiratory B
syncytial I
virus I
( I
RSV I
) I
infections O
. O

Here O
, O
we O
used O
directed O
evolution O
of O
a O
luciferase O
- O
expressing O
pandemic B
H1N1 I
( I
pH1N1 I
) I
2009 O
influenza O
A O
virus O
in O
mice O
to O
restore O
replication O
kinetics O
and O
virulence O
, O
increase O
the O
bioluminescence O
signal O
, O
and O
maintain O
reporter O
gene O
expression O
. O

Mouse O
- O
adapted O
virus O
after O
9 O
rounds O
( O
MA O
- O
9 O
) O
had O
the O
highest O
relative O
bioluminescence O
signal O
and O
had O
wild O
- O
type O
- O
like O
fitness O
and O
virulence O
in O
DBA O
/ O
2 O
mice O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
severe O
respiratory O
illness O
in O
infants O
. O

At O
this O
young O
age O
, O
infants O
typically O
depend O
on O
maternally B
transferred I
antibodies I
( I
matAbs I
) I
and O
their O
innate O
immune O
system O
for O
protection O
against O
infections O
. O

However O
, O
it O
has O
been O
shown O
that O
this O
binding O
may O
lead O
to O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
infection O
or O
reduction O
of O
neutralization O
, O
both O
possibly O
leading O
to O
more O
disease O
. O

We O
then O
demonstrated O
that O
antibodies O
from O
cotton O
rats O
with O
formalin B
- I
inactivated I
( I
FI I
) I
RSV O
- O
induced O
pulmonary O
pathology O
were O
capable O
of O
causing O
ADE O
. O

We O
investigated O
two O
of O
those O
effects O
: O
antibody B
- I
dependent I
enhancement I
of I
infection I
( I
ADE I
) I
and O
neutralization O
reduction O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
severe O
respiratory O
infections O
in O
children O
and O
elderly O
people O
, O
and O
no O
marketed O
vaccine O
exists O
. O

In O
this O
study O
, O
we O
generated O
and O
analyzed O
a O
subunit O
vaccine O
against O
RSV O
based O
on O
a O
novel O
genome O
replication O
- O
deficient O
Sendai B
virus I
( I
SeV I
) I
vector O
. O

IMPORTANCE O
respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
respiratory O
diseases O
in O
young O
children O
and O
elderly O
people O
worldwide O
. O

Bovine B
respiratory I
disease I
( I
BRD I
) I
is O
a O
common O
health O
problem O
for O
both O
dairy O
and O
beef O
cattle O
, O
resulting O
in O
significant O
economic O
loses O
. O

Epstein B
- I
Barr I
virus I
( I
EBV I
) I
is O
the O
etiologic O
agent O
of O
infectious O
mononucleosis O
and O
the O
root O
cause O
of O
B O
- O
cell O
lymphoproliferative O
disease O
in O
individuals O
with O
a O
weakened O
immune O
system O
, O
as O
well O
as O
a O
principal O
cofactor O
in O
nasopharyngeal O
carcinoma O
, O
various O
lymphomas O
, O
and O
other O
cancers O
. O

Peptide O
DDRTTLQLAQNPVYIPETYPYIKWDN O
( O
designated O
peptide O
2 O
) O
and O
peptide O
GSAKPGNGSYFASVKTEMLGNEID O
( O
designated O
peptide O
3 O
) O
were O
designed O
to O
spatially O
represent O
the O
gp350 O
amino O
acids O
predicted O
to O
interact O
with O
the O
72A1 O
antibody O
paratope O
. O

IMPORTANCE O
The O
production O
of O
virus O
- O
neutralizing O
antibodies O
targeting O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
major O
surface O
glycoprotein O
gp350 O
is O
important O
for O
the O
prevention O
of O
infectious O
mononucleosis O
and O
EBV O
- O
related O
cancers O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
infectious O
cause O
of O
severe O
respiratory O
disease O
in O
infants O
and O
a O
major O
cause O
of O
respiratory O
illness O
in O
the O
elderly O
. O

Insufficient O
potency O
, O
homogeneity O
, O
and O
stability O
of O
previous O
RSV O
fusion B
protein I
( I
F I
) I
subunit O
vaccine O
candidates O
have O
hampered O
vaccine O
development O
. O

RSV O
F O
and O
related O
parainfluenza B
virus I
( I
PIV I
) I
F O
proteins O
are O
cleaved O
by O
furin O
during O
intracellular O
maturation O
, O
producing O
disulfide O
- O
linked O
F1 O
and O
F2 O
fragments O
. O

Recent O
studies O
have O
defined O
the O
structures O
that O
the O
RSV O
F O
envelope O
glycoprotein O
adopts O
before O
and O
after O
virus O
entry O
( O
prefusion O
and O
postfusion O
conformations O
, O
respectively O
) O
. O

Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
is O
a O
serious O
respiratory O
pathogen O
in O
infants O
and O
young O
children O
as O
well O
as O
elderly O
and O
immunocompromised O
populations O
. O

We O
have O
explored O
the O
potential O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
as O
an O
RSV O
vaccine O
candidate O
. O

However O
, O
VLPs O
composed O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
nucleocapsid O
and O
membrane O
proteins O
and O
chimera O
proteins O
containing O
the O
ectodomains O
of O
RSV O
F O
and O
G O
proteins O
fused O
to O
the O
transmembrane O
and O
cytoplasmic O
domains O
of O
NDV O
F O
and O
HN O
proteins O
, O
respectively O
, O
were O
quantitatively O
prepared O
from O
avian O
cells O
. O

IgG2a O
/ O
IgG1 O
ratios O
were O
very O
high O
, O
suggesting O
predominantly O
T O
( O
H O
) O
1 O
responses O
. O

Cystic B
fibrosis I
( I
CF I
) I
is O
the O
most O
common O
lethal O
recessive O
genetic O
disease O
in O
the O
Caucasian O
population O
. O

It O
is O
caused O
by O
mutations O
in O
the O
CF B
transmembrane I
conductance I
regulator I
( I
CFTR I
) I
gene O
that O
is O
normally O
expressed O
in O
ciliated O
airway O
epithelial O
cells O
and O
the O
submucosal O
glands O
of O
the O
lung O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
naturally O
infects O
the O
ciliated O
cells O
in O
the O
human O
airway O
epithelium O
. O

5 O
- O
kb O
CFTR O
gene O
could O
be O
expressed O
by O
a O
recombinant O
RSV O
and O
whether O
infectious O
virus O
could O
be O
used O
to O
deliver O
CFTR O
to O
ciliated O
airway O
epithelium O
derived O
from O
CF O
patients O
, O
we O
inserted O
the O
CFTR O
gene O
into O
four O
sites O
in O
a O
recombinant B
green I
fluorescent I
protein I
- I
expressing I
RSV I
( I
rgRSV I
) I
genome O
to O
generate O
virus O
expressing O
four O
different O
levels O
of O
CFTR O
protein O
. O

The O
order O
Mononegavirales O
( O
comprised O
of O
nonsegmented O
negative O
- O
stranded O
RNA O
viruses O
or O
NNSVs O
) O
contains O
many O
important O
pathogens O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
formerly O
known O
as O
simian O
virus O
5 O
, O
is O
a O
prototypical O
paramyxovirus O
and O
encodes O
a O
V O
protein O
, O
which O
has O
a O
cysteine O
- O
rich O
C O
terminus O
that O
is O
conserved O
among O
all O
paramyxoviruses O
. O

The O
phosphoproteins O
( O
P O
proteins O
) O
of O
NNSVs O
are O
essential O
cofactors O
for O
the O
viral O
RNA O
polymerase O
complex O
and O
require O
heavy O
phosphorylation O
for O
their O
activity O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
only O
infectious O
disease O
for O
which O
a O
monoclonal B
antibody I
( I
Mab I
) I
is O
used O
in O
humans O
. O

Palivizumab B
( I
PZ I
) I
is O
a O
humanized O
murine O
MAb O
to O
the O
F O
protein O
of O
RSV O
. O

We O
assessed O
the O
fitness O
of O
two O
PZ O
- O
resistant O
viruses O
( O
F212 O
and O
MP4 O
) O
. O

The O
roles O
of O
both O
classical O
lipid O
rafts O
and O
lipid O
rafts O
associated O
with O
the O
membrane O
cytoskeleton O
in O
the O
assembly O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
were O
investigated O
. O

Kinetic O
analyses O
of O
the O
distribution O
of O
viral O
proteins O
in O
lipid O
rafts O
, O
as O
defined O
by O
detergent B
- I
resistant I
membranes I
( I
DRMs I
) I
, O
in O
non O
- O
lipid O
raft O
membranes O
, O
and O
in O
virions O
showed O
an O
accumulation O
of O
HN O
, O
F O
, O
and O
NP O
viral O
proteins O
in O
lipid O
rafts O
early O
after O
synthesis O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
recently O
described O
human O
pathogen O
of O
the O
pneumovirus O
subfamily O
within O
the O
paramyxovirus O
family O
. O

The O
HMPV O
fusion B
protein I
( I
F I
) I
amino O
acid O
sequence O
contains O
features O
characteristic O
of O
other O
paramyxovirus O
F O
proteins O
, O
including O
a O
putative O
cleavage O
site O
and O
potential O
N O
- O
linked O
glycosylation O
sites O
. O

Propagation O
of O
HMPV O
in O
cell O
culture O
requires O
exogenous O
trypsin O
, O
which O
cleaves O
the O
F O
protein O
, O
and O
HMPV O
, O
like O
several O
other O
pneumoviruses O
, O
is O
infectious O
in O
the O
absence O
of O
its O
attachment O
protein O
( O
G O
) O
. O

Rhinoviruses B
( I
RV I
) I
are O
the O
major O
cause O
of O
acute O
exacerbations O
of O
asthma O
and O
chronic B
obstructive I
pulmonary I
disease I
( I
COPD I
) I
. O

tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
is O
implicated O
in O
the O
pathogenesis O
of O
acute O
exacerbations O
, O
but O
its O
cellular O
source O
and O
mechanisms O
of O
induction O
by O
virus O
infection O
are O
unclear O
. O

The O
infection O
induced O
TNF O
- O
alpha O
release O
in O
a O
time O
- O
and O
dose O
- O
dependent O
, O
RV O
serotype O
- O
and O
receptor O
- O
independent O
manner O
and O
was O
largely O
( O
THP O
- O
1 O
derived O
) O
or O
completely O
( O
monocyte O
derived O
) O
dependent O
upon O
virus O
replication O
. O

To O
address O
this O
issue O
, O
we O
evaluated O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
that O
is O
serotypically O
distinct O
from O
common O
human O
pathogens O
, O
as O
a O
vaccine O
vector O
. O

Two O
strains O
were O
evaluated O
: O
the O
attenuated O
vaccine O
strain O
LaSota O
( O
NDV O
- O
LS O
) O
that O
replicates O
mostly O
in O
the O
chicken O
respiratory O
tract O
and O
the O
Beaudette O
C O
( O
NDV O
- O
BC O
) O
strain O
of O
intermediate O
virulence O
that O
produces O
mild O
systemic O
infection O
in O
chickens O
. O

A O
recombinant O
version O
of O
each O
virus O
was O
modified O
by O
the O
insertion O
, O
between O
the O
P O
and O
M O
genes O
, O
of O
a O
gene O
cassette O
encoding O
the O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
protein O
, O
a O
test O
antigen O
with O
considerable O
historic O
data O
. O

The O
recombinant O
viruses O
were O
administered O
to O
African O
green O
monkeys O
( O
NDV O
- O
BC O
and O
NDV O
- O
LS O
) O
and O
rhesus O
monkeys O
( O
NDV O
- O
BC O
only O
) O
by O
combined O
intranasal O
and O
intratracheal O
routes O
at O
a O
dose O
of O
10 O
( O
6 O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
newly O
described O
member O
of O
the O
Paramyxoviridae O
family O
causing O
acute O
respiratory O
tract O
infections O
, O
especially O
in O
young O
children O
. O

We O
studied O
the O
pathogenesis O
of O
this O
viral O
infection O
in O
two O
experimental O
small O
animal O
models O
( O
BALB O
/ O
c O
mice O
and O
cotton O
rats O
) O
. O

Significant O
viral O
replication O
in O
the O
lungs O
of O
both O
animals O
was O
found O
following O
an O
intranasal O
challenge O
of O
10 O
( O
8 O
) O
50 B
% I
tissue I
culture I
infectious I
doses I
( I
TCID50 I
) I
and O
persisted O
for O
< O
2 O
and O
< O
3 O
weeks O
in O
the O
case O
of O
cotton O
rats O
and O
mice O
, O
respectively O
. O

92 O
X O
10 O
( O
7 O
) O
TCID50 O
/ O
g O
lung O
) O
and O
cotton O
rats O
( O
mean O
of O
1 O
. O

03 O
X O
10 O
( O
5 O
) O
TCID50 O
/ O
g O
) O
. O

Most O
significant O
pulmonary O
inflammatory O
changes O
and O
peak O
expression O
of O
macrophage O
inflammatory O
protein O
lot O
, O
gamma O
interferon O
, O
and O
RANTES O
occurred O
at O
the O
time O
of O
maximal O
viral O
replication O
( O
day O
5 O
) O
in O
both O
models O
. O

Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
are O
closely O
related O
emerging O
viruses O
comprising O
the O
Henipavirus O
genus O
of O
the O
Paramyxovirinae O
, O
which O
are O
distinguished O
by O
their O
ability O
to O
cause O
fatal O
disease O
in O
both O
animal O
and O
human O
hosts O
. O

These O
viruses O
infect O
cells O
by O
a O
pH O
- O
independent O
membrane O
fusion O
event O
mediated O
by O
their O
attachment O
( O
G O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
. O

To O
further O
characterize O
the O
G O
glycoprotein O
and O
its O
unknown O
receptor O
, O
soluble O
forms O
of O
HeV O
G O
( O
sG O
) O
were O
constructed O
by O
replacing O
its O
cytoplasmic O
tail O
and O
transmembrane O
domains O
with O
an O
immunoglobulin O
K O
leader O
sequence O
coupled O
to O
either O
an O
S O
- O
peptide O
tag O
( O
sG O
( O
S O
- O
tag O
) O
) O
or O
myc O
- O
epitope O
tag O
( O
s O
( O
myc O
- O
tag O
) O
) O
to O
facilitate O
purification O
and O
detection O
. O

Palivizumab B
( I
PZ I
) I
is O
the O
only O
monoclonal O
antibody O
currently O
available O
for O
use O
in O
humans O
against O
an O
infectious O
disease O
. O

PZ O
is O
administered O
prophylactically O
for O
respiratory B
syncytial I
virus I
( I
RSV I
) I
infections O
. O

human B
metapneumovirus I
( I
HMPV I
) I
has O
emerged O
as O
an O
important O
human O
respiratory O
pathogen O
causing O
upper O
and O
lower O
respiratory O
tract O
infections O
in O
young O
children O
and O
older O
adults O
. O

46 O
log O
( O
2 O
) O
end O
- O
point O
titers O
by O
day O
28 O
p O
. O

adenovirus B
( I
Ad I
) I
, O
particularly O
Ad O
type O
7 O
( O
AV O
) O
, O
causes O
severe O
lung O
infection O
and O
pneumonia O
. O

interleukin B
- I
8 I
( I
IL I
- I
8 I
) I
is O
the O
major O
lung O
neutrophil O
chemotaxin O
, O
and O
we O
have O
shown O
that O
Ad7 O
induces O
IL O
- O
8 O
release O
from O
the O
A549 O
alveolar O
epithelial O
cell O
line O
. O

CpG O
oligodeoxynucleotides B
( I
ODN I
) I
were O
identified O
that O
stimulated O
immunoglobulin O
production O
and O
cell O
proliferation O
in O
cotton O
rat O
cells O
in O
vitro O
. O

Three O
of O
these O
ODN O
were O
used O
as O
a O
mucosall O
adjuvant O
in O
the O
noses O
of O
cotton O
rats O
immunized O
via O
this O
route O
with O
respiratory O
syncytial O
virus O
fusion O
( O
F O
) O
protein O
. O

Lower O
respiratory O
tract O
disease O
caused O
by O
respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
characterized O
by O
profound O
airway O
mucosa O
inflammation O
, O
both O
in O
infants O
with O
naturally O
acquired O
infection O
and O
in O
experimentally O
inoculated O
animal O
models O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
intranasal O
infection O
of O
BALB O
/ O
c O
mice O
, O
vith O
RSV O
A O
results O
in O
inducible O
expression O
of O
lung O
chemokines O
belonging O
to O
the O
CXC O
( O
MIP O
- O
2 O
and O
IP O
- O
10 O
) O
, O
CC O
( O
RANTES O
, O
eotaxin O
, O
MIP O
- O
1 O
beta O
, O
MIP O
- O
1 O
alpha O
, O
MCP O
- O
1 O
, O
TCA O
- O
3 O
) O
and O
C O
( O
lymphotactin O
) O
families O
. O

Chemokine O
mRNA O
expression O
occurred O
as O
early O
as O
24 O
h O
following O
inoculation O
and O
persisted O
for O
at O
least O
5 O
days O
in O
mice O
inoculated O
with O
the O
highest O
dose O
of O
virus O
( O
10 O
( O
7 O
) O
PFU O
) O
. O

Immunohisthochemical O
studies O
indicated O
that O
RSV O
- O
induced O
expression O
of O
MIP O
- O
1 O
alpha O
, O
one O
of O
the O
most O
abundantly O
expressed O
chemokines O
, O
was O
primarily O
localized O
in O
epithelial O
cells O
of O
the O
alveoli O
and O
bronchioles O
, O
as O
well O
as O
in O
adjoining O
capillary O
endothelium O
, O
Genetically O
altered O
mice O
with O
a O
selective O
deletion O
of O
the O
MIP O
- O
1 O
alpha O
gene O
( O
- O
/ O
- O
mice O
) O
demonstrated O
a O
significant O
reduction O
in O
lung O
inflammation O
following O
RSV O
infection O
, O
compared O
to O
control O
littermates O
( O
+ O
/ O
+ O
mice O
) O
. O

Ideally O
, O
a O
single O
vaccine O
would O
confer O
protection O
against O
several O
pathogens O
and O
would O
induce O
both O
cellular O
and O
humoral O
arms O
of O
the O
immune O
response O
, O
We O
originally O
demonstrated O
that O
two O
virus O
- O
specific O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitopes O
, O
from O
the O
same O
virus O
but O
presented O
by O
different O
major O
histocompatibility O
complex O
alleles O
, O
when O
linked O
in O
tandem O
as O
minigenes O
in O
a O
recombinant O
vaccinia O
virus O
, O
could O
confer O
complete O
protection O
against O
subsequent O
viral O
challenge O
. O

In O
the O
study O
, O
we O
extended O
this O
approach O
, O
which O
we O
termed O
string O
of O
beads O
, O
expanding O
the O
immunogenic O
scope O
in O
two O
ways O
: O
first O
, O
by O
introduction O
of O
T B
helper I
( I
T I
- I
h I
) I
and O
B O
- O
cell O
( O
antibody O
) O
epitopes O
alongside O
CTL O
epitopes O
and O
second O
, O
by O
including O
immunogenic O
sequences O
from O
a O
variety O
of O
infectious O
agents O
, O
five O
viruses O
and O
one O
bacterium O
. O

The O
vaccine O
( O
VV O
- O
sv O
) O
comprises O
CTL O
epitopes O
from O
Sendai O
virus O
, O
respiratory O
syncytial O
virus O
, O
and O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
; O
T O
- O
h O
epitopes O
from O
vesicular O
stomatitis O
virus O
and O
Mycobacterium O
tuberculosis O
; O
and O
an O
antibody O
epitope O
from O
mengovirus O
, O
The O
construct O
contains O
a O
single O
start O
codon O
, O
and O
the O
epitopes O
are O
linked O
directly O
without O
intervening O
spacer O
amino O
acids O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
viral O
zoonosis O
that O
can O
cause O
viral O
encephalitis O
, O
death O
, O
and O
disability O
. O

Here O
, O
we O
found O
that O
mosquito O
defensin O
facilitated O
the O
adsorption O
of O
JEV O
on O
target O
cells O
via O
the O
defensin O
/ O
lipoprotein B
receptor I
- I
related I
protein I
2 I
( I
LRP2 I
) I
axis O
. O

Mosquito O
defensin O
bound O
the O
ED O
III O
domain O
of O
the O
viral O
envelope B
( I
E I
) I
protein O
and O
directly O
mediated O
efficient O
virus O
adsorption O
on O
the O
target O
cell O
surface O
; O
the O
receptor O
LRP2 O
, O
which O
is O
expressed O
on O
the O
cell O
surface O
, O
affected O
defensin O
- O
dependent O
adsorption O
. O

In O
the O
latter O
, O
defensin O
directly O
binds O
the O
ED O
III O
domain O
of O
the O
viral O
E O
protein O
and O
promotes O
the O
adsorption O
of O
JEV O
to O
target O
cells O
by O
interacting O
with O
lipoprotein B
receptor I
- I
related I
protein I
2 I
( I
LRP2 I
) I
, O
thus O
accelerating O
virus O
entry O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
flavivirus O
that O
causes O
Japanese B
encephalitis I
( I
JE I
) I
, O
which O
has O
an O
unclear O
pathogenesis O
. O

The O
effect O
of O
Axl O
deficiency O
on O
JEV O
infection O
was O
mediated O
by O
markedly O
elevated O
serum O
interleukin B
- I
1 I
alpha I
( I
IL I
- I
1 I
alpha I
) I
levels O
, O
which O
devastated O
the O
blood O
- O
brain O
- O
barrier O
and O
promoted O
viral O
neuroinvasion O
within O
24 O
h O
postinfection O
. O

Axl O
deficiency O
enhanced O
cell O
death O
and O
caused O
pyroptosis O
in O
80 O
% O
of O
JEV O
- O
infected O
macrophages O
by O
disrupting O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
- O
Akt O
signaling O
. O

IMPORTANCE O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
mosquito O
- O
borne O
flavivirus O
that O
causes O
Japanese B
encephalitis I
( I
JE I
) I
, O
the O
most O
commonly O
diagnosed O
viral O
encephalitis O
worldwide O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
Axl O
impedes O
the O
pathogenesis O
of O
severe O
JE O
in O
mice O
by O
maintaining O
blood B
- I
brain I
- I
barrier I
( I
BBB I
) I
integrity O
and O
restricting O
viral O
neuroinvasion O
. O

Flavivirus O
nonstructural B
protein I
5 I
( I
NS5 I
) I
contains O
an O
N O
- O
terminal O
methyltransferase B
( I
MTase I
) I
domain O
and O
a O
C O
- O
terminal O
polymerase O
( O
RNA O
- O
dependent O
RNA O
polymerase O
[ O
RdRp O
] O
) O
domain O
fused O
through O
a O
9 O
- O
amino O
- O
acid O
linker O
. O

While O
the O
individual O
NS5 O
domains O
are O
structurally O
conserved O
, O
in O
the O
full O
- O
length O
protein O
, O
their O
relative O
orientations O
fall O
into O
two O
classes O
: O
the O
NS5 O
proteins O
from O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
and O
Zika B
virus I
( I
ZIKV I
) I
adopt O
one O
conformation O
, O
while O
the O
NS5 O
protein O
from O
Dengue B
virus I
serotype I
3 I
( I
DENV3 I
) I
adopts O
another O
. O

Avian O
Tembusu B
virus I
( I
TMUV I
) I
is O
a O
newly O
emerging O
avian O
pathogenic O
flavivirus O
in O
China O
and O
Southeast O
Asia O
with O
features O
of O
rapid O
spread O
, O
an O
expanding O
host O
range O
, O
and O
cross O
- O
species O
transmission O
. O

Here O
, O
we O
investigated O
the O
tropism O
of O
this O
arbovirus O
in O
peripheral O
blood O
mononuclear O
cells O
of O
specific B
- I
pathogen I
- I
free I
( I
SPF I
) I
ducks O
and O
SPF O
chickens O
and O
identified O
monocytes O
/ O
macrophages O
as O
the O
key O
targets O
of O
TMUV O
infection O
. O

Despite O
the O
activation O
of O
major O
pattern O
recognition O
receptor O
signaling O
, O
the O
inductions O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
beta O
were O
blocked O
by O
TMUV O
infection O
on O
transcription O
and O
translation O
levels O
, O
respectively O
. O

Avian O
Tembusu B
virus I
( I
TMUV I
) I
is O
an O
emerging O
mosquito O
- O
borne O
flavivirus O
that O
is O
pathogenic O
for O
many O
avian O
species O
and O
can O
infect O
cells O
derived O
from O
mammals O
and O
humans O
in O
vitro O
. O

The O
flavivirus O
capsid O
protein O
is O
considered O
to O
be O
essential O
for O
the O
formation O
of O
nucleocapsid O
complexes O
with O
viral O
genomic O
RNA O
at O
the O
viral O
replication O
organelle O
that O
appears O
on O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
as O
well O
as O
for O
incorporation O
into O
virus O
particles O
. O

However O
, O
this O
protein O
is O
also O
detected O
at O
the O
lipid B
droplet I
( I
LD I
) I
and O
nucleolus O
, O
and O
physiological O
roles O
of O
these O
off O
- O
site O
localizations O
are O
still O
unclear O
. O

In O
this O
study O
, O
we O
made O
a O
series O
of O
alanine O
substitution O
mutants O
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
capsid O
protein O
that O
cover O
all O
polar O
and O
hydrophobic O
amino O
acid O
residues O
to O
identify O
the O
molecular O
surfaces O
required O
for O
virus O
particle O
formation O
and O
for O
localization O
at O
the O
LD O
and O
nucleolus O
. O

Five O
mutants O
exhibited O
a O
defect O
in O
the O
formation O
of O
infectious O
particles O
, O
and O
two O
of O
these O
mutants O
failed O
to O
be O
incorporated O
into O
the O
subviral B
particles I
( I
SVP I
) I
. O

Accumulated O
evidence O
demonstrates O
that O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
infection O
triggers O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
and O
neuron O
apoptosis O
. O

ER O
stress O
sensor O
protein B
kinase I
R I
- I
like I
endoplasmic I
reticulum I
kinase I
( I
PERK I
) I
has O
been O
reported O
to O
induce O
apoptosis O
under O
acute O
or O
prolonged O
ER O
stress O
. O

IMPORTANCE O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
infection O
triggers O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
and O
neuron O
apoptosis O
. O

ER O
stress O
sensor O
protein B
kinase I
R I
- I
like I
endoplasmic I
reticulum I
kinase I
( I
PERK I
) I
has O
been O
reported O
to O
induce O
apoptosis O
under O
acute O
or O
prolonged O
ER O
stress O
. O

The O
Japanese B
encephalitis I
virus I
( I
JEV I
) I
envelope I
( I
E I
) I
protein O
, O
as O
one O
of O
mediators O
of O
virus O
entry O
into O
host O
cells O
, O
plays O
a O
critical O
role O
in O
determining O
virulence O
. O

The O
Glu O
- O
to O
- O
Lys O
mutation O
of O
residue O
138 O
in O
E O
protein O
( O
El O
38 O
) O
plays O
an O
important O
role O
in O
attenuating O
JEV O
vaccine O
strain O
SA14 O
- O
14 O
- O
2 O
. O

Likewise O
, O
for O
its O
parent O
strain O
( O
HEN0701 O
) O
, O
a O
virulence O
strain O
, O
the O
mutations O
of O
E138 O
are O
responsible O
for O
virulence O
alteration O
. O

Zika B
virus I
( I
ZIKV I
) I
infection O
during O
the O
large O
epidemics O
in O
the O
Americas O
is O
related O
to O
congenital O
abnormities O
or O
fetal O
demise O
. O

Three O
codon O
pair O
- O
deoptimized O
ZIKVs O
( O
Min O
E O
, O
Min O
NS1 O
, O
and O
Min O
E O
+ O
NS1 O
) O
were O
de O
novo O
synthesized O
and O
recovered O
by O
reverse O
genetics O
and O
contained O
large O
amounts O
of O
underrepresented O
codon O
pairs O
in O
the O
E O
gene O
and O
/ O
or O
NS1 O
gene O
. O

The O
codon O
pair O
- O
deoptimized O
variants O
had O
decreased O
replication O
fitness O
in O
Vero O
cells O
( O
Min O
NS1 O
> O
> O
Min O
E O
> O
Min O
E O
+ O
NS1 O
) O
, O
replicated O
more O
efficiently O
in O
insect O
cells O
than O
in O
mammalian O
cells O
, O
and O
demonstrated O
diminished O
virulence O
in O
a O
mouse O
model O
. O

IMPORTANCE O
Due O
to O
unprecedented O
epidemics O
of O
Zika B
virus I
( I
ZIKV I
) I
across O
the O
Americas O
and O
the O
unexpected O
clinical O
symptoms O
, O
including O
Guillain O
- O
Barre O
syndrome O
, O
microcephaly O
, O
and O
other O
birth O
defects O
in O
humans O
, O
there O
is O
an O
urgent O
need O
for O
ZIKV O
vaccine O
development O
. O

Here O
we O
provided O
the O
first O
attenuated O
versions O
of O
ZIKV O
with O
two O
important O
genes O
( O
E O
and O
/ O
or O
NS1 O
) O
that O
were O
subjected O
to O
codon O
pair O
deoptimization O
. O

Duck O
Tembusu B
virus I
( I
TMUV I
) I
, O
like O
other O
mosquito O
- O
borne O
flaviviruses O
, O
such O
as O
Japanese O
encephalitis O
virus O
, O
West O
Nile O
virus O
, O
and O
Bagaza O
virus O
, O
is O
able O
to O
transmit O
vector O
- O
independently O
. O

We O
demonstrate O
that O
the O
envelope O
protein O
of O
TMUV O
and O
its O
amino O
acid O
( O
S O
) O
at O
position O
156 O
is O
responsible O
for O
tissue O
tropism O
and O
transmission O
in O
ducks O
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
causative O
agent O
of O
hand O
, O
foot O
, O
and O
mouth O
disease O
and O
sometimes O
causes O
severe O
or O
fatal O
neurological O
complications O
. O

Viruses O
with O
Glutamic B
acid I
( I
E I
) I
at O
VP1 O
- O
145 O
( O
VP1 O
- O
145E O
) O
are O
virulent O
in O
neonatal O
mice O
and O
transgenic O
mice O
expressing O
human O
scavenger O
receptor O
B2 O
, O
whereas O
those O
with O
Glutamine B
( I
Q I
) I
or O
Glycine B
( I
G I
) I
are O
not O
. O

Infection O
by O
enterovirus B
71 I
( I
EV71 I
) I
is O
affected O
by O
cell O
surface O
receptors O
, O
including O
the O
human B
scavenger I
receptor I
B2 I
( I
hSCARB2 I
) I
, O
which O
are O
required O
for O
viral O
uncoating O
, O
and O
attachment O
receptors O
, O
such O
are O
heparan B
sulfate I
( I
HS I
) I
, O
which O
bind O
virus O
but O
do O
not O
support O
uncoating O
. O

We O
produced O
EV71 O
having O
glycine O
( O
VP1 O
- O
145G O
) O
or O
glutamic O
acid O
( O
VP1 O
- O
145E O
) O
at O
position O
145 O
. O

Our O
previous O
work O
showed O
that O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
enters O
porcine O
kidney O
( O
PK O
- O
15 O
) O
cells O
through O
a O
clathrin O
- O
dependent O
pathway O
that O
requires O
Rab5 O
and O
Rab7 O
. O

The O
entry O
mechanism O
for O
CSFV O
into O
other O
cell O
lines O
remains O
unclear O
, O
for O
instance O
, O
porcine O
alveolar O
macrophages O
( O
3D4 O
/ O
21 O
cells O
) O
. O

In O
this O
study O
, O
entry O
and O
postinternalization O
of O
CSFV O
were O
analyzed O
using O
chemical O
inhibitors O
, O
RNA O
interference O
, O
and O
dominant B
- I
negative I
( I
DN I
) I
mutants O
. O

IMPORTANCE O
Classical O
swine O
fever O
, O
is O
caused O
by O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
. O

The O
disease O
is O
notifiable O
to O
World B
Organisation I
for I
Animal I
Health I
( I
OIE I
) I
in O
most O
countries O
and O
causes O
significant O
financial O
losses O
to O
the O
pig O
industry O
globally O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
an O
arthropod O
- O
borne O
flavivirus O
, O
is O
a O
major O
cause O
of O
acute O
viral O
encephalitis O
in O
humans O
. O

Adaptive O
mutant O
analysis O
uncovered O
that O
replacement O
of O
Q130 O
, O
located O
in O
transmembrane O
domain O
3 O
of O
the O
nonstructural O
NS4B O
protein O
, O
which O
is O
relatively O
conserved O
in O
flaviviruses O
, O
with O
R O
or O
K O
conferred O
JEV O
resistance O
to O
manidipine O
, O
a O
voltage O
- O
gated O
Ca2 O
( O
+ O
) O
channel O
( O
VGCC O
) O
inhibitor O
, O
without O
an O
apparent O
loss O
of O
the O
viral O
growth O
profile O
. O

The O
type B
I I
interferon I
( I
IFN I
) I
response O
is O
part O
of O
the O
first O
- O
line O
defense O
against O
viral O
infection O
. O

In O
the O
present O
study O
, O
we O
found O
that O
the O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
NS5 O
protein O
could O
inhibit O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
induced O
IFN O
- O
beta O
expression O
in O
a O
dose O
- O
dependent O
manner O
. O

Our O
data O
further O
demonstrated O
that O
JEV O
NS5 O
suppressed O
the O
activation O
of O
the O
IFN O
transcriptional O
factors O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
NF O
- O
kappa O
B O
. O

Recently O
, O
a O
novel O
flavivirus O
, O
duck B
Tembusu I
virus I
( I
DTMUV I
) I
, O
was O
identified O
to O
be O
the O
causative O
agent O
of O
a O
serious O
duck O
viral O
disease O
in O
Asia O
. O

Here O
, O
we O
demonstrate O
that O
DTMUV O
is O
not O
pathogenic O
for O
nonhuman O
primates O
and O
is O
highly O
sensitive O
to O
mammal O
type B
I I
interferon I
( I
IFN I
) I
signaling O
. O

A O
novel O
flavivirus O
, O
DTMUV O
( O
also O
known O
as O
duck O
egg O
drop O
syndrome O
flavivirus O
[ O
DEDSV O
] O
) O
was O
identified O
in O
2012 O
in O
ducks O
and O
then O
rapidly O
spread O
to O
several O
Asian O
countries O
. O

Flavivirus O
nonstructural B
protein I
2B I
( I
NS2B I
) I
is O
a O
transmembrane O
protein O
that O
functions O
as O
a O
cofactor O
for O
viral O
NS3 O
protease O
. O

The O
cytoplasmic O
region O
( O
amino O
acids O
51 O
to O
95 O
) O
alone O
of O
NS2B O
is O
sufficient O
for O
NS3 O
protease O
activity O
, O
whereas O
the O
role O
of O
transmembrane B
domains I
( I
TMDs I
) I
remains O
obscure O
. O

Using O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
as O
a O
model O
, O
we O
performed O
a O
systematic O
mutagenesis O
at O
the O
flavivirus O
conserved O
residues O
within O
the O
TMDs O
of O
NS2B O
. O

As O
expected O
, O
some O
mutations O
severely O
attenuated O
( O
L38A O
and O
R101A O
) O
or O
completely O
destroyed O
( O
G12L O
) O
viral O
RNA O
synthesis O
. O

Interestingly O
, O
two O
mutations O
( O
G37L O
and O
P112A O
) O
reduced O
viral O
RNA O
synthesis O
and O
blocked O
virion O
assembly O
. O

For O
mutant O
P112A O
, O
insertion O
of O
Kat O
position O
K127 O
( O
leading O
to O
K127KK O
) O
of O
NS2B O
rescued O
virion O
assembly O
. O

A O
biomolecular B
fluorescent I
complementation I
( I
BiFC I
) I
analysis O
demonstrated O
that O
( O
i O
) O
mutation O
P112A O
selectively O
weakened O
NS2B O
- O
NS2A O
interaction O
and O
( O
ii O
) O
the O
adaptive O
mutation O
K127KK O
restored O
NS2B O
- O
NS2A O
interaction O
. O

The O
envelope B
( I
E I
) I
protein O
of O
flaviviruses O
comprises O
three O
structural O
domains O
, O
of O
which O
domain O
III O
( O
EIII O
) O
represents O
a O
discrete O
subunit O
. O

In O
order O
to O
assess O
potential O
interactions O
between O
EIII O
and O
the O
remainder O
of O
the O
E O
protein O
and O
to O
assess O
the O
effects O
of O
EIII O
sequence O
substitutions O
on O
the O
antigenicity O
, O
growth O
, O
and O
virulence O
of O
a O
representative O
flavivirus O
, O
chimeric O
viruses O
were O
generated O
using O
the O
West B
Nile I
virus I
( I
WNV I
) I
infectious O
clone O
, O
into O
which O
EIIIs O
from O
nine O
flaviviruses O
with O
various O
levels O
of O
genetic O
diversity O
from O
WNV O
were O
substituted O
. O

Of O
the O
constructs O
tested O
, O
chimeras O
containing O
EIIIs O
from O
Koutango B
virus I
( I
KOUV I
) I
, O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
St O
. O

Louis O
encephalitis O
virus O
( O
SLEV O
) O
, O
and O
Bagaza B
virus I
( I
BAGV I
) I
were O
successfully O
recovered O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
can O
invade O
the O
central O
nervous O
system O
and O
consequently O
induce O
neuroinflammation O
, O
which O
is O
characterized O
by O
profound O
neuronal O
cell O
damage O
accompanied O
by O
astrogliosis O
and O
microgliosis O
. O

Albeit O
microRNAs B
( I
miRNAs I
) I
have O
emerged O
as O
major O
regulatory O
noncoding O
RNAs O
with O
profound O
effects O
on O
inflammatory O
response O
, O
it O
is O
unknown O
how O
astrocytic O
miRNAs O
regulate O
JEV O
- O
induced O
inflammation O
. O

Overexpression O
of O
miR O
- O
19b O
- O
3p O
led O
to O
increased O
production O
of O
inflammatory O
cytokines O
, O
including O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
- O
6 O
, O
interleukin O
- O
1 O
beta O
, O
and O
chemokine O
( O
C O
- O
C O
motif O
) O
ligand O
5 O
, O
after O
JEV O
infection O
, O
whereas O
knockdown O
of O
miR O
- O
19b O
- O
3p O
had O
completely O
opposite O
effects O
. O

Zika B
virus I
( I
ZIKV I
) I
had O
remained O
a O
relatively O
obscure O
flavivirus O
until O
a O
recent O
series O
of O
outbreaks O
accompanied O
by O
unexpectedly O
severe O
clinical O
complications O
brought O
this O
virus O
into O
the O
spotlight O
as O
causing O
an O
infection O
of O
global O
public O
health O
concern O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
causative O
agent O
for O
chronic O
liver O
diseases O
such O
as O
hepatitis O
, O
cirrhosis O
, O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

In O
this O
study O
, O
we O
identified O
jumonji B
C I
- I
domain I
- I
containing I
5 I
( I
JMJD5 I
) I
as O
a O
novel O
binding O
partner O
of O
HBx O
interacting O
in O
the O
cytoplasm O
. O

DNA O
microarray O
analysis O
revealed O
that O
JMJD5 B
- I
knockout I
( I
JMJD5KO I
) I
Huh7 O
cells O
exhibited O
a O
significant O
reduction O
in O
the O
expression O
of O
transcriptional O
factors O
involved O
in O
hepatocyte O
differentiation O
, O
such O
as O
HNF4A O
, O
CEBPA O
, O
and O
FOXA3 O
. O

We O
also O
found O
that O
replacing O
Gly O
( O
135 O
) O
with O
Glu O
in O
JMJD5 O
abrogates O
binding O
with O
HBx O
and O
replication O
of O
HBV O
. O

The O
safety O
and O
efficacy O
of O
the O
live O
- O
attenuated O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
SA14 O
- O
14 O
- O
2 O
vaccine O
are O
attributed O
to O
mutations O
that O
accumulated O
in O
the O
viral O
genome O
during O
its O
derivation O
. O

Here O
, O
we O
generated O
recombinant B
JEV I
( I
rJEV I
) I
strains O
containing O
JEV O
SA14 O
- O
14 O
- O
2 O
vaccine O
- O
specific O
mutations O
that O
are O
located O
in O
the O
untranslated B
regions I
( I
UTRs I
) I
and O
seven O
protein O
genes O
or O
are O
introduced O
from O
PCR O
- O
amplified O
regions O
of O
the O
JEV O
SA14 O
- O
14 O
- O
2 O
genome O
. O

The O
authentic O
JEV O
SA14 O
- O
14 O
- O
2 O
( O
E O
) O
protein O
, O
with O
amino O
acid O
substitutions O
L107F O
, O
E138K O
, O
I176V O
, O
T177A O
, O
E244G O
, O
Q264H O
, O
K279M O
, O
A315V O
, O
S366A O
, O
and O
K439R O
relative O
to O
the O
wild O
- O
type O
rJEV O
clone O
, O
was O
essential O
and O
sufficient O
for O
complete O
attenuation O
of O
neurovirulence O
. O

Individually O
, O
the O
nucleotide O
substitution O
T39A O
in O
the O
5 O
' O
UTR O
( O
5 O
' O
- O
UTR O
- O
T39A O
) O
, O
the O
Capsid B
( I
C I
) I
protein O
amino O
acid O
substitution O
L66S O
( O
C O
- O
L66S O
) O
, O
and O
the O
complete O
NS1 O
/ O
2A O
genome O
region O
containing O
10 O
mutations O
each O
significantly O
reduced O
virus O
neuroinvasion O
but O
not O
neurovirulence O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
strains O
can O
be O
separated O
into O
5 O
genotypes O
( O
g1 O
to O
g5 O
) O
based O
on O
sequence O
similarity O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
which O
causes O
viral O
encephalitis O
in O
humans O
, O
is O
a O
serious O
risk O
to O
global O
public O
health O
. O

The O
results O
showed O
N154 O
and O
the O
DE O
loop O
are O
not O
the O
only O
or O
major O
receptor O
- O
binding O
motifs O
for O
JEV O
entry O
into O
BHK O
- O
21 O
cells O
; O
four O
residues O
, O
H144 O
, O
H319 O
, O
T410 O
, O
and O
Q258 O
, O
participating O
in O
the O
domain B
I I
( I
DI I
) I
- O
DIII O
interaction O
or O
zippering O
reaction O
are O
important O
to O
maintain O
the O
efficiency O
of O
viral O
membrane O
fusion O
. O

Japanese O
encephalitis O
is O
an O
acute O
zoonotic O
, O
mosquito O
- O
borne O
disease O
caused O
by O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
. O

Japanese O
encephalitis O
is O
characterized O
by O
extensive O
inflammation O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
disruption O
of O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
. O

IMPORTANCE O
Japanese B
encephalitis I
( I
JE I
) I
is O
the O
leading O
cause O
of O
viral O
encephalitis O
in O
Asia O
, O
resulting O
in O
70 O
, O
000 O
cases O
each O
year O
, O
in O
which O
approximately O
20 O
to O
30 O
% O
of O
cases O
are O
fatal O
, O
and O
a O
high O
proportion O
of O
patients O
survive O
with O
serious O
neurological O
and O
psychiatric O
sequelae O
. O

Neutralization O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
ameliorated O
the O
enhancement O
of O
BBB O
permeability O
in O
JEV O
- O
infected O
mice O
, O
suggesting O
that O
IFN O
- O
gamma O
could O
be O
a O
potential O
therapeutic O
target O
. O

We O
have O
previously O
shown O
that O
ablation O
of O
the O
three O
N O
- O
linked O
glycosylation O
sites O
in O
the O
West O
Nile O
virus O
NS1 O
protein O
completely O
attenuates O
mouse O
neuroinvasiveness O
( O
> O
1 O
, O
0 O
, O
000 O
PFU O
) O
. O

Here O
, O
we O
compared O
the O
replication O
of O
the O
NS1 O
( O
130 O
- O
132QQA O
/ O
175A O
/ O
207A O
) O
mutant O
to O
that O
of O
the O
parental O
NY99 O
strain O
in O
monkey O
kidney O
Vero O
cells O
. O

Dengue B
Virus I
( I
DENV I
) I
, O
composed O
of O
four O
distinct O
serotypes O
, O
is O
the O
most O
important O
and O
rapidly O
emerging O
arthropod O
- O
borne O
pathogen O
and O
imposes O
substantial O
economic O
and O
public O
health O
burdens O
. O

We O
constructed O
candidate O
vaccines O
containing O
the O
DNA O
of O
five O
of O
the O
genotypes O
of O
dengue B
virus I
serotype I
2 I
( I
DENV I
- I
2 I
) I
and O
evaluated O
the O
immunogenicity O
, O
the O
neutralizing O
( O
Nt O
) O
activity O
of O
the O
elicited O
antibodies O
, O
and O
the O
protective O
efficacy O
elicited O
in O
mice O
immunized O
with O
the O
vaccine O
candidates O
. O

We O
also O
found O
that O
, O
in O
contrast O
to O
previous O
reports O
, O
more O
than O
50 O
% O
of O
total O
IgG O
targeted O
ectodomain B
III I
( I
EDIII I
) I
of O
the O
E O
protein O
, O
and O
a O
substantial O
fraction O
of O
this O
population O
was O
interdomain O
highly O
neutralizing O
flavivirus O
subgroup O
- O
cross O
- O
reactive O
antibodies O
, O
such O
as O
monoclonal O
antibody O
1B7 O
- O
5 O
. O

In O
addition O
, O
the O
lack O
of O
a O
critical O
epitope O
( O
s O
) O
in O
the O
Sylvatic O
genotype O
virus O
recognized O
by O
interdomain O
antibodies O
could O
be O
the O
major O
cause O
of O
the O
poor O
protection O
of O
mice O
vaccinated O
with O
the O
Asian O
1 O
genotype O
vaccine O
( O
pVD2 O
- O
Asian O
1 O
) O
from O
lethal O
challenge O
with O
virus O
of O
the O
Sylvatic O
genotype O
. O

IMPORTANCE O
Five O
genotype O
- O
specific O
dengue B
virus I
serotype I
2 I
( I
DENV I
- I
2 I
) I
DNA O
vaccine O
candidates O
were O
evaluated O
for O
their O
immunogenicity O
, O
homologous O
and O
heterologous O
neutralizing O
( O
Nt O
) O
antibody O
titers O
, O
and O
cross O
- O
genotype O
protection O
in O
a O
murine O
model O
. O

The O
immunity O
elicited O
by O
our O
prototype O
vaccine O
candidate O
( O
Asian O
1 O
genotype O
strain O
16681 O
) O
in O
mice O
was O
protective O
against O
viruses O
of O
other O
genotypes O
but O
not O
against O
virus O
of O
the O
Sylvatic O
genotype O
, O
whose O
emergence O
and O
potential O
risk O
after O
introduction O
into O
the O
human O
population O
have O
previously O
been O
demonstrated O
. O

The O
DENV O
DNA O
vaccine O
directs O
the O
synthesis O
and O
assembly O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
and O
induces O
immune O
responses O
similar O
to O
those O
elicited O
by O
live O
- O
attenuated O
vaccines O
, O
and O
its O
flexibility O
permits O
the O
fast O
deployment O
of O
vaccine O
to O
combat O
emerging O
viruses O
, O
such O
as O
Sylvatic O
genotype O
viruses O
. O

The O
enhanced O
VLP O
secretion O
obtained O
by O
replacement O
of O
ectodomain B
I I
- I
II I
( I
EDI I
- I
II I
) I
of O
the O
Cosmopolitan O
genotype O
vaccine O
construct O
( O
VD2 O
- O
Cosmopolitan O
) O
with O
the O
Asian O
1 O
EDI O
- O
II O
elicited O
significantly O
higher O
total O
IgG O
and O
Nt O
antibody O
titers O
and O
suggests O
a O
novel O
approach O
to O
enhance O
the O
immunogenicity O
of O
the O
DNA O
vaccine O
. O

Since O
its O
introduction O
in O
New O
York O
City O
, O
NY O
, O
in O
1999 O
, O
West B
Nile I
virus I
( I
WNV I
) I
has O
spread O
to O
all O
48 O
contiguous O
states O
of O
the O
United O
States O
and O
is O
now O
the O
leading O
cause O
of O
epidemic O
encephalitis O
in O
North O
America O
. O

Our O
previous O
work O
has O
shown O
that O
WNV O
growth O
was O
independent O
of O
macroautophagy O
activation O
, O
but O
the O
role O
of O
the O
evolutionarily O
conserved O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
pathway O
during O
WNV O
infection O
was O
not O
well O
understood O
. O

We O
now O
show O
that O
WNV O
activates O
mTOR O
and O
cognate O
downstream O
activators O
of O
cap O
- O
dependent O
protein O
synthesis O
at O
early O
time O
points O
postinfection O
and O
that O
pharmacologic O
inhibition O
of O
mTOR O
( O
KU0063794 O
) O
significantly O
reduced O
WNV O
growth O
. O

We O
used O
an O
inducible O
Raptor O
and O
Rictor O
knockout O
mouse B
embryonic I
fibroblast I
( I
MEF I
) I
system O
to O
further O
define O
the O
role O
of O
mTOR O
complexes O
1 O
and O
2 O
in O
WNV O
growth O
and O
viral O
protein O
synthesis O
. O

Following O
inducible O
genetic O
knockout O
of O
the O
major O
mTOR O
cofactors O
raptor O
( O
TOR O
complex O
1 O
[ O
TORC1 O
] O
) O
and O
rictor O
( O
TORC2 O
) O
, O
we O
now O
show O
that O
TORC1 O
supports O
flavivirus O
protein O
synthesis O
via O
cap O
- O
dependent O
protein O
synthesis O
pathways O
and O
supports O
subsequent O
WNV O
growth O
. O

Interaction O
between O
E O
and O
prM O
proteins O
in O
flavivirus O
- O
infected O
cells O
is O
a O
major O
factor O
for O
virus B
- I
like I
particle I
( I
VLP I
) I
production O
. O

The O
prM O
helical O
( O
prM O
- O
H O
) O
domain O
is O
topologically O
close O
to O
and O
may O
interact O
with O
domain O
II O
of O
the O
E O
protein O
( O
EDII O
) O
. O

IMPORTANCE O
Molecular O
interaction O
between O
E O
and O
prM O
proteins O
of O
Japanese O
encephalitis O
virus O
is O
a O
major O
driving O
force O
for O
virus B
- I
like I
particle I
( I
VLP I
) I
production O
. O

The O
prM O
stem O
region O
contains O
an O
N O
- O
terminal O
loop O
and O
a O
helix O
domain O
( O
prM O
- O
H O
) O
. O

Since O
the O
prM O
- O
H O
domain O
is O
topologically O
close O
to O
domain O
II O
of O
the O
E O
protein O
( O
EDII O
) O
, O
this O
study O
was O
to O
determine O
molecular O
interactions O
between O
the O
prM O
- O
H O
domain O
and O
EDII O
. O

Though O
the O
compromised O
blood B
- I
brain I
barrier I
( I
BBB I
) I
is O
a O
pathological O
hallmark O
of O
Japanese O
encephalitis O
- O
associated O
neurological O
sequelae O
, O
the O
underlying O
mechanisms O
and O
the O
specific O
cell O
types O
involved O
are O
not O
understood O
. O

In O
this O
study O
, O
we O
show O
a O
potential O
mechanism O
of O
disruption O
of O
endothelial O
barrier O
integrity O
during O
the O
course O
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
infection O
through O
the O
activation O
of O
neighboring O
pericytes O
. O

JEV O
- O
infected O
pericytes O
were O
found O
to O
release O
biologically O
active O
molecules O
which O
activated O
ubiquitin O
proteasome O
, O
degraded O
zonula B
occludens I
- I
1 I
( I
ZO I
- I
1 I
) I
, O
and O
disrupted O
endothelial O
barrier O
integrity O
in O
cultured O
brain O
microvascular O
endothelial O
cells O
. O

Infection O
of O
pericytes O
with O
JEV O
was O
found O
to O
elicit O
elevated O
production O
of O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
which O
contributed O
to O
the O
aforementioned O
endothelial O
changes O
. O

We O
further O
demonstrated O
that O
ubiquitin O
- O
protein O
ligase O
E3 O
component O
n O
- O
recognin O
- O
1 O
( O
Ubr O
1 O
) O
was O
a O
key O
upstream O
regulator O
which O
caused O
proteasomal O
degradation O
of O
ZO O
- O
1 O
downstream O
of O
IL O
- O
6 O
signaling O
. O

In O
this O
study O
, O
we O
generated O
26 O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
the O
dengue O
virus O
type O
1 O
Mochizuki O
strain O
. O

Although O
most O
MAbs O
showing O
neutralizing O
activities O
exhibited O
enhancing O
activities O
at O
subneutralizing O
doses O
, O
one O
MAb O
( O
D1 O
- O
IV O
- O
7F4 O
[ O
7F4 O
] O
) O
displayed O
neutralizing O
activities O
without O
showing O
enhancing O
activities O
at O
lower O
concentrations O
. O

In O
contrast O
, O
another O
MAb O
( O
D1 O
- O
V O
- O
3H12 O
[ O
3H12 O
] O
) O
exhibited O
only O
enhancing O
activities O
, O
which O
were O
suppressed O
by O
pretreatment O
of O
cells O
with O
anti O
- O
Fc O
gamma O
RIIa O
. O

Although O
antibody O
engineering O
revealed O
that O
antibody O
subclass O
significantly O
affected O
7F4 O
( O
IgG3 O
) O
and O
3H12 O
( O
IgG1 O
) O
activities O
, O
neutralizing O
/ O
enhancing O
activities O
were O
also O
dependent O
on O
the O
epitope O
targeted O
by O
the O
antibody O
. O

7F4 O
recognized O
an O
epitope O
on O
the O
envelope O
protein O
containing O
E118 O
( O
domain O
II O
) O
and O
had O
a O
neutralizing O
activity O
10 O
- O
to O
1 O
, O
000 O
- O
fold O
stronger O
than O
the O
neutralizing O
activity O
of O
previously O
reported O
human O
or O
humanized O
neutralizing O
MAbs O
targeting O
domain O
I O
and O
/ O
or O
domain O
II O
. O

An O
epitope O
- O
blocking O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
indicated O
that O
a O
dengue O
virus O
- O
immune O
population O
possessed O
antibodies O
sharing O
an O
epitope O
with O
7F4 O
. O

Our O
results O
demonstrating O
induction O
of O
these O
antibody O
species O
( O
7F4 O
and O
3H12 O
) O
in O
Mochizuki O
- O
immunized O
mice O
may O
have O
implications O
for O
dengue O
vaccine O
strategies O
designed O
to O
minimize O
induction O
of O
enhancing O
antibodies O
in O
vaccinated O
humans O
. O

The O
interferon B
- I
inducible I
protein I
with I
tetratricopeptide I
( I
IFIT I
) I
family O
proteins O
inhibit O
replication O
of O
some O
viruses O
by O
recognizing O
several O
types O
of O
RNAs O
, O
including O
5 O
' O
- O
triphosphate O
RNA O
and O
5 O
' O
capped O
2 O
' O
- O
O O
unmethylated O
mRNA O
. O

Replication O
of O
a O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
2 O
' O
- O
O O
methyltransferase B
( I
MTase I
) I
mutant O
was O
markedly O
enhanced O
in O
mouse O
embryonic O
fibroblasts O
and O
macrophages O
lacking O
Ifit1 O
. O

West B
Nile I
virus I
( I
WNV I
) I
, O
currently O
the O
cause O
of O
a O
serious O
U O
. O

epidemic O
, O
is O
a O
mosquito O
- O
borne O
flavivirus O
and O
member O
of O
the O
Japanese B
encephalitis I
( I
JE I
) I
serocomplex O
. O

Given O
the O
availability O
of O
approved O
human O
JE O
vaccines O
, O
this O
study O
asked O
whether O
the O
JE O
- O
ADVAX O
vaccine O
, O
which O
contains O
an O
inactivated O
cell O
culture O
JE O
virus O
antigen O
formulated O
with O
Advax O
delta O
inulin O
adjuvant O
, O
could O
provide O
heterologous O
protection O
against O
WNV O
infection O
in O
wild O
- O
type O
and O
beta O
2 O
- O
microglobulin O
- O
deficient O
( O
beta O
2m O
( O
- O
/ O
- O
) O
) O
murine O
models O
. O

Similarly O
, O
beta O
2m O
( O
- O
/ O
- O
) O
mice O
immunized O
with O
JE O
- O
ADVAX O
were O
protected O
against O
lethal O
WNV O
challenge O
in O
the O
absence O
of O
CD8 O
( O
+ O
) O
T O
cells O
and O
prechallenge O
WNV O
antibody O
titers O
. O

hy926 O
and O
MG O
- O
63 O
) O
that O
are O
nearly O
nonpermissive O
to O
insect O
- O
specific O
baculovirus B
( I
BV I
) I
and O
the O
human B
enterovirus I
echovirus I
1 I
( I
EV1 I
) I
and O
compared O
their O
characteristics O
with O
those O
of O
a O
highly O
permissive O
( O
HepG2 O
) O
cell O
line O
. O

The O
nonpermissive O
and O
permissive O
cell O
lines O
showed O
differential O
expression O
of O
syntenin O
, O
filamentous O
actin O
, O
vimentin O
, O
and O
phosphorylated O
protein B
kinase I
C I
subtype I
alpha I
( I
pPKC I
alpha I
) I
. O

Here O
we O
show O
that O
West B
Nile I
virus I
( I
WNV I
) I
NS1 O
' O
and O
NS1 O
localize O
to O
the O
same O
cellular O
compartments O
when O
expressed O
from O
plasmid O
DNAs O
and O
also O
colocalize O
to O
viral O
RNA O
replication O
sites O
in O
infected O
cells O
. O

In O
this O
study O
, O
we O
characterized O
the O
antiviral O
mechanism O
of O
action O
of O
AZD0530 O
and O
dasatinib O
, O
two O
pharmacological O
inhibitors O
of O
host O
kinases O
, O
that O
also O
inhibit O
dengue B
virus I
( I
DV I
) I
infection O
. O

In O
order O
to O
identify O
the O
cellular O
target O
of O
AZD0530 O
and O
dasatinib O
mediating O
this O
anti O
- O
DV2 O
activity O
, O
we O
examined O
the O
effects O
of O
RNA B
interference I
( I
RNAi I
) I
- O
mediated O
depletion O
of O
the O
major O
kinases O
known O
to O
be O
inhibited O
by O
these O
small O
molecules O
. O

JE O
- O
ADVAX O
is O
a O
new O
, O
delta O
inulin O
- O
adjuvanted O
, O
Japanese B
encephalitis I
( I
JE I
) I
candidate O
vaccine O
with O
a O
strong O
safety O
profile O
and O
potent O
immunogenicity O
that O
confers O
efficient O
immune O
protection O
not O
only O
against O
JE O
virus O
but O
also O
against O
related O
neurotropic O
flaviviruses O
such O
as O
West O
Nile O
virus O
. O

In O
this O
study O
, O
we O
investigated O
the O
immunological O
mechanism O
of O
protection O
by O
JE O
- O
ADVAX O
vaccine O
using O
knockout O
mice O
deficient O
in O
B O
cells O
or O
CD8 O
( O
+ O
) O
T O
cells O
and O
poor O
persistence O
of O
neutralizing O
antibody O
or O
by O
adoptive O
transfer O
of O
immune O
splenocyte O
subpopulations O
. O

We O
show O
that O
memory O
B O
cells O
induced O
by O
JE O
- O
ADVAX O
provide O
long O
- O
lived O
protection O
against O
JE O
even O
in O
the O
absence O
of O
detectable O
pre O
- O
exposure O
serum O
neutralizing O
antibodies O
and O
without O
the O
requirement O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

Our O
investigation O
also O
established O
the O
suitability O
of O
a O
novel O
flavivirus O
challenge O
model O
( O
beta O
( O
2 O
) O
- O
microglobulin O
- O
knockout O
mice O
) O
for O
studies O
of O
the O
role O
of O
B O
- O
cell O
memory O
responses O
in O
vaccine O
protection O
. O

First O
, O
we O
demonstrate O
that O
a O
nonpropagating O
vaccine O
vector O
based O
on O
Venezuelan O
equine O
encephalitis O
virus B
replicon I
particles I
( I
VRP I
) I
expressing O
two O
configurations O
of O
dengue O
virus O
E O
antigen O
( O
subviral O
particles O
[ O
prME O
] O
and O
soluble O
E O
dimers O
[ O
E85 O
] O
) O
successfully O
immunized O
and O
protected O
macaques O
against O
dengue O
virus O
, O
while O
antivector O
antibodies O
did O
not O
interfere O
with O
a O
booster O
immunization O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
mosquito O
- O
borne O
pathogenic O
flavivirus O
responsible O
for O
acute O
viral O
encephalitis O
in O
humans O
. O

To O
verify O
the O
roles O
of O
distinct O
pathways O
of O
cell O
entry O
, O
we O
used O
fluorescently O
labeled O
virus O
particles O
, O
a O
combination O
of O
pharmacological O
inhibitors O
, O
RNA B
interference I
( I
RNAi I
) I
, O
and O
dominant B
- I
negative I
( I
DN I
) I
mutants O
of O
regulatory O
proteins O
involved O
in O
endocytosis O
. O

enterovirus B
71 I
( I
EV I
- I
71 I
) I
infections O
are O
usually O
associated O
with O
mild O
hand O
, O
foot O
, O
and O
mouth O
disease O
in O
young O
children O
but O
have O
been O
reported O
to O
cause O
severe O
neurological O
complications O
with O
high O
mortality O
rates O
. O

To O
date O
, O
four O
EV O
- O
71 O
receptors O
have O
been O
identified O
, O
but O
inhibition O
of O
these O
receptors O
by O
antagonists O
did O
not O
completely O
abolish O
EV O
- O
71 O
infection O
, O
implying O
that O
there O
is O
an O
as O
yet O
undiscovered O
receptor O
( O
s O
) O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
mosquito O
- O
borne O
flavivirus O
and O
one O
of O
the O
most O
common O
agents O
of O
viral O
encephalitis O
. O

However O
, O
JEV O
entry O
was O
not O
affected O
by O
chlorpromazine O
, O
overexpression O
of O
a O
dominant O
- O
negative O
form O
of O
EPS O
15 O
protein O
, O
or O
silencing O
of O
the O
clathrin O
heavy O
chain O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

We O
previously O
showed O
that O
a O
noncoding O
subgenomic B
flavivirus I
RNA I
( I
sfRNA I
) I
is O
required O
for O
viral O
pathogenicity O
, O
as O
a O
mutant O
West B
Nile I
virus I
( I
WNV I
) I
deficient O
in O
sfRNA O
production O
replicated O
poorly O
in O
wild O
- O
type O
mice O
. O

To O
investigate O
the O
possible O
immunomodulatory O
or O
immune O
evasive O
functions O
of O
sfRNA O
, O
we O
utilized O
mice O
and O
cells O
deficient O
in O
elements O
of O
the O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

Replication O
of O
the O
sfRNA O
mutant O
WNV O
was O
rescued O
in O
mice O
and O
cells O
lacking O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
and O
IRF O
- O
7 O
and O
in O
mice O
lacking O
the O
type O
I O
alpha O
/ O
beta O
interferon O
receptor O
( O
IFNAR O
) O
, O
suggesting O
a O
contribution O
for O
sfRNA O
in O
overcoming O
the O
antiviral O
response O
mediated O
by O
type O
I O
IFN O
. O

We O
have O
developed O
a O
novel O
strategy O
that O
provides O
an O
extremely O
rapid O
approach O
for O
the O
introduction O
of O
mutations O
into O
the O
structural O
genes O
of O
West B
Nile I
virus I
( I
WNV I
) I
. O

The O
transfection O
of O
cells O
with O
this O
system O
results O
in O
the O
rapid O
release O
of O
WNV O
that O
achieves O
a O
high O
titer O
( O
similar O
to O
10 O
( O
7 O
) O
infectious O
units O
/ O
ml O
in O
48 O
h O
) O
. O

First O
, O
we O
constructed O
and O
characterized O
a O
library O
of O
variants O
encoding O
single O
defined O
amino O
acid O
substitutions O
at O
the O
92 O
residues O
of O
the O
pr O
portion O
of O
the O
precursor B
- I
to I
- I
membrane I
( I
prM I
) I
protein O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
zoonotic O
pathogen O
, O
is O
one O
of O
the O
major O
causes O
of O
viral O
encephalitis O
worldwide O
. O

The O
immunological O
correlates O
for O
recovery O
from O
primary O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
infection O
in O
humans O
and O
experimental O
animals O
remain O
poorly O
defined O
. O

In O
this O
model O
, O
similar O
to O
60 O
% O
of O
the O
mice O
developed O
a O
fatal O
encephalitis O
and O
a O
virus O
burden O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Using O
mice O
lacking O
B O
cells O
( O
mu O
MT O
- O
/ O
- O
mice O
) O
and O
immune O
B O
cell O
transfer O
to O
wild O
- O
type O
mice O
, O
we O
show O
a O
critically O
important O
role O
for O
humoral O
immunity O
in O
preventing O
virus O
spread O
to O
the O
CNS O
. O

JEV O
infection O
resulted O
in O
extensive O
CD8 O
( O
+ O
) O
T O
cell O
activation O
, O
judged O
by O
upregulation O
of O
surface O
markers O
CD69 O
and O
CD25 O
and O
cytokine O
production O
after O
stimulation O
with O
a O
JEV O
NS4B O
protein O
- O
derived O
H O
- O
2D O
( O
b O
) O
- O
binding O
peptide O
and O
trafficking O
of O
virus O
- O
immune O
CD8 O
( O
+ O
) O
T O
cells O
into O
the O
CNS O
. O

However O
, O
no O
significant O
effect O
of O
CD8 O
( O
+ O
) O
T O
cells O
on O
the O
survival O
phenotype O
was O
found O
, O
which O
was O
corroborated O
in O
knockout O
mice O
lacking O
key O
effector O
molecules O
( O
Fas O
receptor O
, O
perforin O
, O
or O
granzymes O
) O
of O
cytolytic O
pathways O
triggered O
by O
T O
lymphocytes O
. O

Accordingly O
, O
CD8 O
( O
+ O
) O
T O
cells O
are O
mostly O
dispensable O
for O
recovery O
from O
infection O
with O
JEV O
. O

This O
finding O
highlights O
the O
conflicting O
role O
that O
CD8 O
( O
+ O
) O
T O
cells O
play O
in O
the O
pathogenesis O
of O
JEV O
and O
closely O
related O
encephalitic O
flaviviruses O
such O
as O
West O
Nile O
virus O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
the O
most O
widely O
distributed O
of O
the O
encephalitic O
flaviviruses O
and O
is O
a O
major O
cause O
of O
encephalitis O
, O
with O
isolates O
obtained O
from O
all O
continents O
, O
apart O
from O
Antarctica O
. O

In O
Africa O
, O
WNV O
exists O
in O
an O
endemic O
cycle O
, O
whereas O
it O
is O
epidemic O
in O
Europe O
, O
being O
reintroduced O
regularly O
from O
Africa O
either O
directly O
( O
in O
western O
Europe O
) O
or O
via O
the O
Middle O
East O
( O
in O
eastern O
Europe O
) O
. O

Likewise O
, O
in O
the O
Americas O
, O
WNV O
was O
successfully O
introduced O
in O
1999 O
and O
subsequently O
became O
endemic O
across O
most O
temperate O
regions O
of O
North B
America I
( I
NA I
) I
. O

In O
contrast O
to O
previous O
suggestions O
, O
an O
isolate O
from O
the O
epidemic O
in O
Israel O
in O
1998 O
was O
not O
the O
direct O
progenitor O
of O
the O
NA O
epidemic O
; O
rather O
, O
both O
epidemics O
originated O
from O
the O
same O
( O
unknown O
) O
location O
. O

Flaviviruses O
have O
been O
shown O
to O
induce O
cell O
surface O
expression O
of O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
through O
the O
activation O
of O
NF O
- O
kappa O
B O
. O

Using O
IKK1 O
( O
- O
/ O
- O
) O
, O
IKK2 O
( O
- O
/ O
- O
) O
, O
NEMO O
( O
- O
/ O
- O
) O
, O
and O
IKK1 O
- O
/ O
- O
IKK2 O
- O
/ O
- O
double O
mutant O
as O
well O
as O
p50 O
( O
- O
/ O
- O
) O
RelA O
( O
- O
/ O
- O
) O
cRel O
( O
- O
/ O
- O
) O
triple O
mutant O
mouse O
embryonic O
fibroblasts O
infected O
with O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
we O
show O
that O
this O
flavivirus O
utilizes O
the O
canonical O
pathway O
to O
activate O
NF O
- O
kappa O
B O
in O
an O
IKK2 O
- O
and O
NEMO O
- O
, O
but O
not O
IKK1 O
- O
, O
dependent O
manner O
. O

type B
I I
interferon I
( I
IFN I
) I
production O
was O
significantly O
decreased O
but O
not O
completely O
abolished O
upon O
virus O
infection O
in O
cells O
defective O
in O
NF O
- O
kappa O
B O
activation O
. O

In O
contrast O
, O
induction O
of O
classical O
MHC O
- O
I O
( O
class O
1a O
) O
genes O
and O
their O
cell O
surface O
expression O
remained O
unaffected O
in O
these O
NF O
- O
kappa O
B O
- O
defective O
cells O
. O

However O
, O
MHC O
- O
I O
induction O
was O
impaired O
in O
IFNAR O
( O
- O
/ O
- O
) O
cells O
that O
lack O
the O
alpha O
/ O
beta O
IFN O
receptor O
, O
indicating O
a O
dominant O
role O
of O
type O
I O
IFNs O
but O
not O
NF O
- O
kappa O
B O
for O
the O
induction O
of O
MHC O
- O
I O
molecules O
by O
Japanese O
encephalitis O
virus O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
a O
mosquito O
- O
borne O
RNA O
virus O
and O
one O
of O
the O
most O
important O
flaviviruses O
in O
the O
medical O
and O
veterinary O
fields O
. O

To O
clarify O
the O
infection O
mechanisms O
of O
JEV O
, O
we O
generated O
pseudotype O
( O
JEVpv O
) O
and O
recombinant O
( O
JEVrv O
) O
vesicular O
stomatitis O
viruses O
bearing O
the O
JEV O
envelope O
protein O
. O

Furthermore O
, O
treatment O
of O
cells O
with O
sphingomyelinase B
( I
SMase I
) I
, O
which O
hydrolyzes O
membrane O
- O
bound O
sphingomyelin O
to O
ceramide O
, O
drastically O
enhanced O
infection O
with O
JEVpv O
and O
propagation O
of O
JEVrv O
, O
and O
these O
enhancements O
were O
inhibited O
by O
treatment O
with O
an O
SMase O
inhibitor O
or O
C O
- O
6 O
- O
ceramide O
. O

One O
of O
these O
, O
nonstructural B
protein I
3 I
( I
NS3 I
) I
, O
is O
an O
enzyme O
with O
both O
serine O
protease O
and O
NTPase O
/ O
helicase O
activities O
. O

Using O
West B
Nile I
virus I
( I
WNV I
) I
as O
a O
model O
, O
we O
show O
that O
replicating O
replicons O
in O
BHK O
- O
21 O
cells O
suppress O
subsequent O
WNV O
infection O
. O

The O
sequencing O
of O
the O
selected O
viruses O
revealed O
mutations O
in O
structural O
( O
prM O
S90R O
or O
envelope O
E138K O
) O
and O
nonstructural O
genes O
( O
NS4a O
K124R O
and O
peptide O
2K O
V9M O
) O
. O

Mechanistic O
analysis O
showed O
that O
the O
envelope O
mutation O
functions O
through O
the O
enhancement O
of O
virion O
attachment O
to O
BHK O
- O
21 O
cells O
, O
whereas O
the O
2K O
mutation O
( O
and O
, O
to O
a O
lesser O
extent O
, O
the O
NS4a O
mutation O
) O
functions O
through O
the O
enhancement O
of O
viral O
RNA O
synthesis O
. O

Three O
Dengue B
virus I
type I
4 I
( I
DENV I
- I
4 I
) I
vaccine O
candidates O
containing O
deletions O
in O
the O
3 O
' O
noncoding O
region O
were O
prepared O
by O
passage O
in O
DBS O
- O
FRhL O
- O
2 O
( O
FRhL O
) O
cells O
. O

Consensus O
sequence O
analysis O
revealed O
that O
each O
of O
the O
three O
viruses O
, O
as O
well O
as O
the O
parental O
DENV O
- O
4 O
when O
passaged O
in O
FRhL O
cells O
, O
rapidly O
acquired O
a O
single O
Glu O
( O
327 O
) O
- O
Gly O
substitution O
in O
domain B
III I
( I
DIII I
) I
of O
the O
envelope B
protein I
( I
E I
) I
. O

The O
Glu O
( O
327 O
) O
- O
Gly O
substitution O
was O
predicted O
by O
molecular O
modeling O
to O
increase O
the O
net O
positive O
charge O
on O
the O
surface O
of O
E O
. O

The O
Glu O
( O
327 O
) O
- O
Gly O
variant O
of O
the O
full O
- O
length O
DENV O
- O
4 O
selected O
after O
three O
passages O
in O
FRhL O
cells O
showed O
increased O
affinity O
for O
heparan O
sulfate O
compared O
to O
the O
unpassaged O
DENV O
- O
4 O
, O
as O
measured O
by O
heparin O
binding O
and O
infectivity O
inhibition O
assays O
. O

Evidence O
indicates O
that O
the O
Glu O
( O
327 O
) O
- O
Gly O
mutation O
in O
DIII O
of O
the O
DENV O
- O
4 O
E O
protein O
was O
responsible O
for O
reduced O
infectivity O
and O
immunogenicity O
in O
rhesus O
monkeys O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
and O
dengue B
virus I
serotype I
2 I
( I
DEN I
- I
2 I
) I
are O
enveloped O
flaviviruses O
that O
enter O
cells O
through O
receptor O
- O
mediated O
endocytosis O
and O
low O
pH O
- O
triggered O
membrane O
fusion O
and O
then O
replicate O
in O
intracellular O
membrane O
structures O
. O

Existing O
live O
- O
attenuated O
flavivirus O
vaccines O
( O
LAV O
) O
could O
be O
improved O
by O
reducing O
their O
potential O
to O
recombine O
with O
naturally O
circulating O
viruses O
in O
the O
field O
. O

Since O
the O
highly O
conserved O
cyclization B
sequences I
( I
CS I
) I
found O
in O
the O
termini O
of O
flavivirus O
genomes O
must O
be O
complementary O
to O
each O
other O
to O
support O
genome O
replication O
, O
we O
set O
out O
to O
identify O
paired O
mutant O
CS O
that O
could O
support O
the O
efficient O
replication O
of O
LAV O
but O
would O
be O
unable O
to O
support O
replication O
in O
recombinant O
viruses O
harboring O
one O
wild B
- I
type I
( I
WT I
) I
CS O
. O

By O
systematic O
evaluation O
of O
paired O
mutated O
CS O
encoded O
in O
West B
Nile I
virus I
( I
WNV I
) I
replicons O
, O
we O
identified O
variants O
having O
single O
and O
double O
mutations O
in O
the O
5 O
' O
- O
and O
3 O
' O
- O
CS O
components O
that O
could O
support O
genome O
replication O
at O
WT O
levels O
. O

The O
yellow B
fever I
virus I
( I
YFV I
) I
17D O
strain O
is O
one O
of O
the O
most O
effective O
live O
vaccines O
for O
human O
use O
, O
but O
the O
in O
vivo O
mechanisms O
for O
virulence O
attenuation O
of O
the O
vaccine O
and O
the O
corresponding O
molecular O
determinants O
remain O
elusive O
. O

The O
vaccine O
differs O
phenotypically O
from O
wild O
- O
type O
YFV O
by O
the O
loss O
of O
viscerotropism O
, O
despite O
replicative O
fitness O
in O
cell O
culture O
, O
and O
genetically O
by O
20 O
amino O
acid O
changes O
predominantly O
located O
in O
the O
envelope B
( I
E I
) I
protein O
. O

One O
of O
these O
residues O
( O
Arg380 O
) O
is O
a O
dominant O
glycosaminoglycan O
- O
binding O
determinant O
, O
which O
mainly O
accounts O
for O
more O
rapid O
in O
vivo O
clearance O
of O
17D O
from O
the O
bloodstream O
in O
comparison O
to O
17D O
- O
derived O
variants O
with O
wild O
- O
type O
- O
like O
E O
protein O
. O

A O
candidate O
pediatric O
Dengue B
Virus I
( I
DENV I
) I
vaccine O
based O
on O
nonpropagating O
Venezuelan O
equine O
encephalitis O
virus B
replicon I
particles I
( I
VRP I
) I
was O
tested O
for O
immunogenicity O
and O
protective O
efficacy O
in O
weanling O
mice O
in O
the O
presence O
and O
absence O
of O
potentially O
interfering O
maternal O
antibodies O
. O

A O
gene O
cassette O
encoding O
envelope O
proteins O
prM O
and O
E O
from O
mouse O
- O
adapted O
DENV B
type I
2 I
( I
DENV2 I
) I
strain O
NGC O
was O
cloned O
into O
a O
VEE O
replicon O
vector O
and O
packaged O
into O
VRP O
, O
which O
programmed O
proper O
in O
vitro O
expression O
and O
processing O
of O
DENV2 O
envelope O
proteins O
upon O
infection O
of O
Vero O
cells O
. O

West B
Nile I
virus I
( I
WNV I
) I
infection O
causes O
neurological O
disease O
at O
all O
levels O
of O
the O
neural O
axis O
, O
accompanied O
by O
neuroinflammation O
and O
neuronal O
loss O
, O
although O
the O
underlying O
mechanisms O
remain O
uncertain O
. O

Analysis O
of O
autopsied O
neural O
tissues O
from O
humans O
with O
WNV B
encephalomyelitis I
( I
WNVE I
) I
revealed O
WNV O
infection O
of O
both O
neurons O
and O
glia O
. O

Upregulation O
of O
proinflammatory O
genes O
, O
CXCL10 O
, O
interleukin O
- O
1 O
beta O
, O
and O
indolamine O
- O
2 O
' O
, O
3 O
' O
- O
deoxygenase O
with O
concurrent O
suppression O
of O
the O
protective O
astrocytespecific O
endoplasmic O
reticulum O
stress O
sensor O
gene O
, O
OASIS O
( O
for O
old O
astrocyte O
specifically O
induced O
substance O
) O
, O
was O
evident O
in O
WNVE O
patients O
compared O
to O
non O
- O
WNVE O
controls O
. O

The O
expression O
of O
the O
WNV O
- O
NY99 O
capsid O
protein O
in O
neurons O
and O
glia O
by O
a O
Sindbis O
virus O
- O
derived O
vector O
( O
SINrep5 O
- O
WNVc O
) O
caused O
neuronal O
death O
and O
the O
release O
of O
neurotoxic O
factors O
by O
infected O
astrocytes O
, O
coupled O
with O
proinflammatory O
gene O
induction O
and O
suppression O
of O
OASIS O
. O

In O
this O
study O
, O
we O
found O
a O
small O
capsid O
protein O
in O
cells O
infected O
with O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
but O
not O
in O
the O
viral O
particles O
. O

An O
in O
vitro O
cleavage O
assay O
revealed O
that O
cathepsin O
L O
cleaves O
the O
capsid O
protein O
between O
amino O
acid O
residues O
Lys O
( O
18 O
) O
and O
Arg O
( O
19 O
) O
, O
which O
are O
well O
conserved O
among O
the O
mosquito O
- O
borne O
flaviviruses O
. O

The O
mutant O
JEV O
exhibited O
growth O
kinetics O
similar O
to O
those O
of O
the O
wild O
- O
type O
JEV O
in O
monkey O
( O
Vero O
) O
, O
mosquito O
( O
C6 O
/ O
36 O
) O
, O
and O
porcine O
( O
PK15 O
) O
cell O
lines O
, O
whereas O
replication O
of O
the O
mutant O
JEV O
in O
mouse O
macrophage O
( O
RAW264 O
. O

7 O
) O
and O
neuroblastoma O
( O
N18 O
) O
cells O
was O
impaired O
. O

All O
pathogenic O
flaviviruses O
examined O
thus O
far O
inhibit O
host O
interferon B
( I
IFN I
) I
responses O
by O
suppressing O
the O
Janus B
kinase I
- I
signal I
transducer I
and I
activator I
of I
transcription I
( I
JAK I
- I
STAT I
) I
pathway O
. O

Both O
Langat O
virus O
( O
LGTV O
; O
a O
member O
of O
the O
tick O
- O
borne O
encephalitis O
virus O
serogroup O
) O
and O
Japanese O
encephalitis O
virus O
use O
the O
nonstructural O
protein O
NS5 O
to O
suppress O
JAK O
- O
STAT O
signaling O
. O

However O
, O
NS5 O
is O
also O
critical O
to O
virus O
replication O
, O
contributing O
methyltransferase O
and O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activities O
. O

Here O
, O
we O
demonstrate O
that O
the O
LGTV O
NS5 O
JAK O
- O
STAT O
inhibitory O
domain O
is O
contained O
between O
amino O
acids O
355 O
and O
735 O
( O
of O
903 O
) O
, O
a O
range O
which O
lies O
within O
the O
RdRP O
domain O
. O

The O
unfolded B
protein I
response I
( I
UPR I
) I
is O
a O
coordinated O
change O
in O
gene O
expression O
triggered O
by O
perturbations O
in O
functions O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

Here O
, O
we O
report O
that O
XBP1 O
was O
activated O
during O
flaviviral O
infection O
, O
as O
evidenced O
by O
XBP1 O
mRNA O
splicing O
and O
protein O
expression O
, O
as O
well O
as O
induction O
of O
the O
downstream O
genes O
ERdj4 O
, O
EDEM1 O
, O
and O
p58 O
( O
IPK O
) O
in O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
- O
and O
dengue B
virus I
serotype I
2 I
( I
DEN I
- I
2 I
) I
- O
infected O
cells O
. O

Notably O
, O
nonstructural O
protein O
NS2B O
- O
3 O
of O
DEN O
- O
2 O
, O
but O
not O
of O
JEV O
, O
was O
a O
potent O
inducer O
of O
XBP1 O
splicing O
through O
an O
unclear O
mechanism O
( O
s O
) O
. O

Previous O
studies O
have O
demonstrated O
that O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
an O
epitope O
on O
the O
lateral O
surface O
of O
domain B
III I
( I
DIII I
) I
of O
the O
West B
Nile I
virus I
( I
WNV I
) I
envelope I
( I
E I
) I
strongly O
protect O
against O
infection O
in O
animals O
. O

Herein O
, O
we O
observed O
significantly O
less O
efficient O
neutralization O
by O
89 O
MAbs O
that O
recognized O
domain B
I I
( I
DI I
) I
or O
II O
( O
DII O
) O
of O
WNV O
E O
protein O
. O

Approximately O
45 O
% O
of O
DI O
- O
DII O
- O
specific O
MAbs O
showed O
reduced O
binding O
with O
mutations O
in O
the O
highly O
conserved O
fusion O
loop O
in O
DII O
: O
85 O
% O
of O
these O
( O
34 O
of O
40 O
) O
cross O
- O
reacted O
with O
the O
distantly O
related O
Dengue B
Virus I
( I
DENV I
) I
. O

We O
performed O
a O
mutational O
analysis O
of O
the O
NS3 O
helicase O
of O
dengue O
virus O
to O
test O
insights O
gleaned O
from O
its O
crystal O
structure O
and O
identified O
four O
residues O
in O
the O
full O
- O
length O
protein O
that O
severely O
impaired O
either O
its O
RTPase O
and O
ATPase O
( O
Arg O
- O
457 O
- O
458 O
, O
Arg O
- O
460 O
, O
Arg O
- O
463 O
) O
or O
helicase O
( O
Ile O
- O
365 O
, O
Arg O
- O
376 O
) O
activity O
. O

West B
Nile I
virus I
( I
WNV I
) I
causes O
a O
severe O
central B
nervous I
system I
( I
CNS I
) I
infection O
in O
humans O
, O
primarily O
in O
the O
elderly O
and O
immunocompromised O
. O

Prior O
studies O
have O
established O
an O
essential O
protective O
role O
of O
several O
innate O
immune O
response O
elements O
, O
including O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
, O
immunoglobulin O
M O
, O
gamma O
delta O
T O
cells O
, O
and O
complement O
against O
WNV O
infection O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
a O
lack O
of O
IFN O
- O
gamma O
production O
or O
signaling O
results O
in O
increased O
vulnerability O
to O
lethal O
WNV O
infection O
by O
a O
subcutaneous O
route O
in O
mice O
, O
with O
a O
rise O
in O
mortality O
from O
30 O
% O
( O
wild O
- O
type O
mice O
) O
to O
90 O
% O
( O
IFN O
- O
gamma O
( O
- O
/ O
- O
) O
or O
IFN O
- O
gamma O
R O
- O
/ O
- O
mice O
) O
and O
a O
decrease O
in O
the O
average O
survival O
time O
. O

This O
survival O
pattern O
in O
IFN O
- O
gamma O
( O
- O
/ O
- O
) O
and O
IFN O
- O
gamma O
R O
- O
/ O
- O
mice O
correlated O
with O
higher O
viremia O
and O
greater O
viral O
replication O
in O
lymphoid O
tissues O
. O

The O
increase O
in O
peripheral O
infection O
led O
to O
early O
CNS O
seeding O
since O
infectious O
WNV O
was O
detected O
several O
days O
earlier O
in O
the O
brains O
and O
spinal O
cords O
of O
IFN O
- O
gamma O
( O
- O
/ O
- O
) O
or O
IFN O
- O
gamma O
R O
- O
/ O
- O
mice O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
flavivirus O
that O
causes O
severe O
human O
disease O
, O
has O
been O
shown O
to O
block O
the O
interferon B
( I
IFN I
) I
- O
induced O
Janus O
kinase O
signal O
transducer O
and O
activation O
of O
transcription O
( O
Jak O
- O
Stat O
) O
signaling O
cascade O
by O
preventing O
Tyk2 O
tyrosine O
phosphorylation O
and O
Stat O
activation O
. O

Furthermore O
, O
the O
molecular O
mechanism O
responsible O
for O
IFN O
antagonism O
by O
NS5 O
probably O
involves O
protein B
tyrosine I
phosphatases I
( I
PTPs I
) I
, O
as O
the O
IFN O
- O
blocking O
events O
in O
both O
JEV O
- O
infected O
and O
NS5 O
- O
expressing O
cells O
were O
reversed O
by O
sodium O
orthovanadate O
, O
a O
broad O
- O
spectrum O
inhibitor O
of O
PTPs O
. O

Monocyte O
/ O
macrophage O
lineage O
cells O
are O
target O
cells O
in O
vivo O
for O
porcine B
circovirus I
2 I
( I
PCV2 I
) I
replication O
. O

Glycosaminoglycans B
( I
GAG I
) I
are O
used O
by O
several O
viruses O
as O
receptors O
. O

Heparin O
, O
heparan B
sulfate I
( I
HS I
) I
, O
chondroitin B
sulfate I
B I
( I
CS I
- I
B I
) I
, O
but O
not O
CS O
- O
A O
, O
and O
keratan O
sulfate O
reduced O
PCV2 O
infection O
when O
these O
GAG O
were O
incubated O
with O
PCV2 O
prior O
to O
and O
during O
inoculation O
of O
3D4 O
/ O
31 O
cells O
. O

Similarly O
, O
when O
PCV2 O
virus B
- I
like I
particles I
( I
VLP I
) I
were O
allowed O
to O
bind O
onto O
3D4 O
/ O
31 O
cells O
in O
the O
presence O
of O
heparin O
and O
CS O
- O
B O
, O
attachment O
was O
strongly O
reduced O
. O

When O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cells O
were O
inoculated O
with O
PCV2 O
, O
relative O
percentages O
of O
PCV2 O
- O
infected O
cells O
were O
27 O
% O
+ O
/ O
- O
8 O
% O
for O
HS O
- O
deficient O
and O
12 O
% O
+ O
/ O
- O
10 O
% O
for O
GAG O
- O
deficient O
cells O
compared O
to O
wild O
- O
type O
cells O
( O
100 O
% O
) O
. O

Flaviviruses O
such O
as O
dengue B
virus I
( I
DEN I
) I
and O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
are O
medically O
important O
in O
humans O
. O

The O
lipid O
kinase O
, O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
and O
its O
downstream O
target O
Akt O
have O
been O
implicated O
in O
the O
regulation O
of O
diverse O
cellular O
functions O
such O
as O
proliferation O
, O
and O
apoptosis O
. O

We O
found O
that O
Akt O
phosphorylation O
was O
noticeable O
in O
the O
JEV O
- O
and O
DEN B
serotype I
2 I
( I
DEN I
- I
2 I
) I
- O
infected O
neuronal O
N18 O
cells O
in O
an O
early O
, O
transient O
, O
PI3K O
- O
and O
lipid O
raft O
- O
dependent O
manner O
. O

Blocking O
of O
PI3K O
activation O
by O
its O
specific O
inhibitor O
LY294002 O
or O
wortmannin O
greatly O
enhanced O
virus O
- O
induced O
cytopathic O
effects O
( O
CPEs O
) O
, O
even O
at O
an O
early O
stage O
of O
infection O
, O
but O
had O
no O
effect O
on O
virus O
production O
. O

This O
severe O
CPE O
was O
characterized O
as O
apoptotic O
cell O
death O
as O
evidenced O
by O
TUNEL O
( O
terminal O
deoxynucleotidyltransferase O
- O
mediated O
dUTP O
- O
biotin O
nick O
end O
labeling O
) O
staining O
and O
cleavage O
of O
caspase O
- O
3 O
and O
Poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( I
PARP I
) I
. O

A O
series O
of O
carboxyl O
- O
terminally O
truncated O
prM O
mutant O
baculoviruses O
was O
constructed O
to O
demonstrate O
that O
the O
truncations O
of O
the O
transmembrane B
( I
TM I
) I
region O
resulted O
in O
a O
reduction O
of O
the O
formation O
of O
the O
stable O
prM O
- O
E O
complex O
by O
approximately O
40 O
% O
for O
the O
TM1 O
( O
at O
residues O
130 O
to O
147 O
[ O
prM130 O
- O
147 O
] O
) O
truncation O
and O
20 O
% O
for O
TM2 O
( O
at O
prM153 O
- O
167 O
) O
truncation O
. O

Neurotropic O
viruses O
, O
such O
as O
Sindbis B
virus I
( I
SV I
) I
, O
cause O
encephalomyelitis O
through O
their O
ability O
to O
replicate O
in O
neurons O
. O

Passive O
immunization O
with O
monoclonal O
antibodies O
from O
humans O
or O
nonhuman O
primates O
represents O
an O
attractive O
alternative O
to O
vaccines O
for O
prevention O
of O
illness O
caused O
by O
Dengue B
viruses I
( I
DENV I
) I
and O
other O
flaviviruses O
, O
including O
the O
West O
Nile O
virus O
. O

In O
a O
previous O
study O
, O
repertoire O
cloning O
to O
recover O
Fab O
fragments O
from O
bone O
marrow O
mRNA O
of O
chimpanzees O
infected O
with O
all O
four O
DENV O
serotypes O
( O
dengue O
virus O
serotype O
1 O
[ O
DENV O
- O
1 O
] O
to O
DENV O
- O
4 O
) O
was O
described O
. O

In O
that O
study O
, O
a O
humanized O
Immunoglobulin B
G1 I
( I
IgG1 I
) I
antibody O
that O
efficiently O
neutralized O
DENV O
- O
4 O
was O
recovered O
and O
characterized O
. O

Three O
of O
the O
Fabs O
competed O
with O
each O
other O
for O
binding O
to O
DENV O
- O
1 O
and O
DENV O
- O
2 O
, O
although O
each O
of O
these O
Fabs O
contained O
a O
distinct O
complementarity B
determining I
region I
3 I
( I
CDR3 I
) I
- O
H O
sequence O
. O

Fabs O
that O
shared O
an O
identical O
or O
nearly O
identical O
CDR3 O
- O
H O
sequences O
cross O
- O
neutralized O
DENV O
- O
1 O
and O
DENV O
- O
2 O
at O
a O
similar O
high O
50 B
% I
plaque I
reduction I
neutralization I
test I
( I
PRNT50 I
) I
titer O
, O
ranging O
from O
0 O
. O

The O
availability O
of O
ChimeriVax O
vaccine O
technology O
for O
delivery O
of O
flavivirus O
protective O
antigens O
at O
the O
time O
West B
Nile I
( I
WN I
) I
virus O
was O
first O
detected O
in O
North O
America O
in O
1999 O
contributed O
to O
the O
rapid O
development O
of O
the O
vaccine O
candidate O
against O
WN O
virus O
described O
here O
. O

ChimeriVax O
- O
Japanese B
encephalitis I
( I
JE I
) I
, O
the O
first O
live O
- O
attenuated O
vaccine O
developed O
with O
this O
technology O
has O
successfully O
undergone O
phase O
I O
and O
11 O
clinical O
trials O
. O

The O
ChimeriVax O
technology O
utilizes O
yellow B
fever I
virus I
( I
YF I
) I
17D O
vaccine O
strain O
capsid O
and O
nonstructural O
genes O
to O
deliver O
the O
envelope O
gene O
of O
other O
flaviviruses O
as O
live O
- O
attenuated O
chimeric O
viruses O
. O

Amino O
acid O
sequence O
homology O
between O
the O
envelope B
protein I
( I
E I
) I
of O
JE O
and O
WN O
viruses O
facilitated O
targeting O
attenuating O
mutation O
sites O
to O
develop O
the O
WN O
vaccine O
. O

Natural O
isolates O
and O
laboratory O
strains O
of O
West B
Nile I
virus I
( I
WNV I
) I
and O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
were O
attenuated O
for O
neuroinvasiveness O
in O
mouse O
models O
for O
flavivirus O
encephalitis O
by O
serial O
passage O
in O
human O
adenocarcinoma O
( O
SW13 O
) O
cells O
. O

Therefore O
, O
host O
cell O
adaptation O
of O
passage O
variants O
was O
most O
likely O
a O
consequence O
of O
altered O
receptor O
usage O
for O
virus O
attachment O
- O
entry O
with O
the O
involvement O
of O
cell O
surface O
Glycosaminoglycans B
( I
GAG I
) I
in O
this O
process O
. O

In O
vivo O
blood O
clearance O
kinetics O
of O
the O
passage O
variants O
was O
markedly O
faster O
and O
viremia O
was O
reduced O
relative O
to O
the O
parental O
viruses O
, O
suggesting O
that O
affinity O
for O
GAG O
( O
ubiquitously O
present O
on O
cell O
surfaces O
and O
extracellular O
matrices O
) O
is O
a O
key O
determinant O
for O
the O
neuroinvasiveness O
of O
encephalitic O
flaviviruses O
. O

C57BL O
/ O
6J O
mice O
infected O
intravenously O
with O
the O
Sarafend O
strain O
of O
West B
Nile I
virus I
( I
WNV I
) I
develop O
a O
characteristic O
central B
nervous I
system I
( I
CNS I
) I
disease O
, O
including O
an O
acute O
inflammatory O
reaction O
. O

At O
high O
doses O
of O
infection O
( O
10 O
( O
8 O
) O
PFU O
) O
, O
direct O
infection O
of O
the O
brain O
occurred O
within O
24 O
h O
, O
resulting O
in O
100 O
% O
mortality O
with O
a O
6 O
- O
day O
mean O
survival O
time O
( O
MST O
) O
, O
and O
there O
was O
minimal O
destruction O
of O
neural O
tissue O
. O

A O
low O
dose O
( O
10 O
( O
3 O
) O
PFU O
) O
of O
infection O
resulted O
in O
27 O
% O
mortality O
( O
MST O
, O
11 O
days O
) O
, O
and O
virus O
could O
be O
detected O
in O
the O
CNS O
7 O
days O
postinfection O
( O
p O
. O

The O
cellular O
infiltrates O
in O
brain O
consisted O
predominantly O
of O
CD8 O
( O
+ O
) O
, O
but O
not O
CD4 O
( O
+ O
) O
, O
T O
cells O
. O

CD8 O
( O
+ O
) O
T O
cells O
in O
the O
brain O
and O
the O
spleen O
expressed O
the O
activation O
markers O
CD69 O
early O
and O
expressed O
CD25 O
at O
later O
time O
points O
. O

CD8 O
( O
+ O
) O
T O
- O
cell O
- O
deficient O
mice O
infected O
with O
10 O
( O
3 O
) O
PFU O
of O
WNV O
showed O
increased O
mortalities O
but O
prolonged O
MST O
and O
early O
infection O
of O
the O
CNS O
compared O
to O
wild O
- O
type O
mice O
. O

These O
results O
provide O
evidence O
that O
CD8 O
( O
+ O
) O
T O
cells O
are O
involved O
in O
both O
recovery O
and O
immunopathology O
in O
WNV O
infection O
. O

Four O
genotypes O
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
are O
presently O
recognized O
( O
representatives O
of O
genotypes O
I O
to O
III O
have O
been O
fully O
sequenced O
) O
, O
but O
its O
origin O
is O
not O
known O
. O

We O
have O
determined O
the O
complete O
nucleotide O
and O
amino O
acid O
sequence O
of O
a O
genotype O
IV O
Indonesian O
isolate O
( O
JKT6468 O
) O
which O
represents O
the O
oldest O
lineage O
, O
compared O
it O
with O
other O
fully O
sequenced O
genomes O
, O
and O
examined O
the O
geographical O
distribution O
of O
all O
known O
isolates O
. O

Three O
signature O
amino O
acids O
in O
the O
envelope O
protein O
( O
including O
E327 O
Leu O
- O
- O
> O
Thr O
/ O
Ser O
on O
the O
exposed O
lateral O
surface O
of O
the O
putative O
receptor O
binding O
domain O
) O
distinguished O
genotype O
W O
strains O
from O
more O
recent O
genotypes O
. O

Protection O
against O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
antibody O
dependent O
, O
and O
neutralizing O
antibodies O
alone O
are O
sufficient O
to O
impart O
protection O
. O

Previously O
, O
we O
have O
synthesized O
large O
amounts O
of O
Johnson B
grass I
mosaic I
virus I
( I
JGMV I
) I
coat I
protein I
( I
CP I
) I
in O
Escherichia O
coli O
and O
have O
shown O
that O
it O
autoassembled O
to O
form O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

The O
envelope B
( I
E I
) I
protein O
of O
JEV O
contains O
the O
virus O
- O
neutralization O
epitopes O
. O

A O
hamster O
viscerotropic O
strain O
of O
yellow B
fever I
( I
YF I
) I
virus O
has O
been O
derived O
after O
serial O
passage O
of O
strain O
Asibi O
through O
hamsters O
. O

The O
majority O
of O
these O
substitutions O
( O
five O
of O
seven O
) O
fall O
within O
the O
envelope B
( I
E I
) I
protein O
at O
positions O
Q27H O
, O
D28G O
, O
D155A O
, O
K323R O
, O
and O
K331R O
. O

A O
chimeric O
yellow B
fever I
( I
YF I
) I
virus O
/ O
Japanese B
encephalitis I
( I
JE I
) I
virus O
vaccine O
( O
ChimeriVax O
- O
JE O
) O
was O
constructed O
by O
insertion O
of O
the O
prM O
- O
E O
genes O
from O
the O
attenuated O
JE O
virus O
SA14 O
- O
14 O
- O
2 O
vaccine O
strain O
into O
a O
full O
- O
length O
cDNA O
clone O
of O
YF O
17D O
virus O
. O

Passage O
in O
fetal B
rhesus I
lung I
( I
FRhL I
) I
cells O
led O
to O
the O
emergence O
of O
a O
small O
- O
plaque O
virus O
containing O
a O
single O
Met O
- O
- O
> O
Lys O
amino O
acid O
mutation O
at O
E279 O
, O
reverting O
this O
residue O
from O
the O
SA14 O
- O
14 O
- O
2 O
to O
the O
wild O
- O
type O
amino O
acid O
. O

In O
independent O
transfection O
- O
passage O
studies O
with O
FRhL O
or O
Vero O
cells O
, O
mutations O
appeared O
most O
frequently O
in O
hinge O
4 O
( O
bounded O
by O
amino O
acids O
E266 O
to O
E284 O
) O
, O
reflecting O
genomic O
instability O
in O
this O
functionally O
important O
region O
. O

After O
intracerebral O
inoculation O
, O
the O
E279 O
Lys O
virus O
was O
restricted O
with O
respect O
to O
extraneural O
replication O
in O
monkeys O
, O
as O
viremia O
and O
antibody O
levels O
( O
markers O
of O
viscerotropism O
) O
were O
significantly O
reduced O
compared O
to O
those O
for O
the O
E279 O
Met O
virus O
. O

Whether O
flaviviruses O
require O
an O
activated O
nuclear O
factor O
( O
s O
) O
to O
complete O
their O
life O
cycle O
and O
trigger O
apoptosis O
in O
infected O
cells O
remains O
elusive O
. O

Flavivirus O
infections O
quickly O
activate O
Nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappaB I
) I
, O
and O
salicylates O
have O
been O
shown O
to O
inhibit O
NF O
- O
kappaB O
activation O
. O

This O
inhibition O
of O
flaviviruses O
by O
salicylates O
could O
be O
partially O
reversed O
by O
a O
specific O
p38 O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase O
inhibitor O
, O
SB203580 O
. O

Langat B
virus I
( I
LGT I
) I
, O
strain O
TP21 O
, O
a O
naturally O
avirulent O
tick O
- O
borne O
flavivirus O
, O
was O
used O
to O
construct O
a O
chimeric O
candidate O
virus O
vaccine O
which O
contained O
LGT O
genes O
for O
premembrane O
( O
preM O
) O
and O
envelope B
( I
E I
) I
glycoprotein O
and O
all O
other O
sequences O
derived O
from O
dengue B
type I
4 I
virus I
( I
DEN4 I
) I
. O

Significantly O
, O
the O
chimera O
protected O
immunocompetent O
mice O
against O
the O
most O
virulent O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
. O

Subsequently O
, O
rhesus O
monkeys O
were O
immunized O
in O
groups O
of O
4 O
with O
10 O
( O
5 O
) O
or O
10 O
( O
7 O
) O
PFU O
of O
LGT O
strain O
TP21 O
, O
with O
105 O
PFU O
of O
DEN4 O
, O
or O
with O
10 O
( O
3 O
) O
, O
10 O
( O
5 O
) O
, O
or O
10 O
( O
7 O
) O
PFU O
of O
the O
chimera O
. O

We O
previously O
reported O
construction O
of O
a O
chimeric O
yellow B
fever I
- I
dengue I
type I
2 I
virus I
( I
YF I
/ I
DEN2 I
) I
and O
determined O
its O
safety O
and O
protective O
efficacy O
in O
rhesus O
monkeys O
( O
F O
. O

In O
this O
paper O
, O
we O
describe O
construction O
of O
three O
additional O
YF O
/ O
DEN O
chimeras O
using O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
genes O
of O
wild B
- I
type I
( I
WT I
) I
clinical O
isolates O
: O
DEN1 O
( O
strain O
PUO359 O
, O
isolated O
in O
1980 O
in O
Thailand O
) O
, O
DEN3 O
( O
strain O
PaH881 O
/ O
88 O
, O
isolated O
in O
1988 O
in O
Thailand O
) O
, O
and O
DEN4 O
( O
strain O
1228 O
, O
isolated O
in O
1978 O
in O
Indonesia O
) O
. O

These O
chimeric O
viruses O
( O
YF O
/ O
DEN1 O
, O
YF O
/ O
DEN3 O
, O
and O
YF O
/ O
DEN4 O
) O
replicated O
to O
similar O
to7 O
. O

5 O
log O
( O
10 O
) O
PFU O
/ O
ml O
in O
Vero O
cells O
, O
were O
not O
neurovirulent O
in O
3 O
- O
to O
4 O
- O
week O
- O
old O
ICR O
mice O
inoculated O
by O
the O
intracerebral O
route O
, O
and O
were O
immunogenic O
in O
monkeys O
. O

All O
rhesus O
monkeys O
inoculated O
subcutaneously O
with O
one O
dose O
of O
these O
chimeric O
viruses O
( O
as O
monovalent O
or O
tetravalent O
formulation O
) O
developed O
viremia O
with O
magnitudes O
similar O
to O
that O
of O
the O
YF O
17D O
vaccine O
strain O
( O
YF O
- O
VAX O
) O
but O
significantly O
lower O
than O
those O
of O
their O
parent O
WT O
viruses O
. O

The O
nucleoside B
triphosphatase I
( I
NTPase I
) I
/ O
helicase O
associated O
with O
nonstructural O
protein O
3 O
of O
West B
Nile I
( I
WN I
) I
virus O
was O
purified O
from O
cell O
culture O
medium O
harvested O
from O
virus O
- O
infected O
Vero O
cells O
. O

Under O
optimized O
reaction O
conditions O
the O
enzyme O
catalyzed O
the O
hydrolysis O
of O
ATP O
and O
the O
unwinding O
of O
the O
DNA O
duplex O
with O
k O
( O
cat O
) O
values O
of O
133 O
and O
5 O
. O

5 O
x O
10 O
( O
- O
3 O
) O
s O
( O
- O
1 O
) O
, O
respectively O
. O

Characterization O
of O
the O
NTPase O
activity O
of O
the O
WN O
virus O
enzyme O
revealed O
that O
optimum O
conditions O
with O
respect O
to O
the O
Mg2 O
+ O
requirement O
and O
the O
monovalent O
salt O
or O
polynucleotide O
response O
differed O
from O
those O
of O
other O
flavivirus O
NTPases O
, O
Initial O
kinetic O
studies O
demonstrated O
that O
the O
inhibition O
( O
or O
activation O
) O
of O
ATPase O
activity O
by O
ribavirin O
- O
5 O
' O
- O
triphosphate O
is O
not O
directly O
related O
to O
changes O
in O
the O
helicase O
activity O
of O
the O
enzyme O
. O

rubella B
virus I
( I
RUB I
) I
is O
a O
small O
plus O
- O
strand O
RNA O
virus O
classified O
in O
the O
Rubivirus O
genus O
of O
the O
family O
Togaviridae O
. O

In O
this O
study O
, O
such O
a O
vector O
was O
constructed O
using O
a O
recently O
developed O
RUB O
infectious O
cDNA O
clone O
( O
Robo O
) O
. O

Using O
a O
standard O
strategy O
employed O
to O
produce O
expression O
and O
vaccine O
vectors O
with O
other O
togaviruses O
, O
the O
subgenomic O
promoter O
was O
duplicated O
to O
produce O
a O
recombinant O
construct O
( O
termed O
dsRobo O
) O
that O
expressed O
reporter O
genes O
such O
as O
chloramphenicol O
acetyltransferase O
and O
green O
fluorescent O
protein O
( O
GIT O
) O
under O
control O
of O
the O
second O
subgenomic O
promoter O
. O

To O
improve O
the O
stability O
of O
the O
vector O
, O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
a O
picornavirus O
, O
encephalomyocarditis O
virus O
, O
was O
used O
instead O
of O
the O
second O
subgenomic O
promoter O
to O
eliminate O
homology O
. O

We O
have O
constructed O
a O
chimeric O
yellow O
fever O
/ O
dengue O
( O
YF O
/ O
DEN O
) O
virus O
, O
which O
expresses O
the O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
genes O
from O
DEN B
type I
2 I
( I
DEN I
- I
2 I
) I
virus O
in O
a O
YF O
virus O
( O
YFV O
- O
17D O
) O
genetic O
background O
. O

A O
chimeric O
yellow B
fever I
( I
YF I
) I
- O
dengue O
type O
2 O
( O
dengue O
- O
2 O
) O
virus O
( O
ChimeriVax O
- O
D2 O
) O
was O
constructed O
using O
a O
recombinant O
cDNA O
infectious O
clone O
of O
a O
YF O
vaccine O
strain O
( O
YF O
17D O
) O
as O
a O
backbone O
into O
which O
we O
inserted O
the O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
genes O
of O
dengue O
- O
2 O
virus O
( O
strain O
PUO O
- O
218 O
from O
a O
case O
of O
dengue O
fever O
in O
Bangkok O
, O
Thailand O
) O
. O

3 O
log O
( O
10 O
) O
PFU O
/ O
ml O
, O
The O
ChimeriVax O
- O
D2 O
was O
not O
neurovirulent O
for O
4 O
- O
week O
- O
old O
outbred O
mice O
inoculated O
intracerebrally O
, O
This O
virus O
was O
evaluated O
in O
rhesus O
monkeys O
for O
its O
safety O
( O
induction O
of O
viremia O
) O
and O
protective O
efficacy O
( O
induction O
of O
anti O
- O
dengue O
- O
2 O
neutralizing O
antibodies O
and O
protection O
against O
challenge O
) O
. O

In O
one O
experiment O
, O
groups O
of O
non O
- O
YF O
- O
immune O
monkeys O
received O
graded O
doses O
of O
ChimeriVax O
- O
D2 O
; O
a O
control O
group O
received O
only O
the O
vaccine O
diluents O
, O
All O
monkeys O
( O
except O
the O
control O
group O
) O
developed O
a O
brief O
viremia O
and O
showed O
no O
signs O
of O
illness O
. O

0 O
log O
( O
10 O
) O
Focus B
Forming I
Units I
( I
FFU I
) I
of O
a O
wild O
- O
type O
dengue O
- O
2 O
virus O
. O

7 O
log O
( O
10 O
) O
FFU O
/ O
ml O
) O
was O
detected O
in O
any O
vaccinated O
group O
, O
whereas O
ail O
animals O
in O
the O
placebo O
control O
group O
developed O
viremia O
. O

Plasmid O
vectors O
containing O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
genes O
were O
constructed O
that O
expressed O
prM O
and O
E O
proteins O
under O
the O
control O
of O
a O
cytomegalovirus O
immediate O
- O
early O
gene O
promoter O
. O

COS O
- O
1 O
cells O
transformed O
with O
this O
plasmid O
vector O
( O
JE O
- O
4B O
clone O
) O
secreted O
JEV O
- O
specific O
extracellular B
particles I
( I
EPs I
) I
into O
the O
culture O
media O
. O

ChimeriVax O
- O
JE O
is O
a O
live O
, O
attenuated O
recombinant O
virus O
prepared O
by O
replacing O
the O
genes O
encoding O
two O
structural O
proteins O
( O
prM O
and O
E O
) O
of O
yellow O
fever O
17D O
virus O
with O
the O
corresponding O
genes O
of O
an O
attenuated O
strain O
of O
Japanese O
encephalitis O
virus O
( O
JE O
) O
, O
SA14 O
- O
14 O
- O
2 O
( O
T O
. O

The O
prM O
- O
E O
genome O
sequence O
of O
the O
ChimeriVax O
- O
JE O
in O
diploid O
fetal O
rhesus O
lung O
cells O
( O
FRhL O
, O
a O
substrate O
acceptable O
for O
human O
vaccines O
) O
was O
identical O
to O
that O
of O
JE O
SA14 O
- O
14 O
- O
2 O
vaccine O
and O
differed O
from O
sequences O
of O
virulent O
wild O
- O
type O
strains O
( O
SA14 O
and O
Nakayama O
) O
at O
six O
amino O
acid O
residues O
in O
the O
envelope O
gene O
( O
E107 O
, O
E138 O
, O
E176 O
, O
E279 O
, O
E315 O
, O
and O
E439 O
) O
. O

) O
route O
, O
whereas O
commercial O
yellow O
fever O
17D O
vaccine O
( O
YF O
- O
Vax O
) O
caused O
lethal O
encephalitis O
with O
a O
50 O
% O
lethal O
dose O
of O
1 O
. O

67 O
log O
( O
10 O
) O
PFU O
. O

0 O
log O
( O
10 O
) O
PFU O
of O
ChimeriVax O
- O
JE O
. O

1 O
log O
( O
10 O
) O
PFU O
/ O
ml O
; O
mean O
duration O
, O
1 O
. O

Neutralizing O
antibody O
titers O
to O
the O
homologous O
( O
vaccine O
) O
strain O
were O
higher O
than O
to O
the O
heterologous O
wild O
- O
type O
JE O
strains O
. O

2 O
log O
( O
10 O
) O
PFU O
of O
wild O
- O
type O
JE O
. O

Immunized O
monkeys O
developed O
significant O
( O
greater O
than O
or O
equal O
to O
4 O
- O
fold O
) O
increases O
in O
serum O
and O
cerebrospinal O
fluid O
neutralizing O
antibodies O
after O
i O
. O

Infection O
with O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
flavivirus O
, O
may O
cause O
acute O
encephalitis O
in O
humans O
and O
induce O
severe O
cytopathic O
effects O
in O
various O
types O
of O
cultured O
cells O
. O

We O
observed O
that O
JEV O
replication O
rendered O
infected O
baby B
hamster I
kidney I
( I
BHK I
- I
21 I
) I
cells O
sensitive O
to O
the O
translational O
inhibitor O
hygromycin O
B O
or O
alpha O
- O
sarcine O
, O
to O
which O
mock O
- O
infected O
cells O
were O
insensitive O
. O

However O
, O
little O
is O
known O
about O
whether O
any O
JEV O
nonstructural B
( I
NS I
) I
proteins O
contribute O
to O
virus O
- O
induced O
changes O
in O
membrane O
permeability O
. O

For O
Japanese B
encephalitis I
( I
JE I
) I
, O
we O
previously O
reported O
that O
recombinant O
vaccine O
- O
induced O
protection O
from O
disease O
does O
not O
prevent O
challenge O
virus O
replication O
in O
mice O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
role O
of O
postchallenge O
immune O
responses O
in O
determining O
the O
outcome O
of O
JE O
virus O
infection O
, O
using O
mice O
immunized O
with O
a O
plasmid O
, O
pcDNA3JEME O
, O
encoding O
the O
JE O
virus O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
coding O
regions O
. O

In O
the O
first O
experiment O
, O
10 O
mice O
were O
vaccinated O
once O
( O
five O
animals O
) O
or O
twice O
( O
remainder O
) O
with O
100 O
mu O
g O
of O
pcDNA3JEME O
. O

All O
of O
these O
mice O
showed O
low O
( O
6 O
of O
10 O
) O
or O
undetectable O
( O
4 O
of O
10 O
) O
levels O
of O
neutralizing O
antibodies O
. O

In O
the O
second O
experiment O
, O
JE O
virus O
- O
specific O
primary O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
activity O
was O
detected O
in O
BALB O
/ O
c O
mice O
immunized O
once O
with O
100 O
mu O
g O
of O
pcDNA3JEME O
4 O
days O
after O
challenge O
, O
indicating O
a O
strong O
postchallenge O
recall O
of O
CTLs O
. O

A O
system O
has O
been O
developed O
for O
generating O
chimeric O
yellow B
fever I
/ I
Japanese I
encephalitis I
( I
YF I
/ I
JE I
) I
viruses O
from O
cDNA O
templates O
encoding O
the O
structural O
proteins O
prM O
and O
E O
of O
JE O
virus O
within O
the O
backbone O
of O
a O
molecular O
clone O
of O
the O
YF17D O
strain O
. O

Chimeric O
viruses O
incorporating O
the O
proteins O
of O
two O
JE O
strains O
, O
SA O
( O
14 O
) O
- O
14 O
- O
2 O
( O
human O
vaccine O
strain O
) O
and O
JE O
Nakayama O
( O
JE O
- O
N O
[ O
virulent O
mouse O
brain O
- O
passaged O
strain O
] O
) O
, O
were O
studied O
in O
cell O
culture O
and O
laboratory O
mice O
. O

The O
JE O
envelope B
protein I
( I
E I
) I
retained O
antigenic O
and O
biological O
properties O
when O
expressed O
with O
its O
prM O
protein O
together O
with O
the O
YF O
capsid O
; O
however O
, O
viable O
chimeric O
viruses O
incorporating O
the O
entire O
JE O
structural O
region O
( O
C O
- O
prM O
- O
E O
) O
could O
not O
be O
obtained O
. O

YF O
/ O
JE O
( O
prM O
- O
E O
) O
chimeric O
viruses O
grew O
efficiently O
in O
cells O
of O
vertebrate O
or O
mosquito O
origin O
compared O
to O
the O
parental O
viruses O
. O

The O
YF O
/ O
JE O
SA O
( O
14 O
) O
- O
14 O
- O
2 O
virus O
was O
unable O
to O
kill O
young O
adult O
mice O
by O
intracerebral O
challenge O
, O
even O
at O
doses O
of O
10 O
( O
6 O
) O
PFU O
, O
In O
contrast O
, O
the O
YF O
/ O
JE O
- O
N O
virus O
was O
neurovirulent O
, O
but O
the O
phenotype O
resembled O
parental O
YF O
virus O
rather O
than O
JE O
- O
N O
, O
Ten O
predicted O
amino O
acid O
differences O
distinguish O
the O
JE O
E O
proteins O
of O
the O
two O
chimeric O
viruses O
, O
therefore O
implicating O
one O
or O
more O
residues O
as O
virus O
- O
specific O
determinants O
of O
mouse O
neuroviruleuce O
in O
this O
chimeric O
system O
. O

This O
study O
indicates O
the O
feasibility O
of O
expressing O
protective O
antigens O
of O
JE O
virus O
in O
the O
context O
of O
a O
live O
, O
attenuated O
flavivirus O
vaccine O
strain O
( O
YF17D O
) O
and O
also O
establishes O
a O
genetic O
system O
for O
investigating O
the O
molecular O
basis O
for O
neurovirulence O
determinants O
encoded O
within O
the O
JE O
E O
protein O
. O

Here O
we O
report O
that O
severe B
combined I
immunodeficient I
( I
SCID I
) I
mice O
engrafted O
with O
human O
K562 O
cells O
( O
K562 O
- O
SCID O
mice O
) O
can O
be O
used O
as O
an O
animal O
model O
to O
study O
dengue B
virus I
( I
DEN I
) I
infection O
. O

We O
analyzed O
the O
CD4 O
( O
+ O
) O
T O
- O
lymphocyte O
responses O
of O
two O
donors O
who O
had O
received O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
vaccine O
6 O
or O
12 O
months O
earlier O
. O

Bulk O
culture O
proliferation O
assays O
showed O
that O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
responded O
to O
JEV O
antigens O
( O
Ag O
) O
but O
also O
responded O
at O
lower O
levels O
to O
West B
Nile I
virus I
( I
WNV I
) I
and O
dengue O
virus O
type O
1 O
, O
2 O
, O
and O
4 O
( O
D1V O
, O
D2V O
, O
and O
D4V O
, O
respectively O
) O
Ag O
, O
Five O
JEV O
- O
specific O
CD4 O
( O
+ O
) O
human O
T O
- O
cell O
clones O
and O
one O
subclone O
were O
established O
from O
PBMC O
of O
these O
two O
donors O
. O

A O
DNA O
vaccine O
plasmid O
containing O
the O
Japanese B
encephalitis I
( I
JE I
) I
virus O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
genes O
( O
designated O
pcDNA3JEME O
) O
was O
evaluated O
for O
immunogenicity O
and O
protective O
efficacy O
in O
mice O
. O

Two O
immunizations O
of O
4 O
- O
week O
- O
old O
female O
ICR O
mice O
with O
pcDNA3JEME O
by O
intramuscular O
or O
intradermal O
injections O
at O
a O
dose O
of O
10 O
or O
100 O
mu O
g O
per O
mouse O
elicited O
neutralizing B
( I
NEUT I
) I
antibodies O
at O
titers O
of O
1 O
: O
10 O
to O
1 O
: O
20 O
( O
90 O
% O
plaque O
reduction O
) O
, O
and O
all O
immunized O
mice O
survived O
a O
challenge O
with O
10 O
, O
000 O
50 O
% O
lethal O
doses O
of O
the O
P3 O
strain O
of O
JE O
virus O
. O

Spleen O
cells O
obtained O
from O
BALB O
/ O
c O
mice O
immunized O
once O
with O
10 O
or O
100 O
mu O
g O
of O
pcDNA3JEME O
contained O
JE O
virus O
- O
specific O
memory O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
flavivirus O
, O
is O
a O
zoonotic O
pathogen O
that O
is O
prevalent O
in O
some O
Southeast O
Asian O
countries O
and O
causes O
acute O
encephalitis O
in O
humans O
. O

To O
evaluate O
the O
potential O
application O
of O
gene O
immunization O
to O
JEV O
infection O
, O
we O
characterized O
the O
immune O
responses O
from O
mice O
intramuscularly O
injected O
with O
plasmid O
DNA O
encoding O
JEV O
glycoproteins O
, O
including O
the O
precursor B
membrane I
( I
prM I
) I
plus O
envelope B
( I
E I
) I
proteins O
and O
the O
nonstructural O
protein O
NS1 O
. O

As O
a O
control O
, O
the O
mice O
immunized O
with O
the O
DNA O
vector O
pcDNA3 O
showed O
a O
low O
level O
( O
40 O
% O
) O
of O
protection O
, O
suggesting O
a O
nonspecific O
adjuvant O
effect O
of O
the O
plasmid O
DNA O
. O

By O
contrast O
, O
immunization O
with O
a O
construct O
expressing O
a O
longer O
NS1 O
protein O
( O
NS1 O
' O
) O
, O
containing O
an O
extra O
60 O
- O
amino O
- O
acid O
portion O
from O
the O
N O
terminus O
of O
NS2A O
, O
failed O
to O
protect O
mice O
against O
a O
lethal O
challenge O
. O

Infection O
by O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
flavivirus O
, O
causes O
acute O
encephalitis O
in O
humans O
and O
induces O
severe O
cytopathic O
effects O
in O
different O
types O
of O
cultured O
cells O
. O

According O
to O
our O
results O
, O
the O
replication O
of O
JEV O
, O
and O
not O
the O
UV O
- O
inactivated O
virions O
per O
se O
, O
triggered O
apoptosis O
in O
these O
cell O
lines O
, O
as O
evidenced O
by O
nuclear O
condensation O
, O
DNA O
fragmentation O
ladder O
, O
and O
in O
situ O
end O
labeling O
of O
DNA O
strand O
breaks O
with O
terminal O
transferase O
( O
terminal O
deoxynucleotidyltransferase O
- O
mediated O
dUTP O
- O
biotin O
nick O
end O
labeling O
assay O
) O
. O

To O
study O
this O
cleavage O
, O
we O
developed O
a O
cell O
- O
free O
trans O
cleavage O
assay O
for O
yellow B
fever I
virus I
( I
YF I
) I
- O
specific O
proteolytic O
activity O
by O
using O
a O
substrate O
spanning O
the O
C O
protein O
dibasic O
site O
. O

Previous O
cell O
- O
free O
studies O
led O
to O
a O
hypothesis O
that O
processing O
in O
the O
C O
- O
prM O
region O
involves O
( O
i O
) O
translation O
of O
C O
followed O
by O
translocation O
and O
core O
glycosylation O
of O
prM O
by O
using O
an O
internal O
signal O
sequence O
, O
( O
ii O
) O
signalase O
cleavage O
to O
produce O
a O
membrane O
- O
anchored O
form O
of O
the O
C O
protein O
( O
anchC O
) O
and O
the O
N O
terminus O
of O
prM O
, O
and O
( O
iii O
) O
NS2B O
- O
3 O
- O
mediated O
cleavage O
at O
the O
anchC O
dibasic O
site O
to O
produce O
the O
C O
terminus O
of O
the O
virion O
C O
protein O
. O

We O
constructed O
recombinant O
vaccinia O
virus O
vectors O
for O
expression O
of O
the O
structural O
region O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Infection O
of O
mammalian O
cells O
with O
a O
vector O
( O
vv O
/ O
HCV1 O
- O
906 O
) O
encoding O
C O
- O
E1 O
- O
E2 O
- O
NS2 O
generated O
major O
protein O
species O
of O
22 O
kDa O
( O
C O
) O
, O
33 O
to O
35 O
kDa O
( O
E1 O
) O
, O
and O
70 O
to O
72 O
kDa O
( O
E2 O
) O
, O
as O
observed O
previously O
with O
other O
mammalian O
expression O
systems O
. O

The O
role O
of O
the O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
premembrane B
( I
PrM I
) I
protein O
in O
maturation O
of O
the O
envelope B
( I
E I
) I
glycoprotein O
was O
evaluated O
by O
using O
recombinant O
vaccinia O
viruses O
encoding O
E O
in O
the O
presence O
( O
vP829 O
) O
or O
absence O
( O
vP658 O
) O
of O
prM O
. O

Beta B
interferon I
( I
IFN I
- I
beta I
) I
is O
a O
major O
component O
of O
innate O
immunity O
in O
mammals O
, O
but O
information O
on O
the O
in O
vivo O
source O
of O
this O
cytokine O
after O
pathogen O
infection O
is O
still O
scarce O
. O

Numerous O
luciferase O
- O
positive O
cells O
were O
detected O
in O
regions O
of O
La B
Crosse I
virus I
( I
LACV I
) I
- O
infected O
mouse O
brains O
that O
contained O
many O
infected O
cells O
. O

La B
Crosse I
virus I
( I
LACV I
) I
is O
a O
leading O
cause O
of O
pediatric O
encephalitis O
and O
aseptic O
meningitis O
in O
the O
midwestern O
and O
southern O
United O
States O
, O
where O
it O
is O
considered O
an O
emerging O
human O
pathogen O
. O

The O
results O
presented O
here O
suggest O
( O
i O
) O
that O
a O
substantial O
proportion O
of O
the O
sequence O
divergence O
evident O
between O
the O
consensus O
sequence O
and O
sequences O
of O
laboratory O
strains O
of O
AR339 O
has O
resulted O
from O
selection O
for O
efficient O
growth O
in O
cell O
culture O
, O
( O
ii O
) O
that O
many O
of O
these O
changes O
affect O
the O
virulence O
of O
the O
virus O
in O
animal O
models O
, O
and O
( O
iii O
) O
that O
such O
modified O
genetic O
backgrounds O
present O
in O
laboratory O
strains O
can O
exert O
a O
significant O
influence O
on O
genetic O
studies O
of O
virus O
pathogenesis O
and O
host O
range O
, O
A O
laboratory O
strain O
of O
Sindbis O
virus O
AR339 O
was O
sequenced O
and O
cloned O
as O
a O
cDNA O
( O
pTRSB O
) O
from O
which O
infectious O
virus O
( O
TRSB O
) O
could O
be O
derived O
. O

The O
consensus O
sequence O
was O
deduced O
from O
the O
complete O
sequences O
of O
pTRSB O
and O
HR O
( O
sp O
) O
( O
E O
. O

The O
sequence O
of O
neither O
HR O
( O
sp O
) O
nor O
TRSB O
was O
representative O
of O
the O
consensus O
Sindbis O
virus O
AR339 O
sequence O
, O
HR O
( O
sp O
) O
differed O
from O
the O
consensus O
sequence O
by O
eight O
coding O
changes O
, O
and O
TRSB O
differed O
by O
three O
coding O
changes O
, O
In O
the O
5 O
' O
untranslated O
region O
, O
HR O
( O
sp O
) O
differed O
from O
the O
consensus O
sequence O
at O
nucleotide B
( I
nt I
) I
5 O
. O

These O
differences O
were O
likely O
the O
result O
of O
cell O
culture O
passage O
of O
the O
original O
AR339 O
isolate O
, O
At O
three O
of O
the O
difference O
loci O
( O
one O
in O
TRSB O
and O
two O
in O
HR O
( O
sp O
) O
) O
, O
selection O
of O
cell O
- O
culture O
- O
adaptive O
mutations O
was O
documented O
with O
Sindbis O
virus O
or O
other O
alphaviruses O
. O

Selection O
in O
cell O
culture O
often O
results O
in O
attenuation O
of O
virulence O
in O
animals O
, O
Considering O
the O
TRSB O
and O
HR O
( O
sp O
) O
sequences O
together O
, O
one O
noncoding O
difference O
from O
the O
consensus O
( O
an O
A O
- O
for O
- O
G O
substitution O
in O
the O
5 O
' O
untranslated O
region O
at O
nt O
5 O
) O
and O
six O
coding O
differences O
in O
the O
glycoprotein O
genes O
( O
at O
E2 O
amino O
acids O
1 O
, O
3 O
, O
70 O
, O
and O
172 O
and O
at O
E1 O
amino O
acids O
72 O
and O
237 O
) O
were O
at O
loci O
which O
, O
either O
individually O
or O
in O
combination O
, O
significantly O
affected O
alphavirus O
virulence O
in O
mice O
, O
Although O
the O
levels O
of O
virulence O
of O
isogenic O
strains O
Containing O
either O
nt O
5 O
A O
or O
nt O
5 O
G O
did O
not O
differ O
significantly O
in O
neonatal O
mice O
, O
the O
presence O
of O
nt O
5 O
A O
greatly O
enhanced O
the O
effect O
of O
a O
second O
attenuating O
mutation O
in O
the O
E2 O
gene O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
regulatory O
proteins O
Tax O
and O
HBZ O
play O
indispensable O
roles O
in O
regulating O
viral O
and O
cellular O
gene O
expression O
. O

We O
sought O
to O
investigate O
the O
physical O
interaction O
between O
HBZ O
and O
BRG1 O
and O
to O
determine O
the O
effect O
of O
these O
interactions O
on O
Tax O
- O
mediated O
long B
terminal I
repeat I
( I
LTR I
) I
activation O
. O

We O
reveal O
that O
HTLV O
- O
1 O
cell O
lines O
and O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
cells O
harbor O
high O
levels O
of O
BRG1 O
. O

Using O
glutathione B
S I
- I
transferase I
( I
GST I
) I
pulldown O
and O
coimmunoprecipitation O
assays O
, O
we O
have O
demonstrated O
physical O
interactions O
between O
BRG1 O
and O
HBZ O
and O
characterized O
the O
protein O
domains O
involved O
. O

Finally O
, O
using O
a O
chromatin B
immunoprecipitation I
- I
quantitative I
PCR I
( I
ChIP I
- I
qPCR I
) I
assay O
, O
we O
illustrate O
that O
HBZ O
facilitates O
the O
downregulation O
of O
HTLV O
- O
1 O
transcription O
by O
deregulating O
the O
recruitment O
of O
SWI O
/ O
SNF O
complexes O
to O
the O
promoter O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
a O
highly O
aggressive O
T O
- O
cell O
malignancy O
induced O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
. O

long B
noncoding I
RNA I
( I
lncRNA I
) I
plays O
a O
critical O
role O
in O
the O
development O
and O
progression O
of O
multiple O
human O
cancers O
. O

This O
activation O
was O
independent O
of O
the O
histone B
methyltransferase I
( I
HMT I
) I
activity O
of O
EZH2 O
but O
required O
the O
formation O
of O
an O
ANRIL O
/ O
EZH2 O
/ O
p65 O
ternary O
complex O
. O

IMPORTANCE O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
pathogen O
that O
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
which O
is O
a O
unique O
malignancy O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

A O
role O
for O
long B
noncoding I
RNA I
( I
lncRNA I
) I
in O
HTLV O
- O
1 O
- O
mediated O
cellular O
transformation O
has O
not O
been O
described O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
a O
fatal O
malignancy O
of O
CD4 O
( O
+ O
) O
T O
cells O
infected O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
. O

ATL O
cells O
often O
exhibit O
random O
gross O
chromosomal O
rearrangements O
that O
are O
associated O
with O
the O
induction O
and O
improper O
repair O
of O
double B
- I
stranded I
DNA I
breaks I
( I
DSBs I
) I
. O

The O
viral O
oncoprotein O
HTLV O
- O
1 O
basic B
leucine I
zipper I
( I
bZIP I
) I
factor O
( O
HBZ O
) O
is O
consistently O
expressed O
prior O
to O
and O
throughout O
disease O
progression O
, O
but O
it O
is O
unclear O
whether O
it O
also O
influences O
DSB O
repair O
. O

We O
report O
that O
HBZ O
attenuates O
DSB O
repair O
by O
nonhomologous B
end I
joining I
( I
NHEJ I
) I
, O
in O
a O
manner O
dependent O
upon O
the O
bZIP O
domain O
. O

We O
observed O
that O
HBZ O
expression O
also O
resulted O
in O
a O
bZIP O
- O
dependent O
delay O
in O
DNA B
protein I
kinase I
( I
DNA I
- I
PK I
) I
activation O
following O
treatment O
with O
etoposide O
. O

IMPORTANCE O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infects O
15 O
million O
to O
20 O
million O
people O
worldwide O
. O

About O
5 O
% O
of O
the O
HTLV O
- O
1 O
- O
positive O
population O
develop O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
a O
fatal O
disease O
that O
is O
not O
highly O
responsive O
to O
treatment O
. O

Here O
, O
we O
present O
evidence O
that O
HBZ O
could O
promote O
the O
accumulation O
of O
double B
- I
stranded I
DNA I
breaks I
( I
DSBs I
) I
through O
the O
attenuation O
of O
the O
non B
- I
homologous I
end I
joining I
( I
NHEJ I
) I
repair O
pathway O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
which O
is O
frequently O
resistant O
to O
currently O
available O
therapies O
and O
has O
a O
very O
poor O
prognosis O
. O

This O
study O
aimed O
to O
develop O
a O
potential O
therapy O
by O
generating O
recombinant B
vesicular I
stomatitis I
viruses I
( I
rVSVs I
) I
that O
lack O
an O
envelope O
glycoprotein O
G O
and O
instead O
encode O
an O
HTLV O
- O
1 O
receptor O
with O
human O
glucose B
transporter I
1 I
( I
GLUT1 I
) I
, O
neuropilin B
1 I
( I
NRP1 I
) I
, O
or O
heparan B
sulfate I
proteoglycans I
( I
HSPGs I
) I
, O
including O
syndecan B
1 I
( I
SDC1 I
) I
, O
designated O
VSV O
triangle O
G O
- O
GL O
, O
VSV O
triangle O
G O
- O
NP O
, O
or O
VSV O
triangle O
G O
- O
SD O
, O
respectively O
. O

The O
present O
study O
demonstrates O
VSV O
triangle O
G O
- O
GL O
, O
VSV O
triangle O
G O
- O
NP O
, O
VSV O
triangle O
G O
- O
GLN O
, O
and O
VSV O
triangle O
G O
- O
GLNS O
have O
tropism O
for O
HTLV B
- I
1 I
envelope I
( I
Env I
) I
- O
expressing O
cells O
. O

In O
this O
study O
, O
we O
developed O
rVSVs O
that O
specifically O
target O
and O
kill O
HTLV O
- O
1 O
Env O
- O
expressing O
cells O
( O
not O
ATL O
cells O
, O
which O
generally O
do O
not O
express O
Env O
in O
vivo O
) O
through O
replacement O
of O
the O
G O
gene O
with O
HTLV O
- O
1 O
receptor O
gene O
( O
s O
) O
in O
the O
VSV O
genome O
. O

The O
pathogenesis O
of O
human B
T I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
strongly O
linked O
to O
the O
viral O
regulatory O
proteins O
Tax1 O
and O
HBZ O
, O
whose O
opposing O
functions O
contribute O
to O
the O
clinical O
outcome O
of O
infection O
. O

Type B
I I
interferons I
alpha I
and I
beta I
( I
IFN I
- I
alpha I
and I
IFN I
- I
beta I
) I
are O
key O
cytokines O
involved O
in O
innate O
immunity O
, O
and O
IFN O
- O
alpha O
, O
in O
combination O
with O
other O
antivirals O
, O
is O
extensively O
used O
in O
the O
treatment O
of O
HTLV O
- O
1 O
infection O
. O

Here O
we O
report O
that O
HBZ O
significantly O
enhances O
interferon B
regulatory I
factor I
7 I
( I
IRF7 I
) I
- O
induced O
IFN O
- O
alpha O
- O
and O
IFN B
- I
stimulated I
response I
element I
( I
ISRE I
) I
promoter O
activities O
and O
IFN O
- O
alpha O
production O
and O
can O
counteract O
the O
inhibitory O
effect O
of O
Tax1 O
. O

IMPORTANCE O
Type O
I O
interferons O
are O
powerful O
antiviral O
cytokines O
and O
are O
used O
extensively O
in O
the O
treatment O
of O
HTLV O
- O
1 O
- O
induced O
Adult B
T I
cell I
leukemia I
( I
ATL I
) I
. O

We O
previously O
reported O
that O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
repertoire O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
Tax O
( O
301 O
- O
309 O
) O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic O
T O
cells O
( O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
) O
was O
highly O
restricted O
and O
a O
particular O
amino O
acid O
sequence O
motif O
, O
the O
PDR O
motif O
, O
was O
conserved O
among O
HLA O
- O
A O
* O
24 O
: O
02 O
- O
positive O
( O
HLA O
- O
A O
* O
24 O
: O
02 O
( O
+ O
) O
) O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
patients O
who O
had O
undergone O
allogeneic O
hematopoietic O
cell O
transplantation O
( O
allo O
- O
HSCT O
) O
. O

On O
the O
other O
hand O
, O
the O
TCR O
repertoires O
in O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
of O
asymptomatic B
HTLV I
- I
1 I
carriers I
( I
ACs I
) I
remain O
unclear O
. O

In O
this O
study O
, O
we O
directly O
identified O
the O
DNA O
sequence O
of O
complementarity B
- I
determining I
region I
3 I
( I
CDR3 I
) I
of O
the O
TCR O
- O
beta O
chain O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
at O
the O
single O
- O
cell O
level O
and O
compared O
not O
only O
the O
TCR O
repertoires O
but O
also O
the O
frequencies O
and O
phenotypes O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
between O
ACs O
and O
ATL O
patients O
. O

We O
did O
not O
observe O
any O
essential O
difference O
in O
the O
frequencies O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
between O
ACs O
and O
ATL O
patients O
. O

In O
the O
single O
- O
cell O
TCR O
repertoire O
analysis O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
, O
1 O
, O
458 O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
and O
140 O
clones O
were O
identified O
in O
this O
cohort O
. O

Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
showed O
highly O
restricted O
TCR O
repertoires O
with O
a O
strongly O
biased O
usage O
of O
BV7 O
, O
and O
PDR O
, O
the O
unique O
motif O
in O
TCR O
- O
beta O
CDR3 O
, O
was O
exclusively O
observed O
in O
all O
ACs O
and O
ATL O
patients O
. O

However O
, O
there O
was O
no O
correlation O
between O
PDR O
+ O
CTL O
frequencies O
and O
HTLV O
- O
1 O
proviral B
load I
( I
PVL I
) I
. O

In O
conclusion O
, O
we O
have O
identified O
, O
for O
the O
first O
time O
, O
a O
unique O
amino O
acid O
sequence O
, O
PDR O
, O
as O
a O
public O
TCR O
- O
CDR3 O
motif O
against O
Tax O
in O
HLA O
- O
A O
* O
24 O
: O
02 O
( O
+ O
) O
HTLV O
- O
1 O
- O
infected O
individuals O
. O

The O
HTLV O
- O
1 O
regulatory O
protein O
Tax O
aggressively O
promotes O
the O
proliferation O
of O
HTLV O
- O
1 O
- O
infected O
lymphocytes O
and O
is O
also O
a O
major O
target O
antigen O
for O
CD8 O
( O
+ O
) O
CTLs O
. O

In O
our O
previous O
evaluation O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
, O
we O
found O
that O
a O
unique O
amino O
acid O
sequence O
motif O
, O
PDR O
, O
in O
CDR3 O
of O
the O
TCR O
- O
beta O
chain O
of O
Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
was O
conserved O
among O
ATL O
patients O
after O
allo O
- O
HSCT O
. O

Furthermore O
, O
the O
PDR O
+ O
Tax O
( O
301 O
- O
309 O
) O
- O
CTL O
clones O
selectively O
expanded O
and O
showed O
strong O
cytotoxic O
activities O
against O
HTLV O
- O
1 O
. O

On O
the O
other O
hand O
, O
it O
remains O
unclear O
how O
Tax O
( O
301 O
- O
309 O
) O
- O
CTL O
repertoire O
exists O
in O
ACs O
. O

Tax O
( O
301 O
- O
309 O
) O
- O
CTLs O
showed O
highly O
restricted O
TCR O
repertoires O
with O
a O
strongly O
biased O
usage O
of O
BV7 O
, O
and O
PDR O
, O
the O
unique O
motif O
in O
TCR O
- O
beta O
CDR3 O
, O
was O
conserved O
in O
all O
ACs O
and O
ATL O
patients O
, O
regardless O
of O
clinical O
subtype O
in O
HTLV O
- O
1 O
infection O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
retrovirus O
, O
and O
, O
as O
such O
, O
its O
genome O
becomes O
chromosomally O
integrated O
following O
infection O
. O

The O
resulting O
provirus O
contains O
identical O
5 O
' O
and O
3 O
' O
peripheral O
long B
terminal I
repeats I
( I
LTRs I
) I
containing O
bidirectional O
promoters O
. O

Both O
the O
HBZ O
and O
Tax O
proteins O
are O
implicated O
in O
the O
development O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
a O
T O
- O
cell O
malignancy O
caused O
by O
HTLV O
- O
1 O
infection O
. O

Consistent O
with O
the O
ability O
of O
Tax O
to O
induce O
cell O
cycle O
arrest O
, O
this O
population O
was O
arrested O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
type O
2 O
( O
HTLV O
- O
2 O
) O
are O
highly O
related O
retroviruses O
that O
transform O
T O
cells O
in O
vitro O
but O
have O
distinct O
pathological O
outcomes O
in O
vivo O
. O

HTLV O
- O
1 O
encodes O
a O
protein O
from O
the O
antisense O
strand O
of O
its O
proviral O
genome O
, O
the O
HTLV B
- I
1 I
basic I
leucine I
zipper I
factor I
( I
HBZ I
) I
, O
which O
inhibits O
Tax O
- O
1 O
- O
mediated O
viral O
transcription O
and O
promotes O
cell O
proliferation O
, O
a O
high O
proviral O
load O
, O
and O
persistence O
in O
vivo O
. O

In O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
cell O
lines O
and O
patient O
T O
cells O
, O
hbz O
is O
often O
the O
only O
viral O
gene O
expressed O
. O

Herein O
, O
we O
examined O
the O
effect O
of O
APH O
- O
2 O
on O
several O
known O
HBZ O
- O
modulated O
pathways O
: O
NF O
- O
kappa O
B O
( O
p65 O
) O
transactivation O
, O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
signaling O
, O
and O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
transactivation O
. O

This O
block O
to O
HIV O
replication O
occurs O
between O
reverse O
transcription O
and O
nuclear O
entry O
, O
and O
passaging O
experiments O
selected O
for O
a O
single O
- O
amino O
- O
acid O
change O
in O
capsid B
( I
CA I
) I
that O
leads O
to O
resistance O
to O
overexpressed O
SUN2 O
. O

Furthermore O
, O
using O
chemical O
inhibition O
or O
silencing O
of O
cyclophilin B
A I
( I
CypA I
) I
, O
as O
well O
as O
CA O
mutant O
viruses O
, O
we O
implicated O
CypA O
in O
the O
SUN2 O
- O
imposed O
block O
to O
HIV O
infection O
. O

Adult B
T I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
is O
an O
aggressive O
cancer O
of O
CD4 O
/ O
CD25 O
( O
+ O
) O
T O
lymphocytes O
, O
the O
etiological O
agent O
of O
which O
is O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
. O

Oncolytic O
viruses O
such O
as O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
are O
being O
considered O
as O
anticancer O
agents O
since O
they O
readily O
infect O
transformed O
cells O
compared O
to O
normal O
cells O
, O
the O
former O
appearing O
to O
exhibit O
defective O
innate O
immune O
responses O
. O

Here O
, O
we O
have O
evaluated O
the O
efficacy O
and O
safety O
of O
a O
recombinant O
VSV O
that O
has O
been O
retargeted O
to O
specifically O
infect O
and O
replicate O
in O
transformed O
CD4 O
( O
+ O
) O
cells O
. O

This O
was O
achieved O
by O
replacing O
the O
single O
VSV O
glycoprotein B
( I
G I
) I
with O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
gp160 O
to O
create O
a O
hybrid O
fusion O
protein O
, O
gp160G O
. O

VSV O
- O
gp160G O
was O
further O
noted O
to O
be O
highly O
attenuated O
and O
did O
not O
replicate O
efficiently O
in O
or O
induce O
significant O
cell O
death O
of O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

Accordingly O
, O
VSV O
- O
gp160G O
did O
not O
elicit O
any O
evidence O
of O
neurotoxicity O
even O
in O
severely O
immunocompromised O
animals O
such O
as O
NOD B
/ I
Shi I
- I
scid I
, I
IL I
- I
2R I
gamma I
- I
c I
- I
null I
( I
NSG I
) I
mice O
. O

Our O
data O
indicate O
that O
VSV O
- O
gp160G O
exerts O
potent O
oncolytic O
efficacy O
against O
CD4 O
( O
+ O
) O
malignant O
cells O
and O
either O
alone O
or O
in O
conjunction O
with O
established O
therapies O
may O
provide O
an O
effective O
treatment O
in O
patients O
displaying O
ATL O
. O

IMPORTANCE O
Adult B
T I
cell I
leukemia I
( I
ATL I
) I
is O
a O
serious O
form O
of O
cancer O
with O
a O
high O
mortality O
rate O
. O

In O
this O
study O
, O
we O
developed O
a O
recombinant O
strain O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
that O
specifically O
targets O
transformed O
CD4 O
( O
+ O
) O
T O
cells O
through O
replacement O
of O
the O
G O
protein O
of O
VSV O
with O
a O
hybrid O
fusion O
protein O
, O
combining O
domains O
from O
gp160 O
of O
HIV O
- O
1 O
and O
VSV O
- O
G O
. O

This O
modification O
eliminated O
the O
normally O
broad O
tropism O
of O
VSV O
and O
restricted O
infection O
to O
primarily O
the O
transformed O
CD4 O
( O
+ O
) O
cell O
population O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
transforms O
T O
cells O
in O
vitro O
. O

To O
our O
knowledge O
, O
the O
functional O
role O
of O
reactive B
oxygen I
species I
( I
ROS I
) I
- O
generating O
NADPH B
oxidase I
5 I
( I
Nox5 I
) I
in O
HTLV O
- O
1 O
transformation O
remains O
undefined O
. O

Upregulation O
of O
the O
Nox5 O
alpha O
variant O
was O
transcriptionally O
sustained O
by O
the O
constitutive O
Janus O
family O
tyrosine O
kinase O
( O
Jak O
) O
- O
STAT5 O
signaling O
pathway O
in O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- O
independent O
HTLV O
- O
1 O
- O
transformed O
cell O
lines O
, O
including O
MT1 O
and O
MT2 O
, O
whereas O
it O
was O
transiently O
induced O
by O
the O
IL O
- O
2 O
- O
triggered O
Jak O
- O
STAT5 O
axis O
in O
uninfected O
T O
cells O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
induced O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
is O
an O
aggressive O
malignancy O
. O

HTLV B
- I
1 I
Tax I
transactivator I
( I
Tax I
- I
1 I
) I
contributes O
to O
leukemogenesis O
via O
NF O
- O
kappa O
B O
. O

We O
demonstrate O
that O
Tax O
- O
1 O
but O
not O
Tax O
- O
2 O
induces O
ommatidial O
perturbation O
and O
increased O
plasmatocyte O
proliferation O
and O
that O
the O
eye O
phenotype O
is O
dependent O
on O
Kenny O
( O
IKK O
gamma O
/ O
NEMO O
) O
, O
thus O
validating O
this O
new O
in O
vivo O
model O
. O

Human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
( O
HTLV O
- O
1 O
) O
is O
an O
oncogenic O
retrovirus O
considered O
to O
be O
the O
etiological O
agent O
of O
adult B
Tcell I
leukemia I
( I
ATL I
) I
. O

Here O
, O
we O
demonstrate O
that O
Tax O
potently O
inhibits O
the O
activity O
of O
DEx O
( O
D O
/ O
H O
) O
box O
helicases O
RIG O
- O
I O
and O
MDA5 O
as O
well O
as O
Toll O
- O
dependent O
TIR B
- I
domain I
- I
containing I
adapter I
- I
inducing I
interferon I
- I
beta I
( I
TRIF I
) I
, O
which O
function O
as O
cellular O
sensors O
or O
mediators O
of O
viral O
RNA O
and O
facilitate O
innate O
immune O
responses O
, O
including O
the O
production O
of O
type O
I O
IFN O
. O

Tax O
manifested O
this O
function O
by O
binding O
to O
the O
RIP B
homotypic I
interaction I
motif I
( I
RHIM I
) I
domains O
of O
TRIF O
and O
RIP1 O
to O
disrupt O
interferon B
regulatory I
factor I
7 I
( I
IRF7 I
) I
activity O
, O
a O
critical O
type O
I O
IFN O
transcription O
factor O
. O

For O
example O
, O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
has O
been O
reported O
to O
infect O
up O
to O
25 O
million O
people O
worldwide O
and O
is O
the O
causative O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

brain B
- I
derived I
neurotrophic I
factor I
( I
BDNF I
) I
is O
a O
neurotrophin O
that O
promotes O
neuronal O
proliferation O
, O
survival O
, O
and O
plasticity O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
a O
fatal O
malignancy O
caused O
by O
infection O
with O
the O
complex O
retrovirus O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
. O

Furthermore O
, O
levels O
of O
both O
BDNF O
and O
TrkB O
mRNAs O
are O
elevated O
in O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
from O
ATL O
patients O
, O
and O
ATL O
patient O
sera O
contain O
higher O
concentrations O
of O
BDNF O
than O
sera O
from O
noninfected O
individuals O
. O

Finally O
, O
chemical O
inhibition O
of O
TrkB O
signaling O
increases O
apoptosis O
in O
HTLV O
- O
1 O
- O
infected O
T O
cells O
and O
reduces O
phosphorylation O
of O
glycogen B
synthase I
kinase I
3 I
beta I
( I
GSK I
- I
3 I
beta I
) I
, O
a O
downstream O
target O
in O
the O
signaling O
pathway O
. O

IMPORTANCE O
Infection O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
can O
cause O
a O
rare O
form O
of O
leukemia O
designated O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

The O
present O
study O
employed O
mass O
sequencing O
of O
small O
RNA O
libraries O
to O
identify O
the O
repertoire O
of O
small O
noncoding O
RNAs O
expressed O
in O
normal O
CD4 O
( O
+ O
) O
T O
cells O
compared O
to O
cells O
transformed O
with O
human B
T I
- I
cellleukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
the O
causative O
agent O
of O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
. O

The O
results O
revealed O
distinct O
patterns O
of O
microRNA O
expression O
in O
HTLV O
- O
1infected O
CD4 O
( O
+ O
) O
T O
- O
cell O
lines O
with O
respect O
to O
their O
normal O
counterparts O
. O

One O
of O
the O
most O
abundant O
tRNA O
fragments O
( O
tRF O
- O
3019 O
) O
was O
derived O
from O
the O
3 O
' O
end O
of O
tRNA O
- O
proline O
. O

Human O
T O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
mainly O
causes O
adult O
T O
cell O
leukemia O
and O
predominantly O
immortalizes O
/ O
transforms O
CD4 O
( O
+ O
) O
T O
cells O
in O
culture O
. O

HTLV O
- O
2 O
is O
aleukemic O
and O
predominantly O
immortalizes O
/ O
transforms O
CD8 O
( O
+ O
) O
T O
cells O
in O
culture O
. O

The O
surface B
component I
( I
SU I
) I
of O
the O
HTLV O
- O
1 O
envelope O
is O
responsible O
for O
binding O
to O
the O
cellular O
receptors O
for O
entry O
. O

HTLV O
- O
1 O
/ O
SU2 O
shifted O
the O
CD4 O
( O
+ O
) O
T O
cell O
immortalization O
tropism O
of O
wildtype B
HTLV I
- I
1 I
( I
wtHTLV I
- I
1 I
) I
to O
a O
CD8 O
( O
+ O
) O
T O
cell O
preference O
. O

195 O
) O
resulted O
in O
a O
shift O
to O
a O
CD8 O
( O
+ O
) O
T O
cell O
immortalization O
tropism O
preference O
. O

Longitudinal O
phenotyping O
analyses O
of O
the O
in O
vitro O
transformation O
process O
revealed O
that O
CD4 O
( O
+ O
) O
T O
cells O
emerged O
as O
the O
predominant O
population O
by O
week O
5 O
in O
wtHTLV O
- O
1 O
cultures O
, O
while O
CD8 O
( O
+ O
) O
T O
cells O
emerged O
as O
the O
predominant O
population O
by O
weeks O
4 O
and O
7 O
in O
wtHTLV O
- O
2 O
and O
Ach O
. O

Our O
results O
indicate O
that O
SU O
domain O
independently O
influences O
the O
preferential O
T O
cell O
immortalization O
tropism O
irrespective O
of O
the O
envelope O
counterpart O
transmembrane B
( I
TM I
) I
domain O
. O

We O
further O
showed O
that O
asparagine O
at O
position O
195 O
in O
HTLV O
- O
1 O
SU O
is O
involved O
in O
determining O
this O
CD4 O
( O
+ O
) O
T O
cell O
immortalization O
tropism O
. O

The O
slower O
emergence O
of O
the O
CD8 O
( O
+ O
) O
T O
cell O
predominance O
in O
Ach O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

Previous O
studies O
in O
our O
laboratory O
, O
using O
the O
yeast O
2 O
- O
hybrid O
approach O
to O
screen O
a O
T O
- O
cell O
library O
for O
Tax1 O
- O
interacting O
partners O
, O
identified O
the O
cellular B
Four I
and I
a I
Half I
Lim I
domain I
protein I
3 I
( I
FHL3 I
) I
as O
a O
possible O
Tax1 O
- O
interacting O
candidate O
. O

We O
have O
demonstrated O
that O
FHL3 O
enhances O
Tax1 O
- O
mediated O
activation O
of O
the O
viral O
long B
terminal I
repeat I
( I
LTR I
) I
without O
affecting O
basal O
activity O
and O
that O
FHL1 O
to O
- O
3 O
regulate O
NF O
- O
kappa O
B O
activation O
by O
Tax1 O
in O
a O
cell O
- O
specific O
manner O
. O

Infection O
with O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
results O
in O
a O
variety O
of O
diseases O
including O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
a O
fatal O
malignancy O
characterized O
by O
the O
uncontrolled O
proliferation O
of O
virally O
infected O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
HTLV B
- I
1 I
basic I
leucine I
zipper I
factor I
( I
HBZ I
) I
is O
believed O
to O
contribute O
to O
development O
and O
maintenance O
of O
ATL O
. O

Unlike O
the O
other O
HTLV O
- O
1 O
genes O
, O
the O
hbz O
gene O
is O
encoded O
on O
the O
complementary O
strand O
of O
the O
provirus O
and O
therefore O
is O
not O
under O
direct O
control O
of O
the O
promoter O
within O
the O
5 O
' O
long B
terminal I
repeat I
( I
LTR I
) I
of O
the O
provirus O
. O

Human O
T O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
and O
HTLV O
- O
2 O
are O
related O
but O
pathogenically O
distinct O
viruses O
. O

In O
vitro O
, O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
predominantly O
transform O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
, O
respectively O
: O
the O
genetic O
determinant O
maps O
to O
the O
viral O
envelope O
. O

Since O
most O
individuals O
are O
chronically O
infected O
at O
the O
time O
of O
detection O
, O
we O
utilized O
an O
established O
rabbit O
model O
to O
longitudinally O
measure O
the O
early O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
infection O
and O
replication O
kinetics O
in O
purified O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

HTLV O
- O
1 O
and O
HTLV O
- O
2 O
were O
detected O
in O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
within O
1 O
week O
postinoculation O
. O

In O
HTLV O
- O
1 O
- O
infected O
rabbit O
CD4 O
( O
+ O
) O
T O
cells O
, O
proviral O
burden O
and O
tax O
/ O
rex O
mRNA O
expression O
peaked O
early O
, O
and O
expression O
levels O
were O
directly O
proportional O
to O
each O
other O
. O

The O
late O
expression O
of O
the O
antisense O
transcript O
( O
Hbz O
or O
Aph O
- O
2 O
) O
correlated O
directly O
with O
a O
late O
proviral O
burden O
peak O
in O
HTLV O
- O
1 O
- O
or O
HTLV O
- O
2 O
- O
infected O
rabbit O
CD8 O
( O
+ O
) O
T O
cells O
, O
respectively O
. O

At O
the O
early O
weeks O
, O
both O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
showed O
proportionate O
growth O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

miR O
- O
155 O
, O
processed O
from O
the O
B B
- I
cell I
integration I
cluster I
( I
BIC I
) I
, O
is O
one O
of O
the O
few O
well O
- O
studied O
microRNAs B
( I
miRNAs I
) I
and O
is O
involved O
in O
both O
innate O
immunity O
and O
tumorigenesis O
. O

We O
have O
identified O
two O
conserved O
potential O
interferon B
( I
IFN I
) I
regulatory O
factor O
( O
IRF O
) O
- O
binding O
/ O
interferon O
- O
stimulated O
response O
element O
motifs O
in O
the O
Bic O
gene O
promoter O
. O

Correspondingly O
, O
the O
endogenous O
levels O
of O
IRF4 O
and O
- O
7 O
are O
correlated O
with O
that O
of O
the O
BIC O
transcript O
in O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- O
transformed O
cells O
. O

However O
, O
RNA O
interference O
studies O
have O
shown O
that O
depletion O
of O
IRF4 O
, O
rather O
than O
of O
IRF7 O
, O
dramatically O
decreases O
the O
endogenous O
level O
of O
BIC O
by O
up O
to O
70 O
% O
in O
EBV O
- O
or O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV1 I
) I
- O
transformed O
cell O
lines O
and O
results O
in O
apoptosis O
and O
reduction O
of O
proliferation O
rates O
that O
are O
restored O
by O
transient O
expression O
of O
miR O
- O
155 O
. O

Furthermore O
, O
the O
level O
of O
IRF4 O
mRNA O
is O
significantly O
correlated O
with O
that O
of O
BIC O
in O
adult B
T I
- I
cell I
lymphoma I
/ I
leukemia I
( I
ATLL I
) I
tumors O
. O

Infection O
by O
human B
T I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
a O
fatal O
hematopoietic O
malignancy O
termed O
Adult B
T I
cell I
leukemia I
( I
ATL I
) I
. O

Here O
, O
we O
report O
that O
ubiquitin O
- O
specific O
peptidase O
USP20 O
deubiquitinates O
TRAF6 O
and O
Tax O
and O
suppresses O
interleukin B
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
- O
and O
Tax O
- O
induced O
NF O
- O
kappa O
B O
activation O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
causative O
agent O
of O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
, O
a O
malignancy O
of O
CD4 O
( O
+ O
) O
T O
cells O
whose O
etiology O
is O
thought O
to O
be O
associated O
with O
the O
viral O
trans O
- O
activator O
Tax O
. O

We O
have O
shown O
recently O
that O
Tax O
can O
drastically O
upregulate O
the O
expression O
of O
p27 O
( O
Kip1 O
) O
and O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
through O
protein O
stabilization O
and O
mRNA O
trans O
- O
activation O
and O
stabilization O
, O
respectively O
. O

The O
Tax O
- O
induced O
surge O
in O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
and O
p27 O
( O
Kip1 O
) O
begins O
in O
S O
phase O
and O
results O
in O
cellular O
senescence O
. O

Here O
we O
use O
time O
- O
lapse O
microscopy O
to O
investigate O
the O
effect O
of O
Tax O
on O
cell O
cycle O
progression O
in O
two O
reporter O
cell O
lines O
, O
HeLa O
/ O
18x21 O
- O
EGFP O
and O
HeLa O
- O
FUCCI O
, O
that O
express O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
under O
the O
control O
of O
18 O
copies O
of O
the O
Tax O
- O
responsive O
21 O
- O
bp O
repeat O
element O
and O
fluorescent O
ubiquitin O
cell O
cycle O
indicators O
, O
respectively O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
the O
cause O
of O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
, O
transforms O
CD4 O
( O
+ O
) O
T O
cells O
to O
permanent O
growth O
through O
its O
transactivator O
Tax O
. O

HTLV O
- O
1 O
- O
transformed O
cells O
share O
phenotypic O
properties O
with O
memory O
and O
regulatory B
T I
cells I
( I
T I
- I
reg I
) I
. O

Murine O
T O
- O
reg O
- O
mediated O
suppression O
employs O
elevated O
cyclic B
AMP I
( I
cAMP I
) I
levels O
as O
a O
key O
regulator O
. O

We O
found O
specific O
downregulation O
of O
the O
cAMP O
- O
degrading O
phosphodiesterase B
3B I
( I
PDE3B I
) I
in O
HTLV O
- O
1 O
- O
transformed O
cells O
, O
which O
was O
independent O
of O
Tax O
in O
transient O
expression O
experiments O
. O

Human B
T I
- I
lymphotropic I
virus I
1 I
( I
HTLV I
- I
1 I
) I
causes O
an O
aggressive O
malignancy O
of O
T O
lymphocytes O
called O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
, O
and O
expression O
of O
HTLV O
- O
1 O
Tax O
influences O
cell O
survival O
, O
proliferation O
, O
and O
genomic O
stability O
in O
the O
infected O
T O
lymphocytes O
. O

Cyclin O
- O
dependent O
kinase O
inhibitor O
1A O
( O
CDKN1A O
/ O
p21 O
( O
waf1 O
/ O
Cip1 O
) O
) O
is O
upregulated O
by O
Tax O
, O
without O
perturbation O
of O
cell O
cycle O
control O
. O

In O
both O
the O
HTLV O
- O
1 O
- O
infected O
and O
ATLL O
cell O
lines O
, O
we O
found O
that O
activated O
Akt O
phosphorylates O
CDKN1A O
at O
threonine O
145 O
( O
T145 O
) O
, O
leading O
to O
cytoplasmic O
localization O
of O
CDKNIA O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
induces O
cell O
proliferation O
after O
infection O
, O
leading O
to O
efficient O
transmission O
by O
cell O
- O
to O
- O
cell O
contact O
. O

After O
a O
long O
latent O
period O
, O
a O
fraction O
of O
carriers O
develop O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

The O
sequence O
context O
of O
G O
- O
to O
- O
A O
mutations O
was O
in O
accordance O
with O
the O
preferred O
target O
sequence O
of O
human B
APOBEC3G I
( I
hA3G I
) I
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
causes O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
and O
is O
associated O
with O
a O
variety O
of O
lymphocyte O
- O
mediated O
disorders O
. O

Twelve O
- O
week O
- O
old O
rabbits O
were O
injected O
intravenously O
with O
cell O
- O
associated O
HTLV O
- O
1 O
( O
ACH O
- O
transformed O
R49 O
) O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
caused O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
. O

Elevated O
expression O
of O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
in O
ATL O
patients O
is O
associated O
with O
leukemic O
cell O
invasion O
and O
infiltration O
in O
different O
organs O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
, O
and O
it O
encodes O
a O
number O
of O
nonstructural O
proteins O
that O
are O
involved O
in O
virus O
replication O
and O
immune O
evasion O
. O

Consistently O
with O
previous O
studies O
, O
p12 O
( O
- O
) O
and O
p12 O
( O
+ O
) O
cell O
lines O
produced O
similar O
amounts O
of O
virus O
particles O
released O
into O
the O
supernatant O
of O
cultured O
cells O
, O
although O
we O
found O
that O
p12 O
expression O
greatly O
enhanced O
virus O
transmission O
. O

Moreover O
, O
we O
found O
that O
inter O
- O
leukin O
- O
2 O
( O
IL O
- O
2 O
) O
stimulation O
also O
increased O
HTLV O
- O
1 O
transmission O
whether O
p12 O
was O
expressed O
or O
not O
, O
and O
inversely O
, O
that O
the O
inhibition O
of O
Jak O
signaling O
significantly O
reduced O
HTLV O
- O
1 O
transmission O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
causes O
adult O
T O
- O
cell O
leukemia O
and O
is O
associated O
with O
a O
variety O
of O
lymphocyte O
- O
mediated O
disorders O
. O

In O
this O
study O
, O
real O
- O
time O
reverse O
transcriptase O
PCR O
was O
used O
to O
determine O
the O
kinetics O
of O
viral O
gene O
expression O
in O
cells O
transiently O
transfected O
with O
an O
HTLV O
- O
1 O
proviral O
plasmid O
, O
in O
newly O
infected O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMCs I
) I
, O
and O
in O
PBMCs O
from O
newly O
infected O
rabbits O
. O

gag O
/ O
pol O
, O
tax O
/ O
rex O
, O
and O
env O
mRNA O
were O
detected O
first O
and O
at O
the O
highest O
levels O
, O
whereas O
the O
expression O
levels O
of O
the O
accessory O
genes O
, O
including O
the O
antisense O
Hbz O
, O
were O
significantly O
lower O
than O
the O
tax O
/ O
rex O
levels O
( O
ranging O
from O
1 O
to O
4 O
logs O
depending O
on O
the O
specific O
mRNA O
) O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
an O
oncogenic O
retrovirus O
etiologically O
causal O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
. O

The O
transforming O
ability O
of O
Tax O
, O
the O
viral O
oncoprotein O
, O
is O
believed O
to O
depend O
on O
interactions O
with O
cell O
cycle O
regulators O
and O
on O
transactivation O
of O
genes O
that O
control O
cellular O
proliferation O
, O
including O
proliferating B
cell I
nuclear I
antigen I
( I
PCNA I
) I
, O
a O
cofactor O
associated O
with O
DNA O
replication O
and O
repair O
. O

The O
etiology O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
induced O
adult O
T O
- O
cell O
leukemia O
is O
linked O
to O
the O
expression O
of O
the O
viral O
oncoprotein O
Tax O
. O

In O
this O
study O
, O
we O
examined O
the O
interplay O
between O
Tax O
and O
the O
potent O
proto O
- O
oncogene O
B B
- I
cell I
chronic I
leukemia I
protein I
3 I
( I
Bcl3 I
) I
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
associated O
with O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
infection O
. O

The O
tumor B
suppressor I
lung I
cancer I
1 I
( I
TSLC1 I
) I
gene O
was O
previously O
identified O
as O
a O
novel O
cell O
surface O
marker O
for O
ATL O
, O
and O
this O
study O
demonstrated O
the O
involvement O
of O
TSLC1 O
expression O
in O
tumor O
growth O
and O
organ O
infiltration O
of O
ATL O
cells O
. O

In O
experiments O
using O
NOD O
/ O
SCID O
/ O
gamma O
c O
( O
null O
) O
mice O
, O
both O
leukemia O
cell O
lines O
and O
primary O
ATL O
cells O
with O
high O
TSLC1 O
expression O
caused O
more O
tumor O
formation O
and O
aggressive O
infiltration O
of O
various O
organs O
of O
mice O
. O

Infection O
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
thought O
to O
cause O
dysregulated O
T O
- O
cell O
proliferation O
, O
which O
in O
turn O
leads O
to O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
. O

HTLV O
- O
1 O
- O
infected O
HeLa O
cells O
, O
like O
their O
tax O
- O
transduced O
counterparts O
, O
expressed O
high O
levels O
of O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
and O
p27 O
( O
KIP1 O
) O
, O
developed O
mitotic O
abnormalities O
, O
and O
became O
arrested O
in O
G O
, O
in O
senescence O
. O

In O
contrast O
, O
cells O
of O
a O
human B
osteosarcoma I
lineage I
( I
HOS I
) I
continued O
to O
divide O
after O
HTLV O
- O
1 O
infection O
or O
Tax O
expression O
, O
albeit O
at O
a O
reduced O
growth O
rate O
and O
with O
mitotic O
aberrations O
. O

Unique O
to O
HOS O
cells O
is O
the O
dramatic O
reduction O
of O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
and O
p27 O
( O
KIP1 O
) O
expression O
, O
which O
is O
in O
part O
associated O
with O
the O
constitutive O
activation O
of O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( I
PI3K I
) I
- O
protein B
kinase I
B I
( I
Akt I
) I
pathway O
. O

The O
loss O
of O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
and O
p27 O
( O
KIP1 O
) O
in O
HOS O
cells O
apparently O
allows O
HTLV O
- O
1 O
- O
and O
Tax O
- O
induced O
G O
, O
arrest O
to O
be O
bypassed O
. O

However O
, O
T O
cells O
containing O
somatic O
mutations O
that O
inactivate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
and O
p27 O
( O
KIP1 O
) O
may O
continue O
to O
proliferate O
after O
HTLV O
- O
I O
infection O
and O
Tax O
expression O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
the O
aggressive O
and O
fatal O
disease O
adult O
T O
- O
cell O
leukemia O
. O

Given O
these O
attributes O
, O
we O
were O
interested O
in O
the O
activity O
of O
small O
- O
molecule O
inhibitor O
9 B
- I
aminoacridine I
( I
9AA I
) I
, O
an O
anticancer O
drug O
that O
targets O
two O
important O
stress O
response O
pathways O
, O
NF O
- O
kappa O
B O
and O
p53 O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
Tax O
transactivator O
is O
known O
to O
induce O
or O
repress O
various O
cellular O
genes O
, O
several O
of O
them O
encoding O
transcription O
factors O
. O

As O
Tax O
is O
known O
to O
deregulate O
various O
basic O
bHLH O
factors O
, O
we O
looked O
more O
specifically O
at O
its O
effect O
on O
TAL1 O
( O
T O
- O
cell O
acute O
lymphoblastic O
leukemia O
1 O
) O
, O
also O
known O
as O
SCL B
( I
stem I
cell I
leukemia I
) I
. O

Adult O
T O
- O
cell O
leukemia O
, O
which O
can O
result O
from O
infection O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
is O
associated O
with O
extensive O
genomic O
instability O
that O
has O
been O
attributed O
to O
the O
viral O
oncoprotein O
Tax O
. O

Simian B
immunodeficiency I
virus I
( I
SIV I
) I
persistence O
in O
wild O
populations O
of O
African O
nonhuman B
primates I
( I
NHPs I
) I
may O
occur O
through O
horizontal O
and O
vertical O
transmission O
. O

However O
, O
the O
mechanism O
( O
s O
) O
and O
timing O
of O
the O
latter O
type O
of O
transmission O
have O
not O
been O
investigated O
to O
date O
. O

All O
female O
mandrills O
became O
infected O
, O
as O
demonstrated O
by O
both O
plasma O
viral B
loads I
( I
VLs I
) I
and O
anti O
- O
SIVmnd O
- O
1 O
seroconversion O
. O

At O
the O
peak O
of O
SIVmnd O
- O
1 O
viral O
replication O
( O
days O
7 O
to O
10 O
postinoculation O
) O
, O
plasma O
VLs O
were O
high O
( O
8 O
x O
10 O
( O
6 O
) O
to O
8 O
x O
10 O
( O
8 O
) O
RNA O
copies O
/ O
ml O
) O
and O
paralleled O
the O
high O
VLs O
in O
milk O
( O
4 O
. O

7 O
x O
10 O
( O
4 O
) O
to O
5 O
. O

6 O
x O
10 O
( O
5 O
) O
RNA O
/ O
ml O
) O
. O

Since O
we O
observed O
a O
markedly O
lower O
expression O
of O
CCR5 O
on O
the O
CD4 O
( O
+ O
) O
T O
cells O
of O
young O
mandrills O
and O
African O
green O
monkeys O
than O
on O
those O
of O
adults O
, O
we O
propose O
that O
low O
levels O
of O
this O
viral O
coreceptor O
on O
CD4 O
( O
+ O
) O
T O
cells O
may O
be O
involved O
in O
the O
lack O
of O
breast O
- O
feeding O
transmission O
in O
natural O
hosts O
of O
SIVs O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
candidate O
oncolytic O
virus O
that O
replicates O
and O
induces O
cell O
death O
in O
cancer O
cells O
while O
sparing O
normal O
cells O
. O

We O
previously O
demonstrated O
that O
VSV O
infection O
induces O
apoptosis O
in O
proliferating O
CD4 O
+ O
T O
lymphocytes O
from O
adult O
T O
- O
cell O
leukemia O
samples O
but O
not O
in O
resting O
T O
lymphocytes O
or O
primary O
chronic O
lymphocytic O
leukemia O
cells O
that O
remain O
arrested O
in O
G O
( O
0 O
) O
. O

VSV O
replication O
is O
specifically O
impaired O
by O
the O
cell O
cycle O
inhibitor O
olomoucine O
or O
rapamycin O
, O
which O
induces O
early O
G O
( O
1 O
) O
arrest O
, O
but O
not O
by O
aphidicolin O
or O
Taxol O
, O
which O
blocks O
at O
the O
G O
( O
1 O
) O
1S O
or O
G O
( O
2 O
) O
1M O
phase O
, O
respectively O
; O
this O
result O
suggests O
a O
requirement O
for O
cell O
cycle O
entry O
for O
efficient O
VSV O
replication O
. O

The O
relationship O
between O
increased O
protein O
translation O
following O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
transition O
and O
VSV O
permissiveness O
is O
highlighted O
by O
the O
absence O
of O
mTOR O
and O
/ O
or O
eIF4E O
phosphorylation O
whenever O
VSV O
replication O
is O
impaired O
. O

These O
results O
demonstrate O
that O
VSV O
replication O
in O
primary O
T O
lymphocytes O
relies O
on O
cell O
cycle O
transition O
from O
the O
G O
( O
0 O
) O
phase O
to O
the O
G O
( O
1 O
) O
phase O
, O
which O
is O
characterized O
by O
a O
sharp O
increase O
in O
ribogenesis O
and O
protein O
synthesis O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

In O
particular O
, O
the O
CD70 O
gene O
was O
upregulated O
more O
than O
1 O
, O
000 O
- O
fold O
and O
the O
enhanced O
expression O
of O
the O
CD70 O
molecule O
was O
confirmed O
by O
laser O
flow O
cytometry O
for O
various O
HTLV O
- O
1 O
- O
carrying O
T O
- O
cell O
lines O
and O
primary O
CD4 O
( O
+ O
) O
T O
cells O
isolated O
from O
acute O
- O
type O
ATL O
patients O
. O

Such O
expression O
was O
not O
observed O
for O
primary O
CD4 O
( O
+ O
) O
T O
cells O
isolated O
from O
healthy O
donors O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
for O
adult O
T O
- O
cell O
leukemia O
. O

To O
further O
investigate O
the O
role O
of O
methyltransferases O
in O
viral O
transcription O
, O
we O
utilized O
adenosine O
- O
2 O
, O
3 O
- O
dialdehyde O
( O
AdOx O
) O
, O
an O
adenosine O
analog O
and O
S O
- O
adenosylmethionine O
- O
dependent O
methyltransferase O
inhibitor O
. O

Our O
data O
further O
demonstrated O
that O
AdOx O
induced O
G O
( O
2 O
) O
/ O
M O
cell O
cycle O
arrest O
and O
cell O
death O
in O
HTLV O
- O
1 O
- O
transformed O
but O
not O
control O
lymphocytes O
. O

cytotoxic B
T I
cells I
( I
CTL I
) I
play O
a O
central O
role O
in O
the O
control O
of O
viral O
infections O
. O

However O
, O
the O
viral O
factor O
( O
s O
) O
that O
influences O
the O
selection O
of O
one O
or O
the O
other O
pathway O
for O
pathogen O
control O
is O
elusive O
. O

Here O
we O
investigate O
the O
role O
of O
viral O
replication O
levels O
in O
the O
induction O
and O
activation O
of O
CTL O
, O
including O
their O
effector O
potential O
, O
during O
acute O
Friend B
marine I
leukemia I
virus I
( I
F I
- I
MuLV I
) I
infection O
. O

F O
- O
MuLV O
inoculation O
results O
in O
a O
low O
- O
level O
infection O
of O
adult O
C57BL O
/ O
6 O
mice O
that O
is O
enhanced O
about O
500 O
- O
fold O
upon O
coinfection O
with O
the O
spleen B
focus I
- I
forming I
virus I
( I
SFFV I
) I
. O

Both O
the O
low O
- O
and O
high O
- O
level O
F O
- O
MuLV O
infections O
generated O
CD8 O
( O
+ O
) O
effector O
T O
cells O
that O
were O
essential O
for O
the O
control O
of O
viral O
replication O
. O

However O
, O
the O
low O
- O
level O
infection O
induced O
CD8 O
( O
+ O
) O
T O
cells O
expressing O
solely O
FasL O
but O
not O
the O
cytotoxic O
molecules O
granzymes O
A O
and O
B O
, O
whereas O
the O
high O
- O
level O
infection O
resulted O
in O
induction O
of O
CD8 O
( O
+ O
) O
effector O
T O
cells O
secreting O
molecules O
of O
the O
granule O
exocytosis O
pathway O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
but O
not O
HTLV O
- O
2 O
is O
associated O
with O
adult O
T O
- O
cell O
leukemia O
, O
and O
the O
distinct O
pathogenicity O
of O
these O
two O
closely O
related O
viruses O
is O
thought O
to O
stem O
from O
the O
distinct O
biological O
functions O
of O
the O
respective O
transforming O
proteins O
, O
HTLV O
- O
1 O
Tax1 O
and O
HTLV O
- O
2 O
Tax2 O
. O

Using O
RNA O
interference O
methods O
, O
we O
further O
show O
that O
NF O
- O
kappa O
B2 O
/ O
p100 O
is O
required O
for O
the O
transformation O
induced O
by O
Tax1 O
, O
as O
determined O
by O
the O
ability O
to O
convert B
a I
T I
- I
cell I
line I
( I
CTLL I
- I
2 I
) I
from O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- O
dependent O
to O
- O
independent O
growth O
. O

While O
Tax2 O
shows O
a O
reduced O
transforming O
activity O
relative O
to O
Tax1 O
, O
Tax2 O
fused O
with O
a O
PDZ B
domain I
binding I
motif I
( I
PBM I
) I
present O
only O
in O
Tax1 O
shows O
transforming O
activity O
equivalent O
to O
that O
of O
Tax1 O
in O
CTLL O
- O
2 O
cells O
expressing O
an O
inducer O
of O
p52 O
processing O
. O

Recently O
it O
was O
found O
that O
pituitary O
tumor O
transforming O
gene O
( O
PTTG O
; O
also O
called O
Pds1p O
or O
securin O
) O
is O
overexpressed O
in O
many O
different O
tumors O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
retrovirus O
that O
primarily O
infects O
CD4 O
( O
+ O
) O
T O
lymphocytes O
and O
causes O
adult O
T O
- O
cell O
leukemia O
. O

In O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
cells O
, O
a O
defective O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
provirus O
lacking O
the O
5 O
' O
long B
terminal I
repeat I
( I
LTR I
) I
, O
designated O
type O
2 O
defective O
provirus O
, O
is O
frequently O
observed O
. O

In O
four O
cases O
lacking O
the O
6 O
- O
bp O
repeat O
, O
short O
( O
6 O
- O
to O
26 O
- O
bp O
) O
deletions O
in O
the O
host O
genome O
were O
identified O
, O
indicating O
that O
these O
defective O
proviruses O
were O
generated O
after O
integration O
. O

Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
. O

Expression O
of O
the O
c O
- O
fos O
cellular O
oncogene O
is O
regulated O
by O
serum O
Jos B
response I
factor I
( I
SRF I
) I
, O
and O
Tax O
is O
known O
to O
induce O
c O
- O
fos O
gene O
expression O
by O
activating O
SRF O
- O
responsive O
transcription O
. O

SRF O
activates O
cellular O
gene O
expression O
by O
binding O
to O
a O
consensus O
DNA O
sequence O
( O
CArG O
box O
) O
located O
within O
a O
serum B
response I
element I
( I
SRE I
) I
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
, O
a O
disease O
that O
is O
triggered O
after O
a O
long O
latency O
period O
. O

In O
an O
attempt O
to O
study O
the O
events O
in O
early O
stages O
of O
HTLV O
- O
1 O
infection O
, O
we O
inoculated O
uninfected O
human O
peripheral O
blood O
mononuclear O
cells O
and O
the O
HTLV O
- O
1 O
- O
producing O
cell O
line O
MT O
- O
2 O
into O
NOD O
- O
SCID O
, O
common O
gamma O
- O
chain O
knockout O
mice O
( O
human O
PBMC O
- O
NOG O
mice O
) O
. O

Both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
found O
to O
harbor O
the O
provirus O
, O
although O
the O
latter O
population O
harbored O
provirus O
to O
a O
lesser O
extent O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
the O
causative O
agent O
of O
adult O
T O
- O
cell O
leukemia O
, O
is O
transmitted O
vertically O
via O
breastfeeding O
. O

Coculture O
with O
HTLV O
- O
1 O
- O
infected O
MT O
- O
2 O
cells O
increased O
the O
levels O
of O
lactoferrin O
mRNA O
in O
myeloid O
- O
differentiated O
HL O
- O
60 O
cells O
, O
as O
well O
as O
MCF O
- O
7 O
cells O
, O
models O
of O
two O
probable O
sources O
( O
neutrophils O
and O
mammary O
epithelium O
) O
of O
lactoferrin O
in O
breast O
milk O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
the O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
, O
encodes O
unique O
regulatory O
and O
accessory O
proteins O
in O
the O
pX O
region O
of O
the O
provirus O
, O
including O
the O
open O
reading O
frame O
11 O
product O
p13 O
( O
II O
) O
. O

p1 O
( O
II O
) O
localizes O
to O
mitochondria O
, O
binds O
farnesyl O
pyrophosphate O
synthetase O
, O
an O
enzyme O
involved O
in O
post O
- O
translational O
farnesylation O
of O
Ras O
, O
and O
alters O
Ras O
- O
dependent O
cell O
signaling O
and O
control O
of O
apoptosis O
. O

The O
role O
of O
p13 O
( O
II O
) O
in O
virus O
infection O
in O
vivo O
remains O
undetermined O
. O

Herein O
, O
we O
analyzed O
the O
functional O
significance O
of O
p13 O
( O
II O
) O
in O
HTLV O
- O
1 O
infection O
. O

We O
compared O
the O
infectivity O
of O
a O
human O
B O
- O
cell O
line O
that O
harbors O
an O
infectious O
molecular O
clone O
of O
HTLV O
- O
1 O
with O
a O
selective O
mutation O
that O
prevents O
the O
translation O
of O
p1 O
( O
II O
) O
( O
729 O
. O

p13 O
producer O
lines O
had O
comparable O
infectivities O
for O
cultured O
rabbit O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
and O
the O
fidelity O
of O
the O
start O
codon O
mutation O
in O
ACH O
. O

Our O
data O
are O
the O
first O
to O
indicate O
that O
the O
HTLV O
- O
1 O
mitochondrion O
- O
localizing O
protein O
p13 O
( O
II O
) O
has O
an O
essential O
biological O
role O
during O
the O
early O
phase O
of O
virus O
infection O
in O
vivo O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
associated O
with O
prior O
infection O
with O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
; O
however O
, O
the O
mechanism O
by O
which O
HTLV O
- O
1 O
causes O
adult O
T O
- O
cell O
leukemia O
has O
not O
been O
fully O
elucidated O
. O

Recently O
, O
a O
functional O
basic B
leucine I
zipper I
( I
bZIP I
) I
protein O
coded O
in O
the O
minus O
strand O
of O
HTLV O
- O
1 O
genome O
( O
HBZ O
) O
was O
identified O
. O

We O
report O
here O
a O
novel O
isoform O
of O
the O
HTLV B
- I
1 I
bZIP I
factor I
( I
HBZ I
) I
, O
HBZ O
- O
SI O
, O
identified O
by O
means O
of O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
in O
conjunction O
with O
5 O
' O
and O
3 O
' O
rapid B
amplification I
of I
cDNA I
ends I
( I
RACE I
) I
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
an O
oncogenic O
retrovirus O
associated O
primarily O
with O
adult O
T O
- O
cell O
leukemia O
and O
neurological O
disease O
. O

Here O
we O
generated O
and O
characterized O
a O
unique O
proviral O
clone O
( O
H1IT O
) O
in O
which O
the O
tax O
and O
rex O
genes O
were O
separated O
by O
expressing O
Tax O
from O
an O
internal O
ribosome O
entry O
site O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
, O
an O
aggressive O
CD4 O
( O
+ O
) O
malignancy O
. O

Lentivirus O
- O
mediated O
transduction O
of O
CD34 O
( O
+ O
) O
cells O
with O
HTLV O
- O
1 O
Tax O
( O
Tax1 O
) O
induced O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
cell O
cycle O
arrest O
and O
resulted O
in O
the O
concomitant O
suppression O
of O
multilineage O
hematopoiesis O
in O
vitro O
. O

Tax1 O
induced O
transcriptional O
upregulation O
of O
the O
cdk O
inhibitors O
p21 O
( O
cip1 O
/ O
wafl O
) O
( O
p21 O
) O
and O
p27 O
( O
kipI O
) O
( O
p27 O
) O
, O
and O
marked O
suppression O
of O
hematopoiesis O
in O
immature O
( O
CD34 O
( O
+ O
) O
/ O
CD38 O
( O
- O
) O
) O
hematopoietic O
progenitor O
cells O
in O
comparison O
to O
CD34 O
( O
+ O
) O
/ O
CD38 O
( O
+ O
) O
cells O
. O

HTLV O
- O
1 O
infection O
of O
CD34 O
( O
+ O
) O
cells O
also O
induced O
p21 O
and O
p27 O
expression O
. O

Tax1 O
also O
protected O
CD34 O
( O
+ O
) O
cells O
from O
serum O
withdrawal O
- O
mediated O
apoptosis O
. O

In O
contrast O
, O
HTLV O
- O
2 O
Tax O
( O
Tax2 O
) O
did O
not O
detectably O
alter O
p21 O
or O
p27 O
gene O
expression O
, O
failed O
to O
induce O
cell O
cycle O
arrest O
, O
failed O
to O
suppress O
hematopoiesis O
in O
CD34 O
( O
+ O
) O
cells O
, O
and O
did O
not O
protect O
cells O
from O
programmed O
cell O
death O
. O

A O
Tax2 O
/ O
Tax1 O
chimera O
encoding O
the O
C O
- O
terminal O
53 O
amino O
acids O
of O
Tax1 O
fused O
to O
Tax2 O
( O
Tax O
( O
221 O
) O
) O
displayed O
a O
phenotype O
in O
CD34 O
( O
+ O
) O
cells O
similar O
to O
that O
of O
Tax1 O
, O
suggesting O
that O
unique O
domains O
encoded O
within O
the O
C O
terminus O
of O
Tax1 O
may O
account O
for O
the O
phenotypes O
displayed O
in O
human O
hematopoietic O
progenitor O
cells O
. O

These O
remarkable O
differences O
in O
the O
activities O
of O
Tax1 O
and O
Tax2 O
in O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
may O
underlie O
the O
sharp O
differences O
observed O
in O
the O
pathogenesis O
resulting O
from O
infection O
with O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
but O
not O
HTLV O
- O
2 O
is O
associated O
with O
adult O
T O
- O
cell O
leukemia O
. O

We O
found O
that O
HTLV O
- O
2 O
Tax2 O
protein O
stimulated O
reporter O
gene O
expression O
regulated O
by O
the O
Interleukin B
( I
IL I
) I
- O
2 O
promoter O
through O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( I
NFAT I
) I
in O
a O
human O
T O
- O
cell O
line O
( O
Jurkat O
) O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
. O

In O
addition O
to O
typical O
retroviral O
structural O
and O
enzymatic O
gene O
products O
, O
HTLV O
- O
1 O
encodes O
unique O
regulatory O
and O
accessory O
proteins O
, O
including O
a O
singly O
spliced O
pX O
open B
reading I
frame I
II I
( I
ORF I
II I
) I
product O
, O
p13 O
( O
II O
) O
. O

p13 O
( O
II O
) O
localizes O
to O
mitochondria O
and O
reduces O
cell O
growth O
and O
tumorigenicity O
in O
mice O
, O
but O
its O
function O
in O
human O
lymphocytes O
remains O
undetermined O
. O

For O
this O
study O
, O
we O
analyzed O
the O
functional O
properties O
of O
Jurkat O
T O
cells O
expressing O
p13 O
( O
II O
) O
, O
using O
both O
transient O
and O
stable O
expression O
vectors O
. O

Our O
data O
indicate O
that O
p13 O
( O
II O
) O
- O
expressing O
Jurkat O
T O
cells O
are O
sensitive O
to O
caspase O
- O
dependent O
, O
ceramide O
- O
and O
FasL O
- O
induced O
apoptosis O
. O

p13 O
( O
II O
) O
- O
expressing O
Jurkat O
T O
cells O
also O
exhibited O
reduced O
proliferation O
when O
cultured O
at O
a O
high O
density O
. O

Furthermore O
, O
preincubation O
of O
the O
p13 O
( O
II O
) O
- O
expressing O
cells O
with O
a O
farnesyl O
transferase O
inhibitor O
, O
which O
blocks O
the O
posttranslational O
modification O
of O
Ras O
, O
markedly O
reduced O
FasL O
- O
induced O
apoptosis O
, O
indicating O
the O
participation O
of O
the O
Ras O
pathway O
in O
p13 O
( O
II O
) O
' O
s O
influence O
on O
lymphocyte O
survival O
. O

Our O
data O
are O
the O
first O
to O
demonstrate O
that O
p13 O
( O
II O
) O
alters O
Ras O
- O
mediated O
apoptosis O
in O
T O
lymphocytes O
, O
and O
they O
reveal O
a O
potential O
mechanism O
by O
which O
HTLV O
- O
1 O
alters O
lymphocyte O
proliferation O
. O

restricted O
by O
HLA O
- O
A2 O
or O
A24 O
, O
expanded O
in O
vitro O
and O
in O
vivo O
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
some O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
patients O
after O
but O
not O
before O
allogeneic O
hematopoietic B
stem I
cell I
transplantation I
( I
HSCT I
) I
. O

bovine B
leukemia I
virus I
( I
BLV I
) I
is O
a O
deltaretrovirus O
that O
infects O
cattle O
worldwide O
. O

Like O
the O
human B
T I
- I
cell I
leukemia I
virus I
( I
HTLV I
) I
, O
there O
is O
a O
lengthy O
period O
of O
viral O
quiescence O
after O
initial O
infection O
with O
BLV O
. O

This O
inhibitory O
activity O
of O
bovine O
plasma O
has O
been O
attributed O
to O
the O
plasma B
blocking I
factor I
( I
PBF I
) I
. O

By O
use O
of O
two O
- O
dimensional O
polyacrylamide O
gel O
electrophoresis O
and O
matrix O
- O
assisted O
laser O
desorption O
ionization O
- O
time O
of O
flight O
( O
mass O
spectrometry O
) O
, O
a O
protein O
with O
a O
size O
of O
220 O
kDa O
and O
a O
pI O
of O
5 O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
a O
CD4 O
( O
+ O
) O
- O
T O
- O
cell O
malignancy O
caused O
by O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
, O
is O
difficult O
to O
cure O
, O
and O
novel O
treatments O
are O
urgently O
needed O
. O

Apo2 O
ligand O
( O
Apo2L O
; O
also O
tumor O
necrosis O
factor O
- O
related O
apoptosis O
- O
inducing O
ligand O
[ O
TRAIL O
] O
) O
has O
been O
implicated O
in O
antitumor O
therapy O
. O

The O
sensitivity O
to O
Apo2L O
was O
not O
correlated O
with O
expression O
levels O
of O
Apo2L O
receptors O
, O
intracellular O
regulators O
of O
apoptosis O
( O
FLICE O
- O
inhibitory O
protein O
and O
active O
Akt O
) O
. O

The O
resistance O
to O
Apo2L O
- O
induced O
apoptosis O
was O
reversed O
by O
N O
- O
acetyl O
- O
( O
L O
) O
- O
leucinyl O
- O
( O
L O
) O
- O
leucinyl O
- O
( O
L O
) O
- O
norleucinal O
( O
LLnL O
) O
, O
an O
NF O
- O
kappaB O
inhibitor O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
encodes O
a O
40 O
- O
kDa O
Tax O
phosphoprotein O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
retrovirus O
responsible O
for O
adult O
T O
- O
cell O
leukemia O
and O
HTLV O
- O
1 O
- O
associated O
myelopathy O
. O

Remarkably O
, O
we O
further O
demonstrate O
that O
mutation O
of O
lysine O
residues O
in O
the O
C O
- O
terminal O
part O
of O
Tax O
, O
which O
massively O
reduces O
Tax O
ubiquitination O
, O
impairs O
proteasome O
binding O
, O
and O
conversely O
, O
that O
a O
Tax O
mutant O
that O
binds O
poorly O
to O
this O
particle O
( O
M22 O
) O
is O
faintly O
ubiquitinated O
, O
suggesting O
that O
Tax O
ubiquitination O
is O
required O
for O
association O
with O
cellular O
proteasomes O
. O

Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
and O
lymphoma O
, O
an O
aggressive O
clonal O
malignancy O
of O
human O
CD4 O
- O
bearing O
T O
lymphocytes O
. O

Differences O
between O
the O
biological O
activities O
of O
the O
respective O
tax O
gene O
products O
( O
Tax1 O
and O
Tax2 O
) O
may O
be O
one O
factor O
which O
accounts O
for O
the O
differential O
pathogenicities O
associated O
with O
infection O
. O

Jurkat O
cells O
that O
constitutively O
express O
Taxl O
and O
Tax2 O
( O
Tax1 O
/ O
Jurkat O
and O
Tax2 O
/ O
jurkat O
, O
respectively O
) O
showed O
notably O
reduced O
kinetics O
of O
cellular O
replication O
, O
and O
Taxl O
inhibited O
cellular O
replication O
to O
a O
higher O
degree O
in O
comparison O
to O
Tax2 O
. O

Taxl O
markedly O
activated O
transcription O
from O
the O
cdk O
inhibitor O
p21 O
( O
cip1 O
/ O
waft1 O
) O
promoter O
in O
comparison O
to O
Tax2 O
, O
suggesting O
that O
upregulation O
of O
p21 O
( O
cip1 O
/ O
waf1 O
) O
may O
account O
for O
the O
differential O
inhibition O
of O
cellular O
replication O
kinetics O
displayed O
by O
Tax1 O
/ O
Jurkat O
and O
Tax2 O
/ O
jurkat O
cells O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
Tax O
oncoprotein O
induces O
growth O
transformation O
and O
is O
critical O
for O
the O
pathogenesis O
of O
the O
HTLV O
- O
1 O
- O
induced O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

Here O
we O
show O
that O
the O
expression O
of O
interleukin B
- I
13 I
( I
IL I
- I
13 I
) I
is O
upregulated O
as O
a O
consequence O
of O
Tax O
in O
HTLV O
- O
1 O
- O
transformed O
T O
cells O
and O
ATL O
- O
derived O
cultures O
. O

Experiments O
with O
Tax O
mutants O
indicated O
that O
none O
of O
the O
classical O
transactivation O
pathways O
( O
SRF O
, O
CREB O
, O
and O
NF O
- O
kappaB O
) O
is O
sufficient O
for O
the O
transactivation O
; O
at O
least O
two O
different O
Tax O
functions O
are O
required O
for O
full O
transactivation O
. O

The O
following O
observations O
suggest O
that O
IL O
- O
13 O
may O
stimulate O
HTLV O
- O
1 O
- O
transformed O
cells O
by O
an O
autocrine O
mechanism O
: O
( O
i O
) O
the O
HTLV O
- O
1 O
- O
transformed O
cells O
express O
the O
IL O
- O
13 O
receptor O
on O
their O
surface O
, O
and O
( O
ii O
) O
STAT6 O
, O
a O
downstream O
effector O
of O
IL O
- O
13 O
signaling O
, O
is O
constitutively O
activated O
. O

Inhibition O
of O
histone B
deacetylase I
( I
HDAC I
) I
activity O
induces O
growth O
arrest O
, O
differentiation O
, O
and O
, O
in O
certain O
cell O
types O
, O
apoptosis O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
is O
caused O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
remains O
incurable O
. O

FR901228 O
also O
efficiently O
reduced O
the O
DNA O
binding O
of O
NF O
- O
kappaB O
and O
AP O
- O
1 O
in O
HTLV O
- O
1 O
- O
infected O
T O
- O
cell O
lines O
and O
primary O
ATL O
cells O
and O
down O
- O
regulated O
the O
expression O
of O
Bcl O
- O
x O
( O
L O
) O
and O
cyclin O
D2 O
, O
regulated O
by O
NF O
- O
kappaB O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
and O
exhibits O
high O
genetic O
stability O
in O
vivo O
. O

HTLV O
- O
1 O
contains O
four O
open B
reading I
frames I
( I
ORFs I
) I
in O
its O
pX O
region O
. O

ORF O
II O
encodes O
two O
proteins O
, O
p30 O
( O
II O
) O
and O
p13 O
( O
III O
) O
, O
both O
of O
which O
are O
incompletely O
characterized O
. O

p30 O
( O
II O
) O
localizes O
to O
the O
nucleus O
or O
nucleolus O
and O
has O
distant O
homology O
to O
the O
transcription O
factors O
Oct O
- O
1 O
, O
Pit O
- O
1 O
, O
and O
POU O
- O
M1 O
. O

In O
vitro O
studies O
have O
demonstrated O
that O
at O
low O
concentrations O
, O
p30 O
( O
II O
) O
differentially O
regulates O
cellular O
and O
viral O
promoters O
through O
an O
interaction O
with O
CREB O
binding O
protein O
/ O
p300 O
. O

To O
determine O
the O
in O
vivo O
significance O
of O
p30 O
( O
II O
) O
, O
we O
inoculated O
rabbits O
with O
cell O
lines O
expressing O
either O
a O
wild B
- I
type I
clone I
of I
HTLV I
- I
1 I
( I
ACHA I
) I
or O
a O
clone O
containing O
a O
mutation O
in O
ORF O
11 O
, O
which O
eliminated O
wild O
- O
type O
p30 O
( O
II O
) O
expression O
( O
ACH O
. O

Provirus O
could O
be O
consistently O
PCR O
amplified O
from O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
DNA O
in O
all O
ACH O
. O

Here O
, O
we O
aim O
to O
resolve O
this O
issue O
by O
determining O
the O
rates O
of O
cell O
proliferation O
and O
death O
during O
the O
chronic O
stage O
of O
the O
bovine B
leukemia I
virus I
( I
BLV I
) I
infection O
, O
called O
bovine O
persistent B
lymphocytosis I
( I
PL I
) I
. O

057 O
day O
( O
- O
1 O
) O
versus O
0 O
. O

156 O
day O
( O
- O
1 O
) O
in O
the O
asymptomatic O
controls O
) O
. O

0046 O
day O
( O
- O
1 O
) O
versus O
0 O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
HTLV O
- O
2 O
are O
highly O
related O
viruses O
that O
differ O
in O
disease O
manifestation O
. O

We O
previously O
showed O
that O
human O
hematopoietic O
progenitor O
( O
CD34 O
( O
+ O
) O
) O
cells O
can O
be O
infected O
by O
HTLV O
- O
1 O
and O
that O
proviral O
sequences O
were O
maintained O
after O
differentiation O
of O
infected O
CD34 O
( O
+ O
) O
cells O
in O
vitro O
and O
in O
vivo O
. O

To O
investigate O
the O
role O
of O
the O
Tax O
oncoprotein O
of O
HTLV O
on O
hematopoiesis O
, O
bicistronic O
lentiviral O
vectors O
were O
constructed O
encoding O
the O
HTLV O
- O
1 O
or O
HTLV O
- O
2 O
tax O
genes O
( O
Tax1 O
and O
Tax2 O
, O
respectively O
) O
and O
the O
green O
fluorescent O
protein O
marker O
gene O
. O

Human O
hematopoietic O
progenitor O
( O
CD34 O
( O
+ O
) O
) O
cells O
were O
infected O
with O
lentivirus O
vectors O
, O
and O
transduced O
cells O
were O
cultured O
in O
a O
semisolid O
medium O
permissive O
for O
the O
development O
of O
erythroid O
, O
myeloid O
, O
and O
primitive O
progenitor O
colonies O
. O

Tax1 O
- O
transduced O
CD34 O
( O
+ O
) O
cells O
displayed O
a O
two O
- O
to O
fivefold O
reduction O
in O
the O
total O
number O
of O
hematopoietic O
clonogenic O
colonies O
that O
arose O
in O
vitro O
, O
in O
contrast O
to O
Tax2 O
- O
transduced O
cells O
, O
which O
showed O
no O
perturbation O
of O
hematopoiesis O
. O

The O
ratio O
of O
colony O
types O
that O
developed O
from O
Tax1 O
- O
transduced O
CD34 O
( O
+ O
) O
cells O
remained O
unaffected O
, O
suggesting O
that O
Tax1 O
inhibited O
the O
maturation O
of O
relatively O
early O
, O
uncommitted O
hematopoietic O
stem O
cells O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
and O
a O
variety O
of O
lymphoproliferative O
disorders O
. O

The O
HTLV O
- O
1 O
pX O
open O
reading O
frame O
I O
encoding O
protein O
, O
p12 O
( O
I O
) O
, O
is O
critical O
for O
the O
virus O
to O
establish O
persistent O
infection O
in O
vivo O
and O
for O
infection O
in O
quiescent O
primary O
lymphocytes O
in O
vitro O
. O

p12 O
( O
I O
) O
localizes O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
cis O
- O
Golgi O
apparatus O
, O
increases O
intracellular O
calcium O
and O
activates O
nuclear B
factor I
of I
activated I
T I
cells I
( I
NFAT I
) I
- O
mediated O
transcription O
. O

To O
clarify O
the O
function O
of O
p12 O
( O
I O
) O
, O
we O
tested O
the O
production O
of O
IL O
- O
2 O
from O
Jurkat O
T O
cells O
and O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
expressing O
p12 O
( O
I O
) O
. O

Lentiviral O
vector O
expressed O
p12 O
( O
I O
) O
in O
Jurkat O
T O
cells O
enhanced O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
production O
in O
a O
calcium O
pathway O
- O
dependent O
manner O
during O
T B
- I
cell I
receptor I
( I
TCR I
) I
stimulation O
. O

Expression O
of O
p12 O
( O
I O
) O
also O
induced O
higher O
NFAT O
- O
mediated O
reporter O
gene O
activities O
during O
TCR O
stimulation O
in O
Jurkat O
T O
cells O
. O

Finally O
, O
the O
requirement O
of O
ER O
localization O
for O
p12 O
( O
I O
) O
- O
mediated O
NFAT O
activation O
was O
demonstrated O
and O
two O
positive O
regions O
and O
two O
negative O
regions O
in O
p12 O
( O
I O
) O
were O
identified O
for O
the O
activation O
of O
this O
transcription O
factor O
by O
using O
p12 O
( O
I O
) O
truncation O
mutants O
. O

We O
established O
a O
novel O
experimental O
model O
for O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
induced O
tumor O
using O
NOD O
- O
SCID O
/ O
gammac O
( O
null O
) O
( O
NOG O
) O
mice O
. O

This O
model O
is O
very O
useful O
for O
investigating O
the O
mechanism O
of O
tumorigenesis O
and O
malignant O
cell O
growth O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
/ O
lymphoma O
, O
which O
still O
remains O
unclear O
. O

One O
of O
the O
leukemic O
cell O
lines O
, O
ED O
- O
40515 O
( O
- O
) O
, O
was O
unable O
to O
produce O
visible O
tumors O
in O
NOD O
- O
SCID O
mice O
with O
a O
common O
gamma O
- O
chain O
after O
2 O
weeks O
. O

In O
vivo O
NF O
- O
kappaB O
DNA O
binding O
activity O
of O
the O
ED O
- O
40515 O
( O
- O
) O
cell O
line O
was O
higher O
and O
the O
NF O
- O
kappaB O
components O
were O
changed O
compared O
to O
cells O
in O
vitro O
. O

Among O
eight O
samples O
obtained O
from O
a O
French O
primatology O
research O
center O
, O
six O
adult O
guinea O
baboons O
( O
Papio O
hamadryas O
papio O
) O
, O
caught O
in O
the O
wild O
in O
Senegal O
, O
had O
a O
peculiar O
human B
T I
- I
cell I
leukemia I
virus I
type I
2 I
( I
HTLV2 I
) I
- O
like O
Western O
blot O
seroreactivity O
( O
p24 O
( O
+ O
) O
, O
GD21 O
( O
+ O
) O
, O
K55 O
( O
+ O
/ O
- O
) O
) O
. O

Partial O
sequence O
analyses O
of O
the O
tax O
genes O
( O
433 O
bp O
) O
indicated O
that O
these O
baboons O
were O
infected O
by O
a O
novel O
divergent O
Simian B
T I
- I
cell I
lymphotropic I
virus I
( I
STLV I
) I
. O

Analyses O
of O
the O
complete O
proviral O
sequence O
( O
8 O
, O
892 O
bp O
) O
for O
one O
of O
these O
strains O
( O
STLV O
- O
3 O
/ O
PPA O
- O
F3 O
) O
indicate O
that O
this O
STLV O
was O
highly O
divergent O
from O
the O
HTLV O
- O
1 O
( O
61 O
. O

It O
was O
, O
however O
, O
much O
more O
closely O
related O
to O
the O
few O
other O
known O
STLV O
- O
3 O
strains O
, O
exhibiting O
87 O
and O
89 O
% O
of O
nucleotide O
similarity O
with O
STLV O
- O
3 O
/ O
PHA O
- O
PH969 O
( O
formerly O
PTLV O
- O
L O
/ O
PH969 O
) O
and O
STLV O
- O
3 O
/ O
CTO O
- O
604 O
, O
respectively O
. O

In O
all O
phylogenetic O
analyses O
, O
STLV O
- O
3 O
/ O
PPA O
- O
F3 O
clustered O
together O
in O
a O
highly O
supported O
single O
clade O
with O
the O
other O
known O
strains O
of O
STLV O
- O
3 O
, O
indicating O
an O
independent O
evolution O
from O
primate O
T O
- O
cell O
lymphotropic O
virus O
type O
1 O
( O
PTLV O
- O
1 O
) O
and O
PTLV O
- O
2 O
. O

The O
finding O
of O
a O
new O
strain O
of O
STLV O
- O
3 O
in O
a O
West O
African O
monkey O
( O
Guinea O
baboon O
) O
greatly O
enlarges O
the O
geographical O
distribution O
and O
the O
host O
range O
of O
species O
infected O
by O
this O
PTLV O
type O
in O
the O
African O
continent O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
cells O
contain O
integrated O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
proviruses O
. O

Although O
the O
exact O
sequence O
of O
events O
leading O
to O
the O
development O
of O
ATL O
remains O
incompletely O
resolved O
, O
expression O
of O
the O
integrated O
HTLV O
- O
1 O
long B
terminal I
repeat I
( I
LTR I
) I
is O
likely O
required O
at O
some O
point O
during O
the O
process O
of O
T O
- O
cell O
transformation O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
agent O
of O
an O
aggressive O
malignancy O
of O
CD4 O
( O
+ O
) O
T O
lymphocytes O
, O
called O
adult O
T O
- O
cell O
lymphoma O
/ O
leukemia O
, O
and O
is O
associated O
with O
numerous O
immune O
- O
mediated O
diseases O
. O

We O
recently O
demonstrated O
that O
the O
HTLV O
- O
1 O
accessory O
protein O
p12 O
( O
I O
) O
is O
critical O
for O
persistent O
infection O
in O
vivo O
and O
for O
viral O
infectivity O
in O
quiescent O
primary O
lymphocytes O
, O
suggesting O
a O
role O
for O
p12 O
( O
I O
) O
in O
lymphocyte O
activation O
. O

To O
test O
whether O
p12 O
( O
I O
) O
modulates O
signaling O
pathways O
required O
for O
T O
- O
lymphocyte O
activation O
, O
we O
examined O
AP O
- O
1 O
- O
, O
NT O
- O
kappaB O
- O
, O
and O
nuclear B
factor I
of I
activated I
T I
cells I
( I
NFAT I
) I
- O
driven O
reporter O
gene O
activity O
in O
p12 O
( O
I O
) O
- O
expressing O
Jurkat O
T O
cells O
compared O
to O
vector O
- O
transfected O
control O
cells O
. O

HTLV O
- O
1 O
p12 O
( O
I O
) O
specifically O
induced O
NFAT O
- O
mediated O
transcription O
approximately O
20 O
- O
fold O
in O
synergy O
with O
the O
Ras O
/ O
mitogen O
- O
activated O
protein O
kinase O
pathway O
, O
but O
did O
not O
influence O
AP O
- O
1 O
- O
or O
NF O
- O
kappaB O
- O
dependent O
gene O
expression O
. O

Inhibition O
of O
calcium O
- O
dependent O
signals O
by O
cyclosporin O
A O
, O
BAPTA O
- O
AM O
[ O
glycine O
, O
N O
, O
N O
' O
- O
1 O
, O
2 O
- O
ethanedlylbis O
( O
oxy O
- O
2 O
, O
1 O
- O
phenylene O
) O
- O
bis O
- O
N O
- O
2 O
- O
( O
acetyloxy O
) O
methoxy O
- O
2 O
- O
oxoethyl O
] O
- O
[ O
bis O
( O
acetyloxy O
) O
methyl O
ester O
] O
, O
and O
a O
dominant O
negative O
mutant O
of O
NFAT2 O
abolished O
the O
p12 O
( O
I O
) O
- O
mediated O
activation O
of O
NFAT O
- O
dependent O
transcription O
. O

In O
contrast O
, O
inhibition O
of O
phospholipase O
C O
- O
gamma O
and O
LAT B
( I
linker I
for I
activation I
of I
T I
cells I
) I
did O
not O
affect O
p12 O
( O
I O
) O
- O
induced O
NFAT O
activity O
. O

Importantly O
, O
p12 O
( O
I O
) O
functionally O
substituted O
for O
thapsigargin O
, O
which O
selectively O
depletes O
intracellular O
calcium O
stores O
. O

Our O
data O
are O
the O
first O
to O
demonstrate O
a O
role O
for O
HTLV O
- O
1 O
p12 O
( O
I O
) O
in O
calcium O
- O
dependent O
activation O
of O
NFAT O
- O
mediated O
transcription O
in O
lymphoid O
cells O
. O

Among O
65 O
samples O
obtained O
from O
a O
primate O
rescue O
center O
located O
in O
Cameroon O
, O
two O
female O
adult O
red O
- O
capped O
mangabeys O
( O
Cercocebus O
torquatus O
) O
( O
CTO O
- O
602 O
and O
CTO O
- O
604 O
) O
, O
of O
wild O
- O
caught O
origin O
, O
had O
a O
peculiar O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
2 I
( I
HTLV I
- I
2 I
) I
- O
like O
Western O
blot O
seroreactivity O
( O
p24 O
, O
RGD21 O
, O
+ O
/ O
- O
K55 O
) O
. O

Analyses O
of O
the O
simian B
T I
- I
cell I
lymphotropic I
virus I
type I
3 I
( I
STLV I
- I
3 I
) I
/ O
CTO O
- O
604 O
complete O
proviral O
sequence O
( O
8 O
, O
919 O
bp O
) O
indicated O
that O
this O
novel O
strain O
was O
highly O
divergent O
from O
HTLV O
- O
1 O
( O
60 O
% O
nucleotide O
similarity O
) O
, O
HTLV O
- O
2 O
( O
62 O
% O
) O
, O
or O
STLV O
- O
2 O
( O
62 O
% O
) O
prototypes O
. O

It O
was O
, O
however O
, O
related O
to O
STLV O
- O
3 O
/ O
PH O
- O
969 O
( O
87 O
% O
) O
, O
a O
divergent O
STLV O
strain O
previously O
isolated O
from O
an O
Eritrean O
baboon O
. O

In O
all O
phylogenetic O
analyses O
, O
STLV O
- O
3 O
/ O
CTO O
- O
604 O
and O
STLV O
- O
3 O
/ O
PH O
- O
969 O
clustered O
in O
a O
highly O
supported O
single O
clade O
, O
indicating O
an O
evolutionary O
lineage O
independent O
from O
primate B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
PTLV I
- I
1 I
) I
and O
PTLV O
- O
2 O
. O

The O
presence O
of O
two O
related O
viruses O
in O
evolutionarily O
distantly O
related O
African O
monkeys O
species O
, O
living O
in O
two O
opposite O
ecosystems O
( O
rain O
forest O
versus O
desert O
) O
, O
reinforces O
the O
possible O
African O
origin O
of O
PTLV O
and O
opens O
new O
avenues O
regarding O
the O
search O
for O
a O
possible O
human O
counterpart O
of O
these O
viruses O
in O
individuals O
exhibiting O
such O
HTLV O
- O
2 O
- O
like O
seroreactivities O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
suggested O
to O
cause O
adult O
T O
- O
cell O
leukemia O
after O
40 O
to O
50 O
years O
of O
latency O
in O
a O
small O
percentage O
of O
carriers O
, O
However O
, O
little O
is O
known O
about O
the O
pathophysiology O
of O
the O
latent O
period O
and O
the O
reservoir O
organs O
where O
polyclonal O
proliferation O
of O
cells O
harboring O
integrated O
provirus O
occurs O
, O
The O
availability O
of O
animal O
models O
would O
be O
useful O
to O
analyze O
the O
latent O
period O
of O
HTLV O
- O
1 O
infection O
. O

No O
more O
than O
around O
100 O
proviruses O
were O
found O
per O
10 O
( O
5 O
) O
spleen O
cells O
. O

Cellular O
sequences O
flanking O
the O
3 O
' O
long B
terminal I
repeat I
( I
LTR I
) I
and O
the O
clonalities O
of O
the O
cells O
which O
harbor O
integrated O
HTLV O
- O
1 O
provirus O
were O
analyzed O
hy O
linker O
- O
mediated O
PCR O
, O
The O
results O
showed O
that O
the O
flanking O
sequences O
are O
of O
mouse O
genome O
origin O
and O
that O
polyclonal O
proliferation O
of O
the O
spleen O
cells O
harboring O
integrated O
HTLV O
- O
1 O
provirus O
had O
occurred O
in O
three O
mice O
. O

Expression O
of O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
oncoprotein O
Tax O
is O
correlated O
with O
cellular O
transformation O
contributing O
to O
the O
development O
of O
adult O
T O
- O
cell O
leukemia O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
we O
observed O
that O
Tax O
altered O
the O
formation O
of O
a O
complex O
( O
es O
) O
at O
the O
cyclin O
A O
promoter O
- O
derived O
ATF O
site O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
. O

These O
mice O
develop O
primary O
, O
peripheral O
tumors O
consisting O
of O
large B
granular I
lymphocytic I
( I
LGL I
) I
cells O
, O
which O
also O
infiltrate O
the O
lymph O
nodes O
, O
bone O
marrow O
, O
spleen O
, O
liver O
, O
and O
lungs O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
, O
is O
transmitted O
through O
breast O
milk O
and O
seminal O
fluid O
, O
which O
are O
rich O
in O
prostaglandins B
( I
PGs I
) I
, O
We O
demonstrate O
that O
PGE O
, O
upregulates O
the O
HTLV O
- O
1 O
long O
terminal O
repeat O
promoter O
through O
the O
protein O
kinase O
A O
pathway O
, O
induces O
replication O
of O
HTLV O
- O
1 O
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
derived O
from O
asymptomatic O
carriers O
, O
and O
enhances O
transmission O
of O
HTLV O
- O
1 O
to O
cord B
blood I
mononuclear I
cells I
( I
CBMC I
) I
, O
Furthermore O
, O
HTLV O
- O
1 O
Tax O
transactivates O
a O
promoter O
for O
cyclooxygenase O
2 O
, O
a O
PG O
synthetase O
, O
and O
induces O
PGE O
( O
2 O
) O
expression O
in O
PBMC O
or O
CBMC O
, O
Thus O
, O
HTLV O
- O
1 O
interacts O
with O
and O
benefits O
from O
PGs O
, O
constituents O
of O
its O
own O
vehicle O
for O
transmission O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
a O
complex O
retrovirus O
, O
causes O
adult O
T O
- O
cell O
lymphoma O
/ O
leukemia O
and O
is O
linked O
to O
a O
variety O
of O
immune O
- O
mediated O
disorders O
. O

The O
roles O
of O
proteins O
encoded O
in O
the O
pX O
open B
reading I
frame I
( I
ORF I
) I
II O
gene O
region O
in O
HTLV O
- O
1 O
replication O
or O
in O
mediating O
virus O
- O
associated O
diseases O
remain O
to O
be O
defined O
. O

A O
nucleus O
- O
localizing O
30 O
- O
kDa O
protein O
, O
p30 O
( O
II O
) O
, O
encoded O
within O
pX O
ORF O
II O
has O
limited O
homology O
with O
the O
POU O
family O
of O
transcription O
factors O
. O

Herein O
we O
have O
tested O
the O
transcriptional O
ability O
of O
p30 O
( O
II O
) O
in O
mammalian O
cells O
by O
using O
yeast O
Gal4 O
fusion O
protein O
vectors O
and O
transfection O
of O
luciferase O
reporter O
genes O
driven O
by O
CREB O
- O
responsive O
promoters O
. O

p30 O
( O
II O
) O
as O
a O
Gal4 O
DNA B
- I
binding I
domain I
( I
DBD I
) I
fusion O
protein O
transactivates O
Gal4 O
- O
driven O
luciferase O
reporter O
gene O
activity O
up O
to O
25 O
- O
fold O
in O
293 O
and O
HeLa O
- O
tat O
cells O
. O

We O
confirmed O
nuclear O
localization O
of O
p30 O
( O
II O
) O
and O
demonstrate O
dose O
- O
dependent O
binding O
of O
p30 O
( O
II O
) O
- O
Gal4 O
( O
DBD O
) O
to O
Gal4 O
DNA O
- O
binding O
sites O
. O

The O
transcriptional O
activity O
of O
p30 O
( O
II O
) O
- O
Gal4 O
( O
DBD O
) O
was O
independent O
of O
TATA O
box O
flanking O
sequences O
, O
as O
shown O
by O
using O
two O
different O
Gal4 O
reporter O
systems O
. O

Studies O
of O
selected O
p30 O
( O
II O
) O
mutants O
indicated O
that O
domains O
that O
mediate O
transcription O
are O
restricted O
to O
a O
central O
core O
region O
of O
the O
protein O
between O
amino O
acids O
62 O
and O
220 O
. O

Transfection O
of O
a O
p30 O
( O
II O
) O
- O
expressing O
plasmid O
repressed O
cellular O
CRE O
- O
driven O
reporter O
gene O
activity O
, O
with O
or O
without O
Tax O
expression O
. O

In O
contrast O
, O
p30 O
( O
II O
) O
at O
lower O
concentrations O
enhanced O
HTLV O
- O
1 O
long O
terminal O
repeat O
- O
driven O
reporter O
gene O
activity O
independent O
of O
Tax O
expression O
. O

These O
data O
are O
the O
first O
to O
demonstrate O
a O
transcriptional O
function O
for O
p30 O
( O
II O
) O
and O
suggest O
a O
mechanism O
by O
which O
this O
nuclear O
protein O
may O
influence O
HTLV O
- O
1 O
replication O
or O
cellular O
gene O
expression O
in O
vivo O
. O

Several O
studies O
have O
indicated O
that O
the O
genetic O
diversity O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
a O
virus O
associated O
with O
adult O
T O
- O
cell O
Leukemia O
, O
is O
significantly O
lower O
than O
that O
of O
other O
retroviruses O
, O
including O
that O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
To O
test O
whether O
HTLV O
- O
1 O
variation O
is O
lower O
than O
other O
retroviruses O
, O
a O
tractable O
vector O
system O
has O
been O
developed O
to O
measure O
reverse O
transcription O
accuracy O
in O
one O
round O
of O
HTLV O
- O
1 O
replication O
, O
This O
system O
consists O
of O
a O
HTLV O
- O
1 O
vector O
that O
contains O
a O
cassette O
, O
vith O
the O
neomycin O
phosphotransferase O
( O
neo O
) O
gene O
, O
a O
bacterial O
origin O
of O
DNA O
replication O
, O
and O
the O
lacZ O
alpha O
peptide O
gene O
region O
( O
the O
mutational O
target O
) O
. O

The O
in O
vivo O
mutation O
rate O
for O
HTLV O
- O
1 O
was O
determined O
to O
be O
7 O
x O
10 O
( O
- O
6 O
) O
mutations O
per O
target O
base O
pair O
per O
replication O
cycle O
. O

The O
HTLV O
- O
1 O
in O
vivo O
mutation O
rate O
is O
comparable O
to O
that O
of O
bovine B
leukemia I
virus I
( I
BLV I
) I
, O
another O
member O
of O
the O
HTLV O
/ O
BLV O
genus O
of O
retroviruses O
, O
and O
is O
about O
fourfold O
tower O
than O
that O
of O
HIV O
- O
1 O
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
and O
is O
associated O
with O
a O
variety O
of O
immune O
- O
mediated O
disorders O
. O

The O
role O
of O
four O
open B
reading I
frames I
( I
ORFs I
) I
, O
located O
between O
sa O
and O
the O
3 O
' O
long O
terminal O
repeat O
of O
HTLV O
- O
1 O
in O
mediating O
disease O
is O
not O
entirely O
dear O
. O

By O
differential O
splicing O
, O
ORF O
II O
encodes O
two O
proteins O
, O
p13 O
( O
II O
) O
and O
p30 O
( O
II O
) O
, O
both O
of O
which O
have O
not O
been O
functionally O
defined O
. O

p13 O
( O
II O
) O
localizes O
to O
mitochondria O
and O
may O
alter O
the O
configuration O
of O
the O
tubular O
network O
of O
this O
cellular O
organelle O
. O

p30 O
( O
II O
) O
localizes O
to O
the O
nucleolus O
and O
shares O
homology O
with O
the O
transcription O
factors O
Oct O
- O
1 O
and O
- O
2 O
, O
Pit O
- O
1 O
, O
and O
POU O
- O
M1 O
. O

Both O
p13 O
( O
II O
) O
and O
p30 O
( O
II O
) O
are O
dispensable O
for O
infection O
and O
immortalization O
of O
primary O
human O
and O
rabbit O
lymphocytes O
in O
vitro O
. O

Viral O
p19 O
antigen O
was O
transiently O
detected O
in O
ex O
vivo O
cultures O
of O
peripheral B
blood I
mononuclear I
tells I
( I
PBMC I
) I
from O
only O
two O
ACH O
. O

p30 O
( O
II O
) O
p13 O
( O
II O
) O
clone O
could O
provirus O
be O
consistently O
PCR O
amplified O
from O
extracted O
PBMC O
DNA O
and O
quantitative O
competitive O
PCR O
showed O
the O
proviral O
loads O
in O
PBMC O
from O
ACH O
. O

p30 O
( O
II O
) O
/ O
p13 O
( O
II O
) O
- O
infected O
rabbits O
to O
be O
dramatically O
ion O
er O
than O
the O
proviral O
loads O
in O
rabbits O
exposed O
to O
ACH O
. O

Our O
data O
indicate O
selected O
mutations O
in O
pX O
ORF O
II O
diminish O
the O
ability O
of O
HTLV O
- O
1 O
to O
maintain O
high O
viral O
loads O
in O
vivo O
and O
suggest O
an O
important O
function O
far O
p13 O
( O
II O
) O
and O
p30 O
( O
II O
) O
in O
viral O
pathogenesis O
. O

During O
the O
late O
phase O
of O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
, O
a O
severe O
lymphoproliferative O
disorder O
caused O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
leukemic O
cells O
no O
longer O
produce O
interleukin O
- O
2 O
, O
Several O
studies O
have O
reported O
the O
lack O
of O
the O
Src O
- O
like O
protein O
tyrosine O
kinase O
Lck O
and O
overexpression O
of O
Lyn O
and O
Fyn O
in O
these O
cells O
. O

In O
this O
report O
we O
demonstrate O
that O
, O
in O
addition O
to O
the O
downregulation O
of O
TCR O
, O
CD45 O
, O
and O
Lck O
( O
which O
are O
key O
components O
of O
T O
- O
cell O
activation O
) O
, O
HTLV O
- O
1 O
- O
infected O
cell O
lines O
demonstrate O
a O
large O
increase O
of O
FynB O
, O
a O
Fyn O
isoform O
usually O
poorly O
expressed O
in O
T O
cells O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
. O

We O
examined O
the O
effect O
of O
Tax O
activity O
on O
the O
growth O
of O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- O
dependent O
T O
- O
cell O
line O
CTLL O
- O
2 O
. O

However O
, O
both O
pathways O
were O
necessary O
for O
another O
transformation O
- O
related O
activity O
( O
colony O
formation O
in O
soft O
agar O
) O
of O
CTLL O
- O
2 O
/ O
Tax O
. O

The O
Tax O
transactivator O
protein O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
plays O
a O
central O
role O
in O
the O
activation O
of O
viral O
gene O
expression O
. O

bovine B
leukemia I
virus I
( I
BLV I
) I
and O
human O
T O
- O
celi O
leukemia O
virus O
types O
1 O
and O
2 O
( O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
) O
belong O
to O
the O
same O
subfamily O
of O
oncoviruses O
. O

Only O
a O
small O
percentage O
of O
human B
T I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
transformed O
cells O
carry O
p53 O
mutations O
, O
and O
mutated O
p53 O
genes O
have O
been O
found O
in O
only O
one O
- O
fourth O
of O
adult O
T O
- O
cell O
leukemia O
cases O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
an O
oncovirus O
that O
is O
clinically O
associated O
with O
adult O
T O
- O
cell O
leukemia O
. O

143 O
sec O
( O
- O
1 O
) O
at O
pH O
5 O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
for O
adult O
T O
- O
cell O
leukemia O
. O

Moreover O
, O
Tax O
inhibits O
p53 O
function O
by O
interfering O
with O
the O
activity O
of O
the O
N O
- O
terminal O
activation O
domain O
( O
amino O
acids O
1 O
to O
52 O
) O
. O

It O
has O
been O
reported O
recently O
that O
CD4 O
is O
a O
major O
component O
of O
the O
receptor O
for O
human B
herpesvirus I
7 I
( I
HHV I
- I
7 I
) I
, O
which O
has O
been O
newly O
identified O
as O
a O
T O
- O
lymphotropic O
virus O
. O

To O
investigate O
further O
the O
role O
of O
CD4 O
in O
HHV O
- O
7 O
infection O
, O
we O
examined O
the O
susceptibility O
to O
HHV O
- O
7 O
infection O
of O
various O
CD4 O
- O
negative O
or O
weakly O
positive O
cell O
lines O
into O
which O
the O
cDNA O
for O
CD4 O
was O
transferred O
using O
an O
adenovirus O
vector O
( O
Adex1CACD4 O
) O
. O

Because O
subcellular O
localization O
contributes O
importantly O
to O
protein O
function O
, O
we O
determined O
the O
compartment O
( O
s O
) O
within O
the O
cell O
in O
which O
Tax O
is O
found O
. O

A O
novel O
cellular O
gene O
termed O
SFA O
- O
1 O
was O
isolated O
by O
differential O
hybridization O
of O
a O
cDNA O
library O
, O
using O
probes O
obtained O
from O
an O
adult O
T O
- O
cell O
leukemia O
cell O
line O
in O
comparison O
with O
probes O
obtained O
from O
normal O
CD4 O
( O
+ O
) O
T O
cells O
and O
the O
MOLT O
- O
4 O
cell O
line O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
and O
is O
associated O
with O
a O
variety O
of O
immunoregulatory O
disorders O
. O

However O
, O
both O
in O
vivo O
and O
in O
vitro O
, O
the O
provirus O
is O
mostly O
detected O
in O
and O
preferentially O
transforms O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
molecular O
mechanism O
that O
determines O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
tropism O
of O
HTLV O
- O
1 O
has O
not O
been O
determined O
. O

Using O
cocultures O
of O
purified O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
with O
an O
HTLV O
- O
1 O
- O
producing O
cell O
line O
, O
we O
measured O
viral O
transcription O
by O
using O
Northern O
( O
RNA O
) O
blot O
analysis O
, O
protein O
production O
by O
using O
a O
p24 O
antigen O
capture O
assay O
and O
how O
cytometric O
analysis O
for O
viral O
envelope O
, O
and O
proviral O
integration O
by O
using O
DNA O
slot O
blot O
analysis O
. O

We O
further O
measured O
HTLV O
- O
1 O
long O
terminal O
repeat O
- O
directed O
transcription O
in O
purified O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
by O
using O
transient O
transfection O
assays O
and O
in O
vitro O
transcription O
. O

We O
demonstrate O
a O
higher O
rate O
of O
viral O
transcription O
in O
primary O
CD4 O
( O
+ O
) O
T O
cells O
than O
in O
CD8 O
( O
+ O
) O
T O
cells O
. O

HTLV O
- O
1 O
protein O
production O
was O
5 O
- O
to O
25 O
- O
fold O
greater O
in O
CD4 O
( O
+ O
) O
cocultures O
and O
mRNA O
levels O
were O
5 O
- O
fold O
greater O
in O
these O
cultures O
than O
in O
the O
CD8 O
( O
+ O
) O
cocultures O
. O

Transient O
transfection O
and O
in O
vitro O
transcription O
indicated O
a O
modest O
increase O
in O
basal O
transcription O
in O
CD4 O
( O
+ O
) O
T O
cells O
, O
whereas O
there O
was O
a O
20 O
- O
fold O
increase O
in O
reporter O
gene O
activity O
in O
CD4 O
( O
+ O
) O
T O
cells O
cotransfected O
with O
tax O
. O

These O
data O
suggest O
that O
unique O
or O
activated O
transcription O
factors O
, O
particularly O
Tax O
- O
responsive O
factors O
in O
CD4 O
( O
+ O
) O
T O
cells O
, O
recognize O
regulatory O
sequences O
within O
the O
HTLV O
- O
1 O
long O
terminal O
repeat O
, O
and O
this O
mediates O
the O
observed O
enhanced O
viral O
transcription O
and O
ultimately O
the O
cell O
tropism O
and O
leukemogenic O
potential O
of O
the O
virus O
. O

Paradoxically O
, O
recovery O
in O
mice O
immunized O
with O
a O
chimeric O
envelope O
containing O
only O
T O
- O
helper O
( O
T O
- O
H O
) O
and O
B O
- O
cell O
epitopes O
was O
dependent O
on O
CD8 O
( O
+ O
) O
T O
cells O
as O
well O
as O
CD4 O
( O
+ O
) O
T O
cells O
despite O
the O
fact O
that O
the O
vaccine O
contained O
no O
CD8 O
( O
+ O
) O
cytolytic B
T I
- I
Lymphocyte I
( I
CTL I
) I
epitopes O
, O
However O
, O
the O
requirement O
for O
CD8 O
( O
+ O
) O
T O
cells O
was O
overcome O
by O
inclusion O
of O
additional O
T O
- O
H O
and O
B O
- O
cell O
epitopes O
in O
the O
immunizing O
protein O
. O

These O
additional O
epitopes O
primed O
for O
more O
rapid O
production O
of O
virus O
- O
neutralizing O
antibody O
which O
appeared O
to O
limit O
virus O
spread O
sufficiently O
to O
protect O
even O
in O
the O
absence O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

Inclusion O
of O
an O
immunodominant O
CTL O
epitope O
in O
the O
vaccine O
was O
not O
sufficient O
to O
overcome O
dependence O
on O
CD4 O
( O
+ O
) O
T O
cells O
, O
These O
data O
suggest O
that O
T O
- O
H O
priming O
is O
more O
critical O
for O
retrovirus O
immunity O
than O
CTL O
priming O
. O

Previous O
studies O
of O
Cas O
Br O
- O
M O
murine B
leukemia I
virus I
( I
MuLV I
) I
( O
Cas O
- O
MuLV O
) O
infection O
demonstrated O
that O
cytotoxic B
T I
cells I
( I
CTL I
) I
of O
the O
CD8 O
( O
+ O
) O
phenotype O
play O
a O
role O
in O
resistance O
to O
the O
neuropathogenic O
effects O
of O
the O
virus O
in O
NFS O
/ O
N O
mice O
, O
In O
the O
current O
study O
, O
we O
sought O
to O
identify O
the O
Cas O
- O
MuLV O
epitopes O
that O
are O
immunogenic O
for O
the O
CTL O
response O
, O
Infection O
of O
adult O
NPS O
/ O
N O
mice O
with O
a O
well O
- O
characterized O
neuropathogenic O
variant O
of O
Friend O
MuLV O
, O
PVC O
- O
211 O
MuLV O
( O
PVC O
- O
MuLV O
) O
, O
was O
not O
immunogenic O
for O
MuLV O
- O
specific O
CTL O
. O

Infectious O
chimeras O
contained O
the O
Cas O
- O
MuLV O
env O
gene O
on O
a O
PVC O
- O
MuLV O
background O
( O
PVC O
- O
Cas O
- O
( O
env O
) O
MuLV O
) O
and O
the O
PVC O
- O
MuLV O
env O
gene O
on O
a O
Cas O
- O
MuLV O
background O
( O
Cas O
- O
PVC O
( O
env O
) O
MuLV O
) O
. O

Cas O
- O
MuLV O
- O
specific O
CTL O
were O
found O
following O
inoculation O
of O
both O
the O
chimeric O
viruses O
and O
the O
parental O
Cas O
- O
MuLV O
but O
not O
the O
parental O
PVC O
- O
MuLV O
, O
despite O
evidence O
of O
antibody O
responses O
to O
both O
parental O
and O
chimeric O
MuLV O
, O
CTL O
generated O
in O
response O
to O
infection O
with O
PVC O
- O
Cas O
( O
env O
) O
MuLV O
and O
Cas O
- O
PVC O
( O
env O
) O
MuLV O
were O
exclusively O
of O
the O
CD8 O
( O
+ O
) O
phenotype O
. O

Mouse B
AIDS I
( I
MAIDS I
) I
develops O
in O
mice O
infected O
with O
a O
mixture O
of O
replication O
- O
competent O
ecotropic O
and O
mink O
lung O
cell O
focus O
- O
inducing O
murine O
leukemia O
viruses O
and O
an O
etiologic O
replication O
- O
defective O
virus O
. O

Helper O
viruses O
are O
not O
required O
for O
induction O
of O
MAIDS O
, O
but O
the O
time O
course O
of O
disease O
is O
accelerated O
in O
their O
presence O
, O
To O
understand O
the O
possible O
contributions O
of O
ecotropic O
murine O
leukemia O
viruses O
to O
MAIDS O
pathogenesis O
, O
we O
biologically O
cloned O
a O
series O
of O
viruses O
from O
the O
MAIDS O
- O
inducing O
LP O
- O
BM5 O
virus O
mixture O
, O
These O
viruses O
were O
examined O
for O
replication O
in O
tissues O
of O
infected O
mice O
and O
for O
effects O
on O
the O
immune O
system O
, O
All O
virus O
stocks O
replicated O
efficiently O
in O
mice O
, O
Infected O
animals O
showed O
slight O
lymphadenopathy O
and O
splenomegaly O
due O
primarily O
to O
B O
- O
cell O
proliferation O
associated O
with O
differentiation O
to O
immunoglobulin O
secretion O
resulting O
in O
twofold O
increases O
in O
serum O
immunoglobulin O
M O
levels O
; O
however O
, O
B O
- O
cell O
responses O
to O
helper O
T O
- O
cell O
- O
independent O
antigens O
were O
increased O
rather O
than O
decreased O
as O
in O
MAIDS O
, O
Analyses O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
function O
showed O
that O
cytotoxic O
T O
- O
lymphocyte O
responses O
to O
alloantigens O
were O
comparable O
in O
control O
and O
infected O
mice O
, O
Finally O
, O
we O
showed O
that O
infection O
resulted O
in O
enhanced O
expression O
of O
transcripts O
for O
interleukin O
- O
10 O
, O
interleukin O
- O
4 O
, O
and O
gamma O
interferon O
, O
These O
cytokines O
can O
ail O
contribute O
to O
B O
- O
cell O
activation O
and O
may O
promote O
the O
expansion O
of O
a O
target O
cell O
population O
for O
the O
MAIDS O
defective O
virus O
. O

human B
T I
- I
cell I
leukemia I
virus I
( I
HTLV I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
a O
malignancy O
of O
T O
lymphocytes O
that O
is O
characterized O
by O
a O
long O
latency O
period O
after O
virus O
exposure O
. O

Intraperitoneal O
inoculation O
of O
severe B
combined I
immunodeficient I
( I
SCID I
) I
mice O
with O
HTLV O
- O
transformed O
cell O
lines O
and O
ATL O
tumor O
cells O
was O
employed O
to O
investigate O
the O
tumorigenic O
potential O
of O
HTLV O
type O
I O
( O
HTLV O
- O
I O
) O
infected O
cells O
. O

In O
contrast O
to O
inoculation O
of O
ATL O
( O
RV O
- O
ATL O
) O
cells O
into O
SCID O
mice O
, O
which O
resulted O
in O
the O
formation O
of O
lymphomas O
, O
inoculation O
of O
HTLV O
- O
I O
- O
and O
HTLV O
- O
II O
- O
transformed O
cell O
lines O
( O
SLB O
- O
I O
and O
JLB O
- O
II O
cells O
, O
respectively O
) O
did O
not O
result O
in O
tumor O
formation O
. O

Immunosuppression O
of O
SCID O
mice O
, O
either O
by O
whole O
- O
body O
irradiation O
or O
by O
treatment O
with O
an O
antiserum O
, O
anti O
- O
asialo O
GM O
( O
1 O
) O
( O
alpha O
- O
AGM O
( O
1 O
) O
) O
, O
which O
transiently O
abrogates O
natural O
killer O
cell O
activity O
in O
vivo O
, O
was O
necessary O
to O
establish O
the O
growth O
of O
tumors O
derived O
from O
HTLV O
- O
transformed O
cell O
lines O
. O

Using O
a O
panel O
of O
156 O
( O
Mus O
musculus O
X O
Mus O
spretus O
) O
X O
Mus O
musculus O
interspecific O
backcross O
mice O
, O
we O
mapped O
Tpl O
- O
1 O
to O
mouse O
chromosome O
9 O
at O
a O
distance O
of O
1 O
. O

In O
this O
report O
, O
we O
present O
evidence O
that O
all O
the O
known O
Tpl O
- O
1 O
provirus O
insertions O
occurred O
immediately O
5 O
' O
of O
the O
first O
exon O
of O
Ets O
- O
1 O
( O
exon O
A O
) O
and O
that O
the O
earlier O
detected O
distance O
between O
Tpl O
- O
1 O
and O
Ets O
- O
1 O
was O
due O
to O
the O
high O
frequency O
of O
meiotic O
recombination O
in O
the O
region O
between O
the O
site O
of O
provirus O
integration O
and O
exon O
III O
. O

Northern O
( O
RNA O
) O
blot O
analysis O
of O
polyadenylated O
RNA O
from O
normal O
adult O
rat O
tissues O
and O
Moloney O
murine O
leukemia O
virus O
- O
induced O
T O
- O
cell O
lymphomas O
and O
hybridization O
to O
a O
Tpl O
- O
1 O
/ O
Ets O
- O
1 O
probe O
derived O
from O
the O
5 O
' O
end O
of O
the O
gene O
revealed O
two O
lymphoid O
cell O
- O
specific O
RNA O
transcripts O
, O
of O
5 O
. O

Sequence O
analysis O
of O
a O
near O
- O
full O
- O
length O
( O
4 O
, O
991 O
- O
bp O
) O
cDNA O
clone O
of O
the O
5 O
. O

Expression O
of O
the O
parathyroid B
hormone I
- I
related I
protein I
( I
PTHrP I
) I
, O
a O
protein O
that O
plays O
a O
primary O
role O
in O
the O
development O
of O
the O
humoral O
hypercalcemia O
of O
malignancy O
, O
is O
regulated O
by O
two O
distinct O
promoters O
, O
P1 O
and O
P2 O
. O

By O
using O
deletion O
and O
site O
- O
specific O
point O
mutations O
, O
we O
have O
identified O
a O
promoter O
- O
proximal O
sequence O
( O
positions O
- O
72 O
to O
- O
40 O
) O
which O
is O
important O
for O
Tax1 O
transactivation O
. O

Infection O
with O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
adult O
T O
- O
cell O
lymphoma O
/ O
leukemia O
. O

Similarly O
, O
mutation O
of O
the O
peri O
- O
ets O
( O
pets O
) O
site O
, O
not O
previously O
noted O
in O
the O
HTLV O
- O
I O
enhancer O
, O
markedly O
inhibits O
inducible O
enhancer O
function O
but O
not O
Tax O
response O
. O

Southern O
blot O
and O
karyotype O
analyses O
revealed O
that O
WLeuk O
- O
1 O
cells O
had O
retained O
the O
marker O
chromosomes O
and O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
integration O
patterns O
of O
the O
parent O
cell O
line O
, O
TARS O
- O
1 O
. O

The O
additional O
specific O
chromosome O
abnormalities O
3p O
+ O
, O
t O
( O
12 O
; O
13 O
) O
, O
and O
Xq O
+ O
were O
found O
in O
the O
WLeuk O
- O
1 O
cells O
. O

Using O
cellular O
sequences O
flanking O
a O
provirus O
cloned O
from O
one O
of O
these O
thymomas O
, O
we O
found O
that O
the O
viral O
genome O
was O
integrated O
into O
a O
common O
region O
, O
designated O
Vin O
- O
1 O
, O
in O
a O
low O
percentage O
( O
5 O
% O
) O
of O
these O
tumors O
. O

The O
Tax O
protein O
of O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
serves O
as O
a O
potent O
transcriptional O
activator O
of O
its O
own O
long O
terminal O
repeat O
as O
well O
as O
select O
cellular O
genes O
, O
including O
interleukin O
- O
2 O
and O
the O
alpha O
subunit O
of O
the O
interleukin O
- O
2 O
receptor O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
, O
and O
the O
clonally O
derived O
leukemic O
cells O
all O
contain O
proviral O
genomes O
. O

Polymerase O
chain O
reaction O
with O
a O
variety O
of O
primers O
which O
span O
the O
HTLV O
- O
I O
genome O
was O
used O
to O
determine O
that O
a O
significant O
fraction O
of O
patients O
( O
at O
least O
32 O
% O
) O
carry O
deleted O
viral O
genomes O
in O
their O
leukemic O
cells O
. O

An O
autocrine O
mechanism O
of O
proliferation O
may O
play O
a O
significant O
role O
in O
the O
leukemogenesis O
of O
adult O
T O
- O
cell O
leukemia O
, O
a O
mature O
T O
- O
cell O
malignancy O
caused O
by O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
. O

To O
further O
delineate O
the O
role O
of O
HTLV O
- O
I O
and O
the O
interleukin B
2 I
( I
IL2 I
) I
system O
in O
the O
transformation O
process O
, O
human O
primary O
lymphocytes O
were O
infected O
by O
cocultivation O
with O
lethally O
X O
- O
irradiated O
MT2 O
cells O
in O
the O
presence O
or O
absence O
of O
human O
rIL2 O
; O
the O
polymerase O
chain O
amplification O
reaction O
was O
used O
to O
examine O
quantitatively O
the O
expression O
of O
HTLV O
- O
I O
, O
IL2 O
, O
and O
IL2R O
alpha O
mRNAs O
during O
early O
and O
late O
proliferation O
phases O
that O
displayed O
polyclonal O
( O
days O
7 O
to O
49 O
) O
and O
oligoclonal O
( O
days O
100 O
to O
150 O
) O
proviral O
integration O
, O
respectively O
. O

human B
T I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
ethological O
agent O
of O
adult B
T I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
and O
a O
number O
of O
lymphocyte O
- O
mediated O
inflammatory O
conditions O
, O
including O
HTLV O
- O
1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
. O

In O
macaques O
, O
the O
ablation O
of O
orf O
- O
I O
expression O
by O
mutation O
of O
its O
ATG O
initiation O
codon O
abolishes O
the O
infectivity O
of O
the O
molecular O
clone O
HTLV O
- O
1 O
( O
p12KO O
) O
. O

In O
rabbits O
, O
HTLV O
- O
1 O
( O
p12KO O
) O
is O
infective O
and O
persists O
efficiently O
. O

We O
used O
humanized O
mouse O
models O
to O
assess O
the O
infectivity O
of O
both O
wild O
- O
type O
HTLV O
- O
1 O
( O
HTLV O
- O
1 O
( O
WT O
) O
) O
and O
HTLV O
- O
1 O
( O
p12KO O
) O
. O

We O
found O
that O
NOD O
/ O
SCID O
/ O
gamma O
( O
- O
/ O
- O
) O
( O
C O
) O
c O
- O
kit O
( O
+ O
) O
. O

mice O
engrafted O
with O
human O
tissues O
1 O
day O
after O
birth O
( O
designated O
NSG O
- O
1d O
mice O
) O
were O
highly O
susceptible O
to O
infection O
by O
HTLV O
- O
1 O
( O
WT O
) O
, O
with O
a O
syndrome O
characterized O
by O
the O
rapid O
polyclonal O
proliferation O
and O
infiltration O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
into O
vital O
organs O
, O
weight O
loss O
, O
and O
death O
. O

HTLV O
- O
1 O
( O
p12KO O
) O
infection O
in O
a O
bone B
marrow I
- I
liver I
- I
thymus I
( I
BLT I
) I
mouse O
model O
prone O
to O
graft O
- O
versus O
- O
host O
disease O
occurred O
only O
following O
reversion O
of O
the O
orf O
- O
I O
initiation O
codon O
mutation O
within O
weeks O
after O
exposure O
and O
was O
associated O
with O
high O
levels O
of O
HTLV O
- O
1 O
DNA O
in O
blood O
and O
the O
expansion O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
. O

IMPORTANCE O
Humanized O
mice O
constitute O
a O
useful O
model O
for O
studying O
the O
HTLV O
- O
1 O
- O
associated O
polyclonal O
proliferation O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
viral O
integration O
sites O
in O
the O
human O
genome O
. O

Nevertheless O
, O
the O
expansion O
of O
multiple O
clones O
of O
low O
abundance O
in O
these O
humanized O
mice O
mirrors O
the O
early O
phase O
of O
HTLV O
- O
1 O
infection O
in O
humans O
, O
providing O
a O
useful O
model O
to O
investigate O
approaches O
to O
inhibit O
virus O
- O
induced O
CD4 O
( O
+ O
) O
T O
cell O
proliferation O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
causes O
T O
- O
cell O
leukemia O
and O
inflammatory O
diseases O
, O
most O
notably O
including O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

According O
to O
a O
recent O
clinical O
trial O
, O
a O
humanized O
antibody O
that O
targets O
CCR4 O
( O
+ O
) O
cells O
ameliorates O
inflammation O
by O
reducing O
the O
number O
of O
infected O
cells O
in O
the O
central O
nervous O
system O
; O
this O
result O
suggests O
that O
the O
transmigration O
of O
HTLV O
- O
1 O
- O
infected O
cells O
plays O
a O
crucial O
role O
in O
HAM O
/ O
TSP O
. O

pentosan B
polysulfate I
( I
PPS I
) I
, O
a O
semisynthetic O
glycosaminoglycan O
, O
has O
recently O
been O
used O
to O
treat O
HAM O
/ O
TSP O
and O
was O
found O
to O
alleviate O
the O
symptoms O
. O

In O
addition O
, O
PPS O
blocked O
HTLV O
- O
1 O
infection O
of O
primary O
endothelial O
cells O
( O
human O
umbilical O
vascular O
endothelial O
cells O
) O
and O
suppressed O
the O
subsequent O
induction O
of O
proinflammatory O
cytokine O
expression O
. O

PPS O
blocked O
HTLV O
- O
1 O
infection O
in O
a O
mouse O
model O
with O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
- O
humanized O
NOD O
- O
scid O
IL2Rgamma O
( O
null O
) O
( O
huPBMC O
NSG O
) O
mice O
. O

PPS O
was O
also O
found O
to O
suppress O
the O
development O
of O
dermatitis O
and O
lung O
damage O
in O
HTLV B
- I
1 I
bZIP I
factor I
( I
HBZ I
) I
- O
transgenic O
( O
HBZ O
- O
Tg O
) O
mice O
, O
an O
HTLV O
- O
1 O
transgenic O
mouse O
model O
in O
which O
the O
mice O
develop O
systemic O
inflammation O
. O

There O
have O
been O
no O
effective O
therapeutics O
available O
for O
HAM O
/ O
TSP O
, O
but O
recently O
, O
a O
semisynthetic O
glycosaminoglycan O
, O
named O
pentosan B
polysulfate I
( I
PPS I
) I
, O
has O
been O
found O
to O
alleviate O
the O
symptoms O
of O
HAM O
/ O
TSP O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
a O
slowly O
progressive O
neurodegenerative O
disease O
, O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

The O
central O
nervous O
system O
is O
normally O
protected O
by O
a O
physiological O
structure O
called O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
, O
which O
consists O
primarily O
of O
a O
continuous O
endothelium O
with O
tight O
junctions O
. O

In O
this O
study O
, O
we O
investigated O
the O
role O
of O
activated O
leukocyte O
cell O
adhesion O
molecule O
( O
ALCAM O
/ O
CD166 O
) O
, O
a O
member O
of O
the O
immunoglobulin O
superfamily O
, O
in O
the O
crossing O
of O
the O
BBB O
by O
HTLV O
- O
1 O
- O
infected O
lymphocytes O
. O

We O
demonstrated O
that O
ALCAM O
is O
overexpressed O
on O
the O
surface O
of O
HTLV O
- O
1 O
- O
infected O
lymphocytes O
, O
both O
in O
chronically O
infected O
cell O
lines O
and O
in O
primary O
infected O
CD4 O
( O
+ O
) O
T O
lymphocytes O
. O

IMPORTANCE O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
of O
a O
slowly O
progressive O
neurodegenerative O
disease O
, O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

This O
disease O
is O
the O
consequence O
of O
the O
infiltration O
of O
HTLV O
- O
1 O
- O
infected O
lymphocytes O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
mostly O
the O
thoracic O
spinal O
cord O
. O

The O
CNS O
is O
normally O
protected O
by O
a O
physiological O
structure O
called O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
, O
which O
consists O
primarily O
of O
a O
continuous O
endothelium O
with O
tight O
junctions O
. O

Here O
, O
we O
show O
that O
the O
viral O
transactivator O
Tax O
increases O
activated O
leukocyte O
cell O
adhesion O
molecule O
( O
ALCAM O
/ O
CD166 O
) O
expression O
. O

There O
are O
currently O
5 O
million O
to O
10 O
million O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
infected O
people O
, O
and O
many O
of O
them O
will O
develop O
severe O
complications O
resulting O
from O
this O
infection O
. O

As O
a O
first O
step O
in O
designing O
an O
effective O
HTLV O
- O
1 O
vaccine O
, O
we O
defined O
the O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
response O
against O
simian B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
STLV I
- I
1 I
) I
, O
a O
virus O
closely O
related O
to O
HTLV O
- O
1 O
, O
in O
olive O
baboons O
( O
Papio O
anubis O
) O
. O

Consistent O
with O
persistent O
antigenic O
exposure O
, O
we O
observed O
that O
STLV O
- O
1 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
displayed O
an O
effector O
memory O
phenotype O
and O
usually O
expressed O
CD107a O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

Our O
results O
show O
that O
, O
similarly O
to O
humans O
, O
the O
baboon O
CD8 O
( O
+ O
) O
T O
cell O
response O
narrowly O
targeted O
the O
Tax O
protein O
. O

Infection O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
tropical O
spastic O
paraparesis O
. O

type B
I I
interferons I
( I
IFNs I
) I
are O
key O
effectors O
of O
the O
innate O
antiviral O
response O
, O
and O
IFN O
- O
alpha O
combined O
with O
the O
nucleoside O
reverse O
transcriptase O
inhibitor O
zidovudine O
is O
considered O
the O
standard O
first O
- O
line O
therapy O
for O
ATL O
. O

IMPORTANCE O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
cause O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
an O
aggressive O
and O
fatal O
blood O
cancer O
, O
as O
well O
as O
another O
chronic O
disabling O
disease O
of O
the O
spinal O
cord O
. O

Because O
the O
viral O
DNA O
burden O
correlates O
with O
disease O
development O
, O
we O
investigated O
the O
contribution O
of O
monocyte O
subsets O
( O
classical O
, O
intermediate O
, O
and O
nonclassical O
monocytes O
) O
to O
the O
total O
viral O
burden O
in O
22 O
human B
T I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
infected O
individuals O
by O
assessing O
their O
infectivity O
status O
, O
frequency O
, O
as O
well O
as O
chemotactic O
and O
phagocytic O
functions O
. O

The O
level O
of O
viral O
DNA O
in O
the O
monocyte O
subsets O
correlated O
with O
the O
capacity O
to O
migrate O
to O
CCL2 O
, O
CCL5 O
, O
and O
CX3CL1 O
for O
classical O
monocytes O
, O
with O
lower O
levels O
of O
phagocytosis O
for O
intermediate O
monocytes O
, O
and O
with O
the O
level O
of O
viral O
DNA O
in O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
for O
nonclassical O
monocytes O
. O

These O
data O
suggest O
a O
model O
whereby O
HTLV O
- O
1 O
infection O
augments O
the O
number O
of O
classical O
monocytes O
that O
migrate O
to O
tissues O
and O
become O
infected O
and O
the O
number O
of O
infected O
nonclassical O
monocytes O
that O
transmit O
virus O
to O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

The O
viral O
DNA O
level O
in O
nonclassical O
monocytes O
correlated O
with O
the O
viral O
DNA O
level O
in O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
and O
dendritic B
cells I
( I
DCs I
) I
are O
present O
in O
peripheral O
blood O
from O
HTLV O
- O
1 O
carriers O
. O

We O
first O
determined O
that O
human O
primary O
monocyte B
- I
derived I
dendritic I
cells I
( I
mdDCs I
) I
were O
more O
susceptible O
to O
HTLV O
- O
1 O
infection O
than O
their O
autologous O
lymphocyte O
counterparts O
after O
contact O
with O
chronically O
infected O
cells O
. O

Using O
a O
large O
series O
of O
primary O
cell O
samples O
( O
n O
= O
21 O
) O
, O
we O
demonstrated O
a O
higher O
proviral O
load O
in O
MDDCs O
exposed O
to O
viral O
biofilm O
than O
in O
lymphocytes O
. O

However O
, O
during O
the O
primo O
- O
infection O
of O
new O
individuals O
, O
incoming O
viruses O
might O
first O
encounter O
dendritic B
cells I
( I
DCs I
) I
, O
the O
specialized O
immune O
cells O
responsible O
for O
the O
antiviral O
response O
of O
the O
host O
. O

Interaction O
of O
the O
envelope B
glycoprotein I
( I
Env I
) I
of O
Human B
T I
- I
lymphotropic I
virus I
1 I
( I
HTLV I
- I
1 I
) I
with O
the O
glucose O
transporter O
type O
1 O
( O
GLUT1 O
) O
expressed O
in O
target O
cells O
is O
essential O
for O
viral O
entry O
. O

Chimeric O
studies O
between O
GLUT1 O
and O
GLUT3 O
indicated O
that O
the O
extracellular B
loop I
6 I
( I
ECL6 I
) I
of O
GLUT1 O
is O
important O
for O
the O
inhibition O
of O
cell O
- O
cell O
fusion O
mediated O
by O
Env O
. O

When O
GLUT1 O
was O
translocated O
into O
the O
plasma O
membrane O
from O
intracellular O
storage O
sites O
by O
bafilomycin O
A1 O
( O
BFLA1 O
) O
treatment O
in O
293T O
cells O
, O
HTLV O
- O
1 O
Env O
- O
mediated O
cell O
fusion O
and O
infection O
also O
were O
inhibited O
without O
the O
overexpression O
of O
GLUT1 O
, O
indicating O
that O
the O
localization O
of O
GLUT1 O
in O
intracellular O
compartments O
rather O
than O
in O
the O
plasma O
membrane O
is O
crucial O
for O
the O
fusion O
activity O
of O
HTLV O
- O
1 O
Env O
. O

Western O
blot O
analyses O
of O
FLAG O
- O
tagged O
HTLV O
- O
1 O
Env O
in O
virus O
- O
producing O
cells O
and O
the O
incorporation O
of O
HTLV O
- O
1 O
Env O
in O
virus B
- I
like I
particles I
( I
VLPs I
) I
indicate O
that O
the O
processing O
of O
Env O
is O
inhibited O
by O
either O
overexpression O
of O
GLUT1 O
or O
BFLA1 O
treatment O
in O
virus O
- O
producing O
293T O
cells O
. O

IMPORTANCE O
The O
deltaretrovirus O
HTLV O
- O
1 O
is O
a O
causative O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
complex O
human O
retrovirus O
that O
causes O
adult O
T O
cell O
leukemia O
and O
of O
HTLV O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
. O

The O
mRNA O
of O
some O
complex O
retroviruses O
, O
including O
the O
human O
and O
simian O
immunodeficiency O
viruses O
( O
HIV O
and O
SIV O
) O
, O
can O
initiate O
translation O
using O
a O
canonical O
cap O
- O
dependent O
mechanism O
or O
through O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

In O
this O
study O
, O
we O
present O
strong O
evidence O
showing O
that O
like O
HIV O
- O
1 O
and O
SIV O
, O
the O
5 B
' I
- I
untranslated I
region I
( I
5 I
' I
UTR I
) I
of O
the O
HTLV O
- O
1 O
full O
- O
length O
mRNA O
harbors O
an O
IRES O
. O

Characterization O
of O
the O
HTLV O
- O
1 O
IRES O
shows O
that O
its O
activity O
is O
dependent O
on O
the O
ribosomal B
protein I
S25 I
( I
RPS25 I
) I
and O
that O
its O
function O
is O
highly O
sensitive O
to O
the O
drug O
edeine O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
Tax O
protein O
is O
considered O
to O
play O
a O
central O
role O
in O
the O
process O
that O
leads O
to O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
and O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

HTLV O
- O
1 O
Tax O
- O
expressing O
cells O
show O
resistance O
to O
apoptosis O
induced O
by O
Fas B
ligand I
( I
FasL I
) I
and O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
related O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
. O

Here O
, O
we O
report O
that O
HTLV O
- O
1 O
Tax O
deregulates O
the O
autophagy O
pathway O
, O
which O
plays O
a O
protective O
role O
during O
the O
death B
receptor I
( I
DR I
) I
mediated O
apoptosis O
of O
human O
U251 O
astroglioma O
cells O
. O

The O
cellular O
FLICE O
- O
inhibitory O
protein O
( O
c O
- O
FLIP O
) O
, O
which O
is O
upregulated O
by O
Tax O
, O
also O
contributes O
to O
the O
resistance O
against O
DR O
- O
mediated O
apoptosis O
. O

Both O
Tax O
- O
induced O
autophagy O
and O
Tax O
- O
induced O
c O
- O
FLIP O
expression O
require O
Tax O
- O
induced O
activation O
of O
I B
kappa I
B I
kinases I
( I
IKK I
) I
. O

The O
human B
T I
- I
cell I
leukemia I
/ I
lymphoma I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
p30 O
protein O
, O
essential O
for O
virus O
infectivity O
in O
vivo O
, O
is O
required O
for O
efficient O
infection O
of O
human B
dendritic I
cells I
( I
DCs I
) I
but O
not O
B O
and O
T O
cells O
in O
vitro O
. O

p30 O
inhibited O
the O
expression O
of O
interferon B
( I
IFN I
) I
- O
responsive O
genes O
( O
ISG O
) O
following O
stimulation O
by O
lipopolysaccharide B
( I
LPS I
) I
of O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
and O
by O
poly O
( O
I O
. O

Results O
with O
THP O
- O
1 O
mirrored O
those O
for O
ex O
vivo O
human O
primary O
monocytes B
and I
monocyte I
- I
derived I
dendritic I
cells I
( I
Mo I
- I
mDC I
) I
. O

type B
I I
interferon I
( I
IFN I
- I
I I
) I
inhibits O
the O
replication O
of O
different O
viruses O
. O

However O
, O
the O
effect O
of O
IFN O
- O
I O
on O
the O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
viral O
cycle O
is O
controversial O
. O

We O
first O
show O
that O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
efficiently O
impairs O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
de O
novo O
infection O
in O
a O
T O
cell O
line O
and O
in O
primary O
lymphocytes O
. O

Using O
either O
small B
interfering I
RNA I
( I
siRNA I
) I
directed O
against O
PKR O
or O
a O
PKR O
inhibitor O
, O
we O
demonstrate O
that O
PKR O
, O
whose O
expression O
is O
induced O
by O
interferon O
, O
plays O
a O
major O
role O
in O
IFN O
- O
alpha O
- O
induced O
HTLV O
- O
1 O
/ O
2 O
inhibition O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
causative O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

This O
screen O
identified O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
as O
a O
new O
binding O
partner O
of O
Tax O
. O

Treatment O
of O
HTLV O
- O
1 O
- O
transformed O
cells O
with O
the O
HSP90 O
inhibitor O
17 O
- O
DMAG O
elicited O
proteasomal O
degradation O
of O
Tax O
in O
the O
nuclear O
matrix O
with O
concomitant O
inhibition O
of O
NF O
- O
kappa O
B O
and O
HTLV O
- O
1 O
long B
terminal I
repeat I
( I
LTR I
) I
activation O
. O

Permanent O
activation O
of O
the O
NF O
- O
kappa O
B O
pathway O
by O
the O
human B
T I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
Tax O
( O
Tax1 O
) O
viral O
transactivator O
is O
a O
key O
event O
in O
the O
process O
of O
HTLV O
- O
1 O
- O
induced O
T O
lymphocyte O
immortalization O
and O
leukemogenesis O
. O

Although O
encoding O
a O
Tax O
transactivator O
( O
Tax2 O
) O
that O
activates O
the O
canonical O
NF O
- O
kappa O
B O
pathway O
, O
HTLV O
- O
2 O
does O
not O
cause O
leukemia O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
complex O
retrovirus O
associated O
with O
the O
lymphoproliferative O
disease O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
and O
the O
neurodegenerative O
disorder O
tropical B
spastic I
paraparesis I
/ I
HTLV I
- I
1 I
- I
associated I
myelopathy I
( I
TSP I
/ I
HAM I
) I
. O

Previous O
studies O
suggested O
that O
Tax O
activates O
transcription O
from O
the O
viral O
long B
terminal I
repeat I
( I
LTR I
) I
through O
recruitment O
of O
cellular O
CREB O
and O
transcriptional O
coactivators O
. O

As O
opposed O
to O
HIV O
' O
s O
Rev B
- I
responsive I
element I
( I
RRE I
) I
, O
the O
Rex B
- I
responsive I
element I
( I
RxRE I
) I
is O
present O
in O
all O
viral O
mRNAs O
in O
HTLV O
- O
1 O
. O

RNA B
immunoprecipitation I
( I
RNA I
- I
IP I
) I
experiments O
confirmed O
Rex O
binding O
to O
the O
tax O
/ O
rex O
RNA O
in O
both O
transfected O
cells O
with O
HTLV O
- O
1 O
molecular O
clones O
and O
HTLV O
- O
1 O
- O
infected O
T O
cells O
. O

Despite O
the O
susceptibility O
of O
dendritic B
cells I
( I
DCs I
) I
to O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
and O
the O
defined O
role O
of O
these O
cells O
in O
disease O
pathogenesis O
, O
the O
mechanisms O
of O
viral O
binding O
to O
DCs O
have O
not O
been O
fully O
delineated O
. O

Recently O
, O
a O
glucose O
transporter O
, O
GLUT O
- O
1 O
, O
heparan B
sulfate I
proteoglycans I
( I
HSPGs I
) I
, O
and O
neuropilin B
- I
1 I
( I
NRP I
- I
1 I
) I
were O
demonstrated O
to O
facilitate O
HTLV O
- O
1 O
entry O
into O
T O
cells O
. O

DCs O
express O
their O
own O
array O
of O
antigen O
receptors O
, O
the O
most O
important O
being O
the O
DC O
- O
specific O
intercellular B
adhesion I
molecule I
- I
3 I
( I
ICAM I
- I
3 I
) I
- O
grabbing O
nonintegrin O
( O
DC O
- O
SIGN O
) O
with O
respect O
to O
retrovirus O
binding O
. O

Consequently O
, O
the O
role O
of O
DC O
- O
SIGN O
and O
other O
HTLV O
- O
1 O
attachment O
factors O
was O
analyzed O
in O
viral O
binding O
, O
transmission O
, O
and O
productive O
infection O
using O
monocyte B
- I
derived I
DCs I
( I
MDDCs I
) I
, O
blood O
myeloid O
DCs O
, O
and O
B O
- O
cell O
lines O
expressing O
DC O
- O
SIGN O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
HTLV O
- O
1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
, O
and O
other O
inflammatory O
diseases O
. O

HTLV O
- O
1 O
mRNA O
and O
proteins O
in O
HTLV O
- O
1 O
- O
infected O
cells O
markedly O
decreased O
upon O
coculture O
with O
human O
epithelial O
- O
like O
cells O
( O
HEK293T O
) O
or O
mouse O
embryo O
fibroblasts O
( O
NIH O
3T3 O
) O
. O

Coculture O
of O
HTLV O
- O
1 O
- O
infected O
cells O
and O
HEK293T O
cells O
induced O
type O
I O
interferon O
responses O
, O
as O
detected O
by O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
promoter O
activation O
and O
IFN O
- O
stimulated O
gene O
upregulation O
. O

Several O
studies O
have O
recently O
demonstrated O
the O
existence O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
antisense O
transcripts O
, O
which O
allow O
the O
synthesis O
of O
the O
newly O
described O
HBZ O
protein O
. O

The O
p12 O
( O
I O
) O
protein O
of O
human B
T I
- I
cell I
leukemia I
/ I
lymphoma I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
small O
oncoprotein O
that O
increases O
calcium O
release O
following O
protein O
kinase O
C O
activation O
by O
phorbol O
myristate O
acetate O
, O
and O
importantly O
, O
this O
effect O
is O
linker B
for I
activation I
of I
T I
cells I
( I
LAT I
) I
independent O
. O

Here O
, O
we O
demonstrate O
that O
p12 O
( O
I O
) O
inhibits O
the O
phosphorylation O
of O
LAT O
, O
Vav O
, O
and O
phospholipase O
C O
- O
gamma O
1 O
and O
decreases O
NFAT B
( I
nuclear I
factor I
of I
activated I
T I
cells I
) I
activation O
upon O
engagement O
of O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
with O
anti O
- O
CD3 O
antibody O
. O

Furthermore O
, O
we O
demonstrate O
that O
p12 O
( O
I O
) O
localizes O
to O
membrane O
lipid O
rafts O
and O
, O
upon O
engagement O
of O
the O
TCR O
, O
relocalizes O
to O
the O
interface O
between O
T O
cells O
and O
antigen O
- O
presenting O
cells O
, O
defined O
as O
the O
immunological O
synapse O
. O

A O
p12 O
( O
I O
) O
knockout O
molecular O
clone O
of O
HTLV O
- O
1 O
expresses O
more O
virus O
upon O
antigen O
stimulation O
than O
the O
isogenic O
wild O
type O
, O
suggesting O
that O
, O
by O
decreasing O
T O
- O
cell O
responsiveness O
, O
p12 O
( O
I O
) O
curtails O
viral O
expression O
. O

Thus O
, O
p12 O
( O
I O
) O
has O
contrasting O
effects O
on O
TCR O
signaling O
: O
it O
down O
- O
regulates O
TCR O
in O
a O
LAT O
- O
dependent O
manner O
on O
one O
hand O
, O
and O
on O
the O
other O
, O
it O
increases O
calcium O
release O
in O
a O
LAT O
- O
independent O
manner O
. O

The O
negative O
regulation O
of O
T O
- O
cell O
activation O
by O
p12 O
( O
I O
) O
may O
have O
evolved O
to O
minimize O
immune O
recognition O
of O
infected O
CD4 O
( O
+ O
) O
T O
cells O
, O
to O
impair O
the O
function O
of O
infected O
cytotoxic O
CD8 O
( O
+ O
) O
T O
cells O
, O
and O
to O
favor O
viral O
persistence O
in O
the O
infected O
host O
. O

Although O
natural B
killer I
( I
NK I
) I
cell O
- O
mediated O
control O
of O
viral O
infections O
is O
well O
documented O
, O
very O
little O
is O
known O
about O
the O
ability O
of O
NK O
cells O
to O
restrain O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
infection O
. O

In O
the O
current O
study O
we O
show O
that O
NK O
cells O
are O
unable O
to O
kill O
HTLV O
- O
1 O
- O
infected O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

Exposure O
of O
NK O
cells O
to O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
resulted O
in O
only O
a O
marginal O
increase O
in O
their O
ability O
to O
kill O
HTLV O
- O
1 O
- O
infected O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

This O
inability O
of O
NK O
cells O
to O
kill O
HTLV O
- O
1 O
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
occurred O
despite O
the O
downmodulation O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
molecules O
, O
one O
of O
the O
ligands O
for O
the O
major O
NK O
cell O
inhibitory O
receptor O
, O
by O
HTLV O
- O
1 O
p12 O
( O
I O
) O
on O
CD4 O
( O
+ O
) O
T O
cells O
. O

One O
reason O
for O
this O
diminished O
ability O
of O
NK O
cells O
to O
kill O
HTLV O
- O
1 O
- O
infected O
cells O
was O
the O
decreased O
ability O
of O
NK O
cells O
to O
adhere O
to O
HTLV O
- O
1 O
- O
infected O
cells O
because O
of O
HTLV O
- O
1 O
plf O
- O
mediated O
down O
- O
modulation O
of O
intercellular B
adhesion I
molecule I
I I
( I
ICAM I
- I
1 I
) I
and O
ICAM O
- O
2 O
. O

We O
also O
found O
that O
HTLV O
- O
1 O
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
did O
not O
express O
ligands O
for O
NK O
cell O
activating O
receptors O
, O
NCR O
and O
NKG2D O
, O
although O
they O
did O
express O
ligands O
for O
NK O
cell O
coactivating O
receptors O
, O
NTB O
- O
A O
and O
2B4 O
. O

Thus O
, O
despite O
HTLV O
- O
1 O
- O
mediated O
down O
- O
modulation O
of O
MHC O
- O
I O
molecules O
, O
HTLV O
- O
1 O
- O
infected O
primary O
CD4 O
( O
+ O
) O
T O
cells O
avoids O
NK O
cell O
destruction O
by O
modulating O
ICAM O
expression O
and O
shunning O
the O
expression O
of O
ligands O
for O
activating O
receptors O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

To O
develop O
a O
better O
animal O
model O
for O
the O
investigation O
of O
HTLV O
- O
1 O
infection O
, O
we O
established O
a O
transgenic B
( I
Tg I
) I
rat O
carrying O
the O
human B
CRM1 I
( I
hCRM1 I
) I
gene O
, O
which O
encodes O
a O
viral O
RNA O
transporter O
that O
is O
a O
species O
- O
specific O
restriction O
factor O
. O

It O
is O
well O
established O
that O
cell O
- O
free O
infection O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
less O
efficient O
than O
that O
with O
other O
retrovinises O
, O
though O
the O
specific O
infectivities O
of O
only O
a O
limited O
number O
of O
HTLV O
- O
1 O
isolates O
have O
been O
quantified O
. O

Infection O
with O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
can O
result O
in O
the O
development O
of O
HTLV1 B
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
, O
a O
chronic O
inflammatory O
disease O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

We O
demonstrate O
that O
HTLV O
- O
1 O
infection O
in O
astrogliomas O
results O
in O
a O
robust O
induction O
of O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
, O
IL O
- O
1 O
alpha O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
alpha I
) I
, O
TNF O
- O
beta O
, O
and O
IL O
- O
6 O
expression O
. O

A O
Tax2 O
/ O
Tax1 O
chimera O
encoding O
the O
C O
- O
terminal O
53 O
amino O
acids O
of O
the O
Tax1 O
fused O
to O
the O
Tax2 O
gene O
( O
Tax O
( O
221 O
) O
) O
demonstrated O
a O
phenotype O
that O
resembled O
Tax1 O
, O
with O
respect O
to O
proinflammatory O
cytokine O
gene O
expression O
and O
sensitization O
to O
apoptosis O
. O

Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
persistently O
infects O
humans O
, O
and O
the O
proviral O
loads O
that O
persist O
in O
vivo O
vary O
widely O
among O
individuals O
. O

HTLV O
- O
1 O
- O
specific O
T O
- O
cell O
response O
in O
orally O
HTLV O
- O
1 O
- O
infected O
rats O
could O
be O
restored O
by O
subcutaneous O
reimmunization O
with O
mitomycin B
C I
( I
MMC I
) I
- O
treated O
syngeneic O
HTLV O
- O
1 O
- O
transformed O
cells O
. O

Interactions O
between O
the O
oncogenic O
retrovirus O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
dendritic B
cells I
( I
DCs I
) I
are O
poorly O
characterized O
. O

We O
examined O
the O
role O
of O
DC B
- I
specific I
ICAM I
- I
3 I
- I
grabbing I
nonintegrin I
( I
DC I
- I
SIGN I
) I
, O
a O
C O
- O
type O
lectin O
expressed O
in O
DCs O
, O
in O
HTLV O
- O
1 O
- O
induced O
syncytium O
formation O
. O

DC O
- O
SIGN O
is O
known O
to O
bind O
with O
high O
affinity O
to O
various O
viral O
envelope O
glycoproteins O
, O
including O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
and O
hepatitis O
C O
virus O
, O
as O
well O
as O
to O
the O
cellular O
receptors O
ICAM O
- O
2 O
and O
ICAM O
- O
3 O
. O

After O
cocultivating O
DCs O
and O
HTLV O
- O
1 O
- O
infected O
cells O
, O
we O
found O
that O
anti O
- O
DC O
- O
SIGN O
Monoclonal B
antibodies I
( I
MAbs I
) I
were O
able O
to O
decrease O
the O
number O
and O
size O
of O
HTLV O
- O
1 O
- O
induced O
syncytia O
. O

Interestingly O
, O
in O
contrast O
to O
the O
envelope B
( I
env I
) I
glycoproteins O
of O
HIV O
and O
other O
viruses O
, O
that O
of O
HTLV O
- O
1 O
does O
not O
bind O
directly O
to O
DC O
- O
SIGN O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
was O
the O
first O
human O
retrovirus O
identified O
and O
causes O
both O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
and O
tropical O
spastic O
paraparesis O
/ O
HTLV O
- O
1 O
- O
associated O
myelopathy O
, O
among O
other O
disorders O
. O

Despite O
years O
of O
study O
, O
only O
recently O
has O
a O
bona O
fide O
candidate O
cellular O
receptor O
, O
glucose B
transporter I
1 I
( I
glut I
- I
1 I
) I
, O
been O
identified O
. O

Human O
T O
- O
cell O
leukemia O
/ O
lymphoma O
virus O
type O
I O
( O
HTLV O
- O
1 O
) O
infection O
can O
lead O
to O
the O
development O
of O
HTLV1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
( O
RAM O
/ O
TSP O
) O
, O
concomitantly O
with O
or O
without O
other O
inflammatory O
disorders O
such O
as O
myositis O
. O

These O
pathologies O
are O
considered O
immune O
- O
mediated O
diseases O
, O
and O
it O
is O
assumed O
that O
migration O
within O
tissues O
of O
both O
HTLV O
- O
1 O
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
and O
anti O
- O
HTLV O
- O
1 O
cytotoxic O
T O
cells O
represents O
a O
pivotal O
event O
. O

However O
, O
although O
HTLV O
- O
1 O
- O
infected O
T O
cells O
were O
found O
in O
inflamed O
lesions O
, O
the O
antigenic O
specificity O
of O
coinfiltrated O
CD8 O
( O
+ O
) O
T O
cells O
remains O
to O
be O
determined O
. O

We O
found O
that O
both O
HTLV O
- O
1 O
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
and O
CD8 O
( O
+ O
) O
T O
cells O
directed O
to O
the O
dominant O
Tax O
antigen O
can O
be O
amplified O
from O
muscle O
cell O
cultures O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
HTLV O
- O
2 O
are O
complex O
retroviruses O
that O
persist O
in O
the O
host O
, O
eventually O
causing O
leukemia O
and O
neurological O
disease O
in O
a O
small O
percentage O
of O
infected O
individuals O
. O

In O
addition O
to O
structural O
and O
enzymatic O
proteins O
, O
HTLV O
encodes O
regulatory O
( O
Tax O
and O
Rex O
) O
and O
accessory O
( O
open O
reading O
frame O
I O
and O
II O
) O
proteins O
. O

HTLV O
- O
1 O
p30 O
( O
II O
) O
and O
the O
related O
HTLV O
- O
2 O
p28 O
( O
II O
) O
inhibit O
virion O
production O
by O
binding O
to O
and O
retaining O
tax O
/ O
rex O
mRNA O
in O
the O
nucleus O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
. O

To O
understand O
the O
role O
of O
Tax O
in O
ATL O
development O
, O
we O
introduced O
short B
- I
interfering I
RNAs I
( I
siRNAs I
) I
against O
Tax O
in O
a O
rat O
HTLV O
- O
1 O
- O
infected O
T O
- O
cell O
line O
. O

Infection O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
characterized O
by O
long O
latency O
periods O
, O
indicating O
that O
viral O
gene O
expression O
is O
under O
tight O
control O
. O

To O
gain O
insight O
into O
the O
biological O
importance O
of O
externally O
induced O
activation O
pathways O
in O
virus O
gene O
expression O
, O
primary O
and O
established O
T O
cells O
were O
transfected O
with O
HTLV O
- O
1 O
- O
based O
reporter O
gene O
vectors O
and O
then O
were O
treated O
with O
agents O
that O
cross O
- O
linked O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
or O
the O
costimulatory O
CD28 O
molecule O
with O
prostaglandin B
E I
- I
2 I
( I
PGE I
( I
2 I
) I
) I
. O

This O
TCR O
- O
CD28 O
- O
PGE O
( O
2 O
) O
- O
mediated O
increase O
in O
virus O
transcription O
was O
dependent O
on O
protein O
kinase O
A O
activation O
and O
induction O
of O
the O
cAMP O
response O
element O
binding O
protein O
. O

Experiments O
with O
a O
mutated O
reporter O
construct O
further O
revealed O
the O
importance O
of O
the O
Tax O
- O
responsive O
elements O
in O
the O
HTLV O
- O
1 O
LTR O
in O
the O
observed O
up O
regulation O
of O
virus O
gene O
expression O
when O
TCR O
/ O
CD28 O
engagement O
was O
combined O
with O
PGE O
( O
2 O
) O
treatment O
. O

The O
protein O
tyrosine O
kinases O
p56 O
( O
lck O
) O
and O
the O
transmembrane O
tyrosine O
phosphatase O
CD45 O
were O
all O
found O
to O
be O
involved O
in O
TCR O
- O
CD28 O
- O
PGE O
( O
2 O
) O
- O
directed O
increase O
in O
HTLV O
- O
1 O
LTR O
activity O
. O

Significantly O
higher O
frequencies O
of O
tumor O
necrosis O
factor O
alpha O
- O
and O
interleukin O
- O
2 O
- O
secreting O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
were O
present O
in O
the O
peripheral O
blood O
mononuclear O
cells O
of O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
patients O
than O
in O
those O
of O
asymptomatic O
carriers O
with O
similar O
provirus O
loads O
. O

The O
data O
suggest O
that O
HTLV O
- O
1 O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
play O
a O
role O
in O
the O
pathogenesis O
of O
HAM O
/ O
TSP O
. O

adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
occurs O
in O
a O
small O
population O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
infected O
individuals O
. O

CpG O
methylation O
of O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
long I
terminal I
repeat I
( I
LTR I
) I
has O
been O
implicated O
in O
proviral O
latency O
, O
but O
there O
is O
presently O
little O
information O
available O
regarding O
the O
pattern O
of O
LTR O
methylation O
and O
its O
effect O
on O
viral O
gene O
expression O
. O

Surprisingly O
, O
our O
results O
reveal O
selective O
hypermethylation O
of O
the O
5 O
' O
LTR O
and O
accompanying O
hypomethylation O
of O
the O
3 O
' O
LTR O
in O
both O
latently O
infected O
cell O
lines O
and O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
cells O
having O
a O
complete O
provirus O
. O

We O
constructed O
a O
chimeric O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
provirus O
in O
which O
the O
original O
envelope O
precursor O
sequence O
was O
replaced O
by O
that O
of O
ecotropic O
Moloney B
murine I
leukemia I
virus I
( I
Mo I
- I
MuLV I
) I
. O

Chimeric O
particles O
produced O
by O
transient O
transfection O
of O
this O
chimeric O
provirus O
were O
infectious O
for O
murine O
cells O
, O
such O
as O
NIH O
3T3 O
fibroblasts O
, O
lymphoid O
EL4 O
cells O
, O
and O
primary O
CD4 O
( O
+ O
) O
T O
lymphocytes O
, O
whereas O
HTLV O
- O
1 O
particles O
were O
not O
. O

Primary O
murine O
CD4 O
( O
+ O
) O
T O
lymphocytes O
, O
infected O
by O
the O
DeltaR O
chimeric O
virus O
, O
released O
particles O
that O
could O
spread O
the O
infection O
to O
other O
naive O
murine O
lymphoid O
cells O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
in O
infected O
individuals O
after O
a O
long O
incubation O
period O
. O

To O
understand O
the O
interplay O
between O
host O
immunity O
and O
HTLV O
- O
1 O
- O
infected O
cells O
, O
in O
this O
study O
, O
we O
isolated O
several O
HTLV O
- O
1 O
Tax O
- O
specific O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
lines O
from O
rats O
inoculated O
with O
Tax O
- O
coding O
DNA O
and O
investigated O
the O
long O
- O
term O
effects O
of O
the O
CTL O
on O
syngeneic O
HTLV O
- O
1 O
- O
infected O
T O
cells O
. O

Although O
the O
Tax O
expression O
level O
in O
these O
resistant O
cells O
was O
equivalent O
to O
that O
in O
the O
parental O
cells O
, O
expression O
of O
surface O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
was O
significantly O
downregulated O
in O
the O
resistant O
cells O
. O

Downregulation O
of O
MHC O
- O
I O
was O
more O
apparent O
in O
RTLA O
( O
1 O
) O
, O
which O
presents O
a O
Tax O
epitope O
recognized O
by O
the O
CTL O
established O
in O
this O
study O
. O

To O
study O
the O
involvement O
of O
immune O
responses O
against O
Tax O
of O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
in O
the O
growth O
of O
and O
gene O
suppression O
in O
Tax O
- O
expressing O
tumor O
cells O
in O
vivo O
, O
we O
established O
a O
model O
system O
involving O
C57BL O
/ O
6J O
mice O
and O
a O
syngeneic O
lymphoma O
cell O
line O
, O
EL4 O
. O

When O
mice O
were O
immunized O
by O
DNA O
- O
based O
immunization O
with O
Tax O
expression O
plasmids O
, O
solid O
tumor O
formation O
upon O
subcutaneous O
inoculation O
of O
EL4 O
cells O
expressing O
green O
fluorescent O
protein O
- O
fused O
Tax O
( O
Gax O
) O
under O
the O
control O
of O
the O
HTLV O
- O
1 O
enhancer O
was O
strongly O
inhibited O
, O
and O
in O
vitro O
analysis O
showed O
that O
DNA O
immunization O
elicited O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
but O
not O
production O
of O
antibodies O
to O
Tax O
protein O
. O

Rat O
models O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
related O
diseases O
such O
as O
adult O
T O
- O
cell O
leukemia O
and O
HTLV O
- O
1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
have O
been O
reported O
. O

As O
Rex O
function O
depends O
largely O
on O
the O
CRM1 O
protein O
, O
whose O
human O
type O
( O
human O
CRM1 O
[ O
hCRM1 O
] O
) O
directly O
binds O
to O
Rex O
and O
exports O
it O
from O
the O
nucleus O
to O
the O
cytoplasm O
, O
we O
assessed O
whether O
rat B
CRM1 I
( I
rCRM1 I
) I
could O
act O
as O
well O
as O
hCRM1 O
as O
a O
cofactor O
for O
Rex O
activity O
. O

The O
Human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
Tax O
protein O
activates O
the O
HTLV O
- O
1 O
long O
terminal O
repeat O
and O
key O
regulatory O
proteins O
involved O
in O
inflammation O
, O
activation O
, O
and O
proliferation O
and O
may O
induce O
cell O
transformation O
. O

A O
sensitive O
and O
quantitative O
cell O
- O
free O
infection O
assay O
, O
utilizing O
recombinant O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
based O
vectors O
, O
was O
developed O
in O
order O
to O
analyze O
early O
events O
in O
the O
virus O
replication O
cycle O
. O

Virus O
stocks O
were O
generated O
by O
transfecting O
cells O
with O
three O
plasmids O
: O
( O
i O
) O
a O
packaging O
plasmid O
encoding O
HTLV O
- O
1 O
structural O
and O
regulatory O
proteins O
, O
( O
ii O
) O
an O
HTLV O
- O
1 O
transfer O
vector O
containing O
either O
firefly O
luciferase O
or O
enhanced O
yellow O
fluorescent O
protein O
genes O
, O
and O
( O
iii O
) O
an O
envelope O
expression O
plasmid O
. O

Transduction O
was O
dependent O
on O
reverse O
transcription O
and O
integration O
of O
the O
recombinant O
virus O
genome O
, O
as O
shown O
by O
the O
effects O
of O
the O
reverse O
transcriptase O
inhibitor O
3 O
' O
- O
azido O
- O
3 O
' O
- O
deoxythymidine O
( O
AZT O
) O
and O
by O
mutation O
of O
the O
integrase O
gene O
in O
the O
packaging O
vector O
, O
respectively O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
establishes O
a O
persistent O
infection O
in O
the O
host O
despite O
a O
vigorous O
virus O
- O
specific O
immune O
response O
. O

Here O
we O
demonstrate O
that O
an O
HTLV O
- O
l O
- O
encoded O
protein O
, O
p12 O
( O
I O
) O
, O
resides O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
Golgi O
and O
physically O
binds O
to O
the O
free O
human O
major B
histocompatibility I
complex I
class I
I I
heavy I
chains I
( I
MHC I
- I
I I
- I
Hc I
) I
encoded O
by O
the O
HLA O
- O
A2 O
, O
- O
B7 O
, O
and O
- O
Cw4 O
alleles O
. O

As O
a O
result O
of O
this O
interaction O
, O
the O
newly O
synthesized O
MHC O
- O
I O
- O
Hc O
fails O
to O
associate O
with O
beta O
( O
2 O
) O
- O
microglobulin O
and O
is O
retrotranslocated O
to O
the O
cytosol O
, O
where O
it O
is O
degraded O
by O
the O
proteasome O
complex O
. O

Targeting O
of O
the O
free O
MHC O
- O
I O
- O
Hc O
, O
and O
not O
the O
MHC O
- O
I O
- O
Hc O
- O
beta O
( O
2 O
) O
- O
microglobulin O
complex O
, O
by O
p12 O
( O
I O
) O
represents O
a O
novel O
mechanism O
of O
viral O
interference O
and O
disrupts O
the O
intracellular O
trafficking O
of O
MHC O
- O
I O
, O
which O
results O
in O
a O
significant O
decrease O
in O
surface O
levels O
of O
MHC O
- O
I O
on O
human O
T O
- O
cells O
. O

These O
findings O
suggest O
that O
the O
interaction O
of O
p12 O
( O
I O
) O
with O
MHC O
- O
1 O
- O
Hc O
may O
interfere O
with O
antigen O
presentation O
in O
vivo O
and O
facilitate O
escape O
of O
HTLV O
- O
1 O
- O
infected O
cells O
from O
immune O
recognition O
. O

Using O
HLA O
- O
peptide O
tetrameric O
complexes O
, O
we O
isolated O
human O
T O
- O
cell O
lymphotrophic O
virus O
type O
1 O
Tax O
peptide O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
ex O
vivo O
. O

Antigen O
- O
specific O
amino O
acid O
motifs O
were O
identified O
in O
the O
T O
- O
cell O
receptor O
V O
beta O
CDR3 O
region O
of O
clonally O
expanded O
CD8 O
( O
+ O
) O
T O
cells O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
in O
infected O
individuals O
after O
a O
long O
incubation O
period O
. O

In O
the O
present O
study O
, O
we O
induced O
HTLV O
- O
1 O
Tax O
- O
specific O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
immunity O
by O
vaccination O
with O
Tax O
- O
coding O
DNA O
and O
examined O
the O
effects O
of O
the O
DNA O
vaccine O
in O
our O
rat O
ATL O
- O
like O
disease O
model O
. O

Our O
results O
demonstrated O
that O
DNA O
vaccine O
with O
Tax O
effectively O
induced O
Tax O
- O
specific O
CTL O
activity O
in O
F344 O
/ O
N O
Jcl O
- O
rnu O
/ O
+ O
( O
nu O
/ O
+ O
) O
rats O
and O
that O
these O
CTLs O
were O
able O
to O
lyse O
HTLV O
- O
1 O
infected O
syngeneic O
T O
cells O
in O
vitro O
. O

Adoptive O
transfer O
of O
these O
immune O
T O
cells O
effectively O
inhibited O
the O
in O
vivo O
growth O
of O
HTLV O
- O
1 O
- O
transformed O
tumor O
in O
F344 O
/ O
N O
Jcl O
- O
rnu O
/ O
rnu O
( O
nu O
/ O
nu O
) O
rats O
inoculated O
with O
a O
rat O
HTLV O
- O
1 O
infected O
T O
cell O
line O
. O

We O
have O
analyzed O
the O
functional O
activity O
of O
the O
p53 O
tumor O
suppressor O
in O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
2 I
( I
HTLV I
- I
2 I
) I
- O
transformed O
cells O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
and O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

Wild O
- O
type O
but O
not O
a O
mutant O
form O
of O
Tax O
( O
M47 O
) O
transactivated O
the O
p21 O
/ O
waf1 O
promoter O
in O
a O
p53 O
- O
independent O
manner O
and O
utilized O
a O
minimal O
promoter O
that O
contained O
E2A O
and O
TATA O
box O
sequences O
. O

The O
p21 O
/ O
waf1 O
protein O
was O
reproducibly O
observed O
to O
be O
complexed O
with O
cyclin O
A O
/ O
cdk2 O
and O
not O
with O
any O
other O
known O
G O
( O
1 O
) O
, O
S O
, O
or O
G O
( O
2 O
) O
/ O
M O
cyclins O
. O

Functionally O
, O
the O
association O
of O
p21 O
/ O
cyclin O
A O
/ O
cdk2 O
decreased O
histone O
H1 O
phosphorylation O
in O
vitro O
, O
as O
observed O
in O
immunoprecipitations O
followed O
by O
kinase O
assays O
, O
and O
affected O
other O
substrates O
, O
such O
as O
the O
C O
terminus O
of O
Rb O
protein O
involved O
in O
c O
- O
Ab1 O
and O
histone B
deacetylase I
- I
1 I
( I
HDAC1 I
) I
regulation O
. O

Finally O
, O
using O
elutriated O
cell O
cycle O
fractions O
and O
a O
stress O
signal O
, O
we O
observed O
that O
the O
HTLV O
- O
1 O
- O
infected O
T O
cells O
containing O
wild O
- O
type O
Tax O
, O
which O
had O
been O
in O
early O
or O
mid O
- O
G O
( O
1 O
) O
phase O
prior O
to O
gamma O
- O
irradiation O
, O
arrested O
in O
G O
( O
1 O
) O
and O
did O
not O
undergo O
apoptosis O
. O

This O
may O
be O
an O
important O
mechanism O
for O
an O
oncogenic O
virus O
such O
as O
HTLV O
- O
1 O
to O
stop O
the O
host O
at O
the O
G O
( O
1 O
) O
/ O
S O
boundary O
and O
to O
repair O
the O
damaged O
DNA O
upon O
injury O
, O
prior O
to O
S O
- O
phase O
entry O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
a O
variety O
of O
clinical O
manifestations O
. O

including O
tropical O
spastic O
paraparesis O
or O
HTLV O
- O
1 O
- O
associated O
myelopathy O
( O
TSP O
/ O
HAM O
) O
. O

Viral O
detection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
TSP O
/ O
HAM O
patients O
demonstrates O
the O
ability O
of O
HTLV O
- O
1 O
to O
cross O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
. O

To O
investigate O
viral O
entry O
into O
the O
CNS O
, O
rat O
brain O
capillary O
endothelial O
cells O
were O
exposed O
to O
human O
lymphocytes O
chronically O
infected O
by O
HTLV O
- O
1 O
( O
MT2 O
) O
, O
to O
lymphocytes O
isolated O
from O
a O
seropositive O
patient O
, O
or O
to O
a O
control O
lymphoblastoid O
cell O
line O
( O
CEM O
) O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
causative O
agent O
of O
a O
chronic O
progressive O
myelopathy O
called O
tropical B
spastic I
paraparesis I
/ I
HTLV I
- I
1 I
- I
associated I
myelopathy I
( I
TSP I
/ I
HAM I
) I
. O

In O
this O
disease O
, O
lesions O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
are O
associated O
with O
perivascular O
infiltration O
by O
lymphocytes O
. O

Recombinant O
Tax O
- O
1 O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
decreased O
glutamate O
uptake O
by O
astrocytes O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATLL I
) I
, O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
, O
and O
other O
diseases O
, O
The O
mechanisms O
of O
virus O
pathogenesis O
are O
still O
obscure O
. O

The O
occurrence O
of O
defective O
proviruses O
in O
HTLV O
- O
1 O
- O
infected O
cell O
lines O
and O
the O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
of O
infected O
individuals O
is O
a O
frequent O
feature O
of O
virus O
infection O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
distribution O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
in O
various O
organs O
of O
serially O
sacrificed O
squirrel O
monkeys O
( O
Saimiri O
sciureus O
) O
in O
order O
to O
localize O
the O
reservoir O
of O
the O
virus O
and O
to O
evaluate O
the O
relationship O
between O
viral O
expression O
and O
the O
humoral O
or O
cellular O
immune O
response O
during O
infection O
. O

Six O
squirrel O
monkeys O
infected O
with O
HTLV O
- O
1 O
were O
sacrificed O
6 O
, O
12 O
, O
and O
35 O
days O
and O
3 O
, O
6 O
, O
and O
26 O
months O
after O
inoculation O
and O
20 O
organs O
and O
tissues O
were O
collected O
from O
each O
animal O
, O
PCR O
and O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
were O
performed O
with O
gag O
and O
tar O
primers O
. O

Proviral O
DNA O
was O
detected O
by O
PCR O
in O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
monkeys O
sacrificed O
6 O
days O
after O
inoculation O
and O
in O
PBMCs O
, O
spleens O
, O
and O
lymph O
nodes O
of O
monkeys O
sacrificed O
12 O
and O
35 O
days O
and O
3 O
, O
6 O
, O
and O
26 O
months O
after O
inoculation O
. O

Anti O
- O
p40 O
( O
Tax O
) O
and O
anti O
- O
Env O
cytolytic O
T O
- O
cell O
responses O
were O
detected O
2 O
months O
after O
infection O
and O
remained O
detectable O
thereafter O
. O

Host O
immunity O
influences O
clinical O
manifestations O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
HTLV O
- O
1 O
- O
transformed O
tumors O
could O
develop O
in O
immunocompetent O
rats O
by O
blocking O
a O
costimulatory O
signal O
for O
T O
- O
cell O
immune O
responses O
, O
Four O
- O
week O
- O
old O
WKA O
/ O
HKm O
rats O
were O
treated O
with O
Monoclonal B
antibodies I
( I
MAbs I
) I
to O
CD80 O
and O
CD86 O
and O
subcutaneously O
inoculated O
with O
syngeneic O
HTLV O
- O
1 O
- O
infected O
TARS O
- O
1 O
cells O
, O
During O
MAb O
treatment O
for O
14 O
days O
, O
TARS O
- O
1 O
inoculation O
resulted O
in O
the O
development O
of O
solid O
tumors O
at O
the O
site O
of O
inoculation O
, O
which O
metastasized O
to O
the O
lungs O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
for O
adult B
T I
- I
cell I
leukemia I
/ I
lymphoma I
( I
ATL I
) I
and O
HTLV O
- O
1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
. O

Tax O
( O
1 O
) O
is O
a O
40 O
- O
kDa O
phosphoprotein O
, O
predominantly O
localized O
in O
the O
nucleus O
of O
the O
host O
cell O
, O
which O
functions O
to O
transactivate O
both O
viral O
and O
cellular O
promoters O
. O

It O
seems O
likely O
that O
HTLV O
- O
1 O
, O
through O
expression O
of O
the O
viral O
regulatory O
protein O
Tax O
( O
1 O
) O
, O
provides O
some O
initial O
alteration O
in O
cell O
metabolism O
predisposing O
the O
development O
of O
ATL O
. O

Here O
, O
we O
demonstrate O
that O
HTLV O
- O
1 O
infection O
in O
T O
- O
cell O
lines O
and O
patient O
samples O
causes O
overexpression O
of O
an O
early O
G O
( O
1 O
) O
cyclin O
, O
cyclin O
D2 O
. O

More O
important O
, O
we O
find O
that O
overexpression O
of O
cyclin O
D2 O
is O
accompanied O
by O
acquisition O
of O
new O
partners O
such O
as O
cyclin B
- I
dependent I
kinase I
2 I
( I
cdk2 I
) I
, O
cdk4 O
, O
and O
cdk6 O
in O
infected O
cells O
, O
This O
is O
in O
contrast O
to O
uninfected O
T O
cells O
, O
where O
cyclin O
D2 O
associates O
only O
with O
cdk6 O
, O
Functional O
effects O
of O
these O
cyclin O
- O
cdk O
complexes O
in O
infected O
cells O
are O
shown O
by O
hyperphosphorylation O
of O
Rb O
and O
histone O
H1 O
, O
indicators O
of O
active O
progression O
into O
S O
phase O
as O
well O
as O
changes O
in O
cellular O
chromatin O
and O
transcription O
machinery O
. O

Patients O
with O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
( O
HAM O
/ O
TSP O
) O
typically O
have O
a O
high O
HTLV O
- O
1 O
proviral O
load O
in O
peripheral O
blood O
mononuclear O
cells O
and O
abundant O
, O
activated O
HTLV O
- O
1 O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
. O

To O
investigate O
the O
roles O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
envelope I
( I
Env I
) I
proteins O
gp46 O
and O
gp21 O
in O
the O
early O
steps O
of O
infection O
, O
the O
effects O
of O
the O
23 O
synthetic O
peptides O
covering O
the O
entire O
Env O
proteins O
on O
transmission O
of O
cell O
- O
free O
HTLV O
- O
1 O
were O
examined O
by O
PCR O
and O
by O
the O
plaque O
assay O
using O
a O
pseudotype O
of O
vesicular B
stomatis I
virus I
( I
VSV I
) I
bearing O
the O
Env O
of O
HTLV O
- O
1 O
[ O
VSV O
( O
HTLV O
- O
1 O
) O
] O
. O

The O
synthetic O
peptide O
corresponding O
to O
amino O
acids O
400 O
to O
429 O
of O
the O
gp21 O
Env O
protein O
( O
gp21 O
peptide O
400 O
- O
429 O
, O
Cys O
- O
Arg O
- O
Phe O
- O
Pro O
- O
Asn O
- O
Ile O
- O
Thr O
- O
Asn O
- O
Ser O
- O
His O
- O
Val O
- O
Pro O
- O
Ile O
- O
Leu O
- O
Gln O
- O
Glu O
- O
Arg O
- O
Pro O
- O
Pro O
- O
Leu O
- O
Glu O
- O
Asn O
- O
Arg O
- O
Val O
- O
Leu O
- O
Thr O
- O
Gly O
- O
Trp O
- O
Gly O
- O
Leu O
) O
strongly O
inhibited O
infection O
of O
cell O
- O
free O
HTLV O
- O
1 O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
causes O
T O
- O
cell O
malignancies O
in O
a O
small O
percentage O
of O
the O
population O
infected O
with O
the O
virus O
after O
a O
long O
carrier O
state O
. O

However O
, O
a O
similar O
seronegative O
HTLV O
- O
1 O
carrier O
state O
was O
induced O
in O
the O
rats O
inoculated O
with O
mitomycin O
C O
- O
treated O
FPM1 O
cells O
and O
also O
in O
FPM1 O
- O
inoculated O
allogeneic O
rats O
, O
suggesting O
that O
FPM1 O
could O
also O
transmit O
HTLV O
- O
1 O
into O
host O
cells O
in O
vivo O
, O
Our O
findings O
indicated O
that O
( O
i O
) O
HTLV O
- O
1 O
- O
immortalized O
T O
cells O
which O
preferentially O
express O
HTLV O
- O
1 O
Tax O
persisted O
in O
vivo O
hut O
failed O
to O
induce O
any O
diseases O
in O
immunocompetent O
syngeneic O
rats O
and O
that O
( O
ii O
) O
suboptimal O
levels O
of O
HTLV O
- O
1 O
for O
antibody O
responses O
allowed O
the O
establishment O
of O
persistent O
HTLV O
- O
1 O
infection O
. O

The O
HTLV O
- O
1 O
singly O
spliced O
open O
reading O
frame O
I O
protein O
, O
p12 O
( O
I O
) O
, O
is O
highly O
unstable O
and O
appears O
to O
be O
necessary O
for O
persistent O
infection O
in O
rabbits O
. O

Here O
we O
demonstrate O
that O
p12 O
( O
I O
) O
forms O
dimers O
through O
two O
putative O
leucine O
zipper O
domains O
and O
that O
its O
stability O
is O
augmented O
by O
specific O
proteasome O
inhibitors O
. O

p12 O
( O
I O
) O
is O
ubiquitylated O
, O
and O
mutations O
of O
its O
unique O
carboxy O
- O
terminus O
lysine O
residue O
to O
an O
arginine O
greatly O
enhance O
its O
stability O
. O

Interestingly O
, O
analysis O
of O
53 O
independent O
HTLV O
- O
1 O
strains O
revealed O
that O
the O
natural O
p12 O
( O
I O
) O
alleles O
found O
in O
ex O
vivo O
samples O
of O
tropical O
spastic O
paraparesis O
- O
HTLV O
- O
1 O
- O
associated O
myelopathy O
patients O
contain O
a O
Lys O
at O
position O
88 O
in O
some O
cases O
, O
whereas O
arginine O
is O
consistently O
found O
at O
position O
88 O
in O
HTLV O
- O
1 O
strains O
from O
all O
adult B
T I
- I
cell I
leukemia I
- I
lymphoma I
( I
ATLL I
) I
cases O
and O
healthy O
carriers O
studied O
. O

This O
apparent O
segregation O
of O
different O
alleles O
in O
tropical O
spastic O
paraparesis O
- O
HTLV O
- O
associated O
myelopathy O
and O
ATLL O
or O
healthy O
carriers O
may O
be O
relevant O
in O
vivo O
, O
since O
p12 O
( O
I O
) O
binds O
the O
interleukin O
- O
2 O
receptor O
beta O
and O
gamma O
( O
c O
) O
chains O
, O
raising O
the O
possibility O
that O
the O
two O
natural O
alleles O
might O
affect O
differently O
the O
regulation O
of O
these O
molecules O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
has O
been O
shown O
to O
be O
the O
etiologic O
agent O
of O
adult B
T I
- I
cell I
leukemia I
( I
ATL I
) I
, O
but O
the O
in O
vivo O
mechanism O
by O
which O
the O
virus O
causes O
the O
malignant O
transformation O
is O
largely O
unknown O
. O

When O
previously O
established O
cell O
lines O
, O
F344 O
- O
S1 O
and O
TARS O
- O
1 O
, O
but O
not O
TART O
- O
1 O
or O
W7TM O
- O
1 O
, O
were O
inoculated O
, O
systemic O
multiple O
tumor O
development O
was O
observed O
in O
adult O
nude O
( O
nu O
/ O
nu O
) O
rats O
. O

FPM1 O
cells O
, O
newly O
established O
from O
a O
heterozygous O
( O
nu O
/ O
+ O
) O
rat O
syngeneic O
to O
nu O
/ O
nu O
rats O
, O
caused O
transient O
tumors O
only O
at O
the O
injection O
site O
in O
adult O
nu O
/ O
nu O
rats O
, O
but O
could O
progressively O
grow O
in O
newborn O
nu O
/ O
nu O
rats O
and O
metastasize O
in O
lymph O
nodes O
. O

The O
derivative O
cell O
line O
( O
FPM1 O
- O
V1AX O
) O
serially O
passed O
through O
newborn O
nu O
/ O
nu O
rats O
acquired O
the O
potency O
to O
grow O
in O
adult O
nu O
/ O
nu O
rats O
. O

The O
development O
of O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
l O
) O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
( O
HAM O
/ O
TSP O
) O
is O
closely O
associated O
with O
the O
activation O
of O
T O
cells O
which O
are O
HTLV O
- O
1 O
specific O
but O
may O
cross O
- O
react O
with O
neural O
antigens B
( I
Ags I
) I
, O
Immature O
dendritic B
cells I
( I
DCs I
) I
, O
differentiated O
from O
normal O
donor O
monocytes O
by O
using O
recombinant O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
and O
recombinant O
interleukin O
- O
4 O
, O
were O
pulsed O
with O
HTLV O
- O
1 O
in O
vitro O
. O

The O
DCs O
matured O
by O
lipopolysaccharides O
stimulated O
autologous O
CD4 O
( O
+ O
) O
T O
cells O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
a O
viral O
dose O
- O
dependent O
manner O
. O

However O
, O
the O
proliferation O
level O
of O
CD4 O
( O
+ O
) O
T O
cells O
was O
five O
- O
to O
sixfold O
higher O
than O
that O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
contrast O
to O
virus O
- O
infected O
DCs O
, O
DCs O
pulsed O
with O
heat O
- O
inactivated O
virions O
activated O
only O
CD4 O
( O
+ O
) O
T O
cells O
. O

DCs O
from O
two O
of O
five O
patients O
expressed O
HTLV O
- O
1 O
Gag O
Ag O
, O
Furthermore O
, O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
from O
the O
patients O
were O
greatly O
stimulated O
by O
contact O
with O
autologous O
DCs O
pulsed O
with O
inactivated O
viral O
Ag O
as O
well O
as O
HTLV O
- O
l O
- O
infected O
DCs O
, O
These O
results O
suggest O
that O
DCs O
are O
susceptible O
to O
HTLV O
- O
1 O
infection O
and O
that O
their O
cognate O
interaction O
with O
T O
cells O
may O
contribute O
to O
the O
development O
of O
HAM O
/ O
TSP O
. O

The O
major O
route O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
infection O
is O
mother O
- O
to O
child O
transmission O
caused O
by O
breast O
- O
feeding O
. O

Expression O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
regulated O
both O
by O
the O
HTLV O
- O
1 O
Tax O
transactivator O
and O
by O
cellular O
transcriptional O
factors O
binding O
to O
the O
viral O
long B
terminal I
repeat I
( I
LTR I
) I
, O
suggesting O
that O
cellular O
signals O
may O
play O
a O
role O
in O
regulating O
viral O
expression O
. O

, O
phorbol12 O
- O
myristate O
13 O
- O
acetate O
[ O
PMA O
] O
) O
, O
phytohemagglutinin B
( I
PHA I
) I
, O
sodium O
butyrate O
, O
or O
combinations O
of O
cytokines O
resulted O
in O
induction O
of O
HTLV O
- O
1 O
gene O
expression O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
associated O
with O
adult O
T O
cell O
leukemia O
/ O
lymphoma O
, O
HTLVI O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
, O
and O
other O
diseases O
. O

We O
injected O
HTLV O
- O
1 O
- O
producing O
T O
cells O
( O
MT O
- O
2 O
) O
intraperitoneally O
into O
neonatal O
C3H O
/ O
HeJ O
mice O
. O

HTLV O
- O
1 O
provirus O
was O
present O
at O
the O
level O
of O
0 O
to O
30 O
molecules O
in O
10 O
( O
5 O
) O
spleen O
cells O
at O
the O
age O
of O
15 O
weeks O
. O

We O
identified O
a O
potential O
new O
subtype O
within O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
2 I
( I
HTLV I
- I
2 I
) I
, O
HTLV O
- O
2d O
, O
present O
in O
members O
of O
an O
isolated O
Efe O
Bambuti O
Pygmy O
tribe O
. O

4 O
% O
( O
tax O
/ O
rex O
) O
to O
10 O
. O

7 O
% O
( O
long O
terminal O
repeat O
) O
from O
both O
subtypes O
HTLV O
- O
2a O
and O
HTLV O
- O
2b O
, O
yet O
major O
functional O
elements O
are O
conserved O
. O

In O
the O
proximal O
pX O
region O
, O
one O
of O
the O
two O
alternative O
splice O
acceptor O
sites O
is O
abolished O
in O
HTLV O
- O
2 O
Efe2 O
, O
Another O
interesting O
feature O
of O
this O
potential O
new O
subtype O
is O
that O
it O
has O
a O
Tax O
protein O
of O
344 O
amino B
acids I
( I
aa I
) I
, O
which O
is O
intermediate O
in O
length O
between O
the O
HTLV O
- O
2a O
Tax O
protein O
( O
331 O
aa O
) O
and O
the O
HTLV O
- O
2b O
and O
- O
2c O
Tax O
proteins O
( O
356 O
aa O
) O
and O
similar O
to O
the O
simian B
T I
- I
cell I
lymphotropic I
virus I
type I
2 I
( I
STLV I
- I
2 I
) I
PP1664 O
Tax O
protein O
. O

In O
vitro O
infection O
by O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
and O
2 O
( O
HTLV O
- O
I O
and O
HTLV O
- O
2 O
) O
can O
result O
in O
syncytium O
formation O
, O
facilitating O
viral O
entry O
. O

We O
previously O
reported O
that O
the O
region O
corresponding O
to O
amino O
acids O
197 O
to O
216 O
of O
the O
gp46 O
surface O
glycoprotein O
( O
gp46 O
- O
197 O
) O
served O
as O
a O
binding O
domain O
for O
the O
interaction O
between O
gp46 O
and O
trypsin O
- O
sensitive O
membrane O
components O
of O
the O
target O
cell O
, O
leading O
to O
syncytium O
formation O
induced O
by O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
bearing O
cells O
, O
Our O
new O
evidence O
shows O
that O
the O
71 O
- O
kDa O
heat O
shock O
cognate O
protein O
( O
HSC70 O
) O
acts O
as O
a O
cellular O
receptor O
for O
syncytium O
formation O
. O

Using O
affinity O
chromatography O
with O
the O
peptide O
gp46 O
- O
197 O
, O
followed O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
, O
we O
isolated O
three O
components O
( O
bands O
A O
, O
B O
, O
and O
C O
) O
from O
MOLT O
- O
4 O
cell O
lysate O
which O
exhibited O
specific O
interactions O
with O
gp46 O
and O
inhibitory O
activities O
for O
syncytium O
formation O
induced O
by O
HTLV O
- O
1 O
- O
bearing O
cells O
. O

Human O
T O
- O
cell O
lymphotrophic O
virus O
type O
2 O
( O
HTLV O
- O
2 O
) O
, O
a O
common O
infection O
of O
intravenous O
drug O
users O
and O
subpopulations O
of O
Native O
Americans O
, O
is O
uncommon O
in O
the O
general O
population O
. O

All O
HTLV O
- O
2 O
- O
transformed O
populations O
were O
CD2 O
and O
/ O
or O
CD3 O
positive O
and O
B1 O
negative O
and O
were O
either O
CD4 O
( O
+ O
) O
or O
CD8 O
( O
+ O
) O
populations O
or O
a O
mixture O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
lymphocytes O
. O

Recruitment O
and O
extravasation O
of O
T O
cells O
through O
the O
blood O
- O
brain O
barrier O
are O
favored O
by O
adhesion O
molecule O
- O
mediated O
interactions O
of O
circulating O
T O
cells O
with O
endothelial O
cells O
, O
Since O
a O
common O
pathological O
finding O
in O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
associated O
diseases O
is O
the O
infiltration O
of O
HTLV O
- O
1 O
- O
infected O
T O
lymphocytes O
into O
various O
organs O
, O
we O
have O
looked O
for O
the O
profile O
of O
adhesion O
molecules O
expressed O
by O
HTLV O
- O
1 O
- O
transformed O
T O
cells O
, O
Flow O
cytometry O
analysis O
indicated O
that O
these O
cells O
were O
expressing O
high O
levels O
of O
vascular O
cell O
adhesion O
molecule O
1 O
( O
VCAM O
- O
1 O
[ O
CD106 O
] O
) O
, O
a O
110 O
- O
kDa O
member O
of O
the O
immunoglobulin O
gene O
superfamily O
, O
first O
identified O
on O
endothelial O
cells O
stimulated O
with O
inflammatory O
cytokines O
, O
This O
adhesion O
molecule O
was O
also O
expressed O
by O
T O
cells O
obtained O
from O
one O
patient O
with O
HTLV O
- O
1 O
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
but O
not O
by O
activated O
T O
cells O
isolated O
from O
one O
normal O
blood O
donor O
, O
The O
role O
of O
the O
viral O
trans O
- O
activator O
Tax O
protein O
in O
the O
induction O
of O
VCAM O
- O
1 O
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion O
molecule O
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
, O
The O
effect O
of O
Tax O
on O
VCAM O
- O
1 O
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax O
sequences O
under O
the O
control O
of O
an O
inducible O
promoter O
, O
Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM O
- O
1 O
promoter O
performed O
with O
chloramphenicol O
acetyltransferase O
constructs O
revealed O
that O
Tax O
was O
trans O
activating O
the O
VCAM O
- O
1 O
promoter O
via O
two O
NF O
- O
kappa O
B O
sites O
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM O
- O
1 O
gene O
promoter O
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax O
- O
induced O
expression O
of O
this O
adhesion O
molecule O
, O
Finally O
, O
gel O
mobility O
shift O
assays O
demonstrated O
the O
nuclear O
translocation O
of O
proteins O
specifically O
bound O
to O
these O
two O
NF O
- O
kappa O
B O
motifs O
, O
confirming O
that O
VCAM O
- O
1 O
was O
induced O
on O
Tax O
- O
expressing O
cells O
in O
a O
kappa O
B O
- O
dependent O
manner O
, O
Collectively O
, O
these O
results O
therefore O
suggest O
that O
the O
exclusive O
Tax O
- O
induced O
expression O
of O
VCAM O
- O
1 O
on O
T O
cells O
may O
represent O
a O
pivotal O
event O
in O
the O
progression O
of O
HTLV O
- O
1 O
- O
associated O
diseases O
. O

To O
examine O
the O
role O
of O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
I O
) O
Tax O
( O
1 O
) O
in O
the O
development O
of O
neurological O
disease O
, O
we O
studied O
the O
effects O
of O
extracellular O
Tax O
( O
1 O
) O
on O
gene O
expression O
in O
NT2 O
- O
N O
cells O
, O
postmitotic O
cells O
that O
share O
morphologic O
, O
phenotypic O
, O
and O
functional O
features O
with O
mature O
human O
primary O
neurons O
, O
Treatment O
with O
soluble O
HTLV O
- O
1 O
Tax O
( O
1 O
) O
resulted O
in O
the O
induction O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
gene O
expression O
, O
as O
detected O
by O
reverse O
- O
transcribed O
PCR O
and O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
, O
TNF O
- O
alpha O
induction O
was O
completely O
blocked O
by O
clearance O
, O
vith O
anti O
- O
Tax O
( O
1 O
) O
monoclonal O
antibodies O
, O
Furthermore O
, O
cells O
treated O
with O
either O
a O
mock O
bacterial O
extract O
or O
with O
lipopolysaccharide O
produced O
no O
detectable O
TNF O
- O
alpha O
, O
Synthesis O
of O
TNF O
- O
alpha O
in O
response O
to O
soluble O
Tax O
( O
1 O
) O
occurred O
in O
a O
dose O
- O
dependent O
fashion O
between O
0 O
. O

25 O
and O
75 O
nM O
and O
peaked O
within O
6 O
h O
of O
treatment O
, O
Interestingly O
, O
culturing O
NT2 O
- O
N O
cells O
in O
the O
presence O
of O
soluble O
Tax O
( O
1 O
) O
for O
as O
little O
as O
5 O
min O
was O
sufficient O
to O
result O
in O
TNF O
- O
alpha O
production O
, O
indicating O
that O
the O
induction O
of O
TNF O
- O
alpha O
in O
NT2 O
- O
N O
does O
not O
require O
Tax O
( O
1 O
) O
to O
be O
continually O
present O
in O
the O
culture O
medium O
, O
Treatment O
of O
the O
undifferentiated O
parental O
embryonal O
carcinoma O
cell O
line O
NT2 O
with O
soluble O
Tax O
( O
1 O
) O
did O
not O
result O
in O
TNF O
- O
alpha O
synthesis O
, O
suggesting O
that O
differentiation O
- O
dependent O
, O
neuron O
- O
specific O
factors O
may O
be O
required O
, O
These O
results O
provide O
the O
first O
experimental O
evidence O
that O
neuronal O
cells O
are O
sensitive O
to O
HTLV O
- O
1 O
Tax O
( O
1 O
) O
as O
an O
extracellular O
cytokine O
, O
with O
a O
potential O
role O
in O
the O
pathology O
of O
HTLV O
- O
1 O
- O
associated O
/ O
tropical O
spastic O
paraparesis O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
remains O
latent O
throughout O
the O
life O
of O
the O
carrier O
, O
with O
cells O
containing O
the O
provirus O
and O
viral O
gene O
expression O
efficiently O
down O
- O
regulated O
. O

In O
vitro O
experiments O
then O
revealed O
that O
potent O
cia B
- I
acting I
inhibitory I
elements I
( I
CIEs I
) I
are O
indeed O
contained O
in O
two O
discrete O
fragments O
from O
the O
pol O
region O
and O
weaker O
ones O
in O
the O
env O
region O
. O

The O
effect O
of O
CIEs O
is O
relieved O
by O
the O
HTLV O
- O
1 O
posttranscriptional O
regulator O
Rex O
through O
binding O
to O
the O
Rex B
- I
responsive I
element I
( I
RxRE I
) I
, O
suggesting O
that O
Rex O
might O
interfere O
with O
pre O
- O
mRNA O
degradation O
and O
/ O
or O
activate O
the O
export O
of O
mRNA O
molecules O
harboring O
both O
of O
the O
inhibitory O
elements O
and O
RxRE O
on O
the O
same O
RNA O
molecule O
. O

The O
proviral O
DNA O
of O
the O
simian B
T I
- I
leukemia I
/ I
lymphotropic I
virus I
( I
STLV I
) I
isolate O
, O
originally O
obtained O
from O
a O
captive O
colony O
of O
pygmy O
chimpanzees O
( O
Pan O
paniscus O
) O
( O
STLV O
( O
pan O
- O
p O
) O
) O
, O
was O
cloned O
from O
the O
DNA O
of O
the O
chronically O
infected O
human O
T O
- O
cell O
line O
L93 O
- O
79B O
. O

The O
entire O
proviral O
DNA O
sequence O
was O
obtained O
and O
compared O
with O
sequences O
of O
the O
known O
genotypes O
of O
STLV O
and O
human O
T O
- O
leukemia O
/ O
lymphotropic O
virus O
types O
1 O
and O
2 O
( O
HTLV O
- O
1 O
and O
- O
2 O
) O
. O

Phylogenetic O
analysis O
indicates O
that O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
is O
an O
early O
divergence O
within O
the O
type O
2 O
lineage O
and O
should O
he O
referred O
to O
as O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
Since O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
has O
been O
found O
in O
African O
nonhuman O
primates O
, O
we O
investigated O
its O
infectiousness O
and O
pathogenicity O
in O
Asian O
monkeys O
. O

Pigtailed O
macaques O
were O
inoculated O
with O
human O
cells O
harboring O
STLV O
( O
pan O
- O
p O
) O
, O
and O
infection O
was O
assessed O
by O
virus O
isolation O
, O
PCR O
analysis O
of O
peripheral O
blood O
mononuclear O
cells O
, O
and O
seroconversion O
against O
viral O
antigens O
in O
HTLV O
- O
1 O
/ O
HTLV O
- O
2 O
and O
Western O
blot O
assay O
. O

Pigtailed O
macaques O
became O
persistently O
infected O
by O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
, O
and O
the O
virus O
could O
be O
transferred O
by O
blood O
transfusion O
from O
an O
infected O
pigtailed O
macaque O
to O
a O
rhesus O
macaque O
. O

In O
addition O
, O
like O
HTLV O
- O
1 O
and O
HTLV O
- O
2 O
, O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
was O
infectious O
in O
rabbits O
. O

In O
summary O
, O
STLV O
- O
2 O
( O
pan O
- O
p O
) O
is O
a O
novel O
retrovirus O
distantly O
related O
to O
HTLV O
- O
2 O
and O
displays O
a O
host O
range O
similar O
to O
that O
demonstrated O
for O
other O
HTLV O
and O
STLV O
strains O
. O

To O
gain O
new O
insights O
on O
the O
origin O
, O
evolution O
, O
and O
modes O
of O
dissemination O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
, O
we O
performed O
a O
molecular O
analysis O
of O
58 O
new O
African O
HTLV O
- O
1 O
strains O
( O
18 O
from O
West O
Africa O
, O
36 O
from O
Central O
Africa O
, O
and O
4 O
from O
South O
Africa O
) O
originating O
from O
13 O
countries O
. O

Of O
particular O
interest O
were O
eight O
strains O
from O
Pygmies O
of O
remote O
areas O
of O
Cameroon O
and O
the O
Central B
African I
Republic I
( I
CAR I
) I
, O
considered O
to O
be O
the O
oldest O
inhabitants O
of O
these O
regions O
. O

A O
fragment O
of O
the O
env O
gene O
encompassing O
most O
of O
the O
gp21 O
transmembrane O
legion O
was O
sequenced O
for O
the O
58 O
new O
strains O
, O
while O
the O
complete O
long B
terminal I
repeat I
( I
LTR I
) I
region O
was O
sequenced O
for O
9 O
strains O
, O
including O
4 O
from O
Pygmies O
. O

Comparative O
sequence O
analyses O
and O
phylogenetic O
studies O
performed O
on O
both O
the O
env O
and O
LTR O
regions O
by O
the O
neighbor O
- O
joining O
and O
DNA O
parsimony O
methods O
demonstrated O
that O
all O
22 O
strains O
from O
West O
and O
South O
Africa O
belong O
to O
the O
widespread O
cosmopolitan O
subtype O
( O
also O
called O
HTLV O
- O
1 O
subtype O
A O
) O
. O

Within O
or O
alongside O
the O
previously O
described O
Zairian O
cluster O
( O
HTLV O
- O
1 O
subtype O
B O
) O
, O
we O
discovered O
a O
number O
of O
new O
HTLV O
- O
1 O
variants O
forming O
different O
subgroups O
corresponding O
mainly O
to O
the O
geographical O
origins O
of O
the O
infected O
persons O
, O
Cameroon O
, O
Gabon O
, O
and O
Zaire O
. O

Furthermore O
, O
three O
new O
strains O
( O
two O
originating O
from O
Pygmies O
from O
Cameroon O
and O
the O
CAR O
, O
respectively O
, O
and O
one O
from O
a O
Gabonese O
individual O
) O
were O
particularly O
divergent O
and O
formed O
a O
distinct O
new O
phylogenetic O
cluster O
, O
characterized O
by O
specific O
mutations O
and O
occupying O
in O
most O
analyses O
a O
unique O
phylogenetic O
position O
between O
the O
large O
Central O
African O
genotype O
( O
HTLV O
1 O
subtype O
B O
) O
and O
the O
Melanesian O
subtype O
( O
HTLV O
- O
1 O
subtype O
C O
) O
. O

While O
the O
HTLV O
- O
1 O
subtype O
D O
strains O
were O
not O
closely O
related O
to O
any O
known O
African O
strain O
of O
simian B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
STLV I
- I
1 I
) I
, O
other O
Pygmy O
strains O
and O
some O
of O
the O
new O
Cameroonian O
and O
Gabonese O
HTLV O
- O
1 O
strains O
were O
very O
similar O
( O
> O
98 O
% O
nucleotide O
identity O
) O
to O
chimpanzee O
STLV O
- O
1 O
strains O
, O
reinforcing O
the O
hypothesis O
of O
interspecies O
transmission O
between O
humans O
and O
monkeys O
in O
Central O
Africa O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
envelope O
proteins O
play O
an O
important O
role O
in O
viral O
entry O
into O
target O
cells O
, O
In O
a O
syncytium O
formation O
assay O
consisting O
of O
a O
coculture O
of O
HTLV O
- O
1 O
- O
bearing O
cells O
and O
target O
cells O
, O
mature O
gp46 O
and O
gp21 O
proteins O
each O
inhibited O
syncytium O
formation O
induced O
by O
HTLV O
- O
1 O
- O
bearing O
cells O
. O

A O
dual O
amino O
acid O
substitution O
mutant O
of O
Tax O
, O
M47 O
( O
L319R O
, O
L320S O
) O
, O
completely O
abrogated O
for O
activation O
of O
the O
human O
T O
- O
lymphotropic O
virus O
type O
I O
long O
terminal O
repeat O
as O
a O
result O
of O
a O
defect O
in O
the O
transactivation O
domain O
, O
continues O
to O
stimulate O
binding O
of O
bZip O
proteins O
to O
DNA O
. O

Previously O
, O
we O
showed O
that O
surface O
expression O
of O
intercellular B
adhesion I
molecule I
1 I
( I
ICAM I
- I
1 I
) I
was O
strongly O
upregulated O
in O
T O
cells O
carrying O
proviral O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
and O
that O
the O
viral O
transactivator O
protein O
Tax1 O
was O
capable O
of O
inducing O
the O
ICAM O
- O
1 O
gene O
, O
To O
determine O
the O
responsive O
elements O
in O
the O
human O
ICAM O
- O
1 O
gene O
promoter O
, O
a O
reporter O
construct O
in O
which O
the O
5 O
' O
- O
flanking O
4 O
. O

4 O
- O
kb O
region O
of O
the O
ICAM O
- O
1 O
gene O
was O
linked O
to O
the O
promoterless O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
was O
cotransfected O
with O
expression O
vectors O
for O
Tax1 O
and O
Tax2 O
, O
both O
of O
which O
were O
separately O
confirmed O
to O
be O
potent O
transactivators O
of O
the O
HTLV O
- O
1 O
long B
terminal I
repeat I
( I
LTR I
) I
. O

Tax1 O
strongly O
activated O
the O
ICAM O
- O
1 O
promoter O
in O
all O
the O
cell O
lines O
tested O
: O
three O
T O
- O
cell O
lines O
( O
Jurkat O
, O
MOLT O
- O
4 O
, O
and O
CEM O
) O
, O
one O
monocytoid O
cell O
line O
( O
U937 O
) O
, O
and O
HeLa O
. O

3 O
- O
kb O
5 O
' O
- O
flanking O
region O
, O
we O
found O
that O
Tax1 O
transactivated O
the O
ICAM O
- O
1 O
promoter O
mainly O
via O
a O
cyclic B
AMP I
- I
responsive I
element I
( I
CRE I
) I
- O
like O
site O
at O
- O
630 O
to O
- O
624 O
in O
the O
Jurkat O
T O
- O
cell O
line O
and O
via O
an O
NF O
- O
kappa O
B O
site O
at O
- O
185 O
to O
- O
177 O
and O
an O
SP O
- O
1 O
site O
at O
- O
59 O
to O
- O
54 O
its O
HeLa O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
involved O
in O
the O
disease O
HTLV O
- O
1 O
- O
associated O
myelopathy O
, O
or O
tropical O
spastic O
paraparesis O
( O
HAM O
/ O
TSP O
) O
. O

In O
a O
model O
in O
vitro O
, O
we O
demonstrate O
that O
HTLV O
- O
1 O
induces O
an O
imbalance O
in O
the O
expression O
of O
two O
astrocyte O
enzymes O
, O
at O
both O
the O
transcriptional O
and O
translational O
levels O
, O
In O
both O
human O
astrocyte O
precursors O
and O
rat O
glial O
cells O
, O
the O
levels O
of O
expression O
of O
glutamine B
synthetase I
( I
GS I
) I
and O
glutamate B
dehydrogenase I
( I
GDH I
) I
were O
increased O
and O
decreased O
, O
respectively O
, O
after O
coculture O
with O
HTLV O
- O
1 O
T O
cells O
. O

The O
enhancement O
of O
GS O
expression O
may O
result O
from O
the O
action O
of O
the O
protein O
Tax O
, O
which O
is O
demonstrated O
to O
transactivate O
the O
GS O
gene O
promoter O
, O
while O
the O
decreased O
expression O
of O
GDH O
seems O
to O
reflect O
some O
compensatory O
mechanism O
in O
response O
to O
GS O
induction O
, O
GS O
and O
GDH O
are O
involved O
in O
the O
conversion O
of O
glutamate O
into O
glutamine O
or O
alpha O
- O
ketoglutarate O
, O
which O
then O
acts O
as O
a O
precursor O
for O
glutamatergic O
and O
gamma B
- I
aminobutyric I
acid I
( I
GABA I
) I
- O
ergic O
neurons O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
a O
human O
retrovirus O
associated O
with O
two O
diseases O
for O
which O
no O
successful O
treatment O
is O
yet O
available O
; O
the O
development O
of O
a O
vaccine O
is O
therefore O
an O
important O
issue O
. O

Since O
HTLV O
- O
1 O
is O
a O
persistent O
virus O
, O
an O
efficient O
vaccine O
will O
probably O
require O
a O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
in O
addition O
to O
the O
production O
of O
antibodies O
. O

To O
identify O
potential O
CTL O
epitopes O
, O
we O
have O
selected O
, O
within O
all O
of O
the O
HTLV O
- O
1 O
proteins O
, O
nonapeptides O
containing O
anchor O
residues O
required O
for O
association O
with O
HLA O
- O
A2 O
molecules O
( O
residues O
at O
positions O
2 O
and O
9 O
) O
, O
which O
is O
the O
most O
frequently O
occurring O
A O
allele O
in O
all O
human O
populations O
. O

Anchor O
motifs O
selected O
were O
those O
containing O
two O
major O
anchor O
residues O
( O
L O
( O
2 O
) O
/ O
M O
( O
2 O
) O
/ O
I O
- O
2 O
- O
V O
- O
9 O
/ O
L O
( O
9 O
) O
/ O
I O
- O
9 O
) O
( O
one O
letter O
amino O
- O
acid O
code O
) O
and O
those O
including O
tolerated O
anchor O
residues O
( O
V O
- O
2 O
/ O
A O
( O
2 O
) O
/ O
T O
- O
2 O
and O
/ O
or O
A O
( O
9 O
) O
/ O
M O
( O
9 O
) O
/ O
T O
- O
9 O
) O
. O

p12 O
( O
I O
) O
is O
a O
small O
hydrophobic O
protein O
encoded O
by O
the O
human O
T O
- O
cell O
leukemia O
/ O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
that O
interacts O
with O
the O
I6 O
- O
kDa O
component O
of O
the O
H O
+ O
vacuolar O
ATPase O
and O
cooperates O
with O
bovine O
papillomavirus O
1 O
E5 O
oncoprotein O
in O
cell O
transformation O
. O

Just O
as O
an O
important O
step O
in O
E5 O
action O
appears O
to O
be O
its O
binding O
to O
the O
platelet O
- O
derived O
growth O
factor O
receptor O
, O
it O
was O
found O
that O
p12 O
( O
I O
) O
binds O
specifically O
to O
both O
the O
beta O
and O
gamma O
( O
c O
) O
chains O
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
. O

The O
IL O
- O
2R O
beta O
and O
gamma O
( O
c O
) O
chains O
associated O
with O
p12 O
( O
I O
) O
are O
endoglycosidase O
- O
H O
sensitive O
, O
suggesting O
that O
their O
interaction O
occurs O
in O
a O
pre O
- O
Golgi O
compartment O
. O

p12 O
( O
I O
) O
stabilizes O
the O
immature O
forms O
of O
the O
IL O
- O
2R O
beta O
and O
gamma O
( O
c O
) O
chains O
and O
decreases O
their O
cell O
surface O
expression O
. O

The O
interactions O
of O
p12 O
( O
I O
) O
with O
IL O
- O
2R O
beta O
and O
gamma O
( O
c O
) O
may O
have O
important O
implications O
in O
the O
immunosuppressive O
effect O
of O
HTLV O
- O
1 O
in O
vivo O
as O
well O
as O
in O
the O
ligand O
- O
independent O
HTLV O
- O
1 O
- O
mediated O
T O
- O
cell O
proliferation O
. O

Many O
cell O
signals O
such O
as O
CD28 O
and O
CD4 O
binding O
can O
costimulate O
cytokine O
gene O
expression O
in O
activated O
T O
cells O
, O
We O
have O
found O
that O
the O
human O
T O
leukemia O
/ O
lymphotropic O
virus O
type O
1 O
viral O
protein O
Tax O
can O
also O
strongly O
costimulate O
expression O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
IL O
- O
3 O
, O
and O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
mRNA O
in O
T O
cells O
activated O
with O
the O
phorbol O
ester O
phorbol B
myristate I
acetate I
( I
PMA I
) I
and O
calcium O
ionophore O
, O
which O
can O
mimic O
activation O
through O
the O
antigen O
specific O
T O
- O
cell O
receptor O
, O
Reporter O
constructs O
also O
showed O
strong O
synergy O
between O
both O
stimuli O
and O
showed O
that O
Tax O
and O
the O
PMA O
- O
Ca2 O
+ O
ionophore O
act O
through O
different O
regions O
of O
the O
IL O
- O
2 O
and O
GM O
- O
CSF O
genes O
. O

Furthermore O
, O
the O
Tax B
- I
responsive I
regions I
( I
TxRR I
) I
from O
both O
GM O
- O
CSF O
and O
IL O
- O
2 O
respond O
to O
costimulation O
through O
the O
CD28 O
surface O
receptor O
, O
The O
GM O
- O
CSF O
and O
IL O
- O
2 O
TxRRs O
showed O
significantly O
higher O
levels O
of O
NF O
- O
kappa O
B O
/ O
rel O
binding O
, O
following O
induction O
by O
Tax O
, O
compared O
with O
that O
of O
the O
PMA O
- O
Ca2 O
+ O
ionophore O
with O
only O
Tax O
capable O
of O
inducing O
c O
- O
Rel O
binding O
to O
a O
consensus O
KB O
element O
within O
the O
GM O
- O
CSF O
TxRR O
. O

Tax O
protein O
mutants O
, O
however O
, O
showed O
that O
a O
pathway O
( O
s O
) O
other O
than O
NF O
- O
kappa O
B O
/ O
rel O
induction O
could O
also O
cooperate O
with O
the O
PMA O
- O
Ca2 O
+ O
ionophore O
to O
activate O
the O
GM O
- O
CSF O
and O
IL O
- O
2 O
genes O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiologic O
agent O
of O
adult O
T O
- O
cell O
leukemia O
and O
lymphoma O
and O
HTLV O
- O
1 O
- O
associated O
myelopathy O
- O
tropical O
spastic O
paraparesis O
. O

We O
examined O
whether O
HTLV O
could O
productively O
infect O
human O
hematopoietic O
progenitor O
cells O
, O
CD34 O
( O
+ O
) O
cells O
were O
enriched O
from O
human O
fetal O
liver O
cells O
and O
cocultivated O
with O
cell O
lines O
transformed O
with O
HTLV O
- O
1 O
and O
- O
2 O
, O
HTLV O
- O
1 O
infection O
was O
established O
in O
between O
10 O
and O
> O
95 O
% O
of O
the O
enriched O
CD34 O
( O
+ O
) O
cell O
population O
, O
as O
demonstrated O
by O
quantitative O
PCR O
analysis O
, O
HTLV O
- O
1 O
p19 O
Gag O
expression O
was O
also O
detected O
in O
infected O
hematopoietic O
progenitor O
cells O
. O

HTLV O
- O
1 O
- O
infected O
hematopoietic O
progenitor O
cells O
were O
cultured O
in O
semisolid O
medium O
permissive O
for O
the O
development O
of O
erythroid O
( O
BFU O
- O
E O
) O
, O
myeloid O
( O
CFU O
- O
GM O
) O
, O
and O
primitive O
progenitor O
( O
CFU O
- O
GEMM O
, O
HPP O
- O
CFC O
, O
or O
CFU O
- O
A O
) O
colonies O
, O
HTLV O
- O
1 O
sequences O
were O
detected O
in O
colonies O
of O
all O
hematopoietic O
lineages O
; O
furthermore O
, O
the O
ratio O
of O
HTLV O
genomes O
to O
the O
number O
of O
human O
cells O
in O
each O
infected O
colony O
was O
1 O
: O
1 O
, O
consistent O
with O
each O
colony O
arising O
from O
a O
single O
infected O
hematopoietic O
progenitor O
cell O
, O
Severe O
combined O
immunodeficient O
mice O
engrafted O
with O
human O
fetal O
thymus O
and O
liver O
tissues O
( O
SCID O
- O
hu O
) O
develop O
a O
conjoint O
organ O
which O
supports O
human O
thymocyte O
differentiation O
and O
maturation O
. O

Inoculation O
of O
SCID O
- O
hu O
mice O
with O
HTLV O
- O
1 O
- O
infected O
T O
cells O
or O
enriched O
populations O
of O
CD34 O
( O
+ O
) O
cells O
establshed O
viral O
infection O
of O
thymocytes O
4 O
to O
6 O
weeks O
postreconstitution O
, O
Thymocytes O
from O
two O
mice O
with O
the O
greatest O
HTLV O
- O
1 O
proviral O
burdens O
showed O
increased O
expression O
of O
the O
CD25 O
marker O
and O
the O
interleukin O
2 O
receptor O
alpha O
chain O
and O
perturbation O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
thymocyte O
subset O
distribution O
profiles O
. O

In O
familial O
neurofibromatosis B
type I
1 I
( I
NF1 I
) I
, O
individuals O
with O
a O
germ O
line O
- O
transmitted O
NF1 O
mutation O
develop O
multiple O
neurofibromas O
. O

To O
explain O
the O
observation O
that O
transgenic O
mice O
expressing O
the O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
tax O
gene O
under O
the O
control O
of O
the O
viral O
regulatory O
element O
also O
develop O
multiple O
neurofibromas O
, O
we O
demonstrate O
that O
the O
Tax O
trans O
- O
regulator O
can O
functionally O
repress O
NF1 O
gene O
expression O
through O
a O
cis O
- O
acting O
element O
located O
immediately O
upstream O
of O
its O
transcriptional O
start O
site O
, O
thereby O
allowing O
the O
development O
of O
benign O
neurofibromas O
without O
the O
need O
for O
direct O
mutations O
in O
NF1 O
. O

To O
identify O
the O
regions O
that O
are O
important O
in O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
envelope O
function O
, O
we O
synthesized O
23 O
kinds O
of O
peptides O
covering O
the O
envelope O
proteins O
and O
examined O
the O
inhibitory O
effect O
of O
each O
peptide O
on O
syncytium O
formation O
induced O
by O
HTLV O
- O
1 O
- O
bearing O
cells O
, O
Of O
the O
23 O
synthetic O
peptides O
, O
2 O
, O
corresponding O
to O
amino O
acids O
197 O
to O
216 O
on O
gp46 O
and O
400 O
to O
429 O
on O
gp21 O
, O
inhibited O
syncytium O
formation O
induced O
by O
HTLV O
- O
l O
- O
bearing O
cells O
but O
did O
not O
affect O
syncytium O
formation O
induced O
by O
human O
immunodeficiency O
virus O
type O
1 O
- O
producing O
cells O
, O
The O
peptide O
concentrations O
giving O
50 O
% O
inhibition O
of O
syncytium O
formation O
for O
gp O
16 O
197 O
to O
216 O
and O
gp21 O
400 O
to O
429 O
were O
14 O
. O

A O
syncytium O
formation O
assay O
with O
overlapping O
synthetic O
peptides O
containing O
amino O
acids O
175 O
to O
236 O
and O
391 O
to O
438 O
of O
the O
envelope O
proteins O
showed O
that O
syncytium O
formation O
was O
inhibited O
by O
peptides O
that O
contained O
the O
amino O
acid O
sequences O
197 O
to O
205 O
( O
Asp O
- O
His O
- O
Ile O
- O
Leu O
- O
Glu O
- O
Pro O
Ser O
- O
Ile O
- O
Pro O
) O
and O
397 O
to O
406 O
( O
Gln O
Glu O
- O
Gln O
- O
Cys O
- O
Arg O
- O
Phe O
Fro O
- O
Asn O
- O
Ile O
- O
Thr O
) O
These O
observations O
suggest O
that O
the O
two O
regions O
corresponding O
to O
amino O
acids O
197 O
to O
216 O
and O
400 O
to O
429 O
are O
involved O
in O
HTLV O
- O
1 O
envelope O
function O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
associated O
myelopathy O
/ O
tropical O
spastic O
paraparesis O
( O
HAM O
/ O
TSP O
) O
is O
a O
chronic O
, O
progressive O
neurological O
disease O
characterized O
by O
marked O
degeneration O
of O
the O
spinal O
cord O
and O
the O
presence O
of O
antibodies O
against O
HTLV O
- O
1 O
. O

Patients O
with O
HAM O
/ O
TSP O
, O
but O
not O
asymptomatic O
carriers O
, O
show O
very O
high O
precursor O
frequencies O
of O
HTLV O
- O
1 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
peripheral O
blood O
and O
cerebrospinal O
fluid O
, O
suggestive O
of O
a O
role O
of O
these O
T O
cells O
in O
the O
pathogenesis O
of O
the O
disease O
, O
In O
HLA O
- O
A2 O
( O
+ O
) O
HAM O
/ O
TSP O
patients O
, O
HTLV O
- O
1 O
- O
specific O
T O
cells O
were O
demonstrated O
to O
be O
directed O
predominantly O
against O
one O
HTLV O
- O
1 O
epitope O
, O
namely O
, O
Tax11 O
- O
19 O
. O

In O
the O
present O
study O
, O
we O
analyzed O
HLA O
- O
A2 O
- O
restricted O
HTLV O
- O
1 O
Tax11 O
- O
19 O
- O
specific O
cytotoxic O
T O
cells O
from O
three O
patients O
with O
HAM O
/ O
TSP O
, O
An O
analysis O
of O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
repertoire O
of O
these O
cells O
revealed O
an O
absence O
of O
restricted O
variable O
( O
V O
) O
region O
usage O
, O
Different O
combinations O
of O
TCR O
V O
alpha O
and O
V O
beta O
genes O
were O
utilized O
between O
, O
but O
also O
within O
, O
the O
individual O
patients O
for O
the O
recognition O
of O
Tax11 O
- O
19 O
. O

PCR B
- I
in I
situ I
hybridization I
( I
PCR I
- I
ISH I
) I
was O
developed O
and O
utilized O
to O
determine O
the O
distribution O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
tax O
proviral O
DNA O
in O
peripheral B
blood I
lymphocytes I
( I
PBL I
) I
from O
patients O
with O
HTLV B
- I
1 I
- I
associated I
myelopathy I
/ I
tropical I
spastic I
paraparesis I
( I
HAM I
/ I
TSP I
) I
. O

PCR O
- O
ISH O
was O
sensitive O
, O
because O
a O
positive O
signal O
was O
consistently O
demonstrated O
from O
the O
HTLV O
- O
l O
- O
infected O
cell O
lines O
HUT O
- O
102 O
( O
which O
contains O
four O
to O
six O
copies O
of O
HTLV O
- O
1 O
proviral O
DNA O
per O
cell O
) O
and O
MT O
- O
1 O
( O
which O
contains O
one O
to O
three O
copies O
of O
HTLV O
- O
1 O
proviral O
DNA O
per O
cell O
) O
. O

A O
study O
of O
simian B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
STLV I
- I
1 I
) I
infection O
in O
a O
captive O
colony O
of O
23 O
Macaca O
tonkeana O
macaques O
indicated O
that O
17 O
animals O
had O
high O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
antibody O
titers O
. O

The O
first O
complete O
nucleotide O
sequence O
of O
an O
STLV O
- O
1 O
( O
9 O
, O
025 O
bp O
) O
, O
obtained O
for O
one O
of O
these O
isolates O
, O
indicated O
an O
overall O
genetic O
organization O
similar O
to O
that O
of O
HTLV O
- O
1 O
but O
with O
a O
nucleotide O
variability O
for O
the O
structural O
genes O
ranging O
from O
7 O
. O

The O
Tax O
and O
Rex O
regulatory O
proteins O
were O
well O
conserved O
, O
while O
the O
pX O
region O
, O
known O
to O
encode O
new O
proteins O
in O
HTLV O
- O
1 O
( O
open O
reading O
frames O
I O
and O
II O
) O
, O
was O
more O
divergent O
than O
that O
in O
the O
ATK O
strain O
. O

Phylogenetic O
trees O
constructed O
, O
vith O
the O
long O
terminal O
repeat O
and O
env O
( O
gp46 O
and O
gp21 O
) O
regions O
demonstrated O
that O
this O
new O
STLV O
- O
1 O
occupies O
a O
unique O
position O
within O
the O
Asian O
STLV O
- O
1 O
and O
HTLV O
- O
1 O
isolates O
, O
being O
, O
by O
most O
analyses O
, O
related O
more O
to O
the O
Australo O
- O
Melanesian O
HTLV O
- O
1 O
topotype O
than O
to O
any O
other O
Asian O
STLV O
- O
1 O
. O

Human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
I O
) O
infection O
has O
been O
discovered O
recently O
in O
people O
of O
Amerindian O
descent O
living O
in O
coastal O
areas O
of O
British O
Columbia O
, O
Canada O
. O

DNA O
sequencing O
combined O
with O
phylogenetic O
analysis O
and O
restriction B
fragment I
length I
polymorphism I
( I
RFLP I
) I
typing O
of O
HTLV O
- O
1 O
strains O
recovered O
from O
these O
British B
Columbia I
Indians I
( I
BCI I
) I
was O
conducted O
. O

Sequence O
- O
based O
phylogenetic O
trees O
distributed O
the O
BCI O
isolates O
among O
the O
Japanese O
subcluster O
( O
subcluster O
B O
) O
and O
the O
geographically O
widely O
distributed O
subcluster O
( O
subcluster O
A O
) O
of O
the O
large O
HTLV O
- O
1 O
cosmopolitan O
cluster O
. O

long B
terminal I
repeat I
( I
LTR I
) I
RFLP O
typing O
revealed O
three O
distinct O
, O
equally O
frequent O
LTR O
cleavage O
patterns O
, O
two O
of O
which O
were O
of O
previously O
recognized O
Japanese O
and O
widely O
dispersed O
cosmopolitan O
types O
. O

Our O
results O
suggest O
multiple O
origins O
for O
HTLV O
- O
1 O
in O
BCI O
, O
which O
are O
equally O
consistent O
with O
( O
i O
) O
a O
cluster O
of O
recent O
sporadic O
infections O
, O
( O
ii O
) O
ancient O
endemic O
vertical O
transmission O
through O
Amerindian O
lineages O
, O
or O
( O
iii O
) O
both O
. O

The O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
is O
the O
etiological O
agent O
for O
adult O
T O
- O
cell O
leukemia O
and O
tropical O
spastic O
paraparesis O
/ O
HTLV O
- O
1 O
- O
associated O
myelopathy O
. O

The O
HTLV O
- O
1 O
Tax O
( O
1 O
) O
gene O
product O
has O
been O
shown O
. O

To O
examine O
the O
biochemical O
mechanism O
of O
Tax O
( O
1 O
) O
transactivation O
, O
we O
have O
developed O
an O
in O
vitro O
transactivation O
assay O
in O
which O
wild O
- O
type O
Tax O
( O
1 O
) O
is O
able O
to O
specifically O
transactivate O
a O
polymerase O
II O
promoter O
through O
upstream O
Tax O
( O
1 O
) O
- O
responsive O
elements O
. O

Purified O
Tax O
( O
1 O
) O
specifically O
transactivates O
this O
template O
5 O
- O
to O
10 O
- O
fold O
in O
a O
concentration O
- O
dependent O
manner O
. O

No O
transactivation O
of O
the O
ovalbumin O
promoter O
( O
pLovTATA O
) O
template O
control O
was O
observed O
. O

Tax O
( O
1 O
) O
transactivation O
was O
inhibited O
by O
low O
concentrations O
of O
alpha O
- O
amanitin O
and O
was O
effectively O
neutralized O
by O
anti O
- O
Tax O
( O
1 O
) O
but O
not O
control O
sera O
. O

Consistent O
with O
in O
vivo O
transactivating O
activity O
, O
Tax O
( O
1 O
) O
NF O
- O
kappa O
B O
mutant O
M22 O
, O
but O
not O
cyclic O
AMP O
- O
responsive O
element O
- O
binding O
protein O
mutant O
M47 O
, O
transactivated O
the O
template O
containing O
the O
tandem O
21 O
- O
bp O
repeat O
. O

In O
a O
reconstituted O
in O
vitro O
transcription O
assay O
, O
Tax O
( O
1 O
) O
transactivation O
was O
dependent O
upon O
basal O
transcription O
factors O
TFIIB O
, O
TFIIF O
, O
Pol O
II O
, O
TFIID O
, O
and O
TFIIA O
. O

TATA O
- O
binding O
protein O
did O
not O
functionally O
substitute O
for O
TFIID O
in O
the O
transactivation O
assay O
by O
Tax O
( O
1 O
) O
but O
was O
sufficient O
for O
basal O
transcription O
. O

Finally O
, O
we O
have O
used O
anti O
- O
TFIIA O
antibody O
( O
p55 O
) O
to O
ask O
if O
Tax O
( O
1 O
) O
transactivation O
required O
TFIIA O
activity O
. O

Addition O
of O
TFIIA O
antibody O
to O
in O
vitro O
transcription O
reactions O
, O
as O
well O
as O
depletion O
of O
TFIIA O
by O
preclearing O
with O
antibody O
, O
showed O
that O
TFIIA O
was O
required O
for O
Tax O
( O
1 O
) O
transactivation O
. O

Only O
a O
slight O
( O
twofold O
) O
drop O
of O
basal O
transcription O
was O
observed O
. O

Tax O
( O
1 O
) O
transactivation O
was O
restored O
when O
purified O
HeLa O
TFIIA O
was O
added O
back O
into O
the O
reconstituted O
system O
. O

We O
propose O
that O
Tax O
( O
1 O
) O
utilizes O
a O
transactivation O
pathway O
involving O
the O
activator O
regulated O
basal O
transcription O
factors O
TFIID O
and O
TFIIA O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
is O
associated O
with O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
and O
tropical O
spastic O
paraparesis O
/ O
HTLV O
- O
associated O
myelopathy O
. O

An O
infectious O
molecular O
clone O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
was O
derived O
from O
an O
HTLV O
- O
I O
- O
transformed O
rabbit O
T O
- O
cell O
line O
, O
RH O
/ O
K30 O
, O
obtained O
by O
coculture O
of O
rabbit O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
with O
the O
human O
HTLV O
- O
I O
- O
transformed O
cell O
line O
MT O
- O
2 O
. O

A O
genomic O
DNA O
fragment O
containing O
the O
intact O
HTLV O
- O
I O
provirus O
was O
cloned O
into O
bacteriophage O
lambda O
( O
K30 O
phi O
) O
and O
subcloned O
into O
a O
plasmid O
vector O
( O
K30p O
) O
. O

HTLV O
- O
I O
p24 O
( O
gag O
) O
protein O
was O
detected O
in O
culture O
supernatants O
of O
human O
and O
rabbit O
T O
- O
cell O
and O
fibroblast O
lines O
transfected O
with O
these O
clones O
, O
at O
levels O
comparable O
to O
those O
of O
the O
parental O
cell O
line O
RH O
/ O
K30 O
. O

Tumaco O
, O
Colombia O
, O
is O
an O
area O
with O
elevated O
rates O
of O
tropical O
spastic O
paraparesis O
/ O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
- O
associated O
myelopathy O
( O
TSP O
/ O
HAM O
) O
. O

We O
have O
identified O
a O
mutation O
in O
nucleotide O
7959 O
of O
the O
tax O
gene O
of O
14 O
Tumaco O
HTLV O
- O
I O
isolates O
( O
14 O
positive O
of O
14 O
tested O
) O
that O
was O
present O
in O
5 O
of O
14 O
( O
35 O
% O
) O
TSP O
/ O
HAM O
patients O
from O
Japan O
and O
in O
8 O
of O
11 O
( O
72 O
% O
) O
TSP O
/ O
HAM O
patients O
from O
other O
geographic O
locations O
. O

There O
is O
a O
high O
degree O
of O
intraisolate O
sequence O
heterogeneity O
in O
the O
tax O
gene O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
, O
although O
the O
sequence O
variation O
between O
patients O
is O
small O
compared O
with O
that O
of O
human O
immunodeficiency O
virus O
type O
1 O
. O

In O
the O
present O
study O
, O
we O
investigated O
whether O
naturally O
occurring O
amino O
acid O
substitutions O
changed O
the O
properties O
of O
the O
Tax O
protein O
in O
two O
respects O
: O
first O
, O
recognition O
of O
the O
protein O
by O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
and O
second O
, O
the O
ability O
of O
the O
Tax O
protein O
to O
transactivate O
various O
promoters O
. O

We O
found O
that O
( O
i O
) O
all O
of O
the O
observed O
amino O
acid O
substitutions O
that O
occur O
in O
known O
CTL O
epitopes O
abolished O
the O
recognition O
of O
the O
synthetic O
peptide O
representing O
the O
respective O
epitope O
; O
( O
ii O
) O
these O
substitutions O
occurred O
significantly O
more O
frequently O
in O
subjects O
carrying O
HLA O
- O
A2 O
; O
and O
( O
iii O
) O
most O
of O
the O
amino O
acid O
substitutions O
severely O
reduced O
the O
ability O
of O
Tax O
protein O
to O
transactivate O
three O
promoters O
: O
the O
HTLV O
- O
I O
long O
terminal O
repeat O
, O
the O
c O
- O
fos O
promoter O
, O
and O
the O
interleukin O
- O
2 O
receptor O
alpha O
chain O
promoter O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
transactivator O
Tax O
augments O
transcription O
from O
three O
( O
cyclic B
AMP I
response I
element I
( I
CRE I
) I
- O
containing O
21 O
- O
bp O
repeats O
in O
the O
viral O
long O
terminal O
repeat O
and O
several O
other O
cis O
regulatory O
elements O
, O
including O
the O
NF O
- O
kappa O
B O
binding O
sites O
and O
the O
serum O
response O
element O
. O

We O
have O
shown O
recently O
that O
Tax O
forms O
multiprotein O
complexes O
with O
the O
heterodimeric O
and O
homodimeric O
forms O
of O
a O
ubiquitous O
cellular O
transcription O
factor O
, O
CREB B
( I
CRE I
binding I
protein I
) I
. O

In O
vitro O
selection O
for O
preferred O
Tax O
- O
CREB O
binding O
sites O
indicates O
that O
the O
Tax O
- O
CREB O
complex O
exhibits O
greatly O
increased O
DNA O
recognition O
specificity O
and O
assembles O
preferentially O
on O
CRE O
motifs O
, O
TGACGT O
/ O
C O
, O
flanked O
by O
long O
runs O
of O
G O
( O
5 O
' O
) O
and O
/ O
or O
C O
( O
3 O
' O
) O
residues O
, O
as O
found O
is O
the O
HTLV O
- O
I O
21 O
- O
bp O
repeats O
. O

Tax O
mutants O
with O
alterations O
in O
the O
NH2 O
terminus O
, O
including O
three O
deletion O
mutants O
, O
Tax O
( O
6 O
- O
353 O
) O
, O
Tax O
( O
21 O
- O
353 O
) O
, O
and O
Tax O
( O
89 O
- O
353 O
) O
, O
and O
two O
amino O
acid O
substitution O
mutants O
, O
M1 O
( O
H3S O
) O
and O
M7 O
( O
C29A O
, O
P30S O
) O
, O
all O
failed O
to O
interact O
with O
CREB O
in O
vitro O
. O

In O
contrast O
, O
a O
short O
COOH O
- O
terminal O
deletion O
, O
Tax O
( O
1 O
- O
319 O
) O
, O
and O
a O
Tax O
mutant O
with O
amino O
acid O
substitutions O
near O
the O
COOH O
end O
, O
M47 O
( O
L319R O
, O
L320S O
) O
, O
were O
able O
to O
interact O
with O
CREB O
and O
the O
21 O
- O
bp O
repeats O
to O
assemble O
ternary O
Tax O
- O
CREB O
- O
DNA O
complexes O
. O

As O
anticipated O
, O
a O
Tax O
mutant O
, O
M22 O
( O
G137A O
, O
L138S O
) O
which O
activated O
transcription O
from O
the O
21 O
- O
bp O
repeats O
with O
reduced O
capacity O
and O
was O
defective O
in O
trans O
activating O
the O
NF O
- O
KB O
binding O
sites O
, O
continued O
to O
interact O
with O
CREB O
in O
vitro O
, O
albeit O
with O
a O
lower O
level O
of O
efficiency O
. O

Finally O
, O
a O
glutathione B
S I
- I
transferase I
( I
GST I
) I
- O
Tax O
fusion O
protein O
with O
the O
GST O
moiety O
fused O
to O
the O
NH2 O
terminus O
of O
Tax O
failed O
to O
interact O
with O
CREB O
. O

The O
ability O
of O
molecular O
clones O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
to O
direct O
the O
synthesis O
of O
infectious O
virions O
has O
not O
previously O
been O
demonstrated O
. O

The O
current O
env O
- O
based O
subtyping O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
II I
( I
HTLV I
- I
II I
) I
identifies O
only O
two O
heterogenetic O
groups O
, O
HTLV O
- O
IIa O
and O
HTLV O
- O
IIb O
. O

To O
better O
understand O
the O
genetic O
diversity O
and O
phylogeny O
of O
HTLV O
- O
II O
, O
we O
examined O
the O
most O
divergent O
genomic O
region O
of O
HTLV O
- O
II O
, O
the O
long O
terminal O
repeat O
, O
by O
using O
restriction B
fragment I
length I
polymorphism I
( I
RFLP I
) I
and O
sequence O
analysis O
. O

Long O
terminal O
repeat O
sequences O
were O
amplified O
from O
peripheral O
blood O
mononuclear O
cells O
by O
PCR O
and O
digested O
with O
seven O
restriction O
endonucleases O
that O
differentiated O
HTLV O
- O
II O
into O
five O
HTLV O
- O
IIa O
( O
IIa0 O
to O
IIa4 O
) O
and O
six O
HTLV O
- O
IIb O
( O
IIb0 O
to O
IIb5 O
) O
restriction O
types O
, O
with O
HTLV O
- O
IIa0 O
and O
HTLV O
- O
IIb0 O
being O
prototypes O
for O
the O
MoT O
and O
NRA O
isolates O
, O
respectively O
. O

We O
examined O
169 O
HTLV O
- O
II O
- O
infected O
samples O
, O
including O
123 O
from O
blood O
donors O
and O
intravenous B
drug I
users I
( I
IDU I
) I
from O
the O
Americas O
, O
16 O
from O
IDU O
from O
Europe O
, O
and O
30 O
from O
Amerindians O
. O

Twelve O
Guaymi O
and O
all O
ten O
Seminole O
samples O
were O
single O
restriction O
types O
( O
IIb1 O
and O
IIb5 O
, O
respectively O
) O
, O
whereas O
the O
two O
Navajo O
and O
six O
Pueblo O
samples O
had O
a O
mixture O
of O
restriction O
types O
IIa0 O
, O
IIa4 O
, O
and O
IIb5 O
. O

8 O
% O
appear O
to O
have O
originated O
from O
the O
North O
Amerindian O
( O
IIb5 O
) O
, O
while O
57 O
. O

The O
derived O
topologies O
revealed O
three O
HTLV O
- O
IIa O
phylogroups O
( O
A O
- O
I O
to O
A O
- O
III O
) O
and O
four O
HTLV O
- O
IIb O
phylogroups O
( O
B O
- O
I O
to O
B O
- O
IV O
) O
. O

In O
the O
HTLV O
- O
IIa O
cluster O
, O
a O
Navajo O
( O
A O
- O
I O
) O
and O
a O
Brazilian O
( O
A O
- O
II O
) O
sequence O
formed O
separate O
phylogroups O
, O
while O
the O
remaining O
IIa O
sequences O
formed O
a O
single O
phylogroup O
( O
A O
- O
III O
) O
. O

The O
four O
HTLV O
- O
IIb O
phylogroups O
were O
represented O
predominantly O
by O
a O
New O
York O
IDU O
( O
B O
- O
I O
) O
, O
European O
IDU O
( O
B O
- O
II O
) O
, O
North O
Amerindian O
and O
NRA O
( O
B O
- O
III O
) O
, O
and O
Central O
Guaymi O
Indian O
( O
B O
- O
IV O
) O
scquence O
( O
s O
) O
. O

We O
demonstrate O
a O
significantly O
high O
incidence O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
- O
associated O
myelopathy O
( O
HAM O
) O
- O
or O
tropical B
spastic I
paraparesis I
( I
TSP I
) I
- O
like O
symptoms O
in O
WKA O
rats O
after O
injection O
with O
HTLV O
- O
1 O
- O
producing O
MT O
- O
2 O
cells O
, O
while O
no O
symptoms O
were O
observed O
in O
F344 O
rats O
injected O
with O
MT O
- O
2 O
cells O
or O
in O
control O
WKA O
rats O
. O

Five O
of O
the O
eight O
( O
63 O
% O
) O
WKA O
rats O
injected O
with O
MT O
- O
2 O
cells O
showed O
HAM O
/ O
TSP O
- O
like O
paraparesis O
at O
105 O
weeks O
of O
age O
, O
but O
none O
of O
seven O
MT O
- O
2 O
- O
injected O
F344 O
rats O
or O
eight O
control O
WKA O
rats O
showed O
symptoms O
. O

Six O
of O
the O
eight O
( O
75 O
% O
) O
WKA O
rats O
injected O
with O
MT O
- O
2 O
cells O
showed O
HAM O
/ O
TSP O
- O
like O
paraparesis O
at O
108 O
weeks O
of O
age O
. O

The O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
promoter O
contains O
the O
structural O
features O
of O
a O
typical O
RNA B
polymerase I
II I
( I
Pol I
II I
) I
template O
. O

The O
promoter O
contains O
a O
TATA O
box O
30 O
bp O
upstream O
of O
the O
transcription O
initiation O
site O
and O
binding O
sites O
for O
several O
pol O
II O
transcription O
factors O
, O
and O
long O
poly O
( O
A O
) O
( O
+ O
) O
RNA O
is O
synthesized O
from O
the O
integrated O
HTLV O
- O
I O
proviral O
DNA O
in O
vivo O
. O

In O
HeLa O
whole O
cell O
extracts O
, O
however O
, O
the O
HTLV O
- O
I O
long O
terminal O
repeat O
also O
contains O
an O
overlapping B
transcription I
unit I
( I
OTU I
) I
. O

HTLV O
- O
I O
OTU O
transcription O
is O
initiated O
at O
the O
same O
nucleotide O
site O
as O
the O
RNA O
isolated O
from O
the O
HTLV O
- O
I O
- O
infected O
cell O
line O
MT O
- O
2 O
but O
was O
not O
inhibited O
by O
the O
presence O
of O
cu O
- O
amanitin O
at O
concentrations O
which O
inhibited O
the O
adenovirus O
major O
late O
pol O
II O
promoter O
( O
6 O
mu O
g O
/ O
ml O
) O
. O

HTLV O
- O
I O
transcription O
was O
inhibited O
when O
higher O
concentrations O
of O
cx O
- O
amanitin O
( O
60 O
mu O
g O
/ O
ml O
) O
were O
used O
, O
in O
the O
range O
of O
a O
typical O
pol O
III O
promoter O
( O
VA O
- O
I O
) O
. O

In O
order O
to O
define O
neutralization O
regions O
on O
the O
envelope O
antigen O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
, O
me O
have O
generated O
a O
number O
of O
new O
anti O
- O
envelope O
gp46 O
monoclonal O
antibodies O
from O
rats O
and O
mice O
. O

Ovalbumin O
- O
conjugated O
synthetic O
gp46 O
peptides O
containing O
these O
neutralization O
epitopes O
, O
pep190 O
- O
199 O
( O
a O
synthetic O
gp46 O
peptide O
containing O
amino O
acids O
190 O
to O
199 O
) O
and O
pep180 O
- O
204 O
, O
but O
not O
pep185 O
- O
194 O
or O
pep194 O
- O
203 O
, O
could O
give O
rise O
to O
HTLV O
- O
I O
- O
neutralizing O
antibody O
responses O
in O
rabbits O
. O

These O
immune O
or O
nonimmune O
rabbits O
were O
then O
challenged O
with O
HTLV O
- O
I O
by O
intravenous O
inoculation O
with O
5 O
x O
10 O
( O
7 O
) O
live O
HTLV O
- O
I O
- O
producing O
ILT O
- O
8M2 O
cells O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
causes O
T O
- O
cell O
leukemia O
and O
tropical B
spastic I
paraparesis I
( I
TSP I
) I
in O
a O
minority O
of O
infected O
people O
, O
whereas O
the O
majority O
remain O
healthy O
. O

The O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
- O
encoded O
protein O
, O
Tax O
, O
is O
capable O
of O
trans O
- O
activating O
HTLV O
- O
I O
transcription O
by O
interacting O
with O
specific O
sequences O
in O
the O
HTLV O
- O
I O
long B
terminal I
repeat I
( I
LTR I
) I
which O
comprise O
an O
inducible O
enhancer O
containing O
three O
imperfect O
tandem O
repeats O
of O
a O
21 O
- O
bp O
sequence O
. O

Utilizing O
electrophoretic B
mobility I
shift I
( I
EMS I
) I
analyses O
, O
we O
have O
detected O
both O
21 O
- O
bp O
repeat O
- O
specific O
and O
glial O
cell O
specific O
DNA O
- O
protein O
complexes O
. O

Several O
21 O
- O
bp O
repeat O
- O
specific O
DNA O
- O
protein O
complexes O
were O
detected O
when O
nuclear O
extracts O
derived O
from O
cells O
of O
lymphoid O
( O
Jurkat O
, O
SupT1 O
, O
and O
H9 O
) O
, O
neuronal O
( O
IMR O
- O
32 O
and O
SK O
- O
N O
- O
MC O
) O
, O
and O
glial O
( O
U O
- O
373 O
MG O
, O
Hs683 O
, O
and O
U O
- O
118 O
) O
origin O
were O
used O
in O
reactions O
with O
each O
of O
the O
three O
21 O
- O
bp O
repeat O
elements O
, O
In O
addition O
, O
a O
glial O
cell O
- O
specific O
DNA O
- O
protein O
complex O
was O
detected O
when O
nuclear O
extracts O
derived O
from O
U O
- O
373 O
MG O
, O
Hs683 O
, O
and O
U O
- O
118 O
glial O
cell O
lines O
reacted O
with O
the O
promoter O
- O
distal O
and O
central O
21 O
- O
bp O
repeat O
elements O
. O

Furthermore O
, O
EMS O
analyses O
performed O
with O
nuclear O
extracts O
derived O
from O
lymphocytic O
and O
glial O
cell O
origin O
and O
a O
223 O
- O
bp O
fragment O
of O
the O
HTLV O
- O
I O
long O
terminal O
repeat O
encompassing O
the O
three O
21 O
- O
bp O
repeat O
elements O
( O
designated O
Tax O
- O
responsive O
elements O
1 O
and O
2 O
, O
TRE O
- O
1 O
/ O
2 O
) O
have O
also O
resulted O
in O
the O
detection O
of O
glial O
cell O
type O
- O
specific O
DNA O
- O
protein O
complexes O
. O

CD8 O
( O
+ O
) O
T O
cells O
were O
freshly O
isolated O
from O
a O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
- O
infected O
patient O
with O
tropical O
spastic O
paraparesis O
. O

Recognition O
of O
the O
immunodominant O
epitope O
was O
restricted O
by O
human B
leukocyte I
antigen I
( I
HLA I
) I
B15 O
, O
and O
recognition O
of O
all O
the O
others O
was O
by O
HLA O
A2 O
. O

Homologous O
env O
sequences O
from O
17 O
human B
T I
- I
leukemia I
/ I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
strains O
from O
throughout O
the O
world O
and O
from O
25 O
simian B
T I
- I
leukemia I
/ I
lymphotropic I
virus I
type I
I I
( I
STLV I
- I
I I
) I
strains O
from O
12 O
simian O
species O
in O
Asia O
and O
Africa O
were O
analyzed O
in O
a O
phylogenetic O
context O
as O
an O
approach O
to O
resolving O
the O
natural O
history O
of O
these O
related O
retroviruses O
. O

STLV O
- O
I O
exhibited O
greater O
overall O
sequence O
variation O
between O
strains O
( O
1 O
to O
18 O
% O
compared O
with O
0 O
to O
9 O
% O
for O
HTLV O
- O
I O
) O
, O
supporting O
the O
simian O
origin O
of O
the O
modern O
viruses O
in O
all O
species O
. O

Three O
HTLV O
- O
I O
phylogenetic O
clusters O
or O
clades O
( O
cosmopolitan O
, O
Zaire O
, O
and O
Melanesia O
) O
were O
resolved O
with O
phenetic O
, O
parsimony O
, O
and O
likelihood O
analytical O
procedures O
. O

Seven O
phylogenetic O
clusters O
of O
STLV O
- O
I O
were O
resolved O
with O
the O
most O
primitive O
( O
deeply O
rooted O
) O
divergence O
involving O
several O
STLV O
- O
I O
strains O
from O
Asian O
primate O
species O
. O

We O
interpret O
these O
evolutionary O
associations O
as O
support O
for O
the O
occurrence O
of O
multiple O
discrete O
interspecies O
transmissions O
of O
ancestral O
viruses O
, O
between O
primate O
species O
( O
including O
human O
) O
that O
led O
to O
recognizable O
phylogenetic O
clades O
that O
persist O
in O
modern O
species O
. O

human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
is O
associated O
with O
a O
neurologic O
disease O
, O
HTLV O
- O
I O
- O
associated O
myelopathy O
- O
tropical O
spastic O
paraparesis O
, O
in O
which O
both O
pathological O
and O
immunological O
changes O
are O
observed O
within O
the O
central O
nervous O
system O
. O

HTLV O
- O
I O
infection O
of O
the O
neuroblastoma O
cells O
was O
confirmed O
by O
verifying O
the O
presence O
of O
HTLV O
- O
I O
gp46 O
surface O
antigens O
by O
flow O
cytometry O
and O
by O
verifying O
the O
presence O
of O
HTLV O
- O
I O
pX O
RNA O
by O
Northern O
( O
RNA O
) O
blotting O
and O
in O
situ O
hybridization O
techniques O
. O

Transcription O
regulation O
of O
the O
oncogenic O
retrovirus O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
involves O
the O
composite O
activity O
of O
both O
viral O
and O
cellular O
transcription O
factors O
. O

The O
tar O
gene O
sequence O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
II I
isolate I
G12 I
( I
HTLV I
- I
II I
( I
G12 I
) I
) I
was O
found O
to O
encode O
an O
extended O
Tax O
protein O
when O
compared O
with O
that O
of O
HTLV O
- O
II O
( O
MoT O
) O
. O

In O
vitro O
transcription O
- O
translation O
of O
the O
HTLV O
- O
II O
( O
G12 O
) O
tar O
gene O
produced O
a O
40 O
- O
kDa O
Tax O
protein O
that O
specifically O
reacted O
with O
serum O
specimens O
from O
HTLV O
- O
II O
- O
infected O
individuals O
. O

Limited O
sequence O
analysis O
demonstrated O
that O
isolates O
with O
an O
extended O
Tax O
protein O
were O
all O
HTLV B
- I
II I
subtype I
b I
( I
HTLV I
- I
IIb I
) I
. O

The O
human B
T I
- I
cell I
leukemia I
/ I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
induces O
T O
- O
cell O
leukemia O
and O
transforms O
human O
T O
cells O
in O
vitro O
. O

A O
recently O
identified O
protein O
with O
a O
molecular O
weight O
of O
12 O
, O
000 O
( O
12K O
) O
( O
p12I O
) O
, O
encoded O
by O
single O
- O
and O
double O
- O
spliced O
mRNAs O
transcribed O
from O
the O
3 O
' O
end O
of O
the O
HTLV O
- O
I O
genome O
, O
has O
been O
shown O
to O
localize O
in O
the O
perinuclear O
compartment O
and O
in O
the O
cellular O
endomembranes O
. O

The O
p12I O
protein O
exhibits O
significant O
amino O
acid O
sequence O
similarity O
to O
the O
E5 O
oncoprotein O
of O
bovine B
papillomavirus I
type I
1 I
( I
BPV I
- I
1 I
) I
. O

Both O
proteins O
are O
very O
hydrophobic O
, O
contain O
a O
glutamine O
residue O
in O
the O
middle O
of O
a O
potential O
transmembrane O
region O
( O
s O
) O
, O
and O
are O
localized O
in O
similar O
cellular O
compartments O
. O

The O
mitogenic O
activity O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
is O
triggering O
the O
proliferation O
of O
human O
resting O
T O
lymphocytes O
through O
the O
induction O
of O
the O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
/ O
IL O
- O
2 O
receptor O
autocrine O
loop O
. O

The O
complete O
nucleotide O
sequence O
of O
a O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
II I
( I
HTLV I
- I
II I
) I
isolate O
from O
a O
Panamanian O
Guaymi O
Indian O
was O
determined O
and O
analyzed O
. O

When O
this O
new O
viral O
isolate O
( O
HTLV O
- O
II O
( O
G12 O
) O
) O
was O
compared O
with O
prototypic O
HTLV O
- O
II O
( O
MoT O
) O
, O
the O
overall O
nucleotide O
sequence O
similarity O
was O
95 O
. O

Although O
the O
overall O
percentage O
of O
nucleotide O
and O
amino O
acid O
identity O
with O
prototypic O
HTLV O
- O
II O
( O
MoT O
) O
( O
subtype O
a O
) O
was O
high O
, O
HTLV O
- O
II O
( O
G12 O
) O
displayed O
several O
distinctive O
features O
that O
defined O
it O
as O
an O
HTLV O
- O
II O
subtype O
b O
. O

In O
addition O
, O
two O
nucleotide O
changes O
in O
the O
C O
terminus O
of O
the O
Tax O
protein O
coding O
sequence O
inserted O
an O
Arg O
residue O
for O
a O
stop O
codon O
and O
appeared O
to O
result O
in O
a O
larger O
tax O
gene O
product O
in O
HTLV O
- O
II O
( O
G12 O
) O
. O

Although O
the O
HTLV O
- O
II O
( O
G12 O
) O
isolate O
appears O
to O
be O
a O
variant O
of O
the O
prototypic O
HTIV O
- O
IIb O
, O
this O
information O
represents O
the O
first O
complete O
nucleotide O
sequence O
of O
any O
HTLV O
- O
II O
subtype O
b O
. O

The O
Tax O
protein O
of O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
has O
been O
shown O
to O
induce O
nuclear O
expression O
of O
Rel O
family O
NF O
- O
kappaB O
- O
binding O
proteins O
. O

The O
presence O
of O
a O
high O
number O
of O
activated O
T O
cells O
in O
the O
bloodstream O
and O
spontaneous O
proliferation O
of O
peripheral O
blood O
mononuclear O
cells O
in O
vitro O
are O
striking O
characteristics O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
infection O
. O

In O
this O
study O
, O
HTLV O
- O
I O
- O
producing O
cell O
lines O
and O
purified O
virus O
from O
the O
cell O
lines O
were O
examined O
for O
the O
ability O
to O
activate O
peripheral B
blood I
lymphocytes I
( I
PBLs I
) I
and O
Jurkat O
cells O
. O

Induction O
of O
interleukin O
- O
2 O
expression O
was O
inhibited O
by O
anti O
- O
CD2 O
and O
anti O
- O
lymphocyte B
function I
- I
associated I
antigen I
3 I
( I
LFA I
- I
3 I
) I
monoclonal O
antibodies O
but O
not O
anti O
- O
human O
leukocyte O
antigen O
- O
DR O
, O
anti O
- O
CD4 O
, O
anti O
- O
LFA O
- O
1 O
, O
or O
anti O
- O
intercellular O
adhesion O
molecule O
1 O
. O

Three O
protein O
isoforms O
are O
encoded O
by O
the O
human O
T O
- O
cell O
leukemia O
/ O
lymphotropic O
virus O
type O
I O
pX O
region O
open B
reading I
frames I
( I
ORF I
) I
I O
and O
II O
through O
alternative O
splicing O
. O

Both O
the O
singly O
and O
doubly O
spliced O
mRNAs O
from O
ORF O
I O
encode O
a O
single O
12 O
- O
kDa O
protein O
( O
p12I O
) O
, O
whereas O
two O
distinct O
proteins O
of O
13 O
kDa O
( O
p13II O
) O
and O
30 O
kDa O
( O
p30II O
) O
are O
encoded O
from O
the O
ORF O
II O
alternatively O
spliced O
mRNA O
. O

A O
human O
T O
- O
lymphotropic O
virus O
type O
I O
( O
HTLV O
- O
1 O
) O
strain O
was O
isolated O
in O
a O
CD4 O
+ O
T O
- O
lymphocyte O
culture O
established O
from O
a O
healthy O
seropositive O
Australian O
Aboriginal O
. O

This O
isolate O
, O
identified O
as O
HTLV O
- O
I O
( O
MSHR O
- O
1 O
) O
, O
was O
detected O
by O
immunofluorescence O
with O
monoclonal O
antibodies O
, O
by O
the O
presence O
of O
gag O
- O
encoded O
protein O
p24 O
in O
the O
culture O
supernatant O
, O
and O
by O
cocultivation O
leading O
to O
infection O
and O
transformation O
of O
lymphocytes O
from O
an O
HTLV O
- O
I O
- O
negative O
donor O
. O

By O
using O
the O
polymerase O
chain O
reaction O
technique O
, O
the O
env O
gene O
and O
segments O
of O
the O
pol O
and O
pX O
regions O
of O
the O
proviral O
genome O
of O
HTLV O
- O
I O
( O
MSHR O
- O
1 O
) O
were O
amplified O
and O
sequenced O
. O

Differential O
reactivity O
with O
monoclonal O
antibodies O
suggests O
that O
gag O
protein O
p19 O
of O
HTLV O
- O
I O
( O
MSHR O
- O
1 O
) O
is O
also O
divergent O
. O

The O
high O
prevalences O
of O
antibodies O
against O
human B
T I
- I
cell I
leukemia I
( I
lymphotropic I
) I
virus I
type I
I I
( I
HTLV I
- I
1 I
) I
reported O
for O
remote O
populations O
in O
Papua O
New O
Guinea O
and O
the O
Solomon O
Islands O
and O
for O
some O
aboriginal O
populations O
in O
Australia O
have O
been O
verified O
by O
virus O
isolation O
. O

Limited O
genetic O
analysis O
of O
the O
transmembrane O
portion O
( O
gp21 O
) O
of O
the O
envelope O
gene O
of O
these O
viruses O
indicates O
the O
existence O
of O
highly O
divergent O
HTLV O
- O
I O
strains O
in O
Melanesia O
. O

Here O
, O
we O
report O
the O
complete O
nucleotide O
sequence O
of O
an O
HTLV O
- O
1 O
isolate O
( O
designated O
HTLV O
- O
I O
( O
MELS O
) O
) O
from O
the O
Solomon O
Islands O
. O

The O
overall O
nucleotide O
divergence O
of O
HTLV O
- O
I O
( O
MELS O
) O
from O
the O
prototype O
HTLV O
- O
I O
( O
ATK O
) O
was O
approximately O
8 O
. O

5 O
to O
25 O
% O
) O
for O
the O
regulatory O
( O
tax O
and O
rex O
) O
genes O
and O
the O
other O
genes O
encoded O
by O
the O
pX O
region O
. O

Since O
HTLV O
- O
I O
( O
MELS O
) O
was O
as O
distantly O
related O
to O
HTLV O
- O
II O
as O
to O
the O
other O
known O
HTLV O
- O
I O
strains O
, O
it O
could O
not O
have O
arisen O
from O
a O
recombinational O
event O
involving O
HTLV O
- O
II O
but O
rather O
might O
be O
an O
example O
of O
independent O
viral O
evolution O
in O
this O
remote O
population O
. O

The O
immediate O
- O
early O
1 O
and O
2 O
gene O
locus O
of O
human B
cytomegalovirus I
( I
HCMV I
) I
that O
encodes O
trans O
- O
activator O
proteins O
with O
effects O
on O
both O
homologous O
and O
heterologous O
promoters O
is O
expressed O
under O
control O
of O
a O
complex O
enhancer O
/ O
promoter O
regulatory O
region O
. O

Twelve O
synthetic O
peptides O
containing O
hydrophilic O
amino O
acid O
sequences O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
envelope O
glycoprotein O
were O
coupled O
to O
tetanus O
toxoid O
and O
used O
to O
raise O
epitope O
- O
specific O
antisera O
in O
goats O
and O
rabbits O
. O

Low O
neutralizing O
antibody O
titers O
( O
1 O
: O
10 O
to O
1 O
: O
20 O
) O
raised O
in O
rabbits O
to O
peptides O
SP O
- O
2 O
( O
envelope O
amino O
acids O
[ O
aa O
] O
86 O
to O
107 O
) O
, O
SP O
- O
3 O
( O
aa O
176 O
to O
189 O
) O
, O
and O
SP O
- O
4A O
( O
aa O
190 O
to O
209 O
) O
as O
well O
as O
to O
combined O
peptide O
SP O
- O
3 O
/ O
4A O
( O
aa O
176 O
to O
209 O
) O
were O
detected O
in O
the O
vesicular O
stomatitis O
virus O
- O
HTLV O
- O
I O
pseudotype O
assay O
. O

Higher O
- O
titered O
neutralizing O
antibody O
responses O
to O
HTLV O
- O
I O
( O
1 O
: O
10 O
to O
1 O
: O
640 O
) O
were O
detected O
with O
pseudotype O
and O
syncytium O
inhibition O
assays O
in O
four O
goats O
immunized O
with O
a O
combined O
inoculum O
containing O
peptides O
SP O
- O
2 O
, O
SP O
- O
3 O
, O
and O
SP O
- O
4A O
linked O
to O
tetanus O
toxoid O
. O

Neutralizing O
antibodies O
in O
sera O
from O
three O
goats O
could O
be O
adsorbed O
with O
peptide O
SP O
- O
2 O
( O
aa O
86 O
to O
107 O
) O
as O
well O
as O
truncated O
peptides O
containing O
envelope O
aa O
90 O
to O
98 O
, O
but O
not O
with O
equimolar O
amounts O
of O
peptides O
lacking O
envelope O
aa O
90 O
to O
98 O
. O

Peptide O
DP O
- O
90 O
, O
containing O
the O
homologous O
region O
of O
HTLV O
- O
II O
envelope O
glycoprotein O
( O
aa O
82 O
to O
97 O
) O
, O
elicited O
antipeptide O
neutralizing O
antibodies O
to O
HTLV O
- O
II O
in O
goats O
that O
were O
type O
specific O
. O

In O
further O
adsorption O
experiments O
, O
it O
was O
determined O
that O
amino O
acid O
differences O
between O
homologous O
HTLV O
- O
I O
and O
HTLV O
- O
II O
envelope O
sequences O
at O
HTLV O
- O
I O
aa O
95 O
( O
N O
to O
Q O
) O
and O
97 O
( O
G O
to O
L O
) O
determined O
the O
type O
specificity O
of O
these O
neutralizing O
sites O
. O

human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
immortalizes O
human O
CD4 O
+ O
T O
lymphocytes O
in O
culture O
. O

A O
trans O
- O
acting O
regulatory O
gene O
product O
p40tax O
( O
Tax O
) O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
is O
one O
of O
the O
main O
target O
antigens O
recognized O
by O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
specific O
for O
HTLV O
- O
I O
. O

We O
have O
studied O
the O
genetic O
variation O
of O
human B
T I
- I
cell I
leukemia I
/ I
lymphoma I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
isolates O
in O
the O
same O
individuals O
over O
time O
, O
as O
well O
as O
of O
HTLV O
- O
I O
isolates O
from O
various O
parts O
of O
the O
world O
. O

DNA O
analyses O
of O
HTLV O
- O
I O
sequences O
demonstrated O
that O
( O
i O
) O
little O
or O
no O
genetic O
variation O
occurred O
in O
vivo O
in O
the O
same O
individual O
or O
in O
different O
hosts O
from O
the O
same O
region O
carrying O
the O
same O
virus O
, O
regardless O
of O
their O
clinical O
statuses O
; O
( O
ii O
) O
changes O
in O
nucleotide O
sequences O
in O
some O
regions O
of O
the O
HTLV O
- O
I O
genome O
were O
diagnostic O
of O
the O
geographical O
origin O
of O
the O
viruses O
; O
( O
iii O
) O
HTLV O
- O
I O
sequences O
from O
West O
African O
countries O
( O
Mauritania O
and O
Guinea O
Bissau O
) O
and O
some O
from O
the O
Ivory O
Coast O
and O
Central O
African O
Republic O
were O
virtually O
identical O
to O
those O
from O
the O
French O
West O
Indies O
, O
Haiti O
, O
French O
Guyana O
, O
and O
Peru O
, O
strongly O
suggesting O
that O
at O
least O
some O
HTLV O
- O
I O
strains O
were O
introduced O
into O
the O
New O
World O
through O
infected O
individuals O
during O
the O
slave O
trade O
events O
; O
and O
( O
iv O
) O
the O
Zairian O
HTLV O
- O
I O
isolates O
represent O
a O
separate O
HTLV O
- O
I O
cluster O
, O
in O
which O
intrastrain O
variability O
was O
also O
observed O
, O
and O
are O
more O
divergent O
from O
the O
other O
HTLV O
- O
I O
isolates O
. O

Human O
T O
- O
cell O
leukemia O
( O
or O
lymphotropic O
) O
virus O
type O
II O
( O
HTLV O
- O
II O
) O
was O
isolated O
from O
eight O
HTLV O
- O
seropositive O
patients O
, O
six O
of O
whom O
were O
also O
infected O
with O
human O
immunodeficiency O
virus O
, O
by O
cocultivation O
of O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
with O
BJAB O
, O
a O
continuous O
B O
- O
cell O
line O
. O

Exploitation O
of O
differences O
in O
restriction O
endonucleas O
sites O
allowed O
polymerase O
chain O
reaction O
amplification O
to O
detect O
and O
differentiate O
the O
two O
subtypes O
in O
fresh O
PBMCs O
of O
HTLV O
- O
seropositive O
intravenous B
drug I
abusers I
( I
IVDAs I
) I
. O

Recent O
studies O
have O
established O
the O
presence O
of O
human B
T I
- I
cell I
lymphoma I
/ I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
in O
Melanesia O
. O

Sequence O
analyses O
of O
amplified O
regions O
of O
pol O
, O
env O
, O
and O
pX O
genes O
of O
this O
variant O
indicate O
marked O
heterogeneity O
( O
approximately O
7 O
% O
) O
from O
prototype O
HTLV O
- O
I O
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
envelope O
protein O
is O
synthesized O
as O
a O
gp61 O
precursor O
product O
cleaved O
into O
two O
mature O
proteins O
, O
a O
gp45 O
exterior O
protein O
and O
a O
gp20 O
anchoring O
the O
envelope O
at O
the O
cell O
membrane O
. O

We O
show O
here O
that O
experimental O
conditions O
resulting O
in O
the O
absence O
of O
precursor O
cleavage O
( O
tunicamycin O
, O
monensin O
treatments O
, O
and O
use O
of O
inhibitors O
of O
the O
reticulum O
steps O
of O
the O
N O
glycosylations O
) O
also O
result O
in O
no O
cell O
surface O
expression O
of O
envelope O
protein O
. O

When O
the O
precursor O
is O
cleaved O
in O
the O
Golgi O
stack O
( O
no O
treatment O
or O
treatment O
with O
inhibitors O
of O
the O
Golgi O
steps O
of O
the O
N O
glycosylations O
) O
, O
it O
is O
transported O
to O
the O
cell O
surface O
in O
all O
the O
cases O
examined O
. O

Expression O
of O
the O
c O
- O
myb O
gene O
is O
induced O
in O
mitogen O
- O
and O
/ O
or O
antigen O
- O
stimulated O
T O
lymphocytes O
, O
which O
are O
also O
the O
preferential O
target O
cells O
of O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
in O
vivo O
and O
in O
vitro O
. O

We O
report O
here O
that O
Myb O
binds O
to O
the O
HTLV O
- O
I O
long B
terminal I
repeat I
( I
LTR I
) I
in O
four O
different O
regions O
in O
a O
sequence O
- O
specific O
manner O
. O

We O
recently O
demonstrated O
that O
members O
of O
the O
c O
- O
ets O
proto O
- O
oncogene O
family O
, O
Ets1 O
and O
Ets2 O
, O
are O
sequence O
- O
specific O
transcriptional O
activators O
of O
the O
human B
T I
- I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
long I
terminal I
repeat I
( I
LTR I
) I
. O

To O
investigate O
the O
geography O
- O
and O
disease O
- O
associated O
genomic O
variation O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
, O
we O
studied O
ex O
vivo O
DNA O
from O
peripheral O
blood O
lymphocytes O
from O
nine O
patients O
by O
polymerase O
chain O
reaction O
and O
direct O
DNA O
sequencing O
. O

While O
no O
specific O
mutation O
could O
be O
linked O
to O
any O
pathology O
( O
adult O
T O
- O
cell O
leukemia O
/ O
lymphoma O
or O
tropical O
spastic O
paraparesis O
/ O
HTLV O
- O
I O
- O
associated O
myelopathy O
) O
, O
variations O
among O
HTLV O
- O
I O
isolates O
from O
different O
geographic O
areas O
( O
Ivory O
Coast O
, O
Caribbean O
, O
and O
Japan O
) O
existed O
. O

human B
T I
- I
cell I
lymphotropic I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
encodes O
a O
40 O
- O
kDa O
nuclear O
transactivating O
phosphoprotein O
, O
TAX1 O
. O

The O
results O
presented O
in O
this O
study O
demonstrate O
that O
deletion O
of O
amino O
acids O
2 O
through O
59 O
of O
TAX1 O
( O
DELTA O
- O
58 O
TAX1 O
) O
decreased O
transactivation O
of O
the O
HTLV O
- O
I O
long O
terminal O
repeat O
10 O
- O
to O
20 O
- O
fold O
. O

A O
series O
of O
synthetic O
peptides O
derived O
from O
the O
corresponding O
regions O
of O
the O
gag O
, O
pol O
, O
and O
env O
proteins O
of O
human B
T I
- I
cell I
lymphotropic I
virus I
types I
I I
( I
HTLV I
- I
I I
) I
and O
II O
( O
HTLV O
- O
II O
) O
were O
used O
in O
an O
enzyme O
immunoassay O
to O
map O
the O
immunodominant O
epitopes O
of O
HTLV O
. O

Serum O
specimens O
from O
79 O
of O
87 O
( O
91 O
% O
) O
HTLV O
- O
I O
- O
infected O
patients O
reacted O
with O
the O
synthetic O
peptide O
Gag O
- O
1a O
( O
amino O
acids O
[ O
a O
. O

Minimal O
cross O
- O
reactivity O
( O
11 O
% O
) O
was O
observed O
with O
serum O
specimens O
from O
HTLV O
- O
II O
- O
infected O
patients O
. O

487 O
to O
502 O
) O
, O
reacted O
with O
serum O
specimens O
from O
both O
HTLV O
- O
I O
- O
and O
HTLV O
- O
II O
- O
infected O
patients O
( O
94 O
and O
86 O
% O
, O
respectively O
) O
. O

Tropical O
spastic O
paraparesis O
/ O
human O
T O
- O
cell O
leukemia O
- O
lymphoma O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
- O
associated O
myelopathy O
( O
TSP O
/ O
HAM O
) O
is O
a O
chronic O
neurological O
illness O
epidemiologically O
associated O
with O
HTLV O
- O
I O
infection O
. O

We O
investigated O
the O
role O
of O
HTLV O
- O
I O
in O
the O
pathogenesis O
of O
this O
disease O
by O
studying O
viral O
expression O
in O
fresh O
uncultured O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
six O
patients O
of O
Caribbean O
origin O
with O
TSP O
/ O
HAM O
. O

The O
PBMC O
genomic O
DNA O
of O
all O
the O
patients O
studied O
carried O
HTLV O
- O
I O
provirus O
, O
but O
viral O
expression O
was O
not O
detected O
by O
Northern O
( O
RNA O
) O
blot O
analysis O
of O
total O
cellular O
PBMC O
RNA O
. O

When O
the O
reverse O
transcriptase O
polymerase O
chain O
reaction O
technique O
was O
used O
with O
primers O
specific O
for O
the O
tax O
- O
rex O
mRNA O
, O
all O
of O
the O
samples O
were O
positive O
for O
this O
viral O
mRNA O
species O
, O
regardless O
of O
the O
duration O
of O
the O
illness O
( O
range O
, O
2 O
to O
13 O
years O
) O
. O

The O
splice O
junctions O
for O
the O
tax O
- O
rex O
mRNA O
described O
in O
cases O
of O
HTLV O
- O
I O
- O
induced O
adult O
T O
- O
cell O
leukemia O
( O
position O
5183 O
of O
the O
envelope O
and O
position O
7302 O
of O
the O
pX O
region O
) O
were O
identical O
in O
three O
TSP O
/ O
HAM O
cases O
studied O
. O

To O
ascertain O
whether O
viral O
expression O
occurred O
at O
a O
low O
level O
in O
many O
cells O
or O
at O
a O
high O
level O
in O
a O
few O
permissive O
cells O
, O
we O
performed O
in O
situ O
hybridization O
on O
fresh O
PBMCs O
from O
two O
patients O
( O
2 O
and O
7 O
years O
after O
clinical O
diagnosis O
) O
, O
seeking O
HTLV O
- O
I O
RNA O
sequences O
. O

Our O
finding O
indicated O
that O
in O
vivo O
HTLV O
- O
I O
expression O
occurred O
at O
a O
high O
level O
in O
a O
few O
cells O
( O
1 O
of O
every O
5 O
, O
000 O
PBMCs O
) O
in O
both O
cases O
studied O
. O

The O
fact O
that O
cells O
of O
all O
six O
patients O
with O
TSP O
/ O
HAM O
were O
positive O
for O
viral O
expression O
, O
regardless O
of O
the O
time O
lag O
from O
diagnosis O
, O
suggests O
that O
persistent O
expression O
of O
a O
viral O
product O
( O
s O
) O
may O
be O
pivotal O
in O
the O
pathogenesis O
of O
TSP O
/ O
HAM O
. O

The O
New O
World O
mammarenavirus O
Tacaribe B
virus I
( I
TCRV I
) I
has O
been O
isolated O
from O
fruit O
bats O
, O
mosquitoes O
, O
and O
ticks O
, O
whereas O
all O
other O
known O
New O
World O
mammarenaviruses O
are O
maintained O
in O
rodents O
. O

TCRV O
has O
not O
been O
linked O
to O
human O
disease O
, O
but O
it O
has O
been O
shown O
to O
protect O
against O
Argentine O
hemorrhagic O
fever O
- O
like O
disease O
in O
marmosets O
infected O
with O
the O
New O
World O
mammarenavirus O
Junin B
virus I
( I
JUNV I
) I
, O
indicating O
the O
potential O
of O
TCRV O
as O
a O
live O
- O
attenuated O
vaccine O
for O
the O
treatment O
of O
Argentine O
hemorrhagic O
fever O
. O

In O
this O
study O
, O
we O
developed O
, O
for O
the O
first O
time O
, O
reverse O
genetics O
approaches O
for O
the O
generation O
of O
recombinant B
TCRV I
( I
rTCRV I
) I
. O

We O
successfully O
rescued O
a O
wild B
- I
type I
( I
WT I
) I
rTCRV O
( O
a O
trisegmented O
form O
of O
TCRV O
expressing O
two O
reporter O
genes O
[ O
r3TCRV O
] O
) O
and O
a O
bisegmented O
TCRV O
expressing O
a O
single O
reporter O
gene O
from O
a O
bicistronic O
viral O
mRNA O
( O
rTCRV O
/ O
GFP O
) O
. O

Notably O
, O
we O
identified O
a O
39 O
- O
nucleotide B
( I
nt I
) I
deletion O
( O
. O

39 O
) O
in O
the O
noncoding O
intergenic B
region I
( I
IGR I
) I
of O
the O
viral O
large B
( I
L I
) I
segment O
that O
is O
required O
for O
optimal O
virus O
multiplication O
. O

Accordingly O
, O
an O
rT O
- O
CRV O
containing O
this O
39 O
- O
nt O
deletion O
in O
the O
L O
- O
IGR O
( O
rTCRV O
/ O
Delta O
39 O
) O
exhibited O
decreased O
viral O
fitness O
in O
cultured O
cells O
, O
suggesting O
the O
feasibility O
of O
using O
this O
deletion O
in O
the O
L O
- O
IGR O
as O
an O
approach O
to O
attenuate O
TCRV O
, O
and O
potentially O
other O
mammarenaviruses O
, O
for O
their O
implementation O
as O
live O
- O
attenuated O
vaccines O
or O
vaccine O
vectors O
. O

IMPORTANCE O
To O
date O
, O
no O
Food B
and I
Drug I
Administration I
( I
FDA I
) I
- O
approved O
vaccines O
are O
available O
to O
combat O
hemorrhagic O
fever O
caused O
by O
mammarenavirus O
infections O
in O
humans O
. O

Tacaribe B
virus I
( I
TCRV I
) I
, O
the O
prototype O
member O
of O
the O
New O
World O
mammarenaviruses O
, O
is O
nonpathogenic O
in O
humans O
but O
able O
to O
provide O
protection O
against O
Junin B
virus I
( I
JUNV I
) I
, O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
, O
demonstrating O
the O
feasibility O
of O
using O
TCRV O
as O
a O
liveattenuated O
vaccine O
vector O
for O
the O
treatment O
of O
JUNV O
and O
potentially O
other O
viral O
infections O
. O

Here O
, O
we O
describe O
for O
the O
first O
time O
the O
feasibility O
of O
generating O
recombinant B
TCRV I
( I
rTCRV I
) I
using O
reverse O
genetics O
approaches O
, O
which O
paves O
the O
way O
to O
study O
the O
biology O
of O
TCRV O
and O
also O
its O
potential O
use O
as O
a O
live O
- O
attenuated O
vaccine O
or O
a O
vaccine O
vector O
for O
the O
treatment O
of O
mammarenavirus O
and O
/ O
or O
other O
viral O
infections O
in O
humans O
. O

Argentine O
hemorrhagic O
fever O
is O
a O
potentially O
lethal O
disease O
that O
is O
caused O
by O
Junin B
virus I
( I
JUNV I
) I
. O

The O
live O
attenuated O
vaccine O
strain O
Candid B
#1 I
( I
Can I
) I
is O
approved O
for O
use O
in O
regions O
of O
endemicity O
and O
has O
substantially O
decreased O
the O
number O
of O
annual O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
cases O
. O

The O
glycoprotein B
( I
GPC I
) I
gene O
is O
primarily O
responsible O
for O
attenuation O
of O
the O
Can O
strain O
, O
and O
we O
have O
shown O
that O
the O
absence O
of O
an O
N O
- O
linked O
glycosylation O
motif O
in O
the O
subunit O
G1 O
of O
the O
glycoprotein O
complex O
of O
Can O
, O
which O
is O
otherwise O
present O
in O
the O
wild O
- O
type O
pathogenic O
JUNV O
, O
causes O
GPC O
retention O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

Cells O
infected O
with O
the O
wild O
- O
type O
Romero B
( I
Rom I
) I
strain O
do O
not O
produce O
aggregates O
that O
are O
observed O
in O
Can O
infection O
, O
and O
the O
stress O
on O
the O
ER O
remains O
minimal O
. O

While O
the O
mutation O
of O
the O
N O
- O
linked O
glycosylation O
motif O
( O
T168A O
) O
is O
primarily O
responsible O
for O
the O
formation O
of O
aggregates O
, O
other O
mutations O
within O
61 O
that O
occurred O
earlier O
in O
the O
passage O
history O
of O
the O
Can O
strain O
also O
contribute O
to O
aggregation O
of O
the O
GPC O
within O
the O
ER O
. O

Machupo B
virus I
( I
MACV I
) I
, O
the O
causative O
agent O
of O
Bolivian B
hemorrhagic I
fever I
( I
BHF I
) I
, O
is O
a O
New O
World O
arenavirus O
that O
was O
first O
isolated O
in O
Bolivia O
from O
a O
human O
spleen O
in O
1963 O
. O

In O
this O
study O
, O
we O
used O
DNA O
vaccination O
against O
the O
MACV O
glycoprotein B
precursor I
complex I
( I
GPC I
) I
and O
murine O
hybridoma O
technology O
to O
generate O
25 O
mouse B
monoclonal I
antibodies I
( I
MAbs I
) I
against O
the O
GPC O
of O
MACV O
. O

Out O
of O
25 O
MAbs O
, O
five O
were O
found O
to O
have O
potent O
neutralization O
activity O
in O
vitro O
against O
a O
recombinant O
vesicular B
stomatitis I
virus I
expressing I
MACV I
GPC I
( I
VSV I
- I
MACV I
) I
as O
well O
as O
against O
authentic O
MACV O
. O

Furthermore O
, O
the O
five O
neutralizing O
MAbs O
exhibited O
strong O
antibody B
- I
dependent I
cellular I
cytotoxicity I
( I
ADCC I
) I
activity O
in O
a O
reporter O
assay O
. O

When O
tested O
in O
vivo O
using O
VSV O
- O
MACV O
in O
a O
Stat2 O
( O
- O
/ O
- O
) O
mouse O
model O
, O
three O
MAbs O
significantly O
lowered O
viral O
loads O
in O
the O
spleen O
. O

Several O
clade O
B O
New B
World I
arenaviruses I
( I
NWAs I
) I
can O
cause O
severe O
and O
often O
fatal O
hemorrhagic O
fever O
, O
for O
which O
preventive O
and O
therapeutic O
measures O
are O
severely O
limited O
. O

These O
NWAs O
use O
Human B
transferrin I
receptor I
1 I
( I
hTfR1 I
) I
as O
a O
host O
cell O
receptor O
for O
virus O
entry O
. O

The O
most O
prevalent O
of O
the O
pathogenic O
NWAs O
is O
Junin B
virus I
( I
JUNV I
) I
, O
the O
etiological O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

We O
provide O
evidence O
that O
the O
guinea B
pig I
TfR1 I
( I
gpTfR1 I
) I
is O
the O
principal O
receptor O
for O
JUNV O
, O
while O
hamster O
and O
mouse O
orthologs O
fail O
to O
support O
viral O
entry O
/ O
infection O
of O
pseudotyped O
murine O
leukemia O
viruses O
expressing O
pathogenic O
NWA O
glycoproteins O
or O
JUNV O
. O

Junin B
virus I
( I
JUNV I
) I
, O
a O
member O
of O
the O
family O
Arenaviridae O
, O
is O
the O
etiological O
agent O
of O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
, O
a O
potentially O
deadly O
endemicepidemic O
disease O
affecting O
the O
population O
of O
the O
most O
fertile O
farming O
land O
of O
Argentina O
. O

We O
determined O
the O
role O
of O
autophagy O
in O
JUNV O
- O
infected O
cells O
by O
analyzing O
LC3 O
, O
a O
cytoplasmic O
protein O
( O
LC3 O
- O
I O
) O
that O
becomes O
vesicle O
membrane O
associated O
( O
LC3 O
- O
II O
) O
upon O
induction O
of O
autophagy O
. O

Cells O
overexpressing O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
- O
LC3 O
and O
infected O
with O
JUNV O
showed O
an O
increased O
number O
of O
LC3 O
punctate O
structures O
, O
similar O
to O
those O
obtained O
after O
starvation O
or O
bafilomycin O
A1 O
treatment O
, O
which O
leads O
to O
autophagosome O
induction O
or O
accumulation O
, O
respectively O
. O

Also O
, O
we O
assayed O
the O
replication O
capacity O
of O
JUNV O
in O
Atg5 O
knockout O
or O
Beclin O
1 O
knockdown O
cells O
( O
both O
critical O
components O
of O
the O
autophagic O
pathway O
) O
and O
found O
a O
significant O
decrease O
in O
JUNV O
replication O
. O

1 O
against O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
, O
licensed O
for O
human O
use O
in O
areas O
of O
endemicity O
in O
Argentina O
. O

In O
particular O
, O
Junin B
mammarenavirus I
( I
JUNV I
) I
is O
the O
etiologic O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

At O
present O
, O
little O
is O
known O
about O
the O
cellular O
proteins O
that O
the O
arenavirus O
matrix O
protein O
( O
Z O
) O
hijacks O
to O
accomplish O
its O
various O
functions O
, O
including O
driving O
the O
process O
of O
virus O
release O
. O

To O
address O
these O
deficiencies O
, O
we O
used O
mass O
spectrometry O
to O
identify O
human O
proteins O
that O
( O
i O
) O
interact O
with O
the O
JUNV O
matrix O
protein O
inside O
cells O
or O
within O
virus B
- I
like I
particles I
( I
VLPs I
) I
and O
/ O
or O
( O
ii O
) O
are O
incorporated O
into O
bona O
fide O
JUNV O
strain O
Candid# O
1 O
particles O
. O

Bioinformatics O
analyses O
revealed O
that O
multiple O
classes O
of O
human O
proteins O
were O
overrepresented O
in O
the O
data O
sets O
, O
including O
ribosomal O
proteins O
, O
Ras O
superfamily O
proteins O
, O
and O
endosomal B
sorting I
complex I
required I
for I
transport I
( I
ESCRT I
) I
proteins O
. O

Several O
of O
these O
proteins O
were O
required O
for O
the O
propagation O
of O
JUNV O
( O
ADP O
ribosylation O
factor O
1 O
[ O
ARF1 O
] O
, O
ATPase O
, O
H O
+ O
transporting O
, O
lysosomal O
38 O
- O
kDa O
, O
V0 O
subunit O
d1 O
[ O
ATP6V0D1 O
] O
, O
and O
peroxiredoxin O
3 O
[ O
PRDX3 O
] O
) O
, O
lymphocytic B
choriomeningitis I
mammarenavirus I
( I
LCMV I
) I
( O
Rab5c O
) O
, O
or O
both O
viruses O
( O
ATP O
synthase O
, O
H O
+ O
transporting O
, O
mitochondrial O
F1 O
complex O
, O
beta O
polypeptide O
[ O
ATP5B O
] O
and O
IMP O
dehydrogenase O
2 O
[ O
IMPDH2 O
] O
) O
. O

Using O
Junin B
mammarenavirus I
( I
JUNV I
) I
, O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
, O
as O
a O
model O
organism O
, O
we O
mapped O
the O
human O
proteins O
that O
are O
incorporated O
into O
JUNV O
particles O
or O
that O
associate O
with O
the O
JUNV O
matrix O
protein O
. O

Recent O
studies O
have O
revealed O
that O
Candid#1 O
attenuation O
is O
entirely O
dependent O
on O
a O
phenylalanine O
- O
to O
- O
isoleucine O
substitution O
at O
position O
427 O
in O
the O
fusion O
subunit O
( O
GP2 O
) O
of O
the O
viral O
envelope O
glycoprotein B
complex I
( I
GPC I
) I
, O
thereby O
raising O
concerns O
regarding O
the O
potential O
for O
reversion O
to O
virulence O
. O

In O
this O
study O
, O
we O
report O
the O
identification O
and O
characterization O
of O
an O
intragenic O
epistatic O
interaction O
between O
the O
attenuating O
F427I O
mutation O
in O
GP2 O
and O
a O
lysine O
- O
to O
- O
serine O
mutation O
at O
position O
33 O
in O
the O
stable B
signal I
peptide I
( I
SSP I
) I
subunit O
of O
GPC O
, O
and O
we O
demonstrate O
the O
utility O
of O
this O
interaction O
in O
creating O
an O
evolutionary O
barrier O
against O
reversion O
to O
the O
pathogenic O
genotype O
. O

We O
show O
that O
the O
recombinant B
Candid#1 I
( I
rCan I
) I
virus O
bearing O
K33S O
GPC O
is O
viable O
and O
retains O
its O
attenuated O
genotype O
under O
cell O
culture O
conditions O
that O
readily O
select O
for O
reversion O
in O
the O
parental O
rCan O
virus O
. O

Recent O
findings O
that O
a O
single O
missense O
mutation O
in O
the O
viral O
envelope O
glycoprotein B
complex I
( I
GPC I
) I
is O
responsible O
for O
attenuation O
raise O
the O
prospect O
of O
facile O
reversion O
to O
pathogenicity O
. O

Unlike O
other O
class O
I O
viral O
fusion O
proteins O
, O
GPC O
retains O
its O
stable B
signal I
peptide I
( I
SSP I
) I
as O
an O
essential O
third O
subunit O
in O
the O
mature O
complex O
. O

In O
order O
to O
examine O
the O
role O
of O
SSP O
myristoylation O
in O
the O
context O
of O
the O
intact O
virus O
, O
we O
used O
reverse O
genetics O
to O
generate O
Junin O
viruses O
( O
Candid O
#1 O
isolate O
) O
in O
which O
the O
critical O
glycine O
- O
2 O
residue O
in O
SSP O
was O
either O
replaced O
by O
alanine O
( O
G2A O
) O
or O
deleted O
( O
Delta O
G2 O
) O
. O

Unlike O
other O
viral O
envelope O
glycoproteins O
, O
GPC O
contains O
a O
myristoylated O
stable B
signal I
peptide I
( I
SSP I
) I
as O
an O
essential O
third O
subunit O
. O

In O
the O
present O
study O
, O
we O
produced O
arenavirus O
neutralizing O
antibodies O
by O
DNA O
vaccination O
of O
rabbits O
with O
plasmids O
encoding O
the O
full O
- O
length O
glycoprotein O
precursors O
of O
Junin B
virus I
( I
JUNV I
) I
, O
Machupo B
virus I
( I
MACV I
) I
, O
and O
Guanarito B
virus I
( I
GTOV I
) I
. O

Geometric O
mean O
neutralizing O
antibody O
titers O
, O
as O
measured O
by O
the O
50 B
% I
plaque I
reduction I
neutralization I
test I
( I
PRNT50 I
) I
, O
exceeded O
5 O
, O
000 O
against O
homologous O
viruses O
. O

Anti O
- O
JUNV O
glycoprotein O
rabbit O
antiserum O
protected O
Hartley O
guinea O
pigs O
from O
lethal O
intraperitoneal O
infection O
with O
JUNV O
strain O
Romero O
when O
the O
antiserum O
was O
administered O
2 O
days O
after O
challenge O
and O
provided O
some O
protection O
( O
similar O
to O
30 O
% O
) O
when O
administered O
4 O
days O
after O
challenge O
. O

We O
then O
expanded O
on O
this O
cocktail O
approach O
by O
simultaneously O
vaccinating O
rabbits O
with O
a O
combination O
of O
plasmids O
encoding O
glycoproteins O
from O
JUNV O
, O
MACV O
, O
GTOV O
, O
and O
Sabia B
virus I
( I
SABV I
) I
. O

Machupo B
virus I
( I
MACV I
) I
is O
the O
causative O
agent O
of O
Bolivian O
hemorrhagic O
fever O
. O

Our O
previous O
study O
demonstrated O
that O
a O
MACV O
strain O
with O
a O
single O
amino O
acid O
substitution O
( O
F438I O
) O
in O
the O
transmembrane O
domain O
of O
glycoprotein O
is O
attenuated O
but O
genetically O
unstable O
in O
mice O
. O

MACV O
is O
closely O
related O
to O
Junin B
virus I
( I
JUNV I
) I
, O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

Recombinant O
MACV O
with O
the O
Candid#1 B
glycoprotein I
( I
rMACV I
/ I
Cd#1 I
- I
GPC I
) I
exhibited O
growth O
properties O
similar O
to O
those O
of O
Candid#1 O
and O
was O
genetically O
stable O
in O
vitro O
. O

The O
arenavirus O
Junin B
virus I
( I
JUNV I
) I
is O
the O
etiologic O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

We O
characterized O
the O
JUNV O
infection O
of O
human B
peripheral I
blood I
- I
derived I
plasmacytoid I
dendritic I
cells I
( I
hpDC I
) I
, O
demonstrating O
that O
hpDC O
are O
susceptible O
to O
infection O
with O
the O
C#1 O
strain O
( O
attenuated O
) O
and O
even O
more O
susceptible O
to O
infection O
with O
the O
P O
( O
virulent O
) O
JUNV O
strain O
. O

Arenaviruses O
have O
a O
significant O
impact O
on O
public O
health O
and O
pose O
a O
credible O
biodefense O
threat O
, O
but O
the O
development O
of O
safe O
and O
effective O
arenavirus O
vaccines O
has O
remained O
elusive O
, O
and O
currently O
, O
no O
Food B
and I
Drug I
Administration I
( I
FDA I
) I
- O
licensed O
arenavirus O
vaccines O
are O
available O
. O

Here O
, O
we O
explored O
the O
use O
of O
a O
codon B
deoptimization I
( I
CD I
) I
- O
based O
approach O
as O
a O
novel O
strategy O
to O
develop O
live O
- O
attenuated O
arenavirus O
vaccines O
. O

We O
recoded O
the O
nucleoprotein B
( I
NP I
) I
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
with O
the O
least O
frequently O
used O
codons O
in O
mammalian O
cells O
, O
which O
caused O
lower O
LCMV O
NP O
expression O
levels O
in O
transfected O
cells O
that O
correlated O
with O
decreased O
NP O
activity O
in O
cell O
- O
based O
functional O
assays O
. O

We O
used O
reverse O
- O
genetics O
approaches O
to O
rescue O
a O
battery O
of O
recombinant O
LCMVs O
( O
rLCMVs O
) O
encoding O
CD O
NPs O
( O
rLCMV O
/ O
NPCD O
) O
that O
showed O
attenuated O
growth O
kinetics O
in O
vitro O
. O

Moreover O
, O
experiments O
using O
the O
well O
- O
characterized O
mouse O
model O
of O
LCMV O
infection O
revealed O
that O
rLCMV O
/ O
NPCD1 O
and O
rLCMV O
/ O
NPCD2 O
were O
highly O
attenuated O
in O
vivo O
but O
, O
upon O
a O
single O
immunization O
, O
conferred O
complete O
protection O
against O
a O
subsequent O
lethal O
challenge O
with O
wild B
- I
type I
( I
WT I
) I
recombinant O
LCMV O
( O
rLCMV O
/ O
WT O
) O
. O

Here O
, O
we O
describe O
the O
generation O
of O
recombinant O
versions O
of O
the O
prototypic O
arenavirusLCMVencoding O
codon O
- O
deoptimized O
viral O
nucleoproteins O
( O
rLCMV O
/ O
NPCD O
) O
. O

Previously O
, O
we O
demonstrated O
that O
Junin O
virus O
, O
the O
etiological O
agent O
responsible O
for O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
, O
activates O
an O
early O
innate O
immune O
response O
via O
an O
interaction O
between O
the O
viral O
glycoprotein O
and O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
. O

Moreover O
, O
we O
show O
that O
TLR2 O
- O
mediated O
immune O
response O
plays O
a O
role O
in O
viral O
clearance O
because O
wild O
- O
type O
mice O
cleared O
Candid O
1 O
( O
JUNV O
C1 O
) O
, O
the O
vaccine O
strain O
of O
Junin O
virus O
, O
more O
rapidly O
than O
did O
TLR2 O
knockout O
mice O
. O

This O
clearance O
correlated O
with O
the O
generation O
of O
Junin O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Food B
and I
Drug I
Administration I
( I
FDA I
) I
- O
approved O
vaccines O
or O
therapeutics O
to O
prevent O
or O
treat O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
. O

The O
causative O
agent O
of O
AHF O
is O
Junin B
virus I
( I
JUNV I
) I
; O
a O
New O
World O
arenavirus O
classified O
as O
a O
National O
Institute O
of O
Allergy O
and O
Infectious O
Disease O
/ O
Centers O
for O
Disease O
Control O
and O
Prevention O
category O
A O
priority O
pathogen O
. O

The O
PTAP O
late B
( I
L I
) I
domain O
motif O
within O
JUNV O
Z O
protein O
facilitates O
virion O
egress O
and O
transmission O
by O
recruiting O
host O
Tsg101 O
and O
other O
ESCRT O
complex O
proteins O
to O
promote O
scission O
of O
the O
virus O
particle O
from O
the O
plasma O
membrane O
. O

Here O
, O
we O
describe O
a O
novel O
compound O
( O
compound O
0013 O
) O
that O
blocks O
the O
JUNV O
Z O
- O
Tsg101 O
interaction O
and O
inhibits O
budding O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
driven O
by O
ectopic O
expression O
of O
the O
Z O
protein O
and O
live O
- O
attenuated O
JUNV O
Candid O
- O
1 O
strain O
in O
cell O
culture O
. O

Junin B
virus I
( I
JUNV I
) I
belongs O
to O
the O
New O
World O
arenavirus O
serogroup O
of O
the O
Arenaviridae O
and O
is O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

We O
have O
demonstrated O
that O
infection O
with O
JUNV O
in O
cell O
culture O
does O
not O
induce O
apoptosis O
but O
leads O
to O
cleavage O
of O
the O
nucleoprotein B
( I
NP I
) I
into O
discrete O
products O
resembling O
caspase O
cleavage O
events O
. O

Candid#1 B
( I
Cd1 I
) I
is O
an O
attenuated O
vaccine O
strain O
of O
Junin O
virus O
, O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
. O

We O
functionally O
characterized O
the O
substitutions O
present O
in O
the O
Cd1 O
glycoprotein B
( I
GP I
) I
and O
identified O
F427I O
in O
the O
transmembrane O
domain O
of O
the O
GP2 O
subunit O
as O
reducing O
infectivity O
in O
a O
reconstituted O
viral O
system O
. O

Lastly O
, O
we O
identified O
an O
increased O
dependence O
of O
Cd1 O
GP O
on O
human B
transferrin I
receptor I
type I
1 I
( I
hTfR I
- I
1 I
) I
for O
entry O
, O
which O
may O
affect O
the O
tropism O
of O
the O
attenuated O
strain O
in O
vivo O
. O

Using O
Candid O
1 O
, O
as O
well O
as O
virus O
- O
like O
particles O
bearing O
the O
viral O
glycoprotein O
, O
to O
infect O
different O
primary O
cells O
and O
established O
macrophage O
cell O
lines O
with O
deletions O
in O
the O
Toll B
- I
like I
receptor I
( I
TLR I
) I
pathway O
, O
we O
show O
that O
TLR2 O
is O
a O
cellular O
sensor O
of O
both O
the O
Parodi O
and O
Candid O
1 O
viral O
glycoproteins O
. O

An O
off O
- O
label O
use O
of O
the O
purine O
nucleoside O
analogue O
ribavirin O
( O
1 O
- O
beta O
- O
D O
- O
ribofuranosyl O
- O
1 O
- O
H O
- O
1 O
, O
2 O
, O
4 O
- O
triazole O
- O
3 O
- O
carboxamide O
) O
is O
the O
only O
antiviral O
treatment O
currently O
available O
for O
arenavirus O
infections O
. O

Here O
we O
document O
that O
ribavirin O
is O
mutagenic O
for O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
cell O
culture O
. O

The O
mutagenic O
activity O
of O
ribavirin O
on O
LCMV O
was O
observed O
under O
single O
- O
and O
multiple O
- O
passage O
regimes O
and O
could O
not O
be O
accounted O
for O
by O
a O
decrease O
of O
the O
intracellular O
GTP O
pool O
promoted O
by O
ribavirin O
- O
mediated O
inhibition O
of O
inosine B
monophosphate I
dehydrogenase I
( I
IMPDH I
) I
. O

The O
New O
World O
arenavirus O
Junin B
virus I
( I
JUNV I
) I
is O
the O
causative O
agent O
of O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
, O
which O
is O
associated O
with O
high O
morbidity O
and O
significant O
mortality O
. O

Several O
pathogenic O
strains O
of O
JUNV O
have O
been O
documented O
, O
and O
a O
highly O
attenuated O
vaccine O
strain O
( O
Candid O
#1 O
) O
was O
generated O
and O
used O
to O
vaccinate O
the O
human O
population O
at O
risk O
. O

Both O
recombinant B
Candid I
#1 I
( I
rCandid I
#1 I
) I
and O
Romero O
( O
rRomero O
) O
had O
the O
same O
growth O
properties O
and O
phenotypic O
features O
in O
cultured O
cells O
and O
in O
vivo O
as O
their O
corresponding O
parental O
viruses O
. O

Junin B
virus I
( I
JUNV I
) I
causes O
a O
highly O
lethal O
human O
disease O
, O
Argentine O
hemorrhagic O
fever O
. O

To O
date O
, O
two O
distinct O
cellular O
receptors O
have O
been O
identified O
that O
are O
used O
by O
different O
pathogenic O
viruses O
, O
alpha O
- O
dystroglycan O
by O
Lassa O
fever O
virus O
and O
transferrin B
receptor I
I I
( I
TfR1 I
) I
by O
certain O
New O
World O
clade O
B O
viruses O
. O

In O
the O
present O
study O
, O
we O
examined O
the O
use O
of O
TfR1 O
by O
the O
glycoproteins B
( I
GPs I
) I
from O
a O
panel O
of O
New O
World O
clade O
B O
arenaviruses O
comprising O
three O
pathogenic O
and O
two O
nonpathogenic O
strains O
. O

Accordingly O
, O
we O
vaccinated O
44 O
macaques O
with O
vaccinia O
virus O
- O
expressed O
Lassa O
virus O
structural O
proteins O
separately O
and O
in O
combination O
, O
with O
the O
object O
of O
inducing O
a O
predominantly O
TH1 O
- O
type O
immune O
response O
, O
Following O
Lassa O
virus O
challenge O
, O
all O
unvaccinated O
animals O
died O
( O
DQ O
survival O
) O
. O

Nine O
of O
10 O
animals O
vaccinated O
with O
all O
proteins O
survived O
( O
90 O
% O
survival O
) O
. O

Although O
no O
animals O
that O
received O
full O
- O
length O
glycoprotein O
alone O
had O
a O
high O
titer O
of O
antibody O
, O
17 O
of O
19 O
survived O
challenge O
( O
88 O
% O
) O
. O

In O
contrast O
, O
all O
animals O
vaccinated O
with O
nucleoprotein O
developed O
high O
titers O
of O
antibody O
but O
12 O
of O
15 O
died O
( O
20 O
% O
survival O
) O
. O

All O
animals O
vaccinated O
with O
single O
glycoproteins O
, O
G1 O
or O
G2 O
, O
died O
, O
but O
all O
those O
that O
received O
both O
single O
glycoproteins O
( O
GI O
plus O
G2 O
) O
at O
separate O
sites O
survived O
, O
showing O
that O
both O
glycoproteins O
are O
independently O
important O
in O
protection O
. O

The O
periodic O
emergence O
of O
novel O
Coronaviruses B
( I
CoVs I
) I
represents O
an O
ongoing O
public O
health O
concern O
with O
significant O
health O
and O
financial O
burdens O
worldwide O
. O

The O
most O
recent O
occurrence O
originated O
in O
the O
city O
of O
Wuhan O
, O
China O
, O
where O
a O
novel O
coronavirus O
( O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
[ O
SARS O
- O
CoV O
- O
2 O
] O
) O
emerged O
causing O
severe O
respiratory O
illness O
and O
pneumonia O
. O

The O
CoV O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
has O
been O
shown O
to O
promote O
cellular O
mRNA O
degradation O
, O
block O
host O
cell O
translation O
, O
and O
inhibit O
the O
innate O
immune O
response O
to O
virus O
infection O
. O

Here O
, O
we O
report O
the O
high O
- O
resolution O
crystal O
structure O
of O
the O
amino O
globular O
portion O
of O
SARS O
- O
CoV O
- O
2 O
nsp1 O
( O
residues O
10 O
to O
127 O
) O
at O
1 O
. O

Paired O
with O
the O
recently O
published O
structure O
of O
the O
carboxyl O
end O
of O
nsp1 O
( O
residues O
148 O
to O
180 O
) O
, O
our O
results O
provide O
the O
groundwork O
for O
future O
studies O
focusing O
on O
SARS O
- O
CoV O
- O
2 O
nsp1 O
structure O
and O
function O
during O
the O
viral O
life O
cycle O
. O

IMPORTANCE O
severe B
acute I
respiratory I
syndrome I
coronavirus I
2 I
( I
SARS I
- I
CoV I
- I
2 I
) I
is O
the O
causative O
agent O
of O
the O
COVID O
- O
19 O
pandemic O
. O

One O
protein O
known O
to O
play O
a O
critical O
role O
in O
the O
coronavirus O
life O
cycle O
is O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
. O

In O
pythons O
, O
nidovirus O
( O
recently O
reclassified O
as O
serpentovirus O
) O
infection O
induces O
an O
inflammation O
of O
the O
upper O
respiratory O
and O
alimentary O
tract O
which O
can O
develop O
into O
a O
severe O
, O
often O
fatal O
proliferative O
pneumonia O
. O

We O
observed O
pyogranulomatous O
and O
fibrinonecrotic O
lesions O
in O
organ O
systems O
other O
than O
the O
respiratory O
tract O
during O
full O
postmortem O
examinations O
on O
30 O
serpentovirus O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
- O
positive O
pythons O
of O
varying O
species O
originating O
from O
Switzerland O
and O
Spain O
. O

IMPORTANCE O
During O
the O
last O
years O
, O
python O
nidoviruses O
( O
now O
reclassified O
as O
serpentoviruses O
) O
have O
become O
a O
primary O
cause O
of O
fatal O
disease O
in O
pythons O
. O

Nidovirales O
is O
an O
order O
of O
animal O
and O
human O
viruses O
that O
comprises O
important O
zoonotic O
pathogens O
such O
as O
Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
, O
severe O
acute O
respiratory O
syndrome O
corona O
virus O
( O
SARS O
- O
CoV O
) O
, O
and O
SARS O
- O
CoV O
- O
2 O
. O

Human B
adenovirus I
type I
55 I
( I
HAdV55 I
) I
represents O
an O
emerging O
respiratory O
pathogen O
and O
causes O
severe O
pneumonia O
with O
high O
fatality O
in O
humans O
. O

In O
this O
study O
, O
we O
found O
that O
HAdV55 O
binding O
and O
infection O
were O
sharply O
reduced O
by O
disrupting O
the O
interaction O
of O
viral O
fiber O
protein O
with O
human B
desmoglein I
- I
2 I
( I
hDSG2 I
) I
but O
only O
slightly O
reduced O
by O
disrupting O
the O
interaction O
of O
viral O
fiber O
protein O
with O
human B
CD46 I
( I
hCD46 I
) I
. O

Although O
nontransgenic O
mice O
were O
resistant O
to O
HAdV55 O
infection O
, O
infection O
with O
HAdV55 O
was O
significantly O
increased O
in O
hDSG2 O
( O
+ O
/ O
+ O
) O
mice O
but O
was O
much O
less O
increased O
in O
hCD46 O
( O
+ O
/ O
+ O
) O
mice O
. O

IMPORTANCE O
Human B
adenovirus I
type I
55 I
( I
HAdV55 I
) I
has O
recently O
emerged O
as O
a O
highly O
virulent O
respiratory O
pathogen O
and O
has O
been O
linked O
to O
severe O
and O
even O
fatal O
pneumonia O
in O
immunocompetent O
adults O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
human B
desmoglein I
- I
2 I
( I
hDSG2 I
) I
plays O
the O
major O
roles O
during O
HAdV55 O
infection O
. O

human B
CD46 I
( I
hCD46 I
) I
could O
also O
mediate O
the O
infection O
of O
HAdV55 O
, O
but O
the O
efficiency O
was O
much O
lower O
than O
for O
hDSG2 O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
widely O
prevalent O
in O
pigs O
, O
resulting O
in O
significant O
economic O
losses O
worldwide O
. O

In O
the O
present O
study O
, O
we O
found O
that O
interleukin B
- I
17 I
( I
IL I
- I
17 I
) I
was O
upregulated O
by O
PRRSV O
infection O
. O

Subsequently O
, O
we O
demonstrated O
that O
PI3K O
and O
p38MAPK O
signaling O
pathways O
were O
essential O
for O
PRRSV O
- O
induced O
IL O
- O
17 O
production O
as O
addition O
of O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
and O
p38MAPK O
inhibitors O
dramatically O
reduced O
IL O
- O
17 O
production O
. O

More O
specifically O
, O
we O
demonstrate O
that O
PRRSV O
nonstructural B
protein I
11 I
( I
nsp11 I
) I
induced O
IL O
- O
17 O
production O
, O
which O
was O
also O
dependent O
on O
PI3K O
- O
p38MAPK O
- O
C O
/ O
EBP O
beta O
/ O
CREB O
pathways O
. O

IMPORTANCE O
Highly B
pathogenic I
porcine I
reproductive I
and I
respiratory I
syndrome I
virus I
( I
HP I
- I
PRRSV I
) I
associated O
with O
severe O
pneumonia O
has O
been O
one O
of O
the O
most O
important O
viral O
pathogens O
in O
pigs O
. O

A O
/ O
H1N1 O
2009 O
pandemic O
influenza O
virus O
( O
A O
/ O
H1N1 O
/ O
pdm09 O
) O
was O
first O
identified O
as O
a O
novel O
pandemic O
influenza B
A I
virus I
( I
IAV I
) I
in O
2009 O
. O

Previously O
, O
we O
reported O
that O
many O
viral O
antigens O
were O
detected O
in O
type B
II I
alveolar I
epithelial I
cells I
( I
AEC I
- I
IIs I
) I
within O
autopsied O
lung O
tissue O
from O
a O
patient O
with O
A O
/ O
H1N1 O
/ O
pdm09 O
pneumonia O
. O

To O
investigate O
the O
distribution O
of O
virus O
particles O
and O
morphological O
changes O
in O
host O
cells O
, O
the O
autopsied O
lung O
specimens O
from O
this O
patient O
were O
examined O
using O
Transmission B
electron I
microscopy I
( I
TEM I
) I
and O
a O
novel O
scanning B
electron I
microscopy I
( I
SEM I
) I
method O
. O

We O
focused O
on O
AEC O
- O
IIs O
as O
viral O
antigen O
- O
positive O
cells O
and O
on O
monocytes O
/ O
macrophages O
( O
Ms O
/ O
M O
phi O
s O
) O
and O
neutrophils O
( O
Neus O
) O
as O
innate O
immune O
cells O
. O

We O
identified O
virus O
particles O
and O
intranuclear O
dense O
tubules O
, O
which O
are O
associated O
with O
matrix B
1 I
( I
M1 I
) I
proteins O
from O
IAV O
. O

A O
single O
whole O
- O
cell O
analysis O
using O
a O
serial B
section I
array I
( I
SSA I
) I
- O
SEM O
identified O
virus O
particles O
in O
vesicles O
within O
the O
cytoplasm O
and O
/ O
or O
around O
the O
surfaces O
of O
AEC O
- O
11s O
, O
Ms O
/ O
M O
phi O
s O
, O
and O
Neus O
; O
however O
, O
intranuclear O
dense O
tubules O
were O
found O
only O
in O
AEC O
- O
11s O
. O

Computer O
- O
assisted O
processing O
of O
SSA O
- O
SEM O
images O
from O
each O
cell O
type O
enabled O
three B
- I
dimensional I
( I
3D I
) I
modeling O
of O
the O
distribution O
of O
virus O
particles O
within O
an O
ACE O
- O
II O
, O
a O
M O
/ O
M O
phi O
, O
and O
a O
Neu O
. O

This O
was O
because O
the O
majority O
of O
A O
/ O
H1N1 O
/ O
pdm09 O
in O
the O
lung O
tissue O
harbored O
an O
aspartic O
acid O
- O
to O
- O
glycine O
substitution O
at O
position O
222 O
( O
D222G O
) O
of O
the O
hemagglutinin O
protein O
. O

Genomes O
of O
viruses O
not O
currently O
known O
to O
infect O
humans O
, O
including O
members O
of O
the O
families O
Parvoviridae O
, O
Partitiviridae O
, O
Dicistroviridae O
, O
and O
Iflaviridae O
and O
circular B
Rep I
- I
encoding I
single I
- I
stranded I
DNA I
( I
CRESS I
- I
DNA I
) I
virus O
, O
were O
also O
detected O
in O
nasal O
swabs O
, O
possibly O
reflecting O
environmental O
contamination O
from O
insect O
, O
fungal O
, O
or O
unknown O
sources O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
respiratory O
infection O
in O
young O
children O
and O
high O
- O
risk O
adults O
. O

In O
this O
study O
, O
we O
discovered O
that O
an O
exchange B
protein I
directly I
activated I
by I
cyclic I
AMP I
( I
EPAC I
) I
can O
serve O
as O
a O
potential O
therapeutic O
target O
for O
RSV O
. O

In O
both O
lower O
and O
upper O
epithelial O
cells O
, O
treatment O
with O
EPAC O
inhibitor O
( O
ESI O
- O
09 O
) O
, O
but O
not O
protein O
kinase O
A O
inhibitor O
( O
H89 O
) O
, O
significantly O
inhibits O
RSV O
replication O
and O
proinflammatory O
cytokine O
/ O
chemokine O
induction O
. O

Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
continues O
to O
be O
the O
leading O
viral O
cause O
of O
severe O
acute O
lower O
respiratory O
tract O
disease O
in O
infants O
and O
children O
worldwide O
. O

Like O
RSV O
, O
Murine B
pneumonia I
virus I
( I
MPV I
) I
is O
a O
member O
of O
the O
genus O
Orthopneumovirus O
, O
family O
Pneumoviridae O
. O

We O
evaluated O
MPV O
as O
an O
RSV O
vaccine O
vector O
expressing O
the O
RSV O
fusion O
( O
F O
) O
glycoprotein O
. O

The O
RSV O
F O
open B
reading I
frame I
( I
ORF I
) I
was O
codon O
optimized O
, O
and O
the O
encoded O
RSV O
F O
protein O
was O
made O
identical O
to O
an O
early O
passage O
of O
RSV O
strain O
A2 O
. O

The O
RSV O
F O
ORF O
was O
placed O
under O
the O
control O
of O
MPV O
transcription O
signals O
and O
inserted O
at O
the O
first O
( O
rMPV O
- O
F1 O
) O
, O
third O
( O
rMPV O
- O
F3 O
) O
, O
or O
fourth O
( O
rMPV O
- O
F4 O
) O
gene O
position O
of O
a O
version O
of O
the O
MPV O
genome O
that O
contained O
a O
codon O
- O
pair O
- O
optimized O
polymerase O
( O
L O
) O
gene O
. O

IMPORTANCE O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
is O
an O
important O
human O
pathogen O
that O
lacks O
a O
licensed O
vaccine O
or O
antiviral O
drug O
suitable O
for O
routine O
use O
. O

We O
describe O
here O
the O
evaluation O
of O
recombinant B
murine I
pneumonia I
virus I
( I
rMPV I
) I
as O
a O
live O
- O
attenuated O
vector O
that O
expresses O
the O
RSV O
F O
protein O
, O
the O
major O
RSV O
neutralization O
antigen O
, O
as O
an O
experimental O
RSV O
vaccine O
. O

Previously O
, O
we O
demonstrated O
that O
the O
virus B
- I
encoded I
cyclin I
( I
v I
- I
cyclin I
) I
of O
murine O
gammaherpesvirus O
68 O
( O
gamma O
HV68 O
) O
is O
essential O
for O
optimal O
reactivation O
from O
latency O
in O
normal O
mice O
but O
not O
in O
mice O
lacking O
the O
host O
tumor O
suppressor O
p18 O
( O
INK4c O
) O
( O
p18 O
) O
. O

Here O
, O
we O
generated O
recombinant O
viruses O
in O
which O
we O
replaced O
the O
viral O
cyclin O
with O
the O
cellular O
p18 O
( O
INK4c O
) O
gene O
( O
p18KI O
) O
for O
targeted O
expression O
of O
p18 O
, O
specifically O
within O
infected O
cells O
. O

We O
find O
that O
the O
p18KI O
virus O
is O
similar O
to O
the O
cyclin B
- I
deficient I
virus I
( I
cycKO I
) I
in O
lytic O
infection O
, O
establishment O
of O
latency O
, O
and O
infected O
cell O
reservoirs O
. O

This O
work O
characterizes O
the O
role O
of O
a O
novel O
inhibitor O
of O
reactivation O
, O
host O
p18 O
( O
INK4c O
) O
, O
thereby O
bringing O
more O
clarity O
to O
a O
complex O
process O
with O
significant O
outcomes O
for O
infected O
individuals O
. O

human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
is O
a O
negative O
- O
sense O
singlestranded O
RNA O
virus O
belonging O
to O
the O
Paramyxoviridae O
family O
. O

The O
activation O
of O
the O
inflammasome O
by O
pathogens O
results O
in O
the O
production O
of O
proinflammatory O
cytokines O
such O
as O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
during O
infection O
. O

Activated O
caspase O
- O
1 O
cleaves O
pro O
- O
IL O
- O
1 O
beta O
into O
its O
mature O
( O
and O
active O
) O
secretory O
form O
. O

Furthermore O
, O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
activation O
( O
first O
signal O
) O
and O
potassium O
efflux O
( O
second O
signal O
) O
constituted O
two O
cellular O
events O
mediating O
inflammasome O
activation O
following O
HPIV3 O
infection O
. O

The O
HPIV3 O
C O
protein O
is O
an O
accessory O
protein O
encoded O
by O
the O
open O
reading O
frame O
of O
the O
viral O
phosphoprotein B
( I
P I
) I
gene O
. O

IMPORTANCE O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
is O
a O
paramyxovirus O
that O
causes O
respiratory O
tract O
diseases O
during O
infancy O
and O
childhood O
. O

Therefore O
, O
in O
order O
to O
develop O
anti O
- O
HPIV3 O
agents O
( O
therapeutics O
and O
vaccines O
) O
, O
it O
is O
important O
to O
study O
the O
HPIV3 O
- O
host O
interaction O
during O
the O
immune O
response O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
infects O
alveolar O
macrophages O
( O
AM O
phi O
) O
, O
causing O
dysregulated O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
production O
through O
a O
mechanism O
( O
s O
) O
yet O
to O
be O
resolved O
. O

Here O
, O
we O
show O
that O
AM O
phi O
infected O
with O
PRRSV O
secreted O
a O
reduced O
quantity O
of O
IFN O
- O
alpha O
following O
exposure O
of O
the O
cell O
to O
synthetic O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
. O

Rather O
, O
it O
coincided O
with O
two O
events O
that O
occurred O
late O
during O
infection O
and O
that O
were O
indicative O
of O
translational O
attenuation O
, O
specifically O
, O
the O
activation O
of O
eukaryotic B
translation I
initiation I
factor I
2 I
alpha I
( I
eIF2 I
alpha I
) I
and O
the O
appearance O
of O
stress O
granules O
. O

Notably O
, O
the O
typical O
rapid O
production O
of O
TNF O
- O
alpha O
by O
AM O
phi O
exposed O
to O
lipopolysaccharide B
( I
LPS I
) I
was O
suppressed O
or O
enhanced O
by O
PRRSV O
, O
depending O
on O
when O
the O
LPS O
exposure O
occurred O
after O
virus O
infection O
. O

If O
exposure O
was O
delayed O
until O
6 O
h B
postinfection I
( I
hpi I
) I
so O
that O
the O
development O
of O
the O
cytokine O
response O
coincided O
with O
the O
time O
in O
which O
phosphorylation O
of O
eIF2 O
alpha O
by O
the O
stress O
sensor O
PERK O
( O
protein O
kinase O
RNA O
[ O
PKR O
] O
- O
like O
ER O
kinase O
) O
occurred O
, O
inhibition O
of O
TNF O
- O
alpha O
production O
was O
observed O
. O

However O
, O
if O
LPS O
exposure O
occurred O
at O
2 O
hpi O
, O
prior O
to O
a O
detectable O
onset O
of O
eIF2 O
alpha O
phosphorylation O
, O
a O
synergistic O
response O
was O
observed O
due O
to O
the O
earlier O
NF O
- O
kappa O
B O
activation O
via O
the O
stress O
sensor O
IRE1 O
alpha O
( O
inositol O
- O
requiring O
kinase O
1 O
alpha O
) O
. O

These O
results O
suggest O
that O
the O
asynchronous O
actions O
of O
two O
branches O
of O
the O
unfolded B
protein I
response I
( I
UPR I
) I
, O
namely O
, O
IRE1 O
alpha O
, O
and O
PERK O
, O
activated O
by O
ER O
stress O
resulting O
from O
the O
virus O
infection O
, O
are O
associated O
with O
enhancement O
or O
suppression O
of O
TNF O
- O
alpha O
production O
, O
respectively O
. O

In O
2014 O
we O
observed O
a O
noticeable O
increase O
in O
the O
number O
of O
sudden O
deaths O
among O
green O
tree O
pythons O
( O
Morelia O
viridis O
) O
. O

Since O
routine O
microbiological O
tests O
failed O
to O
identify O
a O
causative O
agent O
, O
we O
studied O
lung O
tissue O
samples O
from O
a O
few O
diseased O
snakes O
by O
next B
- I
generation I
sequencing I
( I
NGS I
) I
. O

Ultrastructural O
examination O
of O
concentrated O
cell O
culture O
supernatants O
showed O
the O
presence O
of O
nidovirus O
particles O
, O
and O
subsequent O
NGS O
analysis O
yielded O
the O
full O
genome O
of O
the O
novel O
virus O
Morelia B
viridis I
nidovirus I
( I
MVNV I
) I
. O

Herein O
we O
report O
on O
the O
isolation O
and O
identification O
of O
a O
further O
nidovirus O
from O
green O
tree O
pythons O
( O
Morelia O
viridis O
) O
with O
fatal O
pneumonia O
. O

Bovine B
herpesvirus I
1 I
( I
BoHV I
- I
1 I
) I
, O
an O
important O
bovine O
pathogen O
, O
establishes O
lifelong O
latency O
in O
sensory O
neurons O
. O

The O
immediate O
early O
transcription O
unit O
1 O
( O
IEtu1 O
) O
promoter O
, O
which O
drives O
bovine B
ICP0 I
( I
bICP0 I
) I
and O
bICP4 O
expression O
, O
is O
stimulated O
by O
dexamethasone O
because O
it O
contains O
two O
glucocorticoid B
receptor I
( I
GR I
) I
response O
elements O
( O
GREs O
) O
. O

Several O
Kruppel B
- I
like I
transcription I
factors I
( I
KLF I
) I
, O
including O
KLF15 O
, O
are O
induced O
during O
reactivation O
from O
latency O
, O
and O
they O
stimulate O
certain O
viral O
promoters O
and O
productive O
infection O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
GR O
and O
KLF15 O
were O
frequently O
expressed O
in O
the O
same O
trigeminal B
ganglion I
( I
TG I
) I
neuron O
during O
reactivation O
and O
cooperatively O
stimulated O
productive O
infection O
and O
IEtu1 O
GREs O
in O
mouse O
neuroblastoma O
cells O
( O
Neuro O
- O
2A O
) O
. O

To O
test O
this O
hypothesis O
, O
BoHV O
- O
1 O
DNA O
fragments O
( O
less O
than O
400 O
bp O
) O
containing O
potential O
GR O
and O
KLF O
binding O
sites O
were O
identified O
and O
examined O
for O
transcriptional O
activation O
by O
stress O
- O
induced O
transcription O
factors O
. O

Intergenic O
regions O
within O
the O
unique O
long O
52 O
gene O
( O
UL52 O
; O
a O
component O
of O
the O
DNA O
primase O
/ O
helicase O
complex O
) O
, O
bICP4 O
, O
IEtu2 O
, O
and O
the O
unique O
short O
region O
were O
stimulated O
by O
KLF15 O
and O
the O
GR O
. O

IMPORTANCE O
Bovine B
herpesvirus I
1 I
( I
BoHV I
- I
1 I
) I
is O
an O
important O
viral O
pathogen O
that O
causes O
respiratory O
disease O
and O
suppresses O
immune O
responses O
in O
cattle O
; O
consequently O
, O
life O
- O
threatening O
bacterial O
pneumonia O
can O
occur O
. O

Two O
stress O
- O
induced O
cellular O
transcription O
factors O
, O
Kruppel B
- I
like I
transcription I
factor I
15 I
( I
KLF15 I
) I
and O
the O
glucocorticoid B
receptor I
( I
GR I
) I
, O
cooperate O
to O
stimulate O
productive O
infection O
and O
viral O
transcription O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
most O
important O
viral O
agent O
of O
severe O
pediatric O
respiratory O
tract O
disease O
worldwide O
, O
but O
it O
lacks O
a O
licensed O
vaccine O
or O
suitable O
antiviral O
drug O
. O

A O
live O
attenuated O
chimeric O
bovine O
/ O
human O
parainfluenza O
virus O
type O
3 O
( O
rB O
/ O
HPIV3 O
) O
was O
developed O
previously O
as O
a O
vector O
expressing O
RSV O
fusion O
( O
F O
) O
protein O
to O
confer O
bivalent O
protection O
against O
RSV O
and O
HPIV3 O
. O

We O
previously O
modified O
RSV O
F O
with O
a O
designed O
disulfide B
bond I
( I
DS I
) I
to O
increase O
stability O
in O
the O
prefusion O
( O
pre O
- O
F O
) O
conformation O
and O
to O
be O
efficiently O
packaged O
in O
the O
vector O
virion O
. O

Here O
, O
we O
further O
stabilized O
pre O
- O
F O
by O
adding O
both O
disulfide O
and O
cavity O
- O
filling O
mutations O
( O
DS O
- O
Cav1 O
) O
, O
and O
we O
also O
modified O
RSV O
F O
codon O
usage O
to O
have O
a O
lower O
CpG O
content O
and O
a O
higher O
level O
of O
expression O
. O

This O
RSV O
F O
open O
reading O
frame O
was O
evaluated O
in O
rB O
/ O
HPIV3 O
in O
three O
forms O
: O
( O
i O
) O
pre O
- O
F O
without O
vector O
- O
packaging O
signal O
, O
( O
ii O
) O
pre O
- O
F O
with O
vector O
- O
packaging O
signal O
, O
and O
( O
iii O
) O
secreted O
pre O
- O
F O
ectodomain O
trimer O
. O

Palivizumab O
, O
a O
humanized O
murine O
monoclonal O
antibody O
that O
recognizes O
antigenic O
site O
II O
on O
both O
the O
prefusion O
( O
pre O
- O
F O
) O
and O
postfusion O
( O
post O
- O
F O
) O
conformations O
of O
the O
respiratory B
syncytial I
virus I
( I
RSV I
) I
F O
glycoprotein O
, O
is O
the O
only O
prophylactic O
agent O
approved O
for O
use O
for O
the O
treatment O
of O
RSV O
infection O
. O

We O
isolated O
a O
pre O
- O
F O
protein O
- O
specific O
, O
high O
- O
potency O
neutralizing O
antibody O
( O
5C4 O
) O
that O
recognizes O
antigenic O
site O
empty O
set O
and O
compared O
its O
efficacy O
to O
that O
of O
the O
murine O
precursor O
of O
palivizumab O
( O
antibody O
1129 O
) O
matched O
for O
isotype O
and O
pre O
- O
F O
protein O
binding O
affinities O
. O

coxsackievirus B
A10 I
( I
CVA10 I
) I
is O
one O
of O
the O
major O
pathogens O
associated O
with O
hand B
, I
foot I
, I
and I
mouth I
disease I
( I
HFMD I
) I
. O

The O
severity O
of O
illness O
was O
associated O
with O
abnormally O
high O
expression O
of O
the O
proinflammatory O
cytokine O
interleukin B
6 I
( I
IL I
- I
6 I
) I
. O

IMPORTANCE O
Hand O
, O
foot O
, O
and O
mouth O
disease O
cases O
in O
infancy O
, O
arising O
from O
coxsackievirus B
A10 I
( I
CVA10 I
) I
infections O
, O
are O
typically O
benign O
, O
resolving O
without O
any O
significant O
adverse O
events O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
a O
respiratory O
disease O
, O
caused O
by O
a O
coronavirus O
( O
SARS O
- O
CoV O
) O
, O
that O
is O
characterized O
by O
atypical O
pneumonia O
. O

The O
nucleocapsid B
protein I
( I
N I
protein I
) I
of O
SARS O
- O
CoV O
plays O
an O
important O
role O
in O
inhibition O
of O
type B
I I
interferon I
( I
IFN I
) I
production O
via O
an O
unknown O
mechanism O
. O

In O
this O
study O
, O
the O
SARS O
- O
CoV O
N O
protein O
was O
found O
to O
bind O
to O
the O
SPRY O
domain O
of O
the O
tripartite B
motif I
protein I
25 I
( I
TRIM25 I
) I
E3 O
ubiquitin O
ligase O
, O
thereby O
interfering O
with O
the O
association O
between O
TRIM25 O
and O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
and O
inhibiting O
TRIM25 O
- O
mediated O
RIG O
- O
I O
ubiquitination O
and O
activation O
. O

C O
or O
Sendai B
virus I
( I
SeV I
) I
was O
suppressed O
by O
the O
SARS O
- O
CoV O
N O
protein O
. O

We O
also O
found O
that O
the O
Middle B
East I
respiratory I
syndrome I
CoV I
( I
MERS I
- I
CoV I
) I
N O
protein O
interacted O
with O
TRIM25 O
and O
inhibited O
RIG O
- O
I O
signaling O
. O

Although O
early O
clinical O
studies O
reported O
low O
detection O
rates O
, O
the O
development O
of O
molecular O
diagnostic O
techniques O
by O
PCR O
has O
led O
to O
an O
increased O
recognition O
that O
respiratory O
virus O
infections O
are O
associated O
with O
morbidity O
and O
acute O
exacerbations O
of O
chronic O
lung O
diseases O
, O
such O
as O
Cystic B
fibrosis I
( I
CF I
) I
. O

Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
is O
a O
natural O
rodent O
pathogen O
that O
replicates O
in O
bronchial O
epithelial O
cells O
and O
reproduces O
many O
clinical O
and O
pathological O
features O
of O
the O
more O
severe O
forms O
of O
disease O
associated O
with O
human O
respiratory O
syncytial O
virus O
. O

In O
order O
to O
track O
virus O
- O
target O
cell O
interactions O
during O
acute O
infection O
in O
vivo O
, O
we O
developed O
rK2 O
- O
PVM O
, O
bacterial O
artificial O
chromosome O
- O
based O
recombinant O
PVM O
strain O
J3666 O
that O
incorporates O
the O
fluorescent O
tag O
monomeric B
Katushka I
2 I
( I
mKATE2 I
) I
. O

Using O
recombinant O
virus O
, O
we O
demonstrate O
for O
the O
first O
time O
PVM O
infection O
of O
both O
dendritic O
cells O
( O
DCs O
; O
CD11c O
( O
+ O
) O
major O
histocompatibility O
complex O
class O
II O
+ O
) O
and O
alveolar O
macrophages O
( O
AMs O
; O
CD11c O
( O
+ O
) O
sialic O
acid O
- O
binding O
immunoglobulin O
- O
like O
lectin O
F O
+ O
) O
in O
vivo O
and O
likewise O
detect O
mKATE2 O
( O
+ O
) O
DCs O
in O
mediastinal O
lymph O
nodes O
from O
infected O
mice O
. O

Furthermore O
, O
we O
report O
that O
priming O
of O
the O
respiratory O
tract O
with O
immunobiotic O
Lactobacillus O
plantarum O
, O
a O
regimen O
that O
results O
in O
protection O
against O
the O
lethal O
inflammatory O
sequelae O
of O
acute O
respiratory O
virus O
infection O
, O
resulted O
in O
differential O
recruitment O
of O
neutrophils O
, O
DCs O
, O
and O
lymphocytes O
to O
the O
lungs O
in O
response O
to O
rK2 O
- O
PVM O
and O
a O
reduction O
from O
similar O
to O
40 O
% O
to O
< O
10 O
% O
mKATE2 O
( O
+ O
) O
AMs O
in O
association O
with O
a O
2 O
- O
log O
drop O
in O
the O
release O
of O
infectious O
virions O
. O

IMPORTANCE O
Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
is O
a O
natural O
mouse O
pathogen O
that O
serves O
as O
a O
model O
for O
severe O
human O
respiratory O
syncytial O
virus O
disease O
. O

Wehave O
developed O
a O
fully O
functional O
recombinant O
PVM O
strain O
with O
a O
fluorescent O
reporter O
protein O
( O
rK2 O
- O
PVM O
) O
that O
permits O
us O
to O
track O
infection O
of O
target O
cells O
in O
vivo O
. O

Adenovirus B
14p1 I
( I
Ad14p1 I
) I
is O
an O
emergent O
variant O
of O
Ad B
serotype I
14 I
( I
Ad14 I
) I
that O
has O
caused O
increased O
severity O
of O
respiratory O
illnesses O
during O
globally O
distributed O
outbreaks O
, O
including O
cases O
of O
acute O
respiratory O
distress O
syndrome O
and O
death O
. O

We O
found O
that O
human O
cell O
infection O
with O
Ad14p1 O
results O
in O
markedly O
decreased O
expression O
of O
the O
E1B O
20 O
- O
kilodalton O
( O
20K O
) O
protein O
compared O
to O
that O
with O
infection O
with O
wild B
- I
type I
( I
WT I
) I
Ad14 O
. O

Acanthamoeba B
polyphaga I
mimivirus I
( I
APMV I
) I
is O
a O
giant O
virus O
from O
the O
Mimiviridae O
family O
. O

This O
adhesion O
is O
mediated O
by O
glycans O
, O
specifically O
, O
mannose O
and O
N O
- O
acetylglucosamine O
( O
a O
monomer O
of O
chitin O
and O
peptidoglycan O
) O
, O
both O
of O
which O
are O
largely O
distributed O
in O
nature O
as O
structural O
components O
of O
several O
organisms O
. O

This O
prompted O
us O
to O
predict O
that O
( O
i O
) O
arthropods O
, O
mainly O
insects O
, O
might O
act O
as O
mimivirus O
dispersers O
and O
( O
ii O
) O
by O
attaching O
to O
other O
microorganisms O
, O
APMV O
could O
be O
ingested O
by O
amoebae O
, O
leading O
to O
the O
successful O
production O
of O
viral O
progeny O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
and O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
are O
the O
first O
and O
second O
leading O
viral O
agents O
of O
severe O
respiratory O
tract O
disease O
in O
infants O
and O
young O
children O
worldwide O
. O

A O
live O
attenuated O
chimeric O
recombinant B
bovine I
/ I
human I
PIV3 I
( I
rB I
/ I
HPIV3 I
) I
vector O
expressing O
the O
RSV O
fusion O
( O
F O
) O
glycoprotein O
from O
an O
added O
gene O
has O
been O
under O
development O
as O
a O
bivalent O
vaccine O
against O
RSV O
and O
HPIV3 O
. O

In O
a O
hamster O
model O
, O
prefusion O
F O
induced O
increased O
quantity O
and O
quality O
of O
RSV O
- O
neutralizing O
serum O
antibodies O
and O
increased O
protection O
against O
wild B
- I
type I
( I
WT I
) I
RSV O
challenge O
. O

IMPORTANCE O
respiratory B
syncytial I
virus I
( I
RSV I
) I
and O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
are O
two O
major O
causes O
of O
pediatric O
pneumonia O
and O
bronchiolitis O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
acute O
respiratory O
tract O
viral O
infection O
in O
infants O
, O
causing O
bronchiolitis O
and O
pneumonia O
. O

The O
host O
antiviral O
response O
to O
RSV O
acts O
via O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
. O

We O
show O
here O
that O
RSV O
infection O
upregulates O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
expression O
through O
the O
induction O
of O
NLRC5 O
, O
a O
NOD O
- O
like O
, O
CARD O
domain O
- O
containing O
intracellular O
protein O
that O
has O
recently O
been O
identified O
as O
a O
class O
I O
MHC O
transactivator O
( O
CITA O
) O
. O

RSV O
infection O
of O
A549 O
cells O
promotes O
upregulation O
of O
NLRC5 O
via O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
, O
since O
the O
NLRC5 O
- O
inducing O
activity O
in O
a O
conditioned O
medium O
from O
RSV O
- O
infected O
A549 O
cells O
was O
removed O
by O
antibody O
to O
IFN O
- O
beta O
, O
but O
not O
by O
antibody O
to O
IFN O
- O
gamma O
. O

IMPORTANCE O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
bronchiolitis O
and O
pneumonia O
in O
infants O
and O
young O
children O
worldwide O
. O

Infection O
early O
in O
life O
is O
linked O
to O
persistent O
wheezing O
and O
allergic O
asthma O
in O
later O
life O
, O
possibly O
related O
to O
upregulation O
of O
major B
histocompatibility I
class I
I I
( I
MHC I
- I
I I
) I
on O
the O
cell O
surface O
, O
which O
facilitates O
cytotoxic O
T O
cell O
activation O
and O
antiviral O
immunity O
. O

human B
coronavirus I
( I
HCoV I
) I
HKU1 O
is O
one O
of O
six O
hCoVs O
identified O
to O
date O
and O
the O
only O
one O
with O
an O
unidentified O
cellular O
receptor O
. O

hCoV O
- O
HKU1 O
encodes O
a O
hemagglutinin B
- I
esterase I
( I
HE I
) I
protein O
that O
is O
unique O
to O
the O
group O
a O
betacoronaviruses O
( O
group O
2a O
) O
. O

Pretreatment O
of O
RD O
cells O
with O
neuraminidase B
( I
NA I
) I
and O
trypsin O
greatly O
reduced O
the O
binding O
, O
suggesting O
that O
the O
binding O
was O
mediated O
by O
sialic O
acids O
on O
glycoproteins O
. O

, O
hCoV O
- O
OC43 O
, O
for O
which O
9 O
- O
O O
- O
acetylated O
sialic O
acid O
( O
9 O
- O
O O
- O
Ac O
- O
Sia O
) O
serves O
as O
a O
receptor O
determinant O
, O
HKU1 O
- O
S1 O
bound O
with O
neither O
9 O
- O
O O
- O
Ac O
- O
Sia O
- O
containing O
glycoprotein O
( O
s O
) O
nor O
rat O
and O
mouse O
erythrocytes O
. O

Nonetheless O
, O
the O
HKU1 O
- O
HE O
was O
similar O
to O
OC43 O
- O
HE O
, O
also O
possessed O
sialate O
- O
O O
- O
acetylesterase O
activity O
, O
and O
acted O
as O
a O
receptor B
- I
destroying I
enzyme I
( I
RDE I
) I
capable O
of O
eliminating O
the O
binding O
of O
HKU1 O
- O
S1 O
to O
RD O
cells O
, O
whereas O
the O
O O
- O
acetylesterase O
- O
inactive O
HKU1 O
- O
HE O
mutant O
lost O
this O
capacity O
. O

Using O
primary O
human O
ciliated O
airway O
epithelial O
( O
HAE O
) O
cell O
cultures O
, O
the O
only O
in O
vitro O
replication O
model O
for O
hCoV O
- O
HKU1 O
infection O
, O
we O
confirmed O
that O
pretreatment O
of O
HAE O
cells O
with O
HE O
but O
not O
the O
enzymatically O
inactive O
mutant O
blocked O
hCoV O
- O
HKU1 O
infection O
. O

IMPORTANCE O
Human B
coronaviruses I
( I
hCoV I
) I
are O
important O
human O
respiratory O
pathogens O
. O

It O
is O
also O
unclear O
whether O
hemagglutinin B
- I
esterase I
( I
HE I
) I
protein O
plays O
a O
role O
in O
viral O
entry O
. O

In O
addition O
, O
we O
determined O
that O
the O
HKU1 O
- O
HE O
protein O
is O
an O
O O
- O
acetylesterase O
and O
acts O
as O
a O
receptor B
- I
destroying I
enzyme I
( I
RDE I
) I
for O
hCoV O
- O
HKU1 O
. O

Hydrogen O
sulfide O
( O
H2S O
) O
is O
an O
endogenous O
gaseous O
mediator O
that O
has O
gained O
increasing O
recognition O
as O
an O
important O
player O
in O
modulating O
acute O
and O
chronic O
inflammatory O
diseases O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
upper O
and O
lower O
respiratory O
tract O
infections O
in O
children O
for O
which O
no O
vaccine O
or O
effective O
treatment O
is O
available O
. O

Using O
the O
slow O
- O
releasing O
H2S O
donor O
GYY4137 O
and O
propargylglycin B
( I
PAG I
) I
, O
an O
inhibitor O
of O
cystathionine B
- I
gamma I
- I
lyase I
( I
CSE I
) I
, O
a O
key O
enzyme O
that O
produces O
intracellular O
H2S O
, O
we O
found O
that O
RSV O
infection O
led O
to O
a O
reduced O
ability O
to O
generate O
and O
maintain O
intracellular O
( O
HS O
) O
- O
S O
- O
2 O
levels O
in O
airway B
epithelial I
cells I
( I
AECs I
) I
. O

GYY4137 O
also O
significantly O
reduced O
replication O
and O
inflammatory O
chemokine O
production O
induced O
by O
human B
metapneumovirus I
( I
HMPV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
, O
suggesting O
a O
broad O
inhibitory O
effect O
of O
H2S O
on O
paramyxovirus O
infections O
. O

GYY4137 O
inhibition O
of O
proinflammatory O
gene O
expression O
occurred O
by O
modulation O
of O
the O
activation O
of O
the O
key O
transcription O
factors O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
and O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
at O
a O
step O
subsequent O
to O
their O
nuclear O
translocation O
. O

The O
emergence O
of O
Middle B
East I
respiratory I
syndrome I
- I
coronavirus I
( I
MERS I
- I
CoV I
) I
in O
the O
Middle O
East O
since O
2012 O
has O
caused O
more O
than O
900 O
human O
infections O
with O
similar O
to O
40 O
% O
mortality O
to O
date O
. O

Nonhuman O
primates O
( O
rhesus O
macaques O
and O
marmosets O
) O
are O
expensive O
models O
of O
limited O
availability O
. O

Although O
a O
mouse O
lung O
infection O
model O
has O
been O
described O
using O
adenovirus O
vectors O
expressing O
human O
CD26 O
/ O
dipeptidyl B
peptidase I
4 I
( I
DPP4 I
) I
, O
it O
is O
believed O
that O
a O
transgenic O
mouse O
model O
is O
needed O
for O
MERS O
- O
CoV O
research O
. O

Infected O
Tg O
( O
+ O
) O
mice O
developed O
a O
progressive O
pneumonia O
, O
characterized O
by O
extensive O
inflammatory O
infiltration O
. O

Moreover O
, O
infected O
Tg O
( O
+ O
) O
mice O
were O
able O
to O
activate O
genes O
encoding O
for O
many O
antiviral O
and O
inflammatory O
mediators O
within O
the O
lungs O
and O
brains O
, O
coinciding O
with O
the O
high O
levels O
of O
viral O
replication O
. O

neuraminidase B
( I
NA I
) I
inhibitors O
( O
NAIs O
) O
are O
the O
only O
class O
of O
drugs O
available O
to O
treat O
influenza O
A O
and O
B O
virus O
infections O
, O
so O
the O
development O
of O
NAI O
- O
resistant O
viruses O
with O
superior O
fitness O
is O
a O
public O
health O
concern O
. O

Here O
we O
examined O
the O
replicative O
capacity O
and O
relative O
fitness O
in O
normal B
human I
bronchial I
epithelial I
( I
NHBE I
) I
cells O
of O
recombinant O
influenza O
B O
/ O
Yamanashi O
/ O
166 O
/ O
1998 O
viruses O
containing O
a O
single O
amino O
acid O
substitution O
in O
NA O
generated O
by O
reverse B
genetics I
( I
RG I
) I
that O
is O
associated O
with O
NAI O
resistance O
. O

The O
replication O
in O
NHBE O
cells O
of O
viruses O
with O
reduced O
inhibition O
by O
oseltamivir O
( O
recombinant O
virus O
with O
the O
E119A O
mutation O
generated O
by O
reverse O
genetics O
[ O
rg O
- O
E119A O
] O
, O
rg O
- O
D198E O
, O
rg O
- O
I222T O
, O
rg O
- O
H274Y O
, O
rg O
- O
N294S O
, O
and O
rg O
- O
R371K O
, O
N2 O
numbering O
) O
or O
zanamivir O
( O
rg O
- O
E119A O
and O
rg O
- O
R371K O
) O
failed O
to O
be O
inhibited O
by O
the O
presence O
of O
the O
respective O
NAI O
. O

We O
coinfected O
NHBE O
cells O
with O
NAI O
- O
susceptible O
and O
- O
resistant O
viruses O
and O
used O
next O
- O
generation O
deep O
sequencing O
to O
reveal O
the O
order O
of O
relative O
fitness O
compared O
to O
that O
of O
recombinant O
wild B
- I
type I
( I
WT I
) I
virus O
generated O
by O
reverse O
genetics O
( O
rgWT O
) O
: O
rg O
- O
H274Y O
> O
rg O
- O
WT O
> O
rg O
- O
I222T O
> O
rg O
- O
N294S O
> O
rg O
- O
D198E O
> O
rg O
- O
E119A O
> O
> O
rg O
- O
R371K O
. O

The O
development O
of O
resistance O
to O
a O
single O
class O
of O
available O
antivirals O
, O
the O
neuraminidase B
( I
NA I
) I
inhibitors O
( O
NAIs O
) O
, O
is O
a O
public O
health O
concern O
. O

Here O
we O
used O
normal B
human I
bronchial I
epithelial I
( I
NHBE I
) I
cells O
, O
a O
model O
of O
the O
human O
upper O
respiratory O
tract O
, O
to O
examine O
the O
replicative O
capacities O
and O
fitness O
of O
NAI O
- O
resistant O
influenza O
B O
viruses O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
infects O
epithelial O
cells O
of O
the O
respiratory O
tract O
and O
is O
a O
major O
cause O
of O
bronchiolitis O
and O
pneumonia O
in O
children O
and O
the O
elderly O
. O

Oligomerization O
of O
the O
matrix B
protein I
( I
M I
) I
is O
a O
key O
step O
in O
the O
process O
of O
assembly O
and O
infectious O
virus O
production O
. O

IMPORTANCE O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
is O
the O
most O
frequent O
cause O
of O
infantile O
bronchiolitis O
and O
pneumonia O
. O

We O
noted O
variations O
in O
clinical O
disease O
outcomes O
and O
the O
volume O
of O
inoculum O
administered O
and O
investigated O
these O
differences O
by O
administering O
two O
influenza O
viruses O
( O
A O
/ O
California O
/ O
07 O
/ O
2009 O
[ O
H1N1 O
pandemic O
] O
and O
A O
/ O
Minnesota O
/ O
11 O
/ O
2010 O
[ O
H3N2 O
variant O
] O
) O
to O
ferrets O
intranasally O
at O
a O
dose O
of O
10 O
( O
6 O
) O
50 O
% O
tissue O
culture O
infective O
doses O
in O
a O
range O
of O
inoculum O
volumes O
( O
0 O
. O

Paramyxovirus O
particles O
, O
like O
other O
enveloped O
virus O
particles O
, O
are O
formed O
by O
budding O
from O
membranes O
of O
infected O
cells O
, O
and O
matrix B
( I
M I
) I
proteins O
are O
critical O
for O
this O
process O
. O

To O
identify O
the O
M O
protein O
important O
for O
this O
process O
, O
we O
have O
characterized O
the O
budding O
of O
the O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
M O
protein O
. O

Our O
results O
showed O
that O
expression O
of O
the O
HPIV3 O
M O
protein O
alone O
is O
sufficient O
to O
initiate O
the O
release O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

We O
identified O
a O
leucine O
( O
L302 O
) O
residue O
within O
the O
C O
terminus O
of O
the O
HPIV3 O
M O
protein O
that O
is O
critical O
for O
M O
protein O
- O
mediated O
VLP O
production O
by O
regulating O
the O
ubiquitination O
of O
the O
M O
protein O
. O

IMPORTANCE O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
is O
an O
enveloped O
virus O
with O
a O
non O
segmented O
negative O
- O
strand O
RNA O
genome O
. O

Here O
, O
we O
show O
that O
a O
leucine O
residue O
( O
L302 O
) O
located O
at O
the O
C O
terminus O
of O
the O
HPIV3 O
M O
protein O
is O
essential O
for O
efficient O
production O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Here O
, O
we O
generated O
a O
replication O
- O
incompetent O
hemagglutinin O
knockout O
( O
HA O
- O
KO O
) O
influenza O
virus O
possessing O
the O
sequence O
for O
the O
antigenic O
region O
of O
pneumococcal B
surface I
protein I
A I
( I
PspA I
) I
. O

Although O
this O
virus O
( O
HA O
- O
KO O
/ O
PspA O
virus O
) O
could O
replicate O
only O
in O
an O
HA O
- O
expressing O
cell O
line O
, O
it O
infected O
wild O
- O
type O
cells O
and O
expressed O
both O
viral O
proteins O
and O
PspA O
. O

We O
found O
that O
L13a O
is O
released O
from O
the O
60S O
ribosomal O
subunit O
in O
response O
to O
infection O
by O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
an O
RNA O
virus O
of O
the O
Pneumovirus O
genus O
and O
a O
serious O
lung O
pathogen O
. O

In O
all O
L13a O
- O
deficient O
cells O
tested O
, O
translation O
of O
RSV O
matrix B
( I
M I
) I
protein O
was O
specifically O
stimulated O
, O
as O
judged O
by O
a O
greater O
abundance O
of O
M O
protein O
and O
greater O
association O
of O
the O
M O
mRNA O
with O
polyribosomes O
, O
while O
general O
translation O
was O
unaffected O
. O

In O
silico O
RNA O
folding O
analysis O
and O
translational O
reporter O
assays O
revealed O
a O
putative O
hairpin O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
M O
mRNA O
with O
significant O
structural O
similarity O
to O
the O
cellular O
GAIT O
( O
gamma O
- O
activated O
- O
inhibitor O
of O
translation O
) O
RNA O
hairpin O
, O
previously O
shown O
to O
be O
responsible O
for O
assembling O
a O
large O
, O
L13a O
- O
containing O
ribonucleoprotein O
complex O
that O
promoted O
translational O
silencing O
in O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
activated O
myeloid O
cells O
. O

However O
, O
RNA O
- O
protein O
interaction O
studies O
revealed O
that O
this O
complex O
, O
which O
we O
named O
VAIT O
( O
respiratory O
syncytial O
virus O
- O
activated O
inhibitor O
of O
translation O
) O
is O
functionally O
different O
from O
the O
GAIT O
complex O
. O

Here O
, O
we O
analyzed O
the O
role O
of O
the O
nuclear O
import O
factor O
importin O
- O
alpha O
7 O
in O
H1N1 O
influenza O
virus O
pulmonary O
tropism O
by O
using O
various O
ex O
vivo O
imaging O
techniques O
( O
magnetic O
resonance O
imaging O
, O
confocal O
laser O
scanning O
microscopy O
, O
and O
correlative O
light O
- O
electron O
microscopy O
) O
. O

We O
infected O
importin O
- O
alpha O
7 O
gene O
- O
deficient O
( O
alpha O
7 O
( O
- O
/ O
- O
) O
) O
mice O
with O
a O
recombinant O
H1N1 O
influenza O
virus O
and O
compared O
the O
in O
vivo O
viral O
kinetics O
with O
those O
in O
wild B
- I
type I
( I
WT I
) I
mice O
. O

Conversely O
, O
in O
alpha O
7 O
( O
- O
/ O
- O
) O
mice O
, O
virus O
replication O
was O
restricted O
mostly O
to O
the O
bronchial O
epithelium O
with O
marginal O
alveolar O
infection O
, O
resulting O
in O
significantly O
reduced O
lung O
damage O
and O
enhanced O
animal O
survival O
. O

The O
ability O
of O
macrophages O
to O
support O
or O
clear O
the O
virus O
infection O
, O
as O
well O
as O
the O
host O
cellular O
immune O
responses O
, O
did O
not O
significantly O
differ O
between O
WT O
and O
alpha O
7 O
( O
- O
/ O
- O
) O
mice O
. O

Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
is O
the O
most O
common O
cause O
of O
bronchiolitis O
and O
pneumonia O
in O
infants O
and O
the O
elderly O
worldwide O
; O
however O
, O
there O
is O
no O
licensed O
RSV O
vaccine O
or O
effective O
drug O
treatment O
available O
. O

The O
RSV O
matrix B
( I
M I
) I
protein O
plays O
key O
roles O
in O
virus O
assembly O
and O
budding O
, O
but O
the O
protein O
interactions O
that O
govern O
budding O
of O
infectious O
virus O
are O
not O
known O
. O

In O
this O
study O
, O
we O
focus O
on O
M O
protein O
and O
identify O
a O
key O
phosphorylation O
site O
( O
Thr205 O
) O
in O
M O
that O
is O
critical O
for O
RSV O
infectious O
virus O
production O
. O

Recombinant O
virus O
with O
a O
nonphosphorylatable O
alanine B
( I
Ala I
) I
residue O
at O
the O
site O
was O
markedly O
attenuated O
, O
whereas O
virus O
with O
a O
phosphomimetic O
aspartate O
( O
Asp O
) O
resulted O
in O
a O
nonviable O
virus O
which O
could O
only O
be O
recovered O
with O
an O
additional O
mutation O
in O
M O
( O
serine O
to O
asparagine O
at O
position O
220 O
) O
, O
strongly O
implying O
that O
Thr205 O
is O
critical O
for O
viral O
infectivity O
. O

In O
transfected O
and O
infected O
cells O
, O
Asp O
substitution O
of O
Thr205 O
appeared O
to O
impair O
M O
oligomerization O
; O
typical O
filamentous O
structures O
still O
formed O
at O
the O
plasma O
membrane O
, O
but O
M O
assembly O
during O
the O
ensuing O
elongation O
process O
seemed O
to O
be O
impaired O
, O
resulting O
in O
shorter O
and O
more O
branched O
filaments O
as O
observed O
using O
electron B
microscopy I
( I
EM I
) I
. O

Comparing O
the O
sequences O
( O
amino O
acids O
[ O
aa O
] O
61 O
to O
87 O
using O
PB1 O
- O
F2 O
amino O
acid O
numbering O
) O
of O
the O
PB1 O
- O
F2 O
- O
derived O
C O
- O
terminal O
peptides O
from O
influenza O
A O
viruses O
inducing O
high O
or O
low O
levels O
of O
cell O
death O
, O
we O
identified O
a O
unique O
I68 O
, O
L69 O
, O
and O
V70 O
motif O
in O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
PB1 O
- O
F2 O
responsible O
for O
promotion O
of O
the O
peptide O
' O
s O
cytotoxicity O
and O
permeabilization O
of O
the O
mitochondrial O
membrane O
. O

When O
administered O
to O
mice O
, O
a O
27 O
- O
mer O
PB1 O
- O
F2 O
- O
derived O
C O
- O
terminal O
peptide O
with O
this O
amino O
acid O
motif O
caused O
significantly O
greater O
weight O
loss O
and O
pulmonary O
inflammation O
than O
the O
peptide O
without O
it O
( O
due O
to O
I68T O
, O
L69Q O
, O
and O
V70G O
mutations O
) O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
is O
associated O
with O
an O
outbreak O
of O
more O
than O
90 O
cases O
of O
severe O
pneumonia O
with O
high O
mortality O
( O
greater O
than O
50 O
% O
) O
. O

To O
rapidly O
identify O
potential O
inhibitors O
of O
MERS O
- O
CoV O
replication O
, O
we O
expressed O
the O
papain B
- I
like I
protease I
( I
PLpro I
) I
and O
the O
3 B
- I
chymotrypsin I
- I
like I
protease I
( I
3CLpro I
) I
from O
MERS O
- O
CoV O
and O
developed O
luciferase O
- O
based O
biosensors O
to O
monitor O
protease O
activity O
in O
cells O
. O

To O
investigate O
MERS O
- O
CoV O
3CLpro O
activity O
, O
we O
expressed O
the O
protease O
in O
context O
with O
flanking O
nonstructural B
protein I
4 I
( I
nsp4 I
) I
and O
the O
amino O
- O
terminal O
portion O
of O
nsp6 O
and O
detected O
processing O
of O
the O
luciferase O
- O
based O
biosensors O
containing O
the O
canonical O
3CLpro O
cleavage O
site O
VRLQS O
. O

Importantly O
, O
we O
found O
that O
a O
small O
- O
molecule O
inhibitor O
that O
blocks O
replication O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
CoV O
and O
murine O
CoV O
also O
inhibits O
the O
activity O
of O
MERS O
- O
CoV O
3CLpro O
. O

cytotoxic B
T I
cells I
( I
CTL I
) I
play O
a O
critical O
role O
in O
the O
clearance O
of O
respiratory O
viral O
infections O
, O
but O
they O
also O
contribute O
to O
disease O
manifestations O
. O

In O
this O
study O
, O
we O
infected O
mice O
with O
a O
genetically O
modified O
Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
that O
allowed O
visualization O
of O
virus O
- O
specific O
CTL O
and O
infected O
cells O
in O
situ O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
death O
due O
to O
a O
viral O
etiology O
in O
infants O
. O

It O
has O
been O
shown O
that O
infection O
of O
BALB O
/ O
cJ O
mice O
with O
RSV O
clinical O
isolate O
A2001 O
/ O
2 O
- O
20 O
( O
2 O
- O
20 O
) O
results O
in O
a O
higher O
early O
viral O
load O
, O
greater O
airway O
necrosis O
, O
and O
higher O
levels O
of O
interleukin B
- I
13 I
( I
IL I
- I
13 I
) I
and O
airway O
mucin O
expression O
than O
infection O
with O
RSV O
laboratory O
strain O
A2 O
. O

We O
hypothesized O
that O
the O
fusion O
( O
F O
) O
protein O
of O
RSV O
2 O
- O
20 O
is O
a O
mucus O
- O
inducing O
viral O
factor O
. O

Our O
data O
are O
consistent O
with O
a O
model O
in O
which O
the O
F O
and O
attachment O
( O
G O
) O
glycoprotein O
functional O
interaction O
leads O
to O
enhanced O
fusion O
and O
F O
is O
a O
key O
factor O
in O
airway O
epithelium O
infection O
, O
pathogenesis O
, O
and O
subsequent O
airway O
mucin O
expression O
. O

Infection O
with O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
is O
associated O
with O
the O
common O
cold O
and O
may O
result O
in O
pneumonia O
in O
immunocompromised O
patients O
. O

The O
viral O
spike B
( I
S I
) I
protein O
is O
incorporated O
into O
the O
viral O
envelope O
and O
mediates O
infectious O
entry O
of O
HCoV O
- O
229E O
into O
host O
cells O
, O
a O
process O
that O
depends O
on O
the O
activation O
of O
the O
S O
- O
protein O
by O
host O
cell O
proteases O
. O

Here O
we O
show O
that O
the O
type O
II O
transmembrane O
serine O
proteases O
TMPRSS2 O
and O
HAT O
cleave O
the O
HCoV O
- O
229E O
S O
- O
protein O
( O
229E O
- O
S O
) O
and O
augment O
229E O
- O
S O
- O
driven O
cell O
- O
cell O
fusion O
, O
suggesting O
that O
TMPRSS2 O
and O
HAT O
can O
activate O
229E O
- O
S O
. O

Finally O
, O
immunohistochemistry O
revealed O
that O
TMPRSS2 O
is O
coexpressed O
with O
CD13 O
, O
the O
HCoV O
- O
229E O
receptor O
, O
in O
human B
airway I
epithelial I
( I
HAE I
) I
cells O
, O
and O
that O
CD13 O
( O
+ O
) O
TMPRSS2 O
( O
+ O
) O
cells O
are O
preferentially O
targeted O
by O
HCoV O
- O
229E O
, O
suggesting O
that O
TMPRSS2 O
can O
activate O
HCoV O
- O
229E O
in O
infected O
humans O
. O

Previous O
studies O
indicated O
a O
prominent O
role O
of O
the O
Hemagglutinin B
( I
HA I
) I
gene O
in O
efficient O
replication O
and O
high O
virulence O
of O
the O
1918 O
virus O
in O
mice O
. O

Here O
, O
we O
examined O
the O
biological O
properties O
of O
reassortant O
viruses O
between O
the O
1918 O
virus O
and O
a O
contemporary O
human O
H1N1 O
virus O
( O
A O
/ O
Kawasaki O
/ O
173 O
/ O
2001 O
[ O
K173 O
] O
) O
in O
a O
mouse O
model O
. O

human B
cytomegalovirus I
( I
HCMV I
) I
is O
the O
leading O
viral O
cause O
of O
birth O
defects O
and O
life O
- O
threatening O
lung O
- O
associated O
diseases O
in O
premature O
infants O
and O
immunocompromised O
children O
. O

Human O
fetal O
lung O
tissue O
was O
implanted O
into O
severe O
combined O
immunodeficient O
( O
CB17 O
- O
scid O
) O
mice O
and O
inoculated O
by O
direct O
injection O
with O
the O
VR1814 O
clinical O
isolate O
of O
HCMV O
. O

pneumoniae O
at O
different O
days O
after O
primary O
influenza O
A O
( O
X31 O
) O
virus O
infection O
. O

Our O
findings O
show O
that O
the O
induction O
of O
type B
I I
interferons I
( I
IFNs I
) I
during O
a O
primary O
nonlethal O
influenza O
virus O
infection O
is O
sufficient O
to O
promote O
a O
deadly O
S O
. O

Moreover O
, O
mice O
deficient O
in O
type O
I O
interferon O
receptor O
( O
IFNAR O
knockout O
[ O
KO O
] O
mice O
) O
effectively O
cleared O
the O
secondary O
bacterial O
infection O
from O
their O
lungs O
, O
increased O
the O
recruitment O
of O
neutrophils O
, O
and O
demonstrated O
an O
enhanced O
innate O
expression O
of O
interleukin B
- I
17 I
( I
IL I
- I
17 I
) I
relative O
to O
wild B
- I
type I
( I
WT I
) I
mice O
. O

Viral O
pneumonia O
has O
been O
frequently O
reported O
during O
early O
stages O
of O
influenza O
virus O
pandemics O
and O
in O
many O
human O
cases O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
infection O
. O

To O
better O
understand O
the O
pathogenesis O
of O
this O
disease O
, O
we O
produced O
nonlethal O
viral O
pneumonia O
in O
rhesus O
macaques O
by O
using O
an O
HPAI O
H5N1 O
virus O
( O
A O
/ O
Anhui O
/ O
2 O
/ O
2005 O
; O
referred O
to O
as O
Anhui O
/ O
2 O
) O
. O

Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
, O
a O
relative O
of O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
, O
causes O
respiratory O
disease O
in O
mice O
. O

To O
investigate O
replication O
in O
primates O
, O
African B
green I
monkeys I
( I
AGM I
) I
and O
rhesus O
macaques O
( O
n O
= O
4 O
) O
were O
inoculated O
with O
PVM O
by O
the O
respiratory O
route O
. O

PVM O
efficiently O
replicated O
in O
cultured O
human O
cells O
and O
inhibited O
the O
type B
I I
interferon I
( I
IFN I
) I
response O
in O
these O
cells O
. O

Sera O
from O
a O
single O
child O
( O
6 O
% O
) O
and O
40 O
% O
of O
adults O
had O
low O
neutralizing O
activity O
against O
PVM O
, O
which O
could O
be O
consistent O
with O
increasing O
incidence O
of O
exposure O
following O
early O
childhood O
. O

Serum O
reactivity O
was O
further O
evaluated O
by O
flow O
cytometry O
using O
unfixed O
Vero O
cells O
infected O
with O
PVM O
or O
RSV O
expressing O
green B
fluorescent I
protein I
( I
GFP I
) I
as O
a O
measure O
of O
viral O
gene O
expression O
. O

SARS B
coronavirus I
( I
SARS I
- I
CoV I
) I
causes O
severe O
acute O
respiratory O
tract O
disease O
characterized O
by O
diffuse O
alveolar O
damage O
and O
hyaline O
membrane O
formation O
. O

This O
pathology O
often O
progresses O
to O
acute O
respiratory O
distress O
( O
such O
as O
acute O
respiratory O
distress O
syndrome O
[ O
ARDS O
] O
) O
and O
atypical O
pneumonia O
in O
humans O
, O
with O
characteristic O
age O
- O
related O
mortality O
rates O
approaching O
50 O
% O
or O
more O
in O
immunosenescent O
populations O
. O

Since O
young O
and O
aged O
( O
1 O
- O
year O
- O
old O
) O
mice O
do O
not O
develop O
severe O
clinical O
disease O
following O
infection O
with O
wild O
- O
type O
SARS O
- O
CoV O
, O
a O
mouse O
- O
adapted O
strain O
of O
SARS O
- O
CoV O
( O
called O
MA15 O
) O
was O
developed O
and O
was O
shown O
to O
cause O
lethal O
infection O
in O
these O
animals O
. O

We O
found O
that O
mutations O
in O
the O
viral O
spike B
( I
S I
) I
glycoprotein O
and O
, O
to O
a O
much O
less O
rigorous O
extent O
, O
in O
the O
nsp9 O
nonstructural O
protein O
, O
were O
primarily O
associated O
with O
the O
acquisition O
of O
virulence O
in O
young O
animals O
. O

The O
mutations O
in O
S O
likely O
increase O
recognition O
of O
the O
mouse O
angiotensin B
- I
converting I
enzyme I
2 I
( I
ACE2 I
) I
receptor O
not O
only O
in O
MA15 O
but O
also O
in O
two O
additional O
, O
independently O
isolated O
mouse O
- O
adapted O
SARS O
- O
CoVs O
. O

The O
presence O
of O
the O
PB1 O
- O
F2 O
noninflammatory O
( O
P62 O
, O
H75 O
, O
Q79 O
, O
and O
S82 O
) O
sequence O
in O
the O
wild O
- O
type O
virus O
mediated O
an O
antibacterial O
effect O
. O

Here O
we O
used O
primary O
cultures O
of O
differentiated O
human O
alveolar O
type O
II O
cells O
, O
alveolar O
type O
I O
- O
like O
cells O
, O
and O
alveolar O
macrophages O
isolated O
from O
the O
same O
individual O
to O
investigate O
viral O
replication O
competence O
and O
host O
innate O
immune O
responses O
to O
influenza O
H5N1 O
( O
A O
/ O
HK O
/ O
483 O
/ O
97 O
) O
and O
H1N1 O
( O
A O
/ O
HK O
/ O
54 O
/ O
98 O
) O
virus O
infection O
. O

The O
viral O
replication O
kinetics O
and O
cytokine O
and O
chemokine O
responses O
were O
compared O
by O
quantitative B
PCR I
( I
qPCR I
) I
and O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

Monkeypox B
virus I
( I
MPXV I
) I
infection O
has O
recently O
expanded O
in O
geographic O
distribution O
and O
can O
be O
fatal O
in O
up O
to O
10 O
% O
of O
cases O
. O

) O
inoculation O
of O
nonhuman B
primates I
( I
NHPs I
) I
results O
in O
an O
accelerated O
fulminant O
disease O
course O
compared O
to O
that O
of O
naturally O
occurring O
MPXV O
infection O
in O
humans O
. O

Human B
rhinoviruses I
( I
HRVs I
) I
were O
discovered O
as O
common O
cold O
pathogens O
over O
50 O
years O
ago O
. O

Until O
a O
few O
years O
ago O
, O
only O
two O
groups O
of O
HRVs O
( O
A O
and O
B O
) O
had O
been O
recognized O
. O

However O
, O
full O
and O
partial O
sequencing O
of O
HRVs O
led O
to O
the O
discovery O
of O
a O
third O
species O
of O
HRV O
( O
HRV O
- O
C O
) O
that O
has O
distinct O
structural O
and O
biologic O
features O
. O

Virus O
strain O
BJx109 O
( O
H3N2 O
) O
infected O
macrophages O
with O
high O
efficiency O
and O
was O
associated O
with O
mild O
disease O
following O
intranasal O
infection O
of O
mice O
. O

In O
contrast O
, O
virus O
strain O
PR8 O
( O
H1N1 O
) O
was O
poor O
in O
its O
ability O
to O
infect O
macrophages O
and O
highly O
virulent O
for O
mice O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
was O
identified O
to O
be O
the O
causative O
agent O
of O
SARS O
with O
atypical O
pneumonia O
. O

angiotensin B
- I
converting I
enzyme I
2 I
( I
ACE2 I
) I
is O
the O
major O
receptor O
for O
SARS O
- O
CoV O
. O

To O
understand O
the O
pathogenesis O
of O
SARS O
- O
CoV O
, O
human O
type O
II O
pneumocyte O
( O
A549 O
) O
cells O
were O
incubated O
with O
the O
viral O
spike O
protein O
or O
with O
SARS O
- O
CoV O
virus O
- O
like O
particles O
containing O
the O
viral O
spike O
protein O
to O
examine O
cytokine O
modulation O
in O
lung O
cells O
. O

Results O
from O
oligonucleotide O
- O
based O
microarray O
, O
real O
- O
time O
PCR O
, O
and O
enzyme O
- O
linked O
immunosorbent O
assays O
indicated O
an O
upregulation O
of O
the O
fibrosis O
- O
associated O
chemokine O
( O
C O
- O
C O
motif O
) O
ligand O
2 O
( O
CCL2 O
) O
by O
the O
viral O
spike O
protein O
and O
the O
virus O
- O
like O
particles O
. O

The O
upregulation O
of O
CCL2 O
by O
SARS O
- O
CoV O
spike O
protein O
was O
mainly O
mediated O
by O
extracellular B
signal I
- I
regulated I
kinase I
1 I
and I
2 I
( I
ERK1 I
/ I
2 I
) I
and O
AP O
- O
1 O
but O
not O
the O
I O
kappa O
B O
alpha O
- O
NF O
- O
kappa O
B O
signaling O
pathway O
. O

Here O
we O
show O
that O
interleukin B
- I
15 I
( I
IL I
- I
15 I
) I
knockout I
( I
KO I
) I
mice O
exhibited O
reduced O
mortality O
after O
infection O
with O
influenza O
virus O
A O
/ O
FM O
/ O
1 O
/ O
47 O
( O
H1N1 O
, O
a O
mouse O
- O
adapted O
strain O
) O
albeit O
the O
viral O
titers O
of O
these O
mice O
showed O
no O
difference O
from O
those O
of O
control O
mice O
. O

There O
were O
significantly O
fewer O
antigen O
- O
specific O
CD44 O
( O
+ O
) O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
lungs O
of O
infected O
IL O
- O
15 O
KO O
mice O
, O
and O
adoptive O
transfer O
of O
the O
CD8 O
( O
+ O
) O
T O
cells O
caused O
reduced O
survival O
of O
IL O
- O
15 O
KO O
mice O
following O
influenza O
virus O
infection O
. O

Mice O
deficient O
in O
beta O
( O
2 O
) O
- O
microglobulin O
by O
gene O
targeting O
and O
those O
depleted O
of O
CD8 O
( O
+ O
) O
T O
cells O
by O
in O
vivo O
administration O
of O
anti O
- O
CD8 O
monoclonal O
antibody O
displayed O
a O
reduced O
mortality O
rate O
after O
infection O
. O

These O
results O
indicate O
that O
IL O
- O
15 O
- O
dependent O
CD8 O
( O
+ O
) O
T O
cells O
are O
at O
least O
partly O
responsible O
for O
the O
pathogenesis O
of O
acute O
pneumonia O
caused O
by O
influenza O
A O
virus O
. O

Aleutian B
mink I
disease I
virus I
( I
AMDV I
) I
is O
currently O
the O
only O
known O
member O
of O
the O
genus O
Amdovirus O
in O
the O
family O
Parvoviridae O
. O

In O
this O
study O
, O
we O
report O
that O
the O
capsid O
proteins O
were O
specifically O
cleaved O
at O
aspartic O
acid O
residue O
420 O
( O
D420 O
) O
during O
virus O
infection O
, O
resulting O
in O
the O
previously O
observed O
cleavage O
product O
. O

Expression O
of O
the O
capsid O
proteins O
alone O
in O
Crandell B
feline I
kidney I
( I
CRFK I
) I
cells O
reproduced O
the O
cleavage O
of O
the O
capsid O
proteins O
in O
virus O
infection O
. O

A O
deletion O
of O
about O
20 O
amino O
acids O
in O
the O
stalk O
of O
the O
neuraminidase B
( I
NA I
) I
is O
frequently O
detected O
upon O
transmission O
of O
influenza O
A O
viruses O
from O
waterfowl O
to O
domestic O
poultry O
. O

Using O
reverse O
genetics O
, O
a O
recombinant O
virus O
derived O
from O
a O
wild O
duck O
influenza O
virus O
isolate O
, O
A O
/ O
Mallard O
/ O
Marquenterre O
/ O
Z237 O
/ O
83 O
( O
MZ O
) O
, O
and O
an O
NA O
stalk O
deletion O
variant O
( O
MZ O
- O
delNA O
) O
were O
produced O
. O

The O
MZ O
- O
delNA O
- O
inoculated O
chickens O
showed O
significantly O
increased O
levels O
of O
mRNAs O
encoding O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
transforming B
growth I
factor I
- I
beta I
4 I
( I
TGF I
- I
beta I
4 I
) I
, O
and O
CCL5 O
in O
the O
lungs O
and O
a O
higher O
frequency O
of O
apoptotic O
cells O
in O
the O
liver O
than O
did O
their O
MZ O
- O
inoculated O
counterparts O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
critical O
for O
the O
control O
of O
chronic O
infection O
with O
murine O
gammaherpesvirus O
68 O
( O
gamma O
HV68 O
) O
. O

Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
strain O
15 O
causes O
fatal O
pneumonia O
in O
mice O
and O
provides O
a O
convenient O
model O
for O
human O
respiratory O
syncytial O
virus O
pathogenesis O
and O
immunobiology O
. O

In O
Vero O
cells O
, O
which O
lack O
type B
I I
interferon I
( I
IFN I
) I
, O
deletion O
of O
these O
proteins O
had O
no O
effect O
on O
the O
efficiency O
of O
virus O
growth O
. O

In O
IFN O
- O
competent O
mouse O
embryo O
fibroblasts O
, O
wild B
- I
type I
( I
WT I
) I
PVM O
and O
the O
Delta O
NS1 O
virus O
grew O
efficiently O
and O
strongly O
inhibited O
the O
IFN O
response O
, O
whereas O
virus O
lacking O
NS2 O
was O
highly O
attenuated O
and O
induced O
high O
levels O
of O
IFN O
and O
IFN O
- O
inducible O
genes O
. O

The O
titers O
of O
Delta O
NS2 O
and O
Delta O
NS12 O
were O
somewhat O
lower O
on O
day O
3 O
and O
decreased O
further O
by O
day O
6 O
; O
in O
addition O
, O
these O
viruses O
induced O
a O
more O
circumscribed O
set O
of O
cytokines O
/ O
chemokines O
( O
IFN O
, O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
] O
, O
and O
CXCL10 O
) O
that O
were O
detected O
on O
day O
3 O
and O
had O
largely O
subsided O
by O
day O
6 O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
recently O
described O
paramyxovirus O
that O
causes O
respiratory O
tract O
infections O
. O

Both O
groups O
of O
superinfected O
mice O
demonstrated O
significant O
weight O
loss O
( O
mean O
of O
15 O
% O
) O
and O
higher O
levels O
of O
airway O
obstruction O
( O
mean O
enhanced O
pause O
value O
of O
2 O
. O

Bacterial O
counts O
increased O
from O
5 O
x O
10 O
( O
2 O
) O
CFU O
/ O
lung O
in O
mice O
infected O
with O
pneumococcus O
only O
to O
10 O
( O
7 O
) O
and O
10 O
( O
9 O
) O
CFU O
/ O
lung O
in O
mice O
with O
prior O
infections O
with O
hMPV O
and O
influenza O
A O
virus O
, O
respectively O
. O

A O
more O
pronounced O
interstitial O
and O
alveolar O
inflammation O
correlated O
with O
higher O
levels O
of O
inflammatory O
cytokines O
and O
chemokines O
such O
as O
interleukin B
- I
1 I
alpha I
( I
IL I
- I
1 I
alpha I
) I
, O
IL O
- O
1 O
beta O
, O
IL O
- O
6 O
, O
IL O
- O
12 O
, O
monocyte O
chemotactic O
protein O
1 O
, O
macrophage O
inflammatory O
protein O
1 O
alpha O
, O
KC O
, O
and O
granulocyte O
colony O
- O
stimulating O
factor O
, O
as O
well O
as O
greater O
expression O
of O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
, O
TLR6 O
, O
TLR7 O
, O
and O
TLR13 O
in O
the O
lungs O
of O
superinfected O
animals O
compared O
to O
results O
for O
single O
infections O
, O
with O
similar O
immunological O
effects O
seen O
in O
both O
coinfection O
models O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
common O
cause O
of O
infection O
that O
is O
associated O
with O
a O
range O
of O
respiratory O
illnesses O
, O
from O
common O
cold O
- O
like O
symptoms O
to O
serious O
lower O
respiratory O
tract O
illnesses O
such O
as O
pneumonia O
and O
bronchiolitis O
. O

Toll B
- I
like I
receptors I
( I
TLRs I
) I
activate O
innate O
and O
acquired O
immunity O
and O
are O
candidates O
for O
playing O
key O
roles O
in O
the O
host O
immune O
response O
to O
RSV O
. O

Using O
knockout O
mice O
, O
we O
have O
demonstrated O
that O
TLR2 O
and O
TLR6 O
signaling O
in O
leukocytes O
can O
activate O
innate O
immunity O
against O
RSV O
by O
promoting O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
- O
6 O
, O
CCL2 O
( O
monocyte O
chemoattractant O
protein O
1 O
) O
, O
and O
CCL5 O
( O
RANTES O
) O
. O

Infection O
of O
mice O
with O
Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
is O
used O
as O
a O
natural O
host O
experimental O
model O
for O
studying O
the O
pathogenesis O
of O
infection O
with O
the O
closely O
related O
human O
respiratory O
syncytial O
virus O
. O

More O
recently O
, O
three O
novel O
coronaviruses O
associated O
with O
severe O
human O
respiratory O
disease O
were O
found O
, O
including O
( O
i O
) O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
, O
associated O
with O
a O
significant O
atypical O
pneumonia O
and O
10 O
% O
mortality O
; O
( O
ii O
) O
HKU O
- O
1 O
, O
associated O
with O
chronic O
pulmonary O
disease O
; O
and O
( O
iii O
) O
NL63 O
, O
associated O
with O
both O
upper O
and O
lower O
respiratory O
tract O
disease O
in O
children O
and O
adults O
worldwide O
. O

In O
addition O
, O
we O
engineered O
the O
heterologous O
green O
fluorescent O
protein O
gene O
in O
place O
of O
open B
reading I
frame I
3 I
( I
ORF3 I
) I
of O
the O
NL63 O
clone O
, O
simultaneously O
creating O
a O
unique O
marker O
for O
NL63 O
infection O
and O
demonstrating O
that O
the O
ORF3 O
protein O
product O
is O
nonessential O
for O
the O
replication O
of O
NL63 O
in O
cell O
culture O
. O

The O
newly O
emergent O
human O
coronavirus O
HKU1 O
( O
HCoV O
- O
HKU1 O
) O
was O
first O
identified O
in O
Hong O
Kong O
in O
2005 O
. O

The O
CoV O
main O
protease O
( O
M O
- O
pro O
) O
, O
which O
is O
a O
key O
enzyme O
in O
viral O
replication O
via O
the O
proteolytic O
processing O
of O
the O
replicase O
polyproteins O
, O
has O
been O
recognized O
as O
an O
attractive O
target O
for O
rational O
drug O
design O
. O

Combined O
with O
structural O
data O
from O
other O
CoV O
M O
( O
pro O
) O
s O
, O
the O
HCoV O
- O
HKU1 O
MP O
- O
structure O
reported O
here O
provides O
insights O
into O
both O
substrate O
preference O
and O
the O
design O
of O
antivirals O
targeting O
CoVs O
. O

Here O
, O
CCL3 O
( O
- O
/ O
- O
) O
mice O
were O
used O
to O
investigate O
the O
role O
of O
this O
chemokine O
during O
respiratory O
herpesvirus O
infection O
. O

Compared O
to O
wild O
- O
type O
mice O
, O
CCL3 O
( O
- O
/ O
- O
) O
mice O
infected O
with O
the O
alphaherpesvirus O
equine B
herpesvirus I
1 I
( I
ERV I
- I
1 I
) I
displayed O
reduced O
body O
weight O
loss O
but O
had O
higher O
pulmonary O
viral O
loads O
. O

Lungs O
from O
infected O
CCL3 O
( O
- O
/ O
- O
) O
mice O
suffered O
a O
milder O
interstitial O
pneumonia O
, O
and O
fewer O
immune O
cells O
were O
recovered O
from O
the O
pulmonary O
airways O
after O
infection O
. O

We O
could O
also O
demonstrate O
that O
herpesvirus O
- O
encoded O
chemokine O
- O
binding O
glycoprotein B
G I
( I
gG I
) I
was O
capable O
of O
inhibiting O
the O
chemotactic O
functions O
of O
CCL3 O
. O

The O
pathogenesis O
and O
optimal O
treatments O
for O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
are O
unclear O
, O
although O
corticosteroids O
were O
used O
to O
reduce O
lung O
and O
systemic O
inflammation O
. O

Because O
the O
pulmonary O
pathology O
of O
porcine B
respiratory I
coronavirus I
( I
PRCV I
) I
in O
pigs O
resembles O
SARS O
, O
we O
used O
PRCV O
as O
a O
model O
to O
clarify O
the O
effects O
of O
the O
corticosteroid O
dexamethasone B
( I
DEX I
) I
on O
Coronavirus B
( I
CoV I
) I
- O
induced O
pneumonia O
. O

Conventional O
weaned O
pigs O
( O
n O
= O
130 O
) O
in O
one O
of O
four O
groups O
( O
PRCV O
/ O
phosphate O
- O
buffered O
saline O
[ O
PBS O
] O
[ O
n O
= O
41 O
] O
, O
PRCV O
/ O
DEX O
[ O
n O
= O
41 O
] O
, O
mock O
/ O
PBS O
[ O
n O
= O
23 O
] O
, O
and O
mock O
/ O
DEX O
[ O
n O
= O
25 O
] O
) O
were O
inoculated O
intranasally O
and O
intratracheally O
with O
the O
ISU O
- O
1 O
strain O
of O
PRCV O
( O
1 O
x O
10 O
( O
7 O
) O
PFU O
) O
or O
cell O
culture O
medium O
. O

DEX O
was O
administered O
( O
once O
daily O
, O
2 O
mg O
/ O
kg O
of O
body O
weight O
/ O
day O
, O
intramuscularly O
) O
from O
postinoculation B
day I
( I
PID I
) I
1 O
to O
6 O
. O

Significantly O
lower O
numbers O
of O
CD2 O
( O
+ O
) O
, O
CD3 O
( O
+ O
) O
, O
CD4 O
( O
+ O
) O
, O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
also O
observed O
in O
lungs O
of O
PRCV O
/ O
DEX O
pigs O
than O
in O
those O
of O
PRCV O
/ O
PBS O
pigs O
at O
PID O
8 O
and O
10 O
, O
coincident O
with O
fewer O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
secreting O
cells O
in O
the O
tracheobronchial O
lymph O
nodes O
as O
determined O
by O
enzyme O
- O
linked O
immunospot O
assay O
. O

Our O
results O
confirm O
that O
DEX O
treatment O
alleviates O
PRCV O
pneumonia O
early O
( O
PID O
2 O
) O
in O
the O
infection O
but O
continued O
use O
through O
PID O
6 O
exacerbates O
later O
stages O
of O
infection O
( O
PID O
4 O
, O
10 O
, O
and O
21 O
) O
, O
possibly O
by O
decreasing O
cellular O
immune O
responses O
in O
the O
lungs O
( O
IFN O
- O
gamma O
- O
secreting O
T O
cells O
) O
, O
thereby O
creating O
an O
environment O
for O
more O
- O
extensive O
viral O
replication O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
bronchiolitis O
and O
viral O
pneumonia O
in O
young O
children O
and O
a O
serious O
health O
risk O
in O
immunocompromised O
individuals O
and O
the O
elderly O
. O

Pneumonia B
virus I
of I
mice I
( I
PVM I
) I
is O
a O
murine O
relative O
of O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
. O

As O
a O
first O
step O
, O
we O
evaluated O
recombinant O
mutants O
bearing O
a O
deletion O
of O
the O
entire O
G O
gene O
( O
Delta O
G O
) O
or O
expressing O
a O
G O
protein O
lacking O
its O
cytoplasmic O
tail O
( O
Gt O
) O
. O

Although O
nonimmune O
serum O
neutralized O
influenza O
virus O
, O
the O
mechanism O
of O
virus B
neutralization I
( I
VN I
) I
required O
antibody O
, O
as O
sera O
from O
RAG1 O
- O
deficient O
mice O
lacked O
VN O
activity O
; O
moreover O
, O
purified O
natural O
Immunoglobulin B
M I
( I
IgM I
) I
restored O
VN O
activity O
to O
antibody O
- O
deficient O
sera O
. O

In O
the O
present O
study O
, O
we O
examine O
the O
effects O
on O
ion O
transport O
by O
the O
mouse O
tracheal O
epithelium O
of O
a O
third O
major O
respiratory O
pathogen O
, O
respiratory B
syncytial I
virus I
( I
RSV I
) I
. O

This O
effect O
is O
mediated O
by O
protein O
kinase O
C O
and O
is O
reproduced O
by O
recombinant O
viral O
F O
( O
fusion O
) O
protein O
. O

Since O
this O
inhibition O
is O
not O
accompanied O
by O
any O
alteration O
in O
the O
epithelial O
responses O
to O
carbachol O
or O
to O
forskolin O
plus O
3 O
- O
isobutyl O
- O
1 O
- O
methylxanthine O
( O
IBMX O
) O
, O
it O
is O
not O
due O
to O
a O
nonspecific O
toxic O
action O
of O
the O
virus O
. O

Since O
the O
concentration O
range O
over O
which O
this O
inhibition O
is O
observed O
( O
10 O
( O
2 O
) O
to O
10 O
( O
5 O
) O
PFU O
/ O
ml O
) O
is O
comparable O
to O
the O
viral O
concentrations O
observed O
in O
clinical O
and O
experimental O
RSV O
infections O
, O
it O
seems O
likely O
that O
direct O
inhibition O
by O
the O
virus O
of O
epithelial O
Na O
+ O
transport O
may O
contribute O
to O
the O
fluid O
accumulation O
that O
is O
observed O
in O
RSV O
infections O
. O

Animal O
models O
for O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
infection O
of O
humans O
are O
needed O
to O
elucidate O
SARS O
pathogenesis O
and O
develop O
vaccines O
and O
antivirals O
. O

High O
virus O
titers O
were O
detected O
in O
the O
lungs O
and O
brains O
of O
transgene O
- O
positive O
( O
Tg O
( O
+ O
) O
) O
mice O
on O
days O
1 O
and O
3 O
after O
infection O
. O

In O
contrast O
, O
infected O
transgene O
- O
negative O
( O
Tg O
( O
- O
) O
) O
mice O
survived O
without O
showing O
any O
clinical O
illness O
. O

Pathologic O
examination O
suggests O
that O
the O
extensive O
involvement O
of O
the O
central O
nervous O
system O
likely O
contributed O
to O
the O
death O
of O
Tg O
( O
+ O
) O
mice O
, O
even O
though O
viral O
pneumonia O
was O
present O
. O

Importantly O
, O
despite O
significant O
weight O
loss O
, O
infected O
Tg O
( O
+ O
) O
AC63 O
mice O
eventually O
recovered O
from O
the O
illness O
without O
any O
mortality O
. O

Screening O
of O
a O
panel O
of O
primary O
cell O
cultures O
from O
seven O
different O
animal O
species O
revealed O
that O
porcine O
cells O
support O
productive O
replication O
of O
human B
adenovirus I
type I
5 I
( I
Ad5 I
) I
nearly O
as O
efficiently O
as O
human O
A549 O
cells O
, O
while O
release O
of O
infectious O
virus O
by O
cells O
from O
other O
animal O
species O
tested O
was O
diminished O
by O
several O
orders O
of O
magnitude O
. O

A O
reevaluation O
of O
the O
transcription O
profile O
of O
Aleutian B
mink I
disease I
parvovirus I
( I
AMDV I
) I
- O
infected O
CRFK O
cells O
at O
either O
32 O
degrees O
C O
or O
37 O
degrees O
C O
has O
determined O
that O
strain O
AMDV O
- O
G O
encodes O
six O
species O
of O
mRNAs O
produced O
by O
alternative O
splicing O
and O
alternative O
polyadenylation O
of O
a O
pre O
- O
mRNA O
generated O
by O
a O
single O
promoter O
at O
the O
left O
end O
of O
the O
genome O
. O

Three O
different O
splicing O
patterns O
are O
used O
, O
and O
each O
type O
is O
found O
polyadenylated O
at O
either O
the O
3 O
' O
end O
of O
the O
genome O
( O
the O
distal O
site O
) O
or O
at O
a O
site O
in O
the O
center O
of O
the O
genome O
( O
the O
proximal O
site O
) O
. O

Massive O
numbers O
of O
palm O
civets O
were O
culled O
to O
remove O
sources O
for O
the O
reemergence O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
in O
Guangdong O
Province O
, O
China O
, O
in O
January O
2004 O
, O
following O
SARS O
coronavirus O
detection O
in O
market O
animals O
. O

Twenty O
- O
seven O
novel O
signature B
variation I
residues I
( I
SNVs I
) I
were O
identified O
on O
the O
spike O
gene O
and O
were O
analyzed O
for O
their O
phylogenetic O
relationships O
, O
based O
on O
17 O
sequences O
obtained O
from O
animals O
in O
our O
study O
and O
from O
other O
published O
studies O
. O

Advanced O
age O
has O
repeatedly O
been O
identified O
as O
an O
independent O
correlate O
of O
adverse O
outcome O
and O
a O
predictor O
of O
mortality O
in O
cases O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
and O
highly B
active I
antiretroviral I
therapy I
( I
HAART I
) I
are O
known O
to O
exert O
strong O
evolutionary O
pressures O
on O
the O
virus O
population O
during O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
infection O
. O

To O
study O
the O
effect O
of O
immunologic O
pressure O
on O
viral O
sequences O
during O
HAART O
, O
we O
identified O
10 O
targeted O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
epitopes O
in O
five O
treatment O
- O
naive O
patients O
, O
sequenced O
each O
epitope O
in O
plasma O
- O
derived O
viruses O
, O
and O
then O
identified O
evidence O
of O
immunologic O
pressure O
at O
these O
epitopes O
by O
comparing O
the O
frequency O
of O
viral O
variants O
in O
plasma O
to O
the O
frequency O
of O
the O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
for O
each O
variant O
identified O
. O

Interstitial O
pneumonia O
is O
a O
major O
clinical O
manifestation O
of O
primary O
or O
recurrent O
cytomegalovirus B
( I
CMV I
) I
infection O
in O
immunocompromised O
recipients O
of O
a O
bone O
marrow O
transplant O
. O

Pulmonary O
latency O
of O
murine O
CMV O
is O
characterized O
by O
high O
viral O
genome O
burden O
and O
a O
low O
incidence O
of O
variegated O
immediate B
- I
early I
( I
IE I
) I
gene O
expression O
, O
reflecting O
a O
sporadic O
activity O
of O
the O
major O
IE O
promoters O
( O
MIEPs O
) O
and O
enhancer O
. O

In O
accordance O
with O
previous O
work O
of O
others O
, O
we O
show O
here O
that O
signaling O
by O
the O
proinflammatory O
cytokine O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
activates O
IEI O
/ O
3 O
transcription O
in O
vivo O
. O

In O
conclusion O
, O
TNF O
- O
alpha O
is O
an O
important O
inductor O
of O
IE O
gene O
transcriptional O
reactivation O
, O
whereas O
early O
genes O
downstream O
in O
the O
viral O
replicative O
cycle O
appear O
to O
be O
the O
rate O
- O
limiting O
checkpoint O
( O
s O
) O
for O
virus O
recurrence O
. O

In O
the O
past O
3 O
years O
, O
several O
novel O
respiratory O
viruses O
, O
including O
human O
metapneumovirus O
, O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
( O
SARSCoV O
) O
, O
and O
human O
coronavirus O
NL63 O
, O
were O
discovered O
. O

Here O
we O
report O
the O
discovery O
of O
another O
novel O
coronavirus O
, O
coronavirus B
HKU1 I
( I
CoV I
- I
HKU1 I
) I
, O
from O
a O
71 O
- O
year O
- O
old O
man O
with O
pneumonia O
who O
had O
just O
returned O
from O
Shenzhen O
, O
China O
. O

6 O
X O
10 O
( O
6 O
) O
copies O
per O
ml O
in O
his O
nasopharyngeal B
aspirates I
( I
NPAs I
) I
during O
the O
first O
week O
of O
the O
illness O
and O
dropped O
progressively O
to O
undetectable O
levels O
in O
subsequent O
weeks O
. O

He O
developed O
increasing O
serum O
levels O
of O
specific O
antibodies O
against O
the O
recombinant O
nucleocapsid O
protein O
of O
CoV O
- O
HKU1 O
, O
with O
Immunoglobulin B
M I
( I
IgM I
) I
titers O
of O
1 O
: O
20 O
, O
1 O
: O
40 O
, O
and O
1 O
: O
80 O
and O
IgG O
titers O
of O
< O
1 O
: O
1 O
, O
0 O
, O
1 O
: O
2 O
, O
0 O
, O
and O
1 O
: O
8 O
, O
000 O
in O
the O
first O
, O
second O
and O
fourth O
weeks O
of O
the O
illness O
, O
respectively O
. O

13 O
X O
10 O
( O
6 O
) O
copies O
per O
ml O
, O
from O
a O
35 O
- O
year O
- O
old O
woman O
with O
pneumonia O
. O

We O
have O
derived O
and O
characterized O
a O
highly O
pathogenic O
molecular O
isolate O
of O
feline B
immunodeficiency I
virus I
subtype I
C I
( I
FIV I
- I
C I
) I
CABCpady00C O
. O

Clone O
FIV O
- O
C36 O
was O
obtained O
by O
lambda O
cloning O
from O
cats O
that O
developed O
severe O
immunodeficiency O
disease O
when O
infected O
with O
CABCpady00C O
( O
Abbotsford O
, O
British O
Columbia O
, O
Canada O
) O
. O

Clone O
FIV O
- O
C36 O
Env O
is O
96 O
% O
identical O
to O
the O
noninfectious O
FIV O
- O
C O
isolate O
sequence O
deposited O
in O
GenBank O
( O
FIV O
- O
Cgb O
; O
GenBank O
accession O
number O
AF474246 O
) O
( O
A O
. O

) O
but O
is O
much O
more O
divergent O
in O
Env O
when O
compared O
to O
the O
subgroup O
A O
clones O
Petaluma O
( O
34TF10 O
) O
and O
FIV O
- O
PPR O
( O
76 O
and O
78 O
% O
divergence O
, O
respectively O
) O
. O

At O
4 O
to O
5 O
weeks O
postinfection O
( O
PI O
) O
, O
3 O
of O
4 O
animals O
developed O
CD4 O
( O
+ O
) O
- O
T O
- O
cell O
depletion O
, O
fever O
, O
weight O
loss O
, O
diarrhea O
, O
and O
opportunistic O
infections O
, O
including O
ulcerative O
stomatitis O
and O
tonsillitis O
associated O
with O
abundant O
bacterial O
growth O
, O
pneumonia O
, O
and O
pyelonephritis O
, O
requiring O
euthanasia O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
a O
newly O
identified O
group O
2 O
coronavirus O
, O
is O
the O
causative O
agent O
of O
severe O
acute O
respiratory O
syndrome O
, O
a O
life O
- O
threatening O
form O
of O
pneumonia O
in O
humans O
. O

Here O
, O
we O
characterized O
the O
enzymatic O
activities O
of O
a O
recombinant O
form O
of O
the O
SARS O
- O
CoV O
helicase O
( O
nonstructural O
protein O
[ O
nsp O
] O
13 O
) O
, O
a O
superfamily O
1 O
helicase O
with O
an O
N O
- O
terminal O
zinc O
- O
binding O
domain O
. O

Characterization O
of O
the O
nsp13 O
- O
associated O
( O
deoxy O
) O
nucleoside O
triphosphatase O
( O
[ O
dNTPase O
) O
activities O
revealed O
that O
all O
natural O
nucleotides O
and O
deoxynucleotides O
are O
substrates O
of O
nsp13 O
, O
with O
ATP O
, O
dATP O
, O
and O
GTP O
being O
hydrolyzed O
slightly O
more O
efficiently O
than O
other O
nucleotides O
. O

The O
data O
suggest O
that O
the O
( O
d O
) O
NTPase O
and O
RNA O
5 O
' O
- O
triphosphatase O
activities O
of O
nsp13 O
have O
a O
common O
active O
site O
. O

The O
severe B
acute I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
SARS I
- I
CoV I
) I
causes O
severe O
pneumonia O
with O
a O
fatal O
outcome O
in O
approximately O
10 O
% O
of O
patients O
. O

We O
functionally O
analyzed O
SARS O
- O
CoV O
S O
using O
pseudotyped O
lentiviral O
particles O
( O
pseudotypes O
) O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
a O
deadly O
form O
of O
pneumonia O
caused O
by O
a O
novel O
coronavirus O
, O
a O
viral O
family O
responsible O
for O
mild O
respiratory O
tract O
infections O
in O
a O
wide O
variety O
of O
animals O
including O
humans O
, O
pigs O
, O
cows O
, O
mice O
, O
cats O
, O
and O
birds O
. O

In O
this O
report O
, O
we O
describe O
a O
bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
challenge O
model O
in O
which O
both O
classical O
bRSV O
respiratory O
infection O
and O
vaccine O
- O
enhanced O
immune O
pathology O
were O
reproduced O
. O

The O
classical O
, O
formalin B
- I
inactivated I
( I
FI I
) I
bRSV O
vaccine O
that O
has O
been O
associated O
with O
vaccine O
failure O
was O
efficient O
in O
inducing O
high O
antibody O
titers O
and O
reducing O
viral O
loads O
but O
also O
primed O
calves O
for O
a O
far O
more O
serious O
enhanced O
respiratory O
disease O
after O
a O
bRSV O
challenge O
, O
thereby O
mimicking O
the O
enhanced O
clinical O
situation O
in O
FI O
human B
RSV I
( I
hRSV I
) I
- O
immunized O
and O
hRSV O
- O
infected O
infants O
in O
the O
1960s O
. O

Infection O
with O
adenovirus B
serotype I
7 I
( I
Ad7 I
) I
frequently O
causes O
lower O
respiratory O
pneumonia O
and O
is O
associated O
with O
severe O
lung O
inflammation O
and O
neutrophil O
infiltration O
. O

Earlier O
studies O
indicated O
release O
of O
proinflammatory O
cytokines O
, O
specifically O
interleukin B
- I
8 I
( I
IL I
- I
8 I
) I
, O
by O
pulmonary O
epithelial O
cells O
following O
infection O
by O
Ad7 O
. O

Ovine B
pulmonary I
carcinoma I
( I
OPC I
) I
is O
a O
contagious O
neoplasm O
of O
alveolar B
epithelial I
type I
II I
( I
ATII I
) I
or O
Clara O
cells O
caused O
by O
a O
type O
DIB O
chimeric O
retrovirus O
, O
jaagsiekte B
sheep I
retrovirus I
( I
JSRV I
) I
, O
Here O
we O
report O
the O
isolation O
, O
sequencing O
, O
pathogenicity O
, O
and O
integration O
site O
of O
a O
JSRV O
provirus O
isolated O
from O
a O
sheep O
lung O
tumor O
cell O
line O
( O
JS7 O
) O
, O
The O
sequence O
of O
the O
virus O
was O
93 O
to O
99 O
% O
identical O
to O
other O
JSRV O
isolates O
and O
contained O
all O
of O
the O
expected O
open O
reading O
frames O
. O

To O
produce O
virions O
and O
test O
its O
infectivity O
, O
the O
JS7 O
provirus O
( O
JSRV O
( O
JS7 O
) O
) O
was O
cloned O
into O
a O
plasmid O
containing O
a O
cytomegalovirus O
promoter O
and O
transfected O
into O
293T O
cells O
. O

After O
intratracheal O
inoculation O
with O
virions O
from O
concentrated O
supernatant O
fluid O
, O
JSRV O
- O
associated O
OPC O
lesions O
were O
found O
in O
one O
of O
four O
lambs O
, O
confirming O
that O
JSRV O
( O
JS7 O
) O
is O
pathogenic O
, O
In O
JS7 O
- O
cell O
DNA O
, O
the O
viral O
genome O
was O
inserted O
in O
the O
protein O
- O
coding O
region O
for O
the O
surfactant B
protein I
A I
( I
SP I
- I
A I
) I
gene O
, O
which O
is O
highly O
expressed O
in O
ATII O
cells O
, O
in O
an O
orientation O
opposite O
to O
the O
direction O
of O
transcription O
of O
the O
SP O
- O
A O
gene O
. O

human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
is O
one O
of O
the O
major O
causes O
of O
bronchiolitis O
, O
pneumonia O
, O
and O
croup O
in O
newborns O
and O
infants O
. O

Cellular O
immunity O
involving O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
and O
class O
II O
molecules O
plays O
an O
important O
role O
in O
controlling O
virus O
infection O
. O

Several O
viruses O
have O
been O
shown O
to O
down O
- O
regulate O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
mediated O
MHC O
class O
II O
expression O
. O

The O
culture O
supernatant O
of O
HPIV3 O
- O
infected O
cells O
also O
inhibited O
IFN O
- O
gamma O
- O
induced O
MHC O
class O
II O
expression O
, O
a O
phenomenon O
that O
was O
found O
to O
be O
due O
, O
in O
large O
part O
, O
to O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
. O

Class B
II I
transactivator I
( I
CIITA I
) I
is O
the O
unique O
mediator O
of O
IFN O
- O
gamma O
- O
induced O
transcription O
from O
the O
MHC O
class O
II O
promoter O
, O
By O
RNase O
protection O
analysis O
, O
CIITA O
expression O
was O
found O
to O
be O
strongly O
inhibited O
in O
HPIV3 O
- O
infected O
cells O
. O

Interstitial B
pneumonia I
( I
IP I
) I
is O
a O
severe O
organ O
manifestation O
of O
cytomegalovirus B
( I
CMV I
) I
disease O
in O
the O
immunocompromised O
host O
, O
in O
particular O
in O
recipients O
of O
bone B
marrow I
transplantation I
( I
BMT I
) I
. O

Notably O
, O
after O
clearance O
of O
acute O
infection O
, O
CD62L O
( O
lo O
) O
and O
CD62L O
( O
hi O
) O
subsets O
of O
CD44 O
( O
+ O
) O
memory O
CDS O
T O
cells O
were O
found O
to O
persist O
in O
lung O
tissue O
. O

One O
can O
thus O
operationally O
distinguish O
an O
early O
CMV O
- O
positive O
IP O
( O
phase O
1 O
) O
and O
a O
late O
CMV O
- O
negative O
IP O
( O
phase O
2 O
) O
, O
According O
to O
the O
definition O
, O
phase O
2 O
histopathology O
would O
not O
be O
diagnosed O
as O
a O
CMV O
- O
IP O
and O
could O
instead O
be O
misinterpreted O
as O
a O
CMV O
- O
induced O
immunopathology O
. O

Previous O
attempts O
to O
construct O
a O
mouse O
adenovirus O
type O
1 O
Early B
region I
3 I
( I
E3 I
) I
null O
mutant O
by O
initiator O
codon O
mutagenesis O
were O
unsuccessful O
because O
one O
of O
the O
E3 O
proteins O
, O
gp11K O
, O
is O
synthesized O
as O
a O
fusion O
protein O
from O
a O
late O
viral O
mRNA O
( O
A O
. O

This O
strategy O
produced O
a O
mutant O
, O
pmE314 O
, O
that O
was O
null O
for O
the O
expression O
of O
E3 O
proteins O
as O
determined O
by O
immunoprecipitation O
with O
E3 O
- O
specific O
antisera O
, O
This O
mutant O
grew O
as O
well O
as O
wild B
- I
type I
( I
WT I
) I
virus O
in O
both O
3T6 O
mouse O
fibroblasts O
and O
mouse O
brain O
microvascular O
endothelial O
cells O
. O

nitric B
oxide I
( I
NO I
) I
has O
been O
shown O
to O
contribute O
to O
the O
pathogenesis O
of O
influenza O
virus O
- O
induced O
pneumonia O
in O
mouse O
models O
. O

human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
infection O
causes O
severe O
damage O
to O
the O
lung O
epithelium O
, O
leading O
to O
bronchiolitis O
, O
pneumonia O
, O
and O
croup O
in O
newborns O
and O
infants O
. O

In O
this O
study O
, O
we O
investigated O
the O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
and O
II O
molecules O
on O
human O
lung O
epithelial O
( O
A549 O
) O
and O
epithelium O
- O
like O
( O
HT1080 O
) O
cells O
following O
HPIV3 O
infection O
. O

MHC O
class O
I O
was O
induced O
by O
HPIV3 O
in O
these O
cells O
at O
levels O
similar O
to O
those O
observed O
with O
natural O
inducers O
such O
as O
beta O
and O
gamma O
interferon O
( O
IFN O
- O
beta O
and O
- O
gamma O
) O
. O

Together O
, O
these O
data O
indicate O
that O
the O
HPIV3 O
gene O
product O
( O
s O
) O
is O
directly O
involved O
in O
the O
induction O
of O
MHC O
class O
I O
and O
II O
molecules O
. O

Interstitial O
pneumonia O
is O
a O
frequent O
and O
critical O
manifestation O
of O
human B
cytomegalovirus I
( I
CMV I
) I
disease O
in O
immunocompromised O
patients O
, O
in O
particular O
in O
recipients O
of O
bone O
marrow O
transplantation O
. O

We O
demonstrate O
here O
that O
transcription O
of O
the O
immediate B
- I
early I
( I
IE I
) I
transcription O
unit O
ie1 O
- O
ie3 O
selectively O
generates O
iel O
- O
specific O
transcripts O
during O
latency O
. O

cytomegalovirus B
( I
CMV I
) I
infection O
during O
the O
transient O
immunodeficiency O
after O
bone B
marrow I
transplantation I
( I
BMT I
) I
develops O
into O
disease O
unless O
antiviral O
CD8 O
T O
cells O
are O
restored O
in O
due O
course O
. O

Complications O
may O
include O
a O
rejection O
response O
against O
the O
foreign O
major B
histocompatibility I
complex I
( I
MHC I
) I
antigens O
and O
a O
lack O
of O
antiviral O
control O
resulting O
from O
a O
misfit O
between O
donor O
- O
derived O
T O
cells O
and O
the O
antigenic O
viral O
peptides O
presented O
in O
recipient O
tissues O
. O

Specifically O
, O
BALB O
/ O
c O
bone O
marrow O
cells O
expressing O
the O
prevailing O
antigen O
- O
presenting O
molecule O
L O
- O
d O
were O
transplanted O
into O
the O
Ld O
gene O
deletion O
mutant O
BALB O
/ O
c O
- O
H O
- O
2 O
( O
dm2 O
) O
, O
an O
experimental O
setting O
that O
entails O
a O
selective O
risk O
of O
host O
- O
versus O
- O
graft O
but O
not O
graft O
- O
versus O
- O
host O
response O
. O

The O
lungs O
are O
a O
major O
organ O
site O
of O
cytomegalovirus B
( I
CMV I
) I
infection O
, O
pathogenesis O
, O
and O
latency O
. O

Interstitial O
CMV O
pneumonia O
represents O
a O
critical O
manifestation O
of O
CMV O
disease O
, O
in O
particular O
in O
recipients O
of O
bone B
marrow I
transplantation I
( I
BMT I
) I
. O

The O
infiltrate O
provided O
a O
microenvironment O
in O
which O
the O
CD8 O
T O
cells O
differentiated O
into O
mature O
effector O
cells O
, O
that O
is O
, O
into O
functionally O
active O
cytolytic B
T I
lymphocytes I
( I
CTL I
) I
. O

The O
contribution O
of O
the O
previously O
identified O
immediate B
- I
early I
1 I
( I
IE1 I
) I
nonapeptide O
of O
murine O
CMV O
was O
evaluated O
by O
comparison O
, O
vith O
the O
CD3 O
epsilon O
- O
redirected O
cytolytic O
activity O
used O
as O
a O
measure O
of O
the O
overall O
CTL O
response O
in O
the O
lungs O
. O

bovine B
herpesvirus I
1 I
( I
BHV I
- I
1 I
) I
induces O
apoptotic O
cell O
death O
in O
bovine O
peripheral O
blood O
mononuclear O
cells O
and O
B O
- O
lymphoma O
cells O
. O

Influenza O
virus O
A O
/ O
Phil O
/ O
82 O
( O
H3N2 O
) O
grew O
to O
significantly O
higher O
titers O
in O
the O
lungs O
of O
diabetic O
than O
nondiabetic O
mice O
. O

Growth O
of O
A O
/ O
HKx31 O
( O
H3N2 O
) O
virus O
was O
also O
enhanced O
in O
diabetic O
mice O
, O
whereas O
the O
highly O
virulent O
strain O
; O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
showed O
no O
difference O
in O
virus O
yields O
in O
diabetic O
and O
nondiabetic O
mice O
, O
even O
with O
low O
inocula O
. O

A O
/ O
Phil O
/ O
82 O
and O
A O
/ O
HKx31 O
are O
sensitive O
to O
neutralization O
in O
vitro O
by O
the O
pulmonary O
collectin O
surfactant B
protein I
D I
( I
SP I
- I
D I
) I
, O
whereas O
A O
/ O
PR O
/ O
8 O
/ O
34 O
is O
essentially O
resistant O
. O

We O
investigated O
the O
effects O
of O
pharmacological O
and O
lentivirus O
- O
induced O
immunosuppression O
on O
bluetongue B
virus I
( I
BTV I
) I
pathogenesis O
as O
a O
mechanism O
for O
virus O
persistence O
and O
induction O
of O
clinical O
disease O
. O

Immunologically O
normal O
and O
immunosuppressed O
sheep O
were O
infected O
subcutaneously O
with O
BTV B
serotype I
3 I
( I
BTV I
- I
3 I
) I
, O
a O
foreign O
isolate O
with O
unknown O
pathogenicity O
in O
North O
American O
livestock O
, O
and O
with O
North O
American O
serotype O
11 O
( O
BTV O
- O
11 O
) O
, O
Erythrocyte O
- O
associated O
BTV O
RNA O
was O
detected O
earlier O
and O
at O
greater O
concentrations O
in O
sheep O
treated O
with O
immunosuppressive O
drugs O
. O

Similarly O
, O
viral O
RNA O
and O
infectious O
virus O
were O
detected O
in O
blood O
monocytes O
earlier O
and O
at O
higher O
frequency O
in O
immunosuppressed O
animals O
: O
as O
many O
as O
1 O
in O
970 O
monocytes O
revealed O
BTV O
RNA O
at O
peak O
viremia O
, O
compared O
to O
< O
1 O
in O
10 O
( O
5 O
) O
monocytes O
from O
immunocompetent O
sheep O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
most O
important O
cause O
of O
bronchiolitis O
and O
pneumonia O
in O
infants O
and O
young O
children O
worldwide O
. O

As O
yet O
, O
there O
is O
no O
effective O
vaccine O
against O
RSV O
infection O
, O
and O
previous O
attempts O
to O
develop O
a O
formalin O
- O
inactivated O
vaccine O
resulted O
in O
exacerbated O
disease O
in O
recipients O
subsequently O
exposed O
to O
the O
virus O
, O
In O
the O
work O
described O
here O
, O
a O
combinatorial O
solid O
- O
phase O
peptide O
library O
was O
screened O
with O
a O
protective O
monoclonal O
antibody O
( O
MAb O
19 O
) O
to O
identify O
peptide O
mimics O
( O
mimotopes O
) O
of O
a O
conserved O
and O
conformationally O
- O
determined O
epitope O
of O
RSV O
fusion O
( O
F O
) O
protein O
, O
Two O
sequences O
identified O
( O
S1 O
[ O
HWYISKPQ O
] O
and O
S2 O
[ O
HWYDAEVL O
] O
) O
reacted O
specifically O
with O
MAb O
19 O
when O
they O
were O
presented O
as O
solid O
- O
phase O
peptides O
, O
Further O
morel O
after O
amino O
acid O
substitution O
analyses O
, O
three O
sequences O
derived O
from O
S1 O
( O
S1S O
[ O
HWSISKPQ O
] O
, O
S1K O
[ O
KWYISKPQ O
] O
, O
and O
S1P O
[ O
HPYISKPQ O
] O
) O
, O
presented O
as O
multiple B
antigen I
peptides I
( I
MAPs I
) I
, O
also O
showed O
strong O
reactivity O
with O
MAb O
19 O
. O

19 O
x O
10 O
( O
9 O
) O
and O
4 O
. O

93 O
x O
10 O
( O
9 O
) O
M O
- O
1 O
for O
S1 O
and O
S1S O
, O
respectively O
, O
Immunization O
of O
BALB O
/ O
c O
mice O
, O
vith O
these O
mimotopes O
, O
presented O
as O
MAPs O
resulted O
in O
the O
induction O
of O
anti O
- O
peptide O
antibodies O
that O
inhibited O
the O
binding O
of O
MAb O
19 O
to O
RSV O
and O
neutralized O
viral O
infection O
in O
vitro O
, O
with O
titers O
equivalent O
to O
those O
in O
sera O
from O
RSV O
- O
infected O
animals O
, O
Following O
RSV O
challenge O
of O
S1S O
mimotope O
- O
immunized O
mire O
, O
a O
98 O
. O

We O
have O
determined O
the O
nucleotide O
sequences O
of O
the O
regions O
3 O
' O
and O
5 O
' O
proximal O
to O
the O
avian B
pneumovirus I
( I
APV I
) I
N O
and O
L O
genes O
, O
respectively O
. O

These O
sequences O
were O
used O
in O
the O
construction O
of O
a O
synthetic O
minireplicon O
construct O
in O
which O
the O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
was O
flanked O
at O
its O
3 O
' O
end O
with O
the O
APV O
leader O
together O
with O
the O
APV O
N O
gene O
start O
signal O
and O
at O
its O
5 O
' O
end O
with O
the O
APV O
L O
gene O
end O
signal O
and O
the O
genome O
trailer O
region O
. O

The O
two O
parvoviruses O
of O
mink O
cause O
very O
different O
diseases O
, O
Mink B
enteritis I
virus I
( I
MEV I
) I
is O
associated O
with O
rapid O
, O
high O
- O
level O
viral O
replication O
and O
acute O
disease O
, O
In O
contrast O
, O
infection O
with O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
is O
associated O
with O
persistent O
, O
low O
- O
level O
viral O
replication O
and O
chronic O
severe O
immune O
dysregulation O
, O
In O
the O
present O
report O
, O
we O
have O
compared O
viral O
transcription O
in O
synchronized O
CRFK O
cells O
infected O
with O
either O
MEV O
or O
ADV O
using O
a O
nonradioactive O
RNase O
protection O
assay O
, O
The O
overall O
level O
of O
viral O
transcription O
was O
20 O
- O
fold O
higher O
in O
MEV O
- O
than O
in O
ADV O
- O
infected O
cells O
. O

Furthermore O
, O
MEV O
mRNA O
encoding O
structural O
proteins O
( O
MEV O
mRNA O
R3 O
) O
was O
dominant O
throughout O
the O
infectious O
cycle O
, O
comprising O
approximately O
80 O
% O
of O
the O
total O
viral O
transcription O
products O
, O
In O
marked O
contrast O
, O
in O
ADV O
- O
infected O
cells O
, O
transcripts O
encoding O
nonstructural O
proteins O
( O
ADV O
mRNA O
R1 O
and O
R2 O
) O
comprised O
more O
than O
84 O
% O
of O
the O
total O
transcripts O
at O
all O
times O
after O
infection O
, O
whereas O
ADV O
mRNA O
R3 O
comprised O
less O
than O
16 O
% O
, O
Thus O
, O
the O
ADV O
mRNA O
coding O
for O
structural O
proteins O
( O
ADV O
mRNA O
R3 O
) O
was O
present O
at O
a O
level O
at O
least O
100 O
- O
fold O
lower O
than O
the O
corresponding O
MEV O
mRNA O
R3 O
, O
These O
findings O
paralleled O
previous O
biochemical O
studies O
analysing O
in O
vitro O
activities O
of O
the O
ADV O
and O
MEV O
promoters O
( O
J O
. O

Chimeric O
simian B
/ I
human I
immunodeficiency I
virus I
( I
SHIV I
) I
consists O
of O
the O
env O
, O
vpu O
, O
tat O
, O
and O
rev O
genes O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
on O
a O
background O
of O
simian B
immunodeficiency I
virus I
( I
SN I
) I
, O
We O
derived O
a O
SHIV O
that O
caused O
CD4 O
( O
+ O
) O
cell O
loss O
and O
AIDS O
in O
pig O
- O
tailed O
macaques O
( O
S O
. O

McClure O
, O
and O
O O
, O
Narayan O
, O
J O
, O
Virol O
, O
70 O
: O
3189 O
- O
3197 O
, O
1996 O
) O
and O
used O
a O
cell O
- O
free O
stock O
of O
this O
virus O
( O
SHIVKU O
- O
1 O
) O
to O
inoculate O
macaques O
by O
the O
intravaginal O
route O
, O
Macaques O
developed O
high O
virus O
burdens O
and O
severe O
loss O
of O
CD4 O
( O
+ O
) O
cells O
within O
1 O
month O
, O
even O
when O
inoculated O
with O
only O
a O
single O
animal O
infectious O
dose O
of O
the O
virus O
by O
the O
intravaginal O
route O
. O

The O
infection O
was O
characterized O
by O
a O
burst O
of O
virus O
replication O
that O
peaked O
during O
the O
first O
week O
following O
intravenous O
inoculation O
and O
a O
week O
later O
in O
the O
intravaginally O
inoculated O
animals O
, O
Intravaginally O
inoculated O
animals O
died O
within O
6 O
months O
, O
with O
CD4 O
( O
+ O
) O
counts O
of O
< O
30 O
/ O
mu O
l O
in O
peripheral O
blood O
, O
anemia O
, O
weight O
loss O
, O
and O
opportunistic O
infections O
( O
malaria O
, O
toxoplasmosis O
, O
cryptosporidiosis O
, O
and O
Pneumocystis O
carinii O
pneumonia O
) O
, O
To O
evaluate O
the O
kinetics O
of O
virus O
spread O
, O
we O
inoculated O
macaques O
intravaginally O
and O
euthanized O
them O
after O
2 O
, O
4 O
, O
7 O
, O
and O
15 O
days O
postinoculation O
, O
In O
situ O
hybridization O
and O
immunocytochemistry O
revealed O
cells O
expressing O
viral O
RNA O
and O
protein O
in O
the O
vagina O
, O
uterus O
, O
and O
pelvic O
and O
mesenteric O
lymph O
nodes O
in O
the O
macaque O
euthanized O
on O
day O
2 O
, O
By O
day O
4 O
, O
virus O
- O
infected O
cells O
had O
disseminated O
to O
the O
spleen O
and O
thymus O
, O
and O
by O
day O
15 O
, O
global O
elimination O
of O
CD4 O
( O
+ O
) O
T O
cells O
was O
in O
full O
progress O
, O
Kinetics O
of O
viral O
replication O
and O
CD4 O
( O
+ O
) O
loss O
were O
similar O
in O
an O
animal O
inoculated O
with O
pathogenic O
SHIV O
orally O
, O
This O
provides O
a O
sexual O
- O
transmission O
model O
of O
human O
AIDS O
that O
can O
be O
used O
to O
study O
the O
pathogenesis O
of O
mucosal O
infection O
and O
to O
evaluate O
the O
efficacy O
of O
vaccines O
and O
drugs O
directed O
against O
HIV O
- O
1 O
. O

We O
examined O
replication O
of O
the O
autonomous O
parovirus O
Aleutian B
mink I
disease I
parovirus I
( I
ADV I
) I
in O
relation O
to O
cell O
cycle O
progression O
of O
permissive O
Crandell B
feline I
kidney I
( I
CRFK I
) I
cells O
. O

ADV O
- O
induced O
cell O
cycle O
arrest O
occurred O
exclusively O
in O
cells O
containing O
de O
novo O
- O
synthesized O
viral O
nonstructural B
( I
NS I
) I
proteins O
. O

Formation O
of O
population O
A O
was O
not O
prevented O
by O
VM O
- O
26 O
, O
indicating O
that O
these O
cells O
were O
arrested O
in O
late O
S O
or O
G O
( O
2 O
) O
phase O
. O

A O
second O
, O
postmitotic O
, O
NS O
+ O
population O
( O
termed O
population O
B O
) O
arose O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
, O
downstream O
of O
population O
A O
. O

Since O
the O
nature O
of O
this O
DNA O
synthesis O
was O
not O
examined O
, O
we O
cannot O
at O
present O
differentiate O
between O
G O
( O
1 O
) O
and O
early O
S O
arrest O
in O
population O
B O
. O

Cells O
that O
became O
NS O
+ O
during O
S O
phase O
entered O
population O
A O
, O
whereas O
population O
B O
cells O
apparently O
remained O
NS O
- O
during O
S O
phase O
and O
expressed O
high O
NS O
levels O
postmitosis O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
. O

This O
suggested O
that O
population O
B O
resulted O
from O
leakage O
of O
cells O
with O
subthreshold O
levels O
of O
ADV O
products O
through O
the O
late O
S O
/ O
G O
( O
2 O
) O
block O
and O
, O
consequently O
, O
that O
the O
binary O
pattern O
of O
ADV O
- O
induced O
cell O
cycle O
arrest O
may O
be O
governed O
merely O
by O
viral O
replication O
levels O
within O
a O
single O
S O
phase O
. O

Reovirus O
type B
3 I
Dearing I
( I
T3D I
) I
causes O
a O
prominent O
neutrophil O
influx O
, O
substantially O
greater O
than O
seen O
with O
reovirus O
type B
1 I
Lang I
( I
T1L I
) I
in O
a O
rat O
model O
of O
viral O
pneumonia O
, O
We O
sought O
to O
measure O
reovirus O
- O
mediated O
increases O
in O
chemokine O
mRNA O
expression O
in O
pulmonary O
cells O
. O

We O
found O
that O
the O
neutrophilia O
induced O
by O
T1L O
and O
T3D O
infection O
in O
vivo O
correlated O
directly O
with O
increased O
levels O
of O
chemokine O
mRNA O
expression O
in O
T3D O
- O
infected O
compared O
with O
those O
of O
T1L O
- O
infected O
lungs O
, O
In O
vitro O
, O
reovirus O
- O
infected O
normal O
alveolar B
macrophages I
( I
AMs I
) I
and O
the O
rat O
AM O
cell O
line O
NR8383 O
expressed O
greater O
levels O
of O
macrophage O
inflammatory O
protein O
2 O
, O
KC O
, O
and O
tumor O
necrosis O
factor O
alpha O
mRNA O
, O
A O
synergism O
between O
reovirus O
and O
lipopolysaccharide O
was O
also O
detected O
for O
macrophage O
inflammatory O
protein O
2 O
and O
KC O
mRNA O
expression O
. O

Studies O
with O
mouse O
models O
of O
liver O
- O
and O
lung O
- O
directed O
gene O
therapy O
suggested O
that O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
are O
effecters O
that O
contribute O
to O
extinction O
of O
transgene O
expression O
. O

Early B
region I
3 I
( I
E3 I
) I
of O
mouse O
adenovirus O
type O
I O
has O
the O
potential O
to O
produce O
three O
proteins O
which O
have O
identical O
amino O
termini O
but O
unique O
carboxy O
- O
terminal O
sequences O
. O

Late O
mRNA O
production O
was O
analyzed O
by O
Northern O
( O
RNA O
) O
blotting O
and O
found O
to O
be O
similar O
in O
wild O
- O
type O
and O
mutant O
viruses O
. O

Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
DNA O
was O
identified O
by O
PCR O
in O
samples O
from O
mink O
and O
raccoons O
on O
commercial O
ranches O
during O
an O
outbreak O
of O
Aleutian B
disease I
( I
AD I
) I
. O

A O
gamma O
delta O
T O
- O
ceH O
hybridoma O
established O
from O
influenza O
virus O
- O
infected O
mice O
responded O
in O
a O
reproducible O
way O
when O
cultured O
with O
influenza O
virus O
- O
infected O
stimulators O
, O
Subclones O
of O
this O
line O
responded O
to O
cells O
infected O
with O
influenza O
viruses O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
, O
S O
- O
31 O
( O
H3N2 O
) O
, O
and O
B O
/ O
HK O
/ O
8 O
/ O
73 O
but O
not O
to O
cells O
infected O
with O
vaccinia O
virus O
or O
Sendai O
virus O
, O
This O
spectrum O
of O
response O
to O
both O
type O
A O
and O
type O
B O
orthomyxoviruses O
has O
never O
been O
recognized O
for O
the O
alpha O
beta O
T O
- O
cell O
receptor O
- O
positive O
subsets O
. O

There O
was O
no O
response O
to O
cells O
infected O
with O
a O
panel O
of O
recombinant O
vaccinia O
viruses O
expressing O
all O
individual O
influenza O
virus O
proteins O
, O
and O
so O
it O
is O
unlikely O
that O
the O
stimulating O
antigen O
is O
of O
viral O
origin O
, O
The O
alternative O
is O
that O
the O
antigen O
is O
a O
cellular O
molecule O
induced O
in O
influenza O
virus O
- O
infected O
cells O
, O
Infectious O
virus O
was O
required O
for O
stimulation O
, O
and O
immunofluorescence O
studies O
showed O
increased O
expression O
of O
heat B
shock I
protein I
60 I
( I
Hsp60 I
) I
in O
influenza O
virus O
but O
not O
Sendai O
virus O
- O
or O
vaccinia O
virus O
- O
infected O
cells O
, O
Both O
the O
hybridoma O
generated O
from O
influenza O
virus O
- O
infected O
mice O
and O
an O
established O
hybridoma O
which O
uses O
the O
same O
gamma O
delta O
T O
- O
cell O
receptor O
combination O
responded O
to O
recombinant O
Hsp60 O
. O

We O
undertook O
the O
present O
study O
to O
elucidate O
the O
pathogenesis O
of O
the O
pathologic O
response O
to O
reovirus O
infection O
in O
the O
lungs O
and O
further O
understand O
the O
interactions O
of O
reoviruses O
with O
pulmonary O
cells O
, O
We O
found O
that O
reoviruses O
were O
capable O
of O
causing O
acute O
pneumonia O
in O
25 O
- O
to O
28 O
- O
day O
- O
old O
Sprague O
- O
Dawley O
rats O
following O
intratracheal O
inoculation O
with O
the O
reoviruses O
type B
1 I
Lang I
( I
T1L I
) I
and O
type B
3 I
Dearing I
( I
T3D I
) I
, O
The O
onset O
of O
the O
pneumonia O
was O
rapid O
, O
marked O
by O
type O
I O
alveolar O
epithelial O
cell O
degeneration O
, O
type O
II O
alveolar O
epithelial O
cell O
hyperplasia O
, O
and O
the O
infiltration O
of O
leukocytes O
into O
the O
alveolar O
spaces O
, O
More O
neutrophils O
were O
recruited O
into O
the O
lungs O
during O
T3D O
infection O
than O
during O
T1L O
infection O
, O
and O
the O
serotype O
difference O
in O
the O
neutrophil O
response O
was O
mapped O
to O
the O
S1 O
gene O
of O
reovirus O
, O
Viral O
replication O
in O
the O
lungs O
was O
required O
for O
the O
development O
of O
pneumonia O
due O
to O
T1L O
and O
T3D O
infections O
, O
and O
replication O
occurred O
in O
type O
I O
alveolar O
epithelial O
cells O
, O
T1L O
grew O
to O
higher O
titers O
in O
the O
lungs O
than O
did O
either O
T3D O
or O
type O
3 O
clone O
9 O
, O
and O
the O
S1 O
gene O
was O
found O
to O
play O
a O
role O
in O
determining O
the O
level O
of O
viral O
replication O
, O
We O
propose O
that O
experimental O
reovirus O
infection O
in O
the O
lungs O
can O
serve O
as O
a O
model O
for O
the O
pathogenesis O
of O
viral O
pneumonia O
in O
which O
pulmonary O
inflammation O
results O
following O
direct O
infection O
of O
lung O
epithelial O
cells O
. O

Sendai O
virus O
, O
a O
paramyxovirus O
which O
causes O
murine O
pneumonia O
, O
grew O
to O
approximately O
10 O
- O
fold O
higher O
titers O
and O
was O
cleared O
less O
rapidly O
from O
the O
lungs O
of O
129 O
/ O
J O
( O
129 O
) O
than O
H O
- O
( O
2b O
) O
- O
compatible O
C57BL O
/ O
6J O
( O
B6 O
) O
mice O
. O

The O
more O
susceptible O
129 O
mice O
also O
made O
higher O
titers O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
virus O
- O
specific O
antibody O
. O

Analysis O
with O
acutely O
irradiated O
( O
950 O
rads O
) O
mice O
and O
immunoIogicalIy O
reconstituted O
bone B
marrow I
( I
BM I
) I
radiation O
chimeras O
indicated O
that O
the O
enhanced O
virus O
growth O
was O
a O
function O
of O
the O
radiation O
- O
resistant O
respiratory O
epithelium O
. O

Prolonged O
exposure O
to O
more O
virus O
in O
turn O
influenced O
the O
magnitude O
of O
IFN O
- O
gamma O
production O
, O
most O
of O
which O
was O
made O
by O
CD4 O
( O
+ O
) O
T O
lymphocytes O
. O

Further O
analysis O
of O
double O
chimeras O
( O
B6 O
+ O
129 O
BM O
- O
- O
> O
B6 O
recipients O
) O
confirmed O
that O
the O
divergent O
humoral O
immune O
response O
to O
Sendai O
virus O
in O
B6 O
and O
129 O
mice O
is O
largely O
determined O
by O
the O
inherent O
characteristics O
of O
the O
lymphoid O
cells O
. O

HeLa O
and O
293 O
cell O
lines O
that O
express O
biologically O
active O
adenovirus O
type O
5 O
precursor B
terminal I
protein I
( I
pTP I
) I
have O
been O
made O
. O

Cotton O
rats O
were O
used O
to O
study O
the O
replication O
and O
pathogenesis O
of O
bovine B
parainfluenza I
virus I
type I
3 I
( I
BPIV3 I
) I
and O
to O
test O
the O
efficacy O
of O
the O
F O
and O
HN O
glycoproteins O
in O
modulating O
infection O
. O

) O
inoculation O
of O
cotton O
rats O
with O
10 O
( O
7 O
) O
PFU O
resulted O
in O
peak O
recovery O
of O
virus O
after O
2 O
days O
( O
8 O
x O
10 O
( O
4 O
) O
PFU O
/ O
g O
of O
lung O
tissue O
) O
and O
significant O
bronchiolitis O
with O
lymphocyte O
infiltration O
5 O
to O
7 O
days O
postinfection O
. O

Serum O
antibody O
responses O
were O
evaluated O
by O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISA I
) I
, O
hemagglutination B
inhibition I
( I
HAI I
) I
, O
and O
serum B
neutralization I
( I
SN I
) I
. O

When O
an O
intramuscular O
inoculation O
of O
10 O
( O
7 O
) O
PFU O
was O
administered O
10 O
days O
prior O
to O
the O
i O
. O

Recombinant O
adenoviruses O
are O
an O
attractive O
vehicle O
for O
gene O
therapy O
to O
the O
lung O
in O
the O
treatment O
of O
Cystic B
fibrosis I
( I
CF I
) I
. O

In O
this O
study O
, O
we O
have O
used O
mice O
deficient O
in O
immunological O
effector O
Functions O
in O
combination O
with O
adoptive O
and O
passive O
transfer O
techniques O
to O
define O
antigen O
- O
specific O
cellular O
and O
humoral O
immune O
responses O
that O
underlie O
these O
important O
limitations O
, O
Our O
studies O
indicate O
that O
major O
histocompatibility O
complex O
class O
I O
- O
restricted O
CD8 O
( O
+ O
) O
cytotoxic O
T O
lymphocytes O
are O
activated O
in O
response O
to O
newly O
synthesized O
antigens O
, O
leading O
to O
destruction O
of O
virus O
infected O
cells O
and O
loss O
of O
transgene O
expression O
. O

Major O
histocompatibility O
complex O
class O
II O
- O
associated O
presentation O
of O
exogenous O
viral O
antigens O
activates O
CD4 O
( O
+ O
) O
T O
- O
helper O
( O
T O
- O
H O
) O
cells O
of O
the O
T O
- O
H1 O
subset O
and O
, O
to O
a O
lesser O
extent O
, O
of O
the O
T O
- O
H2 O
subset O
, O
CD4 O
( O
+ O
) O
cell O
- O
mediated O
responses O
are O
insufficient O
in O
the O
absence O
of O
cytotoxic O
T O
cells O
to O
completely O
eliminate O
transgene O
containing O
cells O
; O
however O
, O
they O
contribute O
to O
the O
formation O
of O
neutralizing O
antibodies O
in O
the O
airway O
which O
block O
subsequent O
adenovirus O
- O
mediated O
gene O
transfer O
. O

Respiratory B
syncytial I
( I
RS I
) I
virus O
infects O
the O
epithelium O
of O
the O
respiratory O
tract O
. O

Cytokine O
profiles O
for O
both O
the O
respiratory O
tract O
and O
the O
draining O
mediastinal B
lymph I
node I
( I
MLN I
) I
of O
virus O
- O
infected O
C57BL O
/ O
6J O
mice O
were O
quantified O
by O
using O
the O
single O
- O
cell O
cytokine O
( O
ELISPOT O
) O
assay O
with O
freshly O
isolated O
cell O
populations O
and O
enzyme O
- O
linked O
immunosorbent O
assay O
for O
lung O
lavage O
fluids O
and O
culture O
supernatants O
. O

Maximal O
levels O
of O
interleukin B
2 I
( I
IL I
- I
2 I
) I
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
tumor O
necrosis O
factor O
, O
IL O
- O
6 O
, O
and O
IL O
- O
10 O
were O
detected O
at O
the O
inflammatory O
site O
7 O
to O
10 O
days O
after O
infection O
, O
about O
the O
time O
that O
virus O
is O
cleared O
from O
the O
lung O
. O

The O
frequencies O
of O
cells O
producing O
IL O
- O
2 O
, O
IL O
- O
4 O
, O
IL O
- O
6 O
, O
IL O
- O
10 O
, O
IFN O
- O
gamma O
, O
and O
tumor O
necrosis O
factor O
were O
much O
higher O
for O
the O
Bronchoalveolar B
lavage I
( I
BAL I
) I
cell O
population O
than O
for O
the O
MLN O
cell O
population O
. O

Cytokine O
production O
after O
in O
vitro O
restimulation O
of O
MLN O
cells O
was O
dominated O
by O
IL O
- O
2 O
and O
IFN O
- O
gamma O
, O
with O
low O
levels O
of O
IL O
- O
10 O
and O
IL O
- O
6 O
also O
being O
present O
, O
Most O
of O
the O
cytokine O
was O
produced O
by O
the O
CD4 O
( O
+ O
) O
cells O
, O
although O
the O
CD8 O
( O
+ O
) O
subset O
was O
also O
involved O
, O
No O
IL O
- O
4 O
was O
found O
in O
the O
BAL O
fluid O
or O
in O
culture O
supernatants O
from O
restimulated O
BAL O
or O
MLN O
cells O
, O
although O
a O
high O
frequency O
of O
IL O
- O
4 O
producing O
cells O
was O
demonstrated O
in O
the O
BAL O
population O
by O
ELISPOT O
analysis O
. O

In O
July O
1991 O
, O
an O
influenza O
A O
virus O
, O
designated O
A O
/ O
Maryland O
/ O
12 O
/ O
91 O
( O
A O
/ O
MD O
) O
, O
was O
isolated O
from O
the O
bronchial O
secretions O
of O
a O
27 O
- O
year O
- O
old O
animal O
caretaker O
. O

Antigenic O
analyses O
with O
postinfection O
ferret O
antisera O
and O
monoclonal O
antibodies O
to O
recent O
H1 O
swine O
hemagglutinins O
indicated O
that O
the O
hemagglutinin O
of O
this O
virus O
was O
antigenically O
related O
to O
, O
but O
distinguishable O
from O
, O
those O
of O
other O
influenza O
A O
( O
H1N1 O
) O
viruses O
currently O
circulating O
in O
swine O
. O

We O
investigated O
the O
role O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
the O
pathogenesis O
of O
rat B
cytomegalovirus I
( I
RCMV I
) I
infection O
. O

TNF O
- O
alpha O
levels O
found O
in O
the O
sera O
of O
radiation O
- O
immunosuppressed O
rats O
in O
the O
course O
of O
infection O
( O
> O
350 O
pg O
/ O
ml O
) O
correlated O
with O
the O
development O
of O
RCMV O
disease O
. O

Neonatal O
mink O
kits O
infected O
with O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
develop O
an O
acute O
interstitial O
pneumonia O
with O
clinical O
symptoms O
and O
pathological O
lesions O
that O
resemble O
those O
seen O
in O
preterm O
human O
infants O
with O
respiratory O
distress O
syndrome O
and O
in O
human O
adults O
with O
adult O
respiratory O
distress O
syndrome O
. O

Furthermore O
, O
Northern O
( O
RNA O
) O
blot O
hybridization O
showed O
that O
the O
infection O
caused O
a O
significant O
decrease O
of O
surfactant O
- O
associated O
protein O
C O
mRNA O
produced O
by O
the O
alveolar O
type O
II O
cells O
. O

We O
suppressed O
the O
B O
- O
cell O
development O
and O
antibody O
response O
in O
mink O
by O
using O
treatment O
with O
polyclonal O
anti O
- O
immunoglobulin O
M O
( O
anti O
- O
IgM O
) O
to O
study O
the O
effects O
of O
antiviral O
antibodies O
on O
development O
of O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
- O
induced O
disease O
in O
more O
detail O
. O

7K O
protein O
) O
encoded O
by O
the O
adenovirus B
( I
Ad I
) I
E3 O
region O
inhibits O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
lysis O
of O
cells O
in O
tissue O
culture O
experiments O
, O
but O
the O
relevance O
of O
this O
effect O
in O
vivo O
is O
incompletely O
understood O
. O

7K O
protein O
- O
encoding O
gene O
into O
vaccinia O
virus O
( O
W O
) O
, O
permitting O
its O
study O
in O
isolation O
from O
other O
Ad O
E3 O
immunomodulatory O
proteins O
. O

7K O
gene O
to O
ensure O
that O
each O
cell O
infected O
with O
the O
W O
recombinant O
would O
express O
both O
the O
agonist O
( O
TNF O
) O
and O
its O
antagonist O
( O
14 O
. O

Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
infects O
macrophages O
in O
adult O
mink O
. O

The O
enhancing O
activity O
was O
present O
in O
the O
protein O
A O
- O
binding O
immunoglobulin O
G O
fraction O
in O
the O
serum O
, O
but O
F O
( O
ab O
' O
) O
2 O
fragments O
failed O
to O
enhance O
the O
infection O
. O

On O
the O
other O
hand O
, O
the O
same O
sera O
inhibited O
ADV O
- O
G O
infection O
of O
Crandell B
feline I
kidney I
( I
CRFK I
) I
cells O
. O

Recurrence O
of O
infectious O
virus O
from O
the O
latent O
viral O
genomes O
is O
the O
initiating O
event O
in O
the O
pathogenesis O
of O
cytomegalovirus B
( I
CMV I
) I
disease O
during O
states O
of O
immunodeficiency O
. O

Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
infection O
causes O
both O
acute O
and O
chronic O
disease O
in O
mink O
, O
and O
we O
have O
previously O
shown O
that O
it O
is O
the O
level O
of O
viral O
gene O
expression O
that O
determines O
the O
disease O
pattern O
. O

To O
study O
the O
gene O
regulation O
of O
ADV O
, O
we O
have O
cloned O
the O
P3 O
ADV O
and O
P36 O
ADV O
promoters O
in O
front O
of O
a O
reporter O
gene O
, O
the O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
, O
and O
analyzed O
these O
constructs O
by O
transient O
transfection O
in O
a O
feline O
kidney O
cell O
line O
and O
mouse O
NIH O
3T3 O
cells O
. O

The O
genes O
for O
ADV O
structural O
proteins O
( O
VP1 O
and O
VP2 O
) O
and O
the O
nonstructural O
proteins O
( O
NS O
- O
1 O
, O
NS O
- O
2 O
, O
and O
NS O
- O
3 O
) O
were O
cloned O
into O
a O
eukaryotic O
expression O
vector O
, O
and O
their O
functions O
in O
regulation O
of O
the O
P3 O
ADV O
and O
P36 O
ADV O
promoters O
were O
examined O
in O
cotransfection O
experiments O
. O

Constitutive O
activities O
of O
the O
P3 O
ADV O
and O
P36 O
ADV O
promoters O
were O
weaker O
than O
those O
of O
the O
corresponding O
promoters O
from O
the O
prototypic O
parvovirus O
minute B
virus I
of I
mice I
( I
MVM I
) I
and O
canine B
parvovirus I
( I
CPV I
) I
. O

This O
finding O
may O
indicate O
a O
different O
mechanism O
of O
transactivation O
of O
the O
early O
promoters O
( O
P3 O
ADV O
and O
P4 O
MVM O
) O
compared O
with O
the O
late O
( O
P36 O
ADV O
and O
P38 O
MVM O
) O
promoters O
. O

We O
are O
currently O
investigating O
the O
regulation O
of O
transcription O
of O
the O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
. O

This O
slow O
replication O
is O
an O
intrinsic O
property O
of O
ADV O
and O
distinguishes O
it O
from O
the O
more O
prototypic O
parvoviruses O
such O
as O
minute B
virus I
of I
mice I
( I
MVM I
) I
and O
canine B
parvovirus I
( I
CPV I
) I
. O

We O
found O
the O
weak O
constitutive O
activity O
of O
the O
ADV O
P36 O
promoter O
to O
be O
caused O
by O
suboptimal O
promoter O
proximal O
sequences O
, O
while O
the O
low O
level O
of O
transactivation O
was O
caused O
mainly O
by O
an O
upstream O
region O
including O
sequences O
with O
homology O
to O
the O
transactivation O
responsive O
element O
( O
tar O
) O
of O
the O
H O
- O
1 O
parvovirus O
( O
M O
. O

On O
the O
basis O
of O
comparative O
data O
for O
ADV O
, O
MVM O
, O
CPV O
, O
and O
H O
- O
1 O
, O
a O
new O
clustered O
motif O
( O
TTGGTT O
) O
is O
proposed O
to O
be O
the O
responsive O
cis O
- O
acting O
element O
for O
transactivation O
. O

Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
mRNAs O
are O
found O
in O
macrophages O
in O
lymph O
nodes O
and O
peritoneal O
exudate O
cells O
from O
ADV O
- O
infected O
mink O
. O

Cotton O
rats O
( O
Sigmodon O
hispidus O
) O
were O
inoculated O
intranasally O
with O
10 O
( O
2 O
. O

These O
changes O
could O
be O
divided O
into O
two O
phases O
: O
an O
early O
phase O
( O
affecting O
alveoli O
, O
bronchiolar O
epithelium O
, O
and O
peribronchiolar O
regions O
) O
with O
an O
infiltrate O
consisting O
primarily O
of O
monocytes O
- O
macrophages O
and O
neutrophils O
, O
with O
occasional O
lymphocytes O
, O
and O
a O
later O
phase O
( O
affecting O
peribronchiolar O
and O
perivascular O
regions O
) O
with O
an O
infiltrate O
consisting O
almost O
exclusively O
of O
lymphocytes O
. O

We O
have O
previously O
published O
a O
detailed O
transcription O
map O
of O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
and O
Proposed O
a O
model O
for O
the O
translation O
of O
the O
two O
virion O
structural O
proteins O
( O
Vp1 O
and O
Vp2 O
) O
and O
three O
nonstructural O
proteins O
( O
NS O
- O
1 O
, O
NS O
- O
2 O
, O
and O
NS O
- O
3 O
) O
( O
S O
. O

The O
complete O
genome O
of O
the O
jaagsiekte B
sheep I
retrovirus I
( I
JSRV I
) I
, O
the O
suspected O
etiological O
agent O
of O
ovine O
pulmonary O
carcinoma O
, O
has O
been O
cloned O
from O
viral O
particles O
secreted O
in O
lung O
exudates O
of O
affected O
animals O
and O
sequenced O
. O

Different O
isolates O
of O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
were O
cloned O
and O
nucleotide O
sequenced O
. O

Tick B
- I
borne I
flaviviruses I
( I
TBF I
) I
are O
widely O
dispersed O
across O
Africa O
, O
Europe O
, O
Asia O
, O
Oceania O
, O
and O
North O
America O
, O
and O
some O
present O
a O
significant O
threat O
to O
human O
health O
. O

Seminal O
studies O
on O
tick O
- O
borne O
encephalitis O
viruses O
( O
TBEV O
) O
, O
based O
on O
partial O
envelope O
gene O
sequences O
, O
predicted O
a O
westward O
clinal O
pattern O
of O
evolution O
and O
dispersal O
across O
northern O
Eurasia O
, O
terminating O
in O
the O
British O
Isles O
. O

We O
tested O
this O
hypothesis O
using O
all O
available O
full O
- O
length O
open B
reading I
frame I
( I
ORF I
) I
TBF O
sequences O
. O

Here O
, O
we O
show O
that O
the O
expression O
of O
Andes B
( I
ANDV I
) I
and O
Puumala B
( I
PUUV I
) I
hantavirus O
Gn O
and O
Gc O
envelope O
glycoproteins O
lead O
to O
their O
self O
- O
assembly O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
which O
were O
released O
to O
cell O
supernatants O
. O

Until O
recently O
, O
the O
single O
known O
exception O
to O
the O
rodent O
- O
hantavirus O
association O
was O
Thottapalayam B
virus I
( I
TPMV I
) I
, O
a O
long O
- O
unclassified O
virus O
isolated O
from O
the O
Asian O
house O
shrew O
( O
Suncus O
murinus O
) O
. O

Here O
, O
we O
report O
the O
characterization O
of O
a O
newly O
identified O
hantavirus O
, O
designated O
Imjin O
virus O
( O
MJNV O
) O
, O
isolated O
from O
the O
lung O
tissues O
of O
Ussuri O
white O
- O
toothed O
shrews O
of O
the O
species O
Crocidura O
lasiura O
( O
order O
Soricomorpha O
, O
family O
Soricidae O
, O
subfamily O
Crocidurinae O
) O
captured O
near O
the O
demilitarized O
zone O
in O
the O
Republic O
of O
Korea O
during O
2004 O
and O
2005 O
. O

After O
day O
26 O
, O
the O
viral O
titers O
and O
the O
levels O
of O
the O
small B
( I
S I
) I
, O
medium B
( I
M I
) I
, O
and O
large B
( I
L I
) I
viral O
RNAs O
varied O
cyclically O
until O
the O
end O
of O
the O
studies O
. O

Deletions O
at O
the O
3 O
' O
termini O
of O
S O
, O
M O
, O
and O
L O
virus O
- O
sense O
RNAs O
( O
vRNAs O
) O
accumulated O
during O
the O
acute O
phase O
of O
infection O
just O
before O
the O
time O
that O
the O
viral O
titer O
and O
the O
concentration O
of O
vRNAs O
and O
virus O
complementary O
- O
sense O
RNAs O
( O
cRNAs O
) O
began O
to O
decline O
. O

Sin B
Nombre I
virus I
( I
SNV I
) I
, O
a O
member O
of O
the O
Hantavirus O
genus O
, O
causes O
acute O
viral O
pneumonia O
in O
humans O
and O
is O
thought O
to O
persistently O
infect O
mice O
. O

The O
lungs O
consistently O
presented O
with O
the O
highest O
levels O
of O
viral O
antigen O
by O
immunohistochemistry O
and O
with O
the O
highest O
levels O
of O
nucleic O
acid O
by O
reverse B
transcriptase I
( I
RT I
) I
PCR O
. O

To O
investigate O
the O
ability O
of O
a O
vaccinia O
virus O
- O
vectored O
vaccine O
expressing O
the O
M O
and O
the O
S O
segments O
of O
Hantaan B
( I
HTN I
) I
virus O
( O
C O
. O

Dalrymple O
, O
Vaccine O
10 O
: O
10 O
- O
13 O
, O
1992 O
) O
to O
elicit O
a O
protective O
immune O
response O
against O
other O
hantaviruses O
, O
we O
vaccinated O
hamsters O
with O
the O
recombinant O
vaccine O
and O
challenged O
them O
with O
HTN O
, O
Seoul B
( I
SEO I
) I
, O
or O
Puumala B
( I
PUU I
) I
virus O
. O

To O
assay O
for O
virus O
in O
the O
blood O
and O
tissues O
of O
the O
hamsters O
, O
we O
developed O
a O
nested O
reverse B
transcriptase I
( I
RT I
) I
- O
PCR O
with O
cross O
- O
reactive O
outer O
primers O
and O
serotype O
- O
specific O
inner O
primers O
. O

The O
primary O
pathophysiologic O
finding O
of O
the O
viral O
disease O
known O
as O
Korean O
hemorrhagic O
fever O
, O
the O
etiological O
agent O
of O
which O
is O
Hantaan B
virus I
( I
HTV I
) I
, O
is O
vascular O
instability O
. O

To O
investigate O
whether O
HTV O
was O
able O
to O
infect O
cells O
derived O
from O
human O
vascular O
tissue O
and O
alter O
their O
behavior O
, O
we O
infected O
in O
vitro O
primary O
adult O
human O
endothelial O
cells O
from O
saphenous O
veins O
( O
HSVEC O
) O
. O

We O
were O
able O
to O
detect O
the O
presence O
of O
viral O
antigens O
in O
infected O
cells O
both O
by O
immunofluorescence O
and O
by O
Western O
blot O
( O
immunoblot O
) O
analysis O
as O
early O
as O
day O
1 O
postinfection O
. O

HSVEC O
infected O
with O
HTV O
produce O
infectious O
virus O
during O
the O
first O
3 O
days O
of O
infection O
but O
, O
at O
later O
times O
( O
days O
4 O
to O
8 O
) O
, O
show O
decreasing O
yields O
of O
virus O
. O

Bovine B
ephemeral I
fever I
virus I
( I
BEFV I
) I
is O
an O
arthropod O
- O
borne O
rhabdovirus O
that O
causes O
a O
debilitating O
disease O
of O
cattle O
in O
Africa O
, O
Asia O
, O
and O
Australia O
; O
however O
, O
its O
global O
geodynamics O
are O
poorly O
understood O
. O

An O
evolutionary O
analysis O
of O
G O
gene O
( O
envelope O
glycoprotein O
) O
ectodomain O
sequences O
of O
97 O
BEFV O
isolates O
collected O
from O
Australia O
during O
1956 O
to O
2012 O
revealed O
that O
all O
have O
a O
single O
common O
ancestor O
and O
are O
phylogenetically O
distinct O
from O
BEFV O
sampled O
in O
other O
geographical O
regions O
. O

Notably O
, O
the O
Australian O
clade O
has O
evolved O
as O
a O
single O
genetic O
lineage O
across O
the O
continent O
and O
at O
a O
high O
evolutionary O
rate O
of O
10 O
( O
- O
3 O
) O
nucleotide O
substitutions O
/ O
site O
/ O
year O
. O

Finally O
, O
we O
propose O
that O
positive O
selection O
on O
residue O
215 O
was O
due O
to O
cross O
- O
reacting O
neutralizing O
antibody O
to O
Kimberley O
virus O
( O
KIMV O
) O
. O

The O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
serocomplex O
, O
which O
also O
includes O
Murray B
Valley I
encephalitis I
virus I
( I
MVEV I
) I
, O
is O
a O
group O
of O
antigenically O
closely O
related O
, O
mosquito O
- O
borne O
flaviviruses O
that O
are O
responsible O
for O
severe O
encephalitic O
disease O
in O
humans O
. O

Here O
we O
have O
evaluated O
the O
cross O
- O
protective O
values O
of O
an O
inactivated O
JEV O
vaccine O
( O
JE O
- O
VAX O
) O
and O
a O
live O
chimeric B
JEV I
vaccine I
( I
ChimeriVax I
- I
JE I
) I
against O
MVEV O
in O
two O
mouse O
models O
of O
flaviviral O
encephalitis O
. O

We O
show O
that O
( O
i O
) O
a O
three O
- O
dose O
vaccination O
schedule O
with O
JE O
- O
VAX O
provides O
cross O
- O
protective O
immunity O
, O
albeit O
only O
partial O
in O
the O
more O
severe O
challenge O
model O
; O
( O
ii O
) O
a O
single O
dose O
of O
ChimeriVax O
- O
JE O
gives O
complete O
protection O
in O
both O
challenge O
models O
; O
( O
iii O
) O
the O
cross O
- O
protective O
immunity O
elicited O
with O
ChimeriVax O
- O
JE O
is O
durable O
( O
> O
= O
5 O
months O
) O
and O
broad O
( O
also O
giving O
protection O
against O
West O
Nile O
virus O
) O
; O
( O
iv O
) O
humoral O
and O
cellular O
immunities O
elicited O
with O
ChimeriVax O
- O
JE O
contribute O
to O
protection O
against O
lethal O
challenge O
with O
MVEV O
; O
( O
v O
) O
ChimeriVax O
- O
JE O
remains O
fully O
attenuated O
in O
immunodeficient O
mice O
lacking O
type O
I O
and O
type O
II O
interferon O
responses O
; O
and O
( O
vi O
) O
immunization O
with O
JE O
- O
VAX O
, O
but O
not O
ChimeriVax O
- O
JE O
, O
can O
prime O
heterologous O
infection O
enhancement O
in O
recipients O
of O
vaccination O
on O
a O
low O
- O
dose O
schedule O
, O
designed O
to O
mimic O
vaccine O
failure O
or O
waning O
of O
vaccine O
- O
induced O
immunity O
. O

The O
in O
vivo O
mechanism O
for O
virulence O
attenuation O
of O
laboratory O
- O
derived O
variants O
of O
two O
flaviviruses O
in O
the O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
serocomplex O
is O
described O
. O

Host O
cell O
adaptation O
of O
JEV O
and O
Murray B
Valley I
encephalitis I
virus I
( I
MVE I
) I
by O
serial O
passage O
in O
adenocarcinoma O
cells O
selected O
for O
variants O
characterized O
by O
( O
i O
) O
a O
small O
plaque O
phenotype O
, O
( O
ii O
) O
increased O
affinity O
to O
heparin O
- O
Sepharose O
, O
( O
iii O
) O
enhanced O
susceptibility O
to O
inhibition O
of O
infectivity O
by O
heparin O
, O
and O
( O
iv O
) O
loss O
of O
neuroinvasiveness O
in O
a O
mouse O
model O
for O
flaviviral O
encephalitis O
. O

We O
previously O
suggested O
that O
virulence O
attenuation O
of O
the O
host O
cell O
- O
adapted O
variants O
of O
NIVE O
is O
a O
consequence O
of O
their O
increased O
dependence O
on O
cell O
surface O
glycosaminoglycans B
( I
GAGs I
) I
for O
attachment O
and O
entry O
( O
E O
. O

Despite O
the O
close O
genetic O
relatedness O
of O
JEV O
and O
NINE O
, O
the O
variants O
selected O
for O
the O
two O
viruses O
were O
altered O
at O
different O
residues O
in O
the O
envelope B
( I
E I
) I
protein O
, O
viz O
. O

, O
Glu O
( O
306 O
) O
and O
Asp O
( O
390 O
) O
for O
JEV O
and O
MVE O
, O
respectively O
. O

1 O
to O
10 O
( O
5 O
) O
PFU O
of O
virus O
gave O
mortality O
in O
similar O
to50 O
% O
of O
animals O
despite O
low O
or O
undetectable O
virus O
growth O
in O
extraneural O
tissues O
. O

A O
neuroadapted O
strain O
of O
yellow B
fever I
virus I
( I
YFV I
) I
17D O
derived O
from O
a O
multiply O
mouse O
brain O
- O
passaged O
virus O
( O
Porterfield O
YF17D O
) O
was O
additionally O
passaged O
in O
SCUD O
and O
normal O
, O
mice O
. O

The O
virulence O
properties O
of O
this O
virus O
( O
SPYF O
) O
could O
be O
distinguished O
from O
nonneuroadapted O
virus O
( O
YF5 O
. O

The O
envelope B
( I
E I
) I
protein O
contained O
five O
substitutions O
, O
within O
all O
three O
functional O
domains O
. O

Substitutions O
were O
also O
present O
in O
regions O
encoding O
the O
NS1 O
, O
NS2A O
, O
NS4A O
, O
and O
NS5 O
proteins O
and O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
. O

A O
study O
of O
immunopathology O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
during O
infection O
with O
a O
virulent O
strain O
of O
Murray B
Valley I
encephalitis I
virus I
( I
MVE I
) I
in O
weanling O
Swiss O
mice O
following O
peripheral O
inoculation O
is O
presented O
. O

Depletion O
of O
neutrophils O
with O
a O
cytotoxic O
monoclonal O
antibody O
( O
RB6 O
- O
8C5 O
) O
resulted O
in O
prolonged O
survival O
and O
decreased O
mortality O
in O
MVE O
- O
infected O
mice O
. O

In O
addition O
, O
neutrophil O
infiltration O
and O
disease O
onset O
correlated O
with O
expression O
of O
the O
enzyme O
- O
inducible B
nitric I
oxide I
synthase I
( I
iNOS I
) I
within O
the O
CNS O
, O
Inhibition O
of O
iNOS O
by O
aminoguanidine O
resulted O
in O
prolonged O
survival O
and O
decreased O
mortality O
in O
MVE O
- O
infected O
mice O
. O

Studies O
of O
genetic O
resistance O
to O
flavivirus O
infection O
in O
laboratory O
mice O
have O
led O
to O
the O
development O
of O
a O
single O
model O
in O
which O
resistance O
is O
conferred O
by O
an O
autosomal O
dominant O
gene O
designated O
Flv O
( O
r O
) O
. O

Because O
of O
evidence O
suggesting O
that O
wild O
mice O
carry O
virus O
resistance O
genes O
which O
are O
not O
present O
in O
laboratory O
mice O
, O
we O
compared O
flavivirus O
resistance O
in O
the O
inbred O
strains O
CASA O
/ O
Rk O
, O
CAST O
/ O
Ei O
, O
and O
MOLD O
/ O
Rk O
, O
which O
are O
derived O
directly O
from O
wild O
mice O
, O
and O
the O
congenic O
strains O
C3H O
/ O
RV O
( O
Flv O
( O
r O
) O
/ O
Flv O
( O
r O
) O
) O
and O
C3H O
/ O
HeJ O
( O
Flv O
( O
s O
) O
/ O
Flv O
( O
s O
) O
) O
. O

Our O
data O
indicate O
that O
flavivirus O
resistance O
in O
the O
CASA O
/ O
Rk O
strain O
is O
due O
to O
a O
gene O
which O
is O
similar O
or O
identical O
to O
Flv O
( O
r O
) O
, O
whereas O
resistance O
in O
the O
MOLD O
/ O
Rk O
strain O
is O
due O
to O
a O
previously O
undescribed O
gene O
which O
we O
designate O
Flv O
( O
mr O
) O
to O
indicate O
minor O
resistance O
to O
flavivirus O
infection O
. O

Synthetic O
peptides O
from O
the O
envelope O
glycoprotein O
sequence O
of O
Murray B
Valley I
encephalitis I
( I
MVE I
) I
virus O
were O
previously O
evaluated O
in O
various O
strains O
of O
mice O
for O
both O
the O
induction O
of O
antibody O
and O
the O
in O
vitro O
proliferation O
of O
peptide O
- O
primed O
T B
- I
helper I
( I
Th I
) I
cells O
. O

MVE O
peptide O
6 O
( O
amino O
acids O
230 O
to O
251 O
) O
elicited O
reciprocal O
Th O
- O
and O
B O
- O
cell O
reactivity O
with O
native O
MVE O
virus O
after O
primary O
inoculation O
of O
C57BL O
/ O
6 O
mice O
. O

One O
element O
demonstrable O
after O
primary O
immunization O
, O
located O
in O
the O
carboxy O
terminus O
, O
associated O
only O
with O
major O
histocompatibility O
complex O
class O
II O
IA O
( O
b O
) O
and O
IA O
( O
b O
) O
IE O
( O
k O
) O
glycoproteins O
. O

Functional O
stimulation O
with O
the O
peptides O
in O
association O
with O
IA O
( O
k O
) O
IE O
( O
k O
) O
and O
IA O
( O
d O
) O
IE O
( O
d O
) O
molecules O
was O
observed O
only O
after O
in O
vivo O
secondary O
stimulation O
. O

Peptide O
6 O
- O
1 O
( O
amino O
acids O
230 O
to O
241 O
) O
was O
nonimmunogenic O
but O
could O
be O
recognized O
by O
Th O
cells O
from O
peptide O
6 O
- O
immunized O
mice O
. O

Further O
association O
of O
peptide O
6 O
with O
the O
IA O
( O
k O
) O
IE O
( O
k O
) O
and O
IA O
( O
d O
) O
IE O
( O
d O
) O
subregions O
was O
demonstrated O
by O
the O
finding O
that O
T O
cells O
from O
MVE O
peptide O
6 O
- O
inoculated O
C3H O
and O
BALB O
/ O
c O
mice O
primed O
for O
an O
antibody O
response O
to O
MVE O
virus O
. O

avian B
influenza I
viruses I
( I
AIVs I
) I
are O
zoonotic O
viruses O
that O
exhibit O
a O
range O
of O
infectivity O
and O
severity O
in O
the O
human O
host O
. O

Severe O
human O
cases O
of O
AIV O
infection O
are O
often O
accompanied O
by O
neurological O
symptoms O
; O
however O
, O
the O
factors O
involved O
in O
the O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
are O
not O
well O
known O
. O

In O
this O
study O
, O
we O
discovered O
that O
the O
avian O
- O
like O
sialic B
acid I
( I
SA I
) I
- O
alpha B
2 I
, I
3 I
- I
galactose I
( I
alpha I
2 I
, I
3 I
- I
Gal I
) I
receptor O
is O
highly O
presented O
in O
mammalian O
( O
human O
and O
mouse O
) O
brains O
. O

In O
the O
generation O
of O
a O
mouse O
- O
adapted O
neurotropic O
H9N2 O
AIV O
( O
SD16 O
- O
MA O
virus O
) O
in O
BALB O
/ O
c O
mice O
, O
we O
identified O
key O
adaptive O
mutations O
in O
its O
Hemagglutinin B
( I
HA I
) I
and O
polymerase B
basic I
protein I
2 I
( I
PB2 I
) I
genes O
that O
conferred O
viral O
replication O
ability O
in O
the O
mouse O
brain O
. O

We O
further O
established O
that O
host O
fragile B
X I
mental I
retardation I
protein I
( I
FMRP I
) I
, O
a O
highly O
expressed O
protein O
in O
the O
brain O
that O
is O
physically O
associated O
with O
viral O
nucleocapsid B
protein I
( I
NP I
) I
to O
facilitate O
RNP O
assembly O
and O
export O
, O
was O
an O
essential O
host O
factor O
for O
the O
neuronal O
replication O
of O
neurotropic O
AIVs O
( O
H9N2 O
, O
H5N1 O
, O
and O
H10N7 O
viruses O
) O
. O

Importantly O
, O
we O
showed O
that O
host O
FMRP O
was O
a O
crucial O
host O
factor O
that O
was O
necessary O
for O
neurotropic O
AIVs O
( O
H9N2 O
, O
H5N1 O
, O
and O
H10N7 O
viruses O
) O
to O
replicate O
in O
neuronal O
cells O
. O

influenza B
A I
virus I
( I
IAV I
) I
epidemiology O
in O
wild O
birds O
has O
been O
based O
primarily O
on O
surveillance O
programs O
focused O
on O
dabbling O
duck O
species O
, O
particularly O
mallard O
( O
Anas O
platyrhynchos O
) O
. O

Surveillance O
in O
Eurasia O
has O
shown O
that O
in O
mallards O
, O
some O
subtypes O
are O
commonly O
( O
H1 O
to O
H7 O
and O
H10 O
) O
, O
intermediately O
( O
H8 O
, O
H9 O
, O
H11 O
, O
and O
H12 O
) O
, O
or O
rarely O
( O
H13 O
to O
H16 O
) O
detected O
, O
contributing O
to O
discussions O
on O
virus O
host O
range O
and O
reservoir O
competence O
. O

Here O
, O
we O
investigated O
the O
attachment O
patterns O
of O
all O
avian O
IAV O
subtypes O
( O
H1 O
to O
H16 O
) O
to O
the O
respiratory O
and O
intestinal O
tracts O
of O
four O
dabbling O
duck O
species O
( O
Mareca O
and O
Anas O
spp O
. O

We O
found O
that O
IAV O
subtypes O
generally O
showed O
abundant O
attachment O
to O
colon O
of O
the O
Anas O
duck O
species O
, O
mallard O
, O
and O
Eurasian O
teal O
( O
Anas O
crecca O
) O
, O
supporting O
the O
fecal O
- O
oral O
transmission O
route O
in O
these O
species O
. O

IMPORTANCE O
influenza B
A I
viruses I
( I
IAVs I
) I
circulate O
in O
wild O
birds O
worldwide O
. O

A O
high O
IAV O
diversity O
has O
been O
found O
in O
mallards O
( O
Anas O
platyrhynchos O
) O
, O
which O
are O
most O
often O
sampled O
as O
part O
of O
surveillance O
programs O
; O
meanwhile O
, O
little O
is O
known O
about O
the O
role O
of O
other O
duck O
species O
in O
IAV O
ecology O
and O
epidemiology O
. O

In O
this O
study O
, O
we O
investigated O
the O
attachment O
of O
all O
avian O
IAV O
Hemagglutinin B
( I
HA I
) I
subtypes O
( O
H1 O
to O
H16 O
) O
to O
tissues O
of O
six O
different O
duck O
species O
and O
chicken O
as O
an O
indicator O
of O
virus O
host O
range O
. O

The O
H5N8 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
Glade O
2 O
. O

Viruses O
with O
the O
wild O
bird O
virus O
backbone O
and O
either O
PB1 O
, O
NP O
, O
or O
the O
entire O
polymerase O
complex O
of O
the O
chicken O
isolate O
caused O
higher O
and O
earlier O
mortality O
in O
chickens O
, O
with O
three O
mutations O
( O
PB1 O
E180D O
, O
M317V O
, O
and O
NP O
11091 O
) O
identified O
to O
increase O
polymerase O
activity O
in O
chicken O
cells O
. O

The O
reassortant O
virus O
with O
the O
HA O
and O
NA O
from O
the O
chicken O
virus O
, O
where O
mutations O
in O
functionally O
known O
gene O
regions O
were O
acquired O
as O
the O
virus O
circulated O
in O
turkeys O
( O
HA O
S141P O
and O
NA O
S416G O
) O
and O
later O
in O
chickens O
( O
HA O
M66I O
, O
L322Q O
) O
, O
showed O
faster O
virus O
growth O
, O
bigger O
plaque O
size O
, O
and O
enhanced O
heat O
persistence O
in O
vitro O
and O
increased O
pathogenicity O
and O
transmissibility O
in O
chickens O
. O

IMPORTANCE O
H5Nx O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
of O
the O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
lineage O
continue O
to O
circulate O
widely O
, O
affecting O
both O
poultry O
and O
wild O
birds O
. O

The O
recent O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
and O
H7N9 O
viruses O
have O
caused O
hundreds O
of O
human O
infections O
with O
high O
mortality O
rates O
. O

Here O
, O
we O
report O
the O
generation O
and O
evaluation O
of O
two O
reassortant O
influenza O
viruses O
, O
PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
and O
PR8 B
- I
H7 I
- I
H5 I
( I
NA I
) I
. O

These O
viruses O
contain O
six O
internal O
segments O
from O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
( O
PR8 O
) O
, O
the O
HA O
segment O
from O
either O
A O
/ O
Alberta O
/ O
01 O
/ O
2014 O
( O
H5N1 O
) O
[ O
AB14 O
( O
H5N1 O
) O
] O
or O
A O
/ O
British O
Columbia O
/ O
01 O
/ O
2015 O
( O
H7N9 O
) O
[ O
BC15 B
( I
H7N9 I
) I
] O
, O
and O
a O
chimeric O
NA O
segment O
with O
either O
the O
BC15 B
( I
H7N9 I
) I
HA O
gene O
or O
the O
AB14 O
( O
H5N1 O
) O
HA O
gene O
flanked O
by O
the O
NA O
packaging O
signals O
of O
PR8 O
. O

Moreover O
, O
intranasal O
vaccination O
with O
PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
elicited O
robust O
immune O
responses O
to O
both O
H5 O
and O
H7 O
viruses O
, O
conferring O
complete O
protection O
against O
both O
AB14 O
( O
H5N1 O
) O
and O
BC15 B
( I
H7N9 I
) I
challenges O
in O
mice O
. O

Conversely O
, O
vaccination O
with O
PR8 B
- I
H7 I
- I
H5 I
( I
NA I
) I
only O
elicited O
robust O
immune O
responses O
toward O
the O
H7 O
virus O
, O
which O
conferred O
complete O
protection O
against O
BC15 B
( I
H7N9 I
) I
but O
not O
against O
AB14 O
( O
H5N1 O
) O
in O
mice O
. O

Therefore O
, O
PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
has O
strong O
potential O
to O
serve O
as O
a O
vaccine O
candidate O
against O
both O
H5 O
and O
H7 O
subtypes O
of O
influenza O
viruses O
. O

We O
generated O
and O
evaluated O
two O
reassortant O
influenza O
viruses O
, O
PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
and O
PR8 B
- I
H7 I
- I
H5 I
( I
NA I
) I
, O
as O
vaccine O
candidates O
. O

Vaccination O
of O
PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
virus O
confers O
protection O
to O
both O
H5N1 O
and O
H7N9 O
virus O
challenge O
; O
conversely O
, O
vaccination O
of O
PR8 B
- I
H7 I
- I
H5 I
( I
NA I
) I
provides O
protection O
only O
to O
H7N9 O
virus O
challenge O
. O

PR8 B
- I
H5 I
- I
H7 I
( I
NA I
) I
has O
strong O
potential O
to O
serve O
as O
a O
vaccine O
candidate O
against O
both O
H5 O
and O
H7 O
subtypes O
of O
influenza O
viruses O
. O

Previously O
, O
our O
group O
has O
demonstrated O
the O
effectiveness O
of O
Hemagglutinin B
( I
HA I
) I
antigens O
derived O
using O
computationally B
optimized I
broadly I
reactive I
antigen I
( I
COBRA I
) I
methodology O
against O
H1N1 O
, O
H3N2 O
, O
and O
H5N1 O
viruses O
. O

In O
this O
study O
, O
the O
effectiveness O
of O
H2 O
COBRA O
HA O
antigens O
( O
Z1 O
, O
Z3 O
, O
Z5 O
, O
and O
Z7 O
) O
was O
evaluated O
in O
DBA O
/ O
2J O
mice O
and O
compared O
to O
that O
of O
wild O
- O
type O
H2 O
HA O
antigens O
. O

The O
COBRA O
HA O
vaccines O
elicited O
neutralizing O
antibodies O
to O
the O
majority O
of O
viruses O
in O
our O
H2 O
HA O
panel O
and O
across O
all O
three O
clades O
as O
measured O
by O
hemagglutination B
inhibition I
( I
HAI I
) I
and O
neutralization O
assays O
. O

1 O
avian O
influenza O
viruses O
( O
H5N1 O
) O
are O
unique O
to O
Egypt O
and O
generally O
carry O
the O
human O
adaptation O
PB2 O
- O
E627K O
substitution O
during O
their O
dissemination O
in O
nature O
. O

1 O
avian O
influenza O
viruses O
( O
H5N1 O
) O
are O
unique O
to O
Egypt O
and O
have O
caused O
the O
highest O
number O
of O
human O
H5N1 O
influenza O
cases O
worldwide O
, O
presenting O
a O
serious O
global O
public O
health O
threat O
. O

Laninamivir B
( I
LAN I
) I
is O
a O
long O
- O
acting O
neuraminidase B
( I
NA I
) I
inhibitor O
( O
NAI O
) O
with O
a O
similar O
binding O
profile O
in O
the O
influenza O
NA O
enzyme O
active O
site O
as O
those O
of O
other O
NAIs O
, O
oseltamivir B
( I
OS I
) I
, O
zanamivir B
( I
ZAN I
) I
, O
and O
peramivir O
, O
and O
may O
share O
common O
resistance O
markers O
with O
these O
NAIs O
. O

We O
screened O
viruses O
with O
NA O
substitutions O
previously O
found O
during O
OS O
and O
ZAN O
selection O
in O
avian B
influenza I
viruses I
( I
AIVs I
) I
of O
the O
N3 O
to O
N9 O
subtypes O
for O
LAN O
susceptibility O
. O

To O
determine O
whether O
the O
in O
vitro O
susceptibility O
of O
multi O
- O
NAI O
- O
resistant O
AIVs O
is O
associated O
with O
in O
vivo O
susceptibility O
, O
we O
infected O
BALB O
/ O
c O
mice O
with O
recombinant O
AIVs O
with O
R292K O
( O
ma81K O
- O
N3 O
( O
R292K O
) O
) O
or O
Q136K O
( O
ma81K O
- O
N8 O
( O
Q136K O
) O
) O
NA O
substitutions O
, O
which O
impart O
in O
vitro O
susceptibility O
only O
to O
LAN O
or O
OS O
, O
respectively O
. O

Both O
ma81KN3 O
( O
R292K O
) O
and O
ma81K O
- O
N8 O
( O
Q136K O
) O
virus O
- O
infected O
mice O
exhibited O
reduced O
weight O
loss O
, O
mortality O
, O
and O
lung O
viral O
titers O
when O
treated O
with O
their O
susceptible O
NAIs O
, O
confirming O
the O
in O
vitro O
susceptibility O
of O
these O
substitutions O
. O

IMPORTANCE O
The O
chemical O
structures O
of O
Neuraminidase B
inhibitors I
( I
NAIs I
) I
possess O
similarities O
, O
but O
slight O
differences O
can O
result O
in O
variable O
susceptibility O
of O
avian B
influenza I
viruses I
( I
AIVs I
) I
carrying O
resistance O
- O
associated O
NA O
substitutions O
. O

This O
is O
of O
particular O
concern O
in O
Bangladesh O
, O
where O
highly O
pathogenic O
avian O
influenza O
viruses O
of O
the O
A O
( O
H5N1 O
) O
subtype O
are O
endemic O
and O
cocirculate O
with O
other O
influenza O
viruses O
. O

Active O
surveillance O
of O
avian O
influenza O
viruses O
in O
Bangladeshi O
live O
poultry O
markets O
detected O
three O
A O
( O
H5 O
) O
genotypes O
, O
designated O
H5N1 O
- O
R1 O
, O
H5N1 O
- O
R2 O
, O
and O
H5N2 O
- O
R3 O
, O
that O
arose O
from O
reassortment O
of O
A O
( O
H5N1 O
) O
clade O
2 O
. O

The O
H5N1 O
- O
R1 O
and O
H5N1 O
- O
R2 O
viruses O
contained O
HA O
, O
NA O
, O
and O
M O
genes O
from O
the O
A O
( O
H5N1 O
) O
clade O
2 O
. O

H5N2 O
- O
R3 O
viruses O
contained O
the O
HA O
gene O
from O
circulating O
A O
( O
H5N1 O
) O
clade O
2 O
. O

1a O
viruses O
, O
NA O
and O
M O
genes O
from O
concurrently O
circulating O
A O
( O
H9N2 O
) O
influenza O
viruses O
, O
and O
PB2 O
, O
PB1 O
, O
PA O
, O
NP O
, O
and O
NS O
genes O
from O
other O
Eurasian O
influenza O
viruses O
. O

1a O
strain O
( O
H5N1 O
- O
R0 O
) O
infected O
and O
replicated O
in O
mice O
without O
prior O
adaptation O
; O
the O
H5N2 O
- O
R3 O
virus O
replicated O
to O
the O
highest O
titers O
in O
the O
lung O
. O

Our O
findings O
demonstrate O
that O
although O
the O
A O
( O
H5N1 O
) O
viruses O
circulating O
in O
Bangladesh O
have O
the O
capacity O
to O
infect O
and O
replicate O
in O
mammals O
, O
they O
show O
very O
limited O
capacity O
for O
transmission O
. O

IMPORTANCE O
Highly O
pathogenic O
avian O
influenza O
A O
( O
H5N1 O
) O
viruses O
have O
circulated O
continuously O
in O
Bangladesh O
since O
2007 O
, O
and O
active O
surveillance O
has O
detected O
viral O
evolution O
driven O
by O
mutation O
and O
reassortment O
. O

Recently O
, O
three O
genetically O
distinct O
A O
( O
H5N1 O
) O
reassortant O
viruses O
were O
detected O
in O
live O
poultry O
markets O
in O
Bangladesh O
. O

Avian B
influenza I
virus I
( I
AIV I
) I
can O
cross O
species O
barriers O
to O
infect O
humans O
and O
other O
mammals O
. O

Current O
research O
about O
host O
restriction O
focuses O
mainly O
on O
the O
barriers O
of O
cell O
membrane O
, O
nuclear O
envelope O
, O
and O
host O
proteins O
; O
whether O
microRNAs B
( I
miRNAs I
) I
play O
a O
role O
in O
host O
restriction O
is O
largely O
unknown O
. O

In O
this O
study O
, O
we O
used O
porcine B
alveolar I
macrophage I
( I
PAM I
) I
cells O
as O
a O
model O
to O
elucidate O
the O
role O
of O
miRNAs O
in O
host O
range O
restriction O
. O

Among O
them O
, O
two O
Sus O
scrofa O
( O
ssc O
; O
swine O
) O
miRNAs O
, O
ssc O
- O
miR O
- O
221 O
- O
3p O
and O
ssc O
- O
miR O
- O
222 O
, O
could O
inhibit O
the O
infection O
and O
replication O
of O
AIV O
in O
PAM O
cells O
by O
directly O
targeting O
viral O
genome O
and O
inducing O
cell O
apoptosis O
via O
inhibiting O
the O
expression O
of O
anti O
- O
apoptotic O
protein O
HMBOX1 O
. O

Importantly O
, O
we O
found O
that O
ssc O
- O
miR O
- O
221 O
- O
3p O
and O
ssc O
- O
miR O
- O
222 O
could O
also O
be O
specifically O
upregulated O
upon O
AIV O
infection O
in O
newborn B
pig I
tracheal I
epithelial I
( I
NPTr I
) I
cells O
and O
also O
exerted O
anti O
- O
AIV O
function O
. O

Wild O
aquatic O
birds O
maintain O
a O
large O
, O
genetically O
diverse O
pool O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
, O
which O
can O
be O
transmitted O
to O
lower O
mammals O
and O
, O
ultimately O
, O
humans O
. O

H9N2 O
avian B
influenza I
viruses I
( I
AIVs I
) I
circulate O
in O
poultry O
throughout O
much O
of O
Asia O
, O
the O
Middle O
East O
, O
and O
Africa O
. O

H7N9 O
avian B
influenza I
viruses I
( I
AIVs I
) I
continue O
to O
evolve O
and O
remain O
a O
huge O
threat O
to O
human O
health O
and O
the O
poultry O
industry O
. O

Previously O
, O
serially O
passaging O
the O
H7N9 O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
virus O
in O
the O
presence O
of O
homologous O
ferret O
antiserum O
resulted O
in O
immune O
escape O
viruses O
containing O
amino O
acid O
substitutions O
alanine O
to O
threonine O
at O
residues O
125 O
( O
A125T O
) O
and O
151 O
( O
A151T O
) O
and O
leucine O
to O
glutamine O
at O
residue O
217 O
( O
L217Q O
) O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
. O

Our O
results O
showed O
the O
serum O
escape O
mutant O
formed O
large O
plaques O
in O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
and O
grew O
robustly O
in O
vitro O
and O
in O
ovo O
. O

This O
study O
demonstrates O
that O
the O
immune O
escape O
mutants O
also O
( O
i O
) O
gained O
greater O
replication O
ability O
in O
cultured O
cells O
and O
in O
chicken O
embryos O
as O
well O
as O
( O
ii O
) O
increased O
acid O
and O
thermal O
stability O
but O
( O
iii O
) O
lost O
preferences O
for O
binding O
to O
human O
- O
type O
receptor O
while O
maintaining O
binding O
for O
the O
avian O
- O
like O
receptor O
. O

Some O
avian B
influenza I
( I
AI I
) I
viruses O
have O
a O
deletion O
of O
up O
to O
20 O
to O
30 O
amino O
acids O
in O
their O
neuraminidase B
( I
NA I
) I
stalk O
. O

To O
systematically O
analyze O
the O
effect O
of O
NA O
stalk O
length O
and O
concomitant O
( O
de O
) O
glycosylation O
on O
G1 O
replication O
and O
host O
range O
, O
we O
generated O
G1 O
viruses O
that O
had O
various O
NA O
stalk O
lengths O
and O
that O
were O
either O
glycosylated O
or O
not O
glycosylated O
. O

However O
, O
with O
a O
Hemagglutinin B
( I
HA I
) I
with O
a O
higher O
a2 O
, O
6 O
- O
linked O
sialylglycan O
affinity O
, O
the O
effect O
of O
NA O
stalk O
length O
on O
G1 O
virus O
infection O
was O
reversed O
, O
with O
shorter O
NA O
stalks O
reducing O
virus O
entry O
into O
human O
cells O
. O

IMPORTANCE O
H9N2 O
avian B
influenza I
( I
AI I
) I
virus O
, O
one O
of O
the O
most O
prevalent O
AI O
viruses O
, O
has O
caused O
repeated O
poultry O
and O
human O
infections O
, O
posing O
a O
huge O
public O
health O
risk O
. O

Low O
- O
pathogenicity O
avian O
influenza O
A O
( O
H9N2 O
) O
viruses O
, O
enzootic O
in O
poultry O
populations O
in O
Asia O
, O
are O
associated O
with O
fewer O
confirmed O
human O
infections O
but O
higher O
rates O
of O
seropositivity O
compared O
to O
A O
( O
H5 O
) O
or O
A O
( O
H7 O
) O
subtype O
viruses O
. O

Cocirculation O
of O
A O
( O
H5 O
) O
and O
A O
( O
H7 O
) O
viruses O
leads O
to O
the O
generation O
of O
reassortant O
viruses O
bearing O
A O
( O
H9N2 O
) O
internal O
genes O
with O
markers O
of O
mammalian O
adaptation O
, O
warranting O
continued O
surveillance O
in O
both O
avian O
and O
human O
populations O
. O

While O
A O
( O
H9N2 O
) O
viruses O
from O
both O
poultry O
and O
humans O
exhibited O
features O
associated O
with O
mammalian O
adaptation O
, O
one O
human O
isolate O
from O
2018 O
, O
A O
/ O
Anhui O
- O
Lujiang O
/ O
39 O
/ O
2018 O
, O
exhibited O
increased O
capacity O
for O
replication O
and O
transmission O
, O
demonstrating O
the O
pandemic O
potential O
of O
A O
( O
H9N2 O
) O
viruses O
. O

IMPORTANCE O
A O
( O
H9N2 O
) O
influenza O
viruses O
are O
widespread O
in O
poultry O
in O
many O
parts O
of O
the O
world O
and O
for O
over O
20 O
years O
have O
sporadically O
jumped O
species O
barriers O
to O
cause O
human O
infection O
. O

As O
these O
viruses O
continue O
to O
diversify O
genetically O
and O
antigenically O
, O
it O
is O
critical O
to O
closely O
monitor O
viruses O
responsible O
for O
human O
infections O
, O
to O
ascertain O
if O
A O
( O
H9N2 O
) O
viruses O
are O
acquiring O
properties O
that O
make O
them O
better O
suited O
to O
infect O
and O
spread O
among O
humans O
. O

Assessment O
of O
a O
recent O
A O
( O
H9N2 O
) O
virus O
isolated O
from O
an O
individual O
in O
China O
in O
2018 O
is O
also O
reported O
, O
and O
it O
was O
found O
to O
exhibit O
properties O
of O
adaptation O
to O
humans O
and O
, O
importantly O
, O
it O
shows O
similarities O
to O
strains O
isolated O
from O
the O
live O
bird O
markets O
of O
Vietnam O
. O

Equine O
- O
origin O
H3N8 O
and O
avian O
- O
origin O
H3N2 O
canine B
influenza I
viruses I
( I
CIVs I
) I
prevalent O
in O
dogs O
are O
thought O
to O
pose O
a O
public O
health O
threat O
arising O
from O
intimate O
contact O
between O
dogs O
and O
humans O
. O

Influenza O
A O
virus O
PA O
- O
X O
is O
a O
fusion O
protein O
encoded O
in O
part O
by O
a O
+ O
1 O
frameshifted O
open B
reading I
frame I
( I
X I
- I
ORF I
) I
in O
segment O
3 O
. O

The O
X O
- O
ORF O
can O
be O
translated O
in O
full O
- O
length O
( O
61 O
- O
amino O
- O
acid O
) O
or O
truncated O
( O
41 O
- O
amino O
- O
acid O
) O
form O
. O

low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
are O
genetically O
highly O
variable O
and O
have O
diversified O
into O
multiple O
evolutionary O
lineages O
that O
are O
primarily O
associated O
with O
wild O
- O
bird O
reservoirs O
. O

We O
investigated O
the O
evolutionary O
history O
and O
intercontinental O
gene O
flow O
based O
on O
the O
Hemagglutinin B
( I
HA I
) I
gene O
and O
used O
representative O
viruses O
from O
genetically O
distinct O
lineages O
to O
determine O
their O
antigenic O
properties O
by O
hemagglutination O
inhibition O
assays O
. O

IMPORTANCE O
Wild O
birds O
play O
a O
major O
role O
in O
the O
epidemiology O
of O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
, O
which O
are O
occasionally O
transmitted O
- O
directly O
or O
indirectly O
- O
from O
them O
to O
other O
species O
, O
including O
domestic O
animals O
, O
wild O
mammals O
, O
and O
humans O
, O
where O
they O
can O
cause O
subclinical O
to O
fatal O
disease O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
are O
enzootic O
in O
wild O
birds O
and O
poultry O
and O
continue O
to O
cause O
human O
infections O
with O
high O
mortality O
. O

Upon O
rescue O
of O
21 O
mutant O
viruses O
, O
most O
substitutions O
in O
the O
Receptor B
binding I
site I
( I
RBS I
) I
resulted O
in O
viable O
virus O
, O
but O
virus O
replication O
, O
entry O
, O
and O
stability O
were O
often O
impeded O
. O

Avian O
influenza O
viruses O
need O
several O
adaptive O
mutations O
to O
bind O
to O
human O
- O
type O
receptors O
, O
increase O
Hemagglutinin B
( I
HA I
) I
stability O
, O
and O
replicate O
in O
human O
cells O
. O

The O
discovery O
in O
1976 O
of O
waterfowl O
as O
the O
primary O
reservoir O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
has O
since O
spurred O
decades O
of O
waterfowl O
surveillance O
efforts O
by O
researchers O
dedicated O
to O
understanding O
the O
ecology O
of O
IAV O
and O
its O
subsequent O
threat O
to O
human O
and O
animal O
health O
. O

A O
total O
of O
96 O
Hemagglutinin B
( I
HA I
) I
/ O
neuraminidase B
( I
NA I
) I
subtype O
combinations O
were O
isolated O
, O
which O
included O
most O
HA O
( O
H1 O
to O
H14 O
) O
and O
all O
9 O
NA O
subtypes O
. O

IMPORTANCE O
Wild O
aquatic O
birds O
are O
the O
primary O
natural O
reservoir O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
and O
are O
therefore O
responsible O
for O
the O
dispersal O
and O
maintenance O
of O
IAVs O
representing O
a O
broad O
range O
of O
antigenic O
and O
genetic O
diversity O
. O

We O
previously O
found O
that O
replacement O
of O
the O
human O
- O
origin O
PA O
gene O
segment O
in O
Avian B
influenza I
virus I
( I
AIV I
) I
could O
overcome O
barriers O
to O
cross O
- O
species O
transmission O
. O

IMPORTANCE O
Four O
influenza O
pandemics O
in O
humans O
( O
the O
Spanish O
flu O
of O
1918 O
[ O
H1N1 O
] O
, O
the O
Asian O
flu O
of O
1957 O
[ O
H2N2 O
] O
, O
the O
Hong O
Kong O
flu O
of O
1968 O
[ O
H3N2 O
] O
, O
and O
the O
swine O
origin O
flu O
of O
2009 O
[ O
H1N1 O
] O
) O
are O
all O
proposed O
to O
have O
been O
caused O
by O
avian O
or O
swine O
influenza O
viruses O
that O
acquired O
virulence O
factors O
through O
adaptive O
mutation O
or O
reassortment O
with O
circulating O
human O
viruses O
. O

Highly O
pathogenic O
avian O
influenza O
A O
( O
H5N8 O
) O
viruses O
first O
emerged O
in O
China O
in O
2010 O
and O
in O
2014 O
spread O
throughout O
Asia O
and O
to O
Europe O
and O
the O
United O
States O
via O
migrating O
birds O
. O

Influenza O
A O
( O
H5N8 O
) O
viruses O
were O
first O
detected O
in O
the O
Netherlands O
in O
2014 O
and O
caused O
five O
outbreaks O
in O
poultry O
farms O
but O
were O
infrequently O
detected O
in O
wild O
birds O
. O

In O
2016 O
, O
influenza O
A O
( O
H5N8 O
) O
viruses O
were O
reintroduced O
into O
the O
Netherlands O
, O
resulting O
in O
eight O
poultry O
farm O
outbreaks O
. O

Here O
, O
we O
investigated O
the O
differences O
in O
virulence O
between O
the O
2014 O
- O
15 O
and O
the O
2016 O
- O
17 O
outbreaks O
by O
characterizing O
the O
polymerase O
complex O
of O
influenza O
A O
( O
H5N8 O
) O
viruses O
from O
both O
outbreaks O
. O

Interestingly O
, O
the O
2014 O
- O
15 O
polymerase O
complexes O
induced O
significantly O
higher O
levels O
of O
interferon B
beta I
( I
IFN I
- I
beta I
) I
than O
the O
polymerase O
complexes O
of O
the O
2016 O
- O
17 O
outbreak O
viruses O
, O
mediated O
via O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
. O

Inoculation O
of O
primary O
duck O
cells O
with O
recombinant O
influenza O
A O
( O
H5N8 O
) O
viruses O
, O
including O
viruses O
with O
reassorted O
polymerase O
complexes O
, O
showed O
that O
the O
polymerase O
complexes O
from O
the O
2014 O
- O
15 O
outbreak O
induced O
higher O
levels O
of O
IFN O
- O
beta O
despite O
relatively O
minor O
differences O
in O
replication O
capacity O
. O

Together O
, O
these O
data O
suggest O
that O
despite O
the O
lower O
levels O
of O
polymerase O
activity O
, O
the O
higher O
2016 O
- O
17 O
influenza O
A O
( O
H5N8 O
) O
virus O
virulence O
may O
be O
attributed O
to O
the O
lower O
level O
of O
activation O
of O
the O
innate O
immune O
system O
. O

IMPORTANCE O
Compared O
to O
the O
2014 O
- O
15 O
outbreak O
, O
the O
2016 O
- O
17 O
outbreak O
of O
influenza O
A O
( O
H5N8 O
) O
viruses O
in O
the O
Netherlands O
and O
Europe O
was O
more O
virulent O
; O
the O
number O
of O
dead O
or O
diseased O
wild O
birds O
found O
and O
the O
severity O
of O
pathological O
changes O
were O
higher O
during O
the O
2016 O
- O
17 O
outbreak O
. O

The O
polymerase O
complex O
plays O
an O
important O
role O
in O
influenza O
virus O
virulence O
, O
and O
the O
gene O
segments O
of O
influenza O
A O
( O
H5N8 O
) O
viruses O
reassorted O
extensively O
between O
the O
outbreaks O
. O

These O
findings O
suggest O
that O
the O
higher O
virulence O
of O
influenza O
A O
( O
H5N8 O
) O
viruses O
from O
the O
2016 O
- O
17 O
outbreak O
may O
be O
related O
to O
the O
lower O
induction O
of O
IFN O
- O
beta O
. O

An O
attenuated O
interferon O
response O
could O
lead O
to O
increased O
dissemination O
, O
pathology O
, O
and O
mortality O
, O
as O
observed O
in O
( O
wild O
) O
birds O
infected O
during O
the O
2016 O
- O
2017 O
outbreak O
. O

Using O
recombinant O
H1N1 O
and O
H5N1 O
strains O
sharing O
6 O
internal O
genes O
, O
we O
demonstrate O
that O
H5N1 O
( O
2 O
: O
6 O
) O
infection O
in O
mice O
causes O
higher O
stimulation O
and O
increased O
migration O
of O
lung O
dendritic O
cells O
to O
the O
draining O
lymph O
nodes O
, O
resulting O
in O
greater O
numbers O
of O
virus O
- O
specific O
T O
cells O
in O
the O
lungs O
. O

Despite O
robust O
T O
cell O
responses O
in O
the O
lungs O
, O
H5N1 O
( O
2 O
: O
6 O
) O
- O
infected O
mice O
showed O
inefficient O
and O
delayed O
viral O
clearance O
compared O
with O
H1N1 O
- O
infected O
mice O
. O

In O
addition O
, O
we O
observed O
higher O
levels O
of O
inhibitory O
signals O
, O
including O
increased O
PD O
- O
1 O
and O
interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
expression O
by O
cytotoxic O
T O
cells O
in O
H5N1 O
( O
2 O
: O
6 O
) O
- O
infected O
mice O
, O
suggesting O
that O
delayed O
viral O
clearance O
of O
H5N1 O
( O
2 O
: O
6 O
) O
was O
due O
to O
the O
suppression O
of O
T O
cell O
functions O
in O
vivo O
. O

Importantly O
, O
H5N1 O
( O
2 O
: O
6 O
) O
- O
infected O
mice O
displayed O
decreased O
numbers O
of O
tissue O
- O
resident O
memory O
T O
cells O
compared O
with O
H1N1 O
- O
infected O
mice O
; O
however O
, O
despite O
the O
decreased O
number O
of O
tissue O
- O
resident O
memory O
T O
cells O
, O
H5N1 O
( O
2 O
: O
6 O
) O
was O
protected O
against O
a O
heterologous O
challenge O
from O
H3N2 O
virus O
( O
X31 O
) O
. O

low B
- I
pathogenicity I
avian I
influenza I
( I
LPAI I
) I
viruses O
of O
subtypes O
H5 O
and O
H7 O
have O
the O
ability O
to O
spontaneously O
mutate O
to O
highly B
pathogenic I
( I
HPAI I
) I
virus O
variants O
, O
causing O
high O
mortality O
in O
poultry O
. O

The O
highly O
pathogenic O
phenotype O
is O
caused O
by O
mutation O
of O
the O
Hemagglutinin B
( I
HA I
) I
cleavage O
site O
, O
but O
additional O
mutations O
may O
play O
a O
role O
. O

We O
identified O
additional O
mutations O
in O
HA O
and O
polymerase B
basic I
protein I
1 I
( I
PB1 I
) I
in O
the O
HPAI O
virus O
, O
which O
were O
already O
present O
as O
minority O
variants O
in O
the O
LPAI O
virus O
population O
. O

IMPORTANCE O
low B
- I
pathogenicity I
avian I
influenza I
( I
LPAI I
) I
viruses O
circulate O
in O
wild O
birds O
and O
can O
be O
transmitted O
to O
poultry O
. O

LPAI O
viruses O
can O
mutate O
to O
become O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
causing O
severe O
disease O
and O
death O
in O
poultry O
. O

Of O
note O
, O
some O
reassortant O
viruses O
bearing O
the O
internal O
genes O
of O
the O
2009 O
pandemic O
H1N1 O
( O
2009 O
/ O
H1N1 O
) O
virus O
sporadically O
caused O
human O
infection O
, O
which O
highlights O
their O
potential O
threats O
to O
human O
public O
health O
. O

In O
this O
study O
, O
we O
performed O
phylogenetic O
analysis O
on O
swine B
influenza I
viruses I
( I
SIVs I
) I
circulating O
in O
Liaoning O
Province O
, O
China O
. O

H1N1 O
viruses O
formed O
four O
genotypes O
, O
which O
included O
Eurasian O
avian O
- O
like O
H1N1 O
( O
EA O
H1N1 O
) O
and O
double O
/ O
triple O
reassortant O
H1N1 O
derived O
from O
EA O
H1N1 O
, O
2009 O
/ O
H1N1 O
, O
and O
triple O
reassortant O
H1N2 O
( O
TR O
H1N2 O
) O
viruses O
. O

We O
further O
characterized O
two O
naturally O
isolated O
H1N1 O
SIVs O
that O
had O
similar O
viral O
genomes O
but O
differed O
substantially O
in O
their O
virulence O
in O
mice O
and O
found O
that O
a O
single O
amino O
acid O
at O
position O
431 O
in O
the O
basic B
polymerase I
2 I
( I
PB2 I
) I
protein O
significantly O
affected O
the O
viral O
replication O
capacity O
and O
virulence O
of O
these O
two O
viruses O
. O

Seasonal O
influenza O
carrying O
key O
Hemagglutinin B
( I
HA I
) I
head O
region O
glycosylation O
sites O
can O
be O
removed O
from O
the O
lung O
by O
pulmonary O
surfactant B
protein I
D I
( I
SP I
- I
D I
) I
. O

Little O
is O
known O
about O
HA O
head O
glycosylation O
of O
low B
- I
pathogenicity I
avian I
influenza I
virus I
( I
LPAIV I
) I
subtypes O
. O

We O
found O
that O
glycosite O
N165 O
( O
H3 O
numbering O
) O
is O
occupied O
by O
high O
- O
mannose O
glycans O
in O
H3 O
HA O
but O
by O
complex O
glycans O
in O
all O
LPAIV O
HAs O
. O

IMPORTANCE O
low B
- I
pathogenicity I
avian I
influenza I
virus I
( I
LPAIV I
) I
subtypes O
can O
reassort O
with O
circulating O
human O
strains O
and O
pandemic O
viruses O
can O
emerge O
in O
human O
populations O
, O
as O
was O
seen O
in O
the O
1957 O
pandemic O
, O
in O
which O
an O
H2 O
virus O
reassorted O
with O
the O
circulating O
H1N1 O
to O
create O
a O
novel O
H2N2 O
genotype O
. O

Lung O
surfactant B
protein I
D I
( I
SP I
- I
D I
) I
, O
a O
key O
factor O
in O
first O
- O
line O
innate O
immunity O
defense O
, O
removes O
influenza O
type O
A O
virus O
( O
IAV O
) O
through O
interaction O
with O
Hemagglutinin B
( I
HA I
) I
head O
region O
high O
- O
mannose O
glycan O
( O
s O
) O
. O

The O
majority O
of O
antibodies O
induced O
by O
influenza O
neuraminidase B
( I
NA I
) I
, O
like O
those O
against O
Hemagglutinin B
( I
HA I
) I
, O
are O
relatively O
specific O
to O
viruses O
isolated O
within O
a O
limited O
time O
window O
, O
as O
seen O
in O
serological O
studies O
and O
the O
analysis O
of O
many O
murine B
monoclonal I
antibodies I
( I
MAbs I
) I
. O

Two O
were O
isolated O
from O
a O
young O
adult O
vaccinated O
with O
trivalent B
influenza I
vaccine I
( I
TIV I
) I
, O
which O
inhibited O
N1 O
NA O
from O
viruses O
isolated O
from O
humans O
over O
a O
period O
of O
a O
hundred O
years O
. O

influenza B
A I
virus I
( I
IAV I
) I
is O
a O
human O
respiratory O
pathogen O
that O
causes O
yearly O
global O
epidemics O
, O
as O
well O
as O
sporadic O
pandemics O
due O
to O
human O
adaptation O
of O
pathogenic O
strains O
. O

HeLa O
cells O
were O
refractory O
to O
the O
growth O
of O
human O
H1N1 O
and O
H3N2 O
viruses O
and O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
viruses O
. O

Interestingly O
, O
a O
human O
isolate O
of O
the O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
successfully O
propagated O
in O
HeLa O
cells O
to O
levels O
comparable O
to O
those O
in O
a O
human O
lung O
cell O
line O
. O

Heterokaryon O
cells O
generated O
by O
fusion O
of O
HeLa O
and O
permissive O
cells O
supported O
H1N1 O
virus O
growth O
, O
suggesting O
the O
absence O
of O
a O
host O
factor O
( O
s O
) O
required O
for O
the O
replication O
of O
H1N1 O
, O
but O
not O
H5N1 O
, O
viruses O
in O
HeLa O
cells O
. O

The O
absence O
of O
this O
factor O
( O
s O
) O
was O
mapped O
to O
reduced O
nuclear O
import O
, O
replication O
, O
and O
translation O
, O
as O
well O
as O
deficient O
viral O
budding O
. O

Using O
reassortant O
H1N1 O
: O
H5N1 O
viruses O
, O
we O
found O
that O
the O
combined O
introduction O
of O
nucleoprotein B
( I
NP I
) I
and O
Hemagglutinin B
( I
HA I
) I
from O
an O
H5N1 O
virus O
was O
necessary O
and O
sufficient O
to O
enable O
H1N1 O
virus O
growth O
. O

A O
/ O
chicken O
/ O
Guangdong O
/ O
SD098 O
/ O
2017 O
( O
CK O
/ O
SD098 O
) O
is O
avirulent O
, O
with O
a O
50 B
% I
mouse I
lethal I
dose I
( I
MLD50 I
) I
of O
> O
7 O
. O

5 O
log O
( O
10 O
) O
50 B
% I
egg I
infectious I
dose I
( I
EID50 I
) I
, O
whereas O
A O
/ O
chicken O
/ O
Hunan O
/ O
S1220 O
/ O
2017 O
( O
CK O
/ O
S1220 O
) O
is O
virulent O
in O
mice O
, O
with O
an O
MLD50 O
of O
3 O
. O

2 O
log O
( O
10 O
) O
EID50 O
. O

We O
found O
that O
the O
reassortant O
CK O
/ O
1220 O
- O
SD098 O
- O
NP O
, O
carrying O
the O
nucleoprotein B
( I
NP I
) I
of O
CK O
/ O
SD098 O
, O
was O
avirulent O
in O
mice O
, O
with O
an O
MLD50 O
of O
> O
10 O
( O
7 O
. O

Previous O
studies O
revealed O
that O
certain O
avian O
influenza B
A I
viruses I
( I
IAVs I
) I
, O
including O
zoonotic O
H5N1 O
and O
H7N9 O
IAVs O
, O
infect O
cultured O
human B
lung I
microvascular I
endothelial I
cells I
( I
HULEC I
) I
more O
efficiently O
than O
other O
IAVs O
and O
that O
tropism O
to O
HULEC O
is O
determined O
by O
viral O
Hemagglutinin B
( I
HA I
) I
. O

We O
next O
studied O
effects O
on O
viral O
infectivity O
of O
single O
- O
point O
amino O
acid O
substitutions O
in O
the O
HA O
of O
2 O
: O
6 O
recombinant O
virus O
ANietnam O
/ O
1203 O
/ O
2004 O
- O
PR8 O
( O
H5N1 O
) O
. O

Substitutions O
H8Q O
, O
H103Y O
, O
T315I O
, O
and O
K58 O
( O
2 O
) O
I O
( O
K58I O
in O
the O
HA2 O
subunit O
) O
, O
which O
increased O
stability O
of O
the O
HA O
, O
markedly O
reduced O
viral O
infectivity O
for O
HULEC O
, O
whereas O
substitutions O
K189N O
and O
K218Q O
, O
which O
altered O
typical O
H5N1 O
virus O
- O
like O
receptor O
specificity O
and O
reduced O
binding O
avidity O
of O
the O
HA O
, O
led O
to O
only O
marginal O
reduction O
of O
infectivity O
. O

The O
influenza B
A I
virus I
( I
IAV I
) I
nonstructural I
protein I
1 I
( I
NS1 I
) I
contributes O
to O
disease O
pathogenesis O
through O
the O
inhibition O
of O
host O
innate O
immune O
responses O
. O

dendritic B
cells I
( I
DCs I
) I
release O
Interferons B
( I
IFNs I
) I
and O
proinflammatory O
cytokines O
and O
promote O
adaptive O
immunity O
upon O
viral O
infection O
. O

In O
order O
to O
characterize O
the O
strainspecific O
effects O
of O
IAV O
NS1 O
on O
human O
DC O
activation O
, O
we O
infected O
human O
DCs O
with O
a O
panel O
of O
recombinant O
viruses O
with O
the O
same O
backbone O
( O
A O
/ O
Puerto O
Rico O
/ O
08 O
/ O
1934 O
) O
expressing O
different O
NS1 O
proteins O
from O
human O
and O
avian O
origin O
. O

Specifically O
, O
viruses O
expressing O
NS1 O
from O
human O
IAV O
( O
either O
H1N1 O
or O
H3N2 O
) O
induced O
higher O
levels O
of O
expression O
of O
type O
I O
( O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
) O
and O
type O
III O
( O
IFN O
- O
lambda O
1 O
to O
IFN O
lambda O
3 O
) O
IFNs O
than O
viruses O
expressing O
avian O
IAV O
NS1 O
proteins O
( O
H5N1 O
, O
H7N9 O
, O
and O
H7N2 O
) O
, O
but O
the O
differences O
observed O
in O
the O
expression O
levels O
of O
proinflammatory O
cytokines O
like O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
or O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
were O
not O
significant O
. O

IMPORTANCE O
influenza B
A I
viruses I
( I
IAVs I
) I
cause O
seasonal O
epidemics O
which O
result O
in O
an O
important O
health O
and O
economic O
burden O
. O

The O
nonstructural B
1 I
( I
NS1 I
) I
protein O
of O
IAV O
is O
an O
important O
antagonist O
of O
the O
innate O
immune O
response O
. O

Previously O
, O
we O
identified O
a O
set O
of O
long O
noncoding O
RNAs O
( O
lncRNAs O
) O
that O
were O
differentially O
expressed O
in O
influenza B
A I
virus I
( I
IAV I
) I
- O
infected O
cells O
. O

However O
, O
lnc O
- O
MxA O
inhibits O
the O
Sendai B
virus I
( I
SeV I
) I
- O
and O
IAV O
- O
induced O
activation O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
. O

A O
luciferase O
assay O
indicated O
that O
lnc O
- O
MxA O
inhibits O
the O
activation O
of O
the O
IFN O
- O
beta O
reporter O
upon O
stimulation O
with O
RIG O
- O
I O
, O
MAVS O
, O
TBK1 O
, O
or O
active O
IRF3 O
( O
IRF3 O
- O
5D O
) O
. O

A O
chromatin B
immunoprecipitation I
( I
ChIP I
) I
assay O
showed O
that O
the O
enrichment O
of O
IRF3 O
and O
p65 O
at O
the O
IFN O
- O
beta O
promoter O
in O
lnc O
- O
MxA O
- O
overexpressing O
cells O
was O
significantly O
lower O
than O
that O
in O
control O
cells O
, O
indicating O
that O
lnc O
- O
MxA O
interfered O
with O
the O
binding O
of O
IRF3 O
and O
p65 O
to O
the O
IFN O
- O
beta O
promoter O
. O

Chromatin O
isolation O
by O
RNA O
purification O
( O
ChIRP O
) O
, O
triplex O
pulldown O
, O
and O
biolayer O
interferometry O
assays O
indicated O
that O
lnc O
- O
MxA O
can O
bind O
to O
the O
IFN O
- O
beta O
promoter O
. O

Furthermore O
, O
an O
electrophoretic B
mobility I
shift I
assay I
( I
EMSA I
) I
showed O
that O
lnc O
- O
MxA O
can O
form O
complexes O
with O
the O
IFN O
- O
g O
promoter O
fragment O
. O

Using O
a O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
infection O
assay O
, O
we O
confirmed O
that O
lnc O
- O
MxA O
can O
repress O
the O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
- O
mediated O
antiviral O
immune O
response O
and O
influence O
the O
antiviral O
status O
of O
cells O
. O

In O
conclusion O
, O
we O
revealed O
that O
lnc O
- O
MxA O
is O
an O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
that O
negatively O
regulates O
the O
transcription O
of O
IFN O
- O
beta O
by O
forming O
an O
RNA O
- O
DNA O
triplex O
. O

The O
potential O
avian O
influenza O
pandemic O
remains O
a O
threat O
to O
public O
health O
, O
as O
the O
avian B
- I
origin I
influenza I
A I
( I
H7N9 I
) I
virus O
has O
caused O
more O
than O
1 O
, O
560 O
laboratory O
- O
confirmed O
human O
infections O
since O
2013 O
, O
with O
nearly O
40 O
% O
mortality O
. O

Development O
of O
low O
- O
pathogenic O
candidate O
vaccine O
viruses O
( O
CWs O
) O
for O
vaccine O
production O
is O
essential O
for O
pandemic O
preparedness O
. O

By O
introducing O
a O
single O
adaptive O
substitution O
, O
G218E O
, O
into O
the O
Hemagglutinin B
( I
HA I
) I
, O
we O
generated O
reassortant O
A O
( O
H7N9 O
) O
- O
G218E O
CVVs O
that O
were O
characterized O
by O
significantly O
enhanced O
growth O
in O
both O
cells O
and O
eggs O
. O

We O
found O
that O
the O
suboptimal O
replication O
of O
the O
parental O
H7 O
CWs O
was O
associated O
with O
impeded O
progeny O
virus O
release O
as O
a O
result O
of O
strong O
HA O
receptor O
binding O
relative O
to O
weak O
neuraminidase B
( I
NA I
) I
cleavage O
of O
receptors O
. O

Our O
findings O
revealed O
that O
a O
single O
amino O
acid O
mutation O
at O
residue O
218 O
of O
the O
HA O
improved O
the O
growth O
of O
A O
( O
H7N9 O
) O
influenza O
virus O
by O
balancing O
HA O
and O
NA O
functions O
, O
shedding O
light O
on O
an O
alternative O
approach O
for O
optimizing O
certain O
influenza O
CWs O
. O

IMPORTANCE O
The O
circulating O
avian O
influenza O
A O
( O
H7N9 O
) O
has O
caused O
recurrent O
epidemic O
waves O
with O
high O
mortality O
in O
China O
since O
2013 O
, O
in O
which O
the O
alarming O
fifth O
wave O
crossing O
2016 O
and O
2017 O
was O
highlighted O
by O
a O
large O
number O
of O
human O
infections O
and O
the O
emergence O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
( O
H7N9 O
) O
strains O
in O
human O
cases O
. O

We O
generated O
low O
- O
pathogenic O
reassortant O
CVVs O
derived O
from O
the O
emerging O
A O
( O
H7N9 O
) O
with O
improved O
virus O
replication O
and O
protein O
yield O
in O
both O
MDCK O
cells O
and O
eggs O
by O
introducing O
a O
single O
substitution O
, O
G218E O
, O
into O
HA O
, O
which O
was O
associated O
with O
reducing O
HA O
receptor O
binding O
and O
subsequently O
balancing O
HA O
- O
NA O
functions O
. O

The O
in O
vitro O
and O
in O
vivo O
experiments O
demonstrated O
comparable O
antigenicity O
of O
the O
G218E O
CVVs O
with O
that O
of O
their O
wild B
- I
type I
( I
WT I
) I
counterparts O
, O
and O
both O
the O
WT O
and O
the O
G218E O
CVVs O
fully O
protected O
ferrets O
from O
parental O
HPAI O
virus O
challenge O
. O

With O
high O
yield O
traits O
and O
the O
anticipated O
antigenicity O
, O
the O
G218E O
CVVs O
should O
benefit O
preparedness O
against O
the O
threat O
of O
an O
A O
( O
H7N9 O
) O
influenza O
pandemic O
. O

Using O
a O
CRISPR O
approach O
, O
we O
show O
that O
the O
human B
acidic I
nuclear I
phosphoproteins I
( I
ANPs I
) I
ANP32A O
and O
ANP32B O
are O
functionally O
redundant O
but O
essential O
host O
factors O
for O
mammalian O
- O
adapted O
influenza B
A I
virus I
( I
IAV I
) I
and O
influenza B
B I
virus I
( I
IBV I
) I
replication O
in O
human O
cells O
. O

We O
show O
, O
using O
a O
domain O
swap O
and O
point O
mutations O
, O
that O
the O
leucine B
- I
rich I
repeat I
( I
LRR I
) I
5 O
region O
comprises O
an O
important O
functional O
domain O
for O
mammalian O
ANP32 O
proteins O
. O

Outbreaks O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
subtype O
H7N3 O
have O
been O
occurring O
in O
commercial O
chickens O
in O
Mexico O
since O
its O
first O
introduction O
in O
2012 O
. O

Full O
- O
genome O
sequencing O
showed O
115 O
amino O
acid O
differences O
between O
the O
2012 O
and O
the O
2016 O
viruses O
, O
with O
some O
of O
these O
changes O
previously O
associated O
with O
changes O
in O
replication O
in O
avian O
species O
, O
including O
Hemagglutinin B
( I
HA I
) I
A125T O
, O
nucleoprotein B
( I
NP I
) I
M105V O
, O
and O
NP O
S377N O
. O

IMPORTANCE O
Not O
much O
is O
known O
about O
changes O
in O
host O
adaptation O
of O
avian B
influenza I
( I
AI I
) I
viruses O
in O
birds O
after O
long O
- O
term O
circulation O
in O
chickens O
or O
other O
terrestrial O
poultry O
. O

Subtype O
H10 O
influenza B
A I
viruses I
( I
IAVs I
) I
have O
been O
recovered O
from O
domestic O
poultry O
and O
various O
aquatic O
bird O
species O
, O
and O
sporadic O
transmission O
of O
these O
IAVs O
from O
avian O
species O
to O
mammals O
( O
i O
. O

IMPORTANCE O
Subtype O
H10 O
avian O
influenza B
A I
viruses I
( I
IAVs I
) I
have O
caused O
sporadic O
human O
infections O
and O
enzootic O
outbreaks O
among O
seals O
. O

Coronaviruses B
( I
CoVs I
) I
assemble O
by O
budding O
into O
the O
lumen O
of O
the O
early O
Golgi O
complex O
prior O
to O
exocytosis O
. O

The O
small O
CoV O
envelope B
( I
E I
) I
protein O
plays O
roles O
in O
assembly O
, O
virion O
release O
, O
and O
pathogenesis O
. O

CoV O
E O
has O
a O
single O
hydrophobic B
domain I
( I
HD I
) I
, O
is O
targeted O
to O
Golgi O
membranes O
, O
and O
has O
cation O
channel O
activity O
in O
vitro O
. O

The O
E O
protein O
from O
avian B
infectious I
bronchitis I
virus I
( I
IBV I
) I
has O
dramatic O
effects O
on O
the O
secretory O
system O
, O
which O
require O
residues O
in O
the O
HD O
. O

Mutation O
of O
the O
HD O
of O
IBV O
E O
in O
a O
recombinant O
virus O
background O
results O
in O
impaired O
growth O
kinetics O
, O
impaired O
release O
of O
infectious O
virions O
, O
accumulation O
of O
IBV B
spike I
( I
S I
) I
protein O
on O
the O
plasma O
membrane O
compared O
to O
wild B
- I
type I
( I
WT I
) I
IBV O
- O
infected O
cells O
, O
and O
aberrant O
cleavage O
of O
IBV O
S O
on O
virions O
. O

Wild O
birds O
harbor O
a O
huge O
diversity O
of O
avian O
avulaviruses O
( O
formerly O
avian O
paramyxoviruses O
) O
. O

We O
show O
that O
Adelie O
penguins O
( O
Pygoscelis O
adeliae O
) O
are O
hosts O
for O
four O
different O
avian O
avulavirus O
species O
, O
the O
recently O
described O
avian O
avulaviruses O
17 O
to O
19 O
and O
avian O
avulavirus O
10 O
- O
like O
, O
never O
before O
isolated O
in O
Antarctica O
. O

Following O
infection O
in O
specific B
- I
pathogen I
- I
free I
( I
SPF I
) I
chickens O
, O
all O
four O
avian O
avulavirus O
species O
were O
shed O
from O
the O
oral O
cavity O
for O
up O
to O
7 O
days O
postinfection O
. O

Through O
the O
detection O
of O
avian O
avulaviruses O
in O
penguins O
from O
Antarctica O
, O
we O
have O
been O
able O
to O
expand O
upon O
our O
understanding O
of O
three O
avian O
avulavirus O
species O
( O
avian O
avulaviruses O
17 O
to O
19 O
) O
and O
report O
a O
potentially O
novel O
avulavirus O
species O
. O

To O
further O
characterize O
this O
model O
, O
we O
developed O
a O
differentiated O
primary O
ferret B
nasal I
epithelial I
cell I
( I
FNEC I
) I
culture O
model O
for O
investigation O
of O
influenza O
A O
virus O
infection O
and O
virus O
- O
host O
interactions O
. O

Both O
alpha O
2 O
, O
6 O
- O
linked O
and O
alpha O
2 O
, O
3 O
- O
linked O
sialic B
acid I
( I
SA I
) I
receptors O
, O
which O
preferentially O
bind O
the O
Hemagglutinin B
( I
HA I
) I
of O
human O
and O
avian O
influenza O
viruses O
, O
respectively O
, O
were O
detected O
on O
the O
apical O
surface O
of O
the O
culture O
with O
different O
cellular O
tropisms O
. O

In O
accordance O
with O
the O
distribution O
of O
SA O
receptors O
, O
we O
observed O
that O
a O
pre O
- O
2009 O
seasonal O
A O
( O
H1N1 O
) O
virus O
infected O
both O
ciliated O
and O
nonciliated O
cells O
, O
whereas O
a O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
( O
H5N1 O
) O
virus O
primarily O
infected O
nonciliated O
cells O
. O

Upon O
infection O
, O
the O
HPAI O
A O
( O
H5N1 O
) O
virus O
replicated O
to O
titers O
higher O
than O
those O
of O
the O
human O
A O
( O
H1N1 O
) O
virus O
at O
37 O
degrees O
C O
; O
however O
, O
replication O
of O
the O
A O
( O
H5N1 O
) O
virus O
was O
significantly O
attenuated O
at O
33 O
degrees O
C O
. O

Furthermore O
, O
we O
found O
that O
infection O
with O
the O
A O
( O
H5N1 O
) O
virus O
induced O
higher O
expression O
levels O
of O
immune O
mediator O
genes O
and O
resulted O
in O
more O
cell O
damage O
/ O
loss O
than O
with O
the O
human O
A O
( O
H1N1 O
) O
virus O
. O

Memory B
B I
cells I
( I
MBCs I
) I
are O
key O
determinants O
of O
the O
B O
cell O
response O
to O
influenza O
virus O
infection O
and O
vaccination O
, O
but O
the O
effect O
of O
different O
forms O
of O
influenza O
antigen O
exposure O
on O
MBC O
populations O
has O
received O
little O
attention O
. O

IMPORTANCE O
Rapid O
and O
vigorous O
virus O
- O
specific O
antibody O
responses O
to O
influenza O
virus O
infection O
and O
vaccination O
result O
from O
activation O
of O
preexisting O
virus O
- O
specific O
Memory B
B I
cells I
( I
MBCs I
) I
. O

influenza B
A I
viruses I
( I
IAVs I
) I
remain O
a O
significant O
public O
health O
threat O
, O
causing O
more O
than O
300 O
, O
000 O
hospitalizations O
in O
the O
United O
States O
during O
the O
2015 O
- O
2016 O
season O
alone O
. O

Notably O
, O
recent O
H9N2 O
viruses O
have O
acquired O
molecular O
markers O
that O
allow O
for O
a O
transition O
from O
avian O
- O
like O
to O
human O
- O
like O
terminal O
sialic B
acid I
( I
SA I
) I
receptor O
recognition O
via O
a O
single O
amino O
acid O
change O
at O
position O
226 O
( O
H3 O
numbering O
) O
, O
from O
glutamine O
( O
Q226 O
) O
to O
leucine O
( O
L226 O
) O
, O
within O
the O
hemagglutinin B
( I
HA I
) I
receptor I
- I
binding I
site I
( I
RBS I
) I
. O

IMPORTANCE O
A O
single O
amino O
acid O
change O
at O
position O
226 O
in O
the O
Hemagglutinin B
( I
HA I
) I
from O
Glutamine B
( I
Q I
) I
to O
leucine B
( I
L I
) I
has O
been O
shown O
to O
play O
a O
key O
role O
in O
receptor O
specificity O
switching O
in O
various O
influenza O
virus O
HA O
subtypes O
, O
including O
H9 O
. O

IMPORTANCE O
Close O
interaction O
between O
avian B
influenza I
( I
AI I
) I
viruses O
and O
humans O
in O
Egypt O
appears O
to O
have O
resulted O
in O
many O
of O
the O
worldwide O
cases O
of O
human O
infections O
by O
both O
H5N1 O
and O
H9N2 O
AI O
viruses O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
are O
viral O
pathogens O
that O
cause O
epidemics O
and O
occasional O
pandemics O
of O
significant O
mortality O
. O

Here O
, O
we O
used O
enzymatically O
produced O
IAV O
- O
specific O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
molecules O
and O
Giardia O
intestinalis O
Dicer O
for O
the O
generation O
of O
a O
swarm O
of O
small B
interfering I
RNA I
( I
siRNA I
) I
molecules O
. O

In O
mammalian O
cells O
, O
the O
produced O
25 O
- O
to O
27 O
- O
nucleotide O
- O
long O
siRNA O
molecules O
are O
processed O
by O
endogenous O
Dicer O
into O
21 O
- O
nucleotide O
siRNAs O
and O
are O
thus O
designated O
Dicer B
- I
substrate I
siRNAs I
( I
DsiRNAs I
) I
. O

We O
demonstrated O
here O
that O
a O
swarm O
of O
small B
interfering I
RNA I
( I
siRNA I
) I
molecules O
, O
including O
more O
than O
100 O
different O
antiviral O
RNA O
molecules O
targeting O
the O
most O
conserved O
regions O
of O
the O
influenza O
A O
virus O
genome O
, O
could O
efficiently O
inhibit O
the O
replication O
of O
all O
tested O
avian O
and O
seasonal O
influenza O
A O
variants O
in O
human O
primary O
monocyte O
- O
derived O
macrophages O
and O
dendritic O
cells O
. O

The O
analysis O
showed O
that O
the O
emergent O
immune O
escape O
viruses O
contained O
mutations O
A125T O
, O
A151T O
, O
and O
L217Q O
in O
the O
Hemagglutinin B
( I
HA I
) I
glycoprotein O
as O
early O
as O
passage O
5 O
and O
that O
these O
mutations O
persisted O
until O
passage O
10 O
. O

The O
results O
revealed O
that O
a O
single O
mutation O
, O
L217Q O
, O
in O
the O
HA O
of O
H7N9 O
virus O
led O
to O
23 O
- O
and O
8 O
- O
fold O
reductions O
in O
hemagglutination B
inhibition I
( I
HI I
) I
titer O
with O
ferret O
and O
chicken O
antisera O
, O
respectively O
. O

Mutations O
to O
the O
virus O
Hemagglutinin B
( I
HA I
) I
glycoprotein O
can O
modulate O
virus O
antigenicity O
and O
facilitate O
virus O
escape O
from O
natural O
or O
vaccine O
- O
induced O
immunity O
. O

To O
achieve O
this O
, O
we O
propagated O
low O
- O
pathogenicity O
H7N9 O
virus O
in O
the O
presence O
of O
polyclonal O
antiserum O
derived O
from O
ferrets O
infected O
with O
the O
same O
strain O
of O
virus O
( O
homologous O
antiserum O
) O
. O

The O
HA O
gene O
sequences O
of O
viruses O
recovered O
after O
the O
fifth O
passage O
showed O
that O
the O
viruses O
readily O
acquired O
mutations O
at O
three O
different O
amino O
acid O
positions O
( O
A125T O
, O
A151T O
, O
and O
L217Q O
) O
. O

To O
cross O
the O
human O
species O
barrier O
, O
influenza B
A I
viruses I
( I
IAV I
) I
of O
avian O
origin O
have O
to O
overcome O
the O
interferon O
- O
induced O
host O
restriction O
factor O
MxA O
by O
acquiring O
distinct O
mutations O
in O
their O
nucleoprotein B
( I
NP I
) I
. O

We O
found O
that O
the O
NP O
of O
the O
influenza O
virus O
isolate O
A O
/ O
Swine O
/ O
Belzig O
/ O
2 O
/ O
2001 O
( O
Belzig O
- O
NP O
) O
exhibits O
increased O
MxA O
escape O
, O
similar O
in O
extent O
to O
that O
with O
human O
IAV O
NPs O
. O

We O
found O
that O
PA O
- O
X O
protein O
from O
the O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
strain O
had O
significantly O
lower O
repressive O
activity O
against O
cellular O
gene O
expression O
than O
PA O
- O
X O
proteins O
from O
the O
avian O
strains O
A O
/ O
turkey O
/ O
England O
/ O
50 O
- O
92 O
/ O
91 O
( O
H5N1 O
) O
( O
T O
/ O
E O
) O
and O
A O
/ O
chicken O
/ O
Rostock O
/ O
34 O
( O
H7N1 O
) O
. O

Loss O
of O
normal O
PA O
- O
X O
expression O
, O
either O
by O
mutation O
of O
the O
frameshift O
site O
or O
by O
truncating O
the O
X O
open B
reading I
frame I
( I
ORF I
) I
, O
had O
little O
effect O
on O
the O
infectious O
virus O
titer O
of O
PR8 O
or O
PR8 O
7 O
: O
1 O
reassortants O
with O
T O
/ O
E O
segment O
3 O
grown O
in O
embryonated O
hens O
' O
eggs O
. O

Purified O
PA O
- O
X O
mutant O
virus O
particles O
displayed O
an O
increased O
ratio O
of O
Hemagglutinin B
( I
HA I
) I
to O
nucleoprotein B
( I
NP I
) I
and O
M1 O
compared O
to O
values O
for O
their O
wild B
- I
type I
( I
WT I
) I
counterparts O
, O
suggesting O
altered O
virion O
composition O
. O

When O
the O
PA O
- O
X O
gene O
was O
mutated O
in O
the O
background O
of O
poorly O
growing O
PR8 O
6 O
: O
2 O
vaccine O
reassortant O
analogues O
containing O
the O
HA O
and O
neuraminidase B
( I
NA I
) I
segments O
from O
H1N1 O
2009 O
pandemic O
viruses O
or O
from O
an O
avian O
H7N3 O
strain O
, O
HA O
yield O
increased O
up O
to O
2 O
- O
fold O
. O

The O
fifth O
wave O
of O
the O
H7N9 O
influenza O
epidemic O
in O
China O
was O
distinguished O
by O
a O
sudden O
increase O
in O
human O
infections O
, O
an O
extended O
geographic O
distribution O
, O
and O
the O
emergence O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
. O

Here O
, O
several O
human O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
and O
HPAI O
H7N9 O
virus O
isolates O
from O
the O
fifth O
epidemic O
wave O
were O
assessed O
for O
their O
pathogenicity O
and O
transmissibility O
in O
mammalian O
models O
, O
as O
well O
as O
their O
ability O
to O
replicate O
in O
human O
airway O
epithelial O
cells O
. O

The O
H1N1 O
influenza O
virus O
responsible O
for O
the O
most O
recent O
pandemic O
in O
2009 O
( O
H1N1pdm O
) O
has O
spread O
to O
swine O
populations O
worldwide O
while O
it O
replaced O
the O
previous O
seasonal O
H1N1 O
virus O
in O
humans O
. O

From O
these O
isolates O
, O
17 O
whole O
- O
genome O
sequences O
were O
obtained O
, O
as O
were O
6 O
additional O
Hemagglutinin B
( I
HA I
) I
/ O
neuraminidase B
( I
NA I
) I
sequences O
, O
in O
order O
to O
perform O
spatial O
and O
temporal O
analyses O
of O
genetic O
diversity O
and O
to O
compare O
evolutionary O
patterns O
of O
H1N1pdm O
in O
pigs O
to O
patterns O
for O
human O
strains O
. O

IMPORTANCE O
Pigs O
are O
a O
mixing O
vessel O
for O
influenza B
A I
viruses I
( I
IAVs I
) I
because O
of O
their O
ability O
to O
be O
infected O
by O
avian O
and O
human O
IAVs O
and O
their O
propensity O
to O
facilitate O
viral O
genomic O
reassortment O
events O
. O

Live B
attenuated I
influenza I
virus I
vaccines I
( I
LAIVs I
) I
may O
provide O
superior O
responses O
compared O
to O
inactivated O
vaccines O
because O
the O
former O
can O
better O
elicit O
a O
combination O
of O
humoral O
and O
cellular O
responses O
by O
mimicking O
a O
natural O
infection O
. O

Unfortunately O
, O
during O
the O
2013 O
- O
2014 O
, O
2014 O
- O
2015 O
, O
and O
2015 O
- O
2016 O
seasons O
, O
concerns O
emerged O
about O
the O
effectiveness O
of O
the O
only O
LAIV O
approved O
in O
the O
United O
States O
that O
prevented O
the O
Advisory B
Committee I
on I
Immunization I
Practices I
( I
ACIP I
) I
from O
recommending O
its O
use O
. O

The O
resulting O
attenuated B
( I
att I
) I
influenza O
A O
and O
B O
viruses O
were O
safe O
, O
immunogenic O
, O
and O
protective O
against O
lethal O
influenza O
virus O
challenge O
in O
a O
variety O
of O
animal O
models O
. O

In O
this O
report O
, O
we O
provide O
evidence O
of O
the O
potential O
use O
of O
our O
att O
strategy O
in O
a O
quadrivalent B
LAIV I
( I
QIV I
) I
formulation O
carrying O
H3N2 O
and O
H1N1 O
influenza O
A O
virus O
subtype O
viruses O
and O
two O
antigenic O
lineages O
of O
influenza O
B O
viruses O
. O

In O
naive O
DBA O
/ O
2J O
mice O
, O
two O
doses O
of O
the O
QIV O
elicited O
hemagglutination B
inhibition I
( I
HI I
) I
responses O
with O
HI O
titers O
of O
> O
= O
40 O
and O
effectively O
protected O
against O
lethal O
challenge O
with O
prototypical O
pandemic O
H1N1 O
influenza O
A O
and O
influenza O
B O
virus O
strains O
. O

In O
this O
study O
, O
we O
tested O
an O
alternative O
quadrivalent O
live O
attenuated O
influenza O
virus O
vaccine O
( O
QIV O
) O
formulation O
whose O
individual O
components O
have O
been O
previously O
shown O
to O
provide O
protection O
. O

The O
influenza B
A I
virus I
( I
IAV I
) I
neuraminidase I
( I
NA I
) I
protein O
plays O
an O
essential O
role O
in O
the O
release O
of O
virus O
particles O
from O
cells O
and O
decoy O
receptors O
. O

The O
NA O
enzymatic O
activity O
presumably O
needs O
to O
match O
the O
activity O
of O
the O
IAV O
Hemagglutinin B
( I
HA I
) I
attachment O
protein O
and O
the O
host O
sialic B
acid I
( I
SIA I
) I
receptor O
repertoire O
. O

We O
analyzed O
the O
enzymatic O
activities O
of O
N1 O
NA O
proteins O
derived O
from O
avian O
( O
H5N1 O
) O
and O
human O
( O
H1N1 O
) O
IAVs O
and O
analyzed O
the O
role O
of O
the O
second O
SIA O
- O
binding O
site O
, O
located O
adjacent O
to O
the O
conserved O
catalytic O
site O
, O
therein O
. O

IMPORTANCE O
Avian O
and O
human O
influenza B
A I
viruses I
( I
IAVs I
) I
preferentially O
bind O
alpha O
2 O
, O
3 O
- O
and O
alpha O
2 O
, O
6 O
- O
linked O
sialic B
acids I
( I
SIAs I
) I
, O
respectively O
. O

A O
functional O
balance O
between O
the O
Hemagglutinin B
( I
HA I
) I
attachment O
and O
neuraminidase B
( I
NA I
) I
proteins O
is O
thought O
to O
be O
important O
for O
host O
tropism O
. O

microRNAs B
( I
miRNAs I
) I
are O
small O
noncoding O
RNAs O
that O
are O
crucial O
post O
- O
transcriptional O
regulators O
for O
host O
mRNAs O
. O

In O
this O
study O
, O
we O
showed O
that O
expression O
of O
cellular O
miRNA O
miR O
- O
324 O
- O
5p O
was O
downregulated O
in O
A549 O
cells O
in O
response O
to O
infection O
with O
RNA O
viruses O
H5N1 O
, O
A O
/ O
PR8 O
/ O
H1N1 O
, O
and O
Newcastle B
disease I
virus I
( I
NDV I
) I
and O
transfection O
with O
poly O
( O
I O
. O

In O
addition O
, O
transcriptome O
analysis O
revealed O
that O
miR O
- O
324 O
- O
5p O
enhanced O
the O
expression O
of O
type O
I O
interferon O
, O
type O
III O
interferon O
, O
and O
interferon O
- O
inducible O
genes O
( O
ISGs O
) O
by O
targeting O
CUEDC2 O
, O
the O
negative O
regulator O
of O
the O
JAK1 O
- O
STAT3 O
pathway O
. O

IMPORTANCE O
Highly B
pathogenic I
influenza I
A I
virus I
( I
HPAIV I
) I
continues O
to O
pose O
a O
pandemic O
threat O
globally O
. O

This O
work O
shows O
that O
miR O
- O
324 O
- O
5p O
suppresses O
H5N1 O
HPAIV O
replication O
by O
directly O
targeting O
the O
viral O
genome O
( O
thereby O
inhibiting O
viral O
gene O
expression O
) O
and O
cellular O
CUEDC2 O
gene O
, O
the O
negative O
regulator O
of O
the O
interferon O
pathway O
( O
thereby O
enhancing O
antiviral O
genes O
) O
. O

Wild O
- O
bird O
origin O
influenza O
A O
viruses O
( O
IAVs O
or O
avian O
influenza O
) O
have O
led O
to O
sporadic O
outbreaks O
among O
domestic O
poultry O
in O
the O
United O
States O
and O
Canada O
, O
resulting O
in O
economic O
losses O
through O
the O
implementation O
of O
costly O
containment O
practices O
and O
destruction O
of O
birds O
. O

We O
used O
evolutionary O
analyses O
of O
virus O
sequence O
data O
to O
determine O
that O
78 O
H5 O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
isolated O
from O
domestic O
poultry O
in O
the O
United O
States O
and O
Canada O
during O
2001 O
to O
2017 O
resulted O
from O
18 O
independent O
virus O
introductions O
from O
wild O
birds O
. O

Zoonotic O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
have O
raised O
serious O
public O
health O
concerns O
of O
a O
novel O
pandemic O
. O

These O
strains O
emerge O
from O
low O
- O
pathogenic O
precursors O
by O
the O
acquisition O
of O
a O
polybasic O
Hemagglutinin B
( I
HA I
) I
cleavage O
site O
, O
the O
prime O
virulence O
determinant O
. O

IMPORTANCE O
Zoonotic O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
have O
raised O
serious O
public O
health O
concerns O
of O
a O
novel O
pandemic O
. O

Their O
prime O
virulence O
determinant O
is O
the O
polybasic O
Hemagglutinin B
( I
HA I
) I
cleavage O
site O
. O

However O
, O
required O
coadaptations O
in O
the O
HA O
( O
and O
other O
genes O
) O
remained O
uncertain O
. O

H7N9 O
- O
specific O
antibody O
concentrations O
declined O
over O
time O
, O
and O
protective O
antibodies O
persisted O
longer O
in O
severely O
ill O
patients O
admitted O
to O
the O
intensive B
care I
unit I
( I
ICU I
) I
and O
patients O
presenting O
with O
acute B
respiratory I
distress I
syndrome I
( I
ARDS I
) I
than O
in O
patients O
with O
mild O
disease O
. O

Frequencies O
of O
virus O
- O
specific O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
secreting O
T O
cells O
were O
lower O
in O
critically O
ill O
patients O
requiring O
ventilation O
than O
in O
patients O
without O
ventilation O
within O
4 O
months O
after O
infection O
. O

Elevated O
levels O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
expressing O
the O
lung O
- O
homing O
marker O
CD49a O
were O
observed O
at O
6 O
to O
8 O
months O
after O
H7N9 O
infection O
compared O
to O
those O
in O
samples O
obtained O
at O
1 O
. O

Higher O
levels O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
expressing O
the O
lung O
- O
homing O
marker O
CD49a O
were O
detected O
at O
6 O
to O
8 O
months O
after O
infection O
. O

We O
previously O
identified O
a O
potent O
and O
broadly B
neutralizing I
antibody I
( I
bnAb I
) I
, O
13D4 O
, O
against O
the O
H5N1 O
virus O
. O

Here O
, O
we O
report O
the O
co O
- O
crystal O
structure O
of O
13D4 O
in O
complex O
with O
the O
Hemagglutinin B
( I
HA I
) I
of O
A O
/ O
Vietnam O
/ O
1194 O
/ O
2004 O
( O
H5N1 O
) O
. O

We O
show O
that O
heavy B
- I
chain I
complementarity I
- I
determining I
region I
3 I
( I
HCDR3 I
) I
of O
13D4 O
confers O
broad O
yet O
specific O
neutralization O
against O
H5N1 O
, O
undergoing O
conformational O
rearrangement O
to O
bind O
to O
the O
Receptor B
binding I
site I
( I
RBS I
) I
. O

Viruses O
bearing O
Asn193 O
instead O
of O
Lys O
/ O
Arg O
can O
evade O
13D4 O
neutralization O
, O
indicating O
that O
Lys193 O
polymorphism O
might O
be O
, O
at O
least O
in O
part O
, O
involved O
in O
the O
antigenicity O
of O
recent O
H5 O
genotypes O
( O
such O
as O
H5N6 O
and O
H5N8 O
) O
as O
distinguished O
from O
H5N1 O
. O

Structural O
analysis O
revealed O
that O
13D4 O
uses O
heavy B
- I
chain I
complementarity I
- I
determining I
region I
3 I
( I
HCDR3 I
) I
to O
fit O
the O
Receptor B
binding I
site I
( I
RBS I
) I
via O
conformational O
rearrangement O
. O

Broadly O
cross O
- O
reactive O
antibodies B
( I
Abs I
) I
that O
recognize O
conserved O
epitopes O
within O
the O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
stalk O
domain O
are O
of O
particular O
interest O
for O
their O
potential O
use O
as O
therapeutic O
and O
prophylactic O
agents O
against O
multiple O
influenza O
virus O
subtypes O
, O
including O
zoonotic O
virus O
strains O
. O

Here O
, O
we O
characterized O
four O
human O
HA O
stalk O
- O
reactive O
Monoclonal B
antibodies I
( I
MAbs I
) I
for O
their O
binding O
breadth O
and O
affinity O
, O
in O
vitro O
neutralization O
capacity O
, O
and O
in O
vivo O
protective O
potential O
against O
an O
highly O
pathogenic O
avian O
influenza O
virus O
. O

The O
monoclonal O
antibodies O
were O
isolated O
from O
individuals O
shortly O
following O
infection O
with O
( O
70 O
- O
1F02 O
and O
1009 O
- O
3B05 O
) O
or O
vaccination O
against O
( O
05 O
- O
2G02 O
and O
09 O
- O
3A01 O
) O
A O
( O
H1N1 O
) O
pdm09 O
. O

All O
four O
antibodies O
prophylactically O
protected O
mice O
against O
a O
lethal O
challenge O
with O
the O
highly O
pathogenic O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
strain O
. O

Finally O
, O
we O
show O
that O
antibodies O
that O
compete O
with O
these O
MAbs O
are O
prevalent O
in O
serum O
from O
an O
individual O
recently O
infected O
with O
the O
A O
( O
H1N1 O
) O
pdm09 O
virus O
. O

Avian O
- O
origin O
H3N2 O
canine B
influenza I
virus I
( I
CIV I
) I
transferred O
to O
dogs O
in O
Asia O
around O
2005 O
, O
becoming O
enzootic O
throughout O
China O
and O
South O
Korea O
before O
reaching O
the O
United O
States O
in O
early O
2015 O
. O

CIV O
must O
therefore O
rely O
on O
metapopulations O
of O
high O
host O
density O
( O
such O
as O
animal O
shelters O
and O
kennels O
) O
within O
the O
greater O
dog O
population O
and O
reintroduction O
from O
other O
populations O
or O
face O
complete O
epidemic O
extinction O
. O

IMPORTANCE O
The O
relatively O
recent O
appearance O
of O
influenza B
A I
virus I
( I
IAV I
) I
epidemics O
in O
dogs O
expands O
our O
understanding O
of O
IAV O
host O
range O
and O
ecology O
, O
providing O
useful O
and O
relevant O
models O
for O
understanding O
critical O
factors O
involved O
in O
viral O
emergence O
. O

Here O
we O
integrate O
viral O
whole O
- O
genome O
sequence O
analysis O
and O
comprehensive O
surveillance O
data O
to O
examine O
the O
evolution O
of O
the O
emerging O
avian O
- O
origin O
H3N2 O
canine B
influenza I
virus I
( I
CIV I
) I
, O
particularly O
the O
factors O
driving O
ongoing O
circulation O
and O
recent O
increases O
in O
incidence O
of O
the O
virus O
within O
the O
United O
States O
. O

The O
avian O
influenza O
A O
( O
H7N9 O
) O
virus O
continues O
to O
cause O
human O
infections O
in O
China O
and O
is O
a O
major O
ongoing O
public O
health O
concern O
. O

Five O
epidemic O
waves O
of O
A O
( O
H7N9 O
) O
infection O
have O
occurred O
since O
2013 O
, O
and O
the O
recent O
fifth O
epidemic O
wave O
saw O
the O
emergence O
of O
two O
distinct O
lineages O
with O
elevated O
numbers O
of O
human O
infection O
cases O
and O
broader O
geographic O
distribution O
of O
viral O
diseases O
compared O
to O
the O
first O
four O
epidemic O
waves O
. O

Moreover O
, O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
( O
H7N9 O
) O
viruses O
were O
also O
isolated O
during O
the O
fifth O
epidemic O
wave O
. O

Here O
, O
we O
present O
a O
detailed O
structural O
and O
biochemical O
analysis O
of O
the O
surface O
Hemagglutinin B
( I
HA I
) I
antigen O
from O
viruses O
isolated O
during O
this O
recent O
epidemic O
wave O
. O

We O
also O
studied O
three O
mutations O
, O
V177K O
- O
K184T O
- O
G219S O
, O
that O
were O
recently O
reported O
to O
switch O
a O
2013 O
A O
( O
H7N9 O
) O
HA O
to O
human O
- O
type O
receptor O
specificity O
. O

IMPORTANCE O
The O
A O
( O
H7N9 O
) O
viruses O
circulating O
in O
China O
are O
of O
great O
public O
health O
concern O
. O

Here O
, O
we O
report O
a O
molecular O
and O
structural O
study O
of O
the O
major O
surface O
proteins O
from O
several O
recent O
A O
( O
H7N9 O
) O
influenza O
viruses O
. O

Transmission O
of O
avian B
influenza I
( I
AI I
) I
viruses O
to O
mammals O
involves O
phylogenetic O
bottlenecks O
that O
select O
small O
numbers O
of O
variants O
for O
transmission O
to O
new O
host O
species O
. O

Here O
, O
we O
analyzed O
the O
Hemagglutinin B
( I
HA I
) I
genetic O
diversity O
produced O
during O
AI O
H5N1 O
single O
- O
virus O
infection O
of O
primary O
human O
airway O
cells O
and O
characterized O
the O
phenotypes O
of O
these O
variants O
. O

These O
variants O
generally O
had O
decreased O
HA O
thermostability O
, O
an O
indicator O
of O
decreased O
transmissibility O
, O
that O
appeared O
to O
compensate O
for O
their O
increase O
in O
alpha B
2 I
, I
6 I
- I
linked I
sialic I
acid I
( I
alpha I
2 I
, I
6 I
Sia I
) I
binding O
specificity O
and O
/ O
or O
in O
the O
membrane O
fusion O
pH O
threshold O
, O
each O
of O
which O
is O
an O
advantageous O
mutational O
change O
for O
viral O
infection O
of O
human O
airway O
epithelia O
. O

Highly O
pathogenic O
influenza B
A I
viruses I
( I
IAV I
) I
from O
avian O
hosts O
were O
first O
reported O
to O
directly O
infect O
humans O
20 O
years O
ago O
. O

This O
short O
( O
90 O
- O
amino O
- O
acid O
) O
peptide O
does O
not O
harbor O
an O
enzymatic O
function O
. O

PB1 O
- O
F2 O
binds O
to O
HCLS1 O
- O
associated O
protein O
X1 O
( O
HAX O
- O
1 O
) O
, O
a O
recently O
identified O
host O
restriction O
factor O
of O
the O
PA O
subunit O
of O
IAV O
polymerase O
complexes O
. O

We O
also O
showed O
HAX O
- O
1 O
sensitivity O
for O
PAs O
of O
A O
/ O
Brevig O
Mission O
/ O
1 O
/ O
1918 O
( O
H1N1 O
) O
and O
A O
/ O
Shanghai O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
, O
two O
avian O
- O
origin O
zoonotic O
IAV O
. O

Geographical O
distribution O
analysis O
indicated O
that O
the O
newly O
emerging O
highly B
pathogenic I
( I
HP I
) I
and O
low B
- I
pathogenicity I
( I
LP I
) I
H7N9 O
viruses O
were O
cocirculating O
, O
causing O
human O
and O
poultry O
infections O
across O
China O
. O

Genetic O
analysis O
indicated O
that O
dynamic O
reassortment O
of O
the O
internal O
genes O
among O
LP O
- O
H7N9 O
/ O
H9N2 O
/ O
H6Ny O
and O
HP O
- O
H7N9 O
, O
as O
well O
as O
of O
the O
surface O
genes O
, O
between O
the O
Yangtze O
and O
Pearl O
River O
Delta O
lineages O
resulted O
in O
at O
least O
36 O
genotypes O
, O
with O
three O
major O
genotypes O
( O
G1 O
[ O
A O
/ O
chicken O
/ O
Jiangsu O
/ O
SC537 O
/ O
2013 O
- O
like O
] O
, O
G3 O
[ O
A O
/ O
Chicken O
/ O
Zhongshan O
/ O
ZS O
/ O
2017 O
- O
like O
] O
, O
and O
G11 O
[ O
A O
/ O
Anhui O
/ O
40094 O
/ O
2015 O
- O
like O
] O
) O
. O

The O
HP O
- O
H7N9 O
genotype O
likely O
evolved O
from O
G1 O
LP O
- O
H7N9 O
by O
the O
insertion O
of O
a O
KRTA O
motif O
at O
the O
cleavage B
site I
( I
CS I
) I
and O
then O
evolved O
into O
15 O
genotypes O
with O
four O
different O
CS O
motifs O
, O
including O
PKGKRTAR O
/ O
G O
, O
PKGKRIAR O
/ O
G O
, O
PKRKRAAR O
/ O
G O
, O
and O
PKRKRTAR O
/ O
G O
. O

Approximately O
46 O
% O
( O
28 O
/ O
61 O
) O
of O
HP O
strains O
belonged O
to O
G3 O
. O

Importantly O
, O
neuraminidase B
( I
NA I
) I
inhibitor O
( O
NAI O
) O
resistance O
( O
R292K O
in O
NA O
) O
and O
mammalian O
adaptation O
( O
e O
. O

Our O
results O
showed O
that O
HP O
- O
H7N9 O
and O
LP O
- O
H7N9 O
had O
spread O
virtually O
throughout O
China O
and O
underwent O
dynamic O
reassortment O
with O
different O
subtypes O
( O
H7N9 O
/ O
H9N2 O
and O
H6Ny O
) O
and O
lineages O
( O
Yangtze O
and O
Pearl O
River O
Delta O
lineages O
) O
, O
resulting O
in O
totals O
of O
36 O
and O
3 O
major O
genotypes O
, O
respectively O
. O

Notably O
, O
the O
NAI O
drug O
- O
resistant O
( O
R292K O
in O
NA O
) O
and O
mammalian O
- O
adapted O
( O
e O
. O

Influenza O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
lymphocytes O
( O
CTLs O
) O
contribute O
to O
clearance O
of O
influenza O
virus O
infections O
and O
reduce O
disease O
severity O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
naturally O
occurring O
variation O
at O
residues O
outside O
the O
conserved O
immunodominant O
and O
HLA O
* O
0201 O
- O
restricted O
M1 O
( O
58 O
- O
66 O
) O
epitope O
, O
located O
in O
the O
influenza O
virus O
M1 O
protein O
, O
on O
the O
extent O
of O
virus O
replication O
in O
the O
presence O
of O
CTLs O
specific O
for O
the O
epitope O
. O

To O
this O
end O
, O
we O
used O
isogenic O
viruses O
with O
an O
M1 O
gene O
segment O
derived O
from O
either O
an O
avian O
or O
a O
human O
influenza O
virus O
, O
HLA O
- O
transgenic O
human O
epithelial O
cells O
, O
human O
T O
cell O
clones O
specific O
for O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
or O
a O
control O
epitope O
, O
and O
a O
novel O
, O
purposely O
developed O
in O
vitro O
system O
to O
coculture O
influenza O
virus O
- O
infected O
cells O
with O
T O
cells O
. O

We O
found O
that O
the O
M O
gene O
segment O
of O
a O
human O
influenza O
A O
/ O
H3N2 O
virus O
afforded O
the O
virus O
the O
capacity O
to O
replicate O
better O
in O
the O
presence O
of O
M1 O
( O
58 O
- O
66 O
) O
- O
specific O
CTLs O
than O
the O
M O
gene O
segment O
of O
avian O
viruses O
. O

These O
findings O
are O
in O
concordance O
with O
previously O
observed O
differential O
CTL O
activation O
, O
caused O
by O
variation O
at O
extra O
- O
epitopic O
residues O
, O
and O
may O
reflect O
an O
immune O
adaptation O
strategy O
of O
human O
influenza O
viruses O
that O
allows O
them O
to O
cope O
with O
potent O
CTL O
immunity O
to O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
in O
HLA O
- O
A O
* O
0201 O
- O
positive O
individuals O
, O
resulting O
in O
increased O
virus O
replication O
and O
shedding O
and O
possibly O
increasing O
disease O
severity O
. O

CD8 O
( O
+ O
) O
T O
lymphocytes O
display O
a O
high O
degree O
of O
cross O
- O
reactivity O
with O
influenza O
A O
viruses O
of O
various O
subtypes O
and O
are O
considered O
an O
important O
correlate O
of O
protection O
. O

Unraveling O
viral O
immune O
evasion O
strategies O
and O
identifying O
signs O
of O
immune O
adaptation O
are O
important O
for O
defining O
the O
role O
of O
CD8 O
( O
+ O
) O
T O
lymphocytes O
in O
affording O
protection O
more O
accurately O
. O

Improving O
our O
insight O
into O
the O
interaction O
between O
influenza O
viruses O
and O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
lymphocyte O
immunity O
may O
help O
to O
advance O
our O
understanding O
of O
influenza O
virus O
epidemiology O
, O
aid O
in O
risk O
assessment O
of O
potentially O
pandemic O
influenza O
virus O
strains O
, O
and O
benefit O
the O
design O
of O
vaccines O
that O
induce O
more O
broadly O
protective O
immunity O
. O

We O
have O
recently O
shown O
that O
human O
influenza O
viruses O
preferentially O
bind O
to O
alpha O
2 O
- O
6 O
- O
sialylated O
branched O
N O
- O
linked O
glycans O
, O
where O
the O
sialic O
acids O
on O
each O
branch O
can O
bind O
to O
receptor O
sites O
on O
two O
protomers O
of O
the O
same O
Hemagglutinin B
( I
HA I
) I
trimer O
. O

Human B
papillomavirus I
( I
HPV I
) I
is O
the O
causative O
agent O
of O
cervical O
cancer O
. O

Recent O
epidemiological O
studies O
indicate O
that O
up O
to O
50 O
% O
women O
who O
are O
HPV O
positive O
( O
HPV O
+ O
) O
are O
infected O
with O
more O
than O
one O
HPV O
type O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
are O
common O
pathogens O
of O
birds O
that O
occasionally O
establish O
endemic O
infections O
in O
mammals O
. O

The O
viral O
nonstructural B
1 I
( I
NS1 I
) I
protein O
counteracts O
the O
interferon B
( I
IFN I
) I
response O
, O
a O
central O
component O
of O
the O
host O
species O
barrier O
. O

We O
characterized O
the O
NS1 O
proteins O
of O
equine B
influenza I
virus I
( I
EIV I
) I
, O
a O
mammalian O
IAV O
lineage O
of O
avian O
origin O
. O

We O
showed O
that O
evolutionarily O
distinct O
NS1 O
proteins O
counteract O
the O
IFN O
response O
using O
different O
and O
mutually O
exclusive O
mechanisms O
: O
while O
the O
NS1 O
proteins O
of O
early O
EIVs O
block O
general O
gene O
expression O
by O
binding O
to O
cellular B
polyadenylation I
- I
specific I
factor I
30 I
( I
CPSF30 I
) I
, O
NS1 O
proteins O
from O
more O
evolved O
EIVs O
specifically O
block O
the O
induction O
of O
IFN O
- O
stimulated O
genes O
by O
interfering O
with O
the O
JAK O
/ O
STAT O
pathway O
. O

IMPORTANCE O
influenza B
A I
viruses I
( I
IAVs I
) I
infect O
certain O
avian O
reservoir O
species O
and O
occasionally O
transfer O
to O
and O
cause O
epidemics O
of O
infections O
in O
some O
mammalian O
hosts O
. O

H3N8 O
equine B
influenza I
virus I
( I
EIV I
) I
is O
an O
avian O
- O
origin O
virus O
that O
successfully O
established O
a O
new O
lineage O
in O
horses O
in O
the O
early O
1960s O
and O
is O
currently O
circulating O
worldwide O
in O
the O
equine O
population O
. O

Here O
, O
we O
analyzed O
the O
molecular O
evolution O
of O
the O
virulence O
factor O
nonstructural B
protein I
1 I
( I
NS1 I
) I
and O
show O
that O
NS1 O
proteins O
from O
different O
time O
periods O
after O
EIV O
emergence O
counteract O
the O
host O
innate O
immune O
response O
using O
contrasting O
strategies O
, O
which O
are O
associated O
with O
two O
mutations O
that O
appeared O
sequentially O
during O
EIV O
evolution O
. O

In O
this O
study O
, O
we O
determined O
the O
crystal O
structure O
of O
viral O
Hemagglutinin B
( I
HA I
) I
globular O
head O
bound O
to O
the O
fragment O
antigen O
- O
binding O
region O
( O
Fab O
) O
of O
HNIgGA6 O
. O

The O
crystal O
structure O
shows O
that O
the O
tip O
of O
the O
HNIgGA6 O
heavy B
- I
chain I
complementarity I
- I
determining I
region I
3 I
( I
HCDR3 I
) I
directly O
interposes O
into O
the O
Receptor B
binding I
site I
( I
RBS I
) I
and O
mimics O
, O
in O
many O
respects O
, O
the O
interaction O
of O
the O
sialic O
acid O
receptor O
. O

Recently O
, O
two O
influenza B
A I
virus I
( I
FLUAV I
) I
genomes O
were O
identified O
in O
Central O
and O
South O
American O
bats O
. O

Unexpectedly O
, O
we O
found O
that O
bat O
FLUAV O
NS1s O
are O
unique O
in O
being O
unable O
to O
bind O
host O
p85 O
beta O
, O
a O
regulatory O
subunit O
of O
the O
cellular O
metabolism O
- O
regulating O
enzyme O
, O
phosphoinositide B
3 I
- I
kinase I
( I
PI3K I
) I
. O

Structure O
- O
guided O
mutagenesis O
revealed O
that O
the O
bat O
FLUAV O
NS1 O
- O
p85 O
beta O
interaction O
can O
be O
reengineered O
( O
in O
a O
strain O
- O
specific O
manner O
) O
by O
changing O
two O
to O
four O
NS1 O
residues O
( O
96L O
, O
99M O
, O
100I O
, O
and O
145T O
) O
, O
thereby O
creating O
a O
hydrophobic O
patch O
. O

To O
study O
the O
influenza O
virus O
determinants O
of O
pathogenicity O
, O
we O
characterized O
two O
highly O
pathogenic O
avian O
H5N1 O
influenza O
viruses O
isolated O
in O
Vietnam O
in O
2012 O
( O
A O
/ O
duck O
/ O
Vietnam O
/ O
QT1480 O
/ O
2012 O
[ O
QT1480 O
] O
) O
and O
2013 O
( O
A O
/ O
duck O
/ O
Vietnam O
/ O
QT1728 O
/ O
2013 O
[ O
QT1728 O
] O
) O
and O
found O
that O
the O
activity O
of O
their O
polymerase O
complexes O
differed O
significantly O
, O
even O
though O
both O
viruses O
were O
highly O
pathogenic O
in O
mice O
. O

Further O
studies O
revealed O
that O
the O
PA O
- O
S343A O
/ O
E347D O
( O
PA O
with O
the O
S O
- O
to O
- O
A O
change O
at O
position O
343 O
and O
the O
E O
- O
to O
- O
D O
change O
at O
position O
347 O
) O
mutations O
reduced O
viral O
polymerase O
activity O
and O
mouse O
virulence O
when O
tested O
in O
the O
genetic O
background O
of O
QT1728 O
virus O
. O

The O
PA O
- O
343S O
residue O
( O
which O
alone O
increased O
viral O
polymerase O
activity O
and O
mouse O
virulence O
significantly O
relative O
to O
viral O
replication O
complexes O
encoding O
PA O
- O
343A O
) O
is O
frequently O
found O
in O
H5N1 O
influenza O
viruses O
of O
several O
subclades O
; O
infection O
with O
a O
virus O
possessing O
this O
amino O
acid O
may O
pose O
an O
increased O
risk O
to O
humans O
. O

Several O
subtypes O
of O
avian B
influenza I
viruses I
( I
AIVs I
) I
are O
emerging O
as O
novel O
human O
pathogens O
, O
and O
the O
frequency O
of O
related O
infections O
has O
increased O
in O
recent O
years O
. O

Although O
neuraminidase B
( I
NA I
) I
inhibitors O
( O
NAIs O
) O
are O
the O
only O
class O
of O
antiviral O
drugs O
available O
for O
therapeutic O
intervention O
for O
AIV O
- O
infected O
patients O
, O
studies O
on O
NAI O
resistance O
among O
AIVs O
have O
been O
limited O
, O
and O
markers O
of O
resistance O
are O
poorly O
understood O
. O

We O
generated O
libraries O
of O
mutant O
influenza O
viruses O
using O
reverse B
genetics I
( I
RG I
) I
and O
selected O
resistant O
variants O
in O
the O
presence O
of O
the O
NAIs O
oseltamivir O
carboxylate O
and O
zanamivir O
in O
MDCK O
cells O
. O

In O
addition O
, O
two O
substitutions O
, O
H274Y O
and O
R292K O
( O
N2 O
numbering O
) O
, O
were O
introduced O
into O
each O
NA O
gene O
for O
comparison O
. O

We O
identified O
37 O
amino O
acid O
substitutions O
within O
the O
NA O
gene O
, O
16 O
of O
which O
( O
4 O
in O
N4 O
, O
4 O
in O
N5 O
, O
4 O
in O
N6 O
, O
and O
4 O
in O
N8 O
) O
conferred O
resistance O
to O
NAIs O
( O
oseltamivir O
carboxylate O
, O
zanamivir O
, O
or O
peramivir O
) O
as O
determined O
using O
a O
fluorescence O
- O
based O
NA O
inhibition O
assay O
. O

Substitutions O
conferring O
NAI O
resistance O
were O
mainly O
categorized O
as O
either O
novel O
NA O
subtype O
specific O
( O
G O
/ O
N147V O
/ O
I O
, O
A246V O
, O
and O
I427L O
) O
or O
previously O
reported O
in O
other O
subtypes O
( O
E119A O
/ O
D O
/ O
V O
, O
Q136K O
, O
E276D O
, O
R292K O
, O
and O
R371K O
) O
. O

IMPORTANCE O
The O
frequency O
of O
human O
infections O
with O
avian B
influenza I
viruses I
( I
AIVs I
) I
has O
increased O
in O
recent O
years O
. O

Despite O
the O
availability O
of O
vaccines O
, O
Neuraminidase B
inhibitors I
( I
NAIs I
) I
, O
as O
the O
only O
available O
class O
of O
drugs O
for O
AIVs O
in O
humans O
, O
have O
been O
constantly O
used O
for O
treatment O
, O
leading O
to O
the O
inevitable O
emergence O
of O
drug O
- O
resistant O
variants O
. O

Since O
its O
emergence O
in O
2013 O
, O
the O
H7N9 O
low B
- I
pathogenic I
avian I
influenza I
virus I
( I
LPAIV I
) I
has O
been O
circulating O
in O
domestic O
poultry O
in O
China O
, O
causing O
five O
waves O
of O
human O
infections O
. O

A O
novel O
H7N9 O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
variant O
possessing O
multiple O
basic O
amino O
acids O
at O
the O
cleavage O
site O
of O
the O
Hemagglutinin B
( I
HA I
) I
protein O
was O
first O
reported O
in O
two O
cases O
of O
human O
infection O
in O
January O
2017 O
. O

Notably O
, O
humanorigin O
viruses O
were O
more O
pathogenic O
in O
mice O
than O
avian O
viruses O
, O
and O
the O
mutations O
in O
the O
PB2 O
gene O
associated O
with O
adaptation O
to O
mammals O
( O
E627K O
, O
A588V O
, O
and O
D701N O
) O
were O
identified O
by O
next B
- I
generation I
sequencing I
( I
NGS I
) I
and O
Sanger O
sequencing O
of O
the O
isolates O
from O
infected O
mice O
. O

IMPORTANCE O
Due O
to O
the O
recent O
increased O
numbers O
of O
zoonotic O
infections O
in O
poultry O
and O
persistent O
human O
infections O
in O
China O
, O
influenza O
A O
( O
H7N9 O
) O
virus O
has O
remained O
a O
public O
health O
threat O
. O

Most O
of O
the O
influenza O
A O
( O
H7N9 O
) O
viruses O
reported O
previously O
have O
been O
of O
low O
pathogenicity O
. O

microRNAs B
( I
miRNAs I
) I
have O
been O
used O
previously O
to O
generate O
attenuated O
influenza O
A O
viruses O
for O
use O
as O
a O
vaccine O
. O

Here O
, O
we O
systematically O
targeted O
individual O
influenza O
gene O
mRNAs O
using O
the O
same O
miRNA O
to O
determine O
the O
segment O
( O
s O
) O
that O
yields O
maximal O
attenuation O
potential O
. O

Here O
we O
aimed O
to O
identify O
novel O
high O
- O
yield O
signatures O
for O
influenza O
viruses O
in O
continuous O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
and O
Vero O
cells O
. O

Using O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
virus O
as O
the O
testing O
platform O
and O
an O
integrating O
error O
- O
prone O
PCR O
- O
based O
mutagenesis O
strategy O
, O
we O
identified O
a O
Y161F O
mutation O
in O
Hemagglutinin B
( I
HA I
) I
that O
not O
only O
enhanced O
the O
infectivity O
of O
the O
resultant O
virus O
by O
more O
than O
300 O
- O
fold O
but O
also O
increased O
its O
thermostability O
without O
changing O
its O
original O
antigenic O
properties O
. O

The O
vaccine O
produced O
from O
the O
Y161F O
mutant O
fully O
protected O
mice O
against O
lethal O
challenge O
with O
wild O
- O
type O
A O
( O
H1N1 O
) O
pdm09 O
. O

Compared O
with O
A O
( O
H1N1 O
) O
pdm09 O
, O
the O
Y161F O
mutant O
had O
significantly O
higher O
avidity O
for O
avian O
- O
like O
and O
human O
- O
like O
receptor O
analogs O
. O

Of O
note O
, O
the O
introduction O
of O
the O
Y161F O
mutation O
into O
HA O
of O
seasonal O
H3N2 O
influenza B
A I
virus I
( I
IAV I
) I
and O
canine O
H3N8 O
IAV O
also O
increased O
yields O
and O
thermostability O
in O
MDCK O
cells O
and O
chicken O
embryotic O
eggs O
. O

In O
this O
study O
, O
we O
identified O
a O
molecular O
signature O
, O
Y161F O
, O
in O
Hemagglutinin B
( I
HA I
) I
that O
resulted O
in O
increased O
virus O
growth O
in O
Madin O
- O
Darby O
canine O
kidney O
and O
Vero O
cells O
, O
two O
cell O
lines O
commonly O
used O
for O
influenza O
vaccine O
manufacturing O
. O

In O
the O
event O
of O
a O
pandemic O
, O
antiviral O
agents O
are O
the O
mainstay O
for O
treatment O
, O
but O
broadly B
neutralizing I
antibodies I
( I
bNAbs I
) I
may O
be O
a O
viable O
alternative O
for O
short O
- O
term O
prophylaxis O
or O
treatment O
. O

Therefore O
, O
we O
evaluated O
these O
antibodies O
against O
human O
- O
and O
animal O
- O
origin O
H2 O
viruses O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
1960 O
( O
H2N2 O
) O
( O
AA60 O
) O
and O
A O
/ O
swine O
/ O
MO O
/ O
4296424 O
/ O
06 O
( O
H2N3 O
) O
( O
Sw06 O
) O
. O

Using O
engineered O
bNAb O
variants O
, O
antibody O
- O
mediated O
cell O
cytotoxicity O
reporter O
assays O
, O
and O
Fc O
gamma O
receptor O
- O
deficient O
( O
Fcer1g O
( O
- O
/ O
- O
) O
) O
mice O
, O
we O
show O
that O
the O
in O
vivo O
efficacy O
of O
CR9114 O
against O
AA60 O
is O
mediated O
by O
Fc O
gamma O
receptor O
- O
dependent O
mechanisms O
. O

The O
novel O
low B
- I
pathogenic I
avian I
influenza I
A I
H7N9 I
viruses I
( I
LPAI I
H7N9 I
viruses I
) I
have O
been O
a O
threat O
to O
public O
health O
since O
their O
emergence O
in O
2013 O
because O
of O
the O
high O
rates O
of O
mortality O
and O
morbidity O
that O
they O
cause O
. O

Recently O
, O
highly O
pathogenic O
variants O
of O
these O
avian O
influenza O
A O
H7N9 O
viruses O
( O
HPAI O
H7N9 O
viruses O
) O
have O
emerged O
and O
caused O
human O
infections O
and O
outbreaks O
among O
poultry O
in O
mainland O
China O
. O

After O
introduction O
into O
the O
Pearl O
River O
Delta O
region O
, O
the O
origin O
LPAI O
H7N9 O
virus O
acquired O
four O
amino O
acid O
insertions O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
cleavage O
site O
and O
mutated O
into O
the O
HPAI O
H7N9 O
virus O
in O
late O
May O
2016 O
. O

Here O
, O
we O
constructed O
DNA O
vaccines O
encoding O
the O
Hemagglutinin B
( I
HA I
) I
from O
influenza O
A O
/ O
chicken O
/ O
Italy O
/ O
13474 O
/ O
99 O
( O
H7N1 O
) O
. O

In O
order O
to O
increase O
the O
efficacy O
of O
DNA O
vaccination O
, O
HA O
was O
targeted O
to O
either O
major O
histocompatibility O
complex O
class O
II O
molecules O
or O
chemokine B
receptors I
1 I
, I
3 I
, I
and I
5 I
( I
CCR1 I
/ I
3 I
/ I
5 I
) I
that O
are O
expressed O
on O
antigen B
- I
presenting I
cells I
( I
APC I
) I
. O

Furthermore O
, O
the O
APC O
- O
targeted O
vaccines O
increased O
the O
levels O
of O
antigen O
- O
specific O
cytotoxic O
T O
cells O
, O
and O
a O
single O
DNA O
vaccination O
could O
confer O
protection O
against O
a O
lethal O
challenge O
with O
influenza O
A O
/ O
turkey O
/ O
Italy O
/ O
3889 O
/ O
1999 O
( O
H7N1 O
) O
in O
mice O
. O

Seasonal O
human O
influenza O
virus O
continues O
to O
cause O
morbidity O
and O
mortality O
annually O
, O
and O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
along O
with O
other O
emerging O
influenza O
viruses O
continue O
to O
pose O
pandemic O
threats O
. O

Current O
vaccines O
focus O
on O
eliciting O
specific O
antibody O
responses O
against O
the O
Hemagglutinin B
( I
HA I
) I
surface O
glycoprotein O
; O
however O
, O
the O
diversity O
of O
HAs O
across O
species O
and O
antigenic O
drift O
of O
circulating O
strains O
enable O
the O
evasion O
of O
virus O
- O
inhibiting O
antibody O
responses O
, O
resulting O
in O
vaccine O
failure O
. O

The O
neuraminidase B
( I
NA I
) I
surface O
glycoprotein O
, O
while O
diverse O
, O
has O
a O
conserved O
enzymatic O
site O
and O
presents O
an O
appealing O
target O
for O
priming O
broadly O
effective O
antibody O
responses O
. O

Here O
we O
show O
that O
vaccination O
with O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
a O
promising O
live O
viral O
vector O
expressing O
NA O
from O
avian O
( O
H5N1 O
) O
or O
pandemic O
( O
H1N1 O
) O
influenza O
virus O
, O
elicited O
NA O
- O
specific O
antibody O
and O
T O
cell O
responses O
, O
which O
conferred O
protection O
against O
homologous O
and O
heterologous O
influenza O
virus O
challenges O
. O

Vaccination O
with O
PIV5 O
- O
N1 O
NA O
provided O
cross O
- O
protection O
against O
challenge O
with O
a O
heterosubtypic O
( O
H3N2 O
) O
virus O
. O

Currently O
licensed O
influenza O
virus O
vaccines O
rely O
on O
the O
antigenic O
match O
of O
Hemagglutinin B
( I
HA I
) I
for O
vaccine O
strain O
selection O
, O
and O
most O
vaccines O
rely O
on O
HA O
inhibition O
titers O
to O
determine O
efficacy O
, O
despite O
the O
growing O
awareness O
of O
the O
contribution O
of O
neuraminidase B
( I
NA I
) I
to O
influenza O
virus O
vaccine O
efficacy O
. O

Although O
NA O
is O
immunologically O
subdominant O
to O
HA O
, O
and O
clinical O
studies O
have O
shown O
variable O
NA O
responses O
to O
vaccination O
, O
in O
this O
study O
, O
we O
show O
that O
vaccination O
with O
a O
parainfluenza O
virus O
5 O
recombinant O
vaccine O
candidate O
expressing O
NA O
( O
PIV5 O
- O
NA O
) O
from O
a O
pandemic O
influenza O
( O
pdmH1N1 O
) O
virus O
or O
highly O
pathogenic O
avian O
influenza O
( O
H5N1 O
) O
virus O
elicits O
robust O
, O
cross O
- O
reactive O
protection O
from O
influenza O
virus O
infection O
in O
two O
animal O
models O
. O

The O
cocirculation O
of O
zoonotic O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
of O
subtype O
H5N1 O
and O
Avian B
influenza I
virus I
( I
AIV I
) I
of O
subtype O
H9N2 O
among O
poultry O
in O
Egypt O
for O
at O
least O
6 O
years O
should O
render O
that O
country O
a O
hypothetical O
hot O
spot O
for O
the O
emergence O
of O
reassortant O
, O
phenotypically O
altered O
viruses O
, O
yet O
no O
reassortants O
have O
been O
detected O
in O
Egypt O
. O

4 O
H5 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
. O

7 O
log O
( O
10 O
) O
) O
support O
direct O
introduction O
and O
infection O
of O
these O
species O
as O
observed O
in O
mixed O
backyard O
poultry O
during O
the O
early O
outbreaks O
. O

4 O
H5 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
that O
occurred O
in O
the O
United O
States O
in O
2014 O
and O
2015 O
represents O
the O
worst O
livestock O
disease O
event O
in O
the O
country O
, O
with O
unprecedented O
socioeconomic O
and O
commercial O
consequences O
. O

canine B
influenza I
viruses I
( I
CIVs I
) I
are O
the O
causative O
agents O
of O
canine O
influenza O
, O
a O
contagious O
respiratory O
disease O
in O
dogs O
, O
and O
include O
the O
equine O
- O
origin O
H3N8 O
and O
the O
avian O
- O
origin O
H3N2 O
viruses O
. O

influenza B
A I
virus I
( I
IAV I
) I
nonstructural I
protein I
1 I
( I
NS1 I
) I
is O
a O
virulence O
factor O
essential O
for O
counteracting O
the O
innate O
immune O
response O
. O

We O
found O
that O
H3N8 O
CIV O
NS1 O
was O
able O
to O
efficiently O
counteract O
interferon B
( I
IFN I
) I
responses O
but O
was O
unable O
to O
block O
general O
gene O
expression O
in O
human O
or O
canine O
cells O
. O

Such O
ability O
was O
restored O
by O
a O
single O
amino O
acid O
substitution O
in O
position O
186 O
( O
K186E O
) O
that O
resulted O
in O
NS1 O
binding O
to O
the O
30 O
- O
kDa O
subunit O
of O
the O
cleavage B
and I
polyadenylation I
specificity I
factor I
( I
CPSF30 I
) I
, O
a O
cellular O
protein O
involved O
in O
pre O
- O
mRNA O
processing O
. O

We O
also O
examined O
the O
frequency O
distribution O
of O
K186 O
and O
E186 O
among O
H3N8 O
CIVs O
and O
equine B
influenza I
viruses I
( I
ElVs I
) I
, O
the O
ancestors O
of O
H3N8 O
CIV O
, O
and O
experimentally O
determined O
the O
impact O
of O
amino O
acid O
186 O
in O
the O
ability O
of O
different O
CIV O
and O
EIV O
NS1s O
to O
inhibit O
general O
gene O
expression O
. O

The O
H3N8 O
CIV O
NS1 O
did O
not O
block O
host O
gene O
expression O
, O
but O
this O
activity O
was O
restored O
by O
a O
single O
amino O
acid O
substitution O
( O
K186E O
) O
, O
which O
was O
responsible O
for O
NS1 O
binding O
to O
the O
host O
factor O
CPSF30 O
. O

Two O
subtypes O
of O
influenza B
A I
virus I
( I
IAV I
) I
, O
avian O
- O
origin O
canine B
influenza I
virus I
( I
CIV I
) I
H3N2 O
( O
CIV O
- O
H3N2 O
) O
and O
equine O
- O
origin O
CIV O
H3N8 O
( O
CIV O
- O
H3N8 O
) O
, O
are O
enzootic O
in O
the O
canine O
population O
. O

Dogs O
have O
been O
demonstrated O
to O
seroconvert O
in O
response O
to O
diverse O
IAVs O
, O
and O
naturally O
occurring O
reassortants O
of O
CIV O
- O
H3N2 O
and O
the O
2009 O
H1N1 O
pandemic O
virus O
( O
pdmH1N1 O
) O
have O
been O
isolated O
. O

We O
assessed O
the O
public O
health O
risk O
of O
CIV O
- O
H3N2 O
x O
pandemic O
H1N1 O
( O
pdmH1N1 O
) O
reassortants O
by O
characterizing O
their O
in O
vitro O
genetic O
compatibility O
and O
in O
vivo O
pathogenicity O
and O
transmissibility O
. O

Using O
a O
luciferase O
minigenome O
assay O
, O
we O
quantified O
the O
polymerase O
activity O
of O
all O
possible O
16 O
ribonucleoprotein B
( I
RNP I
) I
complexes O
( O
PB2 O
, O
PB1 O
, O
PA O
, O
NP O
) O
between O
CIV O
- O
H3N2 O
and O
pdmH1N1 O
, O
identifying O
some O
combinations O
that O
were O
more O
active O
than O
either O
parental O
virus O
complex O
. O

Using O
reverse O
genetics O
and O
fixing O
the O
CIV O
- O
H3N2 O
Hemagglutinin B
( I
HA I
) I
, O
we O
found O
that O
51 O
of O
the O
127 O
possible O
reassortant O
viruses O
were O
viable O
and O
able O
to O
be O
rescued O
. O

Avian O
influenza O
viruses O
of O
the O
H7 O
Hemagglutinin B
( I
HA I
) I
subtype O
present O
a O
significant O
public O
health O
threat O
, O
as O
evidenced O
by O
the O
ongoing O
outbreak O
of O
human O
A O
( O
H7N9 O
) O
infections O
in O
China O
. O

When O
evaluated O
by O
hemagglutination B
inhibition I
( I
HI I
) I
and O
microneutralization B
( I
MN I
) I
assays O
, O
H7 O
viruses O
and O
vaccines O
are O
found O
to O
induce O
lower O
level O
of O
neutralizing B
antibodies I
( I
NAb I
) I
than O
do O
their O
seasonal O
counterparts O
, O
making O
it O
difficult O
to O
develop O
and O
evaluate O
prepandemic O
vaccines O
. O

In O
this O
study O
, O
we O
immunized O
mice O
with O
whole O
inactivated O
reverse O
genetics O
reassortant O
( O
RG O
) O
viruses O
expressing O
HA O
and O
neuraminidase B
( I
NA I
) I
from O
3 O
different O
H7 O
viruses O
[ O
A O
/ O
Shanghai O
/ O
2 O
/ O
2013 O
( O
H7N9 O
) O
, O
A O
/ O
Netherlands O
/ O
219 O
/ O
2003 O
( O
H7N7 O
) O
, O
and O
A O
/ O
New O
York O
/ O
107 O
/ O
2003 O
( O
H7N2 O
) O
] O
or O
with O
human O
A O
( O
H1N1 O
) O
pdm09 O
( O
A O
/ O
California O
/ O
07 O
/ O
2009 O
- O
like O
) O
or O
A O
( O
H3N2 O
) O
( O
A O
/ O
Perth16 O
/ O
2009 O
) O
viruses O
. O

Mice O
produced O
equivalent O
titers O
of O
antibodies O
to O
all O
viruses O
as O
measured O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

For O
seasonal O
influenza O
viruses O
, O
protection O
is O
correlated O
with O
antibody O
titers O
measured O
by O
hemagglutination B
inhibition I
( I
HI I
) I
and O
virus O
microneutralization B
( I
MN I
) I
assays O
. O

We O
show O
that O
in O
mice O
H7 O
whole B
inactivated I
virus I
vaccines I
( I
WIVs I
) I
were O
as O
immunogenic O
as O
seasonal O
WIVs O
, O
as O
they O
induced O
similar O
levels O
of O
overall O
serum O
antibodies O
. O

By O
combining O
data O
on O
weight O
loss O
, O
viral O
replication O
, O
and O
the O
cross O
- O
reactive O
antibody O
response O
, O
we O
identified O
A O
/ O
mallard O
/ O
Portugal O
/ O
79906 O
/ O
2009 O
( O
H10N7 O
) O
as O
a O
suitable O
virus O
for O
vaccine O
development O
. O

Infection O
caused O
mild O
to O
moderate O
weight O
loss O
( O
5 O
to O
15 O
% O
) O
, O
with O
robust O
viral O
replication O
in O
the O
nasal O
tissues O
and O
variable O
replication O
in O
the O
lung O
. O

By O
evaluating O
the O
cross O
- O
reactive O
antibody O
response O
to O
the O
H10 O
viruses O
and O
combining O
this O
analysis O
with O
viral O
replication O
and O
weight O
loss O
findings O
, O
we O
identified O
A O
/ O
mallard O
/ O
Portugal O
/ O
79906 O
/ O
2009 O
( O
H10N7 O
) O
as O
a O
suitable O
H10 O
vaccine O
strain O
. O

In O
December O
2016 O
, O
a O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
A O
( O
H7N2 O
) O
virus O
was O
identified O
to O
be O
the O
causative O
source O
of O
an O
outbreak O
in O
a O
cat O
shelter O
in O
New O
York O
City O
, O
which O
subsequently O
spread O
to O
multiple O
shelters O
in O
the O
states O
of O
New O
York O
and O
Pennsylvania O
. O

The O
virus O
isolated O
from O
the O
human O
case O
, O
A O
/ O
New O
York O
/ O
108 O
/ O
2016 O
( O
NY O
/ O
108 O
) O
, O
caused O
mild O
and O
transient O
illness O
in O
ferrets O
and O
mice O
but O
did O
not O
transmit O
to O
naive O
cohoused O
ferrets O
following O
traditional O
or O
aerosol O
- O
based O
inoculation O
methods O
. O

We O
have O
developed O
pandemic B
live I
attenuated I
influenza I
vaccines I
( I
pLAIVs I
) I
against O
clade O
1 O
H5N1 O
viruses O
on O
an O
Ann O
Arbor O
cold B
- I
adapted I
( I
ca I
) I
backbone O
that O
induced O
long O
- O
term O
immune O
memory O
. O

1 O
) O
of O
goose B
/ I
Guangdong I
( I
gs I
/ I
GD I
) I
lineage O
H5N1 O
viruses O
were O
reported O
in O
Egypt O
, O
which O
prompted O
updating O
of O
the O
H5N1 O
pLAIV O
. O

The O
first O
approach O
was O
to O
modify O
the O
hemagglutinin O
gene O
of O
a O
highly O
pathogenic O
wild B
- I
type I
( I
WT I
) I
clade O
2 O
. O

1 O
virus O
, O
A O
/ O
Egypt O
/ O
N03434 O
/ O
2009 O
( O
Egy O
/ O
09 O
) O
( O
H5N1 O
) O
, O
with O
its O
unmodified O
neuraminidase B
( I
NA I
) I
gene O
; O
this O
virus O
was O
designated O
Egy O
/ O
09 O
ca O
. O

We O
selected O
the O
low O
- O
pathogenicity O
A O
/ O
duck O
/ O
Hokkaido O
/ O
69 O
/ O
2000 O
( O
H5N3 O
) O
( O
dk O
/ O
Hok O
/ O
00 O
) O
virus O
for O
this O
purpose O
. O

A O
similar O
defect O
in O
intronless O
Hemagglutinin B
( I
HA I
) I
mRNA O
nuclear O
export O
was O
seen O
with O
an O
NS1 O
mutant O
virus O
. O

Poultry O
vaccination O
against O
H9N2 O
viruses O
has O
been O
employed O
in O
many O
regions O
; O
however O
, O
vaccine O
effectiveness O
is O
frequently O
compromised O
due O
to O
antigenic O
drift O
arising O
from O
amino O
acid O
substitutions O
in O
the O
major O
influenza O
virus O
antigen O
Hemagglutinin B
( I
HA I
) I
. O

Using O
selection O
with O
HA O
- O
specific O
monoclonal O
antibodies O
, O
we O
previously O
identified O
H9N2 O
antibody O
escape O
mutants O
that O
contained O
deletions O
of O
amino O
acids O
in O
the O
220 O
loop O
of O
the O
HA O
receptor B
binding I
sites I
( I
RBSs I
) I
. O

H5N6 O
Avian B
influenza I
virus I
( I
AIV I
) I
has O
posed O
a O
potential O
threat O
to O
public O
health O
since O
its O
emergence O
in O
China O
in O
2013 O
. O

To O
understand O
the O
evolution O
and O
emergence O
of O
H5N6 O
AIV O
in O
the O
avian O
population O
, O
we O
performed O
molecular O
surveillance O
of O
live B
poultry I
markets I
( I
LPMs I
) I
in O
Wugang O
Prefecture O
, O
Hunan O
Province O
, O
in O
central O
China O
, O
during O
2014 O
and O
2015 O
. O

To O
better O
understand O
the O
evolution O
and O
emergence O
of O
H5N6 O
viruses O
, O
we O
surveyed O
live B
poultry I
markets I
( I
LPMs I
) I
in O
Wugang O
Prefecture O
before O
the O
reported O
human O
death O
, O
with O
a O
focus O
on O
revealing O
the O
diversity O
and O
genomic O
origins O
of O
H5N6 O
in O
birds O
during O
2014 O
and O
2015 O
. O

Influenza O
A O
H15 O
viruses O
are O
members O
of O
a O
subgroup O
( O
H7 O
- O
H10 O
- O
H15 O
) O
of O
group O
2 O
hemagglutinin O
IHA O
) O
subtypes O
that O
include O
H7N9 O
and O
H10N8 O
viruses O
that O
were O
isolated O
from O
humans O
during O
2013 O
. O

The O
HAs O
of O
H15 O
viruses O
contain O
an O
insertion O
in O
the O
150 O
- O
loop O
( O
loop O
beginning O
at O
position O
150 O
) O
of O
the O
receptor O
- O
binding O
site O
common O
to O
this O
subgroup O
and O
a O
unique O
insertion O
in O
the O
260 O
- O
loop O
compared O
to O
any O
other O
subtype O
. O

The O
replication O
and O
pathogenicity O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
critically O
depend O
on O
their O
ability O
to O
tolerate O
the O
antiviral O
interferon B
( I
IFN I
) I
response O
. O

To O
determine O
a O
potential O
role O
for O
the O
IAV O
Hemagglutinin B
( I
HA I
) I
in O
viral O
sensitivity O
to O
IFN O
, O
we O
studied O
the O
restriction O
of O
IAV O
infection O
in O
IFN O
- O
beta O
- O
treated O
human O
epithelial O
cells O
by O
using O
2 O
: O
6 O
recombinant O
IAVs O
that O
shared O
six O
gene O
segments O
of O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
virus O
( O
PR8 O
) O
and O
contained O
HAs O
and O
neuraminidases O
of O
representative O
avian O
, O
human O
, O
and O
zoonotic O
H5N1 O
and O
H7N9 O
viruses O
. O

Furthermore O
, O
similar O
effects O
of O
the O
viral O
fusion O
pH O
on O
IFN O
sensitivity O
were O
observed O
in O
experiments O
with O
( O
i O
) O
primary O
human O
type O
II O
alveolar O
epithelial O
cells O
and O
differentiated O
cultures O
of O
human O
airway O
epithelial O
cells O
, O
( O
ii O
) O
nonrecombinant O
zoonotic O
and O
pandemic O
IAVs O
, O
and O
( O
iii O
) O
preparations O
of O
IFN O
- O
alpha O
and O
IFN O
- O
lambda O
1 O
. O

In O
vivo O
immunization O
with O
representatives O
of O
each O
group O
revealed O
that O
while O
groupspecific O
cross O
- O
reactivity O
was O
induced O
, O
cross O
- O
reactive O
hemagglutination B
inhibition I
( I
HI I
) I
titers O
were O
approximately O
4 O
- O
fold O
lower O
against O
heterologous O
group O
viruses O
than O
against O
homologous O
group O
viruses O
. O

Moreover O
, O
the O
group O
I O
( O
RgW109 O
/ O
06 O
) O
vaccine O
protected O
100 O
% O
of O
immunized O
mice O
from O
various O
group O
I O
viruses O
, O
while O
only O
20 O
to O
40 O
% O
of O
immunized O
mice O
survived O
lethal O
challenge O
with O
heterologous O
group O
II O
viruses O
and O
exhibited O
high O
viral O
titers O
in O
the O
lung O
. O

Moreover O
, O
while O
the O
group O
II O
( O
RgW478 O
/ O
14 O
) O
vaccine O
also O
protected O
mice O
from O
lethal O
challenge O
with O
group O
II O
viruses O
, O
it O
failed O
to O
elicit O
cross O
- O
protection O
against O
group O
I O
viruses O
. O

Due O
to O
the O
increasing O
concerns O
regarding O
the O
global O
public O
health O
risk O
posed O
by O
H7 O
viruses O
, O
we O
evaluated O
the O
genetic O
relationships O
between O
Eurasian O
H7 O
avian O
influenza O
viruses O
and O
the O
cross O
- O
protective O
efficacies O
of O
three O
different O
H7 O
viruses O
: O
W109 O
/ O
06 O
( O
group O
I O
) O
, O
W478 O
/ O
14 O
( O
group O
II O
) O
, O
and O
Anhui1 O
/ O
13 O
( O
a O
sublineage O
of O
group O
I O
) O
. O

The O
emergence O
of O
the O
novel O
influenza B
A I
virus I
( I
IAV I
) I
H7N9 O
since O
2013 O
has O
caused O
concerns O
about O
the O
ability O
of O
the O
virus O
to O
spread O
between O
humans O
. O

Analysis O
of O
the O
receptor O
- O
binding O
properties O
of O
the O
H7 O
protein O
of O
a O
human O
isolate O
revealed O
modestly O
increased O
binding O
to O
alpha O
2 O
, O
6 O
sialosides O
and O
reduced O
, O
but O
still O
dominant O
, O
binding O
to O
alpha O
2 O
, O
3 O
- O
linked O
sialic B
acids I
( I
SIAs I
) I
compared O
to O
a O
closely O
related O
avian O
H7N9 O
virus O
from O
2008 O
. O

Here O
, O
we O
show O
that O
the O
corresponding O
N9 O
neuraminidases B
( I
NAs I
) I
display O
equal O
enzymatic O
activities O
on O
a O
soluble O
monovalent O
substrate O
and O
similar O
substrate O
specificities O
on O
a O
glycan O
array O
. O

Our O
phylogenetic O
analyses O
show O
that O
substitution O
T401A O
occurred O
prior O
to O
substitutions O
in O
Hemagglutinin B
( I
HA I
) I
, O
causing O
the O
altered O
receptor O
- O
binding O
properties O
mentioned O
above O
. O

Introductions O
of O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
viruses O
of O
subtypes O
H5 O
and O
H7 O
into O
poultry O
from O
wild O
birds O
have O
the O
potential O
to O
mutate O
to O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
, O
but O
such O
viruses O
' O
origins O
are O
often O
unclear O
. O

To O
determine O
the O
virus O
' O
s O
origin O
, O
we O
sequenced O
the O
genomes O
of O
441 O
wild O
- O
bird O
origin O
influenza B
A I
viruses I
( I
IAVs I
) I
from O
North O
America O
and O
subjected O
them O
to O
evolutionary O
analyses O
. O

Preceding O
the O
outbreak O
, O
an O
isolate O
with O
six O
gene O
segments O
( O
PB2 O
, O
PB1 O
, O
PA O
, O
HA O
, O
NA O
, O
and O
NS O
) O
sharing O
> O
99 O
% O
sequence O
identity O
with O
those O
of O
H7N8 O
turkey O
isolates O
was O
recovered O
from O
a O
diving O
duck O
sampled O
in O
Kentucky O
, O
USA O
. O

H4N8 O
IAVs O
from O
other O
diving O
ducks O
possessed O
five O
H7N8 O
- O
like O
gene O
segments O
( O
PB2 O
, O
PB1 O
, O
NA O
, O
MP O
, O
and O
NS O
; O
> O
98 O
% O
sequence O
identity O
) O
. O

One O
of O
the O
key O
features O
of O
the O
G57 O
genotype O
is O
the O
replacement O
of O
the O
earlier O
A O
/ O
chicken O
/ O
Beijing O
/ O
1 O
/ O
1994 O
( O
BJ O
/ O
94 O
) O
- O
like O
M O
gene O
with O
the O
A O
/ O
quail O
/ O
Hong O
Kong O
/ O
G1 O
/ O
1997 O
( O
G1 O
) O
- O
like O
M O
gene O
of O
quail O
origin O
. O

H9N2 O
virus O
housing O
the O
G1 O
- O
like O
M O
gene O
, O
in O
place O
of O
the O
BJ O
/ O
94 O
- O
like O
M O
gene O
, O
showed O
an O
early O
surge O
in O
viral O
mRNA O
and O
viral B
RNA I
( I
vRNA I
) I
transcription O
that O
was O
associated O
with O
enhanced O
viral O
protein O
production O
and O
with O
an O
early O
elevated O
release O
of O
progeny O
virus O
comprising O
largely O
spherical O
rather O
than O
filamentous O
virions O
. O

Five O
highly O
represented O
signature O
amino O
acid O
residues O
( O
37A O
, O
95K O
, O
224N O
, O
and O
242N O
in O
the O
M1 O
protein O
and O
21G O
in O
the O
M2 O
protein O
) O
encoded O
by O
the O
prevalent O
G1 O
- O
like O
M O
gene O
were O
demonstrated O
to O
be O
prime O
contributors O
to O
enhanced O
infectivity O
. O

IMPORTANCE O
We O
recently O
described O
the O
circulation O
of O
a O
dominant O
genotype O
( O
genotype O
G57 O
) O
of O
H9N2 O
viruses O
in O
countrywide O
outbreaks O
in O
chickens O
in O
China O
, O
which O
was O
responsible O
, O
through O
reassortment O
, O
for O
the O
emergence O
of O
H7N9 O
viruses O
that O
cause O
severe O
human O
infections O
. O

Using O
precisioncut O
slices O
from O
the O
porcine O
lung O
to O
passage O
the O
parental O
virus O
, O
isolates O
from O
each O
of O
the O
three O
passages O
( O
P1 O
to O
P3 O
) O
were O
characterized O
by O
assessing O
growth O
curves O
and O
ciliostatic O
effects O
. O

The O
HA212 O
mutant O
alone O
differed O
only O
slightly O
from O
the O
parental O
virus O
; O
however O
, O
the O
combination O
of O
both O
mutations O
( O
HA190 O
+ O
HA212 O
) O
increased O
the O
binding O
affinity O
to O
those O
glycans O
recognized O
by O
the O
HA190 O
mutant O
. O

Avian O
influenza B
A I
viruses I
( I
IAV I
) I
of O
the O
H9N2 O
subtype O
have O
successfully O
infected O
hosts O
from O
different O
species O
but O
have O
not O
established O
a O
stable O
lineage O
. O

The O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
continue O
to O
circulate O
in O
nature O
and O
threaten O
public O
health O
. O

By O
using O
reverse O
genetics O
, O
we O
found O
that O
a O
single O
amino O
acid O
at O
position O
158 O
of O
the O
Hemagglutinin B
( I
HA I
) I
protein O
substantially O
affected O
the O
systemic O
replication O
and O
pathogenicity O
of O
these O
H5N1 O
influenza O
viruses O
in O
mice O
. O

IMPORTANCE O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
continue O
to O
evolve O
in O
nature O
and O
threaten O
human O
health O
. O

Key O
mutations O
in O
the O
virus O
Hemagglutinin B
( I
HA I
) I
protein O
or O
reassortment O
with O
other O
pandemic O
viruses O
endow O
HPAI O
H5N1 O
viruses O
with O
the O
potential O
for O
aerosol O
transmissibility O
in O
mammals O
. O

In O
order O
to O
produce O
a O
dually O
effective O
vaccine O
against O
H9 O
and O
H5 O
avian O
influenza O
viruses O
that O
aligns O
with O
the O
DIVA O
( O
differentiating O
infected O
from O
vaccinated O
animals O
) O
strategy O
, O
we O
generated O
a O
chimeric O
H9 O
/ O
H5N2 O
recombinant O
vaccine O
that O
expressed O
the O
whole O
HA1 O
region O
of O
A O
/ O
CK O
/ O
Korea O
/ O
04163 O
/ O
04 O
( O
H9N2 O
) O
and O
the O
HA2 O
region O
of O
recent O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
/ O
MD O
/ O
Korea O
/ O
W452 O
/ O
14 O
( O
H5N8 O
) O
viruses O
. O

The O
chimeric O
H9 O
/ O
H5N2 O
virus O
showed O
in O
vitro O
and O
in O
vivo O
growth O
properties O
and O
virulence O
that O
were O
similar O
to O
those O
of O
the O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
H9 O
virus O
. O

An O
inactivated O
vaccine O
based O
on O
this O
chimeric O
virus O
induced O
serum O
neutralizing O
( O
SN O
) O
antibodies O
against O
both O
H9 O
and O
H5 O
viruses O
but O
induced O
cross O
- O
reactive O
hemagglutination B
inhibition I
( I
HI I
) I
antibody O
only O
against O
H9 O
viruses O
. O

Furthermore O
, O
each O
HA1 O
- O
and O
HA2 O
stalk O
- O
specific O
antibody O
response O
was O
sufficient O
to O
inhibit O
viral O
replication O
and O
protect O
the O
chimeric O
virusimmunized O
mice O
from O
lethal O
challenge O
with O
both O
mouse O
- O
adapted O
H9N2 O
and O
wild O
- O
type O
HPAI O
H5N1 O
viruses O
, O
although O
differences O
in O
vaccine O
efficacy O
against O
a O
homologous O
H9 O
virus O
( O
HA1 O
head O
domain O
immune O
- O
mediated O
protection O
) O
and O
a O
heterosubtypic O
H5 O
virus O
( O
HA2 O
stalk O
domain O
immune O
- O
mediated O
protection O
) O
were O
observed O
. O

IMPORTANCE O
Current O
influenza O
virus O
killed O
vaccines O
predominantly O
induce O
antihemagglutinin O
( O
anti O
- O
HA O
) O
antibodies O
that O
are O
commonly O
strain O
specific O
in O
that O
the O
antibodies O
have O
potent O
neutralizing O
activity O
against O
homologous O
strains O
but O
do O
not O
crossreact O
with O
HAs O
of O
other O
influenza O
virus O
subtypes O
. O

Whole O
- O
genome O
sequences O
of O
representative O
highly O
pathogenic O
avian O
influenza O
A O
( O
H5 O
) O
viruses O
from O
Vietnam O
were O
generated O
, O
comprising O
samples O
from O
poultry O
outbreaks O
and O
active O
market O
surveillance O
collected O
from O
January O
2012 O
to O
August O
2015 O
. O

4 O
viruses O
( O
H5N1 O
and O
H5N6 O
) O
were O
likely O
introduced O
in O
April O
2014 O
and O
appeared O
to O
gain O
dominance O
across O
northern O
and O
central O
regions O
. O

4 O
candidate B
vaccine I
viruses I
( I
CVV I
) I
indicated O
the O
need O
for O
an O
updated O
vaccine O
virus O
. O

A O
/ O
Sichuan O
/ O
26221 O
/ O
2014 O
( O
H5N6 O
) O
virus O
was O
developed O
, O
and O
ferret O
antisera O
generated O
against O
this O
virus O
were O
demonstrated O
to O
inhibit O
some O
but O
not O
all O
clade O
2 O
. O

IMPORTANCE O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
( O
H5 O
) O
viruses O
have O
circulated O
continuously O
in O
Vietnam O
since O
2003 O
, O
resulting O
in O
hundreds O
of O
poultry O
outbreaks O
and O
sporadic O
human O
infections O
. O

Given O
the O
overlapping O
geographic O
distributions O
of O
multiple O
, O
antigenically O
distinct O
clades O
of O
HPAI O
A O
( O
H5 O
) O
viruses O
in O
Vietnam O
, O
the O
vaccine O
efficacy O
of O
bivalent O
poultry O
vaccine O
formulations O
should O
be O
tested O
in O
the O
future O
. O

4 O
highly O
pathogenic O
avian O
influenza O
viruses O
( O
H5Nx O
) O
have O
spread O
from O
Asia O
to O
other O
parts O
of O
the O
world O
. O

Three O
major O
reassortant O
H5N6 O
viruses O
( O
reassortants O
A O
, O
B O
, O
and O
C O
) O
were O
generated O
. O

4 O
highly O
pathogenic O
avian O
influenza O
( O
H5Nx O
) O
viruses O
have O
caused O
many O
outbreaks O
in O
both O
wild O
and O
domestic O
birds O
globally O
. O

Canine O
influenza O
is O
a O
respiratory O
disease O
of O
dogs O
caused O
by O
canine B
influenza I
virus I
( I
CIV I
) I
. O

Currently O
, O
only O
inactivated B
influenza I
vaccines I
( I
IIVs I
) I
are O
available O
for O
the O
prevention O
of O
CIV O
in O
dogs O
. O

Using O
reverse O
genetics O
techniques O
, O
we O
have O
developed O
a O
live B
- I
attenuated I
CIV I
vaccine I
( I
LACIV I
) I
for O
the O
prevention O
of O
H3N8 O
CIV O
. O

IMPORTANCE O
Two O
influenza O
A O
virus O
subtypes O
has O
been O
reported O
in O
dogs O
in O
the O
last O
16 O
years O
: O
the O
canine B
influenza I
viruses I
( I
CIV I
) I
H3N8 O
and O
H3N2 O
of O
equine O
and O
avian O
origins O
, O
respectively O
. O

To O
date O
, O
only O
inactivated B
influenza I
vaccines I
( I
IIVs I
) I
are O
available O
to O
prevent O
CIV O
infections O
. O

Here O
, O
we O
report O
the O
generation O
of O
a O
recombinant O
, O
temperature O
- O
sensitive O
H3N8 O
CIV O
as O
a O
live B
- I
attenuated I
influenza I
vaccine I
( I
LAIV I
) I
, O
which O
was O
attenuated O
in O
mice O
and O
dog O
tracheal O
, O
explants O
compared O
to O
CIV O
H3N8 O
wild O
type O
. O

Despite O
this O
, O
the O
disease O
- O
causing O
potential O
of O
the O
precursor O
low B
- I
pathogenic I
( I
LP I
) I
H7 O
viruses O
from O
the O
wild O
bird O
reservoir O
has O
not O
been O
investigated O
. O

Without O
prior O
mammalian O
adaptation O
, O
the O
majority O
of O
viruses O
, O
27 O
( O
90 O
% O
) O
, O
caused O
mortality O
in O
mice O
. O

7 O
% O
) O
caused O
100 O
% O
mortality O
and O
24 O
were O
of O
pathogenicity O
similar O
to O
that O
of O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
, O
which O
is O
highly O
pathogenic O
in O
mice O
. O

IMPORTANCE O
low B
- I
pathogenic I
( I
LP I
) I
avian O
H7 O
influenza O
A O
viruses O
are O
widely O
distributed O
in O
the O
avian O
reservoir O
and O
are O
the O
precursors O
of O
numerous O
outbreaks O
of O
highly O
pathogenic O
avian O
influenza O
viruses O
in O
commercial O
poultry O
farms O
. O

Head O
- O
to O
- O
head O
comparisons O
of O
conventional O
influenza O
vaccines O
with O
adenovirus B
( I
Ad I
) I
gene O
- O
based O
vaccines O
demonstrated O
that O
these O
viral O
vectors O
can O
mediate O
more O
potent O
protection O
against O
influenza O
virus O
infection O
in O
animal O
models O
. O

In O
most O
cases O
, O
Ad O
vaccines O
are O
engineered O
to O
be O
replication B
- I
defective I
( I
RD I
- I
Ad I
) I
vectors O
. O

In O
contrast O
, O
replication B
- I
competent I
Ad I
( I
RC I
- I
Ad I
) I
vaccines O
are O
markedly O
more O
potent O
but O
risk O
causing O
adenovirus O
diseases O
in O
vaccine O
recipients O
and O
health O
care O
workers O
. O

To O
harness O
antigen O
gene O
replication O
but O
avoid O
production O
of O
infectious O
virions O
, O
we O
developed O
single B
- I
cycle I
adenovirus I
( I
SC I
- I
Ad I
) I
vectors O
. O

To O
test O
them O
as O
potential O
vaccines O
, O
we O
engineered O
RD O
and O
SC O
versions O
of O
adenovirus O
serotype O
6 O
( O
Ad6 O
) O
to O
express O
the O
Hemagglutinin B
( I
HA I
) I
gene O
from O
influenza O
A O
/ O
PR O
/ O
8 O
/ O
34 O
virus O
. O

SC O
- O
Ad O
produced O
markedly O
higher O
HA O
binding O
and O
hemagglutination B
inhibition I
( I
HAI I
) I
titers O
than O
RD O
- O
Ad O
in O
Syrian O
hamsters O
. O

IMPORTANCE O
Most O
adenovirus O
vaccines O
that O
are O
being O
tested O
are O
replication B
- I
defective I
adenoviruses I
( I
RD I
- I
Ads I
) I
. O

This O
work O
describes O
testing O
newer O
single B
- I
cycle I
adenovirus I
( I
SC I
- I
Ad I
) I
vectors O
that O
replicate O
transgenes O
to O
amplify O
protein O
production O
and O
immune O
responses O
. O

Introduced O
in O
2010 O
, O
microminipigs O
weigh O
around O
10 O
kg O
at O
an O
early O
stage O
of O
maturity O
( O
6 O
to O
7 O
months O
old O
) O
and O
are O
easy O
to O
handle O
. O

To O
evaluate O
the O
microminipig O
as O
an O
animal O
model O
for O
influenza O
A O
virus O
infection O
, O
we O
compared O
the O
receptor O
distribution O
of O
10 O
- O
week O
- O
old O
male O
pigs O
( O
Yorkshire O
Large O
White O
) O
and O
microminipigs O
. O

The O
first O
block O
is O
during O
viral O
entry O
, O
where O
virions O
with O
relatively O
acid O
- O
stable O
Hemagglutinin B
( I
HA I
) I
proteins O
are O
rendered O
incapable O
of O
pH O
- O
induced O
triggering O
for O
membrane O
fusion O
, O
resulting O
in O
lysosomal O
degradation O
. O

We O
previously O
showed O
that O
only O
a O
subset O
of O
highly B
pathogenic I
avian I
( I
HPAI I
) I
H5N1 O
influenza O
virus O
strains O
could O
productively O
replicate O
in O
murine O
macrophages O
through O
a O
Hemagglutinin B
( I
HA I
) I
- O
mediated O
mechanism O
. O

These O
studies O
expand O
upon O
this O
work O
and O
demonstrate O
that O
productive O
replication O
is O
not O
specific O
to O
unique O
HPAI O
H5N1 O
viruses O
; O
an O
H1N1 O
strain O
( O
A O
/ O
WSN O
/ O
33 O
) O
can O
also O
replicate O
in O
macrophages O
. O

Importantly O
, O
we O
identify O
two O
cellular O
blocks O
limiting O
replication O
that O
can O
be O
overcome O
by O
an O
avian O
- O
like O
pH O
of O
activation O
for O
nuclear O
entry O
and O
a O
yet O
- O
to O
- O
be O
- O
identified O
mechanism O
( O
s O
) O
to O
overcome O
a O
postnuclear O
entry O
block O
. O

We O
found O
that O
a O
subset O
of O
avian O
influenza O
viruses O
, O
including O
potentially O
pandemic O
H5N1 O
, O
H7N9 O
, O
and O
H9N2 O
viruses O
, O
could O
infect O
human B
pulmonary I
endothelial I
cells I
( I
HULEC I
) I
with O
high O
efficiency O
compared O
to O
human O
H1N1 O
or O
H3N2 O
viruses O
. O

IFITM3 O
knockdown O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
could O
partially O
rescue O
H1N1 O
virus O
infection O
in O
HULEC O
, O
suggesting O
IFITM3 O
proteins O
were O
involved O
in O
blocking O
human O
influenza O
virus O
infection O
in O
endothelial O
cells O
. O

Although O
acute B
respiratory I
distress I
syndrome I
( I
ARDS I
) I
and O
progressive O
pulmonary O
endothelial O
damage O
are O
known O
to O
be O
present O
during O
severe O
human O
infections O
, O
the O
role O
of O
pulmonary O
endothelial O
cells O
in O
the O
pathogenesis O
of O
avian O
influenza O
virus O
infections O
is O
largely O
unknown O
. O

We O
show O
that O
human O
influenza O
virus O
infection O
is O
blocked O
during O
the O
early O
stages O
of O
virus O
entry O
, O
which O
is O
likely O
due O
to O
the O
relatively O
high O
expression O
of O
the O
host O
antiviral O
factors O
IFITMs O
( O
interferon O
- O
induced O
transmembrane O
proteins O
) O
located O
in O
membrane O
- O
bound O
compartments O
inside O
cells O
. O

In O
early O
2016 O
, O
the O
presence O
of O
H7N8 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
and O
closely O
related O
H7N8 O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
viruses O
was O
confirmed O
in O
commercial O
turkey O
farms O
in O
Indiana O
. O

An O
H7N8 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
and O
an O
H7N8 O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
virus O
were O
recently O
isolated O
from O
commercial O
turkey O
farms O
in O
Indiana O
. O

Avian B
influenza I
virus I
( I
AIV I
) I
surveillance O
in O
Antarctica O
during O
2013 O
revealed O
the O
prevalence O
of O
evolutionarily O
distinct O
influenza O
viruses O
of O
the O
H11N2 O
subtype O
in O
Adelie O
penguins O
. O

The O
H5N1 O
avian O
influenza O
viruses O
emerged O
in O
Southeast O
Asia O
in O
the O
late O
20th O
century O
and O
have O
evolved O
into O
multiple O
phylogenetic O
clades O
based O
on O
their O
Hemagglutinin B
( I
HA I
) I
- O
encoding O
genes O
. O

Full O
genome O
sequence O
analysis O
revealed O
that O
the O
seven O
viruses O
formed O
two O
subtypes O
( O
four O
H5N1 O
viruses O
and O
three O
H5N2 O
viruses O
) O
and O
four O
genotypes O
by O
deriving O
genes O
from O
other O
influenza O
viruses O
. O

The O
four O
viruses O
exclusively O
bound O
to O
avian O
- O
type O
receptors O
and O
replicated O
only O
in O
the O
turbinates O
and O
/ O
or O
lungs O
of O
mice O
; O
none O
of O
them O
were O
lethal O
to O
mice O
at O
a O
dosage O
of O
10 O
( O
6 O
) O
50 B
% I
egg I
infective I
doses I
( I
EID50 I
) I
. O

H9N2 O
Avian B
influenza I
virus I
( I
AIV I
) I
has O
an O
extended O
host O
range O
, O
but O
the O
molecular O
basis O
underlying O
H9N2 O
AIV O
transmission O
to O
mammals O
remains O
unclear O
. O

These O
isolates O
were O
categorized O
into O
8 O
genotypes O
( O
B64 O
to O
B71 O
) O
and O
formed O
a O
distinct O
antigenic O
subgroup O
. O

Three O
isolates O
belonging O
to O
genotype O
B69 O
, O
which O
is O
a O
predominant O
genotype O
circulating O
in O
China O
, O
replicated O
efficiently O
in O
mice O
, O
while O
the O
viruses O
tested O
in O
parallel O
in O
other O
genotypes O
replicated O
poorly O
, O
although O
they O
, O
like O
the O
three O
B69 O
isolates O
, O
have O
a O
leucine O
at O
position O
226 O
in O
the O
Hemagglutinin B
( I
HA I
) I
receptor O
binding O
site O
, O
which O
is O
critical O
for O
binding O
human O
type O
sialic O
acid O
receptors O
. O

Further O
molecular O
and O
single O
mutation O
analysis O
revealed O
that O
a O
Valine B
( I
V I
) I
residue O
at O
position O
190 O
in O
HA O
is O
responsible O
for O
efficient O
replication O
of O
these O
H9N2 O
viruses O
in O
mice O
. O

Wild O
aquatic O
birds O
have O
been O
associated O
with O
the O
intercontinental O
spread O
of O
H5 O
subtype O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
of O
the O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
Gs O
/ O
GD O
) O
lineage O
during O
2005 O
, O
2010 O
, O
and O
2014 O
, O
but O
dispersion O
by O
wild O
waterfowl O
has O
not O
been O
implicated O
with O
spread O
of O
other O
HPAI O
viruses O
. O

Infections O
with O
H7 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
remain O
a O
major O
public O
health O
concern O
. O

Here O
we O
used O
whole O
- O
genome O
gene B
fragment I
phage I
display I
libraries I
( I
GFPDLs I
) I
expressing O
peptides O
of O
15 O
to O
350 O
amino O
acids O
across O
the O
complete O
genome O
of O
the O
HPAI O
H7N7 O
A O
/ O
Netherlands O
/ O
33 O
/ O
03 O
virus O
. O

The O
Hemagglutinin B
( I
HA I
) I
antibody O
epitope O
repertoires O
of O
15 O
H7N7 O
- O
exposed O
humans O
identified O
clear O
differences O
between O
individuals O
with O
no O
hemagglutination B
inhibition I
( I
HI I
) I
titers O
( O
< O
1 O
: O
10 O
) O
and O
those O
with O
HI O
titers O
of O
> O
1 O
: O
40 O
. O

Several O
potentially O
protective O
H7N7 O
epitopes O
close O
to O
the O
HA O
receptor B
binding I
domain I
( I
RBD I
) I
and O
neuraminidase B
( I
NA I
) I
catalytic O
site O
were O
identified O
. O

surface B
plasmon I
resonance I
( I
SPR I
) I
analysis O
identified O
a O
strong O
correlation O
between O
HA1 O
( O
but O
not O
HA2 O
) O
binding O
antibodies O
and O
H7N7 O
HI O
titers O
. O

In O
this O
study O
, O
we O
investigated O
convalescent O
- O
phase O
sera O
from O
H7N7 O
- O
exposed O
individuals O
by O
using O
a O
whole O
- O
genome O
phage O
display O
library O
( O
H7N7 O
- O
GFPDL O
) O
to O
explore O
the O
complete O
repertoire O
of O
post O
- O
H7N7exposure O
antibodies O
. O

We O
identified O
strong O
antibody O
reactivity O
against O
PA O
- O
X O
in O
most O
H7N7 O
- O
exposed O
individuals O
( O
but O
not O
in O
unexposed O
adults O
) O
, O
providing O
the O
first O
evidence O
for O
in O
vivo O
expression O
of O
PA O
- O
X O
and O
its O
recognition O
by O
the O
immune O
system O
during O
human O
infection O
with O
pathogenic O
H7N7 O
avian O
influenza O
virus O
. O

The O
polymerase B
basic I
2 I
( I
PB2 I
) I
subunit O
of O
the O
RNA O
polymerase O
complex O
of O
seasonal O
human O
influenza O
A O
viruses O
has O
been O
shown O
to O
localize O
to O
the O
mitochondria O
. O

In O
particular O
, O
PB2 O
has O
been O
shown O
to O
inhibit O
interferon O
expression O
by O
associating O
with O
the O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
protein O
, O
which O
acts O
downstream O
of O
RIG O
- O
I O
and O
MDA O
- O
5 O
in O
the O
interferon O
induction O
pathway O
. O

Here O
, O
we O
used O
enhanced O
ascorbate O
peroxidase O
( O
APEX O
) O
- O
tagged O
PB2 O
proteins O
and O
electron O
microscopy O
to O
study O
the O
localization O
of O
PB2 O
in O
mitochondria O
. O

We O
also O
showed O
that O
a O
virus O
encoding O
nonmitochondrial O
PB2 O
is O
attenuated O
in O
mouse B
embryonic I
fibroblasts I
( I
MEFs I
) I
compared O
with O
an O
isogenic O
virus O
encoding O
mitochondrial O
PB2 O
, O
in O
a O
MAVS O
- O
independent O
manner O
, O
suggesting O
a O
role O
for O
PB2 O
within O
the O
mitochondrial O
matrix O
. O

Two O
alleles O
of O
segment O
8 O
( O
NS O
) O
circulate O
in O
nonchiropteran O
influenza O
A O
viruses O
. O

This O
might O
reflect O
the O
fact O
that O
one O
or O
both O
of O
its O
encoded O
proteins O
( O
NS1 O
and O
NEP O
) O
are O
maladapted O
for O
replication O
in O
mammalian O
hosts O
. O

Exemplar O
reassortant O
viruses O
also O
replicated O
to O
similar O
titers O
in O
mice O
, O
although O
mice O
infected O
with O
viruses O
with O
the O
avian O
virus O
- O
derived O
segment O
8s O
had O
reduced O
weight O
loss O
compared O
to O
that O
achieved O
in O
mice O
infected O
with O
the O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
( O
H1N1 O
) O
parent O
. O

IMPORTANCE O
influenza B
A I
virus I
( I
IAV I
) I
can O
adapt O
to O
poultry O
and O
mammalian O
species O
, O
inflicting O
a O
great O
socioeconomic O
burden O
on O
farming O
and O
health O
care O
sectors O
. O

The O
role O
of O
NF O
- O
kappa O
B O
in O
influenza B
A I
virus I
( I
IAV I
) I
infection O
does O
not O
reveal O
a O
coherent O
picture O
, O
as O
pro O
- O
and O
also O
antiviral O
functions O
of O
this O
transcription O
factor O
have O
been O
described O
. O

To O
address O
this O
issue O
, O
we O
used O
clustered B
regularly I
interspaced I
short I
palindromic I
repeat I
with I
Cas9 I
( I
CRISPR I
- I
Cas9 I
) I
- O
mediated O
genome O
engineering O
to O
generate O
murine O
MLE O
- O
15 O
cells O
lacking O
two O
essential O
components O
of O
the O
NF O
- O
kappa O
B O
pathway O
. O

Cells O
devoid O
of O
either O
the O
central B
NF I
- I
kappa I
B I
essential I
modulator I
( I
NEMO I
) I
scaffold O
protein O
and O
thus O
defective O
in O
I B
kappa I
B I
kinase I
( I
IKK I
) I
activation O
or O
cells O
not O
expressing O
the O
NF O
- O
kappa O
B O
DNA O
- O
binding O
and O
transactivation O
subunit O
p65 O
were O
tested O
for O
propagation O
of O
the O
SC35 O
virus O
, O
which O
has O
an O
avian O
host O
range O
, O
and O
its O
mouse O
- O
adapted O
variant O
, O
SC35M O
. O

The O
defect O
in O
NF O
- O
kappa O
B O
signaling O
resulted O
in O
diminished O
IAV O
- O
triggered O
phosphorylation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
expression O
of O
the O
antiviral O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
. O

SC35 O
viruses O
containing O
the O
SC35M O
segment O
encoding O
neuraminidase B
( I
NA I
) I
were O
completely O
inert O
to O
the O
inhibitory O
effect O
of O
NF O
- O
kappa O
B O
, O
emphasizing O
the O
importance O
of O
the O
viral O
genotype O
for O
susceptibility O
to O
the O
antiviral O
functions O
of O
NF O
- O
kappa O
B O
. O

We O
found O
that O
PA B
mutation I
K356R I
( I
PA I
- I
K356R I
) I
has O
become O
predominant O
since O
2014 O
in O
avian O
H9N2 O
viruses O
in O
China O
as O
with O
seasonal O
human O
H1N1 O
viruses O
. O

IMPORTANCE O
Mutations O
of O
the O
polymerase O
complex O
( O
PB1 O
, O
PB2 O
, O
and O
PA O
) O
of O
influenza O
A O
virus O
are O
necessary O
for O
viral O
adaptation O
to O
new O
hosts O
. O

Using O
the O
modified B
vaccinia I
Ankara I
( I
MVA I
) I
virus O
, O
we O
had O
previously O
generated O
a O
recombinant O
vaccine O
against O
highly O
pathogenic O
avian O
influenza O
virus O
( O
H5N1 O
) O
based O
on O
an O
in O
silico O
mosaic O
approach O
. O

We O
have O
now O
further O
characterized O
the O
immune O
responses O
using O
immunodepletion O
of O
T O
cells O
and O
passive O
serum O
transfer O
, O
and O
these O
studies O
indicate O
that O
antibodies O
are O
the O
main O
contributors O
in O
homosubtypic O
protection O
( O
H5N1 O
clades O
) O
. O

Compared O
to O
a O
MVA O
construct O
expressing O
Hemagglutinin B
( I
HA I
) I
from O
influenza O
virus O
A O
/ O
VN O
/ O
1203 O
/ O
04 O
( O
MVA O
- O
HA O
) O
, O
the O
MVA O
- O
H5M O
vaccine O
markedly O
increased O
and O
broadened O
B O
cell O
and O
T O
cell O
responses O
against O
H5N1 O
virus O
. O

In O
addition O
, O
MVA O
- O
H5M O
induced O
CD8 O
( O
+ O
) O
T O
cell O
responses O
that O
play O
a O
major O
role O
in O
heterosubtypic O
protection O
( O
H1N1 O
) O
. O

Influenza O
virus O
Hemagglutinin B
( I
HA I
) I
N O
- O
glycans O
play O
important O
regulatory O
roles O
in O
the O
control O
of O
virus O
virulence O
, O
antigenicity O
, O
receptor O
- O
binding O
specificity O
, O
and O
viral O
escape O
from O
the O
immune O
response O
. O

Considered O
essential O
for O
controlling O
innate O
and O
adaptive O
immune O
responses O
against O
influenza O
virus O
infections O
, O
dendritic B
cells I
( I
DCs I
) I
trigger O
proinflammatory O
and O
adaptive O
immune O
responses O
in O
hosts O
. O

In O
this O
study O
, O
we O
engineered O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cell O
lines O
expressing O
recombinant O
HA O
from O
pandemic O
H1 O
, O
H5 O
, O
and O
H7 O
influenza O
viruses O
. O

rH1HA O
, O
rH5HA O
, O
and O
rH7HA O
were O
obtained O
as O
wild O
- O
type O
proteins O
or O
in O
the O
presence O
of O
kifunensine O
( O
KIF O
) O
or O
further O
with O
endo O
- O
beta O
- O
N O
- O
acetylglucosaminidase O
- O
treated O
KIF O
( O
KIF O
+ O
E O
) O
to O
generate O
single O
- O
N B
- I
acetylglucosamine I
( I
GlcNAc I
) I
N O
- O
glycans O
consisting O
of O
( O
i O
) O
terminally O
sialylated O
complex O
- O
type O
N O
- O
glycans O
, O
( O
ii O
) O
high O
- O
mannose O
- O
type O
N O
- O
glycans O
, O
and O
( O
iii O
) O
single O
- O
GlcNAc O
- O
type O
N O
- O
glycans O
. O

Our O
data O
indicate O
that O
native O
avian O
rHA O
proteins O
( O
H5N1 O
and O
H7N9 O
) O
are O
more O
immunostimulatory O
than O
human O
rHA O
protein O
( O
pH1N1 O
) O
. O

HA O
- O
stimulated O
DC O
activation O
was O
accomplished O
partially O
through O
a O
mannose O
receptor O
( O
s O
) O
. O

The O
emergent O
H5N6 O
viruses O
, O
which O
share O
high O
sequence O
similarity O
with O
the O
human O
isolate O
A O
/ O
Guangzhou O
/ O
39715 O
/ O
2014 O
( O
H5N6 O
) O
, O
were O
fully O
infective O
and O
highly O
transmissible O
by O
direct O
contact O
in O
ferrets O
but O
showed O
less O
- O
severe O
pathogenicity O
than O
the O
parental O
H5N1 O
virus O
. O

Here O
, O
we O
use O
deep O
- O
sequencing O
data O
obtained O
from O
clinical O
samples O
collected O
from O
five O
industrial O
holdings O
and O
a O
backyard O
farm O
infected O
during O
the O
2013 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H7N7 O
epidemic O
in O
Italy O
to O
unravel O
( O
i O
) O
the O
epidemic O
virus O
population O
diversity O
, O
( O
ii O
) O
the O
evolution O
of O
virus O
pathogenicity O
, O
and O
( O
iii O
) O
the O
pathways O
of O
viral O
transmission O
between O
different O
holdings O
and O
sheds O
. O

4 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
A O
( O
H5N8 O
) O
virus O
caused O
poultry O
outbreaks O
around O
the O
world O
. O

In O
late O
2014 O
/ O
early O
2015 O
, O
the O
virus O
was O
detected O
in O
wild O
birds O
in O
Canada O
and O
the O
United O
States O
, O
and O
these O
viruses O
also O
gave O
rise O
to O
reassortant O
progeny O
, O
composed O
of O
viral B
RNA I
segments I
( I
vRNAs I
) I
from O
both O
Eurasian O
and O
North O
American O
lineages O
. O

Due O
to O
enzootic O
infections O
in O
poultry O
and O
persistent O
human O
infections O
in O
China O
, O
influenza O
A O
( O
H7N9 O
) O
virus O
has O
remained O
a O
public O
health O
threat O
. O

In O
spring O
2014 O
, O
increased O
mortality O
of O
harbor O
seals O
( O
Phoca O
vitulina O
) O
, O
associated O
with O
infection O
with O
an O
influenza O
A O
( O
H10N7 O
) O
virus O
, O
was O
reported O
in O
Sweden O
and O
Denmark O
. O

Genetic O
analysis O
of O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
of O
this O
seal O
influenza O
A O
( O
H10N7 O
) O
virus O
revealed O
that O
it O
was O
most O
closely O
related O
to O
various O
avian O
influenza O
A O
( O
H10N7 O
) O
viruses O
. O

Sequence O
data O
for O
samples O
collected O
from O
41 O
different O
seals O
from O
four O
different O
countries O
between O
April O
2014 O
and O
January O
2015 O
were O
obtained O
by O
Sanger O
sequencing O
and O
next O
- O
generation O
sequencing O
to O
describe O
the O
molecular O
epidemiology O
of O
the O
seal O
influenza O
A O
( O
H10N7 O
) O
virus O
. O

Reassortment O
between O
H5 O
or O
H9 O
subtype O
avian O
and O
mammalian O
influenza B
A I
viruses I
( I
IAV I
) I
can O
generate O
a O
novel O
virus O
that O
causes O
disease O
and O
transmits O
between O
mammals O
. O

We O
evaluated O
the O
ability O
of O
a O
low O
- O
pathogenicity O
North O
American O
avian O
H7N3 O
virus O
( O
A O
/ O
shorebird O
/ O
Delaware O
/ O
22 O
/ O
2006 O
) O
to O
reassort O
with O
mammalian O
or O
avian O
viruses O
using O
a O
plasmid O
- O
based O
competition O
assay O
. O

In O
addition O
to O
genome O
segments O
derived O
from O
an O
avian O
H7N9 O
virus O
, O
the O
H7N3 O
virus O
reassorted O
efficiently O
with O
the O
PB2 O
, O
NA O
, O
and O
M O
segments O
from O
the O
2009 O
pandemic O
H1N1 O
( O
( O
P O
) O
H1N1 O
) O
virus O
. O

In O
vitro O
and O
in O
vivo O
evaluation O
of O
the O
H7N3 O
: O
( O
P O
) O
H1N1 O
( O
7 O
+ O
1 O
) O
reassortant O
viruses O
revealed O
that O
the O
PB2 O
, O
NA O
, O
or O
M O
segments O
from O
( O
P O
) O
H1N1 O
largely O
do O
not O
attenuate O
the O
H7N3 O
virus O
, O
whereas O
the O
PB1 O
, O
PA O
, O
NP O
, O
or O
NS O
genome O
segments O
from O
( O
P O
) O
H1N1 O
do O
. O

Additionally O
, O
we O
assessed O
the O
functionality O
of O
the O
H7N3 O
: O
( O
P O
) O
H1N1 O
7 O
+ O
1 O
reassortant O
viruses O
by O
measuring O
the O
inflammatory O
response O
in O
vivo O
. O

We O
found O
that O
infection O
with O
wild O
- O
type O
H7N3 O
resulted O
in O
increased O
inflammatory O
cytokine O
production O
relative O
to O
that O
seen O
with O
the O
( O
P O
) O
H1N1 O
strain O
and O
that O
the O
increase O
was O
further O
exacerbated O
by O
substitution O
of O
( O
P O
) O
H1N1 O
PB2 O
but O
not O
NA O
or O
M O
. O

Finally O
, O
we O
assessed O
if O
any O
adaptations O
occurred O
in O
the O
individually O
substituted O
segments O
after O
in O
vivo O
inoculation O
and O
found O
no O
mutations O
, O
suggesting O
that O
( O
P O
) O
H1N1 O
PB2 O
, O
NA O
, O
and O
M O
are O
genetically O
stable O
in O
the O
background O
of O
this O
H7N3 O
virus O
. O

To O
investigate O
whether O
the O
continuous O
circulation O
and O
adaptation O
of O
these O
viruses O
in O
terrestrial O
poultry O
increased O
their O
infectivity O
to O
pigs O
, O
we O
conducted O
a O
serological O
survey O
in O
pig O
herds O
with O
H9N2 O
viruses O
selected O
from O
the O
aquatic O
avian O
gene O
pool O
( O
Y439 O
lineage O
) O
and O
the O
enzootic O
terrestrial O
poultry O
viruses O
( O
G1 O
and O
Y280 O
lineages O
) O
. O

The O
viral B
ribonucleoprotein I
( I
vRNP I
) I
complex O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
contains O
an O
RNA B
- I
dependent I
RNA I
polymerase I
complex I
( I
RdRp I
) I
and O
nucleoprotein B
( I
NP I
) I
and O
is O
the O
functional O
unit O
for O
viral O
RNA O
transcription O
and O
replication O
. O

In O
our O
study O
, O
we O
identified O
host O
protein O
Moloney O
leukemia O
virus O
10 O
( O
MOV10 O
) O
as O
an O
inhibitor O
of O
IAV O
replication O
, O
since O
depletion O
of O
MOV10 O
resulted O
in O
a O
significant O
increase O
in O
virus O
yield O
. O

Importantly O
, O
as O
an O
interferon B
( I
IFN I
) I
- O
inducible O
protein O
, O
MOV10 O
exerted O
a O
novel O
mechanism O
for O
IFNs O
to O
inhibit O
the O
replication O
of O
influenza O
viruses O
. O

Two O
experimentally O
introduced O
mutations O
in O
the O
viral O
Hemagglutinin B
( I
HA I
) I
receptor O
- O
binding O
domain O
conferred O
binding O
to O
human O
- O
type O
receptors O
but O
reduced O
HA O
stability O
. O

Compensatory O
mutations O
in O
HA O
( O
acquired O
during O
virus O
replication O
in O
ferrets O
) O
were O
essential O
to O
restore O
HA O
stability O
. O

To O
identify O
additional O
stabilizing O
mutations O
in O
an O
H5 O
HA O
, O
we O
subjected O
a O
virus O
library O
possessing O
random O
mutations O
in O
the O
ectodomain O
of O
an O
H5 O
HA O
( O
altered O
to O
bind O
human O
- O
type O
receptors O
) O
to O
three O
rounds O
of O
treatment O
at O
50 O
degrees O
C O
. O

To O
understand O
the O
response O
to O
viral O
infection O
and O
the O
role O
of O
individual O
1918 O
genes O
on O
the O
host O
response O
to O
the O
1918 O
virus O
, O
we O
examined O
reassortant O
avian O
viruses O
nearly O
identical O
to O
the O
pandemic O
1918 O
virus O
( O
1918 O
- O
like O
avian O
virus O
) O
carrying O
either O
the O
1918 O
Hemagglutinin B
( I
HA I
) I
or O
PB2 O
gene O
. O

IMPORTANCE O
As O
viral O
pathogenesis O
is O
determined O
in O
part O
by O
the O
host O
response O
, O
understanding O
the O
key O
host O
molecular O
driver O
( O
s O
) O
of O
virus O
- O
mediated O
disease O
, O
in O
relation O
to O
individual O
viral O
genes O
, O
is O
a O
promising O
approach O
to O
host O
- O
oriented O
drug O
efforts O
in O
preventing O
disease O
. O

H4 O
Avian B
influenza I
virus I
( I
AIV I
) I
is O
one O
of O
the O
most O
prevalent O
influenza O
virus O
subtypes O
in O
the O
world O
. O

The O
H1N1 O
Eurasian B
avian I
- I
like I
swine I
( I
EAsw I
) I
influenza O
viruses O
originated O
from O
an O
avian O
H1N1 O
virus O
. O

To O
characterize O
potential O
changes O
in O
the O
membrane O
fusion O
activity O
of O
the O
Hemagglutinin B
( I
HA I
) I
during O
avian O
- O
to O
- O
swine O
adaptation O
of O
the O
virus O
, O
we O
studied O
EAsw O
viruses O
isolated O
in O
the O
first O
years O
of O
their O
circulation O
in O
pigs O
and O
closely O
related O
contemporary O
H1N1 O
viruses O
of O
wild O
aquatic O
birds O
. O

Eight O
amino O
acid O
substitutions O
in O
the O
HA O
were O
found O
to O
separate O
the O
EAsw O
viruses O
from O
their O
putative O
avian O
precursor O
; O
four O
substitutions O
- O
T49 O
( O
2 O
) O
S O
, O
N72 O
( O
2 O
) O
D O
, O
R75 O
( O
2 O
) O
K O
, O
and O
S113 O
( O
2 O
) O
F O
- O
were O
located O
in O
the O
structural O
regions O
of O
the O
HA2 O
subunit O
known O
to O
play O
a O
role O
in O
acid O
- O
induced O
conformational O
transition O
of O
the O
HA O
. O

For O
countries O
where O
antiviral O
drugs O
are O
limited O
, O
the O
World B
Health I
Organization I
( I
WHO I
) I
has O
developed O
a O
risk O
categorization O
for O
different O
levels O
of O
exposure O
to O
environmental O
, O
poultry O
, O
or O
human O
sources O
of O
infection O
. O

Using O
the O
ferret O
model O
of O
H5N1 O
infection O
, O
we O
compared O
the O
commonly O
used O
but O
artificial O
inoculation O
method O
that O
saturates O
the O
total B
respiratory I
tract I
( I
TRT I
) I
with O
virus O
to O
upper B
respiratory I
tract I
( I
URT I
) I
and O
oral O
routes O
of O
delivery O
, O
those O
likely O
to O
be O
encountered O
by O
humans O
in O
nature O
. O

We O
isolated O
two O
H5N1 O
viruses O
, O
A O
/ O
duck O
/ O
Hunan O
/ O
S4020 O
/ O
2008 O
( O
DK O
/ O
08 O
) O
and O
A O
/ O
chicken O
/ O
Guangxi O
/ O
S2039 O
/ O
2009 O
( O
CK O
/ O
09 O
) O
, O
from O
live O
- O
bird O
markets O
during O
routine O
surveillance O
and O
found O
that O
these O
two O
viruses O
are O
genetically O
similar O
but O
differ O
in O
their O
replication O
and O
virulence O
in O
mice O
. O

The O
CK O
/ O
09 O
virus O
is O
lethal O
for O
mice O
with O
a O
50 B
% I
mouse I
lethal I
dose I
( I
MLD50 I
) I
of O
1 O
. O

6 O
log O
( O
10 O
) O
50 B
% I
egg I
infectious I
doses I
( I
EID50 I
) I
, O
whereas O
the O
DK O
/ O
08 O
virus O
is O
nonpathogenic O
for O
mice O
with O
an O
MLD50 O
value O
of O
6 O
. O

2 O
log O
( O
10 O
) O
EID50 O
. O

We O
further O
demonstrated O
that O
the O
mutation O
of O
Glycine B
( I
G I
) I
to O
Aspartic B
acid I
( I
D I
) I
at O
position O
622 O
in O
PB1 O
partially O
impaired O
the O
binding O
of O
PB1 O
to O
viral O
RNA O
, O
thereby O
dramatically O
decreasing O
the O
polymerase O
activity O
and O
attenuating O
H5N1 O
virus O
virulence O
in O
mice O
. O

Using O
hybridoma O
technology O
, O
we O
isolated O
a O
panel O
of O
H10 O
- O
and O
N8 O
- O
directed O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
further O
characterized O
the O
binding O
reactivity O
of O
these O
antibodies O
( O
via O
enzyme O
- O
linked O
immunosorbent O
assay O
) O
to O
a O
range O
of O
purified O
virus O
and O
recombinant O
protein O
substrates O
. O

The O
H10 O
- O
directed O
MAbs O
displayed O
functional O
hemagglutination B
inhibition I
( I
HI I
) I
and O
neutralization O
activity O
, O
and O
the O
N8 O
- O
directed O
antibodies O
displayed O
functional O
neuraminidase B
inhibition I
( I
NI I
) I
activity O
against O
H10N8 O
. O

Surprisingly O
, O
the O
HI O
- O
reactive O
H10 O
antibodies O
, O
as O
well O
as O
a O
previously O
generated O
, O
group O
2 O
Hemagglutinin B
( I
HA I
) I
stalk O
- O
reactive O
antibody O
, O
demonstrated O
NI O
activity O
against O
H10N8 O
and O
an O
H10N7 O
strain O
; O
this O
phenomenon O
was O
absent O
when O
virus O
was O
treated O
with O
detergent O
, O
suggesting O
the O
anti O
- O
HA O
antibodies O
inhibited O
neuraminidase O
enzymatic O
activity O
through O
steric O
hindrance O
. O

All O
three O
antibodies O
were O
protective O
at O
a O
high O
dose O
( O
5 O
mg O
/ O
kg O
) O
. O

Natural O
influenza O
A O
virus O
infections O
elicit O
both O
virus O
- O
specific O
antibody O
and O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
. O

Influenza O
A O
virus O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
contribute O
to O
clearance O
of O
influenza O
virus O
infections O
. O

Due O
to O
functional O
constraints O
, O
some O
epitopes O
, O
like O
the O
immunodominant O
HLA O
- O
A O
( O
star O
) O
0201 O
- O
restricted O
matrix O
protein O
1 O
( O
M1 O
( O
58 O
- O
66 O
) O
) O
epitope O
, O
are O
highly O
conserved O
between O
influenza O
A O
viruses O
regardless O
of O
their O
subtype O
or O
host O
species O
of O
origin O
. O

Here O
, O
we O
show O
that O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
in O
the O
M1 O
protein O
derived O
from O
human O
influenza O
A O
virus O
was O
poorly O
recognized O
compared O
to O
the O
M1 O
protein O
derived O
from O
avian O
influenza O
A O
virus O
. O

Furthermore O
, O
we O
demonstrate O
that O
naturally O
occurring O
variations O
at O
extraepitopic O
amino O
acid O
residues O
affect O
CD8 O
( O
+ O
) O
T O
cell O
recognition O
of O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
. O

These O
data O
indicate O
that O
human O
influenza O
A O
viruses O
can O
impair O
recognition O
by O
M1 O
( O
58 O
- O
66 O
) O
- O
specific O
CTLs O
while O
retaining O
the O
conserved O
amino O
acid O
sequence O
of O
the O
epitope O
, O
which O
may O
represent O
a O
yet O
- O
unknown O
immune O
evasion O
strategy O
for O
influenza O
A O
viruses O
. O

This O
difference O
in O
recognition O
may O
have O
implications O
for O
the O
viral O
replication O
kinetics O
in O
HLA O
- O
A O
( O
star O
) O
0201 O
individuals O
and O
spread O
of O
influenza O
A O
viruses O
in O
the O
human O
population O
. O

CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
are O
directed O
predominantly O
against O
conserved O
internal O
proteins O
and O
confer O
cross O
- O
protection O
, O
even O
against O
influenza O
A O
viruses O
of O
various O
subtypes O
. O

However O
, O
the O
immunodominant O
HLA O
- O
A O
( O
star O
) O
0201 O
- O
restricted O
M1 O
( O
58 O
- O
66 O
) O
epitope O
does O
not O
tolerate O
mutations O
without O
loss O
of O
viral O
fitness O
. O

Here O
, O
we O
describe O
naturally O
occurring O
variations O
in O
amino O
acid O
residues O
outside O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
that O
influence O
the O
recognition O
of O
the O
epitope O
. O

PB1 O
- O
F2 O
protein O
, O
the O
11th O
influenza B
A I
virus I
( I
IAV I
) I
protein O
, O
is O
considered O
to O
play O
an O
important O
role O
in O
primary O
influenza O
virus O
infection O
and O
postinfluenza O
secondary O
bacterial O
pneumonia O
in O
mice O
. O

In O
this O
study O
, O
we O
explored O
the O
role O
of O
PB1 O
- O
F2 O
protein O
of O
triple B
- I
reassortant I
( I
TR I
) I
H3N2 O
swine B
influenza I
virus I
( I
SIV I
) I
in O
pigs O
and O
turkeys O
. O

Using O
the O
eight O
- O
plasmid O
reverse O
genetics O
system O
, O
we O
rescued O
wild O
- O
type O
SIV O
A O
/ O
swine O
/ O
Minnesota O
/ O
1145 O
/ O
2007 O
( O
H3N2 O
) O
( O
SIV O
1145 O
- O
WT O
) O
, O
a O
PB1 O
- O
F2 O
knockout O
mutant O
( O
SIV O
1145 O
- O
KO O
) O
, O
and O
its O
N66S O
variant O
( O
SIV O
1145 O
- O
N66S O
) O
. O

In O
1999 O
, O
after O
circulation O
for O
a O
few O
months O
in O
poultry O
in O
Italy O
, O
low B
- I
pathogenic I
( I
LP I
) I
avian I
influenza I
( I
Al I
) I
H7N1 O
virus O
mutated O
into O
a O
highly B
pathogenic I
( I
HP I
) I
form O
by O
acquisition O
of O
a O
unique O
multibasic B
cleavage I
site I
( I
mCS I
) I
, O
PEIPKGSRVRIR O
* O
GLF O
( O
asterisk O
indicates O
the O
cleavage O
site O
) O
, O
in O
the O
Hemagglutinin B
( I
HA I
) I
and O
additional O
alterations O
with O
hitherto O
unknown O
biological O
function O
. O

To O
elucidate O
these O
virulence O
- O
determining O
alterations O
, O
recombinant O
H7N1 O
viruses O
carrying O
specific O
mutations O
in O
the O
HA O
of O
LPAI O
A O
/ O
chicken O
/ O
Italy O
/ O
473 O
/ O
1999 O
virus O
( O
Lp O
) O
and O
HPAI O
A O
/ O
chicken O
/ O
Italy O
/ O
445 O
/ O
1999 O
virus O
( O
Hp O
) O
were O
generated O
. O

While O
Lp O
with O
a O
multibasic O
cleavage O
site O
( O
Lp_CS445 O
) O
was O
less O
virulent O
than O
Hp O
, O
full O
virulence O
was O
exhibited O
when O
HA2 O
was O
replaced O
by O
that O
of O
Hp O
. O

Coinfection O
of O
ferrets O
with O
H5N1 O
and O
pH1N1 O
viruses O
resulted O
in O
two O
predominate O
genotypes O
in O
the O
lungs O
containing O
surface O
genes O
of O
highly O
pathogenic O
avian O
influenza O
H5N1 O
virus O
in O
the O
backbone O
of O
pandemic O
H1N1 O
2009 O
( O
pH1N1 O
) O
. O

Here O
, O
we O
have O
compared O
the O
effect O
of O
a O
commonly O
used O
dose O
( O
4 O
x O
10 O
( O
6 O
) O
50 O
% O
tissue O
culture O
infective O
doses O
) O
versus O
a O
100 O
- O
fold O
- O
higher O
dose O
, O
administered O
by O
intra O
- O
bronchial O
installation O
, O
to O
two O
groups O
of O
6 O
cynomolgus O
macaques O
. O

Airway O
epithelial O
cells O
are O
susceptible O
to O
infection O
with O
seasonal O
influenza B
A I
viruses I
( I
IAV I
) I
, O
resulting O
in O
productive O
virus O
replication O
and O
release O
. O

Macrophages O
( O
M O
Phi O
) O
are O
also O
permissive O
to O
IAV O
infection O
; O
however O
, O
virus O
replication O
is O
abortive O
. O

Following O
virus O
entry O
, O
we O
demonstrate O
synthesis O
of O
all O
eight O
segments O
of O
genomic O
viral B
RNA I
( I
vRNA I
) I
and O
mRNA O
, O
as O
well O
as O
seven O
distinct O
IAV O
proteins O
, O
in O
IAV O
- O
infected O
mouse O
M O
Phi O
. O

Although O
newly O
synthesized O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
glycoproteins O
are O
incorporated O
into O
the O
plasma O
membrane O
and O
expressed O
at O
the O
cell O
surface O
, O
electron O
microscopy O
confirmed O
that O
virus O
assembly O
was O
defective O
in O
IAV O
- O
infected O
M O
Phi O
, O
defining O
a O
second O
level O
of O
restriction O
late O
in O
the O
virus O
life O
cycle O
. O

IMPORTANCE O
Seasonal O
influenza B
A I
viruses I
( I
IAV I
) I
and O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAI I
) I
infect O
macrophages O
, O
but O
only O
HPAI O
replicate O
productively O
in O
these O
cells O
. O

Hemagglutinin B
( I
HA I
) I
of O
H3N2 O
/ O
1968 O
pandemic O
influenza O
viruses O
differs O
from O
the O
putative O
avian O
precursor O
by O
seven O
amino O
acid O
substitutions O
. O

We O
found O
that O
introduction O
of O
avian O
- O
virus O
- O
like O
amino O
acids O
at O
five O
other O
HA O
positions O
( O
positions O
62 O
, O
81 O
, O
92 O
, O
144 O
, O
and O
193 O
) O
of O
A O
/ O
Hong O
Kong O
/ O
1 O
/ O
1968 O
virus O
decreased O
viral O
replication O
in O
human O
cells O
and O
transmission O
in O
pigs O
. O

The O
increasing O
number O
of O
zoonotic O
infections O
caused O
by O
influenza B
A I
virus I
( I
IAV I
) I
subtypes O
of O
avian O
origin O
( O
e O
. O

To O
evaluate O
the O
current O
feasibility O
of O
global O
analyses O
to O
contribute O
to O
this O
aim O
, O
we O
evaluated O
information O
in O
the O
public O
domain O
to O
explore O
IAV O
evolutionary O
dynamics O
, O
including O
nucleotide O
substitution O
rates O
and O
selection O
pressures O
, O
using O
14 O
IAV O
subtypes O
in O
32 O
different O
countries O
over O
a O
12 O
- O
year O
period O
( O
2000 O
to O
2011 O
) O
. O

In O
contrast O
, O
the O
selection O
pressures O
( O
measured O
as O
ratios O
of O
nonsynonymous O
to O
synonymous O
evolutionary O
changes O
[ O
dN O
/ O
dS O
ratios O
] O
) O
acting O
on O
individual O
subtypes O
showed O
little O
geographic O
variation O
. O

, O
total O
number O
of O
strains O
reported O
) O
and O
health O
care O
spending O
( O
an O
indicator O
of O
economic O
development O
) O
. O

Our O
analyses O
also O
identified O
major O
global O
gaps O
in O
IAV O
reporting O
( O
including O
a O
lack O
of O
sequences O
submitted O
from O
large O
portions O
of O
Africa O
and O
South O
America O
and O
a O
lack O
of O
geolocation O
information O
) O
and O
in O
broad O
subtype O
testing O
which O
, O
until O
addressed O
, O
will O
continue O
to O
hinder O
efforts O
to O
track O
the O
evolution O
and O
diversity O
of O
IAV O
around O
the O
world O
. O

IMPORTANCE O
In O
recent O
years O
, O
an O
increasing O
number O
of O
influenza B
A I
virus I
( I
IAV I
) I
subtypes O
, O
including O
H5N1 O
, O
H7N9 O
, O
and O
H10N8 O
, O
have O
been O
detected O
in O
humans O
. O

Although O
a O
polybasic O
HA O
( O
0 O
) O
cleavage O
site O
is O
considered O
the O
dominant O
virulence O
determinant O
for O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5 O
and O
H7 O
viruses O
, O
naturally O
occurring O
virus O
isolates O
possessing O
a O
polybasic O
HA O
( O
0 O
) O
cleavage O
site O
have O
been O
identified O
that O
are O
low O
pathogenic O
in O
chickens O
. O

In O
this O
study O
, O
we O
generated O
a O
reassortant O
H5N3 O
virus O
that O
possessed O
the O
Hemagglutinin B
( I
HA I
) I
gene O
from O
H5N1 O
HPAI O
A O
/ O
swan O
/ O
Germany O
/ O
R65 O
/ O
2006 O
and O
the O
remaining O
gene O
segments O
from O
low O
pathogenic O
A O
/ O
chicken O
/ O
British O
Columbia O
/ O
CN0006 O
/ O
2004 O
( O
H7N3 O
) O
. O

One O
of O
these O
involved O
the O
catalytic O
site O
of O
the O
neuraminidase O
( O
NA O
; O
R293K O
) O
and O
is O
associated O
with O
decreased O
neuraminidase O
activity O
and O
resistance O
to O
oseltamivir O
. O

Our O
data O
show O
the O
importance O
of O
the O
neuraminidase O
in O
complementing O
a O
polybasic O
HA O
( O
0 O
) O
cleavage O
site O
. O

The O
neuraminidase B
( I
NA I
) I
inhibitors O
( O
NAIs O
) O
are O
the O
frontline O
anti O
- O
influenza O
drugs O
and O
are O
the O
major O
option O
for O
treatment O
of O
newly O
emerging O
influenza O
. O

We O
applied O
random O
mutagenesis O
and O
generated O
recombinant O
influenza O
viruses O
carrying O
single O
or O
double O
NA O
substitution O
( O
s O
) O
with O
seven O
internal O
genes O
from O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
( O
H1N1 O
) O
virus O
. O

In O
a O
fluorescence O
- O
based O
NA O
inhibition O
assay O
, O
we O
identified O
three O
categories O
of O
NA O
substitutions O
associated O
with O
reduced O
inhibition O
by O
NAIs O
( O
oseltamivir O
, O
zanamivir O
, O
and O
peramivir O
) O
: O
( O
i O
) O
novel O
subtype O
- O
specific O
substitutions O
in O
or O
near O
the O
enzyme O
catalytic O
site O
( O
R152W O
, O
A246T O
, O
and O
D293N O
, O
N2 O
numbering O
) O
, O
( O
ii O
) O
subtype O
- O
independent O
substitutions O
( O
E119G O
/ O
V O
and O
/ O
or O
D O
and O
R292K O
) O
, O
and O
( O
iii O
) O
substitutions O
previously O
reported O
in O
other O
subtypes O
( O
Q136K O
, O
I222M O
, O
and O
E276D O
) O
. O

IMPORTANCE O
The O
number O
of O
humans O
infected O
with O
avian O
influenza O
viruses O
is O
increasing O
, O
raising O
concerns O
of O
the O
emergence O
of O
avian O
influenza O
viruses O
resistant O
to O
neuraminidase B
( I
NA I
) I
inhibitors O
( O
NAIs O
) O
. O

H3N8 O
viruses O
have O
not O
been O
isolated O
yet O
from O
humans O
; O
however O
, O
a O
recent O
report O
showed O
that O
equine O
influenza B
A I
viruses I
( I
IAVs I
) I
can O
be O
isolated O
from O
pigs O
, O
although O
an O
established O
infection O
has O
not O
been O
observed O
thus O
far O
in O
this O
host O
. O

To O
gain O
insight O
into O
the O
possibility O
of O
H3N8 O
avian O
IAVs O
to O
cross O
the O
species O
barrier O
into O
pigs O
, O
in O
vitro O
experiments O
and O
an O
experimental O
infection O
in O
pigs O
with O
four O
H3N8 O
viruses O
from O
different O
origins O
( O
equine O
, O
canine O
, O
avian O
, O
and O
seal O
) O
were O
performed O
. O

Interestingly O
, O
antibodies O
against O
hemagglutinin O
could O
not O
be O
detected O
after O
infection O
by O
hemagglutination B
inhibition I
( I
HAI I
) I
test O
with O
avian O
and O
seal O
viruses O
. O

Infections O
of O
domestic O
and O
wild O
birds O
with O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
have O
been O
associated O
with O
protective O
immunity O
to O
subsequent O
infection O
. O

Therefore O
, O
we O
inoculated O
H13N2 O
( O
A O
/ O
black O
- O
headed O
gull O
/ O
Netherlands O
/ O
7 O
/ O
2009 O
) O
and O
H16N3 O
( O
A O
/ O
black O
- O
headed O
gull O
/ O
Netherlands O
/ O
26 O
/ O
2009 O
) O
LPAIVs O
into O
black O
- O
headed O
gulls O
( O
Chroicocephalus O
ridibundus O
) O
, O
their O
natural O
host O
species O
, O
and O
measured O
the O
long O
- O
term O
immune O
response O
and O
protection O
against O
one O
or O
two O
reinfections O
over O
a O
period O
of O
> O
1 O
year O
. O

IMPORTANCE O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
circulate O
mainly O
in O
wild O
water O
birds O
but O
are O
occasionally O
transmitted O
to O
other O
species O
, O
including O
humans O
, O
where O
they O
cause O
subclinical O
to O
fatal O
disease O
. O

The O
findings O
suggest O
that O
H13 O
and O
H16 O
LPAIV O
cycles O
in O
black O
- O
headed O
gull O
populations O
are O
independent O
of O
each O
other O
, O
indicate O
the O
importance O
of O
first O
- O
year O
birds O
in O
LPAIV O
epidemiology O
, O
and O
emphasize O
the O
need O
for O
alternatives O
to O
Avian B
influenza I
virus I
( I
AIV I
) I
- O
specific O
serum O
antibodies O
as O
evidence O
of O
past O
LPAIV O
infection O
and O
correlates O
of O
protection O
against O
LPAIV O
infection O
in O
wild O
birds O
. O

Here O
, O
we O
show O
that O
the O
neuraminidase B
( I
NA I
) I
of O
H5N1 O
influenza O
A O
virus O
markedly O
deglycosylates O
and O
degrades O
lysosome O
- O
associated O
membrane O
proteins O
( O
LAMPs O
; O
the O
most O
abundant O
membrane O
proteins O
of O
lysosome O
) O
, O
which O
induces O
lysosomal O
rupture O
, O
and O
finally O
leads O
to O
cell O
death O
of O
alveolar O
epithelial O
carcinoma O
A549 O
cells O
and O
human O
tracheal O
epithelial O
cells O
. O

This O
study O
shows O
that O
the O
H5N1 O
influenza O
virus O
could O
induce O
lysosomal O
rupture O
through O
deglycosylating O
lysosome B
- I
associated I
membrane I
proteins I
( I
LAMPs I
) I
mediated O
by O
the O
neuraminidase O
activity O
of O
NA O
protein O
. O

The O
emergence O
in O
humans O
of O
the O
A O
( O
H1N1 O
) O
pdm09 O
influenza O
virus O
, O
a O
complex O
reassortant O
virus O
of O
swine O
origin O
, O
highlighted O
the O
importance O
of O
worldwide O
influenza O
virus O
surveillance O
in O
swine O
. O

Contrasting O
epidemiological O
dynamics O
were O
observed O
for O
two O
of O
these O
genotypes O
, O
H1 O
( O
hu O
) O
N2 O
and O
H3N2 O
, O
with O
the O
former O
showing O
multiple O
long O
- O
lived O
geographically O
isolated O
lineages O
, O
while O
the O
latter O
had O
short O
- O
lived O
geographically O
diffuse O
lineages O
. O

At O
least O
32 O
human O
- O
swine O
transmission O
events O
have O
resulted O
in O
A O
( O
H1N1 O
) O
pdm09 O
becoming O
established O
at O
a O
mean O
frequency O
of O
8 O
% O
across O
European O
countries O
. O

Notably O
, O
swine O
in O
the O
United O
Kingdom O
have O
largely O
had O
a O
replacement O
of O
the O
endemic O
Eurasian O
avian O
virus O
- O
like O
( O
avian O
- O
like O
) O
genotypes O
with O
A O
( O
H1N1 O
) O
pdm09 O
- O
derived O
genotypes O
. O

The O
high O
number O
of O
reassortant O
genotypes O
observed O
in O
European O
swine O
, O
combined O
with O
the O
identification O
of O
a O
genotype O
similar O
to O
the O
A O
( O
H3N2 O
) O
v O
genotype O
in O
North O
America O
, O
underlines O
the O
importance O
of O
continued O
swine O
surveillance O
in O
Europe O
for O
the O
purposes O
of O
maintaining O
public O
health O
. O

IMPORTANCE O
The O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
virus O
contains O
a O
reassortant O
genome O
with O
segments O
derived O
from O
separate O
virus O
lineages O
that O
evolved O
in O
different O
regions O
of O
the O
world O
. O

In O
particular O
, O
its O
neuraminidase O
and O
matrix O
segments O
were O
derived O
from O
the O
Eurasian O
avian O
virus O
- O
like O
( O
avian O
- O
like O
) O
lineage O
that O
emerged O
in O
European O
swine O
in O
the O
1970s O
. O

Surveillance O
of O
swine O
herds O
across O
Europe O
between O
2009 O
and O
2013 O
revealed O
that O
the O
A O
( O
H1N1 O
) O
pdm09 O
virus O
is O
established O
in O
European O
swine O
, O
increasing O
the O
number O
of O
circulating O
lineages O
in O
the O
region O
and O
increasing O
the O
possibility O
of O
the O
emergence O
of O
a O
genotype O
with O
human O
pandemic O
potential O
. O

The O
identification O
of O
a O
genotype O
similar O
to O
the O
A O
( O
H3N2 O
) O
v O
genotype O
, O
causing O
zoonoses O
at O
North O
American O
agricultural O
fairs O
, O
underlines O
the O
importance O
of O
continued O
genomic O
characterization O
in O
European O
swine O
. O

A O
novel O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N8 O
virus O
, O
first O
detected O
in O
January O
2014 O
in O
poultry O
and O
wild O
birds O
in O
South O
Korea O
, O
has O
spread O
throughout O
Asia O
and O
Europe O
and O
caused O
outbreaks O
in O
Canada O
and O
the O
United O
States O
by O
the O
end O
of O
the O
year O
. O

The O
spread O
of O
H5N8 O
and O
the O
novel O
reassortant O
viruses O
, O
H5N2 O
and O
H5N1 O
( O
H5Nx O
) O
, O
in O
domestic O
poultry O
across O
multiple O
states O
in O
the O
United O
States O
pose O
a O
potential O
public O
health O
risk O
. O

IMPORTANCE O
In O
2015 O
, O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5 O
viruses O
have O
caused O
outbreaks O
in O
domestic O
poultry O
in O
multiple O
U O
. O

In O
human O
bronchial O
epithelial O
( O
Calu O
- O
3 O
) O
cells O
, O
both O
H5N8 O
and O
H5N2 O
viruses O
replicated O
to O
a O
level O
comparable O
to O
a O
human O
seasonal O
virus O
, O
but O
significantly O
lower O
than O
a O
virulent O
Asian O
- O
lineage O
H5N1 O
( O
A O
/ O
Thailand O
/ O
16 O
/ O
2004 O
) O
virus O
. O

A O
/ O
Silkie O
chicken O
/ O
HK O
/ O
1772 O
/ O
2014 O
( O
SCk1772 O
) O
and O
A O
/ O
HK O
/ O
3263 O
/ O
14 O
( O
HK3263 O
) O
replicated O
to O
comparable O
titers O
in O
chickens O
, O
with O
superior O
oropharyngeal O
over O
cloacal O
shedding O
; O
both O
viruses O
transmitted O
efficiently O
among O
chickens O
via O
direct O
contact O
but O
inefficiently O
via O
the O
airborne O
route O
. O

Using O
chicken O
( O
SCk1772 O
) O
and O
human O
( O
HK3263 O
) O
H7N9 O
isolates O
that O
differed O
by O
four O
amino O
acids O
, O
including O
the O
host O
determinant O
PB2 O
residue O
627 O
, O
we O
observed O
that O
both O
viruses O
transmitted O
efficiently O
among O
chickens O
via O
direct O
contact O
but O
inefficiently O
via O
the O
airborne O
route O
. O

Novel O
reassortants O
of O
H7N9 O
, O
H10N8 O
, O
and O
H5N6 O
avian B
influenza I
viruses I
( I
AIVs I
) I
are O
currently O
circulating O
in O
China O
' O
s O
poultry O
flocks O
, O
occasionally O
infecting O
humans O
and O
other O
mammals O
. O

The O
novel O
H7N9 O
Avian B
influenza I
virus I
( I
AIV I
) I
was O
demonstrated O
to O
cause O
severe O
human O
respiratory O
infections O
in O
China O
. O

Metagenomic O
sequencing O
revealed O
mixed O
subtypes O
( O
H5 O
, O
H7 O
, O
H9 O
, O
N1 O
, O
N2 O
, O
and O
N9 O
) O
. O

Evolutionary O
analysis O
showed O
that O
the O
hemagglutinin O
gene O
of O
the O
novel O
H5N9 O
virus O
originated O
from O
A O
/ O
Muscovy O
duck O
/ O
Vietnam O
/ O
LBM227 O
/ O
2012 O
( O
H5N1 O
) O
, O
which O
belongs O
to O
clade O
2 O
. O

The O
neuraminidase O
gene O
of O
the O
novel O
H5N9 O
virus O
originated O
from O
human O
- O
infective O
A O
/ O
Hangzhou O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
. O

Despite O
having O
avian O
origin O
PA O
and O
PB2 O
, O
the O
2009 O
pandemic O
H1N1 O
virus O
( O
pH1N1 O
) O
can O
replicate O
well O
in O
mammalian O
respiratory O
tracts O
, O
suggesting O
that O
these O
proteins O
have O
acquired O
mutations O
for O
efficient O
growth O
in O
humans O
. O

We O
have O
previously O
shown O
that O
PA O
from O
the O
pH1N1 O
virus O
A O
/ O
California O
/ O
04 O
/ O
09 O
( O
Cal O
) O
strongly O
enhances O
activity O
of O
an O
otherwise O
avian O
polymerase O
complex O
derived O
from O
A O
/ O
chicken O
/ O
Nanchang O
/ O
3 O
- O
120 O
/ O
01 O
( O
Nan O
) O
in O
mammalian O
cells O
. O

influenza B
A I
virus I
( I
IAV I
) I
infection O
provokes O
an O
antiviral O
response O
involving O
the O
expression O
of O
type O
I O
and O
III O
interferons B
( I
IFN I
) I
and O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
in O
infected O
cell O
cultures O
. O

IMPORTANCE O
Interferons O
are O
expressed O
by O
infected O
cells O
in O
response O
to O
IAV O
infection O
and O
play O
important O
roles O
in O
the O
antiviral O
immune O
response O
by O
inducing O
hundreds O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

A O
live O
attenuated O
, O
cold B
- I
adapted I
( I
ca I
) I
H3N8 O
vaccine O
virus O
was O
generated O
by O
reverse O
genetics O
using O
the O
wild B
- I
type I
( I
wt I
) I
hemagglutinin I
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
from O
the O
A O
/ O
blue O
- O
winged O
teal O
/ O
Texas O
/ O
Sg O
- O
00079 O
/ O
2007 O
( O
H3N8 O
) O
( O
tl O
/ O
TX O
/ O
079 O
/ O
07 O
) O
wt O
virus O
and O
the O
six O
internal O
protein O
gene O
segments O
from O
the O
ca O
influenza O
A O
virus O
vaccine O
donor O
strain O
, O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
ca O
( O
H2N2 O
) O
, O
the O
backbone O
of O
the O
licensed O
seasonal O
live O
attenuated O
influenza O
vaccine O
. O

One O
dose O
of O
the O
tl O
/ O
TX O
/ O
079 O
/ O
07 O
ca O
vaccine O
induced O
a O
robust O
neutralizing O
antibody O
response O
against O
the O
homologous O
( O
tl O
/ O
TX O
/ O
079 O
/ O
07 O
) O
and O
two O
heterologous O
influenza O
viruses O
, O
including O
the O
recently O
emerged O
A O
/ O
harbor O
seal O
/ O
New O
Hampshire O
/ O
179629 O
/ O
2011 O
( O
H3N8 O
) O
and O
A O
/ O
northern O
pintail O
/ O
Alaska O
/ O
44228 O
- O
129 O
/ O
2006 O
( O
H3N8 O
) O
viruses O
, O
and O
conferred O
robust O
protection O
against O
the O
homologous O
and O
heterologous O
influenza O
viruses O
. O

We O
identified O
mutations O
in O
the O
viral O
Hemagglutinin B
( I
HA I
) I
and O
the O
nucleoprotein B
( I
NP I
) I
that O
occurred O
during O
pandemic O
progression O
and O
mediate O
increased O
virulence O
in O
mice O
. O

IMPORTANCE O
In O
this O
study O
, O
novel O
determinants O
of O
2009 O
pandemic O
H1N1 O
influenza O
pathogenicity O
were O
identified O
in O
the O
viral O
Hemagglutinin B
( I
HA I
) I
and O
the O
nucleoprotein B
( I
NP I
) I
genes O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
express O
the O
PB1 O
- O
F2 O
protein O
from O
an O
alternate O
reading O
frame O
within O
the O
PB1 O
gene O
segment O
. O

However O
, O
in O
contrast O
to O
other O
avian O
IAVs O
, O
recent O
isolates O
of O
highly O
pathogenic O
H5N1 O
influenza O
viruses O
had O
a O
high O
proportion O
of O
PB1 O
- O
F2 O
truncations O
( O
15 O
% O
since O
2010 O
; O
61 O
% O
of O
isolates O
in O
2013 O
) O
due O
to O
several O
independent O
mutations O
that O
have O
persisted O
and O
expanded O
in O
circulating O
viruses O
. O

In O
vitro O
, O
we O
detected O
expression O
of O
an O
in O
- O
frame O
protein O
( O
C O
- O
terminal O
PB1 O
- O
F2 O
) O
from O
downstream O
ATGs O
in O
PB1 O
- O
F2 O
plasmids O
lacking O
the O
well O
- O
conserved O
ATG O
start O
codon O
. O

Transient O
expression O
of O
full O
- O
length O
PB1 O
- O
F2 O
, O
truncated O
( O
24 O
- O
amino O
- O
acid O
) O
PB1 O
- O
F2 O
, O
and O
PB1 O
- O
F2 O
lacking O
the O
initiating O
ATG O
in O
mammalian O
and O
avian O
cells O
had O
no O
effect O
on O
cell O
apoptosis O
or O
interferon O
expression O
in O
human O
lung O
epithelial O
cells O
. O

IMPORTANCE O
Although O
most O
avian O
influenza O
viruses O
are O
harmless O
for O
humans O
, O
some O
( O
such O
as O
highly O
pathogenic O
H5N1 O
avian O
influenza O
viruses O
) O
are O
capable O
of O
infecting O
humans O
and O
causing O
severe O
disease O
with O
a O
high O
mortality O
rate O
. O

Although O
whole B
inactivated I
virus I
( I
WIV I
) I
vaccine O
via O
intranasal O
pathway O
is O
the O
effective O
method O
of O
blocking O
virus O
transmission O
, O
the O
mucosal O
barrier O
seems O
to O
be O
a O
major O
factor O
hampering O
its O
development O
. O

CpG O
oligodeoxynucleotides O
, O
a O
known O
adjuvant O
, O
can O
target O
downstream O
dendritic B
cells I
( I
DCs I
) I
and O
effectively O
enhance O
the O
mucosal O
and O
systemic O
immune O
responses O
. O

Here O
, O
in O
vitro O
and O
in O
vivo O
, O
we O
showed O
that O
CpGs O
provided O
assistance O
for O
H9N2 O
WIV O
in O
recruiting O
DCs O
to O
the O
nasal O
epithelial B
cells I
( I
ECs I
) I
and O
forming O
transepithelial B
dendrites I
( I
TEDs I
) I
to O
capture O
luminal O
viruses O
. O

CD103 O
( O
+ O
) O
DCs O
participated O
in O
this O
process O
. O

Virus O
- O
loaded O
DCs O
quickly O
migrated O
into O
the O
draining O
cervical B
lymph I
nodes I
( I
CLNs I
) I
for O
antigen O
presentation O
. O

IMPORTANCE O
This O
paper O
demonstrates O
by O
both O
an O
in O
vivo O
and O
an O
in O
vitro O
coculture O
model O
that O
CpG O
oligodeoxynucleotides O
, O
known O
as O
an O
adjuvant O
generally O
targeting O
downstream O
immune O
responses O
, O
also O
are O
crucial O
for O
the O
transport O
of O
H9N2 O
WIV O
across O
nasal O
epithelial B
cells I
( I
ECs I
) I
via O
the O
uptake O
of O
transepithelial B
dendrites I
( I
TEDs I
) I
. O

Migratory O
waterfowl O
in O
the O
order O
Anseriformes O
are O
important O
reservoir O
hosts O
for O
diverse O
populations O
of O
avian B
- I
origin I
influenza I
A I
viruses I
( I
AIVs I
) I
and O
are O
assumed O
to O
spread O
AIVs O
during O
their O
annual O
continental O
- O
scale O
migrations O
. O

We O
conducted O
intensive O
AIV O
surveillance O
of O
waterfowl O
using O
the O
North B
American I
Mississippi I
Migratory I
Flyway I
( I
MMF I
) I
over O
three O
autumn O
migratory O
seasons O
. O

Viral O
isolates O
( O
n O
= O
297 O
) O
from O
multiple O
host O
species O
were O
sequenced O
and O
analyzed O
for O
patterns O
of O
gene O
dispersal O
between O
northern O
staging O
and O
southern O
wintering O
locations O
. O

IMPORTANCE O
Migratory O
birds O
are O
a O
reservoir O
for O
antigenic O
and O
genetic O
diversity O
of O
influenza O
A O
viruses O
( O
AIVs O
) O
and O
are O
implicated O
in O
the O
spread O
of O
virus O
diversity O
that O
has O
contributed O
to O
previous O
pandemic O
events O
. O

highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
of O
hemagglutinin O
H5 O
and O
H7 O
subtypes O
emerge O
after O
introduction O
of O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
from O
wild O
birds O
into O
poultry O
flocks O
, O
followed O
by O
subsequent O
circulation O
and O
evolution O
. O

The O
acquisition O
of O
multiple O
basic O
amino O
acids O
at O
the O
endoproteolytical O
cleavage O
site O
of O
the O
Hemagglutinin B
( I
HA I
) I
is O
a O
molecular O
indicator O
for O
high O
pathogenicity O
, O
at O
least O
for O
infections O
of O
gallinaceous O
poultry O
. O

Apart O
from O
the O
well O
- O
studied O
significance O
of O
the O
multibasic O
HA O
cleavage O
site O
, O
there O
is O
only O
limited O
knowledge O
on O
other O
alterations O
in O
the O
HA O
and O
neuraminidase B
( I
NA I
) I
molecules O
associated O
with O
changes O
in O
tropism O
during O
the O
emergence O
of O
HPAIVs O
from O
LPAIVs O
. O

In O
contrast O
, O
all O
HPAIVs O
differed O
from O
LPAIVs O
by O
a O
higher O
HA O
receptor O
- O
binding O
affinity O
toward O
the O
trisaccharides O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
4GlcNAc O
beta O
( O
3 O
' O
SLN O
) O
and O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
3GlcNAc O
beta O
( O
SiaLe O
( O
c O
) O
) O
and O
by O
the O
ability O
to O
discriminate O
between O
the O
nonfucosylated O
and O
fucosylated O
sialyloligosaccharides O
3 O
' O
SLN O
and O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
4 O
( O
Fuc O
alpha O
1 O
- O
3 O
) O
GlcNAc O
beta O
( O
SiaLe O
( O
x O
) O
) O
, O
respectively O
. O

Human O
infections O
by O
avian O
influenza O
A O
( O
H7N9 O
) O
virus O
entail O
substantial O
morbidity O
and O
mortality O
. O

Treatment O
of O
infected O
patients O
with O
the O
neuraminidase B
( I
NA I
) I
inhibitor O
oseltamivir O
was O
associated O
with O
emergence O
of O
viruses O
carrying O
NA O
substitutions O
. O

In O
the O
NA O
inhibition O
( O
NI O
) O
assay O
, O
R292K O
conferred O
highly O
reduced O
inhibition O
by O
oseltamivir O
, O
while O
E119V O
and O
I222K O
each O
caused O
reduced O
inhibition O
. O

Oseltamivir O
treatment O
( O
5 O
or O
25 O
mg O
/ O
kg O
of O
body O
weight O
/ O
dose O
) O
was O
given O
4 O
h O
postinfection O
, O
followed O
by O
twice O
- O
daily O
treatment O
for O
5 O
days O
. O

5 O
log O
( O
10 O
) O
50 O
% O
tissue O
culture O
infectious O
dose O
[ O
TCID50 O
] O
) O
in O
nasal O
wash O
viral O
titers O
and O
inflammation O
response O
. O

IMPORTANCE O
This O
report O
provides O
more O
evidence O
for O
using O
the O
ferret O
model O
to O
assess O
the O
susceptibility O
of O
influenza O
A O
( O
H7N9 O
) O
viruses O
to O
oseltamivir O
, O
the O
most O
prescribed O
anti O
- O
influenza O
virus O
drug O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
are O
maintained O
mainly O
in O
wild O
birds O
, O
and O
despite O
frequent O
spillover O
infections O
of O
avian O
IAVs O
into O
mammals O
, O
only O
a O
small O
number O
of O
viruses O
have O
become O
established O
in O
mammalian O
hosts O
. O

A O
new O
H3N2 O
canine B
influenza I
virus I
( I
CIV I
) I
of O
avian O
origin O
emerged O
in O
Asia O
in O
the O
mid O
- O
2000s O
and O
is O
now O
circulating O
in O
dog O
populations O
of O
China O
and O
South O
Korea O
, O
and O
possibly O
in O
Thailand O
. O

An O
avian O
- O
origin O
canine B
influenza I
virus I
( I
CIV I
) I
has O
recently O
emerged O
in O
dogs O
and O
is O
spreading O
in O
Asia O
. O

Finally O
, O
we O
provide O
evidence O
of O
multiple O
reassortment O
events O
between O
CIV O
and O
other O
influenza O
viruses O
( O
including O
an O
H5N1 O
avian O
virus O
) O
. O

Neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
can O
serve O
as O
a O
useful O
tool O
for O
preventing O
, O
treating O
, O
and O
detecting O
H5N1 O
. O

Both O
the O
humanized O
and O
mouse O
MAbs O
presented O
positive O
activity O
in O
hemagglutination B
inhibition I
( I
HI I
) I
, O
virus O
neutralization O
, O
and O
immunofluorescence O
assays O
against O
a O
wide O
range O
of O
H5N1 O
strains O
. O

Further O
, O
by O
sequencing O
of O
escape O
mutants O
, O
the O
conformational O
epitope O
of O
8A8 O
was O
found O
to O
be O
located O
within O
the O
receptor B
binding I
domain I
( I
RBD I
) I
of O
H5 O
. O

It O
is O
important O
to O
develop O
a O
humanized O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
against O
all O
of O
the O
clades O
of O
H5N1 O
. O

Vaccines O
are O
used O
in O
integrated O
control O
strategies O
to O
protect O
poultry O
against O
H5N1 O
high B
- I
pathogenicity I
avian I
influenza I
( I
HPAI I
) I
. O

Vaccines O
containing O
A O
/ O
turkey O
/ O
Wisconsin O
/ O
1968 O
( O
WI O
/ O
68 O
) O
, O
A O
/ O
chicken O
/ O
Mexico O
/ O
28159 O
- O
232 O
/ O
1994 O
( O
Mex O
/ O
94 O
) O
, O
and O
A O
/ O
turkey O
/ O
England O
/ O
N28 O
/ O
1973 O
seed O
strains O
had O
high O
serological O
potency O
in O
chickens O
( O
geometric O
mean O
hemagglutination O
inhibition O
[ O
HI O
] O
titers O
, O
> O
= O
1 O
: O
169 O
) O
, O
but O
vaccines O
containing O
strain O
A O
/ O
chicken O
/ O
Guangdong O
/ O
1 O
/ O
1996 O
generated O
by O
reverse O
genetics O
( O
rg O
; O
rgGD O
/ O
96 O
) O
, O
A O
/ O
chicken O
/ O
Legok O
/ O
2003 O
( O
Legok O
/ O
03 O
) O
, O
A O
/ O
chicken O
/ O
Vietnam O
/ O
C57 O
/ O
2004 O
generated O
by O
rg O
( O
rgVN O
/ O
04 O
) O
, O
or O
A O
/ O
chicken O
/ O
Legok O
/ O
2003 O
generated O
by O
rg O
( O
rgLegok O
/ O
03 O
) O
had O
lower O
serological O
potency O
( O
geometric O
mean O
HI O
titers O
, O
< O
= O
1 O
: O
95 O
) O
. O

In O
challenge O
studies O
, O
chickens O
immunized O
with O
any O
of O
the O
H5 O
avian O
influenza O
vaccines O
were O
protected O
against O
A O
/ O
chicken O
/ O
West O
Java O
/ O
SMI O
- O
HAMD O
/ O
2006 O
( O
SMI O
- O
HAMD O
/ O
06 O
) O
and O
were O
partially O
protected O
against O
A O
/ O
chicken O
/ O
Papua O
/ O
TA5 O
/ O
2006 O
( O
Papua O
/ O
06 O
) O
but O
were O
not O
protected O
against O
A O
/ O
chicken O
/ O
West O
Java O
/ O
PWT O
- O
WIJ O
/ O
2006 O
( O
PWT O
/ O
06 O
) O
. O

Experimental O
inactivated O
vaccines O
made O
with O
PWT O
/ O
06 O
HPAI O
virus O
or O
rg O
- O
generated O
PWT O
/ O
06 O
low B
- I
pathogenicity I
avian I
influenza I
( I
LPAI I
) I
virus O
seed O
strains O
protected O
chickens O
from O
lethal O
challenge O
, O
as O
did O
a O
combination O
of O
a O
commercially O
available O
live O
fowl O
poxvirus O
vaccine O
expressing O
the O
H5 O
influenza O
virus O
gene O
and O
inactivated O
Legok O
/ O
03 O
vaccine O
. O

IMPORTANCE O
H5N1 O
high B
- I
pathogenicity I
avian I
influenza I
( I
HPAI I
) I
virus O
has O
become O
endemic O
in O
Indonesian O
poultry O
, O
and O
such O
poultry O
are O
the O
source O
of O
virus O
for O
birds O
and O
mammals O
, O
including O
humans O
. O

Here O
, O
we O
report O
that O
the O
polymerase O
PB2 O
protein O
of O
an O
H5N1 O
influenza O
virus O
isolated O
from O
a O
human O
in O
Vietnam O
( O
A O
/ O
Vietnam O
/ O
UT36285 O
/ O
2010 O
, O
virus O
36285 O
) O
increased O
the O
growth O
ability O
of O
an O
avian O
H5N1 O
virus O
( O
A O
/ O
wild O
bird O
/ O
Anhui O
/ O
82 O
/ O
2005 O
, O
virus O
Wb O
/ O
AH82 O
) O
in O
human O
lung O
epithelial O
A549 O
cells O
( O
however O
, O
the O
reassortant O
virus O
did O
not O
replicate O
more O
efficiently O
than O
human O
36285 O
virus O
) O
. O

Here O
, O
we O
propose O
that O
the O
PA O
of O
an O
H5N1 O
influenza O
virus O
isolated O
from O
a O
human O
in O
Vietnam O
( O
A O
/ O
Vietnam O
/ O
UT36285 O
/ O
2010 O
[ O
36285 O
] O
) O
increased O
the O
ability O
of O
an O
avian O
H5N1 O
virus O
( O
A O
/ O
chicken O
/ O
Vietnam O
/ O
TY31 O
/ O
2005 O
[ O
Ck O
/ O
TY31 O
] O
) O
to O
grow O
in O
human O
lung O
epithelial O
A549 O
cells O
. O

Here O
, O
we O
report O
that O
five O
amino O
acid O
substitutions O
in O
PA O
( O
V44I O
, O
V127A O
, O
C241Y O
, O
A343T O
, O
and O
I573V O
) O
contribute O
to O
the O
replicative O
efficiency O
of O
H5N1 O
viruses O
in O
human O
lung O
cells O
and O
to O
high O
virulence O
in O
mice O
. O

The O
avian O
Hemagglutinin B
( I
HA I
) I
allowed O
the O
hybrid O
viruses O
to O
escape O
preexisting O
immunity O
in O
the O
human O
population O
. O

Using O
seasonal O
H2N2 O
virus O
A O
/ O
California O
/ O
1 O
/ O
66 O
( O
Cal O
) O
as O
a O
surrogate O
precursor O
human O
virus O
and O
pandemic O
virus O
A O
/ O
Hong O
Kong O
/ O
1 O
/ O
68 O
( O
H3N2 O
) O
( O
HK O
) O
as O
a O
source O
of O
avian O
- O
derived O
PB1 O
and O
HA O
gene O
segments O
, O
we O
generated O
four O
reassortant O
recombinant O
viruses O
and O
compared O
pairs O
of O
viruses O
which O
differed O
solely O
by O
the O
origin O
of O
PB1 O
. O

Influenza O
A O
viruses O
enter O
host O
cells O
through O
endosomes O
, O
where O
acidification O
induces O
irreversible O
conformational O
changes O
of O
the O
viral O
Hemagglutinin B
( I
HA I
) I
that O
drive O
the O
membrane O
fusion O
process O
. O

IMPORTANCE O
The O
influenza B
A I
hemagglutinin I
glycoprotein I
( I
HA I
) I
mediates O
the O
receptor O
binding O
and O
membrane O
fusion O
functions O
that O
are O
essential O
for O
virus O
entry O
into O
host O
cells O
. O

To O
produce O
a O
therapeutic O
agent O
that O
is O
highly O
efficacious O
at O
low O
doses O
and O
is O
broadly O
specific O
against O
antigenically O
drifted O
H5N1 O
influenza O
viruses O
, O
we O
developed O
two O
neutralizing O
monoclonal O
antibodies O
and O
combined O
them O
into O
a O
single O
bispecific O
Fc O
fusion O
protein O
( O
the O
Fc O
dual O
- O
affinity O
retargeting O
[ O
FcDART O
] O
molecule O
) O
. O

5 O
mg O
/ O
kg O
of O
body O
weight O
provided O
100 O
% O
protection O
against O
challenge O
with O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
or O
the O
antigenically O
drifted O
strain O
A O
/ O
Whooper O
swan O
/ O
Mongolia O
/ O
244 O
/ O
05 O
( O
H5N1 O
) O
. O

During O
2013 O
, O
three O
new O
avian O
influenza O
A O
virus O
subtypes O
, O
A O
( O
H7N9 O
) O
, O
A O
( O
H6N1 O
) O
, O
and O
A O
( O
H10N8 O
) O
, O
resulted O
in O
human O
infections O
. O

While O
the O
A O
( O
H7N9 O
) O
virus O
resulted O
in O
a O
significant O
epidemic O
in O
China O
across O
19 O
provinces O
and O
municipalities O
, O
both O
A O
( O
H6N1 O
) O
and O
A O
( O
H10N8 O
) O
viruses O
resulted O
in O
only O
a O
few O
human O
infections O
. O

The O
detailed O
structural O
and O
glycan O
microarray O
analyses O
presented O
here O
highlight O
the O
idea O
that O
both O
A O
( O
H6N1 O
) O
and O
A O
( O
H10N8 O
) O
virus O
hemagglutinins O
retain O
a O
strong O
avian O
receptor O
binding O
preference O
and O
thus O
currently O
pose O
a O
low O
risk O
for O
sustained O
human O
infections O
. O

We O
report O
detailed O
structural O
analysis O
and O
glycan O
microarray O
data O
for O
recombinant O
hemagglutinins O
from O
A O
( O
H6N1 O
) O
and O
A O
( O
H10N8 O
) O
viruses O
, O
isolated O
from O
human O
infections O
in O
2013 O
, O
and O
compare O
them O
with O
hemagglutinins O
of O
avian O
origin O
. O

Similar O
to O
H5N1 O
viruses O
, O
A O
( O
H7N9 O
) O
influenza O
viruses O
have O
been O
associated O
with O
severe O
respiratory O
disease O
and O
fatal O
outcomes O
in O
humans O
. O

While O
high O
viral O
load O
, O
hypercytokinemia O
, O
and O
pulmonary O
endothelial O
cell O
involvement O
are O
known O
to O
be O
hallmarks O
of O
H5N1 O
virus O
infection O
, O
the O
pathogenic O
mechanism O
of O
the O
A O
( O
H7N9 O
) O
virus O
in O
humans O
is O
largely O
unknown O
. O

In O
this O
study O
, O
we O
assessed O
the O
ability O
of O
A O
( O
H7N9 O
) O
virus O
to O
infect O
, O
replicate O
, O
and O
elicit O
innate O
immune O
responses O
in O
both O
human O
bronchial O
epithelial O
cells O
and O
pulmonary O
microvascular O
endothelial O
cells O
, O
compared O
with O
the O
abilities O
of O
seasonal O
H3N2 O
, O
avian O
H7N9 O
, O
and O
H5N1 O
viruses O
. O

In O
epithelial O
cells O
, O
A O
( O
H7N9 O
) O
virus O
replicated O
efficiently O
but O
did O
not O
elicit O
robust O
induction O
of O
cytokines O
like O
that O
observed O
for O
H5N1 O
virus O
. O

In O
pulmonary O
endothelial O
cells O
, O
A O
( O
H7N9 O
) O
virus O
efficiently O
initiated O
infection O
; O
however O
, O
no O
released O
infectious O
virus O
was O
detected O
. O

The O
magnitudes O
of O
induction O
of O
host O
cytokine O
responses O
were O
comparable O
between O
A O
( O
H7N9 O
) O
and O
H5N1 O
virus O
infection O
. O

Interestingly O
, O
A O
( O
H7N9 O
) O
virus O
budded O
from O
the O
surfaces O
of O
both O
ciliated O
and O
mucin O
- O
secretory O
cells O
. O

Furthermore O
, O
A O
( O
H7N9 O
) O
virus O
replicated O
to O
a O
significantly O
higher O
titer O
at O
37 O
degrees O
C O
than O
at O
33 O
degrees O
C O
, O
with O
improved O
replication O
capacity O
at O
33 O
degrees O
C O
compared O
to O
that O
of O
H5N1 O
virus O
. O

Improved O
adaptation O
of O
A O
( O
H7N9 O
) O
virus O
to O
human O
upper O
airway O
poses O
an O
important O
threat O
to O
public O
health O
. O

IMPORTANCE O
A O
( O
H7N9 O
) O
influenza O
viruses O
have O
caused O
over O
450 O
documented O
human O
infections O
with O
a O
30 O
% O
fatality O
rate O
since O
early O
2013 O
. O

This O
study O
provides O
greater O
insight O
into O
the O
interaction O
of O
this O
virus O
with O
host O
lung O
epithelial O
cells O
and O
endothelial O
cells O
, O
which O
results O
in O
high O
viral O
load O
, O
epithelial O
cell O
death O
, O
and O
elevated O
immune O
response O
in O
the O
lungs O
, O
revealing O
the O
mechanism O
of O
pathogenesis O
and O
disease O
development O
among O
A O
( O
H7N9 O
) O
- O
infected O
patients O
. O

In O
particular O
, O
we O
characterized O
the O
involvement O
of O
pulmonary O
endothelial O
cells O
, O
a O
cell O
type O
in O
the O
human O
lung O
accessible O
to O
influenza O
virus O
following O
damage O
of O
the O
epithelial O
monolayer O
, O
and O
its O
potential O
role O
in O
the O
development O
of O
severe O
pneumonia O
caused O
by O
A O
( O
H7N9 O
) O
infection O
in O
humans O
. O

However O
, O
the O
role O
of O
PA O
- O
X O
in O
the O
pathogenesis O
of O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
of O
the O
H5N1 O
subtype O
in O
avian O
species O
is O
totally O
unknown O
. O

By O
generating O
two O
PA O
- O
X O
- O
deficient O
viruses O
and O
evaluating O
their O
virulence O
in O
different O
animal O
models O
, O
we O
show O
here O
that O
PA O
- O
X O
diminishes O
the O
virulence O
of O
the O
HPAIV O
H5N1 O
strain O
A O
/ O
Chicken O
/ O
Jiangsu O
/ O
k0402 O
/ O
2010 O
( O
CK10 O
) O
in O
mice O
, O
chickens O
, O
and O
ducks O
. O

IMPORTANCE O
influenza B
A I
virus I
( I
IAV I
) I
continues O
to O
pose O
a O
huge O
threat O
to O
global O
public O
health O
. O

In O
late O
2011 O
, O
an O
A O
( O
H3N8 O
) O
influenza O
virus O
infection O
resulted O
in O
the O
deaths O
of O
162 O
New O
England O
harbor O
seals O
. O

Although O
the O
detection O
of O
this O
virus O
in O
new O
species O
highlights O
an O
increased O
potential O
for O
crosss O
- O
pecies O
transmission O
, O
our O
results O
indicate O
that O
the O
A O
( O
H3N8 O
) O
virus O
currently O
poses O
a O
low O
risk O
to O
humans O
. O

Here O
, O
we O
report O
a O
molecular O
and O
structural O
study O
of O
the O
major O
surface O
proteins O
from O
an O
A O
( O
H3N8 O
) O
influenza O
virus O
isolated O
from O
New O
England O
harbor O
seals O
. O

Influenza O
vaccine O
development O
has O
traditionally O
focused O
on O
producing O
humoral O
and O
/ O
or O
cell O
- O
mediated O
immunity O
, O
often O
against O
the O
viral O
surface O
glycoproteins O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
. O

Here O
, O
we O
describe O
a O
new O
vaccine O
candidate O
that O
utilizes O
a O
replication O
- O
defective O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
vector O
backbone O
that O
lacks O
the O
native O
G O
surface O
glycoprotein O
gene O
( O
VSV O
Delta O
G O
) O
. O

The O
expression O
of O
the O
H5 O
HA O
of O
an O
H5N1 O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
, O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
VN1203 O
) O
, O
and O
the O
NA O
of O
the O
mouse O
- O
adapted O
H1N1 O
influenza O
virus O
A O
/ O
PuertoRico O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
in O
the O
VSV O
Delta O
G O
vector O
restored O
the O
ability O
of O
the O
recombinant O
virus O
to O
replicate O
in O
cell O
culture O
, O
without O
the O
requirement O
for O
the O
addition O
of O
trypsin O
. O

We O
have O
created O
a O
new O
influenza O
vaccine O
that O
utilizes O
an O
attenuated O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
vector O
, O
to O
deliver O
and O
express O
influenza O
virus O
proteins O
against O
which O
vaccinated O
animals O
develop O
potent O
antibody O
responses O
. O

At O
least O
10 O
different O
genotypes O
of O
novel O
reassortant O
H3N2 O
influenza O
viruses O
with O
2009 O
pandemic O
H1N1 O
[ O
A O
( O
H1N1 O
) O
pdm09 O
] O
gene O
( O
s O
) O
have O
been O
identified O
in O
U O
. O

pigs O
, O
including O
the O
H3N2 O
variant O
with O
a O
single O
A O
( O
H1N1 O
) O
pdm09 O
M O
gene O
, O
which O
has O
infected O
more O
than O
300 O
people O
. O

Here O
, O
we O
show O
that O
three O
H3N2 O
reassortant O
viruses O
that O
contain O
3 O
( O
NP O
, O
M O
, O
and O
NS O
) O
or O
5 O
( O
PA O
, O
PB2 O
, O
NP O
, O
M O
, O
and O
NS O
) O
genes O
from O
A O
( O
H1N1 O
) O
pdm09 O
were O
pathogenic O
in O
pigs O
, O
similar O
to O
the O
endemic O
H3N2 O
swine O
virus O
. O

However O
, O
the O
reassortant O
H3N2 O
virus O
with O
3 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
and O
a O
recent O
human O
influenza O
virus O
N2 O
gene O
was O
transmitted O
most O
efficiently O
among O
pigs O
, O
whereas O
the O
reassortant O
H3N2 O
virus O
with O
5 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
was O
transmitted O
less O
efficiently O
than O
the O
endemic O
H3N2 O
virus O
. O

Interestingly O
, O
the O
polymerase O
complex O
of O
reassortant O
H3N2 O
virus O
with O
5 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
showed O
significantly O
higher O
polymerase O
activity O
than O
those O
of O
endemic O
and O
reassortant O
H3N2 O
viruses O
with O
3 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
. O

Further O
studies O
showed O
that O
an O
avian O
- O
like O
glycine O
at O
position O
228 O
at O
the O
Hemagglutinin B
( I
HA I
) I
receptor O
binding O
site O
is O
responsible O
for O
inefficient O
transmission O
of O
the O
reassortant O
H3N2 O
virus O
with O
5 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
. O

Introduction O
of O
2009 O
pandemic O
H1N1 O
virus O
[ O
A O
( O
H1N1 O
) O
pdm09 O
] O
into O
swine O
herds O
has O
resulted O
in O
novel O
reassortant O
influenza O
viruses O
in O
swine O
, O
including O
H3N2 O
and O
H1N2 O
variants O
that O
have O
caused O
human O
infections O
in O
the O
United O
States O
. O

We O
showed O
that O
reassortant O
H3N2 O
influenza O
viruses O
with O
3 O
or O
5 O
genes O
from O
A O
( O
H1N1 O
) O
pdm09 O
isolated O
from O
diseased O
pigs O
are O
pathogenic O
and O
transmissible O
in O
pigs O
, O
but O
the O
reassortant O
H3N2 O
virus O
with O
5 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
displayed O
less O
efficient O
transmissibility O
than O
the O
endemic O
and O
reassortant O
H3N2 O
viruses O
with O
3 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
. O

Further O
studies O
revealed O
that O
an O
avian O
- O
like O
glycine O
at O
the O
HA O
228 O
receptor O
binding O
site O
of O
the O
reassortant O
H3N2 O
virus O
with O
5 O
A O
( O
H1N1 O
) O
pdm09 O
genes O
is O
responsible O
for O
less O
efficient O
transmissibility O
in O
pigs O
. O

Both O
chicken O
and O
duck O
myotubes O
expressed O
avian O
and O
human O
sialic O
acid O
receptors O
and O
were O
readily O
susceptible O
to O
low O
- O
pathogenicity O
( O
H2N3 O
A O
/ O
mallard O
duck O
/ O
England O
/ O
7277 O
/ O
06 O
) O
and O
high O
- O
pathogenicity O
( O
H5N1 O
A O
/ O
turkey O
/ O
England O
/ O
50 O
- O
92 O
/ O
91 O
and O
H5N1 O
A O
/ O
turkey O
/ O
Turkey O
/ O
1 O
/ O
05 O
) O
avian O
and O
human O
H1N1 O
( O
A O
/ O
USSR O
/ O
77 O
) O
influenza O
viruses O
. O

Notably O
, O
the O
rapid O
accumulation O
of O
viral O
nucleoprotein O
and O
matrix B
( I
M I
) I
gene O
RNA O
in O
chicken O
and O
duck O
myotubes O
was O
accompanied O
by O
extensive O
cytopathic O
damage O
with O
marked O
myotube O
apoptosis O
( O
widespread O
microscopic O
blebs O
, O
caspase O
3 O
/ O
7 O
activation O
, O
and O
annexin O
V O
binding O
at O
the O
plasma O
membrane O
) O
. O

Additionally O
, O
in O
chicken O
myotubes O
infected O
with O
H5N1 O
viruses O
, O
the O
induction O
of O
interferon B
beta I
( I
IFN I
- I
beta I
) I
and O
IFN O
- O
inducible O
genes O
, O
including O
the O
melanoma O
differentiation O
- O
associated O
protein O
5 O
( O
MDA O
- O
5 O
) O
gene O
, O
was O
relatively O
weak O
compared O
to O
infection O
with O
the O
corresponding O
H2N3 O
virus O
. O

Bioengineering O
of O
viruses O
and O
virus B
- I
like I
particles I
( I
VLPs I
) I
is O
a O
well O
- O
established O
approach O
in O
the O
development O
of O
new O
and O
improved O
vaccines O
against O
viral O
and O
bacterial O
pathogens O
. O

We O
report O
here O
that O
the O
capsid O
of O
a O
major O
avian O
pathogen O
, O
infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
, O
can O
accommodate O
heterologous O
proteins O
to O
induce O
protective O
immunity O
. O

The O
structural O
units O
of O
the O
similar O
to O
70 O
- O
nm O
- O
diameter O
T O
= O
13 O
IBDV O
capsid O
are O
trimers O
of O
VP2 O
, O
which O
is O
made O
as O
a O
precursor O
( O
pVP2 O
) O
. O

In O
the O
absence O
of O
the O
VP3 O
scaffolding O
protein O
, O
466 O
- O
residue O
pVP2 O
intermediates O
bearing O
this O
alpha O
helix O
assemble O
into O
genuine O
VLPs O
only O
when O
expressed O
with O
an O
N O
- O
terminal O
His O
( O
6 O
) O
tag O
( O
the O
HT O
- O
VP2 O
- O
466 O
protein O
) O
. O

HT O
- O
VP2 O
- O
466 O
capsids O
are O
optimal O
for O
protein O
insertion O
, O
as O
they O
are O
large O
enough O
( O
cargo O
space O
, O
similar O
to O
78 O
, O
000 O
nm O
( O
3 O
) O
) O
and O
are O
assembled O
from O
a O
single O
protein O
. O

We O
explored O
HT O
- O
VP2 O
- O
466 O
- O
based O
chimeric O
capsids O
initially O
using O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
. O

The O
native O
EGFP O
structure O
( O
similar O
to O
240 O
copies O
/ O
virion O
) O
was O
successfully O
inserted O
in O
a O
functional O
form O
, O
as O
VLPs O
were O
fluorescent O
, O
and O
three O
- O
dimensional O
cryo O
- O
electron O
microscopy O
showed O
that O
the O
EGFP O
molecules O
incorporated O
at O
the O
inner O
capsid O
surface O
. O

We O
also O
inserted O
Hemagglutinin B
( I
HA I
) I
and O
matrix O
( O
M2 O
) O
protein O
epitopes O
derived O
from O
the O
mouse O
- O
adapted O
A O
/ O
PR O
/ O
8 O
/ O
34 O
influenza O
virus O
and O
engineered O
several O
HA O
- O
and O
M2 O
- O
derived O
chimeric O
capsids O
. O

IMPORTANCE O
virus B
- I
like I
particles I
( I
VLPs I
) I
are O
multimeric O
protein O
cages O
that O
mimic O
the O
infectious O
virus O
capsid O
and O
are O
potential O
candidates O
as O
nonliving O
vaccines O
that O
induce O
long O
- O
lasting O
protection O
. O

We O
report O
the O
biochemical O
, O
structural O
, O
and O
immunological O
characterization O
of O
chimeric O
VLPs O
derived O
from O
infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
, O
an O
important O
poultry O
pathogen O
. O

A O
panel O
of O
airway O
epithelial O
and O
immune O
cells O
from O
mammalian O
and O
avian O
species O
were O
infected O
with O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
H1N1 O
virus O
, O
low O
- O
pathogenicity O
avian O
influenza O
H5N3 O
virus O
( O
A O
/ O
duck O
/ O
Victoria O
/ O
0305 O
- O
2 O
/ O
2012 O
) O
, O
highly O
pathogenic O
avian O
influenza O
H5N1 O
virus O
( O
A O
/ O
chicken O
/ O
Vietnam O
/ O
0008 O
/ O
2004 O
) O
, O
or O
low O
- O
pathogenicity O
avian O
influenza O
H7N9 O
virus O
( O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
) O
. O

Quantitative O
real O
- O
time O
reverse O
transcriptase O
PCR O
showed O
that O
H5N1 O
and O
H7N9 O
viruses O
significantly O
stimulated O
cytokine O
( O
interleukin O
- O
6 O
, O
beta O
interferon O
, O
CXCL10 O
, O
and O
CCL5 O
) O
production O
. O

These O
findings O
suggest O
that O
apocynin O
or O
its O
derivatives O
( O
targeting O
host O
responses O
) O
could O
be O
used O
in O
combination O
with O
antiviral O
strategies O
( O
targeting O
viruses O
) O
as O
therapeutic O
agents O
to O
ameliorate O
disease O
severity O
in O
susceptible O
species O
. O

Our O
study O
shows O
that O
highly O
pathogenic O
avian O
influenza O
H5N1 O
virus O
and O
low O
- O
pathogenicity O
avian O
influenza O
H7N9 O
virus O
( O
both O
associated O
with O
human O
fatalities O
) O
promote O
inactivation O
of O
FoxO3 O
and O
downregulation O
of O
the O
TAM O
receptor O
tyrosine O
kinase O
, O
Tyro3 O
, O
leading O
to O
augmentation O
of O
the O
inflammatory O
cytokine O
response O
. O

The O
envelope O
of O
influenza O
A O
viruses O
contains O
two O
large O
antigens O
, O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
. O

The O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
envelope O
protein O
mediates O
virus O
entry O
by O
first O
binding O
to O
cell O
surface O
receptors O
and O
then O
fusing O
viral O
and O
endosomal O
membranes O
during O
endocytosis O
. O

Cleavage O
of O
the O
HA O
precursor O
( O
HA0 O
) O
into O
a O
surface O
receptor O
- O
binding O
subunit O
( O
HA1 O
) O
and O
a O
fusion O
- O
inducing O
transmembrane O
subunit O
( O
HA2 O
) O
by O
host O
cell O
enzymes O
primes O
HA O
for O
fusion O
competence O
by O
repositioning O
the O
fusion O
peptide O
to O
the O
newly O
created O
N O
terminus O
of O
HA2 O
. O

We O
previously O
reported O
that O
the O
influenza O
virus O
M2 O
protein O
enhances O
pandemic O
2009 O
influenza O
A O
virus O
[ O
( O
H1N1 O
) O
pdm09 O
] O
HA O
- O
pseudovirus O
infectivity O
, O
but O
the O
mechanism O
was O
unclear O
. O

The O
M2 O
activity O
was O
needed O
only O
during O
HA O
biosynthesis O
, O
and O
proteolysis O
experiments O
indicated O
that O
M2 O
proton O
channel O
activity O
helped O
to O
protect O
( O
H1N1 O
) O
pdm09 O
HA O
from O
premature O
conformational O
changes O
as O
it O
traversed O
low O
- O
pH O
compartments O
during O
transport O
to O
the O
cell O
surface O
. O

IMPORTANCE O
Influenza O
virus O
infects O
cells O
when O
the O
Hemagglutinin B
( I
HA I
) I
surface O
protein O
undergoes O
irreversible O
pH O
- O
induced O
conformational O
changes O
after O
the O
virus O
is O
taken O
into O
the O
cell O
by O
endocytosis O
. O

Using O
assays O
that O
focus O
on O
HA O
entry O
and O
fusion O
, O
we O
found O
that O
the O
M2 O
protein O
also O
protects O
( O
H1N1 O
) O
pdm09 O
influenza O
A O
virus O
HA O
from O
premature O
conformational O
changes O
as O
it O
transits O
low O
- O
pH O
compartments O
during O
biosynthesis O
. O

Interferon O
- O
induced O
Mx O
proteins O
show O
strong O
antiviral O
activity O
against O
influenza B
A I
viruses I
( I
IAVs I
) I
. O

We O
recently O
demonstrated O
that O
the O
viral O
nucleoprotein B
( I
NP I
) I
determines O
resistance O
of O
seasonal O
and O
pandemic O
human O
influenza O
viruses O
to O
Mx O
, O
while O
avian O
isolates O
retain O
Mx O
sensitivity O
. O

We O
identified O
a O
surface O
- O
exposed O
cluster O
of O
amino O
acids O
in O
NP O
of O
pandemic O
A O
/ O
BM O
/ O
1 O
/ O
1918 O
( O
H1N1 O
) O
, O
comprising O
isoleucine O
- O
100 O
, O
proline O
- O
283 O
, O
and O
tyrosine O
- O
313 O
, O
that O
is O
essential O
for O
reduced O
Mx O
sensitivity O
in O
cell O
culture O
and O
in O
vivo O
. O

This O
cluster O
has O
been O
maintained O
in O
all O
descendant O
seasonal O
strains O
, O
including O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
PR O
/ O
8 O
) O
. O

Accordingly O
, O
two O
substitutions O
in O
the O
NP O
of O
PR O
/ O
8 O
[ O
PR O
/ O
8 O
( O
mut O
) O
] O
to O
the O
Mx O
- O
sensitive O
amino O
acids O
( O
P283L O
and O
Y313F O
) O
led O
to O
attenuation O
in O
Mx1 O
- O
positive O
mice O
. O

Serial O
lung O
passages O
of O
PR O
/ O
8 O
( O
mut O
) O
in O
Mx1 O
mice O
resulted O
in O
a O
single O
exchange O
of O
tyrosine O
to O
asparagine O
at O
position O
52 O
in O
NP O
( O
in O
close O
proximity O
to O
the O
amino O
acid O
cluster O
at O
positions O
100 O
, O
283 O
, O
and O
313 O
) O
, O
which O
partially O
compensates O
loss O
of O
Mx O
resistance O
in O
PR O
/ O
8 O
( O
mut O
) O
. O

IMPORTANCE O
The O
natural O
host O
of O
influenza B
A I
viruses I
( I
IAVs I
) I
are O
aquatic O
birds O
. O

Neuraminidase B
inhibitors I
( I
NAIs I
) I
have O
been O
widely O
used O
to O
control O
influenza O
virus O
infection O
, O
but O
their O
increased O
use O
could O
promote O
the O
global O
emergence O
of O
resistant O
variants O
. O

We O
therefore O
screened O
a O
known O
mutation O
( O
s O
) O
that O
could O
confer O
multidrug O
resistance O
to O
the O
currently O
approved O
NAIs O
oseltamivir O
, O
zanamivir O
, O
and O
peramivir O
by O
assessing O
recombinant O
viruses O
with O
mutant O
NA O
- O
encoding O
genes O
( O
catalytic O
residues O
R152K O
and O
R292K O
, O
framework O
residues O
E119A O
/ O
D O
/ O
G O
, O
D198N O
, O
H274Y O
, O
and O
N294S O
) O
in O
the O
backbones O
of O
The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
and O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
. O

Of O
the O
14 O
single O
and O
double O
mutant O
viruses O
recovered O
in O
the O
backbone O
of O
pH1N1 O
, O
four O
variants O
( O
E119D O
, O
E119A O
/ O
D O
/ O
G O
- O
H274Y O
) O
exhibited O
reduced O
inhibition O
by O
all O
of O
the O
NAIs O
and O
two O
variants O
( O
E119D O
and O
E119D O
- O
H274Y O
) O
retained O
the O
overall O
properties O
of O
gene O
stability O
, O
replicative O
efficiency O
, O
pathogenicity O
, O
and O
transmissibility O
in O
vitro O
and O
in O
vivo O
. O

Of O
the O
nine O
recombinant O
H5N1 O
viruses O
, O
four O
variants O
( O
E119D O
, O
E119A O
/ O
D O
/ O
G O
- O
H274Y O
) O
also O
showed O
reduced O
inhibition O
by O
all O
of O
the O
NAIs O
, O
though O
their O
overall O
viral O
fitness O
was O
impaired O
in O
vitro O
and O
/ O
or O
in O
vivo O
. O

IMPORTANCE O
There O
has O
been O
a O
widespread O
emergence O
of O
influenza O
virus O
strains O
with O
reduced O
susceptibility O
to O
Neuraminidase B
inhibitors I
( I
NAIs I
) I
. O

We O
found O
that O
recombinant O
E119D O
and O
E119A O
/ O
D O
/ O
G O
/ O
- O
H274Y O
mutant O
viruses O
demonstrated O
reduced O
inhibition O
by O
all O
of O
the O
NAIs O
tested O
in O
both O
the O
backbone O
of O
the B
2009 I
H1N1 I
pandemic I
( I
pH1N1 I
) I
and O
highly O
pathogenic O
avian O
influenza O
H5N1 O
viruses O
. O

Entry O
is O
mediated O
by O
the O
viral O
membrane O
protein O
Hemagglutinin B
( I
HA I
) I
, O
which O
triggers O
membrane O
fusion O
and O
genome O
release O
under O
acidic O
conditions O
in O
the O
endosome O
. O

Using O
single B
- I
particle I
- I
tracking I
( I
SPT I
) I
techniques O
, O
individual O
membrane O
fusion O
events O
can O
be O
observed O
under O
specific O
conditions O
, O
which O
provide O
detailed O
information O
regarding O
HA O
pH O
sensitivity O
and O
acid O
stability O
and O
the O
rate O
and O
extent O
of O
membrane O
fusion O
. O

We O
used O
SPT O
to O
quantify O
the O
fusion O
properties O
of O
three O
H3 O
influenza O
strains O
: O
A O
/ O
Aichi O
/ O
68 O
/ O
H3N2 O
( O
X O
: O
31 O
) O
, O
A O
/ O
Udorn O
/ O
72 O
/ O
H3N2 O
( O
Udorn O
) O
, O
and O
A O
/ O
Brisbane O
/ O
07 O
/ O
H3N2 O
( O
Brisbane O
) O
. O

The O
rate O
of O
fusion O
for O
the O
most O
clinically O
relevant O
strain O
, O
Brisbane O
, O
is O
generally O
insensitive O
to O
decreasing O
pH O
, O
while O
the O
fusion O
of O
the O
egg O
- O
adapted O
strains O
Udorn O
and O
X O
: O
31 O
is O
strongly O
dependent O
on O
pH O
( O
and O
is O
faster O
) O
as O
the O
pH O
decreases O
. O

All O
strains O
exhibit O
similar O
acid O
stability O
( O
the O
length O
of O
time O
that O
they O
remain O
fusogenic O
in O
an O
acidic O
environment O
) O
at O
higher O
pHs O
, O
but O
the O
egg O
- O
adapted O
strains O
become O
less O
acid O
stable O
at O
lower O
pHs O
. O

Using O
a O
single B
- I
particle I
- I
tracking I
( I
SPT I
) I
technique O
, O
we O
show O
here O
that O
the O
highest O
pH O
that O
initiates O
fusion O
is O
not O
necessarily O
the O
pH O
at O
which O
the O
kinetics O
of O
fusion O
is O
fastest O
and O
most O
abundant O
for O
a O
given O
strain O
. O

Here O
, O
we O
show O
that O
a O
mouse O
- O
adapted O
PB2 O
gene O
with O
a O
phenylalanine O
- O
to O
- O
leucine O
mutation O
( O
F404L O
) O
mainly O
contributes O
to O
enhanced O
polymerase O
activity O
, O
replication O
, O
and O
pathogenicity O
of O
H9N2 O
in O
mice O
and O
also O
increases O
the O
virulence O
of O
the O
H5N1 O
and O
2009 O
pandemic O
H1N1 O
influenza O
viruses O
. O

Since O
1998 O
, O
cyclic O
mortality O
events O
in O
common O
eiders O
( O
Somateria O
mollissima O
) O
, O
numbering O
in O
the O
hundreds O
to O
thousands O
of O
dead O
birds O
, O
have O
been O
documented O
along O
the O
coast O
of O
Cape O
Cod O
, O
MA O
, O
USA O
. O

Here O
, O
we O
identify O
a O
novel O
orthomyxovirus O
, O
tentatively O
named O
Wellfleet B
Bay I
virus I
( I
WFBV I
) I
, O
as O
a O
potential O
causative O
agent O
of O
these O
outbreaks O
. O

Similar O
to O
other O
members O
of O
the O
genus O
, O
WFBV O
contains O
an O
alphabaculovirus O
gp64 O
- O
like O
glycoprotein O
that O
was O
demonstrated O
to O
have O
fusion O
activity O
; O
this O
also O
tentatively O
suggests O
that O
ticks O
( O
and O
/ O
or O
insects O
) O
may O
vector O
the O
virus O
in O
nature O
. O

However O
, O
in O
addition O
to O
the O
six O
RNA O
segments O
encoding O
the O
prototypical O
structural O
proteins O
identified O
in O
other O
quaranjaviruses O
, O
a O
previously O
unknown O
RNA O
segment O
( O
segment O
7 O
) O
encoding O
a O
novel O
protein O
designated O
VP7 O
was O
discovered O
in O
WFBV O
. O

Although O
WFBV O
shows O
low O
to O
moderate O
levels O
of O
sequence O
similarity O
to O
Quaranfil O
virus O
and O
Johnston O
Atoll O
virus O
, O
the O
original O
members O
of O
the O
Quaranjavirus O
genus O
, O
additional O
antigenic O
and O
genetic O
analyses O
demonstrated O
that O
it O
is O
closely O
related O
to O
the O
recently O
identified O
Cygnet B
River I
virus I
( I
CyRV I
) I
from O
South O
Australia O
, O
suggesting O
that O
WFBV O
and O
CyRV O
may O
be O
geographic O
variants O
of O
the O
same O
virus O
. O

Here O
, O
we O
describe O
the O
emergence O
of O
a O
novel O
orthomyxovirus O
, O
Wellfleet B
Bay I
virus I
( I
WFBV I
) I
, O
which O
has O
been O
associated O
with O
cyclic O
large O
- O
scale O
bird O
die O
- O
offs O
in O
the O
northeastern O
United O
States O
. O

To O
address O
this O
, O
we O
generated O
a O
mouse B
- I
adapted I
( I
MA I
) I
swine O
influenza O
H6N6 O
virus O
( O
A O
/ O
swine O
/ O
Guangdong O
/ O
K6 O
/ O
2010 O
[ O
GDK6 O
- O
MA O
] O
) O
which O
exhibited O
greater O
virulence O
than O
the O
wild O
- O
type O
virus O
( O
GDK6 O
) O
. O

Amino O
acid O
substitutions O
in O
PB2 O
( O
E627K O
) O
, O
PA O
( O
I38M O
) O
, O
and O
hemagglutinin O
( O
[ O
HA O
] O
L111F O
, O
H156N O
, O
and O
S263R O
) O
occurred O
in O
GDK6 O
- O
MA O
. O

HA O
with O
the O
H156N O
mutation O
[ O
HA O
( O
H156N O
) O
] O
resulted O
in O
enlarged O
plaque O
sizes O
on O
MDCK O
cells O
and O
enhanced O
early O
- O
stage O
viral O
replication O
in O
mammalian O
cells O
. O

PA O
( O
I38M O
) O
raised O
polymerase O
activity O
in O
vitro O
but O
did O
not O
change O
virus O
replication O
in O
either O
mammalian O
cells O
or O
mice O
. O

These O
single O
substitutions O
had O
only O
limited O
effects O
on O
virulence O
; O
however O
, O
a O
combination O
of O
HA O
( O
H156N O
S263R O
) O
with O
PA O
( O
I38M O
) O
in O
the O
GDK6 O
backbone O
led O
to O
a O
significantly O
more O
virulent O
variant O
. O

This O
suggests O
that O
these O
substitutions O
can O
compensate O
for O
the O
lack O
of O
PB2 O
( O
627K O
) O
and O
modulate O
virulence O
, O
revealing O
a O
new O
determinant O
of O
pathogenicity O
for O
H6N6 O
viruses O
in O
mice O
, O
which O
might O
also O
pose O
a O
threat O
to O
human O
health O
. O

To O
examine O
the O
molecular O
mechanisms O
of O
adaptation O
, O
a O
mouse O
- O
adapted O
avian O
- O
origin O
swine O
influenza O
H6N6 O
virus O
( O
GDK6 O
- O
MA O
) O
, O
which O
had O
higher O
virulence O
than O
its O
parental O
virus O
, O
was O
generated O
. O

Specific O
mutations O
were O
found O
in O
PB2 O
( O
E627K O
) O
, O
PA O
( O
I38M O
) O
, O
and O
HA O
( O
L111F O
, O
H156N O
, O
and O
S263R O
) O
and O
were O
assessed O
for O
their O
virulence O
in O
mice O
. O

The O
combination O
of O
HA O
( O
H156N O
S263R O
) O
and O
PA O
( O
I38M O
) O
compensated O
for O
the O
lack O
of O
PB2 O
( O
627K O
) O
and O
showed O
increased O
pathogenicity O
in O
mice O
, O
revealing O
a O
novel O
mechanism O
that O
can O
affect O
the O
virulence O
of O
influenza O
viruses O
. O

Specifically O
, O
lysine O
at O
position O
185 O
of O
A O
/ O
duck O
/ O
Vietnam O
/ O
TY165 O
/ O
2010 O
( O
TY165 O
; O
H5N1 O
) O
PA O
induced O
strongly O
attenuating O
effects O
in O
vitro O
and O
in O
vivo O
. O

We O
found O
that O
the O
viral O
PA O
polymerase O
subunit O
of O
several O
H5N1 O
viruses O
possesses O
amino O
acid O
changes O
that O
attenuate O
virus O
replication O
in O
mammalian O
cells O
( O
yet O
the O
H5N1 O
viruses O
possessing O
these O
mutations O
are O
highly O
pathogenic O
in O
mice O
) O
. O

Human O
infections O
with O
influenza O
A O
( O
H5N1 O
) O
virus O
in O
Cambodia O
increased O
sharply O
during O
2013 O
. O

Molecular O
characterization O
of O
viruses O
detected O
in O
clinical O
specimens O
from O
human O
cases O
revealed O
the O
presence O
of O
mutations O
associated O
with O
the O
alteration O
of O
receptor O
- O
binding O
specificity O
( O
K189R O
, O
Q222L O
) O
and O
respiratory O
droplet O
transmission O
in O
ferrets O
( O
N220K O
with O
Q222L O
) O
. O

Discovery O
of O
quasispecies O
at O
position O
222 O
( O
Q O
/ O
L O
) O
, O
in O
addition O
to O
the O
absence O
of O
the O
mutations O
in O
poultry O
/ O
environmental O
samples O
, O
suggested O
that O
the O
mutations O
occurred O
during O
human O
infection O
and O
did O
not O
transmit O
further O
. O

Initial O
reports O
of O
H7N9 O
infection O
compared O
them O
to O
infections O
caused O
by O
highly B
pathogenic I
avian I
( I
HPAI I
) I
H5N1 O
viruses O
. O

The O
conformational O
change O
of O
the O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
protein O
mediating O
the O
fusion O
between O
the O
virus O
envelope O
and O
the O
endosomal O
membrane O
was O
hypothesized O
to O
be O
induced O
by O
protonation O
of O
specific O
histidine O
residues O
since O
their O
pK O
( O
a O
) O
s O
match O
the O
pHs O
of O
late O
endosomes O
( O
pK O
( O
a O
) O
of O
similar O
to O
6 O
. O

Computational O
modeling O
of O
the O
protonated O
His184 O
revealed O
that O
His184 O
is O
central O
in O
a O
conserved O
interaction O
network O
possibly O
regulating O
the O
pH O
dependence O
of O
conformational O
change O
via O
its O
pK O
( O
a O
) O
. O

As O
the O
propensity O
of O
histidine O
to O
get O
protonated O
largely O
depends O
on O
its O
local O
environment O
, O
mutation O
of O
residues O
in O
the O
vicinity O
of O
histidine O
may O
affect O
its O
pK O
( O
a O
) O
. O

These O
results O
are O
in O
support O
of O
a O
pK O
( O
a O
) O
- O
modulating O
effect O
of O
neighboring O
residues O
. O

IMPORTANCE O
The O
main O
pathogenic O
determinant O
of O
influenza O
viruses O
, O
the O
Hemagglutinin B
( I
HA I
) I
protein O
, O
triggers O
a O
key O
step O
of O
the O
infection O
process O
: O
the O
fusion O
of O
the O
virus O
envelope O
with O
the O
endosomal O
membrane O
releasing O
the O
viral O
genome O
. O

Mutations O
of O
neighboring O
residues O
which O
may O
affect O
the O
pK O
( O
a O
) O
of O
His184 O
could O
play O
an O
important O
role O
in O
virus O
adaptation O
to O
a O
specific O
host O
. O

We O
suggest O
that O
mutation O
of O
neighboring O
residue O
216 O
, O
which O
is O
present O
in O
all O
highly O
pathogenic O
phenotypes O
of O
H5N1 O
influenza O
virus O
strains O
, O
contributed O
to O
the O
adaptation O
of O
these O
viruses O
to O
the O
human O
host O
via O
its O
effect O
on O
the O
pK O
( O
a O
) O
of O
His184 O
. O

Live O
attenuated O
influenza O
vaccines O
in O
the O
United O
States O
are O
derived O
from O
a O
human O
virus O
that O
is O
temperature O
sensitive O
( O
ts O
) O
, O
characterized O
by O
restricted O
( O
> O
= O
100 O
- O
fold O
) O
replication O
at O
39 O
degrees O
C O
. O

The O
ts O
genetic O
signature O
( O
ts O
sig O
) O
has O
been O
mapped O
to O
5 O
loci O
in O
3 O
genes O
: O
PB1 O
( O
391E O
, O
581G O
, O
and O
661T O
) O
, O
PB2 O
( O
265S O
) O
, O
and O
NP O
( O
34G O
) O
. O

To O
investigate O
the O
reason O
for O
this O
, O
we O
introduced O
the O
ts O
sig O
into O
the O
human O
origin O
virus O
A O
/ O
WSN O
/ O
33 O
( O
WSN O
) O
, O
the O
avian O
- O
origin O
virus O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
VN04 O
) O
, O
and O
the O
swine O
origin O
triple O
reassortant O
2009 O
pandemic O
H1N1 O
virus O
A O
/ O
California O
/ O
07 O
/ O
2009 O
( O
CA07 O
) O
, O
which O
contains O
gene O
segments O
from O
human O
, O
avian O
, O
and O
swine O
viruses O
. O

The O
VN04 O
( O
ts O
) O
( O
sig O
) O
and O
CA07 O
( O
ts O
) O
( O
sig O
) O
viruses O
replicated O
efficiently O
in O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
at O
39 O
degrees O
C O
, O
but O
the O
replication O
of O
WSNts O
( O
sig O
) O
was O
restricted O
> O
= O
100 O
- O
fold O
compared O
to O
that O
at O
33 O
degrees O
C O
. O

Reassortant O
CA07 O
( O
ts O
) O
sig O
viruses O
were O
generated O
with O
individual O
polymerase O
gene O
segments O
from O
WSN O
, O
and O
vice O
versa O
. O

In O
ferrets O
, O
the O
CA07 O
( O
ts O
) O
sig O
virus O
replicated O
in O
the O
upper O
and O
lower O
respiratory O
tract O
, O
but O
the O
replication O
of O
a O
reassortant O
CA07 O
( O
ts O
sig O
) O
virus O
with O
a O
WSN O
PB2 O
gene O
was O
severely O
restricted O
in O
the O
lungs O
. O

IMPORTANCE O
Live B
attenuated I
influenza I
vaccines I
( I
LAIVs I
) I
on O
temperature B
- I
sensitive I
( I
ts I
) I
backbones O
derived O
from O
animal O
origin O
influenza O
viruses O
are O
being O
sought O
for O
use O
in O
the O
poultry O
and O
swine O
industries O
and O
to O
protect O
people O
against O
animal O
origin O
influenza O
. O

We O
generated O
seven O
reassortant O
pandemic B
live I
attenuated I
influenza I
vaccines I
( I
pLAIVs I
) I
with O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
derived O
from O
animal O
influenza O
viruses O
on O
the O
backbone O
of O
the O
six O
internal O
protein O
gene O
segments O
of O
the O
temperature O
sensitive O
, O
cold B
- I
adapted I
( I
ca I
) I
A O
/ O
Ann O
Arbor O
/ O
60 O
( O
H2N2 O
) O
virus O
( O
AA O
/ O
60 O
ca O
) O
of O
the O
licensed O
seasonal O
LAIV O
. O

We O
investigated O
the O
HA O
stability O
of O
pandemic O
live O
attenuated O
influenza O
vaccine O
( O
pLAIV O
) O
viruses O
and O
observed O
that O
the O
pLAIV O
viruses O
consistently O
had O
a O
less O
stable O
HA O
than O
the O
corresponding O
wild O
- O
type O
influenza O
viruses O
. O

We O
have O
constructed O
a O
recombinant O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
that O
expresses O
an O
H5N1 O
mosaic O
hemagglutinin O
( O
H5M O
) O
( O
MVA O
- O
H5M O
) O
. O

A O
single O
dose O
of O
MVA O
- O
H5M O
provided O
100 O
% O
protection O
in O
mice O
against O
clade O
0 O
, O
1 O
, O
and O
2 O
avian O
influenza O
viruses O
and O
also O
protected O
against O
seasonal O
H1N1 O
virus O
( O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
) O
. O

It O
also O
provided O
short O
- O
term O
( O
10 O
days O
) O
and O
long O
- O
term O
( O
6 O
months O
) O
protection O
postvaccination O
. O

Both O
neutralizing O
antibodies O
and O
antigen O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
still O
detected O
at O
5 O
months O
postvaccination O
, O
suggesting O
that O
MVA O
- O
H5M O
provides O
long O
- O
lasting O
immunity O
. O

Influenza O
pandemics O
occur O
when O
influenza B
A I
viruses I
( I
IAV I
) I
adapted O
to O
other O
host O
species O
enter O
humans O
and O
spread O
through O
the O
population O
. O

To O
identify O
mutations O
that O
facilitate O
growth O
of O
avian O
IAV O
in O
humans O
, O
we O
have O
adapted O
influenza O
A O
/ O
duck O
/ O
Alberta O
/ O
35 O
/ O
1976 O
( O
H1N1 O
) O
( O
dk O
/ O
AB O
/ O
76 O
) O
virus O
to O
a O
high O
- O
growth O
phenotype O
in O
differentiated O
human O
tracheo O
- O
bronchial O
epithelial O
( O
HTBE O
) O
cells O
. O

The O
majority O
of O
changes O
were O
located O
in O
the O
polymerase O
complex O
and O
nucleoprotein B
( I
NP I
) I
, O
and O
all O
isolates O
carried O
mutations O
in O
the O
PB2 O
627 O
domain O
and O
regions O
of O
NP O
thought O
to O
interact O
with O
PB2 O
. O

In O
addition O
, O
minimal O
combinations O
of O
three O
( O
PB2 O
Q236H O
, O
E627K O
, O
and O
NP O
N309K O
) O
or O
two O
( O
PB2 O
Q591K O
and O
NP O
S50G O
) O
mutations O
were O
sufficient O
to O
recapitulate O
the O
efficient O
growth O
in O
HTBE O
cells O
of O
dk O
/ O
AB O
/ O
76 O
viruses O
isolated O
after O
10 O
passages O
in O
this O
substrate O
. O

Previously O
, O
we O
used O
recombinant O
viruses O
containing O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
from O
the O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
H5N1 O
strain O
and O
other O
internal O
genes O
from O
two O
low O
- O
pathogenicity O
avian O
influenza O
viruses O
isolated O
from O
chicken O
and O
wild O
- O
bird O
hosts O
( O
LP O
and O
WB O
, O
respectively O
) O
to O
demonstrate O
that O
the O
pathogenicity O
of O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
of O
subtype O
H5N1 O
in O
chickens O
is O
regulated O
by O
the O
PB1 O
gene O
( O
Y O
. O

IMPORTANCE O
We O
identified O
2 O
novel O
amino O
acid O
substitutions O
in O
the O
avian O
influenza O
virus O
PB1 O
gene O
that O
affect O
the O
characteristics O
of O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
of O
the O
H5N1 O
subtype O
, O
such O
as O
viral O
replication O
and O
polymerase O
activity O
in O
vitro O
and O
pathogenicity O
and O
transmissibly O
in O
chickens O
. O

To O
explore O
the O
molecular O
mechanism O
for O
the O
airborne O
transmission O
of O
H9N2 O
virus O
, O
we O
compared O
two O
genetically O
close O
strains O
isolated O
from O
chickens O
in O
2001 O
, O
A O
/ O
chicken O
/ O
Shanghai O
/ O
7 O
/ O
2001 O
( O
SH7 O
) O
and O
A O
/ O
chicken O
/ O
Shanghai O
/ O
14 O
/ O
2001 O
( O
SH14 O
) O
. O

We O
used O
reverse O
genetics O
and O
gene O
swapping O
to O
derive O
recombinant B
SH7 I
( I
rSH7 I
) I
, O
rSH14 O
, O
and O
a O
panel O
of O
reassortant O
viruses O
. O

Ferrets O
inoculated O
by O
the O
ocular O
aerosol O
route O
with O
an O
avian O
( O
H7N7 O
, O
H7N9 O
) O
or O
human O
( O
H1N1 O
, O
H3N2v O
) O
virus O
were O
capable O
of O
transmitting O
the O
virus O
to O
naive O
animals O
in O
direct O
- O
contact O
or O
respiratory O
- O
droplet O
models O
, O
respectively O
. O

Nuclear O
export O
of O
influenza O
virus B
ribonucleoprotein I
( I
vRNP I
) I
from O
infected O
cells O
has O
been O
shown O
to O
be O
mediated O
by O
exportin O
1 O
( O
XPO1 O
) O
interaction O
with O
viral O
nuclear O
export O
protein O
tethered O
to O
vRNP O
. O

The O
Streptomyces O
metabolite O
XPO1 O
inhibitor O
leptomycin B
B I
( I
LMB I
) I
has O
been O
shown O
to O
limit O
influenza O
virus O
replication O
in O
vitro O
; O
however O
, O
LMB O
is O
toxic O
in O
vivo O
, O
which O
makes O
it O
unsuitable O
for O
therapeutic O
use O
. O

In O
this O
study O
, O
we O
tested O
the O
anti O
- O
influenza O
virus O
activity O
of O
a O
new O
class O
of O
orally O
available O
small O
- O
molecule O
selective O
inhibitors O
of O
nuclear O
export O
, O
specifically O
, O
the O
XPO1 O
antagonist O
KPT O
- O
335 O
( O
verdinexor O
) O
. O

This O
study O
addressed O
critical O
preclinical O
studies O
for O
the O
development O
of O
verdinexor O
( O
KPT O
- O
335 O
) O
as O
a O
novel O
antiviral O
drug O
. O

Therefore O
, O
we O
characterized O
the O
transcriptomic O
response O
of O
BALB O
/ O
c O
mice O
infected O
with O
H7N9 O
( O
A O
/ O
Anhui O
/ O
01 O
/ O
2013 O
) O
virus O
and O
compared O
it O
to O
the O
responses O
induced O
by O
H5N1 O
( O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
) O
, O
H7N7 O
( O
A O
/ O
Netherlands O
/ O
219 O
/ O
2003 O
) O
, O
and O
pandemic O
2009 O
H1N1 O
( O
A O
/ O
Mexico O
/ O
4482 O
/ O
2009 O
) O
influenza O
viruses O
. O

Two O
- O
way O
transmission O
of O
influenza O
viruses O
between O
humans O
and O
swine O
has O
been O
frequently O
observed O
, O
and O
the O
occurrence O
of O
the O
2009 O
H1N1 O
pandemic O
influenza O
virus O
( O
pdm O
/ O
09 O
) O
demonstrated O
that O
swine O
- O
origin O
viruses O
could O
facilitate O
the O
genesis O
of O
a O
pandemic O
strain O
. O

Although O
multiple O
introductions O
to O
and O
reassortment O
in O
swine O
of O
the O
pdm O
/ O
09 O
virus O
have O
been O
repeatedly O
reported O
in O
both O
Eurasia O
and O
the O
Americas O
, O
its O
long O
- O
term O
impact O
on O
the O
development O
of O
swine B
influenza I
viruses I
( I
SIVs I
) I
has O
not O
been O
systematically O
explored O
. O

The O
main O
persistent O
pdm O
/ O
09 O
- O
origin O
reassortant O
forms O
had O
at O
least O
five O
pdm O
/ O
09 O
- O
origin O
internal O
genes O
, O
and O
their O
surface O
genes O
were O
primarily O
of O
European B
avian I
- I
like I
( I
EA I
) I
or O
human O
H3N2 O
- O
like O
SIV O
origin O
. O

IMPORTANCE O
Shortly O
after O
the O
emergence O
of O
the O
2009 O
pandemic O
H1N1 O
( O
pdm O
/ O
09 O
) O
influenza O
virus O
, O
it O
was O
transmitted O
from O
humans O
to O
pigs O
and O
this O
continues O
to O
occur O
around O
the O
world O
. O

Many O
reassortants O
between O
pdm O
/ O
09 O
- O
origin O
viruses O
and O
enzootic O
swine B
influenza I
viruses I
( I
SIVs I
) I
have O
been O
detected O
. O

Influenza O
virus O
neuraminidase B
( I
NA I
) I
is O
an O
interesting O
target O
of O
small O
- O
molecule O
antiviral O
drugs O
. O

We O
isolated O
a O
set O
of O
H5N1 O
NA O
- O
specific O
single O
- O
domain O
antibodies O
( O
N1 O
- O
VHHm O
) O
and O
evaluated O
their O
in O
vitro O
and O
in O
vivo O
antiviral O
potential O
. O

Second O
, O
bivalent O
N1 O
- O
VHH O
- O
Fc O
proteins O
were O
obtained O
by O
genetic O
fusion O
of O
the O
N1 O
- O
VHHm O
moiety O
with O
the O
crystallizable O
region O
of O
mouse O
IgG2a O
( O
Fc O
) O
. O

The O
A O
/ O
Guangdong O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
virus O
isolated O
from O
the O
Guangdong O
patient O
on O
10 O
August O
2013 O
was O
divergent O
from O
previously O
sequenced O
H7N9 O
viruses O
and O
more O
closely O
related O
to O
local O
circulating O
H9N2 O
viruses O
in O
the O
NS O
and O
NP O
genes O
. O

Phylogenetic O
analyses O
revealed O
that O
four O
internal O
genes O
of O
the O
A O
/ O
Guangdong O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
virus O
- O
the O
NS O
, O
NP O
, O
PB1 O
, O
and O
PB2 O
genes O
- O
were O
in O
clusters O
different O
from O
those O
for O
H7N9 O
viruses O
identified O
previously O
in O
other O
provinces O
of O
China O
. O

The O
discovery O
presented O
here O
suggests O
that O
continuing O
reassortment O
led O
to O
the O
emergence O
of O
the O
A O
/ O
Guangdong O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
virus O
as O
a O
novel O
H7N9 O
virus O
in O
Guangdong O
, O
China O
, O
and O
that O
viral O
adaptation O
to O
avian O
and O
human O
hosts O
must O
be O
assessed O
. O

Live O
attenuated O
cold B
- I
adapted I
( I
ca I
) I
H5N1 O
, O
H7N3 O
, O
H6N1 O
, O
and O
H9N2 O
influenza O
vaccine O
viruses O
replicated O
in O
the O
respiratory O
tract O
of O
mice O
and O
ferrets O
, O
and O
2 O
doses O
of O
vaccines O
were O
immunogenic O
and O
protected O
these O
animals O
from O
challenge O
infection O
with O
homologous O
and O
heterologous O
wild B
- I
type I
( I
WT I
) I
viruses O
of O
the O
corresponding O
subtypes O
. O

Therefore O
, O
we O
sought O
a O
model O
that O
would O
better O
reflect O
the O
findings O
in O
humans O
and O
evaluated O
African B
green I
monkeys I
( I
AGMs I
) I
as O
a O
nonhuman O
primate O
model O
. O

The O
distribution O
of O
sialic B
acid I
( I
SA I
) I
receptors O
in O
the O
respiratory O
tract O
of O
AGMs O
was O
similar O
to O
that O
in O
humans O
. O

We O
evaluated O
the O
replication O
of O
wt O
and O
ca O
viruses O
of O
avian B
influenza I
( I
AI I
) I
virus O
subtypes O
H5N1 O
, O
H6N1 O
, O
H7N3 O
, O
and O
H9N2 O
in O
the O
respiratory O
tract O
of O
AGMs O
. O

We O
used O
African B
green I
monkeys I
( I
AGMs I
) I
as O
a O
nonhuman B
primate I
( I
NHP I
) I
model O
for O
a O
comprehensive O
and O
comparative O
evaluation O
of O
pairs O
of O
wild O
- O
type O
and O
pandemic B
live I
attenuated I
influenza I
virus I
vaccines I
( I
pLAIV I
) I
representing O
four O
subtypes O
of O
avian O
influenza O
viruses O
and O
found O
that O
pLAIVs O
replicate O
similarly O
in O
AGMs O
and O
humans O
and O
that O
AGMs O
can O
be O
useful O
for O
evaluation O
of O
the O
protective O
efficacy O
of O
pLAIV O
. O

Nonetheless O
, O
strains O
of O
the O
Eurasian B
avian I
- I
like I
swine I
( I
EAsw I
) I
lineage O
contain O
a O
change O
at O
this O
position O
: O
position O
41 O
of O
A O
/ O
swine O
/ O
Spain O
/ O
53207 O
/ O
04 O
( O
H1N1 O
) O
( O
SPN04 O
) O
encodes O
a O
proline O
. O

To O
assess O
the O
impact O
of O
this O
naturally O
occurring O
polymorphism O
on O
viral O
fitness O
, O
we O
utilized O
reverse O
genetics O
to O
produce O
recombinant O
viruses O
encoding O
wild O
- O
type O
M1 O
41P O
( O
rSPN04 O
- O
P O
) O
and O
consensus O
41A O
( O
rSPN04 O
- O
A O
) O
residues O
. O

The O
lab O
- O
adapted O
human O
isolate O
, O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
( O
PR8 O
) O
, O
is O
nontransmissible O
in O
the O
guinea O
pig O
model O
, O
making O
it O
a O
useful O
background O
in O
which O
to O
identify O
certain O
viral O
factors O
that O
enhance O
transmissibility O
. O

Thus O
, O
we O
sought O
to O
determine O
if O
a O
highly O
pathogenic O
influenza O
A O
H7N1 O
( O
A O
/ O
H7N1 O
) O
virus O
with O
no O
history O
of O
human O
infection O
could O
become O
capable O
of O
airborne O
transmission O
among O
ferrets O
. O

Four O
amino O
acid O
mutations O
( O
PB2 O
T81I O
, O
NP O
V284M O
, O
and O
M1 O
R95K O
and O
Q211K O
) O
in O
the O
internal O
genes O
and O
a O
minimal O
amino O
acid O
mutation O
( O
K O
/ O
R313R O
) O
in O
the O
stalk O
region O
of O
the O
hemagglutinin O
protein O
were O
associated O
with O
airborne O
transmission O
. O

We O
detected O
three O
avian O
influenza B
hemagglutinin I
( I
HA I
) I
subtypes O
( O
H7 O
, O
H9 O
, O
and O
H5 O
) O
and O
two O
neuraminidase B
( I
NA I
) I
subtypes O
( O
N9 O
and O
N2 O
) O
, O
as O
well O
as O
H7N9 O
- O
related O
H9N9 O
reassortant O
intermediates O
, O
cocirculating O
among O
poultry O
in O
Huzhou O
, O
China O
, O
during O
April O
2013 O
. O

Following O
the O
2012 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
outbreaks O
, O
surveillance O
was O
conducted O
from O
December O
2012 O
to O
July O
2013 O
at O
a O
live O
- O
poultry O
wholesale O
market O
in O
Taipei O
. O

Phylogenetic O
analyses O
revealed O
that O
all O
H5N2 O
viruses O
had O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
derived O
from O
a O
1994 O
Mexican O
- O
like O
virus O
, O
while O
their O
internal O
gene O
complexes O
were O
incorporated O
from O
the O
enzootic O
H6N1 O
virus O
lineage O
by O
multiple O
reassortment O
events O
. O

Pathogenicity O
studies O
demonstrated O
heterogeneous O
results O
even O
though O
all O
tested O
viruses O
had O
motifs O
( O
R O
- O
X O
- O
K O
/ O
R O
- O
R O
) O
supportive O
of O
high O
pathogenicity O
. O

Since O
1997 O
, O
H6 O
viruses O
with O
different O
neuraminidase B
( I
NA I
) I
subtypes O
have O
been O
detected O
frequently O
in O
the O
live O
poultry O
markets O
of O
southern O
China O
. O

To O
help O
identify O
determinants O
of O
transmission O
, O
we O
used O
reverse O
genetics O
to O
introduce O
gene O
segments O
of O
an O
early O
pandemic O
isolate O
, O
A O
/ O
Netherlands O
/ O
602 O
/ O
2009 O
[ O
H1N1 O
] O
( O
NL602 O
) O
, O
into O
the O
background O
of O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
[ O
H1N1 O
] O
( O
PR8 O
) O
and O
evaluated O
the O
resultant O
viruses O
in O
a O
guinea O
pig O
transmission O
model O
. O

H9N2 O
influenza O
virus O
is O
undergoing O
extensive O
genetic O
and O
antigenic O
evolution O
, O
warranting O
detailed O
antigenic O
mapping O
of O
its O
Hemagglutinin B
( I
HA I
) I
. O

An O
understanding O
of O
the O
antigen O
- O
specific O
B O
- O
cell O
response O
to O
the O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
is O
critical O
to O
the O
development O
of O
universal O
influenza O
vaccines O
, O
but O
it O
has O
not O
been O
possible O
to O
examine O
these O
cells O
directly O
because O
HA O
binds O
to O
sialic B
acid I
( I
SA I
) I
on O
most O
cell O
types O
. O

Here O
, O
we O
use O
structure O
- O
based O
modification O
of O
HA O
to O
isolate O
HA O
- O
specific O
B O
cells O
by O
flow O
cytometry O
and O
characterize O
the O
features O
of O
HA O
stem O
antibodies B
( I
Abs I
) I
required O
for O
their O
development O
. O

Incorporation O
of O
a O
previously O
described O
mutation O
( O
Y98F O
) O
to O
the O
Receptor B
binding I
site I
( I
RBS I
) I
causes O
HA O
to O
bind O
only O
those O
B O
cells O
that O
express O
HA O
- O
specific O
Abs O
, O
but O
it O
does O
not O
bind O
nonspecifically O
to O
B O
cells O
, O
and O
this O
mutation O
has O
no O
effect O
on O
the O
binding O
of O
broadly O
neutralizing O
Abs O
to O
the O
RBS O
. O

Cloning O
of O
immunoglobulin O
genes O
from O
HA O
- O
specific O
B O
cells O
isolated O
from O
a O
single O
human O
subject O
demonstrates O
that O
vaccination O
with O
H5N1 O
influenza O
virus O
can O
elicit O
B O
cells O
expressing O
stem O
monoclonal B
Abs I
( I
MAbs I
) I
. O

avian B
influenza I
( I
AI I
) I
viruses O
of O
the O
H7 O
subtype O
have O
the O
potential O
to O
evolve O
into O
highly B
pathogenic I
( I
HP I
) I
viruses O
that O
represent O
a O
major O
economic O
problem O
for O
the O
poultry O
industry O
and O
a O
threat O
to O
global O
health O
. O

However O
, O
the O
emergence O
of O
HPAI O
viruses O
from O
low B
- I
pathogenic I
( I
LPAI I
) I
progenitor O
viruses O
currently O
is O
poorly O
understood O
. O

To O
investigate O
the O
origin O
and O
evolution O
of O
one O
of O
the O
most O
important O
avian O
influenza O
epidemics O
described O
in O
Europe O
, O
we O
investigated O
the O
evolutionary O
and O
spatial O
dynamics O
of O
the O
entire O
genome O
of O
109 O
H7N1 O
( O
46 O
LPAI O
and O
63 O
HPAI O
) O
viruses O
collected O
during O
Italian O
H7N1 O
outbreaks O
between O
March O
1999 O
and O
February O
2001 O
. O

Novel O
avian B
- I
origin I
influenza I
A I
( I
H7N9 I
) I
viruses O
were O
first O
reported O
to O
infect O
humans O
in O
March O
2013 O
. O

By O
using O
sequence O
comparisons O
and O
phylogenetic O
and O
ancestral O
inference O
analyses O
, O
we O
identified O
several O
distinct O
amino O
acids O
in O
the O
A O
( O
H7N9 O
) O
polymerase O
PA O
protein O
, O
some O
of O
which O
may O
be O
mammalian O
adapting O
. O

We O
identified O
several O
mutants O
that O
were O
slightly O
more O
virulent O
in O
mice O
than O
the O
wild O
- O
type O
A O
( O
H7N9 O
) O
virus O
, O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
. O

Our O
findings O
indicate O
that O
the O
PA O
protein O
of O
A O
( O
H7N9 O
) O
viruses O
has O
several O
amino O
acid O
substitutions O
that O
are O
attenuating O
in O
mammals O
. O

To O
explore O
the O
role O
of O
live O
poultry O
markets O
in O
the O
origin O
of O
the O
novel O
H7N9 O
virus O
, O
we O
systematically O
examined O
poultry O
and O
environmental O
specimens O
from O
local O
markets O
and O
farms O
in O
Hangzhou O
, O
using O
real O
- O
time O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
as O
well O
as O
high O
- O
throughput O
next B
- I
generation I
sequencing I
( I
NGS I
) I
. O

In O
contrast O
, O
human O
H7N9 O
infection O
cases O
( O
n O
= O
31 O
) O
were O
all O
negative O
for O
H9N2 O
virus O
according O
to O
real O
- O
time O
RT O
- O
PCR O
. O

Despite O
this O
fact O
, O
RNA B
polymerase I
II I
( I
RNAP I
II I
) I
is O
degraded O
during O
infection O
in O
a O
process O
triggered O
by O
the O
viral O
polymerase O
. O

Reassort O
ant O
viruses O
from O
the O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
strain O
that O
induce O
( O
hvPR8 O
) O
or O
do O
not O
induce O
( O
1vPR8 O
) O
RNAP O
II O
degradation O
led O
to O
the O
identification O
of O
PA O
and O
PB2 O
subunits O
as O
responsible O
for O
the O
degradation O
process O
. O

Three O
changes O
in O
the O
PB2 O
sequence O
( O
I105M O
, O
N456D O
, O
and O
1504V O
) O
and O
two O
in O
PA O
( O
Q193H O
and O
15501 O
) O
differentiate O
PA O
and O
PB2 O
of1vPR8 O
from O
those O
of O
hvPR8 O
. O

Since O
hvPR8 O
is O
more O
pathogenic O
than O
1vPR8 O
in O
mice O
, O
we O
tested O
the O
potential O
contribution O
of O
RNAP O
II O
degradation O
in O
a O
distant O
viral O
strain O
, O
the O
2009 O
pandemic O
A O
/ O
California O
/ O
04 O
/ O
09 O
( O
CAL O
) O
virus O
, O
whose O
PA O
and O
PB2 O
subunits O
are O
of O
avian O
origin O
. O

It O
has O
been O
shown O
that O
an O
E O
- O
to O
- O
K O
amino O
acid O
change O
at O
residue O
627 O
of O
polyrnerase B
basic I
protein I
2 I
( I
PB2 I
) I
occurred O
frequently O
in O
the O
H7N9 O
isolates O
obtained O
from O
humans O
but O
not O
in O
viruses O
isolated O
from O
poultry O
. O

Mice O
infected O
with O
the O
H7N9 O
mutant O
containing O
the O
avian O
signature O
protein O
PB2 O
- O
627E O
showed O
a O
marked O
decrease O
in O
disease O
severity O
( O
weight O
loss O
) O
and O
pathology O
compared O
to O
mice O
infected O
with O
the O
wild O
- O
type O
strain O
( O
PB2 O
- O
627K O
) O
or O
other O
PB2 O
mutants O
. O

We O
report O
here O
that O
, O
in O
the O
guinea O
pig O
model O
, O
a O
human O
isolate O
of O
novel O
H7N9 O
influenza O
virus O
, O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
( O
An O
/ O
13 O
) O
, O
is O
highly O
dissimilar O
to O
an O
H7N1 O
avian O
isolate O
and O
instead O
behaves O
similarly O
to O
a O
human O
seasonal O
strain O
in O
several O
respects O
. O

The O
pH O
of O
fusion O
of O
the O
Hemagglutinin B
( I
HA I
) I
and O
the O
binding O
of O
virus O
to O
fixed O
guinea O
pig O
tissues O
were O
also O
examined O
. O

Here O
, O
we O
characterize O
a O
low O
- O
pathogenicity O
avian O
influenza O
virus O
, O
A O
/ O
chicken O
/ O
Israel O
/ O
810 O
/ O
2001 O
( O
H9N2 O
) O
( O
Israel810 O
) O
, O
which O
is O
representative O
of O
influenza O
virus O
strains O
that O
have O
caused O
severe O
morbidity O
and O
mortality O
in O
poultry O
farms O
. O

We O
show O
that O
under O
certain O
circumstances O
the O
Israel810 O
Hemagglutinin B
( I
HA I
) I
can O
be O
activated O
by O
furin O
, O
a O
hallmark O
of O
highly O
pathogenic O
avian O
influenza O
virus O
. O

We O
demonstrate O
that O
Israel810 O
HA O
can O
be O
cleaved O
in O
cells O
with O
high O
levels O
of O
furin O
expression O
and O
that O
a O
mutation O
that O
eliminates O
a O
glycosylation O
site O
in O
HA O
( O
1 O
) O
allows O
the O
Israel810 O
HA O
to O
gain O
universal O
cleavage O
in O
cell O
culture O
. O

In O
both O
the O
avian O
influenza O
A O
( O
H5N1 O
) O
and O
the O
recently O
emerging O
avian O
influenza O
A O
( O
H7N9 O
) O
viruses O
, O
the O
polymerase B
basic I
2 I
protein I
( I
PB2 I
) I
E627K O
mutation O
appears O
to O
be O
of O
key O
importance O
for O
human O
adaptation O
. O

During O
a O
large O
influenza O
A O
( O
H7N7 O
) O
virus O
outbreak O
in O
the O
Netherlands O
in O
2003 O
, O
the O
A O
( O
H7N7 O
) O
virus O
isolated O
from O
a O
fatal O
human O
case O
contained O
the O
PB2 O
E627K O
mutation O
as O
well O
as O
a O
Hemagglutinin B
( I
HA I
) I
K416R O
mutation O
. O

The O
influenza O
virus O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
plays O
critical O
roles O
in O
the O
early O
stage O
of O
virus O
infection O
, O
including O
receptor O
binding O
and O
membrane O
fusion O
, O
making O
it O
a O
potential O
target O
for O
the O
development O
of O
anti O
- O
influenza O
drugs O
. O

The O
two O
compounds O
( O
i O
) O
are O
potent O
( O
50 O
% O
inhibitory O
concentration O
[ O
IC50 O
] O
of O
0 O
. O

9 O
mu O
M O
) O
; O
( O
ii O
) O
are O
selective O
( O
50 O
% O
cytotoxicity O
concentration O
[ O
CC50 O
] O
of O
> O
100 O
mu O
M O
) O
, O
with O
selectivity B
index I
( I
SI I
) I
values O
of O
> O
20 O
to O
200 O
for O
different O
influenza O
virus O
strains O
; O
( O
iii O
) O
inhibit O
a O
wide O
spectrum O
of O
influenza O
A O
viruses O
, O
which O
includes O
the O
2009 O
pandemic O
influenza O
virus O
A O
/ O
H1N1 O
/ O
2009 O
, O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
A O
/ O
H5N1 O
, O
and O
oseltamivir O
- O
resistant O
A O
/ O
H1N1 O
strains O
; O
( O
iv O
) O
exhibit O
large O
volumes O
of O
synergy O
with O
oseltamivir O
( O
36 O
and O
331 O
mu O
M O
- O
2 O
% O
at O
95 O
% O
confidence O
) O
; O
and O
( O
v O
) O
have O
chemically O
tractable O
structures O
. O

Additional O
results O
from O
HA O
- O
mediated O
hemolysis O
of O
chicken B
red I
blood I
cells I
( I
cRBCs I
) I
, O
competition O
assays O
with O
monoclonal B
antibody I
( I
Mab I
) I
C179 O
, O
and O
mutational O
analysis O
suggest O
that O
the O
compounds O
bind O
in O
the O
stem O
region O
of O
the O
HA O
trimer O
and O
inhibit O
HA O
- O
mediated O
fusion O
. O

Plasmids O
containing O
the O
genes O
from O
an O
H9N2 O
virus O
and O
a O
pandemic B
H1N1 I
( I
pH1N1 I
) I
virus O
were O
transfected O
into O
HEK O
293T O
cells O
to O
potentially O
generate O
the O
full O
panel O
of O
possible O
H9 O
reassortants O
. O

Cleavage O
of O
the O
influenza O
virus O
surface O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
by O
host O
cell O
proteases O
is O
essential O
for O
viral O
infectivity O
. O

We O
investigated O
the O
proteolytic O
activation O
of O
influenza O
viruses O
in O
primary O
porcine O
tracheal O
and O
bronchial O
epithelial O
cells O
( O
PTEC O
and O
PBEC O
, O
respectively O
) O
. O

Markers O
of O
mammalian O
adaptation O
in O
Hemagglutinin B
( I
HA I
) I
and O
PB2 O
proteins O
were O
absent O
from O
all O
isolates O
, O
and O
they O
retained O
a O
preference O
for O
avian O
- O
like O
alpha O
2 O
, O
3 O
- O
linked O
sialic O
acid O
receptors O
. O

Most O
isolates O
remained O
antigenically O
similar O
to O
pandemic O
A O
/ O
Singapore O
/ O
1 O
/ O
57 O
( O
H2N2 O
) O
virus O
, O
suggesting O
they O
could O
be O
controlled O
by O
the O
pandemic O
vaccine O
candidate O
. O

Accordingly O
, O
viral O
ribonucleoprotein B
( I
RNP I
) I
reconstitution O
assays O
show O
that O
a O
viral O
polymerase O
containing O
PB2 O
627E O
has O
impaired O
activity O
in O
mammalian O
cells O
compared O
to O
a O
viral O
polymerase O
that O
contains O
PB2 O
627K O
, O
characteristic O
of O
mammalian O
- O
adapted O
influenza O
viruses O
. O

Neutralizing O
antibodies O
against O
conserved O
epitopes O
on O
the O
viral O
Hemagglutinin B
( I
HA I
) I
could O
confer O
immunity O
to O
the O
diverse O
H5N1 O
virus O
strains O
and O
provide O
information O
for O
effective O
vaccine O
design O
. O

Here O
, O
we O
report O
the O
characterization O
of O
a O
broadly O
neutralizing O
murine O
monoclonal O
antibody O
, O
H5M9 O
, O
to O
most O
H5N1 O
clades O
and O
subclades O
that O
was O
elicited O
by O
immunization O
with O
viral O
HA O
of O
A O
/ O
Goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
H5N1 O
) O
, O
the O
immediate O
precursor O
of O
the O
current O
dominant O
strains O
of O
H5N1 O
viruses O
. O

To O
assess O
the O
potential O
genetic O
plasticity O
under O
strong O
selection O
pressure O
, O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
of O
subtype O
H5N1 O
was O
passaged O
50 O
times O
in O
embryonated O
chicken O
eggs O
in O
the O
presence O
of O
a O
neutralizing O
, O
polyclonal O
chicken O
serum O
. O

The O
resulting O
mutant O
acquired O
major O
alterations O
in O
the O
neuraminidase B
( I
NA I
) I
- O
encoding O
segment O
. O

Interferon B
- I
inducible I
transmembrane I
protein I
3 I
( I
IFITM3 I
) I
is O
an O
effector O
protein O
of O
the O
innate O
immune O
system O
. O

Most O
of O
the O
novel O
genotypes O
emerged O
as O
PB2 O
( O
E627K O
) O
, O
HA O
( O
F128V O
) O
, O
HA O
( O
F454L O
) O
, O
or O
HA O
( O
H300P O
) O
variations O
, O
and O
double O
mutations O
frequently O
occurred O
in O
the O
same O
isolate O
. O

Here O
we O
focus O
on O
the O
hemagglutinins B
( I
HAs I
) I
of O
these O
viruses O
and O
assess O
their O
receptor O
binding O
phenotype O
in O
relation O
to O
previous O
HAs O
studied O
. O

Glycan O
microarray O
and O
kinetic O
analyses O
of O
recombinant O
A O
( O
H7N9 O
) O
HAs O
were O
performed O
to O
compare O
the O
receptor O
binding O
profile O
of O
wild O
- O
type O
receptor O
binding O
site O
variants O
at O
position O
217 O
, O
a O
residue O
analogous O
to O
one O
of O
two O
positions O
known O
to O
switch O
avian O
to O
human O
receptor O
preference O
in O
H2N2 O
and O
H3N2 O
viruses O
. O

Two O
recombinant O
A O
( O
H7N9 O
) O
HAs O
were O
structurally O
characterized O
, O
and O
a O
mutational O
study O
of O
the O
receptor O
binding O
site O
was O
performed O
to O
analyze O
important O
residues O
that O
can O
affect O
receptor O
preference O
and O
affinity O
. O

The O
emergence O
of O
the O
human O
2009 O
pandemic O
H1N1 O
( O
H1N1pdm O
) O
virus O
from O
swine O
populations O
refocused O
public O
and O
scientific O
attention O
on O
swine O
as O
an O
important O
source O
of O
influenza O
A O
viruses O
bearing O
zoonotic O
potential O
. O

European O
avian O
influenza O
virus O
- O
derived O
H1N1 O
( O
H1N1av O
) O
viruses O
dominated O
the O
epidemiology O
, O
followed O
by O
human O
- O
derived O
subtypes O
H1N2 O
and O
H3N2 O
. O

H1N1pdm O
viruses O
and O
, O
in O
particular O
, O
recently O
emerging O
reassortants O
between O
H1N1pdm B
and I
porcine I
HxN2 I
viruses I
( I
H1pdmN2 I
) I
were O
detected O
in O
about O
8 O
% O
of O
cases O
. O

Translation O
of O
influenza O
A O
virus O
PB1 O
- O
F2 O
occurs O
in O
a O
second O
open B
reading I
frame I
( I
ORF I
) I
of O
the O
PB1 O
gene O
segment O
. O

As O
the B
2009 I
H1N1 I
( I
H1N1pdm09 I
) I
strain O
highlighted O
, O
some O
swine O
- O
derived O
influenza O
viruses O
have O
the O
capacity O
to O
infect O
human O
hosts O
and O
emerge O
as O
a O
pandemic O
. O

The O
substitution O
of O
Glutamic B
acid I
( I
E I
) I
for O
Lysine B
( I
K I
) I
at O
position O
627 O
of O
the O
PB2 O
protein O
of O
avian O
H5N1 O
viruses O
has O
been O
identified O
as O
a O
virulence O
and O
host O
range O
determinant O
for O
infection O
of O
mammals O
. O

The O
restrictions O
to O
transmissibility O
of O
avian O
influenza O
viruses O
in O
mammals O
are O
multigenic O
, O
and O
overcoming O
them O
requires O
adaptations O
in O
Hemagglutinin B
( I
HA I
) I
and O
PB2 O
genes O
. O

Here O
we O
propose O
that O
a O
further O
restriction O
to O
mammalian O
transmission O
of O
the O
majority O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
may O
be O
the O
short O
stalk O
length O
of O
the O
neuraminidase B
( I
NA I
) I
protein O
. O

A O
/ O
Chicken O
/ O
Jiangsu O
/ O
k0402 O
/ O
2010 O
( O
CK10 O
) O
is O
highly O
pathogenic O
, O
whereas O
A O
/ O
Goose O
/ O
Jiangsu O
/ O
k0403 O
/ O
2010 O
( O
GS10 O
) O
is O
low O
pathogenic O
. O

Expression O
of O
the O
CK10 O
PA O
or O
Hemagglutinin B
( I
HA I
) I
gene O
in O
the O
GS10 O
context O
resulted O
in O
increased O
virulence O
and O
virus O
replication O
. O

To O
gain O
insight O
into O
the O
ecology O
of O
avian B
influenza I
viruses I
( I
AIV I
) I
, O
we O
conducted O
active O
influenza O
virus O
surveillance O
in O
domestic O
ducks O
on O
farms O
located O
on O
the O
flyway O
of O
migratory O
birds O
in O
the O
Dongting O
Lake O
region O
of O
Hunan O
Province O
, O
China O
, O
from O
winter O
2011 O
until O
spring O
2012 O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
is O
a O
promising O
viral O
vector O
for O
vaccine O
development O
. O

We O
have O
recently O
reported O
that O
PIV5 O
expressing O
the O
Hemagglutinin B
( I
HA I
) I
from O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
H5N1 O
( O
PIV5 O
- O
H5 O
) O
provides O
sterilizing O
immunity O
against O
lethal O
doses O
of O
HPAI O
H5N1 O
infection O
in O
mice O
. O

Previously O
, O
we O
have O
shown O
that O
deleting O
the O
SH O
gene O
and O
the O
conserved O
C O
terminus O
of O
the O
V O
gene O
in O
PIV5 O
results O
in O
mutant O
viruses O
( O
PIV5 O
Delta O
SH O
and O
PIV5V O
Delta O
C O
) O
that O
enhance O
induction O
of O
apoptosis O
. O

In O
this O
study O
, O
we O
inserted O
the O
HA O
gene O
of O
H5N1 O
into O
PIV5 O
Delta O
SH O
( O
PIV5 O
Delta O
SH O
- O
H5 O
) O
or O
PIV5V O
Delta O
C O
( O
PIV5V O
Delta O
C O
- O
H5 O
) O
and O
compared O
their O
efficacies O
as O
vaccine O
candidates O
to O
PIV5 O
- O
H5 O
. O

2 O
Eurasian O
- O
lineage O
H5N1 O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
were O
first O
detected O
in O
Qinghai O
Lake O
, O
China O
, O
in O
2005 O
and O
subsequently O
spread O
through O
Asia O
, O
Europe O
, O
and O
Africa O
. O

Importantly O
, O
these O
viruses O
carried O
a O
lysine O
at O
amino O
acid O
position O
627 O
of O
the O
PB2 O
protein O
( O
PB2 O
627K O
) O
, O
a O
known O
mammalian O
adaptation O
motif O
. O

Previous O
avian O
influenza O
virus O
isolates O
have O
carried O
glutamic O
acid O
in O
this O
position O
( O
PB2 O
627E O
) O
, O
commonly O
described O
to O
restrict O
virus O
polymerase O
function O
in O
the O
mammalian O
host O
. O

Viruses O
constructed O
by O
reverse O
genetics O
were O
engineered O
to O
contain O
converse O
PB2 O
627K O
/ O
E O
mutations O
in O
a O
Eurasian O
H5N1 O
virus O
( O
A O
/ O
turkey O
/ O
Turkey O
/ O
5 O
/ O
2005 O
[ O
Ty O
/ O
05 O
] O
) O
and O
, O
for O
comparison O
, O
a O
historical O
pre O
- O
Asian O
H5N1 O
HPAIV O
that O
naturally O
bears O
PB2 O
627E O
( O
A O
/ O
turkey O
/ O
England O
/ O
50 O
- O
92 O
/ O
1991 O
[ O
50 O
- O
92 O
] O
) O
. O

The O
50 O
- O
92 O
PB2 O
627K O
was O
genetically O
unstable O
during O
virus O
propagation O
, O
resulting O
in O
reversion O
to O
PB2 O
627E O
or O
the O
accumulation O
of O
the O
additional O
mutation O
PB2 O
628R O
and O
/ O
or O
a O
synonymous O
mutation O
from O
an O
A O
to O
a O
G O
nucleotide O
at O
nucleotide O
position O
1869 O
( O
PB2 O
A1869G O
) O
. O

In O
June O
of O
2012 O
, O
an O
H7N3 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
was O
identified O
as O
the O
cause O
of O
a O
severe O
disease O
outbreak O
in O
commercial O
laying O
chicken O
farms O
in O
Mexico O
. O

The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
Mexican O
2012 O
H7N3 O
HPAI O
virus O
( O
A O
/ O
chicken O
/ O
Jalisco O
/ O
CPA1 O
/ O
2012 O
) O
and O
determine O
the O
protection O
against O
the O
virus O
conferred O
by O
different O
H7 O
inactivated O
vaccines O
in O
chickens O
. O

H7 O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
viruses O
and O
a O
2006 O
Mexican O
H7 O
LPAI O
virus O
were O
tested O
as O
antigens O
in O
experimental O
oil O
emulsion O
vaccines O
and O
injected O
into O
chickens O
3 O
weeks O
prior O
to O
challenge O
. O

There O
is O
compelling O
evidence O
that O
these O
viruses O
overcome O
this O
obstacle O
by O
acquiring O
adaptive O
mutations O
in O
the O
polymerase O
subunits O
PB1 O
, O
PB2 O
, O
and O
PA O
and O
the O
nucleoprotein B
( I
NP I
) I
as O
well O
as O
in O
the O
novel O
polymerase O
cofactor O
nuclear B
export I
protein I
( I
NEP I
) I
. O

highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
of O
subtypes O
H5 O
and O
H7 O
have O
caused O
numerous O
outbreaks O
in O
diverse O
poultry O
species O
and O
rising O
numbers O
of O
human O
infections O
. O

NS O
reassortment O
of O
H5N1 O
HPAIV O
viruses O
in O
the O
background O
of O
A O
/ O
FPV O
/ O
Rostock O
/ O
1934 O
( O
H7N1 O
) O
HPAIV O
has O
been O
shown O
to O
change O
virus O
replication O
kinetics O
and O
host O
cell O
responses O
in O
mammalian O
cells O
. O

In O
the O
present O
study O
, O
we O
show O
that O
the O
NS O
segment O
of O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
FPV O
NS O
VN O
, O
H5N1 O
) O
HPAIV O
significantly O
altered O
the O
characteristics O
of O
the O
H7 O
prototype O
HPAIV O
in O
tracheal B
organ I
cultures I
( I
TOC I
) I
of O
chicken O
and O
turkey O
in O
vitro O
, O
with O
decreased O
replication O
efficiency O
accompanied O
by O
increased O
induction O
of O
type B
I I
interferon I
( I
IFN I
) I
and O
apoptosis O
. O

The O
nucleoprotein B
( I
NP I
) I
of O
influenza O
A O
virus O
is O
highly O
conserved O
among O
all O
strains O
of O
influenza O
A O
viruses O
and O
has O
been O
explored O
as O
an O
antigen O
for O
developing O
a O
universal O
influenza O
virus O
vaccine O
. O

In O
this O
work O
, O
we O
generated O
a O
recombinant O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
containing O
NP O
from O
H5N1 O
( O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
) O
, O
a O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
, O
between O
HN O
and O
L O
( O
PIV5 O
- O
NP O
- O
HN O
/ O
L O
) O
and O
tested O
its O
efficacy O
. O

Recombinant O
PIV5 O
containing O
NP O
between O
F O
and O
SH O
( O
PIV5 O
- O
NP O
- O
F O
/ O
SH O
) O
or O
between O
SH O
and O
HN O
( O
PIV5 O
- O
NP O
- O
SH O
/ O
HN O
) O
provided O
better O
protection O
against O
H5N1 O
HPAI O
virus O
challenge O
than O
did O
PIV5 O
- O
NP O
- O
HN O
/ O
L O
. O

After O
receptor O
binding O
and O
internalization O
during O
influenza O
virus O
entry O
, O
the O
Hemagglutinin B
( I
HA I
) I
protein O
is O
triggered O
by O
low O
pH O
to O
undergo O
irreversible O
conformational O
changes O
that O
mediate O
membrane O
fusion O
. O

To O
investigate O
how O
mutations O
that O
alter O
the O
activation O
pH O
of O
the O
HA O
protein O
influence O
the O
fitness O
of O
an O
avian O
H5N1 O
influenza O
virus O
in O
a O
mammalian O
model O
, O
we O
infected O
C57BL O
/ O
6J O
or O
DBA O
/ O
2J O
mice O
and O
compared O
the O
replication O
and O
virulence O
of O
recombinant O
A O
/ O
chicken O
/ O
Vietnam O
/ O
C58 O
/ O
04 O
( O
H5N1 O
) O
HA O
- O
Y23 O
( O
1 O
) O
H O
mutant O
, O
wild O
- O
type O
, O
and O
HA O
- O
H24 O
( O
1 O
) O
Q O
and O
HA O
- O
K58 O
( O
2 O
) O
I O
mutant O
viruses O
that O
have O
HA O
activation O
pH O
values O
of O
6 O
. O

The O
HA O
- O
Y23 O
( O
1 O
) O
H O
mutant O
virus O
was O
highly O
susceptible O
to O
acid O
inactivation O
in O
vitro O
and O
was O
attenuated O
for O
growth O
and O
virulence O
in O
mice O
, O
suggesting O
that O
an O
H5N1 O
HA O
protein O
triggered O
at O
pH O
6 O
. O

Wild O
- O
type O
and O
HA O
- O
H24 O
( O
1 O
) O
Q O
viruses O
were O
similar O
in O
pathogenicity O
and O
grew O
to O
similar O
levels O
in O
mice O
, O
ducks O
, O
and O
cell O
cultures O
derived O
from O
both O
avian O
and O
mammalian O
tissues O
, O
suggesting O
that O
H5N1 O
HA O
proteins O
triggered O
at O
pH O
values O
in O
the O
range O
of O
5 O
. O

The O
HA O
- O
K58 O
( O
2 O
) O
I O
mutant O
virus O
had O
greater O
growth O
and O
virulence O
in O
DBA O
/ O
2J O
mice O
than O
the O
wild O
type O
did O
, O
although O
the O
mutant O
virus O
was O
highly O
attenuated O
in O
ducks O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
of O
the O
H5N1 O
subtype O
continue O
to O
evolve O
through O
reassortment O
and O
mutations O
. O

Our O
recent O
phylogenetic O
analysis O
identified O
a O
group O
of O
HPAI O
H5N1 O
viruses O
with O
two O
characteristic O
mutations O
in O
NS1 O
: O
the O
avian O
virus O
- O
type O
PDZ O
domain O
- O
binding O
motif O
ESEV O
( O
which O
affects O
virulence O
) O
was O
replaced O
with O
ESKV O
, O
and O
NS1 O
- O
138F O
( O
which O
is O
highly O
conserved O
among O
all O
influenza O
A O
viruses O
and O
may O
affect O
the O
activation O
of O
the O
phosphatidylinositol O
3 O
- O
kinase O
[ O
PI3K O
] O
/ O
Akt O
signaling O
pathway O
) O
was O
replaced O
with O
NS1 O
- O
138Y O
. O

Here O
, O
we O
show O
that O
an O
HPAI O
H5N1 O
virus O
( O
A O
/ O
duck O
/ O
Hunan O
/ O
69 O
/ O
2004 O
) O
encoding O
NS1 O
- O
ESKV O
and O
NS1 O
- O
138Y O
was O
confined O
to O
the O
respiratory O
tract O
of O
infected O
mice O
, O
whereas O
a O
mutant O
encoding O
NS1 O
- O
ESEV O
and O
NS1 O
- O
138F O
caused O
systemic O
infection O
and O
killed O
mice O
more O
efficiently O
. O

Inactivated O
H5N1 O
vaccines O
induce O
limited O
immune O
responses O
and O
, O
in O
the O
case O
of O
live B
- I
attenuated I
influenza I
virus I
vaccines I
( I
LAIV I
) I
, O
there O
are O
safety O
concerns O
regarding O
the O
possibility O
of O
reassortment O
between O
the O
H5 O
gene O
segment O
and O
circulating O
influenza O
viruses O
. O

In O
order O
to O
overcome O
these O
drawbacks O
, O
we O
rearranged O
the O
genome O
of O
an O
avian O
H9N2 O
influenza O
virus O
and O
expressed O
the O
entire O
H5 O
hemagglutinin O
open B
reading I
frame I
( I
ORF I
) I
from O
the O
segment O
8 O
viral O
RNA O
. O

The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
influenza O
virus O
infection O
resulted O
in O
substantial O
morbidity O
and O
mortality O
in O
humans O
. O

An O
enzyme O
- O
linked O
immunosorbent O
spot O
assay O
was O
used O
to O
analyze O
Hemagglutinin B
( I
HA I
) I
- O
specific O
memory O
B O
cell O
responses O
after O
virus O
antigen O
stimulation O
in O
nose B
- I
associated I
lymphoid I
tissues I
( I
NALT I
) I
from O
children O
and O
adults O
. O

Individuals O
with O
serological O
evidence O
of O
previous O
exposure O
to O
pH1N1 O
showed O
significant O
cross O
- O
reactive O
HA O
- O
specific O
memory O
B O
cell O
responses O
to O
pH1N1 O
, O
seasonal B
H1N1 I
( I
sH1N1 I
) I
, O
and O
avian B
H5N1 I
( I
aH5N1 I
) I
viruses O
upon O
pH1N1 O
virus O
stimulation O
. O

The O
emergence O
of O
a O
highly O
pathogenic O
avian O
influenza O
H7N3 O
virus O
in O
poultry O
throughout O
the O
state O
of O
Jalisco O
, O
Mexico O
, O
resulting O
in O
two O
cases O
of O
human O
infection O
, O
prompted O
us O
to O
examine O
the O
virulence O
of O
this O
virus O
( O
A O
/ O
Mexico O
/ O
InDRE7218 O
/ O
2012 O
[ O
MX O
/ O
7218 O
] O
) O
and O
related O
avian O
H7 O
subtype O
viruses O
in O
mouse O
and O
ferret O
models O
. O

influenza B
A I
virus I
( I
IAV I
) I
infects O
a O
remarkably O
wide O
variety O
of O
avian O
and O
mammalian O
hosts O
. O

To O
better O
understand O
host O
adaptation O
between O
mammalian O
species O
in O
real O
time O
, O
we O
passaged O
mouse O
- O
adapted O
A O
/ O
PR8 O
/ O
34 O
( O
PR8 O
) O
in O
guinea O
pigs O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
H5N1 O
has O
been O
enzootic O
in O
Egypt O
since O
2008 O
. O

Virus O
- O
associated O
mortality O
( O
but O
not O
the O
number O
of O
cases O
) O
in O
humans O
and O
poultry O
seems O
to O
have O
decreased O
over O
time O
, O
but O
the O
reason O
for O
this O
remains O
unknown O
. O

In O
preparing O
for O
the O
threat O
of O
a O
pandemic O
of O
avian O
H5N1 O
influenza O
virus O
, O
we O
need O
to O
consider O
the O
significant O
delay O
( O
4 O
to O
6 O
months O
) O
necessary O
to O
produce O
a O
strain O
- O
matched O
vaccine O
. O

Ferrets O
were O
vaccinated O
with O
two O
intramuscular O
inoculations O
of O
trivalent O
inactivated O
split O
influenza O
vaccine O
or O
subcomponent O
vaccines O
, O
with O
and O
without O
adjuvant O
, O
and O
later O
challenged O
with O
a O
lethal O
dose O
of O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
H5N1 O
) O
influenza O
virus O
. O

The O
protection O
was O
due O
exclusively O
to O
the O
H1N1 O
vaccine O
component O
, O
and O
although O
the O
hemagglutinin O
contributed O
to O
protection O
, O
the O
dominant O
protective O
response O
was O
targeted O
toward O
the O
neuraminidase B
( I
NA I
) I
and O
correlated O
with O
sialic O
acid O
cleavage O
- O
inhibiting O
antibody O
titers O
. O

To O
explore O
the O
impact O
of O
polymerase O
subunits O
on O
protein O
synthesis O
, O
we O
coexpressed O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
or O
luciferase O
together O
with O
each O
polymerase O
component O
or O
NS1 O
of O
A O
/ O
California O
/ O
04 O
/ O
2009 O
( O
Cal O
) O
and O
found O
that O
PA O
has O
a O
significant O
impact O
on O
the O
expression O
of O
eGFP O
and O
luciferase O
. O

Comparison O
of O
the O
suppressive O
activity O
on O
coexpressed O
proteins O
between O
various O
strains O
revealed O
that O
avian O
virus O
or O
avian O
- O
origin O
PAs O
have O
much O
stronger O
activity O
than O
human O
- O
origin O
PAs O
, O
such O
as O
the O
one O
from O
A O
/ O
WSN O
/ O
33 O
( O
WSN O
) O
. O

Further O
characterization O
of O
the O
PA O
fragment O
indicated O
that O
the O
N O
- O
terminal O
domain O
( O
PANt O
) O
, O
which O
includes O
the O
endonuclease O
active O
site O
, O
is O
sufficient O
to O
suppress O
cotransfected O
gene O
expression O
. O

It O
has O
been O
previously O
shown O
that O
the O
pandemic O
2009 O
H1N1 O
( O
H1N1pdm O
) O
virus O
was O
able O
to O
transmit O
efficiently O
in O
ferrets O
. O

In O
coinfection O
studies O
with O
either O
seasonal O
H1N1 O
or O
H3N2 O
strains O
( O
H1N1s O
or O
H3N2s O
, O
respectively O
) O
, O
the O
H1N1pdm O
virus O
was O
able O
to O
outcompete O
these O
strains O
and O
become O
the O
dominant O
transmissible O
virus O
. O

After O
serial O
passages O
in O
ferrets O
, O
a O
dominant O
H1N2 O
virus O
population O
was O
obtained O
with O
a O
constellation O
of O
gene O
segments O
, O
most O
of O
which O
, O
except O
for O
the O
neuraminidase B
( I
NA I
) I
and O
PB1 O
segments O
, O
were O
from O
the O
H1N1pdm O
strain O
. O

The O
rapid O
spread O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
underscores O
the O
importance O
of O
effective O
antiviral O
treatment O
. O

Previously O
, O
we O
developed O
human O
monoclonal O
antibodies O
65C6 O
and O
100F4 O
that O
neutralize O
almost O
all O
( O
sub O
) O
clades O
of O
HPAI O
H5N1 O
. O

Here O
we O
report O
the O
isolation O
of O
an O
H15N4 O
influenza O
A O
virus O
( O
A O
/ O
teal O
/ O
Chany O
/ O
7119 O
/ O
2008 O
) O
in O
Western O
Siberia O
, O
Russia O
. O

Tropism O
and O
adaptation O
of O
influenza O
viruses O
to O
new O
hosts O
is O
partly O
dependent O
on O
the O
distribution O
of O
the O
sialic B
acid I
( I
SA I
) I
receptors O
to O
which O
the O
viral O
Hemagglutinin B
( I
HA I
) I
binds O
. O

We O
found O
that O
human O
- O
like O
( O
alpha O
2 O
, O
6 O
- O
linked O
) O
receptors O
predominated O
on O
ciliated O
cells O
, O
whereas O
avian O
- O
like O
( O
alpha O
2 O
, O
3 O
- O
linked O
) O
receptors O
, O
which O
were O
less O
abundant O
, O
were O
presented O
on O
nonciliated O
cells O
. O

When O
we O
compared O
the O
tropism O
and O
infectivity O
of O
three O
human O
( O
H1 O
and O
H3 O
) O
and O
two O
avian O
( O
H1 O
and O
H5 O
) O
influenza O
viruses O
, O
we O
observed O
that O
the O
human O
influenza O
viruses O
primarily O
infected O
ciliated O
cells O
and O
replicated O
efficiently O
, O
whereas O
a O
highly O
pathogenic O
avian O
H5N1 O
virus O
( O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
) O
replicated O
efficiently O
within O
nonciliated O
cells O
despite O
a O
low O
initial O
infection O
rate O
. O

Furthermore O
, O
compared O
to O
other O
influenza O
viruses O
tested O
, O
VN O
/ O
1203 O
virus O
replicated O
more O
efficiently O
in O
cells O
isolated O
from O
the O
lower O
trachea O
and O
at O
a O
higher O
temperature O
( O
37 O
degrees O
C O
) O
compared O
to O
a O
lower O
temperature O
( O
33 O
degrees O
C O
) O
. O

A O
/ O
Chicken O
/ O
Jiangsu O
/ O
k0402 O
/ O
2010 O
( O
CK10 O
) O
is O
highly O
pathogenic O
, O
whereas O
A O
/ O
Goose O
/ O
Jiangsu O
/ O
k0403 O
/ O
2010 O
( O
GS10 O
) O
is O
nonpathogenic O
. O

We O
further O
determined O
that O
Arginine B
( I
R I
) I
at O
position O
353 O
of O
the O
PA O
gene O
contributes O
to O
the O
high O
virulence O
of O
CK10 O
in O
mice O
. O

Influenza O
A O
virus O
is O
an O
important O
pathogenic O
virus O
known O
to O
induce O
host O
cell O
cycle O
arrest O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
and O
create O
beneficial O
conditions O
for O
viral O
replication O
. O

We O
investigated O
the O
mechanisms O
underlying O
this O
process O
and O
found O
that O
the O
nonstructural B
protein I
1 I
( I
NS1 I
) I
is O
required O
. O

Based O
on O
this O
finding O
, O
we O
generated O
a O
viable O
influenza O
A O
virus O
( O
H1N1 O
) O
lacking O
the O
entire O
NS1 O
gene O
to O
study O
the O
function O
of O
this O
protein O
in O
cell O
cycle O
regulation O
. O

In O
addition O
to O
some O
cell O
cycle O
regulators O
that O
were O
changed O
, O
the O
concentration O
and O
activity O
of O
RhoA O
protein O
, O
which O
is O
thought O
to O
be O
pivotal O
for O
G O
( O
1 O
) O
/ O
S O
phase O
transition O
, O
were O
also O
decreased O
with O
overexpressing O
NS1 O
. O

These O
findings O
indicate O
that O
the O
NS1 O
protein O
induces O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
cell O
cycle O
arrest O
mainly O
through O
interfering O
with O
the O
RhoA O
/ O
pRb O
signaling O
cascade O
, O
thus O
providing O
favorable O
conditions O
for O
viral O
protein O
accumulation O
and O
replication O
. O

We O
further O
investigated O
the O
NS1 O
protein O
of O
avian O
influenza O
virus O
( O
H5N1 O
) O
and O
found O
that O
it O
can O
also O
decrease O
the O
expression O
and O
activity O
of O
RhoA O
, O
suggesting O
that O
the O
H5N1 O
virus O
may O
affect O
the O
cell O
cycle O
through O
the O
same O
mechanism O
. O

The O
NS1 O
/ O
RhoA O
/ O
pRb O
cascade O
, O
which O
can O
induce O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
cell O
cycle O
arrest O
identified O
here O
, O
provides O
a O
unified O
explanation O
for O
the O
seemingly O
different O
NS1 O
functions O
involved O
in O
viral O
replication O
events O
. O

Gene O
expression O
profiles O
during O
pandemic O
H1N1 O
( O
pdmH1N1 O
) O
influenza O
virus O
infection O
were O
analyzed O
by O
digital O
gene O
expression O
and O
solid O
support O
microarrays O
. O

Animal B
influenza I
viruses I
( I
AIVs I
) I
are O
a O
major O
threat O
to O
human O
health O
and O
the O
source O
of O
pandemic O
influenza O
. O

We O
show O
that O
cotton O
rats O
( O
Sigmodon O
hispidus O
) O
are O
susceptible O
to O
avian O
and O
swine O
influenza O
viruses O
. O

Cotton O
rats O
express O
alpha O
2 O
, O
3 O
- O
linked O
sialic B
acid I
( I
SA I
) I
and O
alpha O
2 O
, O
6 O
- O
linked O
SA O
residues O
in O
the O
trachea O
and O
alpha O
2 O
, O
6 O
- O
linked O
SA O
residues O
in O
the O
lung O
parenchyma O
. O

Prototypic O
avian O
influenza O
viruses O
( O
H3N2 O
, O
H9N2 O
, O
and O
H5N1 O
) O
and O
swine O
- O
origin O
2009 O
pandemic O
H1N1 O
viruses O
replicated O
in O
the O
nose O
and O
in O
the O
respiratory O
tract O
of O
cotton O
rats O
without O
prior O
adaptation O
and O
produced O
strong O
lung O
pathology O
that O
was O
characterized O
by O
early O
lung O
neutrophilia O
, O
followed O
by O
subsequent O
pneumonia O
. O

More O
importantly O
, O
we O
show O
that O
the O
different O
avian O
and O
pandemic O
H1N1 O
strains O
tested O
are O
strong O
activators O
of O
the O
type B
I I
interferon I
( I
IFN I
) I
- O
inducible O
MX O
- O
1 O
gene O
both O
locally O
and O
systemically O
. O

In O
this O
study O
, O
we O
identified O
a O
broadly O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
, O
HA O
- O
7 O
, O
that O
potently O
neutralized O
all O
tested O
strains O
of O
H5N1 O
covering O
clades O
0 O
, O
1 O
, O
2 O
. O

HA O
- O
7 O
specifically O
targeted O
the O
globular O
head O
of O
the O
H5N1 O
virus O
Hemagglutinin B
( I
HA I
) I
. O

Using O
electron O
microscopy O
technology O
with O
three B
- I
dimensional I
reconstruction I
( I
3D I
- I
EM I
) I
, O
we O
discovered O
that O
HA O
- O
7 O
bound O
to O
a O
novel O
and O
highly O
conserved O
conformational O
epitope O
that O
was O
centered O
on O
residues O
81 O
to O
83 O
and O
117 O
to O
122 O
of O
HA1 O
( O
H5 O
numbering O
) O
. O

However O
, O
they O
may O
also O
contribute O
to O
severe O
disease O
caused O
by O
the O
highly B
pathogenic I
avian I
( I
HPAI I
) I
H5N1 O
influenza O
viruses O
. O

Influenza O
virus O
infectivity O
requires O
cleavage O
of O
the O
surface O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
at O
a O
distinct O
cleavage O
site O
by O
host O
cell O
proteases O
. O

Here O
, O
we O
investigated O
proteolytic O
activation O
of O
the O
early O
H9N2 O
isolate O
A O
/ O
turkey O
/ O
Wisconsin O
/ O
1 O
/ O
66 O
( O
H9 O
- O
Wisc O
) O
and O
two O
recent O
Asian O
isolates O
, O
A O
/ O
quail O
/ O
Shantou O
/ O
782 O
/ O
00 O
( O
H9 O
- O
782 O
) O
and O
A O
/ O
quail O
/ O
Shantou O
/ O
2061 O
/ O
00 O
( O
H9 O
- O
2061 O
) O
, O
containing O
mono O
- O
, O
di O
- O
, O
and O
tribasic O
HA O
cleavage O
sites O
, O
respectively O
. O

All O
H9N2 O
isolates O
were O
activated O
by O
human O
proteases O
TMPRSS2 O
( O
transmembrane O
protease O
, O
serine O
S1 O
member O
2 O
) O
and O
HAT B
( I
human I
airway I
trypsin I
- I
like I
protease I
) I
. O

Nephrotropism O
of O
H9N2 O
viruses O
has O
been O
observed O
in O
chickens O
, O
and O
here O
we O
found O
that O
H9 O
- O
782 O
and O
H9 O
- O
2061 O
were O
proteolytically O
activated O
in O
canine O
kidney O
( O
MDCK O
- O
II O
) O
and O
chicken B
embryo I
kidney I
( I
CEK I
) I
cells O
, O
whereas O
H9 O
- O
Wisc O
was O
not O
. O

A O
safe O
and O
effective O
vaccine O
is O
the O
best O
way O
to O
prevent O
large O
- O
scale O
highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAI I
) I
H5N1 O
outbreaks O
in O
the O
human O
population O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
a O
paramyxovirus O
, O
is O
not O
known O
to O
cause O
any O
illness O
in O
humans O
. O

In O
our O
studies O
, O
a O
single O
dose O
of O
a O
live O
recombinant O
PIV5 O
expressing O
a O
Hemagglutinin B
( I
HA I
) I
gene O
of O
H5N1 O
( O
rPIV5 O
- O
H5 O
) O
from O
the O
H5N1 O
subtype O
provided O
sterilizing O
immunity O
against O
lethal O
doses O
of O
HPAI O
H5N1 O
infection O
in O
mice O
. O

Interestingly O
, O
insertion O
of O
H5N1 O
HA O
between O
the O
leader O
sequence O
, O
the O
de O
facto O
promoter O
of O
PIV5 O
, O
and O
the O
first O
viral O
gene O
, O
nucleoprotein B
( I
NP I
) I
, O
did O
not O
lead O
to O
a O
viable O
virus O
. O

Insertion O
of O
H5N1 O
HA O
between O
NP O
and O
the O
next O
gene O
, O
V O
/ O
phosphorprotein O
( O
V O
/ O
P O
) O
, O
led O
to O
a O
virus O
that O
was O
defective O
in O
growth O
. O

We O
have O
found O
that O
insertion O
of O
H5N1 O
HA O
at O
the O
junction O
between O
the O
small B
hydrophobic I
( I
SH I
) I
gene O
and O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
gene O
gave O
the O
best O
immunity O
against O
HPAI O
H5N1 O
challenge O
: O
a O
dose O
as O
low O
as O
1 O
, O
000 O
PFU O
was O
sufficient O
to O
protect O
against O
lethal O
HPAI O
H5N1 O
challenge O
in O
mice O
. O

Emerging O
viruses O
, O
such O
as O
the O
H5N1 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
, O
pose O
not O
only O
pandemic O
threats O
but O
also O
challenges O
in O
vaccine O
development O
and O
production O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
is O
an O
appealing O
vector O
for O
vaccine O
development O
, O
and O
we O
have O
previously O
shown O
that O
intranasal O
immunization O
with O
PIV5 O
expressing O
the O
hemagglutinin O
from O
influenza O
virus O
was O
protective O
against O
influenza O
virus O
challenge O
( O
S O
. O

In O
the O
BALB O
/ O
c O
mouse O
model O
, O
a O
single O
intramuscular O
or O
intranasal O
immunization O
with O
a O
live O
rPIV5 O
- O
H5 O
( O
ZL46 O
) O
rapidly O
induced O
robust O
neutralizing O
serum O
antibody O
responses O
and O
protected O
against O
HPAI O
challenge O
, O
although O
mucosal O
IgA O
responses O
primed O
by O
intranasal O
immunization O
more O
effectively O
controlled O
virus O
replication O
in O
the O
lung O
. O

Influenza O
virus O
nucleoprotein O
was O
detected O
by O
Immunohistochemistry B
( I
IHC I
) I
in O
the O
acinar O
tissue O
. O

The O
cytokine O
activation O
profile O
indicated O
a O
significant O
increase O
of O
MIG O
/ O
CXCL9 O
, O
IP O
- O
10 O
/ O
CXCL10 O
, O
RANTES O
/ O
CCL5 O
, O
MIP1b O
/ O
CCL4 O
, O
Groa O
/ O
CXCL1 O
, O
interleukin B
8 I
( I
IL I
- I
8 I
) I
/ O
CXCL8 O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
and O
IL O
- O
6 O
. O

Previously O
, O
others O
have O
proposed O
that O
this O
mutation O
increases O
the O
stability O
of O
the O
viral B
ribonucleoprotein I
complex I
( I
vRNP I
) I
measured O
by O
the O
interaction O
between O
PB2 O
and O
NP O
. O

In O
this O
report O
, O
a O
novel O
H5N2 O
Avian B
influenza I
virus I
( I
AIV I
) I
was O
isolated O
from O
chickens O
in O
Tibet O
in O
2010 O
, O
western O
China O
. O

It O
is O
of O
note O
that O
this O
virus O
has O
an O
HP O
genotype O
with O
HA O
, O
PB2 O
, O
M O
, O
and O
NS O
genes O
homologous O
to O
those O
of O
A O
/ O
peregrine O
falcon O
/ O
Hong O
Kong O
/ O
2142 O
/ O
2008 O
( O
H5N1 O
) O
- O
like O
HPAIV O
isolated O
from O
dead O
wild O
birds O
. O

We O
reported O
the O
complete O
genome O
sequence O
of O
an O
H5N5 O
Avian B
influenza I
virus I
( I
AIV I
) I
that O
was O
first O
isolated O
from O
duck O
in O
central O
China O
in O
2010 O
. O

Here O
, O
we O
report O
the O
complete O
genome O
sequence O
of O
a O
novel O
H4N1 O
influenza O
virus O
[ O
A O
/ O
Swine O
/ O
HuBei O
/ O
06 O
/ O
2009 O
( O
H4N1 O
) O
] O
isolated O
from O
a O
pig O
in O
Central O
China O
in O
2009 O
. O

We O
report O
here O
the O
complete O
genomic O
sequence O
of O
a O
novel O
H6N1 O
avian O
influenza O
virus O
strain O
, O
A O
/ O
Duck O
/ O
Guangxi O
/ O
GXd O
- O
5 O
/ O
2010 O
( O
H6N1 O
) O
, O
isolated O
from O
pockmark O
ducks O
in O
Guangxi O
Province O
, O
Southern O
China O
. O

All O
of O
the O
8 O
gene O
segments O
of O
A O
/ O
Duck O
/ O
Guangxi O
/ O
GXd O
- O
5 O
/ O
2010 O
( O
H6N1 O
) O
are O
attributed O
to O
the O
Eurasian O
lineage O
; O
the O
amino O
acid O
motif O
of O
the O
cleavage O
site O
between O
HA1 O
and O
HA2 O
was O
P O
- O
Q O
- O
I O
- O
E O
- O
T O
- O
R O
- O
G O
. O

Some O
retroviruses O
, O
such O
as O
avian B
sarcoma I
/ I
leukosis I
virus I
( I
ASLV I
) I
, O
employ O
a O
two O
- O
step O
mechanism O
in O
which O
receptor O
binding O
precedes O
low O
- O
pH O
activation O
and O
fusion O
. O

Subtomogram O
averaging O
showed O
that O
the O
oblate O
globular O
domain O
in O
the O
prehairpin O
intermediate O
( O
presumably O
the O
receptor O
- O
binding O
domain O
) O
is O
connected O
to O
both O
the O
target O
and O
the O
viral O
membrane O
by O
2 O
. O

Fusion O
is O
a O
stochastic O
process O
that O
, O
once O
initiated O
, O
must O
be O
rapid O
, O
as O
only O
final O
( O
postfusion O
) O
products O
were O
observed O
. O

A O
/ O
chicken O
/ O
Nanjing O
/ O
908 O
/ O
2009 O
( O
H11N2 O
) O
( O
CK908 O
) O
was O
isolated O
from O
a O
live O
poultry O
market O
in O
Nanjing O
, O
China O
. O

We O
isolated O
a O
recombinant O
H9N2 O
Avian B
influenza I
virus I
( I
AIV I
) I
from O
fresh O
egret O
feces O
in O
the O
Ardeidae O
protection O
region O
of O
the O
Dongting O
Lake O
wetland O
area O
in O
China O
, O
and O
it O
was O
designated O
A O
/ O
Egret O
/ O
Hunan O
/ O
1 O
/ O
2012 O
( O
H9N2 O
) O
. O

Therefore O
, O
it O
is O
important O
to O
enhance O
the O
surveillance O
of O
H3 O
avian B
influenza I
viruses I
( I
AIVs I
) I
. O

In O
this O
study O
, O
A O
/ O
duck O
/ O
Shanghai O
/ O
C84 O
/ O
2009 O
( O
H3N2 O
) O
( O
C84 O
) O
was O
isolated O
from O
a O
live O
poultry O
market O
in O
Shanghai O
, O
China O
. O

A O
/ O
duck O
/ O
Shanghai O
/ O
28 O
- O
1 O
/ O
2009 O
( O
H4N2 O
) O
( O
DK28 O
) O
was O
isolated O
from O
a O
live O
poultry O
market O
in O
Shanghai O
, O
China O
. O

The O
sequence O
analysis O
demonstrated O
that O
this O
H4N2 O
virus O
was O
a O
novel O
multiple O
- O
gene O
reassortant O
Avian B
influenza I
virus I
( I
AIV I
) I
whose O
genes O
originated O
from O
H1N1 O
, O
H1N3 O
, O
H3N3 O
, O
H4N2 O
, O
and O
H4N6 O
. O

An O
H6N5 O
Avian B
influenza I
virus I
( I
AIV I
) I
strain O
, O
designated O
A O
/ O
aquatic O
bird O
/ O
Korea O
/ O
CN5 O
/ O
2009 O
( O
H6N5 O
) O
, O
was O
isolated O
from O
fecal O
swabs O
of O
aquatic O
birds O
in O
2009 O
, O
and O
surprisingly O
, O
it O
showed O
infectivity O
and O
pathogenicity O
in O
mammalian O
species O
without O
evidence O
of O
adaptation O
. O

In O
this O
study O
, O
we O
report O
the O
first O
complete O
genome O
sequence O
containing O
3 O
' O
and O
5 O
' O
noncoding B
regions I
( I
NCRs I
) I
of O
a O
mammalian O
species O
- O
infectious O
and O
pathogenic O
H6N5 O
AIV O
, O
which O
will O
help O
provide O
important O
insights O
into O
the O
molecular O
basis O
of O
pathogenesis O
, O
transmission O
, O
and O
evolution O
of O
AIV O
. O

A O
canine B
influenza I
virus I
( I
CIV I
) I
strain O
of O
avian O
origin O
designated O
A O
/ O
Canine O
/ O
Jiangsu O
/ O
06 O
/ O
2010 O
( O
H3N2 O
) O
was O
isolated O
from O
dogs O
exhibiting O
severe O
respiratory O
disease O
in O
Jiangsu O
, O
China O
. O

We O
demonstrate O
that O
phosphorylation O
of O
the O
NS1 O
protein O
of O
a O
human O
influenza O
A O
virus O
occurs O
not O
only O
at O
the O
threonine B
( I
T I
) I
at O
position O
215 O
but O
also O
at O
serines B
( I
Ss I
) I
, O
specifically O
at O
positions O
42 O
and O
48 O
. O

By O
generating O
recombinant O
influenza O
A O
/ O
Udorn O
/ O
72 O
( O
Ud O
) O
viruses O
that O
encode O
mutant O
NS1 O
proteins O
, O
we O
determined O
the O
roles O
of O
these O
phosphorylations O
in O
virus O
replication O
. O

At O
position O
215 O
only O
a O
T O
- O
to O
- O
A O
substitution O
attenuated O
replication O
, O
whereas O
other O
substitutions O
( O
T O
to O
E O
to O
mimic O
constitutive O
phosphorylation O
, O
T O
to O
N O
, O
and O
T O
to O
P O
, O
the O
amino O
acid O
in O
avian O
influenza O
A O
virus O
NS1 O
proteins O
) O
had O
no O
effect O
. O

We O
show O
that O
protein B
kinase I
C I
alpha I
( I
PKC I
alpha I
) I
catalyzes O
S42 O
phosphorylation O
. O

Infectious B
salmon I
anemia I
( I
ISA I
) I
is O
a O
World B
organization I
for I
animal I
health I
( I
OIE I
) I
- O
listed O
disease O
of O
farmed O
Atlantic O
salmon O
, O
characterized O
by O
slowly O
developing O
anemia O
and O
circulatory O
disturbances O
. O

The O
disease O
is O
caused O
by O
ISA B
virus I
( I
ISAV I
) I
in O
the O
Orthomyxoviridae O
family O
; O
hence O
, O
it O
is O
related O
to O
influenza O
. O

From O
endothelium O
, O
the O
virus O
budded O
apically O
and O
adsorbed O
to O
red B
blood I
cells I
( I
RBCs I
) I
. O

Here O
we O
detected O
the O
preferred O
receptor O
of O
ISAV O
, O
4 O
- O
O O
- O
acetylated O
sialic O
acid O
( O
Neu4 O
, O
5Ac O
( O
2 O
) O
) O
. O

A O
/ O
chicken O
/ O
FJ O
/ O
G9 O
/ O
09 O
( O
FJ O
/ O
G9 O
) O
is O
an O
H9N2 O
subtype O
avian O
influenza O
virus O
( O
H9N2 O
AIV O
) O
strain O
causing O
high O
morbidity O
that O
was O
isolated O
from O
broilers O
in O
Fujian O
Province O
of O
China O
in O
2009 O
. O

The O
hemagglutinin B
protein I
( I
HA I
) I
of O
the O
influenza O
virus O
family O
is O
a O
major O
antigen O
for O
protective O
immunity O
. O

Here O
, O
we O
describe O
a O
human O
CD4 O
( O
+ O
) O
T O
cell O
epitope O
in O
the O
influenza O
virus O
HA O
that O
lies O
in O
the O
fusion O
peptide O
of O
the O
HA O
. O

By O
stimulating O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
from O
a O
healthy O
adult O
donor O
with O
peptides O
covering O
the O
entire O
HA O
protein O
based O
on O
the O
sequence O
of O
A O
/ O
Japan O
/ O
305 O
/ O
1957 O
( O
H2N2 O
) O
, O
we O
generated O
a O
T O
cell O
line O
specific O
to O
this O
epitope O
. O

This O
CD4 O
( O
+ O
) O
T O
cell O
line O
recognizes O
target O
cells O
infected O
with O
influenza O
A O
virus O
seasonal O
H1N1 O
and O
H3N2 O
strains O
, O
a O
reassortant O
H2N1 O
strain O
, O
the O
2009 O
pandemic O
H1N1 O
strain O
, O
and O
influenza O
B O
virus O
in O
cytotoxicity O
assays O
and O
intracellular O
- O
cytokine O
- O
staining O
assays O
. O

We O
screened O
healthy O
adult O
PBMCs O
for O
T O
cell O
responses O
specific O
to O
this O
epitope O
and O
found O
individuals O
who O
had O
ex O
vivo O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
responses O
to O
the O
peptide O
epitope O
in O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assays O
. O

Although O
natural O
infection O
or O
standard O
vaccination O
may O
not O
induce O
strong O
T O
and O
B O
cell O
responses O
to O
this O
highly O
conserved O
epitope O
in O
the O
fusion O
peptide O
, O
it O
may O
be O
possible O
to O
develop O
a O
vaccination O
strategy O
to O
induce O
these O
CD4 O
( O
+ O
) O
T O
cells O
, O
which O
are O
cross O
- O
reactive O
to O
both O
influenza O
A O
and O
B O
viruses O
. O

Phylogenetic O
analysis O
showed O
that O
HA O
and O
NA O
showed O
the O
highest O
sequence O
homologies O
with O
those O
of O
A O
/ O
white O
- O
backed O
munia O
/ O
Hong O
Kong O
/ O
4519 O
/ O
2009 O
( O
H3N2 O
) O
. O

We O
found O
that O
these O
two O
cell O
types O
from O
both O
human O
and O
pig O
showed O
comparable O
susceptibilities O
to O
initial O
infection O
with O
a O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
( O
A O
/ O
turkey O
/ O
Turkey O
/ O
1 O
/ O
05 O
) O
and O
a O
moderately O
pathogenic O
human O
influenza O
H1N1 O
virus O
( O
A O
/ O
USSR O
/ O
77 O
) O
, O
but O
there O
were O
contrasting O
differences O
in O
host O
innate O
immune O
responses O
. O

Human O
cells O
mounted O
vigorous O
cytokine O
( O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
and O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
] O
) O
and O
chemokine O
( O
CXCL9 O
, O
CXCL10 O
, O
and O
CXCL11 O
) O
responses O
to O
H5N1 O
virus O
infection O
. O

suppressor B
of I
cytokine I
signaling I
3 I
( I
SOCS3 I
) I
, O
a O
protein O
suppressor O
of O
the O
JAK O
- O
STAT O
pathway O
, O
was O
constitutively O
highly O
expressed O
and O
transcriptionally O
upregulated O
in O
H5N1 O
virus O
- O
infected O
pig O
epithelial O
cells O
and O
macrophages O
, O
in O
contrast O
to O
the O
corresponding O
human O
cells O
. O

In O
this O
study O
, O
a O
series O
of O
chimeric O
1918 O
influenza O
viruses O
were O
created O
in O
which O
each O
of O
the O
eight O
1918 O
pandemic O
virus O
gene O
segments O
was O
replaced O
individually O
with O
the O
corresponding O
gene O
segment O
of O
a O
prototypical O
low B
- I
pathogenicity I
avian I
influenza I
( I
LPAI I
) I
H1N1 O
virus O
in O
order O
to O
investigate O
functional O
compatibility O
of O
the O
1918 O
virus O
genome O
with O
gene O
segments O
from O
an O
LPAI O
virus O
and O
to O
identify O
gene O
segments O
and O
mutations O
important O
for O
mammalian O
adaptation O
. O

An O
avian O
- O
origin O
Korean O
H3N2 O
canine B
influenza I
virus I
( I
CIV I
) I
strain O
, O
designated O
A O
/ O
canine O
/ O
Korea O
/ O
01 O
/ O
2007 O
( O
H3N2 O
) O
, O
was O
isolated O
from O
nasal O
swabs O
of O
pet O
dogs O
exhibiting O
severe O
respiratory O
syndrome O
in O
2007 O
. O

In O
the O
present O
study O
, O
we O
report O
the O
first O
complete O
genome O
sequence O
containing O
3 O
' O
and O
5 O
' O
noncoding B
regions I
( I
NCRs I
) I
of O
H3N2 O
CIV O
, O
which O
will O
provide O
important O
insights O
into O
the O
molecular O
basis O
of O
pathogenesis O
, O
transmission O
, O
and O
evolution O
of O
CIV O
. O

Severe B
fever I
with I
thrombocytopenia I
syndrome I
( I
SFTS I
) I
is O
an O
emerging O
infectious O
disease O
characterized O
by O
high O
fever O
, O
thrombocytopenia O
, O
multiorgan O
dysfunction O
, O
and O
a O
high O
fatality O
rate O
between O
12 O
and O
30 O
% O
. O

It O
is O
caused O
by O
SFTS O
virus O
( O
SFTSV O
) O
, O
a O
novel O
Phlebovirus O
in O
family O
Bunyaviridae O
. O

We O
examined O
host O
responses O
in O
the O
infected O
cells O
and O
found O
that O
antiviral O
interferon B
( I
IFN I
) I
and O
IFN O
- O
inducible O
proteins O
were O
induced O
upon O
infection O
. O

However O
, O
our O
data O
also O
indicated O
that O
downregulation O
of O
key O
molecules O
such O
as O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
or O
weakened O
activation O
of O
interferon B
regulatory I
factor I
( I
IRF I
) I
and O
NF O
- O
kappa O
B O
responses O
may O
contribute O
to O
a O
restricted O
innate O
immunity O
against O
the O
infection O
. O

NSs O
, O
the O
nonstructural O
protein O
encoded O
by O
the O
S O
segment O
, O
suppressed O
the O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
NF O
- O
kappa O
B O
promoter O
activities O
, O
although O
NF O
- O
kappa O
B O
activation O
appears O
to O
facilitate O
SFTSV O
replication O
in O
human O
monocytes O
. O

Interestingly O
, O
we O
demonstrated O
that O
the O
nucleoprotein B
( I
N I
) I
, O
also O
encoded O
by O
the O
S O
segment O
, O
exhibited O
a O
suppressive O
effect O
on O
the O
activation O
of O
IFN O
- O
beta O
and O
NF O
- O
kappa O
B O
signaling O
as O
well O
. O

Recurrence O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
subtype O
H7 O
in O
poultry O
continues O
to O
be O
a O
public O
health O
concern O
. O

In O
previous O
studies O
, O
the O
virus O
isolated O
from O
this O
fatal O
case O
, O
A O
/ O
Netherlands O
/ O
219 O
/ O
2003 O
( O
NL219 O
) O
caused O
a O
lethal O
infection O
in O
mouse O
models O
and O
had O
increased O
replication O
efficiency O
and O
a O
broader O
tissue O
distribution O
than O
nonlethal O
isolates O
from O
the O
same O
outbreak O
. O

We O
report O
the O
complete O
genome O
sequence O
of O
an O
H5N2 O
Avian B
influenza I
virus I
( I
AIV I
) I
that O
was O
first O
isolated O
from O
a O
parrot O
in O
Guangdong O
in O
southern O
China O
in O
2004 O
. O

An O
H5N1 O
Avian B
influenza I
virus I
( I
AIV I
) I
designated O
A O
/ O
Parrot O
/ O
Guangdong O
/ O
C99 O
/ O
2005 O
( O
H5N1 O
) O
was O
first O
isolated O
from O
a O
sick O
parrot O
in O
Guangdong O
in O
southern O
China O
in O
2005 O
. O

0 O
% O
homology O
to O
A O
/ O
chicken O
/ O
Henan O
/ O
12 O
/ O
2004 O
( O
H5N1 O
) O
. O

Here O
, O
we O
reported O
the O
complete O
genome O
sequence O
of O
a O
novel O
H6N2 O
Avian B
influenza I
virus I
( I
AIV I
) I
isolated O
from O
chicken O
in O
Guangdong O
, O
Southern O
China O
, O
in O
2011 O
which O
was O
a O
natural O
recombinant O
virus O
between O
the O
H6N2 O
and O
H5N1 O
subtypes O
. O

In O
this O
study O
, O
we O
report O
the O
first O
genomic O
information O
on O
an O
H5N1 O
Avian B
influenza I
virus I
( I
AIV I
) I
isolated O
from O
a O
condor O
in O
Guangdong O
Province O
in O
southern O
China O
in O
2003 O
. O

We O
report O
here O
the O
complete O
genomic O
sequence O
of O
an O
H7N3 O
Avian B
influenza I
virus I
( I
AIV I
) I
isolate O
, O
which O
was O
obtained O
from O
duck O
in O
1996 O
. O

Genomic O
sequence O
and O
phylogenetic O
analyses O
showed O
that O
it O
was O
highly O
homologous O
with O
the O
wild O
bird O
virus O
A O
/ O
ruddy O
turnstone O
/ O
Delaware O
Bay O
/ O
135 O
/ O
1996 O
( O
H7N3 O
) O
and O
that O
all O
eight O
genes O
of O
this O
virus O
belonged O
to O
the O
North O
America O
gene O
pool O
. O

An O
H10N8 O
Avian B
influenza I
virus I
( I
AIV I
) I
, O
designated O
A O
/ O
Duck O
/ O
Guangdong O
/ O
E1 O
/ O
2012 O
( O
H10N8 O
) O
, O
was O
isolated O
from O
a O
duck O
in O
January O
2012 O
. O

This O
is O
first O
report O
that O
this O
subtype O
of O
AIV O
was O
isolated O
from O
a O
live B
bird I
market I
( I
LBM I
) I
in O
Guangdong O
Province O
in O
southern O
China O
. O

We O
constructed O
DNA O
plasmids O
encoding O
codon O
- O
optimized O
Hemagglutinin B
( I
HA I
) I
from O
17 O
representative O
strains O
covering O
all O
reported O
clades O
and O
subclades O
of O
highly O
pathogenic O
avian O
influenza O
H5N1 O
viruses O
. O

We O
report O
here O
that O
( O
sub O
) O
clades O
0 O
, O
1 O
, O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
. O

1 O
, O
and O
9 O
were O
grouped O
into O
antigenic O
cluster O
1 O
, O
( O
sub O
) O
clades O
2 O
. O

Importantly O
, O
the O
triclade O
DNA O
vaccine O
encoding O
HAs O
of O
( O
sub O
) O
clades O
0 O
, O
2 O
. O

Group O
II O
H6 O
virus O
showed O
that O
the O
genesis O
and O
development O
of O
multiple O
types O
of O
deletions O
in O
the O
neuraminidase B
( I
NA I
) I
stalk O
region O
could O
occur O
in O
the O
influenza O
viruses O
from O
domestic O
ducks O
. O

microRNAs B
( I
miRNAs I
) I
repress O
the O
expression O
levels O
of O
genes O
by O
binding O
to O
mRNA O
transcripts O
, O
acting O
as O
master O
regulators O
of O
cellular O
processes O
. O

In O
contrast O
, O
limited O
biological O
and O
molecular O
information O
has O
been O
reported O
on O
the O
potential O
role O
of O
cellular O
miRNAs O
in O
the O
life O
cycle O
of O
influenza O
A O
viruses O
( O
infA O
) O
. O

In O
this O
study O
, O
we O
hypothesize O
that O
elucidating O
the O
miRNA O
expression O
signatures O
induced O
by O
low O
- O
pathogenicity O
swine O
- O
origin O
infA O
( O
S O
- O
OIV O
) O
pandemic O
HI O
NI O
( O
2009 O
) O
and O
highly O
pathogenic O
avian O
- O
origin O
infA O
( O
A O
- O
OIV O
) O
H7N7 O
( O
2003 O
) O
infections O
could O
reveal O
temporal O
and O
strain O
- O
specific O
miRNA O
fingerprints O
during O
the O
viral O
life O
cycle O
, O
shedding O
important O
insights O
into O
the O
potential O
role O
of O
cellular O
miRNAs O
in O
host O
- O
infA O
interactions O
. O

By O
identifying O
the O
specific O
and O
dynamic O
molecular O
phenotypic O
changes O
( O
microRNAome O
) O
triggered O
by O
S O
- O
and O
A O
- O
OIV O
infection O
in O
human O
cells O
, O
we O
provide O
experimental O
evidence O
demonstrating O
a O
series O
of O
temporal O
and O
strain O
- O
specific O
host O
molecular O
responses O
involving O
different O
combinatorial O
contributions O
of O
multiple O
cellular O
miRNAs O
. O

The O
rapid O
transmission O
of O
the O
pandemic O
2009 O
H1N1 O
influenza O
virus O
( O
pH1N1 O
) O
among O
humans O
has O
raised O
the O
concern O
of O
a O
potential O
emergence O
of O
reassortment O
between O
pH1N1 O
and O
highly O
pathogenic O
influenza O
strains O
, O
especially O
the O
avian O
H5N1 O
influenza O
virus O
. O

Here O
, O
we O
report O
that O
the O
cold B
- I
adapted I
pH1N1 I
live I
attenuated I
vaccine I
( I
CApH1N1 I
) I
elicits O
cross O
- O
reactive O
immunity O
to O
seasonal O
and O
H5 O
influenza O
A O
viruses O
in O
the O
mouse O
model O
. O

Antiviral O
drugs O
such O
as O
neuraminidase B
( I
NA I
) I
inhibitors O
will O
be O
crucial O
for O
disease O
control O
in O
the O
event O
of O
a O
pandemic O
. O

To O
determine O
the O
likelihood O
and O
mechanisms O
of O
emergence O
of O
NA O
inhibitor O
- O
resistant O
H5N1 O
variants O
in O
humans O
, O
we O
serially O
passaged O
two O
H5N1 O
viruses O
, O
A O
/ O
Hong O
Kong O
/ O
213 O
/ O
03 O
and O
A O
/ O
Turkey O
/ O
65 O
- O
1242 O
/ O
06 O
, O
in O
normal B
human I
bronchial I
epithelial I
( I
NHBE I
) I
cells O
in O
the O
presence O
of O
oseltamivir O
, O
zanamivir O
, O
or O
peramivir O
. O

Under O
pressure O
of O
each O
NA O
inhibitor O
, O
A O
/ O
Turkey O
/ O
65 O
- O
1242 O
/ O
06 O
developed O
mutations O
in O
the O
Hemagglutinin B
( I
HA I
) I
( O
H28R O
and O
P194L O
/ O
T215I O
) O
and O
NA O
( O
E119A O
) O
proteins O
that O
reduced O
virus O
binding O
to O
alpha O
2 O
, O
3 O
- O
sialyl O
receptor O
and O
NA O
activity O
. O

Unlike O
typical O
duck O
influenza O
viruses O
with O
non O
- O
H7 O
Hemagglutinin B
( I
HA I
) I
, O
all O
avian O
H7 O
influenza O
viruses O
, O
irrespective O
of O
the O
host O
species O
, O
displayed O
a O
poultry O
- O
virus O
- O
like O
binding O
specificity O
, O
i O
. O

, O
preferential O
binding O
to O
sulfated O
oligosaccharides O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
4 O
( O
6 O
- O
O O
- O
HSO3 O
) O
GlcNAc O
and O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
4 O
( O
Fuc O
alpha O
1 O
- O
3 O
) O
( O
6 O
- O
O O
- O
HSO3 O
) O
GlcNAc O
. O

We O
investigated O
the O
synergism O
between O
influenza O
virus O
and O
Streptococcus O
pneumoniae O
, O
particularly O
the O
role O
of O
deletions O
in O
the O
stalk O
region O
of O
the O
neuraminidase B
( I
NA I
) I
of O
H2N2 O
and O
H9N2 O
avian O
influenza O
viruses O
. O

Deletions B
in I
the I
NA I
stalk I
( I
Delta I
NA I
) I
had O
no O
effect O
on O
NA O
activity O
or O
on O
the O
adherence O
of O
S O
. O

pneumoniae O
to O
virus O
- O
infected O
human O
alveolar O
epithelial O
( O
A549 O
) O
and O
mouse B
lung I
adenoma I
( I
LA I
- I
4 I
) I
cells O
, O
although O
it O
delayed O
virus O
elution O
from O
turkey O
red O
blood O
cells O
. O

The O
route O
by O
which O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
spreads O
systemically O
, O
including O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
is O
largely O
unknown O
in O
mammals O
. O

Although O
the O
multibasic B
cleavage I
site I
( I
MBCS I
) I
in O
the O
Hemagglutinin B
( I
HA I
) I
of O
HPAI O
H5N1 O
viruses O
is O
a O
major O
determinant O
of O
systemic O
spread O
in O
poultry O
, O
the O
association O
between O
the O
MBCS O
and O
systemic O
spread O
in O
mammals O
is O
less O
clear O
. O

Intranasal O
inoculation O
with O
wild O
- O
type O
H5N1 O
virus O
revealed O
extensive O
replication O
in O
the O
olfactory O
mucosa O
, O
from O
which O
it O
spread O
to O
the O
olfactory O
bulb O
and O
the O
rest O
of O
the O
CNS O
, O
including O
the O
cerebrospinal B
fluid I
( I
CSF I
) I
. O

Influenza O
A O
virus O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
binds O
to O
host O
cell O
surface O
sialic B
acid I
( I
SA I
) I
- O
terminated O
sugars O
in O
glycoproteins O
to O
initiate O
viral O
entry O
. O

It O
is O
thought O
that O
avian O
influenza O
viruses O
preferentially O
bind O
to O
N B
- I
acetylneuraminic I
acid I
alpha I
3 I
( I
NeuAc I
alpha I
3 I
) I
sugars O
, O
while O
human O
influenza O
viruses O
exhibit O
a O
preference O
for O
NeuAc O
alpha O
6 O
- O
containing O
sugars O
. O

Thus O
, O
species O
- O
specific O
SA O
( O
s O
) O
is O
one O
of O
the O
determinants O
in O
viral O
host O
tropism O
. O

Oligosaccharide O
binding O
analysis O
showed O
that O
substituting O
alanine O
at O
Y161 O
of O
HA O
changed O
the O
SA O
binding O
preference O
from O
NeuAc B
to I
N I
- I
glycolylneuraminic I
acid I
( I
NeuGc I
) I
. O

Seventeen O
recombinant O
viruses O
were O
generated O
by O
a O
reverse O
genetic O
technique O
to O
elucidate O
the O
pathogenicity O
of O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
in O
chickens O
. O

The O
recombinant O
viruses O
generated O
possessed O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
from O
an O
HPAIV O
. O

Other O
segments O
were O
combinations O
of O
the O
genes O
from O
an O
HPAIV O
and O
two O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
derived O
from O
chicken O
( O
LP O
) O
and O
wild B
bird I
( I
WB I
) I
. O

Recombinants O
where O
the O
PA O
gene O
was O
exchanged O
from O
LP O
to O
WB O
in O
the O
LP O
gene O
background O
, O
LP O
( O
W O
/ O
PA O
) O
, O
did O
not O
kill O
any O
chickens O
. O

LP O
( O
W O
/ O
PA O
) O
replicated O
less O
efficiently O
both O
in O
vitro O
and O
in O
vivo O
, O
suggesting O
that O
the O
intrinsic O
replication O
ability O
of O
LP O
( O
W O
/ O
PA O
) O
affects O
pathogenicity O
; O
however O
, O
such O
a O
correlation O
was O
not O
seen O
for O
the O
other O
recombinants O
. O

To O
prepare O
for O
influenza O
pandemics O
that O
may O
be O
caused O
by O
the O
H2 O
and O
H6 O
subtype O
influenza O
viruses O
, O
live B
attenuated I
influenza I
virus I
( I
LAIV I
) I
H2 O
and O
H6 O
vaccines O
are O
being O
developed O
and O
evaluated O
. O

The O
viruses O
containing O
Q226 O
and O
G228 O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
bound O
to O
the O
avian O
- O
like O
alpha O
2 O
, O
3 O
- O
sialic B
acid I
( I
SA I
) I
receptor O
and O
replicated O
efficiently O
in O
chicken O
eggs O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
of O
the O
H5 O
and O
H7 O
subtypes O
typically O
possess O
multiple O
basic O
amino O
acids O
around O
the O
cleavage O
site O
( O
MBS O
) O
of O
their O
Hemagglutinin B
( I
HA I
) I
protein O
, O
a O
recognized O
virulence O
motif O
in O
poultry O
. O

To O
determine O
the O
importance O
of O
the O
H5 O
HA O
MBS O
as O
a O
virulence O
factor O
in O
mammals O
, O
recombinant O
wild O
- O
type O
HPAI O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
H5N1 O
) O
viruses O
that O
possessed O
( O
H5N1 O
) O
or O
lacked O
( O
Delta O
H5N1 O
) O
the O
H5 O
HA O
MBS O
were O
generated O
and O
evaluated O
for O
their O
virulence O
in O
BALB O
/ O
c O
mice O
, O
ferrets O
, O
and O
African B
green I
monkeys I
( I
AGMs I
) I
( O
Chlorocebus O
aethiops O
) O
. O

Studies O
on O
Hemagglutinin B
( I
HA I
) I
- O
antibody O
complexes O
by O
electron O
microscopy O
and O
epitope O
mapping O
indicate O
that O
antibody O
65C6 O
binds O
to O
a O
conformational O
epitope O
comprising O
amino O
acid O
residues O
at O
positions O
118 O
, O
121 O
, O
161 O
, O
164 O
, O
and O
167 O
( O
according O
to O
mature O
H5 O
numbering O
) O
on O
the O
tip O
of O
the O
membrane O
- O
distal O
globular O
domain O
of O
HA O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
mast O
cells O
were O
activated O
significantly O
by O
H5N1 O
virus O
( O
A O
/ O
chicken O
/ O
Henan O
/ O
1 O
/ O
2004 O
) O
infection O
both O
in O
vivo O
and O
in O
vitro O
. O

Mast O
cells O
could O
possibly O
intensify O
the O
lung O
injury O
that O
results O
from O
H5N1 O
infection O
by O
releasing O
proinflammatory O
mediators O
, O
including O
histamine O
, O
tryptase O
, O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

However O
, O
does O
replication O
of O
aquatic O
- O
bird O
influenza O
viruses O
in O
quail O
similarly O
result O
in O
their O
efficient O
replication O
in O
humans O
? O
Using O
sialic O
acid O
- O
galactose O
linkage O
- O
specific O
lectins O
, O
we O
found O
both O
avian O
( O
sialic O
acid O
- O
alpha O
2 O
- O
3 O
- O
galactose O
[ O
Sia O
alpha O
2 O
- O
3Gal O
] O
linkages O
on O
sialyloligosaccharides O
) O
- O
and O
human O
( O
Sia O
alpha O
2 O
- O
6Gal O
) O
- O
type O
receptors O
on O
the O
tracheal O
cells O
of O
quail O
, O
consistent O
with O
previous O
reports O
. O

Sequence O
analysis O
revealed O
that O
eight O
mutations O
accumulated O
in O
Hemagglutinin B
( I
HA I
) I
during O
these O
passages O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
continue O
to O
cause O
sporadic O
human O
infections O
with O
a O
high O
fatality O
rate O
. O

Respiratory O
failure O
due O
to O
acute B
respiratory I
distress I
syndrome I
( I
ARDS I
) I
is O
a O
complication O
among O
hospitalized O
patients O
. O

Evaluation O
of O
these O
cells O
for O
the O
presence O
of O
receptors O
preferred O
by O
influenza O
virus O
demonstrated O
that O
avian O
- O
like O
( O
alpha O
2 O
- O
3 O
- O
linked O
) O
receptors O
were O
more O
abundant O
than O
human O
- O
like O
( O
alpha O
2 O
- O
6 O
- O
linked O
) O
receptors O
. O

To O
test O
the O
permissiveness O
of O
pulmonary O
endothelial O
cells O
to O
virus O
infection O
, O
we O
compared O
the O
replication O
of O
selected O
seasonal O
, O
pandemic O
( O
2009 O
H1N1 O
and O
1918 O
) O
, O
and O
potentially O
pandemic O
( O
H5N1 O
) O
influenza O
virus O
strains O
. O

Furthermore O
, O
A O
/ O
Thailand O
/ O
16 O
/ O
2004 O
and O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
VN O
/ O
1203 O
) O
H5N1 O
viruses O
, O
which O
exhibit O
heightened O
virulence O
in O
mammalian O
models O
, O
replicated O
to O
higher O
titers O
than O
less O
virulent O
H5N1 O
strains O
. O

Deletion O
of O
the O
H5 O
Hemagglutinin B
( I
HA I
) I
multibasic O
cleavage O
site O
did O
not O
affect O
virus O
infectivity O
but O
resulted O
in O
decreased O
virus O
replication O
in O
endothelial O
cells O
. O

Influenza O
virus O
Hemagglutinin B
( I
HA I
) I
is O
the O
viral O
envelope O
protein O
that O
mediates O
viral O
attachment O
to O
host O
cells O
and O
elicits O
membrane O
fusion O
. O

Crystal O
structures O
of O
the O
H1 O
HA O
from O
the O
2009 O
human O
pandemic O
( O
A O
/ O
California O
/ O
04 O
/ O
2009 O
[ O
CA04 O
] O
) O
in O
complex O
with O
human O
and O
avian O
receptor O
analogs O
reveal O
conserved O
recognition O
of O
the O
terminal O
sialic O
acid O
of O
the O
glycan O
ligands O
. O

Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
H5N1 O
can O
infect O
mammals O
via O
the O
intestine O
; O
this O
is O
unusual O
since O
influenza O
viruses O
typically O
infect O
mammals O
via O
the O
respiratory O
tract O
. O

Triple O
reassortant O
swine B
influenza I
viruses I
( I
SIVs I
) I
and O
2009 B
pandemic I
H1N1 I
( I
pH1N1 I
) I
virus O
contain O
an O
avian O
- O
origin O
PB2 O
with O
271A O
, O
590S O
, O
591R O
, O
and O
627E O
. O

To O
evaluate O
the O
role O
of O
PB2 O
271A O
, O
590S O
, O
and O
591R O
in O
the O
replication O
and O
virulence O
of O
SIV O
, O
single O
( O
1930 O
- O
TX98 O
- O
PB2 O
- O
271T O
) O
- O
, O
double O
( O
1930 O
- O
TX98 O
- O
PB2 O
- O
590A591A O
) O
- O
, O
and O
triple O
( O
1930 O
- O
TX98 O
- O
PB2 O
- O
271T590A591A O
) O
- O
mutated O
viruses O
were O
generated O
in O
the O
background O
of O
the O
H1N1 O
A O
/ O
swine O
/ O
Iowa O
/ O
15 O
/ O
30 O
( O
1930 O
) O
virus O
with O
an O
avian O
- O
origin O
PB2 O
from O
the O
triple O
- O
reassortant O
A O
/ O
swine O
/ O
Texas O
/ O
4199 O
- O
2 O
/ O
98 O
( O
TX98 O
) O
virus O
, O
called O
the O
parental O
1930 O
- O
TX98 O
- O
PB2 O
. O

avian B
influenza I
viruses I
( I
AIV I
) I
raise O
worldwide O
veterinary O
and O
public O
health O
concerns O
due O
to O
their O
potential O
for O
zoonotic O
transmission O
. O

In O
this O
context O
, O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
is O
the O
main O
cytosolic O
pattern O
recognition O
receptor O
known O
for O
detecting O
influenza O
A O
virus O
infection O
in O
mammalian O
cells O
. O

Chickens O
, O
unlike O
ducks O
, O
lack O
RIG O
- O
I O
, O
yet O
chicken O
cells O
do O
produce O
type B
I I
interferon I
( I
IFN I
) I
in O
response O
to O
AIV O
infection O
. O

Chicken O
mRNA O
encoding O
the O
putative O
chicken O
analogs O
of O
CARDIF O
and O
LGP2 O
( O
chCARDIF O
and O
chLGP2 O
, O
respectively O
) O
were O
identified O
. O

The O
exogenous O
expression O
of O
chCARDIF O
, O
as O
well O
as O
of O
the O
caspase B
activation I
and I
recruitment I
domains I
( I
CARDs I
) I
of O
the O
chicken B
melanoma I
differentiation I
- I
associated I
protein I
5 I
( I
chMDA5 I
) I
, O
strongly O
activated O
the O
chicken B
IFN I
- I
beta I
( I
chIFN I
- I
beta I
) I
promoter O
. O

An O
Asp O
- O
to O
- O
Gly O
change O
at O
position O
222 O
of O
the O
receptor O
- O
binding O
protein O
Hemagglutinin B
( I
HA I
) I
correlates O
with O
more O
- O
severe O
infections O
in O
humans O
. O

The O
amino O
acid O
at O
position O
222 O
of O
HA O
contributes O
to O
receptor O
- O
binding O
specificity O
with O
Asp O
( O
typically O
found O
in O
human O
influenza O
viruses O
) O
and O
Gly O
( O
typically O
found O
in O
avian O
and O
classic O
H1N1 O
swine O
influenza O
viruses O
) O
, O
conferring O
binding O
to O
human O
- O
and O
avian O
- O
type O
receptors O
, O
respectively O
. O

We O
tested O
two O
2009 O
pandemic O
H1N1 O
viruses O
possessing O
HA O
- O
222G O
( O
isolated O
from O
severe O
cases O
) O
and O
two O
viruses O
that O
possessed O
HA O
- O
222D O
. O

Our O
genetic O
and O
molecular O
analyses O
of O
the O
isolate O
revealed O
that O
its O
PB1 O
sequence O
showed O
the O
highest O
evolutionary O
relationship O
to O
those O
of O
highly O
pathogenic O
H5N1 O
avian O
influenza O
viruses O
and O
that O
its O
PA O
protein O
had O
an O
isoleucine O
residue O
at O
position O
97 O
( O
a O
representative O
virulence O
marker O
) O
. O

Further O
studies O
will O
be O
required O
to O
examine O
why O
our O
isolate O
has O
the O
virologic O
characteristics O
of O
mammalian O
influenza O
viruses O
but O
the O
archetypal O
receptor O
binding O
profiles O
of O
avian O
influenza O
viruses O
, O
as O
well O
as O
to O
determine O
whether O
its O
potential O
virulence O
markers O
( O
PB1 O
analogous O
to O
those O
of O
H5N1 O
viruses O
or O
isoleucine O
residue O
at O
position O
97 O
within O
PA O
) O
could O
render O
it O
highly O
pathogenic O
in O
mice O
. O

We O
report O
the O
characterization O
of O
5 O
avian O
influenza O
viruses O
of O
the O
H6 O
Hemagglutinin B
( I
HA I
) I
subtype O
isolated O
from O
rosy O
- O
billed O
pochards O
( O
Netta O
peposaca O
) O
. O

Seeking O
to O
identify O
the O
source O
of O
the O
human O
infections O
, O
we O
sequenced O
31 O
H5N1 O
viruses O
isolated O
from O
humans O
in O
China O
( O
2005 O
to O
2010 O
) O
. O

Guided O
by O
patient O
questionnaire O
data O
, O
we O
also O
obtained O
environmental O
samples O
from O
live O
poultry O
markets O
and O
dwellings O
frequented O
by O
six O
individuals O
prior O
to O
disease O
onset O
( O
2008 O
and O
2009 O
) O
. O

A O
novel O
H1N1 O
influenza O
virus O
emerged O
in O
2009 O
( O
pH1N1 O
) O
to O
become O
the O
first O
influenza O
pandemic O
of O
the O
21st O
century O
. O

To O
investigate O
the O
virulence O
of O
pH1N1 O
- O
H5N1 O
reassortant O
viruses O
, O
we O
created O
pH1N1 O
( O
A O
/ O
California O
/ O
04 O
/ O
2009 O
) O
viruses O
expressing O
individual O
genes O
from O
an O
avian O
H5N1 O
influenza O
strain O
( O
A O
/ O
Hong O
Kong O
/ O
483 O
/ O
1997 O
) O
. O

Using O
several O
in O
vitro O
models O
of O
virus O
replication O
, O
we O
observed O
increased O
replication O
for O
a O
reassortant O
CA O
/ O
09 O
virus O
expressing O
the O
Hemagglutinin B
( I
HA I
) I
gene O
of O
HK O
/ O
483 O
( O
CA O
/ O
09 O
- O
483HA O
) O
relative O
to O
that O
of O
either O
parental O
CA O
/ O
09 O
virus O
or O
reassortant O
CA O
/ O
09 O
expressing O
other O
HK O
/ O
483 O
genes O
. O

To O
examine O
the O
range O
of O
selective O
processes O
that O
potentially O
operate O
when O
poorly O
binding O
influenza O
viruses O
adapt O
to O
replicate O
more O
efficiently O
in O
alternative O
environments O
, O
we O
passaged O
a O
virus O
containing O
an O
attenuating O
mutation O
in O
the O
Hemagglutinin B
( I
HA I
) I
receptor O
binding O
site O
in O
mice O
and O
characterized O
the O
resulting O
mutants O
with O
respect O
to O
the O
structural O
locations O
of O
mutations O
selected O
, O
the O
replication O
phenotypes O
of O
the O
viruses O
, O
and O
their O
binding O
properties O
on O
glycan O
microarrays O
. O

The O
initial O
attenuated O
virus O
had O
a O
tyrosine O
- O
to O
- O
phenylalanine O
mutation O
at O
HA1 O
position O
98 O
( O
Y98F O
) O
, O
located O
in O
the O
receptor O
binding O
pocket O
, O
but O
viruses O
that O
were O
selected O
contained O
second O
- O
site O
pseudoreversion O
mutations O
in O
various O
structural O
locations O
that O
revealed O
a O
range O
of O
molecular O
mechanisms O
for O
modulating O
receptor O
binding O
that O
go O
beyond O
the O
scope O
that O
is O
generally O
mapped O
using O
receptor O
specificity O
mutants O
. O

The O
2009 O
pandemic O
influenza O
H1N1 O
( O
H1N1pdm O
) O
virus O
was O
generated O
by O
reassortment O
of O
swine O
influenza O
viruses O
of O
different O
lineages O
. O

In O
order O
to O
understand O
the O
biological O
determinants O
of O
pandemic O
emergence O
, O
it O
is O
relevant O
to O
compare O
the O
tropism O
of O
different O
lineages O
of O
swine O
influenza O
viruses O
and O
reassortants O
derived O
from O
them O
with O
that O
of O
2009 O
pandemic O
H1N1 O
( O
H1N1pdm O
) O
and O
seasonal O
influenza O
H1N1 O
viruses O
in O
ex O
vivo O
cultures O
of O
the O
human O
nasopharynx O
, O
bronchus O
, O
alveoli O
, O
and O
conjunctiva O
. O

In O
contrast O
, O
representative O
viruses O
from O
the O
classical B
swine I
( I
CS I
) I
( O
H1N1 O
) O
lineage O
could O
not O
infect O
human O
respiratory O
epithelium O
; O
Eurasian B
avian I
- I
like I
swine I
( I
EA I
) I
( O
H1N1 O
) O
viruses O
only O
infected O
alveolar O
epithelium O
and O
North O
American O
triple B
- I
reassortant I
( I
TRIG I
) I
viruses O
only O
infected O
the O
bronchial O
epithelium O
albeit O
inefficiently O
. O

Interestingly O
, O
a O
naturally O
occurring O
triple O
- O
reassortant O
swine O
virus O
, O
A O
/ O
SW O
/ O
HK O
/ O
915 O
/ O
04 O
( O
H1N2 O
) O
, O
with O
a O
matrix O
gene O
segment O
of O
EA O
swine O
derivation O
( O
i O
. O

Recombinant O
viruses O
generated O
by O
swapping O
the O
surface O
proteins O
( O
hemagglutinin O
and O
NA O
) O
of O
H1N1pdm O
and O
seasonal O
H1N1 O
virus O
demonstrated O
that O
these O
two O
gene O
segments O
together O
are O
key O
determinants O
of O
conjunctival O
tropism O
. O

There O
exists O
limited O
information O
about O
whether O
adaptation O
is O
needed O
for O
cross O
- O
species O
transmission O
of O
the O
2009 O
pandemic O
H1N1 O
influenza O
virus O
( O
pH1N1 O
) O
. O

Here O
, O
we O
compare O
the O
pathogenesis O
of O
two O
pH1N1 O
viruses O
, O
one O
derived O
from O
a O
human O
patient O
( O
A O
/ O
CA O
/ O
04 O
/ O
09 O
[ O
CA09 O
] O
) O
and O
the O
other O
from O
swine O
( O
A O
/ O
swine O
/ O
Alberta O
/ O
25 O
/ O
2009 O
[ O
Alb09 O
] O
) O
, O
with O
that O
of O
the O
1918 O
- O
like O
classical O
swine O
influenza O
virus O
( O
A O
/ O
swine O
/ O
Iowa O
/ O
1930 O
[ O
IA30 O
] O
) O
in O
the O
pig O
model O
. O

Transmission O
of O
pathogenic O
avian B
influenza I
viruses I
( I
AIV I
) I
from O
wild O
birds O
to O
domestic O
poultry O
and O
humans O
is O
continuing O
in O
multiple O
countries O
around O
the O
world O
. O

The O
virus B
- I
like I
particle I
( I
VLP I
) I
represents O
an O
economical O
approach O
to O
pandemic O
vaccine O
development O
. O

The O
VLPs O
were O
comprised O
of O
the O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
and O
matrix B
1 I
( I
M1 I
) I
proteins O
. O

H5N1 B
whole I
- I
genome I
fragment I
phage I
display I
libraries I
( I
GFPDL I
) I
were O
used O
to O
elucidate O
the O
antibody O
epitope O
repertoire O
in O
postvaccination O
human O
sera O
. O

During O
the O
last O
decade O
, O
more O
than O
half O
of O
humans O
infected O
with O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
have O
died O
, O
yet O
virus O
- O
induced O
host O
signaling O
has O
yet O
to O
be O
clearly O
elucidated O
. O

Here O
, O
we O
leveraged O
a O
system O
approach O
to O
identify O
and O
statistically O
validate O
signaling O
subnetworks O
that O
define O
the O
dynamic O
transcriptional O
response O
of O
human O
bronchial O
epithelial O
cells O
after O
infection O
with O
influenza O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
H5N1 O
, O
VN1203 O
) O
. O

Ducks O
play O
an O
important O
role O
in O
the O
maintenance O
of O
highly O
pathogenic O
H5N1 O
avian B
influenza I
viruses I
( I
AIVs I
) I
in O
nature O
, O
and O
the O
successful O
control O
of O
AIVs O
in O
ducks O
has O
important O
implications O
for O
the O
eradication O
of O
the O
disease O
in O
poultry O
and O
its O
prevention O
in O
humans O
. O

Live O
attenuated O
duck O
enteritis O
virus O
( O
DEV O
; O
a O
herpesvirus O
) O
vaccine O
is O
used O
routinely O
to O
control O
lethal O
DEV O
infections O
in O
many O
duck O
- O
producing O
areas O
. O

Using O
this O
system O
, O
we O
constructed O
two O
recombinant O
viruses O
, O
rDEV O
- O
ul41HA O
and O
rDEV O
- O
us78HA O
, O
in O
which O
the O
Hemagglutinin B
( I
HA I
) I
gene O
of O
the O
H5N1 O
virus O
A O
/ O
duck O
/ O
Anhui O
/ O
1 O
/ O
06 O
was O
inserted O
and O
stably O
maintained O
within O
the O
ul41 O
gene O
or O
between O
the O
us7 O
and O
us8 O
genes O
of O
the O
DEV O
genome O
. O

Duck O
studies O
indicated O
that O
rDEV O
- O
us78HA O
had O
protective O
efficacy O
similar O
to O
that O
of O
the O
live O
DEV O
vaccine O
against O
lethal O
DEV O
challenge O
; O
importantly O
, O
a O
single O
dose O
of O
10 O
( O
6 O
) O
PFU O
of O
rDEV O
- O
us78HA O
induced O
complete O
protection O
against O
a O
lethal O
H5N1 O
virus O
challenge O
in O
as O
little O
as O
3 O
days O
postvaccination O
. O

Coxsackievirus B
A24 I
variant I
( I
CVA24v I
) I
is O
a O
main O
causative O
agent O
of O
acute B
hemorrhagic I
conjunctivitis I
( I
AHC I
) I
, O
which O
is O
a O
highly O
contagious O
eye O
infection O
. O

Binding O
and O
infection O
experiments O
using O
corneal O
cells O
treated O
with O
deglycosylating O
enzymes O
or O
metabolic O
inhibitors O
of O
de O
novo O
glycosylation O
suggested O
that O
the O
receptor O
( O
s O
) O
used O
by O
CVA24v O
are O
constituted O
by O
sialylated O
O O
- O
linked O
glycans O
that O
are O
linked O
to O
one O
or O
more O
cell O
surface O
proteins O
but O
not O
to O
lipids O
. O

CVA24v O
bound O
better O
to O
mouse O
L929 O
cells O
overexpressing O
human B
P I
- I
selectin I
glycoprotein I
ligand I
- I
1 I
( I
PSGL I
- I
1 I
) I
than O
to O
mock O
- O
transfected O
cells O
, O
suggesting O
that O
PSGL O
- O
1 O
is O
a O
candidate O
receptor O
for O
CVA24v O
. O

Finally O
, O
binding O
competition O
experiments O
using O
a O
library O
of O
mono O
- O
and O
oligosaccharides O
mimicking O
known O
PSGL O
- O
1 O
glycans O
suggested O
that O
CVA24v O
binds O
to O
Neu5Ac O
alpha O
2 O
, O
3Gal O
disaccharides O
( O
Neu5Ac O
is O
N O
- O
acetylneuraminic O
acid O
) O
. O

We O
have O
recently O
reported O
that O
phosphoantigen O
isopentenyl B
pyrophosphate I
( I
IPP I
) I
- O
expanded O
human O
V O
gamma O
9V O
delta O
2 O
T O
cells O
participated O
in O
anti O
- O
influenza O
virus O
immunity O
by O
efficiently O
killing O
both O
human O
and O
avian O
influenza O
virus O
- O
infected O
monocyte B
- I
derived I
macrophages I
( I
MDMs I
) I
in O
vitro O
. O

In O
this O
study O
, O
we O
found O
that O
V O
gamma O
9V O
delta O
2 O
T O
cells O
expressed O
both O
type O
1 O
cytokines O
and O
chemokine O
receptors O
during O
influenza O
virus O
infection O
, O
and O
IPP O
- O
expanded O
cells O
had O
a O
higher O
capacity O
to O
produce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H7 O
virus O
infection O
in O
humans O
frequently O
results O
in O
conjunctivitis O
as O
a O
major O
symptom O
. O

However O
, O
primary O
ocular O
cells O
infected O
with O
HPAI O
H7N7 O
viruses O
were O
found O
to O
have O
elevated O
levels O
of O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
, O
a O
cytokine O
previously O
implicated O
in O
ocular O
disease O
pathology O
. O

That O
pigs O
may O
play O
a O
pivotal O
role O
in O
the O
emergence O
of O
pandemic O
influenza O
was O
indicated O
by O
the O
recent O
H1N1 O
/ O
2009 O
human O
pandemic O
, O
likely O
caused O
by O
a O
reassortant O
between O
viruses O
of O
the O
American O
triple B
- I
reassortant I
( I
TR I
) I
and O
Eurasian B
avian I
- I
like I
( I
EA I
) I
swine O
influenza O
lineages O
. O

To O
explore O
the O
genetic O
basis O
of O
the O
pathogenesis O
and O
adaptation O
of O
avian B
influenza I
viruses I
( I
AIVs I
) I
to O
chickens O
, O
the O
A O
/ O
duck O
/ O
Yokohama O
/ O
aq10 O
/ O
2003 O
( O
H5N1 O
) O
( O
DkYK10 O
) O
virus O
was O
passaged O
five O
times O
in O
the O
brains O
of O
chickens O
. O

Genome O
sequence O
comparison O
of O
two O
viruses O
identified O
a O
single O
amino O
acid O
substitution O
at O
position O
109 O
in O
NP O
from O
isoleucine O
to O
threonine O
( O
NP O
( O
I O
) O
109 O
( O
T O
) O
) O
. O

By O
analyzing O
viruses O
constructed O
by O
the O
reverse O
- O
genetic O
method O
, O
we O
established O
that O
the O
NP O
( O
I O
) O
109 O
( O
T O
) O
substitution O
also O
contributed O
to O
increased O
viral O
replication O
and O
polymerase O
activity O
in O
chicken O
embryo O
fibroblasts O
, O
but O
not O
in O
duck O
embryo O
fibroblasts O
. O

Real O
- O
time O
RT O
- O
PCR O
analysis O
demonstrated O
that O
the O
NP O
I109T O
substitution O
enhances O
mRNA O
synthesis O
quickly O
and O
then O
cRNA O
and O
viral B
RNA I
( I
vRNA I
) I
synthesis O
slowly O
. O

Next O
, O
to O
determine O
the O
mechanism O
underlying O
the O
appearance O
of O
the O
NP O
( O
I O
) O
109 O
( O
T O
) O
substitution O
during O
passages O
, O
four O
H5N1 O
highly B
pathogenic I
AIVs I
( I
HPAIVs I
) I
were O
passaged O
in O
the O
lungs O
and O
brains O
of O
chicken O
embryos O
. O

Single O
- O
nucleotide O
polymorphism O
analysis O
, O
together O
with O
a O
database O
search O
, O
suggests O
that O
the O
NP O
( O
I O
) O
109 O
( O
T O
) O
mutation O
would O
be O
induced O
frequently O
during O
replication O
of O
HPAIVs O
in O
brains O
, O
but O
not O
in O
lungs O
. O

Pigs O
are O
considered O
to O
be O
intermediate O
hosts O
and O
mixing O
vessels O
, O
facilitating O
the O
genesis O
of O
pandemic O
influenza O
viruses O
, O
as O
demonstrated O
by O
the O
emergence O
of O
the O
2009 O
H1N1 O
pandemic O
( O
pdm O
/ O
09 O
) O
virus O
. O

Although O
increasing O
data O
have O
become O
available O
that O
link O
human O
adaptation O
with O
specific O
molecular O
changes O
in O
nonhuman O
influenza O
viruses O
, O
the O
molecular O
changes O
of O
these O
viruses O
during O
a O
large O
highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAI I
) I
outbreak O
in O
poultry O
along O
with O
avian O
- O
to O
- O
human O
transmission O
have O
never O
been O
documented O
. O

By O
comprehensive O
virologic O
analysis O
of O
combined O
veterinary O
and O
human O
samples O
obtained O
during O
a O
large O
HPAI O
A O
( O
H7N7 O
) O
outbreak O
in O
the O
Netherlands O
in O
2003 O
, O
we O
mapped O
the O
acquisition O
of O
human O
adaptation O
markers O
to O
identify O
the O
public O
health O
risk O
associated O
with O
an O
HPAI O
outbreak O
in O
poultry O
. O

Full O
- O
length O
Hemagglutinin B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
and O
PB2 O
sequencing O
of O
A O
( O
H7N7 O
) O
viruses O
obtained O
from O
45 O
human O
cases O
showed O
amino O
acid O
variations O
at O
different O
codons O
in O
HA O
( O
n O
= O
20 O
) O
, O
NA O
( O
n O
= O
23 O
) O
, O
and O
PB2 O
( O
n O
= O
23 O
) O
. O

Polygenic O
accumulation O
and O
farm O
- O
to O
- O
farm O
spread O
of O
known O
virulence O
and O
human O
adaptation O
markers O
in O
A O
( O
H7N7 O
) O
virus O
- O
infected O
poultry O
occurred O
prior O
to O
farm O
- O
to O
- O
human O
transmission O
. O

The O
influenza O
A O
virus O
NS1 O
protein O
contains O
a O
conserved O
4 O
- O
amino O
- O
acid O
- O
residue O
PDZ O
- O
ligand O
binding O
motif O
( O
PBM O
) O
at O
the O
carboxyl O
terminus O
that O
can O
function O
as O
a O
virulence O
determinant O
by O
targeting O
cellular O
PDZ O
proteins O
. O

Infection O
of O
polarized O
MDCK O
cells O
with O
the O
ESEV O
virus O
additionally O
results O
in O
functional O
disruption O
of O
the O
tight B
junction I
( I
TJ I
) I
as O
measured O
by O
altered O
localization O
of O
TJ O
markers O
ZO O
- O
1 O
and O
Occludin O
, O
decreased O
transepithelial O
electrical O
resistance O
, O
and O
increased O
fluorescein B
isothiocyanate I
( I
FITC I
) I
- O
inulin O
diffusion O
across O
the O
polarized O
cell O
monolayer O
. O

A O
similar O
effect O
on O
the O
TJ O
was O
observed O
in O
MDCK O
cells O
depleted O
for O
either O
Scribble O
or O
Dlg1 O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

H5N1 O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
of O
clade O
2 O
. O

Intriguingly O
, O
in O
contrast O
to O
all O
common O
avian O
strains O
specifying O
glutamic O
acid O
at O
position O
627 O
of O
the O
PB2 O
protein O
( O
PB2 O
- O
627E O
) O
, O
they O
carry O
a O
lysine O
at O
this O
position O
( O
PB2 O
- O
627K O
) O
, O
which O
is O
normally O
found O
only O
in O
human O
strains O
. O

To O
analyze O
the O
impact O
of O
this O
mutation O
on O
the O
host O
range O
of O
HPAIV O
H5N1 O
, O
we O
altered O
PB2 O
- O
627K O
to O
PB2 O
- O
627E O
in O
the O
European O
isolate O
A O
/ O
Swan O
/ O
Germany O
/ O
R65 O
/ O
2006 O
( O
R65 O
) O
. O

In O
contrast O
to O
the O
parental O
R65 O
, O
multicycle O
growth O
and O
polymerase O
activity O
of O
the O
resulting O
mutant O
R65 O
- O
PB2 O
( O
K627E O
) O
were O
considerably O
impaired O
in O
mammalian O
but O
not O
in O
avian O
cells O
. O

Correspondingly O
, O
the O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
in O
mice O
was O
increased O
by O
three O
orders O
of O
magnitude O
, O
whereas O
virulence O
in O
chicken O
remained O
unchanged O
, O
resulting O
in O
100 O
% O
lethality O
, O
as O
was O
found O
for O
the O
parental O
R65 O
. O

To O
investigate O
whether O
additional O
R65 O
genes O
influence O
reversion O
, O
we O
passaged O
R65 O
- O
PB2K627E O
reassortants O
containing O
genes O
from O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
97 O
( O
H5N1 O
) O
( O
carrying O
PB2 O
- O
627E O
) O
, O
in O
avian O
and O
mammalian O
cells O
. O

Reversion O
to O
PB2 O
- O
627K O
in O
mammalian O
cells O
required O
the O
presence O
of O
the O
R65 O
nucleoprotein B
( I
NP I
) I
. O

Parental O
and O
reassortant O
phenotype O
viruses O
were O
antigenically O
analyzed O
by O
hemagglutination B
inhibition I
( I
HI I
) I
test O
and O
microneutralization B
( I
MN I
) I
assay O
. O

While O
avian O
infectious B
bronchitis I
coronavirus I
( I
IBV I
) I
infection O
and O
avian O
influenza B
A I
virus I
( I
IAV I
) I
infection O
both O
depend O
on O
alpha O
2 O
, O
3 O
- O
linked O
sialic O
acids O
, O
the O
host O
tropism O
of O
IBV O
is O
restricted O
compared O
to O
that O
of O
IAV O
. O

Here O
we O
investigated O
whether O
the O
interaction O
between O
the O
viral O
attachment O
proteins O
and O
the O
host O
could O
explain O
these O
differences O
by O
using O
recombinant O
spike O
domains O
( O
S1 O
) O
of O
IBV O
strains O
with O
different O
pathogenicities O
, O
as O
well O
as O
the O
Hemagglutinin B
( I
HA I
) I
protein O
of O
IAV O
H5N1 O
. O

UAP56 O
is O
recruited O
by O
the O
nucleoprotein B
( I
NP I
) I
of O
influenza O
A O
viruses O
, O
and O
recent O
data O
revealed O
that O
the O
RNA O
helicase O
is O
required O
for O
the O
nuclear O
export O
of O
a O
subset O
of O
spliced O
and O
unspliced O
viral O
mRNAs O
. O

The O
fact O
that O
influenza O
viruses O
do O
not O
produce O
detectable O
amounts O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
intermediates O
during O
transcription O
/ O
replication O
suggests O
the O
involvement O
of O
cellular O
RNA O
helicases O
. O

The O
small B
interfering I
RNA I
( I
siRNA I
) I
mediated O
depletion O
of O
either O
RNA O
helicase O
reduced O
the O
transport O
of O
M1 O
and O
Hemagglutinin B
( I
HA I
) I
mRNAs O
and O
, O
to O
a O
lesser O
extent O
, O
NP O
and O
NS1 O
mRNAs O
into O
the O
cytoplasm O
. O

In O
parallel O
, O
we O
observed O
a O
robust O
virus O
- O
mediated O
activation O
of O
dsRNA O
- O
dependent O
protein B
kinase I
R I
( I
PKR I
) I
, O
indicating O
that O
the O
cellular O
RNA O
helicase O
UAP56 O
may O
be O
recruited O
by O
influenza O
virus O
to O
prevent O
dsRNA O
formation O
. O

gondii O
soluble O
antigens O
( O
STAg O
) O
elicited O
an O
immune O
response O
similar O
to O
that O
elicited O
by O
live O
parasites O
, O
and O
administration O
of O
STAg O
2 O
days O
after O
H5N1 O
influenza O
virus O
infection O
enhanced O
survival O
, O
lowered O
viral O
titers O
, O
and O
reduced O
clinical O
disease O
. O

Mechanistically O
, O
we O
found O
that O
administration O
of O
STAg O
led O
to O
increased O
production O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
from O
natural B
killer I
( I
NK I
) I
cells O
, O
which O
were O
both O
necessary O
and O
sufficient O
for O
survival O
. O

We O
investigated O
the O
tropism O
, O
host O
responses O
, O
and O
virulence O
of O
two O
variants O
of O
A O
/ O
Quail O
/ O
Hong O
Kong O
/ O
G1 O
/ O
1997 O
( O
H9N2 O
) O
( O
H9N2 O
/ O
G1 O
) O
with O
D253N O
and O
Q591K O
in O
the O
PB2 O
protein O
in O
primary O
human O
macrophages O
and O
bronchial O
epithelium O
in O
vitro O
and O
in O
mice O
in O
vivo O
. O

Virus O
with O
PB2 O
D253N O
and O
Q591K O
had O
greater O
polymerase O
activity O
in O
minireplicon O
assays O
, O
induced O
more O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
human O
macrophages O
, O
replicated O
better O
in O
differentiated O
normal B
human I
bronchial I
epithelial I
( I
NHBE I
) I
cells O
, O
and O
was O
more O
pathogenic O
for O
mice O
. O

We O
compared O
the O
2009 O
pandemic O
influenza O
A O
virus O
[ O
strain O
A O
/ O
Hamburg O
/ O
4 O
/ O
09 O
( O
pH1N1 O
) O
] O
with O
a O
highly O
pathogenic O
avian O
H5N1 O
isolate O
[ O
strain O
A O
/ O
Thailand O
/ O
1 O
( O
KAN O
- O
1 O
) O
/ O
04 O
] O
for O
their O
relative O
sensitivities O
to O
human O
MxA O
and O
murine O
Mx1 O
. O

Substitutions O
of O
the O
viral O
polymerase O
subunits O
or O
the O
nucleoprotein B
( I
NP I
) I
in O
a O
polymerase O
reconstitution O
assay O
demonstrated O
that O
NP O
was O
the O
main O
determinant O
of O
Mx O
sensitivity O
. O

We O
identified O
four O
distinct O
and O
cocirculating O
groups O
( O
A O
, O
B O
, O
C O
, O
and O
D O
) O
, O
each O
of O
which O
has O
undergone O
widespread O
inter O
- O
and O
intrasubtype O
reassortments O
, O
leading O
to O
the O
generation O
of O
viruses O
with O
unknown O
biological O
properties O
. O

From O
infection O
studies O
with O
cultured O
chicken O
cells O
and O
experimental O
mammalian O
hosts O
, O
it O
is O
well O
known O
that O
influenza O
viruses O
use O
the O
nonstructural B
protein I
1 I
( I
NS1 I
) I
to O
suppress O
the O
synthesis O
of O
interferon B
( I
IFN I
) I
. O

To O
address O
the O
question O
of O
why O
influenza O
viruses O
are O
highly O
pathogenic O
in O
chickens O
although O
they O
strongly O
activate O
the O
innate O
immune O
system O
, O
we O
determined O
whether O
recombinant O
chicken O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
can O
inhibit O
the O
growth O
of O
highly O
pathogenic O
avian O
influenza O
viruses O
in O
cultured O
chicken O
cells O
and O
whether O
it O
can O
ameliorate O
virus O
- O
induced O
disease O
in O
5 O
- O
week O
- O
old O
birds O
. O

To O
evaluate O
the O
role O
of O
the O
viral O
polymerase O
replication O
machinery O
in O
producing O
virulent O
pandemic O
( O
H1N1 O
) O
2009 O
influenza O
viruses O
, O
we O
generated O
various O
polymerase O
point O
mutants O
( O
PB2 O
, O
627K O
/ O
701N O
; O
PB1 O
, O
expression O
of O
PB1 O
- O
F2 O
protein O
; O
and O
PA O
, O
97I O
) O
and O
reassortant O
viruses O
with O
various O
sources O
of O
influenza O
viruses O
by O
reverse O
genetics O
. O

Although O
the O
point O
mutations O
produced O
no O
significant O
change O
in O
pathogenicity O
, O
reassortment O
between O
the O
pandemic O
A O
/ O
California O
/ O
04 O
/ O
09 O
( O
CA04 O
, O
H1N1 O
) O
and O
current O
human O
and O
animal O
influenza O
viruses O
produced O
variants O
possessing O
a O
broad O
spectrum O
of O
pathogenicity O
in O
the O
mouse O
model O
. O

Although O
most O
polymerase O
reassortants O
had O
attenuated O
pathogenicity O
( O
including O
those O
containing O
seasonal O
human O
H3N2 O
and O
high O
- O
pathogenicity O
H5N1 O
virus O
segments O
) O
compared O
to O
that O
of O
the O
parental O
CA04 O
( O
H1N1 O
) O
virus O
, O
some O
recombinants O
had O
significantly O
enhanced O
virulence O
. O

Unexpectedly O
, O
one O
of O
the O
five O
highly O
virulent O
reassortants O
contained O
a O
A O
/ O
Swine O
/ O
Korea O
/ O
JNS06 O
/ O
04 O
( O
H3N2 O
) O
- O
like O
PB2 O
gene O
with O
no O
known O
virulence O
factors O
; O
the O
other O
four O
had O
mammalian O
- O
passaged O
avian O
- O
like O
genes O
encoding O
PB2 O
featuring O
627K O
, O
PA O
featuring O
97I O
, O
or O
both O
. O

Although O
we O
observed O
close O
cooperation O
between O
PB2 O
and O
PB1 O
from O
similar O
virus O
origins O
, O
we O
found O
that O
PA O
appears O
to O
be O
crucial O
in O
maintaining O
viral O
gene O
functions O
in O
the O
context O
of O
the O
CA04 O
( O
H1N1 O
) O
virus O
. O

These O
observations O
provide O
helpful O
insights O
into O
the O
pathogenic O
potential O
of O
reassortant O
influenza O
viruses O
composed O
of O
the O
pandemic O
( O
H1N1 O
) O
2009 O
influenza O
virus O
and O
prevailing O
human O
or O
animal O
influenza O
viruses O
that O
could O
emerge O
in O
the O
future O
. O

The O
2009 O
pandemic O
influenza O
virus O
( O
pH1N1 O
) O
is O
a O
swine O
- O
origin O
reassortant O
containing O
human O
, O
avian O
, O
and O
swine O
influenza O
genes O
. O

We O
have O
previously O
shown O
that O
the O
polymerase O
complex O
of O
the O
pH1N1 O
strain O
A O
/ O
California O
/ O
04 O
/ O
2009 O
( O
Cal O
) O
is O
highly O
active O
in O
mammalian O
293T O
cells O
, O
despite O
the O
avian O
origin O
of O
both O
its O
PA O
and O
PB2 O
. O

Characterization O
of O
polymerase O
complexes O
containing O
various O
combinations O
of O
Cal O
and O
avian O
influenza O
virus O
A O
/ O
chicken O
/ O
Nanchang O
/ O
3 O
- O
120 O
/ O
01 O
( O
H3N2 O
) O
( O
Nan O
) O
by O
reporter O
gene O
assay O
indicates O
that O
Cal O
PA O
, O
but O
not O
PB2 O
, O
is O
a O
major O
contributing O
factor O
to O
high O
Cal O
polymerase O
activity O
in O
293T O
cells O
. O

Recombinant O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
( O
WSN O
) O
viruses O
containing O
Nan O
NP O
and O
polymerase O
( O
PA O
, O
PB1 O
, O
PB2 O
) O
genes O
with O
individual O
mutations O
in O
PA O
at O
residues O
85 O
, O
186 O
, O
and O
336 O
produced O
higher O
levels O
of O
viral O
protein O
than O
the O
virus O
containing O
wild B
- I
type I
( I
WT I
) I
Nan O
PA O
. O

Humans O
infected O
by O
the O
highly O
pathogenic O
H5N1 O
avian O
influenza O
viruses O
( O
HPAIV O
) O
present O
unusually O
high O
concentrations O
in O
serum O
of O
proinflammatory O
cytokines O
and O
chemokines O
, O
which O
are O
believed O
to O
contribute O
to O
the O
high O
pathogenicity O
of O
these O
viruses O
. O

The O
hemagglutinins B
( I
HAs I
) I
of O
avian O
influenza O
viruses O
preferentially O
bind O
to O
sialic O
acids O
attached O
through O
alpha O
2 O
, O
3 O
linkages O
( O
SA O
alpha O
2 O
, O
3 O
) O
to O
the O
terminal O
galactose O
of O
carbohydrates O
on O
the O
host O
cell O
surface O
, O
while O
the O
HAs O
from O
human O
strains O
bind O
to O
alpha O
2 O
, O
6 O
- O
linked O
SA O
( O
SA O
alpha O
2 O
, O
6 O
) O
. O

To O
evaluate O
the O
role O
of O
the O
viral O
receptor O
specificity O
in O
promoting O
innate O
immune O
responses O
in O
humans O
, O
we O
generated O
recombinant O
influenza O
viruses O
, O
one O
bearing O
the O
HA O
and O
neuraminidase B
( I
NA I
) I
genes O
from O
the O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
H5N1 O
HPAIV O
in O
an O
influenza O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
( O
A O
/ O
PR O
/ O
8 O
/ O
34 O
) O
backbone O
with O
specificity O
for O
SA O
alpha O
2 O
, O
3 O
and O
the O
other O
a O
mutant O
virus O
( O
with O
Q226L O
and O
G228S O
in O
the O
HA O
) O
with O
preferential O
receptor O
specificity O
for O
SA O
alpha O
2 O
, O
6 O
. O

Viruses O
with O
preferential O
affinity O
for O
SA O
alpha O
2 O
, O
3 O
induced O
higher O
levels O
of O
proinflammatory O
cytokines O
and O
interferon B
( I
IFN I
) I
- O
inducible O
genes O
in O
primary O
human B
dendritic I
cells I
( I
DCs I
) I
than O
viruses O
with O
SA O
alpha O
2 O
, O
6 O
binding O
specificity O
, O
and O
these O
differences O
were O
independent O
of O
viral O
replication O
, O
as O
shown O
by O
infections O
with O
UV O
- O
inactivated O
viruses O
. O

We O
analyzed O
the O
ability O
of O
a O
vaccine O
vector O
based O
on O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
to O
induce O
a O
Neutralizing B
antibody I
( I
NAb I
) I
response O
to O
avian B
influenza I
viruses I
( I
AIVs I
) I
in O
rhesus O
macaques O
. O

Animals O
vaccinated O
with O
vectors O
expressing O
either O
strain O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
1997 O
or O
strain O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
H5 O
Hemagglutinin B
( I
HA I
) I
were O
able O
to O
generate O
robust O
NAb O
responses O
. O

To O
analyze O
the O
immunogenicity O
of O
these O
domains O
, O
we O
used O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
. O

pDCs O
express O
pattern O
recognition O
receptors O
, O
including O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
, O
which O
recognizes O
guanosine O
- O
and O
uridine O
- O
rich O
viral O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
, O
including O
influenza O
virus O
ssRNA O
. O

The O
signaling O
through O
TLR7 O
results O
in O
the O
induction O
of O
inflammatory O
cytokines O
and O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
, O
an O
essential O
process O
for O
the O
induction O
of O
specific O
adaptive O
immune O
responses O
and O
for O
mounting O
a O
robust O
antiviral O
response O
mediated O
by O
IFN O
- O
alpha O
. O

During O
their O
circulation O
in O
nature O
, O
H5N1 O
avian B
influenza I
viruses I
( I
AIVs I
) I
have O
acquired O
the O
ability O
to O
kill O
their O
natural O
hosts O
, O
wild O
birds O
and O
ducks O
. O

In O
this O
study O
, O
we O
compared O
two O
genetically O
similar O
H5N1 O
AIVs O
, O
A O
/ O
duck O
/ O
Hubei O
/ O
49 O
/ O
05 O
( O
DK O
/ O
49 O
) O
and O
A O
/ O
goose O
/ O
Hubei O
/ O
65 O
/ O
05 O
( O
GS O
/ O
65 O
) O
, O
that O
are O
lethal O
for O
chickens O
but O
differ O
in O
their O
virulence O
levels O
in O
ducks O
. O

Viral O
vaccine O
vectors O
have O
emerged O
as O
an O
attractive O
strategy O
for O
the O
development O
of O
a O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
vaccine O
. O

Recombinant B
Newcastle I
disease I
virus I
( I
rNDV I
) I
stands O
out O
as O
a O
vaccine O
vector O
since O
it O
has O
a O
proven O
safety O
profile O
in O
humans O
, O
it O
is O
a O
potent O
inducer O
of O
both O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
beta O
) O
production O
, O
and O
it O
is O
a O
potent O
inducer O
of O
dendritic B
cell I
( I
DC I
) I
maturation O
. O

Our O
group O
has O
previously O
generated O
an O
rNDV O
vector O
expressing O
a O
codon O
- O
optimized O
HIV O
Gag O
protein O
and O
demonstrated O
its O
ability O
to O
induce O
a O
Gag O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
response O
in O
mice O
. O

Targeting O
of O
the O
HIV O
Gag O
antigen O
was O
achieved O
by O
the O
addition O
of O
a O
single O
- O
chain O
Fv O
( O
scFv O
) O
antibody O
specific O
for O
the O
DC O
- O
restricted O
antigen O
uptake O
receptor O
DEC205 O
such O
that O
the O
DEC205 O
scFv O
- O
Gag O
molecule O
was O
encoded O
for O
expression O
as O
a O
fusion O
protein O
. O

The O
vaccination O
of O
mice O
with O
rNDV O
coding O
for O
the O
DC O
- O
targeted O
Gag O
antigen O
induced O
an O
enhanced O
Gag O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
response O
and O
enhanced O
numbers O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
spleen O
relative O
to O
vaccination O
with O
rNDV O
coding O
for O
a O
nontargeted O
Gag O
antigen O
. O

The O
hemagglutinins B
( I
HAs I
) I
of O
human O
H1 O
and O
H3 O
influenza O
viruses O
and O
avian O
H5 O
influenza O
virus O
were O
produced O
as O
recombinant O
fusion O
proteins O
with O
the O
human O
immunoglobulin O
Fc O
domain O
. O

Recombinant O
HA B
- I
human I
immunoglobulin I
Fc I
domain I
( I
HA I
- I
HuFc I
) I
proteins O
were O
secreted O
from O
baculovirus O
- O
infected O
insect O
cells O
as O
glycosylated O
oligomer O
HAs O
of O
the O
anticipated O
molecular O
mass O
, O
agglutinated O
red O
blood O
cells O
, O
were O
purified O
on O
protein O
A O
, O
and O
were O
used O
to O
immunize O
mice O
in O
the O
absence O
of O
adjuvant O
. O

The O
molecular O
basis O
of O
pathogenicity O
of O
H5N1 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
in O
chickens O
remains O
largely O
unknown O
. O

H5N1 O
A O
/ O
chicken O
/ O
Yamaguchi O
/ O
7 O
/ O
2004 O
virus O
( O
CkYM7 O
) O
replicates O
rapidly O
in O
macrophages O
and O
vascular O
endothelial O
cells O
in O
chickens O
, O
causing O
sudden O
death O
without O
fever O
or O
gross O
lesions O
, O
while O
H5N1 O
A O
/ O
duck O
/ O
Yokohama O
/ O
aq10 O
/ O
2003 O
virus O
( O
DkYK10 O
) O
induces O
high O
fever O
, O
severe O
gross O
lesions O
, O
and O
a O
prolonged O
time O
to O
death O
, O
despite O
the O
98 O
% O
amino O
acid O
identity O
between O
the O
two O
viruses O
. O

Inversely O
, O
reassortants O
possessing O
the O
NP O
or O
PB2 O
gene O
of O
CkYM7 O
in O
the O
DkYK10 O
background O
( O
rgDkYK O
- O
PB2 O
( O
Ck O
) O
, O
rgDkYK O
- O
NPCk O
) O
replicated O
quickly O
and O
reached O
higher O
titers O
than O
DkYK10 O
, O
accompanied O
by O
more O
rapid O
and O
frequent O
apoptosis O
of O
macrophages O
. O

The O
rgDkYK O
- O
NPCk O
and O
rgDkYK O
- O
PB2 O
( O
Ck O
) O
reassortants O
also O
replicated O
more O
rapidly O
in O
chicken B
embryo I
fibroblasts I
( I
CEFs I
) I
than O
did O
rgDkYK10 O
, O
but O
replication O
of O
these O
viruses O
was O
similar O
to O
that O
of O
CkYM7 O
and O
DkYK10 O
in O
duck O
embryo O
fibroblasts O
. O

NPCk O
, O
NP105V O
, O
and O
PB2 O
( O
Ck O
) O
enhanced O
the O
polymerase O
activity O
of O
DkYK10 O
in O
CEFs O
. O

The O
host O
adaptation O
of O
influenza O
virus O
is O
partly O
dependent O
on O
the O
sialic B
acid I
( I
SA I
) I
isoform O
bound O
by O
the O
viral O
Hemagglutinin B
( I
HA I
) I
. O

The O
2009 O
H1N1 O
pandemic O
was O
caused O
by O
the O
emergence O
of O
a O
reassortant O
H1N1 O
subtype O
( O
H1N1pdm O
) O
influenza O
A O
virus O
containing O
gene O
segments O
that O
originally O
circulated O
in O
human O
, O
avian O
, O
and O
swine O
virus O
reservoirs O
. O

We O
found O
that O
a O
glutamate O
- O
to O
- O
glycine O
substitution O
at O
residue O
158 O
of O
the O
PB2 O
gene O
( O
PB2 O
- O
E158G O
) O
increased O
the O
morbidity O
and O
mortality O
of O
the O
parental O
H1N1pdm O
virus O
. O

Both O
models O
found O
marked O
differences O
in O
the O
relative O
values O
of O
p O
, O
the O
virion O
production O
rate O
per O
cell O
, O
and O
R O
- O
0 O
, O
an O
index O
of O
the O
spread O
of O
infection O
through O
the O
monolayer O
, O
with O
the O
values O
for O
the O
strains O
in O
the O
following O
rank O
order O
( O
from O
greatest O
to O
least O
) O
: O
pandemic O
strain O
, O
followed O
by O
seasonal O
strain O
, O
followed O
by O
avian O
strain O
, O
as O
expected O
. O

The O
NS1 O
protein O
from O
influenza O
A O
viruses O
contains O
a O
four O
- O
amino O
- O
acid O
sequence O
at O
its O
carboxyl O
terminus O
that O
is O
termed O
the O
PDZ B
- I
binding I
motif I
( I
PBM I
) I
. O

Using O
glutathione B
S I
- I
transferase I
( I
GST I
) I
pull O
- O
down O
assays O
, O
we O
found O
that O
the O
ESEV O
PBM O
enables O
NS1 O
to O
associate O
with O
the O
PDZ O
proteins O
Scribble O
, O
Dlg1 O
, O
MAGI O
- O
1 O
, O
MAGI O
- O
2 O
, O
and O
MAGI O
- O
3 O
. O

In O
addition O
, O
the O
latter O
effect O
was O
eliminated O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
Scribble O
depletion O
. O

highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
with O
reassorted O
NS O
segments O
from O
H5 O
- O
and O
H7 O
- O
type O
avian O
virus O
strains O
placed O
in O
the O
genetic O
background O
of O
the O
A O
/ O
FPV O
/ O
Rostock O
/ O
34 O
HPAIV O
( O
FPV O
; O
H7N1 O
) O
were O
generated O
by O
reverse O
genetics O
. O

Virological O
characterizations O
demonstrated O
that O
the O
growth O
kinetics O
of O
the O
reassortant O
viruses O
differed O
from O
that O
of O
wild B
- I
type I
( I
WT I
) I
FPV O
and O
depended O
on O
whether O
cells O
were O
of O
mammalian O
or O
avian O
origin O
. O

Surprisingly O
, O
molecular O
analysis O
revealed O
that O
the O
different O
reassortant O
NS O
segments O
were O
not O
only O
responsible O
for O
alterations O
in O
the O
antiviral O
host O
response O
but O
also O
affected O
viral O
genome O
replication O
and O
transcription O
as O
well O
as O
nuclear O
ribonucleoprotein B
( I
RNP I
) I
export O
. O

RNP O
reconstitution O
experiments O
demonstrated O
that O
the O
effects O
on O
accumulation O
levels O
of O
viral O
RNA O
species O
were O
dependent O
on O
the O
specific O
NS O
segment O
as O
well O
as O
on O
the O
genetic O
background O
of O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
and O
the O
induction O
of O
apoptosis O
were O
found O
to O
be O
inversely O
correlated O
with O
the O
magnitude O
of O
viral O
growth O
, O
while O
the O
NS O
allele O
, O
virus O
subtype O
, O
and O
nonstructural O
protein O
NS1 O
expression O
levels O
showed O
no O
correlation O
. O

The O
biological O
, O
serological O
, O
and O
genomic O
characterization O
of O
a O
paramyxovirus O
recently O
isolated O
from O
rock O
- O
hopper O
penguins O
( O
Eudyptes O
chrysocome O
) O
suggested O
that O
this O
virus O
represented O
a O
new O
avian B
paramyxovirus I
( I
APMV I
) I
group O
, O
APMV10 O
. O

This O
penguin O
virus O
resembled O
other O
APMVs O
by O
electron O
microscopy O
; O
however O
, O
its O
viral O
hemagglutination B
( I
HA I
) I
activity O
was O
not O
inhibited O
by O
antisera O
against O
any O
of O
the O
nine O
defined O
APMV O
serotypes O
. O

Our O
previous O
report O
highlighted O
the O
role O
that O
Japanese O
quail O
play O
as O
an O
intermediate O
host O
, O
expanding O
the O
host O
range O
of O
a O
mallard O
H2N2 O
virus O
, O
A O
/ O
mallard O
/ O
Potsdam O
/ O
178 O
- O
4 O
/ O
83 O
( O
H2N2 O
) O
, O
through O
viral O
adaptation O
. O

Here O
we O
report O
that O
of O
the O
six O
amino O
acid O
changes O
in O
the O
quail O
- O
adapted O
virus O
, O
a O
single O
change O
in O
the O
Hemagglutinin B
( I
HA I
) I
was O
crucial O
for O
transmission O
in O
quail O
, O
while O
the O
changes O
in O
the O
polymerase O
genes O
favored O
replication O
at O
lower O
temperatures O
than O
those O
for O
the O
wild O
- O
type O
mallard O
virus O
. O

Sequence O
analysis O
indicated O
that O
this O
chicken O
- O
adapted O
virus O
maintained O
all O
quail O
- O
adaptive O
mutations O
, O
as O
well O
as O
an O
additional O
change O
in O
the O
HA O
and O
, O
most O
notably O
, O
a O
27 O
- O
amino O
- O
acid O
deletion O
in O
the O
stalk O
region O
of O
neuraminidase B
( I
NA I
) I
, O
a O
genotypic O
marker O
of O
influenza O
virus O
adaptation O
to O
chickens O
. O

To O
find O
out O
whether O
these O
mutations O
contribute O
to O
the O
phenotypic O
differences O
between O
the O
highly O
pathogenic O
and O
low O
pathogenic O
viruses O
, O
we O
generated O
recombinants O
of O
the O
highly O
pathogenic O
A O
/ O
ostrich O
/ O
Italy O
/ O
984 O
/ O
00 O
strain O
that O
contained O
the O
nuclear O
export O
signal O
and O
/ O
or O
the O
extended O
C O
terminus O
of O
NS1 O
of O
a O
low O
pathogenic O
virus O
( O
A O
/ O
chicken O
/ O
Italy O
/ O
1082 O
/ O
99 O
) O
. O

The O
Infectious B
salmon I
anemia I
virus I
( I
ISAV I
) I
, O
an O
orthomyxovirus O
, O
is O
the O
major O
cause O
of O
outbreaks O
of O
high O
mortality O
rates O
in O
salmon O
in O
Chile O
. O

For O
this O
purpose O
, O
we O
performed O
bioinformatic O
analyses O
of O
( O
i O
) O
functional O
domains O
, O
( O
ii O
) O
specific O
mutations O
, O
( O
iii O
) O
Bayesian O
phylogenetics O
, O
and O
( O
iv O
) O
structural O
comparisons O
between O
ISAV O
and O
influenza O
virus O
glycoproteins O
by O
using O
molecular O
modeling O
. O

A O
live O
attenuated O
H7N7 O
candidate O
vaccine O
virus O
was O
generated O
by O
reverse O
genetics O
using O
the O
modified O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
of O
highly B
pathogenic I
( I
HP I
) I
A O
/ O
Netherlands O
/ O
219 O
/ O
03 O
( O
NL O
/ O
03 O
) O
( O
H7N7 O
) O
wild B
- I
type I
( I
WT I
) I
virus O
and O
the O
six O
internal O
protein O
genes O
of O
the O
cold B
- I
adapted I
( I
ca I
) I
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
ca O
( O
AA O
ca O
) O
( O
H2N2 O
) O
virus O
. O

The O
reassortant O
H7N7 O
NL O
/ O
03 O
ca O
vaccine O
virus O
was O
temperature O
sensitive O
and O
attenuated O
in O
mice O
, O
ferrets O
, O
and O
African B
green I
monkeys I
( I
AGMs I
) I
. O

The O
contribution O
of O
CD8 O
( O
+ O
) O
and O
/ O
or O
CD4 O
( O
+ O
) O
T O
cells O
to O
the O
vaccine O
- O
induced O
protection O
of O
mice O
was O
evaluated O
by O
T O
- O
cell O
depletion O
; O
T O
lymphocytes O
were O
not O
essential O
for O
the O
vaccine O
- O
induced O
protection O
from O
lethal O
challenge O
with O
H7 O
wt O
viruses O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
is O
a O
striking O
disease O
in O
susceptible O
poultry O
, O
which O
leads O
to O
severe O
economic O
losses O
. O

Inactivated O
vaccines O
are O
the O
most O
widely O
used O
vaccines O
in O
Avian B
influenza I
virus I
( I
AIV I
) I
vaccination O
programs O
. O

The O
use O
of O
vaccines O
that O
allow O
differentiation O
between O
infected O
and O
vaccinated O
animals O
( O
DIVA O
strategy O
) O
would O
stop O
current O
stamping O
- O
out O
policies O
. O

Therefore O
, O
novel O
vaccination O
strategies O
are O
needed O
to O
allow O
improved O
protection O
of O
animals O
and O
humans O
against O
HPAI B
virus I
( I
HPAIV I
) I
infection O
. O

The O
presented O
study O
analyzed O
for O
the O
first O
time O
the O
immunogenic O
capacity O
of O
plant O
- O
expressed O
full O
- O
length O
hemagglutinin O
( O
rHA0 O
) O
of O
HPAIV O
H5N1 O
in O
several O
vaccine O
formulations O
within O
the O
highly O
relevant O
host O
species O
chicken O
. O

Real B
- I
time I
reverse I
transcription I
( I
RT I
) I
- O
PCR O
and O
serological O
tests O
demonstrated O
only O
marginally O
increased O
virus O
replication O
in O
animals O
vaccinated O
with O
plant O
- O
derived O
rHA0 O
compared O
to O
animals O
immunized O
with O
an O
inactivated O
reference O
vaccine O
. O

The O
host O
proteome O
response O
and O
molecular O
mechanisms O
that O
drive O
disease O
in O
vivo O
during O
infection O
by O
a O
human O
isolate O
of O
the O
highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAI I
) I
and O
1918 O
pandemic O
influenza O
virus O
remain O
poorly O
understood O
. O

This O
study O
presents O
a O
comprehensive O
characterization O
of O
the O
proteome O
response O
in O
cynomolgus O
macaque O
( O
Macaca O
fascicularis O
) O
lung O
tissue O
over O
7 O
days O
of O
infection O
with O
HPAI O
( O
the O
most O
virulent O
) O
, O
a O
reassortant O
virus O
containing O
1918 O
hemagglutinin O
and O
neuraminidase O
surface O
proteins O
( O
intermediate O
virulence O
) O
, O
or O
a O
human O
seasonal O
strain O
( O
least O
virulent O
) O
. O

In O
this O
study O
, O
two O
recombinant O
influenza O
A O
viruses O
with O
a O
neuraminidase B
( I
NA I
) I
segment O
harboring O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
in O
the O
background O
of O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
were O
generated O
. O

The O
viral B
RNA I
( I
vRNA I
) I
- O
specific O
packaging O
signals O
for O
NA O
were O
largely O
retained O
for O
efficient O
packaging O
. O

Full O
- O
genome O
sequencing O
of O
11 O
Australian O
and O
1 O
New O
Zealand O
avian O
influenza O
A O
virus O
isolate O
( O
all O
subtype O
H7 O
) O
has O
enabled O
comparison O
of O
the O
sequences O
of O
each O
of O
the O
genome O
segments O
to O
those O
of O
other O
subtype O
H7 O
avian O
influenza O
A O
viruses O
. O

These O
results O
, O
in O
conjunction O
with O
the O
occurrence O
of O
five O
different O
combinations O
of O
neuraminidase O
subtypes O
( O
H7N2 O
, O
H7N3 O
, O
H7N4 O
, O
H7N6 O
, O
H7N7 O
) O
among O
the O
11 O
Australian O
isolates O
, O
suggest O
that O
the O
maintenance O
host O
( O
s O
) O
is O
nearly O
exclusively O
associated O
with O
Australia O
. O

Genetic O
determinants O
of O
host O
range O
adaptation O
have O
been O
found O
on O
the O
polymerase O
complex O
( O
PB1 O
, O
PB2 O
, O
and O
PA O
) O
as O
well O
as O
on O
the O
nucleoprotein B
( I
NP I
) I
. O

We O
monitored O
the O
activity O
of O
influenza O
A O
viral O
polymerases O
in O
heterokaryons O
formed O
between O
avian O
( O
DF1 O
) O
and O
human O
( O
293T O
) O
cells O
. O

The O
NS1 O
proteins O
of O
most O
avian O
influenza O
viruses O
bear O
the O
C O
- O
terminal O
ligand O
sequence O
Glu O
- O
Ser O
- O
Glu O
- O
Val O
( O
ESEV O
) O
for O
PDZ O
domains O
present O
in O
multiple O
host O
proteins O
, O
whereas O
no O
such O
motif O
is O
found O
in O
the O
NS1 O
homologues O
of O
seasonal O
human O
virus O
strains O
. O

Here O
, O
we O
demonstrate O
that O
the O
PB2 O
protein O
interacts O
with O
the O
mitochondrial O
antiviral O
signaling O
protein O
, O
MAVS O
( O
also O
known O
as O
IPS O
- O
1 O
, O
VISA O
, O
or O
Cardif O
) O
, O
and O
inhibits O
MAVS O
- O
mediated O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
. O

infectious B
bronchitis I
virus I
( I
IBV I
) I
is O
an O
avian O
coronavirus O
affecting O
the O
respiratory O
tract O
of O
chickens O
. O

To O
analyze O
IBV O
infection O
of O
the O
lower O
respiratory O
tract O
, O
we O
applied O
a O
technique O
that O
uses O
precision O
- O
cut O
lung O
slices O
( O
PCLSs O
) O
. O

8 O
mu O
g O
Hemagglutinin B
( I
HA I
) I
and O
CoVaccine O
HT O
were O
protected O
against O
homologous O
challenge O
infection O
with O
influenza O
virus O
A O
/ O
VN O
/ O
1194 O
/ O
04 O
. O

The O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
phenotype O
is O
restricted O
to O
influenza O
A O
viruses O
of O
the O
H5 O
and O
H7 O
Hemagglutinin B
( I
HA I
) I
subtypes O
. O

To O
obtain O
more O
information O
on O
the O
apparent O
subtype O
- O
specific O
nature O
of O
the O
HPAI O
virus O
phenotype O
, O
a O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
H6N1 O
virus O
was O
generated O
, O
containing O
an O
HPAI O
H5 O
RRRKKR O
down O
arrow O
G O
multibasic B
cleavage I
site I
( I
MBCS I
) I
motif O
in O
HA O
( O
the O
downward O
arrow O
indicates O
the O
site O
of O
cleavage O
) O
. O

The O
H6N1 O
virus O
with O
an O
MBCS O
displayed O
in O
vitro O
characteristics O
similar O
to O
those O
of O
HPAI O
H5 O
viruses O
, O
such O
as O
cleavage O
of O
HA O
( O
0 O
) O
( O
the O
HA O
protein O
of O
influenza O
A O
virus O
initially O
synthesized O
as O
a O
single O
polypeptide O
precursor O
) O
and O
virus O
replication O
in O
the O
absence O
of O
exogenous O
trypsin O
. O

Here O
, O
a O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
against O
the O
Hemagglutinin B
( I
HA I
) I
of O
the O
influenza O
A O
/ O
chicken O
/ O
Hatay O
/ O
2004 O
H5N1 O
virus O
, O
MAb O
9F4 O
, O
was O
generated O
and O
characterized O
. O

To O
investigate O
the O
host O
transcriptional O
response O
induced O
by O
pathogenic O
influenza O
viruses O
, O
we O
used O
a O
functional O
- O
genomics O
approach O
to O
compare O
gene O
expression O
profiles O
in O
lungs O
from O
129S6 O
/ O
SvEv O
mice O
infected O
with O
either O
the O
fully O
reconstructed O
H1N1 O
1918 O
pandemic O
virus O
( O
1918 O
) O
or O
the O
highly O
pathogenic O
avian O
H5N1 O
virus O
Vietnam O
/ O
1203 O
/ O
04 O
( O
VN O
/ O
1203 O
) O
. O

Both O
viruses O
elicited O
expression O
of O
type B
I I
interferon I
( I
IFN I
) I
- O
regulated O
genes O
in O
wild O
- O
type O
mice O
and O
to O
a O
lesser O
extent O
in O
mice O
lacking O
the O
type O
I O
IFN O
receptor O
, O
suggesting O
alternative O
or O
redundant O
pathways O
for O
IFN O
signaling O
. O

The O
majority O
of O
the O
isolates O
( O
13 O
/ O
18 O
) O
induced O
severe O
morbidity O
and O
mortality O
in O
DBA O
/ O
2 O
mice O
upon O
intranasal O
challenge O
with O
1 O
million O
infectious O
doses O
. O

Correspondingly O
, O
we O
used O
the O
DBA O
/ O
2 O
model O
to O
assess O
the O
level O
of O
protection O
afforded O
by O
preexisting O
pandemic O
H1N1 O
2009 O
virus O
( O
H1N1pdm O
) O
cross O
- O
reactive O
human O
antibodies O
detected O
by O
a O
hemagglutination O
inhibition O
assay O
. O

Large O
- O
scale O
sequence O
analyses O
of O
influenza O
viruses O
revealed O
that O
nonstructural B
1 I
( I
NS1 I
) I
proteins O
from O
avian O
influenza O
viruses O
have O
a O
conserved O
C O
- O
terminal O
ESEV O
amino O
acid O
motif O
, O
while O
NS1 O
proteins O
from O
typical O
human O
influenza O
viruses O
have O
a O
C O
- O
terminal O
RSKV O
motif O
. O

The O
continuous O
circulation O
of O
the O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
has O
been O
a O
cause O
of O
great O
concern O
. O

The O
possibility O
of O
this O
virus O
acquiring O
specificity O
for O
the O
human O
influenza O
A O
virus O
receptor O
, O
alpha O
2 O
, O
6 O
- O
linked O
sialic B
acids I
( I
SA I
) I
, O
and O
being O
able O
to O
transmit O
efficiently O
among O
humans O
is O
a O
constant O
threat O
to O
human O
health O
. O

Different O
studies O
have O
described O
amino O
acid O
substitutions O
in O
Hemagglutinin B
( I
HA I
) I
of O
clinical O
HPAI O
H5N1 O
isolates O
or O
that O
were O
introduced O
experimentally O
that O
resulted O
in O
an O
increased O
, O
but O
not O
exclusive O
, O
binding O
of O
these O
virus O
strains O
to O
alpha O
2 O
, O
6 O
- O
linked O
SA O
. O

The O
attachment O
pattern O
to O
ferret O
and O
human O
tissues O
of O
the O
upper O
and O
lower O
respiratory O
tract O
of O
viruses O
with O
alpha O
2 O
, O
6 O
- O
linked O
SA O
receptor O
preference O
was O
then O
determined O
and O
compared O
to O
the O
attachment O
pattern O
of O
a O
human O
Influenza B
A I
virus I
( I
H3N2 I
) I
. O

In O
spring O
2006 O
, O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
of O
subtype O
H5N1 O
was O
detected O
in O
Austria O
in O
119 O
dead O
wild O
birds O
. O

For O
detailed O
analysis O
, O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
of O
27 O
selected O
Austrian O
H5N1 O
viruses O
originating O
from O
different O
regions O
and O
wild O
bird O
species O
were O
analyzed O
phylogenetically O
, O
which O
revealed O
two O
clearly O
separated O
Austrian O
subclusters O
, O
both O
belonging O
to O
European O
cluster O
EMA O
- O
1 O
. O

Subcluster O
South O
( O
SCS O
) O
contains O
virus O
isolates O
from O
the O
south O
of O
Austria O
as O
well O
as O
from O
Slovenia O
, O
Turkey O
, O
Egypt O
, O
and O
Nigeria O
. O

The O
second O
subcluster O
, O
Northwest O
( O
SCN O
) O
, O
covered O
a O
larger O
group O
of O
viruses O
originating O
from O
different O
locations O
and O
wild O
bird O
species O
in O
the O
northern O
and O
very O
western O
parts O
of O
Austria O
, O
as O
well O
as O
from O
Bavaria O
and O
Switzerland O
. O

Together O
with O
isolates O
from O
Bavarian O
, O
the O
Czech O
Republic O
, O
Italy O
, O
and O
Slovakia O
, O
they O
form O
a O
genuine O
subgroup O
, O
named O
subgroup O
Bavaria O
( O
SGB O
) O
. O

This O
reduced O
inflammation O
was O
associated O
with O
enhanced O
early O
recruitment O
of O
T O
cells O
, O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
, O
and O
with O
early O
influenza O
virus O
- O
specific O
cytotoxic O
T O
- O
cell O
responses O
. O

We O
confirmed O
the O
effects O
of O
the O
T271A O
mutation O
using O
recombinant O
WSN O
viruses O
containing O
avian O
NP O
and O
polymerase O
genes O
with O
wild B
- I
type I
( I
WT I
) I
or O
mutant O
PB2 O
. O

The O
characterization O
of O
the O
polymerase O
activity O
of O
A O
/ O
California O
/ O
04 O
/ O
2009 O
( O
H1N1 O
) O
and O
corresponding O
PB2 O
mutants O
indicates O
that O
the O
high O
polymerase O
activity O
of O
the O
pandemic O
strain O
in O
mammalian O
cells O
is O
, O
in O
part O
, O
dependent O
on O
271A O
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
released O
from O
avian O
cells O
expressing O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
strain O
AV O
proteins O
NP O
, O
M O
, O
HN B
( I
hemagglutinin I
- I
neuraminidase I
) I
, O
and O
F O
were O
characterized O
. O

The O
resulting O
immune O
responses O
, O
detected O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
, O
virus O
neutralization O
, O
and O
intracellular O
cytokine O
staining O
, O
were O
comparable O
to O
the O
responses O
to O
equivalent O
amounts O
of O
inactivated O
NDV O
vaccine O
virus O
. O

The O
emergence O
in O
1997 O
and O
continuance O
today O
of O
a O
highly O
lethal O
H5N1 O
Avian B
influenza I
virus I
( I
AIV I
) I
causing O
human O
disease O
has O
raised O
concern O
about O
an O
impending O
pandemic O
and O
the O
need O
for O
a O
vaccine O
to O
prepare O
for O
such O
an O
occurrence O
. O

We O
previously O
generated O
an O
efficacious O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
based O
AIV O
vaccine O
expressing O
H5 O
Hemagglutinin B
( I
HA I
) I
from O
the O
fifth O
genomic O
position O
of O
VSV O
( O
J O
. O

Here O
we O
have O
generated O
and O
characterized O
VSV O
- O
based O
vaccines O
that O
express O
the O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
1997 O
( O
clade O
0 O
) O
H5 O
HA O
from O
the O
first O
position O
of O
the O
VSV O
genome O
. O

Host O
cellular O
proteases O
induce O
influenza O
virus O
entry O
into O
cells O
by O
cleaving O
the O
viral O
surface O
envelope O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
. O

We O
report O
here O
that O
ubiquitous O
type O
II O
transmembrane O
serine O
proteases O
, O
MSPL O
and O
its O
splice O
variant O
TMPRSS13 O
, O
are O
novel O
candidates O
for O
proteases O
processing O
HA O
proteins O
of O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
, O
apart O
from O
the O
previously O
identified O
furin O
and O
proprotein O
convertases O
5 O
and O
6 O
. O

HAs O
from O
all O
HPAI O
virus O
H5 O
and O
H7 O
strains O
have O
one O
of O
two O
cleavage O
site O
motifs O
, O
the O
( O
R O
) O
under O
bar O
- O
X O
- O
K O
/ O
R O
- O
R O
motif O
with O
( O
R O
) O
under O
bar O
at O
position O
P4 O
and O
the O
( O
K O
) O
under O
bar O
- O
K O
/ O
R O
- O
K O
/ O
T O
- O
R O
motif O
with O
( O
K O
) O
under O
bar O
at O
position O
P4 O
. O

In O
studies O
of O
synthetic O
14 O
- O
residue O
HPAI O
virus O
HA O
peptides O
with O
these O
cleavage O
site O
motifs O
, O
furin O
preferentially O
cleaved O
only O
HA O
peptides O
with O
the O
( O
R O
) O
under O
bar O
- O
K O
- O
K O
- O
R O
motif O
in O
the O
presence O
of O
calcium O
and O
not O
peptides O
with O
the O
other O
motif O
, O
whereas O
MSPL O
and O
TMPRSS13 O
cleaved O
both O
types O
of O
HA O
peptides O
( O
those O
with O
the O
( O
R O
) O
under O
bar O
/ O
( O
K O
) O
under O
bar O
- O
K O
- O
K O
- O
R O
motif O
) O
efficiently O
in O
the O
absence O
of O
calcium O
. O

Full O
- O
length O
recombinant O
HPAI O
virus O
HA O
with O
the O
( O
K O
) O
under O
bar O
- O
K O
- O
K O
- O
R O
cleavage O
motif O
exhibited O
poor O
susceptibility O
to O
cleavage O
in O
the O
absence O
of O
MSPL O
or O
TMPRSS13 O
and O
the O
presence O
of O
furin O
in O
infected O
cells O
, O
but O
it O
was O
converted O
to O
mature O
HA O
subunits O
in O
transfected O
cells O
expressing O
MSPL O
or O
TMPRSS13 O
, O
with O
membrane O
- O
fused O
giant O
- O
cell O
formation O
. O

Furthermore O
, O
infection O
with O
and O
multiplication O
of O
genetically O
modified O
live O
HPAI O
virus O
A O
/ O
Crow O
/ O
Kyoto O
/ O
53 O
/ O
2004 O
( O
H5N1 O
) O
with O
the O
( O
K O
) O
under O
bar O
- O
K O
- O
K O
- O
R O
cleavage O
site O
motif O
were O
detected O
only O
in O
MSPL O
- O
and O
TMPRSS13 O
- O
expressing O
cells O
. O

In O
this O
study O
, O
we O
evaluated O
the O
protective O
potential O
of O
an O
immediate O
- O
early O
promoter O
- O
based O
baculovirus O
displaying O
hemagglutinin O
( O
BacHA O
) O
against O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
infection O
in O
a O
mouse O
model O
. O

Gastrointestinal O
delivery O
of O
BacHA O
significantly O
enhanced O
the O
systemic O
immune O
response O
in O
terms O
of O
HA O
- O
specific O
serum O
IgG O
and O
hemagglutination B
inhibition I
( I
HI I
) I
titers O
. O

Viral O
challenge O
studies O
showed O
that O
live O
BacHA O
was O
able O
to O
provide O
100 O
% O
protection O
against O
5 O
50 B
% I
mouse I
lethal I
doses I
( I
MLD50 I
) I
of O
homologous O
( O
clade O
2 O
. O

1 O
) O
and O
heterologous O
( O
clade O
1 O
) O
H5N1 O
. O

We O
have O
demonstrated O
that O
recombinant O
baculovirus O
with O
a O
white B
spot I
syndrome I
virus I
( I
WSSV I
) I
immediate O
- O
early O
promoter O
1 O
( O
ie1 O
) O
acted O
as O
a O
vector O
as O
well O
as O
a O
protein O
vaccine O
and O
will O
enable O
the O
rapid O
production O
of O
prepandemic O
and O
pandemic O
vaccines O
without O
any O
biosafety O
concerns O
. O

Highly O
pathogenic O
A O
/ O
H5N1 O
avian O
influenza O
( O
HPAI O
H5N1 O
) O
viruses O
have O
seriously O
affected O
the O
Nigerian O
poultry O
industry O
since O
early O
2006 O
. O

To O
determine O
the O
spatial O
, O
evolutionary O
, O
and O
population O
dynamics O
of O
the O
multiple O
H5N1 O
lineages O
cocirculating O
in O
Nigeria O
, O
we O
conducted O
a O
phylogenetic O
analysis O
of O
whole O
- O
genome O
sequences O
from O
106 O
HPAI O
H5N1 O
viruses O
isolated O
between O
2006 O
and O
2008 O
and O
representing O
all O
25 O
Nigerian O
states O
and O
the O
Federal B
Capital I
Territory I
( I
FCT I
) I
reporting O
outbreaks O
. O

A O
detailed O
analysis O
of O
viral O
phylogeography O
identified O
two O
major O
source O
populations O
for O
the O
HPAI O
H5N1 O
virus O
in O
Nigeria O
, O
one O
in O
a O
major O
commercial O
poultry O
area O
( O
southwest O
region O
) O
and O
one O
in O
northern O
Nigeria O
, O
where O
contact O
between O
wild O
birds O
and O
backyard O
poultry O
is O
frequent O
. O

In O
the O
first O
6 O
months O
of O
the O
H1N1 O
swine B
- I
origin I
influenza I
virus I
( I
S I
- I
OIV I
) I
pandemic O
, O
the O
vast O
majority O
of O
infections O
were O
relatively O
mild O
. O

Today O
, O
global O
attention O
is O
focused O
on O
two O
influenza O
virus O
strains O
: O
the O
current O
pandemic O
strain O
, O
swine O
origin O
influenza O
virus O
( O
H1N1 O
- O
2009 O
) O
, O
and O
the O
highly O
pathogenic O
avian O
influenza O
virus O
, O
H5N1 O
. O

natural B
killer I
( I
NK I
) I
cells O
are O
one O
of O
the O
innate O
immune O
components O
playing O
an O
important O
role O
in O
fighting O
against O
influenza O
viruses O
. O

Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
subtype O
H5N1 O
causes O
severe O
disease O
and O
mortality O
in O
poultry O
. O

We O
evaluated O
the O
individual O
contributions O
of O
each O
of O
the O
three O
HPAIV O
surface O
proteins O
, O
namely O
, O
the O
Hemagglutinin B
( I
HA I
) I
, O
the O
neuraminidase B
( I
NA I
) I
, O
and O
the O
M2 O
proteins O
, O
to O
the O
induction O
of O
HPAIV O
- O
neutralizing O
serum O
antibodies O
and O
protective O
immunity O
in O
chickens O
. O

Using O
reverse O
genetics O
, O
three O
recombinant B
Newcastle I
disease I
viruses I
( I
rNDVs I
) I
were O
engineered O
, O
each O
expressing O
the O
HA O
, O
NA O
, O
or O
M2 O
protein O
of O
H5N1 O
HPAIV O
. O

Chickens O
were O
immunized O
with O
NDVs O
expressing O
a O
single O
antigen O
( O
HA O
, O
NA O
, O
and O
M2 O
) O
, O
two O
antigens O
( O
HA O
+ O
NA O
, O
HA O
+ O
M2 O
, O
and O
NA O
+ O
M2 O
) O
, O
or O
three O
antigens O
( O
HA O
+ O
NA O
+ O
M2 O
) O
. O

In O
this O
study O
, O
we O
show O
that O
the O
highly O
pathogenic O
H5N1 O
Avian B
influenza I
virus I
( I
AIV I
) I
( O
A O
/ O
crow O
/ O
Kyoto O
/ O
53 O
/ O
04 O
and O
A O
/ O
chicken O
/ O
Egypt O
/ O
CL6 O
/ O
07 O
) O
induced O
apoptosis O
in O
duck B
embryonic I
fibroblasts I
( I
DEF I
) I
. O

In O
contrast O
, O
apoptosis O
was O
reduced O
among O
cells O
infected O
with O
low O
- O
pathogenic O
AIVs O
( O
A O
/ O
duck O
/ O
HK O
/ O
342 O
/ O
78 O
[ O
H5N2 O
] O
, O
A O
/ O
duck O
/ O
HK O
/ O
820 O
/ O
80 O
[ O
H5N3 O
] O
, O
A O
/ O
wigeon O
/ O
Osaka O
/ O
1 O
/ O
01 O
[ O
H7N7 O
] O
, O
and O
A O
/ O
turkey O
/ O
Wisconsin O
/ O
1 O
/ O
66 O
[ O
H9N2 O
] O
) O
. O

We O
then O
analyzed O
Ca2 O
+ O
dynamics O
in O
the O
infected O
cells O
and O
demonstrated O
an O
increase O
in O
the O
concentration O
of O
Ca2 O
+ O
in O
the O
cytosol O
( O
[ O
Ca2 O
+ O
] O
( O
i O
) O
) O
and O
mitochondria O
( O
[ O
Ca2 O
+ O
] O
( O
m O
) O
) O
after O
H5N1 O
- O
AIV O
infection O
. O

Indeed O
, O
EGTA O
, O
which O
chelates O
extracellular O
free O
Ca2 O
+ O
, O
significantly O
reduced O
the O
[ O
Ca2 O
+ O
] O
( O
i O
) O
, O
[ O
Ca2 O
+ O
] O
( O
m O
) O
, O
and O
apoptosis O
induced O
by O
H5N1 O
- O
AIV O
infection O
. O

The O
Hemagglutinin B
( I
HA I
) I
envelope O
protein O
of O
influenza O
viruses O
mediates O
essential O
viral O
functions O
, O
including O
receptor O
binding O
and O
membrane O
fusion O
, O
and O
is O
the O
major O
viral O
antigen O
for O
antibody O
neutralization O
. O

The O
1957 O
H2N2 O
subtype O
( O
Asian O
flu O
) O
was O
one O
of O
the O
three O
great O
influenza O
pandemics O
of O
the O
last O
century O
and O
caused O
1 O
million O
deaths O
globally O
from O
1957 O
to O
1968 O
. O

A O
reassortant O
avian O
influenza O
virus O
( O
designated O
FPV O
NS O
GD O
) O
, O
carrying O
the O
NS O
- O
segment O
of O
the O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
strain O
A O
/ O
Goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
GD O
; O
H5N1 O
) O
in O
the O
genetic O
background O
of O
the O
HPAIV O
strain O
A O
/ O
FPV O
/ O
Rostock O
/ O
34 O
( O
FPV O
; O
H7N1 O
) O
, O
was O
rescued O
by O
reverse O
genetics O
. O

Remarkably O
, O
in O
contrast O
to O
the O
recombinant B
wild I
- I
type I
FPV I
( I
rFPV I
) I
, O
the O
reassortant O
virus O
was O
able O
to O
replicate O
more O
efficiently O
in O
different O
human O
cell O
lines O
and O
primary O
mouse O
epithelia O
cells O
without O
prior O
adaptation O
. O

In O
an O
attempt O
to O
define O
the O
molecular O
basis O
for O
the O
apparent O
differences O
, O
we O
determined O
that O
NS1 O
proteins O
of O
the O
H5N1 O
and O
H7N1 O
strains O
bound O
the O
antiviral O
kinase O
PKR O
and O
the O
F2F3 O
domain O
of O
Cleavage B
and I
polyadenylation I
specificity I
factor I
30 I
( I
CPSF30 I
) I
with O
comparable O
efficiencies O
in O
vitro O
. O

However O
, O
FPV O
NS O
GD O
infection O
resulted O
in O
( O
i O
) O
increased O
expression O
of O
NS1 O
, O
( O
ii O
) O
faster O
and O
stronger O
PKR O
inhibition O
, O
and O
( O
iii O
) O
stronger O
beta O
interferon O
promoter O
inhibition O
than O
rFPV O
. O

Two O
viruses O
isolated O
during O
the O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H7N7 O
virus O
outbreak O
in O
The O
Netherlands O
in O
2003 O
, O
one O
isolated O
from O
a O
person O
with O
conjunctivitis O
and O
one O
from O
a O
person O
who O
died O
as O
the O
result O
of O
infection O
, O
were O
used O
for O
an O
in O
vitro O
study O
of O
influenza O
A O
virus O
pathogenicity O
factors O
. O

Assays O
were O
designed O
to O
investigate O
the O
role O
of O
each O
of O
these O
substitutions O
in O
attachment O
and O
entry O
, O
transcription O
and O
genome O
replication O
, O
and O
virus O
production O
and O
release O
as O
determined O
by O
Hemagglutinin B
( I
HA I
) I
, O
polymerase O
proteins O
, O
nonstructural B
protein I
1 I
( I
NS1 I
) I
, O
and O
neuraminidase B
( I
NA I
) I
. O

These O
in O
vitro O
studies O
confirmed O
the O
roles O
of O
the O
E627K O
substitution O
in O
basic B
polymerase I
2 I
( I
PB2 I
) I
and O
the O
A143T O
substitution O
in O
HA O
in O
pathogenicity O
observed O
in O
a O
mouse O
model O
previously O
. O

However O
, O
the O
in O
vitro O
studies O
identified O
a O
contribution O
of O
acidic B
polymerase I
( I
PA I
) I
and O
NA O
to O
the O
efficient O
replication O
in O
human O
cells O
of O
the O
fatal O
case O
virus O
, O
despite O
the O
fact O
that O
these O
are O
rarely O
marked O
as O
determinants O
of O
pathogenicity O
in O
in O
vivo O
studies O
. O

Mice O
primed O
with O
the O
H1N1 O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
virus O
were O
partially O
protected O
from O
lethality O
following O
respiratory O
infection O
with O
the O
modified O
H5N1 O
virus O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
Delta O
Vn1203 O
) O
. O

In O
contrast O
, O
those O
that O
had O
been O
comparably O
exposed O
to O
the O
HKx31 O
( O
H3N2 O
) O
virus O
succumbed O
to O
the O
Delta O
Vn1203 O
challenge O
, O
despite O
similarities O
in O
viral O
replication O
, O
weight O
loss O
, O
and O
secondary O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
characteristics O
. O

All O
three O
viruses O
share O
the O
internal O
genes O
of O
PR8 O
that O
are O
known O
to O
stimulate O
protective O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
- O
mediated O
immunity O
. O

The O
relative O
protection O
afforded O
by O
PR8 O
priming O
was O
abrogated O
in O
tumor O
necrosis O
factor O
- O
deficient O
( O
TNF O
- O
/ O
- O
) O
mice O
, O
although O
lung O
fluids O
from O
the O
B6 O
HKx31 O
- O
primed O
mice O
contained O
more O
TNF O
early O
after O
challenge O
. O

These O
data O
demonstrate O
that O
the O
nature O
of O
the O
primary O
infection O
can O
influence O
pathological O
outcomes O
following O
virulent O
influenza O
virus O
challenge O
, O
although O
the O
effect O
is O
not O
clearly O
correlated O
with O
classical O
measures O
of O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
- O
mediated O
immunity O
. O

Amino O
acids O
at O
positions O
627 O
and O
701 O
in O
the O
PB2 O
protein O
( O
PB2 O
- O
627 O
and O
PB2 O
- O
701 O
, O
respectively O
) O
of O
avian O
influenza O
A O
viruses O
affect O
virus O
replication O
in O
some O
mammalian O
cells O
. O

Unlike O
the O
paradigmatic O
enveloped O
virus O
fusion O
proteins O
, O
the O
FAST O
proteins O
position O
the O
majority O
of O
their O
mass O
within O
and O
internal O
to O
the O
membrane O
in O
which O
they O
reside O
, O
resulting O
in O
extended O
C B
- I
terminal I
cytoplasmic I
tails I
( I
CTs I
) I
. O

To O
investigate O
the O
molecular O
changes O
that O
occur O
during O
adaptation O
of O
a O
low O
- O
pathogenic O
avian O
influenza O
virus O
subtype O
commonly O
isolated O
from O
migratory O
birds O
to O
a O
mammalian O
host O
, O
we O
serially O
passaged O
the O
avirulent O
wild O
- O
bird O
H5N2 O
strain O
A O
/ O
Aquatic O
bird O
/ O
Korea O
/ O
W81 O
/ O
05 O
( O
W81 O
) O
in O
the O
lungs O
of O
mice O
. O

The O
resulting O
mouse O
- O
adapted O
strain O
( O
ma81 O
) O
was O
highly O
virulent O
( O
50 O
% O
mouse O
lethal O
dose O
= O
2 O
. O

6 O
log O
( O
10 O
) O
50 O
% O
tissue O
culture O
infective O
dose O
) O
and O
highly O
lethal O
. O

Nonconserved O
mutations O
were O
observed O
in O
six O
viral O
genes O
( O
those O
for O
PB2 O
, O
PB1 O
, O
PA O
, O
HA O
, O
NA O
, O
and O
M O
) O
. O

In O
growth O
kinetics O
studies O
, O
ma81 O
showed O
enhanced O
replication O
in O
mammalian O
but O
not O
avian O
cell O
lines O
; O
the O
PA O
( O
97I O
) O
mutation O
in O
strain O
W81 O
increased O
its O
replicative O
fitness O
in O
mice O
but O
not O
in O
chickens O
. O

The O
high O
virulence O
associated O
with O
the O
PA O
( O
97I O
) O
mutation O
in O
mice O
corresponded O
to O
considerably O
enhanced O
polymerase O
activity O
in O
mammalian O
cells O
. O

We O
have O
previously O
shown O
that O
infection O
with O
laboratory O
- O
passaged O
strains O
of O
influenza O
virus O
causes O
both O
specific O
degradation O
of O
the O
largest O
subunit O
of O
the O
RNA B
polymerase I
II I
complex I
( I
RNAP I
II I
) I
and O
inhibition O
of O
host O
cell O
transcription O
. O

To O
evaluate O
whether O
this O
process O
is O
a O
general O
feature O
of O
nonattenuated O
viruses O
, O
we O
studied O
the O
behavior O
of O
the O
influenza O
virus O
strains O
A O
/ O
PR8 O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
and O
the O
cold O
- O
adapted O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
( O
AA O
) O
, O
which O
are O
currently O
used O
as O
the O
donor O
strains O
for O
vaccine O
seeds O
due O
to O
their O
attenuated O
phenotype O
. O

In O
addition O
, O
a O
hypervirulent B
PR8 I
( I
hvPR8 I
) I
variant O
that O
multiplies O
much O
faster O
than O
standard O
PR8 O
( O
lvPR8 O
) O
in O
infected O
cells O
and O
is O
more O
virulent O
in O
mice O
than O
the O
parental O
PR8 O
virus O
, O
efficiently O
induces O
RNAP O
II O
degradation O
. O

To O
model O
host O
factors O
in O
the O
context O
of O
influenza O
virus O
infection O
, O
we O
determined O
the O
lethal O
dose O
of O
a O
highly O
pathogenic O
H5N1 O
virus O
( O
A O
/ O
Hong O
Kong O
/ O
213 O
/ O
03 O
) O
in O
C57BL O
/ O
6J O
and O
DBA O
/ O
2J O
mice O
and O
identified O
genetic O
elements O
associated O
with O
survival O
after O
infection O
. O

Gene O
mapping O
with O
recombinant O
inbred O
BXD O
strains O
revealed O
five O
loci O
or O
Qivr O
( O
quantitative O
trait O
loci O
for O
influenza O
virus O
resistance O
) O
located O
on O
chromosomes O
2 O
, O
7 O
, O
11 O
, O
15 O
, O
and O
17 O
associated O
with O
resistance O
to O
H5N1 O
virus O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
virus O
H5N1 O
infects O
water O
and O
land O
fowl O
and O
can O
infect O
and O
cause O
mortality O
in O
mammals O
, O
including O
humans O
. O

Since O
most O
experimental O
studies O
of O
the O
basis O
of O
virulence O
in O
mammals O
have O
been O
small O
in O
scale O
, O
we O
undertook O
a O
meta O
- O
analysis O
of O
available O
experimental O
studies O
and O
used O
Bayesian B
graphical I
models I
( I
BGM I
) I
to O
increase O
the O
power O
of O
inference O
. O

The O
analyses O
show O
that O
virulence O
in O
mammals O
is O
a O
complex O
genetic O
trait O
directly O
influenced O
by O
mutations O
in O
polymerase B
basic I
1 I
( I
PB1 I
) I
and O
PB2 O
, O
nonstructural B
1 I
( I
NS1 I
) I
, O
and O
Hemagglutinin B
( I
HA I
) I
genes O
. O

Following O
the O
reported O
crystal O
structure O
of O
the O
endonuclease O
domain O
from O
the O
avian O
influenza O
virus O
polymerase O
PA O
subunit O
, O
here O
we O
report O
the O
results O
of O
a O
systematic O
X O
- O
ray O
crystallographic O
analysis O
of O
its O
complex O
with O
adenosine O
, O
uridine O
, O
and O
thymidine O
nucleoside B
monophosphates I
( I
NMPs I
) I
. O

Phylogenetic O
analysis O
revealed O
that O
these O
H9N2 O
viruses O
have O
undergone O
extensive O
reassortment O
to O
generate O
multiple O
novel O
genotypes O
, O
including O
four O
genotypes O
( O
J O
, O
F O
, O
K O
, O
and O
L O
) O
that O
have O
never O
been O
recognized O
before O
. O

The O
major O
H9N2 O
influenza O
viruses O
represented O
by O
A O
/ O
Chicken O
/ O
Beijing O
/ O
1 O
/ O
1994 O
( O
Ck O
/ O
BJ O
/ O
1 O
/ O
94 O
) O
- O
like O
viruses O
circulating O
in O
poultry O
in O
eastern O
China O
before O
1998 O
have O
been O
gradually O
replaced O
by O
A O
/ O
Chicken O
/ O
Shanghai O
/ O
F O
/ O
1998 O
( O
Ck O
/ O
SH O
/ O
F O
/ O
98 O
) O
- O
like O
viruses O
, O
which O
have O
a O
genotype O
different O
from O
that O
of O
viruses O
isolated O
in O
southern O
China O
. O

By O
analyzing O
multiple O
viral O
genome O
sequences O
sampled O
from O
individual O
influenza O
patients O
we O
reveal O
a O
high O
level O
of O
mixed O
infection O
, O
including O
diverse O
lineages O
of O
the O
same O
influenza O
virus O
subtype O
, O
drug O
- O
resistant O
and O
- O
sensitive O
strains O
, O
those O
that O
are O
likely O
to O
differ O
in O
antigenicity O
, O
and O
even O
viruses O
of O
different O
influenza O
virus O
types O
( O
A O
and O
B O
) O
. O

The O
hemagglutination O
gene O
of O
the O
H5N1 O
virus O
isolated O
from O
pikas O
reveals O
two O
distinct O
evolutionary O
clades O
, O
a O
mixed O
/ O
Vietnam O
H5N1 O
virus O
sublineage O
( O
MV O
- O
like O
pika O
virus O
) O
and O
a O
wild O
bird O
Qinghai B
( I
QH I
) I
like O
H5N1 O
virus O
sublineage O
( O
QH O
- O
like O
pika O
virus O
) O
. O

The O
amino O
acid O
residue O
( O
glutamic O
acid O
) O
at O
position O
627 O
encoded O
by O
the O
PB2 O
gene O
of O
the O
MV O
- O
like O
pika O
virus O
was O
different O
from O
that O
of O
the O
QH O
- O
like O
pika O
virus O
; O
the O
residue O
of O
the O
MV O
- O
like O
pika O
virus O
was O
the O
same O
as O
that O
of O
the O
goose O
H5N1 O
virus O
( O
A O
/ O
GS O
/ O
Guangdong O
[ O
GD O
] O
/ O
1 O
/ O
96 O
) O
. O

To O
this O
end O
, O
ferrets O
were O
coinfected O
with O
recent O
avian O
H5N1 O
( O
A O
/ O
Thailand O
/ O
16 O
/ O
04 O
) O
and O
human O
H3N2 O
( O
A O
/ O
Wyoming O
/ O
3 O
/ O
03 O
) O
viruses O
. O

Approximately O
34 O
% O
of O
the O
recovered O
reassortant O
viruses O
possessed O
the O
H5 O
Hemagglutinin B
( I
HA I
) I
gene O
, O
with O
five O
unique O
H5 O
subtypes O
recovered O
. O

The O
Asian O
H5N1 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
viruses O
have O
been O
increasing O
in O
pathogenicity O
in O
diverse O
avian O
species O
since O
1996 O
and O
are O
now O
widespread O
in O
Asian O
, O
European O
, O
and O
African O
countries O
. O

To O
better O
understand O
the O
basis O
of O
the O
increased O
pathogenicity O
of O
recent O
Asian O
H5N1 O
HPAI O
viruses O
in O
chickens O
, O
we O
compared O
the O
fevers O
and O
mean B
death I
times I
( I
MDTs I
) I
of O
chickens O
infected O
with O
the O
Asian O
H5N1 O
A O
/ O
chicken O
/ O
Yamaguchi O
/ O
7 O
/ O
04 O
( O
CkYM7 O
) O
strain O
with O
those O
infected O
with O
the O
H5N1 O
Duck O
/ O
Yokohama O
/ O
aq10 O
/ O
03 O
( O
DkYK10 O
) O
strain O
, O
using O
a O
wireless O
thermosensor O
. O

Real O
- O
time O
PCR O
analyses O
of O
cytokine O
mRNA O
expressions O
showed O
that O
CkYM7 O
quickly O
induced O
antiviral O
and O
proinflammatory O
cytokine O
mRNA O
expressions O
at O
24 O
h B
postinfection I
( I
hpi I
) I
that O
suddenly O
decreased O
at O
32 O
hpi O
. O

Examined O
here O
are O
the O
dose O
of O
viral O
Hemagglutinin B
( I
HA I
) I
and O
the O
number O
of O
inoculations O
required O
for O
two O
different O
H5N1 O
vaccines O
to O
achieve O
protection O
in O
ferrets O
after O
lethal O
H5N1 O
challenge O
. O

8 O
mu O
g O
of O
HA O
with O
Iscomatrix O
( O
ISCOMATRIX O
, O
referred O
to O
as O
Iscomatrix O
herein O
, O
is O
a O
registered O
trademark O
of O
CSL O
Limited O
) O
adjuvant O
, O
were O
completely O
protected O
against O
death O
and O
disease O
after O
H5N1 O
challenge O
, O
and O
the O
protection O
lasted O
at O
least O
15 O
months O
. O

We O
found O
that O
in O
contrast O
to O
human O
( O
H3N2 O
and O
H1N1 O
) O
viruses O
, O
H7N7 O
viruses O
isolated O
from O
The O
Netherlands O
in O
2003 O
and O
H7N3 O
viruses O
isolated O
from O
British O
Columbia O
, O
Canada O
, O
in O
2004 O
, O
two O
subtypes O
that O
were O
highly O
virulent O
for O
poultry O
, O
replicated O
to O
a O
significant O
titer O
in O
the O
mouse O
eye O
. O

This O
correlated O
with O
efficient O
replication O
of O
highly O
pathogenic O
H7 O
and O
H5 O
subtypes O
in O
murine O
corneal O
epithelial O
sheets O
( O
ex O
vivo O
) O
and O
primary O
human O
corneal O
epithelial O
cells O
( O
in O
vitro O
) O
. O

We O
have O
focused O
on O
four O
viral O
proteins O
that O
have O
distinct O
intracellular O
distributions O
in O
infected O
cells O
, O
Hemagglutinin B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
nucleoprotein O
, O
and O
the O
NS1 O
protein O
, O
which O
is O
expressed O
in O
infected O
cells O
but O
excluded O
from O
virion O
particles O
. O

The O
NS1 O
protein O
of O
the O
influenza O
A O
virus O
is O
a O
potent O
virulence O
factor O
that O
inhibits O
type B
I I
interferon I
( I
IFN I
) I
synthesis O
, O
allowing O
the O
virus O
to O
overcome O
host O
defenses O
and O
replicate O
efficiently O
. O

We O
used O
NS1 O
truncated O
mutant O
influenza O
viruses O
derived O
from O
the O
human O
isolate O
influenza O
A O
/ O
TX O
/ O
91 O
( O
TX O
WT O
, O
where O
WT O
is O
wild O
type O
) O
to O
study O
the O
functions O
of O
NS1 O
in O
infected O
primary O
cells O
. O

Additionally O
, O
human B
dendritic I
cells I
( I
DCs I
) I
infected O
with O
human O
NS1 O
mutant O
viruses O
showed O
higher O
levels O
of O
activation O
and O
stimulated O
naive O
T O
- O
cells O
better O
than O
TX O
WT O
virus O
- O
infected O
DCs O
. O

We O
also O
compared O
infections O
of O
DCs O
with O
TX O
WT O
and O
our O
previously O
characterized O
laboratory O
strain O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
and O
its O
NS1 O
knockout O
strain O
, O
deltaNS1 O
. O

Influenza O
virus B
- I
like I
particles I
( I
VLPs I
) I
displaying O
functional O
viral O
proteins O
are O
effective O
vaccines O
against O
replication O
- O
competent O
homologous O
virus O
, O
but O
their O
ability O
to O
induce O
heterotypic O
immunity O
has O
not O
been O
adequately O
tested O
. O

Mucosal O
vaccination O
of O
mice O
with O
1918 O
VLPs O
induced O
higher O
levels O
of O
cross O
- O
reactive O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgA O
antibodies O
than O
did O
parenteral O
vaccination O
. O

Although O
the O
pathogenic O
mechanism O
( O
s O
) O
of O
H5N1 O
influenza O
viruses O
has O
not O
been O
fully O
elucidated O
, O
it O
has O
been O
suggested O
that O
the O
ability O
to O
evade O
host O
innate O
responses O
, O
such O
as O
the O
type O
I O
interferon O
response O
, O
may O
contribute O
to O
the O
virulence O
of O
these O
viruses O
in O
mammals O
. O

We O
investigated O
the O
role O
that O
type O
I O
interferons O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
might O
play O
in O
H5N1 O
pathogenicity O
in O
vivo O
, O
by O
comparing O
the O
kinetics O
and O
outcomes O
of O
H5N1 O
virus O
infection O
in O
IFN B
- I
alpha I
/ I
beta I
receptor I
( I
IFN I
- I
alpha I
/ I
beta I
R I
) I
- O
deficient O
and O
SvEv129 O
wild O
- O
type O
mice O
using O
two O
avian O
influenza O
A O
viruses O
isolated O
from O
humans O
, O
A O
/ O
Hong O
Kong O
/ O
483 O
/ O
97 O
( O
HK O
/ O
483 O
) O
and O
A O
/ O
Hong O
Kong O
/ O
486 O
/ O
97 O
( O
HK O
/ O
486 O
) O
, O
which O
exhibit O
high O
and O
low O
lethality O
in O
mice O
, O
respectively O
. O

highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIV I
) I
differ O
from O
all O
other O
strains O
by O
a O
polybasic O
cleavage O
site O
in O
their O
hemagglutinin O
. O

In O
order O
to O
investigate O
whether O
the O
acquisition O
of O
a O
polybasic O
cleavage O
site O
by O
an O
avirulent O
avian O
influenza O
virus O
strain O
with O
a O
hemagglutinin O
other O
than O
H5 O
or O
H7 O
is O
sufficient O
for O
immediate O
transformation O
into O
an O
HPAIV O
, O
we O
adapted O
the O
hemagglutinin O
cleavage O
site O
of O
A O
/ O
Duck O
/ O
Ukraine O
/ O
1 O
/ O
1963 O
( O
H3N8 O
) O
to O
that O
of O
the O
HPAIV O
A O
/ O
Chicken O
/ O
Italy O
/ O
8 O
/ O
98 O
( O
H5N2 O
) O
, O
A O
/ O
Chicken O
/ O
HongKong O
/ O
220 O
/ O
97 O
( O
H5N1 O
) O
, O
or O
A O
/ O
Chicken O
/ O
Germany O
/ O
R28 O
/ O
03 O
( O
H7N7 O
) O
and O
generated O
the O
recombinant O
wild O
- O
type O
and O
cleavage O
site O
mutants O
. O

Mice O
were O
immunized O
to O
assess O
protective O
immunity O
after O
high O
- O
dose O
challenge O
with O
the O
highly O
virulent O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
H5N1 O
) O
strain O
. O

Following O
circulation O
of O
avian O
influenza O
H5 O
and O
H7 O
viruses O
in O
poultry O
, O
the O
Hemagglutinin B
( I
HA I
) I
can O
acquire O
additional O
glycosylation O
sites O
, O
and O
the O
neuraminidase B
( I
NA I
) I
stalk O
becomes O
shorter O
. O

The O
receptor O
specificity O
and O
cleavability O
of O
the O
Hemagglutinin B
( I
HA I
) I
protein O
have O
been O
shown O
to O
regulate O
influenza O
A O
virus O
transmissibility O
and O
pathogenicity O
, O
but O
little O
is O
known O
about O
how O
its O
pH O
of O
activation O
contributes O
to O
these O
important O
biological O
properties O
. O

To O
identify O
amino O
acid O
residues O
that O
regulate O
the O
acid O
stability O
of O
the O
HA O
protein O
of O
H5N1 O
influenza O
viruses O
, O
we O
performed O
a O
mutational O
analysis O
of O
the O
HA O
protein O
of O
the O
moderately O
pathogenic O
A O
/ O
chicken O
/ O
Vietnam O
/ O
C58 O
/ O
04 O
( O
H5N1 O
) O
virus O
. O

The O
type B
I I
interferon I
( I
IFN I
) I
response O
represents O
one O
of O
the O
first O
lines O
of O
defense O
against O
influenza O
virus O
infections O
. O

We O
evaluated O
the O
ability O
of O
intranasal O
treatment O
with O
human O
alpha O
interferon O
( O
alpha O
- O
IFN O
) O
to O
reduce O
lung O
and O
nasal O
wash O
titers O
in O
guinea O
pigs O
challenged O
with O
the O
reconstructed O
1918 O
pandemic O
H1N1 O
virus O
or O
a O
contemporary O
H5N1 O
virus O
. O

The O
HA2 O
glycopolypeptide B
( I
gp I
) I
is O
highly O
conserved O
in O
all O
influenza O
A O
virus O
strains O
, O
and O
it O
is O
known O
to O
play O
a O
major O
role O
in O
the O
fusion O
of O
the O
virus O
with O
the O
endosomal O
membrane O
in O
host O
cells O
during O
the O
course O
of O
viral O
infection O
. O

So O
far O
, O
there O
have O
been O
no O
studies O
on O
the O
possible O
therapeutic O
effects O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
specifically O
against O
the O
fusion O
peptide O
of O
Hemagglutinin B
( I
HA I
) I
, O
upon O
lethal O
infections O
with O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
. O

The O
influenza O
virus O
load O
was O
assessed O
in O
lung O
samples O
from O
mice O
challenged O
after O
pretreatment O
with O
MAb O
1C9 O
( O
24 O
h O
prior O
to O
challenge O
) O
and O
from O
mice O
receiving O
early O
treatment O
( O
24 O
h O
after O
challenge O
) O
. O

It O
was O
shown O
that O
A O
/ O
chicken O
/ O
Yamaguchi O
/ O
7 O
/ O
2004 O
( O
H5N1 O
) O
[ O
Ck O
/ O
Yamaguchi O
/ O
04 O
( O
H5N1 O
) O
] O
did O
not O
replicate O
in O
pigs O
( O
N O
. O

In O
the O
present O
study O
, O
the O
genetic O
basis O
for O
this O
host O
range O
restriction O
was O
determined O
using O
reassortant O
viruses O
generated O
between O
Ck O
/ O
Yamaguchi O
/ O
04 O
( O
H5N1 O
) O
and O
A O
/ O
swine O
/ O
Hokkaido O
/ O
2 O
/ O
1981 O
( O
H1N1 O
) O
[ O
Sw O
/ O
Hokkaido O
/ O
81 O
( O
H1N1 O
) O
] O
. O

Two O
in O
vivo O
- O
generated O
single O
- O
gene O
reassortant O
virus O
clones O
of O
the O
H5N1 O
subtype O
( O
virus O
clones O
1 O
and O
2 O
) O
, O
whose O
PB2 O
gene O
was O
of O
Sw O
/ O
Hokkaido O
/ O
81 O
( O
H1N1 O
) O
origin O
and O
whose O
remaining O
seven O
genes O
were O
of O
Ck O
/ O
Yamaguchi O
/ O
04 O
( O
H5N1 O
) O
origin O
, O
were O
recovered O
from O
the O
experimentally O
infected O
pigs O
. O

The O
replicative O
potential O
of O
virus O
clones O
1 O
and O
2 O
was O
further O
confirmed O
by O
using O
reassortant O
virus O
( O
rg O
- O
Ck O
- O
Sw O
/ O
PB2 O
) O
generated O
by O
reverse O
genetics O
. O

Interestingly O
, O
the O
PB2 O
gene O
of O
Ck O
/ O
Yamaguchi O
/ O
04 O
( O
H5N1 O
) O
did O
not O
restrict O
the O
replication O
of O
Sw O
/ O
Hokkaido O
/ O
81 O
( O
H1N1 O
) O
, O
as O
determined O
by O
using O
reassortant O
virus O
rg O
- O
Sw O
- O
Ck O
/ O
PB2 O
. O

The O
rg O
- O
Sw O
- O
Ck O
/ O
PB2 O
virus O
replicated O
to O
moderate O
levels O
and O
for O
a O
shorter O
duration O
than O
parental O
Sw O
/ O
Hokkaido O
/ O
81 O
( O
H1N1 O
) O
. O

These O
results O
indicate O
that O
the O
PB2 O
protein O
restricts O
the O
growth O
of O
Ck O
/ O
Yamaguchi O
/ O
04 O
( O
H5N1 O
) O
in O
pigs O
. O

Due O
to O
the O
high O
mortality O
associated O
with O
recent O
, O
widely O
circulating O
strains O
of O
H5N1 O
influenza O
virus O
in O
poultry O
, O
the O
recurring O
introduction O
of O
H5N1 O
viruses O
from O
birds O
to O
humans O
, O
and O
the O
difficulties O
in O
H5N1 O
eradication O
by O
elimination O
of O
affected O
flocks O
, O
an O
effective O
vaccine O
against O
HPAI B
( I
highly I
pathogenic I
avian I
influenza I
) I
is O
highly O
desirable O
. O

In O
a O
chicken O
model O
, O
vaccination O
with O
a O
single O
dose O
of O
a O
selected O
virus O
encoding O
the O
NS1 O
1 O
- O
99 O
protein O
completely O
protected O
chickens O
from O
lethal O
challenge O
with O
homologous O
HPAI O
virus O
A O
/ O
Viet O
Nam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
and O
provided O
a O
high O
level O
of O
protection O
from O
a O
heterologous O
virus O
, O
A O
/ O
egret O
/ O
Egypt O
/ O
01 O
/ O
06 O
( O
H5N1 O
) O
. O

Strong O
determinants O
of O
the O
host O
range O
of O
influenza O
A O
viruses O
have O
been O
identified O
on O
the O
polymerase O
complex O
formed O
by O
the O
PB1 O
, O
PB2 O
, O
and O
PA O
subunits O
and O
on O
the O
nucleoprotein B
( I
NP I
) I
. O

Avian O
influenza O
A O
virus O
A O
/ O
teal O
/ O
HK O
/ O
W312 O
/ O
97 O
( O
H6N1 O
) O
possesses O
seven O
gene O
segments O
that O
are O
highly O
homologous O
to O
those O
of O
highly O
pathogenic O
human O
influenza O
H5N1 O
viruses O
, O
suggesting O
that O
a O
W312 O
- O
like O
H6N1 O
virus O
might O
have O
been O
involved O
in O
the O
generation O
of O
the O
A O
/ O
HK O
/ O
97 O
H5N1 O
viruses O
. O

Each O
of O
the O
H6 O
vaccine O
strains O
is O
a O
6 O
: O
2 O
reassortant O
ca O
virus O
containing O
HA O
and O
NA O
gene O
segments O
from O
an O
H6 O
virus O
and O
the O
six O
internal O
gene O
segments O
from O
cold O
- O
adapted O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
( O
AA O
ca O
) O
, O
the O
master O
donor O
virus O
that O
is O
used O
to O
make O
live O
attenuated O
influenza O
virus O
FluMist O
( O
intranasal O
) O
vaccine O
. O

All O
three O
H6 O
vaccine O
candidates O
exhibited O
phenotypic O
properties O
of O
temperature B
sensitivity I
( I
ts I
) I
, O
ca O
, O
and O
attenuation B
( I
att I
) I
conferred O
by O
the O
internal O
gene O
segments O
from O
AA O
ca O
. O

Intranasal O
administration O
of O
a O
single O
dose O
of O
the O
three O
H6 O
ca O
vaccine O
viruses O
induced O
neutralizing O
antibodies O
in O
mice O
and O
ferrets O
and O
fully O
protected O
mice O
and O
ferrets O
from O
homologous O
wild B
- I
type I
( I
WT I
) I
virus O
challenge O
. O

The O
genetic O
basis O
for O
virulence O
and O
host O
switching O
in O
influenza B
A I
viruses I
( I
FLUAV I
) I
is O
largely O
unknown O
. O

Because O
the O
Hemagglutinin B
( I
HA I
) I
protein O
is O
a O
determinant O
of O
these O
properties O
, O
HA O
evolution O
was O
mapped O
in O
an O
experimental O
model O
of O
mouse O
lung O
adaptation O
. O

Variants O
of O
prototype O
A O
/ O
Hong O
Kong O
/ O
1 O
/ O
68 O
( O
H3N2 O
) O
( O
wild O
- O
type O
[ O
wt O
] O
HK O
) O
human O
virus O
were O
selected O
in O
both O
longitudinal O
and O
parallel O
studies O
of O
lung O
adaptation O
. O

The O
adaptive O
mutations O
demonstrated O
multiple O
instances O
of O
convergent O
evolution O
involving O
four O
amino O
acid O
positions O
( O
162 O
, O
210 O
, O
and O
218 O
in O
HA1 O
and O
154 O
in O
HA2 O
) O
. O

To O
elucidate O
the O
mechanism O
of O
H5N1 O
pathogenesis O
, O
we O
prepared O
primary O
airway O
epithelial O
cells O
from O
alveolar O
tissues O
from O
1 O
- O
year O
- O
old O
pigs O
and O
measured O
the O
growth O
kinetics O
of O
three O
avian O
H5 O
influenza O
viruses O
( O
A O
/ O
Crow O
/ O
Kyoto O
/ O
53 O
/ O
2004 O
[ O
H5N1 O
] O
, O
A O
/ O
Duck O
/ O
Hong O
Kong O
/ O
342 O
/ O
78 O
[ O
H5N2 O
] O
, O
and O
A O
/ O
Duck O
/ O
Hong O
Kong O
/ O
820 O
/ O
80 O
[ O
H5N3 O
] O
) O
, O
the O
resultant O
cytopathicity O
, O
and O
possible O
associated O
mechanisms O
. O

H5N1 O
, O
but O
not O
the O
other O
H5 O
viruses O
, O
strongly O
induced O
cell O
death O
in O
porcine B
alveolar I
epithelial I
cells I
( I
pAEpC I
) I
, O
although O
all O
three O
viruses O
induced O
similar O
degrees O
of O
cytopathicity O
in O
chicken O
embryonic O
fibroblasts O
. O

We O
identified O
three O
clusters O
of O
differentially O
expressed O
innate O
immune O
response O
genes O
in O
lungs O
from O
H5N1 O
( O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
) O
influenza O
virus O
- O
infected O
ferrets O
by O
oligonucleotide O
microarray O
analysis O
. O

Here O
, O
we O
describe O
the O
pathogenicity O
of O
dominant O
clades O
( O
clades O
1 O
and O
2 O
) O
of O
H5N1 O
influenza O
A O
viruses O
circulating O
in O
birds O
in O
Asia O
. O

We O
also O
demonstrate O
the O
efficacy O
, O
cross O
- O
protectiveness O
, O
and O
immunogenicity O
of O
three O
different O
inactivated O
oil O
emulsion O
whole O
- O
virus O
H5 O
influenza O
vaccines O
( O
derived O
by O
implementing O
reverse O
genetics O
) O
to O
the O
viruses O
in O
domestic O
ducks O
. O

A O
single O
dose O
of O
the O
vaccines O
containing O
1 O
mu O
g O
of O
hemagglutinin O
protein O
provides O
complete O
protection O
against O
a O
lethal O
A O
/ O
Duck O
/ O
Laos O
/ O
25 O
/ O
06 O
( O
H5N1 O
) O
influenza O
virus O
challenge O
, O
with O
no O
evidence O
of O
morbidity O
, O
mortality O
, O
or O
shedding O
of O
the O
challenge O
virus O
. O

Interestingly O
, O
the O
vaccines O
induce O
low O
or O
undetectable O
titers O
of O
hemagglutination B
inhibition I
( I
HI I
) I
, O
cross O
- O
HI O
, O
and O
/ O
or O
virus O
neutralization O
antibodies O
. O

The O
Asn631 O
polymorphism O
of O
the O
chicken O
Mx O
protein O
found O
in O
the O
Shamo B
( I
SHK I
) I
chicken O
line O
was O
previously O
reported O
to O
be O
crucial O
for O
the O
antiviral O
activity O
of O
this O
highly O
polymorphic O
chicken O
gene O
. O

Unexpectedly O
, O
we O
found O
that O
the O
Asn631 O
genotype O
had O
no O
impact O
on O
multicycle O
replication O
of O
influenza O
virus O
( O
A O
/ O
WSN O
/ O
33 O
[ O
H1N1 O
] O
) O
in O
primary O
chicken O
embryo O
fibroblast O
lines O
. O

Furthermore O
, O
expression O
of O
the O
Shamo B
( I
SHK I
) I
chicken O
Mx O
protein O
in O
transfected O
293T O
cells O
did O
not O
inhibit O
viral O
gene O
expression O
( O
A O
/ O
PR O
/ O
8 O
/ O
34 O
[ O
H1N1 O
] O
, O
A O
/ O
Duck O
/ O
England O
/ O
62 O
[ O
H4N6 O
] O
, O
and O
A O
/ O
Duck O
/ O
Singapore O
/ O
97 O
[ O
H5N3 O
] O
) O
. O

Lastly O
, O
in O
minireplicon O
systems O
( O
A O
/ O
PR O
/ O
8 O
/ O
34 O
and O
A O
/ O
Turkey O
/ O
England O
/ O
50 O
- O
92 O
/ O
91 O
[ O
H5N1 O
] O
) O
, O
which O
were O
highly O
sensitive O
to O
inhibition O
by O
the O
murine O
Mx1 O
and O
human O
MxA O
proteins O
, O
respectively O
, O
Shamo O
chicken O
Mx O
also O
proved O
ineffective O
in O
the O
context O
of O
avian O
as O
well O
as O
mammalian O
cell O
backgrounds O
. O

Here O
, O
we O
systematically O
analyze O
various O
forms O
of O
recombinant O
Hemagglutinin B
( I
HA I
) I
protein O
for O
their O
potential O
efficacy O
as O
vaccines O
. O

After O
infection O
with O
seasonal O
influenza O
A O
viruses O
of O
the O
H3N2 O
and O
H1N1 O
subtypes O
, O
individuals O
develop O
virus O
- O
specific O
cytotoxic O
T O
- O
lymphocyte O
responses O
, O
which O
are O
mainly O
directed O
against O
the O
relatively O
conserved O
internal O
proteins O
of O
the O
virus O
, O
like O
the O
nucleoprotein B
( I
NP I
) I
. O

Virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
are O
known O
to O
contribute O
to O
protective O
immunity O
against O
infection O
, O
but O
knowledge O
about O
the O
extent O
of O
cross O
- O
reactivity O
with O
avian O
H5N1 O
influenza O
viruses O
is O
sparse O
. O

The O
virulence O
determinants O
for O
highly O
pathogenic O
avian B
influenza I
viruses I
( I
AIVs I
) I
are O
considered O
multigenic O
, O
although O
the O
best O
characterized O
virulence O
factor O
is O
the O
Hemagglutinin B
( I
HA I
) I
cleavage O
site O
. O

The O
10 O
progenitor O
viruses O
were O
genotype O
Z O
and O
shared O
high O
similarity O
( O
> O
= O
99 O
% O
) O
with O
their O
corresponding O
descendant O
viruses O
in O
most O
gene O
segments O
. O

Previously O
, O
we O
and O
others O
demonstrated O
that O
deletions O
of O
the O
M2 O
cytoplasmic O
tail O
caused O
a O
growth O
defect O
in O
A O
/ O
WSN O
/ O
33 O
( O
HIN1 O
) O
influenza O
A O
virus O
in O
vitro O
( O
K O
. O

First O
we O
generated O
a O
series O
of O
highly O
pathogenic O
H5N1 O
( O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
[ O
VN1203 O
] O
) O
M2 O
cytoplasmic O
tail O
deletion O
mutants O
and O
examined O
their O
growth O
properties O
in O
vitro O
and O
in O
vivo O
. O

We O
found O
that O
one O
mutant O
, O
which O
contains O
an O
11 O
- O
amino O
- O
acid O
deletion O
from O
the O
C O
terminus O
( O
M2del11 O
virus O
) O
, O
grew O
as O
well O
as O
the O
wild O
- O
type O
virus O
but O
replicated O
in O
mice O
less O
efficiently O
. O

We O
then O
generated O
a O
recombinant O
VN1203M2del11 O
virus O
whose O
Hemagglutinin B
( I
HA I
) I
gene O
was O
modified O
by O
replacing O
sequences O
at O
the O
cleavage O
site O
with O
those O
of O
an O
avirulent O
type O
of O
HA O
( O
M2de111 O
- O
HAavir O
virus O
) O
. O

This O
M2del11 O
- O
HAavir O
virus O
protected O
mice O
against O
challenge O
with O
lethal O
doses O
of O
homologous O
( O
VN1203 O
; O
clade O
1 O
) O
and O
antigenically O
distinct O
heterologous O
( O
A O
/ O
Indonesia O
/ O
7 O
/ O
2005 O
; O
clade O
2 O
) O
H5N1 O
viruses O
. O

We O
generated O
a O
recombinant O
Newcastle B
disease I
virus I
( I
NDV I
) I
possessing O
a O
two O
- O
segmented O
genome O
. O

A O
reporter O
gene O
encoding O
green B
fluorescent I
protein I
( I
GFP I
) I
was O
inserted O
into O
one O
segment O
, O
and O
a O
red O
fluorescent O
protein O
dsRed O
gene O
was O
inserted O
into O
the O
other O
segment O
in O
order O
to O
easily O
detect O
the O
replication O
and O
transcription O
of O
segments O
in O
infected O
cells O
. O

To O
verify O
the O
role O
of O
H5N1 O
- O
encoded O
NS1 O
in O
inducing O
apoptosis O
, O
the O
NS1 O
gene O
was O
cloned O
and O
expressed O
in O
human O
airway O
epithelial O
cells O
( O
NCI O
- O
H292 O
cells O
) O
. O

Western O
blot O
analyses O
also O
showed O
that O
there O
was O
prominent O
cleavage O
of O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
and O
activation O
of O
caspase O
- O
3 O
, O
caspase O
- O
7 O
, O
and O
caspase O
- O
8 O
during O
the O
NS1 O
- O
induced O
apoptosis O
. O

Interestingly O
, O
the O
ability O
of O
H5N1 O
NS1 O
protein O
to O
induce O
apoptosis O
was O
much O
enhanced O
in O
cells O
pretreated O
with O
Fas O
ligand O
( O
the O
time O
posttransfection O
required O
to O
reach O
> O
30 O
% O
apoptosis O
was O
reduced O
from O
24 O
to O
6 O
h O
) O
. O

Coxsackievirus B
A24 I
variant I
( I
CVA24v I
) I
has O
pandemic O
potential O
and O
is O
a O
major O
cause O
of O
acute O
hemorrhagic O
conjunctivitis O
, O
but O
its O
cellular O
receptor O
has O
hitherto O
been O
unknown O
. O

In O
this O
study O
, O
we O
explored O
the O
molecular O
basis O
determining O
the O
virulence O
of O
H5N1 O
avian O
influenza O
viruses O
in O
mammalian O
hosts O
by O
comparing O
two O
viruses O
, O
A O
/ O
Duck O
/ O
Guangxi O
/ O
12 O
/ O
03 O
( O
DK O
/ O
12 O
) O
and O
A O
/ O
Duck O
/ O
Guangxi O
/ O
27 O
/ O
03 O
( O
DK O
/ O
27 O
) O
, O
which O
are O
genetically O
similar O
but O
differ O
in O
their O
pathogenicities O
in O
mice O
. O

We O
found O
that O
a O
single O
- O
amino O
- O
acid O
substitution O
of O
serine O
for O
proline O
at O
position B
42 I
( I
P42S I
) I
in O
the O
NS1 O
protein O
dramatically O
increased O
the O
virulence O
of O
the O
DK O
/ O
12 O
virus O
in O
mice O
, O
whereas O
the O
substitution O
of O
proline O
for O
serine O
at O
the O
same O
position O
( O
S42P O
) O
completely O
attenuated O
the O
DK O
/ O
27 O
virus O
. O

We O
mapped O
the O
Hemagglutinin B
( I
HA I
) I
antigenic O
epitopes O
of O
a O
highly O
pathogenic O
H5N1 O
influenza O
virus O
on O
the O
three O
- O
dimensional O
RA O
structure O
by O
characterizing O
escape O
mutants O
of O
a O
recombinant O
virus O
containing O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
Delta O
HA O
and O
neuraminidase O
genes O
in O
the O
genetic O
background O
of O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
virus O
. O

The O
mutants O
were O
selected O
with O
a O
panel O
of O
eight O
anti O
- O
HA O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
seven O
to O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
virus O
and O
one O
to O
A O
/ O
Chicken O
/ O
Pennsylvania O
/ O
8125 O
/ O
83 O
( O
H5N2 O
) O
virus O
, O
and O
the O
mutants O
' O
RA O
genes O
were O
sequenced O
. O

The O
RA O
antigenic O
structure O
differs O
substantially O
between O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
virus O
and O
the O
low O
- O
pathogenic O
A O
/ O
Mallard O
/ O
Pennsylvania O
/ O
10218 O
/ O
84 O
( O
H5N2 O
) O
virus O
we O
previously O
characterized O
( O
N O
. O

Wild O
- O
bird O
surveillance O
in O
North O
America O
for O
avian B
influenza I
( I
AI I
) I
viruses O
with O
a O
goal O
of O
early O
identification O
of O
the O
Asian O
H5N1 O
highly O
pathogenic O
AI O
virus O
has O
identified O
at O
least O
six O
low O
- O
pathogenicity O
H5N1 O
AI O
viruses O
between O
2004 O
and O
2006 O
. O

The O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
from O
all O
6 O
H5N1 O
viruses O
and O
an O
additional O
38 O
North O
American O
wild O
- O
bird O
- O
origin O
H5 O
subtype O
and O
28 O
NI O
subtype O
viruses O
were O
sequenced O
and O
compared O
with O
sequences O
available O
in O
GenBank O
by O
phylogenetic O
analysis O
. O

It O
is O
therefore O
crucial O
to O
evaluate O
the O
possible O
threat O
posed O
by O
neuraminidase B
( I
NA I
) I
inhibitor O
- O
resistant O
influenza O
viruses O
with O
pandemic O
potential O
. O

Four O
NA O
mutations O
( O
E119G O
, O
H274Y O
, O
R292K O
, O
and O
N294S O
) O
that O
have O
been O
reported O
to O
confer O
resistance O
to O
NA O
inhibitors O
were O
each O
introduced O
into O
recombinant O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
VN1203 O
) O
H5N1 O
influenza O
virus O
. O

For O
comparison O
, O
the O
same O
mutations O
were O
introduced O
into O
recombinant O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
PR8 O
) O
H1N1 O
influenza O
virus O
. O

In O
both O
backgrounds O
, O
the O
H274Y O
and O
N294S O
mutations O
conferred O
resistance O
to O
oseltamivir O
carboxylate O
( O
50 O
% O
inhibitory O
concentration O
[ O
IC50 O
] O
increases O
, O
> O
250 O
- O
fold O
and O
> O
20 O
- O
fold O
, O
respectively O
) O
, O
and O
the O
N294S O
mutation O
reduced O
susceptibility O
to O
zanamivir O
( O
IC50 O
increase O
, O
> O
10 O
- O
fold O
) O
. O

The O
different O
enzyme O
kinetic O
parameters O
( O
V O
- O
max O
and O
K O
- O
m O
) O
of O
avian O
- O
like O
VN1203 O
NA O
and O
human O
- O
like O
PR8 O
NA O
suggest O
that O
resistance O
- O
associated O
NA O
mutations O
can O
cause O
different O
levels O
of O
functional O
loss O
in O
NA O
glycoproteins O
of O
the O
same O
subtype O
. O

The O
unparalleled O
spread O
of O
highly B
pathogenic I
avian I
influenza I
A I
( I
HPAI I
) I
H5N1 O
viruses O
has O
resulted O
in O
devastating O
outbreaks O
in O
domestic O
poultry O
and O
sporadic O
human O
infections O
with O
a O
high O
fatality O
rate O
. O

To O
better O
understand O
the O
mechanism O
( O
s O
) O
of O
H5N1 O
virus O
pathogenesis O
and O
host O
responses O
in O
humans O
, O
we O
utilized O
a O
polarized O
human O
bronchial O
epithelial O
cell O
model O
that O
expresses O
both O
avian O
alpha O
- O
2 O
, O
3 O
- O
and O
human O
alpha O
- O
2 O
, O
6 O
- O
linked O
sialic O
acid O
receptors O
on O
the O
apical O
surface O
and O
supports O
productive O
replication O
of O
both O
H5N1 O
and O
H3N2 O
viruses O
. O

Using O
this O
model O
, O
we O
compared O
the O
abilities O
of O
selected O
2004 O
HPAI O
H5N1 O
viruses O
isolated O
from O
humans O
and O
a O
recent O
human O
H3N2 O
virus O
to O
trigger O
the O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

H5N1 O
viruses O
elicited O
significantly O
less O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
nuclear O
translocation O
, O
as O
well O
as O
delayed O
and O
reduced O
production O
of O
IFN O
- O
beta O
compared O
with O
the O
H3N2 O
virus O
. O

Furthermore O
, O
phosphorylation O
of O
Stat2 O
and O
induction O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
such O
as O
MX1 O
, O
ISG15 O
, O
IRF7 O
, O
and O
retinoic O
acid O
- O
inducible O
gene O
1 O
, O
were O
substantially O
delayed O
and O
reduced O
in O
cells O
infected O
with O
H5N1 O
viruses O
. O

Low B
- I
virulence I
Newcastle I
disease I
viruses I
( I
loNDV I
) I
are O
frequently O
recovered O
from O
wild O
bird O
species O
, O
but O
little O
is O
known O
about O
their O
distribution O
, O
genetic O
diversity O
, O
or O
potential O
to O
cause O
disease O
in O
poultry O
. O

NDV O
isolates O
recovered O
from O
cloacal O
samples O
of O
apparently O
healthy O
waterfowl B
and I
shorebirds I
( I
WS I
) I
in O
the O
United O
States O
during O
1986 O
to O
2005 O
were O
examined O
for O
genomic O
diversity O
and O
their O
potential O
for O
virulence O
( O
n O
= O
249 O
) O
. O

live B
bird I
markets I
( I
LBMs I
) I
were O
analyzed O
and O
found O
to O
be O
genetically O
distinct O
from O
NDV O
used O
in O
live O
vaccines O
but O
related O
to O
WS O
- O
origin O
NDV O
. O

A O
random O
PCR O
- O
based O
molecular O
screening O
method O
was O
used O
to O
identify O
the O
infectious O
agent O
as O
avian O
paramyxovirus O
1 O
( O
APMV O
- O
1 O
; O
a O
group O
encompassing O
Newcastle O
disease O
virus O
) O
, O
which O
is O
a O
highly O
contagious O
poultry O
pathogen O
that O
has O
only O
rarely O
been O
found O
in O
human O
infections O
. O

Our O
previous O
study O
demonstrated O
that O
quail O
harbor O
increasingly O
diverse O
novel O
H9N2 O
reassortants O
, O
including O
both O
Chicken O
/ O
Beijing O
/ O
1 O
/ O
94 O
( O
Ck O
/ O
Bei O
- O
like O
) O
and O
Quail O
/ O
Hong O
Kong O
/ O
G1 O
/ O
97 O
( O
G1 O
- O
like O
) O
viruses O
. O

An O
H6N1 O
virus O
, O
A O
/ O
teal O
/ O
Hong O
Kong O
/ O
W312 O
/ O
97 O
( O
W312 O
) O
, O
was O
isolated O
during O
the O
bird O
flu O
incident O
in O
Hong O
Kong O
in O
1997 O
. O

Genetic O
analysis O
suggested O
that O
this O
virus O
might O
be O
the O
progenitor O
of O
the O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
97 O
( O
HK O
/ O
97 O
) O
H5N1 O
virus O
, O
as O
seven O
of O
eight O
gene O
segments O
of O
those O
viruses O
had O
a O
common O
source O
. O

Reassortment O
between O
a O
W312 O
- O
like O
H6N1 O
virus O
and O
an O
A O
/ O
quail O
/ O
Hong O
Kong O
/ O
G1 O
/ O
97 O
( O
HK O
/ O
97 O
) O
- O
like O
H9N2 O
virus O
simultaneously O
generated O
novel O
H6N2 O
subtype O
viruses O
that O
were O
persistent O
in O
poultry O
. O

On O
the O
basis O
of O
phylogenetic O
data O
, O
induction O
of O
broadly O
cross O
- O
neutralizing O
antibodies O
in O
mouse O
and O
ferret O
antisera O
, O
and O
their O
ability O
to O
replicate O
in O
mice O
, O
we O
have O
selected O
A O
/ O
Netherlands O
/ O
219 O
/ O
03 O
( O
subtype O
H7N7 O
) O
and O
A O
/ O
chicken O
/ O
BC O
/ O
CN O
- O
7 O
/ O
04 O
( O
subtype O
H7N3 O
) O
viruses O
for O
vaccine O
development O
. O

Mice O
were O
infected O
intranasally O
with O
H7 O
viruses O
of O
high O
and O
low O
pathogenicity O
isolated O
from O
The O
Netherlands O
in O
2003 O
( O
Netherlands O
/ O
03 O
) O
, O
the O
northeastern O
United O
States O
in O
2002 O
- O
2003 O
, O
and O
Canada O
in O
2004 O
and O
were O
monitored O
for O
morbidity O
, O
mortality O
, O
viral O
replication O
, O
and O
proinflammatory O
cytokine O
production O
in O
respiratory O
organs O
. O

Only O
A O
/ O
NL O
/ O
219 O
/ O
03 O
( O
NL O
/ O
219 O
) O
, O
an O
H7N7 O
virus O
isolated O
from O
a O
single O
fatal O
human O
case O
, O
was O
highly O
lethal O
for O
mice O
and O
caused O
severe O
disease O
in O
ferrets O
. O

Cells O
expressing O
the O
low O
pH O
- O
triggered O
class O
11 O
viral O
fusion O
protein O
Ell O
of O
Semliki B
Forest I
virus I
( I
SFV I
) I
were O
fused O
to O
target O
cells O
. O

This O
study O
describes O
a O
method O
for O
increasing O
the O
immunogenicity O
of O
influenza O
virus O
vaccines O
by O
exploiting O
the O
natural O
anti O
- O
Gal O
antibody O
to O
effectively O
target O
vaccines O
to O
antigen B
- I
presenting I
cells I
( I
APC I
) I
. O

This O
method O
is O
based O
on O
enzymatic O
engineering O
of O
carbohydrate O
chains O
on O
virus O
envelope O
hemagglutinin O
to O
carry O
the O
alpha O
- O
Gal O
epitope O
( O
Gall O
alpha O
1 O
- O
3Gal O
beta O
1 O
- O
4GlcNAc O
- O
R O
) O
. O

This O
epitope O
interacts O
with O
anti O
- O
Gal O
, O
the O
most O
abundant O
antibody O
in O
humans O
( O
1 O
% O
of O
immunoglobulins O
) O
. O

The O
efficacy O
of O
such O
an O
influenza O
vaccine O
was O
demonstrated O
in O
alpha O
1 O
, O
3galactosyltransferase O
( O
alpha O
1 O
, O
3GT O
) O
knockout O
mice O
, O
which O
produce O
anti O
- O
Gal O
, O
using O
the O
influenza O
virus O
strain O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
- O
H1N1 O
( O
PR8 O
) O
. O

Synthesis O
of O
alpha O
- O
Gal O
epitopes O
on O
carbohydrate O
chains O
of O
PR8 O
virus O
( O
PR8 O
( O
alpha O
gal O
) O
) O
was O
catalyzed O
by O
recombinant O
alpha O
1 O
, O
3GT O
, O
the O
glycosylation O
enzyme O
that O
synthesizes O
alpha O
- O
Gal O
epitopes O
in O
cells O
of O
nonprimate O
mammals O
. O

Mice O
immunized O
with O
PR8 O
( O
alpha O
gal O
) O
displayed O
much O
higher O
numbers O
of O
PR8 O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
( O
determined O
by O
intracellular O
cytokine O
staining O
and O
enzyme O
- O
linked O
immunospot O
assay O
) O
and O
produced O
anti O
- O
PR8 O
antibodies O
with O
much O
higher O
titers O
than O
mice O
immunized O
with O
PR8 O
lacking O
alpha O
- O
Gal O
epitopes O
. O

Mice O
immunized O
with O
PR8 O
( O
alpha O
gal O
) O
also O
displayed O
a O
much O
higher O
level O
of O
protection O
than O
PR8 O
immunized O
mice O
after O
being O
challenged O
with O
lethal O
doses O
of O
live O
PR8 O
virus O
. O

As O
recently O
shown O
, O
mutations O
in O
the O
polymerase O
genes O
causing O
increased O
polymerase O
activity O
in O
mammalian O
cells O
are O
responsible O
for O
the O
adaptation O
of O
the O
highly O
pathogenic O
avian O
influenza O
virus O
SC35 O
( O
H7N7 O
) O
to O
mice O
( O
G O
. O

Avian O
influenza O
viruses O
preferentially O
recognize O
sialosugar O
chains O
terminating O
in O
sialic O
acid O
- O
alpha O
2 O
, O
3 O
- O
galactose O
( O
SA O
alpha O
2 O
, O
3Gal O
) O
, O
whereas O
human O
influenza O
viruses O
preferentially O
recognize O
SA O
alpha O
2fiGal O
. O

A O
conversion O
to O
SA O
alpha O
2fiGal O
specificity O
is O
believed O
to O
be O
one O
of O
the O
changes O
required O
for O
the O
introduction O
of O
new O
Hemagglutinin B
( I
HA I
) I
subtypes O
to O
the O
human O
population O
, O
which O
can O
lead O
to O
pandemics O
. O

We O
investigated O
the O
binding O
of O
human B
parainfluenza I
virus I
types I
I I
and I
3 I
( I
hPIV1 I
and I
hPIV3 I
, I
respectively I
) I
to O
the O
glycan O
array O
of O
the O
Consortium O
for O
Functional O
Glycomics O
and O
binding O
and O
their O
release O
from O
erythrocytes O
under O
conditions O
where O
neuraminidase O
is O
inactive O
or O
active O
. O

hPIV1 O
and O
hPIV3 O
bind O
modifications O
of O
Neu5Ac O
alpha O
2 O
- O
3Gal O
beta O
1 O
- O
40GlcNAc O
, O
including O
the O
sialyl O
- O
Lewis O
( O
x O
) O
motif O
and O
structures O
containing O
6 O
- O
sulfogalactose O
. O

The O
highly B
pathogenic I
( I
HP I
) I
influenza O
viruses O
H5 O
and O
H7 O
are O
usually O
nonpathogenic O
in O
mallard O
ducks O
. O

To O
establish O
the O
molecular O
basis O
of O
this O
phenotype O
, O
we O
cloned O
the O
human O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
influenza O
virus O
isolate O
that O
is O
highly O
pathogenic O
in O
ferrets O
, O
mice O
, O
and O
mallards O
and O
found O
it O
to O
be O
a O
heterogeneous O
mixture O
. O

There O
were O
two O
differences O
in O
the O
Hemagglutinin B
( I
HA I
) I
gene O
( O
K52T O
and O
A544V O
) O
, O
one O
in O
the O
PA O
gene O
( O
T515A O
) O
, O
and O
two O
in O
the O
PB1 O
gene O
( O
K207R O
and O
Y436H O
) O
. O

The O
HA O
gene O
mutations O
and O
the O
PB1 O
gene O
K207R O
mutation O
did O
not O
alter O
the O
HP O
phenotype O
of O
the O
large O
- O
plaque O
virus O
, O
whereas O
constructs O
with O
the O
PA O
( O
T515A O
) O
and O
PB1 O
( O
Y436H O
) O
gene O
mutations O
were O
nonpathogenic O
in O
orally O
inoculated O
ducks O
. O

The O
PB1 O
( O
Y436H O
) O
construct O
was O
not O
efficiently O
transmitted O
in O
ducks O
, O
whereas O
the O
PA O
( O
T515A O
) O
construct O
replicated O
as O
well O
as O
the O
wild O
- O
type O
virus O
did O
and O
was O
transmitted O
efficiently O
. O

The O
effects O
of O
viral O
pathogenicity O
and O
receptor O
binding O
specificity O
( O
affinity O
to O
synthetic O
sialosaccharides O
with O
alpha O
2 O
, O
3 O
or O
alpha O
2 O
, O
6 O
linkages O
) O
on O
transmissibility O
were O
assessed O
. O

A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
and O
A O
/ O
Vietnani O
/ O
JP36 O
- O
2 O
/ O
05 O
viruses O
, O
which O
possess O
avian O
- O
like O
alpha O
2 O
, O
3 O
- O
linked O
sialic B
acid I
( I
SA I
) I
receptor O
specificity O
, O
caused O
neurological O
symptoms O
and O
death O
in O
ferrets O
inoculated O
with O
10 O
( O
3 O
) O
50 O
% O
tissue O
culture O
infectious O
doses O
. O

highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
viruses O
are O
now O
endemic O
in O
many O
Asian O
countries O
, O
resulting O
in O
repeated O
outbreaks O
in O
poultry O
and O
increased O
cases O
of O
human O
infection O
. O

The O
immediate O
precursor O
of O
these O
HPAI O
viruses O
is O
believed O
to O
be O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
Gs O
/ O
GD O
) O
- O
like O
H5N1 O
HPAI O
viruses O
first O
detected O
in O
Guangdong O
, O
China O
, O
in O
1996 O
. O

Here O
we O
characterize O
low B
- I
pathogenic I
avian I
influenza I
( I
LPAI I
) I
H5 O
subtype O
viruses O
isolated O
from O
poultry O
and O
migratory O
birds O
in O
southern O
China O
and O
Europe O
from O
the O
1970s O
to O
the O
2000s O
. O

In O
this O
study O
, O
we O
used O
HLA O
- O
DR O
transgenic O
mice O
to O
directly O
and O
comprehensively O
identify O
the O
specificities O
of O
Hemagglutinin B
( I
HA I
) I
- O
specific O
CD4 O
T O
cells O
restricted O
to O
a O
human O
class O
II O
molecule O
that O
were O
elicited O
following O
intranasal O
infection O
with O
a O
strain O
of O
influenza O
virus O
that O
has O
been O
endemic O
in O
U O
. O

While O
some O
avian O
H9N2 O
viruses O
have O
Glutamine B
( I
Q I
) I
at O
amino O
acid O
position O
226 O
of O
the O
Hemagglutinin B
( I
HA I
) I
receptor O
- O
binding O
site O
, O
an O
increasing O
number O
of O
isolates O
have O
leucine B
( I
L I
) I
at O
this O
position O
, O
which O
has O
been O
associated O
with O
the O
establishment O
of O
stable O
lineages O
of O
the O
H2 O
and O
H3 O
subtypes O
of O
viruses O
in O
humans O
. O

We O
show O
here O
that O
during O
the O
course O
of O
a O
single O
cycle O
of O
infection O
in O
human B
airway I
epithelial I
( I
HAE I
) I
cells O
cultured O
in O
vitro O
, O
the O
L O
- O
226 O
- O
containing O
H9N2 O
viruses O
displayed O
human O
virus O
- O
like O
cell O
tropisms O
( O
preferentially O
infecting O
nonciliated O
cells O
) O
different O
from O
the O
tropisms O
showed O
by O
Q O
- O
226 O
- O
containing O
H9N2 O
isolates O
( O
which O
infect O
both O
ciliated O
and O
nonciliated O
cells O
at O
ratios O
of O
1 O
: O
1 O
to O
3 O
: O
2 O
) O
or O
other O
waterfowl O
viruses O
( O
which O
preferentially O
infect O
ciliated O
cells O
) O
. O

Influenza O
virus B
- I
like I
particles I
( I
VLPs I
) I
have O
been O
suggested O
to O
be O
a O
promising O
vaccine O
approach O
. O

In O
this O
study O
, O
we O
developed O
VLPs O
containing O
influenza O
virus O
A O
/ O
PR8 O
/ O
34 O
( O
H1N1 O
) O
Hemagglutinin B
( I
HA I
) I
and O
matrix O
( O
M1 O
) O
proteins O
and O
investigated O
their O
immunogenicity O
, O
long O
- O
term O
cross O
- O
protective O
efficacy O
, O
and O
effects O
on O
lung O
proinflammatory O
cytokines O
in O
mice O
. O

Intranasal O
immunization O
with O
VLPs O
containing O
HA O
induced O
high O
serum O
and O
mucosal O
antibody O
titers O
and O
neutralizing O
activity O
against O
PR8 O
and O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
viruses O
. O

Many O
viruses O
, O
including O
human O
influenza O
A O
virus O
, O
have O
developed O
strategies O
for O
counteracting O
the O
host O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
initiates O
infection O
with O
attachment O
of O
the O
viral O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
to O
sialic O
acid O
- O
containing O
receptors O
, O
followed O
by O
fusion O
of O
viral O
and O
cell O
membranes O
, O
which O
is O
mediated O
by O
the O
fusion O
( O
F O
) O
protein O
. O

We O
found O
that O
inhibitors O
of O
cell O
surface O
thiol O
/ O
disulfide O
isomerase O
activity O
- O
5 O
' O
5 O
- O
dithio O
- O
bis O
( O
2 O
- O
nitrobenzoic O
acid O
) O
( O
DTNB O
) O
, O
bacitracin O
, O
and O
anti O
- O
protein O
disulfide O
isomerase O
antibody O
- O
inhibited O
cell O
- O
cell O
fusion O
and O
virus O
entry O
but O
had O
no O
effect O
on O
cell O
viability O
, O
glycoprotein O
surface O
expression O
, O
or O
HN O
protein O
attachment O
or O
neuraminidase O
activities O
. O

Using O
biotin O
maleimide O
( O
MPB O
) O
, O
a O
reagent O
that O
binds O
to O
free O
thiols O
, O
free O
thiols O
were O
detected O
on O
surface O
- O
expressed O
F O
protein O
, O
but O
not O
HN O
protein O
. O

To O
better O
understand O
the O
basis O
of O
pathogenesis O
of O
H5N1 O
viruses O
, O
we O
have O
investigated O
the O
role O
of O
proinflammatory O
cytokines O
in O
transgenic O
mice O
deficient O
in O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
macrophage B
inflammatory I
protein I
1 I
alpha I
( I
MIP I
- I
1 I
alpha I
) I
, O
IL B
- I
1 I
receptor I
( I
IL I
- I
1R I
) I
, O
or O
Tumor B
necrosis I
factor I
receptor I
1 I
( I
TNFR1 I
) I
by O
the O
use O
of O
two O
avian O
influenza O
A O
viruses O
isolated O
from O
humans O
, O
A O
/ O
Hong O
Kong O
/ O
483 O
/ O
97 O
( O
HK O
/ O
483 O
) O
and O
A O
/ O
Hong O
Kong O
/ O
486 O
/ O
97 O
( O
HK O
/ O
486 O
) O
, O
which O
exhibit O
high O
and O
low O
lethality O
in O
mice O
, O
respectively O
. O

Avian B
influenza I
virus I
( I
AIV I
) I
A O
/ O
turkey O
/ O
Oregon O
/ O
71 O
- O
SEPRL O
( O
TK O
/ O
OR O
/ O
71 O
- O
SEPRL O
) O
( O
H7N3 O
) O
encodes O
a O
full O
- O
length O
NS1 O
protein O
and O
is O
a O
weak O
inducer O
of O
interferon B
( I
IFN I
) I
. O

A O
variant O
, O
TK O
/ O
OR O
/ O
71 O
- O
delNS1 O
( O
H7N3 O
) O
, O
produces O
a O
truncated O
NS1 O
protein O
and O
is O
a O
strong O
inducer O
of O
IFN O
. O

The O
high O
titer O
of O
virus O
observed O
in O
kidney O
tissue O
( O
approximate O
to O
10 O
( O
9 O
) O
50 O
% O
embryo O
lethal O
doses O
/ O
g O
) O
from O
1 O
- O
day O
- O
old O
chickens O
infected O
intravenously O
by O
the O
weak O
IFN O
- O
inducing O
strain O
is O
attributed O
to O
the O
capacity O
of O
chicken O
kidney O
cells O
to O
activate O
the O
hemagglutinin O
fusion O
peptide O
along O
with O
their O
unresponsiveness O
to O
inducers O
of O
IFN O
as O
measured O
in O
vitro O
. O

The O
Hemagglutinin B
( I
HA I
) I
protein O
is O
the O
major O
target O
of O
protective O
antibody O
responses O
induced O
by O
viral O
infection O
and O
by O
vaccination O
with O
both O
inactivated O
and O
live O
- O
attenuated O
flu O
vaccines O
, O
but O
knowledge O
about O
the O
optimal O
designs O
of O
protective O
HA O
antigens O
from O
different O
flu O
serotypes O
is O
still O
limited O
. O

In O
this O
study O
, O
we O
have O
significantly O
improved O
the O
immunogenicity O
of O
RA O
- O
expressing O
DNA O
vaccines O
by O
using O
codon O
- O
optimized O
HA O
sequences O
for O
either O
an O
III O
serotype O
( O
A O
/ O
NewCaV20 O
/ O
99 O
) O
or O
an O
H3 O
serotype O
( O
A O
/ O
Panama O
/ O
2007 O
/ O
99 O
) O
human O
influenza O
A O
virus O
and O
then O
used O
these O
constructs O
as O
model O
antigens O
to O
identify O
the O
optimal O
RA O
antigen O
designs O
to O
elicit O
high O
- O
level O
protective O
antibody O
responses O
. O

Two O
forms O
of O
HA O
antigen O
, O
a O
wild O
- O
type O
, O
full O
- O
length O
HA O
and O
a O
secreted O
form O
with O
transmembrane B
( I
TM I
) I
domain O
- O
truncated O
RA O
, O
were O
produced O
. O

Interestingly O
, O
the O
abilities O
of O
H1 O
HA O
and O
H3 O
RA O
antigens O
to O
elicit O
hemagglutination B
inhibition I
( I
HI I
) I
and O
Neutralizing B
antibody I
( I
NAb I
) I
responses O
differ O
. O

For O
these O
purposes O
, O
we O
infected O
six O
pigtailed O
macaques O
( O
Macaca O
nemestrina O
) O
with O
reconstructed O
influenza O
A O
/ O
Texas O
/ O
36 O
/ O
91 O
virus O
and O
three O
control O
animals O
with O
a O
sham O
inoculate O
. O

Swine B
influenza I
viruses I
( I
SIV I
) I
naturally O
infect O
pigs O
and O
can O
be O
transmitted O
to O
humans O
. O

Previously O
, O
we O
have O
shown O
that O
an O
H3N2 O
SIN O
( O
A O
/ O
swine O
/ O
Texas O
/ O
4199 O
- O
2 O
/ O
98 O
[ O
TX98 O
] O
) O
containing O
a O
deleted O
NS1 O
gene O
expressing O
a O
truncated O
NS1 O
protein O
of O
126 O
amino O
acids O
, O
NS1 O
triangle O
126 O
, O
was O
attenuated O
in O
swine O
. O

In O
this O
study O
, O
4 O
- O
week O
- O
old O
pigs O
were O
vaccinated O
with O
the O
TX98 O
NS1 O
triangle O
126 O
modified B
live I
virus I
( I
MLV I
) I
. O

A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
GS O
/ O
GD O
/ O
1 O
/ O
96 O
) O
is O
a O
highly O
pathogenic O
virus O
for O
chickens O
, O
whereas O
A O
/ O
goose O
/ O
Guangdong O
/ O
2 O
/ O
96 O
( O
GS O
/ O
GD O
/ O
2 O
/ O
96 O
) O
is O
unable O
to O
replicate O
in O
chickens O
. O

We O
demonstrate O
that O
a O
recombinant O
virus O
expressing O
the O
GS O
/ O
GD O
/ O
1 O
/ O
96 O
NS1 O
protein O
with O
Ala149 O
is O
able O
to O
antagonize O
the O
induction O
of O
interferon O
protein O
levels O
in O
chicken B
embryo I
fibroblasts I
( I
CEFs I
) I
, O
but O
a O
recombinant O
virus O
carrying O
a O
Val149 O
substitution O
is O
not O
capable O
of O
the O
same O
effect O
. O

Important O
determinants O
for O
virus O
infection O
are O
epithelial O
cell O
receptors O
identified O
as O
glyeans O
terminated O
by O
an O
alpha O
2 O
, O
3 O
- O
linked O
sialic B
acid I
( I
SA I
) I
that O
preferentially O
bind O
avian O
strains O
and O
glycans O
terminated O
by O
an O
alpha O
2 O
, O
6 O
- O
linked O
SA O
that O
bind O
human O
strains O
. O

An O
H7N3 O
Avian B
influenza I
virus I
( I
AIV I
) I
was O
isolated O
from O
a O
Cinnamon O
Teal O
( O
Anas O
cyanoptera O
) O
( O
A O
/ O
CinnamonTeal O
/ O
Bolivia O
/ O
4537 O
/ O
01 O
) O
during O
a O
survey O
of O
wild O
waterfowl O
in O
Bolivia O
in O
2001 O
. O

We O
describe O
the O
characterization O
of O
influenza O
A O
virus O
infection O
of O
an O
established O
in O
vitro O
model O
of O
human O
pseudostratified O
mucociliary O
airway O
epithelium O
( O
HAE O
) O
. O

Since O
the O
introduction O
of O
H3N2 O
swine B
influenza I
viruses I
( I
SIVs I
) I
into O
U O
. O

In O
2004 O
, O
a O
new O
reassortant O
H3N1 O
virus O
( O
A O
/ O
Swine O
/ O
Minnesota O
/ O
00395 O
/ O
2004 O
) O
was O
identified O
from O
coughing O
pigs O
. O

Here O
, O
we O
examined O
coronavirus O
- O
cell O
fusion O
and O
entry O
employing O
the O
avian O
coronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
. O

Fusion O
was O
reduced O
, O
but O
still O
occurred O
, O
at O
lower O
temperatures O
( O
20 O
degrees O
C O
) O
. O

The O
recent O
emergence O
of O
highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAI I
) I
strains O
in O
poultry O
and O
their O
subsequent O
transmission O
to O
humans O
in O
Southeast O
Asia O
have O
raised O
concerns O
about O
the O
potential O
pandemic O
spread O
of O
lethal O
disease O
. O

In O
this O
paper O
we O
describe O
the O
development O
and O
testing O
of O
an O
adenovirus O
- O
based O
influenza O
A O
virus O
vaccine O
directed O
against O
the O
hemagglutinin B
( I
RA I
) I
protein O
of O
the O
A O
/ O
Vietnam O
/ O
1203 O
/ O
2004 O
( O
H5N1 O
) O
( O
VN O
/ O
1203 O
/ O
04 O
) O
strain O
isolated O
during O
the O
lethal O
human O
outbreak O
in O
Vietnam O
from O
2003 O
to O
2005 O
. O

A O
survey O
of O
avian O
influenza O
viruses O
was O
conducted O
on O
tree O
sparrows O
( O
Passer O
montanus O
) O
collected O
in O
China O
in O
2004 O
. O

The O
four O
tree O
sparrow O
viruses O
were O
different O
from O
the O
2003 O
tree O
sparrow O
strain O
( O
genotype O
Z O
) O
in O
Hong O
Kong O
. O

Reverse O
genetics O
techniques O
to O
rescue O
influenza O
viruses O
have O
thus O
far O
been O
based O
on O
the O
use O
of O
a O
human O
polymerase O
I O
( O
Poll O
) O
promoter O
to O
direct O
the O
synthesis O
of O
the O
eight O
viral O
RNAs O
. O

The O
surface B
( I
SU I
) I
and O
transmembrane B
( I
TM I
) I
subunits O
of O
Moloney B
murine I
leukemia I
virus I
( I
Mo I
- I
MLV I
) I
Env O
are O
disulfide O
linked O
. O

This O
arrested O
membrane O
fusion O
, O
but O
the O
activity O
could O
be O
rescued O
by O
cleaving O
the O
intersubunit O
disulfide O
bond O
with O
Dithiothreitol B
( I
DTT I
) I
. O

The O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
envelope I
glycoproteins I
( I
Envs I
) I
function O
as O
a O
trimer O
, O
mediating O
virus O
entry O
by O
promoting O
the O
fusion O
of O
the O
viral O
and O
target O
cell O
membranes O
. O

We O
studied O
viruses O
with O
mixed O
heterotrimers O
of O
wild O
- O
type O
and O
dominant O
- O
negative O
Envs O
to O
determine O
the O
number O
( O
T O
) O
of O
Env O
trimers O
required O
for O
HIV O
- O
1 O
entry O
. O

A O
similar O
approach O
was O
applied O
to O
investigate O
the O
entry O
stoichiometry O
of O
envelope O
glycoproteins O
from O
amphotropic O
murine O
leukemia O
virus O
( O
A O
- O
MLV O
) O
, O
avian B
sarcoma I
/ I
leukosis I
virus I
type I
A I
( I
ASLV I
- I
A I
) I
, O
and O
influenza O
A O
virus O
. O

However O
, O
clinical O
manifestations O
in O
the O
affected O
flock O
were O
consistent O
with O
avian O
influenza O
caused O
by O
a O
low O
- O
pathogenicity O
AIV O
and O
the O
representative O
virus O
( O
A O
/ O
chicken O
/ O
Texas O
/ O
298313 O
/ O
04 O
[ O
TX O
/ O
04 O
] O
) O
was O
not O
virulent O
for O
experimentally O
inoculated O
chickens O
. O

The O
Hemagglutinin B
( I
HA I
) I
gene O
of O
the O
TX O
/ O
04 O
isolate O
was O
similar O
in O
sequence O
to O
A O
/ O
chicken O
/ O
Texas O
/ O
167280 O
- O
4 O
/ O
02 O
( O
TX O
/ O
02 O
) O
, O
a O
low O
- O
pathogenicity O
AIV O
isolate O
recovered O
from O
chickens O
in O
Texas O
in O
2002 O
. O

The O
TX O
/ O
04 O
isolate O
was O
similar O
in O
sequence O
to O
TX O
/ O
02 O
isolate O
in O
several O
internal O
genes O
( O
NP O
, O
M O
, O
and O
NS O
) O
, O
but O
some O
genes O
( O
PA O
, O
PB1 O
, O
and O
PB2 O
) O
had O
sequence O
of O
a O
clearly O
different O
origin O
. O

Here O
, O
we O
show O
that O
the O
Hemagglutinin B
( I
HA I
) I
of O
the O
virus O
that O
caused O
the O
1918 O
influenza O
pandemic O
has O
strain O
- O
specific O
differences O
in O
its O
receptor O
binding O
specificity O
. O

The O
A O
/ O
South O
Carolina O
/ O
1 O
/ O
18 O
HA O
preferentially O
binds O
the O
alpha O
2 O
, O
6 O
sialic O
acid O
( O
human O
) O
cellular O
receptor O
, O
whereas O
the O
A O
/ O
New O
York O
/ O
1 O
/ O
18 O
HA O
, O
which O
differs O
by O
only O
one O
amino O
acid O
, O
binds O
both O
the O
a2 O
, O
6 O
and O
the O
a2 O
, O
3 O
sialic O
acid O
( O
avian O
) O
cellular O
receptors O
. O

N2 O
neuraminidase B
( I
NA I
) I
genes O
of O
the O
1957 O
and O
1968 O
pandemic O
influenza O
virus O
strains O
possessed O
avian O
- O
like O
low O
- O
pH O
stability O
of O
sialidase O
activity O
, O
unlike O
most O
epidemic O
strains O
. O

We O
generated O
four O
reverse O
- O
genetics O
viruses O
from O
a O
genetic O
background O
of O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
that O
included O
parental O
N2 O
NAs O
of O
1968 O
pandemic O
( O
H3N2 O
) O
and O
epidemic O
( O
H2N2 O
) O
strains O
or O
their O
counterpart O
N2 O
NAs O
in O
which O
the O
low O
- O
pH O
stability O
of O
the O
sialidase O
activity O
was O
changed O
by O
substitutions O
of O
one O
or O
two O
amino O
acid O
residues O
. O

We O
found O
that O
the O
transfectant O
viruses O
bearing O
low O
- O
pH O
- O
stable O
sialidase O
( O
WSN O
/ O
Stable O
- O
NAs O
) O
showed O
25 O
- O
to O
80 O
- O
times O
- O
greater O
ability O
to O
replicate O
in O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
than O
did O
the O
transfectant O
viruses O
bearing O
low O
- O
pH O
- O
unstable O
sialidase O
( O
WSN O
/ O
Unstable O
- O
NAs O
) O
. O

Inhibition O
of O
sialidase O
activity O
of O
WSN O
/ O
Stable O
- O
NAs O
on O
the O
endocytic O
pathway O
by O
pretreatment O
with O
4 O
- O
guanidino O
- O
2 O
, O
4 O
- O
dideoxy O
- O
N O
- O
acetylneuraminic O
acid O
( O
zanamivir O
) O
resulted O
in O
a O
significant O
decrease O
in O
progeny O
viruses O
. O

A O
/ O
duck O
/ O
Guangxi O
/ O
22 O
/ O
2001 O
( O
DKGX O
/ O
22 O
) O
is O
nonpathogenic O
in O
mice O
, O
whereas O
A O
/ O
duck O
/ O
Guangxi O
/ O
35 O
/ O
2001 O
( O
DKGX O
/ O
35 O
) O
is O
highly O
pathogenic O
. O

A O
single O
amino O
acid O
substitution O
( O
Asp O
to O
Asn O
) O
at O
position O
701 O
of O
PB2 O
enabled O
DKGX O
/ O
22 O
to O
infect O
and O
become O
lethal O
for O
mice O
. O

In O
2003 O
, O
H5N1 O
avian O
influenza O
virus O
infections O
were O
diagnosed O
in O
two O
Hong O
Kong O
residents O
who O
had O
visited O
the O
Fujian O
province O
in O
mainland O
China O
, O
affording O
us O
the O
opportunity O
to O
characterize O
one O
of O
the O
viral O
isolates O
, O
A O
/ O
Hong O
Kong O
/ O
213 O
/ O
03 O
( O
HK213 O
; O
H5N1 O
) O
. O

We O
previously O
demonstrated O
that O
in O
contrast O
to O
human O
influenza O
A O
virus O
subtypes O
including O
H1N1 O
or O
H3N2 O
, O
the O
H5N1 O
virus O
associated O
with O
the O
bird O
flu O
outbreak O
in O
Hong O
Kong O
in O
1997 O
( O
H5N1 O
/ O
97 O
) O
hyperinduces O
proinflammatory O
cytokines O
, O
including O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
in O
primary O
human O
macrophages O
in O
vitro O
. O

However O
, O
we O
demonstrated O
that O
unlike O
H1N1 O
virus O
, O
H5N1 O
/ O
97 O
strongly O
activates O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
, O
including O
p38 O
MAPK O
and O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
. O

The O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
has O
three O
conserved O
cysteine O
residues O
at O
its O
C O
terminus O
serving O
as O
acylation O
sites O
. O

To O
analyze O
the O
structural O
and O
functional O
roles O
of O
acylation O
, O
we O
have O
generated O
by O
reverse O
genetics O
a O
series O
of O
mutants O
( O
Ac1 O
, O
Ac2 O
, O
and O
Ac3 O
) O
of O
fowl B
plague I
virus I
( I
FPV I
) I
containing O
HA O
in O
which O
the O
acylation O
sites O
at O
positions O
551 O
, O
559 O
, O
and O
562 O
, O
respectively O
, O
have O
been O
abolished O
. O

When O
the O
affinity O
to O
detergent B
- I
insoluble I
glycolipid I
( I
DIG I
) I
domains O
was O
analyzed O
by O
Triton O
X O
- O
100 O
treatment O
of O
infected O
cells O
and O
virions O
, O
solubilization O
of O
Ac2 O
and O
Ac3 O
HAs O
was O
markedly O
facilitated O
. O

Since O
1997 O
, O
outbreaks O
of O
highly B
pathogenic I
( I
HP I
) I
H5N1 O
and O
circulation O
of O
H9N2 O
viruses O
among O
domestic O
poultry O
in O
Asia O
have O
posed O
a O
threat O
to O
public O
health O
. O

To O
better O
understand O
the O
extent O
of O
transmission O
of O
avian B
influenza I
viruses I
( I
AIV I
) I
to O
humans O
in O
Asia O
, O
we O
conducted O
a O
cross O
- O
sectional O
virologic O
study O
in O
live B
bird I
markets I
( I
LBM I
) I
in O
Hanoi O
, O
Vietnam O
, O
in O
October O
2001 O
. O

Four O
influenza O
A O
viruses O
of O
the O
H4N6 O
( O
n O
= O
1 O
) O
, O
H5N2 O
( O
n O
= O
1 O
) O
, O
and O
H9N3 O
( O
n O
= O
2 O
) O
subtypes O
were O
isolated O
from O
healthy O
ducks O
for O
an O
isolation O
frequency O
of O
over O
30 O
% O
from O
this O
species O
. O

The O
Hemagglutinin B
( I
HA I
) I
genes O
of O
these O
H5N1 O
viruses O
possessed O
multiple O
basic O
amino O
acid O
motifs O
at O
the O
cleavage O
site O
, O
were O
HP O
for O
experimentally O
infected O
chickens O
, O
and O
were O
thus O
characterized O
as O
HP O
AIV O
. O

In O
wild O
aquatic O
birds O
and O
poultry O
around O
the O
world O
, O
influenza O
A O
viruses O
carrying O
15 O
antigenic O
subtypes O
of O
Hemagglutinin B
( I
HA I
) I
and O
9 O
antigenic O
subtypes O
of O
neuraminidase B
( I
NA I
) I
have O
been O
described O
. O

Here O
we O
describe O
a O
previously O
unidentified O
antigenic O
subtype O
of O
HA O
( O
1116 O
) O
, O
detected O
in O
viruses O
circulating O
in O
black O
- O
headed O
gulls O
in O
Sweden O
. O

Developmentally O
aged O
chicken O
embryo O
cells O
which O
hyperproduce O
interferon B
( I
IFN I
) I
when O
induced O
were O
used O
to O
quantify O
IFN O
production O
and O
its O
suppression O
by O
eight O
strains O
of O
type O
A O
influenza O
viruses O
( O
AM O
. O

The O
IFN O
- O
inducer O
moiety O
of O
AIV O
appears O
to O
preexist O
in O
, O
or O
be O
generated O
by O
, O
virions O
termed O
IFN O
- O
inducing O
particles O
( O
IFP O
) O
and O
was O
detectable O
under O
conditions O
in O
which O
a O
single O
molecule O
of O
double O
- O
stranded O
RNA O
introduced O
into O
a O
cell O
via O
endocytosis O
induced O
IFN O
, O
whereas O
single O
- O
stranded O
RNA O
did O
not O
. O

Some O
AIV O
strains O
suppressed O
IFN O
production O
, O
an O
activity O
that O
resided O
in O
a O
noninfectious O
virion O
termed O
an O
IFN O
induction B
- I
suppressing I
particle I
( I
ISP I
) I
. O

AIV O
is O
known O
to O
prevent O
IFN O
induction O
and O
/ O
or O
production O
by O
expressing O
NS1 O
from O
a O
small O
UV O
target O
( O
gene O
NS O
) O
. O

In O
this O
study O
, O
we O
investigated O
superinfection O
exclusion O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
positive O
- O
sense O
RNA O
pestivirus O
. O

The O
avian B
sarcoma I
/ I
leukosis I
virus I
( I
ASLV I
) I
is O
activated O
for O
fusion O
by O
a O
two O
- O
step O
mechanism O
. O

For O
ASLV B
subgroup I
A I
( I
ASLV I
- I
A I
) I
, O
association O
with O
its O
receptor O
( O
Tva O
) O
at O
neutral O
pH O
converts O
virions O
to O
a O
form O
that O
can O
bind O
target O
membranes O
and O
, O
in O
some O
assays O
, O
induce O
the O
lipid O
- O
mixing O
stage O
of O
fusion O
. O

ASLV B
- I
A I
env I
( I
EnvA I
) I
exists O
on O
the O
viral O
surface O
as O
a O
trimer O
of O
heterodimers O
consisting O
of O
receptor O
binding O
( O
SU O
- O
A O
) O
and O
fusion O
- O
mediating O
( O
TM O
- O
A O
) O
subunits O
. O

To O
begin O
to O
understand O
the O
effect O
of O
the O
binding O
of O
a O
soluble O
47 O
- O
residue O
domain O
of O
the O
receptor O
( O
sTva O
) O
on O
this O
coupling O
and O
the O
subsequent O
function O
of O
low O
pH O
, O
we O
prepared O
recombinant O
proteins O
representing O
full O
- O
length O
SU O
- O
A O
and O
a O
nested O
set O
of O
deletion O
mutant O
proteins O
. O

An O
unprecedented O
outbreak O
of O
H5N1 O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
has O
been O
reported O
for O
poultry O
in O
eight O
different O
Asian O
countries O
, O
including O
South O
Korea O
, O
since O
December O
2003 O
. O

A O
phylogenetic O
analysis O
of O
the O
eight O
viral O
genes O
showed O
that O
the O
H5N1 O
poultry O
isolates O
from O
South O
Korea O
were O
of O
avian O
origin O
and O
contained O
the O
hemagglutinin O
and O
neuraminidase O
genes O
of O
the O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
Gs O
/ O
Gd O
) O
lineage O
. O

The O
membrane O
fusion O
function O
of O
murine B
leukemia I
virus I
( I
MLV I
) I
is O
carried O
by O
the O
Env O
protein O
. O

A O
10 O
- O
kDa O
nonstructural O
transmembrane O
protein O
( O
p10 O
) O
encoded O
by O
a O
reovirus O
, O
Nelson O
Bay O
virus O
, O
has O
been O
shown O
to O
induce O
syncytium O
formation O
( O
34 O
) O
. O

Sequence O
analysis O
and O
structural O
studies O
identified O
p10 O
as O
a O
type O
I O
membrane O
protein O
with O
a O
central O
transmembrane O
domain O
, O
a O
cytoplasmic O
basic O
region O
, O
and O
an O
N O
- O
terminal O
hydrophobic B
domain I
( I
HD I
) I
that O
was O
hypothesized O
to O
function O
as O
a O
fusion O
peptide O
. O

We O
studied O
the O
pathogenicity O
of O
four O
human O
and O
nine O
avian O
H5N1 O
/ O
04 O
influenza O
viruses O
in O
ferrets O
( O
an O
excellent O
model O
for O
influenza O
studies O
) O
. O

The O
human O
isolate O
A O
/ O
Vietnam O
/ O
1203 O
/ O
04 O
( O
H5N1 O
) O
was O
the O
most O
pathogenic O
isolate O
; O
the O
severity O
of O
disease O
was O
associated O
with O
a O
broad O
tissue O
tropism O
and O
high O
virus O
titers O
in O
multiple O
organs O
, O
including O
the O
brain O
. O

The O
nucleoprotein B
( I
NP I
) I
gene O
of O
the O
1918 O
pandemic O
influenza O
A O
virus O
has O
been O
amplified O
and O
sequenced O
from O
archival O
material O
. O

Influenza O
virus O
neuraminidase B
( I
NA I
) I
plays O
an O
essential O
role O
in O
release O
and O
spread O
of O
progeny O
virions O
, O
following O
the O
intracellular O
viral O
replication O
cycle O
. O

Although O
it O
is O
established O
that O
the O
cleavage O
site O
and O
glycosylation O
patterns O
in O
the O
hemagglutinin B
( I
RA I
) I
play O
important O
roles O
in O
determining O
the O
pathogenicity O
of O
H5 O
avian O
influenza O
viruses O
, O
some O
viruses O
exist O
that O
are O
not O
highly O
pathogenic O
despite O
possessing O
the O
known O
characteristics O
of O
high O
pathogenicity O
( O
i O
. O

Further O
investigation O
revealed O
that O
an O
additional O
glycosylation O
site O
within O
the O
neuraminidase B
( I
NA I
) I
protein O
globular O
head O
contributed O
to O
the O
high O
virulence O
of O
the O
H5N1 O
virus O
. O

A O
subsequent O
refolding O
event O
creates O
a O
trimer O
of O
hairpins O
( O
often O
termed O
a O
six O
- O
helix O
bundle O
) O
in O
which O
the O
previously O
well O
- O
separated O
transmembrane O
domain O
and O
fusion O
peptide O
( O
and O
their O
attached O
membranes O
) O
are O
brought O
together O
, O
thereby O
driving O
membrane O
fusion O
. O

In O
this O
study O
we O
analyzed O
conformational O
states O
of O
the O
transmembrane B
subunit I
( I
TM I
) I
, O
the O
fusion O
subunit O
, O
of O
the O
Env O
glycoprotein O
of O
the O
subtype O
A O
avian B
sarcoma I
and I
leukosis I
virus I
( I
ASLV I
- I
A I
) I
. O

Following O
interaction O
of O
virions O
with O
a O
soluble O
form O
of O
the O
ASLV O
- O
A O
receptor O
at O
37degreesC O
, O
the O
metastable O
form O
of O
EnvA O
TM O
( O
which O
migrates O
at O
37 O
kDa O
) O
transits O
to O
a O
70 O
- O
kDa O
and O
then O
to O
a O
150 O
- O
kDa O
species O
. O

Following O
subsequent O
exposure O
to O
a O
low O
pH O
( O
or O
an O
elevated O
temperature O
or O
the O
fusion O
promoting O
agent O
chlorpromazine O
) O
, O
an O
additional O
set O
of O
bands O
at O
> O
150 O
kDa O
, O
and O
then O
a O
final O
band O
at O
100 O
kDa O
, O
forms O
. O

Both O
an O
EnvA O
C O
- O
helix O
peptide O
( O
which O
inhibits O
virus O
fusion O
and O
infectivity O
) O
and O
the O
fusion O
- O
inhibitory O
agent O
lysophosphatidylcholine O
inhibit O
the O
formation O
of O
the O
> O
150 O
- O
and O
100 O
- O
kDa O
bands O
. O

In O
addition O
to O
resolving O
fusion O
- O
relevant O
conformational O
intermediates O
of O
EnvA O
TM O
, O
our O
data O
are O
compatible O
with O
a O
model O
in O
which O
the O
EnvA O
protein O
is O
activated O
by O
its O
receptor O
( O
at O
neutral O
pH O
and O
a O
temperature O
greater O
than O
or O
equal O
to O
room O
temperature O
) O
to O
form O
prehairpin O
conformations O
of O
EnvA O
TM O
, O
and O
in O
which O
subsequent O
exposure O
to O
a O
low O
pH O
is O
required O
to O
stabilize O
the O
final O
six O
- O
helix O
bundle O
, O
which O
drives O
a O
later O
stage O
of O
fusion O
. O

An O
outbreak O
of O
avian B
influenza I
( I
AI I
) I
caused O
by O
a O
low O
- O
pathogenic O
H5N2 O
type O
A O
influenza O
virus O
began O
in O
Mexico O
in O
1993 O
and O
several O
highly O
pathogenic O
strains O
of O
the O
virus O
emerged O
in O
1994 O
- O
1995 O
. O

Antigenic O
and O
phylogenetic O
analysis O
of O
Hemagglutinin B
( I
HA I
) I
showed O
that O
all O
of O
the O
19 O
isolates O
found O
except O
one O
belonged O
to O
the O
lineage O
represented O
by O
A O
/ O
Duck O
/ O
Hong O
Kong O
/ O
Y280 O
/ O
97 O
( O
H9N2 O
) O
. O

The O
exception O
was O
A O
/ O
Guinea O
fowl O
/ O
NT184 O
/ O
03 O
( O
H9N2 O
) O
, O
whose O
HA O
is O
most O
closely O
related O
to O
that O
of O
the O
human O
isolate O
A O
/ O
Guangzhou O
/ O
333 O
/ O
99 O
( O
H9N2 O
) O
, O
a O
virus O
belonging O
to O
the O
A O
/ O
Chicken O
/ O
Beijing O
/ O
1 O
/ O
94 O
- O
like O
( O
H9N2 O
) O
lineage O
. O

The O
majority O
of O
the O
viruses O
had O
nonstructural O
( O
and O
HA O
) O
genes O
derived O
from O
the O
A O
/ O
Duck O
/ O
Hong O
Kong O
/ O
Y280 O
/ O
97 O
- O
like O
virus O
lineage O
but O
had O
other O
genes O
of O
mixed O
avian O
virus O
origin O
, O
including O
genes O
similar O
to O
those O
of O
H5N1 O
viruses O
isolated O
in O
2001 O
. O

Therefore O
, O
we O
investigated O
the O
ecology O
and O
emergence O
of O
influenza O
viruses O
by O
conducting O
phylogenetic O
analysis O
of O
70 O
matrix B
( I
M I
) I
genes O
of O
influenza O
viruses O
isolated O
from O
shorebirds O
and O
gulls O
in O
the O
Delaware O
Bay O
region O
and O
from O
ducks O
in O
Alberta O
, O
Canada O
, O
during O
> O
18 O
years O
of O
surveillance O
. O

Binding O
of O
avian B
sarcoma I
and I
leukosis I
virus I
( I
ASLV I
) I
to O
its O
cognate O
receptor O
on O
the O
cell O
surface O
causes O
conformational O
changes O
in O
its O
envelope B
protein I
( I
Env I
) I
. O

To O
elucidate O
the O
role O
of O
low O
pH O
, O
we O
studied O
the O
association O
between O
ASLV B
subgroup I
B I
( I
ASLV I
- I
B I
) I
and O
liposomes O
and O
fusion O
between O
effector O
cells O
expressing O
Env O
from O
ASLV O
- O
A O
and O
ASLV O
- O
B O
and O
target O
cells O
expressing O
cognate O
receptors O
. O

We O
recently O
identified O
a O
packaging O
signal O
in O
the O
neuraminidase B
( I
NA I
) I
viral I
RNA I
( I
vRNA I
) I
segment O
of O
an O
influenza O
A O
virus O
, O
allowing O
us O
to O
produce O
a O
mutant O
virus O
[ O
GFP O
( O
NA O
) O
- O
Flu O
] O
that O
lacks O
most O
of O
the O
NA O
open O
reading O
frame O
but O
contains O
instead O
the O
gene O
encoding O
green B
fluorescent I
protein I
( I
GFP I
) I
. O

Compared O
to O
wild O
- O
type O
virus O
, O
GFP O
( O
NA O
) O
- O
Flu O
was O
highly O
attenuated O
in O
normal O
cultured O
cells O
but O
was O
able O
to O
grow O
to O
a O
titer O
of O
> O
10 O
( O
6 O
) O
PFU O
/ O
ml O
in O
a O
mutant O
cell O
line O
expressing O
reduced O
levels O
of O
sialic O
acid O
on O
the O
cell O
surface O
. O

We O
attribute O
the O
attenuated O
growth O
of O
GFP O
( O
NA O
) O
- O
Flu O
to O
virion O
aggregation O
at O
the O
surface O
of O
bronchiolar O
epithelia O
. O

In O
studies O
to O
test O
the O
potential O
of O
this O
mutant O
as O
a O
live O
attenuated O
influenza O
vaccine O
, O
all O
mice O
vaccinated O
with O
greater O
than O
or O
equal O
to O
10 O
( O
5 O
) O
PFU O
of O
GFP O
( O
NA O
) O
- O
Flu O
survived O
when O
challenged O
with O
lethal O
doses O
of O
the O
parent O
virus O
. O

The O
spring O
- O
loaded O
model O
stipulates O
that O
influenza O
virus O
infection O
is O
coupled O
to O
the O
transition O
of O
the O
virus O
Hemagglutinin B
( I
HA I
) I
from O
a O
metastable O
conformation O
to O
a O
highly O
stable O
conformation O
at O
low O
pH O
. O

As O
a O
test O
of O
this O
hypothesis O
, O
the O
requirements O
for O
avian B
leukosis I
virus I
A I
( I
ALV I
- I
A I
) I
infection O
were O
examined O
. O

Using O
a O
recently O
developed O
small O
- O
animal O
model O
, O
we O
investigated O
the O
mechanisms O
by O
which O
astrovirus O
induces O
diarrhea O
and O
the O
role O
of O
both O
the O
adaptive O
and O
innate O
immune O
responses O
to O
turkey B
astrovirus I
type I
- I
2 I
( I
TAstV I
- I
2 I
) I
infection O
. O

Astrovirus O
- O
infected O
animals O
were O
analyzed O
for O
changes O
in O
total O
lymphocyte O
populations O
, O
alterations O
in O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
ratios O
, O
production O
of O
virus O
- O
specific O
antibodies B
( I
Abs I
) I
, O
and O
macrophage O
activation O
. O

There O
were O
no O
changes O
in O
the O
numbers O
of O
circulating O
or O
splenic O
lymphocytes O
or O
in O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
ratios O
compared O
to O
controls O
. O

However O
, O
adherent O
spleen O
cells O
from O
infected O
animals O
produced O
more O
nitric B
oxide I
( I
NO I
) I
in O
response O
to O
ex O
vivo O
stimulation O
with O
lipopolysaccharide O
. O

The O
binding O
specificities O
of O
a O
panel O
of O
avian O
influenza O
virus O
subtype O
H5 O
hemagglutinin B
( I
RA I
) I
proteins O
bearing O
mutations O
at O
key O
residues O
in O
the O
receptor O
binding O
site O
were O
investigated O
. O

An O
additional O
structural O
protein O
, O
VP4 O
, O
is O
present O
in O
avian B
polyomavirus I
( I
APV I
) I
particles O
. O

As O
it O
had O
been O
reported O
that O
expression O
of O
APV O
VP1 O
in O
insect O
cells O
did O
not O
result O
in O
the O
formation O
of O
virus B
- I
like I
particles I
( I
VLP I
) I
, O
the O
prerequisites O
for O
particle O
formation O
were O
analyzed O
. O

To O
this O
end O
, O
recombinant O
influenza O
viruses O
were O
created O
to O
( O
co O
) O
express O
the O
structural O
proteins O
of O
APV O
in O
chicken O
embryo O
cells O
, O
permissive O
for O
APV O
replication O
. O

VP1 O
expressed O
individually O
or O
coexpressed O
with O
VP4 O
did O
not O
result O
in O
VLP O
formation O
; O
both O
proteins O
( O
co O
) O
localized O
in O
the O
cytoplasm O
. O

These O
results O
support O
a O
model O
of O
APV O
capsid O
assembly O
in O
which O
complexes O
of O
the O
structural O
proteins O
VP1 O
, O
VP3 O
( O
or O
VP2 O
) O
, O
and O
VP4 O
, O
formed O
within O
the O
cytoplasm O
, O
are O
transported O
to O
the O
nucleus O
using O
the O
nuclear O
localization O
signal O
of O
VP3 O
( O
or O
VP2 O
) O
; O
there O
, O
capsid O
formation O
is O
induced O
by O
the O
nuclear O
environment O
. O

The O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
of O
H7 O
Avian B
influenza I
virus I
( I
AIV I
) I
isolated O
between O
1994 O
and O
2002 O
from O
live B
- I
bird I
markets I
( I
LBMs I
) I
in O
the O
northeastern O
United O
States O
and O
from O
three O
outbreaks O
in O
commercial O
poultry O
have O
been O
characterized O
. O

It O
has O
been O
demonstrated O
that O
the O
V O
protein O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
functions O
as O
an O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
antagonist O
( O
M O
. O

In O
order O
to O
study O
V O
functions O
in O
vivo O
, O
recombinant B
NDV I
( I
rNDV I
) I
mutants O
, O
defective O
in O
the O
expression O
of O
the O
V O
protein O
, O
were O
generated O
. O

These O
rNDV O
mutants O
grow O
poorly O
in O
both O
embryonated O
chicken O
eggs O
and O
chicken B
embryo I
fibroblasts I
( I
CEFs I
) I
compared O
to O
the O
wild B
- I
type I
( I
WT I
) I
rNDV O
. O

However O
, O
insertion O
of O
the O
NS1 O
gene O
of O
influenza O
virus O
A O
/ O
PR8 O
/ O
34 O
into O
the O
NDV O
V O
( O
- O
) O
genome O
[ O
rNDV O
V O
( O
- O
) O
/ O
NS1 O
] O
restores O
impaired O
growth O
to O
wt O
levels O
in O
embryonated O
chicken O
eggs O
and O
CEFs O
. O

Interestingly O
, O
in O
human O
cells O
, O
the O
titer O
of O
wt O
rNDV O
is O
10 O
times O
lower O
than O
that O
of O
rNDV O
V O
( O
- O
) O
/ O
NS1 O
. O

Some O
of O
them O
contain O
gene O
segments O
that O
are O
closely O
related O
to O
those O
of O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
97 O
( O
H5N1 O
/ O
97 O
, O
H5N1 O
) O
or O
A O
/ O
Quail O
/ O
Hong O
Kong O
/ O
G1 O
/ O
97 O
( O
G1 O
- O
like O
, O
H9N2 O
) O
. O

We O
previously O
showed O
that O
the O
envelope B
glycoprotein I
( I
EnvA I
) I
of O
avian B
sarcoma I
/ I
leukosis I
virus I
subtype I
A I
( I
ASLV I
- I
A I
) I
binds O
to O
liposomes O
at O
neutral O
pH O
following O
incubation O
with O
its O
receptor O
, O
Tva O
, O
at O
greater O
than O
or O
equal O
to22degreesC O
. O

Lipid O
mixing O
of O
ASLV O
- O
A O
was O
inhibited O
by O
a O
peptide O
designed O
to O
prevent O
six O
- O
helix O
bundle O
formation O
in O
EnvA O
; O
the O
same O
peptide O
inhibits O
virus O
infection O
and O
EnvA O
- O
mediated O
cell O
- O
cell O
fusion O
( O
at O
both O
neutral O
and O
low O
pHs O
) O
. O

Bafilomycin O
and O
dominant O
- O
negative O
dynamin O
inhibited O
lipid O
mixing O
of O
Sindbis O
virus O
( O
which O
requires O
low O
pH O
for O
fusion O
) O
, O
but O
not O
of O
ASLV O
- O
A O
, O
with O
host O
cells O
. O

We O
studied O
the O
pathogenicity O
of O
five O
different O
genotypes O
( O
A O
to O
E O
) O
of O
highly O
pathogenic O
avian O
H5N1 O
viruses O
, O
which O
contained O
HA O
genes O
similar O
to O
those O
of O
the O
H5N1 O
virus O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
and O
five O
different O
combinations O
of O
internal O
genes O
, O
in O
a O
mouse O
model O
. O

One O
bird O
, O
captured O
in O
1917 O
, O
was O
infected O
with O
a O
virus O
of O
the O
same O
Hemagglutinin B
( I
HA I
) I
subtype O
as O
that O
of O
the O
1918 O
pandemic O
virus O
. O

The O
1917 O
HA O
is O
more O
closely O
related O
to O
that O
of O
modern O
avian O
viruses O
than O
it O
is O
to O
that O
of O
the O
pandemic O
virus O
, O
suggesting O
( O
i O
) O
that O
there O
was O
little O
drift O
in O
avian O
sequences O
over O
the O
past O
85 O
years O
and O
( O
ii O
) O
that O
the O
1918 O
pandemic O
virus O
did O
not O
acquire O
its O
HA O
directly O
from O
a O
bird O
. O

Phylogenetic O
analysis O
of O
the O
Hemagglutinin B
( I
HA I
) I
gene O
of O
A O
/ O
Duck O
/ O
Anyang O
/ O
AVL O
- O
1 O
/ O
01 O
showed O
that O
the O
virus O
clustered O
with O
the O
H5 O
Goose O
/ O
Guandong O
/ O
1 O
/ O
96 O
lineage O
and O
1997 O
Hong O
Kong O
human O
isolates O
and O
possessed O
an O
HA O
cleavage O
site O
sequence O
identical O
to O
these O
isolates O
. O

Ferrets O
infected O
intranasally O
with O
10 O
( O
7 O
) O
50 B
% I
egg I
infectious I
doses I
( I
EID50 I
) I
of O
either O
H5N1 O
virus O
exhibited O
severe O
lethargy O
, O
fever O
, O
weight O
loss O
, O
transient O
lymphopenia O
, O
and O
replication O
in O
the O
upper O
and O
lower O
respiratory O
tract O
, O
as O
well O
as O
multiple O
systemic O
organs O
, O
including O
the O
brain O
. O

In O
contrast O
, O
weight O
loss O
and O
severe O
lethargy O
were O
not O
noted O
in O
ferrets O
infected O
with O
10 O
( O
7 O
) O
EID50 O
of O
two O
recent O
human O
H3N2 O
viruses O
, O
although O
these O
viruses O
were O
also O
isolated O
from O
the O
brains O
, O
but O
not O
other O
extrapulmonary O
organs O
, O
of O
infected O
animals O
. O

Previous O
studies O
have O
associated O
influenza O
virus O
- O
induced O
expression O
of O
inflammatory O
cytokines O
, O
including O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
with O
influenza O
pathogenesis O
in O
the O
human O
respiratory O
tract O
and O
have O
suggested O
that O
alpha O
and O
beta O
interferons O
are O
the O
first O
cytokines O
recruited O
to O
counteract O
such O
infection O
. O

To O
analyze O
the O
compatibility O
of O
avian O
influenza O
A O
virus O
hemagglutinins B
( I
HAs I
) I
and O
human O
influenza O
A O
virus O
matrix B
( I
M I
) I
proteins O
M1 O
and O
M2 O
, O
we O
doubly O
infected O
Madin O
- O
Darby O
canine O
kidney O
cells O
with O
amantadine O
( O
1 O
- O
aminoadamantane O
hydrochloride O
) O
- O
resistant O
human O
viruses O
and O
amantadine O
- O
sensitive O
avian O
strains O
. O

Most O
of O
the O
avian O
HAs O
that O
we O
tested O
efficiently O
cooperated O
with O
the O
M O
gene O
products O
of O
the O
early O
human O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
virus O
; O
however O
, O
the O
avian O
HAs O
did O
not O
effectively O
cooperate O
with O
the O
most O
recently O
isolated O
human O
virus O
that O
we O
tested O
, O
A O
/ O
Nanchang O
/ O
933 O
/ O
95 O
( O
H3N2 O
) O
. O

Cooperation O
between O
the O
avian O
HAs O
and O
the O
M O
proteins O
of O
the O
human O
A O
/ O
Singapore O
/ O
57 O
( O
H2N2 O
) O
virus O
was O
moderate O
. O

Because O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
- O
like O
( O
H5N1 O
; O
Go O
/ O
Gd O
) O
viruses O
are O
the O
proposed O
donors O
of O
the O
hemagglutinin O
gene O
of O
the O
H5N1 O
virus O
, O
we O
investigated O
the O
continued O
circulation O
, O
host O
range O
, O
and O
transmissibility O
of O
Go O
/ O
Gd O
- O
like O
viruses O
in O
poultry O
. O

The O
high O
degree O
of O
susceptibility O
of O
quail O
to O
Go O
/ O
Gd O
( O
H5N1 O
) O
- O
like O
viruses O
and O
the O
continued O
circulation O
of O
H6N1 O
and O
H9N2 O
viruses O
in O
quail O
support O
the O
hypothesis O
that O
quail O
were O
the O
host O
of O
origin O
of O
the O
H5N1 O
/ O
97 O
virus O
. O

The O
ease O
of O
transmission O
of O
Go O
/ O
Gd O
( O
H5N1 O
) O
- O
like O
viruses O
to O
land O
- O
based O
birds O
, O
especially O
quail O
, O
supports O
the O
wisdom O
of O
separating O
aquatic O
and O
land O
- O
based O
poultry O
in O
the O
markets O
in O
Hong O
Kong O
and O
the O
need O
for O
continued O
surveillance O
in O
the O
field O
and O
live O
- O
bird O
markets O
in O
which O
different O
types O
of O
poultry O
are O
in O
contact O
with O
one O
another O
. O

The O
1957 O
human O
pandemic O
strain O
of O
influenza O
A O
virus O
contained O
an O
avian O
virus O
hemagglutinin B
( I
RA I
) I
and O
neuraminidase B
( I
NA I
) I
, O
both O
of O
which O
acquired O
specificity O
for O
the O
human O
receptor O
, O
N O
- O
acetylneuraminic O
acid O
linked O
to O
galactose O
of O
cellular O
glycoconjugates O
via O
an O
alpha2 O
- O
6 O
bond O
( O
NeuAc O
alpha2 O
- O
6Gal O
) O
. O

To O
test O
this O
possibility O
, O
we O
generated O
a O
panel O
of O
reassortant O
viruses O
that O
expressed O
the O
NA O
genes O
of O
human O
H2N2 O
viruses O
isolated O
from O
1957 O
to O
1968 O
with O
all O
other O
genes O
from O
the O
avian O
virus O
A O
/ O
duck O
/ O
Hong O
Kong O
/ O
278 O
/ O
78 O
( O
H9N2 O
) O
. O

Five O
of O
these O
six O
residues O
( O
excluding O
Asn400 O
) O
were O
required O
and O
sufficient O
for O
the O
full O
specific O
activity O
of O
the O
A O
/ O
Singapore O
/ O
1 O
/ O
57 O
NA O
. O

Prospective O
virological O
surveillance O
carried O
out O
between O
March O
1998 O
and O
June O
2000 O
in O
Hong O
Kong O
, O
Special O
Administrative O
Region O
, O
People O
' O
s O
Republic O
of O
China O
, O
on O
pigs O
imported O
from O
southeastern O
China O
, O
provides O
the O
first O
evidence O
of O
interspecies O
transmission O
of O
avian O
H9N2 O
viruses O
to O
pigs O
and O
documents O
their O
cocirculation O
with O
contemporary O
human O
H3N2 O
( O
A O
/ O
Sydney O
/ O
5 O
/ O
97 O
- O
like O
, O
Sydney97 O
- O
like O
) O
viruses O
. O

All O
gene O
segments O
of O
the O
porcine O
H9N2 O
viruses O
were O
closely O
related O
to O
viruses O
similar O
to O
chicken O
/ O
Beijing O
/ O
1 O
/ O
94 O
( O
H9N2 O
) O
, O
duck O
/ O
Hong O
KongIY280 O
/ O
97 O
( O
H9N2 O
) O
, O
and O
the O
descendants O
of O
the O
latter O
virus O
lineage O
. O

The O
Sydney97 O
- O
like O
( O
H3N2 O
) O
viruses O
isolated O
from O
pigs O
were O
related O
closely O
to O
contemporary O
human O
H3N2 O
viruses O
in O
all O
gene O
segments O
and O
had O
not O
undergone O
genetic O
reassortment O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
influence O
of O
low O
temperature O
( O
33 O
degreesC O
) O
on O
RNA O
replication O
of O
avian O
and O
human O
viruses O
in O
cultured O
cells O
. O

Two O
antigenically O
and O
genetically O
distinct O
groups O
of O
H9N2 O
viruses O
( O
G1 O
and O
G9 O
) O
are O
prevalent O
in O
China O
. O

In O
1997 O
and O
1998 O
, O
H9N2 O
influenza O
A O
viruses O
were O
isolated O
from O
the O
respiratory O
organs O
of O
Indian O
ring O
- O
necked O
parakeets O
( O
Psittacula O
Krameri O
manillensis O
) O
that O
had O
been O
imported O
from O
Pakistan O
to O
Japan O
. O

The O
two O
isolates O
were O
closely O
related O
to O
each O
other O
( O
> O
99 O
% O
as O
determined O
by O
nucleotide O
analysis O
of O
eight O
RNA O
segments O
) O
, O
indicating O
that O
H9N2 O
viruses O
of O
the O
same O
lineage O
were O
maintained O
in O
these O
birds O
for O
at O
least O
1 O
year O
. O

Adoptive O
transfer O
of O
T O
lymphocytes O
or O
CD8 O
( O
+ O
) O
T O
cells O
from O
inbred O
chickens O
( O
B O
- O
2 O
/ O
B O
- O
2 O
) O
infected O
with O
an O
H9N2 O
influenza O
virus O
to O
naive O
inbred O
chickens O
( O
B2 O
/ O
B2 O
) O
protected O
them O
from O
lethal O
H5N1 O
influenza O
virus O
. O

In O
vitro O
cytotoxicity O
assays O
showed O
that O
T O
lymphocytes O
or O
CD8 O
( O
+ O
) O
T O
cells O
from O
chickens O
infected O
with O
an O
H9N2 O
influenza O
virus O
recognized O
target O
cells O
infected O
with O
either O
an O
H5N1 O
or O
H9N2 O
influenza O
virus O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
hemagglutinin O
( O
IU O
) O
of O
H3 O
human O
influenza O
viruses O
does O
not O
support O
viral O
replication O
in O
duck O
intestine O
despite O
its O
avian O
origin O
. O

A O
Leu O
- O
to O
- O
Gin O
mutation O
at O
position O
226 O
and O
a O
Ser O
- O
to O
- O
Gly O
mutation O
at O
position O
228 O
in O
the O
HA O
of O
human O
A O
/ O
Udorn O
/ O
307 O
/ O
72 O
( O
H3N2 O
) O
permit O
a O
reassortant O
virus O
[ O
human O
Udorn O
HA O
, O
with O
all O
other O
genes O
from O
A O
/ O
mallard O
/ O
New O
York O
/ O
6750 O
/ O
78 O
( O
H2N2 O
) O
] O
to O
replicate O
in O
ducks O
. O

The O
results O
indicate O
that O
the O
recognition O
of O
a O
glycoconjugate O
moiety O
possessing O
N O
- O
glycolneuramic O
acid O
( O
NeuGc O
) O
linked O
to O
galactose O
by O
the O
alpha O
2 O
, O
3 O
linkage O
( O
NeuGc O
alpha O
2 O
, O
3Gal O
) O
is O
associated O
with O
viral O
replication O
in O
duck O
intestine O
. O

The O
tissue O
tropism O
and O
spread O
of O
infection O
of O
the O
highly O
pathogenic O
avian O
influenza O
virus O
A O
/ O
FPV O
/ O
Rostock O
/ O
34 O
( O
H7N1 O
) O
( O
FPV O
) O
were O
analyzed O
in O
11 O
- O
day O
- O
old O
chicken O
embryos O
, O
As O
shown O
by O
in O
situ O
hybridization O
, O
the O
virus O
caused O
generalized O
infection O
that O
was O
strictly O
confined O
to O
endothelial O
cells O
in O
all O
organs O
, O
Studies O
with O
reassortants O
of O
FPV O
and O
the O
apathogenic O
avian O
strain O
A O
/ O
chick O
/ O
Germany O
/ O
N O
/ O
49 O
( O
H10N7 O
) O
revealed O
that O
endotheliotropism O
was O
linked O
to O
FPV O
hemagglutinin O
( O
EW O
) O
. O

Two O
antigenically O
distinct O
reassortant O
viruses O
( O
H3N2 O
) O
were O
isolated O
from O
infected O
animals O
: O
a O
double O
- O
reassortant O
virus O
containing O
genes O
similar O
to O
those O
of O
human O
and O
swine O
viruses O
, O
and O
a O
triple O
- O
reassortant O
virus O
containing O
genes O
similar O
to O
those O
of O
human O
, O
swine O
, O
and O
avian O
influenza O
viruses O
( O
N O
. O

hemagglutination B
inhibition I
( I
HI I
) I
assays O
of O
4 O
, O
382 O
serum O
samples O
from O
swine O
in O
23 O
states O
indicated O
that O
28 O
. O

Analysis O
of O
the O
1999 O
swine O
H3N2 O
isolates O
showed O
that O
the O
internal O
gene O
complex O
of O
the O
triple O
- O
reassortant O
viruses O
was O
associated O
with O
three O
recent O
phylogenetically O
distinct O
human O
- O
like O
Hemagglutinin B
( I
HA I
) I
molecules O
. O

Interspecies O
transmission O
of O
influenza O
A O
viruses O
circulating O
in O
wild O
aquatic O
birds O
occasionally O
results O
in O
influenza O
outbreaks O
in O
mammals O
, O
including O
humans O
, O
To O
identify O
early O
changes O
in O
the O
receptor O
binding O
properties O
of O
the O
avian O
virus O
Hemagglutinin B
( I
HA I
) I
after O
interspecies O
transmission O
and O
to O
determine O
the O
amino O
acid O
substitutions O
responsible O
for O
these O
alterations O
, O
we O
studied O
the O
HAs O
of O
the O
initial O
isolates O
from O
the O
human O
pandemics O
of O
1957 O
( O
H2N2 O
) O
and O
1968 O
( O
H3N2 O
) O
, O
the O
European O
swine O
epizootic O
of O
1979 O
( O
H1N1 O
) O
, O
and O
the O
seal O
epizootic O
of O
1992 O
( O
H3N3 O
) O
, O
all O
of O
which O
were O
caused O
by O
the O
introduction O
of O
avian O
virus O
HAs O
into O
these O
species O
. O

The O
viruses O
were O
assayed O
for O
their O
ability O
to O
bind O
the O
synthetic O
sialylglycopolymers O
3 O
' O
SL O
- O
PAA O
and O
6 O
' O
SLN O
- O
PAA O
, O
which O
contained O
, O
respectively O
, O
3 O
' O
- O
sialyllactose O
( O
the O
receptor O
determinant O
preferentially O
recognized O
by O
avian O
influenza O
viruses O
) O
and O
6 O
' O
- O
sialyl O
( O
N O
- O
acetyllactosamine O
) O
( O
the O
receptor O
determinant O
for O
human O
viruses O
) O
, O
Avian O
and O
seat O
viruses O
bound O
6 O
' O
SLN O
- O
PAA O
very O
weakly O
, O
whereas O
the O
earliest O
available O
human O
and O
swine O
epidemic O
viruses O
bound O
this O
polymer O
with O
a O
higher O
affinity O
. O

We O
sequenced O
the O
gene O
segments O
of O
a O
heterogeneous O
group O
of O
viruses O
of O
seven O
different O
serotypes O
( O
H3N8 O
, O
H4N8 O
, O
H6N1 O
, O
H6N9 O
, O
H11N1 O
, O
H11N9 O
, O
and O
H11N8 O
) O
isolated O
from O
various O
bird O
species O
. O

An O
H6N1 O
virus O
isolated O
from O
teal O
( O
A O
/ O
teal O
/ O
Hong O
Kong O
/ O
W312 O
/ O
97 O
[ O
H6N1 O
] O
) O
showed O
very O
high O
( O
> O
98 O
% O
) O
nucleotide O
homology O
to O
the O
human O
influenza O
virus O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
97 O
( O
H5N1 O
) O
in O
the O
six O
internal O
genes O
. O

The O
deduced O
hemagglutinin O
amino O
acid O
sequence O
of O
the O
H6N1 O
virus O
was O
most O
similar O
to O
that O
of O
A O
/ O
shearwater O
/ O
Australia O
/ O
1 O
/ O
72 O
( O
H6N5 O
) O
. O

Current O
models O
of O
retroviral O
entry O
hypothesize O
that O
interactions O
between O
the O
host O
cell O
receptor O
( O
s O
) O
and O
viral O
envelope O
protein O
induce O
structural O
changes O
in O
the O
envelope O
protein O
that O
convert O
it O
to O
an O
active O
conformation O
, O
allowing O
it O
to O
mediate O
fusion O
with O
the O
membrane O
. O

Recent O
evidence O
supporting O
this O
hypothesis O
is O
the O
demonstration O
that O
Tva O
, O
the O
receptor O
for O
subgroup O
A O
avian B
sarcoma I
and I
leukosis I
virus I
( I
ASLV I
- I
A I
) I
, O
induces O
conformational O
changes O
in O
the O
viral O
envelope O
protein O
. O

To O
determine O
whether O
binding O
of O
the O
soluble B
Tva I
( I
sTva I
) I
receptor O
was O
sufficient O
to O
activate O
fully O
the O
fusogenic O
potential O
of O
the O
ASLV O
- O
A O
envelope O
protein O
, O
we O
have O
evaluated O
the O
ability O
of O
ASLV O
- O
A O
to O
infect O
receptor O
- O
deficient O
cell O
Lines O
in O
the O
presence O
of O
sTva O
. O

These O
samples O
, O
known O
collectively O
as O
A O
/ O
Environment O
/ O
Hong O
Kong O
/ O
437 O
/ O
99 O
( O
A O
/ O
Env O
/ O
HK O
/ O
437 O
/ O
99 O
) O
, O
contained O
four O
viral O
isolates O
, O
which O
were O
compared O
to O
the O
1997 O
H5N1 O
Hong O
Kong O
isolates O
. O

These O
isolates O
and O
the O
1997 O
H5N1 O
Hong O
Kong O
viruses O
encode O
common O
hemagglutinin O
( O
H5 O
) O
genes O
that O
have O
identical O
hemagglutinin O
cleavage O
sites O
. O

The O
A O
/ O
Env O
/ O
HK O
/ O
437 O
/ O
99 O
isolates O
were O
highly O
pathogenic O
in O
chickens O
but O
caused O
a O
longer O
mean O
death O
time O
and O
had O
altered O
cell O
tropism O
compared O
to O
A O
/ O
Hong O
Kong O
/ O
156 O
/ O
97 O
( O
A O
/ O
HK O
/ O
156 O
/ O
97 O
) O
. O

, O
Vaccine O
16 O
: O
472 O
- O
479 O
, O
1998 O
) O
showed O
that O
recombinant B
Marek I
' I
s I
disease I
virus I
type I
1 I
( I
rMDV1 I
) I
expressing O
the O
fusion O
( O
F O
) O
protein O
of O
Newcastle B
disease I
virus I
( I
NDV I
- I
F I
) I
under O
the O
control O
of O
the O
simian O
virus O
40 O
late O
promoter O
[ O
rMDV1 O
- O
US10L O
( O
F O
) O
] O
protected O
specific O
pathogen O
- O
free O
chickens O
from O
NDV O
challenge O
, O
but O
not O
commercial O
chickens O
with O
maternal O
antibodies O
against O
NDV O
and O
MDV1 O
. O

( O
i O
) O
We O
constructed O
rMDV1 O
expressing O
NDV O
- O
F O
under O
the O
control O
of O
the O
MDV1 O
glycoprotein B
B I
( I
gB I
) I
promoter O
[ O
rMDV1 O
- O
US10P O
( O
F O
) O
] O
. O

( O
ii O
) O
Much O
less O
NDV O
- O
F O
protein O
was O
expressed O
in O
cells O
infected O
with O
rMDV1 O
- O
US10P O
( O
F O
) O
than O
in O
those O
infected O
with O
rMDV1 O
- O
US10L O
( O
F O
) O
. O

( O
iii O
) O
The O
antibody O
response O
against O
NDV O
- O
F O
and O
MDV1 O
antigens O
of O
commercial O
chickens O
vaccinated O
with O
rMDV1 O
- O
US10P O
( O
F O
) O
was O
much O
stronger O
and O
faster O
than O
with O
rMDV1 O
- O
US10L O
( O
F O
) O
, O
and O
a O
high O
level O
of O
antibody O
against O
NDV O
- O
F O
persisted O
for O
over O
80 O
weeks O
postvaccination O
. O

( O
iv O
) O
rMDV1 O
- O
US10P O
( O
F O
) O
was O
readily O
reisolated O
from O
the O
vaccinated O
chickens O
, O
and O
the O
recovered O
viruses O
were O
found O
to O
express O
NDV O
- O
F O
. O

( O
v O
) O
Vaccination O
of O
commercial O
chickens O
having O
maternal O
antibodies O
to O
rMDV1 O
- O
US10P O
( O
F O
) O
completely O
protected O
them O
from O
NDV O
challenge O
. O

( O
vi O
) O
rMDV1 O
- O
US10P O
( O
F O
) O
offered O
the O
same O
degree O
of O
protection O
against O
very O
virulent O
MDV1 O
as O
the O
parental O
MDV1 O
and O
commercial O
vaccines O
. O

These O
results O
indicate O
that O
rMDV1 O
- O
US10P O
( O
F O
) O
is O
an O
effective O
and O
stable O
polyvalent O
vaccine O
against O
both O
Marek O
' O
s O
and O
Newcastle O
diseases O
even O
in O
the O
presence O
of O
maternal O
antibodies O
. O

Short O
hydrophobic O
regions O
referred O
to O
as O
fusion O
peptide O
domains O
( O
FPDs O
) O
at O
or O
near O
the O
amino O
terminus O
of O
the O
membrane O
- O
anchoring O
subunit O
of O
viral O
glycoproteins O
are O
believed O
to O
insert O
into O
the O
host O
membrane O
during O
the O
initial O
stage O
of O
enveloped O
viral O
entry O
. O

Avian B
sarcoma I
and I
leukosis I
viruses I
( I
ASLV I
) I
are O
unusual O
among O
retroviruses O
in O
that O
the O
region O
in O
the O
envelope B
glycoprotein I
( I
EnvA I
) I
proposed O
to O
be O
the O
FPD O
is O
internal O
and O
contains O
a O
centrally O
located O
proline O
residue O
. O

In O
1997 O
, O
an O
outbreak O
of O
virulent O
H5N1 O
avian O
influenza O
virus O
occurred O
in O
poultry O
in O
Hong O
Kong O
( O
HK O
) O
and O
was O
linked O
to O
a O
direct O
transmission O
to O
humans O
. O

One O
isolate O
, O
A O
/ O
tk O
/ O
England O
/ O
91 O
( O
H5N1 O
) O
, O
induced O
measurable O
disease O
, O
and O
all O
but O
one O
of O
the O
animals O
recovered O
. O

The O
most O
severe O
and O
widespread O
lesions O
were O
observed O
in O
the O
lungs O
of O
HK O
avian O
influenza O
virus O
- O
infected O
mice O
, O
while O
no O
lesions O
or O
only O
mild O
lesions O
were O
evident O
with O
A O
/ O
ck O
/ O
Scotland O
/ O
59 O
( O
H5N1 O
) O
and O
A O
/ O
ck O
/ O
Queretaro O
/ O
95 O
( O
H5N2 O
) O
, O
The O
A O
/ O
ck O
/ O
Italy O
/ O
97 O
( O
H5N2 O
) O
and O
the O
A O
/ O
tk O
/ O
England O
/ O
91 O
( O
H5N1 O
) O
viruses O
exhibited O
intermediate O
pathogenicity O
, O
producing O
mild O
to O
moderate O
respiratory O
tract O
lesions O
. O

The O
fusion O
peptide O
of O
the O
avian B
sarcoma I
/ I
leukosis I
virus I
( I
ASLV I
) I
envelope I
protein I
( I
Env I
) I
Is O
internal O
, O
near O
the O
N O
terminus O
of O
its O
transmembrane B
( I
TM I
) I
subunit O
. O

Robson O
- O
Garnier O
structure O
predictions O
of O
the O
ASLV O
fusion O
peptide O
and O
immediate O
surrounding O
sequences O
indicate O
a O
region O
of O
order O
( O
B O
- O
sheet O
) O
, O
a O
tight O
reverse O
rum O
containing O
the O
proline O
, O
and O
a O
second O
region O
of O
order O
( O
alpha O
- O
helix O
) O
. O

Similar O
motifs O
( O
order O
, O
turn O
or O
loop O
, O
order O
) O
are O
predicted O
for O
other O
internal O
fusion O
peptides O
, O
In O
this O
study O
, O
we O
made O
and O
analyzed O
12 O
Env O
proteins O
with O
substitutions O
for O
the O
central O
proline O
of O
the O
fusion O
peptide O
. O

( O
i O
) O
All O
mutant O
Envs O
form O
trimers O
, O
but O
when O
the O
bulky O
hydrophobic O
residues O
phenylalanine O
or O
leucine O
are O
substituted O
for O
proline O
, O
trimerization O
is O
weakened O
. O

( O
ii O
) O
Surprisingly O
, O
the O
proline O
is O
required O
for O
maximal O
processing O
of O
the O
Env O
precursor O
into O
its O
surface O
and O
TM O
subunits O
; O
the O
amount O
of O
processing O
correlates O
linearly O
with O
the O
propensity O
of O
the O
substituted O
residue O
to O
be O
found O
in O
a O
reverse O
turn O
, O
( O
iii O
) O
Nonetheless O
, O
proteolytically O
processed O
forms O
of O
all O
Envs O
are O
preferentially O
incorporated O
into O
pseudotyped O
virions O
. O

( O
iv O
) O
All O
Envs O
bind O
receptor O
with O
affinity O
greater O
than O
or O
equal O
to O
wild O
- O
type O
affinity O
: O
( O
v O
) O
Residues O
that O
support O
high O
infectivity O
cluster O
with O
proline O
at O
intermediate O
hydrophobicity O
. O

Infectivity O
is O
not O
supported O
by O
mutant O
Envs O
in O
which O
charged O
residues O
are O
substituted O
for O
proline O
, O
nor O
is O
it O
supported O
by O
: O
the O
trimerization O
- O
defective O
phenylalanine O
and O
leucine O
mutants O
, O
Our O
findings O
suggest O
that O
the O
central O
proline O
in O
the O
ASLV O
fusion O
peptide O
is O
important O
for O
the O
formation O
of O
the O
native O
( O
metastable O
) O
Env O
structure O
as O
well O
as O
for O
membrane O
interactions O
that O
lead O
to O
fusion O
. O

The O
nucleocapsid B
protein I
( I
NP I
) I
( O
56 O
kDa O
) O
of O
human O
influenza O
A O
viruses O
is O
cleaved O
in O
infected O
cells O
into O
a O
53 O
- O
kDa O
form O
. O

Likewise O
, O
influenza O
B O
virus O
NP O
( O
64 O
kDa O
) O
is O
cleaved O
into O
a O
55 O
- O
kDa O
protein O
with O
a O
62 O
- O
kDa O
intermediate O
( O
O O
, O
P O
, O
Zhirnov O
and O
A O
. O

The O
influenza O
virus O
neuraminidase B
( I
NA I
) I
is O
a O
tetrameric O
, O
virus O
surface O
glycoprotein O
possessing O
receptor O
- O
destroying O
activity O
. O

Because O
mutation O
of O
cysteine O
residues O
in O
other O
systems O
has O
resulted O
in O
temperature B
- I
sensitive I
( I
ts I
) I
proteins O
, O
we O
asked O
whether O
mutation O
of O
cysteine O
residues O
in O
the O
influenza O
virus O
NA O
would O
yield O
ts O
mutants O
. O

Ebola O
viruses O
contain O
a O
single O
glycoprotein B
( I
GP I
) I
spike O
, O
which O
functions O
as O
a O
receptor O
binding O
and O
membrane O
fusion O
protein O
. O

It O
contains O
a O
highly O
conserved O
hydrophobic O
region O
( O
amino O
acids O
524 O
to O
539 O
) O
located O
24 O
amino O
acids O
downstream O
of O
the O
N O
terminus O
of O
the O
Ebola O
virus O
GP2 O
. O

To O
test O
this O
hypothesis O
directly O
, O
we O
introduced O
conservative O
( O
alanine O
) O
and O
nonconservative O
( O
arginine O
) O
amino O
acid O
substitutions O
at O
eight O
positions O
in O
this O
region O
of O
the O
GP2 O
molecule O
. O

The O
effects O
of O
these O
mutations O
were O
deduced O
from O
the O
ability O
of O
the O
Ebola O
virus O
GP O
to O
complement O
the O
infectivity O
of O
a O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
lacking O
the O
receptor O
- O
binding O
G O
protein O
. O

Some O
mutations O
, O
such O
as O
Ile O
- O
to O
- O
Arg O
substitutions O
at O
positions O
532 O
( O
I532R O
) O
, O
F535R O
, O
G536A O
, O
and O
P537R O
, O
almost O
completely O
abolished O
the O
ability O
of O
the O
GP O
to O
support O
VSV O
infectivity O
without O
affecting O
the O
transport O
of O
GP O
to O
the O
cell O
surface O
and O
its O
incorporation O
into O
virions O
or O
the O
production O
of O
virus O
particles O
. O

Influenza O
A O
viruses O
possess O
two O
glycoprotein O
spikes O
on O
the O
virion O
surface O
: O
Hemagglutinin B
( I
HA I
) I
, O
which O
binds O
to O
oligosaccharides O
containing O
terminal O
sialic O
acid O
, O
and O
neuraminidase B
( I
NA I
) I
, O
which O
removes O
terminal O
sialic O
acid O
from O
oligosaccharides O
. O

We O
therefore O
investigated O
the O
substrate O
specificities O
of O
NA O
for O
linkages O
between O
N O
- O
acetyl O
sialic O
acid O
and O
galactose O
( O
NeuAc O
alpha O
2 O
- O
3Gal O
and O
NeuAc O
alpha O
2 O
- O
6Gal O
) O
and O
for O
different O
molecular O
species O
of O
sialic O
acids O
( O
N O
- O
acetyl O
and O
N O
- O
glycolyl O
sialic O
acids O
) O
in O
influenza O
A O
viruses O
isolated O
from O
human O
, O
avian O
, O
and O
pig O
hosts O
. O

Substrate O
specificity O
assays O
showed O
that O
all O
viruses O
had O
similar O
specificities O
for O
NeuAc O
alpha O
2 O
- O
3Gal O
, O
while O
the O
activities O
for O
NeuAc O
alpha O
2 O
- O
6Gal O
ranged O
from O
marginal O
, O
as O
represented O
by O
avian O
and O
early O
N2 O
human O
viruses O
, O
to O
high O
( O
although O
only O
one O
- O
third O
the O
activity O
for O
NeuAc O
alpha O
2 O
- O
3Gal O
) O
, O
as O
represented O
by O
swine O
and O
more O
recent O
N2 O
human O
viruses O
. O

Using O
site O
- O
specific O
mutagenesis O
, O
we O
identified O
in O
the O
earliest O
human O
virus O
with O
a O
detectable O
increase O
in O
NeuAc O
alpha O
2 O
- O
6Gal O
specificity O
a O
change O
at O
position O
275 O
( O
from O
isoleucine O
to O
valine O
) O
that O
enhanced O
the O
specificity O
for O
this O
substrate O
. O

A O
similar O
examination O
of O
N B
- I
glycolylneuraminic I
acid I
( I
NeuGc I
) I
specificity O
showed O
that O
avian O
viruses O
and O
most O
human O
viruses O
had O
low O
to O
moderate O
activity O
for O
this O
substrate O
, O
with O
the O
exception O
of O
most O
human O
viruses O
isolated O
between O
1967 O
and O
1969 O
, O
whose O
NeuGc O
specificity O
was O
as O
high O
as O
that O
of O
swine O
viruses O
. O

During O
1997 O
in O
Dong O
Kong O
, O
18 O
human O
cases O
of O
respiratory O
illness O
, O
including O
6 O
fatalities O
, O
were O
caused O
by O
highly O
pathogenic O
avian O
influenza O
A O
( O
H5N1 O
) O
viruses O
. O

The O
mouse O
model O
was O
also O
used O
to O
evaluate O
a O
strategy O
of O
vaccination O
against O
the O
highly O
pathogenic O
avian O
H5N1 O
viruses O
, O
using O
an O
inactivated O
vaccine O
prepared O
from O
nonpathogenic O
A O
/ O
Duck O
/ O
Singapore O
- O
Q O
/ O
F119 O
- O
3 O
/ O
97 O
( O
H5N3 O
) O
virus O
that O
was O
antigenically O
related O
to O
the O
human O
H5N1 O
viruses O
. O

The O
presence O
of O
low O
- O
pathogenic O
H7 O
Avian B
influenza I
virus I
( I
AIV I
) I
, O
which O
is O
associated O
with O
live B
- I
bird I
markets I
( I
LBM I
) I
in O
the O
Northeast O
United O
States O
, O
was O
first O
detected O
in O
1994 O
and O
, O
despite O
efforts O
to O
eradicate O
the O
virus O
, O
surveillance O
of O
these O
markets O
has O
resulted O
in O
numerous O
isolations O
of O
H7 O
AIVs O
from O
several O
states O
from O
1994 O
through O
1998 O
. O

The O
retrovirus O
avian B
sarcoma I
and I
leukosis I
virus I
( I
ASLV I
) I
enters O
cells O
via O
ps O
- O
independent O
membrane O
fusion O
. O

Previous O
mutational O
analysis O
of O
a O
variable O
region O
, O
central O
within O
the O
SU O
subunit O
, O
indicates O
that O
this O
region O
constitutes O
part O
of O
the O
receptor O
- O
binding O
domain O
for O
subgroup O
A B
envelope I
( I
EnvA I
) I
and O
furthermore O
that O
basic O
residues O
( O
R210 O
, O
R213 O
, O
R223 O
, O
R224 O
, O
and O
K227 O
) O
within O
this O
region O
are O
critical O
determinants O
of O
efficient O
ASLV O
infection O
. O

In O
this O
study O
, O
we O
performed O
biochemical O
analysis O
of O
the O
EnvA O
protein O
from O
three O
of O
the O
receptor O
- O
binding O
domain O
mutants O
( O
R213A O
/ O
K227A O
, O
R213A O
/ O
R223A O
/ O
R224A O
, O
and O
R213S O
) O
to O
define O
the O
role O
of O
this O
domain O
in O
early O
molecular O
events O
in O
the O
entry O
pathway O
. O

The O
results O
identified O
two O
distinct O
groups O
of O
viruses O
: O
group O
I O
, O
for O
which O
the O
dose O
lethal O
for O
50 O
% O
of O
mice O
( O
MLD50 O
) O
was O
between O
0 O
. O

3 O
and O
11 O
PFU O
, O
and O
group O
2 O
, O
for O
which O
the O
MLD50 O
was O
more O
than O
10 O
( O
3 O
) O
PFU O
. O

One O
day O
after O
intranasal O
inoculation O
of O
mice O
with O
100 O
PFU O
of O
group O
1 O
viruses O
, O
the O
virus O
titer O
in O
lungs O
was O
10 O
( O
7 O
) O
PFU O
/ O
g O
or O
3 O
log O
units O
higher O
than O
that O
for O
group O
2 O
viruses O
. O

Both O
types O
of O
viruses O
had O
replicated O
to O
high O
titers O
( O
> O
10 O
( O
6 O
) O
PFU O
/ O
g O
) O
in O
the O
lungs O
by O
day O
3 O
and O
maintained O
these O
titers O
through O
day O
6 O
. O

Here O
me O
demonstrate O
that O
the O
H5N1 O
viruses O
circulating O
in O
poultry O
comprised O
two O
distinguishable O
phylogenetic O
lineages O
in O
all O
genes O
that O
were O
in O
very O
rapid O
evolution O
, O
When O
introduced O
into O
new O
hosts O
, O
influenza O
viruses O
usually O
undergo O
rapid O
alteration O
of O
their O
surface O
glycoproteins O
, O
especially O
in O
the O
Hemagglutinin B
( I
HA I
) I
. O

Virol O
, O
131 O
: O
237 O
- O
250 O
, O
1993 O
) O
to O
account O
for O
these O
observations O
and O
the O
successful O
establishment O
of O
an O
avian O
H1N1 O
strain O
in O
swine O
, O
To O
address O
this O
question O
, O
we O
calculated O
the O
mutation O
rates O
of O
A O
/ O
Mallard O
/ O
New O
York O
/ O
6750 O
/ O
78 O
( O
H2N2 O
) O
and O
A O
/ O
Swine O
/ O
Germany O
/ O
2 O
/ O
81 O
( O
H1N1 O
) O
by O
using O
the O
frequency O
of O
amantadine O
- O
resistant O
mutants O
. O

This O
immunity O
was O
induced O
against O
both O
the O
homologous O
A O
/ O
HK O
/ O
156 O
/ O
97 O
( O
H5N1 O
) O
virus O
, O
which O
has O
no O
glycosylation O
site O
at O
residue O
154 O
, O
and O
chicken O
isolate O
A O
/ O
Ck O
/ O
HK O
/ O
258 O
/ O
97 O
( O
H5N1 O
) O
, O
which O
does O
have O
a O
glycosylation O
site O
at O
residue O
154 O
. O

However O
, O
in O
our O
current O
study O
we O
found O
that O
a O
DNA O
vaccine O
encoding O
the O
hemagglutinin O
from O
A O
/ O
Ty O
/ O
Ir O
/ O
1 O
/ O
83 O
( O
H5N8 O
) O
, O
which O
differs O
from O
A O
/ O
HK O
/ O
156 O
/ O
97 O
( O
H5N1 O
) O
by O
12 O
% O
in O
HA1 O
, O
prevented O
death O
but O
not O
H5N1 O
infection O
in O
mice O
. O

To O
identify O
possible O
phenotypic O
changes O
in O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
of O
the O
H5 O
viruses O
during O
interspecies O
transfer O
, O
we O
compared O
the O
receptor O
- O
binding O
properties O
and O
NA O
activities O
of O
the O
human O
and O
chicken O
H5N1 O
isolates O
from O
Hong O
Kong O
and O
of O
H5N3 O
and O
H5N1 O
viruses O
from O
wild O
aquatic O
birds O
. O

Here O
we O
show O
that O
the O
envelope O
glycoprotein O
from O
the O
Zaire O
strain O
of O
Ebola O
virus O
( O
Ebo O
- O
GP O
) O
is O
proteolytically O
processed O
into O
two O
subunits O
, O
GP O
, O
and O
GP O
, O
, O
that O
are O
likely O
covalently O
associated O
through O
a O
disulfide O
linkage O
, O
Murine O
leukemia O
virions O
pseudotyped O
with O
Ebo O
- O
GP O
contain O
almost O
exclusively O
processed O
glycoprotein O
, O
indicating O
that O
this O
is O
the O
mature O
form O
of O
Ebo O
- O
GP O
, O
Mutational O
analysis O
identified O
a O
dibasic O
motif O
, O
reminiscent O
of O
furin O
- O
like O
protease O
processing O
sites O
, O
as O
the O
Ebo O
- O
GP O
cleavage O
site O
. O

An O
extremely O
virulent O
H3N8 O
avian O
influenza O
A O
virus O
has O
been O
used O
to O
infect O
both O
immunoglobulin O
- O
expressing O
( O
Ig O
( O
+ O
/ O
+ O
) O
) O
and O
Ig O
( O
- O
/ O
- O
) O
mice O
primed O
previously O
with O
a O
laboratory O
- O
adapted O
H3N2 O
virus O
. O

The O
cross O
- O
reactive O
antibody O
response O
was O
very O
protective O
, O
while O
the O
recall O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
memory O
in O
the O
Ig O
- O
/ O
- O
mice O
provided O
some O
small O
measure O
of O
resistance O
to O
a O
low O
- O
dose O
H3N8 O
challenge O
. O

The O
H3N8 O
virus O
also O
replicated O
in O
the O
respiratory O
tracts O
of O
the O
H3N2 O
- O
primed O
Ig O
( O
+ O
/ O
+ O
) O
mice O
, O
generating O
secondary O
CD8 O
+ O
and O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
that O
may O
contribute O
to O
recovery O
. O

Although O
amino O
acids O
at O
positions O
226 O
and O
228 O
of O
hemagglutinin O
( O
I O
- O
IA O
) O
of O
the O
H3 O
subtype O
are O
known O
to O
be O
important O
for O
this O
host O
range O
restriction O
, O
the O
contributions O
of O
specific O
amino O
acids O
at O
these O
positions O
to O
restriction O
were O
not O
known O
. O

H3N2 O
human O
influenza O
viruses O
that O
are O
resistant O
to O
horse O
, O
pig O
, O
or O
rabbit O
serum O
possess O
unique O
amino O
acid O
mutations O
in O
their O
Hemagglutinin B
( I
HA I
) I
protein O
. O

Pig O
serum O
- O
resistant O
variants O
displayed O
a O
markedly O
decreased O
affinity O
for O
total O
pig O
serum O
sialylglycoproteins O
( O
which O
contain O
predominantly O
2 O
- O
6 O
linkage O
between O
sialic O
acid O
and O
galactose O
residues O
) O
and O
for O
the O
sialyloligosaccharide O
6 O
' O
- O
sialyl O
( O
N O
- O
acetyllactosamine O
) O
. O

In O
addition O
to O
a O
somewhat O
reduced O
affinity O
for O
6 O
' O
- O
sialyl O
( O
N O
- O
acetyllactosamine O
) O
- O
containing O
receptors O
, O
horse O
serum O
- O
resistant O
variants O
lost O
the O
ability O
to O
bind O
the O
viral O
neuraminidase O
- O
resistant O
CO O
- O
acetylated O
sialic O
acid O
moieties O
of O
equine O
alpha O
( O
2 O
) O
- O
macroglobulin O
because O
of O
the O
mutation O
145N O
- O
- O
> O
K O
/ O
D O
in O
their O
HA1 O
. O

Avian O
strains O
bound O
4 O
- O
O O
- O
acetylated O
sialic O
acid O
residues O
of O
equine O
alpha O
( O
2 O
) O
- O
macroglobulin O
, O
whereas O
equine O
strains O
did O
not O
. O

Genes O
of O
an O
influenza O
A O
( O
H5N1 O
) O
virus O
from O
a O
human O
in O
Hong O
Kong O
isolated O
in O
May O
1997 O
were O
sequenced O
and O
found O
to O
be O
all O
avian O
- O
like O
( O
K O
. O

However O
, O
neither O
isolate O
' O
s O
gene O
sequence O
was O
closely O
( O
> O
95 O
% O
sequence O
identity O
) O
related O
to O
any O
other O
gene O
sequences O
found O
in O
the O
GenBank O
database O
. O

Studies O
analyzing O
Ebola O
virus O
replication O
have O
been O
severely O
hampered O
by O
the O
extreme O
pathogenicity O
of O
this O
virus O
, O
To O
permit O
analysis O
of O
the O
host O
range O
and O
function O
of O
the O
Ebola B
virus I
glycoprotein I
( I
Ebo I
- I
GP I
) I
, O
we O
have O
developed O
a O
system O
for O
pseudotyping O
these O
glycoproteins O
into O
murine B
leukemia I
virus I
( I
MLV I
) I
, O
This O
pseudotyped O
virus O
, O
MLV O
( O
Ebola O
) O
, O
can O
be O
readily O
concentrated O
to O
titers O
which O
exceed O
5 O
x O
10 O
( O
6 O
) O
infectious O
units O
/ O
ml O
and O
is O
effectively O
neutralized O
by O
antibodies O
specific O
for O
Ebo O
- O
GP O
, O
Analysis O
of O
MLV O
( O
Ebola O
) O
infection O
revealed O
that O
the O
host O
range O
conferred O
by O
Ebo O
- O
GP O
is O
very O
broad O
, O
extending O
to O
cells O
of O
a O
variety O
of O
species O
, O
Notably O
, O
all O
lymphoid O
cell O
lines O
tested O
were O
completely O
resistant O
to O
infection O
; O
we O
speculate O
that O
this O
is O
due O
to O
the O
absence O
of O
a O
cellular O
receptor O
for O
Ebo O
- O
GP O
on O
B O
and O
T O
cells O
, O
The O
generation O
of O
high O
- O
titer O
MLV O
( O
Ebola O
) O
pseudotypes O
will O
be O
useful O
for O
the O
analysis O
of O
immune O
responses O
to O
Ebola O
virus O
infection O
, O
development O
of O
neutralizing O
antibodies O
, O
analysis O
of O
glycoprotein O
function O
, O
and O
isolation O
of O
the O
cellular O
receptor O
( O
s O
) O
for O
the O
Ebola O
virus O
. O

The O
transmembrane B
subunit I
( I
TM I
) I
of O
the O
avian B
leukosis I
and I
sarcoma I
virus I
( I
ALSV I
) I
envelope I
glucoprotein I
( I
Env I
) I
contains O
a O
stretch O
of O
conserved O
hydrophobic O
amino O
acids O
internal O
to O
its O
amino O
terminus O
( O
residues O
21 O
to O
42 O
) O
. O

We O
investigated O
the O
role O
of O
this O
region O
by O
changing O
each O
of O
three O
hydrophobic O
residues O
( O
Ile O
- O
21 O
, O
Val O
- O
30 O
, O
and O
Ile O
- O
39 O
) O
to O
glutamatic O
acid O
and O
lysine O
in O
the O
ALSV O
subgroup O
A O
Env O
. O

Like O
wild B
- I
type I
( I
WT I
) I
Env O
, O
all O
six O
mutant O
Env O
proteins O
were O
proteolytically O
processed O
, O
oligomerized O
, O
and O
expressed O
at O
the O
cell O
surface O
in O
a O
form O
that O
bound O
Tva O
, O
the O
ALSV O
subgroup O
A O
receptor O
. O

Past O
efforts O
to O
employ O
a O
structure O
- O
based O
approach O
to O
design O
an O
inhibitor O
of O
the O
fusion O
- O
inducing O
conformational O
change O
in O
the O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
yielded O
a O
family O
of O
small O
benzoquinones O
and O
hydroquinones O
, O
The O
most O
potent O
of O
these O
, O
tert B
- I
butyl I
hydroquinone I
( I
TBHQ I
) I
, O
inhibits O
both O
the O
conformational O
change O
in O
HA O
from O
strain O
X O
: O
31 O
influenza O
virus O
and O
viral O
infectivity O
in O
tissue O
culture O
cells O
with O
50 O
% O
inhibitory O
concentrations O
in O
the O
micromolar O
range O
( O
D O
. O

A O
new O
structure O
- O
based O
inhibitor O
design O
search O
was O
begun O
which O
involved O
( O
i O
) O
the O
recently O
refined O
crystal O
structure O
( O
2 O
. O

1 O
- O
Angstrom O
resolution O
) O
of O
the O
HA O
ectodomain O
, O
( O
ii O
) O
new O
insights O
into O
the O
conformational O
change O
, O
and O
( O
iii O
) O
improvements O
in O
the O
molecular O
docking O
program O
, O
DOCK O
. O

Cleavage O
of O
influenza O
A O
virus O
Hemagglutinin B
( I
HA I
) I
is O
required O
for O
expression O
of O
fusion O
activity O
and O
virus O
entry O
into O
cells O
. O

The O
N1 O
and O
N9 O
neuraminidase B
( I
NA I
) I
subtypes O
of O
influenza O
A O
viruses O
exhibit O
significant O
hemadsorption O
activity O
that O
localizes O
to O
a O
site O
distinct O
from O
that O
of O
the O
enzymatic O
active O
site O
, O
To O
determine O
the O
conservation O
of O
hemadsorption O
activity O
among O
different O
NAs O
, O
we O
have O
examined O
most O
of O
the O
NA O
subtypes O
from O
avian O
, O
swine O
, O
equine O
, O
and O
human O
virus O
isolates O
, O
All O
subtypes O
of O
avian O
virus O
NAs O
examined O
and O
one O
equine O
virus O
N8 O
NA O
possessed O
high O
levels O
of O
hemadsorption O
activity O
, O
A O
swine O
virus O
N1 O
NA O
exhibited O
only O
weak O
hemadsorption O
activity O
, O
while O
in O
human O
virus O
N1 O
and O
N2 O
NAs O
, O
the O
activity O
was O
detected O
at O
a O
much O
lower O
level O
than O
in O
avian O
virus O
NAs O
, O
NAs O
which O
possessed O
hemadsorption O
activity O
for O
chicken O
erythrocytes O
( O
RBCs O
) O
were O
similarly O
able O
to O
adsorb O
human O
RBCs O
, O
However O
, O
none O
of O
the O
hemadsorption O
- O
positive O
NAs O
could O
bind O
equine O
, O
swine O
, O
or O
bovine O
RBCs O
, O
suggesting O
that O
RBCs O
from O
these O
species O
lack O
molecules O
, O
recognized O
by O
the O
NA O
hemadsorption O
site O
, O
present O
on O
human O
and O
chicken O
RBCs O
, O
Mutagenesis O
of O
the O
putative O
hemadsorption O
site O
of O
A O
/ O
duck O
/ O
Hong O
Kong O
/ O
7 O
/ O
75 O
N2 O
NA O
abolished O
the O
high O
level O
of O
hemadsorption O
activity O
exhibited O
by O
the O
wild O
- O
type O
protein O
but O
also O
resulted O
in O
a O
50 O
% O
reduction O
of O
the O
NA O
enzymatic O
activity O
, O
A O
transfectant O
virus O
, O
generated O
by O
reverse O
genetics O
, O
containing O
this O
mutated O
NA O
replicated O
10 O
- O
fold O
less O
efficiently O
in O
chicken O
embryo O
fibroblast O
cultures O
than O
did O
a O
transfectant O
virus O
expressing O
the O
wild O
- O
type O
NA O
, O
However O
, O
both O
viruses O
replicated O
equally O
well O
in O
Peking O
ducks O
, O
Although O
conservation O
of O
NA O
hemadsorption O
activity O
among O
avian O
virus O
NAs O
suggests O
the O
maintenance O
of O
a O
required O
function O
of O
NA O
, O
loss O
of O
the O
activity O
does O
not O
preclude O
the O
replication O
of O
the O
virus O
in O
an O
avian O
host O
. O

Mallards O
( O
Anas O
platyrhynchos O
) O
and O
pintails O
( O
A O
. O

Inoculation O
of O
mice O
with O
Hemagglutinin B
( I
HA I
) I
- O
expressing O
DNA O
affords O
reliable O
protection O
against O
lethal O
influenza O
virus O
infection O
, O
while O
in O
chickens O
the O
same O
strategy O
has O
yielded O
variable O
results O
, O
Here O
we O
show O
that O
gene O
gun O
delivery O
of O
DNA O
encoding O
an O
H5 O
HA O
protein O
confers O
complete O
immune O
protection O
to O
chickens O
challenged O
, O
vith O
lethal O
H5 O
viruses O
, O
In O
tests O
of O
the O
influence O
of O
promoter O
selection O
on O
vaccine O
efficacy O
, O
close O
correlations O
were O
obtained O
between O
immune O
responses O
and O
the O
dose O
of O
DNA O
administered O
, O
whether O
a O
cytomegalovirus B
( I
CMV I
) I
immediate O
- O
early O
promoter O
or O
a O
chicken O
beta O
- O
actin O
promoter O
was O
used O
, O
Perhaps O
most O
important O
, O
the O
HA O
- O
DNA O
vaccine O
conferred O
95 O
% O
cross O
- O
protection O
against O
challenge O
with O
lethal O
antigenic O
variants O
that O
differed O
from O
the O
primary O
antigen O
by O
11 O
to O
13 O
% O
( O
HAL O
amino O
acid O
sequence O
homology O
) O
, O
Overall O
, O
the O
high O
levels O
of O
protection O
seen O
with O
gene O
gun O
delivery O
of O
HA O
- O
DNA O
were O
as O
good O
as O
, O
if O
not O
better O
than O
, O
those O
achieved O
with O
a O
conventional O
whole O
- O
virus O
vaccine O
, O
with O
fewer O
instances O
of O
morbidity O
and O
death O
. O

Previously O
, O
mutant O
Tva O
receptors O
were O
classified O
as O
either O
partially O
or O
completely O
defective O
in O
mediating O
subgroup O
A O
avian B
leukosis I
and I
sarcoma I
virus I
( I
ALSV I
- I
A I
) I
entry O
( O
C O
. O

69 O
: O
4261 O
- O
4266 O
, O
1995 O
) O
, O
To O
specifically O
test O
the O
abilities O
of O
these O
mutant O
Tva O
proteins O
to O
bind O
ALSV O
- O
A O
surface B
( I
SU I
) I
protein O
, O
binding O
studies O
were O
performed O
with O
a O
subgroup O
A O
SU O
- O
immunoadhesin O
, O
This O
fusion O
protein O
is O
composed O
of O
the O
subgroup O
A O
Schmidt O
- O
Ruppin O
SU O
protein O
fused O
in O
frame O
to O
a O
rabbit O
immunoglobulin O
constant O
region O
, O
This O
reagent O
was O
conjugated O
to O
fluorescein O
isothiocyanate O
and O
used O
for O
flow O
cytometric O
analysis O
with O
transfected O
human O
293 O
cells O
expressing O
different O
forms O
of O
Tva O
. O

Avian O
influenza O
A O
viruses O
from O
Asia O
are O
recognized O
as O
the O
source O
of O
genes O
that O
reasserted O
with O
human O
viral O
genes O
to O
generate O
the O
Asian O
/ O
57 O
( O
H2N2 O
) O
and O
Hong O
Kong O
/ O
68 O
( O
H3N2 O
) O
pandemic O
strains O
earlier O
in O
this O
century O
. O

We O
recently O
reported O
that O
Tva O
, O
the O
host O
cell O
receptor O
for O
subgroup O
A O
avian O
leukosis O
and O
sarcoma O
viruses O
, O
binds O
specifically O
to O
the O
subgroup O
A B
envelope I
glycoprotein I
( I
Env I
- I
A I
) I
( O
J O
. O

A O
temperature O
- O
dependent O
conformational O
change O
, O
demonstrated O
by O
the O
generation O
of O
a O
specific O
thermolysin O
digestion O
product O
of O
the O
surface B
( I
SU I
) I
subunit O
, O
occurred O
when O
a O
soluble B
form I
of I
Tva I
( I
sTva I
) I
was O
incubated O
with O
Env O
- O
A O
. O

However O
sTva O
did O
induce O
the O
conformational O
change O
in O
Env O
- O
A O
CL O
that O
had O
been O
pretreated O
in O
vitro O
to O
produce O
the O
SU O
and O
transmembrane B
( I
TM I
) I
subunits O
, O
Moreover O
, O
interaction O
of O
Tva O
with O
Env O
- O
A O
at O
25 O
degrees O
C O
, O
but O
not O
at O
4 O
degrees O
C O
, O
appeared O
to O
reveal O
a O
previously O
buried O
segment O
of O
the O
putative O
fusion O
peptide O
of O
Env O
- O
A O
Our O
results O
suggest O
that O
binding O
of O
Tva O
to O
Env O
- O
A O
results O
in O
specific O
conformational O
changes O
in O
the O
Env O
- O
A O
glycoprotein O
that O
are O
relevant O
to O
the O
activation O
of O
its O
fusion O
function O
. O

Transfection O
of O
an O
artificial O
M O
ribonucleoprotein O
complex O
of O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
, O
a O
naturally O
occurring O
amantadine O
- O
resistant O
virus O
, O
and O
superinfection O
with O
amantadine O
- O
sensitive O
A O
/ O
equine O
/ O
Miami O
/ O
1 O
/ O
63 O
( O
H3N8 O
) O
, O
followed O
by O
cultivation O
in O
the O
presence O
of O
the O
drug O
, O
led O
to O
the O
generation O
of O
a O
transfectant O
virus O
with O
the O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
M O
gene O
. O

With O
this O
system O
, O
we O
attempted O
io O
generate O
a O
virus O
containing O
a O
deletion O
in O
an O
M B
- I
gene I
product I
( I
M2 I
protein I
) I
. O

The O
putative O
subgroup O
A O
avian B
leukosis I
- I
sarcoma I
virus I
( I
ALSV I
) I
receptor O
( O
Tva O
) O
was O
recently O
cloned O
by O
gene O
transfer O
( O
P O
. O

We O
established O
stable O
NIH O
3T3 O
cell O
lines O
expressing O
either O
Tva O
, O
the O
subgroup O
A B
envelope I
glycoprotein I
( I
Env I
- I
A I
) I
, O
or O
the O
subgroup O
C B
envelope I
glycoprotein I
( I
Env I
- I
C I
) I
and O
used O
them O
in O
conjunction O
with O
soluble O
forms O
of O
these O
molecules O
to O
demonstrate O
specific O
binding O
. O

Among O
the O
proprotein O
- O
processing O
subtilisin O
- O
related O
endoproteases O
, O
furin O
has O
been O
a O
leading O
candidate O
for O
the O
enzyme O
that O
activates O
the O
Hemagglutinin B
( I
HA I
) I
of O
virulent O
avian O
influenza O
viruses O
. O

In O
the O
present O
study O
, O
we O
examined O
the O
cleavage O
activity O
of O
tno O
other O
recently O
isolated O
ubiquitous O
subtilisin O
- O
related O
pretenses O
, O
PACE4 O
and O
PC6 O
, O
using O
wild O
- O
type O
HA O
of O
A O
/ O
turkey O
/ O
Ireland O
/ O
1378 O
/ O
83 O
( O
H5N8 O
) O
and O
a O
series O
of O
its O
mutant O
HAs O
. O

When O
LoVo O
cells O
were O
infected O
with O
a O
virulent O
avian O
virus O
, O
A O
/ O
turkey O
/ O
Ontario O
/ O
7732 O
/ O
66 O
( O
H5N9 O
) O
, O
only O
noninfectious O
virions O
were O
produced O
because O
of O
the O
lack O
of O
HA O
cleavage O
. O

On O
the O
basis O
of O
theoretical O
structural O
and O
comparative O
studies O
of O
various O
avian O
leukosis O
virus O
SU B
( I
surface I
) I
envelope O
proteins O
, O
we O
have O
identified O
four O
small O
regions O
( O
I O
, O
II O
, O
III O
, O
and O
IV O
) O
in O
their O
receptor O
- O
binding O
domains O
that O
could O
potentially O
be O
involved O
in O
binding O
to O
receptors O
. O

In O
previous O
studies O
, O
we O
observed O
that O
the O
virulent O
avian O
influenza O
A O
virus O
A O
/ O
Turkey O
/ O
Ontario O
/ O
7732 O
/ O
66 O
( O
Ty O
/ O
Ont O
) O
induced O
severe O
lymphoid O
depletion O
in O
vivo O
and O
rapidly O
killed O
an O
avian O
lymphocyte O
cell O
line O
( O
RP9 O
) O
in O
vitro O
. O

In O
fact O
, O
a O
variety O
of O
influenza O
A O
viruses O
( O
avian O
, O
equine O
, O
swine O
, O
and O
human O
) O
, O
as O
well O
as O
human O
influenza O
B O
viruses O
, O
induced O
DNA O
fragmentation O
in O
a O
permissive O
mammalian O
cell O
line O
, O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
, O
and O
this O
correlated O
with O
the O
development O
of O
a O
cytopathic O
effect O
during O
viral O
infection O
. O

Since O
the O
proto O
- O
oncogene O
bcl O
- O
2 O
is O
a O
known O
inhibitor O
of O
apoptosis O
, O
we O
transfected O
MDCK O
cells O
with O
the O
human O
bcl O
- O
2 O
gene O
; O
these O
stably O
transfected O
cells O
( O
MDCKbcl O
- O
2 O
) O
did O
not O
undergo O
DNA O
fragmentation O
after O
virus O
infection O
. O

To O
obtain O
direct O
evidence O
for O
a O
relationship O
between O
Hemagglutinin B
( I
HA I
) I
cleavability O
and O
the O
virulence O
of O
avian O
influenza O
A O
viruses O
, O
we O
generated O
a O
series O
of O
HA O
cleavage O
mutants O
from O
a O
virulent O
virus O
, O
A O
/ O
turkey O
/ O
Ontario O
/ O
7732 O
/ O
66 O
( O
H5N9 O
) O
, O
by O
reverse O
genetics O
. O

A O
transfectant O
virus O
containing O
the O
wild O
- O
type O
HA O
with O
R O
- O
R O
- O
RK O
- O
K O
- O
R O
at O
the O
cleavage O
site O
, O
which O
was O
readily O
cleaved O
by O
endogenous O
proteases O
in O
chicken B
embryo I
fibroblasts I
( I
CEF I
) I
, O
was O
highly O
virulent O
in O
intramuscularly O
or O
intranasally O
/ O
orally O
inoculated O
chickens O
. O

By O
contrast O
, O
a O
mutant O
containing O
the O
HA O
with O
an O
avirulent O
- O
like O
sequence O
( O
R O
- O
E O
- O
T O
- O
R O
) O
at O
the O
cleavage O
site O
, O
which O
was O
not O
cleaved O
by O
the O
proteases O
in O
CEF O
, O
was O
avirulent O
in O
chickens O
, O
indicating O
that O
a O
genetic O
alteration O
confined O
to O
the O
HA O
cleavage O
site O
can O
affect O
cleavability O
and O
virulence O
. O

Mutant O
viruses O
with O
HA O
cleavage O
site O
sequences O
of O
T O
- O
R O
- O
R O
- O
K O
- O
K O
- O
R O
or O
T O
- O
T O
- O
R O
- O
K O
- O
K O
- O
R O
were O
as O
virulent O
as O
viruses O
with O
the O
wild O
- O
type O
HA O
, O
whereas O
a O
mutant O
, O
vith O
a O
two O
- O
amino O
- O
acid O
deletion O
but O
retention O
of O
four O
consecutive O
basic O
residues O
( O
R O
- O
K O
- O
K O
- O
R O
) O
was O
as O
avirulent O
as O
a O
virus O
with O
the O
avirulent O
- O
type O
HA O
. O

These O
are O
relevant O
to O
the O
evolution O
of O
the O
specific O
gene O
( O
or O
set O
of O
genes O
) O
, O
but O
the O
resulting O
phylogeny O
may O
vary O
depending O
on O
the O
particular O
sequence O
chosen O
for O
analysis O
( O
or O
comparison O
) O
. O

The O
sequences O
were O
analyzed O
with O
respect O
to O
( O
i O
) O
genomic O
compositional O
extremes O
; O
( O
ii O
) O
total O
distances O
within O
and O
between O
genomes O
; O
( O
iii O
) O
partial O
orderings O
among O
genomes O
relative O
to O
a O
set O
of O
sequence O
standards O
; O
( O
iv O
) O
concordance O
correlations O
of O
genome O
distances O
; O
and O
( O
v O
) O
consistency O
with O
the O
alpha O
- O
, O
beta O
- O
, O
gammaherpesvirus O
classification O
. O

The O
gammaherpesviruses O
, O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
, O
herpesvirus O
saimiri O
, O
and O
bovine O
herpesvirus O
4 O
are O
both O
diverse O
and O
separate O
from O
other O
herpesvirus O
classes O
, O
whereas O
alpha O
- O
and O
betaherpesviruses O
overlap O
. O

The O
analysis O
revealed O
that O
the O
most O
central O
genome O
( O
closest O
to O
a O
consensus O
herpesvirus O
genome O
and O
most O
individual O
herpesvirus O
sequences O
of O
different O
classes O
) O
is O
that O
of O
human O
herpesvirus O
6 O
, O
suggesting O
that O
this O
genome O
is O
closest O
to O
a O
progenitor O
herpesvirus O
. O

In O
our O
collection O
, O
equine O
herpesvirus O
1 O
( O
EHV1 O
) O
stands O
out O
as O
the O
most O
central O
alphaherpesvirus O
, O
suggesting O
it O
may O
approximate O
an O
ancestral O
alphaherpesvirus O
. O

In O
the O
DNA O
partial O
orderings O
, O
the O
chicken O
sequence O
collection O
is O
invariably O
as O
close O
as O
or O
closer O
to O
all O
herpesvirus O
sequences O
than O
the O
human O
sequence O
collection O
is O
, O
which O
may O
imply O
that O
the O
chicken O
( O
or O
other O
avian O
species O
) O
is O
a O
more O
natural O
or O
more O
ancient O
host O
of O
herpesviruses O
. O

In O
this O
analysis O
, O
the O
alignment O
of O
the O
two O
betaherpesviruses O
( O
human O
cytomegalovirus O
versus O
human O
herpesvirus O
6 O
) O
shelved O
lower O
scores O
compared O
with O
alignments O
within O
alphaherpesviruses O
( O
i O
. O

, O
among O
EHV1 O
, O
herpes O
simplex O
virus O
type O
1 O
, O
varicella O
- O
zoster O
virus O
, O
pseudorabies O
virus O
type O
1 O
and O
Marek O
' O
s O
disease O
virus O
) O
and O
within O
gammaherpesviruses O
( O
EBV O
versus O
herpesvirus O
saimiri O
) O
. O

The O
evolutionary O
development O
of O
genes O
among O
viruses O
( O
and O
species O
) O
is O
more O
dependent O
on O
each O
individual O
gene O
. O

The O
virulence O
of O
avian O
influenza O
viruses O
correlates O
with O
the O
sensitivity O
of O
their O
Hemagglutinin B
( I
HA I
) I
to O
cellular O
proteases O
. O

We O
therefore O
compared O
the O
specificity O
of O
furin O
with O
those O
of O
proteases O
in O
a O
variety O
of O
cultured O
cells O
and O
in O
a O
rat O
Golgi O
fraction O
, O
using O
the O
HA O
cleavage O
mutants O
of O
a O
virulent O
avian O
influenza O
virus O
, O
A O
/ O
Turkey O
/ O
Ireland O
/ O
1378 O
/ O
85 O
( O
H5N8 O
) O
. O

An O
avian O
- O
human O
influenza O
A O
virus O
PB2 O
single O
- O
gene O
reassortant O
virus O
( O
with O
an O
avian O
influenza O
A O
virus O
PB2 O
gene O
) O
that O
replicates O
efficiently O
in O
avian O
tissue O
but O
poorly O
in O
mammalian O
cells O
was O
used O
as O
a O
helper O
virus O
to O
rescue O
a O
transfected O
synthetic O
RNA O
derived O
from O
a O
human O
influenza O
A O
virus O
PB2 O
gene O
. O

Previously O
, O
this O
amino O
acid O
substitution O
had O
been O
shown O
to O
specify O
both O
a O
temperature B
- I
sensitive I
( I
ts I
) I
and O
an O
attenuation B
( I
att I
) I
phenotype O
. O

We O
have O
expressed O
in O
oocytes O
of O
Xenopus O
laevis O
the O
M2 O
protein O
of O
human O
influenza O
virus O
A O
/ O
Udorn O
/ O
72 O
and O
the O
avian O
virus O
A O
/ O
chicken O
/ O
Germany O
/ O
34 O
( O
fowl O
plague O
virus O
, O
Rostock O
) O
and O
derivatives O
of O
the O
Rostock O
ion O
channel O
altered O
in O
the O
presumed O
pore O
region O
. O

The O
channels O
were O
found O
to O
be O
activated O
by O
pH O
in O
a O
similar O
manner O
but O
differed O
in O
their O
apparent O
K O
( O
i O
) O
s O
for O
amantadine O
block O
. O

3 O
x O
10 O
( O
- O
3 O
) O
substitutions O
per O
site O
per O
year O
) O
. O

The O
single O
gene O
reassortant O
virus O
that O
derives O
its O
PB2 O
gene O
from O
the O
avian O
influenza O
A O
/ O
Mallard O
/ O
NY O
/ O
78 O
virus O
and O
remaining O
genes O
from O
the O
human O
influenza O
A O
/ O
Los O
Angeles O
/ O
2 O
/ O
87 O
virus O
exhibits O
a O
host B
range I
restriction I
( I
hr I
) I
phenotype O
characterized O
by O
efficient O
replication O
in O
avian O
tissue O
and O
failure O
to O
produce O
plaques O
in O
mammalian O
Madin O
- O
Darby O
canine O
kidney O
cells O
. O

The O
nucleotide O
sequences O
of O
the O
PB2 O
gene O
of O
each O
of O
the O
four O
hr O
mutants O
revealed O
that O
a O
single O
amino O
acid O
substitution O
at O
position O
627 O
( O
Glu O
- O
- O
> O
Lys O
) O
was O
responsible O
for O
the O
restoration O
of O
the O
ability O
of O
the O
PB2 O
single O
gene O
reassortant O
to O
replicate O
in O
Madin O
- O
Darby O
canine O
kidney O
cells O
. O

To O
investigate O
the O
biologic O
importance O
of O
the O
neuraminidase B
( I
NA I
) I
stalk O
of O
influenza O
A O
virus O
, O
we O
generated O
mutant O
viruses O
of O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
with O
stalks O
of O
various O
lengths O
( O
0 O
to O
52 O
amino O
acids O
) O
, O
by O
using O
the O
recently O
developed O
reverse O
genetics O
system O
. O

The O
NA O
stalkless O
mutant O
was O
highly O
attenuated O
in O
mice O
; O
none O
of O
the O
animals O
died O
even O
after O
intranasal O
inoculation O
of O
10 O
( O
6 O
) O
PFU O
of O
the O
virus O
( O
the O
dose O
of O
the O
parent O
virus O
required O
to O
kill O
50 O
% O
of O
mice O
was O
10 O
( O
2 O
. O

We O
have O
investigated O
what O
protein O
sequences O
are O
necessary O
for O
glycoprotein O
incorporation O
into O
Rous B
sarcoma I
virus I
( I
RSV I
) I
virions O
by O
utilizing O
the O
hemagglutinin B
( I
RA I
) I
protein O
of O
influenza O
virus O
. O

As O
the O
initial O
step O
in O
generating O
a O
live O
attenuated O
influenza O
A O
vaccine O
, O
we O
attempted O
to O
substitute O
an O
unrelated O
amino O
acid O
sequence O
( O
FLAG O
) O
for O
a O
portion O
of O
the O
neuraminidase B
( I
NA I
) I
molecule O
in O
influenza O
virus O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
, O
using O
a O
recently O
developed O
technique O
( O
reverse O
genetics O
[ O
W O
. O

This O
technique O
allowed O
us O
to O
rescue O
the O
NA O
molecules O
containing O
the O
FLAG O
sequence O
( O
Asp O
- O
Tyr O
- O
Lys O
- O
Asp O
- O
Asp O
- O
Asp O
- O
Asp O
- O
Lys O
) O
at O
the O
bottom O
portion O
of O
the O
boxlike O
head O
of O
the O
molecule O
immediately O
above O
the O
stalk O
region O
( O
amino O
acid O
residues O
63 O
to O
70 O
[ O
WSN O
NA O
numbering O
] O
) O
. O

The O
point O
mutation O
rate O
of O
a O
murine B
leukemia I
virus I
( I
MuLV I
) I
genome O
( O
AKV O
) O
was O
determined O
under O
conditions O
in O
which O
the O
number O
of O
replicative O
cycles O
was O
carefully O
controlled O
and O
the O
point O
mutation O
rate O
was O
determined O
by O
direct O
examination O
of O
the O
RNA O
genomes O
of O
progeny O
viruses O
. O

A O
clonal O
cell O
line O
infected O
at O
a O
low O
multiplicity O
of O
infection O
( O
2 O
x O
10 O
( O
- O
3 O
) O
) O
was O
derived O
to O
provide O
a O
source O
of O
virus O
with O
high O
genetic O
homogeneity O
. O

The O
combined O
fingerprinting O
and O
sequencing O
analyses O
yielded O
a O
mutation O
rate O
for O
infectious O
progeny O
viruses O
of O
one O
base O
change O
per O
50 O
, O
000 O
( O
2 O
x O
10 O
( O
- O
5 O
) O
) O
bases O
per O
replication O
cycle O
. O

We O
investigated O
the O
amino O
acid O
sequence O
requirements O
for O
intracellular O
cleavage O
of O
the O
Rous O
sarcoma O
virus O
glycoprotein O
precursor O
by O
introducing O
mutations O
into O
the O
region O
encoding O
the O
cleavage O
recognition O
site O
( O
Arg O
- O
Arg O
- O
Lys O
- O
Arg O
) O
. O

In O
addition O
to O
mutants O
G1 O
( O
Arg O
- O
Arg O
- O
Glu O
- O
Arg O
) O
and O
Dr1 O
( O
deletion O
of O
all O
four O
codons O
) O
that O
we O
have O
reported O
on O
previously O
( O
L O
. O

61 O
: O
1609 O
- O
1614 O
, O
1987 O
) O
, O
we O
constructed O
two O
additional O
mutants O
, O
AR1 O
( O
Arg O
- O
Arg O
- O
Arg O
- O
Arg O
) O
, O
in O
which O
the O
highly O
conserved O
lysine O
is O
replaced O
by O
an O
arginine O
, O
and O
S19 O
( O
Ser O
- O
Arg O
- O
Glu O
- O
Arg O
) O
, O
in O
which O
no O
dibasic O
pairs O
remain O
. O

The O
results O
of O
these O
studies O
demonstrate O
that O
when O
the O
cleavage O
sequence O
is O
deleted O
( O
Dr1 O
) O
or O
modified O
to O
contain O
unpaired O
basic O
residues O
( O
S19 O
) O
, O
intracellular O
cleavage O
of O
the O
glycoprotein O
precursor O
is O
completely O
blocked O
. O

This O
demonstrates O
that O
the O
cellular O
endopeptidase O
responsible O
for O
cleavage O
has O
a O
stringent O
requirement O
for O
the O
presence O
of O
a O
pair O
of O
basic O
residues O
( O
Arg O
- O
Arg O
or O
Lys O
- O
Arg O
) O
. O

Phylogenetic O
analysis O
of O
42 O
membrane B
protein I
( I
M I
) I
genes O
of O
influenza O
A O
viruses O
from O
a O
variety O
of O
hosts O
and O
geographic O
locations O
showed O
that O
these O
genes O
have O
evolved O
into O
at O
least O
four O
major O
host O
- O
related O
lineages O
: O
( O
i O
) O
A O
/ O
Equine O
/ O
Prague O
/ O
56 O
, O
which O
has O
the O
most O
divergent O
M O
gene O
; O
( O
ii O
) O
a O
lineage O
containing O
only O
H13 O
gull O
viruses O
; O
( O
iii O
) O
a O
lineage O
containing O
both O
human O
and O
classical O
swine O
viruses O
; O
and O
( O
iv O
) O
an O
avian O
lineage O
subdivided O
into O
North O
American O
avian O
viruses O
( O
including O
recent O
equine O
viruses O
) O
and O
Old O
World O
avian O
viruses O
( O
including O
avianlike O
swine O
strains O
) O
. O

To O
examine O
the O
prerequisites O
for O
cleavage O
activation O
of O
the O
hemagglutinin O
of O
human O
influenza O
viruses O
, O
a O
cDNA O
clone O
obtained O
from O
strain O
A O
/ O
Port O
Chalmers O
/ O
1 O
/ O
73 O
( O
serotype O
H3 O
) O
was O
subjected O
to O
site O
- O
directed O
mutagenesis O
and O
expressed O
in O
CV O
- O
1 O
cells O
by O
using O
a O
simian O
virus O
40 O
vector O
. O

A O
phylogenetic O
analysis O
of O
52 O
published O
and O
37 O
new O
nucleoprotein B
( I
NP I
) I
gene O
sequences O
addressed O
the O
evolution O
and O
origin O
of O
human O
and O
swine O
influenza O
A O
viruses O
. O

Sequences O
derived O
from O
the O
gp85 O
- O
coding O
domain O
within O
the O
env O
gene O
of O
a O
mammal O
- O
tropic O
subgroup O
D O
virus O
( O
Schmidt O
- O
Ruppin O
D O
strain O
of O
Rous O
sarcoma O
virus O
[ O
SR O
- O
D O
RSV O
] O
) O
and O
a O
non O
- O
mammal O
- O
tropic O
subgroup O
B O
virus O
( O
Rous O
- O
associated O
virus O
type O
2 O
) O
were O
recombined O
to O
map O
genetic O
determinants O
that O
allow O
penetration O
of O
mammalian O
cells O
. O

( O
i O
) O
The O
determinants O
of O
gp85 O
that O
result O
in O
the O
mammal O
tropism O
phenotype O
of O
SR O
- O
D O
RSV O
are O
encoded O
within O
the O
160 O
codons O
that O
lie O
3 O
' O
of O
codon O
121 O
from O
the O
corresponding O
amino O
terminus O
of O
the O
gp85 O
protein O
. O

( O
ii O
) O
Small O
linear O
domains O
of O
the O
SR O
- O
D O
RSV O
gp85 O
- O
coding O
domain O
placed O
in O
the O
subgroup O
B O
background O
did O
not O
yield O
viruses O
with O
titers O
equal O
to O
that O
of O
the O
subgroup O
D O
virus O
in O
a O
human O
cell O
line O
. O

( O
iii O
) O
Recombinant O
viruses O
that O
contained O
subgroup O
D O
sequences O
within O
the O
hr1 O
variable O
domain O
of O
gp85 O
showed O
modest O
- O
to O
- O
significant O
increases O
in O
infectivity O
on O
human O
cells O
relative O
to O
chicken O
cells O
. O

The O
cleavability O
of O
the O
Hemagglutinin B
( I
HA I
) I
molecule O
is O
related O
to O
the O
virulence O
of O
avian O
influenza O
A O
viruses O
, O
but O
its O
influence O
on O
human O
influenza O
virus O
strains O
is O
unknown O
. O

The O
importance O
of O
these O
properties O
in O
the O
cleavability O
of O
a O
human O
influenza O
A O
virus O
( O
A O
/ O
Aichi O
/ O
2 O
/ O
68 O
) O
HA O
was O
investigated O
by O
using O
mutants O
that O
contained O
or O
lacked O
an O
oligosaccharide O
side O
chain O
and O
had O
either O
four O
or O
six O
basic O
amino O
acids O
. O

Junin B
virus I
( I
JUNV I
) I
and O
Lassa B
virus I
( I
LASV I
) I
can O
both O
cause O
significant O
outbreaks O
of O
severe O
and O
often O
fatal O
human O
disease O
throughout O
their O
respective O
areas O
of O
endemicity O
. O

Further O
, O
these O
cDNAs O
were O
used O
in O
combination O
with O
LASV O
cDNAs O
to O
successfully O
generate O
two O
recombinant O
Candid1 O
JUNV O
/ O
LASV O
chimeric O
viruses O
( O
via O
envelope O
glycoprotein O
[ O
GPC O
] O
exchange O
) O
. O

It O
was O
found O
that O
while O
the O
GPC O
extravirion O
domains O
were O
readily O
exchangeable O
, O
homologous O
stable B
signal I
peptide I
( I
SSP I
) I
and O
G2 O
transmembrane O
and O
cytoplasmic O
tail O
domains O
were O
essential O
for O
correct O
GPC O
maturation O
and O
production O
of O
infectious O
chimeric O
viruses O
. O

In O
late O
2013 O
, O
chikungunya B
virus I
( I
CHIKV I
) I
was O
introduced O
into O
the O
Americas O
, O
leading O
to O
widespread O
epidemics O
. O

A O
large O
epidemic O
caused O
by O
the O
Asian B
chikungunya I
virus I
( I
CHIKV I
) I
lineage O
occurred O
in O
Managua O
, O
Nicaragua O
, O
in O
2015 O
. O

Samples O
were O
collected O
upon O
enrollment O
and O
on O
day O
14 O
or O
35 O
and O
tested O
by O
real B
- I
time I
reverse I
transcription I
- I
PCR I
( I
rRT I
- I
PCR I
) I
, O
IgM B
capture I
enzyme I
- I
linked I
immunosorbent I
assays I
( I
IgM I
- I
ELISAs I
) I
, O
and O
inhibition O
ELISAs O
to O
detect O
pre O
- O
and O
postenrollment O
CHIKV O
infections O
. O

Of O
236 O
household O
contacts O
, O
55 O
( O
23 O
% O
) O
had O
experienced O
previous O
or O
very O
recent O
infections O
, O
41 O
( O
17 O
% O
) O
had O
active O
infections O
at O
enrollment O
, O
and O
21 O
( O
9 O
% O
) O
experienced O
incident O
infections O
. O

Among O
63 O
active O
and O
incident O
infections O
, O
31 O
( O
49 O
% O
[ O
95 O
% O
confidence O
interval O
{ O
CI O
} O
, O
36 O
% O
, O
62 O
% O
] O
) O
were O
asymptomatic O
, O
yielding O
a O
ratio O
of O
symptomatic O
to O
asymptomatic O
infections O
of O
1 O
: O
0 O
. O

Although O
our O
estimate O
is O
outside O
the O
3 O
% O
to O
28 O
% O
range O
reported O
previously O
, O
Bayesian O
and O
simulation O
analyses O
, O
informed O
by O
a O
systematic O
literature O
search O
, O
suggested O
that O
the O
proportion O
of O
inapparent O
CHIKV O
infections O
is O
lineage O
dependent O
and O
that O
more O
inapparent O
infections O
are O
associated O
with O
the O
Asian O
lineage O
than O
the O
East B
/ I
Central I
/ I
South I
African I
( I
ECSA I
) I
lineage O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
understudied O
threat O
to O
human O
health O
. O

We O
estimated O
that O
31 O
( O
49 O
% O
) O
of O
63 O
at O
- O
risk O
participants O
had O
asymptomatic O
CHIKV O
infections O
, O
which O
is O
significantly O
outside O
the O
3 O
% O
to O
28 O
% O
range O
reported O
in O
literature O
reviews O
. O

During O
the O
dengue B
virus I
type I
3 I
( I
DENV I
- I
3 I
) I
epidemic O
that O
occurred O
in O
Havana O
in O
2001 O
to O
2002 O
, O
severe O
disease O
was O
associated O
with O
the O
infection O
sequence O
DENV O
- O
1 O
followed O
by O
DENV O
- O
3 O
( O
DENV O
- O
1 O
/ O
DENV O
- O
3 O
) O
, O
while O
the O
sequence O
DENV O
- O
2 O
/ O
DENV O
- O
3 O
was O
associated O
with O
mild O
/ O
asymptomatic O
infections O
. O

Remarkably O
, O
significant O
intrahost O
genetic O
variation O
was O
demonstrated O
within O
the O
same O
patient O
during O
the O
course O
of O
secondary O
infection O
with O
DENV O
- O
1 O
/ O
DENV O
- O
3 O
, O
including O
changes O
in O
the O
structural O
proteins O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
. O

Lassa B
virus I
( I
LASV I
) I
, O
for O
example O
, O
is O
endemic O
in O
several O
West O
African O
countries O
, O
where O
it O
is O
responsible O
for O
an O
estimated O
500 O
, O
000 O
infections O
and O
5 O
, O
000 O
deaths O
annually O
. O

African B
swine I
fever I
( I
ASF I
) I
is O
an O
asymptomatic O
infection O
of O
warthogs O
and O
bushpigs O
, O
which O
has O
become O
an O
emergent O
disease O
of O
domestic O
pigs O
, O
characterized O
by O
hemorrhage O
, O
lymphopenia O
, O
and O
disseminated O
intravascular O
coagulation O
. O

It O
is O
caused O
by O
a O
large O
icosohedral O
double O
- O
stranded O
DNA O
virus O
, O
African B
swine I
fever I
virus I
( I
ASFV I
) I
, O
with O
infection O
of O
macrophages O
well O
characterized O
in O
vitro O
and O
in O
vivo O
. O

This O
study O
shows O
that O
virulent O
isolates O
of O
ASFV O
also O
infect O
primary O
cultures O
of O
porcine O
aortic O
endothelial O
cells O
and O
bushpig B
endothelial I
cells I
( I
BPECs I
) I
in O
vitro O
. O

However O
, O
ASFV O
- O
infected O
endothelial O
cells O
died O
by O
apoptosis O
, O
detected O
morphologically O
by O
terminal O
deoxynucleotidyltransferase O
- O
mediated O
dUTP O
nick O
end O
labeling O
and O
nuclear O
condensation O
and O
biochemically O
by O
Poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( I
PARP I
) I
cleavage O
at O
4 O
h B
postinfection I
( I
hpi I
) I
. O

Immediate O
- O
early O
proinflammatory O
responses O
were O
inhibited O
, O
characterized O
by O
a O
lack O
of O
E O
- O
selectin O
surface O
expression O
and O
interleukin B
6 I
( I
IL I
- I
6 I
) I
and O
IL O
- O
8 O
mRNA O
synthesis O
. O

Five O
New B
World I
( I
NW I
) I
arenaviruses O
cause O
human O
hemorrhagic O
fevers O
. O

Four O
of O
these O
arenaviruses O
are O
known O
to O
enter O
cells O
by O
binding O
Human B
transferrin I
receptor I
1 I
( I
hTfR1 I
) I
. O

The O
mosquito O
- O
borne O
West B
Nile I
virus I
( I
WNV I
) I
is O
responsible O
for O
outbreaks O
of O
viral O
encephalitis O
in O
humans O
, O
horses O
, O
and O
birds O
, O
with O
particularly O
virulent O
strains O
causing O
recent O
outbreaks O
of O
disease O
in O
eastern O
Europe O
, O
the O
Middle O
East O
, O
North O
America O
, O
and O
Australia O
. O

Previous O
studies O
have O
phylogenetically O
separated O
WNV O
strains O
into O
two O
main O
genetic O
lineages O
( O
I O
and O
II O
) O
containing O
virulent O
strains O
associated O
with O
neurological O
disease O
. O

In O
a O
comparative O
analysis O
with O
the O
highly O
virulent O
lineage O
I O
American O
strain O
( O
WNVNY99 O
) O
, O
the O
low O
- O
pathogenicity O
lineage O
II O
strain O
( O
B956 O
) O
, O
a O
benign O
Australian O
strain O
, O
Kunjin O
( O
WNVKUN O
) O
, O
the O
African O
WNV O
- O
like O
Koutango O
virus O
( O
WNVKOU O
) O
, O
and O
a O
WNV O
- O
like O
isolate O
from O
Sarawak O
, O
Malaysia O
( O
WNVSarawak O
) O
, O
were O
assessed O
for O
neuroinvasive O
properties O
in O
a O
murine O
model O
and O
for O
their O
replication O
kinetics O
in O
vitro O
. O

Enhanced O
virulence O
of O
WNVKOU O
also O
was O
associated O
with O
poor O
viral O
clearance O
in O
the O
periphery O
( O
sera O
and O
spleen O
) O
, O
a O
skewed O
innate O
immune O
response O
, O
and O
poor O
neutralizing O
antibody O
development O
. O

We O
identified O
a O
West O
Nile O
- O
like O
virus O
, O
Koutango O
virus O
( O
WNVKOU O
) O
, O
that O
was O
more O
virulent O
than O
a O
known O
virulent O
lineage O
I O
virus O
, O
WNVNY99 O
. O

Flavivirus O
genomes O
with O
deletions O
in O
the O
Capsid B
( I
C I
) I
gene O
are O
attractive O
vaccine O
candidates O
, O
as O
they O
secrete O
highly O
immunogenic O
subviral B
particles I
( I
SVPs I
) I
without O
generating O
infectious O
virus O
. O

Here O
, O
we O
report O
that O
cytomegalovirus O
promoter O
- O
driven O
cDNA O
of O
West O
Nile O
virus O
Kunjin B
( I
KUNV I
) I
containing O
a O
glycosylation O
motif O
in O
the O
envelope B
( I
E I
) I
gene O
and O
a O
combined O
deletion O
of O
alpha O
helices O
1 O
, O
2 O
, O
and O
4 O
in O
C O
produces O
significantly O
more O
SVPs O
than O
KUNV O
cDNAs O
with O
nonglycosylated O
E O
and O
various O
other O
deletions O
in O
C O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
an O
emerging O
pathogen O
that O
is O
now O
the O
leading O
cause O
of O
mosquito O
- O
borne O
and O
epidemic O
encephalitis O
in O
the O
United O
States O
. O

Here O
, O
we O
describe O
the O
generation O
and O
preclinical O
efficacy O
of O
a O
hydrogen O
peroxide O
( O
H2O2 O
) O
- O
inactivated O
WNV B
Kunjin I
strain I
( I
WNV I
- I
KUNV I
) I
vaccine O
as O
a O
candidate O
for O
further O
development O
. O

The O
E O
protein O
of O
most O
flaviviruses O
is O
modified O
by O
Asn O
- O
linked O
glycosylation O
at O
residue O
153 O
/ O
154 O
and O
in O
the O
case O
of O
the O
four O
Dengue B
Virus I
( I
DENV I
) I
serotypes O
by O
a O
second O
glycan O
at O
residue O
67 O
. O

Flavivirus O
nonstructural B
( I
NS I
) I
proteins O
are O
involved O
in O
RNA O
replication O
and O
modulation O
of O
the O
host O
antiviral O
response O
; O
however O
, O
evidence O
is O
mounting O
that O
some O
NS O
proteins O
also O
have O
essential O
roles O
in O
virus O
assembly O
. O

Kunjin B
virus I
( I
KUN I
) I
NS2A O
is O
a O
small O
, O
hydrophobic O
, O
transmembrane O
protein O
that O
is O
part O
of O
the O
replication O
complex O
and O
inhibits O
interferon O
induction O
. O

Previously O
, O
we O
have O
shown O
that O
an O
Isoleucine B
( I
I I
) I
- O
to O
- O
Asparagine B
( I
N I
) I
substitution O
at O
position O
59 O
of O
the O
NS2A O
protein O
blocked O
the O
production O
of O
secreted O
virus O
particles O
in O
cells O
electroporated O
with O
viral O
RNA O
carrying O
this O
mutation O
. O

We O
now O
show O
that O
prolonged O
incubation O
of O
mutant O
KUN O
NS2A O
- O
159N O
replicon O
RNA O
, O
in O
an O
inducible O
BHK O
- O
derived O
packaging O
cell O
line O
( O
expressing O
KUN O
structural O
proteins O
C O
, O
prM O
, O
and O
E O
) O
, O
generated O
escape O
mutants O
that O
rescued O
the O
secretion O
of O
infectious O
virus O
- O
like O
particles O
. O

Sequencing O
identified O
three O
groups O
of O
revertants O
that O
included O
( O
i O
) O
reversions O
to O
wild O
- O
type O
, O
hydrophobic O
lie O
, O
( O
ii O
) O
pseudorevertants O
to O
more O
hydrophobic O
residues O
( O
Ser O
, O
Thr O
, O
and O
Tyr O
) O
at O
codon O
59 O
, O
and O
( O
iii O
) O
pseudorevertants O
retaining O
Asn O
at O
NS2A O
codon O
59 O
but O
containing O
a O
compensatory O
mutation O
( O
Thr O
- O
to O
- O
Pro O
) O
at O
NS2A O
codon O
149 O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
human O
pathogen O
that O
can O
cause O
symptomatic O
infections O
associated O
with O
meningitis O
and O
encephalitis O
. O

Previously O
, O
we O
demonstrated O
that O
replication O
of O
WNV O
inhibits O
the O
interferon B
( I
IFN I
) I
signal O
transduction O
pathway O
by O
preventing O
the O
accumulation O
of O
phosphorylated O
Janus B
kinase I
1 I
( I
JAK1 I
) I
and O
tyrosine B
kinase I
2 I
( I
TYK2 I
) I
( O
J O
. O

Through O
a O
genetic O
analysis O
, O
we O
have O
now O
identified O
a O
determinant O
on O
the O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
that O
controls O
IFN O
resistance O
in O
HeLa O
cells O
expressing O
subgenomic O
WNV O
replicons O
lacking O
the O
structural O
genes O
. O

In O
this O
study O
, O
we O
purified O
a O
recombinant O
, O
secreted O
form O
of O
West B
Nile I
virus I
( I
WNV I
) I
NS1 O
glycoprotein O
from O
baculovirus O
- O
infected O
insect O
cells O
and O
generated O
22 O
new O
NS1 O
- O
specific O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

By O
performing O
competitive O
binding O
assays O
and O
expressing O
truncated O
NS1 O
proteins O
on O
the O
surface O
of O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
and O
in O
bacteria O
, O
we O
mapped O
21 O
of O
the O
newly O
generated O
MAbs O
to O
three O
NS1 O
fragments O
. O

Prophylaxis O
of O
C57BL O
/ O
6 O
mice O
with O
any O
of O
four O
MAbs O
( O
10NS1 O
, O
14NS1 O
, O
16NS1 O
, O
and O
17NS1 O
) O
strongly O
protected O
against O
lethal O
WNV O
infection O
( O
75 O
to O
95 O
% O
survival O
, O
respectively O
) O
compared O
to O
saline O
- O
treated O
controls O
( O
17 O
% O
survival O
) O
. O

West B
Nile I
virus I
( I
WNV I
) I
encodes O
two O
envelope O
proteins O
, O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
. O

Similar O
to O
other O
flaviviruses O
, O
expression O
of O
WNV O
prM O
and O
E O
resulted O
in O
the O
release O
of O
subviral B
particles I
( I
SVPs I
) I
. O

Similar O
results O
were O
obtained O
in O
the O
context O
of O
either O
reporter B
virus I
particles I
( I
RVPs I
) I
or O
infectious O
lineage O
11 O
WNV O
. O

RVPs O
or O
virions O
bearing O
combinations O
of O
glycosylated O
and O
nonglycosylated O
forms O
of O
prM O
and O
E O
could O
infect O
mammalian O
, O
avian O
, O
and O
mosquito O
cells O
( O
BHK O
- O
21 O
, O
QT6 O
, O
and O
C6 O
/ O
36 O
, O
respectively O
) O
. O

The O
West B
Nile I
virus I
( I
WNV I
) I
nonstructural O
protein O
NS1 O
is O
a O
protein O
of O
unknown O
function O
that O
is O
found O
within O
, O
associated O
with O
, O
and O
secreted O
from O
infected O
cells O
. O

A O
sensitive O
antigen O
capture O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
for O
detection O
of O
WNW O
NS1 O
( O
polyclonal O
- O
ACE O
) O
was O
developed O
, O
as O
well O
as O
a O
capture O
ELISA O
for O
the O
specific O
detection O
of O
NS1 O
multimers O
( O
4G4 O
- O
ACE O
) O
. O

In O
experimentally O
infected O
hamsters O
, O
NS1 O
was O
detected O
in O
the O
serum O
between O
days O
3 O
and O
8 O
postinfection O
, O
peaking O
on O
day O
5 O
, O
the O
day O
prior O
to O
the O
onset O
of O
clinical O
disease O
; O
Immunoglobulin B
M I
( I
IgM I
) I
antibodies O
were O
detected O
at O
low O
levels O
on O
day O
5 O
postinfection O
. O

Although O
real O
- O
time O
PCR O
gave O
the O
earliest O
indication O
of O
infection O
( O
day O
1 O
) O
, O
the O
diagnostic O
performance O
of O
the O
4G4 O
- O
ACE O
was O
comparable O
to O
that O
of O
real O
- O
time O
PCR O
during O
the O
time O
period O
when O
NS1 O
was O
secreted O
. O

A O
trans O
- O
packaging O
system O
for O
West B
Nile I
virus I
( I
WNV I
) I
subgenomic O
replicon O
RNAs O
( O
repRNAs O
) O
, O
deleted O
for O
the O
structural O
coding O
region O
, O
was O
developed O
. O

Infectious O
virus B
- I
like I
particles I
( I
VLPs I
) I
were O
produced O
in O
titers O
of O
up O
to O
10 O
( O
9 O
) O
infectious O
units O
/ O
ml O
. O

The O
ability O
of O
self O
- O
replicating O
RNA O
( O
replicon O
) O
vaccine O
vectors O
derived O
from O
the O
Australian O
flavivirus O
Kunjin O
( O
KUN O
) O
to O
induce O
protective O
alphabeta O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
was O
examined O
. O

KUN O
replicons O
encoding O
a O
model O
immunogen O
were O
delivered O
by O
three O
different O
vaccine O
modalities O
: O
( O
i O
) O
as O
naked O
RNA O
transcribed O
in O
vitro O
, O
( O
ii O
) O
as O
plasmid O
DNA O
constructed O
to O
allow O
in O
vivo O
transcription O
of O
replicon O
RNA O
by O
cellular O
RNA O
polymerase O
II O
( O
DNA O
based O
) O
, O
and O
( O
iii O
) O
as O
replicon O
RNA O
encapsidated O
into O
virus O
- O
like O
particles O
. O

A O
single O
immunization O
with O
any O
of O
these O
KUN O
replicon O
vaccines O
induced O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
at O
levels O
comparable O
to O
those O
induced O
by O
recombinant O
vaccinia O
virus O
encoding O
the O
same O
immunogen O
. O

1 O
mug O
of O
DNA O
- O
based O
KUN O
replicons O
elicited O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
similar O
to O
those O
seen O
after O
immunization O
with O
100 O
mug O
of O
a O
conventional O
DNA O
vaccine O
. O

These O
results O
demonstrate O
the O
value O
of O
KUN O
replicon O
vectors O
for O
inducing O
protective O
antiviral O
and O
anticancer O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

The O
intracellular O
assembly O
site O
for O
flaviviruses O
in O
currently O
not O
known O
but O
is O
presumed O
to O
be O
located O
within O
the O
lumen O
of O
the O
rough B
endoplasmic I
reticulum I
( I
rER I
) I
, O
Building O
on O
previous O
studies O
involving O
immunofluorescence B
( I
IF I
) I
and O
cryoimmunoelectron O
microscopy O
of O
Kunjin B
virus I
( I
KUN I
) I
- O
infected O
cells O
, O
we O
sought O
to O
identify O
the O
steps O
involved O
in O
the O
assembly O
and O
maturation O
of O
KUN O
. O

Immunogold O
labeling O
of O
cryosections O
of O
infected O
cells O
indicated O
that O
E O
and O
minor O
envelope O
protein O
prM O
were O
localized O
to O
reticulum O
membranes O
continuous O
with O
KUN O
- O
induced O
convoluted B
membranes I
( I
CM I
) I
or O
paracrystalline B
arrays I
( I
PC I
) I
and O
that O
sometimes O
the O
RER O
contained O
immunogold O
- O
labeled O
virus O
particles O
. O

dimensional O
structure O
of O
the O
envelope B
( I
E I
) I
protein O
; O
the O
base O
of O
domain O
II O
, O
believed O
to O
serve O
as O
a O
hinge O
during O
pH O
- O
dependent O
conformational O
change O
in O
the O
endosome O
, O
and O
the O
lateral O
face O
of O
domain O
III O
, O
which O
contains O
an O
integrin O
- O
binding O
motif O
Arg B
- I
Gly I
- I
Asp I
( I
RGD I
) I
in O
mosquito O
- O
borne O
flaviviruses O
and O
is O
believed O
to O
form O
the O
receptor O
- O
binding O
site O
of O
the O
protein O
. O

In O
an O
effort O
to O
better O
understand O
the O
nature O
of O
attenuation O
caused O
by O
mutations O
in O
these O
two O
regions O
, O
a O
full O
- O
length O
infectious O
cDNA O
clone O
of O
Murray O
Valley O
encephalitis O
virus O
prototype O
strain O
1 O
- O
51 O
( O
MVE O
- O
1 O
- O
51 O
) O
was O
employed O
to O
produce O
a O
panel O
of O
site O
- O
directed O
mutants O
with O
substitutions O
at O
amino O
acid O
positions O
277 O
( O
E O
- O
277 O
; O
hinge O
region O
) O
or O
390 O
( O
E O
- O
390 O
; O
RGD O
motif O
) O
. O

Viruses O
with O
mutations O
at O
E O
- O
277 O
( O
Ser O
- O
- O
> O
Ile O
, O
Ser O
- O
- O
> O
Asn O
, O
Ser O
- O
- O
> O
Val O
, O
and O
Ser O
- O
- O
> O
Pro O
) O
showed O
various O
levels O
of O
in O
vitro O
and O
in O
vivo O
attenuation O
dependent O
on O
the O
level O
of O
hydrophobicity O
of O
the O
substituted O
amino O
acid O
. O

Similarly O
, O
viruses O
with O
mutations O
at O
E O
- O
390 O
( O
Asp O
- O
- O
> O
Asn O
, O
Asp O
- O
- O
> O
Glu O
, O
and O
Asp O
- O
- O
> O
Tyr O
) O
were O
also O
attenuated O
in O
vitro O
and O
in O
vivo O
; O
however O
, O
the O
absorption O
and O
penetration O
rates O
of O
these O
viruses O
were O
similar O
to O
those O
of O
wild O
- O
type O
virus O
. O

A O
possible O
role O
in O
RNA O
replication O
for O
interactions O
between O
conserved O
complementary O
( O
cyclization O
) O
sequences O
in O
the O
5 O
' O
- O
and O
3 O
' O
- O
terminal O
regions O
of O
Flavivirus O
RNA O
was O
previously O
suggested O
but O
never O
tested O
in O
vivo O
. O

Using O
the O
M O
- O
fold O
program O
for O
RNA O
secondary O
- O
structure O
predictions O
, O
we O
examined O
for O
the O
first O
time O
the O
base O
- O
pairing O
interactions O
between O
the O
covalently O
linked O
5 O
' O
genomic O
region O
( O
first O
similar O
to O
160 O
nucleotides O
) O
and O
the O
3 O
' O
untranslated O
region O
( O
last O
similar O
to O
115 O
nucleotides O
) O
for O
a O
range O
of O
mosquito O
borne O
Flavivirus O
species O
. O

In O
order O
to O
obtain O
experimental O
evidence O
of O
the O
predicted O
interactions O
, O
the O
putative O
cyclization O
sequences O
( O
5 O
' O
or O
3 O
' O
) O
in O
the O
replicon O
RNA O
of O
the O
mosquito O
- O
borne O
Kunjin O
virus O
, O
were O
mutated O
either O
separately O
, O
to O
destroy O
base O
- O
pairing O
, O
or O
simultaneously O
, O
to O
restore O
the O
complementarity O
. O

The O
flavivirus O
receptor O
- O
binding O
domain O
has O
been O
putatively O
assigned O
to O
a O
hydrophilic O
region O
( O
FG O
loop O
) O
in O
the O
envelope B
( I
E I
) I
protein O
. O

In O
some O
flaviviruses O
this O
domain O
harbors O
the O
integrin O
- O
binding O
motif O
Arg B
- I
Gly I
- I
Asp I
( I
RGD I
) I
, O
One O
of O
us O
has O
shown O
earlier O
that O
host O
cell O
adaptation O
of O
Murray B
Valley I
encephalitis I
virus I
( I
MVE I
) I
can O
result O
in O
the O
selection O
of O
attenuated O
variants O
altered O
at O
E O
protein O
residue O
Asp O
( O
390 O
) O
, O
which O
is O
part O
of O
an O
RGD O
motif O
. O

Here O
, O
a O
full O
- O
length O
, O
infectious O
cDNA O
clone O
of O
MVE O
was O
constructed O
and O
employed O
to O
systematically O
investigate O
the O
impact O
of O
single O
amino O
acid O
changes O
at O
Asp O
( O
390 O
) O
on O
cell O
tropism O
, O
virus O
entry O
, O
and O
virulence O
. O

Three O
mutants O
( O
Gly O
( O
390 O
) O
, O
Ala O
( O
390 O
) O
, O
and O
His O
( O
390 O
) O
) O
showed O
pronounced O
differences O
from O
an O
infectious O
clone O
- O
derived O
control O
virus O
in O
growth O
in O
mammalian O
and O
mosquito O
cells O
, O
The O
altered O
cell O
tropism O
correlated O
with O
( O
i O
) O
a O
difference O
in O
entry O
kinetics O
, O
( O
ii O
) O
an O
increased O
dependence O
on O
glycosaminoglycans O
( O
determined O
by O
inhibition O
of O
virus O
infectivity O
by O
heparin O
) O
for O
attachment O
of O
the O
three O
mutants O
to O
different O
mammalian O
cells O
, O
and O
( O
iii O
) O
the O
loss O
of O
virulence O
in O
mice O
. O

primary O
features O
of O
the O
flavivirus O
Kunjin O
( O
KUN O
) O
subgenomic O
replicons O
include O
continuous O
noncytopathic O
replication O
in O
host O
cell O
cytoplasm O
and O
the O
ability O
to O
be O
encapsidated O
into O
secreted O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Previously O
we O
reported O
preparation O
of O
RNA O
- O
based O
KUN O
replicon O
vectors O
and O
expression O
of O
heterologous B
genes I
( I
HG I
) I
in O
cell O
culture O
after O
RNA O
transfection O
or O
after O
infection O
with O
recombinant O
KUN O
VLPs O
( O
A O
. O

These O
DNA O
- O
based O
vectors O
were O
able O
to O
direct O
stable O
expression O
of O
beta O
- O
galactosidase O
( O
beta O
- O
Gal O
) O
in O
several O
mammalian O
cell O
lines O
, O
and O
expression O
remained O
high O
( O
similar O
to O
150 O
pg O
per O
cell O
) O
throughout O
cell O
passaging O
. O

Kunjin B
virus I
( I
KUN I
) I
replicon O
RNA O
was O
encapsidated O
by O
a O
procedure O
involving O
two O
consecutive O
electroporations O
of O
BHK O
- O
21 O
cells O
, O
first O
with O
KUN O
replicon O
RNA O
C20DXrep O
( O
with O
prME O
and O
most O
of O
C O
deleted O
) O
and O
about O
24 O
h O
later O
with O
a O
recombinant O
Semliki B
Forest I
virus I
( I
SFV I
) I
replicon O
RNA O
( O
s O
) O
expressing O
KUN O
structural O
proteins O
, O
The O
presence O
of O
KUN O
replicon O
RNA O
in O
encapsidated O
particles O
was O
demonstrated O
by O
its O
amplification O
and O
expression O
in O
newly O
infected O
BHK O
21 O
cells O
, O
detected O
by O
Northern O
blotting O
with O
a O
KUN O
- O
specific O
probe O
and O
by O
immunofluorescence O
analysis O
with O
anti O
- O
NS3 O
antibodies O
. O

No O
infectious O
particles O
were O
produced O
when O
C20DXrep O
RNA O
and O
recombinant O
SFV O
RNAs O
were O
electroporated O
simultaneously O
, O
When O
the O
second O
electroporation O
was O
performed O
with O
a O
single O
SFV O
replicon O
RNA O
expressing O
the O
KUN O
contiguous O
prME O
genes O
and O
the O
KUN O
C O
gene O
together O
but O
under O
control O
of O
two O
separate O
26S O
subgenomic O
promoters O
( O
SFV O
- O
prME O
- O
C107 O
) O
, O
a O
10 O
- O
fold O
- O
higher O
titer O
of O
infectious O
particles O
was O
achieved O
than O
when O
two O
different O
SFV O
replicon O
RNAs O
expressing O
the O
KUN O
C O
gene O
( O
SFV O
- O
C107 O
) O
and O
prME O
genes O
( O
SFV O
- O
prME O
) O
separately O
were O
used O
. O

Possible O
applications O
of O
the O
developed O
packaging O
system O
include O
the O
definition O
of O
the O
packaging O
signal O
( O
s O
) O
in O
flavivirus O
RNA O
as O
well O
as O
the O
amino O
acid O
motif O
( O
s O
) O
in O
the O
structural O
proteins O
involved O
in O
RNA O
encapsidation O
, O
virion O
assembly O
, O
and O
secretion O
. O

The O
subcellular O
location O
of O
the O
nonstructural O
proteins O
NS1 O
, O
NS2B O
, O
and O
NS3 O
in O
Vero O
cells O
infected O
with O
the O
flavivirus O
Kunjin O
was O
investigated O
using O
indirect O
immunofluorescence O
and O
cryoimmunoelectron O
microscopy O
with O
monospecific O
antibodies O
, O
Comparisons O
were O
also O
made O
by O
dual O
immunolabelling O
using O
antibodies O
to O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
the O
putative O
template O
in O
the O
flavivirus O
replication O
complex O
, O
At O
8 O
h O
postinfection O
, O
the O
immunofluorescent O
patterns O
showed O
NS1 O
, O
NS2B O
, O
NS3 O
, O
and O
dsRNA O
located O
in O
a O
perinuclear O
rim O
with O
extensions O
into O
the O
peripheral O
cytoplasm O
, O
By O
16 O
h O
, O
at O
the O
end O
of O
the O
latent O
period O
, O
all O
patterns O
had O
changed O
to O
some O
discrete O
perinuclear O
foci O
associated O
with O
a O
thick O
cytoplasmic O
reticulum O
, O
By O
24 O
h O
, O
this O
localization O
in O
perinuclear O
foci O
was O
more O
apparent O
and O
some O
foci O
were O
dual O
labelled O
with O
antibodies O
to O
dsRNA O
, O
In O
immuno O
- O
gold O
- O
labelled O
cryosections O
of O
infected O
cells O
at O
24 O
h O
, O
all O
antibodies O
were O
associated O
with O
clusters O
of O
induced O
membrane O
structures O
in O
the O
perinuclear O
region O
, O
Two O
important O
and O
novel O
observations O
were O
made O
, O
First O
, O
one O
set O
of O
induced O
membranes O
comprised O
vesicle O
packets O
of O
smooth O
membranes O
dual O
labelled O
with O
anti O
- O
dsRNA O
and O
anti O
- O
NS1 O
or O
anti O
- O
NS3 O
antibodies O
, O
Second O
, O
adjacent O
masses O
of O
paracrystalline O
arrays O
or O
of O
convoluted O
smooth O
membranes O
, O
which O
appeared O
to O
be O
structurally O
related O
, O
were O
strongly O
labelled O
only O
with O
anti O
- O
NS2B O
and O
anti O
- O
NS3 O
antibodies O
, O
Paired O
membranes O
similar O
in O
appearance O
to O
the O
rough O
endoplasmic O
reticulum O
were O
also O
labelled O
, O
but O
less O
strongly O
, O
with O
antibodies O
to O
the O
three O
nonstructural O
proteins O
, O
Other O
paired O
membranes O
adjacent O
to O
the O
structures O
discussed O
above O
enclosed O
accumulated O
virus O
particles O
but O
were O
not O
labelled O
with O
any O
of O
the O
four O
antibodies O
, O
The O
collection O
of O
induced O
membranes O
may O
represent O
virus O
factories O
in O
which O
translation O
, O
RNA O
synthesis O
. O

Completion O
of O
the O
Kunjin B
virus I
( I
KUN I
) I
RNA O
sequence O
showed O
that O
it O
is O
the O
longest O
flavivirus O
sequence O
reported O
( O
11 O
, O
022 O
bases O
) O
, O
commencing O
with O
a O
5 O
' O
noncoding O
region O
of O
96 O
bases O
. O

In O
contrast O
, O
populations O
of O
other O
important O
Australian O
arboviruses O
( O
Murray O
Valley O
encephalitis O
, O
Kunjin O
, O
and O
Sindbis O
viruses O
) O
are O
distributed O
across O
the O
Australian O
continent O
as O
minor O
variants O
of O
one O
strain O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
2 I
( I
SARS I
- I
CoV I
- I
2 I
) I
is O
the O
causative O
agent O
of O
COVID O
- O
19 O
, O
the O
disease O
at O
the O
center O
of O
the O
current O
global O
pandemic O
. O

While O
knowledge O
of O
highly O
structured O
regions O
is O
integral O
for O
mechanistic O
insights O
into O
the O
viral O
infection O
cycle O
, O
very O
little O
is O
known O
about O
the O
location O
and O
folding O
stability O
of O
functional O
elements O
within O
the O
massive O
( O
similar O
to O
30 O
- O
kb O
) O
SARS O
- O
CoV O
- O
2 O
RNA O
genome O
. O

We O
report O
that O
the O
SARS O
- O
CoV O
- O
2 O
genomic O
propensity O
for O
stable O
RNA O
folding O
is O
exceptional O
among O
RNA O
viruses O
, O
superseding O
even O
that O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
one O
of O
the O
most O
structured O
viral O
RNAs O
in O
nature O
. O

Furthermore O
, O
our O
analysis O
suggests O
various O
levels O
of O
RNA O
structure O
across O
genomic O
functional O
regions O
, O
with O
accessory O
and O
structural O
open B
reading I
frames I
( I
ORFs I
) I
containing O
the O
highest O
structural O
density O
in O
the O
viral O
genome O
. O

Finally O
, O
we O
took O
a O
step O
further O
to O
examine O
how O
individual O
RNA O
structures O
formed O
by O
these O
ORFs O
are O
affected O
by O
the O
differences O
in O
genomic O
and O
subgenomic O
contexts O
, O
which O
, O
given O
the O
technical O
difficulty O
of O
experimentally O
separating O
cellular O
mixtures O
of O
subgenomic O
RNA O
( O
sgRNA O
) O
from O
genomic B
RNA I
( I
gRNA I
) I
, O
is O
a O
unique O
advantage O
of O
our O
in O
silico O
pipeline O
. O

However O
, O
protection O
of O
non O
- O
human O
primates O
against O
Lassa B
fever I
virus I
( I
LASV I
) I
is O
possible O
through O
the O
inoculation O
of O
the O
closely O
related O
but O
nonpathogenic O
Mopeia B
virus I
( I
MOPV I
) I
before O
challenge O
with O
LASV O
. O

After O
showing O
evidence O
of O
exoribonuclease B
( I
ExoN I
) I
activity O
in O
NP O
of O
MOPV O
, O
we O
found O
that O
this O
activity O
was O
essential O
for O
multiplication O
in O
antigen O
- O
presenting O
cells O
. O

The O
introduction O
of O
multiple O
mutations O
in O
the O
ExoN O
site O
of O
MOPV O
NP O
generated O
a O
hyperattenuated O
strain O
( O
MOPVExoN6b O
) O
that O
is O
( O
i O
) O
genetically O
stable O
over O
passages O
, O
( O
ii O
) O
has O
increased O
immunogenic O
properties O
compared O
to O
those O
of O
MOPV O
, O
and O
( O
iii O
) O
still O
promotes O
a O
strong O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

Our O
MOPV O
- O
based O
vaccine O
candidate O
for O
LASV O
, O
MOPEVAC O
( O
LASV O
) O
, O
was O
used O
in O
a O
one O
- O
shot O
immunization O
assay O
in O
nonhuman O
primates O
and O
fully O
protected O
them O
from O
a O
lethal O
challenge O
with O
LASV O
. O

The O
recently O
identified O
arenavirus O
Lujo B
virus I
( I
LUJV I
) I
causes O
fatal O
hemorrhagic O
fever O
in O
humans O
. O

LUJV O
GPC O
is O
cleaved O
by O
site B
1 I
protease I
( I
S1P I
) I
at O
the O
RKLM O
motif O
, O
and O
treatment O
with O
the O
S1P O
inhibitor O
PF O
- O
429242 O
reduced O
LUJV O
production O
. O

During O
the O
arenavirus O
life O
cycle O
, O
processing O
of O
the O
viral O
envelope O
glycoprotein B
precursor I
( I
GPC I
) I
by O
the O
cellular O
subtilisin B
kexin I
isozyme I
1 I
( I
SKI I
- I
1 I
) I
/ O
site B
1 I
protease I
( I
S1P I
) I
is O
crucial O
for O
productive O
infection O
. O

A O
crucial O
step O
in O
productive O
arenavirus O
infection O
of O
human O
cells O
is O
the O
processing O
of O
the O
viral O
envelope O
glycoprotein O
by O
the O
cellular O
subtilisin B
kexin I
isozyme I
1 I
( I
SKI I
- I
1 I
) I
/ O
site B
1 I
protease I
( I
S1P I
) I
. O

To O
identify O
host O
factors O
associated O
with O
arenavirus O
virulence O
, O
we O
used O
a O
cynomolgus O
macaque O
model O
to O
evaluate O
the O
pathogenesis O
of O
Lujo B
virus I
( I
LUJV I
) I
, O
a O
recently O
emerged O
arenavirus O
that O
caused O
an O
outbreak O
of O
severe O
viral O
hemorrhagic O
fever O
in O
southern O
Africa O
. O

We O
then O
compared O
this O
to O
contrasting O
clinical O
outcomes O
during O
arenavirus O
infection O
, O
specifically O
to O
samples O
obtained O
from O
macaques O
infected O
with O
three O
highly O
pathogenic O
lines O
of O
Lassa B
virus I
( I
LASV I
) I
, O
the O
causative O
agent O
of O
Lassa B
fever I
( I
LF I
) I
. O

We O
assessed O
gene O
expression O
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
and O
determined O
genes O
that O
significantly O
changed O
expression O
relative O
to O
that O
in O
uninfected O
animals O
over O
the O
course O
of O
infection O
. O

We O
find O
that O
the O
Z O
proteins O
of O
all O
known O
pathogenic O
arenaviruses O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
Lassa O
, O
Junin O
, O
Machupo O
, O
Sabia O
, O
Guanarito O
, O
Chapare O
, O
Dandenong O
, O
and O
Lujo O
viruses O
, O
can O
inhibit O
retinoic B
acid I
- I
inducible I
gene I
1 I
( I
RIG I
- I
I I
) I
and O
Melanoma B
Differentiation I
- I
Associated I
protein I
5 I
( I
MDA5 I
) I
, O
in O
sharp O
contrast O
to O
those O
of O
14 O
other O
nonpathogenic O
arenaviruses O
. O

Inhibition O
of O
the O
RIG B
- I
I I
- I
like I
receptors I
( I
RLRs I
) I
by O
pathogenic O
Z O
proteins O
is O
mediated O
by O
the O
protein O
- O
protein O
interactions O
of O
Z O
and O
RLRs O
, O
which O
lead O
to O
the O
disruption O
of O
the O
interactions O
between O
RLRs O
and O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
. O

The O
Z O
- O
RLR O
interactive O
interfaces O
are O
located O
within O
the O
N B
- I
terminal I
domain I
( I
NTD I
) I
of O
the O
Z O
protein O
and O
the O
N O
- O
terminal O
CARD O
domains O
of O
RLRs O
. O

Swapping O
of O
the O
LCMV O
Z O
NTD O
into O
the O
nonpathogenic O
Pichinde B
virus I
( I
PICV I
) I
genome O
does O
not O
affect O
virus O
growth O
in O
Vero O
cells O
but O
significantly O
inhibits O
the O
type B
I I
interferon I
( I
IFN I
) I
responses O
and O
increases O
viral O
replication O
in O
human O
primary O
macrophages O
. O

Several O
arenaviruses O
are O
known O
to O
cause O
viral B
hemorrhagic I
fever I
( I
VHF I
) I
in O
sub O
- O
Saharan O
Africa O
and O
South O
America O
, O
where O
VHF O
is O
a O
major O
public O
health O
and O
medical O
concern O
. O

Due O
to O
difficulties O
associated O
with O
handling O
live O
viruses O
, O
pseudotype O
viruses O
, O
which O
transiently O
bear O
arenavirus O
envelope O
proteins O
based O
on O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
or O
retrovirus O
, O
have O
been O
developed O
as O
surrogate O
virus O
systems O
. O

Here O
, O
we O
report O
the O
development O
of O
a O
pseudotype O
VSV O
bearing O
each O
envelope O
protein O
of O
various O
species O
of O
arenaviruses O
( O
AREpv O
) O
, O
including O
the O
newly O
identified O
Lujo B
virus I
( I
LUJV I
) I
and O
Chapare O
virus O
. O

The O
infections O
by O
New O
World O
and O
Old O
World O
AREpv O
were O
dependent O
on O
their O
receptors O
( O
human O
transferrin O
receptor O
1 O
[ O
hTfR1 O
] O
and O
alpha O
- O
dystro O
- O
glycan O
[ O
alpha O
DG O
] O
, O
respectively O
) O
. O

However O
, O
infection O
by O
pseudotype O
VSV O
bearing O
the O
LUJV O
envelope O
protein O
( O
LUJpv O
) O
occurred O
independently O
of O
hTfR1 O
and O
alpha O
DG O
, O
indicating O
that O
LUJpv O
utilizes O
an O
unidentified O
receptor O
. O

Furthermore O
, O
the O
infectivity O
of O
LUJpv O
was O
significantly O
decreased O
in O
the O
Niemann B
- I
Pick I
C1 I
( I
NPC1 I
) I
- O
deficient O
cell O
line O
, O
suggesting O
the O
necessity O
for O
NPC1 O
activity O
for O
efficient O
LUJpv O
infection O
. O

While O
developing O
this O
system O
, O
we O
discovered O
that O
reconstructing O
infectious O
Lujo O
virus O
using O
the O
previously O
reported O
L O
segment O
intergenic B
region I
( I
IGR I
) I
, O
comprising O
the O
arenaviral O
transcription O
termination O
signal O
, O
yielded O
an O
attenuated O
Lujo O
virus O
. O

Andes B
virus I
( I
ANDV I
) I
is O
associated O
with O
a O
lethal O
vascular O
leak O
syndrome O
in O
humans O
termed O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Andes B
virus I
( I
ANDV I
) I
and O
Sin B
Nombre I
virus I
( I
SNV I
) I
are O
rodent O
- O
borne O
hantaviruses O
that O
cause O
a O
highly O
lethal O
hemorrhagic O
fever O
in O
humans O
known O
as O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Multimerization O
of O
the O
Hantaan O
virus O
nucleocapsid B
protein I
( I
NP I
) I
in O
Hantaan O
virus O
- O
infected O
Vero O
E6 O
cells O
was O
observed O
in O
a O
competitive O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

Two O
regions O
, O
amino O
acids O
100 O
to O
125 O
( O
region O
1 O
) O
and O
amino O
acids O
404 O
to O
429 O
( O
region O
2 O
) O
, O
were O
essential O
for O
the O
NP O
- O
NP O
interaction O
in O
yeast O
. O

The O
NP O
of O
Seoul O
virus O
in O
which O
the O
tryptophan O
at O
amino O
acid O
number O
119 O
was O
replaced O
by O
alanine O
( O
W119A O
mutation O
) O
did O
not O
multimerize O
in O
the O
yeast O
two O
- O
hybrid O
assay O
, O
indicating O
that O
tryptophan O
119 O
in O
region O
1 O
is O
important O
for O
the O
NP O
- O
NP O
interaction O
in O
yeast O
. O

Hantaviruses O
cause O
two O
severe O
human O
diseases O
: O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
and O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Here O
we O
show O
that O
infection O
of O
cynomolgus O
macaques O
by O
wild O
- O
type O
Puumala O
hantavirus O
resulted O
in O
typical O
signs O
of O
HFRS O
including O
lethargy O
, O
anorexia O
, O
proteinuria O
, O
and O
/ O
or O
hematuria O
, O
in O
addition O
to O
cytokine O
( O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
IL O
- O
10 O
, O
and O
tumor O
necrosis O
factor O
alpha O
) O
, O
C O
- O
reactive O
protein O
, O
creatinine O
, O
and O
nitric O
oxide O
responses O
. O

Viral O
RNA O
was O
detected O
in O
plasma O
from O
days O
3 O
to O
7 O
postinoculation O
until O
days O
24 O
to O
28 O
postinoculation O
, O
infectious O
virus O
was O
recovered O
, O
and O
the O
virus O
- O
specific O
immune O
responses O
( O
immunoglobulin O
M O
[ O
IgM O
] O
, O
IgG O
, O
and O
neutralizing O
antibodies O
) O
mimicked O
those O
seen O
in O
humans O
. O

Puumala B
virus I
( I
PUUV I
) I
is O
a O
negative O
- O
stranded O
RNA O
virus O
in O
the O
genus O
Hantavirits O
, O
family O
Bunyaviridae O
. O

7 O
X O
10 O
( O
- O
7 O
) O
to O
2 O
. O

2 O
x O
10 O
( O
- O
6 O
) O
nt O
substitutions O
per O
site O
per O
year O
. O

We O
demonstrated O
virus O
- O
specific O
responses O
in O
bulk O
cultures O
of O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
all O
donors O
; O
Bulk O
T O
- O
cell O
responses O
were O
directed O
against O
either O
Hantaan O
virus O
nucleocapsid B
( I
N I
) I
or O
G1 O
protein O
, O
and O
these O
responses O
varied O
between O
donors O
. O

We O
established O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
N O
- O
specific O
cell O
lines O
from O
two O
donors O
and O
CD4 O
( O
+ O
) O
G1 O
- O
specific O
cell O
lines O
from O
a O
third O
donor O
. O

All O
CD8 O
( O
+ O
) O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
lines O
recognized O
one O
of O
two O
epitopes O
on O
the O
nucleocapsid O
protein O
: O
one O
epitope O
spanning O
amino O
acids O
12 O
to O
20 O
and O
the O
other O
spanning O
amino O
acids O
421 O
to O
429 O
. O

wild B
- I
type I
( I
WT I
) I
( O
bank O
vole O
- O
passaged O
) O
and O
Vero O
E6 O
cell O
- O
cultured O
variants O
of O
Puumala O
virus O
strain O
Kazan O
were O
analyzed O
for O
their O
virologic O
and O
genetic O
properties O
. O

Four B
Corners I
hantavirus I
( I
FCV I
) I
is O
the O
tentative O
name O
of O
the O
suspected O
etiologic O
agent O
of O
the O
newly O
identified O
hantavirus B
- I
associated I
respiratory I
distress I
syndrome I
( I
HARDS I
) I
. O

Limited O
nucleotide O
sequence O
data O
from O
the O
FCV O
glycoprotein B
- I
2 I
( I
G2 I
) I
confirmed O
that O
FCV O
is O
a O
hantavirus O
and O
showed O
that O
it O
is O
most O
closely O
related O
to O
Prospect O
Hill O
and O
Puumala O
viruses O
. O

Evolutionary O
pressures O
appear O
to O
have O
maintained O
genomic O
sequences O
encoding O
both O
a O
stop O
codon O
( O
opal O
) O
and O
an O
open O
reading O
frame O
( O
arginine O
) O
as O
a O
general O
feature O
of O
the O
O B
' I
nyong I
- I
nyong I
virus I
( I
ONNV I
) I
genome O
, O
indicating O
that O
both O
are O
required O
at O
some O
point O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
virus O
jis O
a O
mosquito O
- O
borne O
RNA O
virus O
responsible O
for O
large O
explosive O
outbreaks O
of O
acute O
febrile O
disease O
in O
humans O
and O
livestock O
in O
Africa O
with O
significant O
mortality O
and O
economic O
impact O
. O

Virus O
genetic O
diversity O
was O
low O
( O
similar O
to O
5 O
% O
) O
and O
primarily O
involved O
accumulation O
of O
mutations O
at O
an O
average O
of O
2 O
. O

9 O
x O
10 O
( O
- O
4 O
) O
substitution O
s O
/ O
site O
/ O
year O
, O
although O
some O
evidence O
of O
RNA O
segment O
reassortment O
was O
found O
. O

Ross B
River I
virus I
( I
RRV I
) I
belongs O
to O
the O
genus O
Alphavirus O
and O
is O
prevalent O
in O
Australia O
. O

Type O
I O
interferons B
( I
IFN I
) I
are O
the O
primary O
antiviral O
cytokines O
and O
trigger O
activation O
of O
the O
host O
innate O
immune O
system O
to O
suppress O
the O
replication O
of O
invading O
viruses O
. O

To O
identify O
the O
determinants O
involved O
in O
type O
I O
IFN O
modulation O
, O
the O
region O
encoding O
the O
nonstructural B
proteins I
( I
nsPs I
) I
of O
RRV O
2548 O
was O
sequenced O
, O
and O
42 O
amino O
acid O
differences O
from O
RRV O
- O
T48 O
were O
identified O
. O

IMPORTANCE O
By O
identifying O
natural O
Ross B
River I
virus I
( I
RRV I
) I
amino O
acid O
determinants O
for O
type B
I I
interferon I
( I
IFN I
) I
modulation O
, O
this O
study O
gives O
further O
insight O
into O
the O
mechanism O
of O
type O
I O
IFN O
modulation O
by O
alphaviruses O
. O

This O
study O
also O
provides O
a O
comparison O
of O
the O
roles O
of O
different O
parts O
of O
the O
RRV O
nonstructural O
region O
in O
type O
I O
IFN O
modulation O
, O
highlighting O
the O
importance O
of O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
and O
nsP2 O
in O
this O
process O
. O

Ross B
River I
virus I
( I
RRV I
) I
is O
one O
of O
a O
group O
of O
mosquito O
- O
transmitted O
alphaviruses O
that O
cause O
debilitating O
, O
and O
often O
chronic O
, O
musculoskeletal O
disease O
in O
humans O
. O

Previously O
, O
we O
reported O
that O
replacement O
of O
the O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
gene O
of O
the O
mouse O
- O
virulent O
RRV O
strain O
T48 O
with O
that O
from O
the O
mouse O
- O
avirulent O
strain O
DC5692 O
generated O
a O
virus O
that O
was O
attenuated O
in O
a O
mouse O
model O
of O
disease O
. O

RRV O
T48 O
carrying O
the O
six O
nonsynonymous O
DC5692 O
nucleotide O
differences O
( O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
) O
was O
attenuated O
in O
both O
wild O
- O
type O
and O
Rag1 O
( O
- O
/ O
- O
) O
mice O
. O

Despite O
the O
attenuated O
phenotype O
, O
RRV O
T48 O
and O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
loads O
in O
tissues O
of O
wild O
- O
type O
and O
Rag1 O
( O
- O
/ O
- O
) O
mice O
were O
indistinguishable O
from O
1 O
to O
3 O
days O
postinoculation O
. O

RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
loads O
in O
skeletal O
muscle O
tissue O
, O
but O
not O
in O
other O
tissues O
, O
decreased O
dramatically O
by O
5 O
days O
postinoculation O
in O
both O
wild O
- O
type O
and O
Rag1 O
( O
- O
/ O
- O
) O
mice O
, O
suggesting O
that O
the O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
mutant O
is O
more O
sensitive O
to O
innate O
antiviral O
effectors O
than O
RRV O
- O
T48 O
in O
a O
tissue O
- O
specific O
manner O
. O

In O
agreement O
with O
these O
findings O
, O
RRV O
T48 O
and O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
loads O
were O
similar O
in O
mice O
deficient O
in O
the O
type O
I O
interferon O
receptor O
. O

Dengue B
viruses I
( I
DV I
) I
, O
composed O
of O
four O
distinct O
serotypes O
( O
DV1 O
to O
DV4 O
) O
, O
cause O
50 O
to O
100 O
million O
infections O
annually O
. O

antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
, O
a O
process O
best O
described O
in O
vitro O
, O
is O
epidemiologically O
linked O
to O
complicated O
DV O
infections O
, O
especially O
in O
Southeast O
Asia O
. O

Here O
we O
report O
for O
the O
first O
time O
the O
ADE O
phenomenon O
in O
primary O
human B
dendritic I
cells I
( I
DC I
) I
, O
early O
targets O
of O
DV O
infection O
, O
and O
human O
cell O
lines O
bearing O
Fc O
receptors O
. O

We O
show O
that O
ADE O
is O
inversely O
correlated O
with O
surface O
expression O
of O
DC O
- O
SIGN O
( O
DC O
- O
specific O
intercellular O
adhesion O
molecule O
- O
3 O
- O
grabbing O
nonintegrin O
) O
and O
requires O
Fc B
gamma I
receptor I
IIa I
( I
Fc I
gamma I
RIIa I
) I
. O

Interestingly O
, O
tumor O
necrosis O
factor O
alpha O
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
but O
not O
IL O
- O
10 O
and O
gamma O
interferon O
, O
were O
released O
in O
the O
presence O
of O
dengue O
patient O
sera O
but O
generally O
only O
at O
enhancement O
titers O
, O
suggesting O
a O
signaling O
component O
of O
ADE O
. O

DV O
versatility O
in O
entry O
routes O
( O
Fc O
gamma O
RIIa O
or O
DC O
- O
SIGN O
) O
in O
mature O
DC O
broadens O
target O
options O
and O
suggests O
additional O
ways O
for O
DC O
to O
contribute O
to O
the O
pathogenesis O
of O
severe O
DV O
infection O
. O

Utilizing O
a O
mouse O
model O
of O
Ross B
River I
virus I
( I
RRV I
) I
disease O
, O
we O
found O
that O
the O
primary O
targets O
of O
RRV O
infection O
are O
bone O
, O
joint O
, O
and O
skeletal O
muscle O
tissues O
of O
the O
hind O
limbs O
in O
both O
outbred O
CD O
- O
1 O
mice O
and O
adult O
C57BL O
/ O
6J O
mice O
. O

cells O
, O
and O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
lymphocytes O
. O

To O
determine O
the O
contribution O
of O
the O
adaptive O
immune O
system O
, O
the O
outcome O
of O
RRV O
- O
induced O
disease O
was O
examined O
in O
C57BL O
/ O
6J O
RAG O
- O
1 O
( O
- O
/ O
- O
) O
mice O
, O
which O
lack O
functional O
T O
and O
B O
lymphocytes O
. O

RAG O
- O
1 O
( O
- O
/ O
- O
) O
and O
wild O
- O
type O
mice O
developed O
similar O
disease O
signs O
, O
infiltration O
of O
inflammatory O
macrophages O
and O
NK O
cells O
, O
and O
muscle O
pathology O
, O
suggesting O
that O
the O
adaptive O
immune O
response O
does O
not O
play O
a O
critical O
role O
in O
the O
development O
of O
disease O
. O

Three O
Aedes O
albopictus O
( O
mosquito O
) O
cell O
lines O
persistently O
infected O
with O
Sindbis O
virus O
excluded O
the O
replication O
of O
both O
homologous O
( O
various O
strains O
of O
Sindbis O
) O
and O
heterologous O
( O
Aura O
, O
Semliki O
Forest O
, O
and O
Ross O
River O
) O
alphaviruses O
. O

At O
least O
five O
New B
World I
( I
NW I
) I
arenaviruses O
cause O
hemorrhagic O
fevers O
in O
South O
America O
. O

These O
pathogenic O
clade O
B O
viruses O
, O
as O
well O
as O
nonpathogenic O
arenaviruses O
of O
the O
same O
clade O
, O
use O
transferrin B
receptor I
1 I
( I
TfR1 I
) I
of O
their O
host O
species O
to O
enter O
cells O
. O

Pathogenic O
viruses O
are O
distinguished O
from O
closely O
related O
nonpathogenic O
ones O
by O
their O
additional O
ability O
to O
utilize O
human B
TfR1 I
( I
hTfR1 I
) I
. O

Notably O
, O
one O
of O
these O
viruses O
, O
AV96010151 O
, O
closely O
related O
to O
the O
prototype O
Whitewater B
Arroyo I
virus I
( I
WWAV I
) I
, O
entered O
cells O
using O
hTfR1 O
, O
consistent O
with O
a O
role O
for O
a O
WWAV O
- O
like O
virus O
in O
three O
fatal O
human O
infections O
whose O
causative O
agent O
has O
not O
been O
identified O
. O

Several O
arenaviruses O
, O
including O
Lassa B
virus I
( I
LASV I
) I
, O
are O
causative O
agents O
of O
hemorrhagic O
fever O
, O
for O
which O
effective O
therapeutic O
options O
are O
lacking O
. O

The O
LASV O
envelope O
glycoprotein B
( I
GP I
) I
gene O
was O
used O
to O
generate O
lentiviral O
pseudotypes O
to O
identify O
small O
- O
molecule O
inhibitors O
of O
viral O
entry O
. O

Subsequent O
lead O
optimization O
for O
antiviral O
activity O
identified O
a O
modified O
structure O
, O
ST O
- O
193 O
, O
with O
a O
50 B
% I
inhibitory I
concentration I
( I
IC50 I
) I
of O
1 O
. O

ST O
- O
193 O
inhibited O
pseudotypes O
generated O
with O
other O
arenavirus O
envelopes O
as O
well O
, O
including O
the O
remaining O
four O
commonly O
associated O
with O
hemorrhagic O
fever O
( O
IC O
( O
50 O
) O
s O
for O
Junin O
, O
Machupo O
, O
Guanarito O
, O
and O
Sabia O
were O
in O
the O
0 O
. O

2 O
to O
12 O
nM O
range O
) O
but O
exhibited O
no O
antiviral O
activity O
against O
pseudotypes O
incorporating O
either O
the O
GP O
from O
the O
LASV O
- O
related O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
or O
the O
unrelated O
G O
protein O
from O
vesicular O
stomatitis O
virus O
, O
at O
concentrations O
of O
up O
to O
10 O
mu O
M O
. O

tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
is O
transmitted O
to O
humans O
primarily O
through O
tick O
bites O
or O
oral O
consumption O
of O
accordingly O
contaminated O
unpasteurized O
milk O
or O
milk O
products O
. O

Interferon O
alpha O
receptor O
1 O
- O
deficient O
( O
Ifnar1 O
( O
- O
/ O
- O
) O
) O
mice O
, O
which O
lack O
the O
interferon O
alpha O
/ O
beta O
responses O
, O
develop O
neurologic O
manifestations O
after O
infection O
with O
TBEV O
and O
Langat B
virus I
( I
LGTV I
) I
. O

IMPORTANCE O
Tick O
- O
borne O
encephalitis O
is O
a O
severe O
disease O
of O
the O
central O
nervous O
system O
caused O
by O
the O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
. O

Furthermore O
, O
paramyxoviral O
fusion O
occurs O
at O
the O
host O
cell O
membrane O
and O
is O
essential O
for O
both O
virus O
entry O
( O
virus O
- O
cell O
fusion O
) O
and O
syncytium O
formation O
( O
cell O
- O
cell O
fusion O
) O
, O
central O
to O
viral O
pathogenicity O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
deadly O
member O
of O
the O
Paramyxoviridae O
family O
, O
which O
also O
includes O
Hendra O
, O
measles O
, O
mumps O
, O
human O
parainfluenza O
, O
and O
various O
veterinary O
viruses O
. O

We O
used O
a O
combination O
of O
methyl O
beta O
cyclodextrin O
( O
M O
beta O
CD O
) O
, O
lovastatin O
, O
and O
cholesterol O
to O
deplete O
or O
enrich O
cell O
membrane O
cholesterol O
outside O
cytotoxic O
concentrations O
. O

These O
phenotypes O
were O
paralleled O
using O
NiV O
/ O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
pseudotyped O
viral O
infection O
assays O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
highly O
pathogenic O
enveloped O
virus O
in O
the O
Henipavirus O
genus O
within O
the O
Paramyxoviridae O
family O
, O
capable O
of O
causing O
a O
high O
mortality O
rate O
in O
humans O
and O
high O
morbidity O
in O
domestic O
and O
agriculturally O
important O
animals O
. O

The O
Tembusu B
virus I
( I
TMUV I
) I
PS O
strain O
, O
derived O
by O
several O
passages O
and O
plaque O
purifications O
in O
BHK O
- O
21 O
cells O
, O
displays O
markedly O
lower O
virulence O
in O
Pekin O
ducklings O
relative O
to O
a O
natural O
isolate O
of O
TMUV O
, O
but O
the O
potential O
virulence O
determinants O
and O
the O
in O
vivo O
mechanisms O
for O
substantial O
virulence O
attenuation O
of O
the O
passage O
variant O
remain O
unknown O
. O

We O
showed O
that O
residue O
304 O
in O
the O
envelope B
( I
E I
) I
protein O
is O
the O
molecular O
determinant O
of O
TMUV O
virulence O
. O

Further O
investigations O
with O
mutant O
and O
parental O
viruses O
demonstrated O
that O
acquisition O
of O
positive O
charges O
at O
E O
protein O
residue O
304 O
plays O
a O
critical O
role O
in O
substantial O
attenuation O
of O
neurovirulence O
and O
neuroinvasiveness O
, O
which O
is O
linked O
to O
enhanced O
binding O
affinity O
for O
glycosaminoglycans B
( I
GAGs I
) I
. O

type B
I I
interferon I
( I
IFN I
) I
- O
mediated O
antiviral O
responses O
are O
critical O
for O
modulating O
host O
- O
virus O
responses O
, O
and O
indeed O
, O
viruses O
have O
evolved O
strategies O
to O
antagonize O
this O
pathway O
. O

encephalomyocarditis B
virus I
( I
EMCV I
) I
is O
an O
important O
zoonotic O
pathogen O
, O
which O
causes O
myocarditis O
, O
encephalitis O
, O
neurological O
disease O
, O
reproductive O
disorders O
, O
and O
diabetes O
in O
pigs O
. O

This O
occurs O
via O
the O
degradation O
of O
the O
MDA5 O
- O
mediated O
cytoplasmic O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
antiviral O
sensing O
RIG B
- I
I I
like I
receptor I
( I
RLR I
) I
pathway O
. O

classical B
swine I
fever I
( I
CSF I
) I
, O
caused O
by O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
is O
a O
highly O
contagious O
disease O
of O
swine O
with O
high O
morbidity O
and O
mortality O
that O
negatively O
affects O
the O
pig O
industry O
worldwide O
, O
in O
particular O
in O
China O
. O

The O
endocytosis B
sorting I
complex I
required I
for I
transport I
( I
ESCRT I
) I
system O
is O
a O
central O
molecular O
machine O
for O
membrane O
protein O
sorting O
and O
scission O
in O
eukaryotic O
cells O
that O
plays O
an O
essential O
role O
in O
many O
physiological O
metabolic O
processes O
, O
including O
invasion O
and O
egress O
of O
envelope O
viruses O
. O

Tsg101 O
assists O
the O
virus O
in O
entering O
the O
host O
cell O
through O
the O
late O
endosome O
( O
Rab7 O
and O
Rab9 O
) O
and O
finally O
reaching O
the O
lysosome O
( O
Lamp O
- O
1 O
) O
. O

Finally O
, O
confocal O
microscopy O
showed O
that O
the O
replication O
complex O
of O
Tsg101 O
and O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
or O
NS4B O
and O
NS5B O
protein O
was O
close O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
not O
the O
Golgi O
, O
in O
the O
cytoplasm O
. O

IMPORTANCE O
CSF O
, O
caused O
by O
CSFV O
, O
is O
a O
World B
organization I
for I
animal I
health I
( I
OIE I
) I
notifiable O
disease O
and O
causes O
significant O
financial O
losses O
to O
the O
pig O
industry O
globally O
. O

Two O
of O
the O
top O
candidates O
identified O
, O
CMP B
N I
- I
acetylneuraminic I
acid I
synthetase I
( I
Cmas I
) I
and O
solute B
carrier I
family I
35 I
member I
A1 I
( I
Slc35a1 I
) I
, O
promote O
sialic O
acid O
expression O
on O
the O
cell O
surface O
. O

Two O
reovirus O
strains O
that O
differ O
in O
the O
capacity O
to O
bind O
sialic O
acid O
, O
T3SA O
( O
+ O
) O
and O
T3SA O
( O
- O
) O
, O
were O
used O
to O
evaluate O
Cmas O
and O
Slc35a1 O
as O
potential O
host O
genes O
required O
for O
reovirus O
infection O
. O

These O
results O
correlated O
with O
decreased O
binding O
of O
strain O
T3SA O
( O
+ O
) O
, O
which O
is O
capable O
of O
engaging O
sialic O
acid O
. O

Disruption O
of O
either O
gene O
did O
not O
alter O
the O
low O
- O
level O
binding O
of O
T3SA O
( O
- O
) O
, O
which O
does O
not O
engage O
sialic O
acid O
. O

Furthermore O
, O
infectivity O
of O
T3SA O
( O
+ O
) O
was O
diminished O
to O
levels O
similar O
to O
those O
of O
T3SA O
( O
- O
) O
in O
cells O
lacking O
Cmas O
and O
Slc35a1 O
by O
CRISPR O
ablation O
. O

However O
, O
exogenous O
expression O
of O
Cmas O
and O
Slc35a1 O
into O
the O
respective O
null O
cells O
restored O
sialic O
acid O
expression O
and O
T3SA O
( O
+ O
) O
binding O
and O
infectivity O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
highly O
pathogenic O
zoonotic O
arbovirus O
endemic O
in O
many O
African O
countries O
and O
the O
Arabian O
Peninsula O
. O

In O
humans O
, O
an O
estimated O
1 O
to O
2 O
% O
of O
RVFV O
infections O
result O
in O
severe O
disease O
( O
encephalitis O
, O
hepatitis O
, O
or O
retinitis O
) O
with O
a O
high O
rate O
of O
lethality O
when O
associated O
with O
hemorrhagic O
fever O
. O

In O
this O
work O
, O
we O
have O
analyzed O
the O
effects O
of O
NSs O
expression O
on O
the O
actin O
cytoskeleton O
while O
conducting O
infections O
with O
the O
NSs O
- O
expressing O
virulent O
( O
ZH548 O
) O
and O
attenuated O
( O
MP12 O
) O
strains O
of O
RVFV O
and O
the O
nonNSs O
- O
expressing O
avirulent O
( O
ZH548 O
Delta O
NSs O
) O
strain O
, O
as O
well O
as O
after O
the O
ectopic O
expression O
of O
NSs O
. O

In O
macrophages O
, O
fibroblasts O
, O
and O
hepatocytes O
, O
NSs O
expression O
prevented O
the O
upregulation O
of O
Abl2 O
( O
a O
major O
regulator O
of O
the O
actin O
cytoskeleton O
) O
expression O
otherwise O
induced O
by O
avirulent O
infections O
and O
identified O
here O
as O
part O
of O
the O
antiviral O
response O
. O

IMPORTANCE O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
dangerous O
human O
and O
animal O
pathogen O
that O
was O
ranked O
by O
the O
World O
Health O
Organization O
in O
2018 O
as O
among O
the O
eight O
pathogens O
of O
most O
concern O
for O
being O
likely O
to O
cause O
wide O
epidemics O
in O
the O
near O
future O
and O
for O
which O
there O
are O
no O
, O
or O
insufficient O
, O
countermeasures O
. O

In O
this O
study O
, O
we O
found O
that O
a O
novel O
goose O
astrovirus O
( O
GAstV O
) O
, O
GAstV O
- O
GD O
, O
and O
its O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
could O
efficiently O
activate O
the O
innate O
immune O
response O
and O
induce O
a O
high O
level O
of O
OASL O
in O
vitro O
and O
in O
vivo O
. O

The O
role O
of O
a O
signaling O
pathway O
through O
Macrophage B
colony I
- I
stimulating I
factor I
( I
mCSF I
) I
and O
its O
receptor O
, O
Macrophage B
colony I
- I
stimulating I
factor I
1 I
receptor I
( I
CSF1R I
) I
, O
during O
experimental O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
encephalitis O
( O
HSE O
) O
was O
studied O
by O
two O
different O
approaches O
. O

) O
, O
brain O
viral O
titers O
were O
significantly O
decreased O
, O
whereas O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
was O
significantly O
increased O
in O
mice O
treated O
with O
MCSF O
compared O
to O
mice O
treated O
with O
saline O
. O

The O
number O
of O
CD68 O
+ O
( O
a O
phagocytosis O
marker O
) O
microglial O
cells O
was O
significantly O
increased O
in O
MCSF O
- O
treated O
mice O
compared O
to O
the O
saline O
treated O
group O
. O

Secondly O
, O
we O
conditionally O
depleted O
CSF1R O
on O
microglial O
cells O
of O
CSF1R O
- O
loxP O
- O
CX3CR1 O
- O
cre O
/ O
ERT2 O
mice O
( O
in O
a O
C57BL O
/ O
6 O
background O
) O
through O
induction O
with O
tamoxifen O
. O

The O
survival O
rate O
of O
mice O
depleted O
of O
CSF1R O
( O
knockout O
[ O
KO O
] O
mice O
) O
was O
significantly O
lower O
than O
that O
of O
wild B
- I
type I
( I
WT I
) I
mice O
( O
0 O
% O
versus O
67 O
% O
) O
. O

IMPORTANCE O
Microglia O
appear O
to O
be O
one O
of O
the O
principal O
regulators O
of O
neuroinflammation O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Hence O
, O
the O
role O
of O
microglia O
during O
Herpes B
simplex I
virus I
encephalitis I
( I
HSE I
) I
has O
not O
been O
fully O
characterized O
. O

Coxsackie B
B I
viruses I
( I
CVB I
) I
cause O
a O
wide O
spectrum O
of O
diseases O
, O
ranging O
from O
mild O
respiratory O
syndromes O
and O
hand O
, O
foot O
, O
and O
mouth O
disease O
to O
life O
- O
threatening O
conditions O
, O
such O
as O
pancreatitis O
, O
myocarditis O
, O
and O
encephalitis O
. O

Two O
CVB3 O
strains O
( O
CVB3 O
- O
H3 O
and O
CVB3 O
Nancy O
) O
were O
passaged O
in O
HeLa O
cells O
in O
the O
presence O
of O
sCAR O
- O
Fc O
. O

The O
CVB3 O
- O
H3 O
strain O
did O
not O
develop O
resistance O
, O
whereas O
two O
populations O
of O
CVB3 O
Nancy O
mutants O
emerged O
, O
one O
with O
complete O
( O
CVB3 O
( O
M O
) O
) O
and O
one O
with O
partial O
( O
CVB3 O
( O
K O
) O
) O
resistance O
. O

DNA O
sequence O
alignment O
of O
the O
resistant O
virus O
variant O
CVB3 O
( O
M O
) O
with O
CVB3 O
Nancy O
revealed O
an O
amino O
acid O
exchange O
from O
Asn O
( O
N O
) O
to O
Ser O
( O
S O
) O
at O
position O
139 O
of O
the O
CVB3 O
capsid O
protein O
VP2 O
( O
N2139S O
) O
, O
an O
amino O
acid O
predicted O
to O
be O
involved O
in O
the O
virus O
' O
s O
interaction O
with O
its O
cognate O
receptor O
CAR O
. O

Interestingly O
, O
development O
of O
resistance O
by O
CVB3 O
- O
H3 O
( O
N2139S O
) O
and O
the O
exemplarily O
investigated O
CVB3 O
( O
M O
) O
- O
clone O
2 O
( O
CVB3 O
( O
M2 O
) O
) O
against O
soluble O
CAR O
did O
not O
compromise O
the O
use O
of O
cellular O
CAR O
for O
viral O
infection O
. O

Upon O
infection O
, O
paramyxoviruses O
cause O
a O
second O
type O
of O
membrane O
fusion O
, O
cell O
- O
cell O
fusion O
( O
syncytium O
formation O
) O
, O
which O
is O
linked O
to O
pathogenicity O
. O

Host O
cell O
receptor O
binding O
causes O
conformational O
changes O
in O
the O
attachment O
glycoprotein O
( O
HN O
, O
H O
, O
or O
G O
) O
that O
trigger O
a O
conformational O
cascade O
in O
the O
fusion O
( O
F O
) O
glycoprotein O
that O
mediates O
membrane O
fusion O
. O

F O
, O
a O
class O
I O
fusion O
protein O
, O
contains O
the O
archetypal O
heptad B
repeat I
regions I
1 I
( I
HR1 I
) I
and O
2 O
( O
HR2 O
) O
. O

In O
this O
study O
, O
we O
uncovered O
a O
novel O
fusion O
- O
modulatory O
role O
of O
a O
third O
structurally O
conserved O
helical O
region O
( O
HR3 O
) O
in O
F O
. O

Based O
on O
its O
location O
within O
the O
F O
structure O
, O
and O
structural O
differences O
between O
its O
prefusion O
and O
postfusion O
conformations O
, O
we O
hypothesized O
that O
the O
HR3 O
modulates O
triggering O
of O
the O
F O
conformational O
cascade O
( O
still O
requiring O
G O
) O
. O

We O
used O
the O
deadly O
Nipah B
virus I
( I
NiV I
) I
as O
an O
important O
paramyxoviral O
model O
to O
perform O
alanine O
scan O
mutagenesis O
and O
a O
series O
of O
multidisciplinary O
structural O
/ O
functional O
analyses O
that O
dissect O
the O
various O
states O
of O
the O
membrane O
fusion O
cascade O
. O

IMPORTANCE O
The O
Paramyxoviridae O
family O
includes O
important O
human O
and O
animal O
pathogens O
, O
such O
as O
measles O
, O
mumps O
, O
and O
parainfluenza O
viruses O
and O
the O
deadly O
henipaviruses O
Nipah O
( O
NiV O
) O
and O
Hendra O
( O
HeV O
) O
viruses O
. O

Paramyxoviruses O
infect O
the O
respiratory O
tract O
and O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
can O
be O
highly O
infectious O
. O

In O
this O
study O
, O
we O
uncovered O
a O
novel O
role O
of O
a O
third O
helical O
region O
( O
HR3 O
) O
of O
the O
NiV O
fusion O
glycoprotein O
in O
the O
membrane O
fusion O
process O
that O
leads O
to O
viral O
entry O
. O

duck B
Tembusu I
virus I
( I
DTMUV I
) I
( O
genus O
Flavivirus O
) O
is O
a O
causative O
agent O
of O
duck O
egg O
drop O
syndrome O
and O
has O
zoonotic O
potential O
. O

In O
this O
study O
, O
we O
show O
that O
RNAs O
containing O
5 O
' O
and O
3 O
' O
untranslated B
regions I
( I
UTRs I
) I
of O
DTMUV O
, O
mosquito O
- O
borne O
Tembusu B
virus I
( I
TMUV I
) I
, O
and O
Japanese O
encephalitis O
virus O
can O
be O
translated O
in O
a O
cap O
- O
independent O
manner O
in O
mammalian O
, O
avian O
, O
and O
mosquito O
cells O
. O

The O
ability O
of O
the O
5 O
' O
UTRs O
of O
flaviviruses O
to O
direct O
the O
translation O
of O
a O
second O
open O
reading O
frame O
in O
bicistronic O
RNAs O
was O
much O
less O
than O
that O
observed O
for O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
encephalomyocarditis O
virus O
, O
indicating O
a O
lack O
of O
substantial O
IRES O
activity O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
can O
induce O
damage O
in O
brain O
regions O
that O
in O
- O
clude O
the O
hippocampus O
and O
associated O
limbic O
structures O
. O

These O
neurogenic O
niches O
are O
important O
because O
they O
are O
associated O
with O
memory O
formation O
and O
are O
highly O
enriched O
with O
neural O
progenitor O
cells O
( O
NPCs O
) O
. O

We O
differentiated O
human B
induced I
pluripotent I
stem I
cells I
( I
hiPSCs I
) I
into O
NPCs O
to O
generate O
two B
- I
dimensional I
( I
2D I
) I
and O
three B
- I
dimensional I
( I
3D I
) I
culture O
models O
to O
examine O
the O
interaction O
of O
HSV O
- O
1 O
with O
NPCs O
. O

Here O
, O
we O
show O
that O
( O
i O
) O
NPCs O
can O
be O
effi O
- O
ciently O
infected O
by O
HSV O
- O
1 O
, O
but O
infection O
does O
not O
result O
in O
cell O
death O
of O
most O
NPCs O
, O
even O
at O
high O
multiplicities B
of I
infection I
( I
MOIs I
) I
; O
( O
ii O
) O
limited O
HSV O
- O
1 O
replication O
and O
gene O
expres O
- O
sion O
can O
be O
detected O
in O
the O
infected O
NPCs O
; O
( O
iii O
) O
a O
viral O
silencing O
mechanism O
is O
established O
in O
NPCs O
exposed O
to O
the O
antivirals O
( O
E O
) O
- O
5 O
- O
( O
2 O
- O
bromovinyl O
) O
- O
2 O
= O
- O
deoxyuridine O
( O
5BVdU O
) O
and O
alpha O
interferon O
( O
IFN O
- O
a O
) O
and O
when O
the O
antivirals O
are O
removed O
, O
spontaneous O
reactivation O
can O
oc O
- O
cur O
at O
low O
frequency O
; O
( O
iv O
) O
HSV O
- O
1 O
impairs O
the O
ability O
of O
NPCs O
to O
migrate O
in O
a O
dose O
- O
dependent O
fashion O
in O
the O
presence O
of O
5BVdU O
plus O
IFN O
- O
a O
; O
and O
( O
v O
) O
3D O
cultures O
of O
NPCs O
are O
less O
susceptible O
to O
HSV O
- O
1 O
infection O
than O
2D O
cultures O
. O

These O
results O
suggest O
that O
NPC O
pools O
could O
be O
sites O
of O
HSV O
- O
1 O
reactivation O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

IMPORTANCE O
This O
study O
employed O
human B
induced I
pluripotent I
stem I
cells I
( I
hiPSCs I
) I
to O
model O
the O
interaction O
of O
HSV O
- O
1 O
with O
NPCs O
, O
which O
reside O
in O
the O
neurogenic O
niches O
of O
the O
CNS O
and O
play O
a O
fundamental O
role O
in O
adult O
neurogenesis O
. O

1 O
, O
HSV O
- O
1 O
can O
establish O
a O
latent O
state O
, O
sug O
- O
gesting O
that O
( O
i O
) O
a O
variant O
of O
classical O
HSV O
- O
1 O
latency O
can O
be O
established O
during O
earlier O
stages O
of O
neuronal O
differentiation O
and O
( O
ii O
) O
neurogenic O
niches O
in O
the O
brain O
may O
constitute O
additional O
sites O
of O
viral O
reactivation O
. O

A O
difference O
in O
susceptibility O
to O
HSV O
- O
1 O
infection O
between O
two B
- I
dimensional I
( I
2D I
) I
and O
three B
- I
dimensional I
( I
3D I
) I
NPC O
cultures O
was O
observed O
, O
highlighting O
the O
potential O
value O
of O
3D O
cultures O
for O
modeling O
host O
- O
pathogen O
in O
- O
teractions O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
infection O
alters O
microRNA B
( I
miRNA I
) I
expression O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

We O
discovered O
global O
degradation O
of O
mature O
miRNA O
in O
mouse O
brains O
and O
neuroblastoma O
( O
NA O
) O
cells O
after O
JEV O
infection O
. O

Transfection O
with O
miRNA O
466d O
- O
3p O
( O
miR O
- O
466d O
- O
3p O
) O
decreased O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
expression O
and O
inhibited O
JEV O
replication O
in O
NA O
cells O
. O

The O
NS3 O
proteins O
of O
Zika O
virus O
, O
West O
Nile O
virus O
, O
and O
dengue B
virus I
serotype I
1 I
( I
DENV I
- I
1 I
) I
and O
DENV O
- O
2 O
also O
decreased O
miR O
- O
466d O
- O
3p O
expression O
. O

Rabies O
, O
caused O
by O
rabies B
virus I
( I
RABV I
) I
, O
is O
a O
fatal O
encephalitis O
in O
humans O
and O
other O
mammals O
, O
which O
continues O
to O
present O
a O
public O
health O
threat O
in O
most O
parts O
of O
the O
world O
. O

Our O
previous O
study O
demonstrated O
that O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
is O
essential O
in O
the O
induction O
of O
anti O
- O
RABV O
antibodies O
via O
the O
facilitation O
of O
germinal O
center O
formation O
. O

Using O
isolated O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
, O
we O
demonstrated O
that O
TLR7 O
is O
an O
innate O
recognition O
receptor O
for O
RABV O
. O

When O
RABV O
invaded O
from O
the O
periphery O
, O
TLR7 O
detected O
viral O
single O
- O
stranded O
RNA O
and O
triggered O
immune O
responses O
that O
limited O
the O
virus O
' O
s O
entry O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Tembusu B
virus I
( I
TMUV I
) I
is O
a O
flavivirus O
responsible O
for O
panzootic O
outbreaks O
of O
severe O
egg O
- O
drop O
and O
fatal O
encephalitis O
of O
domestic O
waterfowl O
in O
China O
. O

Here O
, O
we O
performed O
site O
- O
directed O
mutagenesis O
on O
five O
envelope B
( I
E I
) I
protein O
amino O
acid O
residues O
in O
accordance O
with O
the O
attenuated O
TMUV O
generated O
in O
our O
recent O
study O
. O

Our O
results O
showed O
that O
the O
Thr O
- O
to O
- O
Lys O
mutation O
of O
residue O
367 O
in O
E O
protein O
( O
E367 O
) O
plays O
a O
predominant O
role O
in O
viral O
cell O
adaptation O
and O
virulence O
attenuation O
in O
ducks O
compared O
with O
mutations O
in O
other O
residues O
. O

We O
further O
demonstrated O
that O
the O
positively O
charged O
basic O
amino O
acid O
substitution O
at O
E367 O
enhanced O
the O
viral O
binding O
affinity O
for O
glycosaminoglycans B
( I
GAGs I
) I
and O
reduced O
viremia O
levels O
and O
the O
efficiency O
of O
replication O
in O
major O
target O
organs O
in O
subcutaneously O
inoculated O
ducks O
. O

IMPORTANCE O
Outbreaks O
of O
Tembusu B
virus I
( I
TMUV I
) I
infection O
have O
caused O
huge O
economic O
losses O
in O
the O
production O
of O
domestic O
waterfowl O
since O
the O
virus O
was O
first O
recognized O
in O
China O
in O
2010 O
. O

We O
demonstrated O
that O
the O
T367K O
mutation O
attenuates O
TMUV O
through O
reducing O
viral O
replication O
in O
the O
blood O
, O
brain O
, O
heart O
( O
ducklings O
) O
, O
and O
ovaries O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
a O
mosquito O
- O
borne O
flavivirus O
responsible O
for O
dengue O
disease O
, O
a O
major O
human O
health O
concern O
for O
which O
no O
specific O
therapies O
are O
available O
. O

We O
identified O
DPM1 O
and O
- O
3 O
, O
two O
subunits O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
resident O
dolichol B
- I
phosphate I
mannose I
synthase I
( I
DPMS I
) I
complex O
, O
as O
host O
dependency O
factors O
for O
DENV O
and O
other O
related O
flaviviruses O
, O
such O
as O
Zika B
virus I
( I
ZIKV I
) I
. O

The O
DPMS O
complex O
catalyzes O
the O
synthesis O
of O
dolichol B
- I
phosphate I
mannose I
( I
DPM I
) I
, O
which O
serves O
as O
mannosyl O
donor O
in O
pathways O
leading O
to O
N O
- O
glycosylation O
, O
glycosylphosphatidylinositol B
( I
GPI I
) I
anchor O
biosynthesis O
, O
and O
C O
- O
or O
O O
- O
mannosylation O
of O
proteins O
in O
the O
ER O
lumen O
. O

Similarly O
, O
genetic O
ablation O
of O
ALG3 O
, O
a O
mannosyltransferase O
that O
transfers O
mannose O
to O
lipid B
- I
linked I
oligosaccharide I
( I
LLO I
) I
, O
rendered O
cells O
poorly O
susceptible O
to O
DENV O
. O

IMPORTANCE O
Dengue O
disease O
, O
which O
is O
caused O
by O
Dengue B
Virus I
( I
DENV I
) I
, O
has O
emerged O
as O
the O
most O
important O
mosquito O
- O
borne O
viral O
disease O
in O
humans O
and O
is O
a O
major O
global O
health O
concern O
. O

Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
, O
a O
T O
- O
lymphotropic O
virus O
, O
infects O
almost O
exclusively O
humans O
. O

For O
HHV O
- O
6B O
replication O
, O
adequate O
human O
T O
- O
cell O
activation O
( O
which O
becomes O
susceptible O
to O
HHV O
- O
6B O
) O
is O
necessary O
in O
this O
murine O
model O
. O

Here O
, O
we O
found O
that O
an O
additional O
transfer O
of O
human O
mononuclear O
cells O
to O
humanized O
mice O
resulted O
in O
an O
explosive O
proliferation O
of O
human O
activated O
T O
cells O
, O
which O
could O
be O
representative O
of O
graft B
- I
versus I
- I
host I
disease I
( I
GVHD I
) I
because O
the O
primary O
transfer O
of O
human O
cells O
was O
not O
sufficient O
to O
increase O
the O
number O
and O
ratio O
of O
human O
T O
cells O
. O

IMPORTANCE O
Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
is O
a O
ubiquitous O
virus O
that O
establishes O
lifelong O
latent O
infection O
only O
in O
humans O
, O
and O
the O
infection O
can O
reactivate O
, O
with O
severe O
complications O
that O
cause O
major O
problems O
. O

The O
explosive O
spread O
of O
Zika B
virus I
( I
ZIKV I
) I
has O
been O
associated O
with O
major O
variations O
in O
severe O
disease O
and O
congenital O
afflictions O
among O
infected O
populations O
, O
suggesting O
an O
influence O
of O
host O
genes O
. O

We O
then O
show O
that O
Collaborative B
Cross I
( I
CC I
) I
mice O
, O
which O
exhibit O
a O
broad O
genetic O
diversity O
, O
in O
which O
the O
type O
I O
interferon O
receptor O
( O
IFNAR O
) O
was O
blocked O
by O
an O
anti O
- O
IFNAR O
antibody O
expressed O
phenotypes O
ranging O
from O
complete O
resistance O
to O
severe O
symptoms O
and O
death O
, O
with O
large O
variations O
in O
the O
peak O
and O
the O
rate O
of O
decrease O
in O
the O
plasma O
viral O
load O
, O
in O
the O
brain O
viral O
load O
, O
in O
brain O
histopathology O
, O
and O
in O
the O
viral O
replication O
rate O
in O
infected O
cells O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
one O
of O
the O
important O
human O
and O
animal O
pathogens O
. O

It O
forms O
replication O
enzyme O
complexes O
( O
RCs O
) O
containing O
viral O
nonstructural B
proteins I
( I
nsPs I
) I
that O
mediate O
the O
synthesis O
of O
virus O
- O
specific O
RNAs O
. O

Our O
study O
demonstrates O
that O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
VEEV O
nsP3 O
interacts O
with O
the O
members O
of O
the O
FXR O
family O
of O
cellular O
proteins O
and O
also O
binds O
the O
Src B
homology I
3 I
( I
SH3 I
) I
domain O
- O
containing O
proteins O
CD2AP O
and O
SH3KBP1 O
. O

Some O
of O
these O
critical O
host O
factors O
interact O
with O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
alphavirus O
nsP3 O
. O

RNA B
interference I
( I
RNAi I
) I
is O
a O
conserved O
antiviral O
immune O
defense O
in O
eukaryotes O
, O
and O
numerous O
viruses O
have O
been O
found O
to O
encode O
viral B
suppressors I
of I
RNAi I
( I
VSRs I
) I
to O
counteract O
antiviral O
RNAi O
. O

In O
this O
study O
, O
we O
identified O
that O
Semliki B
Forest I
virus I
( I
SFV I
) I
capsid O
protein O
can O
efficiently O
suppress O
RNAi O
in O
both O
insect O
and O
mammalian O
cells O
by O
sequestrating O
double O
- O
stranded O
RNA O
and O
small O
interfering O
RNA O
. O

RNA B
interference I
( I
RNAi I
) I
is O
one O
of O
the O
most O
important O
antiviral O
mechanisms O
in O
plants O
and O
insects O
. O

In O
response O
to O
antiviral O
RNAi O
, O
viruses O
have O
evolved O
to O
encode O
viral B
suppressors I
of I
RNAi I
( I
VSRs I
) I
to O
antagonize O
the O
RNAi O
pathway O
. O

In O
this O
study O
, O
we O
first O
uncovered O
that O
capsid O
protein O
encoded O
by O
Semliki B
Forest I
virus I
( I
SFV I
) I
, O
a O
prototypic O
alphavirus O
, O
had O
a O
potent O
VSR O
activity O
that O
can O
antagonize O
antiviral O
RNAi O
in O
the O
context O
of O
SFV O
infection O
in O
mammalian O
cells O
, O
and O
this O
mechanism O
is O
probably O
used O
by O
other O
alphaviruses O
. O

Several O
members O
of O
the O
tripartite B
motif I
( I
TRIM I
) I
family O
of O
E3 O
ubiquitin O
ligases O
regulate O
immune O
pathways O
, O
including O
the O
antiviral O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
system O
. O

Despite O
having O
evolved O
numerous O
mechanisms O
to O
restrict O
the O
vertebrate O
host O
' O
s O
IFN O
- O
I O
response O
, O
West B
Nile I
virus I
( I
WNV I
) I
replication O
is O
sensitive O
to O
pretreatment O
with O
IFN O
- O
I O
. O

Consistent O
with O
WNV O
' O
s O
sensitivity O
to O
IFN O
- O
I O
, O
we O
found O
that O
in O
TRIM6 O
knockout O
( O
TRIM6 O
- O
KO O
) O
A549 O
cells O
, O
WNV O
replication O
is O
significantly O
increased O
and O
IFN O
- O
I O
induction O
and O
signaling O
are O
impaired O
compared O
to O
wild B
- I
type I
( I
WT I
) I
cells O
. O

VAMP8 O
knockdown O
resulted O
in O
reduced O
JAK1 O
and O
STAT1 O
phosphorylation O
and O
impaired O
induction O
of O
several O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
following O
WNV O
infection O
or O
IFN O
- O
beta O
treatment O
. O

Demyelinating O
central B
nervous I
system I
( I
CNS I
) I
disorders O
like O
multiple B
sclerosis I
( I
MS I
) I
and O
acute B
disseminated I
encephalomyelitis I
( I
ADEM I
) I
have O
been O
difficult O
to O
study O
and O
treat O
due O
to O
the O
lack O
of O
understanding O
of O
their O
etiology O
. O

Numerous O
cases O
point O
to O
the O
link O
between O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
infection O
and O
multifocal O
CNS O
demyelination O
in O
humans O
; O
however O
, O
convincing O
evidence O
from O
animal O
models O
has O
been O
missing O
. O

In O
this O
work O
, O
we O
found O
that O
HSV O
- O
1 O
infection O
of O
the O
cotton O
rat O
Sigmodon O
hispidus O
via O
a O
common O
route O
( O
lip O
abrasion O
) O
can O
cause O
multifocal O
CNS O
demyelination O
and O
inflammation O
. O

Sindbis B
virus I
( I
SINV I
) I
infects O
the O
neurons O
of O
rodents O
and O
is O
a O
model O
for O
studying O
factors O
that O
regulate O
infection O
of O
neuronal O
cells O
. O

However O
, O
the O
translation O
of O
structural O
proteins O
was O
impaired O
, O
phosphorylation O
of O
the O
alpha O
subunit O
of O
eukaryotic B
translation I
initiation I
factor I
2 I
( I
eIF2 I
alpha I
) I
was O
decreased O
, O
and O
host O
protein O
synthesis O
was O
maintained O
, O
suggesting O
that O
NF O
- O
kappa O
B O
activation O
was O
involved O
in O
the O
regulation O
of O
translation O
during O
infection O
of O
mature O
neurons O
. O

Inhibition O
or O
deletion O
of O
double B
- I
stranded I
RNA I
- I
activated I
protein I
kinase I
( I
PKR I
) I
also O
decreased O
eIF2 O
alpha O
phosphorylation O
, O
the O
translation O
of O
viral O
structural O
proteins O
, O
and O
virus O
production O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
neurotropic O
flavivirus O
and O
the O
leading O
cause O
of O
mosquito O
- O
borne O
encephalitis O
in O
the O
United O
States O
. O

However O
, O
the O
contributions O
of O
human B
dendritic I
cells I
( I
DCs I
) I
in O
priming O
WNV O
- O
specific O
T O
cell O
immunity O
remains O
poorly O
understood O
. O

Here O
, O
we O
demonstrate O
that O
human B
monocyte I
derived I
DCs I
( I
moDCs I
) I
support O
productive O
viral O
replication O
following O
infection O
with O
a O
pathogenic O
strain O
of O
WNV O
. O

Antiviral O
effector O
gene O
transcription O
was O
strongly O
induced O
during O
the O
log O
phase O
of O
viral O
growth O
, O
while O
secretion O
of O
type O
I O
interferons B
( I
IFN I
) I
occurred O
with O
delayed O
kinetics O
. O

Activation O
of O
RIG B
- I
I I
like I
receptor I
( I
RLR I
) I
or O
type O
I O
IFN O
signaling O
prior O
to O
log O
phase O
viral O
growth O
significantly O
diminished O
viral O
replication O
, O
suggesting O
that O
early O
activation O
of O
antiviral O
programs O
can O
block O
WNV O
infection O
. O

In O
contrast O
to O
the O
induction O
of O
antiviral O
responses O
, O
WNV O
infection O
did O
not O
promote O
transcription O
or O
secretion O
of O
proinflammatory O
( O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
) O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
, O
CCL3 O
, O
CCL5 O
, O
and O
CXCL9 O
) O
or O
T O
cell O
modulatory O
( O
IL O
- O
4 O
, O
IL O
- O
12 O
, O
and O
IL O
- O
15 O
) O
cytokines O
. O

IMPORTANCE O
West B
Nile I
virus I
( I
WNV I
) I
is O
an O
encephalitic O
flavivirus O
that O
remains O
endemic O
in O
the O
United O
States O
. O

Here O
, O
we O
sought O
to O
better O
understand O
the O
ability O
of O
WNV O
to O
program O
human B
dendritic I
cells I
( I
DCs I
) I
to O
prime O
WNV O
- O
specific O
T O
cell O
responses O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
infects O
mucosal O
epithelial O
cells O
and O
establishes O
lifelong O
infections O
in O
sensory O
neurons O
. O

HSV O
- O
1 O
is O
known O
to O
combat O
autophagy O
through O
the O
functions O
of O
the O
gamma O
( O
1 O
) O
34 O
. O

5 O
protein O
, O
which O
prevents O
formation O
of O
the O
autophagophore O
by O
binding O
to O
Beclin O
1 O
, O
a O
key O
factor O
involved O
in O
the O
elongation O
of O
the O
isolation O
membrane O
, O
and O
by O
redirecting O
the O
protein O
phosphatase O
1 O
alpha O
( O
PP1 O
alpha O
) O
to O
dephosphorylate O
the O
translation O
initiation O
factor O
2 O
alpha O
( O
elF2 O
alpha O
) O
to O
prevent O
host O
translational O
shutoff O
. O

Here O
, O
we O
present O
a O
novel O
strategy O
of O
HSV O
- O
1 O
to O
evade O
the O
host O
through O
the O
downregulation O
of O
the O
autophagy O
adaptor O
protein O
sequestosome O
( O
p62 O
/ O
SQSTM1 O
) O
and O
of O
the O
mitophagy O
adaptor O
optineurin B
( I
OPTN I
) I
. O

We O
also O
found O
that O
infected B
cell I
protein I
0 I
( I
ICP0 I
) I
of O
the O
virus O
mediates O
the O
down O
- O
modulation O
of O
the O
two O
autophagy O
adaptors O
in O
a O
mechanism O
independent O
of O
its O
E3 O
ubiquitin O
ligase O
activity O
. O

Here O
, O
we O
present O
a O
novel O
mechanism O
that O
involves O
downregulation O
of O
two O
major O
autophagy O
adaptor O
proteins O
, O
sequestosome O
1 O
( O
p62 O
/ O
SQSTM1 O
) O
and O
optineurin B
( I
OPTN I
) I
. O

nonstructural B
( I
NS I
) I
proteins O
are O
not O
part O
of O
the O
virus O
coat O
and O
are O
thought O
to O
participate O
in O
the O
formation O
of O
these O
viral O
replication B
compartments I
( I
RCs I
) I
. O

Here O
, O
we O
used O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
as O
a O
model O
for O
the O
flaviviruses O
and O
developed O
a O
stable O
human O
cell O
line O
in O
which O
the O
expression O
of O
NS O
proteins O
can O
be O
induced O
without O
viral O
RNA O
replication O
. O

We O
show O
that O
the O
expression O
of O
six O
NS O
proteins O
is O
sufficient O
to O
induce O
infection O
- O
like O
dilation O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
the O
formation O
of O
RC O
- O
like O
membrane O
invaginations O
. O

Zika B
virus I
( I
ZIKV I
) I
infection O
in O
pregnant O
women O
can O
lead O
to O
fetal O
deaths O
and O
malformations O
. O

We O
have O
previously O
reported O
that O
ZIKV O
envelope B
protein I
domain I
III I
( I
EDIII I
) I
is O
a O
subunit O
vaccine O
candidate O
with O
cross O
- O
neutralization O
activity O
; O
however O
, O
like O
many O
other O
subunit O
vaccines O
, O
its O
efficacy O
is O
limited O
. O

More O
specifically O
, O
we O
identified O
an O
epitope O
on O
Zika B
virus I
( I
ZIKV I
) I
envelope I
protein I
domain I
III I
( I
EDIII I
) I
that O
is O
buried O
in O
the O
full O
- O
length O
envelope O
protein O
but O
becomes O
exposed O
in O
recombinant O
EDIII O
. O

The O
adenosine O
analogue O
galidesivir O
( O
BCX4430 O
) O
, O
a O
broad O
- O
spectrum O
RNA O
virus O
inhibitor O
, O
has O
entered O
a O
phase O
1 O
clinical O
safety O
and O
pharmacokinetics O
study O
in O
healthy O
subjects O
and O
is O
under O
clinical O
development O
for O
treatment O
of O
Ebola O
and O
yellow O
fever O
virus O
infections O
. O

Moreover O
, O
galidesivir O
also O
inhibits O
the O
reproduction O
of O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
numerous O
other O
medically O
important O
flaviviruses O
. O

Here O
, O
we O
demonstrate O
that O
an O
E460D O
substitution O
in O
the O
active O
site O
of O
TBEV O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
confers O
resistance O
to O
galidesivir O
in O
cell O
culture O
. O

IMPORTANCE O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
is O
a O
pathogen O
that O
causes O
severe O
human O
neuroinfections O
in O
Europe O
and O
Asia O
and O
for O
which O
there O
is O
currently O
no O
specific O
therapy O
. O

We O
have O
previously O
found O
that O
galidesivir O
( O
BCX4430 O
) O
, O
a O
broad O
- O
spectrum O
RNA O
virus O
inhibitor O
, O
which O
is O
under O
clinical O
development O
for O
treatment O
of O
Ebola O
and O
yellow O
fever O
virus O
infections O
, O
has O
a O
strong O
antiviral O
effect O
against O
TBEV O
. O

Most O
described O
flaviviruses O
( O
family O
Flaviviridae O
) O
are O
disease O
- O
causing O
pathogens O
of O
vertebrates O
maintained O
in O
zoonotic O
cycles O
between O
mosquitoes O
or O
ticks O
and O
vertebrate O
hosts O
. O

In O
this O
study O
, O
we O
discovered O
three O
crustacean O
flaviviruses O
( O
Gammarus O
chevreuxi O
flavivirus O
, O
Gammarus O
pulex O
flavivirus O
, O
and O
Crangon O
crangon O
flavivirus O
) O
and O
two O
cephalopod O
flaviviruses O
( O
Southern O
Pygmy O
squid O
flavivirus O
and O
Firefly O
squid O
flavivirus O
) O
. O

In O
addition O
, O
we O
identify O
variants O
of O
Wenzhou O
shark O
flavivirus O
in O
multiple O
gazami O
crab O
( O
Portunus O
trituberculatus O
) O
populations O
, O
with O
active O
replication O
supported O
by O
evidence O
of O
an O
active O
RNA O
interference O
response O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
has O
infected O
more O
than O
80 O
% O
of O
the O
population O
. O

infected B
cell I
protein I
0 I
( I
ICP0 I
) I
of O
HSV O
- O
1 O
is O
encoded O
by O
an O
immediate O
early O
gene O
and O
plays O
a O
fundamental O
role O
during O
infection O
, O
because O
it O
enables O
viral O
gene O
expression O
and O
blocks O
antiviral O
responses O
. O

A O
Delta O
ICP0 O
virus O
or O
mutants O
with O
deficiencies O
in O
E3 O
ligase O
activity O
cannot O
counteract O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
- O
induced O
restriction O
of O
viral O
infection O
, O
are O
highly O
immunogenic O
, O
are O
avirulent O
, O
and O
fail O
to O
spread O
. O

Here O
we O
explored O
the O
HSV O
- O
1 O
ICP0 O
E3 O
ligase O
as O
a O
potential O
antiviral O
target O
because O
( O
i O
) O
ICP0 O
is O
expressed O
before O
virus O
replication O
, O
( O
ii O
) O
it O
is O
essential O
for O
infection O
in O
vivo O
, O
( O
iii O
) O
it O
is O
required O
for O
efficient O
reactivation O
of O
the O
virus O
from O
latency O
, O
( O
iv O
) O
inhibition O
of O
its O
E3 O
ligase O
activity O
would O
sustain O
host O
immune O
responses O
, O
and O
( O
v O
) O
it O
is O
shared O
by O
other O
herpesviruses O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
establishes O
lifelong O
latent O
infections O
in O
neurons O
. O

We O
hypothesized O
that O
stress O
, O
via O
corticosteroid O
- O
mediated O
activation O
of O
the O
glucocorticoid B
receptor I
( I
GR I
) I
, O
stimulates O
viral O
gene O
expression O
and O
productive O
infection O
during O
reactivation O
from O
latency O
. O

Consequently O
, O
we O
tested O
whether O
GR O
activation O
by O
the O
synthetic O
corticosteroid O
dexamethasone O
influenced O
virus O
shedding O
during O
reactivation O
from O
latency O
using O
trigeminal B
ganglion I
( I
TG I
) I
explants O
from O
Swiss O
Webster O
mice O
latently O
infected O
with O
HSV O
- O
1 O
, O
strain O
McKrae O
. O

Conversely O
, O
virus O
shedding O
from O
TG O
explants O
was O
significantly O
impaired O
when O
they O
were O
incubated O
with O
medium O
containing O
a O
GR O
- O
specific O
antagonist O
( O
CORT O
- O
108297 O
) O
or O
stripped O
fetal O
bovine O
serum O
, O
which O
lacks O
nuclear O
hormones O
and O
other O
growth O
factors O
. O

Strikingly O
, O
VP16 O
protein O
expression O
was O
detected O
in O
TG O
neurons O
at O
8 O
hours O
after O
explant O
whereas O
infected B
- I
cell I
protein I
0 I
( I
ICP0 I
) I
and O
ICP4 O
protein O
expression O
was O
not O
readily O
detected O
until O
16 O
hours O
after O
explant O
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
establishes O
lifelong O
latent O
infections O
in O
neurons O
within O
trigeminal B
ganglia I
( I
TG I
) I
; O
periodically O
, O
reactivation O
from O
latency O
occurs O
, O
leading O
to O
virus O
transmission O
and O
recurrent O
disease O
. O

Conversely O
, O
a O
glucocorticoid B
receptor I
( I
GR I
) I
antagonist O
significantly O
impaired O
reactivation O
from O
latency O
, O
indicating O
that O
GR O
activation O
stimulated O
explant O
- O
induced O
reactivation O
. O

The O
viral O
regulatory O
protein O
VP16 O
was O
readily O
detected O
in O
TG O
neurons O
prior O
to O
infected B
- I
cell I
protein I
0 I
( I
ICP0 I
) I
and O
ICP4 O
during O
explant O
- O
induced O
reactivation O
. O

central B
nervous I
system I
( I
CNS I
) I
disease O
is O
one O
of O
the O
most O
common O
extrarespiratory O
tract O
complications O
of O
influenza O
A O
virus O
infections O
. O

Here O
, O
we O
determined O
the O
replication O
kinetics O
of O
a O
seasonal O
, O
pandemic O
, O
zoonotic O
, O
and O
lab O
- O
adapted O
influenza O
A O
virus O
in O
human O
neuron O
- O
like O
( O
SK O
- O
N O
- O
SH O
) O
and O
astrocyte O
- O
like O
( O
U87 O
- O
MG O
) O
cells O
and O
primary O
mouse O
cortex O
neurons O
. O

In O
general O
, O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
H5N1 O
virus O
replicated O
most O
efficiently O
in O
all O
cells O
, O
which O
was O
associated O
with O
efficient O
attachment O
and O
infection O
. O

Removal O
of O
the O
multibasic B
cleavage I
site I
( I
MBCS I
) I
from O
HPAI O
H5N1 O
virus O
attenuated O
, O
but O
did O
not O
abrogate O
, O
replication O
. O

This O
suggests O
that O
both O
an O
alternative O
Hemagglutinin B
( I
HA I
) I
cleavage O
mechanism O
and O
preference O
for O
alpha O
- O
2 O
, O
3 O
- O
linked O
sialic O
acids O
allowing O
efficient O
attachment O
contribute O
to O
the O
ability O
of O
influenza O
A O
viruses O
to O
replicate O
efficiently O
in O
cells O
of O
the O
CNS O
. O

IMPORTANCE O
central B
nervous I
system I
( I
CNS I
) I
disease O
is O
one O
of O
the O
most O
common O
extrarespiratory O
tract O
complications O
of O
influenza O
A O
virus O
infections O
, O
and O
the O
frequency O
and O
severity O
differ O
between O
seasonal O
, O
pandemic O
, O
and O
zoonotic O
influenza O
viruses O
. O

Reovirus O
encephalitis O
in O
mice O
was O
used O
as O
a O
model O
system O
to O
investigate O
astrocyte O
activation O
( O
astrogliosis O
) O
following O
viral O
infection O
of O
the O
brain O
. O

Reovirus O
infection O
resulted O
in O
astrogliosis O
, O
as O
evidenced O
by O
increased O
expression O
of O
glial B
fibrillary I
acidic I
protein I
( I
GFAP I
) I
, O
and O
the O
upregulation O
of O
genes O
that O
have O
been O
previously O
associated O
with O
astrocyte O
activation O
. O

Astrogliosis O
also O
occurred O
following O
reovirus O
infection O
of O
ex O
vivo O
brain B
slice I
cultures I
( I
BSCs I
) I
, O
demonstrating O
that O
factors O
intrinsic O
to O
the O
brain O
are O
sufficient O
to O
activate O
astrocytes O
and O
that O
this O
process O
can O
occur O
in O
the O
absence O
of O
any O
contribution O
from O
the O
peripheral O
immune O
response O
. O

Reovirus O
- O
infected O
neurons O
produce O
interferon B
beta I
( I
IFN I
- I
beta I
) I
. O

Exanthem O
subitum O
is O
a O
common O
childhood O
illness O
caused O
by O
primary O
infection O
with O
Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
. O

Mouse O
- O
derived O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
the O
HHV O
- O
6B O
envelope O
glycoprotein O
complex O
gH O
/ O
gL O
/ O
gQ1 O
/ O
gQ2 O
have O
been O
shown O
to O
neutralize O
the O
viral O
infection O
. O

IMPORTANCE O
Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
establishes O
lifelong O
latent O
infection O
in O
most O
individuals O
after O
the O
primary O
infection O
. O

A O
clinical O
isolate O
of O
measles B
virus I
( I
MeV I
) I
bearing O
a O
single O
amino O
acid O
alteration O
in O
the O
viral O
fusion O
protein O
( O
F O
; O
L454W O
) O
was O
previously O
identified O
in O
two O
patients O
with O
lethal O
sequelae O
of O
MeV O
central B
nervous I
system I
( I
CNS I
) I
infection O
. O

While O
this O
virus O
could O
feasibly O
have O
arisen O
via O
intrahost O
evolution O
of O
the O
wild B
- I
type I
( I
WT I
) I
virus O
, O
it O
was O
recently O
shown O
that O
the O
same O
mutation O
emerged O
under O
the O
selective O
pressure O
of O
small O
- O
molecule O
antiviral O
treatment O
. O

Thus O
, O
either O
during O
lethal O
MeV O
CNS O
infection O
or O
during O
antiviral O
treatment O
in O
vitro O
, O
neuropathogenic O
MeV O
can O
emerge O
, O
can O
infect O
new O
hosts O
via O
the O
respiratory O
route O
, O
and O
is O
more O
pathogenic O
( O
at O
least O
in O
these O
animal O
models O
) O
than O
wt O
MeV O
. O

IMPORTANCE O
measles B
virus I
( I
MeV I
) I
infection O
can O
be O
severe O
in O
immunocompromised O
individuals O
and O
lead O
to O
complications O
, O
including O
measles B
inclusion I
body I
encephalitis I
( I
MIBE I
) I
. O

In O
some O
cases O
, O
MeV O
persistence O
and O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
occur O
even O
in O
the O
face O
of O
an O
intact O
immune O
response O
. O

This O
work O
addresses O
the O
hypothesis O
that O
despite O
a O
dysregulated O
viral O
fusion O
complex O
, O
central B
nervous I
system I
( I
CNS I
) I
- O
adapted O
measles O
virus O
can O
spread O
outside O
the O
CNS O
within O
an O
infected O
host O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
neurotropic O
mosquito O
- O
borne O
flavivirus O
of O
global O
importance O
. O

type B
I I
interferon I
( I
IFN I
- I
I I
) I
is O
crucial O
for O
promoting O
antiviral O
defenses O
through O
the O
induction O
of O
antiviral O
effectors O
, O
which O
function O
to O
restrict O
viral O
replication O
and O
spread O
. O

Here O
, O
we O
present O
WNV O
- O
inclusive O
single O
- O
cell O
RNA O
sequencing O
( O
scRNA O
- O
seq O
) O
, O
an O
approach O
to O
examine O
the O
transcriptional O
variation O
and O
viral O
RNA O
burden O
across O
single O
cells O
. O

IMPORTANCE O
West B
Nile I
virus I
( I
WNV I
) I
is O
a O
clinically O
relevant O
pathogen O
responsible O
for O
recurrent O
epidemics O
of O
neuroinvasive O
disease O
. O

Alphavirus O
infections O
are O
characterized O
by O
global O
inhibition O
of O
cellular O
transcription O
and O
rapid O
induction O
of O
a O
cytopathic B
effect I
( I
CPE I
) I
in O
cells O
of O
vertebrate O
origin O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
highly O
pathogenic O
alphavirus O
representative O
, O
and O
its O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
plays O
critical O
roles O
in O
both O
inhibition O
of O
transcription O
and O
CPE O
development O
. O

Previously O
, O
we O
have O
identified O
a O
small O
peptide O
in O
Sindbis B
virus I
( I
SINV I
) I
nsP2 O
( O
VLoop O
) O
that O
determined O
the O
protein O
' O
s O
transcriptional O
inhibition O
function O
. O

Consequently O
, O
they O
were O
cleared O
from O
interferon B
( I
IFN I
) I
- O
competent O
cells O
without O
CPE O
development O
. O

Dengue B
Virus I
( I
DENV I
) I
utilizes O
host O
factors O
throughout O
its O
life O
cycle O
. O

In O
this O
study O
, O
we O
identified O
RNA O
helicase O
A O
( O
RHA O
) O
, O
a O
member O
of O
the O
DEAD O
/ O
H O
helicase O
family O
, O
as O
an O
important O
host O
factor O
of O
DENV O
. O

Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
DNA O
is O
frequently O
detected O
in O
human O
samples O
. O

We O
used O
RNA O
sequencing O
to O
characterize O
and O
compare O
the O
HHV O
- O
6B O
transcriptome O
in O
multiple O
sample O
types O
, O
including O
( O
i O
) O
whole O
blood O
from O
hematopoietic B
cell I
transplant I
( I
HCT I
) I
recipients O
with O
and O
without O
HHV O
- O
6B O
plasma O
viremia O
, O
( O
ii O
) O
tumor O
tissue O
samples O
from O
subjects O
with O
large O
B O
cell O
lymphoma O
infected O
with O
HHV O
- O
6B O
, O
( O
iii O
) O
lymphoblastoid B
cell I
lines I
( I
LCLs I
) I
from O
subjects O
with O
inherited O
chromosomally O
integrated O
HHV O
- O
6B O
or O
latent O
infection O
with O
HHV O
- O
6B O
, O
and O
( O
iv O
) O
HHV O
- O
6B O
Z29 O
infected O
SupT1 O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
HHV O
- O
6B O
viral O
polymerase O
gene O
U38 O
was O
the O
only O
HHV O
- O
6B O
transcript O
detected O
in O
all O
next O
- O
generation O
RNA B
sequencing I
( I
RNA I
- I
seq I
) I
data O
sets O
and O
was O
one O
of O
the O
most O
highly O
expressed O
genes O
. O

No O
HHV O
- O
6B O
U38 O
transcripts O
were O
detected O
by O
RNA O
- O
seq O
or O
reverse O
transcription O
- O
real B
- I
time I
quantitative I
PCR I
( I
RT I
- I
qPCR I
) I
in O
whole O
- O
blood O
samples O
from O
subjects O
without O
HHV O
- O
6B O
plasma O
detection O
or O
from O
latently O
infected O
LCLs O
. O

IMPORTANCE O
Human B
herpesvirus I
6B I
( I
HHV I
- I
6B I
) I
is O
a O
DNA O
virus O
that O
infects O
most O
children O
within O
the O
first O
few O
years O
of O
life O
. O

Since O
the O
discovery O
of O
enterovirus B
A71 I
( I
EV I
- I
A71 I
) I
half O
a O
century O
ago O
, O
it O
has O
been O
recognized O
as O
the O
cause O
of O
large O
- O
scale O
outbreaks O
of O
hand O
- O
foot O
- O
and O
- O
mouth O
disease O
worldwide O
, O
particularly O
in O
the O
Asia O
- O
Pacific O
region O
, O
causing O
great O
concern O
for O
public O
health O
and O
economic O
burdens O
. O

In O
the O
present O
study O
, O
NOD O
- O
scid O
IL2R O
gamma O
( O
- O
/ O
- O
) O
( O
NSG O
) O
mice O
with O
a O
human O
immune O
system O
( O
humanized O
mice O
) O
at O
the O
age O
of O
4 O
weeks O
were O
found O
to O
be O
susceptible O
to O
a O
human O
isolate O
of O
EV O
- O
A71 O
infection O
. O

The O
numbers O
of O
activated O
human O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
upregulated O
after O
EV O
- O
A71 O
infection O
, O
and O
EV O
- O
A71 O
- O
specific O
human O
T O
cell O
responses O
were O
found O
. O

Furthermore O
, O
the O
secretion O
of O
several O
proinflammatory O
cytokines O
, O
such O
as O
human O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
interleukin B
- I
8 I
( I
IL I
- I
8 I
) I
, O
and O
IL O
- O
17A O
, O
was O
elevated O
in O
the O
EV O
- O
A71 O
- O
infected O
humanized O
mice O
. O

The O
mosquito O
- O
borne O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
causes O
severe O
central O
nervous O
system O
diseases O
and O
cycles O
between O
Culex O
mosquitoes O
and O
different O
vertebrates O
. O

Using O
nasal O
mucosal O
tissue O
explants O
and O
primary O
porcine O
nasal B
epithelial I
cells I
( I
NEC I
) I
at O
the O
air B
- I
liquid I
interface I
( I
ALI I
) I
and O
macrophages O
as O
ex O
vivo O
and O
in O
vitro O
models O
, O
we O
determined O
that O
the O
nasal O
epithelium O
could O
represent O
the O
route O
of O
entry O
and O
exit O
for O
JEV O
in O
pigs O
. O

Sindbis B
virus I
( I
SINV I
) I
is O
a O
representative O
member O
of O
the O
Alphavirus O
genus O
in O
the O
Togaviridae O
family O
. O

The O
hallmark O
of O
SINV O
replication O
in O
vertebrate O
cells O
is O
a O
rapid O
development O
of O
the O
cytopathic B
effect I
( I
CPE I
) I
, O
which O
usually O
occurs O
within O
24 O
h O
postinfection O
. O

Defined O
mutations O
in O
the O
nsP2 O
- O
specific O
peptide O
between O
amino B
acids I
( I
aa I
) I
674 O
and O
688 O
prevent O
virus O
- O
induced O
degradation O
of O
the O
catalytic O
subunit O
of O
cellular O
- O
DNA O
- O
dependent O
RNA O
polymerase O
II O
and O
transcription O
inhibition O
and O
make O
SINV O
a O
strong O
type B
I I
interferon I
( I
IFN I
) I
inducer O
without O
affecting O
its O
replication O
rates O
. O

In O
this O
study O
, O
by O
using O
Sindbis B
virus I
( I
SINV I
) I
as O
a O
model O
of O
the O
Old O
World O
alphaviruses O
, O
we O
demonstrated O
that O
SINV O
- O
specific O
CPE O
is O
redundantly O
determined O
by O
viral O
nsP2 O
and O
nsP3 O
proteins O
. O

Mammalian O
orthoreoviruses O
( O
reoviruses O
) O
spread O
systemically O
in O
newborn O
mice O
to O
cause O
serotype O
- O
specific O
disease O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Serotype O
1 O
( O
T1 O
) O
reovirus O
infects O
ependymal O
cells O
to O
cause O
nonlethal O
hydrocephalus O
, O
whereas O
serotype O
3 O
( O
T3 O
) O
reovirus O
infects O
neurons O
to O
cause O
fulminant O
and O
lethal O
encephalitis O
. O

Mammalian O
orthoreoviruses O
are O
promising O
oncolytic O
therapeutics O
for O
humans O
but O
establish O
virulent O
, O
serotype O
- O
dependent O
disease O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
many O
young O
mammals O
. O

Morbidity O
and O
mortality O
were O
significantly O
delayed O
in O
Malt1 O
( O
- O
/ O
- O
) O
compared O
to O
Malt1 O
( O
- O
/ O
- O
) O
mice O
, O
and O
this O
effect O
was O
associated O
with O
lower O
viral O
load O
, O
proinflammatory O
gene O
expression O
, O
and O
infiltration O
and O
activation O
of O
immune O
cells O
in O
the O
brain O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
most O
prevalent O
mosquito O
- O
transmitted O
viral O
pathogen O
in O
humans O
. O

DENV O
containing O
an O
amino O
acid O
deletion O
( O
K188 O
) O
in O
nonstructural B
protein I
2A I
( I
NS2A I
) I
is O
fully O
competent O
in O
viral O
RNA O
replication O
but O
is O
completely O
defective O
in O
virion O
assembly O
. O

When O
trans O
- O
complemented O
with O
wild O
- O
type O
NS2A O
protein O
, O
the O
virion O
assembly O
defect O
could O
be O
rescued O
, O
generating O
pseudoinfectious O
virus O
( O
PIVNS2A O
) O
that O
could O
initiate O
single O
- O
round O
infection O
. O

The O
trans O
- O
complementation O
efficiency O
could O
be O
significantly O
improved O
through O
selection O
for O
adaptive O
mutations O
, O
leading O
to O
high O
- O
yield O
PIVNS2A O
production O
, O
with O
titers O
of O
> O
10 O
( O
7 O
) O
infectious B
- I
focus I
units I
( I
IFU I
) I
/ O
ml O
. O

Zika B
virus I
( I
ZIKV I
) I
glycoproteins O
are O
the O
primary O
target O
of O
the O
humoral O
immune O
response O
. O

We O
first O
created O
a O
panel O
of O
ZIKV O
mutants O
with O
the O
FLAG O
epitope O
inserted O
in O
the O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
glycoprotein O
regions O
. O

IMPORTANCE O
Zika B
virus I
( I
ZIKV I
) I
infections O
are O
associated O
with O
severe O
birth O
defects O
and O
neurological O
disease O
. O

We O
previously O
isolated O
a O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
mutant O
, O
KOS O
- O
NA O
, O
that O
carries O
two O
nonsynonymous O
mutations O
in O
UL39 O
, O
resulting O
in O
L393P O
and O
R950H O
amino O
acid O
substitutions O
in O
infected B
cell I
protein I
6 I
( I
ICP6 I
) I
. O

Immunizations O
with O
the O
ICP0 O
( O
- O
) O
, O
ICP8 O
( O
- O
) O
, O
and O
KOS O
- O
NA O
viruses O
all O
reduced O
replication O
of O
wild O
- O
type O
HSV O
- O
1 O
challenge O
virus O
in O
the O
corneal O
epithelium O
to O
similar O
extents O
. O

Low O
immunizing O
doses O
of O
KOS O
- O
NA O
and O
the O
ICP8 O
( O
- O
) O
virus O
, O
but O
not O
the O
ICP0 O
( O
- O
) O
virus O
, O
protected O
mice O
against O
eyelid O
disease O
( O
blepharitis O
) O
. O

Notably O
, O
only O
KOS O
- O
NA O
protected O
almost O
completely O
against O
corneal O
disease O
( O
keratitis O
) O
and O
greatly O
reduced O
latent O
infection O
by O
challenge O
virus O
. O

In O
this O
study O
, O
we O
tested O
the O
protective O
potential O
of O
a O
neuroattenuated O
HSV O
- O
1 O
mutant O
( O
KOS O
- O
NA O
) O
as O
a O
vaccine O
in O
mice O
. O

We O
compared O
the O
effects O
of O
immunization O
with O
KOS O
- O
NA O
to O
those O
of O
two O
other O
attenuated O
viruses O
, O
a O
replication O
- O
competent O
( O
ICP0 O
( O
- O
) O
) O
virus O
and O
a O
replication O
- O
incompetent O
( O
ICP8 O
( O
- O
) O
) O
virus O
. O

human B
coronaviruses I
( I
HCoVs I
) I
are O
recognized O
respiratory O
pathogens O
for O
which O
accumulating O
evidence O
indicates O
that O
in O
vulnerable O
patients O
the O
infection O
can O
cause O
more O
severe O
pathologies O
. O

HCoVs O
are O
not O
always O
confined O
to O
the O
upper O
respiratory O
tract O
and O
can O
invade O
the O
central B
nervous I
system I
( I
CNS I
) I
under O
still O
unclear O
circumstances O
. O

Their O
neuropathogenicity O
is O
being O
increasingly O
recognized O
in O
humans O
, O
and O
the O
presence O
and O
persistence O
of O
Human B
coronaviruses I
( I
hCoV I
) I
in O
human O
brains O
have O
been O
proposed O
to O
cause O
long O
- O
term O
sequelae O
. O

However O
, O
the O
exact O
mechanisms O
of O
injury O
to O
the O
central B
nervous I
system I
( I
CNS I
) I
during O
flavivirus O
infections O
remain O
poorly O
understood O
. O

Depletion O
of O
microglia O
resulted O
in O
increased O
mortality O
and O
viral O
titer O
in O
the O
brain O
following O
infection O
with O
either O
West B
Nile I
virus I
( I
WNV I
) I
or O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
. O

In O
contrast O
, O
and O
as O
expected O
, O
expression O
of O
the O
macrophage O
marker O
triggering B
receptor I
expressed I
on I
myeloid I
cells I
2 I
( I
TREM2 I
) I
was O
decreased O
in O
virus O
- O
infected O
, O
PLX5622 O
- O
treated O
mice O
compared O
to O
virus O
- O
infected O
controls O
. O

Lassa B
virus I
( I
LASV I
) I
belongs O
to O
the O
Mammarenavirus O
genus O
( O
family O
Arenaviridae O
) O
and O
causes O
severe O
hemorrhagic O
fever O
in O
humans O
. O

At O
present O
, O
there O
are O
no O
Food B
and I
Drug I
Administration I
( I
FDA I
) I
- O
approved O
drugs O
or O
vaccines O
specific O
for O
LASV O
. O

Here O
, O
high O
- O
throughput O
screening O
of O
an O
FDA O
- O
approved O
drug O
library O
was O
performed O
against O
LASV O
entry O
by O
using O
pseudotype O
virus O
bearing O
LASV O
envelope O
glycoprotein B
( I
GPC I
) I
. O

Adaptive O
mutant O
analyses O
demonstrated O
that O
replacement O
of O
T40 O
, O
located O
in O
the O
ectodomain O
of O
the O
stable B
- I
signal I
peptide I
( I
SSP I
) I
, O
with O
Lysine B
( I
K I
) I
conferred O
LASV O
resistance O
to O
lacidipine O
. O

Furthermore O
, O
lacidipine O
showed O
antiviral O
activity O
against O
LASV O
, O
the O
closely O
related O
Mopeia B
virus I
( I
MOPV I
) I
, O
and O
the O
New O
World O
arenavirus O
Guanarito B
virus I
( I
GTOV I
) I
. O

protein B
phosphatase I
1 I
( I
PP1 I
) I
is O
a O
serine O
/ O
threonine O
phosphatase O
which O
has O
been O
implicated O
in O
the O
regulation O
of O
a O
number O
of O
viruses O
, O
including O
HIV O
- O
1 O
, O
Ebolavirus O
, O
and O
Rift O
Valley O
fever O
virus O
. O

Catalytic O
subunits O
of O
PP1 O
( O
PP1 O
alpha O
, O
PP1 O
beta O
, O
and O
PP1 O
gamma O
) O
interact O
with O
a O
host O
of O
regulatory O
subunits O
and O
target O
a O
wide O
variety O
of O
cellular O
substrates O
through O
a O
combination O
of O
short O
binding O
motifs O
, O
including O
an O
RVxF O
motif O
present O
in O
the O
majority O
of O
PP1 O
regulatory O
subunits O
. O

In O
this O
study O
, O
we O
determined O
the O
effect O
of O
PP1 O
on O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
replication O
. O

Viral O
replication O
was O
also O
decreased O
after O
treatment O
with O
PP1 O
alpha O
- O
targeting O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
causes O
moderate O
flu O
- O
like O
symptoms O
and O
can O
lead O
to O
severe O
encephalitic O
disease O
and O
potentially O
death O
. O

The O
significance O
of O
our O
research O
is O
in O
identifying O
the O
interaction O
between O
protein B
phosphatase I
1 I
( I
PP1 I
) I
and O
the O
viral O
capsid O
protein O
. O

Signal B
peptidase I
complex I
subunit I
1 I
( I
SPCS1 I
) I
is O
a O
newly O
identified O
host O
factor O
that O
regulates O
flavivirus O
replication O
, O
but O
the O
molecular O
mechanism O
is O
not O
fully O
understood O
. O

Here O
, O
using O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
as O
a O
model O
, O
we O
investigated O
the O
mechanism O
through O
which O
the O
host O
factor O
SPCS1 O
regulates O
the O
replication O
of O
flaviviruses O
. O

SPCS1 O
was O
found O
to O
interact O
with O
nonstructural B
protein I
2B I
( I
NS2B I
) I
, O
which O
is O
involved O
in O
posttranslational O
protein O
processing O
and O
virus O
assembly O
. O

Serial O
deletion O
mutation O
of O
the O
JEV O
NS2B O
protein O
revealed O
that O
two O
transmembrane O
domains O
, O
NS2B O
( O
1 O
- O
49 O
) O
and O
NS2B O
( O
84 O
- O
131 O
) O
, O
interact O
with O
SPCS1 O
. O

Further O
mutagenesis O
analysis O
of O
conserved O
flavivirus O
residues O
in O
two O
SPCS1 O
interaction O
domains O
of O
NS2B O
demonstrated O
that O
G12A O
, O
G37A O
, O
and O
G47A O
in O
NS2B O
( O
1 O
- O
49 O
) O
and O
P112A O
in O
NS2B O
( O
84 O
- O
131 O
) O
weakened O
the O
interaction O
with O
SPCS1 O
. O

Deletion O
mutation O
of O
SPCS1 O
revealed O
that O
SPCS1 O
( O
91 O
- O
169 O
) O
, O
which O
contains O
two O
transmembrane O
domains O
, O
was O
involved O
in O
interactions O
with O
both O
NS2B O
( O
1 O
- O
49 O
) O
and O
NS2B O
( O
84 O
- O
131 O
) O
. O

The O
mouse O
model O
of O
West B
Nile I
virus I
( I
WNV I
) I
, O
which O
is O
a O
leading O
cause O
of O
mosquito O
- O
borne O
encephalitis O
worldwide O
, O
has O
provided O
fundamental O
insights O
into O
the O
host O
and O
viral O
factors O
that O
regulate O
viral O
pathogenesis O
and O
infection O
outcome O
. O

In O
particular O
, O
CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
controlling O
WNV O
replication O
and O
promoting O
protection O
against O
infection O
. O

Here O
, O
we O
present O
the O
characterization O
of O
a O
T B
cell I
receptor I
( I
TCR I
) I
- O
transgenic O
mouse O
with O
specificity O
for O
the O
immunodominant O
epitope O
in O
the O
WNV O
NS4B O
protein O
( O
here O
referred O
to O
as O
transgenic O
WNV O
- O
I O
mice O
) O
. O

Using O
an O
adoptive O
- O
transfer O
model O
, O
we O
found O
that O
WNV O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
behave O
similarly O
to O
endogenous O
CD8 O
( O
+ O
) O
T O
cell O
responses O
, O
with O
an O
expansion O
phase O
in O
the O
periphery O
beginning O
around O
day O
7 O
postinfection O
( O
p O
. O

Through O
the O
use O
of O
in O
vivo O
intravascular O
immune O
cell O
staining O
, O
we O
determined O
the O
kinetics O
, O
expansion O
, O
and O
differentiation O
into O
effector O
and O
memory O
subsets O
of O
WNV O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
within O
the O
spleen O
and O
brain O
. O

We O
found O
that O
red O
- O
pulp O
WNV O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
were O
more O
effector O
- O
like O
than O
white O
- O
pulp O
WNV O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
displayed O
increased O
differentiation O
into O
memory O
precursor O
cells O
. O

Within O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
we O
found O
that O
WNV O
- O
I O
CD8 O
( O
+ O
) O
T O
cells O
were O
polyfunctional O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
and O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
) O
, O
displayed O
tissue O
- O
resident O
characteristics O
( O
CD69 O
( O
+ O
) O
and O
CD103 O
( O
+ O
) O
) O
, O
persisted O
in O
the O
brain O
through O
day O
15 O
p O
. O

The O
use O
of O
these O
TCR O
- O
transgenic O
WNV O
- O
I O
mice O
provides O
a O
new O
resource O
to O
dissect O
the O
immunological O
mechanisms O
of O
CD8 O
( O
+ O
) O
T O
cell O
- O
mediated O
protection O
during O
WNV O
infection O
. O

IMPORTANCE O
West B
Nile I
virus I
( I
WNV I
) I
is O
the O
leading O
cause O
of O
mosquito O
- O
borne O
encephalitis O
worldwide O
. O

CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
controlling O
WNV O
replication O
and O
protecting O
against O
infection O
. O

Our O
findings O
provide O
a O
new O
resource O
to O
dissect O
the O
immunological O
mechanisms O
of O
CD8 O
( O
+ O
) O
T O
cell O
- O
mediated O
protection O
during O
WNV O
infection O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
is O
a O
neurotropic O
pathogen O
that O
can O
infect O
many O
types O
of O
cells O
and O
establishes O
latent O
infections O
in O
the O
neurons O
of O
sensory O
ganglia O
. O

Cells O
infected O
with O
several O
different O
types O
of O
viruses O
may O
secrete O
microvesicles B
( I
MVs I
) I
containing O
viral O
proteins O
and O
RNAs O
. O

Interestingly O
, O
the O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cell O
line O
, O
which O
is O
resistant O
to O
infection O
by O
free O
HSV O
- O
1 O
virions O
, O
was O
susceptible O
to O
HSV O
- O
1 O
infection O
after O
being O
exposed O
to O
virus O
- O
containing O
microvesicles O
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
is O
a O
neurotropic O
pathogen O
that O
can O
infect O
many O
types O
of O
cells O
and O
establishes O
latent O
infections O
in O
neurons O
. O

type B
I I
interferons I
( I
IFNs I
) I
are O
induced O
in O
response O
to O
viral O
infection O
and O
stimulate O
the O
expression O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
including O
that O
encoding O
viperin O
( O
virus O
- O
inhibitory O
protein O
, O
endoplasmic O
reticulum O
associated O
, O
IFN O
inducible O
) O
, O
which O
shows O
antiviral O
activity O
against O
a O
broad O
spectrum O
of O
viruses O
, O
including O
several O
flaviviruses O
. O

Here O
we O
describe O
a O
novel O
antiviral O
mechanism O
employed O
by O
viperin O
against O
two O
prominent O
flaviviruses O
, O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
Zika B
virus I
( I
ZIKV I
) I
. O

Viperin O
was O
found O
to O
interact O
and O
colocalize O
with O
the O
structural O
proteins O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
of O
TBEV O
, O
as O
well O
as O
with O
nonstructural B
( I
NS I
) I
proteins O
NS2A O
, O
NS2B O
, O
and O
NS3 O
. O

We O
also O
found O
that O
although O
viperin O
interacted O
with O
NS3 O
of O
mosquito O
- O
borne O
flaviviruses O
( O
ZIKV O
, O
Japanese O
encephalitis O
virus O
, O
and O
yellow O
fever O
virus O
) O
, O
only O
ZIKV O
was O
sensitive O
to O
the O
antiviral O
effect O
of O
viperin O
. O

Here O
we O
have O
identified O
a O
novel O
mechanism O
employed O
by O
viperin O
to O
inhibit O
the O
replication O
of O
two O
flaviviruses O
: O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
Zika B
virus I
( I
ZIKV I
) I
. O

Viperin O
induced O
selective O
degradation O
via O
the O
proteasome O
of O
TBEV O
and O
ZIKV O
non B
- I
structural I
3 I
( I
NS3 I
) I
protein O
, O
which O
is O
involved O
in O
several O
steps O
of O
the O
viral O
life O
cycle O
. O

JC B
polyomavirus I
( I
JCPyV I
) I
establishes O
a O
lifelong O
persistence O
in O
roughly O
half O
the O
human O
population O
worldwide O
. O

In O
an O
immunosuppressed O
host O
, O
JCPyV O
can O
become O
reactivated O
and O
cause O
progressive B
multifocal I
leukoencephalopathy I
( I
PML I
) I
, O
a O
fatal O
demyelinating O
disease O
of O
the O
central O
nervous O
system O
. O

The O
type B
I I
interferon I
( I
IFN I
) I
system O
represents O
an O
essential O
innate O
immune O
response O
that O
renders O
cells O
resistant O
to O
virus O
growth O
via O
the O
molecular O
actions O
of O
IFN O
- O
induced O
effector O
proteins O
. O

Here O
we O
report O
the O
identification O
and O
characterization O
of O
N O
- O
( O
methylcarbamoyl O
) O
- O
2 O
- O
{ O
[ O
5 O
- O
( O
4 O
- O
methylphenyl O
) O
- O
1 O
, O
3 O
, O
4 O
- O
oxadiazol O
- O
2 O
- O
yl O
] O
sulfanyl O
} O
- O
2 O
- O
phenylacetamide O
( O
referred O
to O
as O
C11 O
) O
, O
a O
novel O
compound O
capable O
of O
inducing O
IFN O
secretion O
from O
human O
cells O
. O

Previous O
studies O
in O
mice O
with O
a O
virulent O
strain O
( O
neuroadapted O
SINV O
[ O
NSV O
] O
) O
of O
the O
alphavirus O
Sindbis B
virus I
( I
SINV I
) I
identified O
a O
role O
for O
Th17 O
cells O
and O
regulation O
by O
interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
in O
the O
pathogenesis O
of O
fatal O
encephalomyelitis O
( O
K O
. O

To O
determine O
the O
role O
of O
virus O
virulence O
in O
generation O
of O
immune O
responses O
, O
we O
analyzed O
the O
modulatory O
effects O
of O
IL O
- O
10 O
on O
disease O
severity O
, O
virus O
clearance O
, O
and O
the O
CD4 O
( O
+ O
) O
T O
cell O
response O
to O
infection O
with O
a O
recombinant O
strain O
of O
SINV O
of O
intermediate O
virulence O
( O
TE12 O
) O
. O

More O
severe O
disease O
and O
impaired O
virus O
clearance O
in O
IL O
- O
10 O
( O
- O
/ O
- O
) O
mice O
were O
associated O
with O
more O
Th1 O
cells O
, O
fewer O
Th2 O
cells O
, O
innate O
lymphoid O
type O
2 O
cells O
, O
regulatory O
cells O
, O
and O
B O
cells O
, O
and O
delayed O
production O
of O
antiviral O
antibody O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
without O
an O
effect O
on O
Th17 O
cells O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
representative O
member O
of O
the O
New O
World O
alphaviruses O
. O

In O
this O
study O
, O
we O
investigated O
the O
possibility O
of O
using O
a O
modified O
nucleoside O
analog O
, O
beta O
- O
D O
- O
N O
- O
4 O
- O
hydroxycytidine O
( O
NHC O
) O
, O
as O
an O
anti O
- O
VEEV O
agent O
and O
defined O
the O
mechanism O
of O
its O
anti O
- O
VEEV O
activity O
. O

IMPORTANCE O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
can O
cause O
widespread O
epidemics O
among O
humans O
and O
domestic O
animals O
. O

Our O
study O
demonstrates O
that O
beta O
- O
D O
- O
N O
- O
4 O
- O
hydroxycytidine O
( O
NHC O
) O
is O
a O
very O
potent O
anti O
- O
VEEV O
compound O
, O
with O
the O
50 O
% O
effective O
concentration O
being O
below O
1 O
mu O
M O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
is O
an O
emerging O
arboviral O
disease O
of O
livestock O
and O
humans O
. O

Some O
individuals O
infected O
with O
RVF B
virus I
( I
RVFV I
) I
develop O
meningoencephalitis O
, O
resulting O
in O
morbidity O
and O
mortality O
. O

African B
green I
monkeys I
( I
AGM I
) I
exposed O
to O
aerosols O
containing O
RVFV O
develop O
a O
reproducibly O
lethal O
neurological O
disease O
that O
resembles O
human O
illness O
. O

Divergence O
between O
lethal O
and O
sublethal O
infections O
occurred O
as O
early O
as O
2 O
days O
postinfection O
( O
dpi O
) O
, O
at O
which O
point O
CD8 O
( O
+ O
) O
T O
cells O
from O
lethally O
infected O
AGM O
expressed O
activated O
caspase O
- O
3 O
and O
simultaneously O
failed O
to O
increase O
levels O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
molecules O
, O
in O
contrast O
to O
surviving O
animals O
. O

At O
4 O
dpi O
, O
lethally O
infected O
animals O
failed O
to O
demonstrate O
proliferation O
of O
total O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
, O
in O
contrast O
to O
survivors O
. O

In O
addition O
, O
an O
early O
proinflammatory O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
, O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
IL O
- O
8 O
, O
monocyte O
chemoattractant O
protein O
1 O
[ O
MCP O
- O
1 O
] O
) O
and O
antiviral O
( O
IFN O
- O
gamma O
) O
response O
was O
seen O
in O
survivors O
, O
while O
very O
late O
cytokine O
expression O
was O
found O
in O
animals O
with O
lethal O
infections O
. O

IMPORTANCE O
Rift B
Valley I
fever I
( I
RVF I
) I
is O
an O
important O
emerging O
viral O
disease O
for O
which O
we O
lack O
both O
an O
effective O
human O
vaccine O
and O
treatment O
. O

African B
green I
monkeys I
( I
AGM I
) I
develop O
lethal O
neurological O
disease O
when O
infected O
with O
RVF O
virus O
by O
inhalation O
. O

In O
this O
work O
, O
we O
evaluated O
the O
relevance O
of O
the O
ubiquitin B
- I
proteasome I
system I
( I
UPS I
) I
in O
the O
replication O
of O
Yuc8 O
, O
a O
human O
astrovirus O
serotype O
8 O
strain O
. O

The O
inhibition O
of O
proteasome O
activity O
decreases O
viral O
RNA O
levels O
and O
viral O
protein O
synthesis O
; O
similarly O
, O
the O
inhibition O
of O
ubiquitination O
by O
chemical O
inhibitors O
or O
RNA B
interference I
( I
RNAi I
) I
reduces O
the O
production O
of O
viral O
progeny O
as O
well O
as O
viral O
protein O
synthesis O
. O

We O
describe O
here O
a O
novel O
flavivirus O
inhibition O
mechanism O
that O
results O
in O
interferon O
- O
mediated O
obstruction O
of O
tick O
- O
borne O
encephalitis O
virus O
particle O
assembly O
and O
involves O
release O
of O
malfunctioning O
membrane O
- O
associated O
Capsid B
( I
C I
) I
particles O
. O

Through O
analysis O
of O
the O
viperin O
- O
interactome O
, O
we O
identified O
the O
Golgi O
brefeldin O
A O
- O
resistant O
guanine B
nucleotide I
exchange I
factor I
1 I
( I
GBF1 I
) I
as O
the O
cellular O
protein O
targeted O
by O
viperin O
. O

In O
this O
study O
, O
we O
show O
that O
viperin O
induces O
capsid O
particle O
release O
by O
interacting O
and O
inhibiting O
the O
function O
of O
the O
cellular O
protein O
Golgi O
brefeldin O
A O
- O
resistant O
guanine B
nucleotide I
exchange I
factor I
1 I
( I
GBF1 I
) I
. O

enterovirus B
A71 I
( I
EV I
- I
A71 I
) I
causes O
various O
clinical O
manifestations O
with O
occasional O
severe O
neurological O
complications O
. O

After O
viral O
invasion O
, O
we O
identified O
a O
haplotype O
switch O
and O
dominant O
haplotype O
, O
with O
glycine O
at O
VP1 B
residue I
31 I
( I
VP1 I
- I
31G I
) I
in O
viral O
particles O
disseminated O
into O
the O
integumentary O
and O
central O
nervous O
systems O
. O

The O
innate O
immune O
system O
protects O
cells O
against O
viral O
pathogens O
in O
part O
through O
the O
autocrine O
and O
paracrine O
actions O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
( O
type O
I O
) O
, O
IFN O
- O
gamma O
( O
type O
II O
) O
, O
and O
IFN O
- O
lambda O
( O
type O
III O
) O
. O

The O
transcription O
factor O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
has O
a O
demonstrated O
role O
in O
shaping O
innate O
and O
adaptive O
antiviral O
immunity O
by O
inducing O
the O
expression O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
and O
mediating O
signals O
downstream O
of O
IFN O
- O
gamma O
. O

Here O
, O
we O
infected O
Irf1 O
( O
- O
/ O
- O
) O
mice O
with O
two O
distantly O
related O
arthritogenic O
alphaviruses O
, O
chikungunya B
virus I
( I
CHIKV I
) I
and O
Ross B
River I
virus I
( I
RRV I
) I
, O
and O
assessed O
the O
early O
antiviral O
functions O
of O
IRF O
- O
1 O
prior O
to O
induction O
of O
adaptive O
B O
and O
T O
cell O
responses O
. O

Virological O
and O
histological O
analyses O
revealed O
greater O
infection O
of O
muscle O
tissues O
in O
Irf1 O
( O
- O
/ O
- O
) O
mice O
than O
in O
wild O
- O
type O
mice O
. O

IMPORTANCE O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
is O
a O
transcription O
factor O
that O
regulates O
the O
expression O
of O
a O
broad O
range O
of O
antiviral O
host O
defense O
genes O
. O

In O
this O
study O
, O
using O
Irf1 O
( O
- O
/ O
- O
) O
mice O
, O
we O
investigated O
the O
role O
of O
IRF O
- O
1 O
in O
modulating O
pathogenesis O
of O
two O
related O
arthritogenic O
alphaviruses O
, O
chikungunya O
virus O
and O
Ross O
River O
virus O
. O

Immediate O
early O
proteins O
of O
Human B
herpesvirus I
6A I
( I
HHV I
- I
6A I
) I
are O
expressed O
at O
the O
outset O
of O
lytic O
infection O
and O
thereby O
regulate O
viral O
gene O
expression O
. O

Immediate B
early I
protein I
2 I
( I
IE2 I
) I
of O
HHV O
- O
6A O
is O
a O
transactivator O
that O
drives O
a O
variety O
of O
promoters O
. O

In O
this O
study O
, O
the O
structure O
of O
the O
IE2 B
C I
- I
terminal I
domain I
( I
IE2 I
- I
CTD I
) I
was O
determined O
by O
X O
- O
ray O
crystallography O
at O
a O
resolution O
of O
2 O
. O

Unexpectedly O
, O
the O
core O
structure O
resembles O
those O
of O
the O
gammaherpesvirus O
factors O
EBNA1 O
of O
Epstein O
- O
Barr O
virus O
and O
LANA O
of O
Kaposi O
sarcoma O
- O
associated O
herpesvirus O
, O
but O
the O
interchanging O
loops O
are O
longer O
in O
IE2 O
- O
CTD O
and O
form O
helix B
- I
turn I
- I
helix I
( I
HTH I
) I
- O
like O
motifs O
at O
their O
tips O
. O

The O
apparent O
DNA O
- O
binding O
site O
( O
based O
on O
structural O
similarity O
with O
EBNA1 O
and O
LANA O
) O
resides O
on O
the O
opposite O
side O
of O
the O
HTH O
- O
like O
motifs O
, O
surrounded O
by O
positive O
electrostatic O
potential O
. O

IMPORTANCE O
Human B
herpesvirus I
6A I
( I
HHV I
- I
6A I
) I
and O
HHV O
- O
6B O
belong O
to O
betaherpesvirus O
subfamily O
. O

Immediate B
early I
protein I
2 I
( I
IE2 I
) I
of O
HHV O
- O
6A O
and O
HHV O
- O
6B O
is O
a O
transactivator O
that O
triggers O
viral O
replication O
and O
contains O
a O
DNA O
- O
binding O
domain O
shared O
with O
other O
betaherpesviruses O
such O
as O
human O
herpesvirus O
7 O
and O
human O
cytomegalovirus O
. O

borne O
encephalitis O
virus O
( O
TBEV O
) O
causes O
a O
severe O
and O
potentially O
fatal O
neuroinfection O
in O
humans O
. O

Here O
we O
demonstrate O
that O
treatment O
with O
a O
nucleoside O
analog O
, O
7 O
- O
deaza O
- O
2 O
' O
- O
C O
- O
methyladenosine O
( O
7 O
- O
deaza O
- O
2 O
' O
- O
CMA O
) O
, O
substantially O
improved O
disease O
outcomes O
, O
increased O
survival O
, O
and O
reduced O
signs O
of O
neuroinfection O
and O
viral O
titers O
in O
the O
brains O
of O
mice O
infected O
with O
a O
lethal O
dose O
of O
TBEV O
. O

The O
two O
clones O
shared O
a O
signature O
amino O
acid O
substitution O
, O
S603T O
, O
in O
the O
viral O
NS5 O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
domain O
. O

This O
mutation O
conferred O
resistance O
to O
various O
2 O
' O
- O
C O
- O
methylated O
nucleoside O
derivatives O
, O
but O
no O
cross O
- O
resistance O
was O
seen O
with O
other O
nucleoside O
analogs O
, O
such O
as O
4 O
' O
- O
C O
- O
azidocytidine O
and O
2 O
' O
- O
deoxy O
- O
2 O
' O
- O
beta O
- O
hydroxy O
- O
4 O
' O
- O
azidocytidine O
( O
RO O
- O
9187 O
) O
. O

To O
investigate O
its O
phenotype O
, O
the O
S603T O
mutation O
was O
introduced O
into O
a O
recombinant O
TBEV O
strain O
( O
Oshima O
- O
IC O
) O
generated O
from O
an O
infectious O
cDNA O
clone O
and O
into O
a O
TBEV O
replicon O
that O
expresses O
a O
reporter O
luciferase O
gene O
( O
Oshima O
- O
REP O
- O
luc2A O
) O
. O

IMPORTANCE O
This O
study O
found O
that O
the O
nucleoside O
analog O
7 O
- O
deaza O
- O
2 O
' O
- O
C O
- O
methyl O
- O
adenosine O
( O
7 O
- O
deaza O
- O
2 O
' O
- O
CMA O
) O
has O
high O
antiviral O
activity O
against O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
, O
a O
pathogen O
that O
causes O
severe O
human O
neuroinfections O
in O
large O
areas O
of O
Europe O
and O
Asia O
and O
for O
which O
there O
is O
currently O
no O
specific O
therapy O
. O

Viral O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
is O
complicated O
by O
the O
mostly O
irreplaceable O
nature O
of O
neurons O
, O
as O
the O
loss O
of O
neurons O
has O
the O
potential O
to O
result O
in O
permanent O
damage O
to O
brain O
function O
. O

To O
address O
this O
question O
, O
we O
used O
the O
rJHM O
strain O
( O
rJ O
) O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
neurotropic O
coronavirus O
that O
causes O
acute O
encephalitis O
in O
susceptible O
strains O
of O
mice O
. O

To O
determine O
whether O
neurons O
or O
other O
CNS O
cells O
survive O
acute O
infection O
with O
this O
virulent O
virus O
, O
we O
developed O
a O
recombinant O
JHMV O
that O
expresses O
Cre O
recombinase O
( O
rJ O
- O
Cre O
) O
and O
infected O
mice O
that O
universally O
expressed O
a O
silent O
( O
floxed O
) O
version O
of O
tdTomato O
. O

Astrovirus O
VA1 O
/ O
HMO O
- O
C O
( O
VA1 O
; O
mamastrovirus O
9 O
) O
is O
a O
recently O
discovered O
astrovirus O
genotype O
that O
is O
divergent O
from O
the O
classic O
human O
astroviruses O
( O
mamastrovirus O
1 O
) O
. O

Furthermore O
, O
VA1 O
was O
sensitive O
to O
the O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
response O
, O
as O
VA1 O
RNA O
levels O
were O
reduced O
by O
pretreatment O
of O
Caco O
- O
2 O
cells O
with O
IFN O
- O
beta O
1a O
. O

During O
infection O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
generally O
enters O
host O
cells O
via O
receptor O
- O
mediated O
clathrin O
- O
dependent O
endocytosis O
. O

In O
this O
study O
, O
entry O
and O
post O
- O
internalization O
of O
JEV O
were O
analyzed O
using O
biochemical O
inhibitors O
, O
RNA O
interference O
, O
and O
dominant B
negative I
( I
DN I
) I
mutants O
. O

The O
effect O
on O
JEV O
infection O
of O
dominant B
negative I
( I
DN I
) I
mutants O
of O
four O
Rab O
proteins O
that O
regulate O
endosomal O
trafficking O
was O
examined O
. O

IMPORTANCE O
Although O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
utilizes O
different O
endocytic O
pathways O
depending O
on O
the O
cell O
type O
being O
infected O
, O
the O
detailed O
mechanism O
of O
its O
entry O
into O
BHK O
- O
21 O
cells O
is O
unknown O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
mosquito O
- O
borne O
flavivirus O
that O
causes O
epidemics O
of O
encephalitis O
and O
viscerotropic O
disease O
worldwide O
. O

The O
interferon B
( I
IFN I
) I
- O
mediated O
antiviral O
response O
represents O
an O
important O
component O
of O
virus O
- O
host O
interactions O
and O
plays O
an O
essential O
role O
in O
regulating O
viral O
replication O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
the O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
WNV O
antagonizes O
IFN O
- O
beta O
production O
, O
most O
likely O
through O
suppression O
of O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
like O
receptor O
( O
RLR O
) O
activation O
. O

NS1 O
also O
suppressed O
the O
activation O
of O
the O
IFN O
- O
beta O
promoter O
when O
it O
was O
stimulated O
by O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
/ O
5D O
or O
its O
upstream O
molecules O
in O
the O
RLR O
signaling O
pathway O
. O

Mechanistically O
, O
WNV O
NS1 O
targets O
RIG O
- O
I O
and O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
by O
interacting O
with O
them O
and O
subsequently O
causing O
their O
degradation O
by O
the O
proteasome O
. O

IMPORTANCE O
WNV O
Nile O
virus O
( O
WNV O
) O
has O
received O
increased O
attention O
since O
its O
introduction O
to O
the O
United O
States O
. O

This O
study O
demonstrated O
that O
the O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
WNV O
antagonizes O
the O
induction O
of O
interferon B
beta I
( I
IFN I
- I
beta I
) I
by O
interacting O
with O
and O
degrading O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
and O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
, O
which O
are O
crucial O
viral O
sensors O
in O
the O
host O
innate O
immune O
system O
. O

Further O
experiments O
suggested O
that O
NS1 O
- O
mediated O
inhibition O
of O
the O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
signaling O
pathway O
involves O
inhibition O
of O
RIG O
- O
I O
K63 O
- O
linked O
polyubiquitination O
and O
that O
the O
proteasome O
plays O
a O
role O
in O
RIG O
- O
I O
degradation O
. O

In O
contrast O
, O
we O
found O
no O
evidence O
that O
geographic O
location O
played O
a O
major O
role O
in O
shaping O
RNA O
virus O
diversity O
, O
and O
several O
viruses O
discovered O
here O
exhibited O
high O
similarity O
( O
95 O
to O
98 O
% O
nucleotide O
identity O
) O
to O
those O
from O
Indonesia O
and O
China O
. O

Herpes B
Simplex I
Virus I
( I
HSV I
) I
infection O
is O
widespread O
in O
the O
human O
population O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
zoonotic O
emerging O
paramyxovirus O
that O
can O
cause O
fatal O
respiratory O
illness O
or O
encephalitis O
in O
humans O
. O

Despite O
many O
efforts O
, O
the O
molecular O
mechanisms O
of O
NiV O
- O
induced O
acute B
lung I
injury I
( I
ALI I
) I
remain O
unclear O
. O

Interestingly O
, O
these O
mice O
can O
undergo O
human O
immune O
system O
reconstitution O
by O
the O
bone O
marrow O
, O
liver O
, O
and O
thymus O
( O
BLT O
) O
reconstitution O
method O
, O
in O
addition O
to O
lung O
tissue O
engraftment O
, O
giving O
altogether O
a O
realistic O
model O
to O
study O
human O
respiratory O
viral O
infections O
. O

Here O
, O
we O
characterized O
NiV B
Bangladesh I
strain I
( I
NiV I
- I
B I
) I
infection O
of O
human O
lung O
grafts O
from O
human O
immune O
system O
- O
reconstituted O
mice O
in O
order O
to O
identify O
the O
overall O
effect O
of O
immune O
cells O
on O
NiV O
pathogenesis O
of O
the O
lung O
. O

IMPORTANCE O
Nipah B
virus I
( I
NiV I
) I
is O
an O
emerging O
paramyxovirus O
that O
can O
cause O
a O
lethal O
respiratory O
and O
neurological O
disease O
in O
humans O
. O

Only O
limited O
data O
are O
available O
on O
NiV O
pathogenesis O
in O
the O
human O
lung O
, O
and O
the O
relative O
contribution O
of O
the O
innate O
immune O
response O
and O
NiV O
to O
acute B
lung I
injury I
( I
ALI I
) I
is O
still O
unknown O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
mosquito O
- O
borne O
RNA O
virus O
that O
causes O
low O
mortality O
but O
high O
morbidity O
rates O
in O
humans O
. O

Human B
polyclonal I
antibodies I
( I
PAbs I
) I
are O
ideal O
, O
but O
this O
is O
dependent O
upon O
serum O
from O
convalescent O
human O
donors O
, O
which O
is O
in O
limited O
supply O
. O

To O
address O
these O
issues O
, O
transchromosomic B
( I
Tc I
) I
bovines O
have O
been O
created O
, O
which O
can O
produce O
potent O
neutralizing O
human O
antibodies O
in O
response O
to O
hyperimmunization O
. O

These O
studies O
demonstrate O
that O
prophylactic O
or O
therapeutic O
administration O
of O
the O
polyclonal O
antibody O
preparations O
( O
TcPAbs O
) O
can O
protect O
mice O
against O
lethal O
subcutaneous O
or O
aerosol O
challenge O
with O
VEEV O
. O

By O
using O
a O
transchromosomic B
( I
Tc I
) I
bovine O
platform O
, O
it O
is O
theoretically O
possible O
to O
produce O
antigen O
- O
specific O
highly O
neutralizing O
therapeutic B
polyclonal I
human I
antibody I
( I
TcPAb I
) I
preparations O
in O
6 O
months O
or O
less O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
Tc O
bovine O
- O
derived O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
- O
specific O
TcPAbs O
are O
highly O
effective O
against O
VEEV O
infection O
that O
mimics O
not O
only O
the O
natural O
route O
of O
infection O
but O
also O
infection O
via O
aerosol O
exposure O
. O

For O
HIV O
- O
1 O
infection O
, O
during O
entry O
, O
the O
virus O
triggers O
early O
actin O
activity O
by O
hijacking O
chemokine O
coreceptor O
signaling O
, O
which O
activates O
a O
host O
dependency O
factor O
, O
cofilin O
, O
and O
its O
kinase O
, O
the O
LIM B
domain I
kinase I
( I
LIMK I
) I
. O

Although O
knockdown O
of O
human O
LIM B
domain I
kinase I
1 I
( I
LIMK1 I
) I
with O
short B
hairpin I
RNA I
( I
shRNA I
) I
inhibits O
HIV O
infection O
, O
no O
specific O
small O
- O
molecule O
inhibitor O
of O
LIMK O
has O
been O
available O
. O

In O
addition O
, O
R10015 O
inhibits O
multiple O
viruses O
, O
including O
Zaire O
ebolavirus B
( I
EBOV I
) I
, O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
and O
herpes B
simplex I
virus I
1 I
( I
H5V I
- I
1 I
) I
, O
suggesting O
that O
LIMK O
inhibitors O
could O
be O
developed O
as O
a O
new O
class O
of O
broad O
- O
spectrum O
antiviral O
drugs O
. O

In O
cells O
, O
actin O
dynamics O
are O
regulated O
by O
kinases O
, O
such O
as O
the O
LIM B
domain I
kinase I
( I
LIMK I
) I
, O
which O
regulates O
actin O
activity O
through O
phosphorylation O
of O
cofilin O
, O
an O
actin O
- O
depolymerizing O
factor O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
mosquito O
- O
transmitted O
flavivirus O
that O
can O
cause O
debilitating O
encephalitis O
. O

This O
leukocytosis O
resulted O
in O
a O
significant O
enhancement O
of O
leukocyte O
accumulation O
within O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
an O
arthropod O
- O
borne O
flavivirus O
prevalent O
in O
Asia O
and O
the O
Western O
Pacific O
and O
is O
the O
leading O
cause O
of O
viral O
encephalitis O
. O

The O
C O
- O
type O
lectin O
mosquito B
galactose I
- I
specific I
C I
- I
type I
lectin I
7 I
( I
mosGCTL I
- I
7 I
) I
( O
VectorBase O
accession O
no O
. O

The O
viral O
burden O
in O
vivo O
and O
in O
vitro O
was O
significantly O
decreased O
by O
mosPTP O
- O
1 O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
treatment O
, O
and O
infection O
was O
abolished O
by O
anti O
- O
mosGCTL O
- O
7 O
antibodies O
. O

We O
have O
previously O
shown O
that O
the O
live O
- O
attenuated O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
mutant O
lacking O
the O
nuclear B
localization I
signal I
( I
NLS I
) I
on O
the O
ICP0 O
gene O
( O
0 O
Delta O
NLS O
) O
is O
sensitive O
to O
inhibition O
by O
interferon B
beta I
( I
IFN I
- I
beta I
) I
in O
vitro O
and O
functions O
as O
a O
highly O
efficacious O
experimental O
vaccine O
. O

Additionally O
, O
we O
explore O
the O
role O
of O
type O
1 O
interferon O
( O
IFN O
- O
alpha O
/ O
beta O
) O
signaling O
on O
virulence O
and O
immunogenicity O
of O
HSV O
- O
1 O
0 O
Delta O
NLS O
and O
uncover O
a O
probable O
sex O
bias O
in O
the O
induction O
of O
IFN O
- O
alpha O
/ O
beta O
in O
the O
cornea O
during O
HSV O
- O
1 O
infection O
. O

The O
demonstrated O
clinical O
efficacy O
of O
a O
recombinant B
vesicular I
stomatitis I
virus I
( I
rVSV I
) I
vaccine O
vector O
has O
stimulated O
the O
investigation O
of O
additional O
serologically O
distinct O
Vesiculovirus O
vectors O
as O
therapeutic O
and O
/ O
or O
prophylactic O
vaccine O
vectors O
to O
combat O
emerging O
viral O
diseases O
. O

Among O
these O
viral O
threats O
are O
the O
encephalitic O
alphaviruses O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
and O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
, O
which O
have O
demonstrated O
potential O
for O
natural O
disease O
outbreaks O
, O
yet O
no O
licensed O
vaccines O
are O
available O
in O
the O
event O
of O
an O
epidemic O
. O

Here O
we O
report O
the O
rescue O
of O
recombinant B
Isfahan I
virus I
( I
rISFV I
) I
from O
genomic O
cDNA O
as O
a O
potential O
new O
vaccine O
vector O
platform O
. O

The O
recent O
reemergence O
and O
spread O
of O
flaviviruses O
, O
including O
Dengue B
Virus I
( I
DENV I
) I
, O
West B
Nile I
virus I
( I
WNV I
) I
, O
and O
Zika B
virus I
( I
ZIKV I
) I
, O
highlight O
the O
importance O
of O
performing O
basic O
research O
on O
this O
important O
group O
of O
pathogens O
. O

microRNAs B
( I
miRNAs I
) I
are O
small O
, O
noncoding O
RNAs O
that O
modulate O
gene O
expression O
posttranscriptionally O
and O
have O
been O
demonstrated O
to O
regulate O
a O
broad O
range O
of O
cellular O
processes O
. O

We O
have O
screened O
a O
library O
of O
known O
human O
miRNA O
mimics O
for O
their O
effect O
on O
the O
replication O
of O
three O
flaviviruses O
, O
DENV O
, O
WNV O
, O
and O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
using O
a O
high O
- O
content O
immunofluorescence O
screen O
. O

Previous O
research O
suggested O
a O
possible O
link O
between O
the O
Wnt O
and O
type B
I I
interferon I
( I
IFN I
) I
signaling O
pathways O
. O

Therefore O
, O
we O
investigated O
the O
role O
of O
type O
I O
IFN O
induction O
in O
the O
antiviral O
effects O
of O
the O
miR O
- O
34 O
family O
and O
confirmed O
that O
these O
miRNAs O
potentiate O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
phosphorylation O
and O
translocation O
to O
the O
nucleus O
, O
the O
induction O
of O
IFN O
- O
responsive O
genes O
, O
and O
the O
release O
of O
type O
I O
IFN O
from O
transfected O
cells O
. O

We O
further O
demonstrate O
that O
the O
intersection O
between O
the O
Wnt O
and O
IFN O
signaling O
pathways O
occurs O
at O
the O
point O
of O
glycogen O
synthase O
kinase O
3 O
beta O
( O
GSK3 O
beta O
) O
- O
TANK B
- I
binding I
kinase I
1 I
( I
TBK1 I
) I
binding O
, O
inducing O
TBK1 O
to O
phosphorylate O
IRF3 O
and O
initiate O
downstream O
IFN O
signaling O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
a O
mosquito O
- O
borne O
flavivirus O
, O
is O
the O
leading O
cause O
of O
viral O
encephalitis O
in O
Southeast O
Asia O
with O
potential O
to O
become O
a O
global O
pathogen O
. O

Here O
, O
we O
identify O
glucose B
- I
regulated I
protein I
78 I
( I
GRP78 I
) I
as O
an O
important O
host O
protein O
for O
virus O
entry O
and O
replication O
. O

Using O
the O
plasma O
membrane O
fractions O
from O
mouse O
neuronal O
( O
Neuro2a O
) O
cells O
, O
mass O
spectroscopy O
analysis O
identified O
GRP78 O
as O
a O
protein O
interacting O
with O
recombinant O
JEV O
envelope O
protein O
domain O
III O
. O

Depletion O
of O
GRP78 O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
significantly O
blocked O
JEV O
entry O
into O
Neuro2a O
cells O
, O
further O
supporting O
its O
role O
in O
virus O
uptake O
. O

interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
, O
an O
inflammatory O
cytokine O
and O
IL O
- O
1 O
receptor O
ligand O
, O
has O
diverse O
activities O
in O
the O
brain O
. O

We O
examined O
whether O
IL O
- O
1 O
signaling O
contributes O
to O
the O
encephalitis O
observed O
in O
mouse B
adenovirus I
type I
1 I
( I
MAV I
- I
1 I
) I
infection O
, O
using O
mice O
lacking O
the O
IL O
- O
1 O
receptor O
( O
Il1r1 O
( O
- O
/ O
- O
) O
mice O
) O
. O

Il1r1 O
( O
- O
/ O
- O
) O
mice O
demonstrated O
reduced O
survival O
, O
greater O
disruption O
of O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
, O
higher O
brain O
viral O
loads O
, O
and O
higher O
brain O
inflammatory O
cytokine O
and O
chemokine O
levels O
than O
control O
C57BL O
/ O
6J O
mice O
. O

We O
also O
examined O
infections O
of O
mice O
defective O
in O
IL O
- O
1 O
beta O
production O
( O
Pycard O
( O
- O
/ O
- O
) O
mice O
) O
and O
mice O
defective O
in O
trafficking O
of O
Toll O
- O
like O
receptors O
to O
the O
endosome O
( O
Unc93b1 O
( O
- O
/ O
- O
) O
mice O
) O
. O

Pycard O
( O
- O
/ O
- O
) O
and O
Unc93b1 O
( O
- O
/ O
- O
) O
mice O
showed O
lower O
survival O
( O
similar O
to O
Il1r1 O
( O
- O
/ O
- O
) O
mice O
) O
than O
control O
mice O
but O
, O
unlike O
Il1r1 O
( O
- O
/ O
- O
) O
mice O
, O
did O
not O
have O
increased O
brain O
viral O
loads O
or O
BBB O
disruption O
. O

Based O
on O
the O
brain O
cytokine O
levels O
, O
MAV O
- O
1 O
- O
infected O
Unc93b1 O
( O
- O
/ O
- O
) O
mice O
had O
a O
very O
different O
inflammatory O
profile O
from O
infected O
Il1r1 O
( O
- O
/ O
- O
) O
and O
Pycard O
( O
- O
/ O
- O
) O
mice O
. O

Histological O
examination O
demonstrated O
pathological O
findings O
consistent O
with O
encephalitis O
in O
control O
and O
knockout O
mice O
; O
however O
, O
intranuclear O
viral O
inclusions O
were O
seen O
only O
in O
Il1r1 O
( O
- O
/ O
- O
) O
mice O
. O

A O
time O
course O
of O
infection O
of O
control O
and O
Il1r1 O
( O
- O
/ O
- O
) O
mice O
evaluating O
the O
kinetics O
of O
viral O
replication O
and O
cytokine O
production O
revealed O
differences O
between O
the O
mouse O
strains O
primarily O
at O
7 O
to O
8 O
days O
after O
infection O
, O
when O
mice O
began O
succumbing O
to O
MAV O
- O
1 O
infection O
. O

In O
the O
absence O
of O
IL O
- O
1 O
signaling O
, O
we O
noted O
an O
increase O
in O
the O
transcription O
of O
type B
I I
interferon I
( I
IFN I
) I
- O
stimulated O
genes O
. O

Their O
transmission O
by O
arthropods O
, O
particularly O
mosquitoes O
, O
facilitates O
large O
emergence O
events O
such O
as O
witnessed O
with O
Zika B
virus I
( I
ZIKV I
) I
or O
West O
Nile O
virus O
in O
the O
Americas O
. O

Every O
vector O
- O
borne O
flavivirus O
examined O
thus O
far O
that O
causes O
disease O
in O
humans O
, O
from O
dengue O
virus O
to O
ZIKV O
, O
antagonizes O
the O
host O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
response O
by O
preventing O
JAK O
- O
STAT O
signaling O
, O
suggesting O
that O
suppression O
of O
this O
pathway O
is O
an O
important O
determinant O
of O
infection O
. O

The O
alphaviruses O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
, O
and O
Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
are O
arthropod O
- O
borne O
positive O
- O
strand O
RNA O
viruses O
that O
are O
capable O
of O
causing O
acute O
and O
fatal O
encephalitis O
in O
many O
mammals O
, O
including O
humans O
. O

These O
viruses O
utilize O
programmed O
- O
1 O
ribosomal O
frameshifting O
( O
- O
1 O
PRF O
) O
to O
synthesize O
the O
viral O
trans B
- I
frame I
( I
TF I
) I
protein O
, O
which O
has O
previously O
been O
shown O
to O
be O
important O
for O
neuropathogenesis O
in O
the O
related O
Sindbis O
virus O
. O

IMPORTANCE O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
select O
agent O
that O
has O
been O
weaponized O
. O

VEEV O
and O
related O
alphaviruses O
utilize O
programmed O
- O
1 O
ribosomal O
frameshifting O
( O
- O
1 O
PRF O
) O
to O
synthesize O
the O
viral O
trans B
- I
frame I
( I
TF I
) I
protein O
, O
which O
is O
important O
for O
neuropathogenesis O
. O

Flaviviruses O
, O
such O
as O
Zika O
virus O
, O
yellow O
fever O
virus O
, O
dengue O
virus O
, O
and O
West B
Nile I
virus I
( I
WNV I
) I
, O
are O
a O
serious O
concern O
for O
human O
health O
. O

Flaviviruses O
produce O
an O
abundant O
noncoding O
subgenomic B
flavivirus I
RNA I
( I
sfRNA I
) I
in O
infected O
cells O
. O

sfRNA O
results O
from O
stalling O
of O
the O
host O
5 O
' O
- O
3 O
' O
exoribonuclease O
XRN1 O
/ O
Pacman O
on O
conserved O
RNA O
structures O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
viral O
genomic O
RNA O
. O

An O
sfRNA1 O
- O
deficient O
WNV O
was O
generated O
that O
displayed O
growth O
kinetics O
similar O
to O
those O
of O
wild O
- O
type O
WNV O
in O
both O
RNA B
interference I
( I
RNAi I
) I
- O
competent O
and O
- O
compromised O
mosquito O
cell O
lines O
. O

Small O
- O
RNA O
deep O
sequencing O
of O
WNV O
- O
infected O
mosquitoes O
indicated O
an O
active O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
based O
antiviral O
response O
for O
both O
the O
wild O
- O
type O
and O
sfRNA1 O
- O
deficient O
viruses O
. O

Two O
reproducible O
small O
- O
RNA O
hot O
spots O
within O
the O
3 O
' O
UTR O
/ O
sfRNA O
of O
the O
wild O
- O
type O
virus O
mapped O
to O
RNA O
stem O
- O
loops O
SL O
- O
III O
and O
3 O
' O
SL O
, O
which O
stick O
out O
of O
the O
three B
- I
dimensional I
( I
3D I
) I
sfRNA O
structure O
model O
. O

Viral O
infection O
induces O
production O
of O
type B
I I
interferons I
( I
IFNs I
) I
, O
which O
stimulate O
the O
expression O
of O
a O
variety O
of O
antiviral O
factors O
to O
inhibit O
viral O
replication O
. O

A O
neurovirulent O
Sindbis B
virus I
strain I
with I
neuroinvasive I
properties I
( I
SVNI I
) I
causes O
lethal O
encephalitis O
in O
mice O
, O
and O
its O
replication O
in O
cultured O
cells O
is O
inhibited O
by O
the O
zinc B
finger I
antiviral I
protein I
( I
ZAP I
) I
, O
a O
host O
factor O
that O
specifically O
inhibits O
the O
replication O
of O
certain O
viruses O
by O
binding O
to O
the O
viral O
mRNAs O
, O
repressing O
the O
translation O
of O
target O
mRNA O
, O
and O
promoting O
the O
degradation O
of O
target O
mRNA O
. O

ADP O
- O
ribosylation O
is O
a O
posttranslational O
protein O
modification O
in O
which O
ADP O
- O
ribose O
is O
transferred O
from O
NAD O
( O
+ O
) O
to O
specific O
acceptors O
to O
regulate O
a O
wide O
variety O
of O
cellular O
processes O
. O

Here O
, O
we O
report O
that O
the O
macro O
domain O
from O
hepatitis B
E I
virus I
( I
HEV I
) I
serves O
as O
an O
ADP O
- O
ribose O
- O
protein O
hydrolase O
for O
mono B
- I
ADP I
- I
ribose I
( I
MAR I
) I
and O
poly O
( O
ADP O
- O
ribose O
) O
( O
PAR O
) O
chain O
removal O
( O
de O
- O
MARylation O
and O
de O
- O
PARylation O
, O
respectively O
) O
from O
mono O
- O
and O
poly O
( O
ADP O
) O
- O
ribosylated O
proteins O
, O
respectively O
. O

The O
presence O
of O
the O
HEV O
helicase O
in O
cis O
dramatically O
increases O
the O
binding O
of O
the O
macro O
domain O
to O
poly O
( O
ADP O
- O
ribose O
) O
and O
stimulates O
the O
de O
- O
PARylation O
activity O
. O

The O
de O
- O
MARylation O
activity O
is O
present O
in O
all O
three O
pathogenic O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
[ O
( O
+ O
) O
ssRNA O
] O
virus O
families O
which O
carry O
a O
macro O
domain O
: O
Coronaviridae O
( O
severe O
acute O
respiratory O
syndrome O
coronavirus O
and O
human O
coronavirus O
229E O
) O
, O
Togaviridae O
( O
Venezuelan O
equine O
encephalitis O
virus O
) O
, O
and O
Hepeviridae B
( I
HEV I
) I
, O
indicating O
that O
it O
might O
be O
a O
significant O
tropism O
and O
/ O
or O
pathogenic O
determinant O
. O

Various O
poly O
( O
ADP O
- O
ribose O
) O
polymerases O
which O
are O
notorious O
guardians O
of O
cellular O
integrity O
are O
demodified O
by O
macro O
domains O
from O
members O
of O
these O
virus O
families O
. O

In O
addition O
, O
survival O
is O
enhanced O
in O
reovirus O
- O
infected O
Bak O
( O
- O
/ O
- O
) O
mice O
compared O
to O
controls O
, O
demonstrating O
a O
role O
for O
Bak O
in O
reovirus O
pathogenesis O
. O

These O
results O
suggest O
that O
the O
mitochondrial O
localization O
of O
p53 O
regulates O
reovirus O
- O
induced O
pathogenesis O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
through O
its O
interactions O
with O
Bak O
. O

We O
recently O
reported O
that O
p53 O
is O
required O
for O
efficient O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
replication O
in O
cell O
culture O
. O

These O
results O
suggest O
that O
p53 O
is O
an O
important O
host O
cell O
regulator O
of O
HSV O
- O
1 O
replication O
and O
pathogenesis O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
an O
arbovirus O
within O
the O
Bunyaviridae O
family O
capable O
of O
causing O
serious O
morbidity O
and O
mortality O
in O
humans O
and O
livestock O
. O

To O
identify O
host O
factors O
involved O
in O
bunyavirus O
replication O
, O
we O
employed O
genome O
- O
wide O
RNA B
interference I
( I
RNAi I
) I
screening O
and O
identified O
381 O
genes O
whose O
knockdown O
reduced O
infection O
. O

The O
structural O
proteins O
of O
flaviviruses O
carry O
a O
unique O
set O
of O
transmembrane B
domains I
( I
TMDs I
) I
at O
their O
C O
termini O
that O
are O
derived O
from O
the O
mode O
of O
viral O
polyprotein O
processing O
. O

To O
shed O
light O
on O
the O
role O
of O
TMDs O
in O
these O
processes O
, O
we O
engineered O
a O
set O
of O
tick O
- O
borne O
encephalitis O
virus O
mutants O
in O
which O
these O
structural O
elements O
were O
replaced O
in O
different O
combinations O
by O
the O
homologous O
sequences O
of O
a O
distantly O
related O
flavivirus O
( O
Japanese O
encephalitis O
virus O
) O
. O

We O
provide O
evidence O
that O
interactions O
involving O
the O
double O
- O
membrane O
anchor O
of O
the O
envelope O
protein O
E O
( O
a O
unique O
feature O
compared O
to O
other O
viral O
fusion O
proteins O
) O
contribute O
substantially O
to O
particle O
assembly O
, O
stability O
, O
and O
maturation O
. O

The O
emergence O
of O
a O
distinct O
subpopulation O
of O
human O
or O
simian O
immunodeficiency O
virus O
( O
HIV O
/ O
SIV O
) O
sequences O
within O
the O
brain O
( O
compartmentalization O
) O
during O
infection O
is O
hypothesized O
to O
be O
linked O
to O
AIDS O
- O
related O
central B
nervous I
system I
( I
CNS I
) I
neuropathology O
. O

Using O
extensive O
viral O
sampling O
from O
several O
different O
peripheral O
tissues O
and O
cell O
types O
and O
from O
three O
distinct O
regions O
within O
the O
brain O
from O
two O
well O
- O
characterized O
rhesus O
macaque O
models O
of O
the O
neurological O
complications O
of O
HIV O
infection O
( O
neuroAIDS O
) O
, O
we O
have O
been O
able O
to O
perform O
in O
- O
depth O
evolutionary O
analyses O
that O
have O
been O
unattainable O
in O
HIV O
- O
infected O
subjects O
. O

Despite O
the O
success O
of O
combined O
antiretroviral B
therapy I
( I
ART I
) I
, O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
infection O
remains O
a O
lifelong O
infection O
because O
of O
latent O
viral O
reservoirs O
in O
infected O
patients O
. O

The O
contribution O
of O
CD4 O
( O
+ O
) O
T O
cells O
to O
infection O
and O
disease O
progression O
has O
been O
extensively O
studied O
. O

The O
extent O
of O
infection O
of O
monocytes O
and O
macrophages O
has O
not O
been O
rigorously O
assessed O
with O
assays O
comparable O
to O
those O
used O
to O
study O
infection O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
to O
evaluate O
the O
number O
of O
CD4 O
( O
+ O
) O
T O
cells O
that O
harbor O
infectious O
viral O
genomes O
. O

To O
assess O
the O
contribution O
of O
productively O
infected O
monocytes O
and O
macrophages O
to O
HIV O
- O
and O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
- O
infected O
cells O
in O
vivo O
, O
we O
developed O
a O
quantitative B
virus I
outgrowth I
assay I
( I
QVOA I
) I
based O
on O
similar O
assays O
used O
to O
quantitate O
CD4 O
( O
+ O
) O
T O
cell O
latent O
reservoirs O
in O
HIV O
- O
and O
SIV O
- O
infected O
individuals O
in O
whom O
the O
infection O
is O
suppressed O
by O
ART O
. O

T O
cell O
receptor O
beta O
RNA O
was O
measured O
as O
a O
control O
to O
assess O
the O
potential O
contribution O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
the O
assay O
. O

IMPORTANCE O
Infection O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
their O
role O
as O
latent O
reservoirs O
have O
been O
rigorously O
assessed O
; O
however O
, O
the O
frequency O
of O
productively O
infected O
monocytes O
and O
macrophages O
in O
vivo O
has O
not O
been O
similarly O
studied O
. O

In O
the O
study O
described O
here O
we O
compared O
the O
frequency O
of O
productively O
infected O
CD4 O
( O
+ O
) O
T O
cells O
and O
macrophages O
in O
an O
SIV O
- O
infected O
macaque O
model O
. O

Correlates O
of O
immunologic O
protection O
requisite O
for O
an O
efficacious O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
vaccine O
remain O
unclear O
with O
respect O
to O
viral O
pathogenesis O
and O
clinical O
disease O
. O

In O
the O
present O
study O
, O
mice O
were O
vaccinated O
with O
a O
novel O
avirulent O
, O
live O
attenuated O
virus O
( O
0 O
Delta O
NLS O
) O
or O
an O
adjuvanted O
glycoprotein B
D I
subunit I
( I
gD I
- I
2 I
) I
similar O
to O
that O
used O
in O
several O
human O
clinical O
trials O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
previously O
weaponized O
arthropod O
- O
borne O
virus O
responsible O
for O
causing O
acute O
and O
fatal O
encephalitis O
in O
animal O
and O
human O
hosts O
. O

The O
host O
- O
pathogen O
dynamics O
of O
VEEV O
Trinidad O
donkey O
- O
infected O
human O
astrocytoma O
U87MG O
cells O
were O
determined O
by O
carrying O
out O
RNA B
sequencing I
( I
RNA I
- I
seq I
) I
of O
poly O
( O
A O
) O
and O
mRNAs O
. O

Differential O
expression O
of O
interferon O
response O
, O
stress O
response O
factors O
, O
and O
components O
of O
the O
unfolded B
protein I
response I
( I
UPR I
) I
was O
observed O
. O

The O
protein B
kinase I
RNA I
- I
like I
endoplasmic I
reticulum I
kinase I
( I
PERK I
) I
arm O
of O
the O
UPR O
was O
activated O
, O
as O
the O
expression O
of O
both O
activating B
transcription I
factor I
4 I
( I
ATF4 I
) I
and O
CHOP O
( O
DDIT3 O
) O
, O
critical O
regulators O
of O
the O
pathway O
, O
was O
altered O
after O
infection O
. O

Expression O
of O
the O
transcription O
factor O
early B
growth I
response I
1 I
( I
EGR1 I
) I
was O
induced O
in O
a O
PERK O
- O
dependent O
manner O
. O

EGR1 O
( O
- O
/ O
- O
) O
mouse B
embryonic I
fibroblasts I
( I
MEFs I
) I
demonstrated O
lower O
susceptibility O
to O
VEEV O
- O
induced O
cell O
death O
than O
isogenic O
wild O
- O
type O
MEFs O
, O
indicating O
that O
EGR1 O
modulates O
proapoptotic O
pathways O
following O
VEEV O
infection O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
is O
endemic O
to O
Africa O
, O
and O
the O
mosquito O
- O
borne O
disease O
is O
characterized O
by O
abortion O
storms O
in O
ruminants O
and O
by O
hemorrhagic O
fever O
, O
encephalitis O
, O
and O
blindness O
in O
humans O
. O

Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
has O
a O
tripartite O
negative O
- O
stranded O
RNA O
genome O
( O
L O
, O
M O
, O
and O
S O
segments O
) O
. O

temperature B
sensitivity I
( I
ts I
) I
limits O
viral O
replication O
at O
a O
restrictive O
temperature O
and O
may O
be O
involved O
with O
viral O
attenuation O
. O

The O
MP O
- O
12 O
vaccine O
showed O
restricted O
replication O
at O
38 O
degrees O
C O
and O
replication O
shutoff O
( O
100 O
- O
fold O
or O
greater O
reduction O
in O
virus O
titer O
compared O
to O
that O
at O
37 O
degrees O
C O
) O
at O
39 O
degrees O
C O
in O
Vero O
and O
MRC O
- O
5 O
cells O
. O

Attenuation O
has O
been O
achieved O
by O
shortening O
the O
polycytidine O
tract O
in O
the O
5 B
' I
noncoding I
region I
( I
NCR I
) I
. O

A O
poly O
( O
C O
) O
- O
truncated O
strain O
of O
mengovirus O
, O
vMC O
( O
24 O
) O
, O
resulted O
in O
significant O
tumor O
regression O
in O
immunocompetent O
BALB O
/ O
c O
mice O
bearing O
syngeneic O
MPC O
- O
11 O
plasmacytomas O
, O
but O
the O
associated O
toxicities O
were O
unacceptable O
. O

To O
enhance O
its O
safety O
profile O
, O
microRNA O
target O
sequences O
complementary O
to O
miR O
- O
124 O
or O
miR O
- O
125 O
( O
enriched O
in O
nervous O
tissue O
) O
, O
miR O
- O
133 O
and O
miR O
- O
208 O
( O
enriched O
in O
cardiac O
tissue O
) O
, O
or O
miR O
- O
142 O
( O
control O
; O
enriched O
in O
hematopoietic O
tissues O
) O
were O
inserted O
into O
the O
vMC O
( O
24 O
) O
NCRs O
. O

A O
dual O
- O
detargeted O
virus O
named O
vMC O
( O
24 O
) O
- O
NC O
, O
with O
miR O
- O
124 O
targets O
in O
the O
5 O
' O
NCR O
and O
miR O
- O
133 O
plus O
miR O
- O
208 O
targets O
in O
the O
3 O
' O
NCR O
, O
showed O
the O
suppression O
of O
replication O
in O
both O
nervous O
and O
cardiac O
tissues O
but O
retained O
full O
oncolytic O
potency O
when O
administered O
by O
intratumoral O
( O
10 O
( O
6 O
) O
50 O
% O
tissue O
culture O
infectious O
doses O
[ O
TCID50 O
] O
) O
or O
intravenous O
( O
10 O
( O
7 O
) O
to O
10 O
( O
8 O
) O
TCID50 O
) O
injection O
into O
BALB O
/ O
c O
mice O
bearing O
MPC O
- O
11 O
plasmacytomas O
. O

Overall O
survival O
of O
vMC O
( O
24 O
) O
- O
NC O
- O
treated O
tumor O
- O
bearing O
mice O
was O
significantly O
improved O
compared O
to O
that O
of O
nontreated O
mice O
. O

It O
can O
be O
partially O
attenuated O
by O
shortening O
the O
poly O
( O
C O
) O
tract O
in O
the O
5 O
' O
NCR O
but O
remains O
capable O
of O
damaging O
cardiac O
and O
nervous O
tissue O
. O

Here O
, O
we O
further O
enhanced O
the O
safety O
profile O
of O
a O
poly O
( O
C O
) O
- O
truncated O
mengovirus O
by O
incorporating O
muscle O
- O
and O
neuron O
- O
specific O
microRNA O
target O
sequences O
into O
the O
viral O
genome O
. O

We O
have O
discovered O
that O
native O
, O
neuronal O
expression O
of O
alpha O
- O
synuclein O
( O
Asyn O
) O
inhibits O
viral O
infection O
, O
injury O
, O
and O
disease O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Enveloped O
RNA O
viruses O
, O
such O
as O
West B
Nile I
virus I
( I
WNV I
) I
, O
invade O
the O
CNS O
and O
cause O
encephalitis O
, O
yet O
little O
is O
known O
about O
the O
innate O
neuron O
- O
specific O
inhibitors O
of O
viral O
infections O
in O
the O
CNS O
. O

The O
infectious O
titer O
of O
WNV O
and O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
TC83 O
in O
the O
brains O
of O
Asyn O
- O
knockout O
mice O
exhibited O
a O
mean O
increase O
of O
10 O
( O
4 O
. O

Virus O
- O
induced O
Asyn O
localized O
to O
perinuclear O
, O
neuronal O
regions O
expressing O
viral O
envelope O
protein O
and O
the O
endoplasmic B
reticulum I
( I
ER I
) I
- O
associated O
trafficking O
protein O
Rab1 O
. O

The O
mammalian O
host O
responds O
to O
viral O
infections O
by O
inducing O
expression O
of O
hundreds O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

Using O
a O
combination O
of O
ectopic O
expression O
and O
gene O
silencing O
approaches O
in O
cell O
culture O
, O
we O
previously O
identified O
Ifi27l2a O
as O
a O
candidate O
antiviral O
ISG O
within O
neuronal O
subsets O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
that O
restricts O
infection O
by O
West B
Nile I
virus I
( I
WNV I
) I
, O
an O
encephalitic O
flavivirus O
of O
global O
concern O
. O

To O
investigate O
the O
physiological O
relevance O
of O
Ifi27l2a O
in O
the O
context O
of O
viral O
infection O
, O
we O
generated O
Ifi27l2a O
( O
- O
/ O
- O
) O
mice O
. O

Infection O
studies O
in O
a O
primary O
cell O
culture O
revealed O
that O
Ifi27l2a O
( O
- O
/ O
- O
) O
cerebellar O
granule O
cell O
neurons O
and O
macrophages O
but O
not O
cerebral O
cortical O
neurons O
, O
embryonic O
fibroblasts O
, O
or O
dendritic O
cells O
sustained O
higher O
levels O
of O
WNV O
infection O
than O
wild O
- O
type O
cells O
and O
that O
this O
difference O
was O
greater O
under O
conditions O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
pretreatment O
. O

Prior O
studies O
in O
cell O
culture O
suggested O
an O
antiviral O
role O
for O
Ifi27l2a O
during O
infection O
by O
West B
Nile I
virus I
( I
WNV I
) I
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
membrane B
( I
M I
) I
protein O
plays O
important O
structural O
roles O
in O
the O
processes O
of O
fusion O
and O
maturation O
of O
progeny O
virus O
during O
cellular O
infection O
. O

Experiments O
performed O
on O
infectious O
virus O
as O
well O
as O
in O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
system O
indicate O
that O
the O
JEV O
mutant O
expresses O
structural O
proteins O
but O
fails O
to O
form O
infectious O
particles O
in O
mammalian O
cells O
. O

chikungunya B
virus I
( I
CHIKV I
) I
, O
an O
arthritis O
- O
inducing O
alphavirus O
, O
is O
the O
cause O
of O
a O
massive O
ongoing O
outbreak O
in O
the O
Caribbean O
and O
South O
America O
. O

In O
contrast O
to O
CHIKV O
, O
other O
related O
alphaviruses O
, O
such O
as O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
and O
Semliki B
Forest I
virus I
( I
SFV I
) I
, O
can O
cause O
encephalitic O
disease O
. O

CHIKV O
chimeras O
containing O
each O
of O
the O
domains O
of O
the O
E2 O
( O
Delta O
DomA O
, O
Delta O
DomB O
, O
and O
Delta O
DomC O
) O
from O
SFV O
, O
but O
not O
VEEV O
, O
were O
successfully O
rescued O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
has O
caused O
large O
outbreaks O
of O
acute O
and O
chronic O
arthritis O
throughout O
Africa O
and O
Southeast O
Asia O
and O
has O
now O
become O
a O
massive O
public O
health O
threat O
in O
the O
Americas O
, O
causing O
an O
estimated O
1 O
. O

Despite O
the O
threat O
, O
little O
is O
known O
about O
the O
role O
the O
receptor O
binding O
protein O
( O
E2 O
) O
plays O
on O
disease O
outcome O
in O
an O
infected O
host O
. O

To O
study O
this O
, O
our O
laboratory O
generated O
chimeric O
CHIKV O
containing O
corresponding O
regions O
of O
the O
Semliki B
Forest I
virus I
( I
SFV I
) I
E2 O
( O
domains O
A O
, O
B O
, O
and O
C O
) O
substituted O
into O
the O
CHIKV O
genome O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
important O
human O
and O
animal O
pathogen O
, O
for O
which O
no O
safe O
and O
efficient O
vaccines O
or O
therapeutic O
means O
have O
been O
developed O
. O

The O
arthropod O
- O
borne O
West B
Nile I
virus I
( I
WNV I
) I
emerged O
in O
New O
York O
State O
in O
1999 O
and O
quickly O
spread O
throughout O
the O
United O
States O
. O

We O
previously O
showed O
that O
Culex O
tarsalis O
mosquito O
saliva O
and O
salivary B
gland I
extract I
( I
SGE I
) I
enhance O
the O
in O
vivo O
replication O
of O
WNV O
. O

Furthermore O
, O
our O
model O
provides O
a O
robust O
system O
to O
identify O
the O
salivary O
factor O
( O
s O
) O
responsible O
for O
enhancement O
of O
WNV O
replication O
. O

varicella B
- I
zoster I
virus I
( I
VZV I
) I
is O
a O
highly O
neurotropic O
virus O
that O
can O
cause O
infections O
in O
both O
the O
peripheral O
nervous O
system O
and O
the O
central O
nervous O
system O
. O

Several O
studies O
of O
VZV O
reactivation O
in O
the O
peripheral O
nervous O
system O
( O
herpes O
zoster O
) O
have O
been O
published O
, O
while O
exceedingly O
few O
investigations O
have O
been O
carried O
out O
in O
a O
human O
brain O
. O

The O
approach O
included O
not O
only O
VZV O
DNA O
/ O
RNA O
analyses O
but O
also O
a O
delineation O
of O
infected O
cell O
types O
( O
neurons O
, O
microglia O
, O
oligodendrocytes O
, O
and O
astrocytes O
) O
. O

Evidence O
of O
syncytium O
formation O
within O
the O
aggregates O
included O
the O
continuity O
of O
cytoplasm O
positive O
for O
the O
VZV O
glycoprotein B
H I
( I
gH I
) I
fusion O
- O
complex O
protein O
within O
a O
cellular O
profile O
with O
as O
many O
as O
80 O
distinct O
nuclei O
. O

As O
with O
other O
causes O
of O
brain O
injury O
, O
these O
results O
suggested O
that O
astrocytes O
likely O
formed O
a O
defensive O
perimeter O
around O
foci O
of O
VZV O
infection O
( O
astrogliosis O
) O
. O

The O
introduction O
of O
West B
Nile I
virus I
( I
WNV I
) I
into O
North O
America O
in O
1999 O
is O
a O
classic O
example O
of O
viral O
emergence O
in O
a O
new O
environment O
, O
with O
its O
subsequent O
dispersion O
across O
the O
continent O
having O
a O
major O
impact O
on O
local O
bird O
populations O
. O

The O
emergence O
of O
the O
vector O
- O
borne O
West B
Nile I
virus I
( I
WNV I
) I
in O
North O
America O
in O
1999 O
represents O
a O
classic O
example O
of O
this O
process O
. O

In O
a O
further O
mechanistic O
twist O
, O
gB O
- O
mediated O
cell O
- O
cell O
fusion O
appears O
restricted O
by O
its O
intraviral O
or O
cytoplasmic O
domain O
( O
cytodomain O
) O
because O
mutations O
within O
it O
result O
in O
a O
hyperfusogenic O
phenotype O
. O

Here O
, O
we O
characterized O
a O
panel O
of O
hyperfusogenic O
HSV O
- O
1 O
gB O
cytodomain O
mutants O
and O
show O
that O
they O
are O
fully O
functional O
in O
cell O
- O
cell O
fusion O
at O
shorter O
coincubation O
times O
and O
at O
lower O
temperatures O
than O
those O
for O
wild B
- I
type I
( I
WT I
) I
gB O
, O
which O
suggests O
that O
these O
mutations O
reduce O
the O
kinetic O
energy O
barrier O
to O
fusion O
. O

An O
accessory O
gene O
between O
the O
S O
and O
E O
gene O
loci O
is O
contained O
in O
all O
Coronaviruses B
( I
CoVs I
) I
, O
and O
its O
function O
has O
been O
studied O
in O
some O
coronaviruses O
. O

This O
gene O
locus O
in O
human B
coronavirus I
OC43 I
( I
HCoV I
- I
OC43 I
) I
encodes O
the O
ns12 O
. O

9 O
protein O
had O
no O
measurable O
effect O
on O
virus O
entry O
, O
subgenomic B
mRNA I
( I
sgmRNA I
) I
synthesis O
, O
and O
protein O
expression O
. O

9 O
was O
less O
efficient O
in O
virion O
morphogenesis O
than O
recombinant O
wild O
- O
type O
virus O
( O
HCoV O
- O
OC43 O
- O
WT O
) O
. O

A O
peculiarity O
of O
the O
Flaviviridae O
is O
the O
critical O
function O
of O
nonstructural B
( I
NS I
) I
proteins O
for O
virus O
particle O
formation O
. O

For O
pestiviruses O
, O
like O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
uncleaved O
NS2 O
- O
3 O
represents O
an O
essential O
factor O
for O
virion O
morphogenesis O
, O
while O
NS3 O
is O
an O
essential O
component O
of O
the O
viral O
replicase O
. O

Virion O
morphogenesis O
of O
the O
related O
hepatitis B
C I
virus I
( I
HCV I
) I
shows O
a O
major O
deviation O
from O
that O
of O
pestiviruses O
: O
while O
RNA O
replication O
also O
requires O
free O
NS3 O
, O
virion O
formation O
does O
not O
depend O
on O
uncleaved O
NS2 O
- O
NS3 O
. O

The O
present O
study O
demonstrates O
that O
in O
the O
NCP7 O
backbone O
, O
only O
two O
amino O
acid O
exchanges O
in O
NS2 O
( O
E1576V O
) O
and O
NS3 O
( O
V1721A O
) O
are O
sufficient O
and O
necessary O
to O
allow O
for O
efficient O
NS2 O
- O
3 O
- O
independent O
virion O
morphogenesis O
. O

The O
A7 O
( O
74 O
) O
strain O
of O
Semliki O
Forest O
virus O
( O
SFV O
; O
genus O
Alphavirus O
) O
is O
avirulent O
in O
adult O
mice O
, O
while O
the O
L10 O
strain O
is O
virulent O
in O
mice O
of O
all O
ages O
. O

It O
has O
been O
previously O
demonstrated O
that O
this O
phenotypic O
difference O
is O
associated O
with O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

Consensus O
clones O
of O
L10 O
( O
designated O
SFV6 O
) O
and O
A7 O
( O
74 O
) O
( O
designated O
A774wt O
) O
were O
used O
to O
construct O
a O
panel O
of O
recombinant O
viruses O
. O

Interestingly O
, O
replacement O
of O
nsP3 O
of O
SFV6 O
with O
that O
of O
A774wt O
resulted O
in O
a O
virulent O
virus O
; O
the O
virulence O
of O
this O
recombinant O
was O
strongly O
reduced O
by O
functionally O
coupled O
substitutions O
for O
amino O
acid O
residues O
534 O
( O
P4 O
position O
of O
the O
cleavage O
site O
between O
nsP1 O
and O
nsP2 O
) O
and O
1052 O
( O
S4 O
subsite O
residue O
of O
nsP2 O
protease O
) O
in O
the O
nonstructural O
polyprotein O
. O

However O
, O
tumor O
antiviral O
responses O
, O
primarily O
mediated O
by O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
, O
remain O
a O
key O
problem O
that O
severely O
restricts O
viral O
replication O
and O
oncolysis O
. O

We O
show O
here O
that O
the O
Semliki B
Forest I
virus I
( I
SFV I
) I
strain O
SFV4 O
, O
which O
causes O
lethal O
encephalitis O
in O
mice O
, O
is O
able O
to O
infect O
and O
replicate O
independent O
of O
the O
IFN O
- O
I O
defense O
in O
mouse O
glioblastoma O
cells O
and O
cell O
lines O
originating O
from O
primary O
human O
glioblastoma O
patient O
samples O
. O

In O
contrast O
to O
the O
naturally O
attenuated O
strain O
SFV O
A7 O
( O
74 O
) O
and O
its O
derivatives O
, O
SFV4 O
- O
miRT124 O
displayed O
increased O
oncolytic O
potency O
in O
CT O
- O
2A O
murine O
astrocytoma O
cells O
and O
in O
the O
human O
glioblastoma O
cell O
lines O
pretreated O
with O
IFN O
- O
I O
. O

Coronaviruses B
( I
CoVs I
) I
have O
shown O
neuroinvasive O
properties O
in O
humans O
and O
animals O
secondary O
to O
replication O
in O
peripheral O
organs O
, O
but O
the O
mechanism O
of O
neuroinvasion O
is O
unknown O
. O

The O
major O
aim O
of O
our O
work O
was O
to O
evaluate O
the O
ability O
of O
CoVs O
to O
enter O
the O
central B
nervous I
system I
( I
CNS I
) I
through O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
. O

Using O
the O
highly O
hepatotropic O
mouse B
hepatitis I
virus I
type I
3 I
( I
MHV3 I
) I
, O
its O
attenuated O
variant O
, O
51 O
. O

6 O
- O
MHV3 O
, O
which O
shows O
low O
tropism O
for O
endothelial O
cells O
, O
and O
the O
weakly O
hepatotropic O
MHV O
- O
A59 O
strain O
from O
the O
murine O
coronavirus O
group O
, O
we O
investigated O
the O
virus O
- O
induced O
dysfunctions O
of O
BBB O
in O
vivo O
and O
in O
brain B
microvascular I
endothelial I
cells I
( I
BMECs I
) I
in O
vitro O
. O

Brain O
invasion O
was O
observed O
only O
in O
MHV3 O
- O
infected O
mice O
and O
correlated O
with O
enhanced O
BBB O
permeability O
associated O
with O
decreased O
expression O
of O
zona B
occludens I
protein I
1 I
( I
ZO I
- I
1 I
) I
, O
VE O
- O
cadherin O
, O
and O
occludin O
, O
but O
not O
claudin O
- O
5 O
, O
in O
the O
brain O
or O
in O
cultured O
BMECs O
. O

BBB O
breakdown O
in O
MHV3 O
infection O
was O
not O
related O
to O
production O
of O
barrier O
- O
dysregulating O
inflammatory O
cytokines O
or O
chemokines O
by O
infected O
BMECs O
but O
rather O
to O
a O
downregulation O
of O
barrier O
protective O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
. O

IMPORTANCE O
Coronaviruses B
( I
CoVs I
) I
infect O
several O
mammals O
, O
including O
humans O
, O
and O
are O
associated O
with O
respiratory O
, O
gastrointestinal O
, O
and O
/ O
or O
neurological O
diseases O
. O

Indeed O
, O
the O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
causing O
severe O
acute O
respiratory O
syndrome O
, O
and O
the O
CoVs O
OC43 O
and O
229E O
were O
found O
in O
the O
brains O
of O
SARS O
patients O
and O
multiple O
sclerosis O
patients O
, O
respectively O
. O

Zika B
virus I
( I
ZIKV I
) I
is O
an O
emerging O
arbovirus O
of O
the O
Flaviviridae O
family O
, O
which O
includes O
dengue O
, O
West O
Nile O
, O
yellow O
fever O
, O
and O
Japanese O
encephalitis O
viruses O
, O
that O
causes O
a O
mosquito O
- O
borne O
disease O
transmitted O
by O
the O
Aedes O
genus O
, O
with O
recent O
outbreaks O
in O
the O
South O
Pacific O
. O

ZIKV O
induced O
the O
transcription O
of O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
, O
RIG O
- O
I O
, O
and O
MDA5 O
, O
as O
well O
as O
several O
interferon O
- O
stimulated O
genes O
, O
including O
OAS2 O
, O
ISG15 O
, O
and O
MX1 O
, O
characterized O
by O
strongly O
enhanced O
beta O
interferon O
gene O
expression O
. O

IMPORTANCE O
Zika B
virus I
( I
ZIKV I
) I
is O
an O
arbovirus O
belonging O
to O
the O
Flaviviridae O
family O
. O

The O
antibody O
response O
to O
proteins O
may O
be O
modulated O
by O
the O
presence O
of O
preexisting O
antigen O
- O
specific O
antibodies O
and O
the O
formation O
of O
immune B
complexes I
( I
ICs I
) I
. O

In O
this O
study O
, O
we O
investigated O
influences O
of O
IC O
immunization O
on O
the O
fine O
specificity O
of O
antibody O
responses O
in O
a O
structurally O
well O
- O
defined O
system O
, O
using O
the O
envelope B
( I
E I
) I
protein O
of O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
as O
an O
immunogen O
. O

Mice O
were O
immunized O
with O
a O
dimeric O
soluble O
form O
of O
E O
( O
sE O
) O
alone O
or O
in O
complex O
with O
monoclonal O
antibodies O
specific O
for O
each O
of O
the O
three O
domains O
of O
E O
, O
and O
the O
antibody O
response O
induced O
by O
these O
ICs O
was O
compared O
to O
that O
seen O
after O
immunization O
with O
sE O
alone O
. O

There O
were O
substantially O
different O
responses O
with O
two O
of O
the O
ICs O
, O
and O
the O
differences O
could O
be O
mechanistically O
related O
to O
( O
i O
) O
epitope O
shielding O
and O
( O
ii O
) O
antibody O
- O
mediated O
structural O
changes O
leading O
to O
dissociation O
of O
the O
sE O
dimer O
. O

IMPORTANCE O
Infections O
with O
flaviviruses O
such O
as O
yellow O
fever O
, O
dengue O
, O
Japanese O
encephalitis O
, O
West O
Nile O
, O
and O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
viruses O
pose O
substantial O
public O
health O
problems O
in O
different O
parts O
of O
the O
world O
. O

Neuroadapted B
Sindbis I
virus I
( I
NSV I
) I
causes O
uniformly O
fatal O
disease O
in O
adult O
C57BL O
/ O
6 O
( O
B6 O
) O
mice O
, O
but O
adult O
BALB O
/ O
c O
( O
Bc O
) O
mice O
recover O
from O
infection O
. O

B6 O
mice O
had O
higher O
levels O
of O
virus O
replication O
, O
higher O
levels O
of O
type B
I I
interferon I
( I
IFN I
) I
, O
and O
slower O
virus O
clearance O
than O
did O
Bc O
mice O
. O

B6 O
mice O
had O
more O
infiltration O
of O
inflammatory O
cells O
and O
higher O
levels O
of O
IL1b O
, O
IL O
- O
6 O
, O
TNFa O
, O
Csf2 O
, O
and O
CCL2 O
mRNAs O
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
IFN O
- O
gamma O
, O
and O
C B
- I
C I
motif I
ligand I
2 I
( I
CCL2 I
) I
protein O
in O
brains O
than O
Bc O
mice O
. O

However O
, O
Bc O
mice O
had O
more O
brain O
antibody O
at O
day O
7 O
and O
a O
higher O
percentage O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

CD4 O
( O
+ O
) O
T O
cells O
in O
the O
brains O
of O
Bc O
mice O
included O
fewer O
Th17 O
cells O
and O
more O
regulatory O
T O
cells O
( O
Tregs O
) O
producing O
IL O
- O
10 O
than O
B6 O
mice O
, O
accompanied O
by O
higher O
levels O
of O
Il2 O
and O
Cxcl10 O
mRNAs O
. O

This O
enzyme O
harbors O
methyltransferase B
( I
MTase I
) I
and O
nsP1 O
guanylylation B
( I
GT I
) I
activities O
catalyzing O
the O
transfer O
of O
the O
methyl O
group O
from O
S O
- O
adenosylmethionine O
( O
AdoMet O
) O
to O
the O
N7 O
position O
of O
a O
GTP O
molecule O
followed O
by O
the O
formation O
of O
an O
m O
( O
7 O
) O
GMP O
- O
nsP1 O
adduct O
. O

Subsequent O
transfer O
of O
m O
( O
7 O
) O
GMP O
onto O
the O
5 O
' O
end O
of O
the O
viral O
mRNA O
has O
not O
been O
demonstrated O
in O
vitro O
yet O
. O

Here O
we O
report O
the O
biochemical O
characterization O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
nsP1 O
. O

The O
MTase O
and O
GT O
reaction O
activities O
were O
followed O
using O
a O
nonhydrolyzable O
GTP O
( O
GIDP O
) O
substrate O
and O
an O
original O
Western O
blot O
assay O
using O
anti O
- O
m O
( O
3 O
) O
G O
/ O
m O
( O
7 O
) O
G O
- O
cap O
monoclonal O
antibody O
, O
respectively O
. O

The O
GT O
reaction O
is O
stimulated O
by O
S O
- O
adenosyl O
- O
L O
- O
homocysteine O
( O
Ado O
- O
Hcy O
) O
, O
the O
product O
of O
the O
preceding O
MTase O
reaction O
, O
and O
metallic O
ions O
. O

The O
covalent O
linking O
between O
nsP1 O
and O
m O
( O
7 O
) O
GMP O
involves O
a O
phosphamide O
bond O
between O
the O
nucleotide O
and O
a O
histidine O
residue O
. O

Finally O
, O
the O
inhibitory O
effects O
of O
sinefungin O
, O
Aurintricarboxylic B
acid I
( I
ATA I
) I
, O
and O
ribavirin O
triphosphate O
on O
MTase O
and O
capping O
reactions O
were O
investigated O
, O
providing O
possible O
avenues O
for O
antiviral O
research O
. O

The O
different O
steps O
for O
this O
capping O
are O
performed O
by O
the O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
. O

While O
a O
clear O
understanding O
of O
the O
events O
leading O
to O
successful O
establishment O
of O
host O
- O
specific O
viral O
populations O
and O
productive O
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
has O
not O
yet O
been O
reached O
, O
the O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
- O
infected O
rhesus O
macaque O
provides O
a O
powerful O
model O
for O
the O
study O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
intrahost O
evolution O
and O
neuropathogenesis O
. O

The O
evolution O
of O
the O
gp120 O
and O
nef O
genes O
, O
which O
encode O
two O
key O
proteins O
required O
for O
the O
establishment O
and O
maintenance O
of O
infection O
, O
was O
assessed O
in O
macaques O
that O
were O
intravenously O
inoculated O
with O
the O
same O
viral O
swarm O
and O
allowed O
to O
naturally O
progress O
to O
simian O
AIDS O
and O
potential O
SIV B
- I
associated I
encephalitis I
( I
SIVE I
) I
. O

Host O
- O
specific O
sequence O
populations O
were O
detected O
in O
nef O
( O
similar O
to O
92 O
days O
) O
before O
they O
were O
detected O
in O
gp120 O
( O
similar O
to O
182 O
days O
) O
. O

On O
the O
other O
hand O
, O
nef O
sequences O
in O
brain O
tissues O
, O
collected O
at O
necropsy O
of O
two O
animals O
with O
detectable O
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
revealed O
convergent O
evolution O
. O

Powassan B
virus I
( I
POWV I
) I
is O
an O
encephalitic O
tick O
- O
borne O
flavivirus O
which O
can O
result O
in O
serious O
neuroinvasive O
disease O
with O
up O
to O
a O
10 O
% O
case O
fatality O
rate O
. O

The O
study O
objective O
was O
to O
determine O
whether O
the O
salivary B
gland I
extract I
( I
SGE I
) I
from O
Ixodes O
scapularis O
ticks O
facilitates O
the O
transmission O
and O
dissemination O
of O
POWV O
in O
a O
process O
known O
as O
saliva O
- O
activated O
transmission O
. O

IMPORTANCE O
Powassan B
virus I
( I
POWV I
) I
is O
a O
tick O
- O
borne O
flavivirus O
that O
continues O
to O
emerge O
in O
the O
United O
States O
, O
as O
is O
evident O
by O
the O
surge O
in O
number O
and O
expanding O
geographic O
range O
of O
confirmed O
cases O
in O
the O
past O
decade O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
causes O
one O
of O
the O
most O
prevalent O
herpesviral O
infections O
in O
humans O
and O
is O
the O
leading O
etiological O
agent O
of O
viral O
encephalitis O
and O
eye O
infections O
. O

In O
this O
study O
, O
we O
investigated O
the O
cellular O
substrate B
( I
S I
) I
phosphorylated O
by O
US3 O
and O
how O
it O
mediates O
US3 O
suppression O
of O
CD1d O
recycling O
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
is O
among O
the O
most O
common O
human O
pathogens O
. O

enterovirus B
71 I
( I
EV71 I
) I
infection O
causes O
severe O
mortality O
involving O
multiple O
possible O
mechanisms O
, O
including O
cytokine O
storm O
, O
brain O
stem O
encephalitis O
, O
and O
fulminant O
pulmonary O
edema O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
may O
confer O
anti O
- O
EV71 O
activity O
; O
however O
, O
the O
claim O
that O
disease O
severity O
is O
highly O
correlated O
to O
an O
increase O
in O
IFN O
- O
gamma O
is O
controversial O
and O
would O
indicate O
an O
immune O
escape O
initiated O
by O
EV71 O
. O

In O
vitro O
results O
showed O
that O
IFN O
- O
gamma O
pretreatment O
reduced O
EV71 O
yield O
, O
whereas O
EV71 O
infection O
caused O
IFN O
- O
gamma O
resistance O
with O
attenuated O
IFN O
- O
gamma O
signaling O
in O
IFN O
regulatory O
factor O
1 O
( O
IRF1 O
) O
gene O
transactivation O
. O

To O
study O
the O
immunoediting O
ability O
of O
EV71 O
proteins O
in O
IFN O
- O
gamma O
signaling O
, O
11 O
viral O
proteins O
were O
stably O
expressed O
in O
cells O
without O
cytotoxicity O
; O
however O
, O
viral O
proteins O
2A O
and O
3D O
blocked O
IFN O
- O
gamma O
- O
induced O
IRF1 O
transactivation O
following O
a O
loss O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
nuclear O
translocation O
. O

IMPORTANCE O
Immunosurveillance O
by O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
may O
confer O
anti B
- I
enterovirus I
71 I
( I
anti I
- I
EV71 I
) I
activity O
; O
however O
, O
the O
claim O
that O
disease O
severity O
is O
highly O
correlated O
to O
an O
increase O
in O
IFN O
- O
gamma O
is O
controversial O
and O
would O
indicate O
an O
immune O
escape O
initiated O
by O
EV71 O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
is O
a O
mosquito O
- O
borne O
zoonotic O
disease O
endemic O
to O
Africa O
and O
characterized O
by O
a O
high O
rate O
of O
abortion O
in O
ruminants O
and O
hemorrhagic O
fever O
, O
encephalitis O
, O
or O
blindness O
in O
humans O
. O

RVF O
is O
caused O
by O
Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
, O
which O
has O
a O
tripartite O
negative O
- O
stranded O
RNA O
genome O
( O
consisting O
of O
the O
S O
, O
M O
, O
and O
L O
segments O
) O
. O

We O
characterized O
the O
attenuation O
of O
wild O
- O
type O
pathogenic O
strain O
ZH501 O
carrying O
a O
mutation O
( O
s O
) O
of O
the O
MP O
- O
12 O
S O
, O
M O
, O
or O
L O
segment O
in O
a O
mouse O
model O
. O

We O
identified O
a O
combination O
of O
3 O
amino O
acid O
changes O
, O
Y259H O
( O
Gn O
) O
, O
R1182G O
( O
Gc O
) O
, O
and O
R1029K O
( O
L O
) O
, O
that O
was O
sufficient O
to O
attenuate O
ZH501 O
. O

IMPORTANCE O
Rift B
Valley I
fever I
( I
RVF I
) I
is O
a O
mosquito O
- O
transmitted O
viral O
disease O
that O
is O
endemic O
to O
Africa O
and O
that O
has O
the O
potential O
to O
spread O
into O
other O
countries O
. O

bluetongue B
virus I
( I
BTV I
) I
causes O
bluetongue O
, O
a O
major O
hemorrhagic O
disease O
of O
ruminants O
. O

In O
order O
to O
investigate O
the O
molecular O
determinants O
of O
BTV O
virulence O
, O
we O
used O
a O
BTV8 O
strain O
minimally O
passaged O
in O
tissue O
culture O
( O
termed O
BTV8 O
( O
L O
) O
in O
this O
study O
) O
and O
a O
derivative O
strain O
passaged O
extensively O
in O
tissue O
culture O
( O
BTV8 O
( O
H O
) O
) O
in O
in O
vitro O
and O
in O
vivo O
studies O
. O

BTV8 O
( O
L O
) O
was O
pathogenic O
in O
both O
IFNAR O
( O
- O
/ O
- O
) O
mice O
and O
in O
sheep O
, O
while O
BTV8 O
( O
H O
) O
was O
attenuated O
in O
both O
species O
. O

To O
identify O
genetic O
changes O
which O
led O
to O
BTV8 O
( O
H O
) O
attenuation O
, O
we O
generated O
34 O
reassortants O
between O
BTV8 O
( O
L O
) O
and O
BTV8 O
( O
H O
) O
. O

We O
found O
that O
partial O
attenuation O
of O
BTV8 O
( O
L O
) O
in O
IFNAR O
( O
- O
/ O
- O
) O
mice O
was O
achieved O
by O
simply O
replacing O
genomic O
segment O
2 O
( O
Seg2 O
, O
encoding O
VP2 O
) O
or O
Seg10 O
( O
encoding O
NS3 O
) O
with O
the O
BTV8 O
( O
H O
) O
homologous O
segments O
. O

Fully O
attenuated O
viruses O
required O
at O
least O
two O
genome O
segments O
from O
BTV8 O
( O
H O
) O
, O
including O
Seg2 O
with O
either O
Seg1 O
( O
encoding O
VP1 O
) O
, O
Seg6 O
( O
encoding O
VP6 O
and O
NS4 O
) O
, O
or O
Seg10 O
( O
encoding O
NS3 O
) O
. O

Conversely O
, O
full O
reversion O
of O
virulence O
of O
BTV8 O
( O
H O
) O
required O
at O
least O
five O
genomic O
segments O
of O
BTV8 O
( O
L O
) O
. O

We O
also O
demonstrated O
that O
BTV8 O
( O
H O
) O
acquired O
an O
increased O
affinity O
for O
glycosaminoglycan O
receptors O
during O
passaging O
in O
cell O
culture O
due O
to O
mutations O
in O
its O
VP2 O
protein O
. O

Replication O
of O
BTV8 O
( O
H O
) O
was O
relatively O
poor O
in O
interferon B
( I
IFN I
) I
- O
competent O
primary O
ovine O
endothelial O
cells O
compared O
to O
replication O
of O
BTV8 O
( O
L O
) O
, O
and O
this O
phenotype O
was O
determined O
by O
several O
viral O
genomic O
segments O
, O
including O
Seg4 O
and O
Seg9 O
. O

IMPORTANCE O
Bluetongue O
is O
one O
of O
the O
major O
infectious O
diseases O
of O
ruminants O
, O
and O
it O
is O
listed O
as O
a O
notifiable O
disease O
by O
the B
world I
organization I
for I
animal I
health I
( I
OIE I
) I
. O

Over O
the O
years O
, O
BTV O
serotypes O
/ O
strains O
with O
various O
degrees O
of O
virulence O
( O
including O
nonpathogenic O
strains O
) O
have O
been O
described O
in O
different O
geographical O
locations O
. O

The O
NS2A O
protein O
of O
Dengue B
Virus I
( I
DENV I
) I
has O
eight O
predicted O
transmembrane O
segments O
( O
pTMSs O
; O
pTMS1 O
to O
pTMS8 O
) O
. O

In O
the O
study O
described O
here O
, O
we O
explored O
the O
function O
of O
DENV O
NS2A O
by O
introducing O
a O
series O
of O
double O
or O
triple O
alanine O
substitutions O
into O
the O
C O
- O
terminal O
half O
( O
pTMS4 O
to O
pTMS8 O
) O
of O
NS2A O
in O
the O
context O
of O
a O
DENV O
infectious O
clone O
or O
subgenomic O
replicon O
. O

Fourteen O
( O
8 O
within O
pTMS8 O
) O
of O
35 O
NS2A O
mutants O
displayed O
a O
lethal O
phenotype O
due O
to O
impairment O
of O
RNA O
replication O
by O
a O
replicon O
assay O
. O

Three O
NS2A O
mutants O
with O
mutations O
within O
pTMS7 O
, O
the O
CM20 O
, O
CM25 O
, O
and O
CM27 O
mutants O
, O
displayed O
similar O
phenotypes O
, O
low O
virus O
yields O
( O
> O
100 O
- O
fold O
reduction O
) O
, O
wild O
- O
type O
- O
like O
replicon O
activity O
, O
and O
low O
infectious O
virus O
- O
like O
particle O
yields O
by O
transient O
trans O
- O
packaging O
experiments O
, O
suggesting O
a O
defect O
in O
virus O
assembly O
and O
secretion O
. O

The O
sequencing O
of O
revertant O
viruses O
derived O
from O
CM20 O
, O
CM25 O
, O
and O
CM27 O
mutant O
viruses O
revealed O
a O
consensus O
reversion O
mutation O
, O
leucine B
( I
L I
) I
to O
Phenylalanine B
( I
F I
) I
, O
at O
codon O
181 O
within O
pTMS7 O
. O

In O
particular O
, O
detailed O
mapping O
of O
the O
amino O
acid O
residues O
within O
the O
predicted B
transmembrane I
segments I
( I
pTMSs I
) I
of O
NS2A O
involved O
in O
RNA O
replication O
and O
/ O
or O
virus O
assembly O
and O
secretion O
was O
performed O
. O

All O
coronaviruses O
encode O
a O
macrodomain O
containing O
ADP B
- I
ribose I
- I
1 I
' I
' I
- I
phosphatase I
( I
ADRP I
) I
activity O
within O
the O
N O
terminus O
of O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

Previous O
work O
showed O
that O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
with O
a O
mutated O
catalytic O
site O
( O
N1348A O
) O
replicated O
similarly O
to O
wild O
- O
type O
virus O
but O
was O
unable O
to O
cause O
acute O
hepatitis O
in O
mice O
. O

To O
determine O
whether O
this O
attenuated O
phenotype O
is O
applicable O
to O
multiple O
disease O
models O
, O
we O
mutated O
the O
catalytic O
residue O
in O
the O
JHM O
strain O
of O
MHV O
( O
JHMV O
) O
, O
which O
causes O
acute O
and O
chronic O
encephalomyelitis O
, O
using O
a O
newly O
developed O
bacterial B
artificial I
chromosome I
( I
BAC I
) I
- O
based O
MHV O
reverse O
genetics O
system O
. O

Infection O
of O
mice O
with O
the O
macrodomain O
catalytic O
point O
mutant O
virus O
( O
N1347A O
) O
resulted O
in O
reductions O
in O
lethality O
, O
weight O
loss O
, O
viral O
titers O
, O
proinflammatory O
cytokine O
and O
chemokine O
expression O
, O
and O
immune O
cell O
infiltration O
in O
the O
brain O
compared O
to O
mice O
infected O
with O
wild O
- O
type O
virus O
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
and O
interferon B
( I
IFN I
) I
signaling O
were O
not O
required O
for O
effective O
host O
control O
of O
mutant O
virus O
as O
all O
N1347A O
virus O
- O
infected O
mice O
survived O
the O
infection O
. O

However O
, O
the O
adaptive O
immune O
system O
was O
required O
for O
protection O
since O
N1347A O
virus O
was O
able O
to O
cause O
lethal O
encephalitis O
in O
RAG1 O
( O
- O
/ O
- O
) O
( O
recombination O
activation O
gene O
1 O
knockout O
) O
mice O
although O
disease O
onset O
was O
modestly O
delayed O
. O

New O
attenuated O
variants O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
designed O
in O
this O
study O
combine O
a O
variety O
of O
characteristics O
that O
independently O
contribute O
to O
a O
reduction O
in O
virulence O
. O

IMPORTANCE O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
important O
human O
and O
animal O
pathogen O
, O
which O
causes O
periodic O
outbreaks O
of O
highly O
debilitating O
disease O
. O

The O
flavivirus O
NS5 O
is O
a O
natural O
fusion O
of O
a O
methyltransferase B
( I
MTase I
) I
and O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

By O
solving O
the O
crystal O
structure O
of O
the O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
NS5 O
, O
we O
recently O
identified O
an O
MTase O
- O
RdRP O
interface O
containing O
a O
set O
of O
six O
hydrophobic O
residues O
highly O
conserved O
among O
flaviviruses O
. O

Compared O
to O
the O
wild B
- I
type I
( I
WT I
) I
NS5 O
, O
full O
- O
length O
NS5 O
variants O
exhibited O
consistent O
up O
- O
or O
downregulation O
of O
the O
initiation O
activities O
in O
two O
types O
of O
polymerase O
assays O
. O

Moreover O
, O
constructs O
with O
MTase O
and O
/ O
or O
the O
linker O
region O
( O
residues O
266 O
to O
275 O
) O
removed O
still O
retained O
polymerase O
activities O
, O
albeit O
at O
overall O
lower O
levels O
. O

However O
, O
further O
removal O
of O
the O
N O
- O
terminal O
extension O
( O
residues O
276 O
to O
303 O
) O
abolished O
regular O
template O
- O
directed O
synthesis O
. O

IMPORTANCE O
The O
flavivirus O
NS5 O
is O
very O
unique O
in O
having O
a O
methyltransferase B
( I
MTase I
) I
placed O
on O
the O
immediate O
N O
terminus O
of O
its O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

Expression O
of O
key O
transcription O
factors O
was O
increased O
, O
including O
interferon O
regulatory O
factor O
3 O
and O
7 O
( O
IRF O
- O
3 O
and O
IRF O
- O
7 O
) O
and O
STAT O
- O
1 O
, O
suggesting O
that O
neuronal O
maturation O
may O
enhance O
the O
capacity O
for O
antiviral O
signaling O
upon O
infection O
. O

Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
are O
closely O
related O
henipaviruses O
of O
the O
Paramyxo O
virinae O
. O

To O
investigate O
the O
molecular O
basis O
for O
these O
differences O
, O
we O
first O
established O
a O
highly O
efficient O
reverse O
genetics O
system O
that O
increased O
rescue O
titers O
by O
> O
= O
3 O
log O
units O
, O
which O
offset O
the O
difficulty O
of O
generating O
multiple O
recombinants O
under O
constraining O
biosafety B
level I
4 I
( I
BSL I
- I
4 I
) I
conditions O
. O

We O
then O
replaced O
, O
singly O
and O
in O
combination O
, O
the O
matrix B
( I
M I
) I
, O
fusion O
( O
F O
) O
, O
and O
attachment O
glycoprotein B
( I
G I
) I
genes O
in O
mCherry O
- O
expressing O
recombinant B
NiV I
( I
rNiV I
) I
with O
their O
HeV O
counterparts O
. O

IMPORTANCE O
Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
are O
recently O
emergent O
zoonotic O
and O
highly O
lethal O
pathogens O
with O
pandemic O
potential O
Although O
differences O
have O
been O
observed O
between O
NiV O
and O
HeV O
replication O
and O
pathogenesis O
, O
the O
molecular O
basis O
for O
these O
differences O
has O
not O
been O
examined O
. O

In O
this O
study O
, O
we O
established O
a O
highly O
efficient O
system O
to O
reverse O
engineer O
changes O
into O
replication O
- O
competent O
NiV O
and O
HeV O
, O
which O
facilitated O
the O
generation O
of O
reporter O
- O
expressing O
viruses O
and O
recombinant O
NiV O
- O
HeV O
chimeras O
with O
substitutions O
in O
the O
genes O
responsible O
for O
viral O
exit O
( O
the O
M O
gene O
, O
critical O
for O
assembly O
and O
budding O
) O
and O
viral O
entry O
( O
the O
G O
[ O
attachment O
] O
and O
F O
[ O
fusion O
] O
genes O
) O
. O

Recently O
, O
a O
new O
alphavirus O
, O
Eilat B
virus I
( I
EILV I
) I
, O
was O
described O
, O
and O
in O
contrast O
to O
all O
other O
mosquito O
- O
borne O
viruses O
, O
it O
is O
unable O
to O
replicate O
in O
vertebrate O
cell O
lines O
. O

Utilizing O
Sindbis B
virus I
( I
SINV I
) I
and O
EILV O
chimeras O
, O
we O
show O
that O
the O
EILV O
vertebrate O
host O
range O
restriction O
is O
also O
manifested O
at O
the O
entry O
level O
. O

Furthermore O
, O
the O
EILV O
RNA O
replication O
restriction O
is O
independent O
of O
the O
3 O
' O
untranslated O
genome O
region O
( O
UTR O
) O
. O

These O
data O
demonstrate O
that O
the O
EILV O
host O
range O
restriction O
is O
multigenic O
, O
involving O
at O
least O
one O
gene O
from O
both O
nonstructural B
protein I
( I
nsp I
) I
and O
structural O
protein O
( O
sP O
) O
open B
reading I
frames I
( I
ORFs I
) I
. O

EILV O
is O
related O
to O
pathogenic O
mosquito O
- O
borne O
viruses O
( O
Eastern O
equine O
encephalitis O
virus O
[ O
EEEV O
] O
, O
Western O
equine O
encephalitis O
virus O
[ O
WEEV O
] O
, O
Venezuelan O
equine O
encephalitis O
virus O
[ O
VEEV O
] O
, O
and O
Chikungunya O
virus O
[ O
CHIKV O
] O
) O
that O
cause O
severe O
disease O
in O
humans O
. O

Protective O
immunity O
against O
genital O
pathogens O
causing O
chronic O
infections O
, O
such O
as O
Herpes B
simplex I
virus I
2 I
( I
HSV I
- I
2 I
) I
or O
human O
immunodeficiency O
virus O
, O
requires O
the O
induction O
of O
cell O
- O
mediated O
immune O
responses O
locally O
in O
the O
genital O
tract O
. O

Intranasal O
immunization O
with O
a O
thymidine O
kinase O
- O
deficient O
( O
TK O
- O
) O
mutant O
of O
HSV O
- O
2 O
effectively O
induces O
HSV O
- O
2 O
- O
specific O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
secreting O
memory O
T O
cell O
production O
and O
protective O
immunity O
against O
intravaginal O
challenge O
with O
wild O
- O
type O
HSV O
- O
2 O
. O

Intranasal O
immunization O
is O
an O
effective O
strategy O
for O
eliciting O
high O
levels O
of O
cell O
- O
mediated O
protection O
of O
the O
genital O
tract O
by O
providing O
long O
- O
lasting O
antigen B
( I
Ag I
) I
- O
specific O
local O
effector O
T O
cells O
without O
introducing O
topical O
infection O
or O
inflammation O
. O

) O
vaccines O
against O
sexually O
transmitted O
diseases O
that O
are O
caused O
by O
viruses O
such O
as O
Herpes B
simplex I
virus I
2 I
( I
HSV I
- I
2 I
) I
have O
long O
been O
in O
development O
, O
but O
no O
vaccine O
candidate O
is O
currently O
available O
. O

tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
is O
an O
important O
human O
- O
pathogenic O
flavivirus O
endemic O
in O
large O
parts O
of O
Europe O
and O
Central O
and O
Eastern O
Asia O
. O

IMPORTANCE O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
is O
a O
close O
relative O
of O
yellow O
fever O
, O
dengue O
, O
Japanese O
encephalitis O
, O
and O
West O
Nile O
viruses O
and O
distributed O
in O
large O
parts O
of O
Europe O
and O
Central O
and O
Eastern O
Asia O
. O

The O
four O
Dengue B
Virus I
( I
DENV I
) I
serotypes O
( O
DENV O
serotype O
1 O
[ O
DENV O
- O
1 O
] O
to O
DENV O
- O
4 O
) O
are O
transmitted O
by O
Aedes O
aegypti O
and O
A O
. O

aegypti B
cell I
line I
( I
Aag2 I
) I
and O
A O
. O

Results O
consistently O
showed O
a O
significant O
replicative O
advantage O
of O
NI O
- O
2B O
over O
NI O
- O
1 O
viruses O
early O
after O
infection O
in O
vitro O
, O
and O
in O
mosquitoes O
, O
NI O
- O
2B O
viruses O
attained O
a O
higher O
replicative O
index O
than O
NI O
- O
1 O
isolates O
3 O
to O
7 O
days O
postinfection O
( O
dpi O
) O
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
, O
one O
of O
the O
most O
medically O
important O
arthropod O
- O
borne O
viruses O
, O
is O
transmitted O
to O
humans O
by O
Aedes O
aegypti O
and O
A O
. O

Although O
nonhuman O
primate O
models O
of O
neuro O
- O
AIDS O
have O
made O
tremendous O
contributions O
to O
our O
understanding O
of O
disease O
progression O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
- O
infected O
individuals O
, O
each O
model O
holds O
advantages O
and O
limitations O
. O

SIV O
sm804E O
shows O
efficient O
replication O
in O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
and O
monocyte B
- I
derived I
macrophages I
( I
MDMs I
) I
in O
vitro O
and O
induces O
neuro O
- O
AIDS O
in O
high O
frequencies O
in O
vivo O
. O

Comprehensive O
analysis O
of O
disease O
progression O
in O
the O
animals O
used O
in O
the O
study O
suggested O
that O
host O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
and O
TRIM5 O
alpha O
genotypes O
influence O
the O
disease O
progression O
in O
the O
CNS O
. O

Taken O
together O
, O
our O
findings O
show O
that O
we O
have O
successfully O
isolated O
a O
new O
strain O
of O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
that O
is O
capable O
of O
establishing O
infection O
in O
the O
CNS O
at O
early O
stage O
of O
infection O
and O
causes O
neuropathology O
in O
infected O
rhesus O
macaques O
at O
a O
high O
frequency O
( O
83 O
% O
) O
using O
a O
single O
inoculum O
, O
when O
animals O
with O
restrictive O
MHC O
- O
I O
or O
TRIM5 O
alpha O
genotypes O
are O
excluded O
. O

IMPORTANCE O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
is O
associated O
with O
a O
high O
frequency O
of O
neurologic O
complications O
due O
to O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

enterovirus B
71 I
( I
EV71 I
) I
is O
a O
major O
viral O
pathogen O
in O
China O
and O
Southeast O
Asia O
. O

IMPORTANCE O
Human B
enterovirus I
71 I
( I
EV71 I
) I
has O
emerged O
as O
a O
major O
cause O
of O
viral O
encephalitis O
in O
children O
worldwide O
, O
especially O
in O
the O
Asia O
- O
Pacific O
region O
. O

In O
this O
study O
, O
we O
report O
the O
in O
vitro O
and O
in O
vivo O
efficacy O
of O
NITD008 O
( O
an O
adenosine O
analog O
) O
as O
an O
inhibitor O
of O
EV71 O
. O

La B
Crosse I
virus I
( I
LACV I
) I
is O
the O
major O
cause O
of O
pediatric O
viral O
encephalitis O
in O
the O
United O
States O
; O
however O
, O
the O
mechanisms O
responsible O
for O
age O
- O
related O
susceptibility O
in O
the O
pediatric O
population O
are O
not O
well O
understood O
. O

Our O
current O
studies O
in O
a O
mouse O
model O
of O
LACV O
infection O
indicated O
that O
differences O
in O
myeloid B
dendritic I
cell I
( I
mDC I
) I
responses O
between O
weanling O
and O
adult O
mice O
accounted O
for O
susceptibility O
to O
LACV O
- O
induced O
neurological O
disease O
. O

We O
found O
that O
type B
I I
interferon I
( I
IFN I
) I
responses O
were O
significantly O
stronger O
in O
adult O
than O
in O
weanling O
mice O
. O

Production O
of O
these O
IFNs O
required O
both O
endosomal O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
and O
cytoplasmic O
RIG B
- I
I I
- I
like I
receptors I
( I
RLRs I
) I
. O

Surprisingly O
, O
IFN O
expression O
was O
not O
dependent O
on O
plasmacytoid B
DCs I
( I
pDCs I
) I
but O
rather O
was O
dependent O
on O
mDCs O
, O
which O
were O
found O
in O
greater O
number O
and O
induced O
stronger O
IFN O
responses O
in O
adults O
than O
in O
weanlings O
. O

These O
studies O
provide O
a O
definitive O
mechanism O
for O
age O
- O
related O
susceptibility O
to O
LACV O
encephalitis O
, O
where O
mDCs O
in O
young O
mice O
are O
insufficiently O
activated O
to O
control O
peripheral O
virus O
replication O
, O
thereby O
allowing O
virus O
to O
persist O
and O
eventually O
cause O
central B
nervous I
system I
( I
CNS I
) I
disease O
. O

IMPORTANCE O
La B
Crosse I
virus I
( I
LACV I
) I
is O
the O
primary O
cause O
of O
pediatric O
viral O
encephalitis O
in O
the O
United O
States O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
establishes O
latency O
in O
neurons O
of O
the O
brains O
and O
sensory O
ganglia O
of O
humans O
and O
experimentally O
infected O
mice O
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
establishes O
latency O
in O
neurons O
of O
the O
brains O
and O
sensory O
ganglia O
of O
humans O
and O
experimentally O
infected O
mice O
. O

Japanese B
encephalitis I
( I
JE I
) I
is O
an O
arthropod O
- O
borne O
disease O
associated O
with O
the O
majority O
of O
viral O
encephalitis O
cases O
in O
the O
Asia O
- O
Pacific O
region O
. O

The O
causative O
agent O
, O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
has O
been O
phylogenetically O
divided O
into O
five O
genotypes O
. O

Recent O
surveillance O
data O
indicate O
that O
genotype B
I I
( I
GI I
) I
is O
gradually O
replacing O
genotype B
III I
( I
GIII I
) I
as O
the O
dominant O
genotype O
. O

To O
investigate O
the O
mechanism O
behind O
the O
genotype O
shift O
and O
the O
potential O
consequences O
in O
terms O
of O
vaccine O
efficacy O
, O
human O
cases O
, O
and O
virus O
dissemination O
, O
we O
collected O
( O
i O
) O
all O
full O
- O
length O
and O
partial O
JEV O
molecular O
sequences O
and O
( O
ii O
) O
associated O
genotype O
and O
host O
information O
comprising O
a O
data O
set O
of O
873 O
sequences O
. O

The O
causative O
agent O
, O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
has O
been O
divided O
into O
five O
genotypes O
based O
on O
sequence O
similarity O
. O

Recent O
data O
indicate O
that O
genotype B
I I
( I
GI I
) I
is O
gradually O
replacing O
genotype B
III I
( I
GIII I
) I
as O
the O
dominant O
genotype O
. O

Viral B
infectivity I
factor I
( I
Vif I
) I
is O
required O
for O
lentivirus O
fitness O
and O
pathogenicity O
, O
except O
in O
equine B
infectious I
anemia I
virus I
( I
EIAV I
) I
. O

Core B
- I
binding I
factor I
subunit I
beta I
( I
CBF I
- I
beta I
) I
is O
a O
cell O
factor O
that O
was O
recently O
shown O
to O
be O
important O
for O
the O
primate O
lentiviral O
Vif O
function O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
the O
Vifs O
of O
non O
- O
primate O
lentiviruses O
, O
including O
feline B
immunodeficiency I
virus I
( I
FIV I
) I
, O
bovine B
immunodeficiency I
virus I
( I
BIV I
) I
, O
caprine B
arthritis I
encephalitis I
virus I
( I
CAEV I
) I
, O
and O
maedi B
- I
visna I
virus I
( I
MVV I
) I
, O
do O
not O
interact O
with O
CBF O
- O
beta O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
establishes O
lifelong O
latent O
infections O
in O
the O
sensory O
neurons O
of O
the O
trigeminal B
ganglia I
( I
TG I
) I
, O
wherein O
it O
retains O
the O
capacity O
to O
reactivate O
. O

The O
interferon B
( I
IFN I
) I
- O
driven O
antiviral O
response O
is O
critical O
for O
the O
control O
of O
HSV O
- O
1 O
acute O
replication O
. O

We O
showed O
that O
HSV O
- O
1 O
replication O
was O
comparable O
in O
wild B
- I
type I
( I
WT I
) I
and O
IFN O
signaling O
- O
deficient O
neurons O
and O
fibroblasts O
. O

Unexpectedly O
, O
a O
similar O
pattern O
was O
observed O
for O
the O
IFN O
- O
sensitive O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
is O
a O
ubiquitous O
virus O
that O
establishes O
a O
lifelong O
latent O
infection O
in O
neurons O
. O

Here O
we O
examine O
chemokine O
expression O
and O
leukocyte O
recruitment O
in O
the O
context O
of O
avirulent O
and O
virulent O
Semliki B
Forest I
virus I
( I
SFV I
) I
as O
well O
as O
West O
Nile O
virus O
infection O
and O
demonstrate O
rapid O
and O
robust O
expression O
of O
a O
variety O
of O
inflammatory O
CC O
and O
CXC O
chemokines O
in O
all O
models O
. O

IMPORTANCE O
Brain O
inflammation O
( O
encephalitis O
) O
in O
response O
to O
viral O
infection O
can O
lead O
to O
severe O
illness O
and O
even O
death O
. O

The O
structures O
of O
human B
Venezuelan I
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
an O
alphavirus O
, O
in O
complex O
with O
two O
strongly O
neutralizing O
antibody O
Fab O
fragments O
( O
F5 O
and O
3B4C O
- O
4 O
) O
have O
been O
determined O
using O
a O
combination O
of O
cryo O
- O
electron O
microscopy O
and O
homology O
modeling O
. O

We O
characterize O
these O
monoclonal O
antibody O
Fab O
fragments O
, O
which O
are O
known O
to O
abrogate O
VEEV O
infectivity O
by O
binding O
to O
the O
E2 O
( O
envelope O
) O
surface O
glycoprotein O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
alphavirus O
with O
a O
wide O
distribution O
across O
the O
globe O
. O

Herpes B
Simplex I
Virus I
( I
HSV I
) I
entry O
requires O
multiple O
interactions O
at O
the O
cell O
surface O
and O
activation O
of O
a O
complex O
calcium O
signaling O
cascade O
. O

These O
studies O
were O
designed O
to O
test O
the O
hypothesis O
that O
integrin O
alpha O
v O
beta O
3 O
signaling O
promotes O
the O
release O
of O
intracellular O
calcium O
( O
Ca2 O
+ O
) O
stores O
and O
contributes O
to O
viral O
entry O
and O
cell O
- O
to O
- O
cell O
spread O
. O

Transfection O
of O
cells O
with O
small B
interfering I
RNA I
( I
siRNA I
) I
targeting O
integrin O
alpha O
v O
beta O
3 O
, O
but O
not O
other O
integrin O
subunits O
, O
or O
treatment O
with O
cilengitide O
, O
an O
Arg B
- I
Gly I
- I
Asp I
( I
RGD I
) I
mimetic O
, O
impaired O
HSV O
- O
induced O
Ca2 O
+ O
release O
, O
viral O
entry O
, O
plaque O
formation O
, O
and O
cell O
- O
to O
- O
cell O
spread O
of O
HSV O
- O
1 O
and O
HSV O
- O
2 O
in O
human O
cervical O
and O
primary O
genital O
tract O
epithelial O
cells O
. O

Coimmunoprecipitation O
studies O
and O
proximity O
ligation O
assays O
indicated O
that O
integrin O
alpha O
v O
beta O
3 O
interacts O
with O
glycoprotein B
H I
( I
gH I
) I
. O

Silencing O
of O
integrin O
alpha O
v O
beta O
3 O
and O
deletion O
of O
gH O
prevented O
phosphorylation O
of O
focal B
adhesion I
kinase I
( I
FAK I
) I
and O
the O
transport O
of O
viral O
capsids O
to O
the O
nuclear O
pore O
. O

For O
example O
, O
Nidovirales O
and O
Flaviviridae O
subvert O
the O
membrane O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
for O
their O
replication O
. O

Recent O
reports O
highlight O
the O
analogies O
between O
mouse O
hepatitis O
virus O
- O
, O
equine O
arteritis O
virus O
- O
, O
and O
Japanese O
encephalitis O
virus O
- O
induced O
replication O
platforms O
and O
ER B
- I
associated I
degradation I
( I
ERAD I
) I
tuning O
vesicles O
( O
or O
EDEMosomes O
) O
that O
display O
nonlipidated O
LC3 O
at O
their O
cytosolic O
face O
and O
segregate O
the O
ERAD O
factors O
EDEM1 O
, O
OS O
- O
9 O
, O
and O
SEL1L O
from O
the O
ER O
lumen O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
member O
of O
the O
family O
Flaviviridae O
, O
is O
a O
leading O
cause O
of O
chronic O
liver O
disease O
and O
cancer O
. O

While O
it O
has O
been O
widely O
assumed O
that O
HCV O
E2 O
is O
a O
class O
II O
viral B
fusion I
protein I
( I
VFP I
) I
, O
the O
newly O
determined O
structure O
suggests O
that O
the O
HCV O
E2 O
ectodomain O
shares O
structural O
and O
functional O
similarities O
only O
with O
domain O
III O
of O
class O
II O
VFPs O
. O

We O
have O
previously O
reported O
that O
one O
such O
protein O
, O
Ifit2 O
, O
protects O
neurons O
of O
the O
central O
nervous O
system O
from O
intranasal O
infection O
by O
the O
neurotropic O
rhabdovirus O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

In O
Ifit2 O
( O
- O
/ O
- O
) O
mice O
, O
VSV O
, O
injected O
subcutaneously O
into O
the O
footpad O
, O
entered O
the O
proximal O
lymph O
node O
, O
where O
it O
replicated O
and O
infected O
the O
nodal O
nerve O
endings O
. O

Ifit2 O
protected O
only O
the O
nervous O
system O
from O
VSV O
infection O
; O
other O
tissues O
were O
well O
protected O
even O
in O
Ifit2 O
( O
- O
/ O
- O
) O
mice O
. O

The O
virus O
studied O
here O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
like O
its O
relative O
, O
rabies O
virus O
, O
can O
cause O
neuropathy O
in O
mice O
if O
it O
enters O
the O
peripheral O
nervous O
system O
through O
skin O
lesions O
; O
however O
, O
interferon O
can O
protect O
neurons O
from O
VSV O
infection O
. O

human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
is O
characterized O
by O
replication O
in O
macrophages O
or O
brain O
microglia O
that O
express O
low O
levels O
of O
the O
CD4 O
receptor O
and O
is O
the O
cause O
of O
HIV O
- O
associated O
dementia O
and O
related O
cognitive O
and O
motor O
disorders O
that O
affect O
20 O
to O
30 O
% O
of O
treatment O
- O
naive O
patients O
with O
AIDS O
. O

Independent O
viral O
envelope O
evolution O
in O
the O
brain O
has O
been O
reported O
, O
with O
the O
need O
for O
robust O
replication O
in O
resident O
CD4 O
( O
low O
) O
cells O
, O
as O
well O
as O
CD4 O
- O
negative O
cells O
, O
such O
as O
astrocytes O
, O
proposed O
as O
a O
major O
selective O
pressure O
. O

We O
previously O
reported O
giant O
- O
cell O
encephalitis O
in O
subtype O
B O
and O
C O
R5 O
simian B
- I
human I
immunodeficiency I
virus I
( I
SHIV I
) I
- O
infected O
macaques O
( O
SHIV O
- O
induced O
encephalitis O
[ O
SHIVE O
] O
) O
that O
experienced O
very O
high O
chronic O
viral O
loads O
and O
progressed O
rapidly O
to O
AIDS O
, O
with O
varying O
degrees O
of O
macrophage O
or O
microglia O
infection O
and O
activation O
of O
these O
immune O
cells O
, O
as O
well O
as O
astrocytes O
, O
in O
the O
CNS O
. O

In O
this O
study O
, O
we O
characterized O
envelopes B
( I
Env I
) I
amplified O
from O
the O
brains O
of O
subtype O
B O
and O
C O
R5 O
SHIVE O
macaques O
. O

IMPORTANCE O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
of O
astrocytes O
in O
the O
brain O
has O
been O
suggested O
to O
be O
important O
in O
HIV O
persistence O
and O
neuropathogenesis O
but O
has O
not O
been O
definitively O
demonstrated O
in O
an O
animal O
model O
of O
HIV B
- I
induced I
encephalitis I
( I
HIVE I
) I
. O

Here O
, O
we O
describe O
a O
new O
nonhuman B
primate I
( I
NHP I
) I
model O
of O
R5 O
simian B
- I
human I
immunodeficiency I
virus I
( I
SHIV I
) I
- O
induced O
encephalitis O
( O
SHIVE O
) O
with O
several O
classical O
HIVE O
features O
that O
include O
astrocyte O
infection O
. O

We O
further O
show O
an O
association O
between O
severe O
neuropathological O
changes O
, O
robust O
resident O
microglia O
infection O
, O
and O
evolution O
to O
CD4 O
independence O
of O
viruses O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
with O
expansion O
to O
infection O
of O
truly O
CD4 O
- O
negative O
cells O
in O
vivo O
. O

tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
is O
endemic O
in O
large O
parts O
of O
Europe O
and O
Central O
and O
Eastern O
Asia O
and O
causes O
more O
than O
10 O
, O
000 O
annual O
cases O
of O
neurological O
disease O
in O
humans O
. O

Neutralizing O
antibodies O
are O
directed O
to O
the O
viral O
envelope B
protein I
( I
E I
) I
and O
an O
accepted O
correlate O
of O
immunity O
. O

However O
, O
data O
on O
the O
specificities O
of O
CD4 O
( O
+ O
) O
T O
cells O
that O
recognize O
epitopes O
in O
the O
viral O
structural O
proteins O
and O
thus O
can O
provide O
direct O
help O
to O
the O
B O
cells O
producing O
E O
- O
specific O
antibodies O
are O
lacking O
. O

We O
therefore O
conducted O
a O
study O
on O
the O
CD4 O
( O
+ O
) O
T O
cell O
response O
against O
the O
virion O
proteins O
in O
vaccinated O
people O
in O
comparison O
to O
TBE O
patients O
. O

The O
data O
obtained O
with O
overlapping O
peptides O
in O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
enzyme I
- I
linked I
immunosorbent I
spot I
( I
ELISpot I
) I
assays O
were O
analyzed O
in O
relation O
to O
the O
three O
- O
dimensional O
structures O
of O
the O
Capsid B
( I
C I
) I
and O
E O
proteins O
as O
well O
as O
to O
epitope O
predictions O
based O
on O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
peptide O
affinities O
. O

In O
the O
C O
protein O
, O
peptides O
corresponding O
to O
two O
out O
of O
four O
alpha O
helices O
dominated O
the O
response O
in O
both O
vaccinees O
and O
patients O
, O
whereas O
in O
the O
E O
protein O
concordance O
of O
immunodominance O
was O
restricted O
to O
peptides O
of O
a O
single O
domain O
( O
domain O
III O
) O
. O

Our O
data O
provide O
evidence O
for O
a O
strong O
impact O
of O
protein O
structural O
features O
that O
influence O
peptide O
processing O
, O
contributing O
to O
the O
discrepancies O
observed O
between O
experimentally O
determined O
and O
computer O
- O
predicted O
CD4 O
( O
+ O
) O
T O
cell O
epitopes O
. O

tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
is O
the O
most O
important O
arthropod O
- O
borne O
flavivirus O
endemic O
in O
Europe O
and O
is O
the O
etiological O
agent O
of O
tick O
- O
borne O
encephalitis O
, O
a O
potentially O
fatal O
infection O
of O
the O
central O
nervous O
system O
. O

Infection O
of O
cells O
depleted O
of O
TIA O
- O
1 O
or O
TIAR O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
or O
TIA O
- O
1 O
( O
- O
/ O
- O
) O
mouse O
fibroblasts O
, O
leads O
to O
a O
significant O
increase O
in O
TBEV O
extracellular O
infectivity O
. O

Interestingly O
, O
TIAR O
( O
- O
/ O
- O
) O
fibroblasts O
show O
the O
opposite O
effect O
on O
TBEV O
infection O
, O
and O
this O
phenotype O
appears O
to O
be O
related O
to O
an O
excess O
of O
TIA O
- O
1 O
in O
these O
cells O
. O

Taking O
advantage O
of O
a O
TBE O
- O
luciferase O
replicon O
system O
, O
we O
also O
observed O
increased O
luciferase O
activity O
in O
TIA O
- O
1 O
( O
- O
/ O
- O
) O
mouse O
fibroblasts O
at O
early O
time O
points O
, O
consistent O
with O
TIA O
- O
1 O
- O
mediated O
inhibition O
at O
the O
level O
of O
the O
first O
round O
of O
viral O
translation O
. O

These O
results O
indicate O
that O
, O
in O
response O
to O
TBEV O
infection O
, O
TIA O
- O
1 O
is O
recruited O
to O
sites O
of O
virus O
replication O
to O
bind O
TBEV O
RNA O
and O
modulate O
viral O
translation O
independently O
of O
Stress B
granule I
( I
SG I
) I
formation O
. O

In O
mice O
and O
in O
larvae O
of O
the O
greater O
wax O
moth O
( O
Galleria O
mellonella O
) O
, O
Nodamura O
virus O
- O
infected O
muscle O
cells O
exhibit O
mitochondrial O
aggregation O
and O
membrane O
rearrangement O
, O
leading O
to O
disorganization O
of O
the O
muscle O
fibrils O
on O
the O
tissue O
level O
and O
ultimately O
in O
hind O
limb O
/ O
segment O
paralysis O
. O

tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
Omsk B
hemorrhagic I
fever I
virus I
( I
OHFV I
) I
are O
highly O
pathogenic O
tick O
- O
borne O
flaviviruses O
; O
TBEV O
causes O
neurological O
disease O
in O
humans O
, O
while O
OHFV O
causes O
a O
disease O
typically O
identified O
with O
hemorrhagic O
fever O
. O

microRNAs B
( I
miRNAs I
) I
are O
single O
- O
stranded O
small O
RNA O
molecules O
that O
regulate O
various O
cellular O
processes O
. O

miRNA O
155 O
( O
miR O
- O
155 O
) O
regulates O
various O
aspects O
of O
innate O
and O
adaptive O
immune O
responses O
and O
plays O
a O
key O
role O
in O
various O
viral O
infections O
and O
the O
resulting O
neuroinflammation O
. O

The O
present O
study O
evaluated O
the O
involvement O
of O
miR O
- O
155 O
in O
modulating O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
- O
induced O
neuroinflammation O
. O

In O
the O
present O
study O
, O
we O
confirmed O
targeting O
of O
the O
Src B
homology I
2 I
- I
containing I
inositol I
phosphatase I
1 I
( I
SHIP1 I
) I
3 I
' I
untranslated I
region I
( I
UTR I
) I
by O
miR O
- O
155 O
in O
the O
context O
of O
JEV O
infection O
. O

Inhibition O
of O
SHIP1 O
by O
miR O
- O
155 O
resulted O
in O
higher O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
proinflammatory O
cytokine O
production O
through O
activation O
of O
TANK B
- I
binding I
kinase I
1 I
( I
TBK I
- I
1 I
) I
. O

We O
previously O
developed O
a O
novel O
method O
to O
fully O
exfoliate O
montmorillonite O
clay O
to O
generate O
the O
most O
fundamental O
units O
of O
nanoscale B
silicate I
platelet I
( I
NSP I
) I
. O

We O
further O
modified O
NSP O
by O
capping O
with O
various O
surfactants O
and O
found O
that O
the O
surfactant O
- O
modified O
NSP O
( O
NSQ O
) O
was O
less O
cytotoxic O
. O

Among O
the O
derivatives O
, O
NSP O
modified O
with O
anionic O
sodium O
dodecyl O
sulfate O
( O
NSQc O
) O
, O
but O
not O
the O
pristine O
clay O
, O
unmodified O
NSP O
, O
a O
silver O
nanoparticle O
- O
NSP O
hybrid O
, O
NSP O
modified O
with O
cationic O
n O
- O
octadecanylamine O
hydrochloride O
salt O
, O
or O
NSP O
modified O
with O
nonionic O
Triton O
X O
- O
100 O
, O
significantly O
suppressed O
the O
plaque O
- O
forming O
ability O
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
at O
noncytotoxic O
concentrations O
. O

NSQc O
also O
blocked O
infection O
with O
dengue B
virus I
( I
DEN I
) I
and O
influenza O
A O
virus O
. O

In O
recent O
years O
, O
genotype B
I I
( I
GI I
) I
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
has O
displaced O
genotype B
III I
( I
GIII I
) I
as O
the O
dominant O
virus O
genotype O
throughout O
Asia O
. O

Molecular O
adaptation O
was O
detected O
by O
more O
than O
one O
method O
at O
one O
site O
( O
residue O
15 O
) O
, O
and O
coevolution O
was O
detected O
at O
two O
pairs O
of O
sites O
( O
residues O
89 O
to O
360 O
and O
129 O
to O
141 O
) O
within O
the O
GI O
E O
gene O
protein O
alignment O
. O

Serious O
permanent O
neurological O
or O
psychiatric O
dysfunction O
may O
result O
from O
virus O
infections O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Here O
we O
show O
that O
both O
RNA O
( O
vesicular O
stomatitis O
virus O
[ O
VSV O
] O
) O
and O
DNA O
( O
cytomegalovirus O
[ O
CMV O
] O
) O
virus O
inoculations O
of O
the O
nasal O
mucosa O
leading O
to O
olfactory B
bulb I
( I
OB I
) I
infection O
activate O
long O
- O
distance O
signaling O
that O
upregulates O
antiviral O
interferon B
( I
IFN I
) I
- O
stimulated O
gene O
( O
ISG O
) O
expression O
in O
uninfected O
remote O
regions O
of O
the O
brain O
. O

We O
studied O
systemic O
viral O
spread O
after O
intranasal O
infection O
with O
highly O
pathogenic O
avian O
influenza O
virus O
( O
H5N1 O
[ O
A O
/ O
Viet O
Nam O
/ O
1203 O
/ O
2004 O
] O
) O
in O
ferrets O
with O
or O
without O
prior O
pandemic O
H1N1pdm09 O
( O
A O
/ O
Mexico O
/ O
4108 O
/ O
2009 O
) O
or O
H3N2 O
( O
A O
/ O
Victoria O
/ O
361 O
/ O
2011 O
) O
infection O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
arbovirus O
responsible O
for O
outbreaks O
of O
infection O
throughout O
Asia O
and O
Africa O
, O
causing O
an O
acute O
illness O
characterized O
by O
fever O
, O
rash O
, O
and O
polyarthralgia O
. O

In O
this O
study O
, O
we O
tested O
whether O
glycosaminoglycan B
( I
GAG I
) I
binding O
is O
required O
for O
efficient O
CHIKV O
replication O
using O
CHIKV O
vaccine O
strain O
181 O
/ O
25 O
and O
clinical O
isolate O
SL15649 O
. O

While O
parental O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cells O
are O
permissive O
for O
both O
strains O
, O
neither O
strain O
efficiently O
bound O
to O
or O
infected O
mutant O
CHO O
cells O
devoid O
of O
GAG O
expression O
. O

Reciprocal O
exchange O
at O
residue O
82 O
resulted O
in O
a O
phenotype O
switch O
; O
Gly O
( O
82 O
) O
results O
in O
efficient O
infection O
of O
mutant O
CHO O
cells O
but O
a O
decrease O
in O
heparin O
binding O
, O
whereas O
Arg O
( O
82 O
) O
results O
in O
reduced O
infectivity O
of O
mutant O
cells O
and O
an O
increase O
in O
heparin O
binding O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
infection O
causes O
a O
debilitating O
rheumatic O
disease O
that O
can O
persist O
for O
months O
to O
years O
, O
and O
yet O
there O
are O
no O
licensed O
vaccines O
or O
antiviral O
therapies O
. O

Here O
we O
show O
for O
the O
flavivirus O
Murray B
Valley I
encephalitis I
virus I
( I
MVEV I
) I
that O
incorporation O
of O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
Encephalomyocarditis O
virus O
between O
the O
capsid O
and O
prM O
genes O
strongly O
attenuated O
virulence O
and O
that O
the O
resulting O
bicistronic O
virus O
was O
both O
genetically O
stable O
and O
potently O
immunogenic O
. O

Furthermore O
, O
the O
novel O
bicistronic O
genome O
organization O
facilitated O
the O
generation O
of O
a O
recombinant O
virus O
carrying O
an O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
. O

Nevertheless O
, O
the O
attenuated O
virus O
triggered O
robust O
innate O
and O
adaptive O
immune O
responses O
evidenced O
by O
the O
induced O
expression O
of O
Mx O
proteins O
( O
used O
as O
a O
sensitive O
biomarker O
for O
measuring O
the O
type O
I O
IFN O
response O
) O
and O
the O
generation O
of O
neutralizing O
antibodies O
, O
respectively O
. O

The O
present O
study O
investigated O
the O
effects O
of O
a O
redesigned O
flaviviral O
genome O
and O
the O
coexpression O
of O
an O
antiviral O
protein O
( O
interferon O
) O
on O
virus O
replication O
, O
pathogenicity O
, O
and O
immunogenicity O
. O

human B
coronaviruses I
( I
HCoVs I
) I
are O
recognized O
respiratory O
pathogens O
with O
neuroinvasive O
and O
neurotropic O
properties O
in O
mice O
and O
humans O
. O

HCoV O
strain O
OC43 O
( O
HCoV O
- O
OC43 O
) O
can O
infect O
and O
persist O
in O
human O
neural O
cells O
and O
activate O
neuroinflammatory O
and O
neurodegenerative O
mechanisms O
, O
suggesting O
that O
it O
could O
be O
involved O
in O
neurological O
disease O
of O
unknown O
etiology O
in O
humans O
. O

Moreover O
, O
we O
have O
shown O
that O
HCoV O
- O
OC43 O
is O
neurovirulent O
in O
susceptible O
mice O
, O
causing O
encephalitis O
, O
and O
that O
a O
viral O
mutant O
with O
a O
single O
point O
mutation O
in O
the O
viral O
surface O
spike B
( I
S I
) I
protein O
induces O
a O
paralytic O
disease O
that O
involves O
glutamate O
excitotoxicity O
in O
susceptible O
mice O
. O